[
  {
    "ticker": "ARGX",
    "nct_id": "NCT05670704",
    "title": "A Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of ARGX-119 in Healthy Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "ARGX-119",
      "Placebo"
    ],
    "primary_completion_date": "2024-08-08",
    "completion_date": "2024-08-08",
    "results_first_posted": null,
    "last_update_posted": "2024-08-23",
    "enrollment": null,
    "sponsor": "argenx",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARGX",
    "nct_id": "NCT03334058",
    "title": "A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pemphigus Vulgaris",
      "Pemphigus Foliaceus"
    ],
    "interventions": [
      "ARGX-113"
    ],
    "primary_completion_date": "2020-10-28",
    "completion_date": "2020-10-28",
    "results_first_posted": null,
    "last_update_posted": "2020-12-14",
    "enrollment": null,
    "sponsor": "argenx",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARGX",
    "nct_id": "NCT04188379",
    "title": "A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Primary Immune Thrombocytopenia"
    ],
    "interventions": [
      "efgartigimod",
      "Placebo"
    ],
    "primary_completion_date": "2022-02-03",
    "completion_date": "2022-02-03",
    "results_first_posted": "2025-03-13",
    "last_update_posted": "2025-03-13",
    "enrollment": null,
    "sponsor": "argenx",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARGX",
    "nct_id": "NCT04225156",
    "title": "A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Primary Immune Thrombocytopenia"
    ],
    "interventions": [
      "efgartigimod"
    ],
    "primary_completion_date": "2026-03-11",
    "completion_date": "2026-03-11",
    "results_first_posted": null,
    "last_update_posted": "2025-09-25",
    "enrollment": null,
    "sponsor": "argenx",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARGX",
    "nct_id": "NCT04274452",
    "title": "A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP)",
    "status": "WITHDRAWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Primary Immune Thrombocytopenia (ITP)"
    ],
    "interventions": [
      "efgartigimod",
      "Placebo"
    ],
    "primary_completion_date": "2021-09-01",
    "completion_date": "2021-09-01",
    "results_first_posted": null,
    "last_update_posted": "2020-09-14",
    "enrollment": null,
    "sponsor": "argenx",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARGX",
    "nct_id": "NCT05907096",
    "title": "ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Delayed Graft Function"
    ],
    "interventions": [
      "ARGX-117",
      "Placebo"
    ],
    "primary_completion_date": "2025-11",
    "completion_date": "2026-07-31",
    "results_first_posted": null,
    "last_update_posted": "2025-06-20",
    "enrollment": null,
    "sponsor": "argenx",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT01323465",
    "title": "Study to Evaluate the Effect of Rifampicin, Ketoconazole, and Omeprazole on the Pharmacokinetics of Sativex",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4",
      "Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Potent Inhibitor of CYP3A4",
      "Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a CYP2C19 Inhibitor"
    ],
    "interventions": [
      "Sativex and rifampicin",
      "Sativex and rifampicin",
      "Sativex and ketoconazole",
      "Sativex and ketoconazole",
      "Sativex and omeprazole",
      "Sativex and omeprazole"
    ],
    "primary_completion_date": "2008-03",
    "completion_date": "2008-03",
    "results_first_posted": null,
    "last_update_posted": "2023-04-10",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT05044819",
    "title": "Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lennox Gastaut Syndrome",
      "Dravet Syndrome",
      "Tuberous Sclerosis Complex"
    ],
    "interventions": [
      "Cannabidiol"
    ],
    "primary_completion_date": "2027-08-01",
    "completion_date": "2028-03-31",
    "results_first_posted": null,
    "last_update_posted": "2026-01-15",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02271347",
    "title": "An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ebola Virus"
    ],
    "interventions": [
      "CMX001"
    ],
    "primary_completion_date": "2015-01",
    "completion_date": "2015-01",
    "results_first_posted": null,
    "last_update_posted": "2015-02-02",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02954887",
    "title": "Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Infantile Spasms"
    ],
    "interventions": [
      "GWP42003-P"
    ],
    "primary_completion_date": "2019-06-13",
    "completion_date": "2019-06-13",
    "results_first_posted": "2020-07-23",
    "last_update_posted": "2022-09-02",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02873338",
    "title": "Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Myeloid Leukemia"
    ],
    "interventions": [
      "Dociparstat sodium",
      "Idarubicin",
      "Cytarabine"
    ],
    "primary_completion_date": "2019-06",
    "completion_date": "2019-06",
    "results_first_posted": "2021-10-29",
    "last_update_posted": "2023-09-07",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT01604265",
    "title": "A Study of Sativex in the Treatment of Central Neuropathic Pain Due to Multiple Sclerosis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple Sclerosis",
      "Neuropathic Pain"
    ],
    "interventions": [
      "Placebo",
      "Sativex"
    ],
    "primary_completion_date": "2002-08",
    "completion_date": "2002-08",
    "results_first_posted": "2012-09-19",
    "last_update_posted": "2023-01-10",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT00389428",
    "title": "Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer.",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hematologic Neoplasms"
    ],
    "interventions": [
      "CPX-351 (Cytarabine:Daunorubicin) Liposome Injection"
    ],
    "primary_completion_date": "2008-12",
    "completion_date": "2009-12",
    "results_first_posted": null,
    "last_update_posted": "2012-05-17",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT05772429",
    "title": "Long-Term Follow-Up of a Cohort of Participants Prescribed Epidyolex in France in a Real-life Setting",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Seizures"
    ],
    "interventions": [
      "Epidiolex"
    ],
    "primary_completion_date": "2026-07",
    "completion_date": "2026-07",
    "results_first_posted": null,
    "last_update_posted": "2025-04-13",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT01606202",
    "title": "A Study of Cannabis Based Medicine Extracts and Placebo in Patients With Pain Due to Spinal Cord Injury",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pain"
    ],
    "interventions": [
      "GW-1000-02",
      "Placebo"
    ],
    "primary_completion_date": "2005-01",
    "completion_date": "2005-01",
    "results_first_posted": "2012-09-28",
    "last_update_posted": "2023-01-10",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT05869773",
    "title": "A Switch Study From High-Sodium Oxybate to XYWAV to Evaluate Changes in Blood Pressure in Participants With Narcolepsy",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Narcolepsy"
    ],
    "interventions": [
      "JZP258"
    ],
    "primary_completion_date": "2025-02-25",
    "completion_date": "2025-03-10",
    "results_first_posted": null,
    "last_update_posted": "2025-04-08",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT03532035",
    "title": "Open Label Study of IV Brincidofovir in Adult Transplant Recipients With Adenovirus Viremia",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Adenovirus"
    ],
    "interventions": [
      "Brincidofovir",
      "Standard of Care"
    ],
    "primary_completion_date": "2019-05-10",
    "completion_date": "2019-05-10",
    "results_first_posted": null,
    "last_update_posted": "2021-07-21",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02224560",
    "title": "Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Epilepsy",
      "Lennox Gastaut Syndrome"
    ],
    "interventions": [
      "GWP42003-P",
      "Placebo control"
    ],
    "primary_completion_date": "2016-05-19",
    "completion_date": "2016-05-19",
    "results_first_posted": "2018-07-27",
    "last_update_posted": "2022-09-28",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT05580562",
    "title": "ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "H3 K27M",
      "Glioma"
    ],
    "interventions": [
      "Dordaviprone (ONC201)",
      "Dordaviprone (ONC201) + Placebo",
      "Placebo"
    ],
    "primary_completion_date": "2026-08",
    "completion_date": "2026-08",
    "results_first_posted": null,
    "last_update_posted": "2025-08-26",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT05178316",
    "title": "A Study of JZP150 in Adults With Posttraumatic Stress Disorder",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Post Traumatic Stress Disorder"
    ],
    "interventions": [
      "JZP150",
      "Placebo"
    ],
    "primary_completion_date": "2023-12-05",
    "completion_date": "2023-12-05",
    "results_first_posted": "2024-12-31",
    "last_update_posted": "2024-12-31",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT05126433",
    "title": "Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumor",
      "Metastatic Solid Tumor",
      "Urothelial Cancer",
      "Poorly Differentiated Neuroendocrine Carcinomas",
      "Homologous Recombination Deficient-Positive Malignancies Agnostic"
    ],
    "interventions": [
      "Lurbinectedin"
    ],
    "primary_completion_date": "2023-12-20",
    "completion_date": "2023-12-20",
    "results_first_posted": "2025-02-28",
    "last_update_posted": "2025-02-28",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT04894591",
    "title": "To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Extensive-stage Small-cell Lung Cancer"
    ],
    "interventions": [
      "Zepzelca"
    ],
    "primary_completion_date": "2025-05-27",
    "completion_date": "2025-05-27",
    "results_first_posted": null,
    "last_update_posted": "2025-06-29",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT00713817",
    "title": "A Study to Determine the Maintenance of Effect After Long-term Treatment of Sativex\u00ae in Subjects With Neuropathic Pain",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pain",
      "Peripheral Neuropathy"
    ],
    "interventions": [
      "Sativex\u00ae",
      "Placebo"
    ],
    "primary_completion_date": "2007-07",
    "completion_date": "2007-07",
    "results_first_posted": "2012-08-16",
    "last_update_posted": "2023-05-03",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT01241344",
    "title": "Phase 2 Study to Evaluate Brincidofovir for the Prevention of Adenovirus Disease",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Adenovirus Disease"
    ],
    "interventions": [
      "Brincidofovir",
      "Placebo"
    ],
    "primary_completion_date": "2013-06",
    "completion_date": "2013-06",
    "results_first_posted": "2021-07-16",
    "last_update_posted": "2021-07-21",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT00087555",
    "title": "Trial Comparing the Effects of Xyrem (Sodium Oxybate) With Placebo for the Treatment of Fibromyalgia",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fibromyalgia"
    ],
    "interventions": [
      "Xyrem (sodium oxybate) oral solution",
      "Xyrem (sodium oxybate) oral solution",
      "Placebo"
    ],
    "primary_completion_date": "2005-04",
    "completion_date": "2006-01",
    "results_first_posted": "2012-01-10",
    "last_update_posted": "2012-01-24",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT04592159",
    "title": "Study of the Safety and Efficacy of Nabiximols Oromucosal Spray Versus Placebo in Patients With Post-traumatic Stress Disorder",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Post-Traumatic Stress Disorder"
    ],
    "interventions": [
      "Nabiximols",
      "Placebo"
    ],
    "primary_completion_date": "2023-03",
    "completion_date": "2023-03",
    "results_first_posted": null,
    "last_update_posted": "2022-06-03",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT05485831",
    "title": "Epidyolex\u00ae in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Lennox Gastaut Syndrome",
      "Dravet Syndrome",
      "Tuberous Sclerosis Complex"
    ],
    "interventions": [
      "Epidiolex 100 mg/mL Oral Solution"
    ],
    "primary_completion_date": "2026-01",
    "completion_date": "2026-01",
    "results_first_posted": null,
    "last_update_posted": "2025-12-31",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT01361607",
    "title": "Sativex\u00ae for Relieving Persistent Pain in Patients With Advanced Cancer",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pain",
      "Advanced Cancer"
    ],
    "interventions": [
      "Nabiximols",
      "Placebo (GA-0034)"
    ],
    "primary_completion_date": "2014-11-24",
    "completion_date": "2014-11-24",
    "results_first_posted": "2018-04-23",
    "last_update_posted": "2023-04-12",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT01606137",
    "title": "A Study of the Long-term Safety of Sativex Use",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple Sclerosis",
      "Spasticity",
      "Pain"
    ],
    "interventions": [
      "GW-1000-02"
    ],
    "primary_completion_date": "2004-12",
    "completion_date": "2004-12",
    "results_first_posted": "2012-08-23",
    "last_update_posted": "2023-05-06",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT04145531",
    "title": "An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Lymphoblastic Leukemia",
      "Lymphoblastic Leukemia"
    ],
    "interventions": [
      "IM JZP-458",
      "IV JZP-458"
    ],
    "primary_completion_date": "2022-07-13",
    "completion_date": "2022-07-13",
    "results_first_posted": "2023-11-18",
    "last_update_posted": "2023-11-18",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02221869",
    "title": "A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Narcolepsy With Cataplexy"
    ],
    "interventions": [
      "Xyrem"
    ],
    "primary_completion_date": "2017-02",
    "completion_date": "2019-01-25",
    "results_first_posted": "2019-04-30",
    "last_update_posted": "2019-04-30",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02150928",
    "title": "An Open-Label, Single-Arm, Multicenter Pharmacokinetic Study of Intramuscular Erwinaze\u00ae (Asparaginase Erwinia Chrysanthemi)/Erwinase\u00ae (Crisantaspase)",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)"
    ],
    "interventions": [
      "Erwinaze\u00ae (Asparaginase Erwinia Chrysanthemi)/Erwinase\u00ae (Crisantaspase)"
    ],
    "primary_completion_date": "2015-06",
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2015-05-13",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02091206",
    "title": "A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Epilepsy",
      "Dravet Syndrome"
    ],
    "interventions": [
      "GWP42003-P 5 mg/kg/day Dose",
      "Placebo control",
      "GWP42003-P 10 mg/kg/day Dose",
      "GWP42003-P 20 mg/kg/day Dose"
    ],
    "primary_completion_date": "2015-03-09",
    "completion_date": "2015-03-09",
    "results_first_posted": "2018-07-19",
    "last_update_posted": "2022-09-28",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT01643408",
    "title": "A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Lymphoblastic Leukemia",
      "Lymphoblastic Lymphoma"
    ],
    "interventions": [
      "asparaginase Erwinia chrysanthemi"
    ],
    "primary_completion_date": "2013-08",
    "completion_date": "2013-12",
    "results_first_posted": "2021-06-23",
    "last_update_posted": "2021-06-23",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02073474",
    "title": "An Observational Post-Marketing Safety Registry of Sativex\u00ae",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Multiple Sclerosis",
      "Diabetes",
      "Cancer",
      "Neuropathic Pain"
    ],
    "interventions": [
      "Sativex\u00ae"
    ],
    "primary_completion_date": "2015-01",
    "completion_date": "2015-01",
    "results_first_posted": null,
    "last_update_posted": "2022-12-20",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT00793598",
    "title": "CMX001 in Post-transplant Patients With BK Virus Viruria",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Viruria"
    ],
    "interventions": [
      "Placebo",
      "Brincidofovir"
    ],
    "primary_completion_date": "2010-10",
    "completion_date": "2010-10",
    "results_first_posted": "2021-07-16",
    "last_update_posted": "2021-08-16",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT00710554",
    "title": "A Study of Sativex\u00ae for Pain Relief of Peripheral Neuropathic Pain, Associated With Allodynia",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pain",
      "Peripheral Neuropathy"
    ],
    "interventions": [
      "Sativex",
      "Placebo"
    ],
    "primary_completion_date": "2006-10",
    "completion_date": "2006-10",
    "results_first_posted": "2012-09-14",
    "last_update_posted": "2023-05-03",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT04252586",
    "title": "A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rett Syndrome",
      "RTT"
    ],
    "interventions": [
      "GWP42003-P"
    ],
    "primary_completion_date": "2021-06-09",
    "completion_date": "2021-06-09",
    "results_first_posted": "2022-08-08",
    "last_update_posted": "2022-08-08",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT03849456",
    "title": "Safety and Tolerability of Cannabidivarin (CBDV) in Children and Young Adults With Autism Spectrum Disorder",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Autism Spectrum Disorder"
    ],
    "interventions": [
      "GWP42006"
    ],
    "primary_completion_date": "2020-05-26",
    "completion_date": "2020-05-26",
    "results_first_posted": null,
    "last_update_posted": "2022-09-02",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT04075747",
    "title": "A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Myeloid Leukemia"
    ],
    "interventions": [
      "CPX-351",
      "Venetoclax",
      "Midostaurin",
      "Enasidenib"
    ],
    "primary_completion_date": "2022-02-07",
    "completion_date": "2023-09-12",
    "results_first_posted": null,
    "last_update_posted": "2023-10-16",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02544763",
    "title": "A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Tuberous Sclerosis Complex",
      "Seizures"
    ],
    "interventions": [
      "GWP42003-P",
      "Placebo"
    ],
    "primary_completion_date": "2019-01-22",
    "completion_date": "2019-02-26",
    "results_first_posted": "2020-09-23",
    "last_update_posted": "2022-09-28",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT05864846",
    "title": "A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Tuberous Sclerosis Complex Associated Neuropsychiatric Disease"
    ],
    "interventions": [
      "Cannabidiol Oral Solution [Epidiolex]"
    ],
    "primary_completion_date": "2026-03-26",
    "completion_date": "2026-03-26",
    "results_first_posted": null,
    "last_update_posted": "2026-01-09",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT07233239",
    "title": "A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Focal Seizures"
    ],
    "interventions": [
      "CBD-OS"
    ],
    "primary_completion_date": "2027-11-29",
    "completion_date": "2027-11-29",
    "results_first_posted": null,
    "last_update_posted": "2025-12-23",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02224690",
    "title": "A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Epilepsy",
      "Lennox-Gastaut Syndrome"
    ],
    "interventions": [
      "GWP42003-P 20 mg/kg/day Dose",
      "Placebo"
    ],
    "primary_completion_date": "2016-03-18",
    "completion_date": "2016-03-18",
    "results_first_posted": "2018-07-27",
    "last_update_posted": "2022-09-28",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT01080820",
    "title": "A Safety, Tolerability and Pharmacokinetic Study of a Single Dose of CMX157 in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "CMX157",
      "Placebo",
      "Viread"
    ],
    "primary_completion_date": "2010-12",
    "completion_date": "2010-12",
    "results_first_posted": null,
    "last_update_posted": "2011-07-04",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02056782",
    "title": "A Pilot Study of Dociparstat Sodium (ODSH) in Acute Myeloid Leukemia",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Myeloid Leukemia"
    ],
    "interventions": [
      "Dociparstat sodium"
    ],
    "primary_completion_date": "2015-02",
    "completion_date": "2015-06",
    "results_first_posted": "2023-02-21",
    "last_update_posted": "2023-02-21",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02269579",
    "title": "Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Myeloid Leukemia (AML)",
      "Acute Lymphoblastic Leukemia (ALL)",
      "Myelodysplastic Syndrome (MDS)"
    ],
    "interventions": [
      "CPX-351"
    ],
    "primary_completion_date": "2017-06",
    "completion_date": "2017-06",
    "results_first_posted": null,
    "last_update_posted": "2018-03-14",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT00423813",
    "title": "A Safety and Efficacy Study of Xyrem\u00ae (Sodium Oxybate) to Treat Fibromyalgia.",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fibromyalgia"
    ],
    "interventions": [
      "placebo",
      "Xyrem\u00ae"
    ],
    "primary_completion_date": "2009-04",
    "completion_date": "2009-06",
    "results_first_posted": "2012-01-10",
    "last_update_posted": "2012-01-24",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT01322464",
    "title": "Study to Assess Food Effect on Sativex Bioavailability",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Food Effect"
    ],
    "interventions": [
      "Sativex",
      "Sativex",
      "Sativex",
      "Sativex"
    ],
    "primary_completion_date": "2008-02",
    "completion_date": "2008-02",
    "results_first_posted": null,
    "last_update_posted": "2023-04-10",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT00901732",
    "title": "Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer",
    "status": "UNKNOWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Oral Mucositis"
    ],
    "interventions": [
      "Caphosol"
    ],
    "primary_completion_date": "2010-11",
    "completion_date": "2010-11",
    "results_first_posted": null,
    "last_update_posted": "2009-05-14",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT00780182",
    "title": "Comparative Bioavailability and Effect of Food on CMX001 in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "CMX001"
    ],
    "primary_completion_date": "2008-12",
    "completion_date": "2009-01",
    "results_first_posted": null,
    "last_update_posted": "2010-02-02",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT00132873",
    "title": "Trial of Xyrem\u00ae (Sodium Oxybate) for the Treatment of Narcolepsy",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Narcolepsy"
    ],
    "interventions": [
      "Xyrem (sodium oxybate) oral solution"
    ],
    "primary_completion_date": "2007-09",
    "completion_date": "2007-12",
    "results_first_posted": "2013-11-25",
    "last_update_posted": "2013-11-25",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02348619",
    "title": "\"Six-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA\"",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Obstructive Sleep Apnea"
    ],
    "interventions": [
      "JZP-110"
    ],
    "primary_completion_date": "2016-11",
    "completion_date": "2016-11",
    "results_first_posted": "2019-09-09",
    "last_update_posted": "2019-09-09",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT04541082",
    "title": "Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Central Nervous System Neoplasms",
      "Glioblastoma",
      "Gliosarcoma, Adult",
      "Anaplastic Oligodendroglioma",
      "Anaplastic Astrocytoma",
      "Pilocytic Astrocytoma",
      "Oligodendroglioma",
      "Gliomatosis Cerebri",
      "Pleomorphic Xanthoastrocytoma",
      "Anaplastic Pleomorphic Xanthoastrocytoma",
      "Diffuse Midline Glioma, H3 K27M-Mutant",
      "Ependymoma",
      "Ependymoma, Anaplastic",
      "Medulloblastoma",
      "Teratoid Rhabdoid Tumor",
      "Neuroectodermal Tumors, Primitive",
      "Neuroectodermal Tumors",
      "Anaplastic Meningioma",
      "Atypical Meningioma",
      "Choroid Plexus Neoplasms",
      "Pineal Tumor",
      "Diffuse Astrocytoma",
      "Glial Tumor"
    ],
    "interventions": [
      "ONC206"
    ],
    "primary_completion_date": "2026-07",
    "completion_date": "2026-12",
    "results_first_posted": null,
    "last_update_posted": "2025-12-18",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT05391724",
    "title": "Safety and Pharmacokinetics of CMX001 in Impaired Hepatic Function and Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatic Impairment"
    ],
    "interventions": [
      "CMX001"
    ],
    "primary_completion_date": "2011-09",
    "completion_date": "2011-09",
    "results_first_posted": null,
    "last_update_posted": "2022-05-26",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT01161641",
    "title": "Pilot/Ph I Safety and Efficacy of ODSH in Protein Losing Enteropathy Secondary to Single Ventricle Palliative Surgery",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Protein Losing Enteropathy"
    ],
    "interventions": [
      "ODSH at 0.125 mg/kg/h",
      "ODSH at 0.375 mg/kg/h",
      "ODSH at 0.250 mg/kg/h"
    ],
    "primary_completion_date": "2012-02",
    "completion_date": "2012-02",
    "results_first_posted": null,
    "last_update_posted": "2021-12-02",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT01843634",
    "title": "Ph I Safety and Efficacy of ODSH in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia",
    "status": "COMPLETED",
    "phase": "EARLY_PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Myeloid Leukemia"
    ],
    "interventions": [
      "ODSH"
    ],
    "primary_completion_date": "2015-04",
    "completion_date": "2015-04",
    "results_first_posted": null,
    "last_update_posted": "2021-11-10",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT05651152",
    "title": "A Study to Investigate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JZP441 in Sleep-deprived Healthy Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants"
    ],
    "interventions": [
      "JZP441",
      "Placebo"
    ],
    "primary_completion_date": "2023-11-15",
    "completion_date": "2023-11-15",
    "results_first_posted": null,
    "last_update_posted": "2024-07-30",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT00598078",
    "title": "Multiple-dose,Double-blind,Placebo-controlled Study of Sodium Oxybate in Patients With Essential Tremor",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Essential Tremor"
    ],
    "interventions": [
      "Sodium Oxybate",
      "Sodium Oxybate",
      "Placebo"
    ],
    "primary_completion_date": "2008-08",
    "completion_date": "2008-12",
    "results_first_posted": "2012-01-23",
    "last_update_posted": "2012-01-23",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT01681121",
    "title": "A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Narcolepsy"
    ],
    "interventions": [
      "ADX-N05",
      "Placebo"
    ],
    "primary_completion_date": "2013-08",
    "completion_date": "2013-08",
    "results_first_posted": "2014-09-11",
    "last_update_posted": "2021-05-28",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT01217112",
    "title": "GWMD1092 - GWP42003 : GWP42004 Together Plus Alone in Type II Diabetes",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dyslipidemias",
      "Diabetes Mellitus, Type 2"
    ],
    "interventions": [
      "GWP42003",
      "GWP42003",
      "GWP42004",
      "Placebo"
    ],
    "primary_completion_date": "2012-05",
    "completion_date": "2012-09",
    "results_first_posted": "2014-01-20",
    "last_update_posted": "2022-10-18",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT06143839",
    "title": "VYxeoS Liposomal Italian Observational Study iN the Real Practice",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Acute Myeloid Leukemia (AML)",
      "Acute Myeloid Leukemia With Myelodysplasia-Related Changes",
      "Therapy-Related Acute Myeloid Leukemia"
    ],
    "interventions": [
      "Vyxeos liposomal"
    ],
    "primary_completion_date": "2025-10-23",
    "completion_date": "2025-10-23",
    "results_first_posted": null,
    "last_update_posted": "2025-11-20",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT01143181",
    "title": "Study to Assess Brincidofovir Treatment of Serious Diseases or Conditions Caused by Double-stranded DNA Viruses",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Double-stranded DNA Virus"
    ],
    "interventions": [
      "Brincidofovir"
    ],
    "primary_completion_date": "2012-12",
    "completion_date": "2012-12",
    "results_first_posted": "2021-08-12",
    "last_update_posted": "2021-08-12",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT03101241",
    "title": "A Phase 2 RCT Study of CX-8998 for Essential Tremor",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Essential Tremor"
    ],
    "interventions": [
      "CX-8998",
      "Placebo"
    ],
    "primary_completion_date": "2018-07-16",
    "completion_date": "2018-07-16",
    "results_first_posted": "2021-10-22",
    "last_update_posted": "2021-11-23",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT03526926",
    "title": "A Post-Marketing Observational Study of VYXEOS\u2122",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Acute Myeloid Leukemia With Myelodysplasia-Related Changes",
      "Therapy-Related Acute Myeloid Leukemia"
    ],
    "interventions": [
      "CPX-351"
    ],
    "primary_completion_date": "2019-10-26",
    "completion_date": "2020-06-12",
    "results_first_posted": null,
    "last_update_posted": "2020-08-05",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT03295396",
    "title": "ONC201 in Adults With Recurrent H3 K27M-mutant Glioma",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Glioma"
    ],
    "interventions": [
      "Dordaviprone (ONC201)"
    ],
    "primary_completion_date": "2022-12-31",
    "completion_date": "2023-07-19",
    "results_first_posted": "2025-07-28",
    "last_update_posted": "2025-07-28",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02544750",
    "title": "An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Tuberous Sclerosis Complex",
      "Seizures"
    ],
    "interventions": [
      "GWP42003-P"
    ],
    "primary_completion_date": "2021-06-11",
    "completion_date": "2021-06-11",
    "results_first_posted": "2022-07-14",
    "last_update_posted": "2022-07-14",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02596997",
    "title": "Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease",
    "status": "NO_LONGER_AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Adenovirus"
    ],
    "interventions": [
      "Brincidofovir"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2022-03-14",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02369471",
    "title": "A Study of GWP42006 in People With Focal Seizures - Part A",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Epilepsy",
      "Focal Seizures"
    ],
    "interventions": [
      "GWP42006",
      "Placebo"
    ],
    "primary_completion_date": "2015-10",
    "completion_date": "2015-11",
    "results_first_posted": null,
    "last_update_posted": "2022-12-20",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02565108",
    "title": "A Randomized Controlled Trial to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Epilepsy"
    ],
    "interventions": [
      "GWP42003-P 20 mg/kg/Day Dose",
      "Placebo",
      "Clobazam"
    ],
    "primary_completion_date": "2016-07-21",
    "completion_date": "2016-07-21",
    "results_first_posted": "2018-08-23",
    "last_update_posted": "2022-09-28",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT04943952",
    "title": "JZP458 - Recombinant Erwinia Asparaginase for Treatment of ALL / LBL Patients With Hypersensitivity to E. Coli-derived Asparaginase",
    "status": "APPROVED_FOR_MARKETING",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Acute Lymphoblastic Leukemia",
      "Lymphoblastic Lymphoma"
    ],
    "interventions": [
      "Asparaginase Erwinia Chrysanthemi (recombinant)"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2021-08-03",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT00628498",
    "title": "Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatic Veno-Occlusive Disease"
    ],
    "interventions": [
      "Defibrotide",
      "Defibrotide"
    ],
    "primary_completion_date": "2016-07",
    "completion_date": "2016-09",
    "results_first_posted": "2017-11-30",
    "last_update_posted": "2017-11-30",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02348593",
    "title": "\"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy\"",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Narcolepsy"
    ],
    "interventions": [
      "JZP-110",
      "Placebo oral tablet"
    ],
    "primary_completion_date": "2017-02",
    "completion_date": "2017-02",
    "results_first_posted": "2019-07-23",
    "last_update_posted": "2019-07-23",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT04466891",
    "title": "A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HER2-amplified Biliary Tract Cancers"
    ],
    "interventions": [
      "ZW25 (Zanidatamab)"
    ],
    "primary_completion_date": "2023-07-28",
    "completion_date": "2024-07-11",
    "results_first_posted": "2024-08-21",
    "last_update_posted": "2025-09-15",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT03037203",
    "title": "A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Excessive Sleepiness",
      "Parkinson Disease"
    ],
    "interventions": [
      "JZP-110",
      "Placebo"
    ],
    "primary_completion_date": "2018-08",
    "completion_date": "2018-08",
    "results_first_posted": "2020-01-09",
    "last_update_posted": "2020-01-09",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT05631327",
    "title": "A JZP341 Study in Adult Participants With Advanced or Metastatic Solid Tumors",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumor",
      "Metastatic Solid Tumor"
    ],
    "interventions": [
      "JZP341"
    ],
    "primary_completion_date": "2024-04-24",
    "completion_date": "2024-04-24",
    "results_first_posted": null,
    "last_update_posted": "2024-05-28",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT01610713",
    "title": "An Study to Investigate the Efficacy of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple Sclerosis"
    ],
    "interventions": [
      "GW-1000-02"
    ],
    "primary_completion_date": "2002-07",
    "completion_date": "2002-07",
    "results_first_posted": "2012-09-19",
    "last_update_posted": "2023-01-10",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT04578444",
    "title": "An Expanded Access Treatment Protocol of Zanidatamab (ZW25) in Patients With HER2-Positive Advanced Biliary Tract Cancer",
    "status": "NO_LONGER_AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "HER2-Positive Advanced Biliary Tract Cancer"
    ],
    "interventions": [
      "Zanidatamab"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2025-05-25",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT01696084",
    "title": "Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "High Risk Acute Myeloid Leukemia"
    ],
    "interventions": [
      "CPX-351",
      "7+3 (cytarabine and daunorubicin)"
    ],
    "primary_completion_date": "2015-12-31",
    "completion_date": "2015-12-31",
    "results_first_posted": "2017-10-02",
    "last_update_posted": "2020-08-10",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT04794491",
    "title": "An Interventional Safety Switch Study (Segue Study) of XYWAV in Narcolepsy",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Narcolepsy"
    ],
    "interventions": [
      "JZP-258"
    ],
    "primary_completion_date": "2022-11-15",
    "completion_date": "2022-11-15",
    "results_first_posted": "2024-01-09",
    "last_update_posted": "2024-01-09",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT05169307",
    "title": "CPX-351 Real-World Effectiveness and Safety Study",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Acute Myeloid Leukemia"
    ],
    "interventions": [
      "CPX-351"
    ],
    "primary_completion_date": "2022-06-15",
    "completion_date": "2022-06-15",
    "results_first_posted": null,
    "last_update_posted": "2022-07-12",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02953548",
    "title": "Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Infantile Spasms"
    ],
    "interventions": [
      "GWP42003-P"
    ],
    "primary_completion_date": "2018-05-07",
    "completion_date": "2018-05-07",
    "results_first_posted": "2020-07-23",
    "last_update_posted": "2022-09-02",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT03848832",
    "title": "Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rett Syndrome",
      "RTT"
    ],
    "interventions": [
      "GWP42003-P",
      "Placebo"
    ],
    "primary_completion_date": "2021-01-21",
    "completion_date": "2021-01-21",
    "results_first_posted": "2021-12-29",
    "last_update_posted": "2022-09-02",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02863991",
    "title": "Oral ONC201 in Relapsed/Refractory Multiple Myeloma",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple Myeloma"
    ],
    "interventions": [
      "ONC201",
      "Dexamethasone"
    ],
    "primary_completion_date": "2019-09-17",
    "completion_date": "2019-12-16",
    "results_first_posted": "2024-07-03",
    "last_update_posted": "2024-07-03",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT04803786",
    "title": "A Patient-Centric, Prospective, Observational, Non-Interventional Switch Study of XYWAV in Narcolepsy",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Narcolepsy"
    ],
    "interventions": [
      "Transition from Xyrem to Xywav"
    ],
    "primary_completion_date": "2022-02-24",
    "completion_date": "2022-02-24",
    "results_first_posted": null,
    "last_update_posted": "2022-06-30",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT01337089",
    "title": "Long Term Safety of Sativex Oromucosal Spray (Sativex\u00ae; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pain",
      "Advanced Cancer"
    ],
    "interventions": [
      "Nabiximols"
    ],
    "primary_completion_date": "2016-01-27",
    "completion_date": "2016-01-27",
    "results_first_posted": "2018-04-23",
    "last_update_posted": "2023-04-12",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT01964547",
    "title": "A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple Sclerosis",
      "Spasticity"
    ],
    "interventions": [
      "Sativex",
      "Placebo"
    ],
    "primary_completion_date": "2013-05",
    "completion_date": "2013-05",
    "results_first_posted": "2014-05-02",
    "last_update_posted": "2023-01-12",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT03406702",
    "title": "CX-8998 for Absence Seizures",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Epilepsy"
    ],
    "interventions": [
      "CX-8998"
    ],
    "primary_completion_date": "2019-03-29",
    "completion_date": "2019-03-29",
    "results_first_posted": "2022-09-08",
    "last_update_posted": "2022-09-08",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT03436953",
    "title": "A Phase 2 Study of CX-8998 in Adults With Tremor Associated With Parkinson's Disease",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Parkinson's Disease",
      "Tremor"
    ],
    "interventions": [
      "CX-8998",
      "Placebo"
    ],
    "primary_completion_date": "2020-09",
    "completion_date": "2020-12",
    "results_first_posted": null,
    "last_update_posted": "2021-05-28",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT00713323",
    "title": "A Study to Compare the Safety and Tolerability of Sativex\u00ae in Patients With Neuropathic Pain.",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pain",
      "Peripheral Neuropathy"
    ],
    "interventions": [
      "Sativex\u00ae"
    ],
    "primary_completion_date": "2007-06",
    "completion_date": "2007-06",
    "results_first_posted": "2012-09-14",
    "last_update_posted": "2023-05-03",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT00675948",
    "title": "Study to Compare the Safety and Tolerability of Sativex\u00ae in Patients With Cancer Related Pain",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pain",
      "Cancer"
    ],
    "interventions": [
      "Sativex",
      "GW-2000-02"
    ],
    "primary_completion_date": "2006-09",
    "completion_date": "2006-09",
    "results_first_posted": "2012-09-13",
    "last_update_posted": "2023-05-03",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT00822094",
    "title": "Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Myeloid Leukemia"
    ],
    "interventions": [
      "CPX-351",
      "Intensive Salvage Therapy"
    ],
    "primary_completion_date": "2011-12",
    "completion_date": "2012-01",
    "results_first_posted": "2017-09-29",
    "last_update_posted": "2017-11-24",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02439957",
    "title": "A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cytomegalovirus Disease",
      "Kidney Transplant Infection"
    ],
    "interventions": [
      "Brincidofovir",
      "Valganciclovir"
    ],
    "primary_completion_date": "2016-05-15",
    "completion_date": "2016-07-31",
    "results_first_posted": "2021-07-16",
    "last_update_posted": "2021-07-16",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT04617002",
    "title": "Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas",
    "status": "APPROVED_FOR_MARKETING",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Glioma",
      "H3 K27M"
    ],
    "interventions": [
      "ONC201 (dordaviprone)"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2025-08-20",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT03416530",
    "title": "ONC201 in Pediatric H3 K27M Gliomas",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diffuse Intrinsic Pontine Glioma",
      "Glioma, Malignant"
    ],
    "interventions": [
      "Dordaviprone (ONC201)"
    ],
    "primary_completion_date": "2022-12-31",
    "completion_date": "2023-05-24",
    "results_first_posted": null,
    "last_update_posted": "2025-02-14",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT06282575",
    "title": "Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Biliary Tract Cancer"
    ],
    "interventions": [
      "Zanidatamab",
      "Cisplatin",
      "Gemcitabine",
      "Pembrolizumab",
      "Durvalumab"
    ],
    "primary_completion_date": "2028-12-01",
    "completion_date": "2030-04-01",
    "results_first_posted": null,
    "last_update_posted": "2026-01-20",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT00678795",
    "title": "A Parallel Group Study to Compare Sativex\u00ae With Placebo in the Treatment of Detrusor Overactivity in Patients With Multiple Sclerosis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Detrusor Overactivity",
      "Multiple Sclerosis"
    ],
    "interventions": [
      "Sativex\u00ae",
      "Placebo"
    ],
    "primary_completion_date": "2005-10",
    "completion_date": "2005-10",
    "results_first_posted": "2012-09-21",
    "last_update_posted": "2023-05-03",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02525692",
    "title": "Oral ONC201 in Adult Recurrent Glioblastoma",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Glioblastoma",
      "Diffuse Midline Glioma",
      "H3 K27M Glioma",
      "Thalamic Glioma",
      "Infratentorial Glioma",
      "Basal Ganglia Glioma"
    ],
    "interventions": [
      "Dordaviprone (ONC201)"
    ],
    "primary_completion_date": "2023-04-17",
    "completion_date": "2023-04-17",
    "results_first_posted": "2024-12-24",
    "last_update_posted": "2024-12-24",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02348606",
    "title": "\"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA\"",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Obstructive Sleep Apnea"
    ],
    "interventions": [
      "JZP-110",
      "Placebo oral tablet"
    ],
    "primary_completion_date": "2016-12",
    "completion_date": "2016-12",
    "results_first_posted": "2019-07-23",
    "last_update_posted": "2019-07-23",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT04224272",
    "title": "A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HER2+/HR+ Breast Cancer"
    ],
    "interventions": [
      "ZW25 (Zanidatamab)",
      "Palbociclib",
      "Fulvestrant"
    ],
    "primary_completion_date": "2023-04-28",
    "completion_date": "2025-06-30",
    "results_first_posted": "2024-08-14",
    "last_update_posted": "2025-08-01",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT06108050",
    "title": "JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumor",
      "Metastatic Solid Tumor"
    ],
    "interventions": [
      "JZP898",
      "Pembrolizumab"
    ],
    "primary_completion_date": "2027-11-30",
    "completion_date": "2028-05-31",
    "results_first_posted": null,
    "last_update_posted": "2025-12-16",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02564952",
    "title": "An Open-label Extension Study to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Epilepsy"
    ],
    "interventions": [
      "GWP42003-P",
      "Clobazam"
    ],
    "primary_completion_date": "2017-06-07",
    "completion_date": "2017-06-07",
    "results_first_posted": "2018-09-11",
    "last_update_posted": "2022-09-28",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02365610",
    "title": "A Study of GWP42006 in People With Focal Seizures - Part B",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Epilepsy",
      "Focal Seizures"
    ],
    "interventions": [
      "GWP42006",
      "Placebo Control"
    ],
    "primary_completion_date": "2017-07",
    "completion_date": "2017-09",
    "results_first_posted": null,
    "last_update_posted": "2022-12-20",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02348632",
    "title": "\"A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA\"",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Narcolepsy",
      "Obstructive Sleep Apnea"
    ],
    "interventions": [
      "JZP-110"
    ],
    "primary_completion_date": "2017-12",
    "completion_date": "2017-12",
    "results_first_posted": "2019-06-25",
    "last_update_posted": "2019-06-25",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT04038437",
    "title": "A Trial of CPX-351 Lower Intensity Therapy (LIT) Plus Venetoclax as First Line Treatment for Subjects With AML",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Myeloid Leukemia"
    ],
    "interventions": [
      "CPX-351",
      "Venetoclax"
    ],
    "primary_completion_date": "2022-04-26",
    "completion_date": "2022-09-24",
    "results_first_posted": null,
    "last_update_posted": "2022-11-09",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT00681538",
    "title": "A Study of the Safety and Effectiveness of Sativex\u00ae, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Spasticity",
      "Multiple Sclerosis"
    ],
    "interventions": [
      "Sativex\u00ae",
      "Placebo"
    ],
    "primary_completion_date": "2009-01",
    "completion_date": "2009-01",
    "results_first_posted": "2011-12-07",
    "last_update_posted": "2023-05-06",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT04203498",
    "title": "Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple Sclerosis (MS)"
    ],
    "interventions": [
      "Nabiximols",
      "Placebo"
    ],
    "primary_completion_date": "2023-02-10",
    "completion_date": "2023-02-28",
    "results_first_posted": "2024-05-08",
    "last_update_posted": "2024-05-08",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT04291937",
    "title": "A Multicenter Expanded Access Treatment Protocol of Lurbinectedin in Previously Treated SCLC in the USA",
    "status": "APPROVED_FOR_MARKETING",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Small Cell Lung Cancer"
    ],
    "interventions": [
      "Lurbinectedin"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2020-06-19",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT05557045",
    "title": "A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Cancer",
      "Metastatic Cancer",
      "Solid Tumor"
    ],
    "interventions": [
      "JZP815"
    ],
    "primary_completion_date": "2028-04-01",
    "completion_date": "2028-04-01",
    "results_first_posted": null,
    "last_update_posted": "2025-02-04",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT00594945",
    "title": "Study of Intranasal Clonazepam in Adult Subjects With Epileptic Seizures",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Epilepsy"
    ],
    "interventions": [
      "Clonazepam"
    ],
    "primary_completion_date": "2008-12",
    "completion_date": "2009-06",
    "results_first_posted": "2014-07-01",
    "last_update_posted": "2014-07-01",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02238925",
    "title": "An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Myeloid Leukemia (AML)",
      "Acute Lymphoblastic Leukemia (ALL)",
      "Myelodysplastic Syndrome (MDS)"
    ],
    "interventions": [
      "CPX-351"
    ],
    "primary_completion_date": "2015-05",
    "completion_date": "2016-01",
    "results_first_posted": "2017-11-30",
    "last_update_posted": "2017-11-30",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT04899947",
    "title": "Child and Adolescent Registry for Participants With Narcolepsy",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Narcolepsy"
    ],
    "interventions": [],
    "primary_completion_date": "2024-10-01",
    "completion_date": "2024-10-01",
    "results_first_posted": null,
    "last_update_posted": "2024-08-15",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT00457951",
    "title": "A Study Designed to Evaluate ODSH in Subjects With Exacerbations of COPD",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Obstructive Pulmonary Disease"
    ],
    "interventions": [
      "Open-Label",
      "Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride",
      "ODSH"
    ],
    "primary_completion_date": "2009-08",
    "completion_date": "2009-10",
    "results_first_posted": "2016-12-16",
    "last_update_posted": "2021-12-02",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT01887301",
    "title": "Assessment of the Single Dose Pharmacokinetics and Tolerability of Sativex in Patients With Impaired Hepatic Function and Healthy Patients",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatic Impairment"
    ],
    "interventions": [
      "Sativex"
    ],
    "primary_completion_date": "2014-05",
    "completion_date": "2014-05",
    "results_first_posted": null,
    "last_update_posted": "2022-12-20",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02439970",
    "title": "A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cytomegalovirus Disease"
    ],
    "interventions": [
      "Brincidofovir",
      "Valganciclovir"
    ],
    "primary_completion_date": "2016-01-30",
    "completion_date": "2016-01-30",
    "results_first_posted": "2021-07-16",
    "last_update_posted": "2021-07-16",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT03485729",
    "title": "ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Endometrial Cancer Recurrent"
    ],
    "interventions": [
      "Dordaviprone (ONC201)"
    ],
    "primary_completion_date": "2023-01-19",
    "completion_date": "2023-01-19",
    "results_first_posted": "2024-12-24",
    "last_update_posted": "2024-12-24",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT00361842",
    "title": "Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Cancer",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Colorectal Neoplasms"
    ],
    "interventions": [
      "CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection"
    ],
    "primary_completion_date": "2008-12",
    "completion_date": "2008-12",
    "results_first_posted": "2021-07-02",
    "last_update_posted": "2021-07-02",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT03555955",
    "title": "A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hematologic Malignancy",
      "Acute Myeloid Leukemia",
      "Acute Lymphocytic Leukemia",
      "Acute Lymphoblastic Leukemia",
      "Myelodysplastic Syndromes"
    ],
    "interventions": [
      "CPX-351",
      "CPX-351"
    ],
    "primary_completion_date": "2021-05-26",
    "completion_date": "2021-05-26",
    "results_first_posted": null,
    "last_update_posted": "2021-07-22",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT00371137",
    "title": "A Safety and Efficacy Study of Xyrem\u00ae in Subjects With Fibromyalgia",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fibromyalgia"
    ],
    "interventions": [
      "Xyrem\u00ae",
      "Placebo"
    ],
    "primary_completion_date": "2008-09",
    "completion_date": "2008-12",
    "results_first_posted": "2011-11-30",
    "last_update_posted": "2011-12-29",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT00066170",
    "title": "Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Narcolepsy"
    ],
    "interventions": [
      "Xyrem",
      "Xyrem Placebo",
      "Modafinil at established dose",
      "Modafinil (Placebo)"
    ],
    "primary_completion_date": "2004-07",
    "completion_date": "2004-11",
    "results_first_posted": "2011-11-30",
    "last_update_posted": "2011-12-29",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02257684",
    "title": "A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered as Intravenous (IV) Infusion in Children and Young Adults With Acute Lymphoblastic Leukemia (ALL) /Lymphoblastic Lymphoma (LBL). Following Hypersensitivity to Pegaspargase (Oncaspar)",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Lymphoblastic Leukemia",
      "Lymphoblastic Lymphoma"
    ],
    "interventions": [
      "pegcrisantaspase"
    ],
    "primary_completion_date": "2015-02",
    "completion_date": "2016-01",
    "results_first_posted": "2017-02-23",
    "last_update_posted": "2017-04-04",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT03954106",
    "title": "A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "DLBCL",
      "Neurotoxicity Syndromes"
    ],
    "interventions": [
      "Defibrotide"
    ],
    "primary_completion_date": "2020-09-18",
    "completion_date": "2020-09-30",
    "results_first_posted": "2021-12-09",
    "last_update_posted": "2021-12-09",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02006628",
    "title": "A Study of GWP42003 as Adjunctive Therapy in the First Line Treatment of Schizophrenia or Related Psychotic Disorder",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia",
      "Schizophrenia-related Psychotic Disorder"
    ],
    "interventions": [
      "Placebo",
      "GWP42003"
    ],
    "primary_completion_date": "2015-01-08",
    "completion_date": "2015-01-08",
    "results_first_posted": "2019-07-26",
    "last_update_posted": "2022-09-28",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02420080",
    "title": "A Multicenter Study to Obtain Retrospective Data for Subjects Previously Diagnosed With Adenovirus Infection to Serve as Matched Historical Controls for Study CMX001-304",
    "status": "TERMINATED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Adenovirus"
    ],
    "interventions": [
      "Brincidofovir"
    ],
    "primary_completion_date": "2016-06",
    "completion_date": "2016-09",
    "results_first_posted": null,
    "last_update_posted": "2017-01-09",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02851407",
    "title": "Study Comparing Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Veno-occlusive Disease"
    ],
    "interventions": [
      "Defibrotide",
      "Best Supportive Care"
    ],
    "primary_completion_date": "2020-10-20",
    "completion_date": "2020-10-20",
    "results_first_posted": "2022-03-02",
    "last_update_posted": "2022-03-02",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT00803023",
    "title": "Safety and Tolerability Study Comparing Sodium Oxybate Given as an Oral Solution to a Single-blinded Combination of Oral Tablets Plus Oral Solution in Subjects With Fibromyalgia",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fibromyalgia"
    ],
    "interventions": [
      "Sodium Oxybate",
      "Sodium Oxybate & 6 Tablets",
      "Sodium Oxybate & 8 Tablets",
      "Sodium Oxybate Oral Solution (6 grams)"
    ],
    "primary_completion_date": "2010-07",
    "completion_date": null,
    "results_first_posted": "2011-08-16",
    "last_update_posted": "2011-08-19",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT03339401",
    "title": "The AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Adenovirus"
    ],
    "interventions": [
      "Standard of Care",
      "Brincidofovir"
    ],
    "primary_completion_date": "2019-05-10",
    "completion_date": "2019-05-10",
    "results_first_posted": "2021-01-25",
    "last_update_posted": "2021-01-25",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT01812616",
    "title": "A Safety Study of Sativex Compared With Placebo (Both With Dose-intense Temozolomide) in Recurrent Glioblastoma Patients",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cancer"
    ],
    "interventions": [
      "Sativex",
      "Placebo"
    ],
    "primary_completion_date": "2016-06",
    "completion_date": "2016-06",
    "results_first_posted": null,
    "last_update_posted": "2022-12-20",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02087306",
    "title": "Study to Assess the Safety and Efficacy of Brincidofovir in Treatment of Early Versus Late Adenovirus Infection",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Adenovirus Infection"
    ],
    "interventions": [
      "Brincidofovir"
    ],
    "primary_completion_date": "2016-06",
    "completion_date": "2016-08",
    "results_first_posted": "2021-08-13",
    "last_update_posted": "2021-08-13",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT04133480",
    "title": "Investigation of Cognitive Outcomes With Cannabidiol Oral Solution",
    "status": "WITHDRAWN",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lennox-Gastaut Syndrome"
    ],
    "interventions": [
      "GWP42003-P"
    ],
    "primary_completion_date": "2021-12",
    "completion_date": "2021-12",
    "results_first_posted": null,
    "last_update_posted": "2022-09-01",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT01898520",
    "title": "A Safety, Efficacy and Tolerability Study of Sativex for the Treatment of Spasticity in Children Aged 8 to 18 Years",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cerebral Palsy"
    ],
    "interventions": [
      "Sativex",
      "Placebo"
    ],
    "primary_completion_date": "2016-09",
    "completion_date": "2017-03",
    "results_first_posted": null,
    "last_update_posted": "2022-12-20",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT00788892",
    "title": "Trial of CPX-351 in Newly Diagnosed Elderly AML Patients",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Myeloid Leukemia"
    ],
    "interventions": [
      "CPX-351",
      "Cytarabine",
      "Daunorubicin"
    ],
    "primary_completion_date": "2010-06",
    "completion_date": "2011-12",
    "results_first_posted": "2018-01-12",
    "last_update_posted": "2018-01-12",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02533115",
    "title": "EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML",
    "status": "APPROVED_FOR_MARKETING",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Secondary AML"
    ],
    "interventions": [
      "CPX-351"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2017-08-22",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02892123",
    "title": "Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HER2-expressing Cancers"
    ],
    "interventions": [
      "ZW25 (Zanidatamab)",
      "Paclitaxel",
      "Capecitabine",
      "Vinorelbine",
      "Tucatinib",
      "Tucatinib"
    ],
    "primary_completion_date": "2024-10-31",
    "completion_date": "2024-10-31",
    "results_first_posted": null,
    "last_update_posted": "2024-11-27",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT06435429",
    "title": "A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic HER2-positive Breast Cancer"
    ],
    "interventions": [
      "Zanidatamab",
      "Trastuzumab",
      "Eribulin",
      "Vinorelbine",
      "Gemcitabine",
      "Capecitabine"
    ],
    "primary_completion_date": "2028-09-26",
    "completion_date": "2031-11-26",
    "results_first_posted": null,
    "last_update_posted": "2025-12-02",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT00702468",
    "title": "Evaluate the Maintenance of Effect After Long-term Treatment With Sativex\u00ae in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Spasticity",
      "Multiple Sclerosis"
    ],
    "interventions": [
      "Sativex",
      "Placebo"
    ],
    "primary_completion_date": "2009-01",
    "completion_date": "2009-01",
    "results_first_posted": "2011-06-17",
    "last_update_posted": "2023-05-06",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02053272",
    "title": "A Study of GWP42004 as Add on to Metformin in the Treatment of Participants With Type 2 Diabetes",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes Mellitus, Type 2"
    ],
    "interventions": [
      "GWP42004",
      "Placebo"
    ],
    "primary_completion_date": "2016-02",
    "completion_date": "2016-02",
    "results_first_posted": null,
    "last_update_posted": "2022-12-20",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT01461915",
    "title": "Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Pancreatic Cancer"
    ],
    "interventions": [
      "Nab paclitaxel",
      "Gemcitabine",
      "Dociparstat"
    ],
    "primary_completion_date": "2012-12",
    "completion_date": "2015-06",
    "results_first_posted": null,
    "last_update_posted": "2022-06-06",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT00106860",
    "title": "A Long-Term Study Continuing on From Study 04-001-01 of an Experimental Medication in Adults With Anxiety Disorder",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Anxiety Disorder"
    ],
    "interventions": [
      "a benzodiazepine drug"
    ],
    "primary_completion_date": null,
    "completion_date": "2006-03",
    "results_first_posted": null,
    "last_update_posted": "2008-01-09",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02769780",
    "title": "A Web-based Observational Study of Patient-reported Outcomes in Adults With Narcolepsy",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Narcolepsy"
    ],
    "interventions": [],
    "primary_completion_date": "2021-08-09",
    "completion_date": "2021-08-09",
    "results_first_posted": null,
    "last_update_posted": "2022-04-05",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT00670696",
    "title": "A Study to Compare the Efficacy of Rapydan Versus Tetracaine Gel",
    "status": "WITHDRAWN",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy",
      "Anesthesia"
    ],
    "interventions": [
      "Rapydan",
      "tetracaine gel"
    ],
    "primary_completion_date": "2008-12",
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2012-04-25",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02038699",
    "title": "A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer",
    "status": "WITHDRAWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Glioblastoma",
      "Advanced Colorectal Cancer",
      "Advanced Triple-negative Breast Cancer",
      "Advanced Non-small Cell Lung Cancer"
    ],
    "interventions": [
      "ONC201"
    ],
    "primary_completion_date": "2015-12",
    "completion_date": "2016-12",
    "results_first_posted": null,
    "last_update_posted": "2021-04-30",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02607904",
    "title": "An Open-label Extension Trial to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Epilepsy"
    ],
    "interventions": [
      "GWP42003-P"
    ],
    "primary_completion_date": "2019-05-27",
    "completion_date": "2019-05-27",
    "results_first_posted": null,
    "last_update_posted": "2022-12-20",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT01424566",
    "title": "A Two-Part Study of Sativex\u00ae Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pain",
      "Advanced Cancer"
    ],
    "interventions": [
      "Nabiximols",
      "Placebo (GA-0034)"
    ],
    "primary_completion_date": "2015-07-10",
    "completion_date": "2015-12-28",
    "results_first_posted": "2018-04-23",
    "last_update_posted": "2023-04-12",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT04657666",
    "title": "Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Spasticity in Participants With Multiple Sclerosis"
    ],
    "interventions": [
      "Nabiximols",
      "Placebo"
    ],
    "primary_completion_date": "2022-05-04",
    "completion_date": "2022-05-10",
    "results_first_posted": "2023-07-20",
    "last_update_posted": "2023-07-20",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT07282587",
    "title": "Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Pheochromocytoma and Paraganglioma",
      "PCPG"
    ],
    "interventions": [
      "ONC206",
      "ONC206: Dose 1",
      "ONC206: Dose 2"
    ],
    "primary_completion_date": "2028-12-15",
    "completion_date": "2028-12-15",
    "results_first_posted": null,
    "last_update_posted": "2025-12-15",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT05720494",
    "title": "A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JZP441 in Healthy Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants"
    ],
    "interventions": [
      "JZP441",
      "Placebo"
    ],
    "primary_completion_date": "2023-09-29",
    "completion_date": "2023-09-29",
    "results_first_posted": null,
    "last_update_posted": "2024-10-01",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT06695845",
    "title": "A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Cancer",
      "Gastric Cancer",
      "Esophageal Cancer",
      "Gastroesophageal Cancer",
      "Colorectal Cancer",
      "Endometrial Cancer",
      "Non-small Cell Lung Cancer",
      "Ovarian Cancer",
      "Urothelial Carcinoma",
      "Salivary Gland Cancer",
      "Pancreatic Cancer",
      "HER-2 Protein Overexpression"
    ],
    "interventions": [
      "Zanidatamab"
    ],
    "primary_completion_date": "2026-12-31",
    "completion_date": "2027-12-31",
    "results_first_posted": null,
    "last_update_posted": "2026-01-22",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT05027139",
    "title": "A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HER2-expressing Cancers"
    ],
    "interventions": [
      "Zanidatamab",
      "Evorpacept"
    ],
    "primary_completion_date": "2025-07-07",
    "completion_date": "2025-09-30",
    "results_first_posted": null,
    "last_update_posted": "2025-10-16",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT04571645",
    "title": "Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Myeloid Leukemia"
    ],
    "interventions": [
      "Dociparstat",
      "Control"
    ],
    "primary_completion_date": "2022-05-16",
    "completion_date": "2022-05-16",
    "results_first_posted": "2024-04-15",
    "last_update_posted": "2024-04-15",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02325011",
    "title": "An Study to Evaluate the Effects of Fluconazole on the Pharmacokinetics (PK) of Sativex\u00ae in Healthy Subjects With Cannabis Experience.",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Subjects"
    ],
    "interventions": [
      "Sativex\u00ae (Treatment A)",
      "Sativex\u00ae and fluconazole concomitantly (Treatment B)"
    ],
    "primary_completion_date": "2015-02",
    "completion_date": "2015-02",
    "results_first_posted": null,
    "last_update_posted": "2022-12-20",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT04389840",
    "title": "Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Coronavirus Disease 2019 (COVID-19)",
      "Acute Lung Injury",
      "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)"
    ],
    "interventions": [
      "Dociparstat sodium",
      "Placebo"
    ],
    "primary_completion_date": "2021-05-20",
    "completion_date": "2021-05-20",
    "results_first_posted": "2022-08-30",
    "last_update_posted": "2022-08-30",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT01610687",
    "title": "A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple Sclerosis",
      "Spasticity"
    ],
    "interventions": [
      "GW-1000-02"
    ],
    "primary_completion_date": "2005-02",
    "completion_date": "2005-02",
    "results_first_posted": "2012-08-17",
    "last_update_posted": "2023-01-10",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT04984278",
    "title": "Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Spasticity With Multiple Sclerosis"
    ],
    "interventions": [
      "Nabiximols",
      "Placebo"
    ],
    "primary_completion_date": "2022-11-11",
    "completion_date": "2022-11-11",
    "results_first_posted": "2024-02-05",
    "last_update_posted": "2024-12-11",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT03032016",
    "title": "European VOD Registry",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Hepatic Veno-Occlusive Disease"
    ],
    "interventions": [],
    "primary_completion_date": "2019-07",
    "completion_date": "2019-07",
    "results_first_posted": null,
    "last_update_posted": "2019-10-16",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT01606176",
    "title": "A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pain",
      "Multiple Sclerosis"
    ],
    "interventions": [
      "GW-1000-02",
      "Placebo"
    ],
    "primary_completion_date": "2002-08",
    "completion_date": "2002-08",
    "results_first_posted": "2012-08-24",
    "last_update_posted": "2023-01-10",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT03533114",
    "title": "A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Idiopathic Hypersomnia"
    ],
    "interventions": [
      "JZP-258",
      "Placebo Oral Solution"
    ],
    "primary_completion_date": "2020-06-12",
    "completion_date": "2020-12-18",
    "results_first_posted": "2021-11-24",
    "last_update_posted": "2021-11-24",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT01606189",
    "title": "A Study to Compare Sublingual Cannabis Based Medicine Extracts With Placebo to Treat Brachial Plexus Injury Pain",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pain"
    ],
    "interventions": [
      "GW-1000-02",
      "GW-2000-02",
      "Placebo"
    ],
    "primary_completion_date": "2002-09",
    "completion_date": "2002-09",
    "results_first_posted": "2012-11-19",
    "last_update_posted": "2023-01-10",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT05392374",
    "title": "Expanded Access Use of ONC201 in a Patient With Diffuse Intrinsic Pontine Gliomas",
    "status": "NO_LONGER_AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Glioma"
    ],
    "interventions": [
      "ONC201"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2022-05-26",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT00942305",
    "title": "Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cytomegalovirus Infection"
    ],
    "interventions": [
      "Brincidofovir",
      "Placebo"
    ],
    "primary_completion_date": "2012-01",
    "completion_date": "2012-01",
    "results_first_posted": "2021-07-16",
    "last_update_posted": "2021-07-16",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT06961266",
    "title": "A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy Type 1",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Narcolepsy"
    ],
    "interventions": [
      "JZP441",
      "Matching Placebo"
    ],
    "primary_completion_date": "2026-04-01",
    "completion_date": "2026-04-01",
    "results_first_posted": null,
    "last_update_posted": "2025-09-18",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT05734066",
    "title": "Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Refractory Ewing Sarcoma",
      "Relapsed Ewing Sarcoma",
      "Ewing Sarcoma"
    ],
    "interventions": [
      "Lurbinectedin"
    ],
    "primary_completion_date": "2026-12-01",
    "completion_date": "2027-06-01",
    "results_first_posted": null,
    "last_update_posted": "2025-01-23",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT04285788",
    "title": "Incidence and Outcomes Associated With the Management of Adenovirus Infections in Allogenic Hematopoietic Cell Transplant Recipients",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Adenovirus Infections, Human"
    ],
    "interventions": [],
    "primary_completion_date": "2015-09",
    "completion_date": "2017-01",
    "results_first_posted": null,
    "last_update_posted": "2022-03-25",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT05875974",
    "title": "A Study to Investigate the Effect of XYWAV on Sleepiness, Polysomnography, and Functional Outcomes in Participants With Idiopathic Hypersomnia or Narcolepsy",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Idiopathic Hypersomnia",
      "Narcolepsy"
    ],
    "interventions": [
      "JZP258 (XYWAV)"
    ],
    "primary_completion_date": "2025-03-13",
    "completion_date": "2025-03-13",
    "results_first_posted": null,
    "last_update_posted": "2025-07-17",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02167685",
    "title": "The Chimerix CMX001 Registry",
    "status": "TERMINATED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Outcomes",
      "Survival Rates"
    ],
    "interventions": [
      "CMX001"
    ],
    "primary_completion_date": "2019-05-10",
    "completion_date": "2019-05-10",
    "results_first_posted": null,
    "last_update_posted": "2019-05-17",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT01610700",
    "title": "An Investigation of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis Patients",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple Sclerosis"
    ],
    "interventions": [
      "GW-1000-02",
      "Placebo"
    ],
    "primary_completion_date": "2002-07",
    "completion_date": "2002-07",
    "results_first_posted": "2012-09-19",
    "last_update_posted": "2023-01-12",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT03030599",
    "title": "A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Narcolepsy With Cataplexy"
    ],
    "interventions": [
      "JZP-258",
      "Placebo"
    ],
    "primary_completion_date": "2019-01-24",
    "completion_date": "2019-07-10",
    "results_first_posted": "2020-11-12",
    "last_update_posted": "2020-11-12",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT04485104",
    "title": "Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Seizure in Participants With Tuberous Sclerosis Complex",
      "Seizure in Participants With Dravet Syndrome",
      "Seizure in Participants With Lennox-Gastaut Syndrome"
    ],
    "interventions": [
      "GWP42003-P"
    ],
    "primary_completion_date": "2025-01-28",
    "completion_date": "2025-01-28",
    "results_first_posted": "2025-10-31",
    "last_update_posted": "2025-10-31",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT01322139",
    "title": "Sativex Thorough QT/QTc Study",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Effects of Sativex on ECG"
    ],
    "interventions": [
      "Placebo spray and oral moxifloxacin placebo",
      "Sativex spray and oral moxifloxacin placebo",
      "Sativex spray and oral moxifloxacin placebo",
      "Placebo spray and moxifloxacin"
    ],
    "primary_completion_date": "2008-06",
    "completion_date": "2008-06",
    "results_first_posted": null,
    "last_update_posted": "2023-04-10",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT01599234",
    "title": "A Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity Due to Multiple Sclerosis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple Sclerosis"
    ],
    "interventions": [
      "Sativex",
      "Placebo"
    ],
    "primary_completion_date": "2005-12",
    "completion_date": "2005-12",
    "results_first_posted": "2012-08-16",
    "last_update_posted": "2023-05-03",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT05733390",
    "title": "A Study of JZP541 in Adults With Irritability Associated With Autism Spectrum Disorder",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Irritability Associated With Autism Spectrum Disorder",
      "Autism Spectrum Disorder",
      "ASD"
    ],
    "interventions": [
      "JZP541",
      "Placebo"
    ],
    "primary_completion_date": "2023-11-09",
    "completion_date": "2023-11-09",
    "results_first_posted": null,
    "last_update_posted": "2024-11-08",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT00358501",
    "title": "Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Severe Hepatic Veno-Occlusive Disease"
    ],
    "interventions": [
      "Defibrotide"
    ],
    "primary_completion_date": "2008-09",
    "completion_date": "2015-03",
    "results_first_posted": "2017-01-30",
    "last_update_posted": "2017-01-30",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT00711646",
    "title": "A Study of Sativex\u00ae for Relief of Spasticity in Subjects With Multiple Sclerosis.",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Spasticity",
      "Multiple Sclerosis"
    ],
    "interventions": [
      "Sativex\u00ae",
      "Placebo"
    ],
    "primary_completion_date": "2004-03",
    "completion_date": "2004-03",
    "results_first_posted": "2012-09-14",
    "last_update_posted": "2023-05-06",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT01812603",
    "title": "A Safety Study of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cancer"
    ],
    "interventions": [
      "Sativex"
    ],
    "primary_completion_date": "2015-01",
    "completion_date": "2016-06",
    "results_first_posted": null,
    "last_update_posted": "2022-12-20",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT01323569",
    "title": "Abuse Potential of Sativex",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Evaluation of Abuse Potential of Sativex"
    ],
    "interventions": [
      "Sativex",
      "Sativex",
      "Sativex",
      "Placebo",
      "Marinol",
      "Marinol"
    ],
    "primary_completion_date": "2008-06",
    "completion_date": "2008-06",
    "results_first_posted": null,
    "last_update_posted": "2023-04-10",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT01485770",
    "title": "A Study of the Safety and Effectiveness of ADX-N05 in the Treatment of Excessive Daytime Sleepiness",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Narcolepsy"
    ],
    "interventions": [
      "ADX-N05",
      "Placebo"
    ],
    "primary_completion_date": "2012-05",
    "completion_date": "2012-05",
    "results_first_posted": "2021-07-06",
    "last_update_posted": "2021-07-06",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT00097708",
    "title": "Experimental Medication For the Treatment of Generalized Anxiety Disorder",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Anxiety Disorder"
    ],
    "interventions": [
      "experimental anti-anxiety drug"
    ],
    "primary_completion_date": null,
    "completion_date": "2005-12",
    "results_first_posted": "2014-10-03",
    "last_update_posted": "2014-10-03",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02806908",
    "title": "Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in Narcolepsy",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Narcolepsy",
      "Excessive Sleepiness"
    ],
    "interventions": [
      "JZP-110",
      "Placebo"
    ],
    "primary_completion_date": "2019-05-19",
    "completion_date": "2019-05-19",
    "results_first_posted": "2021-01-13",
    "last_update_posted": "2021-01-13",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT05152147",
    "title": "A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Gastric Neoplasms",
      "Gastroesophageal Adenocarcinoma",
      "Esophageal Adenocarcinoma"
    ],
    "interventions": [
      "Zanidatamab",
      "Tislelizumab",
      "Trastuzumab",
      "Capecitabine",
      "Oxaliplatin",
      "Cisplatin",
      "5-Fluorouracil"
    ],
    "primary_completion_date": "2026-07-31",
    "completion_date": "2027-07-31",
    "results_first_posted": null,
    "last_update_posted": "2026-01-20",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT04268966",
    "title": "An Open-Label Study , Safety and Tolerability of Brincidofovir for Post Exposure Prophylaxis of Ebola",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ebola Virus Disease"
    ],
    "interventions": [
      "Brincidofovir"
    ],
    "primary_completion_date": "2015-11",
    "completion_date": "2015-12",
    "results_first_posted": null,
    "last_update_posted": "2020-02-26",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT03339297",
    "title": "An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Graft-versus-host Disease",
      "Acute-graft-versus-host Disease"
    ],
    "interventions": [
      "Defibrotide",
      "Standard of Care"
    ],
    "primary_completion_date": "2020-05-12",
    "completion_date": "2020-05-12",
    "results_first_posted": "2021-08-18",
    "last_update_posted": "2021-08-18",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT00423605",
    "title": "Safety and Efficacy Study of Xyrem\u00ae (Sodium Oxybate) in Subjects With Fibromyalgia.",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fibromyalgia"
    ],
    "interventions": [
      "Xyrem\u00ae"
    ],
    "primary_completion_date": "2010-01",
    "completion_date": "2010-01",
    "results_first_posted": "2011-10-20",
    "last_update_posted": "2012-03-30",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT05642442",
    "title": "A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Parkinson Disease",
      "Tremor"
    ],
    "interventions": [
      "Placebo",
      "Suvecaltamide"
    ],
    "primary_completion_date": "2024-10-23",
    "completion_date": "2024-11-11",
    "results_first_posted": "2026-01-15",
    "last_update_posted": "2026-01-15",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT05288283",
    "title": "Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Seizures Associated With EMAS"
    ],
    "interventions": [
      "GWP42003-P",
      "Placebo"
    ],
    "primary_completion_date": "2023-09-28",
    "completion_date": "2023-09-28",
    "results_first_posted": "2025-02-03",
    "last_update_posted": "2025-02-03",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT01918735",
    "title": "A Study of the Safety and Tolerability of GWP42006 in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Epilepsy"
    ],
    "interventions": [
      "Placebo",
      "GWP42006"
    ],
    "primary_completion_date": "2013-12",
    "completion_date": "2013-12",
    "results_first_posted": null,
    "last_update_posted": "2022-12-20",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT05122650",
    "title": "A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Essential Tremor"
    ],
    "interventions": [
      "JZP385",
      "Placebo"
    ],
    "primary_completion_date": "2024-05-30",
    "completion_date": "2024-05-30",
    "results_first_posted": "2025-07-24",
    "last_update_posted": "2025-07-24",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT00710424",
    "title": "A Study of Sativex\u00ae for Pain Relief Due to Diabetic Neuropathy",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pain",
      "Diabetic Neuropathy"
    ],
    "interventions": [
      "Sativex",
      "Placebo"
    ],
    "primary_completion_date": "2006-06",
    "completion_date": "2006-06",
    "results_first_posted": "2012-07-31",
    "last_update_posted": "2023-05-03",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT01551524",
    "title": "Phase I Study of mPEG-R-Crisantaspase Given IV",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hematologic Malignancies"
    ],
    "interventions": [
      "mPEG-r-crisantaspase"
    ],
    "primary_completion_date": "2015-02",
    "completion_date": "2015-02",
    "results_first_posted": null,
    "last_update_posted": "2015-05-07",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02607891",
    "title": "A Study of Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Epilepsy"
    ],
    "interventions": [
      "GWP42003-P",
      "Placebo"
    ],
    "primary_completion_date": "2018-09-11",
    "completion_date": "2018-10-02",
    "results_first_posted": null,
    "last_update_posted": "2022-12-20",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT00711880",
    "title": "A Study of Sativex\u00ae for Relief of Peripheral Neuropathic Pain Associated With Allodynia.",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pain",
      "Peripheral Neuropathy"
    ],
    "interventions": [
      "Sativex\u00ae",
      "Placebo"
    ],
    "primary_completion_date": "2004-03",
    "completion_date": "2004-03",
    "results_first_posted": "2012-09-28",
    "last_update_posted": "2023-04-12",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02806895",
    "title": "Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in OSA",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Obstructive Sleep Apnea",
      "Excessive Sleepiness"
    ],
    "interventions": [
      "JZP-110",
      "Placebo"
    ],
    "primary_completion_date": "2019-05-28",
    "completion_date": "2019-05-28",
    "results_first_posted": "2020-06-16",
    "last_update_posted": "2021-01-14",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT00674609",
    "title": "A Study of Sativex\u00ae for Pain Relief in Patients With Advanced Malignancy",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Palliative Care",
      "Pain",
      "Cancer"
    ],
    "interventions": [
      "Placebo",
      "Sativex\u00ae",
      "THC Alone"
    ],
    "primary_completion_date": "2004-02",
    "completion_date": "2004-03",
    "results_first_posted": "2012-08-13",
    "last_update_posted": "2023-05-03",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT01888120",
    "title": "Patient Registry of Intrathecal Ziconotide Management(PRIZM)",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Patients With Severe Chronic Pain"
    ],
    "interventions": [
      "Ziconotide"
    ],
    "primary_completion_date": "2017-01",
    "completion_date": "2017-03",
    "results_first_posted": null,
    "last_update_posted": "2017-03-16",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT01769170",
    "title": "A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "CMV"
    ],
    "interventions": [
      "Brincidofovir",
      "Placebo"
    ],
    "primary_completion_date": "2015-12",
    "completion_date": "2016-01",
    "results_first_posted": "2021-01-05",
    "last_update_posted": "2021-07-21",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT03929666",
    "title": "A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer"
    ],
    "interventions": [
      "ZW25 (Zanidatamab)",
      "Capecitabine",
      "Cisplatin",
      "Fluorouracil",
      "Leucovorin",
      "Oxaliplatin",
      "Bevacizumab",
      "Gemcitabine"
    ],
    "primary_completion_date": "2025-08-30",
    "completion_date": "2025-08-30",
    "results_first_posted": null,
    "last_update_posted": "2025-09-12",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT04421456",
    "title": "Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia"
    ],
    "interventions": [
      "GWP42003-P",
      "Placebo"
    ],
    "primary_completion_date": "2022-03-16",
    "completion_date": "2022-03-16",
    "results_first_posted": "2023-06-15",
    "last_update_posted": "2023-06-15",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT00086281",
    "title": "Trial of Effects of Oral Xyrem and Zolpidem on Sleep-Disordered Breathing in Obstructive Sleep Apnea Patients",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Obstructive Sleep Apnea Syndrome"
    ],
    "interventions": [
      "Xyrem (X)",
      "Zolpidem (Z)",
      "Modafinil (M)",
      "Placebo (P)"
    ],
    "primary_completion_date": "2005-06",
    "completion_date": "2005-11",
    "results_first_posted": "2012-02-24",
    "last_update_posted": "2012-02-24",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02091375",
    "title": "Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Epilepsy",
      "Dravet Syndrome"
    ],
    "interventions": [
      "GWP42003-P 20 mg/kg/day Dose",
      "Placebo control"
    ],
    "primary_completion_date": "2015-11-26",
    "completion_date": "2015-11-26",
    "results_first_posted": "2018-07-20",
    "last_update_posted": "2022-09-28",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT07102381",
    "title": "A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HER2-positive Breast Cancer",
      "Breast Cancer"
    ],
    "interventions": [
      "Zanidatamab",
      "Paclitaxel",
      "Docetaxel",
      "Carboplatin",
      "Trastuzumab",
      "Pertuzumab"
    ],
    "primary_completion_date": "2028-01-01",
    "completion_date": "2030-08-01",
    "results_first_posted": null,
    "last_update_posted": "2026-01-20",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT04745026",
    "title": "Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Autism Spectrum Disorder"
    ],
    "interventions": [
      "GWP42003-P",
      "Placebo"
    ],
    "primary_completion_date": "2023-12-21",
    "completion_date": "2023-12-21",
    "results_first_posted": "2025-03-30",
    "last_update_posted": "2025-03-30",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT06113237",
    "title": "Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancy",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Maternal Complications",
      "Pregnancy Complication",
      "Birth Outcomes, Adverse",
      "Pregnancy"
    ],
    "interventions": [
      "Epidiolex"
    ],
    "primary_completion_date": "2033-08-31",
    "completion_date": "2033-08-31",
    "results_first_posted": null,
    "last_update_posted": "2026-01-09",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT02224703",
    "title": "GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Epilepsy",
      "Dravet Syndrome"
    ],
    "interventions": [
      "GWP42003-P",
      "Placebo Control"
    ],
    "primary_completion_date": "2018-04-09",
    "completion_date": "2018-04-09",
    "results_first_posted": "2019-08-01",
    "last_update_posted": "2022-09-28",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "JAZZ",
    "nct_id": "NCT03134131",
    "title": "Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas",
    "status": "NO_LONGER_AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Glioma"
    ],
    "interventions": [
      "ONC201"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2022-03-14",
    "enrollment": null,
    "sponsor": "Jazz Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT07137195",
    "title": "Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS\u00ae PLUS (Hebei)",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor, Adult"
    ],
    "interventions": [
      "Proton Beam Therapy (PBT)"
    ],
    "primary_completion_date": "2026-09-05",
    "completion_date": "2031-07-31",
    "results_first_posted": null,
    "last_update_posted": "2025-08-22",
    "enrollment": null,
    "sponsor": "Ion Beam Applications",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT07152353",
    "title": "Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS\u00ae PLUS (Sichuan)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor, Adult"
    ],
    "interventions": [
      "Proton Beam Therapy (PBT)"
    ],
    "primary_completion_date": "2026-10",
    "completion_date": "2031-07",
    "results_first_posted": null,
    "last_update_posted": "2026-01-07",
    "enrollment": null,
    "sponsor": "Ion Beam Applications",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GOSS",
    "nct_id": "NCT05548283",
    "title": "Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study",
    "status": "RECRUITING",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cystic Fibrosis",
      "Cystic Fibrosis Pulmonary Exacerbation"
    ],
    "interventions": [
      "Beta-lactam antibiotic",
      "Aminoglycoside"
    ],
    "primary_completion_date": "2026-11-15",
    "completion_date": "2026-11-15",
    "results_first_posted": null,
    "last_update_posted": "2024-08-26",
    "enrollment": null,
    "sponsor": "Chris Goss",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GOSS",
    "nct_id": "NCT07312734",
    "title": "Study to Enable New Diagnostics for Pulmonary Microbes in People With CF",
    "status": "NOT_YET_RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Cystic Fibrosis (CF)",
      "New Diagnostics"
    ],
    "interventions": [],
    "primary_completion_date": "2027-08-01",
    "completion_date": "2027-08-01",
    "results_first_posted": null,
    "last_update_posted": "2025-12-31",
    "enrollment": null,
    "sponsor": "Chris Goss",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GOSS",
    "nct_id": "NCT03801993",
    "title": "Multicenter Study of Patient-reported Gastrointestinal Symptoms in People With Cystic Fibrosis",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Cystic Fibrosis"
    ],
    "interventions": [],
    "primary_completion_date": "2019-09-17",
    "completion_date": "2019-09-17",
    "results_first_posted": "2024-10-15",
    "last_update_posted": "2024-10-15",
    "enrollment": null,
    "sponsor": "Chris Goss",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GOSS",
    "nct_id": "NCT02781610",
    "title": "Standardized Treatment of Pulmonary Exacerbations II",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pulmonary Cystic Fibrosis"
    ],
    "interventions": [
      "Standard of care IV antibiotic(s)"
    ],
    "primary_completion_date": "2020-03-06",
    "completion_date": "2020-03-06",
    "results_first_posted": "2021-04-08",
    "last_update_posted": "2021-05-19",
    "enrollment": null,
    "sponsor": "Chris Goss",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GOSS",
    "nct_id": "NCT05263076",
    "title": "Uterine Transplant for Women With Absolute Uterine Factor Infertility (AUFI)",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Mayer Rokitansky Kuster Hauser Syndrome",
      "Absence of Uterus",
      "Infertility of Uterine Origin"
    ],
    "interventions": [
      "Uterine Transplant"
    ],
    "primary_completion_date": "2030-12",
    "completion_date": "2030-12",
    "results_first_posted": null,
    "last_update_posted": "2025-05-07",
    "enrollment": null,
    "sponsor": "John Goss",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GOSS",
    "nct_id": "NCT05285410",
    "title": "Observational Study Comparing Home to Office Spirometry",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Cystic Fibrosis"
    ],
    "interventions": [],
    "primary_completion_date": "2023-12-19",
    "completion_date": "2023-12-19",
    "results_first_posted": null,
    "last_update_posted": "2024-01-11",
    "enrollment": null,
    "sponsor": "Chris Goss",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GOSS",
    "nct_id": "NCT04294043",
    "title": "IV Gallium Study for Patients With Cystic Fibrosis Who Have NTM (ABATE Study)",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Nontuberculous Mycobacterium Infection"
    ],
    "interventions": [
      "Gallium nitrate"
    ],
    "primary_completion_date": "2027-03-31",
    "completion_date": "2027-03-31",
    "results_first_posted": null,
    "last_update_posted": "2025-10-01",
    "enrollment": null,
    "sponsor": "Chris Goss",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RNA",
    "nct_id": "NCT04064905",
    "title": "Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Zika Virus"
    ],
    "interventions": [
      "mRNA-1893",
      "Placebo"
    ],
    "primary_completion_date": "2021-03-22",
    "completion_date": "2021-03-22",
    "results_first_posted": "2024-06-17",
    "last_update_posted": "2024-08-21",
    "enrollment": null,
    "sponsor": "ModernaTX, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RNA",
    "nct_id": "NCT06694389",
    "title": "Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults \u226550 Years of Age",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID-19",
      "Influenza"
    ],
    "interventions": [
      "mRNA-1083",
      "Placebo",
      "Licensed Influenza Vaccine",
      "SARS-CoV-2 Vaccine"
    ],
    "primary_completion_date": "2025-11-17",
    "completion_date": "2025-11-17",
    "results_first_posted": null,
    "last_update_posted": "2025-12-02",
    "enrollment": null,
    "sponsor": "ModernaTX, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RNA",
    "nct_id": "NCT05708014",
    "title": "Personalized Prevention for Couples: A 16-month Digital RCT",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hiv",
      "HIV Infections",
      "Sexually Transmitted Infection",
      "Sexually Transmitted Diseases",
      "Sexual Behavior",
      "Risk Reduction"
    ],
    "interventions": [
      "Intervention LuvHub",
      "Waitlist Control LuvHub"
    ],
    "primary_completion_date": "2025-08-25",
    "completion_date": "2025-08-25",
    "results_first_posted": null,
    "last_update_posted": "2025-09-17",
    "enrollment": null,
    "sponsor": "Florida International University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RNA",
    "nct_id": "NCT04486404",
    "title": "Needs, Perceptions and Acute Stress of Healtcare Workers Caring for COVID-19 Patients in South America",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Acute Stress Disorder"
    ],
    "interventions": [
      "Online survey"
    ],
    "primary_completion_date": "2020-12-30",
    "completion_date": "2021-12-30",
    "results_first_posted": null,
    "last_update_posted": "2022-09-19",
    "enrollment": null,
    "sponsor": "Universidad Miguel Hernandez de Elche",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RNA",
    "nct_id": "NCT05972174",
    "title": "A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Influenza"
    ],
    "interventions": [
      "mRNA-1018 for H5N8",
      "mRNA-1018 for H7N9",
      "mRNA-1018 for H5 Only",
      "mRNA-1018 for H7 Only",
      "mRNA-1018 for H5 Only-CG"
    ],
    "primary_completion_date": "2024-07-16",
    "completion_date": "2024-07-16",
    "results_first_posted": null,
    "last_update_posted": "2025-07-16",
    "enrollment": null,
    "sponsor": "ModernaTX, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RNA",
    "nct_id": "NCT05105048",
    "title": "A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cytomegalovirus Infection"
    ],
    "interventions": [
      "mRNA-1647",
      "Placebo"
    ],
    "primary_completion_date": "2023-08-10",
    "completion_date": "2023-08-10",
    "results_first_posted": null,
    "last_update_posted": "2023-09-11",
    "enrollment": null,
    "sponsor": "ModernaTX, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RNA",
    "nct_id": "NCT04470427",
    "title": "A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "SARS-CoV-2"
    ],
    "interventions": [
      "mRNA-1273",
      "Placebo"
    ],
    "primary_completion_date": "2022-12-29",
    "completion_date": "2022-12-29",
    "results_first_posted": "2024-03-21",
    "last_update_posted": "2024-03-21",
    "enrollment": null,
    "sponsor": "ModernaTX, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RNA",
    "nct_id": "NCT06694753",
    "title": "Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall Good Health in South Africa.",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HIV Infections"
    ],
    "interventions": [
      "mRNA-1645-eODGT8",
      "mRNA-1645-CoreG28v2",
      "mRNA-1645-N332GT5",
      "Placebo"
    ],
    "primary_completion_date": "2026-12-08",
    "completion_date": "2027-03-31",
    "results_first_posted": null,
    "last_update_posted": "2026-01-15",
    "enrollment": null,
    "sponsor": "International AIDS Vaccine Initiative",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RNA",
    "nct_id": "NCT05531019",
    "title": "COVID-19 Sequelae: Treatment and Monitoring. A Dietary Supplement Based on Sea Urchin Eggs With Echinochroma A",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Long COVID"
    ],
    "interventions": [
      "Echinochrome A",
      "Control"
    ],
    "primary_completion_date": "2022-12-08",
    "completion_date": "2022-12-18",
    "results_first_posted": null,
    "last_update_posted": "2023-02-28",
    "enrollment": null,
    "sponsor": "Fernando Saldarini",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RNA",
    "nct_id": "NCT01448707",
    "title": "A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Human Immunodeficiency Virus (HIV) Infections",
      "Acquired Immunodeficiency Syndrome (AIDS) Virus"
    ],
    "interventions": [
      "Darunavir",
      "Ritonavir"
    ],
    "primary_completion_date": "2014-06-11",
    "completion_date": "2015-03-18",
    "results_first_posted": "2015-12-03",
    "last_update_posted": "2017-11-27",
    "enrollment": null,
    "sponsor": "Janssen-Cilag International NV",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RNA",
    "nct_id": "NCT04911777",
    "title": "Proof of Principle Study to Evaluate the Safety, PK, Viral Shedding and Efficacy of Pentarlandir\u2122 UPPTA for Patients With Early COVID-19",
    "status": "UNKNOWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Coronavirus Disease 2019"
    ],
    "interventions": [
      "Pentarlandir\u2122 UPPTA",
      "Placebo"
    ],
    "primary_completion_date": "2021-12",
    "completion_date": "2022-03",
    "results_first_posted": null,
    "last_update_posted": "2021-12-17",
    "enrollment": null,
    "sponsor": "SyneuRx International (Taiwan) Corp",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RNA",
    "nct_id": "NCT04916431",
    "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-6231 in Healthy Adults",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "mRNA-6231"
    ],
    "primary_completion_date": "2022-08-02",
    "completion_date": "2022-08-02",
    "results_first_posted": null,
    "last_update_posted": "2022-08-10",
    "enrollment": null,
    "sponsor": "ModernaTX, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RNA",
    "nct_id": "NCT01371175",
    "title": "A Phase IIA Trial to Evaluate the Safety and Immunogenicity of a DNA HIV-1 Vaccine Followed by an MVA HIV-1 Vaccine in HIV-uninfected Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HIV Infections"
    ],
    "interventions": [
      "DNA.HIVA",
      "MVA.HIVA",
      "MVA.HIVA",
      "MVA.HIVA"
    ],
    "primary_completion_date": "2005-05",
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2011-06-10",
    "enrollment": null,
    "sponsor": "International AIDS Vaccine Initiative",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RNA",
    "nct_id": "NCT05933304",
    "title": "A Study of the Effectiveness of Moderna COVID-19 Vaccine",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "SARS-CoV-2",
      "COVID-19"
    ],
    "interventions": [],
    "primary_completion_date": "2023-11-17",
    "completion_date": "2023-11-17",
    "results_first_posted": null,
    "last_update_posted": "2025-05-28",
    "enrollment": null,
    "sponsor": "ModernaTX, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RNA",
    "nct_id": "NCT01508286",
    "title": "Early Access Program of Telaprevir With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects",
    "status": "NO_LONGER_AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Hepatitis C"
    ],
    "interventions": [
      "Telaprevir + peginterferon alfa + ribavirin",
      "peginterferon alfa + ribavirin",
      "peginterferon alfa + ribavirin"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2015-07-24",
    "enrollment": null,
    "sponsor": "Janssen-Cilag International NV",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACAD",
    "nct_id": "NCT03575052",
    "title": "A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Neuropsychiatric Symptoms Related to Neurodegenerative Disease"
    ],
    "interventions": [
      "Pimavanserin",
      "Placebo"
    ],
    "primary_completion_date": "2022-05-06",
    "completion_date": "2022-05-06",
    "results_first_posted": "2024-12-31",
    "last_update_posted": "2024-12-31",
    "enrollment": null,
    "sponsor": "ACADIA Pharmaceuticals Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACAD",
    "nct_id": "NCT06983431",
    "title": "DIGITALIZATION OF PERSONALISED HEALTH RISK MANAGEMENT",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pre-obesity",
      "Obesity"
    ],
    "interventions": [
      "technology driven self coaching",
      "Health coaching",
      "Peer coaching",
      "Active Control"
    ],
    "primary_completion_date": "2026-05-05",
    "completion_date": "2026-06-30",
    "results_first_posted": null,
    "last_update_posted": "2025-05-21",
    "enrollment": null,
    "sponsor": "Slovak Academy of Sciences",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACAD",
    "nct_id": "NCT04000009",
    "title": "Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Adjunctive Treatment of Major Depressive Disorder"
    ],
    "interventions": [
      "Pimavanserin"
    ],
    "primary_completion_date": "2021-02-22",
    "completion_date": "2021-02-22",
    "results_first_posted": "2022-04-05",
    "last_update_posted": "2022-04-05",
    "enrollment": null,
    "sponsor": "ACADIA Pharmaceuticals Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACAD",
    "nct_id": "NCT03623321",
    "title": "Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Neuropsychiatric Symptoms Related to Neurodegenerative Disease"
    ],
    "interventions": [
      "Pimavanserin"
    ],
    "primary_completion_date": "2023-05-05",
    "completion_date": "2023-05-05",
    "results_first_posted": "2024-12-20",
    "last_update_posted": "2024-12-20",
    "enrollment": null,
    "sponsor": "ACADIA Pharmaceuticals Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACAD",
    "nct_id": "NCT03968159",
    "title": "Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Adjunctive Treatment of Major Depressive Disorder"
    ],
    "interventions": [
      "Pimavanserin",
      "Placebo"
    ],
    "primary_completion_date": "2020-04-30",
    "completion_date": "2020-05-29",
    "results_first_posted": "2021-11-17",
    "last_update_posted": "2021-11-17",
    "enrollment": null,
    "sponsor": "ACADIA Pharmaceuticals Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACAD",
    "nct_id": "NCT05063760",
    "title": "Exercise in Testicular Germ Cell Cancer Survivors",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Testicular Germ Cell Tumor"
    ],
    "interventions": [
      "aerobic-strength exercise intervention (6-months)"
    ],
    "primary_completion_date": "2023-12-01",
    "completion_date": "2024-06-30",
    "results_first_posted": null,
    "last_update_posted": "2023-12-05",
    "enrollment": null,
    "sponsor": "Slovak Academy of Sciences",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACAD",
    "nct_id": "NCT02253732",
    "title": "Skeletal Muscle as a Mediator of Exercise Induced Effects on Metabolism & Cognitive Function: Role for Myokines & miRNAs",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Mild Cognitive Impairment",
      "Alzheimer Disease",
      "Parkinson Disease",
      "Healthy Volunteers"
    ],
    "interventions": [
      "3 months exercise intervention program"
    ],
    "primary_completion_date": "2017-09",
    "completion_date": "2018-03",
    "results_first_posted": null,
    "last_update_posted": "2018-04-17",
    "enrollment": null,
    "sponsor": "Slovak Academy of Sciences",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACAD",
    "nct_id": "NCT01616095",
    "title": "Effects of Growth Hormone Supplementation to Adults With Growth Hormone Deficient on Metabolism and Adipose Tissue Molecular Phenotype",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Growth Hormone Deficiency"
    ],
    "interventions": [],
    "primary_completion_date": "2013-05",
    "completion_date": "2015-08",
    "results_first_posted": null,
    "last_update_posted": "2018-04-17",
    "enrollment": null,
    "sponsor": "Slovak Academy of Sciences",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACAD",
    "nct_id": "NCT03121586",
    "title": "Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia"
    ],
    "interventions": [
      "Pimavanserin"
    ],
    "primary_completion_date": "2024-04-30",
    "completion_date": "2024-05-30",
    "results_first_posted": "2025-08-24",
    "last_update_posted": "2025-08-24",
    "enrollment": null,
    "sponsor": "ACADIA Pharmaceuticals Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACAD",
    "nct_id": "NCT03325556",
    "title": "Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dementia-related Psychosis"
    ],
    "interventions": [
      "Placebo",
      "Pimavanserin 34 mg",
      "Pimavanserin 20 mg"
    ],
    "primary_completion_date": "2019-07-31",
    "completion_date": "2019-10-30",
    "results_first_posted": "2021-06-21",
    "last_update_posted": "2021-06-21",
    "enrollment": null,
    "sponsor": "ACADIA Pharmaceuticals Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACAD",
    "nct_id": "NCT01553669",
    "title": "Reminiscence Therapy on Depression, Self Esteem, Life Satisfaction, and Loneliness of the Elderly",
    "status": "UNKNOWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Depression"
    ],
    "interventions": [
      "reminiscence therapy"
    ],
    "primary_completion_date": "2012-09",
    "completion_date": "2012-09",
    "results_first_posted": null,
    "last_update_posted": "2012-05-15",
    "enrollment": null,
    "sponsor": "Chinese Academy of Sciences",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACAD",
    "nct_id": "NCT06954298",
    "title": "Molecular Landscape of Complex Lifestyle Modification",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Obesity Prevention",
      "Obesity",
      "Metabolic Disease"
    ],
    "interventions": [
      "supervised lifestyle modification"
    ],
    "primary_completion_date": "2025-12-31",
    "completion_date": "2026-06-30",
    "results_first_posted": null,
    "last_update_posted": "2025-05-01",
    "enrollment": null,
    "sponsor": "Slovak Academy of Sciences",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRSP",
    "nct_id": "NCT04438083",
    "title": "A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Renal Cell Carcinoma"
    ],
    "interventions": [
      "CTX130"
    ],
    "primary_completion_date": "2024-10-08",
    "completion_date": "2024-10-08",
    "results_first_posted": null,
    "last_update_posted": "2025-01-08",
    "enrollment": null,
    "sponsor": "CRISPR Therapeutics AG",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRSP",
    "nct_id": "NCT05795595",
    "title": "A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Clear Cell Renal Cell Carcinoma",
      "Cervical Carcinoma",
      "Esophageal Carcinoma",
      "Pancreatic Adenocarcinoma",
      "Malignant Pleural Mesothelioma"
    ],
    "interventions": [
      "CTX131"
    ],
    "primary_completion_date": "2025-09-18",
    "completion_date": "2025-09-18",
    "results_first_posted": null,
    "last_update_posted": "2025-11-26",
    "enrollment": null,
    "sponsor": "CRISPR Therapeutics AG",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRSP",
    "nct_id": "NCT06492304",
    "title": "A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "T Cell Lymphoma",
      "B Cell Lymphoma",
      "Acute Myeloid Leukemia"
    ],
    "interventions": [
      "CTX131"
    ],
    "primary_completion_date": "2030-05",
    "completion_date": "2030-11",
    "results_first_posted": null,
    "last_update_posted": "2025-06-29",
    "enrollment": null,
    "sponsor": "CRISPR Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRSP",
    "nct_id": "NCT04502446",
    "title": "A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "T Cell Lymphoma"
    ],
    "interventions": [
      "CTX130"
    ],
    "primary_completion_date": "2024-08-30",
    "completion_date": "2024-08-30",
    "results_first_posted": null,
    "last_update_posted": "2025-01-08",
    "enrollment": null,
    "sponsor": "CRISPR Therapeutics AG",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRSP",
    "nct_id": "NCT05643742",
    "title": "A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "B-cell Lymphoma",
      "Non-Hodgkin Lymphoma",
      "B-cell Malignancy",
      "Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)",
      "Follicular Lymphoma",
      "Mantle Cell Lymphoma",
      "Marginal Zone Lymphoma",
      "Large B-cell Lymphoma"
    ],
    "interventions": [
      "CTX112"
    ],
    "primary_completion_date": "2030-01",
    "completion_date": "2030-02",
    "results_first_posted": null,
    "last_update_posted": "2025-11-14",
    "enrollment": null,
    "sponsor": "CRISPR Therapeutics AG",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRSP",
    "nct_id": "NCT06208878",
    "title": "A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Hematologic Malignancy",
      "Solid Malignancy"
    ],
    "interventions": [
      "Non Interventional"
    ],
    "primary_completion_date": "2038-08",
    "completion_date": "2038-08",
    "results_first_posted": null,
    "last_update_posted": "2025-08-14",
    "enrollment": null,
    "sponsor": "CRISPR Therapeutics AG",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRSP",
    "nct_id": "NCT04035434",
    "title": "A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "B-cell Malignancy",
      "Non-Hodgkin Lymphoma",
      "B-cell Lymphoma",
      "Adult B Cell ALL"
    ],
    "interventions": [
      "CTX110"
    ],
    "primary_completion_date": "2024-10-04",
    "completion_date": "2024-10-04",
    "results_first_posted": "2025-10-24",
    "last_update_posted": "2025-10-24",
    "enrollment": null,
    "sponsor": "CRISPR Therapeutics AG",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRSP",
    "nct_id": "NCT06925542",
    "title": "A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "SLE (Systemic Lupus)",
      "Lupus Erythematosus, Systemic",
      "Lupus Nephritis",
      "Systemic Sclerosis",
      "Inflammatory Myopathy, Idiopathic",
      "Myositis",
      "Diffuse Cutaneous Systemic Sclerosis"
    ],
    "interventions": [
      "CTX112"
    ],
    "primary_completion_date": "2031-12-31",
    "completion_date": "2031-12-31",
    "results_first_posted": null,
    "last_update_posted": "2025-12-17",
    "enrollment": null,
    "sponsor": "CRISPR Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRSP",
    "nct_id": "NCT04244656",
    "title": "A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple Myeloma"
    ],
    "interventions": [
      "CTX120"
    ],
    "primary_completion_date": "2024-01-04",
    "completion_date": "2024-01-04",
    "results_first_posted": null,
    "last_update_posted": "2025-01-08",
    "enrollment": null,
    "sponsor": "CRISPR Therapeutics AG",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT07157254",
    "title": "A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Angelman Syndrome"
    ],
    "interventions": [
      "No intervention",
      "GTX-102"
    ],
    "primary_completion_date": "2030-01",
    "completion_date": "2030-01",
    "results_first_posted": null,
    "last_update_posted": "2026-01-20",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT02432144",
    "title": "A Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Therapy in Subjects With Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Sly Syndrome",
      "MPS VII",
      "Mucopolysaccharidosis",
      "Mucopolysaccharidosis VII"
    ],
    "interventions": [
      "UX003"
    ],
    "primary_completion_date": "2019-01-14",
    "completion_date": "2019-01-14",
    "results_first_posted": "2019-07-30",
    "last_update_posted": "2020-07-30",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT05514249",
    "title": "Treatment of a Single Patient With CRD-TMH-001",
    "status": "UNKNOWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy"
    ],
    "interventions": [
      "CRD-TMH-001"
    ],
    "primary_completion_date": "2023-09",
    "completion_date": "2023-09",
    "results_first_posted": null,
    "last_update_posted": "2022-09-01",
    "enrollment": null,
    "sponsor": "Cure Rare Disease, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MRNA",
    "nct_id": "NCT06694389",
    "title": "Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults \u226550 Years of Age",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID-19",
      "Influenza"
    ],
    "interventions": [
      "mRNA-1083",
      "Placebo",
      "Licensed Influenza Vaccine",
      "SARS-CoV-2 Vaccine"
    ],
    "primary_completion_date": "2025-11-17",
    "completion_date": "2025-11-17",
    "results_first_posted": null,
    "last_update_posted": "2025-12-02",
    "enrollment": null,
    "sponsor": "ModernaTX, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MRNA",
    "nct_id": "NCT05105048",
    "title": "A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cytomegalovirus Infection"
    ],
    "interventions": [
      "mRNA-1647",
      "Placebo"
    ],
    "primary_completion_date": "2023-08-10",
    "completion_date": "2023-08-10",
    "results_first_posted": null,
    "last_update_posted": "2023-09-11",
    "enrollment": null,
    "sponsor": "ModernaTX, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MRNA",
    "nct_id": "NCT04470427",
    "title": "A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "SARS-CoV-2"
    ],
    "interventions": [
      "mRNA-1273",
      "Placebo"
    ],
    "primary_completion_date": "2022-12-29",
    "completion_date": "2022-12-29",
    "results_first_posted": "2024-03-21",
    "last_update_posted": "2024-03-21",
    "enrollment": null,
    "sponsor": "ModernaTX, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MRNA",
    "nct_id": "NCT04916431",
    "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-6231 in Healthy Adults",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "mRNA-6231"
    ],
    "primary_completion_date": "2022-08-02",
    "completion_date": "2022-08-02",
    "results_first_posted": null,
    "last_update_posted": "2022-08-10",
    "enrollment": null,
    "sponsor": "ModernaTX, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MRNA",
    "nct_id": "NCT05933304",
    "title": "A Study of the Effectiveness of Moderna COVID-19 Vaccine",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "SARS-CoV-2",
      "COVID-19"
    ],
    "interventions": [],
    "primary_completion_date": "2023-11-17",
    "completion_date": "2023-11-17",
    "results_first_posted": null,
    "last_update_posted": "2025-05-28",
    "enrollment": null,
    "sponsor": "ModernaTX, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MRNA",
    "nct_id": "NCT05606965",
    "title": "A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Influenza"
    ],
    "interventions": [
      "mRNA-1010",
      "Egg-based Quadrivalent Influenza Vaccine",
      "Adjuvanted Quadrivalent Influenza Vaccine",
      "Inactivated Influenza Vaccine",
      "mRNA-1345",
      "mRNA-1045"
    ],
    "primary_completion_date": "2025-11-13",
    "completion_date": "2025-11-13",
    "results_first_posted": null,
    "last_update_posted": "2025-11-24",
    "enrollment": null,
    "sponsor": "ModernaTX, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MRNA",
    "nct_id": "NCT07266558",
    "title": "A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)",
    "status": "RECRUITING",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "SARS-CoV-2"
    ],
    "interventions": [
      "mRNA-1273",
      "mRNA-1283",
      "Placebo"
    ],
    "primary_completion_date": "2027-06-16",
    "completion_date": "2027-06-16",
    "results_first_posted": null,
    "last_update_posted": "2026-01-15",
    "enrollment": null,
    "sponsor": "ModernaTX, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MRNA",
    "nct_id": "NCT06354998",
    "title": "A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "SARS-CoV-2"
    ],
    "interventions": [
      "Investigational mRNA-1273.815",
      "Licensed Spikevax Vaccine"
    ],
    "primary_completion_date": "2024-05-10",
    "completion_date": "2024-05-10",
    "results_first_posted": "2025-05-25",
    "last_update_posted": "2025-05-25",
    "enrollment": null,
    "sponsor": "ModernaTX, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MRNA",
    "nct_id": "NCT06333704",
    "title": "Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT and SPIKEVAX X Injection.",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "SARS-CoV-2"
    ],
    "interventions": [
      "SPIKEVAX Bivalent",
      "SPIKEVAX X"
    ],
    "primary_completion_date": "2028-12-10",
    "completion_date": "2028-12-10",
    "results_first_posted": null,
    "last_update_posted": "2025-03-19",
    "enrollment": null,
    "sponsor": "ModernaTX, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MRNA",
    "nct_id": "NCT07117487",
    "title": "A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants \u226560 Years of Age",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Respiratory Syncytial Virus"
    ],
    "interventions": [
      "mRNA-1345"
    ],
    "primary_completion_date": "2026-04-15",
    "completion_date": "2026-04-15",
    "results_first_posted": null,
    "last_update_posted": "2025-08-12",
    "enrollment": null,
    "sponsor": "ModernaTX, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MRNA",
    "nct_id": "NCT06655870",
    "title": "A Study to Investigate Safety and Tolerability of mRNA-0184 Administered Subcutaneously in Healthy Participants",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants"
    ],
    "interventions": [
      "mRNA-0184"
    ],
    "primary_completion_date": "2026-06-23",
    "completion_date": "2026-06-23",
    "results_first_posted": null,
    "last_update_posted": "2026-01-20",
    "enrollment": null,
    "sponsor": "ModernaTX, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MRNA",
    "nct_id": "NCT05894525",
    "title": "Post-Marketing Safety Study in Japan in Participants With High Risk of Severe Exacerbation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "SARS-CoV-2"
    ],
    "interventions": [],
    "primary_completion_date": "2023-05-26",
    "completion_date": "2023-05-26",
    "results_first_posted": null,
    "last_update_posted": "2024-03-15",
    "enrollment": null,
    "sponsor": "ModernaTX, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MRNA",
    "nct_id": "NCT06585241",
    "title": "A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations",
    "status": "RECRUITING",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "SARS-CoV-2"
    ],
    "interventions": [
      "mRNA-1273 Variant-containing Formulation"
    ],
    "primary_completion_date": "2026-05-07",
    "completion_date": "2026-05-07",
    "results_first_posted": null,
    "last_update_posted": "2025-10-23",
    "enrollment": null,
    "sponsor": "ModernaTX, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MRNA",
    "nct_id": "NCT06067230",
    "title": "A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Respiratory Syncytial Virus"
    ],
    "interventions": [
      "mRNA-1345"
    ],
    "primary_completion_date": "2026-07-30",
    "completion_date": "2026-07-30",
    "results_first_posted": null,
    "last_update_posted": "2025-08-08",
    "enrollment": null,
    "sponsor": "ModernaTX, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MRNA",
    "nct_id": "NCT05683457",
    "title": "A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cytomegalovirus Infection"
    ],
    "interventions": [
      "mRNA-1647",
      "Placebo"
    ],
    "primary_completion_date": "2026-08-01",
    "completion_date": "2026-08-01",
    "results_first_posted": null,
    "last_update_posted": "2025-03-13",
    "enrollment": null,
    "sponsor": "ModernaTX, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MRNA",
    "nct_id": "NCT05085366",
    "title": "A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cytomegalovirus Infection"
    ],
    "interventions": [
      "mRNA-1647",
      "Placebo"
    ],
    "primary_completion_date": "2025-11-04",
    "completion_date": "2025-11-04",
    "results_first_posted": null,
    "last_update_posted": "2025-12-15",
    "enrollment": null,
    "sponsor": "ModernaTX, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MRNA",
    "nct_id": "NCT05127434",
    "title": "A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults \u226560 Years of Age",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Respiratory Syncytial Virus"
    ],
    "interventions": [
      "Placebo",
      "mRNA-1345"
    ],
    "primary_completion_date": "2025-07-28",
    "completion_date": "2025-07-28",
    "results_first_posted": null,
    "last_update_posted": "2025-08-19",
    "enrollment": null,
    "sponsor": "ModernaTX, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MRNA",
    "nct_id": "NCT05975099",
    "title": "A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lyme Disease"
    ],
    "interventions": [
      "mRNA-1975",
      "mRNA-1982",
      "Placebo"
    ],
    "primary_completion_date": "2025-05-30",
    "completion_date": "2025-05-30",
    "results_first_posted": null,
    "last_update_posted": "2025-08-22",
    "enrollment": null,
    "sponsor": "ModernaTX, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MRNA",
    "nct_id": "NCT05397223",
    "title": "A Study of Modified mRNA Vaccines in Healthy Adults",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "SARS-CoV-2",
      "Seasonal Influenza",
      "Respiratory Syncytial Virus",
      "Cytomegalovirus"
    ],
    "interventions": [
      "mRNA-1273",
      "mRNA-1010",
      "mRNA-1345",
      "FLUAD\u00ae",
      "mRNA-1647"
    ],
    "primary_completion_date": "2026-02-21",
    "completion_date": "2026-02-21",
    "results_first_posted": null,
    "last_update_posted": "2025-03-24",
    "enrollment": null,
    "sponsor": "ModernaTX, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MRNA",
    "nct_id": "NCT05375838",
    "title": "A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "SARS-CoV-2",
      "Influenza"
    ],
    "interventions": [
      "mRNA-1073",
      "mRNA-1010",
      "mRNA-1273",
      "Placebo"
    ],
    "primary_completion_date": "2022-12-29",
    "completion_date": "2022-12-29",
    "results_first_posted": "2024-02-28",
    "last_update_posted": "2024-02-28",
    "enrollment": null,
    "sponsor": "ModernaTX, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MRNA",
    "nct_id": "NCT05572658",
    "title": "Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Respiratory Syncytial Virus"
    ],
    "interventions": [
      "mRNA-1345",
      "Placebo"
    ],
    "primary_completion_date": "2023-09-30",
    "completion_date": "2023-09-30",
    "results_first_posted": null,
    "last_update_posted": "2025-01-24",
    "enrollment": null,
    "sponsor": "ModernaTX, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MRNA",
    "nct_id": "NCT05436834",
    "title": "A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "SARS-CoV-2"
    ],
    "interventions": [
      "mRNA-1273.214",
      "mRNA-1273.815"
    ],
    "primary_completion_date": "2025-10-20",
    "completion_date": "2025-10-20",
    "results_first_posted": null,
    "last_update_posted": "2025-11-26",
    "enrollment": null,
    "sponsor": "ModernaTX, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MRNA",
    "nct_id": "NCT04159103",
    "title": "Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Propionic Acidemia"
    ],
    "interventions": [
      "mRNA-3927"
    ],
    "primary_completion_date": "2027-08-31",
    "completion_date": "2027-08-31",
    "results_first_posted": null,
    "last_update_posted": "2026-01-22",
    "enrollment": null,
    "sponsor": "ModernaTX, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MRNA",
    "nct_id": "NCT06113692",
    "title": "A Study on the Clinical Course, Outcomes and Risk Factors of Myocarditis and Pericarditis After Moderna COVID-19 Vaccine",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Myocarditis, Pericarditis"
    ],
    "interventions": [
      "mRNA-1273"
    ],
    "primary_completion_date": "2024-08-31",
    "completion_date": "2025-06-30",
    "results_first_posted": null,
    "last_update_posted": "2025-08-01",
    "enrollment": null,
    "sponsor": "ModernaTX, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MRNA",
    "nct_id": "NCT05894590",
    "title": "Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "SARS-CoV-2"
    ],
    "interventions": [],
    "primary_completion_date": "2023-12-20",
    "completion_date": "2023-12-20",
    "results_first_posted": null,
    "last_update_posted": "2024-03-15",
    "enrollment": null,
    "sponsor": "ModernaTX, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MRNA",
    "nct_id": "NCT05295433",
    "title": "An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Methylmalonic Acidemia"
    ],
    "interventions": [
      "mRNA-3705"
    ],
    "primary_completion_date": "2034-04-02",
    "completion_date": "2034-04-02",
    "results_first_posted": null,
    "last_update_posted": "2025-12-23",
    "enrollment": null,
    "sponsor": "ModernaTX, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MRNA",
    "nct_id": "NCT06147856",
    "title": "A Dose-finding Study to Evaluate mRNA-3210 in Participants With Phenylketonuria",
    "status": "WITHDRAWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Phenylketonuria"
    ],
    "interventions": [
      "mRNA-3210"
    ],
    "primary_completion_date": "2026-08-10",
    "completion_date": "2027-08-05",
    "results_first_posted": null,
    "last_update_posted": "2024-10-22",
    "enrollment": null,
    "sponsor": "ModernaTX, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MRNA",
    "nct_id": "NCT06133010",
    "title": "A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and Recipients",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cytomegalovirus Infection"
    ],
    "interventions": [
      "mRNA-1647",
      "Placebo"
    ],
    "primary_completion_date": "2027-02-14",
    "completion_date": "2027-12-14",
    "results_first_posted": null,
    "last_update_posted": "2024-03-15",
    "enrollment": null,
    "sponsor": "ModernaTX, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT04167072",
    "title": "Observation vs Early Removal of LAMS in EUS Guided Cholecystoenterostomy",
    "status": "WITHDRAWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cholecystitis, Acute",
      "Cholecystitis; Gallstone"
    ],
    "interventions": [
      "Stent removal"
    ],
    "primary_completion_date": "2021-01-31",
    "completion_date": "2021-01-31",
    "results_first_posted": null,
    "last_update_posted": "2020-04-22",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center, El Paso",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT02072226",
    "title": "A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Stroke"
    ],
    "interventions": [
      "Alteplase",
      "Alteplase Placebo",
      "Aspirin",
      "Aspirin Placebo"
    ],
    "primary_completion_date": "2017-03-22",
    "completion_date": "2017-03-22",
    "results_first_posted": "2018-07-03",
    "last_update_posted": "2018-07-03",
    "enrollment": null,
    "sponsor": "Genentech, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT02839226",
    "title": "Safety and Efficacy of Topical AR/101 Compared With Placebo, in Accelerating Granulation Tissue Formation of Hard-to-heal Wounds",
    "status": "UNKNOWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Wounds",
      "Other Ulcers Wounds and Skin Problems"
    ],
    "interventions": [
      "AR/101",
      "Placebo"
    ],
    "primary_completion_date": "2017-12",
    "completion_date": "2017-12",
    "results_first_posted": null,
    "last_update_posted": "2016-07-20",
    "enrollment": null,
    "sponsor": "Arava Bio Tech Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03458702",
    "title": "The Effects of Emotional Exposure on State Anxiety",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Generalized Anxiety Disorder"
    ],
    "interventions": [
      "YogaFit",
      "Quiet Rest"
    ],
    "primary_completion_date": "2014-03-15",
    "completion_date": "2014-05",
    "results_first_posted": "2019-11-25",
    "last_update_posted": "2019-11-25",
    "enrollment": null,
    "sponsor": "Texas Tech University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05148663",
    "title": "CCM Blood Biomarker Validation Study",
    "status": "TERMINATED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Hemorrhagic Stroke, Intracerebral",
      "Cerebral Cavernous Malformation"
    ],
    "interventions": [
      "CCM Hemorrhagic Panel"
    ],
    "primary_completion_date": "2023-08-29",
    "completion_date": "2023-08-29",
    "results_first_posted": null,
    "last_update_posted": "2023-09-01",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center, El Paso",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT02042807",
    "title": "To Evaluate the Effect of MCS\u00ae in Prostate Cancer Prevention",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Prostate Cancer"
    ],
    "interventions": [
      "Placebo",
      "MCS\u00ae"
    ],
    "primary_completion_date": "2024-12",
    "completion_date": "2024-12",
    "results_first_posted": null,
    "last_update_posted": "2024-06-13",
    "enrollment": null,
    "sponsor": "Health Ever Bio-Tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT02933892",
    "title": "Benefit of Transradial Approach in Chronic Kidney Disease Population Undergoing Cardiac Catheterization",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Kidney Disease",
      "Acute Kidney Injury",
      "Heart Disease"
    ],
    "interventions": [
      "Cardiac Catheterization"
    ],
    "primary_completion_date": "2024-08-30",
    "completion_date": "2024-08-30",
    "results_first_posted": null,
    "last_update_posted": "2024-11-06",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03144037",
    "title": "Adherence of Hispanic / Latina Breast Cancer - Patients to Adjuvant Aromatase Inhibitors",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Breast Cancer"
    ],
    "interventions": [],
    "primary_completion_date": "2021-03-19",
    "completion_date": "2021-03-19",
    "results_first_posted": null,
    "last_update_posted": "2021-03-29",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center, El Paso",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03685305",
    "title": "Weight Loss and Cognitive Function in Adults",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Overweight and Obesity"
    ],
    "interventions": [
      "Hypocaloric diet with hunger reduction strategy",
      "Hypocaloric diet without hunger reduction strategy"
    ],
    "primary_completion_date": "2019-08-14",
    "completion_date": "2020-03-31",
    "results_first_posted": null,
    "last_update_posted": "2025-03-21",
    "enrollment": null,
    "sponsor": "Virginia Polytechnic Institute and State University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT06055322",
    "title": "Reducing Suicide Risk Among Aging Caregivers of Persons With AD/ADRD",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Suicide",
      "Depression",
      "Caregiver Burden",
      "Physical Health",
      "Inflammation"
    ],
    "interventions": [
      "Adapted Dialectical Behavior Therapy"
    ],
    "primary_completion_date": "2026-08-31",
    "completion_date": "2026-08-31",
    "results_first_posted": null,
    "last_update_posted": "2025-05-11",
    "enrollment": null,
    "sponsor": "Texas Tech University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03340051",
    "title": "Remote Alcohol Monitoring and Episodic Thinking",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alcohol Dependence",
      "Alcohol-Related Disorders"
    ],
    "interventions": [
      "Episodic Future Thinking (EFT)",
      "Episodic Recent Thinking (ERT)"
    ],
    "primary_completion_date": "2019-09-17",
    "completion_date": "2019-10-03",
    "results_first_posted": null,
    "last_update_posted": "2025-02-12",
    "enrollment": null,
    "sponsor": "Virginia Polytechnic Institute and State University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03673085",
    "title": "Clinical Study of CN128 in Thalassemia Patients",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Thalassemia"
    ],
    "interventions": [
      "CN128",
      "placebo"
    ],
    "primary_completion_date": "2018-10-16",
    "completion_date": "2019-12-17",
    "results_first_posted": null,
    "last_update_posted": "2019-12-19",
    "enrollment": null,
    "sponsor": "Hangzhou Zede Pharma-Tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT04799964",
    "title": "Efficacy and Safety of the Flow Diverter (Tonbridge) for Endovascular Treatment of Intracranial Aneurysms",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Intracranial Aneurysm"
    ],
    "interventions": [
      "Flow Diverter (Tonbridge)",
      "Tubridge (MicroPort)"
    ],
    "primary_completion_date": "2023-09-22",
    "completion_date": "2023-09-22",
    "results_first_posted": null,
    "last_update_posted": "2024-09-19",
    "enrollment": null,
    "sponsor": "Ton-Bridge Medical Tech. Co., Ltd",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT06521255",
    "title": "Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "DLBCL"
    ],
    "interventions": [
      "Tafasitamab",
      "Lenalidomide",
      "Gemcitabine",
      "Oxaliplatin",
      "Rituximab"
    ],
    "primary_completion_date": "2028-09",
    "completion_date": "2029-12",
    "results_first_posted": null,
    "last_update_posted": "2024-07-25",
    "enrollment": null,
    "sponsor": "Beijing InnoCare Pharma Tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03958422",
    "title": "Clinical Study of Cardiomyopeptidin on Postoperative Ischemia-reperfusion Injury in Patients With Primary PCI",
    "status": "UNKNOWN",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Survival Myocardial Area After Acute Myocardial Death",
      "Left Ventricular Ejection Fraction"
    ],
    "interventions": [
      "cardiomyopeptidin"
    ],
    "primary_completion_date": "2019-11-30",
    "completion_date": "2020-01-31",
    "results_first_posted": null,
    "last_update_posted": "2019-05-22",
    "enrollment": null,
    "sponsor": "Dalian Zhen-Ao Bio-Tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03123705",
    "title": "El Paso Public Health Biorepository",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Oral Disease",
      "Bacterial Disease"
    ],
    "interventions": [],
    "primary_completion_date": "2019-08-31",
    "completion_date": "2019-09-30",
    "results_first_posted": null,
    "last_update_posted": "2019-10-28",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center, El Paso",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT06865183",
    "title": "Investigating a Brief Virtual Seminar Series for Parents of Children Ages 2-12",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Positive Parenting Skills"
    ],
    "interventions": [
      "Positive Parenting Seminar Series"
    ],
    "primary_completion_date": "2024-09-16",
    "completion_date": "2025-01-31",
    "results_first_posted": null,
    "last_update_posted": "2025-03-07",
    "enrollment": null,
    "sponsor": "Texas Tech University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT04985097",
    "title": "Home-based Visual Training in Patients Implanted With Trifocal Diffractive Intraocular Lenses",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Visual Disturbances and Blindness",
      "Visual Acuity Reduced Transiently"
    ],
    "interventions": [
      "Implantation of trifocal diffractive intraocular lenses"
    ],
    "primary_completion_date": "2021-06-30",
    "completion_date": "2021-07-20",
    "results_first_posted": null,
    "last_update_posted": "2021-08-06",
    "enrollment": null,
    "sponsor": "Increase-Tech",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT01895660",
    "title": "Children With Hemiparesis Arm and Hand Movement Project (CHAMP Study)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hemiparesis",
      "Cerebral Palsy",
      "Brain Injury"
    ],
    "interventions": [
      "Variations in Pediatric Constraint-Induced Movement Therapy (P-CIMT) versus usual and customary rehabilitation"
    ],
    "primary_completion_date": "2018-12",
    "completion_date": "2019-12",
    "results_first_posted": null,
    "last_update_posted": "2022-03-25",
    "enrollment": null,
    "sponsor": "Virginia Polytechnic Institute and State University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT07161050",
    "title": "Effects of a Low Nicotine Standard and Tobacco Prices on Illegal Cigarette Purchasing",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cigarette Smoking",
      "E-cigarette Use"
    ],
    "interventions": [
      "Nicotine Content",
      "Illegal cigarette price",
      "E-cigarette price"
    ],
    "primary_completion_date": "2026-10-01",
    "completion_date": "2026-10-07",
    "results_first_posted": null,
    "last_update_posted": "2026-01-16",
    "enrollment": null,
    "sponsor": "Virginia Polytechnic Institute and State University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03493217",
    "title": "A Study to Evaluate ICP-022 in Patients With CLL/ SLL",
    "status": "UNKNOWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "CLL/SLL"
    ],
    "interventions": [
      "ICP-022"
    ],
    "primary_completion_date": "2022-12-31",
    "completion_date": "2022-12-31",
    "results_first_posted": null,
    "last_update_posted": "2022-07-06",
    "enrollment": null,
    "sponsor": "Beijing InnoCare Pharma Tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT01421160",
    "title": "Regulating Urine pH Levels to Alleviate Chronic Joint Pain",
    "status": "WITHDRAWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Arthritis"
    ],
    "interventions": [
      "sodium citrate and citric acid"
    ],
    "primary_completion_date": "2012-03",
    "completion_date": "2012-03",
    "results_first_posted": null,
    "last_update_posted": "2017-05-16",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center, El Paso",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT04440059",
    "title": "A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Waldenstrom's Macroglobulinemia Recurrent",
      "Waldenstrom's Macroglobulinemia Refractory"
    ],
    "interventions": [
      "ICP-022"
    ],
    "primary_completion_date": "2024-01-09",
    "completion_date": "2024-01-09",
    "results_first_posted": null,
    "last_update_posted": "2024-04-18",
    "enrollment": null,
    "sponsor": "Beijing InnoCare Pharma Tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05316857",
    "title": "DDI Study of Orelabrutinib",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Person"
    ],
    "interventions": [
      "Orelabrutinib + Rifampin",
      "Orelabrutinib + Itraconazole"
    ],
    "primary_completion_date": "2022-01-04",
    "completion_date": "2022-06-13",
    "results_first_posted": null,
    "last_update_posted": "2022-07-06",
    "enrollment": null,
    "sponsor": "Beijing InnoCare Pharma Tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT07084675",
    "title": "Dehydration, Rehydration, and Impact on Physiology",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Aging"
    ],
    "interventions": [
      "Hydration-Dehydration-Rehydration Protocol (HDR)"
    ],
    "primary_completion_date": "2025-12",
    "completion_date": "2026-12",
    "results_first_posted": null,
    "last_update_posted": "2025-09-17",
    "enrollment": null,
    "sponsor": "Texas Tech University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT01779492",
    "title": "A Randomized, Open-label, Multiple-dose, Two-sequence, Two-period Crossover Study to Investigate The Pharmacokinetics Between a GL2907 and Oxycontin CR Tab. 10mg in Healthy Male Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "GL2907",
      "Oxycontine CR 10mg"
    ],
    "primary_completion_date": "2013-06",
    "completion_date": "2013-08",
    "results_first_posted": null,
    "last_update_posted": "2014-11-13",
    "enrollment": null,
    "sponsor": "GL Pharm Tech Corporation",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT02770105",
    "title": "Theanine and Caffeine on Neurophysiology of Attention",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "L-theanine"
    ],
    "interventions": [
      "Theanine",
      "Caffeine",
      "Theanine-Caffeine Combination",
      "Placebo"
    ],
    "primary_completion_date": "2016-06",
    "completion_date": "2016-06",
    "results_first_posted": null,
    "last_update_posted": "2016-09-02",
    "enrollment": null,
    "sponsor": "Texas Tech University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03732209",
    "title": "A Remotely Delivered Episodic Future Thinking Intervention to Improve Management of Type 2 Diabetes",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 2 Diabetes"
    ],
    "interventions": [
      "Episodic future thinking",
      "Control Thinking"
    ],
    "primary_completion_date": "2021-08-31",
    "completion_date": "2021-08-31",
    "results_first_posted": "2024-11-01",
    "last_update_posted": "2024-11-01",
    "enrollment": null,
    "sponsor": "Virginia Polytechnic Institute and State University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT07047612",
    "title": "ICP-332 in Subjects With Non-segmental Vitiligo",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non Segmental Vitiligo"
    ],
    "interventions": [
      "ICP-332 Tablets",
      "ICP-332 Placebo Tablets"
    ],
    "primary_completion_date": "2029-04",
    "completion_date": "2029-04",
    "results_first_posted": null,
    "last_update_posted": "2025-08-07",
    "enrollment": null,
    "sponsor": "Beijing InnoCare Pharma Tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT01062165",
    "title": "Effect of Weight and/or Obesity on Caspofungin Drug Concentrations",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Obesity",
      "Fungal Infection"
    ],
    "interventions": [
      "Caspofungin"
    ],
    "primary_completion_date": "2010-12",
    "completion_date": "2010-12",
    "results_first_posted": "2013-01-21",
    "last_update_posted": "2017-02-10",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT04561076",
    "title": "Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers",
    "status": "WITHDRAWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID 19"
    ],
    "interventions": [
      "HLX70",
      "Placebo"
    ],
    "primary_completion_date": "2021-09-06",
    "completion_date": "2021-09-18",
    "results_first_posted": null,
    "last_update_posted": "2022-04-01",
    "enrollment": null,
    "sponsor": "Hengenix Biotech Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT06120985",
    "title": "Rural Appalachia Pilot Water Treatment Trial",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Water-Related Diseases",
      "Enteric Pathogens",
      "Exposure to Chemical Pollution"
    ],
    "interventions": [
      "Countertop pitcher water filter"
    ],
    "primary_completion_date": "2025-11-08",
    "completion_date": "2025-11-08",
    "results_first_posted": null,
    "last_update_posted": "2026-01-16",
    "enrollment": null,
    "sponsor": "Virginia Polytechnic Institute and State University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT04685226",
    "title": "A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumors"
    ],
    "interventions": [
      "ICP-723"
    ],
    "primary_completion_date": "2028-01-25",
    "completion_date": "2028-02-25",
    "results_first_posted": null,
    "last_update_posted": "2025-09-02",
    "enrollment": null,
    "sponsor": "Beijing InnoCare Pharma Tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03123263",
    "title": "Echocardiographic Changes During Adjuvant Therapy in Hispanic Women With Her-2 Neu Expressing Breast Cancer",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Breast Cancer"
    ],
    "interventions": [],
    "primary_completion_date": "2019-02-26",
    "completion_date": "2019-02-26",
    "results_first_posted": "2019-09-09",
    "last_update_posted": "2019-09-09",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center, El Paso",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05367232",
    "title": "A Study of ICP-033 in Patients With Advanced Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Patients With Advanced Solid Tumors"
    ],
    "interventions": [
      "ICP-033 tablet"
    ],
    "primary_completion_date": "2024-12",
    "completion_date": "2025-12",
    "results_first_posted": null,
    "last_update_posted": "2024-02-07",
    "enrollment": null,
    "sponsor": "Beijing InnoCare Pharma Tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT06292858",
    "title": "Safety/Tolerability, PK and Efficacy of IMB071703 Injection in Patients With Advanced Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Recurrent or Metastatic, Advanced Solid Tumors"
    ],
    "interventions": [
      "IMB071703 injection"
    ],
    "primary_completion_date": "2025-04",
    "completion_date": "2025-08",
    "results_first_posted": null,
    "last_update_posted": "2024-03-05",
    "enrollment": null,
    "sponsor": "Beijng Immunoah Pharma Tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT04261504",
    "title": "Brain Mechanisms of Reducing Polysubstance Use Following a Novel Body-mind Intervention",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple Drug Use"
    ],
    "interventions": [
      "IBMT",
      "RT"
    ],
    "primary_completion_date": "2023-02-28",
    "completion_date": "2023-02-28",
    "results_first_posted": "2024-05-02",
    "last_update_posted": "2024-05-29",
    "enrollment": null,
    "sponsor": "Texas Tech University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT02163928",
    "title": "Evaluation of Changes in Skin Carotenoid Scores in Medical Students Following Dietary Interventions",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Health Behavior"
    ],
    "interventions": [
      "Food-based intervention; increased fruits and vegetables"
    ],
    "primary_completion_date": "2016-12-14",
    "completion_date": "2016-12-14",
    "results_first_posted": null,
    "last_update_posted": "2020-02-05",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT01002664",
    "title": "Efficacy and Safety of MCS-2 in the Treatment of Lower Urinary Tract Symptoms",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lower Urinary Tract Symptoms",
      "Benign Prostatic Hyperplasia"
    ],
    "interventions": [
      "MCS-2",
      "Placebo"
    ],
    "primary_completion_date": "2014-06",
    "completion_date": "2014-06",
    "results_first_posted": null,
    "last_update_posted": "2018-08-02",
    "enrollment": null,
    "sponsor": "Health Ever Bio-Tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT04031092",
    "title": "Use of Wearable Tech to Increase Physical Activity in Inpatient Rehabilitation for Patients With Chronic Pain",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Pain",
      "Musculoskeletal Pain"
    ],
    "interventions": [
      "Wearable tech with feedback",
      "Wearable tech without feedback",
      "Rehabilitation program"
    ],
    "primary_completion_date": "2020-01-14",
    "completion_date": "2020-01-14",
    "results_first_posted": null,
    "last_update_posted": "2020-01-27",
    "enrollment": null,
    "sponsor": "Norwegian University of Science and Technology",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT06726564",
    "title": "A Study of MT027 in Patients with Pleural Malignant Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Malignant Solid Tumor",
      "Malignant Pleural Effusion",
      "Pleura Carcinoma",
      "Pleural Mesothelioma",
      "Pleural Malignant Mesothelioma",
      "Pleural Metastases"
    ],
    "interventions": [
      "MT027 cells suspension"
    ],
    "primary_completion_date": "2026-05",
    "completion_date": "2029-02",
    "results_first_posted": null,
    "last_update_posted": "2024-12-10",
    "enrollment": null,
    "sponsor": "Suzhou Maximum Bio-tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT02591186",
    "title": "Effect of Acupuncture on Vascular Biomarkers and Psychological Well-Being of Women Undergoing IVF",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Infertility"
    ],
    "interventions": [
      "Acupuncture"
    ],
    "primary_completion_date": "2020-07-01",
    "completion_date": "2020-09-01",
    "results_first_posted": null,
    "last_update_posted": "2020-09-16",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05355766",
    "title": "Long-term Clinical Study of CN128 in Thalassemia With Sever Liver Iron Overloaded Patients",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Thalassemia",
      "Iron Overload"
    ],
    "interventions": [
      "CN128 Tablets"
    ],
    "primary_completion_date": "2024-09-23",
    "completion_date": "2025-03-06",
    "results_first_posted": null,
    "last_update_posted": "2025-03-14",
    "enrollment": null,
    "sponsor": "Hangzhou Zede Pharma-Tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT07267845",
    "title": "The Effect of \u03b1-GPC on Cognitive Function and Sports Performance",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants"
    ],
    "interventions": [
      "Alpha-Glycerophosphocholine\uff08\u03b1-GPC\uff09",
      "Microcrystalline Cellulose (placebo)"
    ],
    "primary_completion_date": "2026-05-15",
    "completion_date": "2026-07-05",
    "results_first_posted": null,
    "last_update_posted": "2025-12-09",
    "enrollment": null,
    "sponsor": "Nanjing Nutrabuilding Bio-tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05280925",
    "title": "Episodic Future Thinking to Improve Management of Type 2 Diabetes: Remote Delivery and Outcomes Assessment",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 2 Diabetes",
      "Overweight and Obesity"
    ],
    "interventions": [
      "Episodic Future Thinking",
      "Healthy Information Thinking"
    ],
    "primary_completion_date": "2025-01-15",
    "completion_date": "2025-04-15",
    "results_first_posted": null,
    "last_update_posted": "2025-06-26",
    "enrollment": null,
    "sponsor": "Virginia Polytechnic Institute and State University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT01002274",
    "title": "Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lower Urinary Tract Symptoms",
      "Benign Prostatic Hyperplasia"
    ],
    "interventions": [
      "MCS-2"
    ],
    "primary_completion_date": "2014-06",
    "completion_date": "2014-06",
    "results_first_posted": null,
    "last_update_posted": "2016-11-11",
    "enrollment": null,
    "sponsor": "Health Ever Bio-Tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT00851591",
    "title": "Effect of Fenugreek on Milk Production",
    "status": "TERMINATED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lactation"
    ],
    "interventions": [
      "fenugreek",
      "Placebo (Psyllium)"
    ],
    "primary_completion_date": "2012-08",
    "completion_date": "2012-08",
    "results_first_posted": "2014-07-28",
    "last_update_posted": "2018-06-26",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03908697",
    "title": "Quantum Natural Family Planning Pilot",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fertility Disorders"
    ],
    "interventions": [
      "Mira monitor comparison to ClearBlue monitor"
    ],
    "primary_completion_date": "2021-02-28",
    "completion_date": "2021-04-22",
    "results_first_posted": null,
    "last_update_posted": "2025-03-24",
    "enrollment": null,
    "sponsor": "Quanovate Tech Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT02061774",
    "title": "Postoperative Opioid Use and Pain Scores in Patients Undergoing Transforaminal Lumbar Interbody Fusion",
    "status": "TERMINATED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Low Back Pain"
    ],
    "interventions": [
      "Acetaminophen",
      "Placebo comparator"
    ],
    "primary_completion_date": "2018-01-11",
    "completion_date": "2018-01-11",
    "results_first_posted": "2020-04-24",
    "last_update_posted": "2020-05-06",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT02132455",
    "title": "The Utility of Timed Segmental Withdrawal During Screening Colonoscopy",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Colonoscopy"
    ],
    "interventions": [
      "colonoscopy"
    ],
    "primary_completion_date": "2015-12",
    "completion_date": "2016-07",
    "results_first_posted": null,
    "last_update_posted": "2017-05-12",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center, El Paso",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT01307917",
    "title": "Flavonoids in the Treatment of Endothelial Dysfunction in Children With Diabetes",
    "status": "WITHDRAWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetic Nephropathy",
      "Endothelial Dysfunction"
    ],
    "interventions": [
      "flavonoids"
    ],
    "primary_completion_date": "2012-09",
    "completion_date": "2012-09",
    "results_first_posted": null,
    "last_update_posted": "2012-12-17",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05616741",
    "title": "Home-based Biofeedback for the Prevention of Migraine",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Migraine"
    ],
    "interventions": [
      "Cerebri biofeedback",
      "Cerebri headache diary"
    ],
    "primary_completion_date": "2024-06-19",
    "completion_date": "2024-09-23",
    "results_first_posted": null,
    "last_update_posted": "2025-09-18",
    "enrollment": null,
    "sponsor": "Nordic Brain Tech AS",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03061357",
    "title": "Physical Activity Intervention Among College Students",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Physical Activity"
    ],
    "interventions": [
      "Activity tracker"
    ],
    "primary_completion_date": "2016-07-31",
    "completion_date": "2016-12-31",
    "results_first_posted": null,
    "last_update_posted": "2017-02-23",
    "enrollment": null,
    "sponsor": "Texas Tech University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT04455295",
    "title": "Testing the Noradrenergic Hypothesis of Transcutaneous Vagus Nerve Stimulation",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "no Condition",
      "Electroencephalography",
      "Pupil Diameter"
    ],
    "interventions": [
      "Transdermal Vagus Nerve Stimulation (tVNS)"
    ],
    "primary_completion_date": "2025-06-01",
    "completion_date": "2025-06-01",
    "results_first_posted": null,
    "last_update_posted": "2024-02-28",
    "enrollment": null,
    "sponsor": "Arkansas Tech University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT04046003",
    "title": "Tai Chi for Knee OA Pain Management: a Mechanistic Study",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Knee Osteoarthritis",
      "Mind-body Exercise"
    ],
    "interventions": [
      "Tai chi exercise"
    ],
    "primary_completion_date": "2024-06-30",
    "completion_date": "2024-08-31",
    "results_first_posted": null,
    "last_update_posted": "2025-03-28",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT02589327",
    "title": "Effects of Exercise on Cardiac Fat in Women With Obesity: a Pilot Study",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Obesity"
    ],
    "interventions": [
      "Exercise Intervention"
    ],
    "primary_completion_date": "2016-05",
    "completion_date": "2016-05",
    "results_first_posted": null,
    "last_update_posted": "2016-05-11",
    "enrollment": null,
    "sponsor": "Texas Tech University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT04309188",
    "title": "Stroboscopic Vision Training in Softball",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Sports Performance",
      "Vision, Ocular"
    ],
    "interventions": [
      "Senaptec Strobe Glasses",
      "Standard softball drills"
    ],
    "primary_completion_date": "2025-10-29",
    "completion_date": "2025-12-29",
    "results_first_posted": null,
    "last_update_posted": "2025-02-19",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03916263",
    "title": "Low Starch Dietary Education Program vs. Traditional Treatment for PCOS",
    "status": "COMPLETED",
    "phase": "EARLY_PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "PCOS",
      "Diet Modification",
      "Metabolism",
      "Nutrition Disorders"
    ],
    "interventions": [
      "Metformin",
      "One-On-One Dietary Instruction",
      "Video Dietary Instruction"
    ],
    "primary_completion_date": "2022-10-10",
    "completion_date": "2022-12-31",
    "results_first_posted": null,
    "last_update_posted": "2023-08-07",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT04711148",
    "title": "A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsing Remitting Multiple Sclerosis"
    ],
    "interventions": [
      "placebo",
      "orelabrutinib"
    ],
    "primary_completion_date": "2026-02-25",
    "completion_date": "2026-03-01",
    "results_first_posted": null,
    "last_update_posted": "2023-04-21",
    "enrollment": null,
    "sponsor": "Beijing InnoCare Pharma Tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT04348357",
    "title": "Utilizing Telemedicine for Delivery of Postoperative Care",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Laparoscopic Gynecologic Surgery"
    ],
    "interventions": [
      "Telemedicine",
      "Office visit"
    ],
    "primary_completion_date": "2020-05-06",
    "completion_date": "2020-05-06",
    "results_first_posted": "2020-07-07",
    "last_update_posted": "2020-07-07",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center, El Paso",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT06845995",
    "title": "Effects of a Synbiotic Supplement on Metabolic & Cognitive Outcomes Among Older Adults",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Older Adults",
      "Bioelectrical Impedance",
      "Appetite Hormones",
      "Metabolic Health",
      "Body Composition Measurement",
      "Cognitive Health"
    ],
    "interventions": [
      "Synbiotic supplement"
    ],
    "primary_completion_date": "2024-07-09",
    "completion_date": "2024-07-09",
    "results_first_posted": null,
    "last_update_posted": "2025-02-25",
    "enrollment": null,
    "sponsor": "Texas Tech University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT04051034",
    "title": "Heat Therapy and Omega 3 on Cardio-Metabolic Health",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypertension"
    ],
    "interventions": [
      "Omega 3",
      "Placebo"
    ],
    "primary_completion_date": "2020-08-01",
    "completion_date": "2020-08-01",
    "results_first_posted": null,
    "last_update_posted": "2019-08-14",
    "enrollment": null,
    "sponsor": "Texas Tech University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT00220896",
    "title": "Prevention of Postoperative Delirium With Donepezil",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cognitively Normal Elderly Individuals"
    ],
    "interventions": [
      "Donepezil"
    ],
    "primary_completion_date": null,
    "completion_date": "2009-03",
    "results_first_posted": null,
    "last_update_posted": "2011-09-14",
    "enrollment": null,
    "sponsor": "Technical University of Munich",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05334992",
    "title": "Reducing Mental Health in Informal Caregivers",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Mental Health Issue",
      "Grief",
      "Burden, Caregiver"
    ],
    "interventions": [
      "Mindfulness Based Cognitive Therapy",
      "Behavior Activation"
    ],
    "primary_completion_date": "2028-12-31",
    "completion_date": "2028-12-31",
    "results_first_posted": null,
    "last_update_posted": "2025-05-11",
    "enrollment": null,
    "sponsor": "Texas Tech University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05619809",
    "title": "Chronic Thermogenic Dietary Supplement Consumption",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Body Composition Changes",
      "Body Weight Changes",
      "Anthropometric Changes",
      "Metabolism Changes",
      "Hemodynamic Changes"
    ],
    "interventions": [
      "Thermogenic dietary supplement",
      "Protein supplement",
      "Placebo supplement"
    ],
    "primary_completion_date": "2023-05-15",
    "completion_date": "2023-05-15",
    "results_first_posted": null,
    "last_update_posted": "2023-10-10",
    "enrollment": null,
    "sponsor": "Texas Tech University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03577626",
    "title": "A Food Effect Study to Assess Pharmacokinetics of Hemay005 in Healthy Volunteers",
    "status": "UNKNOWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Psoriasis"
    ],
    "interventions": [
      "Hemay005",
      "Hemay005"
    ],
    "primary_completion_date": "2018-11-10",
    "completion_date": "2019-03-01",
    "results_first_posted": null,
    "last_update_posted": "2018-07-05",
    "enrollment": null,
    "sponsor": "Tianjin Hemay Bio-Tech Co., Ltd",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT02850835",
    "title": "Video Decision Aid in Latina Women With Pelvic Organ Prolapse",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pelvic Organ Prolapse"
    ],
    "interventions": [
      "Video Decision Aid"
    ],
    "primary_completion_date": "2017-08-17",
    "completion_date": "2018-12-31",
    "results_first_posted": null,
    "last_update_posted": "2019-04-26",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center, El Paso",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT01003171",
    "title": "Pharmacokinetics of MCS in Healthy Volunteers",
    "status": "UNKNOWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "MCS-2 soft-gel capsule"
    ],
    "primary_completion_date": "2012-12",
    "completion_date": "2012-12",
    "results_first_posted": null,
    "last_update_posted": "2011-06-30",
    "enrollment": null,
    "sponsor": "Health Ever Bio-Tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT01916421",
    "title": "The Cellularity Yield of Three Different 22-gauge FNA Needles",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pancreatic or Peripancreatic Lesions",
      "Lesions in the Esophagus, Stomach, Duodenum or Rectum",
      "Mediastinal ( Chest) Masses",
      "Enlarged Lymph Nodes"
    ],
    "interventions": [
      "Endoscopic Ultrasound Fine Needle Aspiration (EUS-FNA)"
    ],
    "primary_completion_date": "2014-09",
    "completion_date": "2014-09",
    "results_first_posted": null,
    "last_update_posted": "2017-05-17",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center, El Paso",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT02945332",
    "title": "Incentivizing Lifestyle Modification to Reduce Disease Burden",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Obesity",
      "Diabetes Mellitus"
    ],
    "interventions": [
      "Required supervised walking",
      "Non-required supervised walking",
      "Fitbit Flex"
    ],
    "primary_completion_date": "2016-12",
    "completion_date": "2016-12",
    "results_first_posted": "2025-11-24",
    "last_update_posted": "2025-11-24",
    "enrollment": null,
    "sponsor": "Texas Tech University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03432572",
    "title": "Investigating Oral Agents for Urine Staining to Facilitate Intraoperative Observation of Ureteral Jets",
    "status": "COMPLETED",
    "phase": "EARLY_PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ureteral Injury"
    ],
    "interventions": [
      "Pyridium",
      "Riboflavin",
      "Thiamine"
    ],
    "primary_completion_date": "2020-06-30",
    "completion_date": "2020-06-30",
    "results_first_posted": null,
    "last_update_posted": "2020-08-11",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05589467",
    "title": "Effects of Potatoes on Blood Pressure in Persons With and Without Type 2 Diabetes Who Follow the DASH Diet for 6 Weeks",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 2 Diabetes",
      "Blood Pressure"
    ],
    "interventions": [
      "DASH-FP",
      "DASH-NFP",
      "Control"
    ],
    "primary_completion_date": "2022-10-13",
    "completion_date": "2022-10-13",
    "results_first_posted": null,
    "last_update_posted": "2024-07-25",
    "enrollment": null,
    "sponsor": "Texas Tech University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT02955472",
    "title": "Bioequivalence Study of Two Formulations of Pregabalin CR (Controlled-release) Table 150 mg",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "GLA5PR GLARS-NF3 tablet 150mg",
      "GLA5PR GLARS-NF1 tablet 150mg"
    ],
    "primary_completion_date": "2016-11",
    "completion_date": "2017-04",
    "results_first_posted": null,
    "last_update_posted": "2017-04-12",
    "enrollment": null,
    "sponsor": "GL Pharm Tech Corporation",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT00978861",
    "title": "Clinical Study to Evaluate of The Whitening Efficacy and Safety of REMEWHITE",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Tooth Whitening"
    ],
    "interventions": [
      "Hydrogen Peroxide"
    ],
    "primary_completion_date": "2009-06",
    "completion_date": "2009-08",
    "results_first_posted": null,
    "last_update_posted": "2009-09-17",
    "enrollment": null,
    "sponsor": "JDC Tech",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT06140420",
    "title": "Naltrexone for Prolonged Grief Disorder",
    "status": "TERMINATED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Naltrexone HCl 50 MG Oral Tablet",
      "Placebo"
    ],
    "interventions": [
      "Naltrexone Oral Product",
      "Placebo"
    ],
    "primary_completion_date": "2025-02-01",
    "completion_date": "2025-02-01",
    "results_first_posted": null,
    "last_update_posted": "2025-06-08",
    "enrollment": null,
    "sponsor": "Texas Tech University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT04180787",
    "title": "Effects of a Caffeine- and Protein-Containing Coffee Beverage on Metabolism and Muscular Performance",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Exercise Performance",
      "Metabolism"
    ],
    "interventions": [
      "Beverage Consumption"
    ],
    "primary_completion_date": "2020-03-09",
    "completion_date": "2020-03-09",
    "results_first_posted": null,
    "last_update_posted": "2020-05-07",
    "enrollment": null,
    "sponsor": "Texas Tech University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT06737146",
    "title": "Study of MT027 in Patients with Recurrent or Progressive High-grade Glioma",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "High-grade Glioma"
    ],
    "interventions": [
      "MT027 cells suspension"
    ],
    "primary_completion_date": "2026-06-30",
    "completion_date": "2026-12-30",
    "results_first_posted": null,
    "last_update_posted": "2024-12-17",
    "enrollment": null,
    "sponsor": "Suzhou Maximum Bio-tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT06952816",
    "title": "Validation Study of the EMILY AI Device in Acute and Chronic Respiratory Failure",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Respiratory Failure",
      "Acute Respiratory Failure"
    ],
    "interventions": [
      "Emily.AI"
    ],
    "primary_completion_date": "2025-06-30",
    "completion_date": "2026-12-30",
    "results_first_posted": null,
    "last_update_posted": "2026-01-09",
    "enrollment": null,
    "sponsor": "Aether Tech S.L.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT07214974",
    "title": "Mild Cognitive Impairment Community Screening and Early Intervention Via Stem Cell Therapy and Wearable Brain Computer Interface Device.",
    "status": "NOT_YET_RECRUITING",
    "phase": "EARLY_PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Mild Cognitive Impairment (MCI)",
      "Early Stages of Cognitive Decline",
      "Alzheimer's Disease Dementia",
      "Alzheimer's Disease Diagnosis",
      "Alzheimer's Disease and Related Dementias",
      "Parkinson's Disease",
      "Parkinson's Disease (PD)",
      "Parkinson's Disease With Wearing-off Motor Fluctuations",
      "Dementia (Diagnosis)",
      "Dementia MCI (Mild Cognitive Impairment)"
    ],
    "interventions": [
      "Structured wellness care",
      "Wearable brain-computer interface devices",
      "Stem Cell Therapy - Experimental",
      "Control - Placebo Comparator"
    ],
    "primary_completion_date": "2029-01-03",
    "completion_date": "2030-01-03",
    "results_first_posted": null,
    "last_update_posted": "2025-10-09",
    "enrollment": null,
    "sponsor": "Noah Tech, Corp.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT00988468",
    "title": "Manual Therapy Versus Exercise on Knee Osteoarthritis",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Knee Osteoarthritis"
    ],
    "interventions": [
      "Manual Therapy",
      "Therapeutic Exercise",
      "Video Observation"
    ],
    "primary_completion_date": "2010-05",
    "completion_date": "2010-08",
    "results_first_posted": null,
    "last_update_posted": "2010-11-16",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT06016478",
    "title": "The Effect of 4 Weeks of L-Citrulline Supplementation on Macro- and Microvascular Function in Type 2 Diabetes",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 2 Diabetes"
    ],
    "interventions": [
      "L-citrulline",
      "Placebo"
    ],
    "primary_completion_date": "2024-07-01",
    "completion_date": "2024-07-01",
    "results_first_posted": null,
    "last_update_posted": "2025-05-15",
    "enrollment": null,
    "sponsor": "Texas Tech University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT01002417",
    "title": "MCS in the Treatment of Lower Urinary Tract Symptoms",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lower Urinary Tract Symptoms",
      "Benign Prostatic Hyperplasia"
    ],
    "interventions": [
      "MCS-2 15 mg/day",
      "MCS-2 30 mg/day",
      "Placebo"
    ],
    "primary_completion_date": "2014-02",
    "completion_date": "2014-02",
    "results_first_posted": null,
    "last_update_posted": "2015-03-03",
    "enrollment": null,
    "sponsor": "Health Ever Bio-Tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03404271",
    "title": "Time-Restricted Feeding Plus Resistance Training in Active Females",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Active Females"
    ],
    "interventions": [
      "Beta-hydroxy beta-methylbutyrate",
      "Resistance Training",
      "Protein Supplementation",
      "Time-Restricted Feeding"
    ],
    "primary_completion_date": "2018-08-15",
    "completion_date": "2018-08-15",
    "results_first_posted": null,
    "last_update_posted": "2018-09-12",
    "enrollment": null,
    "sponsor": "Texas Tech University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT04819386",
    "title": "NEIVATECH Virtual Reality-based System for Amblyopia",
    "status": "TERMINATED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Amblyopia"
    ],
    "interventions": [
      "Active vision therapy sessions with the NEIVATECH Virtual Reality-based system"
    ],
    "primary_completion_date": "2024-07-01",
    "completion_date": "2024-09-30",
    "results_first_posted": null,
    "last_update_posted": "2024-10-04",
    "enrollment": null,
    "sponsor": "Increase-Tech",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05678270",
    "title": "A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Intrahepatic Cholangiocarcinoma (ICC)"
    ],
    "interventions": [
      "ICP-192"
    ],
    "primary_completion_date": "2026-05",
    "completion_date": "2026-12",
    "results_first_posted": null,
    "last_update_posted": "2024-02-07",
    "enrollment": null,
    "sponsor": "Beijing InnoCare Pharma Tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT01671397",
    "title": "Women's Health Project for Women Wanting to Lose Weight",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Obesity"
    ],
    "interventions": [
      "Diet and exercise counseling",
      "Diet, exercise, sleep hygiene counseling"
    ],
    "primary_completion_date": "2014-02",
    "completion_date": "2014-02",
    "results_first_posted": null,
    "last_update_posted": "2014-05-01",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT02303769",
    "title": "Study to Investigate the Efficacy and Safety of GL2702 GLARS-NF1tablet and Harnal-D - Tablet in BPH Patients With LUTS",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Benign Prostatic Hyperplasia"
    ],
    "interventions": [
      "Tamsulosin HCL 0.4mg",
      "Tamsulosin HCL 0.2mg"
    ],
    "primary_completion_date": "2015-05",
    "completion_date": "2015-10",
    "results_first_posted": null,
    "last_update_posted": "2016-02-25",
    "enrollment": null,
    "sponsor": "GL Pharm Tech Corporation",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT02900781",
    "title": "Comparative Effectiveness of an Activity-specific Monitoring Device- StepRite",
    "status": "TERMINATED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Osteoarthritis",
      "Degenerative Joint Disease"
    ],
    "interventions": [
      "Steprite\u2122",
      "Standard of care"
    ],
    "primary_completion_date": "2017-11",
    "completion_date": "2017-11",
    "results_first_posted": "2019-08-09",
    "last_update_posted": "2019-08-09",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT06941181",
    "title": "Neurocognitive Predictors of Health Risk Behaviors",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Substance Use"
    ],
    "interventions": [
      "neurocognitive tasks"
    ],
    "primary_completion_date": "2029-05-31",
    "completion_date": "2029-05-31",
    "results_first_posted": null,
    "last_update_posted": "2025-05-21",
    "enrollment": null,
    "sponsor": "Virginia Polytechnic Institute and State University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05757505",
    "title": "The Efficacy and Safety of Intracranial Stent (Tonbridge) in Endovascular Treatment of Symptomatic Intracranial Atherosclerotic Stenosis",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Intracranial Atherosclerosis"
    ],
    "interventions": [
      "Intracranial Stent (Tonbridge)",
      "Wingspan Stent System (Stryker Neurovascular)"
    ],
    "primary_completion_date": "2026-01",
    "completion_date": "2026-12",
    "results_first_posted": null,
    "last_update_posted": "2026-01-02",
    "enrollment": null,
    "sponsor": "Ton-Bridge Medical Tech. Co., Ltd",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03910075",
    "title": "Perinatal Arterial Stroke: A Multi-site RCT of Intensive Infant Rehabilitation (I-ACQUIRE)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Perinatal Stroke",
      "Hemiparesis"
    ],
    "interventions": [
      "I-ACQUIRE - High Dosage",
      "I-ACQUIRE - Moderate Dosage",
      "Usual & Customary Treatment (U&CT)"
    ],
    "primary_completion_date": "2025-07-31",
    "completion_date": "2025-07-31",
    "results_first_posted": null,
    "last_update_posted": "2026-01-16",
    "enrollment": null,
    "sponsor": "Virginia Polytechnic Institute and State University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT02326987",
    "title": "A Clinical Trial to Compare The Pharmacokinetics of A Pregabalin GLARS-NF1 Tablet 150mg With Immediate Release Formulation and to Assess The Effect of High Fat Diet in Healthy Male Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "Pregabalin 150mg",
      "Pregabalin 75mg"
    ],
    "primary_completion_date": "2013-11",
    "completion_date": "2013-11",
    "results_first_posted": null,
    "last_update_posted": "2014-12-30",
    "enrollment": null,
    "sponsor": "GL Pharm Tech Corporation",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05774704",
    "title": "Curcumin and Retinal Study",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bioavailability",
      "Gut Microbiome",
      "Safety"
    ],
    "interventions": [
      "Low curcumin group",
      "High curcumin group"
    ],
    "primary_completion_date": "2026-12-31",
    "completion_date": "2026-12-31",
    "results_first_posted": null,
    "last_update_posted": "2026-01-13",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05755516",
    "title": "Efficacy and Safety of the Self-expanding Intracranial Stent (Tonbridge) for Endovascular Treatment of Intracranial Aneurysms",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Intracranial Aneurysm"
    ],
    "interventions": [
      "Self-expanding Intracranial Stent (Tonbridge)",
      "LVIS and LVIS Jr. (MicroVention)"
    ],
    "primary_completion_date": "2024-03-10",
    "completion_date": "2024-12-13",
    "results_first_posted": null,
    "last_update_posted": "2026-01-02",
    "enrollment": null,
    "sponsor": "Ton-Bridge Medical Tech. Co., Ltd",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05552937",
    "title": "Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "DLBCL"
    ],
    "interventions": [
      "Tafasitamab and Lenalidomide"
    ],
    "primary_completion_date": "2025-04",
    "completion_date": "2027-04",
    "results_first_posted": null,
    "last_update_posted": "2022-09-23",
    "enrollment": null,
    "sponsor": "Beijing InnoCare Pharma Tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05591612",
    "title": "Increasing Vegetable Intake Using Monosodium Glutamate: A Reduced-Effort Intervention",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Nutrition",
      "Culinary Medicine",
      "Sodium Excess"
    ],
    "interventions": [
      "Salt replacement seasoning (50% salt and 50% MSG) mix",
      "Salt replacement seasoning (70% salt and 30% MSG) mix",
      "NaCl (sodium chloride/table salt)"
    ],
    "primary_completion_date": "2023-11-15",
    "completion_date": "2023-11-15",
    "results_first_posted": null,
    "last_update_posted": "2024-08-01",
    "enrollment": null,
    "sponsor": "Texas Tech University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT01949584",
    "title": "Study of Nasal Airflow Pressure Optimization to Resolve Excessive Snoring",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Snoring"
    ],
    "interventions": [
      "nasal continuous positive airway pressure less than or equal to 6 cm H2O"
    ],
    "primary_completion_date": "2014-07",
    "completion_date": "2014-12",
    "results_first_posted": null,
    "last_update_posted": "2015-03-24",
    "enrollment": null,
    "sponsor": "inSleep Technologies, LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT06585865",
    "title": "Strength Training and Resveratrol",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Sarcopenia",
      "Anabolic Resistance"
    ],
    "interventions": [
      "Resistance training",
      "Resveratrol 500 mg oral once daily.",
      "Placebo"
    ],
    "primary_completion_date": "2026-07",
    "completion_date": "2026-08",
    "results_first_posted": null,
    "last_update_posted": "2025-06-29",
    "enrollment": null,
    "sponsor": "Texas Tech University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT01251406",
    "title": "Efficacy and Safety of Human Neuregulin-1 to Treat Stable Chronic Heart Failure",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Heart Failure"
    ],
    "interventions": [
      "Placebo",
      "rhNRG-1 Dose 1",
      "rhNRG-1 Dose 2"
    ],
    "primary_completion_date": "2012-12",
    "completion_date": "2014-03",
    "results_first_posted": null,
    "last_update_posted": "2025-02-10",
    "enrollment": null,
    "sponsor": "Zensun Sci. & Tech. Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT02596867",
    "title": "Neoadjuvant Propanolol in Breast Cancer",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Cancer"
    ],
    "interventions": [
      "propanolol"
    ],
    "primary_completion_date": "2017-05-01",
    "completion_date": "2017-05-01",
    "results_first_posted": "2018-02-01",
    "last_update_posted": "2018-03-01",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center, El Paso",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT01439893",
    "title": "Study of Efficacy on Cardiac Remodeling of Recombinant Human Neuregulin-1 in Stable Chronic Systolic Heart Failure Patients",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Systolic Heart Failure"
    ],
    "interventions": [
      "rhNRG-1",
      "Placebo"
    ],
    "primary_completion_date": "2012-06",
    "completion_date": "2012-06",
    "results_first_posted": null,
    "last_update_posted": "2017-12-21",
    "enrollment": null,
    "sponsor": "Zensun Sci. & Tech. Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT07275645",
    "title": "A Clinical Trial of Rabies Vaccine\uff08Human Diploid Cell\uff09for Human Use,Freeze-dried in a Population Aged 10 to 60 Years",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rabies"
    ],
    "interventions": [
      "Rabies Vaccine\uff08Human Diploid Cell\uff09for Human Use,Freeze-dried",
      "Rabies Vaccine\uff08Human Diploid Cell\uff09for Human Use,Freeze-dried",
      "Rabies Vaccine\uff08Human Diploid Cell\uff09for Human Use,Freeze-dried",
      "Rabies Vaccine\uff08Human Diploid Cell\uff09for Human Use,Freeze-dried",
      "Rabies Vaccine\uff08Human Diploid Cell\uff09for Human Use,Freeze-dried"
    ],
    "primary_completion_date": "2026-02-18",
    "completion_date": "2027-02-18",
    "results_first_posted": null,
    "last_update_posted": "2025-12-18",
    "enrollment": null,
    "sponsor": "Ab&B Bio-tech Co., Ltd.JS",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT06846099",
    "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ovarian Cancer",
      "Cervical Cancer",
      "Endometrial Cancer",
      "Breast Cancer",
      "Solid Tumor Cancer"
    ],
    "interventions": [
      "RP903"
    ],
    "primary_completion_date": "2025-05-30",
    "completion_date": "2025-05-30",
    "results_first_posted": null,
    "last_update_posted": "2025-12-23",
    "enrollment": null,
    "sponsor": "Risen (Suzhou) Pharma Tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05458778",
    "title": "Detection of Urinary Human Chorionic Gonadotropin (hCG)",
    "status": "UNKNOWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Pregnancy Detection"
    ],
    "interventions": [
      "Daily test with urine by the product"
    ],
    "primary_completion_date": "2023-10-31",
    "completion_date": "2023-10-31",
    "results_first_posted": null,
    "last_update_posted": "2023-05-01",
    "enrollment": null,
    "sponsor": "Quanovate Tech Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03609255",
    "title": "Health Effects of Reducing Sedentary Behavior",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "General Population"
    ],
    "interventions": [
      "Reducing sedentary behavior",
      "Reducing stress",
      "Control"
    ],
    "primary_completion_date": "2018-10-08",
    "completion_date": "2018-10-08",
    "results_first_posted": null,
    "last_update_posted": "2018-10-24",
    "enrollment": null,
    "sponsor": "Texas Tech University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT01048697",
    "title": "Effect of Weight and/or Obesity on Ethambutol Drug Concentrations",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Obesity",
      "Tuberculosis"
    ],
    "interventions": [
      "Ethambutol"
    ],
    "primary_completion_date": "2010-12",
    "completion_date": "2010-12",
    "results_first_posted": "2013-01-24",
    "last_update_posted": "2013-01-24",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT01447849",
    "title": "Lubiprostone and Mucus Secretion in Patients With Chronic Constipation",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Constipation"
    ],
    "interventions": [
      "lubiprostone",
      "placebo"
    ],
    "primary_completion_date": "2012-11",
    "completion_date": "2012-11",
    "results_first_posted": "2013-09-23",
    "last_update_posted": "2017-06-09",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center, El Paso",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT04196426",
    "title": "Nutrition Education to Promote Calcium Intake Among 30-65 Year-old Women in Vietnam",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Osteoporosis"
    ],
    "interventions": [
      "Nutrition education intervention about osteoporosis and calcium"
    ],
    "primary_completion_date": "2019-08-10",
    "completion_date": "2019-08-10",
    "results_first_posted": null,
    "last_update_posted": "2019-12-13",
    "enrollment": null,
    "sponsor": "Texas Tech University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05734443",
    "title": "Effects of Task-Specific Step Training on Reactive Balance",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Accidental Fall"
    ],
    "interventions": [
      "step training",
      "treadmill training"
    ],
    "primary_completion_date": "2023-08-01",
    "completion_date": "2023-08-01",
    "results_first_posted": "2025-09-24",
    "last_update_posted": "2025-09-24",
    "enrollment": null,
    "sponsor": "Virginia Polytechnic Institute and State University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03085511",
    "title": "High Quality Protein for Assisting With Weight Loss",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Obesity"
    ],
    "interventions": [
      "Egg breakfast (EB)",
      "Weight Loss Counseling",
      "Weight Loss Diet",
      "Cereal Breakfast (CB)"
    ],
    "primary_completion_date": "2019-05-17",
    "completion_date": "2019-05-17",
    "results_first_posted": null,
    "last_update_posted": "2019-05-30",
    "enrollment": null,
    "sponsor": "Texas Tech University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03510364",
    "title": "Subjective Social Status and Energy Balance",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Obesity",
      "Social Dominance",
      "Social Behavior",
      "Eating Behavior"
    ],
    "interventions": [
      "Dietary intervention"
    ],
    "primary_completion_date": "2015-06",
    "completion_date": "2015-06",
    "results_first_posted": null,
    "last_update_posted": "2018-04-27",
    "enrollment": null,
    "sponsor": "Texas Tech University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT01786395",
    "title": "Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis Pigmentosa",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Retinitis Pigmentosa"
    ],
    "interventions": [
      "UF-021",
      "Placebo"
    ],
    "primary_completion_date": "2015-04",
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2016-01-29",
    "enrollment": null,
    "sponsor": "R-Tech Ueno, Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT07165899",
    "title": "Effects of Exposure to a Single-electrode Electroencephalography-guided Binaural Beat Audio Track on Sustained Attention and Subjective Well-being Among Healthy Adults",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Psychomotor Speed",
      "Sustained Attention",
      "Inhibitory Control",
      "Memory Encoding",
      "Well-being"
    ],
    "interventions": [
      "EEG-Guided Binaural Beat Audio",
      "Sham Control"
    ],
    "primary_completion_date": "2024-11-26",
    "completion_date": "2024-11-26",
    "results_first_posted": null,
    "last_update_posted": "2025-09-10",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT01112709",
    "title": "Maintaining Resistance Training in Older Prediabetic Adults",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes",
      "Prediabetes"
    ],
    "interventions": [
      "SCT-based Resistance Training exercise program",
      "Standard Intervention with minimal contact"
    ],
    "primary_completion_date": "2014-03",
    "completion_date": "2014-03",
    "results_first_posted": null,
    "last_update_posted": "2014-03-20",
    "enrollment": null,
    "sponsor": "Virginia Polytechnic Institute and State University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05712525",
    "title": "Gut Recovery In Patients Following Surgery",
    "status": "UNKNOWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Gastrointestinal Diseases",
      "Ileus"
    ],
    "interventions": [
      "G-Tech Wireless Patch System (WPS)"
    ],
    "primary_completion_date": "2023-10-06",
    "completion_date": "2024-10-06",
    "results_first_posted": null,
    "last_update_posted": "2023-02-03",
    "enrollment": null,
    "sponsor": "G-Tech Corporation",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT07236099",
    "title": "Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Prurigo Nodularis (PN)"
    ],
    "interventions": [
      "ICP-322",
      "Placebo"
    ],
    "primary_completion_date": "2027-03",
    "completion_date": "2027-10",
    "results_first_posted": null,
    "last_update_posted": "2026-01-06",
    "enrollment": null,
    "sponsor": "Beijing InnoCare Pharma Tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT07239609",
    "title": "ACT for Individuals With MNCD and Their Care Partners",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Depression in Adults",
      "Anxiety Disorder Generalized",
      "Grief"
    ],
    "interventions": [
      "Acceptance Commitment Therapy"
    ],
    "primary_completion_date": "2027-10-31",
    "completion_date": "2027-12-31",
    "results_first_posted": null,
    "last_update_posted": "2025-11-20",
    "enrollment": null,
    "sponsor": "Texas Tech University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT01829204",
    "title": "Prospective Data Bank Creation to Study Vaginal Conditions",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Vulvodynia",
      "Mycoses",
      "Bacterial Vaginosis",
      "Preterm Labor"
    ],
    "interventions": [],
    "primary_completion_date": "2027-07",
    "completion_date": "2027-12",
    "results_first_posted": null,
    "last_update_posted": "2025-12-18",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05303116",
    "title": "Do EEG and Neurocognitive Assessments Correlate With COVID Brainfog Symptoms?",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "COVID-19"
    ],
    "interventions": [
      "Brainscope modified EEG and cognitive testing"
    ],
    "primary_completion_date": "2024-02-19",
    "completion_date": "2024-02-20",
    "results_first_posted": null,
    "last_update_posted": "2025-05-18",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center, El Paso",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT01307930",
    "title": "Effect of Weight and/or Obesity on Anidulafungin Drug Concentrations",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Obesity",
      "Mycoses"
    ],
    "interventions": [
      "Anidulafungin"
    ],
    "primary_completion_date": "2012-11",
    "completion_date": "2012-11",
    "results_first_posted": "2019-01-09",
    "last_update_posted": "2019-01-09",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT04672447",
    "title": "Effect of 4 Weeks of Citrulline and Glutathione Supplementation on Arterial Function",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Menopause",
      "Cardiovascular Risk Factor"
    ],
    "interventions": [
      "L-Citrulline",
      "L-Citrulline",
      "Placebo",
      "Glutathione"
    ],
    "primary_completion_date": "2022-04-27",
    "completion_date": "2022-04-27",
    "results_first_posted": null,
    "last_update_posted": "2022-10-20",
    "enrollment": null,
    "sponsor": "Texas Tech University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT01258127",
    "title": "Pemetrexed/Carboplatin vs Vinorelbine/Carboplatin in Patients With Completely Resected Non-small Cell Lung Cancer (NSCLC)",
    "status": "UNKNOWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Non-small Cell Lung Cancer"
    ],
    "interventions": [],
    "primary_completion_date": "2012-08",
    "completion_date": "2015-08",
    "results_first_posted": null,
    "last_update_posted": "2010-12-10",
    "enrollment": null,
    "sponsor": "Shanghai Nancy Medical Sci-Tech Co. Ltd",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05740124",
    "title": "Workplace Fall Prevention Through Slip Recovery Training",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Accidental Fall"
    ],
    "interventions": [
      "slip recovery training",
      "alternative balance training"
    ],
    "primary_completion_date": "2024-12-15",
    "completion_date": "2025-03-31",
    "results_first_posted": null,
    "last_update_posted": "2025-06-27",
    "enrollment": null,
    "sponsor": "Virginia Polytechnic Institute and State University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03002506",
    "title": "Pharmacokinetics of Ceftolozane/Tazobactam in Patients With Burns",
    "status": "TERMINATED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Burns",
      "Pharmacokinetics"
    ],
    "interventions": [
      "Ceftolozane/tazobactam"
    ],
    "primary_completion_date": "2020-06-01",
    "completion_date": "2020-06-30",
    "results_first_posted": "2021-03-02",
    "last_update_posted": "2021-03-02",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05384158",
    "title": "Valuation in Depressed Mood, Anhedonia, and Anxiety",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Neurobehavioral Components of Reward and Loss Valuation"
    ],
    "interventions": [
      "cognitive behavioral therapy",
      "valuation with instruction",
      "valuation without instruction"
    ],
    "primary_completion_date": "2026-07",
    "completion_date": "2026-07",
    "results_first_posted": null,
    "last_update_posted": "2025-09-09",
    "enrollment": null,
    "sponsor": "Virginia Polytechnic Institute and State University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03273673",
    "title": "Reduction of Risk Factors for ACL Re-injuries Using a Novel Biofeedback Approach",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Anterior Cruciate Ligament Injury"
    ],
    "interventions": [
      "Biofeedback Intervention"
    ],
    "primary_completion_date": "2020-05-05",
    "completion_date": "2020-05-05",
    "results_first_posted": "2020-12-04",
    "last_update_posted": "2020-12-04",
    "enrollment": null,
    "sponsor": "Virginia Polytechnic Institute and State University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05297383",
    "title": "Combining HIIT and n-3 PUFA Supplementation to Reduce Inflammation and Improve Metabolic Health (HIIT&PUFA)",
    "status": "WITHDRAWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Obesity",
      "Inflammation",
      "Insulin Resistance",
      "Dyslipidemias",
      "Gut Microbiome"
    ],
    "interventions": [
      "Omega-3 Polyunsaturated Fatty Acid.",
      "Safflower Oil",
      "High-Intensity Interval Training",
      "Flexibility Training"
    ],
    "primary_completion_date": "2022-06-01",
    "completion_date": "2022-12-31",
    "results_first_posted": null,
    "last_update_posted": "2025-09-11",
    "enrollment": null,
    "sponsor": "Texas Tech University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT00375440",
    "title": "Tranexamic Acid Study",
    "status": "WITHDRAWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Arthroplasty, Replacement, Hip"
    ],
    "interventions": [
      "Tranexamic Acid"
    ],
    "primary_completion_date": "2008-01",
    "completion_date": "2008-01",
    "results_first_posted": null,
    "last_update_posted": "2015-10-05",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05234684",
    "title": "A Study of Orelabrutinib Plus R-CHOP in Treatment-na\u00efve Patients With MCD Subtype Diffuse Large B-cell Lymphoma",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diffuse Large B Cell Lymphoma (DLBCL)"
    ],
    "interventions": [
      "Orelabrutinib + R-CHOP",
      "Placebo + R-CHOP"
    ],
    "primary_completion_date": "2024-07-30",
    "completion_date": "2025-12-30",
    "results_first_posted": null,
    "last_update_posted": "2024-02-07",
    "enrollment": null,
    "sponsor": "Beijing InnoCare Pharma Tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05295719",
    "title": "Combining HIIT and n-3 PUFA to Reduce Inflammation and Improve Metabolic Health",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Obesity",
      "Inflammation",
      "Human Microbiome",
      "Insulin Resistance",
      "Dyslipidemias"
    ],
    "interventions": [
      "Omega-3 polyunsaturated fatty acid",
      "High-Intensity Interval Training",
      "Safflower oil",
      "Low-intensity training"
    ],
    "primary_completion_date": "2024-12-31",
    "completion_date": "2024-12-31",
    "results_first_posted": null,
    "last_update_posted": "2025-09-11",
    "enrollment": null,
    "sponsor": "Texas Tech University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT06349772",
    "title": "Zynrelef vs Exparel: The Battle of Postoperative Pain Control After Robotic Sleeve Gastrectomy",
    "status": "RECRUITING",
    "phase": "EARLY_PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Post Operative Pain"
    ],
    "interventions": [
      "Zynrelef",
      "Exparel"
    ],
    "primary_completion_date": "2025-11-01",
    "completion_date": "2025-12-01",
    "results_first_posted": null,
    "last_update_posted": "2025-03-21",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03534375",
    "title": "Gender Differences of Neuroanatomical and Neurophysiological Correlates of Risk-proneness in Early Adolescents",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Gender",
      "Early Adolescent Behavior"
    ],
    "interventions": [
      "The study is an observational cross sectional study"
    ],
    "primary_completion_date": "2019-04-30",
    "completion_date": "2019-08-31",
    "results_first_posted": null,
    "last_update_posted": "2021-10-25",
    "enrollment": null,
    "sponsor": "Texas Tech University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03007810",
    "title": "Safety and Pharmacokinetics of Hemay005 In Healthy Male Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Psoriasis"
    ],
    "interventions": [
      "Hemay005",
      "Placebos"
    ],
    "primary_completion_date": "2018-06",
    "completion_date": "2018-06",
    "results_first_posted": null,
    "last_update_posted": "2018-06-19",
    "enrollment": null,
    "sponsor": "Tianjin Hemay Bio-Tech Co., Ltd",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT02455388",
    "title": "d13C Added Sugar Intake Biomarker: Determining Validity in Children",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Validation Studies"
    ],
    "interventions": [
      "High added sugar diet",
      "Low added sugar diet"
    ],
    "primary_completion_date": "2016-07",
    "completion_date": "2018-02",
    "results_first_posted": "2018-07-27",
    "last_update_posted": "2019-02-26",
    "enrollment": null,
    "sponsor": "Virginia Polytechnic Institute and State University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03264092",
    "title": "Comparison of Three Tissue Acquiring Techniques During EUS Guided Biopsies of Solid Tumors.",
    "status": "TERMINATED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor"
    ],
    "interventions": [
      "Endoscopic ultrasound guided fine needle biopsy"
    ],
    "primary_completion_date": "2020-10-01",
    "completion_date": "2020-10-01",
    "results_first_posted": "2021-04-01",
    "last_update_posted": "2021-04-01",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center, El Paso",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT02952937",
    "title": "Bioequivalence Study of Two Formulations of Pregabalin CR(Controlled-release) Table 300 mg",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "GLA5PR GLARS-NF3 tablet 300mg",
      "GLA5PR GLARS-NF1 tablet 300mg"
    ],
    "primary_completion_date": "2016-11",
    "completion_date": "2017-04",
    "results_first_posted": null,
    "last_update_posted": "2017-04-12",
    "enrollment": null,
    "sponsor": "GL Pharm Tech Corporation",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT00232362",
    "title": "Effect of Pioglitazone on Left Ventricular Diastolic Function in Type 2 Diabetes Mellitus",
    "status": "WITHDRAWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 2 Diabetes Mellitus"
    ],
    "interventions": [
      "Pioglitazone (Actos)",
      "Anti-diabetic agent other than pioglitazone or rosiglitazone"
    ],
    "primary_completion_date": null,
    "completion_date": "2008-06",
    "results_first_posted": null,
    "last_update_posted": "2015-04-13",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT06004856",
    "title": "Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Primary Immune Thrombocytopenia (ITP)"
    ],
    "interventions": [
      "Orelabrutinib",
      "Placebo"
    ],
    "primary_completion_date": "2025-12-31",
    "completion_date": "2026-04-30",
    "results_first_posted": null,
    "last_update_posted": "2024-05-13",
    "enrollment": null,
    "sponsor": "Beijing InnoCare Pharma Tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT04646083",
    "title": "Depth of Maximal Ileal Insertion During Retrograde Enteroscopy With TTS Balloon",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Obscure Gastrointestinal Bleeding",
      "Anemia, Iron Deficiency"
    ],
    "interventions": [],
    "primary_completion_date": "2025-12-31",
    "completion_date": "2025-12-31",
    "results_first_posted": null,
    "last_update_posted": "2025-06-18",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center, El Paso",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03594578",
    "title": "Prospective Thinking in Hormone-Responsive Breast Cancer",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hormone Receptor Positive Malignant Neoplasm of Breast"
    ],
    "interventions": [
      "Episodic future thinking",
      "Episodic recent thinking"
    ],
    "primary_completion_date": "2019-09-20",
    "completion_date": "2019-09-20",
    "results_first_posted": null,
    "last_update_posted": "2019-10-01",
    "enrollment": null,
    "sponsor": "Virginia Polytechnic Institute and State University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05210868",
    "title": "A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hematoma"
    ],
    "interventions": [
      "CM355"
    ],
    "primary_completion_date": "2026-12-28",
    "completion_date": "2026-12-31",
    "results_first_posted": null,
    "last_update_posted": "2022-01-27",
    "enrollment": null,
    "sponsor": "Beijing InnoCare Pharma Tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT00232388",
    "title": "Association of PICP Serum Marker in Patients With LVSD",
    "status": "TERMINATED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Systolic Dysfunction"
    ],
    "interventions": [
      "Blood draw"
    ],
    "primary_completion_date": null,
    "completion_date": "2007-09",
    "results_first_posted": null,
    "last_update_posted": "2015-10-07",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05051891",
    "title": "A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-na\u0457ve Mantle Cell Lymphoma",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Treatment-na\u0457ve Mantle Cell Lymphoma"
    ],
    "interventions": [
      "Orelabrutinib and R-CHOP",
      "R-CHOP"
    ],
    "primary_completion_date": "2024-12-31",
    "completion_date": "2027-12-31",
    "results_first_posted": null,
    "last_update_posted": "2022-10-12",
    "enrollment": null,
    "sponsor": "Beijing InnoCare Pharma Tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05026697",
    "title": "Validity and Reliability of Commercially Available Bioelectrical Impedance Analysis Devices",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Body Composition"
    ],
    "interventions": [],
    "primary_completion_date": "2021-12-10",
    "completion_date": "2021-12-10",
    "results_first_posted": null,
    "last_update_posted": "2022-08-09",
    "enrollment": null,
    "sponsor": "Texas Tech University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT06365697",
    "title": "Evaluation of the Ton-bridge Carotid Stent for Carotid Artery Stenosis",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Carotid Artery Stenosis"
    ],
    "interventions": [
      "Ton-bridge carotid stent",
      "WALLSTENT carotid stent"
    ],
    "primary_completion_date": "2024-12-11",
    "completion_date": "2026-10",
    "results_first_posted": null,
    "last_update_posted": "2026-01-02",
    "enrollment": null,
    "sponsor": "Ton-Bridge Medical Tech. Co., Ltd",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT02503891",
    "title": "AL-2 MP-1 (Polyimide) Acetabular Liner",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Osteoarthritis",
      "Avascular Necrosis",
      "Rheumatoid Arthritis",
      "Congenital Dysplasia of the Hip",
      "Ankylosing Spondylitis",
      "Post-traumatic; Arthrosis",
      "Injury of Hip"
    ],
    "interventions": [
      "MP-1 Polymer on Ceramic Articulation system"
    ],
    "primary_completion_date": "2018-09",
    "completion_date": "2020-08",
    "results_first_posted": null,
    "last_update_posted": "2017-12-20",
    "enrollment": null,
    "sponsor": "M.M.A Tech Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05341700",
    "title": "Impact Loading Effect on Bone Biomarkers in Female Runners",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relative Energy Deficiency in Sport"
    ],
    "interventions": [
      "Impact Load Exercises",
      "No Impact Load Exercises"
    ],
    "primary_completion_date": "2024-01-23",
    "completion_date": "2024-04-12",
    "results_first_posted": "2025-08-19",
    "last_update_posted": "2025-08-19",
    "enrollment": null,
    "sponsor": "Virginia Polytechnic Institute and State University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT04859621",
    "title": "Phase II Clinical Trial of Vitamin D3 for Reducing Recurrence of Recurrent Lower Urinary Tract Infections",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Recurrent Urinary Tract Infection"
    ],
    "interventions": [
      "Vitamin D3 4000 IU",
      "Vitamin D3 2000 IU",
      "Placebo",
      "standard antibiotic therapy"
    ],
    "primary_completion_date": "2025-04-30",
    "completion_date": "2025-07-30",
    "results_first_posted": null,
    "last_update_posted": "2024-02-02",
    "enrollment": null,
    "sponsor": "Zensun Sci. & Tech. Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT06656494",
    "title": "ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Myelogenous Leukemia",
      "Myelodysplastic Syndromes (MDS)"
    ],
    "interventions": [
      "ICP-248",
      "Azacitidine"
    ],
    "primary_completion_date": "2027-06",
    "completion_date": "2028-01",
    "results_first_posted": null,
    "last_update_posted": "2026-01-02",
    "enrollment": null,
    "sponsor": "Beijing InnoCare Pharma Tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05668793",
    "title": "GNB4 and Riplet Gene Methylation Combined Detection Kit (Fluorescence PCR Method)",
    "status": "UNKNOWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Hepatocellular Carcinoma"
    ],
    "interventions": [
      "GNB4 and Riplet Gene Methylation Combined Detection Kit (Fluorescent PCR Method)"
    ],
    "primary_completion_date": "2023-10",
    "completion_date": "2023-12",
    "results_first_posted": null,
    "last_update_posted": "2022-12-30",
    "enrollment": null,
    "sponsor": "Wuhan Ammunition Life-tech Co., Ltd",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT00293878",
    "title": "Study on the Safety and Effects on Lipids of FM-VP4 in Subjects With Primary Hypercholesterolemia",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypercholesterolemia"
    ],
    "interventions": [
      "Disodium Ascorbyl Phytostanol Phosphate (FM-VP4)"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2007-02-26",
    "enrollment": null,
    "sponsor": "Forbes Medi-Tech",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03119168",
    "title": "Effect of Simethicone on Screening Colonoscopy",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Adenoma Colon"
    ],
    "interventions": [
      "Simethicone Solution",
      "Polyethylenglycol"
    ],
    "primary_completion_date": "2019-04-10",
    "completion_date": "2019-04-10",
    "results_first_posted": "2019-06-05",
    "last_update_posted": "2019-06-05",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center, El Paso",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05688696",
    "title": "Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Systemic Lupus Erythematosus, SLE"
    ],
    "interventions": [
      "Orelabrutinib (Low Dose)",
      "Orelabrutinib (High Dose)",
      "Orelabrutinib Placebo"
    ],
    "primary_completion_date": "2025-08-25",
    "completion_date": "2026-05-30",
    "results_first_posted": null,
    "last_update_posted": "2024-08-16",
    "enrollment": null,
    "sponsor": "Beijing InnoCare Pharma Tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT02017379",
    "title": "Randomized Control Trial Comparing Prokinetics and Their Influence on Endoscopy Outcomes for Upper GI Bleed.",
    "status": "TERMINATED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Upper Gastrointestinal Bleeding"
    ],
    "interventions": [
      "Erythromycin",
      "Metoclopromide"
    ],
    "primary_completion_date": "2014-09",
    "completion_date": "2014-09",
    "results_first_posted": "2021-03-04",
    "last_update_posted": "2021-03-04",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center, El Paso",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT07082686",
    "title": "A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsed or Refractory Mantle Cell Lymphoma (MCL)"
    ],
    "interventions": [
      "ICP-248"
    ],
    "primary_completion_date": "2027-12",
    "completion_date": "2028-07",
    "results_first_posted": null,
    "last_update_posted": "2025-11-21",
    "enrollment": null,
    "sponsor": "Beijing InnoCare Pharma Tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03039868",
    "title": "Use of Pap Smear Derived Cells to Analyze the Expression of SLC6A14 and GPR81 Genes",
    "status": "TERMINATED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Healthy Volunteer"
    ],
    "interventions": [],
    "primary_completion_date": "2018-05",
    "completion_date": "2018-06",
    "results_first_posted": null,
    "last_update_posted": "2019-11-13",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT04069351",
    "title": "Body Composition Changes During Overfeeding Plus Resistance Training",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Weight Gain",
      "Resistance Training",
      "Overeating"
    ],
    "interventions": [
      "High-calorie mass gainer supplement",
      "Resistance Training"
    ],
    "primary_completion_date": "2019-11-26",
    "completion_date": "2019-11-26",
    "results_first_posted": null,
    "last_update_posted": "2020-05-07",
    "enrollment": null,
    "sponsor": "Texas Tech University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03774407",
    "title": "Vaginal Estriol in Multiple Sclerosis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple Sclerosis",
      "Neurogenic Bladder"
    ],
    "interventions": [
      "vaginal estriol"
    ],
    "primary_completion_date": "2020-11-10",
    "completion_date": "2020-11-29",
    "results_first_posted": "2022-09-21",
    "last_update_posted": "2022-09-21",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT06919536",
    "title": "Controlled Feeding With 24 Hour Recall",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Evaluate Accuracy 24 Dietary Recall"
    ],
    "interventions": [
      "No intervention (observational study)"
    ],
    "primary_completion_date": "2025-09-22",
    "completion_date": "2025-09-22",
    "results_first_posted": null,
    "last_update_posted": "2025-11-18",
    "enrollment": null,
    "sponsor": "Texas Tech University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05090293",
    "title": "Optimizing Weight Loss Outcomes Through Body Image Enhancement",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Overweight and Obesity"
    ],
    "interventions": [
      "Experimental: Lifestyle Intervention with Body Image Treatment (LIBI)",
      "Lifestyle Intervention (LI)"
    ],
    "primary_completion_date": "2022-05-08",
    "completion_date": "2022-05-08",
    "results_first_posted": null,
    "last_update_posted": "2022-11-03",
    "enrollment": null,
    "sponsor": "Texas Tech University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03550638",
    "title": "Coil System(Ton-bridgeMT) for Endovascular Embolization of Cranial Aneurysms",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Intracranial Aneurysms"
    ],
    "interventions": [
      "Coil system(Ton-bridgeMT)",
      "Axium Detachable Coil(Medtronic)"
    ],
    "primary_completion_date": "2020-01-03",
    "completion_date": "2020-09-02",
    "results_first_posted": null,
    "last_update_posted": "2021-04-08",
    "enrollment": null,
    "sponsor": "Ton-Bridge Medical Tech. Co., Ltd",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT02464787",
    "title": "Evaluation of Changes in Skin Carotenoid Scores in Medical Students Following a Dietary Supplement-based Intervention",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Health Behavior"
    ],
    "interventions": [
      "LifePak Nano"
    ],
    "primary_completion_date": "2016-03-20",
    "completion_date": "2016-10-14",
    "results_first_posted": null,
    "last_update_posted": "2020-08-14",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT06025357",
    "title": "Effects of L-citrulline Supplementation on Vascular Function in Metabolic Syndrome",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metabolic Syndrome",
      "Menopause"
    ],
    "interventions": [
      "L-Citrulline supplementation",
      "Placebo"
    ],
    "primary_completion_date": "2024-05-01",
    "completion_date": "2024-08-01",
    "results_first_posted": null,
    "last_update_posted": "2025-05-15",
    "enrollment": null,
    "sponsor": "Texas Tech University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT01843894",
    "title": "A Phase 1/2, RU-101 Ophthalmic Solution in Patients With Severe Dry Eye",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dry Eye"
    ],
    "interventions": [
      "RU-101"
    ],
    "primary_completion_date": "2014-07",
    "completion_date": "2014-07",
    "results_first_posted": null,
    "last_update_posted": "2019-09-11",
    "enrollment": null,
    "sponsor": "R-Tech Ueno, Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT07332689",
    "title": "Safety Study of Quadrivalent Subunit Influenza Vaccine in People Aged 3 Years and Older",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Influenza Vaccine"
    ],
    "interventions": [
      "quadrivalent subunit influenza vaccine"
    ],
    "primary_completion_date": "2025-04-28",
    "completion_date": "2025-04-28",
    "results_first_posted": null,
    "last_update_posted": "2026-01-12",
    "enrollment": null,
    "sponsor": "Ab&B Bio-tech Co., Ltd.JS",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT04802018",
    "title": "Clinical Decision Support System Based on Non-invasive Tele-monitoring of COVID-19 Patients",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID-19"
    ],
    "interventions": [
      "Clinical decision support system based on non-invasive multimodal monitoring"
    ],
    "primary_completion_date": "2022-09-28",
    "completion_date": "2022-12-28",
    "results_first_posted": null,
    "last_update_posted": "2023-03-02",
    "enrollment": null,
    "sponsor": "Increase-Tech",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT01680549",
    "title": "Pain Control With Total Knee Replacement",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Postoperative Pain"
    ],
    "interventions": [
      "Gabapentin"
    ],
    "primary_completion_date": "2016-02",
    "completion_date": "2016-02",
    "results_first_posted": "2017-03-17",
    "last_update_posted": "2024-01-31",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT04979858",
    "title": "Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Covid19",
      "SARS-CoV2 Infection"
    ],
    "interventions": [
      "Focal Mask"
    ],
    "primary_completion_date": "2021-10-30",
    "completion_date": "2022-03-15",
    "results_first_posted": "2023-04-03",
    "last_update_posted": "2023-04-03",
    "enrollment": null,
    "sponsor": "Georgia Institute of Technology",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT07309874",
    "title": "Effect of Ultrasound-Guided Dry Needling Targeting Rectus Capitus Posterior Major on Individuals With Headaches",
    "status": "NOT_YET_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Headache Disorders, Primary",
      "Headache, Cervicogenic"
    ],
    "interventions": [
      "Dry needling"
    ],
    "primary_completion_date": "2026-06-01",
    "completion_date": "2026-06-01",
    "results_first_posted": null,
    "last_update_posted": "2025-12-30",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05429385",
    "title": "Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers",
    "status": "WITHDRAWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID-19"
    ],
    "interventions": [
      "HLX70",
      "Placebo"
    ],
    "primary_completion_date": "2021-09-06",
    "completion_date": "2021-09-18",
    "results_first_posted": null,
    "last_update_posted": "2022-06-23",
    "enrollment": null,
    "sponsor": "Shanghai Henlius Biotech",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT04712578",
    "title": "Influence of Caffeinated and Non-caffeinated Pre-workout Supplements on Resistance Exercise Performance",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Resistance Training",
      "Caffeine",
      "Dietary Supplements"
    ],
    "interventions": [
      "Caffeinated pre-workout supplement",
      "Non-caffeinated pre-workout supplement",
      "Placebo"
    ],
    "primary_completion_date": "2021-05-11",
    "completion_date": "2021-05-11",
    "results_first_posted": null,
    "last_update_posted": "2021-06-03",
    "enrollment": null,
    "sponsor": "Texas Tech University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05593224",
    "title": "The Efficacy and Safety of Intracranial Stent (Tonbridge) in Endovascular Treatment of Intracranial Atherosclerotic Stenosis",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Intracranial Atherosclerosis"
    ],
    "interventions": [
      "Intracranial Stent (Tonbridge)"
    ],
    "primary_completion_date": "2023-11",
    "completion_date": "2025-05",
    "results_first_posted": null,
    "last_update_posted": "2022-10-25",
    "enrollment": null,
    "sponsor": "Ton-Bridge Medical Tech. Co., Ltd",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT02058420",
    "title": "Tocotrienols and Bone Health of Postmenopausal Women",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Osteoporosis"
    ],
    "interventions": [
      "Low tocotrienols group",
      "High tocotrienols group"
    ],
    "primary_completion_date": "2022-10",
    "completion_date": "2022-12",
    "results_first_posted": null,
    "last_update_posted": "2023-02-21",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT04363073",
    "title": "Assessment of Annabella Breast Pump Performance",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Feeding"
    ],
    "interventions": [
      "Annabella Breast Pump",
      "Control Breast Pump"
    ],
    "primary_completion_date": "2023-04-01",
    "completion_date": "2023-12-31",
    "results_first_posted": null,
    "last_update_posted": "2024-03-26",
    "enrollment": null,
    "sponsor": "Annabella Tech Ltd",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT04695821",
    "title": "Feasibility of Remote Evaluation and Monitoring of Acoustic Pathophysiological Signals With External Sensor Technology in Covid-19",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Covid19"
    ],
    "interventions": [
      "Senti V1.0 Device"
    ],
    "primary_completion_date": "2021-02",
    "completion_date": "2021-03",
    "results_first_posted": null,
    "last_update_posted": "2021-01-05",
    "enrollment": null,
    "sponsor": "Senti Tech Ltd",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT01680692",
    "title": "Continuous Femoral and Tibial Nerve Blocks in TKA Patients",
    "status": "TERMINATED",
    "phase": "EARLY_PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Analgesia in Total Knee Arthroplasty"
    ],
    "interventions": [
      "Ropivicaine",
      "Continuous Femoral Nerve Catheter",
      "Continuous Tibial Nerve Catheter"
    ],
    "primary_completion_date": "2014-03",
    "completion_date": "2014-03",
    "results_first_posted": null,
    "last_update_posted": "2018-04-25",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center, El Paso",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT04497129",
    "title": "ROMTECH PortableConnect Rehabilitation Device Usage Post Unilateral Total Knee Arthroplasty (TKA)",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Knee Osteoarthritis",
      "Knee Arthritis",
      "Knee Pain Chronic",
      "Knee Disease",
      "Joint Pain",
      "Osteo Arthritis Knee",
      "Osteoarthritis, Knee"
    ],
    "interventions": [
      "ROMTech PortableConnect",
      "Traditional Rehabilitation and CPM Device"
    ],
    "primary_completion_date": "2021-12-31",
    "completion_date": "2021-12-31",
    "results_first_posted": null,
    "last_update_posted": "2025-07-22",
    "enrollment": null,
    "sponsor": "ROM Technologies, INC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT07104539",
    "title": "Strength Training Response of Muscle in GLP-1 Users",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Muscle Mass"
    ],
    "interventions": [
      "Strength Training",
      "Wait first, then strength training"
    ],
    "primary_completion_date": "2026-12",
    "completion_date": "2027-05",
    "results_first_posted": null,
    "last_update_posted": "2026-01-21",
    "enrollment": null,
    "sponsor": "Virginia Polytechnic Institute and State University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05948202",
    "title": "Mindfulness-Enhanced Pivotal Response Group Treatment on Parenting Stress",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Autism Spectrum Disorder"
    ],
    "interventions": [
      "Pivotal Response Treatment"
    ],
    "primary_completion_date": "2020-02-04",
    "completion_date": "2020-02-04",
    "results_first_posted": null,
    "last_update_posted": "2023-07-17",
    "enrollment": null,
    "sponsor": "Virginia Polytechnic Institute and State University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT04000516",
    "title": "The Effects of Early and Late Time-Restricted Feeding on Body Composition",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Time Restricted Feeding"
    ],
    "interventions": [
      "Time restricted feeding"
    ],
    "primary_completion_date": "2019-04-08",
    "completion_date": "2019-04-08",
    "results_first_posted": null,
    "last_update_posted": "2019-06-27",
    "enrollment": null,
    "sponsor": "Texas Tech University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT07136558",
    "title": "Evaluation of ICP-B794 in Patients With Advanced Solid Tumors",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumors"
    ],
    "interventions": [
      "ICP-B794"
    ],
    "primary_completion_date": "2029-06",
    "completion_date": "2030-12",
    "results_first_posted": null,
    "last_update_posted": "2025-08-22",
    "enrollment": null,
    "sponsor": "Beijing InnoCare Pharma Tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT01857349",
    "title": "Efficacy of Surgical Preparation Solutions in Knee Surgery",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Arthroplasty, Replacement"
    ],
    "interventions": [
      "Chlora Prep",
      "Dura Prep"
    ],
    "primary_completion_date": "2018-05-30",
    "completion_date": "2020-07-20",
    "results_first_posted": null,
    "last_update_posted": "2020-10-20",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03120078",
    "title": "A Prospective Study of Diagnostic Accuracy of Ultrasound",
    "status": "TERMINATED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Adenomyosis"
    ],
    "interventions": [],
    "primary_completion_date": "2017-12-14",
    "completion_date": "2017-12-14",
    "results_first_posted": null,
    "last_update_posted": "2018-04-26",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center, El Paso",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT06352047",
    "title": "The Effects of Positioning After Extubation of Preterm Infants on the Respiratory Functions",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Premature Infants"
    ],
    "interventions": [
      "The effect of positioning on respiratory functions of preterm infants after extubation."
    ],
    "primary_completion_date": "2019-06-01",
    "completion_date": "2019-06-01",
    "results_first_posted": null,
    "last_update_posted": "2024-04-08",
    "enrollment": null,
    "sponsor": "Karadeniz Technical University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT00948285",
    "title": "Importance of Magnetic Resonance Imaging (MRI) in Treating Breast Cancer",
    "status": "TERMINATED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Cancer"
    ],
    "interventions": [
      "MRI"
    ],
    "primary_completion_date": "2018-09",
    "completion_date": "2018-12",
    "results_first_posted": null,
    "last_update_posted": "2019-11-13",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05745155",
    "title": "REMAP-WEST-FLARE - FLAg for Review Efficacy Investigation",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COPD"
    ],
    "interventions": [
      "Senti Wear device system with Senti-AI subsystem"
    ],
    "primary_completion_date": "2024-04-30",
    "completion_date": "2024-04-30",
    "results_first_posted": null,
    "last_update_posted": "2024-12-04",
    "enrollment": null,
    "sponsor": "Senti Tech Ltd",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05060367",
    "title": "Pharmacokinetic Analysis of Nutrient Absorption From a Novel Liposomal Multivitamin/Mineral Formulation",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Mineral Absorption"
    ],
    "interventions": [
      "Liposomal multivitamin/mineral",
      "Standard multivitamin/mineral"
    ],
    "primary_completion_date": "2021-11-23",
    "completion_date": "2021-11-23",
    "results_first_posted": null,
    "last_update_posted": "2022-08-10",
    "enrollment": null,
    "sponsor": "Texas Tech University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT02673671",
    "title": "G-Tech Feasibility Study for Early Detection of a Post-op Ileus",
    "status": "UNKNOWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Post-operative Ileus"
    ],
    "interventions": [
      "G-Tech Myoelectric recording device"
    ],
    "primary_completion_date": "2023-12",
    "completion_date": "2023-12",
    "results_first_posted": null,
    "last_update_posted": "2023-01-20",
    "enrollment": null,
    "sponsor": "G-Tech Corporation",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT02327000",
    "title": "A Randomized, Open-label, Single Dose, Parallel Study to Evaluate the Pharmacokinetics Dose Proportionality of GLA5PR GLARS-NF1 Tablet in Healthy Male Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "Pregabalin 150mg",
      "Pregabalin 300mg"
    ],
    "primary_completion_date": "2014-10",
    "completion_date": "2014-10",
    "results_first_posted": null,
    "last_update_posted": "2014-12-30",
    "enrollment": null,
    "sponsor": "GL Pharm Tech Corporation",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT07210684",
    "title": "Effects of Dihydroberberine (DHB) on GLP-1, Glycemic Control, Appetite, and Mood in Adults With Pre-Diabetes",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Prediabetes"
    ],
    "interventions": [
      "Placebo 400 mg",
      "Dihydroberberine\uff08DHB\uff09400 mg"
    ],
    "primary_completion_date": "2026-01-15",
    "completion_date": "2026-03-15",
    "results_first_posted": null,
    "last_update_posted": "2025-10-07",
    "enrollment": null,
    "sponsor": "Nanjing Nutrabuilding Bio-tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT07207070",
    "title": "A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Cancer"
    ],
    "interventions": [
      "JS105",
      "Dalpiciclib",
      "Fulvestrant 50 Mg/mL Intramuscular Solution"
    ],
    "primary_completion_date": "2029-05-31",
    "completion_date": "2030-05-31",
    "results_first_posted": null,
    "last_update_posted": "2025-12-30",
    "enrollment": null,
    "sponsor": "Risen (Suzhou) Pharma Tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT02715713",
    "title": "Autonomic Manifestations of Testosterone Deficiency in Men",
    "status": "WITHDRAWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Autonomic Neuropathy",
      "Male Hypogonadism"
    ],
    "interventions": [],
    "primary_completion_date": "2016-08",
    "completion_date": "2016-08",
    "results_first_posted": null,
    "last_update_posted": "2016-10-18",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03151174",
    "title": "Effects of Vitamin D Supplementation on Strength, Bone Density, and Injury Risk in Collegiate Athletes",
    "status": "COMPLETED",
    "phase": "EARLY_PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Vitamin D Deficiency"
    ],
    "interventions": [
      "Vitamin D 10000 UNT",
      "Vitamin D 5000 UNT"
    ],
    "primary_completion_date": "2018-05-15",
    "completion_date": "2018-06-01",
    "results_first_posted": null,
    "last_update_posted": "2024-10-15",
    "enrollment": null,
    "sponsor": "Virginia Polytechnic Institute and State University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05685524",
    "title": "Clinical Study of Pan-cancer DNA Methylation Test in Plasma",
    "status": "UNKNOWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Cancer"
    ],
    "interventions": [
      "DNA methylation test"
    ],
    "primary_completion_date": "2023-08",
    "completion_date": "2023-12",
    "results_first_posted": null,
    "last_update_posted": "2023-01-17",
    "enrollment": null,
    "sponsor": "Wuhan Ammunition Life-tech Co., Ltd",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03231098",
    "title": "Detection of GABHS in Throat Gargle",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Group A Streptococcus: B Hemolytic Pharyngitis"
    ],
    "interventions": [],
    "primary_completion_date": "2019-02-16",
    "completion_date": "2019-02-16",
    "results_first_posted": null,
    "last_update_posted": "2019-12-10",
    "enrollment": null,
    "sponsor": "Gargle Tech",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT01089478",
    "title": "Cytology Study of Cells From Patients With Low Back Pain",
    "status": "TERMINATED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Back Pain"
    ],
    "interventions": [],
    "primary_completion_date": "2019-09",
    "completion_date": "2019-09",
    "results_first_posted": null,
    "last_update_posted": "2020-01-06",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT04162262",
    "title": "Effects of Exercise Versus Exercise and Instrument-Assisted Soft Tissue Mobilization for Plantar Fasciopathy Treatment",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Plantar Fascitis"
    ],
    "interventions": [
      "Instrumental-assisted soft tissue mobilization (IASTM)",
      "High-Load Strength Training",
      "Plantar Flexor and Gastrocnemius Stretching"
    ],
    "primary_completion_date": "2021-01-15",
    "completion_date": "2021-01-15",
    "results_first_posted": null,
    "last_update_posted": "2021-02-05",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT06751576",
    "title": "Retrospective Clinical Trial Comparing Radiologists' Diagnosis Accuracy in Lung Cancer Screening Population With and Without the Help of an AI/ML Tech-based SaMD",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "High Risk Cancer",
      "Lung Cancer"
    ],
    "interventions": [
      "Median LCS"
    ],
    "primary_completion_date": "2025-01-31",
    "completion_date": "2025-03-12",
    "results_first_posted": null,
    "last_update_posted": "2025-05-06",
    "enrollment": null,
    "sponsor": "Median Technologies",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT04578613",
    "title": "ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL",
    "status": "UNKNOWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Lymphocytic Leukemia",
      "Small Lymphocytic Lymphoma"
    ],
    "interventions": [
      "ICP-022",
      "Chlorambucil",
      "Rituximab"
    ],
    "primary_completion_date": "2024-12-30",
    "completion_date": "2025-06-30",
    "results_first_posted": null,
    "last_update_posted": "2023-06-05",
    "enrollment": null,
    "sponsor": "Beijing InnoCare Pharma Tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT04305197",
    "title": "A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Systemic Lupus Erythematosus"
    ],
    "interventions": [
      "ICP-022",
      "ICP-022",
      "ICP-022",
      "Placebos"
    ],
    "primary_completion_date": "2022-04-28",
    "completion_date": "2022-04-28",
    "results_first_posted": null,
    "last_update_posted": "2022-11-30",
    "enrollment": null,
    "sponsor": "Beijing InnoCare Pharma Tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05827276",
    "title": "Life Story Questionnaire and Physical Therapy Participation",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dementia Alzheimers"
    ],
    "interventions": [
      "Life story questionnaire"
    ],
    "primary_completion_date": "2023-12-30",
    "completion_date": "2024-03-30",
    "results_first_posted": null,
    "last_update_posted": "2023-05-31",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03069313",
    "title": "Vitamin B12 for Aromatase Inhibitors Musculoskeletal Symptoms",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relief of Joint Pain"
    ],
    "interventions": [
      "Vitamin B12"
    ],
    "primary_completion_date": "2016-10-27",
    "completion_date": "2016-10-27",
    "results_first_posted": "2018-02-01",
    "last_update_posted": "2018-02-01",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center, El Paso",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT01541202",
    "title": "Study of the Survival of Recombinant Human Neuregulin-1\u03b2 in Chronic Heart Failure (CHF) Patients",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Heart Failure"
    ],
    "interventions": [
      "rhNRG-1",
      "Placebo"
    ],
    "primary_completion_date": "2017-08",
    "completion_date": "2017-08",
    "results_first_posted": null,
    "last_update_posted": "2017-12-21",
    "enrollment": null,
    "sponsor": "Zensun Sci. & Tech. Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT02162901",
    "title": "The Reach and Effectiveness of Technology-enhanced Diabetes Prevention Programs",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes Prevention"
    ],
    "interventions": [
      "Choice-Class with IVR Calls",
      "Random-Class with IVR calls",
      "Random-Class only",
      "Choice-DVD with IVR calls",
      "Random-DVD with IVR calls"
    ],
    "primary_completion_date": "2017-01-05",
    "completion_date": "2017-04-28",
    "results_first_posted": null,
    "last_update_posted": "2021-04-06",
    "enrollment": null,
    "sponsor": "Virginia Polytechnic Institute and State University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05200845",
    "title": "The Role of Altered Nutrient Partitioning in Food Reward",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Overweight and Obesity"
    ],
    "interventions": [
      "Conditioned Stimulus + (CS+): Flavored beverage solution with 75 calories of sucrose",
      "Conditioned Stimulus - (CS-): Flavored beverage solution with sweetness-matched sucralose",
      "High-Fat Test Meal Inside a Metabolic Chamber",
      "High-Carbohydrate Test Meal Inside a Metabolic Chamber",
      "fMRI Scan"
    ],
    "primary_completion_date": "2023-06-01",
    "completion_date": "2023-06-01",
    "results_first_posted": "2025-02-13",
    "last_update_posted": "2025-09-08",
    "enrollment": null,
    "sponsor": "Virginia Polytechnic Institute and State University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT01635751",
    "title": "A Clinical Trial to Compare The Pharmacokinetics of A Pregabalin GLARS Tablet 150mg With Immediate Release Formulation and to Assess The Effect of High Fat Diet in Healthy Male Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "Pregabalin",
      "Pregabalin",
      "Pregabalin"
    ],
    "primary_completion_date": "2012-11",
    "completion_date": "2012-11",
    "results_first_posted": null,
    "last_update_posted": "2013-01-28",
    "enrollment": null,
    "sponsor": "GL Pharm Tech Corporation",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT06082102",
    "title": "Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsed/Refractory Marginal Zone Lymphoma"
    ],
    "interventions": [
      "Orelabrutinib",
      "Rituximab",
      "Lenalidomide",
      "Rituximab"
    ],
    "primary_completion_date": "2028-08-31",
    "completion_date": "2030-02-25",
    "results_first_posted": null,
    "last_update_posted": "2025-09-15",
    "enrollment": null,
    "sponsor": "Beijing InnoCare Pharma Tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05484999",
    "title": "The Maternal Well-Being Study",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Postpartum Depression",
      "Postpartum Anxiety",
      "Weight Retention, Postpartum",
      "Nutritional and Metabolic Diseases"
    ],
    "interventions": [
      "Meals",
      "Meals + Social Support",
      "Control"
    ],
    "primary_completion_date": "2024-07-30",
    "completion_date": "2025-05-30",
    "results_first_posted": null,
    "last_update_posted": "2024-08-29",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT00813371",
    "title": "Airway Pressure Release Ventilation as a Preventative Strategy",
    "status": "WITHDRAWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Respiratory Distress Syndrome",
      "Acute Lung Injury",
      "Respiratory Failure",
      "Trauma"
    ],
    "interventions": [
      "Airway Pressure Release Ventilation",
      "ARDSnet protocol"
    ],
    "primary_completion_date": "2011-12",
    "completion_date": "2011-12",
    "results_first_posted": null,
    "last_update_posted": "2009-08-25",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT02686671",
    "title": "The Pull Test To Determine Responders To Subacromial Injection In Patients With Shoulder Impingement",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Shoulder Impingement Syndrome"
    ],
    "interventions": [
      "Shoulder clinical examination testing"
    ],
    "primary_completion_date": "2018-12",
    "completion_date": "2018-12",
    "results_first_posted": null,
    "last_update_posted": "2020-01-23",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT04492293",
    "title": "An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bladder Urothelial Cancer"
    ],
    "interventions": [
      "ICP-192"
    ],
    "primary_completion_date": "2024-12-31",
    "completion_date": "2025-06-30",
    "results_first_posted": null,
    "last_update_posted": "2024-02-26",
    "enrollment": null,
    "sponsor": "Beijing InnoCare Pharma Tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT07022249",
    "title": "Evaluation of a Novel Intrasaccular Embolization Device for the Treatment of Intracranial Aneurysms",
    "status": "NOT_YET_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Intracranial Aneurysms"
    ],
    "interventions": [
      "Intrasaccular Embolization Device"
    ],
    "primary_completion_date": "2027-06",
    "completion_date": "2027-06",
    "results_first_posted": null,
    "last_update_posted": "2025-06-15",
    "enrollment": null,
    "sponsor": "Ton-Bridge Medical Tech. Co., Ltd",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT06952569",
    "title": "Human Factors Validation and Usability Testing of the IKE Age-Gating System",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Vaping",
      "Underage"
    ],
    "interventions": [
      "IKE System"
    ],
    "primary_completion_date": "2025-03-30",
    "completion_date": "2025-03-30",
    "results_first_posted": null,
    "last_update_posted": "2025-05-01",
    "enrollment": null,
    "sponsor": "IKE Tech",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03873831",
    "title": "Effects of Therapy Dogs on Social Behavior in Group Social Skills Instruction With Children With Autism",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Autism Spectrum Disorder",
      "Social Skills"
    ],
    "interventions": [
      "Animal-assisted intervention",
      "Social skills group"
    ],
    "primary_completion_date": "2020-12-31",
    "completion_date": "2021-04-26",
    "results_first_posted": null,
    "last_update_posted": "2025-08-12",
    "enrollment": null,
    "sponsor": "Texas Tech University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05454319",
    "title": "Cerebri Biofeedback Feasibility Trial",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Episodic Migraine"
    ],
    "interventions": [
      "Biofeedback"
    ],
    "primary_completion_date": "2022-09-27",
    "completion_date": "2022-09-27",
    "results_first_posted": null,
    "last_update_posted": "2022-11-14",
    "enrollment": null,
    "sponsor": "Nordic Brain Tech AS",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT04308239",
    "title": "Reactive Balance Training Targeting Both Slip- and Trip-Induced Falls",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Accidental Fall"
    ],
    "interventions": [
      "Reactive balance training",
      "Otago Balance Training"
    ],
    "primary_completion_date": "2019-07-01",
    "completion_date": "2019-07-01",
    "results_first_posted": "2020-05-18",
    "last_update_posted": "2020-05-18",
    "enrollment": null,
    "sponsor": "Virginia Polytechnic Institute and State University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03525977",
    "title": "Impact of Fascia Iliaca Block in Hip Fracture Patients",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hip Fractures (i.e. Femoral Neck or Intertrochanteric Hip Fractures)"
    ],
    "interventions": [
      "Fascia iliaca block arm"
    ],
    "primary_completion_date": "2019-05-01",
    "completion_date": "2019-05-01",
    "results_first_posted": null,
    "last_update_posted": "2019-05-28",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center, El Paso",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT01601431",
    "title": "The Utility of Cap Colonoscopy in Increasing Adenoma Detection Rate",
    "status": "TERMINATED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Adenoma"
    ],
    "interventions": [
      "Cap Assisted Colonoscopy",
      "Conventional colonoscopy"
    ],
    "primary_completion_date": "2015-02-02",
    "completion_date": "2015-02-02",
    "results_first_posted": "2018-06-07",
    "last_update_posted": "2018-06-07",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center, El Paso",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03081741",
    "title": "Circulating Tumor DNA in Surgical Lung Cancer Patients",
    "status": "UNKNOWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Lung Neoplasms"
    ],
    "interventions": [],
    "primary_completion_date": "2017-12-01",
    "completion_date": "2020-03-18",
    "results_first_posted": null,
    "last_update_posted": "2017-05-23",
    "enrollment": null,
    "sponsor": "Shenzhen Gene Health Bio Tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT00794742",
    "title": "Antimicrobial Resistance of Bacteria in Burn Patients",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Burns"
    ],
    "interventions": [],
    "primary_completion_date": "2014-05",
    "completion_date": "2014-05",
    "results_first_posted": null,
    "last_update_posted": "2015-04-13",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05174988",
    "title": "Reducing Postoperative Bleeding After Hysterectomy Via Independent Closure of Vaginal Cuff Angles",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Postoperative Bleeding",
      "Patient Satisfaction",
      "Complications",
      "Operative Time"
    ],
    "interventions": [
      "Angle stitch"
    ],
    "primary_completion_date": "2023-08-07",
    "completion_date": "2023-08-07",
    "results_first_posted": null,
    "last_update_posted": "2023-09-21",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center, El Paso",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03626363",
    "title": "Mindfulness and Neural Cardiovascular Control in Humans",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Elevated Blood Pressure"
    ],
    "interventions": [
      "Stress Management"
    ],
    "primary_completion_date": "2022-11-23",
    "completion_date": "2023-01-31",
    "results_first_posted": "2024-11-08",
    "last_update_posted": "2024-11-08",
    "enrollment": null,
    "sponsor": "Michigan Technological University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03690752",
    "title": "Adherence to Walking on an Alter G Anti-Gravity Treadmill",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Severe Obesity"
    ],
    "interventions": [
      "unweighting using Alter-G Anti-Gravity Treadmill",
      "normal weight using Alter-G Anti-Gravity Treadmill"
    ],
    "primary_completion_date": "2018-10-01",
    "completion_date": "2018-10-01",
    "results_first_posted": null,
    "last_update_posted": "2018-10-18",
    "enrollment": null,
    "sponsor": "Texas Tech University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT04227405",
    "title": "TOGETHER: A Couple's Model to Enhance Relationships and Economic Stability",
    "status": "TERMINATED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "No Condition"
    ],
    "interventions": [
      "Connection to community services through case management",
      "TOGETHER Workshop",
      "Employment Support Services"
    ],
    "primary_completion_date": "2019-02-28",
    "completion_date": "2019-02-28",
    "results_first_posted": "2024-02-26",
    "last_update_posted": "2024-02-26",
    "enrollment": null,
    "sponsor": "Virginia Polytechnic Institute and State University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05719701",
    "title": "Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsed and/or Refractory Multiple Myeloma"
    ],
    "interventions": [
      "ICP-490",
      "Dexamethasone"
    ],
    "primary_completion_date": "2025-07-30",
    "completion_date": "2025-12-30",
    "results_first_posted": null,
    "last_update_posted": "2024-04-09",
    "enrollment": null,
    "sponsor": "Beijing InnoCare Pharma Tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05202977",
    "title": "Safety and Efficacy of SinocrownTM Transcatheter Aortic Valve Replacement System",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Transcatheter Aortic Valve Replacement"
    ],
    "interventions": [
      "SinocrownTM Transcatheter Aortic Valve Replacement System"
    ],
    "primary_completion_date": "2021-08-07",
    "completion_date": "2026-08",
    "results_first_posted": null,
    "last_update_posted": "2022-01-24",
    "enrollment": null,
    "sponsor": "Lepu Medical Technology (Beijing) Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT01569516",
    "title": "Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease",
    "status": "UNKNOWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alzheimer's Disease"
    ],
    "interventions": [
      "Octohydroaminoacridine Succinate Tablets",
      "Octohydroaminoacridine Succinate Tablets",
      "Octohydroaminoacridine succinate Tablets",
      "Placebo"
    ],
    "primary_completion_date": "2012-07",
    "completion_date": "2012-10",
    "results_first_posted": null,
    "last_update_posted": "2012-04-09",
    "enrollment": null,
    "sponsor": "Changchun Huayang High-tech Co., Ltd",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03851718",
    "title": "Effect of Acupuncture on Hypogalactia",
    "status": "WITHDRAWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypogalactia"
    ],
    "interventions": [
      "Acupuncture Procedure",
      "Power pumping"
    ],
    "primary_completion_date": "2019-12",
    "completion_date": "2020-06",
    "results_first_posted": null,
    "last_update_posted": "2019-05-03",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT00446706",
    "title": "Estimation of Intrinsic Positive End-Expiratory Pressure (PEEP) in Acute Respiratory Distress Syndrome (ARDS)",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Acute Respiratory Distress Syndrome"
    ],
    "interventions": [],
    "primary_completion_date": "2007-04",
    "completion_date": "2007-04",
    "results_first_posted": null,
    "last_update_posted": "2017-05-09",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center, El Paso",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03705845",
    "title": "Tocotrienols for Obesity of Postmenopausal Women",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Obesity",
      "Postmenopausal Women"
    ],
    "interventions": [
      "placebo softgel",
      "DeltaGold\u00ae Tocotrienol 70%"
    ],
    "primary_completion_date": "2024-12-30",
    "completion_date": "2025-12-30",
    "results_first_posted": null,
    "last_update_posted": "2025-03-28",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT06378138",
    "title": "ICP-248 in Combination With Orelabrutinib in Treatment-na\u00efve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hematologic Malignancies"
    ],
    "interventions": [
      "ICP-248",
      "Orelabrutinib"
    ],
    "primary_completion_date": "2030-11-25",
    "completion_date": "2031-07-25",
    "results_first_posted": null,
    "last_update_posted": "2025-11-21",
    "enrollment": null,
    "sponsor": "Beijing InnoCare Pharma Tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03368638",
    "title": "Physical Therapy Treatments, Including Neural Mobilization and Hip/Back Stretches for People Between 50-89 With Lumbar Spinal Stenosis and Leg Pain Provoked by Walking",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lumbar Spinal Stenosis"
    ],
    "interventions": [
      "Physical therapy intervention"
    ],
    "primary_completion_date": "2019-04-22",
    "completion_date": "2019-04-22",
    "results_first_posted": null,
    "last_update_posted": "2021-01-25",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05372120",
    "title": "A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations",
    "status": "UNKNOWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumor"
    ],
    "interventions": [
      "ICP-192"
    ],
    "primary_completion_date": "2023-12-31",
    "completion_date": "2024-06-30",
    "results_first_posted": null,
    "last_update_posted": "2023-01-04",
    "enrollment": null,
    "sponsor": "Beijing InnoCare Pharma Tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT06903819",
    "title": "Ketamine for Pain, Opioid Use, and Mental Health in Orthopedic Trauma Patients",
    "status": "RECRUITING",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Orthopedic Trauma Surgery Patients",
      "Postoperative Pain",
      "Opioid Use",
      "Depression",
      "Post-traumatic Stress Disorder (PTSD)"
    ],
    "interventions": [
      "Ketamine",
      "standard general anesthesia"
    ],
    "primary_completion_date": "2027-05",
    "completion_date": "2028-05",
    "results_first_posted": null,
    "last_update_posted": "2025-12-03",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT06842199",
    "title": "Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Plaque Psoriasis Patients"
    ],
    "interventions": [
      "ICP-488 Tablets",
      "ICP-488 Placebo"
    ],
    "primary_completion_date": "2026-05",
    "completion_date": "2027-02",
    "results_first_posted": null,
    "last_update_posted": "2025-08-06",
    "enrollment": null,
    "sponsor": "Beijing InnoCare Pharma Tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT06825338",
    "title": "Does the 'CATCH My Breath' Vaping Prevention Program Prevent High School Students in Ontario, Canada From Starting to Vape?",
    "status": "NOT_YET_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Vaping Behaviors"
    ],
    "interventions": [
      "CATCH My Breath"
    ],
    "primary_completion_date": "2026-12",
    "completion_date": "2026-12",
    "results_first_posted": null,
    "last_update_posted": "2025-06-13",
    "enrollment": null,
    "sponsor": "University of Ontario Institute of Technology",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT01268111",
    "title": "Effect of Vitamin D Replacement on Insulin Sensitivity",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Insulin Sensitivity"
    ],
    "interventions": [
      "Ergocalciferols",
      "Placebo"
    ],
    "primary_completion_date": "2012-03",
    "completion_date": "2012-03",
    "results_first_posted": "2013-05-24",
    "last_update_posted": "2015-06-08",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT02712944",
    "title": "Testosterone Replacement in Renal Failure",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypogonadism"
    ],
    "interventions": [
      "Testosterone",
      "Saline"
    ],
    "primary_completion_date": "2018-03",
    "completion_date": "2018-03",
    "results_first_posted": null,
    "last_update_posted": "2019-05-28",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05815264",
    "title": "Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Chinese Population Aged 2 Years and Above",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pneumonia"
    ],
    "interventions": [
      "23-valent pneumococcal polysaccharide vaccine",
      "pneumococcal vaccine polyvalent"
    ],
    "primary_completion_date": "2021-04-06",
    "completion_date": "2021-04-06",
    "results_first_posted": null,
    "last_update_posted": "2026-01-02",
    "enrollment": null,
    "sponsor": "Ab&B Bio-tech Co., Ltd.JS",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT02193009",
    "title": "SipSmarter: A Nutrition Literacy Approach to Reducing Sugary Beverages",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dietary Habits",
      "Physical Activity"
    ],
    "interventions": [
      "SipSmarter",
      "MoveMore"
    ],
    "primary_completion_date": "2015-12",
    "completion_date": "2015-12",
    "results_first_posted": null,
    "last_update_posted": "2022-04-27",
    "enrollment": null,
    "sponsor": "Virginia Polytechnic Institute and State University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT01871389",
    "title": "Impact of Monthly High Dose Oral Cholecalciferol on Serum 25 Hydroxy Vitamin D Levels in Bariatric Surgery Subjects",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Bariatric Surgery"
    ],
    "interventions": [],
    "primary_completion_date": "2013-08",
    "completion_date": "2013-08",
    "results_first_posted": null,
    "last_update_posted": "2014-05-09",
    "enrollment": null,
    "sponsor": "Texas Tech University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03144180",
    "title": "Compare the Q-Cup With Other Umbilical Cord Blood Collection Techniques",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pregnant"
    ],
    "interventions": [
      "Q-cup"
    ],
    "primary_completion_date": "2017-09-14",
    "completion_date": "2017-11-28",
    "results_first_posted": "2020-01-09",
    "last_update_posted": "2020-01-09",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center, El Paso",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03494179",
    "title": "A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL)",
    "status": "UNKNOWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Mantle Cell Lymphoma"
    ],
    "interventions": [
      "ICP-022"
    ],
    "primary_completion_date": "2023-12-31",
    "completion_date": "2023-12-31",
    "results_first_posted": null,
    "last_update_posted": "2023-06-05",
    "enrollment": null,
    "sponsor": "Beijing InnoCare Pharma Tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT02418897",
    "title": "Role of Neuromuscular Junction Function in Motor Fatigue in Multiple Sclerosis",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Multiple Sclerosis"
    ],
    "interventions": [],
    "primary_completion_date": "2016-11",
    "completion_date": "2016-11",
    "results_first_posted": null,
    "last_update_posted": "2016-11-16",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT02938780",
    "title": "Using Behavioral Economics to Achieve Improved Healthy Behavior Outcomes in Breast Cancer Survivors",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Cancer Female"
    ],
    "interventions": [
      "placebo text message",
      "nutrition physical activity text message"
    ],
    "primary_completion_date": "2019-09",
    "completion_date": "2019-12",
    "results_first_posted": null,
    "last_update_posted": "2020-01-18",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT04786379",
    "title": "Surgical Management of Knee Septic Arthritis",
    "status": "TERMINATED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Septic Arthritis"
    ],
    "interventions": [
      "Arthroscopic Irrigation and Debridement",
      "Open Arthrotomy with irrigation and debridement"
    ],
    "primary_completion_date": "2022-04-30",
    "completion_date": "2022-04-30",
    "results_first_posted": null,
    "last_update_posted": "2023-12-08",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center, El Paso",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT02493608",
    "title": "Scalpel vs Diathermy in Repeat Cesarean Delivery",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Complications; Cesarean Section"
    ],
    "interventions": [
      "scalpel",
      "Diathermy"
    ],
    "primary_completion_date": "2017-06",
    "completion_date": "2017-06",
    "results_first_posted": "2020-02-28",
    "last_update_posted": "2020-03-24",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT04104997",
    "title": "A Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of GLH8NDE After Single and Mutiple Ocular Administrations in Healthy Korean and Caucasian Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dry Eye Syndromes"
    ],
    "interventions": [
      "5% GLH8NDE",
      "Placebos"
    ],
    "primary_completion_date": "2020-02-18",
    "completion_date": "2020-07-17",
    "results_first_posted": null,
    "last_update_posted": "2020-12-19",
    "enrollment": null,
    "sponsor": "GL Pharm Tech Corporation",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT06208410",
    "title": "A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumors"
    ],
    "interventions": [
      "JS105",
      "Fulvestrant injection",
      "Dalpiciclib Isetionate Tablets",
      "Toripalimab Injection",
      "Paclitaxel for Injection (Albumin Bound)",
      "Fluzoparib Capsules",
      "Pyrotinib Maleate Tablets",
      "Capecitabine Tablets"
    ],
    "primary_completion_date": "2027-02-26",
    "completion_date": "2027-02-26",
    "results_first_posted": null,
    "last_update_posted": "2025-07-25",
    "enrollment": null,
    "sponsor": "Risen (Suzhou) Pharma Tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05312424",
    "title": "Annatto-derived GG for Statin-associated Myopathy",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Myopathy; Primary"
    ],
    "interventions": [
      "Placebo",
      "Low GG",
      "High GG"
    ],
    "primary_completion_date": "2027-06-30",
    "completion_date": "2027-12-31",
    "results_first_posted": null,
    "last_update_posted": "2025-09-12",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT04502914",
    "title": "The Study on Bacterial Load Following Open-to-air Management in Burn Patients.",
    "status": "WITHDRAWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Burns",
      "Infection Wound",
      "Bacterial Infections"
    ],
    "interventions": [
      "Open-to-air strategy",
      "Traditional closed-wound management"
    ],
    "primary_completion_date": "2021-06-09",
    "completion_date": "2021-06-09",
    "results_first_posted": null,
    "last_update_posted": "2022-01-05",
    "enrollment": null,
    "sponsor": "Texas Tech University Health Sciences Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT05152355",
    "title": "Clinical Equivalence of Budesonide HFA MDI Versus Budesonide Turbuhaler in Mild to Moderate Chinese Asthma Patients",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Asthma"
    ],
    "interventions": [
      "Budesonide 200 microgram/Puff, HFA MDI",
      "Budesonide 100 microgram/Actuation Powder for Inhalation"
    ],
    "primary_completion_date": "2021-05-09",
    "completion_date": "2021-05-09",
    "results_first_posted": null,
    "last_update_posted": "2021-12-09",
    "enrollment": null,
    "sponsor": "Intech Biopharm Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT01016340",
    "title": "Efficacy and Safety of MCS-5 in Treating Male Oligoasthenospermia",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Male Oligoasthenospermia"
    ],
    "interventions": [
      "MCS"
    ],
    "primary_completion_date": "2012-12",
    "completion_date": "2013-06",
    "results_first_posted": null,
    "last_update_posted": "2023-12-21",
    "enrollment": null,
    "sponsor": "Health Ever Bio-Tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECH",
    "nct_id": "NCT03935633",
    "title": "Short-term Clinical Study of CN128 in Thalassemia Patients",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Thalassemia"
    ],
    "interventions": [
      "CN128 Tablets"
    ],
    "primary_completion_date": "2019-05-06",
    "completion_date": "2019-12-17",
    "results_first_posted": null,
    "last_update_posted": "2023-06-09",
    "enrollment": null,
    "sponsor": "Hangzhou Zede Pharma-Tech Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NTRA",
    "nct_id": "NCT07093203",
    "title": "Rezafungin Peritoneal Diffusion for Intra-abdominal Candidiasis",
    "status": "NOT_YET_RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Intra-Abdominal Infection",
      "Candida",
      "Abdominal Surgery Patients",
      "Critically Ill Intensive Care Unit Patients"
    ],
    "interventions": [],
    "primary_completion_date": "2026-05-01",
    "completion_date": "2026-09-01",
    "results_first_posted": null,
    "last_update_posted": "2025-07-30",
    "enrollment": null,
    "sponsor": "Central Hospital, Nancy, France",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "DAWN",
    "nct_id": "NCT03477305",
    "title": "BerryCare: A Community Engagement Program",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cardiovascular Risk Factor"
    ],
    "interventions": [
      "Blackberry Consumption"
    ],
    "primary_completion_date": "2018-09-26",
    "completion_date": "2018-09-26",
    "results_first_posted": null,
    "last_update_posted": "2023-01-19",
    "enrollment": null,
    "sponsor": "Dawn Brewer",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "DAWN",
    "nct_id": "NCT04237571",
    "title": "Community Agriculture Nutritional Enterprises (CANE) Meal Program",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diet, Healthy",
      "Life Style, Healthy"
    ],
    "interventions": [
      "CANE Meal Program"
    ],
    "primary_completion_date": "2020-05-29",
    "completion_date": "2020-05-29",
    "results_first_posted": null,
    "last_update_posted": "2020-07-23",
    "enrollment": null,
    "sponsor": "Dawn Brewer",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "DAWN",
    "nct_id": "NCT05002972",
    "title": "Tanglewood Trail Walking Program in Rural Kentucky 2019",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dietary Habits"
    ],
    "interventions": [
      "walking group led by a community organizer"
    ],
    "primary_completion_date": "2019-09-19",
    "completion_date": "2019-09-19",
    "results_first_posted": "2021-11-04",
    "last_update_posted": "2021-11-04",
    "enrollment": null,
    "sponsor": "Dawn Brewer",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "DAWN",
    "nct_id": "NCT01099618",
    "title": "Ketosis-Prone Diabetes Mellitus (KPDM): Metformin Versus Sitagliptin Treatment",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ketosis Prone Diabetes",
      "Diabetes Ketoacidosis",
      "Hyperglycemia"
    ],
    "interventions": [
      "metformin",
      "placebo",
      "Sitagliptin"
    ],
    "primary_completion_date": "2014-02",
    "completion_date": "2014-08",
    "results_first_posted": "2015-06-18",
    "last_update_posted": "2015-06-18",
    "enrollment": null,
    "sponsor": "Dawn Smiley MD",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "DAWN",
    "nct_id": "NCT03567252",
    "title": "Tanglewood to Table: A Walking Farmer's Market Group and Control",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dietary Habits"
    ],
    "interventions": [
      "Walking Group"
    ],
    "primary_completion_date": "2019-05-21",
    "completion_date": "2019-05-21",
    "results_first_posted": "2021-07-23",
    "last_update_posted": "2021-07-23",
    "enrollment": null,
    "sponsor": "Dawn Brewer",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "DAWN",
    "nct_id": "NCT03495648",
    "title": "Tanglewood Trail Walking Program in Rural Kentucky 2017",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dietary Habits"
    ],
    "interventions": [
      "walking group led by a community organizer"
    ],
    "primary_completion_date": "2020-09-24",
    "completion_date": "2020-09-24",
    "results_first_posted": "2021-11-17",
    "last_update_posted": "2021-11-17",
    "enrollment": null,
    "sponsor": "Dawn Brewer",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "DAWN",
    "nct_id": "NCT05002985",
    "title": "Tanglewood Trail Walking Program in Rural Kentucky 2020",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dietary Habits"
    ],
    "interventions": [
      "walking group led by a community organizer"
    ],
    "primary_completion_date": "2020-09-14",
    "completion_date": "2020-09-14",
    "results_first_posted": "2021-11-05",
    "last_update_posted": "2021-11-05",
    "enrollment": null,
    "sponsor": "Dawn Brewer",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "DAWN",
    "nct_id": "NCT02066532",
    "title": "Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Breast Cancer",
      "Breast Carcinoma",
      "HER-2 Positive Breast Cancer"
    ],
    "interventions": [
      "Ruxolitinib",
      "Trastuzumab"
    ],
    "primary_completion_date": "2020-10-14",
    "completion_date": "2020-10-14",
    "results_first_posted": "2023-08-24",
    "last_update_posted": "2023-08-24",
    "enrollment": null,
    "sponsor": "Dawn L. Hershman",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "DAWN",
    "nct_id": "NCT00691678",
    "title": "Glucosamine and Chondroitin for Aromatase Inhibitor Induced Joint Symptoms in Women With Breast Cancer",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Cancer",
      "Joint Pain"
    ],
    "interventions": [
      "Chondroitin",
      "Glucosamine"
    ],
    "primary_completion_date": "2012-07",
    "completion_date": "2012-09",
    "results_first_posted": "2022-11-08",
    "last_update_posted": "2022-11-08",
    "enrollment": null,
    "sponsor": "Dawn L. Hershman",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "FATE",
    "nct_id": "NCT05069935",
    "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor, Adult"
    ],
    "interventions": [
      "FT538",
      "Cyclophosphamide",
      "Fludarabine",
      "Monoclonal antibody - Dose Escalation",
      "Monoclonal antibody - Dose Expansion"
    ],
    "primary_completion_date": "2023-08-11",
    "completion_date": "2023-08-11",
    "results_first_posted": null,
    "last_update_posted": "2023-09-21",
    "enrollment": null,
    "sponsor": "Fate Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "FATE",
    "nct_id": "NCT04023071",
    "title": "FT516 in Subjects With Advanced Hematologic Malignancies",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Myelogenous Leukemia",
      "B-cell Lymphoma"
    ],
    "interventions": [
      "FT516",
      "Rituximab",
      "Obinutuzumab",
      "Cyclophosphamide",
      "Fludarabine",
      "IL-2",
      "Bendamustine"
    ],
    "primary_completion_date": "2023-10-23",
    "completion_date": "2023-10-23",
    "results_first_posted": null,
    "last_update_posted": "2023-10-26",
    "enrollment": null,
    "sponsor": "Fate Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "FATE",
    "nct_id": "NCT04551885",
    "title": "FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor, Adult"
    ],
    "interventions": [
      "FT516",
      "Avelumab",
      "Cyclophosphamide",
      "Fludarabine",
      "IL-2"
    ],
    "primary_completion_date": "2023-08-11",
    "completion_date": "2023-08-11",
    "results_first_posted": null,
    "last_update_posted": "2023-09-21",
    "enrollment": null,
    "sponsor": "Fate Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "FATE",
    "nct_id": "NCT04629729",
    "title": "FT819 in Subjects With B-cell Malignancies",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lymphoma, B-Cell",
      "Chronic Lymphocytic Leukemia",
      "Precursor B-Cell Acute Lymphoblastic Leukemia"
    ],
    "interventions": [
      "FT819",
      "Cyclophosphamide",
      "Fludarabine",
      "IL-2",
      "Bendamustine"
    ],
    "primary_completion_date": "2025-06-18",
    "completion_date": "2039-09-30",
    "results_first_posted": null,
    "last_update_posted": "2025-12-11",
    "enrollment": null,
    "sponsor": "Fate Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "FATE",
    "nct_id": "NCT01527838",
    "title": "Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-Hodgkin's Lymphoma (NHL)",
      "Hodgkin's Disease",
      "Chronic Lymphocytic Leukemia (CLL)",
      "Acute Myelogenous Leukemia (AML)",
      "Acute Lymphoblastic Leukemia (ALL)"
    ],
    "interventions": [
      "Single FT1050 treated UCB unit"
    ],
    "primary_completion_date": "2013-10",
    "completion_date": "2013-11",
    "results_first_posted": null,
    "last_update_posted": "2016-09-12",
    "enrollment": null,
    "sponsor": "Fate Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "FATE",
    "nct_id": "NCT03319459",
    "title": "FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HER2 Positive Gastric Cancer",
      "Colorectal Cancer",
      "Head and Neck Squamous Cell Carcinoma",
      "EGFR Positive Solid Tumor",
      "Advanced Solid Tumors",
      "HER2-positive Breast Cancer",
      "Hepatocellular Carcinoma",
      "Non Small Cell Lung Cancer",
      "Renal Cell Carcinoma",
      "Pancreatic Cancer",
      "Melanoma"
    ],
    "interventions": [
      "FATE-NK100",
      "Cetuximab",
      "Trastuzumab"
    ],
    "primary_completion_date": "2020-05-29",
    "completion_date": "2020-12-15",
    "results_first_posted": null,
    "last_update_posted": "2021-11-22",
    "enrollment": null,
    "sponsor": "Fate Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "FATE",
    "nct_id": "NCT06308978",
    "title": "A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV)",
      "Idiopathic Inflammatory Myositis (IIM)",
      "Systemic Sclerosis (SSc)",
      "Systemic Lupus Erythematosus (SLE)"
    ],
    "interventions": [
      "FT819",
      "Fludarabine",
      "Cyclophosphamide",
      "Bendamustine"
    ],
    "primary_completion_date": "2027-09-30",
    "completion_date": "2042-09-30",
    "results_first_posted": null,
    "last_update_posted": "2025-11-24",
    "enrollment": null,
    "sponsor": "Fate Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "FATE",
    "nct_id": "NCT02354417",
    "title": "A Phase 1 Trial of a Single ProHema\u00ae CB Product for Pediatric Patients With Hematologic Malignancies",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hematologic Malignancies"
    ],
    "interventions": [
      "Biological: ProHema-CB"
    ],
    "primary_completion_date": "2016-12",
    "completion_date": "2017-02",
    "results_first_posted": "2018-10-10",
    "last_update_posted": "2018-10-10",
    "enrollment": null,
    "sponsor": "Fate Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "FATE",
    "nct_id": "NCT07216105",
    "title": "FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-Small Cell Lung Cancer",
      "Colorectal Cancer",
      "Breast Cancer",
      "Ovarian Cancer",
      "Endometrial Carcinoma",
      "Head and Neck Squamous Cell Carcinoma"
    ],
    "interventions": [
      "FT836",
      "Paclitaxel",
      "Cetuximab",
      "Trastuzumab"
    ],
    "primary_completion_date": "2028-01",
    "completion_date": "2030-01",
    "results_first_posted": null,
    "last_update_posted": "2025-12-17",
    "enrollment": null,
    "sponsor": "Fate Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "FATE",
    "nct_id": "NCT05395052",
    "title": "FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non Small Cell Lung Cancer",
      "Colorectal Cancer",
      "Breast Cancer",
      "Ovarian Cancer",
      "Pancreatic Cancer",
      "Head and Neck Cancer",
      "GastroEsophageal Cancer"
    ],
    "interventions": [
      "FT536",
      "Cyclophosphamide",
      "Fludarabine",
      "IL-2",
      "Avelumab",
      "Pembrolizumab",
      "Nivolumab",
      "Atezolizumab",
      "Trastuzumab",
      "Cetuximab",
      "Amivantamab",
      "IL-2"
    ],
    "primary_completion_date": "2023-08-11",
    "completion_date": "2023-08-11",
    "results_first_posted": null,
    "last_update_posted": "2023-09-21",
    "enrollment": null,
    "sponsor": "Fate Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "FATE",
    "nct_id": "NCT05934097",
    "title": "FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma",
    "status": "WITHDRAWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diffuse Large B Cell Lymphoma",
      "Transformed Indolent Non-Hodgkin's Lymphoma",
      "Follicular Lymphoma",
      "Mantle Cell Lymphoma",
      "Marginal Zone Lymphoma"
    ],
    "interventions": [
      "FT596",
      "Cyclophosphamide",
      "Doxorubicin",
      "Vincristine",
      "Prednisone",
      "Rituximab",
      "Bendamustine"
    ],
    "primary_completion_date": "2026-05",
    "completion_date": "2039-05",
    "results_first_posted": null,
    "last_update_posted": "2023-07-06",
    "enrollment": null,
    "sponsor": "Fate Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "FATE",
    "nct_id": "NCT03841110",
    "title": "FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumors",
      "Lymphoma",
      "Gastric Cancer",
      "Colorectal Cancer",
      "Head and Neck Cancer",
      "Squamous Cell Carcinoma",
      "EGFR Positive Solid Tumor",
      "HER2-positive Breast Cancer",
      "Hepatocellular Carcinoma",
      "Small Cell Lung Cancer",
      "Renal Cell Carcinoma",
      "Pancreas Cancer",
      "Melanoma",
      "NSCLC",
      "Urothelial Carcinoma",
      "Cervical Cancer",
      "Microsatellite Instability",
      "Merkel Cell Carcinoma"
    ],
    "interventions": [
      "FT500",
      "Nivolumab",
      "Pembrolizumab",
      "Atezolizumab",
      "Cyclophosphamide",
      "Fludarabine",
      "IL-2"
    ],
    "primary_completion_date": "2022-11-15",
    "completion_date": "2022-11-15",
    "results_first_posted": null,
    "last_update_posted": "2023-05-01",
    "enrollment": null,
    "sponsor": "Fate Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "FATE",
    "nct_id": "NCT00890500",
    "title": "Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hematologic Malignancies",
      "Allogeneic Stem Cell Transplantation"
    ],
    "interventions": [
      "Fludarabine",
      "Melphalan",
      "Antithymocyte Globulin",
      "Sirolimus",
      "Tacrolimus"
    ],
    "primary_completion_date": "2013-05",
    "completion_date": "2013-10",
    "results_first_posted": null,
    "last_update_posted": "2013-10-08",
    "enrollment": null,
    "sponsor": "Fate Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "FATE",
    "nct_id": "NCT06241456",
    "title": "FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumor"
    ],
    "interventions": [
      "FT825",
      "Fludarabine",
      "Cyclophosphamide",
      "Bendamustine",
      "Docetaxel",
      "Cisplatin",
      "Cetuximab"
    ],
    "primary_completion_date": "2029-05-01",
    "completion_date": "2044-05-01",
    "results_first_posted": null,
    "last_update_posted": "2025-12-09",
    "enrollment": null,
    "sponsor": "Fate Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "FATE",
    "nct_id": "NCT01627314",
    "title": "The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hematologic Malignancies"
    ],
    "interventions": [
      "ProHema-CB",
      "Untreated CB"
    ],
    "primary_completion_date": "2016-03",
    "completion_date": "2017-05",
    "results_first_posted": null,
    "last_update_posted": "2021-11-30",
    "enrollment": null,
    "sponsor": "Fate Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "FATE",
    "nct_id": "NCT05950334",
    "title": "FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsed/Refractory B-Cell Lymphoma"
    ],
    "interventions": [
      "FT522",
      "Rituximab",
      "Cyclophosphamide",
      "Fludarabine",
      "Bendamustine"
    ],
    "primary_completion_date": "2025-06-06",
    "completion_date": "2025-06-30",
    "results_first_posted": null,
    "last_update_posted": "2025-08-22",
    "enrollment": null,
    "sponsor": "Fate Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "FATE",
    "nct_id": "NCT02743351",
    "title": "Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hematologic Malignancies",
      "Acute Myeloid Leukemia",
      "Acute Lymphoblastic Leukemia",
      "Myelodysplastic Syndromes",
      "Chronic Myelogenous Leukemia",
      "Acute Graft-versus-host Disease"
    ],
    "interventions": [
      "ProTmune",
      "Control Arm"
    ],
    "primary_completion_date": "2020-12-04",
    "completion_date": "2021-11-05",
    "results_first_posted": "2023-02-08",
    "last_update_posted": "2023-02-08",
    "enrollment": null,
    "sponsor": "Fate Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "FATE",
    "nct_id": "NCT02354443",
    "title": "A Trial of a Single ProHema-CB Product Transplant in Pediatric Patients With Inherited Metabolic Disorders",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metabolic Disorders"
    ],
    "interventions": [
      "ProHema-CB Transplant"
    ],
    "primary_completion_date": "2016-12",
    "completion_date": "2017-02",
    "results_first_posted": "2018-10-10",
    "last_update_posted": "2018-10-10",
    "enrollment": null,
    "sponsor": "Fate Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "FATE",
    "nct_id": "NCT04106167",
    "title": "Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy",
    "status": "TERMINATED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Advanced Solid Tumor",
      "Lymphoma",
      "Gastric Cancer",
      "Colorectal Cancer",
      "Head and Neck Cancer",
      "Squamous Cell Carcinoma",
      "EGFR Positive Solid Tumor",
      "HER2-positive Breast Cancer",
      "Hepatocellular Carcinoma",
      "Small-cell Lung Cancer",
      "Renal Cell Carcinoma",
      "Pancreas Cancer",
      "Melanoma",
      "NSCLC",
      "Urothelial Carcinoma",
      "Cervical Cancer",
      "Microsatellite Instability",
      "Merkel Cell Carcinoma"
    ],
    "interventions": [
      "Allogeneic natural killer (NK) cell"
    ],
    "primary_completion_date": "2023-08-11",
    "completion_date": "2023-08-11",
    "results_first_posted": null,
    "last_update_posted": "2023-09-21",
    "enrollment": null,
    "sponsor": "Fate Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "FATE",
    "nct_id": "NCT05182073",
    "title": "FT576 in Subjects With Multiple Myeloma",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple Myeloma",
      "Myeloma"
    ],
    "interventions": [
      "FT576 (Allogenic CAR NK cells with BCMA expression)",
      "Cyclophosphamide",
      "Fludarabine",
      "Daratumumab",
      "Bendamustine"
    ],
    "primary_completion_date": "2024-09-20",
    "completion_date": "2024-10-18",
    "results_first_posted": null,
    "last_update_posted": "2025-12-12",
    "enrollment": null,
    "sponsor": "Fate Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "FATE",
    "nct_id": "NCT04093622",
    "title": "Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy",
    "status": "TERMINATED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Hematological Malignancy"
    ],
    "interventions": [
      "Genetically engineered NK cells"
    ],
    "primary_completion_date": "2020-04-09",
    "completion_date": "2020-04-09",
    "results_first_posted": null,
    "last_update_posted": "2022-08-29",
    "enrollment": null,
    "sponsor": "Fate Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "FATE",
    "nct_id": "NCT04245722",
    "title": "FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lymphoma, B-Cell",
      "Chronic Lymphocytic Leukemia"
    ],
    "interventions": [
      "FT596",
      "Cyclophosphamide",
      "Fludarabine",
      "Rituximab",
      "Obinutuzumab",
      "Bendamustine"
    ],
    "primary_completion_date": "2023-09-27",
    "completion_date": "2023-09-27",
    "results_first_posted": null,
    "last_update_posted": "2023-10-26",
    "enrollment": null,
    "sponsor": "Fate Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "FATE",
    "nct_id": "NCT04614636",
    "title": "FT538 in Subjects With Advanced Hematologic Malignancies",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Myeloid Leukemia",
      "AML, Adult",
      "Multiple Myeloma",
      "Myeloma"
    ],
    "interventions": [
      "FT538",
      "Cyclophosphamide",
      "Fludarabine",
      "Daratumumab",
      "Elotuzumab"
    ],
    "primary_completion_date": "2023-07-13",
    "completion_date": "2023-08-08",
    "results_first_posted": null,
    "last_update_posted": "2023-09-21",
    "enrollment": null,
    "sponsor": "Fate Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NTLA",
    "nct_id": "NCT06262399",
    "title": "Long-Term Follow-Up (LTFU) of Subjects Treated With NTLA 2002",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Hereditary Angioedema"
    ],
    "interventions": [],
    "primary_completion_date": "2040-04",
    "completion_date": "2040-04",
    "results_first_posted": null,
    "last_update_posted": "2025-11-28",
    "enrollment": null,
    "sponsor": "Intellia Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "EDIT",
    "nct_id": "NCT03396042",
    "title": "Natural History Study of CEP290-Related Retinal Degeneration",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Blindness",
      "Leber Congenital Amaurosis 10",
      "Vision Disorders",
      "Eye Diseases",
      "Eye Diseases, Hereditary",
      "Eye Disorders Congenital",
      "Retinal Disease",
      "Retinal Degeneration"
    ],
    "interventions": [],
    "primary_completion_date": "2022-05-06",
    "completion_date": "2022-05-06",
    "results_first_posted": null,
    "last_update_posted": "2022-05-19",
    "enrollment": null,
    "sponsor": "Editas Medicine, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BEAM",
    "nct_id": "NCT07304791",
    "title": "This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of BEAM-103 in Healthy Subjects",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Subjects",
      "Healthy Participant Study"
    ],
    "interventions": [
      "BEAM-103",
      "Placebo Comparator"
    ],
    "primary_completion_date": "2026-01-29",
    "completion_date": "2026-05-29",
    "results_first_posted": null,
    "last_update_posted": "2025-12-26",
    "enrollment": null,
    "sponsor": "Beam Therapeutics Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BEAM",
    "nct_id": "NCT05456880",
    "title": "BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Sickle Cell Disease"
    ],
    "interventions": [
      "BEAM-101"
    ],
    "primary_completion_date": "2028-02",
    "completion_date": "2028-02",
    "results_first_posted": null,
    "last_update_posted": "2025-12-16",
    "enrollment": null,
    "sponsor": "Beam Therapeutics Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALLO",
    "nct_id": "NCT03265808",
    "title": "Allogeneic Human Mesenchymal Stem Cell Infusion vs Placebo in Alcohol Use Disorder and Major Depression.",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder",
      "Alcohol Use Disorder"
    ],
    "interventions": [
      "allogeneic human mesenchymal stem cells (allo-hMSCs)",
      "Placebo"
    ],
    "primary_completion_date": "2025-07-30",
    "completion_date": "2025-07-30",
    "results_first_posted": null,
    "last_update_posted": "2026-01-09",
    "enrollment": null,
    "sponsor": "Ihsan M Salloum, MD, MPH",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALLO",
    "nct_id": "NCT05179057",
    "title": "Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Adenovirus Infection"
    ],
    "interventions": [
      "Posoleucel",
      "Placebo"
    ],
    "primary_completion_date": "2024-01-31",
    "completion_date": "2024-01-31",
    "results_first_posted": "2024-05-08",
    "last_update_posted": "2024-05-08",
    "enrollment": null,
    "sponsor": "AlloVir",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALLO",
    "nct_id": "NCT06925685",
    "title": "Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Hematologic Malignancies",
      "Solid Tumors"
    ],
    "interventions": [],
    "primary_completion_date": "2039-01",
    "completion_date": "2039-01",
    "results_first_posted": null,
    "last_update_posted": "2025-04-13",
    "enrollment": null,
    "sponsor": "Allogene Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALLO",
    "nct_id": "NCT02213068",
    "title": "Belatacept 3 Month Post Transplant Conversion Study",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Transplant; Failure, Kidney",
      "EBV"
    ],
    "interventions": [
      "belatacept",
      "Tacrolimus",
      "MPA"
    ],
    "primary_completion_date": "2020-09",
    "completion_date": "2020-09",
    "results_first_posted": "2021-09-08",
    "last_update_posted": "2023-02-08",
    "enrollment": null,
    "sponsor": "Lorenzo Gallon",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "DNLI",
    "nct_id": "NCT06181136",
    "title": "Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Mucopolysaccharidosis Type IIIA"
    ],
    "interventions": [
      "DNL126"
    ],
    "primary_completion_date": "2028-08",
    "completion_date": "2028-08",
    "results_first_posted": null,
    "last_update_posted": "2025-12-05",
    "enrollment": null,
    "sponsor": "Denali Therapeutics Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "DNLI",
    "nct_id": "NCT03757325",
    "title": "Study to Evaluate DNL747 in Subjects With Alzheimer's Disease",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alzheimer Disease"
    ],
    "interventions": [
      "DNL747",
      "Placebo"
    ],
    "primary_completion_date": "2019-12-05",
    "completion_date": "2019-12-05",
    "results_first_posted": null,
    "last_update_posted": "2020-02-26",
    "enrollment": null,
    "sponsor": "Denali Therapeutics Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "DNLI",
    "nct_id": "NCT05006352",
    "title": "A Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral Sclerosis",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Amyotrophic Lateral Sclerosis"
    ],
    "interventions": [
      "DNL343",
      "Placebo"
    ],
    "primary_completion_date": "2022-12-15",
    "completion_date": "2024-06-05",
    "results_first_posted": null,
    "last_update_posted": "2024-09-19",
    "enrollment": null,
    "sponsor": "Denali Therapeutics Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "DNLI",
    "nct_id": "NCT04551534",
    "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL201 in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "DNL201",
      "Placebo"
    ],
    "primary_completion_date": "2018-08-08",
    "completion_date": "2018-08-08",
    "results_first_posted": null,
    "last_update_posted": "2020-09-16",
    "enrollment": null,
    "sponsor": "Denali Therapeutics Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "DNLI",
    "nct_id": "NCT04007536",
    "title": "A Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter Syndrome",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Mucopolysaccharidosis II"
    ],
    "interventions": [
      "No Intervention"
    ],
    "primary_completion_date": "2024-03-01",
    "completion_date": "2024-03-01",
    "results_first_posted": null,
    "last_update_posted": "2024-06-10",
    "enrollment": null,
    "sponsor": "Denali Therapeutics Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "DNLI",
    "nct_id": "NCT05371613",
    "title": "A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Mucopolysaccharidosis II"
    ],
    "interventions": [
      "tividenofusp alfa",
      "idursulfase"
    ],
    "primary_completion_date": "2027-12",
    "completion_date": "2027-12",
    "results_first_posted": null,
    "last_update_posted": "2025-08-05",
    "enrollment": null,
    "sponsor": "Denali Therapeutics Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "DNLI",
    "nct_id": "NCT07328451",
    "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alzheimer Disease, Early Onset"
    ],
    "interventions": [
      "DNL628",
      "Placebo"
    ],
    "primary_completion_date": "2027-02",
    "completion_date": "2027-02",
    "results_first_posted": null,
    "last_update_posted": "2026-01-14",
    "enrollment": null,
    "sponsor": "Denali Therapeutics Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "DNLI",
    "nct_id": "NCT04251026",
    "title": "A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Mucopolysaccharidosis II"
    ],
    "interventions": [
      "tividenofusp alfa"
    ],
    "primary_completion_date": "2031-02",
    "completion_date": "2031-02",
    "results_first_posted": null,
    "last_update_posted": "2025-08-07",
    "enrollment": null,
    "sponsor": "Denali Therapeutics Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "DNLI",
    "nct_id": "NCT03710707",
    "title": "Study to Evaluate DNL201 in Subjects With Parkinson's Disease",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Parkinson Disease"
    ],
    "interventions": [
      "DNL201",
      "Placebo"
    ],
    "primary_completion_date": "2019-12-06",
    "completion_date": "2019-12-06",
    "results_first_posted": null,
    "last_update_posted": "2020-01-13",
    "enrollment": null,
    "sponsor": "Denali Therapeutics Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "DNLI",
    "nct_id": "NCT04581772",
    "title": "A Study to Evaluate the Bioavailability and Safety of DNL343 in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "DNL343",
      "Placebo",
      "DNL343"
    ],
    "primary_completion_date": "2021-06-04",
    "completion_date": "2021-06-04",
    "results_first_posted": null,
    "last_update_posted": "2021-06-11",
    "enrollment": null,
    "sponsor": "Denali Therapeutics Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "DNLI",
    "nct_id": "NCT05450549",
    "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL919 in Healthy Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participant"
    ],
    "interventions": [
      "DNL919",
      "Placebo"
    ],
    "primary_completion_date": "2023-06-08",
    "completion_date": "2023-06-08",
    "results_first_posted": null,
    "last_update_posted": "2023-08-16",
    "enrollment": null,
    "sponsor": "Denali Therapeutics Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "DNLI",
    "nct_id": "NCT04268784",
    "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL343 in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "DNL343",
      "Placebo"
    ],
    "primary_completion_date": "2021-08-03",
    "completion_date": "2021-08-03",
    "results_first_posted": null,
    "last_update_posted": "2022-02-07",
    "enrollment": null,
    "sponsor": "Denali Therapeutics Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "DNLI",
    "nct_id": "NCT07354724",
    "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Disease",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Late-onset Pompe Disease"
    ],
    "interventions": [
      "DNL952"
    ],
    "primary_completion_date": "2028-08",
    "completion_date": "2028-08",
    "results_first_posted": null,
    "last_update_posted": "2026-01-21",
    "enrollment": null,
    "sponsor": "Denali Therapeutics Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "DNLI",
    "nct_id": "NCT06281158",
    "title": "A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-DNL343 Following a Single Oral Dose in Healthy Male Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "[14C]-DNL343"
    ],
    "primary_completion_date": "2024-04-30",
    "completion_date": "2024-04-30",
    "results_first_posted": null,
    "last_update_posted": "2024-06-20",
    "enrollment": null,
    "sponsor": "Denali Therapeutics Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "DNLI",
    "nct_id": "NCT06602193",
    "title": "Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Parkinson Disease"
    ],
    "interventions": [
      "BIIB122 225 mg",
      "BIIB122-Matching Placebo"
    ],
    "primary_completion_date": "2026-04-30",
    "completion_date": "2028-02-28",
    "results_first_posted": null,
    "last_update_posted": "2025-11-28",
    "enrollment": null,
    "sponsor": "Denali Therapeutics Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "DNLI",
    "nct_id": "NCT04557800",
    "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL151 in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "DNL151",
      "Placebo"
    ],
    "primary_completion_date": "2021-02-19",
    "completion_date": "2021-02-19",
    "results_first_posted": null,
    "last_update_posted": "2022-03-07",
    "enrollment": null,
    "sponsor": "Denali Therapeutics Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "DNLI",
    "nct_id": "NCT05262023",
    "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Frontotemporal Dementia"
    ],
    "interventions": [
      "DNL593",
      "Placebo"
    ],
    "primary_completion_date": "2026-12",
    "completion_date": "2028-11",
    "results_first_posted": null,
    "last_update_posted": "2026-01-15",
    "enrollment": null,
    "sponsor": "Denali Therapeutics Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "DNLI",
    "nct_id": "NCT06075537",
    "title": "An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Mucopolysaccharidosis II"
    ],
    "interventions": [
      "tividenofusp alfa"
    ],
    "primary_completion_date": "2027-06",
    "completion_date": "2027-06",
    "results_first_posted": null,
    "last_update_posted": "2025-12-24",
    "enrollment": null,
    "sponsor": "Denali Therapeutics Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GLPG",
    "nct_id": "NCT06652633",
    "title": "Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hematological Malignancies"
    ],
    "interventions": [
      "GLPG CAR T-cell therapy"
    ],
    "primary_completion_date": "2039-07",
    "completion_date": "2039-07",
    "results_first_posted": null,
    "last_update_posted": "2025-09-16",
    "enrollment": null,
    "sponsor": "Galapagos Cell Therapeutics NV",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "HALO",
    "nct_id": "NCT03373006",
    "title": "A Phase II Study to Evaluate Axumin PET/CT for Risk Stratification for Prostate Cancer",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Prostate Cancer"
    ],
    "interventions": [
      "Axumin PET/CT"
    ],
    "primary_completion_date": "2020-01-30",
    "completion_date": "2020-01-30",
    "results_first_posted": "2020-06-04",
    "last_update_posted": "2022-05-25",
    "enrollment": null,
    "sponsor": "HALO Diagnostics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "HALO",
    "nct_id": "NCT05714488",
    "title": "Evaluation of the \"Blue Halo Coil Catheter\" for Patients With Prostatic Obstruction",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Urinary Retention"
    ],
    "interventions": [
      "blue halo coil catheter"
    ],
    "primary_completion_date": "2024-09-01",
    "completion_date": "2024-10-01",
    "results_first_posted": null,
    "last_update_posted": "2024-01-10",
    "enrollment": null,
    "sponsor": "Blue Halo Biomedical, LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "HALO",
    "nct_id": "NCT05423860",
    "title": "Phase I Human Analytics (HALO) Study",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Cardiovascular Diseases",
      "Cancer",
      "Dementia",
      "Traumatic Brain Injury"
    ],
    "interventions": [
      "no interventions will be performed (observational)"
    ],
    "primary_completion_date": "2027-03",
    "completion_date": "2037-03",
    "results_first_posted": null,
    "last_update_posted": "2022-10-14",
    "enrollment": null,
    "sponsor": "HALO Diagnostics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "HALO",
    "nct_id": "NCT02243033",
    "title": "Phase II Laser Focal Therapy of Prostate Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Prostate Cancer"
    ],
    "interventions": [
      "MR-guided laser focal therapy"
    ],
    "primary_completion_date": "2036-05",
    "completion_date": "2036-11",
    "results_first_posted": null,
    "last_update_posted": "2022-03-25",
    "enrollment": null,
    "sponsor": "HALO Diagnostics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KALA",
    "nct_id": "NCT02793817",
    "title": "Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Post Surgical Ocular Inflammation and Pain"
    ],
    "interventions": [
      "KPI-121 1% Ophthalmic Suspension dosed BID",
      "Vehicle of KPI-121 Ophthalmic Suspension dosed BID"
    ],
    "primary_completion_date": "2017-03",
    "completion_date": "2017-03",
    "results_first_posted": "2019-04-17",
    "last_update_posted": "2020-12-16",
    "enrollment": null,
    "sponsor": "Kala Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KALA",
    "nct_id": "NCT02813265",
    "title": "Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dry Eye Syndromes",
      "Keratoconjunctivitis Sicca"
    ],
    "interventions": [
      "KPI-121 0.25% Ophthalmic Suspension",
      "Vehicle of KPI-121 0.25% Ophthalmic Suspension"
    ],
    "primary_completion_date": "2017-10",
    "completion_date": "2017-10",
    "results_first_posted": "2020-12-03",
    "last_update_posted": "2021-02-03",
    "enrollment": null,
    "sponsor": "Kala Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KALA",
    "nct_id": "NCT02163824",
    "title": "Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ocular Infections, Irritations and Inflammations"
    ],
    "interventions": [
      "KPI-121 0.25%",
      "KPI-121 1.0%",
      "Vehicle of KPI-121 0.25%",
      "Vehicle of KPI-121 1.0%"
    ],
    "primary_completion_date": "2014-12",
    "completion_date": "2014-12",
    "results_first_posted": "2020-12-22",
    "last_update_posted": "2021-01-29",
    "enrollment": null,
    "sponsor": "Kala Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KALA",
    "nct_id": "NCT02819284",
    "title": "Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dry Eye Syndromes",
      "Keratoconjunctivitis Sicca"
    ],
    "interventions": [
      "KPI-121 0.25% Ophthalmic Suspension",
      "Vehicle of KPI-121 0.25% Ophthalmic Suspension"
    ],
    "primary_completion_date": "2017-09",
    "completion_date": "2017-09",
    "results_first_posted": "2020-12-03",
    "last_update_posted": "2021-01-05",
    "enrollment": null,
    "sponsor": "Kala Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KALA",
    "nct_id": "NCT03616899",
    "title": "Safety and Efficacy of KPI-121 in Subjects With DED",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Kerato Conjunctivitis Sicca"
    ],
    "interventions": [
      "KPI-121 Ophthalmic Suspension",
      "Vehicle"
    ],
    "primary_completion_date": "2020-02-05",
    "completion_date": "2020-02-05",
    "results_first_posted": "2021-04-02",
    "last_update_posted": "2021-04-02",
    "enrollment": null,
    "sponsor": "Kala Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KALA",
    "nct_id": "NCT02218489",
    "title": "Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Blepharitis"
    ],
    "interventions": [
      "KPI-121",
      "Vehicle"
    ],
    "primary_completion_date": "2015-12",
    "completion_date": "2016-06",
    "results_first_posted": "2021-01-11",
    "last_update_posted": "2021-01-11",
    "enrollment": null,
    "sponsor": "Kala Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KALA",
    "nct_id": "NCT02245516",
    "title": "Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Retinal Vein Occlusion",
      "Diabetic Macular Edema"
    ],
    "interventions": [
      "KPI-121 0.25% Ophthalmic Suspension",
      "KPI-121 1.0% Ophthalmic Suspension"
    ],
    "primary_completion_date": "2014-12",
    "completion_date": "2014-12",
    "results_first_posted": "2020-12-10",
    "last_update_posted": "2020-12-10",
    "enrollment": null,
    "sponsor": "Kala Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KALA",
    "nct_id": "NCT03596723",
    "title": "KPI-121 1% Versus Prednisolone for the Treatment of Inflammation Following Cataract Surgery in Children",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ocular Inflammation"
    ],
    "interventions": [
      "KPI-121 1%",
      "Prednisolone acetate"
    ],
    "primary_completion_date": "2018-09-28",
    "completion_date": "2018-10-18",
    "results_first_posted": "2020-04-07",
    "last_update_posted": "2020-10-19",
    "enrollment": null,
    "sponsor": "Kala Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KALA",
    "nct_id": "NCT02188160",
    "title": "Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dry Eye Syndromes",
      "Keratoconjunctivitis Sicca"
    ],
    "interventions": [
      "KPI-121",
      "Placebo"
    ],
    "primary_completion_date": "2015-01",
    "completion_date": "2015-03",
    "results_first_posted": "2021-01-06",
    "last_update_posted": "2021-01-06",
    "enrollment": null,
    "sponsor": "Kala Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KRYS",
    "nct_id": "NCT04917887",
    "title": "Long-Term Follow-up Protocol",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Dystrophic Epidermolysis Bullosa",
      "Recessive Dystrophic Epidermolysis Bullosa",
      "Dominant Dystrophic Epidermolysis Bullosa"
    ],
    "interventions": [],
    "primary_completion_date": "2028-05-25",
    "completion_date": "2028-05-25",
    "results_first_posted": null,
    "last_update_posted": "2021-06-08",
    "enrollment": null,
    "sponsor": "Krystal Biotech, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SANA",
    "nct_id": "NCT07307209",
    "title": "\"Sliding Jigs vs Retraction Hooks for Maxillary Dentition Distalization Using IZC Miniscrews\"",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Skeletal Class II Malocclusion"
    ],
    "interventions": [
      "Sliding jig",
      "retraction hooks"
    ],
    "primary_completion_date": "2026-03",
    "completion_date": "2026-12",
    "results_first_posted": null,
    "last_update_posted": "2026-01-15",
    "enrollment": null,
    "sponsor": "Sana'a University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SANA",
    "nct_id": "NCT02612493",
    "title": "Obesity and Metabolic Surgery in Patients With Type I Diabetes",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Type I Diabetes"
    ],
    "interventions": [
      "Obese patients with type I diabetes"
    ],
    "primary_completion_date": "2015-11",
    "completion_date": "2015-11",
    "results_first_posted": null,
    "last_update_posted": "2015-11-23",
    "enrollment": null,
    "sponsor": "Sana Klinikum Offenbach",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SANA",
    "nct_id": "NCT05319405",
    "title": "Effectiveness of Sana Treatment in Post-Traumatic Stress Disorder (PTSD)",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Post Traumatic Stress Disorder"
    ],
    "interventions": [
      "Sana Device"
    ],
    "primary_completion_date": "2023-12-01",
    "completion_date": "2023-12-01",
    "results_first_posted": null,
    "last_update_posted": "2024-02-06",
    "enrollment": null,
    "sponsor": "Sana Health",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SANA",
    "nct_id": "NCT07111702",
    "title": "Prophylactic Antibiotics in Groin Hernioplasty",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Surgical Site Infection",
      "Groin Hernia",
      "Hernioplasty"
    ],
    "interventions": [
      "Cefazolin"
    ],
    "primary_completion_date": "2024-05-30",
    "completion_date": "2024-05-30",
    "results_first_posted": null,
    "last_update_posted": "2025-08-13",
    "enrollment": null,
    "sponsor": "Sana'a University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SANA",
    "nct_id": "NCT05167669",
    "title": "Pain Relief in Symptomatic Bone Metastases With Adjuvant Hyperthermia MR Guided HIFU",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bone Metastases",
      "Radiotherapy",
      "Pain",
      "MRI"
    ],
    "interventions": [
      "HIFU-MRI guided"
    ],
    "primary_completion_date": "2024-12-31",
    "completion_date": "2025-01-01",
    "results_first_posted": null,
    "last_update_posted": "2025-04-02",
    "enrollment": null,
    "sponsor": "Sana Boudabbous",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SANA",
    "nct_id": "NCT03810430",
    "title": "Health Promotion Intervention to Reduce Child Morbidity",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diarrhea; Nutritional"
    ],
    "interventions": [
      "health promotion"
    ],
    "primary_completion_date": "2015-12-20",
    "completion_date": "2018-12-31",
    "results_first_posted": null,
    "last_update_posted": "2019-01-23",
    "enrollment": null,
    "sponsor": "Sana'a University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SANA",
    "nct_id": "NCT06324474",
    "title": "Clinical and Immunological Evaluation of HA in Treatment of Periodontitis",
    "status": "NOT_YET_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Periodontitis"
    ],
    "interventions": [
      "Hyaluronic acid",
      "scaling and root planning"
    ],
    "primary_completion_date": "2025-12-12",
    "completion_date": "2025-12-12",
    "results_first_posted": null,
    "last_update_posted": "2024-12-05",
    "enrollment": null,
    "sponsor": "Sana'a University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SANA",
    "nct_id": "NCT04568798",
    "title": "Efficacy of Sana Treatment in Fibromyalgia",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fibromyalgia"
    ],
    "interventions": [
      "Sana Sham Device"
    ],
    "primary_completion_date": "2021-10-30",
    "completion_date": "2022-03-04",
    "results_first_posted": null,
    "last_update_posted": "2022-03-31",
    "enrollment": null,
    "sponsor": "Sana Health",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SANA",
    "nct_id": "NCT05878184",
    "title": "Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non Hodgkin Lymphoma",
      "Chronic Lymphocytic Leukemia"
    ],
    "interventions": [
      "SC291"
    ],
    "primary_completion_date": "2025-11-04",
    "completion_date": "2038-11-04",
    "results_first_posted": null,
    "last_update_posted": "2025-10-02",
    "enrollment": null,
    "sponsor": "Sana Biotechnology",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SANA",
    "nct_id": "NCT07141836",
    "title": "Effectiveness of Elastic Chains Versus Elastics in Maxillary Canine Retraction",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Elastic Chains",
      "Elastics"
    ],
    "interventions": [
      "Elastomeric chain",
      "Elastics"
    ],
    "primary_completion_date": "2025-04-11",
    "completion_date": "2025-05-01",
    "results_first_posted": null,
    "last_update_posted": "2025-09-02",
    "enrollment": null,
    "sponsor": "Sana'a University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SANA",
    "nct_id": "NCT03045679",
    "title": "One-anastomosis Gastric Bypass/Mini-Gastric Bypass Versus Roux-en Y Gastric Bypass",
    "status": "TERMINATED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Obesity"
    ],
    "interventions": [
      "RYGB",
      "OAGB/MGB"
    ],
    "primary_completion_date": "2020-12-01",
    "completion_date": "2020-12-01",
    "results_first_posted": null,
    "last_update_posted": "2023-01-17",
    "enrollment": null,
    "sponsor": "Sana Klinikum Offenbach",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SANA",
    "nct_id": "NCT05394610",
    "title": "Effectiveness of the Sana Device on Fibromyalgia Symptoms",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fibromyalgia",
      "Pain, Chronic",
      "Quality of Life"
    ],
    "interventions": [
      "Sana Device",
      "Sana Device (Control)"
    ],
    "primary_completion_date": "2025-06",
    "completion_date": "2025-06",
    "results_first_posted": null,
    "last_update_posted": "2023-11-21",
    "enrollment": null,
    "sponsor": "Sana Health",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SANA",
    "nct_id": "NCT02947412",
    "title": "Long Term Results After Sleeve Gastrectomy",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Obesity"
    ],
    "interventions": [
      "laparoscopic sleeve gastrectomy"
    ],
    "primary_completion_date": "2015-12",
    "completion_date": "2016-10",
    "results_first_posted": null,
    "last_update_posted": "2018-04-25",
    "enrollment": null,
    "sponsor": "Sana Klinikum Offenbach",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SANA",
    "nct_id": "NCT06856811",
    "title": "Condylar Position Changes in Anterior Disc Displacement with Reduction",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "TMJ Disorder"
    ],
    "interventions": [
      "tmj lavage with ringer lactate solution"
    ],
    "primary_completion_date": "2024-10-30",
    "completion_date": "2024-10-30",
    "results_first_posted": null,
    "last_update_posted": "2025-03-04",
    "enrollment": null,
    "sponsor": "Sana'a University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SANA",
    "nct_id": "NCT05616364",
    "title": "Compair Efficacy of iv Dexmedetomidine & Tramadol for Post Spinal Shivering in Obs Patients Undergoing Cesarean Section",
    "status": "UNKNOWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Post Spinal Shivering"
    ],
    "interventions": [
      "Dexmedetomidine injection",
      "Tramadol"
    ],
    "primary_completion_date": "2024-03",
    "completion_date": "2025-02",
    "results_first_posted": null,
    "last_update_posted": "2022-11-15",
    "enrollment": null,
    "sponsor": "Sana Bahadur",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SANA",
    "nct_id": "NCT02697695",
    "title": "Chronic Inflammation After Obesity Surgery",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Obesity"
    ],
    "interventions": [
      "Laboratory Examination"
    ],
    "primary_completion_date": "2015-12",
    "completion_date": "2016-02",
    "results_first_posted": null,
    "last_update_posted": "2018-07-31",
    "enrollment": null,
    "sponsor": "Sana Klinikum Offenbach",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SANA",
    "nct_id": "NCT07317596",
    "title": "Comparing Methylprednisolone And Hyaluronic Acid To Reduce Wisdom Tooth Surgery Complications",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Wisdom Tooth Removal",
      "Post Operative Complications",
      "Hyaluronic Acid",
      "Methylprednisolone"
    ],
    "interventions": [
      "Methyl Prednisolone (MP)",
      "Hyaluronic Acid (HA)"
    ],
    "primary_completion_date": "2026-01-05",
    "completion_date": "2026-01-08",
    "results_first_posted": null,
    "last_update_posted": "2026-01-15",
    "enrollment": null,
    "sponsor": "Sana'a University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SANA",
    "nct_id": "NCT06394479",
    "title": "Long-term Results After Bariatric Surgery in Type 1 Diabetes Patients",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Bariatric Surgery Status in T1D"
    ],
    "interventions": [
      "Outcome after bariatric surgery in patient with T1D"
    ],
    "primary_completion_date": "2020-02-28",
    "completion_date": "2020-03-28",
    "results_first_posted": null,
    "last_update_posted": "2024-05-01",
    "enrollment": null,
    "sponsor": "Sana Klinikum Offenbach",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SANA",
    "nct_id": "NCT03526783",
    "title": "MGB/OAGB Versus RYGB After Failed Sleeve",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Obesity"
    ],
    "interventions": [
      "Roux en Y gastric bypass",
      "Mini/One anastomosis gastric bypass"
    ],
    "primary_completion_date": "2017-12",
    "completion_date": "2018-09",
    "results_first_posted": null,
    "last_update_posted": "2018-10-02",
    "enrollment": null,
    "sponsor": "Sana Klinikum Offenbach",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SANA",
    "nct_id": "NCT07101315",
    "title": "Early Versus Delayed Laparoscopic Cholecystectomy for Acute Cholecystitis",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Cholecystitis"
    ],
    "interventions": [
      "Laparoscopic Cholecystectomy"
    ],
    "primary_completion_date": "2023-12-30",
    "completion_date": "2023-12-30",
    "results_first_posted": null,
    "last_update_posted": "2025-08-03",
    "enrollment": null,
    "sponsor": "Sana'a University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SANA",
    "nct_id": "NCT02757716",
    "title": "Addiction Remission and Addiction Transfer After Bariatric Surgery",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Obesity"
    ],
    "interventions": [
      "Questionnaire"
    ],
    "primary_completion_date": "2019-01",
    "completion_date": "2019-01",
    "results_first_posted": null,
    "last_update_posted": "2019-05-15",
    "enrollment": null,
    "sponsor": "Sana Klinikum Offenbach",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SANA",
    "nct_id": "NCT04046601",
    "title": "Impedance Spectroscopy in Esophageal Cancer",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cancer of Esophagus"
    ],
    "interventions": [
      "impedance"
    ],
    "primary_completion_date": "2020-02-01",
    "completion_date": "2020-02-15",
    "results_first_posted": null,
    "last_update_posted": "2023-01-17",
    "enrollment": null,
    "sponsor": "Sana Klinikum Offenbach",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SANA",
    "nct_id": "NCT06294236",
    "title": "Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lupus Erythematosus",
      "Systemic Lupus Erythematosus",
      "SLE (Systemic Lupus)",
      "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
      "Granulomatous Polyangiitis",
      "Microscopic Polyangiitis"
    ],
    "interventions": [
      "SC291"
    ],
    "primary_completion_date": "2027-12",
    "completion_date": "2028-03",
    "results_first_posted": null,
    "last_update_posted": "2025-11-25",
    "enrollment": null,
    "sponsor": "Sana Biotechnology",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SANA",
    "nct_id": "NCT05851820",
    "title": "Prevalence and Impact of Diabetes Mellitus in Hospitalized COVID-19 Patients in a Tunisian Center",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Prevalence",
      "Diabetes Mellitus",
      "Impaction",
      "COVID-19"
    ],
    "interventions": [
      "comparison of outcomes/exposure"
    ],
    "primary_completion_date": "2021-08-31",
    "completion_date": "2021-08-31",
    "results_first_posted": null,
    "last_update_posted": "2023-05-10",
    "enrollment": null,
    "sponsor": "Sana Rouis",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SANA",
    "nct_id": "NCT07300371",
    "title": "Intra-oral Evaluation of Force Decay of Pigmented and Transparent Elastomeric Power Chains:",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Orthodontic Treatment",
      "Malocclusion"
    ],
    "interventions": [
      "Matt gray elastomeric power chains",
      "Matt blue elastomeric power chains",
      "Matt pink elastomeric power chains",
      "Matt transparent elastomeric power chains",
      "Matt black elastomeric power chains",
      "American orthodontic gray elastomeric power chains",
      "Americam orthodontic blue elastomeric power chains",
      "Americam orthodontic black elastomeric power chains",
      "Americam orthodontic pink elastomeric power chains",
      "Americam orthodontic transparent elastomeric power chains",
      "SIA pink elastomeric power chains",
      "SIA blue elastomeric power chains",
      "SIA black elastomeric power chains",
      "SIA transparent elastomeric power chains",
      "SIA gray elastomeric power chains"
    ],
    "primary_completion_date": "2024-09-20",
    "completion_date": "2024-09-20",
    "results_first_posted": null,
    "last_update_posted": "2025-12-31",
    "enrollment": null,
    "sponsor": "Sana'a University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SANA",
    "nct_id": "NCT06876155",
    "title": "Prospective, Randomized Comparative Study Between an Anesthesiological, Ultrasound-guided, and a Laparoscopic, Landmark-based Application of a \"Transversus Abdominis Plane (TAP) Block\" Based on Postoperative Pain Perception, Postoperative Analgesic Requirement, and Procedure Duration",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Regional Anaesthesia",
      "Transversus Abdominis Plane Block"
    ],
    "interventions": [
      "Arm 1: The anaesthesiologically performed, ultrasound-guided, 4 quadrant-TAP block ( a combination of a lateral with a subcostal TAP block bilaterally)",
      "Arm2: The surgically performed, laparoscopic landmark-based assisted TAP block"
    ],
    "primary_completion_date": "2025-07",
    "completion_date": "2025-07",
    "results_first_posted": null,
    "last_update_posted": "2025-03-14",
    "enrollment": null,
    "sponsor": "Sana Klinikum Offenbach",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SANA",
    "nct_id": "NCT03556059",
    "title": "Procedure Selection in Obesity and Metabolic Surgery Based on EOSS",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Postoperative Complications"
    ],
    "interventions": [
      "Role of EOSS"
    ],
    "primary_completion_date": "2018-12",
    "completion_date": "2018-12",
    "results_first_posted": null,
    "last_update_posted": "2019-01-24",
    "enrollment": null,
    "sponsor": "Sana Klinikum Offenbach",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SANA",
    "nct_id": "NCT07337434",
    "title": "To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Presented to Tertiary Care Hospital",
    "status": "RECRUITING",
    "phase": "EARLY_PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Plaque Psoriasis"
    ],
    "interventions": [
      "Methotrexate",
      "Apremilast"
    ],
    "primary_completion_date": "2026-06-25",
    "completion_date": "2026-06-25",
    "results_first_posted": null,
    "last_update_posted": "2026-01-13",
    "enrollment": null,
    "sponsor": "Syeda Sana Zaman",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SANA",
    "nct_id": "NCT03532646",
    "title": "Endoscopic Complications After Gastric Bypass",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Obesity, Morbid",
      "Bariatric Surgery Candidate"
    ],
    "interventions": [
      "upper endoscopy"
    ],
    "primary_completion_date": "2019-03",
    "completion_date": "2019-03",
    "results_first_posted": null,
    "last_update_posted": "2024-04-30",
    "enrollment": null,
    "sponsor": "Sana Klinikum Offenbach",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SANA",
    "nct_id": "NCT06285422",
    "title": "Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non Hodgkin's Lymphoma",
      "Large B-cell Lymphoma"
    ],
    "interventions": [
      "SC262"
    ],
    "primary_completion_date": "2025-12",
    "completion_date": "2029-03",
    "results_first_posted": null,
    "last_update_posted": "2025-11-28",
    "enrollment": null,
    "sponsor": "Sana Biotechnology",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SANA",
    "nct_id": "NCT07140471",
    "title": "Comparison of Sublay and Onlay Mesh Repair in Ventral Hernia",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ventral Hernia",
      "Incisional Hernia"
    ],
    "interventions": [
      "Onlay Mesh Repair",
      "Sublay Mesh Repair"
    ],
    "primary_completion_date": "2023-08-28",
    "completion_date": "2023-08-28",
    "results_first_posted": null,
    "last_update_posted": "2025-08-24",
    "enrollment": null,
    "sponsor": "Sana Ehsan ullah",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SANA",
    "nct_id": "NCT02607267",
    "title": "Edmonton Obesity Staging System: Post-operative Outcome and 30-day Mortality",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Postoperative Complications",
      "Other Complications of Other Bariatric Procedure"
    ],
    "interventions": [
      "LSG and LRYGB"
    ],
    "primary_completion_date": "2015-12",
    "completion_date": "2016-01",
    "results_first_posted": null,
    "last_update_posted": "2018-04-25",
    "enrollment": null,
    "sponsor": "Sana Klinikum Offenbach",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SANA",
    "nct_id": "NCT04138472",
    "title": "Comparison Of Dexmedetomidine, Fentanyl And Lignocaine In Attenuation Of Hemodynamic Response To Direct Laryngoscopy And Intubation In Patient Undergoing Laparoscopic Cholecystectomy",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Laparoscopic Cholecystectomy"
    ],
    "interventions": [
      "dexmedetomidine",
      "fentanyl",
      "lidocaine"
    ],
    "primary_completion_date": "2020-02-29",
    "completion_date": "2020-02-29",
    "results_first_posted": null,
    "last_update_posted": "2020-02-07",
    "enrollment": null,
    "sponsor": "Sana Urooj",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SANA",
    "nct_id": "NCT02616003",
    "title": "Preoperative Condition in Giant Obese Patients",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Morbid Obesity",
      "Bariatric Surgery Candidate"
    ],
    "interventions": [
      "Liraglutide",
      "Aminosteril hepa 8%",
      "Caloric diet with 1000 kcal"
    ],
    "primary_completion_date": "2018-01",
    "completion_date": "2018-04",
    "results_first_posted": null,
    "last_update_posted": "2021-03-23",
    "enrollment": null,
    "sponsor": "Sana Klinikum Offenbach",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SPRY",
    "nct_id": "NCT03569163",
    "title": "Pulse Oximeter Test",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Hypoxia"
    ],
    "interventions": [
      "Spry Loop oximeter"
    ],
    "primary_completion_date": "2017-10-30",
    "completion_date": "2017-10-30",
    "results_first_posted": null,
    "last_update_posted": "2018-06-26",
    "enrollment": null,
    "sponsor": "Spry Health",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SPRY",
    "nct_id": "NCT03797300",
    "title": "Pulse Oximeter and Respiratory Rate Test",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypoxia",
      "Hypercapnia",
      "Hypocapnia"
    ],
    "interventions": [
      "Spry Loop Band"
    ],
    "primary_completion_date": "2018-12-14",
    "completion_date": "2018-12-14",
    "results_first_posted": null,
    "last_update_posted": "2019-01-09",
    "enrollment": null,
    "sponsor": "Spry Health",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SPRY",
    "nct_id": "NCT03240926",
    "title": "Loop Band Validation Study",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COPD"
    ],
    "interventions": [
      "Loop Band"
    ],
    "primary_completion_date": "2018-01-22",
    "completion_date": "2018-01-25",
    "results_first_posted": null,
    "last_update_posted": "2018-06-18",
    "enrollment": null,
    "sponsor": "Spry Health",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TARS",
    "nct_id": "NCT06611085",
    "title": "Cold Application, Vibration and Vibrating Ice on Pain, Fear and Satisfaction Level in Children",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fear",
      "Pain",
      "Satisfaction"
    ],
    "interventions": [
      "cold application group",
      "vibration group",
      "vibration and ice group"
    ],
    "primary_completion_date": "2025-04-11",
    "completion_date": "2025-04-11",
    "results_first_posted": null,
    "last_update_posted": "2025-04-15",
    "enrollment": null,
    "sponsor": "Tarsus University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TARS",
    "nct_id": "NCT06076941",
    "title": "Effect Of Oral And Dental Health Education In Pregnant Women",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pregnancy"
    ],
    "interventions": [
      "Education"
    ],
    "primary_completion_date": "2017-04-15",
    "completion_date": "2020-10-14",
    "results_first_posted": null,
    "last_update_posted": "2023-10-11",
    "enrollment": null,
    "sponsor": "Tarsus University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TARS",
    "nct_id": "NCT07281144",
    "title": "Effect of Virtual Reality on Cannulation-Related Procedural Pain, Distress and Comfort Level in Hemodialysis Patients",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hemodialysis, Virtual Reality"
    ],
    "interventions": [
      "Virtual Reality"
    ],
    "primary_completion_date": "2025-12-25",
    "completion_date": "2025-12-25",
    "results_first_posted": null,
    "last_update_posted": "2025-12-15",
    "enrollment": null,
    "sponsor": "Tarsus University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TARS",
    "nct_id": "NCT06938477",
    "title": "Thera-Trainer Exercise Effects on Motor and Cognitive Outcomes in Stroke: RCT",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Stroke"
    ],
    "interventions": [
      "THERA-TRAINER BASED EXERCISES",
      "FUNCTIONAL STROKE TRA\u0130N\u0130NG"
    ],
    "primary_completion_date": "2025-03-15",
    "completion_date": "2025-06-15",
    "results_first_posted": null,
    "last_update_posted": "2025-06-18",
    "enrollment": null,
    "sponsor": "Tarsus University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TARS",
    "nct_id": "NCT06609252",
    "title": "Breast Milk Odour and Mother's Voice on Pain and Comfort",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pain",
      "Breast Milk Odour",
      "Comfort"
    ],
    "interventions": [
      "Breast milk odour",
      "Mother voice"
    ],
    "primary_completion_date": "2025-03-11",
    "completion_date": "2025-04-11",
    "results_first_posted": null,
    "last_update_posted": "2025-04-15",
    "enrollment": null,
    "sponsor": "Tarsus University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TARS",
    "nct_id": "NCT06754579",
    "title": "Impact of High-Volume Upper Limb Training on Physical and Cognitive Outcomes",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Sedentary Behavior"
    ],
    "interventions": [
      "High-Volume Upper Extremity Exercises Training",
      "Low Volume Upper Extremity Exercises Training"
    ],
    "primary_completion_date": "2026-12-01",
    "completion_date": "2026-12-30",
    "results_first_posted": null,
    "last_update_posted": "2026-01-21",
    "enrollment": null,
    "sponsor": "Tarsus University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TARS",
    "nct_id": "NCT07357662",
    "title": "Effects of Rehabilitative Exergame Training on Foot Muscle Activity, Balance, and Mobility in Older Adults",
    "status": "NOT_YET_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Aging",
      "Foot Muscle Dysfunction",
      "Sarcopenia",
      "Age-Related Muscle Weakness"
    ],
    "interventions": [
      "Exergame-based Balance and Foot Muscle Training",
      "Conventional Functional Balance Training"
    ],
    "primary_completion_date": "2026-12-30",
    "completion_date": "2027-12-30",
    "results_first_posted": null,
    "last_update_posted": "2026-01-22",
    "enrollment": null,
    "sponsor": "Tarsus University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TARS",
    "nct_id": "NCT07342751",
    "title": "The Effect of Listening to Music During Mobilization on Pain and Fear in Children Undergoing Abdominal Surgery",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pain",
      "Surgery",
      "Children, Only"
    ],
    "interventions": [
      "music"
    ],
    "primary_completion_date": "2026-11-30",
    "completion_date": "2026-12-31",
    "results_first_posted": null,
    "last_update_posted": "2026-01-15",
    "enrollment": null,
    "sponsor": "Tarsus University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TARS",
    "nct_id": "NCT06598410",
    "title": "Playing Digital Games and Watching Cartoons on Children&Amp;#39;s Pain, Fear, and Anxiety",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pain",
      "Fear",
      "Anxiety",
      "Children",
      "Emergency"
    ],
    "interventions": [
      "Digital gaming",
      "watching cartoon"
    ],
    "primary_completion_date": "2025-04-29",
    "completion_date": "2025-04-29",
    "results_first_posted": null,
    "last_update_posted": "2026-01-07",
    "enrollment": null,
    "sponsor": "Tarsus University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TGTX",
    "nct_id": "NCT01744912",
    "title": "Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-Hodgkins Lymphoma",
      "Chronic Lymphocytic Leukemia",
      "Small Lymphocytic Lymphoma",
      "B-cell Lymphomas",
      "Marginal Zone Lymphoma",
      "Mantle Cell Lymphoma",
      "Waldenstrom's Macroglobulinemia"
    ],
    "interventions": [
      "Ublituximab",
      "Lenalidomide"
    ],
    "primary_completion_date": "2014-02-07",
    "completion_date": "2014-02-07",
    "results_first_posted": null,
    "last_update_posted": "2022-05-11",
    "enrollment": null,
    "sponsor": "TG Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TGTX",
    "nct_id": "NCT01647971",
    "title": "Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-Hodgkins Lymphoma",
      "B-cell Lymphoma",
      "Waldenstrom's Macroglobulinemia",
      "Marginal Zone Lymphoma",
      "Chronic Lymphocytic Leukemia (CLL)",
      "Small Lymphocytic Lymphoma (SLL)",
      "Primary Central Nervous System Lymphoma"
    ],
    "interventions": [
      "Ublituximab"
    ],
    "primary_completion_date": "2015-05",
    "completion_date": "2015-05",
    "results_first_posted": null,
    "last_update_posted": "2022-11-21",
    "enrollment": null,
    "sponsor": "TG Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ADCT",
    "nct_id": "NCT02588092",
    "title": "Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL)",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Myeloid Leukemia",
      "Acute Lymphoblastic Leukemia"
    ],
    "interventions": [
      "ADCT-301"
    ],
    "primary_completion_date": "2018-08-29",
    "completion_date": "2018-08-29",
    "results_first_posted": "2020-02-26",
    "last_update_posted": "2020-02-26",
    "enrollment": null,
    "sponsor": "ADC Therapeutics S.A.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ADCT",
    "nct_id": "NCT04699461",
    "title": "Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsed Follicular Lymphoma",
      "Refractory Follicular Lymphoma"
    ],
    "interventions": [
      "Loncastuximab Tesirine",
      "Idelalisib"
    ],
    "primary_completion_date": "2022-11-25",
    "completion_date": "2022-11-25",
    "results_first_posted": "2023-10-23",
    "last_update_posted": "2023-10-23",
    "enrollment": null,
    "sponsor": "ADC Therapeutics S.A.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ADMA",
    "nct_id": "NCT03164967",
    "title": "Study to Evaluate Safety and Pharmacokinetics of BIVIGAM\u00ae in Primary Immune Deficiency Subjects Aged 2 to 16",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Humoral Immune Response"
    ],
    "interventions": [
      "Bivigam"
    ],
    "primary_completion_date": "2022-08-30",
    "completion_date": "2022-12-31",
    "results_first_posted": null,
    "last_update_posted": "2023-02-01",
    "enrollment": null,
    "sponsor": "ADMA Biologics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ADMA",
    "nct_id": "NCT00538915",
    "title": "Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Primary Immune Deficiency Disorders (PIDD)"
    ],
    "interventions": [
      "Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]"
    ],
    "primary_completion_date": "2009-07",
    "completion_date": "2009-07",
    "results_first_posted": "2012-03-26",
    "last_update_posted": "2021-07-30",
    "enrollment": null,
    "sponsor": "ADMA Biologics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ADMA",
    "nct_id": "NCT00473824",
    "title": "Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Sequelae of Viral Hepatitis",
      "Transplantation Infection",
      "Evidence of Liver Transplantation"
    ],
    "interventions": [
      "Hepatitis C Immune Globulin Intravenous (Human) 5%"
    ],
    "primary_completion_date": "2009-02",
    "completion_date": "2009-02",
    "results_first_posted": "2012-02-07",
    "last_update_posted": "2021-07-30",
    "enrollment": null,
    "sponsor": "ADMA Biologics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ADMA",
    "nct_id": "NCT01814800",
    "title": "Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Primary Immune Deficiency Disorder"
    ],
    "interventions": [
      "RI-002"
    ],
    "primary_completion_date": "2014-12",
    "completion_date": "2015-01",
    "results_first_posted": "2016-10-05",
    "last_update_posted": "2016-10-05",
    "enrollment": null,
    "sponsor": "ADMA Biologics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ADMA",
    "nct_id": "NCT05070455",
    "title": "An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV\u2122 (IGIV) in Pediatric Subjects With Primary Immunodeficiency Diseases (PIDD)",
    "status": "UNKNOWN",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Primary Immune Deficiency"
    ],
    "interventions": [
      "Asceniv\u2122"
    ],
    "primary_completion_date": "2023-03-31",
    "completion_date": "2023-06-30",
    "results_first_posted": null,
    "last_update_posted": "2022-09-16",
    "enrollment": null,
    "sponsor": "ADMA Biologics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ADMA",
    "nct_id": "NCT03037359",
    "title": "A Study About Low Blood Pressure in Patients With Primary Immunodeficiency Disease Treated With Immune Globulin Products",
    "status": "UNKNOWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Primary Immune Deficiency Disorder"
    ],
    "interventions": [
      "Bivigam",
      "Other"
    ],
    "primary_completion_date": "2022-12-31",
    "completion_date": "2023-06-30",
    "results_first_posted": null,
    "last_update_posted": "2023-02-01",
    "enrollment": null,
    "sponsor": "ADMA Biologics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ADMA",
    "nct_id": "NCT00632463",
    "title": "RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Upper Respiratory Tract Infection",
      "Lower Respiratory Tract Infection"
    ],
    "interventions": [
      "RI-001",
      "RI-001",
      "RI-001"
    ],
    "primary_completion_date": "2010-05",
    "completion_date": "2010-05",
    "results_first_posted": "2013-04-24",
    "last_update_posted": "2013-04-24",
    "enrollment": null,
    "sponsor": "ADMA Biologics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT02521857",
    "title": "A Water Consumption Study of ALKS 5461 in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "ALKS 5461"
    ],
    "primary_completion_date": "2015-09",
    "completion_date": "2015-09",
    "results_first_posted": null,
    "last_update_posted": "2015-11-10",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT01098435",
    "title": "ALK33-101: A Study of RDC-0313 (ALKS 33) in Adults With Binge Eating Disorder",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Binge Eating Disorder"
    ],
    "interventions": [
      "RDC-0313 (ALKS 33)",
      "Placebo"
    ],
    "primary_completion_date": "2011-05",
    "completion_date": "2011-06",
    "results_first_posted": null,
    "last_update_posted": "2011-08-23",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT01469039",
    "title": "A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia"
    ],
    "interventions": [
      "ALKS 9072",
      "Placebo"
    ],
    "primary_completion_date": "2014-01",
    "completion_date": "2014-03",
    "results_first_posted": "2016-01-22",
    "last_update_posted": "2019-01-30",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT02161718",
    "title": "A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia",
      "Alcohol Use Disorder"
    ],
    "interventions": [
      "Samidorphan + olanzapine (ALKS 3831)",
      "Placebo + olanzapine"
    ],
    "primary_completion_date": "2017-01-11",
    "completion_date": "2017-02-01",
    "results_first_posted": "2021-10-08",
    "last_update_posted": "2021-10-08",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT02085135",
    "title": "A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder"
    ],
    "interventions": [
      "ALKS 5461"
    ],
    "primary_completion_date": "2014-09",
    "completion_date": "2014-09",
    "results_first_posted": "2019-03-27",
    "last_update_posted": "2019-08-14",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT02218021",
    "title": "A Study of the Abuse Liability Potential of Samidorphan in Healthy, Non-Dependent, Recreational Opioid Users",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "Samidorphan",
      "Placebo",
      "Oxycodone"
    ],
    "primary_completion_date": "2014-11",
    "completion_date": "2014-11",
    "results_first_posted": null,
    "last_update_posted": "2014-12-02",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT01895452",
    "title": "An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia"
    ],
    "interventions": [
      "ALKS 9072, Low Dose",
      "ALKS 9072, High Dose"
    ],
    "primary_completion_date": "2016-06",
    "completion_date": "2016-06",
    "results_first_posted": "2017-08-25",
    "last_update_posted": "2017-08-25",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT03201757",
    "title": "Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia",
      "Schizophreniform Disorder",
      "Bipolar I Disorder"
    ],
    "interventions": [
      "ALKS 3831"
    ],
    "primary_completion_date": "2023-09-06",
    "completion_date": "2023-09-06",
    "results_first_posted": "2024-09-26",
    "last_update_posted": "2024-09-26",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT02873208",
    "title": "A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia"
    ],
    "interventions": [
      "ALKS 3831"
    ],
    "primary_completion_date": "2019-10-17",
    "completion_date": "2019-10-17",
    "results_first_posted": "2021-07-21",
    "last_update_posted": "2021-07-21",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT01381107",
    "title": "ALK33BUP-201: Safety and Tolerability Study of ALKS 33-BUP (ALKS 5461) Administration in Subjects With MDD",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder"
    ],
    "interventions": [
      "ALKS 5461",
      "Placebo"
    ],
    "primary_completion_date": "2011-07",
    "completion_date": "2011-07",
    "results_first_posted": null,
    "last_update_posted": "2011-08-23",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT02634346",
    "title": "A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia"
    ],
    "interventions": [
      "ALK3831",
      "Olanzapine",
      "Placebo"
    ],
    "primary_completion_date": "2017-05-25",
    "completion_date": "2017-06-07",
    "results_first_posted": "2018-06-27",
    "last_update_posted": "2018-06-27",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT02141399",
    "title": "A Long-Term Safety Study of ALKS 5461",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder"
    ],
    "interventions": [
      "ALKS 5461"
    ],
    "primary_completion_date": "2017-11-20",
    "completion_date": "2017-11-20",
    "results_first_posted": "2018-12-14",
    "last_update_posted": "2018-12-14",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT03187769",
    "title": "Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia",
      "Schizophreniform Disorders",
      "Bipolar I Disorder"
    ],
    "interventions": [
      "ALKS 3831",
      "Olanzapine"
    ],
    "primary_completion_date": "2021-12-01",
    "completion_date": "2022-01-03",
    "results_first_posted": "2023-01-19",
    "last_update_posted": "2023-01-19",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT02922426",
    "title": "An Insulin Sensitivity Study in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "ALKS 3831",
      "Olanzapine",
      "Placebo"
    ],
    "primary_completion_date": "2017-07-20",
    "completion_date": "2017-07-20",
    "results_first_posted": null,
    "last_update_posted": "2017-08-22",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT06843590",
    "title": "A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Idiopathic Hypersomnia"
    ],
    "interventions": [
      "ALKS 2680",
      "Placebo"
    ],
    "primary_completion_date": "2026-06",
    "completion_date": "2026-06",
    "results_first_posted": null,
    "last_update_posted": "2025-10-14",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT02479308",
    "title": "A Study to Evaluate the Effect of ALKS 5461 on QT Intervals in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "Moxifloxacin",
      "ALKS 5461",
      "Placebo"
    ],
    "primary_completion_date": "2015-10",
    "completion_date": "2015-10",
    "results_first_posted": null,
    "last_update_posted": "2015-11-23",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT02320032",
    "title": "An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia"
    ],
    "interventions": [
      "Aripiprazole Lauroxil"
    ],
    "primary_completion_date": "2016-04",
    "completion_date": "2016-04",
    "results_first_posted": null,
    "last_update_posted": "2018-08-29",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT03610048",
    "title": "A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD)",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Refractory Major Depressive Disorder"
    ],
    "interventions": [
      "ALKS 5461"
    ],
    "primary_completion_date": "2020-05-01",
    "completion_date": "2020-05-01",
    "results_first_posted": "2021-07-16",
    "last_update_posted": "2021-07-16",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT01366001",
    "title": "ALK33BUP-101: Safety and Pharmacodynamic Effects of ALKS 33-BUP Administered Alone and When Co-administered With Cocaine",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cocaine Abuse"
    ],
    "interventions": [
      "ALKS 33-BUP",
      "ALKS 33",
      "Placebo"
    ],
    "primary_completion_date": "2012-02",
    "completion_date": "2012-02",
    "results_first_posted": null,
    "last_update_posted": "2012-03-09",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT02669758",
    "title": "A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia"
    ],
    "interventions": [
      "ALKS 3831"
    ],
    "primary_completion_date": "2018-06-29",
    "completion_date": "2018-06-29",
    "results_first_posted": "2019-07-09",
    "last_update_posted": "2019-07-26",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT01626456",
    "title": "A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia"
    ],
    "interventions": [
      "ALKS 9072, Low",
      "ALKS 9072, High"
    ],
    "primary_completion_date": "2015-04",
    "completion_date": "2015-04",
    "results_first_posted": "2016-10-27",
    "last_update_posted": "2018-09-25",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT01418092",
    "title": "ALK37-007: Evaluation of Safety and Efficacy of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "OIC"
    ],
    "interventions": [
      "ALKS 37",
      "Placebo"
    ],
    "primary_completion_date": "2012-06",
    "completion_date": "2012-06",
    "results_first_posted": null,
    "last_update_posted": "2012-08-07",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT03919994",
    "title": "Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Schizophrenia"
    ],
    "interventions": [],
    "primary_completion_date": "2023-01-04",
    "completion_date": "2023-01-04",
    "results_first_posted": null,
    "last_update_posted": "2023-02-02",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT05547100",
    "title": "Study of the Breast Milk Pharmacokinetics of Olanzapine and Samidorphan",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Focus of Study is on Healthy Lactating Women"
    ],
    "interventions": [
      "LYBALVI"
    ],
    "primary_completion_date": "2022-11-19",
    "completion_date": "2022-11-19",
    "results_first_posted": null,
    "last_update_posted": "2023-02-10",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT02068105",
    "title": "A Study of ALKS 5461 in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pharmacokinetics"
    ],
    "interventions": [
      "ALKS 5461",
      "Placebo"
    ],
    "primary_completion_date": "2014-03",
    "completion_date": "2014-03",
    "results_first_posted": null,
    "last_update_posted": "2014-04-21",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT02804568",
    "title": "A Phase 1 Safety Study in Adults With Schizophrenia",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia"
    ],
    "interventions": [
      "ALKS 3831"
    ],
    "primary_completion_date": "2016-08",
    "completion_date": "2016-08",
    "results_first_posted": null,
    "last_update_posted": "2016-09-22",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT06358950",
    "title": "A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Narcolepsy Type 1"
    ],
    "interventions": [
      "ALKS 2680",
      "Placebo"
    ],
    "primary_completion_date": "2025-06-19",
    "completion_date": "2025-07-31",
    "results_first_posted": null,
    "last_update_posted": "2025-10-14",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT06555783",
    "title": "A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Narcolepsy Type 2"
    ],
    "interventions": [
      "ALKS 2680",
      "Placebo"
    ],
    "primary_completion_date": "2025-11",
    "completion_date": "2025-11",
    "results_first_posted": null,
    "last_update_posted": "2025-09-24",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT02636842",
    "title": "A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia",
      "Schizoaffective Disorder"
    ],
    "interventions": [
      "Aripiprazole Lauroxil"
    ],
    "primary_completion_date": "2016-06",
    "completion_date": "2016-06",
    "results_first_posted": null,
    "last_update_posted": "2016-07-14",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT06767683",
    "title": "A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Narcolepsy Type 1",
      "Narcolepsy Type 2",
      "Idiopathic Hypersomnia"
    ],
    "interventions": [
      "ALKS 2680, 4mg",
      "ALKS 2680, 6mg",
      "ALKS 2680, 8mg",
      "ALKS 2680, 10mg",
      "ALKS 2680, 14mg",
      "ALKS 2680, 18mg"
    ],
    "primary_completion_date": "2028-06",
    "completion_date": "2028-06",
    "results_first_posted": null,
    "last_update_posted": "2025-10-14",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT03188185",
    "title": "A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder"
    ],
    "interventions": [
      "ALKS 5461",
      "ALKS 5461 Placebo"
    ],
    "primary_completion_date": "2020-02-26",
    "completion_date": "2020-03-05",
    "results_first_posted": "2021-03-15",
    "last_update_posted": "2021-04-08",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT04987658",
    "title": "Phase 1 Study of OLZ/SAM in Pediatric Subjects With Bipolar I Disorder",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bipolar I Disorder"
    ],
    "interventions": [
      "OLZ/SAM"
    ],
    "primary_completion_date": "2023-08-11",
    "completion_date": "2023-08-11",
    "results_first_posted": null,
    "last_update_posted": "2023-11-22",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT02508506",
    "title": "Pharmacokinetics and Safety of ALKS 5461 in Subjects With Renal Impairment and Normal Renal Function",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Renal Impairment"
    ],
    "interventions": [
      "ALKS 5461"
    ],
    "primary_completion_date": "2015-12",
    "completion_date": "2015-12",
    "results_first_posted": null,
    "last_update_posted": "2016-02-04",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT02545439",
    "title": "A Drug-drug Interaction Study of ALKS 5461 in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "ALKS 5461"
    ],
    "primary_completion_date": "2015-10",
    "completion_date": "2015-10",
    "results_first_posted": null,
    "last_update_posted": "2015-11-10",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT04987229",
    "title": "Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bipolar I Disorder",
      "Schizophrenia"
    ],
    "interventions": [
      "OLZ/SAM"
    ],
    "primary_completion_date": "2027-09",
    "completion_date": "2027-09",
    "results_first_posted": null,
    "last_update_posted": "2025-10-10",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT01100151",
    "title": "ALK37-003: A Study of RDC-1036 (ALKS 37) in Adults With Opioid-induced Constipation (OIC)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Opioid-induced Constipation"
    ],
    "interventions": [
      "RDC-1036 (ALKS 37)",
      "Placebo"
    ],
    "primary_completion_date": "2010-12",
    "completion_date": "2010-12",
    "results_first_posted": null,
    "last_update_posted": "2011-08-23",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT02634320",
    "title": "A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia"
    ],
    "interventions": [
      "Aripiprazole Lauroxil"
    ],
    "primary_completion_date": "2017-07-11",
    "completion_date": "2017-07-11",
    "results_first_posted": "2018-11-08",
    "last_update_posted": "2018-12-04",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT02158546",
    "title": "A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder"
    ],
    "interventions": [
      "ALKS 5461",
      "Placebo"
    ],
    "primary_completion_date": "2015-12",
    "completion_date": "2015-12",
    "results_first_posted": "2019-06-25",
    "last_update_posted": "2019-06-25",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT02504463",
    "title": "A Study of [14c]-Samidorphan (Also Known as ALKS 33) in Healthy, Male Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "Samidorphan IV",
      "[14c]-Samidorphan sublingual",
      "[14c]-Samidorphan oral"
    ],
    "primary_completion_date": "2015-09",
    "completion_date": "2015-09",
    "results_first_posted": null,
    "last_update_posted": "2015-09-18",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT02158533",
    "title": "A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder"
    ],
    "interventions": [
      "High Dose ALKS 5461",
      "Low Dose ALKS 5461",
      "Placebo"
    ],
    "primary_completion_date": "2015-12",
    "completion_date": "2015-12",
    "results_first_posted": "2019-03-27",
    "last_update_posted": "2019-08-14",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT01382797",
    "title": "ALK37-005: A Study of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Opioid-induced Constipation"
    ],
    "interventions": [
      "ALKS 37",
      "Placebo"
    ],
    "primary_completion_date": "2012-04",
    "completion_date": "2012-04",
    "results_first_posted": null,
    "last_update_posted": "2012-06-13",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT02413281",
    "title": "A Study of the Abuse Liability Potential of ALKS 5461 in Healthy, Non-Dependent, Recreational Opioid Users",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "ALKS 5461",
      "Buprenorphine",
      "Placebo"
    ],
    "primary_completion_date": "2015-09",
    "completion_date": "2015-09",
    "results_first_posted": null,
    "last_update_posted": "2015-11-10",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT02694328",
    "title": "A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia"
    ],
    "interventions": [
      "ALKS 3831",
      "Olanzapine"
    ],
    "primary_completion_date": "2018-11-07",
    "completion_date": "2018-11-07",
    "results_first_posted": "2020-02-10",
    "last_update_posted": "2020-02-10",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT02272764",
    "title": "A Drug-Drug Interaction Study of ALKS 5461 in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pharmacokinetics"
    ],
    "interventions": [
      "Itraconazole",
      "ALKS 5461"
    ],
    "primary_completion_date": "2014-11",
    "completion_date": "2014-11",
    "results_first_posted": null,
    "last_update_posted": "2014-12-12",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT05303064",
    "title": "Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia",
      "Bipolar I Disorder"
    ],
    "interventions": [
      "OLZ/SAM",
      "Olanzapine"
    ],
    "primary_completion_date": "2026-09",
    "completion_date": "2026-09",
    "results_first_posted": null,
    "last_update_posted": "2025-10-10",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT05019105",
    "title": "Phase 1 ALKS 1140 in Healthy Adults",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Central Nervous System Diseases"
    ],
    "interventions": [
      "Placebo",
      "ALKS 1140"
    ],
    "primary_completion_date": "2022-08-23",
    "completion_date": "2022-08-23",
    "results_first_posted": null,
    "last_update_posted": "2022-09-02",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT02452801",
    "title": "Pharmacokinetics and Safety of ALKS 5461 in Healthy Subjects and Subjects With Hepatic Impairment and Normal Hepatic Function",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatic Impairment"
    ],
    "interventions": [
      "ALKS 5461"
    ],
    "primary_completion_date": "2015-12",
    "completion_date": "2015-12",
    "results_first_posted": null,
    "last_update_posted": "2016-02-04",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT01493726",
    "title": "A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia"
    ],
    "interventions": [
      "ALKS 9072, Low dose",
      "ALKS 9072, Med dose",
      "ALKS 9072, High dose",
      "Placebo"
    ],
    "primary_completion_date": "2013-06",
    "completion_date": "2013-06",
    "results_first_posted": null,
    "last_update_posted": "2018-08-29",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT01903837",
    "title": "A Study of ALKS 3831 in Adults With Schizophrenia",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia"
    ],
    "interventions": [
      "Samidorphan (Low Dose)",
      "Samidorphan (Medium Dose)",
      "Samidorphan (High Dose)",
      "Placebo",
      "Olanzapine"
    ],
    "primary_completion_date": "2014-12",
    "completion_date": "2015-03",
    "results_first_posted": "2021-09-08",
    "last_update_posted": "2021-10-06",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT02218008",
    "title": "A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder"
    ],
    "interventions": [
      "ALKS 5461",
      "Placebo"
    ],
    "primary_completion_date": "2016-09",
    "completion_date": "2016-10",
    "results_first_posted": "2019-03-27",
    "last_update_posted": "2019-08-14",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALKS",
    "nct_id": "NCT01500200",
    "title": "A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder"
    ],
    "interventions": [
      "ALKS 5461",
      "Placebo"
    ],
    "primary_completion_date": "2013-03",
    "completion_date": "2013-03",
    "results_first_posted": "2019-05-21",
    "last_update_posted": "2019-05-21",
    "enrollment": null,
    "sponsor": "Alkermes, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALT",
    "nct_id": "NCT01687465",
    "title": "A Trial to Compare the Laser Treatment (SLT vs. ALT) in Glaucoma Patients",
    "status": "UNKNOWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Glaucoma"
    ],
    "interventions": [
      "Argon laser trabeculoplasty",
      "Selective laser trabeculoplasty"
    ],
    "primary_completion_date": "2018-03",
    "completion_date": "2018-03",
    "results_first_posted": null,
    "last_update_posted": "2018-03-06",
    "enrollment": null,
    "sponsor": "London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALT",
    "nct_id": "NCT00225537",
    "title": "4-Methylumbelliferone as a Treatment for Chronic HBV/HCV",
    "status": "UNKNOWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Hepatitis C",
      "Chronic Hepatitis B"
    ],
    "interventions": [
      "4-Methylumbelliferone (Heparvit\u00ae)"
    ],
    "primary_completion_date": null,
    "completion_date": "2007-08",
    "results_first_posted": null,
    "last_update_posted": "2006-09-11",
    "enrollment": null,
    "sponsor": "MTmedical Institute of Health",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALT",
    "nct_id": "NCT05418868",
    "title": "A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HIV Infections"
    ],
    "interventions": [
      "Cabotegravir 200 mg/mL",
      "Cabotegravir >=400 mg/mL",
      "Cabotegravir Formulation I",
      "CAB Formulation J",
      "rHuPH20",
      "RPV"
    ],
    "primary_completion_date": "2027-06-08",
    "completion_date": "2027-06-08",
    "results_first_posted": null,
    "last_update_posted": "2025-12-18",
    "enrollment": null,
    "sponsor": "ViiV Healthcare",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALT",
    "nct_id": "NCT00197145",
    "title": "Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Infection, Human Immunodeficiency Virus I"
    ],
    "interventions": [
      "GW873140"
    ],
    "primary_completion_date": "2007-09-11",
    "completion_date": "2007-09-11",
    "results_first_posted": "2018-11-02",
    "last_update_posted": "2018-11-02",
    "enrollment": null,
    "sponsor": "ViiV Healthcare",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALT",
    "nct_id": "NCT04180072",
    "title": "Atezolizumab Plus Bevacizumab With HCC and HBV Infection",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Carcinoma, Hepatocellular"
    ],
    "interventions": [
      "Atezolizumab",
      "Bevacizumab"
    ],
    "primary_completion_date": "2025-12-31",
    "completion_date": "2025-12-31",
    "results_first_posted": null,
    "last_update_posted": "2024-07-05",
    "enrollment": null,
    "sponsor": "National Health Research Institutes, Taiwan",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALT",
    "nct_id": "NCT05573607",
    "title": "Effects of a Dietary Supplement on Markers of Glucose Control and Quality of Life",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Blood Glucose"
    ],
    "interventions": [
      "Placebo",
      "Chromium"
    ],
    "primary_completion_date": "2021-07-08",
    "completion_date": "2021-07-08",
    "results_first_posted": null,
    "last_update_posted": "2022-11-10",
    "enrollment": null,
    "sponsor": "The Center for Applied Health Sciences, LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALT",
    "nct_id": "NCT04920292",
    "title": "PK, Safety and Tolerability of Single and Multiple Doses of Oxfendazole Tablets",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Filariasis"
    ],
    "interventions": [
      "Oxfendazole",
      "Placebo"
    ],
    "primary_completion_date": "2022-11-07",
    "completion_date": "2022-11-14",
    "results_first_posted": null,
    "last_update_posted": "2022-12-20",
    "enrollment": null,
    "sponsor": "Swiss Tropical & Public Health Institute",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALT",
    "nct_id": "NCT01913405",
    "title": "Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hemophilia A"
    ],
    "interventions": [
      "PEGylated Recombinant factor VIII (rFVIII)"
    ],
    "primary_completion_date": "2016-09-23",
    "completion_date": "2016-09-23",
    "results_first_posted": "2018-05-14",
    "last_update_posted": "2021-05-24",
    "enrollment": null,
    "sponsor": "Baxalta now part of Shire",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALT",
    "nct_id": "NCT04707651",
    "title": "Formula Diet Treatment for NASH Patients.",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Steatohepatitis, Nonalcoholic"
    ],
    "interventions": [
      "Formula diet"
    ],
    "primary_completion_date": "2024-12-31",
    "completion_date": "2025-03-31",
    "results_first_posted": null,
    "last_update_posted": "2024-07-11",
    "enrollment": null,
    "sponsor": "West German Center of Diabetes and Health",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALT",
    "nct_id": "NCT06310551",
    "title": "First Time in Human Study of Long Acting VH4524184 Formulations",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HIV Infections"
    ],
    "interventions": [
      "Oral VH4524184",
      "VH4524184 Formulation A SC",
      "Placebo Formulation A SC",
      "rHuPH20",
      "VH4524184 Formulation B SC",
      "Placebo Formulation B SC",
      "VH4524184 Formulation C SC",
      "Placebo Formulation C SC",
      "VH4524184 Formulation A IM",
      "Placebo Formulation A IM",
      "VH4524184 Formulation B IM",
      "Placebo Formulation B IM"
    ],
    "primary_completion_date": "2028-01-21",
    "completion_date": "2028-01-21",
    "results_first_posted": null,
    "last_update_posted": "2025-02-24",
    "enrollment": null,
    "sponsor": "ViiV Healthcare",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALT",
    "nct_id": "NCT05950620",
    "title": "Bringing Weight Management Into the Primary Care Pediatric Practice",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Obesity, Childhood"
    ],
    "interventions": [
      "Medical obesity management."
    ],
    "primary_completion_date": "2026-06-30",
    "completion_date": "2026-06-30",
    "results_first_posted": null,
    "last_update_posted": "2023-07-19",
    "enrollment": null,
    "sponsor": "Oregon Health and Science University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALT",
    "nct_id": "NCT04058535",
    "title": "Clinical Study of ALT-L9 to Determine Safety, Efficacy and Pharmacokinetics in Neovascular AMD",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Neovascular Age-related Macular Degeneration"
    ],
    "interventions": [
      "Eylea",
      "ALT-L9"
    ],
    "primary_completion_date": "2020-12-22",
    "completion_date": "2020-12-22",
    "results_first_posted": null,
    "last_update_posted": "2022-01-20",
    "enrollment": null,
    "sponsor": "Alteogen, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALT",
    "nct_id": "NCT06368986",
    "title": "A Study to Investigate the Effect of Food on the Bioavailability of a Capsid Inhibitor (CAI) in Male and Female Healthy Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HIV Infections"
    ],
    "interventions": [
      "VH4011499 Dose A",
      "VH4011499 Dose B"
    ],
    "primary_completion_date": "2024-10-02",
    "completion_date": "2024-10-02",
    "results_first_posted": null,
    "last_update_posted": "2025-02-18",
    "enrollment": null,
    "sponsor": "ViiV Healthcare",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALT",
    "nct_id": "NCT06357962",
    "title": "Semi-permanent Acupuncture Effect on Cervical Ripening",
    "status": "TERMINATED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pregnancy Complications"
    ],
    "interventions": [
      "Semi-permanent acupuncture",
      "Sham of semi-permanent acupuncture"
    ],
    "primary_completion_date": "2025-03-16",
    "completion_date": "2025-04-19",
    "results_first_posted": null,
    "last_update_posted": "2025-12-01",
    "enrollment": null,
    "sponsor": "Consorci Sanitari de l'Alt Pened\u00e8s i Garraf",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALT",
    "nct_id": "NCT02831764",
    "title": "An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment na\u00efve HIV Infected Participants (Gemini 2)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Infection, Human Immunodeficiency Virus",
      "HIV Infections"
    ],
    "interventions": [
      "Dolutegravir (DTG)",
      "Lamivudine (3TC)",
      "Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)"
    ],
    "primary_completion_date": "2018-04-04",
    "completion_date": "2022-06-29",
    "results_first_posted": "2019-04-22",
    "last_update_posted": "2023-12-07",
    "enrollment": null,
    "sponsor": "ViiV Healthcare",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALT",
    "nct_id": "NCT04425902",
    "title": "Evaluation of Pharmacokinetic Interaction Between GSK3640254 and Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin in Healthy Adults",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HIV Infections"
    ],
    "interventions": [
      "GSK3640254 200 mg",
      "Caffeine 200 mg",
      "Metoprolol 100 mg",
      "Montelukast 10 mg",
      "Flurbiprofen 100 mg",
      "Omeprazole 40 mg",
      "Midazolam 5 mg (2.5 mL)",
      "Digoxin 0.25 mg",
      "Pravastatin 40 mg"
    ],
    "primary_completion_date": "2021-03-10",
    "completion_date": "2021-03-10",
    "results_first_posted": "2022-05-23",
    "last_update_posted": "2024-01-05",
    "enrollment": null,
    "sponsor": "ViiV Healthcare",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALT",
    "nct_id": "NCT04827134",
    "title": "A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ\u00ae and DOVATO\u00ae in Healthy Adult Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HIV Infections"
    ],
    "interventions": [
      "TRIUMEQ",
      "DOVATO"
    ],
    "primary_completion_date": "2021-07-23",
    "completion_date": "2021-07-23",
    "results_first_posted": "2023-06-05",
    "last_update_posted": "2023-06-05",
    "enrollment": null,
    "sponsor": "ViiV Healthcare",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALT",
    "nct_id": "NCT02478463",
    "title": "Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Infection, Human Immunodeficiency Virus",
      "HIV Infections"
    ],
    "interventions": [
      "Cabotegravir tablet 30 mg once daily for 28 days.",
      "Cabotegravir injection 3 mL (200 mg/mL) IM given once on Day 1."
    ],
    "primary_completion_date": "2019-07-25",
    "completion_date": "2019-07-25",
    "results_first_posted": "2020-06-22",
    "last_update_posted": "2020-06-22",
    "enrollment": null,
    "sponsor": "ViiV Healthcare",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALT",
    "nct_id": "NCT04555044",
    "title": "Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion (Part A)",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Essential Fatty Acid Deficiency (EFAD)"
    ],
    "interventions": [
      "Clinolipid",
      "Intralipid"
    ],
    "primary_completion_date": "2022-10-16",
    "completion_date": "2022-11-16",
    "results_first_posted": "2023-12-27",
    "last_update_posted": "2023-12-27",
    "enrollment": null,
    "sponsor": "Baxter Healthcare Corporation",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALT",
    "nct_id": "NCT02583685",
    "title": "Switching Regimen in Treating Cirrhotic HCV GT1b Subjects",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Hepatitis C Infection"
    ],
    "interventions": [
      "PR4 + LDV/SOF + ASV 4 wk",
      "PR4 + LDV/SOF + SMV 4 wk",
      "PR4 + LDV/SOF + ASV 6 wk",
      "PR4 + LDV/SOF + SMV 6 wk",
      "PR4 + LDV/SOF + ASV 8 wk",
      "PR4 + LDV/SOF + SMV 8 wk",
      "PR4 + LDV/SOF + ASV 12 wk",
      "PR4 + LDV/SOF + SMV 12 wk"
    ],
    "primary_completion_date": "2024-10-31",
    "completion_date": "2024-10-31",
    "results_first_posted": null,
    "last_update_posted": "2025-03-26",
    "enrollment": null,
    "sponsor": "Humanity and Health Research Centre",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALT",
    "nct_id": "NCT03441984",
    "title": "To Assess the Relative Bioavailability (BA) of TRIUMEQ\u00ae and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HIV Infections"
    ],
    "interventions": [
      "Treatment A",
      "Treatment B",
      "Treatment C",
      "Treatment D",
      "Treatment E",
      "Treatment F"
    ],
    "primary_completion_date": "2018-04-28",
    "completion_date": "2018-04-28",
    "results_first_posted": "2019-12-09",
    "last_update_posted": "2019-12-09",
    "enrollment": null,
    "sponsor": "ViiV Healthcare",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALT",
    "nct_id": "NCT03569826",
    "title": "Canadian Network for Autoimmune Liver Disease",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Primary Bilary Cirrhosis (PBC)",
      "Autoimmune Hepatitis",
      "Overlap Syndrome"
    ],
    "interventions": [
      "Observational; no intervention"
    ],
    "primary_completion_date": "2028-12",
    "completion_date": "2028-12",
    "results_first_posted": null,
    "last_update_posted": "2021-06-07",
    "enrollment": null,
    "sponsor": "University Health Network, Toronto",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALT",
    "nct_id": "NCT05628649",
    "title": "Teaching Kitchen Multisite Trial",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Obesity"
    ],
    "interventions": [
      "Teaching Kitchen Collaborative Curriculum"
    ],
    "primary_completion_date": "2025-10-01",
    "completion_date": "2026-12-01",
    "results_first_posted": null,
    "last_update_posted": "2025-10-03",
    "enrollment": null,
    "sponsor": "Harvard School of Public Health (HSPH)",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALT",
    "nct_id": "NCT05393271",
    "title": "First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4011499 in Healthy Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HIV Infections"
    ],
    "interventions": [
      "VH4011499",
      "Placebo",
      "Midazolam"
    ],
    "primary_completion_date": "2023-04-24",
    "completion_date": "2023-04-24",
    "results_first_posted": "2025-04-01",
    "last_update_posted": "2025-04-01",
    "enrollment": null,
    "sponsor": "ViiV Healthcare",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALT",
    "nct_id": "NCT02764047",
    "title": "Probiotics in the Treatment of NAFLD",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-alcoholic Fatty Liver Disease",
      "Nonalcoholic Steatohepatitis",
      "Fatty Liver, Nonalcoholic",
      "NAFLD"
    ],
    "interventions": [
      "Probiotic"
    ],
    "primary_completion_date": "2017-12",
    "completion_date": "2018-01",
    "results_first_posted": null,
    "last_update_posted": "2017-10-06",
    "enrollment": null,
    "sponsor": "Federal University of Health Science of Porto Alegre",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALT",
    "nct_id": "NCT06171724",
    "title": "Ashwagandha Pharmacokinetics Study in Older Adults",
    "status": "TERMINATED",
    "phase": "EARLY_PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy",
      "Aging"
    ],
    "interventions": [
      "Shoden"
    ],
    "primary_completion_date": "2024-12-09",
    "completion_date": "2024-12-09",
    "results_first_posted": null,
    "last_update_posted": "2025-10-06",
    "enrollment": null,
    "sponsor": "Oregon Health and Science University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALT",
    "nct_id": "NCT06222892",
    "title": "A Study of Camlipixant in Male and Female Healthy Participants and Participants With Hepatic Impairment Aged 18-75 Years of Age",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cough"
    ],
    "interventions": [
      "Camlipixant"
    ],
    "primary_completion_date": "2024-12-17",
    "completion_date": "2024-12-30",
    "results_first_posted": "2026-01-07",
    "last_update_posted": "2026-01-07",
    "enrollment": null,
    "sponsor": "Bellus Health Inc. - a GSK company",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALT",
    "nct_id": "NCT06591767",
    "title": "Quercetin as Possible Supportive Therapy for Mild to Moderate Hyperuricemia",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hyperuricemia"
    ],
    "interventions": [
      "Quercetin",
      "Berberol K\u00ae"
    ],
    "primary_completion_date": "2024-04-30",
    "completion_date": "2024-08-31",
    "results_first_posted": null,
    "last_update_posted": "2024-10-17",
    "enrollment": null,
    "sponsor": "Liaquat University of Medical & Health Sciences",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALT",
    "nct_id": "NCT04128293",
    "title": "A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Participants",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HIV Infections"
    ],
    "interventions": [
      "GSK3640254 Tablet",
      "GSK3640254 Capsule"
    ],
    "primary_completion_date": "2019-11-15",
    "completion_date": "2019-11-15",
    "results_first_posted": "2020-08-25",
    "last_update_posted": "2020-08-25",
    "enrollment": null,
    "sponsor": "ViiV Healthcare",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALT",
    "nct_id": "NCT06315842",
    "title": "Levels of Diagnostic and Therapeutic Intervention in Hospitalized Patients",
    "status": "NOT_YET_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Disease"
    ],
    "interventions": [
      "Levels of Diagnostic and Therapeutic Intervention tool by Fontecha and col.",
      "Usual clinical practice"
    ],
    "primary_completion_date": "2027-08",
    "completion_date": "2027-08",
    "results_first_posted": null,
    "last_update_posted": "2025-12-05",
    "enrollment": null,
    "sponsor": "Consorci Sanitari de l'Alt Pened\u00e8s i Garraf",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALT",
    "nct_id": "NCT04432272",
    "title": "ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS)",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID-19",
      "Severe Acute Respiratory Syndrome (SARS)",
      "Coronavirus Infections"
    ],
    "interventions": [
      "COVID-19 convalescent plasma"
    ],
    "primary_completion_date": "2020-11-13",
    "completion_date": "2020-11-28",
    "results_first_posted": "2021-11-22",
    "last_update_posted": "2022-03-09",
    "enrollment": null,
    "sponsor": "Corewell Health East",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALT",
    "nct_id": "NCT03984825",
    "title": "Effect of GSK3640254 on the Pharmacokinetics of a Combination Oral Contraceptive",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HIV Infections"
    ],
    "interventions": [
      "GSK3640254",
      "Portia"
    ],
    "primary_completion_date": "2019-08-16",
    "completion_date": "2019-08-16",
    "results_first_posted": "2020-08-27",
    "last_update_posted": "2020-08-27",
    "enrollment": null,
    "sponsor": "ViiV Healthcare",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALT",
    "nct_id": "NCT07125443",
    "title": "Effect Inhaled Nitric Oxide in Adult Liver Transplant",
    "status": "NOT_YET_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Liver Diseases",
      "Reperfusion Injury",
      "Vasoplegia"
    ],
    "interventions": [
      "Prospective iNO Administration (\"After\" Group)",
      "No Intervention Retrospective \"Before\" Group"
    ],
    "primary_completion_date": "2026-12-31",
    "completion_date": "2027-01-01",
    "results_first_posted": null,
    "last_update_posted": "2025-08-15",
    "enrollment": null,
    "sponsor": "London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALT",
    "nct_id": "NCT00004850",
    "title": "Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Hepatitis C",
      "Hepatitis B"
    ],
    "interventions": [],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2025-12-26",
    "enrollment": null,
    "sponsor": "National Institutes of Health Clinical Center (CC)",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALT",
    "nct_id": "NCT03095638",
    "title": "Bioavailability Study of 10 Milligram (mg) and 5 mg Tablets Versus Conventional Tablets of Dolutegravir",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HIV Infections"
    ],
    "interventions": [
      "Conventional dolutegravir 10 mg tablet",
      "Conventional dolutegravir 50 mg tablet",
      "Dispersible dolutegravir 5 mg tablet",
      "Conventional dolutegravir 25 mg tablet"
    ],
    "primary_completion_date": "2017-06-23",
    "completion_date": "2017-06-23",
    "results_first_posted": "2018-12-21",
    "last_update_posted": "2019-07-23",
    "enrollment": null,
    "sponsor": "ViiV Healthcare",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALT",
    "nct_id": "NCT04563845",
    "title": "Effect of Therapeutic and Supratherapeutic Oral Doses of GSK3640254 on Cardiac Conduction Compared to Placebo and a Single Oral Dose of Moxifloxacin",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HIV Infections"
    ],
    "interventions": [
      "GSK3640254",
      "Placebo",
      "Moxifloxacin"
    ],
    "primary_completion_date": "2021-10-30",
    "completion_date": "2021-10-30",
    "results_first_posted": "2023-12-06",
    "last_update_posted": "2023-12-06",
    "enrollment": null,
    "sponsor": "ViiV Healthcare",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALT",
    "nct_id": "NCT01970241",
    "title": "Inpatient Diabetes on Corticosteroids",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes Mellitus"
    ],
    "interventions": [
      "NPH",
      "Correction Factor"
    ],
    "primary_completion_date": "2016-06",
    "completion_date": "2016-06",
    "results_first_posted": "2019-10-01",
    "last_update_posted": "2019-10-01",
    "enrollment": null,
    "sponsor": "Hennepin Healthcare Research Institute",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALT",
    "nct_id": "NCT02738931",
    "title": "Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Infection, Human Immunodeficiency Virus"
    ],
    "interventions": [
      "Dolutegravir 50 mg tablet",
      "Lamivudine 300 mg tablet",
      "Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA)",
      "Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)"
    ],
    "primary_completion_date": "2016-06",
    "completion_date": "2016-06",
    "results_first_posted": null,
    "last_update_posted": "2017-01-18",
    "enrollment": null,
    "sponsor": "ViiV Healthcare",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALT",
    "nct_id": "NCT05600777",
    "title": "A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cough",
      "Refractory Chronic Cough"
    ],
    "interventions": [
      "BLU-5937",
      "Placebo"
    ],
    "primary_completion_date": "2026-06-17",
    "completion_date": "2027-03-23",
    "results_first_posted": null,
    "last_update_posted": "2025-10-07",
    "enrollment": null,
    "sponsor": "Bellus Health Inc. - a GSK company",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ATAI",
    "nct_id": "NCT06524830",
    "title": "A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Treatment Resistant Depression"
    ],
    "interventions": [
      "VLS-01-203 BU",
      "VLS-01-BU Placebo"
    ],
    "primary_completion_date": "2025-12-31",
    "completion_date": "2026-03-30",
    "results_first_posted": null,
    "last_update_posted": "2026-01-08",
    "enrollment": null,
    "sponsor": "atai Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ATAI",
    "nct_id": "NCT05029401",
    "title": "A Study of Oral Ibogaine in Opioid Withdrawal",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Opiate Withdrawal Syndrome"
    ],
    "interventions": [
      "DMX-1002",
      "Placebo"
    ],
    "primary_completion_date": "2024-01-16",
    "completion_date": "2024-01-16",
    "results_first_posted": null,
    "last_update_posted": "2024-08-06",
    "enrollment": null,
    "sponsor": "atai Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ATAI",
    "nct_id": "NCT06693609",
    "title": "Exploratory Safety and Efficacy of EMP-01 in Social Anxiety Disorder",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Social Anxiety Disorder"
    ],
    "interventions": [
      "EMP-01",
      "EMP-01 Placebo"
    ],
    "primary_completion_date": "2026-02-04",
    "completion_date": "2026-02-04",
    "results_first_posted": null,
    "last_update_posted": "2025-11-24",
    "enrollment": null,
    "sponsor": "atai Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AURA",
    "nct_id": "NCT06664944",
    "title": "Technology Exposure and Child Health: Wellness Impact and Social Effects: an Observational Product Registry Study",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Mood",
      "Depression Disorders",
      "Anxiety Disorders",
      "Sleep",
      "Eating Disorders",
      "Physical Activity",
      "Loneliness",
      "Stress"
    ],
    "interventions": [],
    "primary_completion_date": "2025-12",
    "completion_date": "2025-12",
    "results_first_posted": null,
    "last_update_posted": "2025-02-04",
    "enrollment": null,
    "sponsor": "Aura",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AURA",
    "nct_id": "NCT02860312",
    "title": "Long Term Physical Activity for Hemodialysis Patients",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "End Stage Renal Disease on Hemodialysis"
    ],
    "interventions": [
      "Intradialytic exercise on stationary bicycles",
      "Non-exercising group"
    ],
    "primary_completion_date": "2018-09",
    "completion_date": "2019-05",
    "results_first_posted": null,
    "last_update_posted": "2016-08-09",
    "enrollment": null,
    "sponsor": "AURA Sante",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AURA",
    "nct_id": "NCT06007690",
    "title": "A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Choroidal Melanoma",
      "Indeterminate Lesions",
      "Uveal Melanoma",
      "Ocular Melanoma"
    ],
    "interventions": [
      "Bel-sar",
      "Suprachoroidal Microinjector",
      "Infrared Laser",
      "Sham Infrared Laser",
      "Sham Microinjector"
    ],
    "primary_completion_date": "2027-11-15",
    "completion_date": "2028-08-15",
    "results_first_posted": null,
    "last_update_posted": "2025-11-24",
    "enrollment": null,
    "sponsor": "Aura Biosciences",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AURA",
    "nct_id": "NCT06643884",
    "title": "Suprachoroidal Administration in Subjects With Metastases to the Choroid",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Eye Cancer",
      "Primary Cancer"
    ],
    "interventions": [
      "AU-011",
      "SCS Microinjector",
      "Laser"
    ],
    "primary_completion_date": "2026-11-30",
    "completion_date": "2027-10-31",
    "results_first_posted": null,
    "last_update_posted": "2026-01-08",
    "enrollment": null,
    "sponsor": "Aura Biosciences",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AURA",
    "nct_id": "NCT07338968",
    "title": "A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma",
    "status": "NOT_YET_RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Choroidal Melanoma",
      "Indeterminate Lesions"
    ],
    "interventions": [
      "Observational"
    ],
    "primary_completion_date": "2033-08-15",
    "completion_date": "2033-08-15",
    "results_first_posted": null,
    "last_update_posted": "2026-01-14",
    "enrollment": null,
    "sponsor": "Aura Biosciences",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AURA",
    "nct_id": "NCT03941379",
    "title": "A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Choroidal Melanoma",
      "Indeterminate Lesions of Eye"
    ],
    "interventions": [],
    "primary_completion_date": "2029-12",
    "completion_date": "2029-12",
    "results_first_posted": null,
    "last_update_posted": "2023-12-21",
    "enrollment": null,
    "sponsor": "Aura Biosciences",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AURA",
    "nct_id": "NCT05266430",
    "title": "Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)",
    "status": "TERMINATED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Choroidal Melanoma",
      "Indeterminate Lesions"
    ],
    "interventions": [
      "Standard of Care",
      "AU-011"
    ],
    "primary_completion_date": "2023-02-01",
    "completion_date": "2023-04-20",
    "results_first_posted": null,
    "last_update_posted": "2023-08-09",
    "enrollment": null,
    "sponsor": "Aura Biosciences",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AURA",
    "nct_id": "NCT03052127",
    "title": "Study in Subjects With Small Primary Choroidal Melanoma",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Uveal Melanoma",
      "Ocular Melanoma",
      "Choroidal Melanoma"
    ],
    "interventions": [
      "Light-activated AU-011",
      "Laser Activation"
    ],
    "primary_completion_date": "2021-01-26",
    "completion_date": "2021-01-26",
    "results_first_posted": "2024-02-01",
    "last_update_posted": "2024-02-01",
    "enrollment": null,
    "sponsor": "Aura Biosciences",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AURA",
    "nct_id": "NCT05483868",
    "title": "A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-muscle-invasive Bladder Cancer",
      "Non-Muscle Invasive Bladder Cancer (&Amp;#34;NMIBC&Amp;#34;) Unresponsive/Intolerant to BCG",
      "NMIBC",
      "Non-Muscle Invasive Bladder Carcinoma",
      "Non-Muscle Invasive Bladder Neoplasms",
      "Non-Muscle Invasive Bladder Urothelial Carcinoma",
      "Urothelial Carcinoma Bladder"
    ],
    "interventions": [
      "AU-011",
      "AU-011 in Combination with Medical Laser Adminstration",
      "AU-011 in Combination with Medical Laser Administration"
    ],
    "primary_completion_date": "2027-03",
    "completion_date": "2027-03",
    "results_first_posted": null,
    "last_update_posted": "2025-12-04",
    "enrollment": null,
    "sponsor": "Aura Biosciences",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AURA",
    "nct_id": "NCT05307601",
    "title": "Immune Response Following COVID-19 in Hemodialysis Patients",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Dialysis; Complications",
      "COVID-19",
      "Cytokine Storm"
    ],
    "interventions": [],
    "primary_completion_date": "2021-09-01",
    "completion_date": "2021-10-30",
    "results_first_posted": null,
    "last_update_posted": "2022-04-01",
    "enrollment": null,
    "sponsor": "AURA Paris",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AURA",
    "nct_id": "NCT04417530",
    "title": "Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Uveal Melanoma",
      "Ocular Melanoma",
      "Choroidal Melanoma"
    ],
    "interventions": [
      "AU-011",
      "Suprachoroidal Microinjector",
      "PDT Laser"
    ],
    "primary_completion_date": "2024-04-22",
    "completion_date": "2024-04-22",
    "results_first_posted": null,
    "last_update_posted": "2025-03-03",
    "enrollment": null,
    "sponsor": "Aura Biosciences",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AVIR",
    "nct_id": "NCT01078701",
    "title": "Dose Finding Study of Single Dose GHB11L1 in Healthy Adults",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Influenza, Human"
    ],
    "interventions": [
      "GHB11L1",
      "Placebo"
    ],
    "primary_completion_date": "2010-05",
    "completion_date": "2010-05",
    "results_first_posted": null,
    "last_update_posted": "2011-01-05",
    "enrollment": null,
    "sponsor": "AVIR Green Hills Biotechnology AG",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AVIR",
    "nct_id": "NCT00724997",
    "title": "Randomized, Double-blind, Placebo-controlled, Phase I Dose-escalation Study of Single Dose GHB01L1 in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Seasonal Human Influenza"
    ],
    "interventions": [
      "GHB01L1"
    ],
    "primary_completion_date": "2008-07",
    "completion_date": "2008-08",
    "results_first_posted": null,
    "last_update_posted": "2009-12-08",
    "enrollment": null,
    "sponsor": "AVIR Green Hills Biotechnology AG",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AVIR",
    "nct_id": "NCT00741806",
    "title": "Dose-escalation Study of Single Dose GHB04L1 in Healthy Adults",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Influenza"
    ],
    "interventions": [
      "GHB04L1",
      "Placebo"
    ],
    "primary_completion_date": "2009-12",
    "completion_date": "2010-03",
    "results_first_posted": null,
    "last_update_posted": "2010-03-02",
    "enrollment": null,
    "sponsor": "AVIR Green Hills Biotechnology AG",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AVIR",
    "nct_id": "NCT03745274",
    "title": "Two Doses of GHB04L1 for Pandemic Influenza Prophylaxis in Healthy Adults",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Influenza, Avian"
    ],
    "interventions": [
      "GHB04L1",
      "Placebo"
    ],
    "primary_completion_date": "2009-05-27",
    "completion_date": "2009-05-27",
    "results_first_posted": null,
    "last_update_posted": "2018-11-20",
    "enrollment": null,
    "sponsor": "AVIR Green Hills Biotechnology AG",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AVIR",
    "nct_id": "NCT01369862",
    "title": "Study of Single Dose GHB16L2 Trivalent Influenza Vaccine in Healthy Adults",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Influenza, Human"
    ],
    "interventions": [
      "GHB16L2",
      "Placebo"
    ],
    "primary_completion_date": "2011-08",
    "completion_date": "2011-08",
    "results_first_posted": null,
    "last_update_posted": "2014-01-10",
    "enrollment": null,
    "sponsor": "AVIR Green Hills Biotechnology AG",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BBOT",
    "nct_id": "NCT06343402",
    "title": "Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-small Cell Lung Cancer",
      "Metastatic Non-Small Cell Lung Cancer",
      "NSCLC",
      "KRAS G12C",
      "Metastatic Lung Cancer",
      "Advanced Lung Carcinoma"
    ],
    "interventions": [
      "BBO-8520",
      "Pembrolizumab"
    ],
    "primary_completion_date": "2027-08",
    "completion_date": "2028-02",
    "results_first_posted": null,
    "last_update_posted": "2026-01-26",
    "enrollment": null,
    "sponsor": "TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BBOT",
    "nct_id": "NCT06625775",
    "title": "Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor, Adult",
      "Metastatic Breast Cancer",
      "Advanced Breast Cancer",
      "HER2 Mutation-Related Tumors",
      "HER2-positive Metastatic Breast Cancer",
      "KRAS Mutant Metastatic Colorectal Cancer",
      "Metastatic Lung Cancer",
      "Metastatic Colorectal Cancer",
      "Advanced Lung Cancer",
      "HR-positive, HER2-negative Advanced Breast Cancer",
      "HER2-positive Advanced Breast Cancer"
    ],
    "interventions": [
      "BBO-10203",
      "Trastuzumab",
      "Fulvestrant",
      "Ribociclib",
      "FOLFOX",
      "Bevacizumab"
    ],
    "primary_completion_date": "2028-11",
    "completion_date": "2028-11",
    "results_first_posted": null,
    "last_update_posted": "2026-01-27",
    "enrollment": null,
    "sponsor": "TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BBOT",
    "nct_id": "NCT06917079",
    "title": "BBO-11818 in Adult Subjects With KRAS Mutant Cancer",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-Small Cell Lung Cancer",
      "NSCLC",
      "PDAC - Pancreatic Ductal Adenocarcinoma",
      "CRC (Colorectal Cancer)",
      "Metastatic Non-Small Lung Cell Cancer",
      "Metastatic Colorectal Cancer (CRC)",
      "KRAS G12A",
      "KRAS G12C",
      "KRAS G12D",
      "KRAS G12S",
      "KRAS G12V",
      "Metastatic Pancreatic Ductal Adenocarcinoma",
      "Advanced Lung Carcinoma",
      "Solid Tumor, Adult"
    ],
    "interventions": [
      "BBO-11818",
      "Pembrolizumab",
      "Platinum chemotherapy (cisplatin or carboplatin)",
      "Pemetrexed",
      "Cetuximab",
      "FOLFOX",
      "NALIRIFOX",
      "Gemcitabine",
      "Nab-paclitaxel"
    ],
    "primary_completion_date": "2027-08",
    "completion_date": "2029-09",
    "results_first_posted": null,
    "last_update_posted": "2026-01-21",
    "enrollment": null,
    "sponsor": "TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT01506388",
    "title": "A Novel Protocol for Labour Induction",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Failed Induction of Labor"
    ],
    "interventions": [
      "foley catheter",
      "Misoprostol",
      "Vaginal IMN"
    ],
    "primary_completion_date": "2013-12",
    "completion_date": "2014-01",
    "results_first_posted": null,
    "last_update_posted": "2014-01-22",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06293586",
    "title": "Comparison Between Peribulbar And Sub-tenon Blocks on Oculocardiac Reflex (OCR) During Pediatric Strabismus Surgery",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Anesthesia, Local",
      "Ophthalmopathy",
      "Strabismus",
      "Pediatric ALL"
    ],
    "interventions": [
      "peribulbar block",
      "sub-tenon block",
      "Paracetamol"
    ],
    "primary_completion_date": "2024-03-30",
    "completion_date": "2024-03-30",
    "results_first_posted": null,
    "last_update_posted": "2024-03-05",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04035070",
    "title": "Effect of Irrigation With Antibiotic-containing Solutions on Postoperative Pain and Intra-canal Bacteria",
    "status": "UNKNOWN",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Necrotic Pulp"
    ],
    "interventions": [
      "co-amoxiclav-clindamycin solution",
      "MTAD",
      "2.5% sodium hypochlorite"
    ],
    "primary_completion_date": "2021-06",
    "completion_date": "2021-06",
    "results_first_posted": null,
    "last_update_posted": "2020-10-14",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT02304042",
    "title": "Carbetocin Versus Oxytocin in the Prevention of Post Partum Haemorrhage (PPH) in Women Delivered Vaginally With at Least 2 Risk Factors for Atonic PPH: A Randomised Controlled Trial",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Delivery"
    ],
    "interventions": [
      "Carbetocin",
      "Oxytocin"
    ],
    "primary_completion_date": "2015-07",
    "completion_date": "2015-07",
    "results_first_posted": null,
    "last_update_posted": "2015-07-02",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06227637",
    "title": "Local Muscle Vibration Versus Muscle Energy Technique In Sacroiliac Joint Dysfunction",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Sacroiliac Joint Dysfunction"
    ],
    "interventions": [
      "Local Muscle Vibration compared to Muscle energy technique in SIJD"
    ],
    "primary_completion_date": "2024-04-15",
    "completion_date": "2024-06-15",
    "results_first_posted": null,
    "last_update_posted": "2024-01-29",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT07099781",
    "title": "Relation Between Hand Grip and Shoulder Muscle Strength After Surgical Stabilization of Shoulder Dislocations",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Arthroscopic Bankart Repair",
      "Arthroscopic Shoulder Surgery",
      "Hand Grip Strength",
      "Rotator Cuff Strength"
    ],
    "interventions": [
      "handheld dynamometer and hand grip dynamometer"
    ],
    "primary_completion_date": "2025-04-30",
    "completion_date": "2025-04-30",
    "results_first_posted": null,
    "last_update_posted": "2025-08-01",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04964622",
    "title": "the Effect of Preoperative Sodium Ibuprofen on Postoperative Endodontic Pain",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Irreversible Pulpitis"
    ],
    "interventions": [
      "nurofen"
    ],
    "primary_completion_date": "2022-07-01",
    "completion_date": "2022-09-01",
    "results_first_posted": null,
    "last_update_posted": "2022-12-07",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04389619",
    "title": "Fractional Microneedling RF vs Intralesional Steroid With & Without Microneedling in Hypertrophic Scars",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypertrophic Scars"
    ],
    "interventions": [
      "Fractional Microneedling Radiofrequency",
      "Intralesional Steroid Injection with and without Microneedling"
    ],
    "primary_completion_date": "2020-12",
    "completion_date": "2020-12",
    "results_first_posted": null,
    "last_update_posted": "2020-05-15",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04635007",
    "title": "Tranexamic Acid Versus Misoprostol in Reducing Blood Loss in Cesarean Section in Primigravida",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cesarean Section Complications",
      "Blood Loss, Surgical",
      "Misoprostol",
      "Tranexamic Acid"
    ],
    "interventions": [
      "Tranexamic acid",
      "Misoprostol 200mcg Tab"
    ],
    "primary_completion_date": "2022-06-01",
    "completion_date": "2022-06-30",
    "results_first_posted": null,
    "last_update_posted": "2022-07-22",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT07276828",
    "title": "Effect of Autogenic Training on Hemodialysis Patients",
    "status": "NOT_YET_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hemodialysis Patient",
      "Restless Leg Syndrome (RLS)",
      "Fatigue",
      "Sleep Disturbance"
    ],
    "interventions": [
      "Autogenic training",
      "conventional physical therapy and hemodialysis care"
    ],
    "primary_completion_date": "2027-03-15",
    "completion_date": "2027-05-15",
    "results_first_posted": null,
    "last_update_posted": "2025-12-22",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03798392",
    "title": "Self-pressurised Air-Q With Blocker Versus Baska Mask in Low Risk Female Patients Undergoing Ambulatory Surgery.",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Supraglottic Airway Devices"
    ],
    "interventions": [
      "Self-pressurizing Air Q blocker mask measuring airway seal pressure of studied supra-glottic airway devices 10 minutes after insertion",
      "Baska mask measuring airway seal pressure of studied supra-glottic airway devices 10 minutes after insertion"
    ],
    "primary_completion_date": "2019-05",
    "completion_date": "2019-06",
    "results_first_posted": null,
    "last_update_posted": "2019-01-10",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03299595",
    "title": "Oral Mucosal Lesions Among Smokers in an Egyptian Population.",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Smokers"
    ],
    "interventions": [
      "printed questionnaire"
    ],
    "primary_completion_date": "2019-03-30",
    "completion_date": "2019-06-30",
    "results_first_posted": null,
    "last_update_posted": "2021-01-08",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06956911",
    "title": "Effect of Early Low Resisted Exercise With Blood Flow Restriction on Pulmonary Function in Post Cardiac Surgery Patient",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Coronary Artery Bypass Grafting",
      "Post Coronary Artery Bypass Grafting"
    ],
    "interventions": [
      "traditional cardiac rehabilitation with early low resisted exercise with blood flow restriction",
      "traditional cardiac rehabilitation"
    ],
    "primary_completion_date": "2025-03-20",
    "completion_date": "2025-06-15",
    "results_first_posted": null,
    "last_update_posted": "2025-05-04",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03686267",
    "title": "Evaluation of the Aesthetic Outcome of Lithium Disilicate (e.Max) All Ceramic Crowns on Titanium Implant Abutments in the Aesthetic Zone After Different Color Masking Approaches",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Aesthetic Outcome of Crowns on Implants"
    ],
    "interventions": [
      "opaqued titanium abutments",
      "lithium disilicate coping (high opacity)",
      "titanium abutment with no color masking"
    ],
    "primary_completion_date": "2020-09-03",
    "completion_date": "2020-09-28",
    "results_first_posted": null,
    "last_update_posted": "2025-06-13",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05730400",
    "title": "Histological Assessment of BMAC Utilized in Sinus Lift",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Implant Site Reaction"
    ],
    "interventions": [
      "BMAC loaded on bovine graft",
      "Bovine graft only"
    ],
    "primary_completion_date": "2023-08-30",
    "completion_date": "2023-09-15",
    "results_first_posted": null,
    "last_update_posted": "2024-02-06",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT02767076",
    "title": "Paramedian Spinal Anaesthesia : Comparison Between Land-mark Guided Technique and Real-time Ultrasound Guided Technique.",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Paramedian Spinal Anaesthesia",
      "Real Time Ultrasound Guiding"
    ],
    "interventions": [
      "conventional paramedian spinal anesthesia",
      "ultrasound guided paramedian spinal anesthesia"
    ],
    "primary_completion_date": "2017-04",
    "completion_date": "2017-09",
    "results_first_posted": null,
    "last_update_posted": "2016-05-10",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05348135",
    "title": "Combined Cognitive and Functional Strength Training in Children With cp",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diplegic Cerebral Palsy"
    ],
    "interventions": [
      "functional strength training",
      "cognitive training",
      "conventional physical therapy"
    ],
    "primary_completion_date": "2022-03-01",
    "completion_date": "2022-03-11",
    "results_first_posted": null,
    "last_update_posted": "2022-04-27",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04632693",
    "title": "Soft Tissue Augmentation Using CAF With Either SCTG and Vitamin C Versus SCTG Alone in Management of RT1 Gingival Recession",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Gingival Thickness"
    ],
    "interventions": [
      "CAF with SCTG and Vitamin C injection",
      "CAF with SCTG alone"
    ],
    "primary_completion_date": "2021-05",
    "completion_date": "2021-06",
    "results_first_posted": null,
    "last_update_posted": "2020-11-17",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03181776",
    "title": "Hemodynamic Effect of Left Tilting in Cesarean Delivery",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cesarean Section Complications",
      "Spinal Anesthetic Complications"
    ],
    "interventions": [
      "left lateral tilting in 15 degrees",
      "left lateral tilting in 30 degrees",
      "supine position"
    ],
    "primary_completion_date": "2018-11-25",
    "completion_date": "2018-12-05",
    "results_first_posted": null,
    "last_update_posted": "2018-07-09",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05585385",
    "title": "Effect of Backward Walking Versus Balance Training in Chronic Ankle Instability Patients",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Ankle Instability"
    ],
    "interventions": [
      "Backward Walking Training",
      "Balance Training",
      "Conventional treatment"
    ],
    "primary_completion_date": "2023-06-01",
    "completion_date": "2023-06-25",
    "results_first_posted": null,
    "last_update_posted": "2023-07-18",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04682743",
    "title": "Prevention of Post-Operative Shivering",
    "status": "COMPLETED",
    "phase": "EARLY_PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Post-Operative Shivering"
    ],
    "interventions": [
      "paracetamol",
      "ondansetron",
      "normal saline"
    ],
    "primary_completion_date": "2022-01-16",
    "completion_date": "2022-02-22",
    "results_first_posted": null,
    "last_update_posted": "2022-03-31",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04777968",
    "title": "Evaluation Of Fluoride Uptake By Dentine Following Silver Diamine Fluoride Under Resin Modified Glass Ionomer Restoration In Carious Primary Molars",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dental Caries"
    ],
    "interventions": [
      "Silver diamine fluoride"
    ],
    "primary_completion_date": "2020-12-01",
    "completion_date": "2021-02-01",
    "results_first_posted": null,
    "last_update_posted": "2021-03-08",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT07040618",
    "title": "Rhomboid Intercostal Block vs Erector Spinae Block",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lung Cancer"
    ],
    "interventions": [
      "Ultrasound-guided Rhomboid Intercostal Block",
      "Ultrasound-guided Erector Spinae Plane Block"
    ],
    "primary_completion_date": "2026-07-01",
    "completion_date": "2026-08-01",
    "results_first_posted": null,
    "last_update_posted": "2025-06-27",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05548985",
    "title": "Midodrine for Prophylaxis Against Post Spinal Hypotension in Elderly Population",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypotension",
      "Spinal Anesthesia",
      "Elderly"
    ],
    "interventions": [
      "Midodrine Oral Tablet",
      "Metoclopramide"
    ],
    "primary_completion_date": "2023-07-15",
    "completion_date": "2023-07-15",
    "results_first_posted": null,
    "last_update_posted": "2023-09-15",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05158088",
    "title": "Video Laryngoscope Versus USB Borescope in Difficult Intubation",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Intubation; Difficult or Failed"
    ],
    "interventions": [
      "Borescope",
      "Video laryngoscope"
    ],
    "primary_completion_date": "2022-03-28",
    "completion_date": "2022-04-01",
    "results_first_posted": null,
    "last_update_posted": "2022-04-15",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04641156",
    "title": "Effect of Physical Therapy Exercise Program and Low-Level Laser Therapy on the Treatment of Cervicogenic Somatosensory Tinnitus",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Tinnitus, Subjective"
    ],
    "interventions": [
      "Exercise Therapy program added to laser therapy"
    ],
    "primary_completion_date": "2019-03-05",
    "completion_date": "2019-04-01",
    "results_first_posted": null,
    "last_update_posted": "2022-02-01",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05445102",
    "title": "Effect of Autogenous Demineralized Dentin as a Bone Graft Substitute in Management of Periodontal Intrabony Defects",
    "status": "UNKNOWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Intrabony Defect"
    ],
    "interventions": [
      "autogenous demineralized dentin graft as bone substitute in treatment of intrabony defect"
    ],
    "primary_completion_date": "2023-05-22",
    "completion_date": "2023-09-22",
    "results_first_posted": null,
    "last_update_posted": "2022-07-06",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05409742",
    "title": "Masseter Muscle Activity and Post-operative Pain in a Group of Egyptian Children Treated With Hall Technique Vs Modified Hall Technique",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Masseter Muscle Activity"
    ],
    "interventions": [
      "Modified Hall technique"
    ],
    "primary_completion_date": "2022-12-31",
    "completion_date": "2023-09-01",
    "results_first_posted": null,
    "last_update_posted": "2022-06-08",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04759469",
    "title": "Effect of Exercise on Cardiometabolic Risk Factors in Type II Diabetic Patients",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes Mellitus, Type 2"
    ],
    "interventions": [
      "High-intensity interval training",
      "Moderate intensity interval training"
    ],
    "primary_completion_date": "2018-12-01",
    "completion_date": "2019-12-01",
    "results_first_posted": null,
    "last_update_posted": "2021-03-22",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03731403",
    "title": "Remineralization Potential of MI Varnish Versus Fluoride Varnish on White Spot Lesions in Maxillary Primary Incisors",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Remineralization Effect of the Varnish on White Spot Lesions"
    ],
    "interventions": [
      "MI varnish"
    ],
    "primary_completion_date": "2020-03-01",
    "completion_date": "2020-07-01",
    "results_first_posted": null,
    "last_update_posted": "2020-07-21",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05983653",
    "title": "Evaluation of Arthrocentesis With and Without PRP Injection in Patients With Disc Displacement With Reduction.",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "TMJ Disc Disorder"
    ],
    "interventions": [
      "arthrocentesis without PRP",
      "arthrocentesis with PRP"
    ],
    "primary_completion_date": "2024-03-01",
    "completion_date": "2024-04-01",
    "results_first_posted": null,
    "last_update_posted": "2024-08-27",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03384537",
    "title": "Antimicrobial Effect of Tropolone Containing Versus Tropolone Free Mouthwash",
    "status": "RECRUITING",
    "phase": "EARLY_PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dental Diseases"
    ],
    "interventions": [
      "Listerine total care zero",
      "Chlorhexidine Mouthwash (0.2%)."
    ],
    "primary_completion_date": "2025-10",
    "completion_date": "2025-12",
    "results_first_posted": null,
    "last_update_posted": "2025-02-12",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05812066",
    "title": "Clinical Assessment of All Ceramic Single-retainer Using Upper Canine as Abutment With Minimum Preparation on the Lingual Surface, to Replace the Upper Lateral Incisor and Will be Compared With the All Ceramic Single-retainer Using Upper Central Incisor.",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Survival, Prosthesis"
    ],
    "interventions": [
      "all ceramic single-retainer resin bonded fixed partial denture"
    ],
    "primary_completion_date": "2025-02-13",
    "completion_date": "2025-02-25",
    "results_first_posted": null,
    "last_update_posted": "2025-07-20",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT02397551",
    "title": "Three Small Doses of HCG Versus Booster Dose of HCG on Ovum Pickup Day",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Infertility"
    ],
    "interventions": [
      "IVF/ICSI",
      "Human Chorionic Gonadotropin"
    ],
    "primary_completion_date": "2018-01",
    "completion_date": "2018-01",
    "results_first_posted": null,
    "last_update_posted": "2018-01-29",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03577210",
    "title": "The Degree of Accuracy of Patient-specific PEEK Implant to Restore Chin Deficiency",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chin Microgenia"
    ],
    "interventions": [
      "augmentation genioplasty"
    ],
    "primary_completion_date": "2019-09",
    "completion_date": "2019-10",
    "results_first_posted": null,
    "last_update_posted": "2018-07-05",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03085030",
    "title": "Can Antioxidants Affect Pregnancy Rate in Patients With Expected Low Number of Egg Retrieval in IVF Cycles?",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Infertility, Female"
    ],
    "interventions": [
      "Antioxidant Formula",
      "Placebo"
    ],
    "primary_completion_date": "2018-12-01",
    "completion_date": "2018-12-01",
    "results_first_posted": null,
    "last_update_posted": "2019-09-04",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06621693",
    "title": "Effect of Neuromuscular Electrical Stimulation on Phrenic Nerve Regeneration Post Cardiac Surgeries",
    "status": "NOT_YET_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Post-cardiac Surgery"
    ],
    "interventions": [
      "Transcutaneous electrical diaphragmatic stimulation intervention",
      "traditional physiotherapy program"
    ],
    "primary_completion_date": "2025-01-15",
    "completion_date": "2025-01-30",
    "results_first_posted": null,
    "last_update_posted": "2024-10-01",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT07353801",
    "title": "Oral Mini Pulse Dexamethasone in Pediatric Vitiligo",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Vitiligo"
    ],
    "interventions": [
      "Dexamethasone (0.1 mg/kg)"
    ],
    "primary_completion_date": "2026-06",
    "completion_date": "2026-06",
    "results_first_posted": null,
    "last_update_posted": "2026-01-20",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05381298",
    "title": "Deep Margin Elevation Vs Crown Lengthening",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Endodontically Treated Teeth"
    ],
    "interventions": [
      "Deep Margin Elevation using resin composite",
      "Surgical Crown Lengthening"
    ],
    "primary_completion_date": "2021-12-15",
    "completion_date": "2022-05-05",
    "results_first_posted": null,
    "last_update_posted": "2022-05-19",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT01612065",
    "title": "Optimum Misoprostol Dose Prior to Office Hysteroscopy",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Infertility",
      "Abnormal Uterine and Vaginal Bleeding, Unspecified",
      "Recurrent Abortion"
    ],
    "interventions": [
      "Misoprostol",
      "Misoprostol"
    ],
    "primary_completion_date": "2013-03",
    "completion_date": "2013-04",
    "results_first_posted": null,
    "last_update_posted": "2013-04-11",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04143399",
    "title": "HoLEP vs BPRP of a Large Volume BPH: a Randomised Controlled Trial",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "BPH With Urinary Obstruction",
      "Male"
    ],
    "interventions": [
      "holmium laser enucleation of the prostate",
      "Bipolar resection of the prostate"
    ],
    "primary_completion_date": "2019-05-01",
    "completion_date": "2019-06-10",
    "results_first_posted": null,
    "last_update_posted": "2019-10-29",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06972316",
    "title": "Global Postural Re-education in Text Neck Syndrome",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Text Neck Posture"
    ],
    "interventions": [
      "The Global postural reeducation",
      "Traditional treatments"
    ],
    "primary_completion_date": "2025-09-10",
    "completion_date": "2025-12-30",
    "results_first_posted": null,
    "last_update_posted": "2025-05-15",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06195644",
    "title": "Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients",
    "status": "UNKNOWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cortical Excitability",
      "Multiple Sclerosis"
    ],
    "interventions": [
      "Galvanic vestibular stimulation",
      "MovAlyzeR\u00ae software from Neuroscript",
      "BODYFIT Mini Portable Pedal Home Exerciser (cyclic ergometer)"
    ],
    "primary_completion_date": "2024-12",
    "completion_date": "2025-12",
    "results_first_posted": null,
    "last_update_posted": "2024-01-08",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03185767",
    "title": "Long Non Coding RNA in Complications of Systemic Lupus",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Complication in Systemic Lupus Erythematosus"
    ],
    "interventions": [
      "blood sampling"
    ],
    "primary_completion_date": "2017-06-30",
    "completion_date": "2017-07-01",
    "results_first_posted": null,
    "last_update_posted": "2017-06-14",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06348953",
    "title": "Bioactive Versus Non-Bioactive Restorative System in Deep Carious Molars",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dental Caries",
      "Dental Diseases",
      "Deep Caries",
      "Tooth Diseases",
      "Tooth Decay",
      "Teeth; Lesion",
      "Caries; Dentin",
      "Dental Restoration Failure of Marginal Integrity",
      "Tooth Demineralization"
    ],
    "interventions": [
      "selective caries removal and conventional non-bioactive restorative system",
      "selective caries removal and bioactive restorative system"
    ],
    "primary_completion_date": "2025-12",
    "completion_date": "2025-12",
    "results_first_posted": null,
    "last_update_posted": "2024-07-19",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT02738177",
    "title": "Misoprostol Versus Effox as Cervical Ripening Agent Prior Surgical Evacuation",
    "status": "UNKNOWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cervical Ripening"
    ],
    "interventions": [
      "Misoprostol",
      "Isosorbide-5-mononitrate",
      "misoprostol and Isosorbide-5-mononitrate"
    ],
    "primary_completion_date": "2016-06",
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2016-04-14",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05647434",
    "title": "Effect of Sustained Inflations on Lung Atelectasis During Pediatric Laparoscopic Surgery",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ventilator Lung"
    ],
    "interventions": [
      "sustained inflations"
    ],
    "primary_completion_date": "2023-06-30",
    "completion_date": "2023-07-30",
    "results_first_posted": null,
    "last_update_posted": "2023-01-04",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06249607",
    "title": "Impact Of Mindfulness Breathing Versus Storytelling On Non- Specific Insomnia In Elderly",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Insomnia",
      "Sleep Disorder"
    ],
    "interventions": [
      "storytelling",
      "Mindfulness breathing",
      "Sleep hygiene"
    ],
    "primary_completion_date": "2024-09-01",
    "completion_date": "2024-09-05",
    "results_first_posted": null,
    "last_update_posted": "2024-09-25",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT01758939",
    "title": "Predictors of Response to Combined Pegylated Interferon and Ribavirin in Chronic Hepatitis C Infected Egyptian Patients",
    "status": "UNKNOWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Hepatitis C, Chronic"
    ],
    "interventions": [],
    "primary_completion_date": "2016-01",
    "completion_date": "2017-01",
    "results_first_posted": null,
    "last_update_posted": "2013-04-17",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05806307",
    "title": "Methods Decreasing Bleeding in Open Myomectomy",
    "status": "UNKNOWN",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Misoprostol Allergy",
      "Oxytocin Allergy",
      "Tranexamic Acid Allergy",
      "Ethamsylate Allergy",
      "Myoma",
      "Blood Loss, Surgical"
    ],
    "interventions": [
      "Misoprostol",
      "Tourniquet",
      "Carbetocin",
      "Oxytocin",
      "combined TXA and ethamsylate",
      "Vasopressin",
      "Bupivacaine Hydrochloride 0.5 % Injectable Solution epinephrine"
    ],
    "primary_completion_date": "2023-10-30",
    "completion_date": "2023-11-30",
    "results_first_posted": null,
    "last_update_posted": "2023-04-10",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06498739",
    "title": "Perioperative Analgesic Effect of Two Different Volumes of Local Anesthetic Solution in Erector Spinae Plane Block in Patients Undergoing Modified Radical Mastectomy",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Erector Spinae Plane Block",
      "Modified Radical Mastectomy"
    ],
    "interventions": [
      "Erector spinae plane block(15 ml bupivacaine 0.5%)",
      "Erector spinae plane block (15 ml bupivacaine 0.5% and 15ml normal saline)"
    ],
    "primary_completion_date": "2024-09-01",
    "completion_date": "2024-09-01",
    "results_first_posted": null,
    "last_update_posted": "2025-05-21",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03556267",
    "title": "Regional Anesthesia of Cesarean Section",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Anesthesia, Obestetric"
    ],
    "interventions": [
      "spinal needle"
    ],
    "primary_completion_date": "2020-10-30",
    "completion_date": "2021-02-14",
    "results_first_posted": null,
    "last_update_posted": "2021-02-16",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06366737",
    "title": "En-mass Retraction by KILBON Versus CAT Appliances",
    "status": "NOT_YET_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Maxillary Prognathism"
    ],
    "interventions": [
      "KILBON Appliance",
      "CAT appliance"
    ],
    "primary_completion_date": "2025-06",
    "completion_date": "2025-08",
    "results_first_posted": null,
    "last_update_posted": "2024-09-19",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05334745",
    "title": "Clinical Comparison of Topical Application of Alvogyl Versus Hyaluronic-Acid Gel in Management of Pain And Palatal Wound Healing",
    "status": "UNKNOWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Wound Healing"
    ],
    "interventions": [
      "Alvogyl"
    ],
    "primary_completion_date": "2022-12-01",
    "completion_date": "2023-01-01",
    "results_first_posted": null,
    "last_update_posted": "2022-04-19",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06219772",
    "title": "Assessment of Dynamic Balance in Idiopathic Scoliosis Compared to Normal Subjects",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Idiopathic Scoliosis"
    ],
    "interventions": [],
    "primary_completion_date": "2024-08-31",
    "completion_date": "2024-08-31",
    "results_first_posted": null,
    "last_update_posted": "2024-09-23",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT02506894",
    "title": "Fetal Middle Cerebral Artery Doppler in Preterm Births Receiving Magnesium Sulfate for Neuroprotection",
    "status": "COMPLETED",
    "phase": "EARLY_PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Preterm Birth"
    ],
    "interventions": [
      "Magnesium Sulfate",
      "0.9% sodium chloride solution"
    ],
    "primary_completion_date": "2015-11",
    "completion_date": "2015-11",
    "results_first_posted": null,
    "last_update_posted": "2016-02-01",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03628170",
    "title": "Soft Tissue Profile Following Socket Preservation With Platelet Rich Fibrin Versus Free Gingival Graft",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Soft Tissue Mass"
    ],
    "interventions": [
      "platelet rich fibrin",
      "Free gingival graft"
    ],
    "primary_completion_date": "2019-01",
    "completion_date": "2019-02",
    "results_first_posted": null,
    "last_update_posted": "2018-08-14",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05466461",
    "title": "Clinical Assessment of Giomer Based Technology Versus Smart Bioactive Restoration in Carious Class V Cavities",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dental Caries"
    ],
    "interventions": [
      "Beautifil Flow Plus X.",
      "Activa bioactive restorative"
    ],
    "primary_completion_date": "2025-01-01",
    "completion_date": "2025-01-01",
    "results_first_posted": null,
    "last_update_posted": "2025-05-21",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04396561",
    "title": "Evaluation of Unilateral Ultrasound Guided Paravertebral Block as Perioperative Analgesia For Lower Limb-Sparing Surgery In Adult Cancer Patients",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Unilateral U/S PVB"
    ],
    "interventions": [
      "Paravertebral group (group P):"
    ],
    "primary_completion_date": "2020-06-09",
    "completion_date": "2020-06-10",
    "results_first_posted": null,
    "last_update_posted": "2020-06-16",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03051594",
    "title": "Reliability of Fluorescent Camera and Caries Detection Dye Versus the Visual Tactile Method",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dental Caries"
    ],
    "interventions": [
      "fluorescent camera",
      "caries detector dye",
      "visual tactile assessment"
    ],
    "primary_completion_date": "2018-03-01",
    "completion_date": "2018-03-30",
    "results_first_posted": null,
    "last_update_posted": "2017-02-13",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04747015",
    "title": "Cervical Traction vs. Active Management of 3rd Stage of Labor",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Post Partum Hemorrhage"
    ],
    "interventions": [
      "Oxytocin",
      "Oxytocin",
      "cervical traction"
    ],
    "primary_completion_date": "2021-12",
    "completion_date": "2021-12",
    "results_first_posted": null,
    "last_update_posted": "2021-02-10",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06653868",
    "title": "Grafting of the Peri-implant Bony Defects Around Immediate Implants Using Xenogenic Versus Alloplastic Sticky Grafts: Randomized Controlled Clinical Trial",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bone Loss, Alveolar"
    ],
    "interventions": [
      "dental implant with bone augmentation"
    ],
    "primary_completion_date": "2026-03-20",
    "completion_date": "2026-03-20",
    "results_first_posted": null,
    "last_update_posted": "2024-10-22",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT07048873",
    "title": "Dexmedetomidine Versus Ketamine on Laryngeal Microsurgery",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Microlaryngeal Surgery"
    ],
    "interventions": [
      "Dexmedetomidine",
      "Ketamine",
      "Saline (control group)"
    ],
    "primary_completion_date": "2024-06-20",
    "completion_date": "2024-06-30",
    "results_first_posted": null,
    "last_update_posted": "2025-07-03",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04651283",
    "title": "Effect of Using Adaptive Seating Equipment on Hand Function",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cerebral Palsy"
    ],
    "interventions": [
      "Traditional seat group",
      "Adaptive seating equipment group"
    ],
    "primary_completion_date": "2018-08-15",
    "completion_date": "2018-08-30",
    "results_first_posted": null,
    "last_update_posted": "2020-12-03",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05151042",
    "title": "Digital Occlusal Wafer Versus Waferless Distal Segment Repositioning for BSSO in Skeletal Mandibular Deformities",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Maxillofacial Abnormalities",
      "Jaw Abnormalities",
      "Prognathism",
      "Retrognathia",
      "Micrognathism",
      "Dentofacial Deformities",
      "Congenital Abnormalities",
      "Craniofacial Abnormalities"
    ],
    "interventions": [
      "wafer-less approach",
      "Computer Guided orthognathic surgery using occlusal wafers"
    ],
    "primary_completion_date": "2022-09",
    "completion_date": "2023-03",
    "results_first_posted": null,
    "last_update_posted": "2021-12-09",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03459508",
    "title": "Ocular Findings in Women With Primary Antiphospholipid Syndrome",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Primary Antiphospholipid Syndrome"
    ],
    "interventions": [
      "Ophthalmological examination"
    ],
    "primary_completion_date": "2018-10-10",
    "completion_date": "2018-10-23",
    "results_first_posted": null,
    "last_update_posted": "2018-10-24",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05288933",
    "title": "Instrument-Assisted Soft Tissue Mobilization Versus High Power Pain Threshold Ultrasound For Trapezius Myofascial Trigger Points",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Myofascial Pain Syndrome of Neck"
    ],
    "interventions": [
      "Instrument assisted soft tissue mobilization ( IASTM ) and Ultrasound"
    ],
    "primary_completion_date": "2022-06-12",
    "completion_date": "2022-06-12",
    "results_first_posted": null,
    "last_update_posted": "2023-01-18",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05647421",
    "title": "A Comparative Study of Visual Outcome of Two Extended Depth of Focus Intraocular Lenses After Cataract Surgery",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Visual To Compare the Visual Outcome Between AcrySof\u2122 IQ Vivity\u2122 and TECNIS Synergy\u2122 Intraocular Lens (Model ZFR00V )"
    ],
    "interventions": [
      "IOL implantation",
      "IOL implantation"
    ],
    "primary_completion_date": "2023-03",
    "completion_date": "2023-05",
    "results_first_posted": null,
    "last_update_posted": "2022-12-13",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05494671",
    "title": "Studying Corneal Epithelial Stability Following Limbal Stem Cell Transplantation in Cases of Limbal Stem Cell Deficiency",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Stem Cell Transplantation"
    ],
    "interventions": [
      "conjunctival limbal autologous transplant"
    ],
    "primary_completion_date": "2023-01-10",
    "completion_date": "2023-11-01",
    "results_first_posted": null,
    "last_update_posted": "2023-08-30",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03094299",
    "title": "Diaphragm Ultrasound in Weaning From Mechanical Ventilation",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Abdominal Sepsis"
    ],
    "interventions": [],
    "primary_completion_date": "2018-03-21",
    "completion_date": "2018-03-23",
    "results_first_posted": null,
    "last_update_posted": "2018-03-27",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT07344415",
    "title": "Anxiety During Caries Removal Using Chemo-mechanical Versus Conventional Methods",
    "status": "NOT_YET_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Caries Active"
    ],
    "interventions": [
      "Cariemove",
      "Drilling using bur"
    ],
    "primary_completion_date": "2026-01-15",
    "completion_date": "2026-01-31",
    "results_first_posted": null,
    "last_update_posted": "2026-01-15",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03683914",
    "title": "Vaginal Dinoprostone Prior to Diagnostic Office Hysteroscopy in Postmenopausal Patients",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Office Hysteroscopy"
    ],
    "interventions": [
      "Dinoprostone 3Mg Vaginal Tablet",
      "placebo vaginal tablet"
    ],
    "primary_completion_date": "2019-01-30",
    "completion_date": "2019-02-28",
    "results_first_posted": null,
    "last_update_posted": "2019-03-26",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06359093",
    "title": "Prevalence Of Non-Carious Cervical Lesions, Associated Risk Indicators and Salivary Assessment Among Middle Adulthood Patients.",
    "status": "NOT_YET_RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Non-carious Cervical Lesions"
    ],
    "interventions": [],
    "primary_completion_date": "2025-09",
    "completion_date": "2026-09",
    "results_first_posted": null,
    "last_update_posted": "2024-08-22",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT02561793",
    "title": "DHEA Versus Placebo in Women With Poor Ovarian Response",
    "status": "UNKNOWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Subfertility"
    ],
    "interventions": [
      "DHEA",
      "Placebo"
    ],
    "primary_completion_date": "2017-09",
    "completion_date": "2017-09",
    "results_first_posted": null,
    "last_update_posted": "2016-07-06",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04682717",
    "title": "Perfusion Index as a Predictor of Postinduction Hypotension of General Anesthesia in Geriatric Patients",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Hypotension on Induction"
    ],
    "interventions": [
      "perfusion index monitoring for postinduction hypotension"
    ],
    "primary_completion_date": "2021-02-28",
    "completion_date": "2021-03-03",
    "results_first_posted": null,
    "last_update_posted": "2021-05-04",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05860283",
    "title": "Core Stability Exercise Versus Diaphragmatic Release on Respiratory Functions on Physical Therapists With Low Back Pain",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Mechanical Low Back Pain",
      "Respiratory Functions"
    ],
    "interventions": [
      "Core stabilization exercise using pressure biofeedback unit",
      "Diaphragmatic release technique"
    ],
    "primary_completion_date": "2024-06-01",
    "completion_date": "2024-08-01",
    "results_first_posted": null,
    "last_update_posted": "2023-07-13",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03264586",
    "title": "The Effect of Lidocaine - Prilocaine Cream (EMLA) Versus Mepivacaine Infiltration on Pain Relief During And After Mediolateral Episiotomies",
    "status": "UNKNOWN",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Episiotomy Pain"
    ],
    "interventions": [
      "Lidocaine-prilocaine cream",
      "mepivacaine infiltration group",
      "mediolateral episiotomy"
    ],
    "primary_completion_date": "2018-03",
    "completion_date": "2018-03",
    "results_first_posted": null,
    "last_update_posted": "2017-08-29",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03605186",
    "title": "Prevention of Oral Mucositis After Using Chamomile Oral Cryotherapy Versus Oral Cryotherapy in Pediatric Cancer Patients Receiving Chemotherapy.",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Oral Mucositis (Ulcerative) Due to Antineoplastic Therapy"
    ],
    "interventions": [
      "Chamomile oral cryotherapy",
      "Oral cryotherapy"
    ],
    "primary_completion_date": "2019-06",
    "completion_date": "2020-03",
    "results_first_posted": null,
    "last_update_posted": "2019-02-27",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05437354",
    "title": "Online Survey: Oncologists' Thoughts Regarding Their Patients",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Oncology"
    ],
    "interventions": [
      "survey"
    ],
    "primary_completion_date": "2022-10-01",
    "completion_date": "2022-10-01",
    "results_first_posted": null,
    "last_update_posted": "2022-10-04",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06356870",
    "title": "Alveolar Cleft Reconstruction Using Bone Marrow Aspirate Concentrate and Allograft vs Iliac Cancellous Bone.",
    "status": "NOT_YET_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alveolar Cleft Grafting"
    ],
    "interventions": [
      "BMAC MIXED WITH ALLOGRAFT",
      "Cancellous bone from anterior iliac crest"
    ],
    "primary_completion_date": "2025-06-01",
    "completion_date": "2026-06-01",
    "results_first_posted": null,
    "last_update_posted": "2024-04-10",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04778254",
    "title": "PEEK Versus Metallic Attachment-retained Obturators",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Maxillary Neoplasms"
    ],
    "interventions": [
      "PEEK attachment retained obturator",
      "metalic attachment retained obturator",
      "conventional obturator"
    ],
    "primary_completion_date": "2019-07-01",
    "completion_date": "2019-08-30",
    "results_first_posted": null,
    "last_update_posted": "2021-03-03",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06984003",
    "title": "Pulsed Electromagnetic Field Versus Active Stretching Exercises on Primary Dysmenorrhoea Randomized Controlled Study",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Primary Dysmenorrhea"
    ],
    "interventions": [
      "stretching exercises"
    ],
    "primary_completion_date": "2025-06-15",
    "completion_date": "2025-07-01",
    "results_first_posted": null,
    "last_update_posted": "2025-07-30",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03791554",
    "title": "Laterally Closed Tunnel VS Tunneling Technique in Recession Type 2",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Gingival Recession"
    ],
    "interventions": [
      "Group A (Lateral closed tunnel subepithelial CT graft)",
      "Group B (Tunnel procedure with subepithelial CT graft)"
    ],
    "primary_completion_date": "2021-03-16",
    "completion_date": "2021-09-01",
    "results_first_posted": null,
    "last_update_posted": "2023-12-06",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03186261",
    "title": "Antibacterial Effect of Nano Silver Fluoride vs Chlorhexidine on Occlusal Carious Molars Treated With Partial Caries Removal Technique",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dental Caries"
    ],
    "interventions": [
      "Nano silver fluoride solution",
      "Cavity Cleanser"
    ],
    "primary_completion_date": "2018-11-01",
    "completion_date": "2018-12-28",
    "results_first_posted": "2021-09-16",
    "last_update_posted": "2021-09-16",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03684356",
    "title": "Comparison of Peri-implant Tissues Using Socket Shield Technique Versus Xenograft",
    "status": "UNKNOWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Socket Shield"
    ],
    "interventions": [
      "socket shield technique",
      "xenograft"
    ],
    "primary_completion_date": "2020-12",
    "completion_date": "2020-12",
    "results_first_posted": null,
    "last_update_posted": "2020-02-18",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT07147582",
    "title": "Effect of Transcranial Alternating Current Stimulation on Sleep Disorder and Anxiety in Elderly Population",
    "status": "NOT_YET_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Sleep Disorders",
      "Anxiety Disorder"
    ],
    "interventions": [
      "Transcranial alternating current stimulation with two electrodes placed on scalp"
    ],
    "primary_completion_date": "2026-01",
    "completion_date": "2026-02",
    "results_first_posted": null,
    "last_update_posted": "2025-11-18",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04789525",
    "title": "Physical Training and Diet for Childhood Obesity",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Obesity, Childhood"
    ],
    "interventions": [
      "High-intensity aerobic training with high protein diet"
    ],
    "primary_completion_date": "2020-10-01",
    "completion_date": "2020-12-25",
    "results_first_posted": null,
    "last_update_posted": "2021-03-11",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05647460",
    "title": "Computer Guided Screw Holes Locating Guide and Custom-made Plates",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Mandibular Fractures"
    ],
    "interventions": [
      "computer guided screw holes locating guide and custom-made plates",
      "conventional plates"
    ],
    "primary_completion_date": "2023-09-30",
    "completion_date": "2023-12-30",
    "results_first_posted": null,
    "last_update_posted": "2022-12-12",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06790524",
    "title": "Comparative Evaluation Between One-piece and Two-piece Implants Supporting Mandibular Screw-retained All-On-Four Full-arch Prosthesis on Peri-implant Bone Changes.",
    "status": "NOT_YET_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Marginal Bone Loss",
      "One-piece Implants Versus Two-piece Implants During the Osseointegration Phase"
    ],
    "interventions": [
      "One-piece dental implants with MUA",
      "Two-piece dental implants"
    ],
    "primary_completion_date": "2025-03",
    "completion_date": "2025-10",
    "results_first_posted": null,
    "last_update_posted": "2025-03-07",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT02433418",
    "title": "Tubal Flushing Using Water Soluble Media for Unexplained Infertility",
    "status": "UNKNOWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Infertility"
    ],
    "interventions": [
      "Tubal flushing by Urografin\u00ae",
      "Diclofenac"
    ],
    "primary_completion_date": "2017-12",
    "completion_date": "2017-12",
    "results_first_posted": null,
    "last_update_posted": "2017-01-23",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05624008",
    "title": "Clinical Performance of Bioceramic vs High Viscosity GIC for Cervical Restorations of Geriatric Patients",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cervical Caries"
    ],
    "interventions": [
      "Bioceramic glass ionomer restoration",
      "Resin modified glass ionomer restoration"
    ],
    "primary_completion_date": "2023-12",
    "completion_date": "2024-02",
    "results_first_posted": null,
    "last_update_posted": "2022-11-21",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06342791",
    "title": "Effect of Laser Acupuncture on Menstrual Back Pain",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Laser Acupuncture",
      "Low Back Pain",
      "Menstruation"
    ],
    "interventions": [
      "laser acupuncture"
    ],
    "primary_completion_date": "2024-05-20",
    "completion_date": "2024-06-20",
    "results_first_posted": null,
    "last_update_posted": "2024-04-02",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT02736058",
    "title": "Surgical Classification of Abnormal Placentation",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Adherent Placenta"
    ],
    "interventions": [
      "Trans- abdominal sonography",
      "Trans-vaginal sonography",
      "post-operative pathological specimen examination"
    ],
    "primary_completion_date": "2016-12",
    "completion_date": "2016-12",
    "results_first_posted": null,
    "last_update_posted": "2016-06-01",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04793308",
    "title": "Radicular Dentin Remaining, Risk of Perforation and Canal Transportation in Manual Versus Rotary Instrumentation in Primary Molars",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Root Canal Infection"
    ],
    "interventions": [
      "Endodontic files"
    ],
    "primary_completion_date": "2021-03-01",
    "completion_date": "2021-03-01",
    "results_first_posted": null,
    "last_update_posted": "2021-03-11",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04592510",
    "title": "Impact of COVID-19 on Pediatric Dental Practice During First, Second And Third Wave.",
    "status": "UNKNOWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "SARS-CoV2"
    ],
    "interventions": [],
    "primary_completion_date": "2021-10",
    "completion_date": "2022-01",
    "results_first_posted": null,
    "last_update_posted": "2021-06-16",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04938050",
    "title": "Diagnostic Accuracy of a Specialized Pro Forma in Assessing Morbidly Adherent Placenta With Correlation to Intra-operative Findings",
    "status": "UNKNOWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Morbidly Adherent Placenta"
    ],
    "interventions": [
      "Ultrasound"
    ],
    "primary_completion_date": "2023-01-30",
    "completion_date": "2023-02-28",
    "results_first_posted": null,
    "last_update_posted": "2022-12-08",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03640091",
    "title": "Pre-extractive Inter-radicular Implant Bed Preparation Versus Conventional Post-extractive Inter-radicular Implant Bed Preparation in Mandibular Molars",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Randomized Clinical Trial"
    ],
    "interventions": [
      "Post-extractive inter-radicular implant bed preparation"
    ],
    "primary_completion_date": "2019-11-01",
    "completion_date": "2019-12-01",
    "results_first_posted": null,
    "last_update_posted": "2019-02-05",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04787224",
    "title": "Vestibular Socket Therapy (VST) in Infected and Non Infected Sockets",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Implant Site Infection"
    ],
    "interventions": [
      "immediate implant with vestibular socket therapy"
    ],
    "primary_completion_date": "2020-11-15",
    "completion_date": "2021-01-30",
    "results_first_posted": null,
    "last_update_posted": "2021-03-10",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03285360",
    "title": "Effectiveness of Bioactiveglass Air Abrasion Versus Fluoride Varnish in Management of Dentin Hypersensitivity",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypersensitivity Dentin",
      "Tooth Hypersensitivity"
    ],
    "interventions": [
      "Sylc",
      "fluoride varnish (Bifluorid 10)"
    ],
    "primary_completion_date": "2018-12-01",
    "completion_date": "2019-01-01",
    "results_first_posted": null,
    "last_update_posted": "2019-01-31",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06591143",
    "title": "Evaluation Of Periodontal Health After Treatment With Hall Technique Versus Atraumatic Restorative Treatment in The Management of Carious Primary Molars",
    "status": "NOT_YET_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Decayed Primary Molars"
    ],
    "interventions": [
      "ART",
      "Hall technique"
    ],
    "primary_completion_date": "2025-09-01",
    "completion_date": "2025-12-01",
    "results_first_posted": null,
    "last_update_posted": "2024-09-19",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT07308197",
    "title": "Effect of Posterior Colpotomy First Technique on the Vaginal Length During Total Abdominal Hysterectomy",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hysterectomy, Benign Uterine Diseases"
    ],
    "interventions": [
      "Abdominal hysterectomy"
    ],
    "primary_completion_date": "2024-03-25",
    "completion_date": "2024-09-16",
    "results_first_posted": null,
    "last_update_posted": "2025-12-29",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03413774",
    "title": "Unexplained Early Miscarriage : Role and Prevalence of Lower Genital Tract Infections",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "First Trimester Abortion"
    ],
    "interventions": [
      "vaginal swab"
    ],
    "primary_completion_date": "2017-12-20",
    "completion_date": "2018-01-15",
    "results_first_posted": null,
    "last_update_posted": "2018-01-29",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT02861313",
    "title": "Oral Health Related Quality of Life and Peri-implant Condition in Single Implant Overdenture",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Quality of Life",
      "Implant"
    ],
    "interventions": [
      "CM LOC attachment",
      "ball attachment"
    ],
    "primary_completion_date": "2017-10",
    "completion_date": "2018-04",
    "results_first_posted": null,
    "last_update_posted": "2019-09-04",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03587597",
    "title": "Socket Shield vs Conventional Immediate Implant",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Preservation of the Labial Bone"
    ],
    "interventions": [
      "socket shield technique",
      "conventional immediate implant placement with immediate temporization"
    ],
    "primary_completion_date": "2019-11",
    "completion_date": "2019-12",
    "results_first_posted": null,
    "last_update_posted": "2019-02-06",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03784560",
    "title": "Effects of Partial Sleep Deprivation on Cognitive Function of Anesthesiologists",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Cognitive Dysfunction",
      "Sleep Deprivation"
    ],
    "interventions": [
      "The Psychomotor Vigilance Task (PVT)",
      "Epworth Sleepiness Scale",
      "Karolinska sleeping scale",
      "Trail making test"
    ],
    "primary_completion_date": "2019-05-28",
    "completion_date": "2019-06-28",
    "results_first_posted": null,
    "last_update_posted": "2019-12-03",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06302946",
    "title": "Effect of Neuromuscular Stimulation and Mindfulness Breathing in Patients With Stroke",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Stroke"
    ],
    "interventions": [
      "neuromuscular stimulation and mindfulness breathing",
      "neuromuscular electrical stimulation"
    ],
    "primary_completion_date": "2025-05-30",
    "completion_date": "2025-12-30",
    "results_first_posted": null,
    "last_update_posted": "2025-02-20",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03682562",
    "title": "Diagnostic Accuracy of Salivary DNA Integrity Index in Oral Malignant and Premalignant Lesions",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Oral Cancer",
      "Oral Lichen Planus",
      "Oral Leukoplakia"
    ],
    "interventions": [
      "DNA Integrity Index"
    ],
    "primary_completion_date": "2020-03-10",
    "completion_date": "2020-03-10",
    "results_first_posted": null,
    "last_update_posted": "2020-07-15",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT07249866",
    "title": "Effect of Robotic Assisted Therapy on Hand Functions, Grip Strength and Proprioception in Children With Hemiplegia",
    "status": "NOT_YET_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cerebral Palsy, Spastic"
    ],
    "interventions": [
      "Hand rehabilitation robotic gloves",
      "occupational therapy"
    ],
    "primary_completion_date": "2026-01",
    "completion_date": "2026-02",
    "results_first_posted": null,
    "last_update_posted": "2025-11-25",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03241602",
    "title": "Multimodal Analgesic Technique for Control of Post-laproscopy Abdominal Pain",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Decrease Post Laproscopy Shoulder and Abdominal Pain"
    ],
    "interventions": [
      "Intraperitoneal lidocaine",
      "Pulmonary Recruitment",
      "Combined intraperitoneal lidocaine and pulmonary recruitment maneuver"
    ],
    "primary_completion_date": "2017-10-28",
    "completion_date": "2017-10-30",
    "results_first_posted": null,
    "last_update_posted": "2018-01-25",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05777239",
    "title": "Dental Implant Approach for Crestal Sinus Elevation; A Novel Technique.",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Maxillary Sinus",
      "Dental Implant",
      "Maxillary Sinus Lift",
      "Maxillary Sinus Elevation"
    ],
    "interventions": [
      "Dental Implant Approach for Crestal Sinus Elevation"
    ],
    "primary_completion_date": "2022-11-15",
    "completion_date": "2023-02-15",
    "results_first_posted": null,
    "last_update_posted": "2023-03-21",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04805281",
    "title": "Wear Behavior of Milled Posterior Crowns Fabricated From the New Monolithic Zirconia 5Y-TZP/3Y-TZP Compared to Lithium Disilicate",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Posterior Teeth",
      "Worn Posterior Teeth",
      "Endodontically Treated Teeth",
      "Crowned Posterior Teeth"
    ],
    "interventions": [
      "monolithic zirconia (5Y-TZP/3-YTZ) ZirCAD Prime.",
      "Lithium Dislicate IPS e.max crown"
    ],
    "primary_completion_date": "2022-03-01",
    "completion_date": "2022-06-01",
    "results_first_posted": null,
    "last_update_posted": "2021-06-10",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06637111",
    "title": "Ultrasound Guidance of Office Hysteroscopy in Patients With History of Failure of Office Hysteroscopy Due to Cervical Stenosis.",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hysteroscopy"
    ],
    "interventions": [
      "Ultrasound guided office hysteroscopy group",
      "Conventional office hysteroscopy group"
    ],
    "primary_completion_date": "2025-04-30",
    "completion_date": "2025-04-30",
    "results_first_posted": null,
    "last_update_posted": "2025-04-30",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05895422",
    "title": "Functional Outcome After Minimally Invasive Pyeloplasty for Adult Patients With UPJO",
    "status": "UNKNOWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ureteropelvic Junction Obstruction"
    ],
    "interventions": [
      "pyeloplasty"
    ],
    "primary_completion_date": "2025-06-01",
    "completion_date": "2025-07-01",
    "results_first_posted": null,
    "last_update_posted": "2023-06-09",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06129695",
    "title": "Computer Guided Placement of Zygomatic Implants in Two Different Approaches",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atrophic Maxilla",
      "Zygomatic Implants"
    ],
    "interventions": [
      "Zygomatic implants"
    ],
    "primary_completion_date": "2024-09-30",
    "completion_date": "2024-11-01",
    "results_first_posted": null,
    "last_update_posted": "2024-02-08",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06851728",
    "title": "Immediate Skeletal and Dento-alveolar Effects of Two and Four Mini-screw Supported Hyrax for Maxillary Expansion in Non-growing Patients",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Transverse Maxillary Deficiency",
      "Posterior Crossbite, Upper Airway"
    ],
    "interventions": [
      "MARPE"
    ],
    "primary_completion_date": "2023-08-02",
    "completion_date": "2024-12-04",
    "results_first_posted": null,
    "last_update_posted": "2025-02-28",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06000800",
    "title": "Timing of Umbilical Cord Clamping in Preterm Neonates",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cord Clamping"
    ],
    "interventions": [
      "Group B",
      "Group C",
      "Group D",
      "Group A"
    ],
    "primary_completion_date": "2022-11-21",
    "completion_date": "2022-12-21",
    "results_first_posted": null,
    "last_update_posted": "2023-08-21",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT07083128",
    "title": "Temporal Change in Parasternal Thickening Fraction as a Predictor for Weaning",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Mechanical Ventilation",
      "Weaning From Mechanical Ventilation",
      "Weaning Failure"
    ],
    "interventions": [
      "Parasternal intercostal thickening"
    ],
    "primary_completion_date": "2026-03-01",
    "completion_date": "2026-03-05",
    "results_first_posted": null,
    "last_update_posted": "2025-12-18",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04629456",
    "title": "Physical Therapy for Liver Cirrhosis",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Liver Cirrhosis, Biliary"
    ],
    "interventions": [
      "neuromuscular electric stimulation",
      "Exercises"
    ],
    "primary_completion_date": "2020-05-12",
    "completion_date": "2020-06-05",
    "results_first_posted": null,
    "last_update_posted": "2020-11-16",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04800445",
    "title": "Salivary C- Reactive Protein, Mean Platelet Volume and Neutrophil Lymphocyte Ratio as Diagnostic Markers for Neonatal Sepsis",
    "status": "UNKNOWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Neonatal Sepsis"
    ],
    "interventions": [
      "Salivary CRP"
    ],
    "primary_completion_date": "2020-12-04",
    "completion_date": "2022-01-10",
    "results_first_posted": null,
    "last_update_posted": "2021-08-09",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT07008157",
    "title": "Rehabilitation Program for Bladder Control in Individuals With Incomplete Spinal Cord Injury",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Spinal Cord Injury"
    ],
    "interventions": [
      "1. IFC",
      "2. Timed voiding.",
      "motor imagery training",
      "pelvic floor muscles training"
    ],
    "primary_completion_date": "2025-04-16",
    "completion_date": "2025-04-16",
    "results_first_posted": null,
    "last_update_posted": "2025-06-06",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03335007",
    "title": "Pretreatment Aceclofenac Effect on Pain and Analgesic Intake After Endodontic Treatment",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Symptomatic Irreversible Pulpitis"
    ],
    "interventions": [
      "Aceclofenac",
      "Placebo"
    ],
    "primary_completion_date": "2017-07",
    "completion_date": "2017-07",
    "results_first_posted": null,
    "last_update_posted": "2017-11-07",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03779763",
    "title": "Prevalence Of Periodontitis Stage III & IV",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Periodontitis"
    ],
    "interventions": [],
    "primary_completion_date": "2019-06-15",
    "completion_date": "2019-09-15",
    "results_first_posted": null,
    "last_update_posted": "2020-07-15",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06612021",
    "title": "Hema Free Versus Hema Containing Adhesives in Posterior Restorations",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dental Caries"
    ],
    "interventions": [
      "Beautibond universal adhesive",
      "Tetric N universal bond"
    ],
    "primary_completion_date": "2024-10-14",
    "completion_date": "2024-11-01",
    "results_first_posted": null,
    "last_update_posted": "2024-09-25",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05861921",
    "title": "Single-retainer Lithium Di-silicate Versus Zirconia Resin Bonded Bridge for Replacement of an Anterior Missing Tooth.",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Missing Teeth"
    ],
    "interventions": [
      "Single-retainer Lithium Di-silicate Resin Bonded Fixed Partial Denture"
    ],
    "primary_completion_date": "2024-06-30",
    "completion_date": "2024-10-30",
    "results_first_posted": null,
    "last_update_posted": "2025-03-10",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05083975",
    "title": "Buzzy System Compared to Topical Anaesthesia During Infiltration Injection in Children.",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Local Anaesthesia"
    ],
    "interventions": [
      "Buzzy System",
      "Topical anesthetic",
      "1.8 ml of 4% articaine hydrochloride with epinephrine 1:100,000"
    ],
    "primary_completion_date": "2022-12-22",
    "completion_date": "2023-05-06",
    "results_first_posted": null,
    "last_update_posted": "2024-03-21",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT07267312",
    "title": "Premature Coronary Artery Disease and Familial Dyslipidemia in Patients Presenting With Acute Coronary Syndrome",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Premature",
      "Coronary Artery Disease",
      "Familial Dyslipidemia",
      "Acute Coronary Syndrome"
    ],
    "interventions": [
      "Cardiovascular risk assessment"
    ],
    "primary_completion_date": "2025-03-27",
    "completion_date": "2025-03-27",
    "results_first_posted": null,
    "last_update_posted": "2025-12-05",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06010381",
    "title": "Muscle Energy Technique Versus Maitland Mobilization on Shoulder Pain and Disability",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Neck Cancer",
      "Mobility Limitation",
      "Pain Syndrome",
      "Shoulder Pain",
      "Surgery"
    ],
    "interventions": [
      "Muscle energy technique",
      "Maitland mobilization",
      "Traditional shoulder exercise"
    ],
    "primary_completion_date": "2023-08-30",
    "completion_date": "2023-09-13",
    "results_first_posted": null,
    "last_update_posted": "2024-04-17",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04518371",
    "title": "Clinical Performance of Milled Resin Composite in Restoration of Endodontically Treated Posterior Teeth Over One Year",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Endodontically Treated Teeth"
    ],
    "interventions": [
      "Reinforced composite for the fabrication of permanent, indirect restorations using a CAD/CAM grinding process."
    ],
    "primary_completion_date": "2022-04-18",
    "completion_date": "2023-04-28",
    "results_first_posted": null,
    "last_update_posted": "2023-08-23",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06224881",
    "title": "Vitamin C Deficiency in Septic Shock",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Septic Shock"
    ],
    "interventions": [
      "Ascorbic acid"
    ],
    "primary_completion_date": "2023-01-31",
    "completion_date": "2023-01-31",
    "results_first_posted": null,
    "last_update_posted": "2024-01-25",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05957965",
    "title": "The Effect of Wii Fit Rehabilitation in Patients With Chronic Ankle Instability a Randomized Control Study",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Instability, Joint"
    ],
    "interventions": [
      "Wii fit",
      "Strengthening, proprioceptive exercises."
    ],
    "primary_completion_date": "2024-11",
    "completion_date": "2024-11",
    "results_first_posted": null,
    "last_update_posted": "2024-01-23",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04442763",
    "title": "The Effect of Osseodensification on Implant Stability in Posterior Maxilla",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Implant Stability"
    ],
    "interventions": [
      "Densah Burs",
      "Standard drills"
    ],
    "primary_completion_date": "2022-12-10",
    "completion_date": "2023-12-20",
    "results_first_posted": null,
    "last_update_posted": "2025-01-03",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06325501",
    "title": "Misoprostol Versus Oxytocin Infusion On Reducing Blood Loss During Abdominal Myomectomy",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Myoma;Uterus"
    ],
    "interventions": [
      "Misoprostol 200mcg Tab",
      "Oxytocin"
    ],
    "primary_completion_date": "2024-12-01",
    "completion_date": "2025-01-01",
    "results_first_posted": null,
    "last_update_posted": "2024-03-22",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06497244",
    "title": "Evaluation of the Effect of Micro-osteoperforation on the Rate of Bone Anchored Molar Distalization",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Microosteoperforations"
    ],
    "interventions": [
      "micro osteo-perforation"
    ],
    "primary_completion_date": "2024-10-10",
    "completion_date": "2024-12-30",
    "results_first_posted": null,
    "last_update_posted": "2024-07-12",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT07125599",
    "title": "The Association Between Different Markers With Development of Maternal and Neonatal Complications in Women With Severe Preeclampsia",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Severe Preeclampsia"
    ],
    "interventions": [],
    "primary_completion_date": "2025-04-30",
    "completion_date": "2025-05-20",
    "results_first_posted": null,
    "last_update_posted": "2025-08-27",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03597906",
    "title": "Topography Guided LASIK by Different Protocols for Treatment of Astigmatism",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Refractive Surgery"
    ],
    "interventions": [
      "topography guided ablation",
      "manifest refraction",
      "full topography modified refraction",
      "partial topography modified refraction"
    ],
    "primary_completion_date": "2019-11-15",
    "completion_date": "2020-01-20",
    "results_first_posted": null,
    "last_update_posted": "2020-01-28",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT02455635",
    "title": "Lower Abdominal Pain During Office Hysteroscopy Can Assess Tubal Patency in Infertile Women",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Infertility"
    ],
    "interventions": [
      "office hystroscopy"
    ],
    "primary_completion_date": "2016-09",
    "completion_date": "2016-09",
    "results_first_posted": null,
    "last_update_posted": "2017-03-21",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03182114",
    "title": "Supine Versus Left Lateral Tilted Position During Cesarean Delivery",
    "status": "UNKNOWN",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cesarean Section Complications"
    ],
    "interventions": [
      "supine position",
      "left lateral tilted position",
      "Bupivacaine"
    ],
    "primary_completion_date": "2019-01-15",
    "completion_date": "2019-01-20",
    "results_first_posted": null,
    "last_update_posted": "2018-07-09",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT07268677",
    "title": "A Single-arm Clinical Study Evaluating Pirfenidone and Sintilimab in Combination With Standard Neoadjuvant Chemotherapy for Colorectal Cancer Patients With Peritoneal Metastasis.",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Colorectal Cancer"
    ],
    "interventions": [
      "pirfenidone plus sintilimab combined with standard neoadjuvant chemotherapy"
    ],
    "primary_completion_date": "2026-12-01",
    "completion_date": "2027-02-01",
    "results_first_posted": null,
    "last_update_posted": "2025-12-08",
    "enrollment": null,
    "sponsor": "Guoxiang Cai",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05141071",
    "title": "Effect of Ivabradine on Microcirculation and Cardiac Output in Septic Shock Patients",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Septic Shock"
    ],
    "interventions": [
      "Ivabradine 5mg Tab",
      "Placebo"
    ],
    "primary_completion_date": "2022-05-25",
    "completion_date": "2022-06-05",
    "results_first_posted": null,
    "last_update_posted": "2022-09-01",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03716232",
    "title": "Kaffes Stent in the Management of Post-surgical Biliary Strictures",
    "status": "UNKNOWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Benign Biliary Stricture",
      "Biliary Stricture",
      "Cholangitis",
      "Bile Duct Stricture",
      "Bile Duct Injury"
    ],
    "interventions": [
      "Metallic stent",
      "Multiple plastic stents"
    ],
    "primary_completion_date": "2020-07-31",
    "completion_date": "2020-12-31",
    "results_first_posted": null,
    "last_update_posted": "2020-03-17",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04020952",
    "title": "Effect of Archwire Gauge on the Rate of Canine Retraction",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Canine Retraction"
    ],
    "interventions": [
      "st.st 0.019\u00d70.025\" wire",
      "st.st 0.016\u00d70.022\" wire",
      "st.st 0.017\u00d70.025\" wire"
    ],
    "primary_completion_date": "2020-09-20",
    "completion_date": "2021-07-15",
    "results_first_posted": null,
    "last_update_posted": "2022-07-22",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05837416",
    "title": "Effect of Oxidant Gel and Anti-oxidant Gel on Wound Healing After Gingival Depigmentation",
    "status": "UNKNOWN",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Gingival Pigmentation"
    ],
    "interventions": [
      "blue\u00aem Gel",
      "NBF GINGIVAL GEL\u00ae",
      "COE-PAK\u2122"
    ],
    "primary_completion_date": "2024-02",
    "completion_date": "2024-05",
    "results_first_posted": null,
    "last_update_posted": "2023-05-01",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04426604",
    "title": "Validity of Fluorescence-Based Devices Versus Visual-Tactile Method in Detection of Secondary Caries Around Resin Composite Restorations: Invivo Diagnostic Accuracy Study",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Secondary Caries Around Resin Composite Restorations"
    ],
    "interventions": [
      "Light induced fluorescence intraoral camera",
      "Laser-induced fluorescence device",
      "Visual-tactile assessment method according to FDI criteria"
    ],
    "primary_completion_date": "2021-09",
    "completion_date": "2021-09",
    "results_first_posted": null,
    "last_update_posted": "2021-08-06",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03944811",
    "title": "Bone Height Gain Following Transcrestal Sinus Floor Elevation Using Piezoelectric Surgery Versus The Conventional Osteotome Technique",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alveolar Bone Loss"
    ],
    "interventions": [
      "piezoelectric device",
      "Summers technique"
    ],
    "primary_completion_date": "2021-01-22",
    "completion_date": "2021-04-01",
    "results_first_posted": null,
    "last_update_posted": "2021-11-05",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03608332",
    "title": "Diaphragmatic Ultrasound as a Guide Tool During Weaning From Mechanical Ventilation",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diaphragmatic Ultrasound in Weaning"
    ],
    "interventions": [
      "diaphragmatic ultrasound"
    ],
    "primary_completion_date": "2019-09-29",
    "completion_date": "2019-09-29",
    "results_first_posted": null,
    "last_update_posted": "2019-10-01",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04680663",
    "title": "Predictor of Postoperative Complications After Lengthy Noncardiac Surgery",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Peripheral Perfusion Index"
    ],
    "interventions": [
      "Peripheral Perfusion index",
      "serum lactate level"
    ],
    "primary_completion_date": "2024-05-12",
    "completion_date": "2024-06-10",
    "results_first_posted": null,
    "last_update_posted": "2025-01-22",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06715033",
    "title": "Relationship Between Ankle Planterflexors Peak Torque and Balance in Patients With Functional Ankle Instability",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Functional Ankle Instability"
    ],
    "interventions": [
      "y balance and SLS"
    ],
    "primary_completion_date": "2024-06-22",
    "completion_date": "2024-10-10",
    "results_first_posted": null,
    "last_update_posted": "2025-06-10",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06637085",
    "title": "Acu Tens Versus Low Level Laser After Open Heart Surgeries",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Heart Arrhythmia"
    ],
    "interventions": [
      "LLLT",
      "traditional physical therapy",
      "ACU TENSE"
    ],
    "primary_completion_date": "2023-11-05",
    "completion_date": "2024-02-03",
    "results_first_posted": null,
    "last_update_posted": "2024-10-15",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05419921",
    "title": "Comparison of the Diagnostic Accuracy of Hysterosalpingo-lidocaine-foam Sonography Versus Hysterosalpingography in Tubal Patency Assessment to the Gold Standard of Laparoscopy and Dye Testing",
    "status": "TERMINATED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Tubal Factor Infertility"
    ],
    "interventions": [
      "Hysterosalpingo-lidocaine-foam-sonography combined with power doppler (HyLiFoSy-PD)"
    ],
    "primary_completion_date": "2023-10-31",
    "completion_date": "2023-10-31",
    "results_first_posted": null,
    "last_update_posted": "2024-12-06",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04982809",
    "title": "Cost-effectiveness Analysis of Three Corticosteroids in ILDs",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Interstitial Lung Disease"
    ],
    "interventions": [
      "Betamethasone, Dexamethasone, Prednisolone"
    ],
    "primary_completion_date": "2020-03-15",
    "completion_date": "2020-03-15",
    "results_first_posted": null,
    "last_update_posted": "2021-07-29",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06570187",
    "title": "The Effect of Dexmedetomidine on the Renal Functions in Septic Critically Ill Patients",
    "status": "RECRUITING",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Sepsis",
      "Septic Shock",
      "Acute Kidney Injury"
    ],
    "interventions": [
      "Dexmedetomidine",
      "Propofol"
    ],
    "primary_completion_date": "2026-10",
    "completion_date": "2026-10",
    "results_first_posted": null,
    "last_update_posted": "2024-10-09",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03279016",
    "title": "Arthroscopic Guided Synovial Biopsies",
    "status": "UNKNOWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Temporomandibular Arthritis"
    ],
    "interventions": [],
    "primary_completion_date": "2019-12",
    "completion_date": "2019-12",
    "results_first_posted": null,
    "last_update_posted": "2018-02-06",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT02190006",
    "title": "Comparison Between the Role of Follicular Output Rate and Preovulatory Count in the Prediction of Pregnancy in Women With Polycystic Ovarian Syndrome Undergoing Intra Cytoplasmic Sperm Injection (ICSI)",
    "status": "UNKNOWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Polycystic Ovarian Syndrome",
      "Subfertility",
      "ICSI"
    ],
    "interventions": [],
    "primary_completion_date": "2017-12",
    "completion_date": "2017-12",
    "results_first_posted": null,
    "last_update_posted": "2017-01-23",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT01544426",
    "title": "Office Hysteroscopy and Endometrial Snip Improve Intrauterine Insemination Outcome",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Infertility"
    ],
    "interventions": [
      "Office hysteroscopy and endometrial snip",
      "Office hysteroscopy"
    ],
    "primary_completion_date": "2014-09",
    "completion_date": "2014-10",
    "results_first_posted": null,
    "last_update_posted": "2014-12-30",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05190692",
    "title": "Role of Simulators in Improving Obstetric Vaginal Examination Skills",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Labour"
    ],
    "interventions": [
      "Use simulators in Obstetrics vaginal examination"
    ],
    "primary_completion_date": "2022-07-10",
    "completion_date": "2022-07-10",
    "results_first_posted": null,
    "last_update_posted": "2022-08-02",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05274711",
    "title": "The Effect of Whole Body Vibration on Neck Disability and Proprioception in Patients With Forward Head Posture",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Forward Head Posture"
    ],
    "interventions": [
      "Whole body vibration training",
      "Conventional physical treatment"
    ],
    "primary_completion_date": "2023-02-01",
    "completion_date": "2023-02-28",
    "results_first_posted": null,
    "last_update_posted": "2023-05-26",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04081571",
    "title": "Prevalence of NAFLD and Correlation With Its Main Risk Factors Among Egyptian",
    "status": "UNKNOWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "NAFLD",
      "Insulin Resistance",
      "Hepatic Steatosis"
    ],
    "interventions": [],
    "primary_completion_date": "2023-10",
    "completion_date": "2023-10",
    "results_first_posted": null,
    "last_update_posted": "2022-03-10",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06260644",
    "title": "Evaluation of Using Self-adhering Flowable Resin Composite in Repairing Old Defective Resin Composite Restorations Over 18 Months Follow up. (A Randomized Clinical Trial)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Occlusal Caries"
    ],
    "interventions": [
      "VertiseTM flowable composite (Kerr,USA)"
    ],
    "primary_completion_date": "2025-09",
    "completion_date": "2025-10",
    "results_first_posted": null,
    "last_update_posted": "2024-02-15",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT02827487",
    "title": "Tramadol Versus Celecoxib in Reducing Pain Associated With IUD Insertion",
    "status": "UNKNOWN",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pain"
    ],
    "interventions": [
      "Tramadol",
      "Celecoxib",
      "Placebo 1",
      "Placebo 2",
      "IUD"
    ],
    "primary_completion_date": "2020-07-01",
    "completion_date": "2020-07-01",
    "results_first_posted": null,
    "last_update_posted": "2019-04-08",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05285293",
    "title": "Periodontal Regeneration Using Vitamin A and PRF Compared to PRF Alone Treating Intra-bony Defects",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Intrabony Periodontal Defect"
    ],
    "interventions": [
      "Platelet Rich Fibrin (PRF)",
      "Platelet Rich Fibrin (PRF) and Retinol"
    ],
    "primary_completion_date": "2022-12-01",
    "completion_date": "2023-12-01",
    "results_first_posted": null,
    "last_update_posted": "2022-03-17",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT02306733",
    "title": "Ergometrine Versus Oxytocin in the Management of Atonic Post-partum Haemorrhage (PPH) in Women Delivered Vaginally",
    "status": "UNKNOWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Post Partum Hemorrhage"
    ],
    "interventions": [
      "Ergometrine",
      "Oxytocin"
    ],
    "primary_completion_date": "2017-10",
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2017-01-23",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT02856932",
    "title": "Clinical Evaluation of Glass Ionomer With Glass Hybrid Technology Versus Conventional High Viscosity Glass Ionomer in Class I Cavities of High Caries Risk Patients",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Class I Cavities in High Caries Risk"
    ],
    "interventions": [
      "Conventional high viscosity glass ionomer",
      "Glass ionomer with glass hybrid technology"
    ],
    "primary_completion_date": "2018-09",
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2016-08-05",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03412487",
    "title": "Ovarian Histopathology and Laparoscopic Assessment of Premature Ovarian Failure",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Premature Ovarian Failure"
    ],
    "interventions": [
      "laparoscopy"
    ],
    "primary_completion_date": "2018-12",
    "completion_date": "2019-01",
    "results_first_posted": null,
    "last_update_posted": "2018-01-26",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT07352293",
    "title": "The Value of Methotrexate in NCES for Stable Vitiligo",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Vitiligo"
    ],
    "interventions": [
      "Non cultured epidermal suspension"
    ],
    "primary_completion_date": "2026-09",
    "completion_date": "2026-09",
    "results_first_posted": null,
    "last_update_posted": "2026-01-20",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04380584",
    "title": "Relation Between Plasma Apelin Level and Diabetic Nephropathy in Type 2 Diabetes Patients.",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Diabetic Nephropathies"
    ],
    "interventions": [
      "plasma Apelin level"
    ],
    "primary_completion_date": "2020-03-20",
    "completion_date": "2020-03-29",
    "results_first_posted": null,
    "last_update_posted": "2020-05-11",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06773247",
    "title": "Effectiveness of Myofascial Release Versus Dry Cupping in Management of Non-Specific Low Back Pain",
    "status": "NOT_YET_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-specific Low Back Pain"
    ],
    "interventions": [
      "I. Myofascial Release Technique ,Cupping Technique and II. Conventional Physical Therapy"
    ],
    "primary_completion_date": "2025-03-03",
    "completion_date": "2025-04-03",
    "results_first_posted": null,
    "last_update_posted": "2025-01-14",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT00756587",
    "title": "Cup Versus Bottle Feeding for Late Preterm Infants",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breastfeeding"
    ],
    "interventions": [
      "Cup Feeding",
      "Bottle Feeding"
    ],
    "primary_completion_date": "2004-08",
    "completion_date": "2004-08",
    "results_first_posted": null,
    "last_update_posted": "2008-10-31",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05078606",
    "title": "Ultrasonographic Assessment of Neck Vessels as Predictors of Spinal Anesthesia Induced Hypotension in Elderly",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Post-spinal Hypotension"
    ],
    "interventions": [
      "IJV Ultrasonography",
      "Carotid Intima Media Thickness",
      "Spinal anesthesia"
    ],
    "primary_completion_date": "2021-11-10",
    "completion_date": "2022-01-21",
    "results_first_posted": null,
    "last_update_posted": "2022-02-21",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05928533",
    "title": "Performance Of Cervical Restorations Using Nitric Acid and Mineral Enriched Adhesive Versus Phosphoric Acid and Universal Adhesive",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Clinical Performance"
    ],
    "interventions": [
      "clean and boost enamel cleanser of vista apex , RE GEN universal adhesive from vista apex , RE GEN Bio active flowable composite form vista apex"
    ],
    "primary_completion_date": "2024-06-01",
    "completion_date": "2025-01-01",
    "results_first_posted": null,
    "last_update_posted": "2025-05-04",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04782310",
    "title": "Duloxetine vs Pregabalin for Thoracotomy Pain",
    "status": "UNKNOWN",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Postoperative Pain"
    ],
    "interventions": [
      "Pregabalin",
      "Duloxetine"
    ],
    "primary_completion_date": "2021-08-10",
    "completion_date": "2021-09-15",
    "results_first_posted": null,
    "last_update_posted": "2021-06-02",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03686020",
    "title": "Sensitivity and Specificity of Serum and Salivary CYFRA21-1 in the Detection of Malignant Transformation in Oral Potentially Malignant Mucosal Lesions (Diagnostic Accuracy Study)",
    "status": "UNKNOWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Oral Potentially Malignant Lesions",
      "Oral Cancer"
    ],
    "interventions": [
      "Enzyme Linked Immunosorbent assay (ELISA)"
    ],
    "primary_completion_date": "2019-10",
    "completion_date": "2019-12",
    "results_first_posted": null,
    "last_update_posted": "2019-07-23",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03370952",
    "title": "Laparoscopy-assisted Ovarian Cystectomy: NEW APPROCH",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ovarian Cysts"
    ],
    "interventions": [
      "laproscopy",
      "combined laproscopic and minilaparotomy ovarian cystectomy"
    ],
    "primary_completion_date": "2019-07-05",
    "completion_date": "2019-08-03",
    "results_first_posted": null,
    "last_update_posted": "2022-01-11",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05625243",
    "title": "Evaluation of the Proximal Contact Quality in Posterior Complex Carious Cavities Restored With Bulk Fill Ormocer and Resin Composite Using a Precontoured Circumferential Matrix System Versus Pre Contoured Sectional Matrix System",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Posterior Complex Carious Proximal Cavities"
    ],
    "interventions": [
      "Bulk-fill ormocer (Admira fusion x-tra, Voco, Cuxhaven, Germany) with Precontoured circumferential matrix system (Palodent 360, Dentsply Caulk, Millford DE, USA)",
      "Bulk-fill ormocer (Admira fusion x-tra, Voco, Cuxhaven, Germany) with Precontoured sectional matrix systym (Saddle matrix, TORVM, Moscow, Russia)",
      "Bulk-fill resin composite (X-tra fill, Voco, Cuxhaven, Germany) with Precontoured circumferential matrix system (Palodent 360, Dentsply Caulk, Millford DE, USA)"
    ],
    "primary_completion_date": "2023-11-06",
    "completion_date": "2023-12",
    "results_first_posted": null,
    "last_update_posted": "2022-11-22",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03037125",
    "title": "The Evaluation Of Bone Width Gain Following Split Crest Technique With Or Without Platelet Rich Fibrin( PRF)",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ridge Deficiency"
    ],
    "interventions": [
      "Split Crest with PRF",
      "Split Crest without PRF"
    ],
    "primary_completion_date": "2019-03-15",
    "completion_date": "2019-06-01",
    "results_first_posted": null,
    "last_update_posted": "2024-05-28",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04267458",
    "title": "Prevalence of Kidney Injury in Patients With HCV Treated With Sofuspovir Containing DAA Therapy",
    "status": "UNKNOWN",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Investigate the Renal Effect of DAAs on Egyption Patients After Completion of Treatment"
    ],
    "interventions": [
      "evaluation of sofuspovir containing DAA regien expected insult on kidney"
    ],
    "primary_completion_date": "2020-04-30",
    "completion_date": "2020-12-30",
    "results_first_posted": null,
    "last_update_posted": "2020-02-12",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04002544",
    "title": "Nitroglycerin to Facilitate Radial Arterial Catheter Insertion in Children",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Radial Artery Canulation"
    ],
    "interventions": [
      "NTG patch",
      "gauze cover"
    ],
    "primary_completion_date": "2019-11-15",
    "completion_date": "2019-11-30",
    "results_first_posted": null,
    "last_update_posted": "2019-12-11",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05822011",
    "title": "Ultrasound Guided Rhomboid Intercostal Subserratus Plane Block vs Erector Spinae Plane Block in Open Nephrectomy",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Post Operative Pain"
    ],
    "interventions": [
      "Rhomboid intercostal subserratus plane block",
      "Erector spinae plane block"
    ],
    "primary_completion_date": "2025-05-15",
    "completion_date": "2025-05-15",
    "results_first_posted": null,
    "last_update_posted": "2025-05-20",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06664099",
    "title": "Comparison of Weight Loss and Nutritional Deficiency After One Anastomosis Gastric Bypass at 150, 170, and 200 cm From the Duodenojejunal Junction",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Obesity",
      "Nutritional Deficiency",
      "Type 2 Diabetes Mellitus (T2DM)",
      "Bariatric Surgery (Gastric Bypass)"
    ],
    "interventions": [
      "One Anastomosis Gastric Bypass (150 cm from Duodenojejunal Junction)",
      "One Anastomosis Gastric Bypass (170 cm from Duodenojejunal Junction)",
      "One Anastomosis Gastric Bypass (200 cm from Duodenojejunal Junction)"
    ],
    "primary_completion_date": "2024-06-20",
    "completion_date": "2024-06-20",
    "results_first_posted": null,
    "last_update_posted": "2024-11-12",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05134363",
    "title": "Dexmedetomidine for Prophylaxis Against PONV in Highly Susceptible Patients.",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Postoperative Nausea and Vomiting",
      "Head and Neck Surgeries"
    ],
    "interventions": [
      "Dexmedetomidine Hydrochloride 0.5 mic/kg bolus",
      "Dexmedetomidine Hydrochloride 0.75 mic/kg bolus",
      "Placebo"
    ],
    "primary_completion_date": "2023-06-20",
    "completion_date": "2023-06-20",
    "results_first_posted": null,
    "last_update_posted": "2023-08-30",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04905433",
    "title": "The Need for Breathing Retraining: the Elephant in the Cardiac Rehabilitation Room",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Heart Failure"
    ],
    "interventions": [
      "Cardiac rehabilitation with breathing retraining",
      "Cardiac rehabilitation"
    ],
    "primary_completion_date": "2020-03-01",
    "completion_date": "2020-03-01",
    "results_first_posted": null,
    "last_update_posted": "2022-01-25",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06520436",
    "title": "Arthroscopic-Assisted Reduction of Hip Dislocation Via Sub-Adductor and Anterolateral Portals",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Developmental Dysplasia of the Hip"
    ],
    "interventions": [
      "Arthroscopic-Assisted Reduction"
    ],
    "primary_completion_date": "2021-05-30",
    "completion_date": "2021-05-30",
    "results_first_posted": null,
    "last_update_posted": "2024-07-25",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05434533",
    "title": "The Prophylactic Role of Tranexamic Acid in High Risk Pregnant Women Undergoing Elective Cesarean Section in Prevention of Postpartum Hemorrhage",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "High Risk Pregnant Women Undergoing Elective Cesarean Section"
    ],
    "interventions": [
      "Tranexamic acid (Kapron, Amoun Pharmaceuticals SAE, Egypt. 5ml Amp, 100mg /1ml)"
    ],
    "primary_completion_date": "2023-01-01",
    "completion_date": "2023-02-10",
    "results_first_posted": null,
    "last_update_posted": "2023-02-21",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05047497",
    "title": "Ventilatory Functions, Oxygen Saturation, and Quality of Life Response to Long Time Cement Dust Exposure",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Occupational Diseases"
    ],
    "interventions": [
      "questionaire and ventilatory function test"
    ],
    "primary_completion_date": "2019-03-05",
    "completion_date": "2019-05-29",
    "results_first_posted": null,
    "last_update_posted": "2021-09-17",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06696508",
    "title": "Comparison Between Classic Laparoscopic Dismembered Pyeloplasty and Insitu Spatulation with Pre-Dismembering Ureteropelvic Angle Suturing.",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pyeloplasty",
      "Ureteropelvic Junction Obstruction"
    ],
    "interventions": [
      "Insitu Spatulation with Pre-Dismembering Ureteropelvic Angle Suturing during laparoscopic pyeloplasty",
      "Classic Laparoscopic Dismembered Pyeloplasty"
    ],
    "primary_completion_date": "2024-08-30",
    "completion_date": "2024-08-30",
    "results_first_posted": null,
    "last_update_posted": "2024-11-21",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04442750",
    "title": "Different Concentrations of Bupivacaine in Erector Spinae Plane Block in Hip Surgeries",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Postoperative Pain"
    ],
    "interventions": [
      "Erector spinae plane block Technique",
      "General anesthesia",
      "Bupivacaine 0.5%",
      "Bupivacaine 0.375%",
      "Bupivacaine 0.25%"
    ],
    "primary_completion_date": "2020-10-20",
    "completion_date": "2020-11-01",
    "results_first_posted": null,
    "last_update_posted": "2020-07-14",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05301205",
    "title": "Perioperative Administration of Gabapentin for Reducing Inhalational Anesthetic Consumption",
    "status": "UNKNOWN",
    "phase": "EARLY_PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Gabapentin"
    ],
    "interventions": [
      "oral gabapentin"
    ],
    "primary_completion_date": "2023-06-13",
    "completion_date": "2023-07-30",
    "results_first_posted": null,
    "last_update_posted": "2022-03-29",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05957302",
    "title": "Hemodynamic Effects of Bolus of Ketamine Versus Fentanyl in Patients With Septic Shock",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ketamine",
      "Fentanyl",
      "Septic Shock"
    ],
    "interventions": [
      "Ketamine",
      "Fentanyl"
    ],
    "primary_completion_date": "2023-12-15",
    "completion_date": "2023-12-15",
    "results_first_posted": null,
    "last_update_posted": "2023-12-22",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT02736019",
    "title": "Tramadol Versus Celecoxib for Reducing Pain During Office Hysteroscopy in Post Menopausal Women",
    "status": "UNKNOWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hysteroscopy"
    ],
    "interventions": [
      "Celecoxib",
      "Tramadol",
      "Placebo 1",
      "Placebo 2"
    ],
    "primary_completion_date": "2017-04",
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2016-07-06",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03253510",
    "title": "Measuring Biting Force of Poly-amide Complete Dentures",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Complete Edentulism"
    ],
    "interventions": [
      "Poly-amide",
      "Poly-methyl methacrylate"
    ],
    "primary_completion_date": "2018-03-01",
    "completion_date": "2018-05-01",
    "results_first_posted": null,
    "last_update_posted": "2017-08-18",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04388462",
    "title": "Comminuted Fractures of the Midshaft of the Tibia; (Interlocking Nail +/- Blocking Screws or Locked Plating With Predicted Distribution of Locking Screws) Choice Based on Finite Element Analysis Correlated With Clinical Outcome and Union.",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Comminuted Fracture Tibia"
    ],
    "interventions": [
      "Finite element analysis"
    ],
    "primary_completion_date": "2019-03-01",
    "completion_date": "2020-05-02",
    "results_first_posted": null,
    "last_update_posted": "2020-05-14",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04482790",
    "title": "Restoring Black Triangle With Bioclear Matrix Versus Celluloid Conventional Matrix Method",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Gingival Black Triangle"
    ],
    "interventions": [
      "Conventional celluloid matrix technique in management of black triangle",
      "Bioclear cervical matrix with injection molding technique"
    ],
    "primary_completion_date": "2021-03-01",
    "completion_date": "2021-05-01",
    "results_first_posted": null,
    "last_update_posted": "2020-07-24",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05586646",
    "title": "Effect of IV Alanyl Glutamine on Healing of Pressure Ulcers in Critically Ill Patients",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pressure Ulcer"
    ],
    "interventions": [
      "alanyl-glutamine"
    ],
    "primary_completion_date": "2022-12",
    "completion_date": "2022-12",
    "results_first_posted": null,
    "last_update_posted": "2022-10-19",
    "enrollment": null,
    "sponsor": "Air Force Specialized Hospital, Cairo, Egypt",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT07364370",
    "title": "Myopia Progression Control Using Atropine 0.05% After Pediatric Cataract Surgery And Intraocular Lens Implantation Surgery",
    "status": "NOT_YET_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pediatric Cataract",
      "IOL Implantation",
      "Myopia Progression"
    ],
    "interventions": [
      "Atropine Eye drops"
    ],
    "primary_completion_date": "2027-08",
    "completion_date": "2027-12",
    "results_first_posted": null,
    "last_update_posted": "2026-01-23",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT02461173",
    "title": "Stimulated Intrauterine Insemination Cycles and Unstimulated Intrauterine Insemination Cycles in Couples With Unexplained Infertility",
    "status": "UNKNOWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Infertility"
    ],
    "interventions": [
      "Merional",
      "IUI",
      "Ovulation detection",
      "Choriomon",
      "shepherd catheter"
    ],
    "primary_completion_date": "2017-05",
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2016-07-29",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03453086",
    "title": "Comparison of Thoracic Paravertebral Block , Pectoral Nerve Block to Serratus Anterior Plane Block in Breast Surgery, A Randomized Controlled Study",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Comparison of Thoracic Paravertebral Block to Serratus Anterior Plane Block in Breast Surgery"
    ],
    "interventions": [
      "Thoracic paravertebral block(TPVB) group"
    ],
    "primary_completion_date": "2018-02-08",
    "completion_date": "2018-02-12",
    "results_first_posted": null,
    "last_update_posted": "2018-03-16",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04575792",
    "title": "Oral Habits Effect on Orofacial Dysfunction and Oral Health Related Quality of Life.",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Oral Habits",
      "Oro-Facial Dysfunction"
    ],
    "interventions": [
      "Practicing oral habits"
    ],
    "primary_completion_date": "2021-04-01",
    "completion_date": "2021-04-01",
    "results_first_posted": null,
    "last_update_posted": "2022-03-09",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT02881606",
    "title": "Evaluation of the Clinical Effectiveness of Naso-alveolar Molding (NAM) Versus Computer Aided Design NAM (CAD/NAM) in Infants With Bilateral Cleft Lip and Palate: A Randomized Clinical Trial",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cleft Lip and Palate"
    ],
    "interventions": [
      "Naso-alveolar molding (NAM)",
      "Computer aided design NAM (CAD/NAM)"
    ],
    "primary_completion_date": "2019-03",
    "completion_date": "2019-05",
    "results_first_posted": null,
    "last_update_posted": "2019-12-03",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05110404",
    "title": "COMPARISON BETWEEN TWO SUB-TYPES OF HIGH INTENSITY INTERVAL TRAINING",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes Mellitus"
    ],
    "interventions": [
      "The high-volume HIIT",
      "The low-volume HIIT"
    ],
    "primary_completion_date": "2022-04-30",
    "completion_date": "2022-05-30",
    "results_first_posted": null,
    "last_update_posted": "2023-02-22",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06044883",
    "title": "Radiological Evaluation of the Penis Before and After a Botox Injection",
    "status": "UNKNOWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Erectile Dysfunction"
    ],
    "interventions": [
      "Injection of Botulinum neurotoxin (BoNT)",
      "Penile duplex and shear wave elastosonography (SWE)."
    ],
    "primary_completion_date": "2023-11-01",
    "completion_date": "2024-01-01",
    "results_first_posted": null,
    "last_update_posted": "2023-09-21",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04358822",
    "title": "Hemodynamic Effects of Delayed Umbilical Cord Clamping in Full-term Newborns",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cardiac Output, High",
      "Cardiac Output, Low"
    ],
    "interventions": [
      "Delayed cord clamping"
    ],
    "primary_completion_date": "2020-03-31",
    "completion_date": "2020-03-31",
    "results_first_posted": null,
    "last_update_posted": "2020-04-24",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04923425",
    "title": "Gustatory Modulators Among a Sample of Depressed Egyptian Adults Under Anti-depressants Therapy",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Taste Disorders"
    ],
    "interventions": [],
    "primary_completion_date": "2020-08-08",
    "completion_date": "2020-10-07",
    "results_first_posted": null,
    "last_update_posted": "2021-06-16",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT02355197",
    "title": "Antioxidants in Gestational Diabetes",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Gestational Diabetes Mellitus"
    ],
    "interventions": [
      "L-ascorbic acid"
    ],
    "primary_completion_date": "2015-02",
    "completion_date": "2015-02",
    "results_first_posted": null,
    "last_update_posted": "2017-03-24",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05529680",
    "title": "Impact of Scapular Mobilization And Strengthening Exercises on Shoulder Function Post Mastectomy",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Oncologic Complications",
      "Exercise Therapy",
      "Shoulder Pain",
      "Shoulder Syndrome"
    ],
    "interventions": [
      "Scapular mobilization and Scapular strengthening exercises",
      "Conventional physical therapy program"
    ],
    "primary_completion_date": "2022-06-28",
    "completion_date": "2022-07-20",
    "results_first_posted": null,
    "last_update_posted": "2022-09-07",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06382974",
    "title": "Evaluation of the Osteoinductivity of Atorvastatin Combined With \u03b2-TCP",
    "status": "NOT_YET_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Infection",
      "Bone Loss"
    ],
    "interventions": [
      "Cyst enucleation and bone grafting"
    ],
    "primary_completion_date": "2025-12",
    "completion_date": "2026-03",
    "results_first_posted": null,
    "last_update_posted": "2024-08-13",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06345261",
    "title": "Diphenhydramine in Catheter Related Bladder Discomfort",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Catheter Complications"
    ],
    "interventions": [
      "DiphenhydrAMINE 50 Mg/mL Injectable Solution",
      "Saline"
    ],
    "primary_completion_date": "2025-04-01",
    "completion_date": "2025-05-01",
    "results_first_posted": null,
    "last_update_posted": "2024-04-03",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06573463",
    "title": "Longevity of Prefabricated Band and Loop Versus Conventional Band and Loop Space Maintainers",
    "status": "NOT_YET_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Premature Tooth Exfoliation"
    ],
    "interventions": [
      "Prefabricated band and loop",
      "Conventional Band and loop"
    ],
    "primary_completion_date": "2025-09",
    "completion_date": "2025-10",
    "results_first_posted": null,
    "last_update_posted": "2024-08-28",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03952663",
    "title": "Effect of Platelet Rich Fibrin Membrane on the Neurosensory Dysfunction After IAN Lateralization for Implant Placement.",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Neurosensory Disorder"
    ],
    "interventions": [
      "inferior alveolar nerve lateralization and dental implant placement.",
      "platelet rich fibrin membrane around the nerve"
    ],
    "primary_completion_date": "2022-12",
    "completion_date": "2022-12",
    "results_first_posted": null,
    "last_update_posted": "2022-03-09",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06287047",
    "title": "The Impact of Using Different Spinal Needle Sizes on the Efficacy of the Dural Puncture Epidural Block",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dural Puncture Epidural Technique"
    ],
    "interventions": [
      "Epidural analgesia"
    ],
    "primary_completion_date": "2022-01-31",
    "completion_date": "2024-06-15",
    "results_first_posted": null,
    "last_update_posted": "2025-04-29",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05963789",
    "title": "Cervical Proprioception and Shoulder Impingement Treatment",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Shoulder Impingement",
      "Shoulder Pain"
    ],
    "interventions": [
      "Cervical proprioceptive training",
      "Traditional exercises"
    ],
    "primary_completion_date": "2023-09",
    "completion_date": "2023-10",
    "results_first_posted": null,
    "last_update_posted": "2023-07-27",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04045548",
    "title": "Vaginal Dinoprostone Administration Prior to Insertion Levonorgestrel-releasing Intrauterine System in Women With no Previous Vaginal Delivery",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Intrauterine Device"
    ],
    "interventions": [
      "Dinoprostone",
      "Placebo"
    ],
    "primary_completion_date": "2020-01-01",
    "completion_date": "2020-01-05",
    "results_first_posted": null,
    "last_update_posted": "2020-01-13",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT01855243",
    "title": "Comparison on Efficacy and Safety of Three Inpatient Insulin Therapy in Type2 DM",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes Mellitus (DM)"
    ],
    "interventions": [
      "regular insulin",
      "70/30 insulin",
      "Glargine",
      "glulisine"
    ],
    "primary_completion_date": "2014-02",
    "completion_date": "2014-06",
    "results_first_posted": "2019-01-15",
    "last_update_posted": "2019-01-15",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06270550",
    "title": "Role of Dynamic Movement Intervention in Children with Spastic Diplegia",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Spastic Diplegia"
    ],
    "interventions": [
      "Dynamic Movement Intervention"
    ],
    "primary_completion_date": "2025-08-01",
    "completion_date": "2025-09-01",
    "results_first_posted": null,
    "last_update_posted": "2025-02-12",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03703115",
    "title": "The Effect of Fasting on ICSI Outcomes in Patients With Polycystic Ovary Syndrome",
    "status": "WITHDRAWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Infertility",
      "Polycystic Ovary Syndrome"
    ],
    "interventions": [
      "Fasting"
    ],
    "primary_completion_date": "2022-04-01",
    "completion_date": "2022-09-01",
    "results_first_posted": null,
    "last_update_posted": "2023-08-30",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT07110025",
    "title": "Functional Electrical Stimulation With Core Stabilization Exercises in Children With Spastic Diplegia",
    "status": "NOT_YET_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Functional Electrical Stimulation",
      "Cerebral Palsy",
      "Core Stability"
    ],
    "interventions": [
      "designed physical therapy program",
      "core stabilization exercise with neuromuscular electrical stimulation"
    ],
    "primary_completion_date": "2025-12-15",
    "completion_date": "2026-01-15",
    "results_first_posted": null,
    "last_update_posted": "2025-08-07",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03104140",
    "title": "Ketamine Versus Low Dose Thiopental for Induction of Anesthesia in Septic Shock",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Septic Shock"
    ],
    "interventions": [
      "Ketamine",
      "Thiopental"
    ],
    "primary_completion_date": "2018-04-01",
    "completion_date": "2018-04-15",
    "results_first_posted": null,
    "last_update_posted": "2018-07-10",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03605823",
    "title": "Pars Plana Ex-Press Shunt in Vitrectomized Eyes",
    "status": "UNKNOWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Glaucoma Secondary"
    ],
    "interventions": [
      "Express Mini shunt"
    ],
    "primary_completion_date": "2019-11-01",
    "completion_date": "2019-11-01",
    "results_first_posted": null,
    "last_update_posted": "2019-04-19",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06513780",
    "title": "A Study of the Correlation Between Portal Vein Thrombosis and Prognosis of Liver Transplantation",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Portal Vein Thrombosis"
    ],
    "interventions": [
      "Observation"
    ],
    "primary_completion_date": "2025-12-31",
    "completion_date": "2025-12-31",
    "results_first_posted": null,
    "last_update_posted": "2025-09-18",
    "enrollment": null,
    "sponsor": "Ru-zhou Cai",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03437291",
    "title": "Comparison Between the Role of Transabdominal Ultrasound Versus Transvaginal Ultrasound in Evaluation of Placental Invasion in Cases of Placenta Previa Anterior Wall With Previous Uterine Scar",
    "status": "UNKNOWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Placenta Accreta"
    ],
    "interventions": [
      "Cesarean section",
      "Transabdominal ultrasound",
      "Transvaginal ultrasound"
    ],
    "primary_completion_date": "2018-02",
    "completion_date": "2018-03",
    "results_first_posted": null,
    "last_update_posted": "2018-02-19",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05329974",
    "title": "Computer Guided Buccal Cortical Plate Separation for Removal of Calcified Benign Odontogenic Tumors Affecting Mandibular Angle Region",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Odontogenic Tumors",
      "Odontoma"
    ],
    "interventions": [
      "Computer guided buccal cortical plate separation"
    ],
    "primary_completion_date": "2021-07-30",
    "completion_date": "2021-07-30",
    "results_first_posted": null,
    "last_update_posted": "2022-04-15",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03747796",
    "title": "The Impact of Semi-sitting Position Versus Supine Position on Gastric Emptying in Children Using Gastric Ultrasound",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Anesthesia",
      "Fasting"
    ],
    "interventions": [
      "Supine position",
      "Semi-sitting position"
    ],
    "primary_completion_date": "2019-01-12",
    "completion_date": "2019-01-13",
    "results_first_posted": null,
    "last_update_posted": "2019-01-15",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT02248038",
    "title": "A Multicenter Clinical Trial on Laparoscopic Colorectal Cancer Surgery Compared With Open Surgery",
    "status": "UNKNOWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Colorectal Cancer"
    ],
    "interventions": [
      "open surgery",
      "laparoscopic surgery"
    ],
    "primary_completion_date": "2019-06",
    "completion_date": "2019-06",
    "results_first_posted": null,
    "last_update_posted": "2014-09-25",
    "enrollment": null,
    "sponsor": "Cai Kailin",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04054674",
    "title": "Clinical Performance Of Lithium Disilicate Crowns Restoring Endodontically Treated Teeth With Two Occlusal Preparation Schemes",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fracture of Lithium Disilicate (e.Max) Crowns"
    ],
    "interventions": [
      "Abutments with flat occlusal scheme preparation restored by lithium disilicate crowns"
    ],
    "primary_completion_date": "2021-07-10",
    "completion_date": "2021-10-10",
    "results_first_posted": null,
    "last_update_posted": "2022-04-15",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03071523",
    "title": "Flap Advancement Techniques in Ridge Augmentation",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Flap Advancement",
      "Primary Wound Closure"
    ],
    "interventions": [
      "coronally advanced lingual flap",
      "periosteal releasing incision"
    ],
    "primary_completion_date": "2019-11-20",
    "completion_date": "2019-12-20",
    "results_first_posted": null,
    "last_update_posted": "2021-07-29",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04196829",
    "title": "Staining Potential and Caries Arresting Effect of Silver Diamine Fluoride\u2044Potassium Iodide and Silver Diamine Fluoride",
    "status": "UNKNOWN",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dental Caries in Children"
    ],
    "interventions": [
      "silver diamine fluoride \u2044 potassium Iodide",
      "Silver Diamine Fluoride"
    ],
    "primary_completion_date": "2021-08-12",
    "completion_date": "2021-10",
    "results_first_posted": null,
    "last_update_posted": "2021-09-10",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04765930",
    "title": "Combined Q-switched Nd:YAG Laser and Platelet Rich Plasma Versus Q- Switched Nd:YAG Laser Alone in Melasma",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hyperpigmentation",
      "Melasma",
      "PRP",
      "Lasers"
    ],
    "interventions": [
      "Q-switched nd:YAG laser toning"
    ],
    "primary_completion_date": "2021-02-15",
    "completion_date": "2021-03-01",
    "results_first_posted": null,
    "last_update_posted": "2021-02-23",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05006612",
    "title": "U/S Guided SAB VS U/S Guided SAB With Modified Pectoral Nerve Block in Modified Radical Mastectomy",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "U/S Guided SAB VS U/S Guided SAB Combined With Modified Pectoral Nerve Block"
    ],
    "interventions": [
      "Serratus Anterior Plane Block"
    ],
    "primary_completion_date": "2021-08-16",
    "completion_date": "2021-08-23",
    "results_first_posted": null,
    "last_update_posted": "2022-07-19",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06761950",
    "title": "Photobiomodulation Therapy on Pain and Range of Motion Following Flexor Tendon Repair",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Photobiomodulation Therapy",
      "Low Level Laser Therapy",
      "Flexor Tendon Rupture",
      "Flexor Tendon Repair"
    ],
    "interventions": [
      "Low Level laser therapy",
      "Placebo low level laser therapy",
      "medical treatment",
      "physical therapy program"
    ],
    "primary_completion_date": "2024-11-01",
    "completion_date": "2024-12-25",
    "results_first_posted": null,
    "last_update_posted": "2025-01-07",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03996213",
    "title": "Comparison of the Hemodynamic Effect of Three Positions During Induction of Anesthesia",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Post-induction Hypotension"
    ],
    "interventions": [
      "head down position",
      "leg elevation position"
    ],
    "primary_completion_date": "2019-10",
    "completion_date": "2019-10",
    "results_first_posted": null,
    "last_update_posted": "2019-06-25",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05311059",
    "title": "Impact of Laparoscopic Ovarian Drilling on Ovarian Reserve in Patients With Anovulatory Polycystic Ovarian Syndrome",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Polycystic Ovary Syndrome"
    ],
    "interventions": [
      "Laparoscopic ovarian drilling"
    ],
    "primary_completion_date": "2020-02-04",
    "completion_date": "2020-03-07",
    "results_first_posted": null,
    "last_update_posted": "2024-02-12",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT07001826",
    "title": "Assessment of the Accuracy of Patient Specific Plates for Correction of Maxillary Cant in Facial Asymmetry",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Facial Asymmetry"
    ],
    "interventions": [
      "Virtual Surgical Planning (VSP) with Patient-Specific Plates (PSPs)"
    ],
    "primary_completion_date": "2026-01-01",
    "completion_date": "2027-01-01",
    "results_first_posted": null,
    "last_update_posted": "2025-06-11",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06851624",
    "title": "Six Months Follow-up of Two and Four Mini Screws Supported Hyrax in Adults",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Transverse Maxillary Deficiency"
    ],
    "interventions": [
      "MARPE"
    ],
    "primary_completion_date": "2024-12-05",
    "completion_date": "2025-01-05",
    "results_first_posted": null,
    "last_update_posted": "2025-02-28",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06904417",
    "title": "Effect of Feldenkrais Method in Enhancing Postural Control for Patients with Diabetic Polyneuropathy",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetic Polyneuropathy"
    ],
    "interventions": [
      "The Feldenkrais-based intervention",
      "conventional balance training program"
    ],
    "primary_completion_date": "2025-04-30",
    "completion_date": "2025-06-30",
    "results_first_posted": null,
    "last_update_posted": "2025-04-01",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03613389",
    "title": "Prevention of Oral Mucositis After Using Oral Topical Vitamin E Versus Voriconazole and Levofloxacin in Pediatric Cancer Patients Receiving Chemotherapy",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Oral Mucositis (Ulcerative) Due to Antineoplastic Therapy"
    ],
    "interventions": [
      "oral topical vitamin E"
    ],
    "primary_completion_date": "2020-06-01",
    "completion_date": "2020-09-01",
    "results_first_posted": null,
    "last_update_posted": "2019-01-31",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT07086846",
    "title": "Effect of Myofascial Release Versus Acupressure on Carpal Tunnel Syndrome in Postnatal Period",
    "status": "NOT_YET_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Carpal Tunnel Syndrome"
    ],
    "interventions": [
      "Night splint",
      "Myofascial release technique",
      "Acupressure",
      "Home advice"
    ],
    "primary_completion_date": "2025-10-20",
    "completion_date": "2025-10-30",
    "results_first_posted": null,
    "last_update_posted": "2025-07-25",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05655806",
    "title": "Effect of Aminophylline Bolus Versus Infusion on Recovery Time in Patients Undergoing Lumbar Spine Surgery",
    "status": "UNKNOWN",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Anesthesia"
    ],
    "interventions": [
      "Aminophylline bolus then infusion",
      "aminophylline bolus",
      "normal saline"
    ],
    "primary_completion_date": "2023-06-30",
    "completion_date": "2023-07-30",
    "results_first_posted": null,
    "last_update_posted": "2023-01-04",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06957197",
    "title": "Clinical Comparison of Xenograft With Hydrogel Versus Xenograft Alone in the Socket Preservation After Tooth Extraction: A Randomized Controlled Clinical Trial",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Socket Perservation"
    ],
    "interventions": [
      "Hydrogel with xenograft",
      "Xenograft"
    ],
    "primary_completion_date": "2026-07-20",
    "completion_date": "2026-08-20",
    "results_first_posted": null,
    "last_update_posted": "2025-05-04",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05739396",
    "title": "Core Stabalization and Rebound Therapy and CP",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Whole Body Vibration",
      "Rebound Therapy",
      "Balance",
      "cp"
    ],
    "interventions": [
      "core stabilization"
    ],
    "primary_completion_date": "2023-06-01",
    "completion_date": "2023-07-11",
    "results_first_posted": null,
    "last_update_posted": "2023-03-01",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06766955",
    "title": "Prevalence of Lower Cross Syndrome Among Female College Students and Its Relation With Dysmenorrhea",
    "status": "NOT_YET_RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Cross Syndrome"
    ],
    "interventions": [
      null
    ],
    "primary_completion_date": "2025-02-25",
    "completion_date": "2025-03-13",
    "results_first_posted": null,
    "last_update_posted": "2025-01-09",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03248817",
    "title": "Phenylephrine Infusion in Cesarean Delivery",
    "status": "UNKNOWN",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cesarean Section Complications",
      "Spinal Anesthesia"
    ],
    "interventions": [
      "single shot phenylephrine",
      "fixed infusion phenylephrine",
      "variable infusion phenylephrine",
      "Bupivacaine"
    ],
    "primary_completion_date": "2020-05-15",
    "completion_date": "2020-05-25",
    "results_first_posted": null,
    "last_update_posted": "2019-11-25",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05263089",
    "title": "Clinical Performance of Injectable Universal Flowable Composite in Proximal Cavities of Posterior Teeth.",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Proximal Cavities of Posterior Teeth"
    ],
    "interventions": [
      "PALFIQUE\u00ae Universal Flow; Tokuyama, Tokyo, Japan (super low flowability)",
      "ESTELITE\u00ae Alpha; Tokuyama, Tokyo, Japan"
    ],
    "primary_completion_date": "2023-04-02",
    "completion_date": "2023-04-02",
    "results_first_posted": null,
    "last_update_posted": "2025-02-12",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT07118384",
    "title": "Comparison of the Clinical Efficacy of Ampicillin/Sulbactam and Cefoperazone/Sulbactam Against Multidrug Resistant Acinetobacter Baumannii Infections in Critically Ill Patients",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acinetobacter Baumannii Infection"
    ],
    "interventions": [
      "Cefoperazone-sulbactam injection",
      "Ampicillin - Sulbactam Injection"
    ],
    "primary_completion_date": "2026-01",
    "completion_date": "2026-01",
    "results_first_posted": null,
    "last_update_posted": "2025-08-12",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06345248",
    "title": "Laparoscopic-assisted Versus Ultrasonography-guided Transversus Abdominis Plane Block in Laparoscopic Sleeve Gastrectomy",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Transversus Abdominis Plane"
    ],
    "interventions": [
      "US-TAP",
      "LAPTAP"
    ],
    "primary_completion_date": "2025-04-01",
    "completion_date": "2025-05-01",
    "results_first_posted": null,
    "last_update_posted": "2024-04-03",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04514055",
    "title": "Connective Tissue Graft Wall Technique in Management of Cairo's RT2 and RT3 With Intra-bony Defects",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Recession, Gingival"
    ],
    "interventions": [
      "De-epithelialized connective tissue graft wall"
    ],
    "primary_completion_date": "2022-06-01",
    "completion_date": "2022-06-01",
    "results_first_posted": null,
    "last_update_posted": "2022-08-30",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT02574117",
    "title": "Cone Beam Computed Tomography for Evaluating Corticotomy-assisted Maxillary Expansion",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Posterior Cross Bite"
    ],
    "interventions": [
      "flap with corticotomy and bone allograft"
    ],
    "primary_completion_date": "2014-05",
    "completion_date": "2014-12",
    "results_first_posted": null,
    "last_update_posted": "2016-04-07",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06396117",
    "title": "Relationship Between Anogenital Distance, Serum AMH, and mTESE in Klinefelter Syndrome",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Azoospermia Anogenital Distance AMH"
    ],
    "interventions": [
      "mTESE (microscopic testicular sperm extraction)"
    ],
    "primary_completion_date": "2024-01-01",
    "completion_date": "2024-02-01",
    "results_first_posted": null,
    "last_update_posted": "2024-05-02",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04928768",
    "title": "Factors Influencing Patient Satisfaction in an Egyptian Sample After Orthodontic Treatment of Different Malocclusions",
    "status": "UNKNOWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Patient Satisfaction"
    ],
    "interventions": [
      "Questionnaire"
    ],
    "primary_completion_date": "2021-12-01",
    "completion_date": "2022-06-30",
    "results_first_posted": null,
    "last_update_posted": "2021-06-16",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05881915",
    "title": "Epinephrine Infusion for Prophylaxis Against Maternal Hypotension After Spinal Anesthesia for Cesarean Delivery",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypotension During Surgery"
    ],
    "interventions": [
      "Phenylephrine",
      "Epinephrine"
    ],
    "primary_completion_date": "2023-12-01",
    "completion_date": "2023-12-01",
    "results_first_posted": null,
    "last_update_posted": "2024-02-28",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT02002897",
    "title": "Fractional Carbon Dioxide Laser Versus UVA 1 in Treatment of Localized Scleroderma",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Localized Scleroderma"
    ],
    "interventions": [
      "Fractional carbon dioxide laser",
      "Ultraviolet A1 phototherapy (UVA1)"
    ],
    "primary_completion_date": "2014-11",
    "completion_date": "2014-12",
    "results_first_posted": null,
    "last_update_posted": "2014-09-11",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06042933",
    "title": "Early Oral Feeding Versus Traditional Delayed Oral Feeding Post-perforated Peptic Ulcer Repair",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Peptic Ulcer Perforation"
    ],
    "interventions": [
      "Post operative early oral feeding",
      "Traditional delayed oral Feeding Post-perforated Peptic Ulcer Repairs"
    ],
    "primary_completion_date": "2024-10-25",
    "completion_date": "2024-11-01",
    "results_first_posted": null,
    "last_update_posted": "2025-08-29",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06631690",
    "title": "Effect of ACL Reconstruction in Biomechanical Properties of Ankle Joint Complex",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Anterior Cruciate Ligament Tear",
      "Ankle Sprains"
    ],
    "interventions": [
      "Isokinetic and functional balance tests"
    ],
    "primary_completion_date": "2024-04-10",
    "completion_date": "2024-12-10",
    "results_first_posted": null,
    "last_update_posted": "2024-10-08",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04817579",
    "title": "Dental Photography and Numeric Shade Quantification as a Substitute to Conventional and Instrumental Shade Matching Techniques in the Esthetic Zone",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Discoloration, Tooth",
      "Chip Tooth",
      "Non Vital Teeth",
      "Trauma Dental"
    ],
    "interventions": [
      "Digital photography combined with eLABor_aid shade analyzing software",
      "Spectrophotometer",
      "Conventional visual shade matching"
    ],
    "primary_completion_date": "2024-09",
    "completion_date": "2024-12",
    "results_first_posted": null,
    "last_update_posted": "2024-06-25",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT02858622",
    "title": "Dual Transversus Abdominis Plane Block in Pediatric Renal Transplant: Effect on Pain Control",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Renal Failure"
    ],
    "interventions": [
      "bupivacaine",
      "Pethidine",
      "perfalgan",
      "fentanyl"
    ],
    "primary_completion_date": "2019-01",
    "completion_date": "2019-03",
    "results_first_posted": null,
    "last_update_posted": "2019-05-07",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04459403",
    "title": "Psychiatric Disturbances and COVID-19 Infection",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Corona Virus Infection"
    ],
    "interventions": [],
    "primary_completion_date": "2020-12-30",
    "completion_date": "2020-12-30",
    "results_first_posted": null,
    "last_update_posted": "2021-01-28",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04545931",
    "title": "Posterior Tibial Nerve Stimulation Vs Desmopressin In Children With Primary Monosymptomatic Nocturnal Enuresis",
    "status": "UNKNOWN",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Primary Monosymptomatic Nocturnal Enuresis"
    ],
    "interventions": [
      "Posterior tibial nerve stimulation",
      "Desmopressin Acetate"
    ],
    "primary_completion_date": "2020-11-15",
    "completion_date": "2020-12-15",
    "results_first_posted": null,
    "last_update_posted": "2020-09-11",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06748781",
    "title": "Clinical and Radiographic Evaluation of Calcium Hypochlorite Versus Saline As Root Canal Irrigants in Pulpectomy of Primary Molars: a Randomized Clinical Trial",
    "status": "NOT_YET_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Irreversible Pulpitis"
    ],
    "interventions": [
      "Pulpectomy using 2.5% Calcium Hypochlorite root canal irrigant.",
      "Pulpectomy using Saline as root canal irrigant"
    ],
    "primary_completion_date": "2026-03-01",
    "completion_date": "2026-04-01",
    "results_first_posted": null,
    "last_update_posted": "2024-12-27",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03345966",
    "title": "Assessment of Bmi-1 on Protein and Molecular Levels in Oral Dysplasia and Squamous Cell Carcinoma: A Diagnostic Study",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Oral Squamous Cell Carcinoma"
    ],
    "interventions": [
      "Bmi-1 antibody"
    ],
    "primary_completion_date": "2018-12",
    "completion_date": "2019-11",
    "results_first_posted": null,
    "last_update_posted": "2017-11-17",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05363566",
    "title": "Clinical Performance of the Baska Mask\u24c7, the I-Gel\u24c7 and the Self-Pressurized Air-Q\u24c7 i",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "The Baska Mask"
    ],
    "interventions": [
      "airway divice"
    ],
    "primary_completion_date": "2023-11-13",
    "completion_date": "2023-11-30",
    "results_first_posted": null,
    "last_update_posted": "2022-05-06",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05471102",
    "title": "Ligation of Anterior Internal Iliac Artery With Conservative Management of Partial or Focal Placenta Accreta Spectrum",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Placenta Accreta"
    ],
    "interventions": [
      "Study group: lower segment resection with ligation of the anterior division of the internal iliac artery",
      "Control group: lower segment resection without ligation of the anterior division of the internal iliac artery"
    ],
    "primary_completion_date": "2024-01-31",
    "completion_date": "2024-01-31",
    "results_first_posted": null,
    "last_update_posted": "2025-07-30",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT07346430",
    "title": "Does Anxiety Affect Balance, Spasticity and Function in Children With Cerebral Palsy",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Cerebral Palsy",
      "Anxiety",
      "Spasticity"
    ],
    "interventions": [],
    "primary_completion_date": "2025-11-10",
    "completion_date": "2025-12-30",
    "results_first_posted": null,
    "last_update_posted": "2026-01-20",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04822428",
    "title": "Effect of Visceral Osteopathic Manipulations on Low Back Pain",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Low Back Pain"
    ],
    "interventions": [
      "Osteopathic manipulation"
    ],
    "primary_completion_date": "2021-03-12",
    "completion_date": "2021-03-12",
    "results_first_posted": null,
    "last_update_posted": "2021-03-30",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT01133561",
    "title": "Pioglitazone in Psoriasis- A Clinical and Molecular Study.",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Psoriasis"
    ],
    "interventions": [
      "actozone A",
      "actozone B"
    ],
    "primary_completion_date": "2010-07",
    "completion_date": "2010-08",
    "results_first_posted": null,
    "last_update_posted": "2011-02-23",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT07050095",
    "title": "Anxiolytic Effect of Virtual Reality Immersion Versus Midazolam Premedication in Patients Undergoing Dacryocystorhinostomy Surgery",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Anxiolytic Effect",
      "Virtual Reality Immersion",
      "Midazolam",
      "Premedication",
      "Dacryocystorhinostomy"
    ],
    "interventions": [
      "Virtual Reality Group",
      "Midazolam Group"
    ],
    "primary_completion_date": "2025-12-30",
    "completion_date": "2025-12-30",
    "results_first_posted": null,
    "last_update_posted": "2025-07-03",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03843827",
    "title": "Randomized Comparative Study Between Classic Laryngeal Mask Airway and I Gel Airway in Obese Patients Having BMI 35-40 During Elective Non Abdominal Surgery.",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "LMA Vs I Gel"
    ],
    "interventions": [
      "Laryngeal Mask Airway",
      "I gel Airway"
    ],
    "primary_completion_date": "2019-05-15",
    "completion_date": "2019-05-18",
    "results_first_posted": null,
    "last_update_posted": "2019-05-21",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03545139",
    "title": "Clinical & Radiographic Evaluation of Neo MTA Versus White MTA in Revascularization of Non-Vital Immature Permanent Teeth",
    "status": "UNKNOWN",
    "phase": "EARLY_PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Nonvital Tooth"
    ],
    "interventions": [
      "NeoMTA nusmile",
      "White MTA"
    ],
    "primary_completion_date": "2020-09",
    "completion_date": "2021-09",
    "results_first_posted": null,
    "last_update_posted": "2020-02-20",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04092920",
    "title": "Implant Stability of Laser vs SLA Surface Treated Implants Placed in Fresh Extraction Sockets",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Implant Site Reaction"
    ],
    "interventions": [
      "laser and SLA"
    ],
    "primary_completion_date": "2020-09",
    "completion_date": "2020-09",
    "results_first_posted": null,
    "last_update_posted": "2019-09-24",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05693597",
    "title": "Evaluation of the Effect of Nigella Sativa for the Prophylaxis to Radiation Induced Dermatitis in Breast Cancer Patients",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Radiation Dermatitis"
    ],
    "interventions": [
      "Imtenan Oil",
      "Baraka Capsules"
    ],
    "primary_completion_date": "2024-02-20",
    "completion_date": "2024-02-20",
    "results_first_posted": null,
    "last_update_posted": "2024-02-23",
    "enrollment": null,
    "sponsor": "German University in Cairo",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04422860",
    "title": "Remineralization Efficacy of Gum Arabic Varnish.",
    "status": "UNKNOWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Caries,Dental",
      "Remineralization",
      "White Spot Lesion"
    ],
    "interventions": [
      "Gum Arabic varnish",
      "Proflourid Varnish,VOCO",
      "MI Varnish,GC Japan Inc."
    ],
    "primary_completion_date": "2021-09",
    "completion_date": "2021-11",
    "results_first_posted": null,
    "last_update_posted": "2020-07-13",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06694220",
    "title": "Impact of Tailored Preventive Exercise Program for Reducing Risk of Hip Adductors Injury",
    "status": "NOT_YET_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Adductor Strain"
    ],
    "interventions": [
      "Tailored preventive exercises",
      "Traditional exercises"
    ],
    "primary_completion_date": "2025-02-10",
    "completion_date": "2025-02-20",
    "results_first_posted": null,
    "last_update_posted": "2024-11-19",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05876442",
    "title": "Efficacy of EPSW Plus HILT on Carpal Tunnel Syndrome Post Burn Injury",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Burn Injury"
    ],
    "interventions": [
      "Extracorporeal Shock Wave Therapy.",
      "High Intensity Laser Therapy",
      "Traditional Physical Therapy Exercise Program"
    ],
    "primary_completion_date": "2024-05-30",
    "completion_date": "2024-06-01",
    "results_first_posted": null,
    "last_update_posted": "2023-10-25",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04460469",
    "title": "Anxiety Level and Oral Hygiene Practice in Dental Students During Covid-19 Pandemic",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Anxiety",
      "Covid19",
      "Oral Hygiene"
    ],
    "interventions": [],
    "primary_completion_date": "2020-09-01",
    "completion_date": "2020-11-01",
    "results_first_posted": null,
    "last_update_posted": "2022-03-10",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05813340",
    "title": "Vascularized Inter-positional Periosteal Connective-tissue Flap Versus Collagen Membrane in Guided Bone Regeneration",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Horizontal Ridge Deficiency"
    ],
    "interventions": [
      "Vascularized inter-positional periosteal connective tissue flap"
    ],
    "primary_completion_date": "2023-06-01",
    "completion_date": "2023-12-01",
    "results_first_posted": null,
    "last_update_posted": "2023-04-14",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06363188",
    "title": "The Impact of ESWT on Healing of Fractured Mandible",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Fractured Mandible Due to Trauma"
    ],
    "interventions": [
      "Radial Extracorporeal shockwave"
    ],
    "primary_completion_date": "2024-08-01",
    "completion_date": "2025-08-30",
    "results_first_posted": null,
    "last_update_posted": "2024-04-12",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03640390",
    "title": "Dexmedetomidine Versus Magnesium Sulfate Infusion During Spinal Anesthesia",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Postoperative Pain"
    ],
    "interventions": [
      "Dexmedetomidine",
      "Magnesium Sulphate",
      "Normal saline"
    ],
    "primary_completion_date": "2019-08-30",
    "completion_date": "2019-09-10",
    "results_first_posted": null,
    "last_update_posted": "2019-11-14",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04508946",
    "title": "Triple Therapy in Septic Shock Patients",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Septic Shock",
      "Sepsis",
      "Organ Dysfunction Syndrome Sepsis"
    ],
    "interventions": [
      "vitamin c - thiamine- hydrocortisone"
    ],
    "primary_completion_date": "2020-11-09",
    "completion_date": "2020-11-09",
    "results_first_posted": null,
    "last_update_posted": "2021-01-26",
    "enrollment": null,
    "sponsor": "Air Force Specialized Hospital, Cairo, Egypt",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03892876",
    "title": "Trial of Stimulus-response Potentiation in Schizophrenia",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia"
    ],
    "interventions": [
      "Auditory High Frequency Tetanizing Stimulation",
      "Sham Comparator"
    ],
    "primary_completion_date": "2021-04-15",
    "completion_date": "2021-04-15",
    "results_first_posted": null,
    "last_update_posted": "2021-07-01",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT06726746",
    "title": "Efficacy of Fractional CO2 Laser Treatment in Post-Menopausal Women With Vaginal Atrophy",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Post Menopausal Vaginal Atrophy"
    ],
    "interventions": [
      "Fractional CO2 laser"
    ],
    "primary_completion_date": "2025-03-01",
    "completion_date": "2025-03-01",
    "results_first_posted": null,
    "last_update_posted": "2024-12-10",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04991350",
    "title": "Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema",
    "status": "TERMINATED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetic Macular Edema",
      "Macular Ischemia",
      "Diabetic Retinopathy",
      "Vascular Endothelial Growth Factor Overexpression"
    ],
    "interventions": [
      "Intravitreal ranibizumab",
      "Intravitreal bevacizumab"
    ],
    "primary_completion_date": "2022-09-01",
    "completion_date": "2022-11-01",
    "results_first_posted": null,
    "last_update_posted": "2023-02-16",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04918862",
    "title": "A COMPARATIVE STUDY BETWEEN 1MG AND 3 MG OF GRANISETRON IN THE PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING IN STRABISMUS OPHTHALMIC SURGERIES DURING GENERAL ANESTHESIA",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "1mg Vs 3 mg of Granisetron"
    ],
    "interventions": [
      "Granisetron"
    ],
    "primary_completion_date": "2021-05-09",
    "completion_date": "2021-05-18",
    "results_first_posted": null,
    "last_update_posted": "2021-06-21",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT03805724",
    "title": "Entamoeba Gingivalis and Periodontal Disease",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Periodontal Diseases"
    ],
    "interventions": [
      "Plaque Samples"
    ],
    "primary_completion_date": "2019-01-18",
    "completion_date": "2019-01-18",
    "results_first_posted": null,
    "last_update_posted": "2019-04-02",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT04554979",
    "title": "COVID-19 Disease Duration and GIT Manifestations. A New Disease Severity Classification. An Egyptian Experience",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Covid19",
      "Diarrhea"
    ],
    "interventions": [
      "Hydroxychloroquine Pill"
    ],
    "primary_completion_date": "2020-07-15",
    "completion_date": "2020-07-15",
    "results_first_posted": null,
    "last_update_posted": "2020-09-22",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CAI",
    "nct_id": "NCT05924386",
    "title": "Marginal Bone Changes in Fixed All-on-Four Mandibular Prosthesis Using OT Bridge Attachment System",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Edentulous Jaw"
    ],
    "interventions": [
      "patients reciveing all on 4 fixed mandibular prosthesis usimg conventionally screw retained multiunit abutments",
      "all on 4 fixed mandibular prosthesis using OTbridge attachment system"
    ],
    "primary_completion_date": "2025-05-28",
    "completion_date": "2026-01-31",
    "results_first_posted": null,
    "last_update_posted": "2025-04-25",
    "enrollment": null,
    "sponsor": "Cairo University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRL",
    "nct_id": "NCT06507137",
    "title": "Fractal-based Gait Training in Older Adults",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Aging"
    ],
    "interventions": [
      "Fractal",
      "Isochronous",
      "Control"
    ],
    "primary_completion_date": "2026-07-31",
    "completion_date": "2026-12-31",
    "results_first_posted": null,
    "last_update_posted": "2025-09-22",
    "enrollment": null,
    "sponsor": "Egas Moniz - Cooperativa de Ensino Superior, CRL",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRL",
    "nct_id": "NCT06051175",
    "title": "Study of the Neurophysiological Response to Foodstuffs",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Nutrition"
    ],
    "interventions": [
      "Bitter taste perception",
      "Salty taste perception",
      "Sweet taste perception",
      "Acid taste perception",
      "Umami taste perception"
    ],
    "primary_completion_date": "2023-07-01",
    "completion_date": "2023-07-21",
    "results_first_posted": null,
    "last_update_posted": "2023-09-22",
    "enrollment": null,
    "sponsor": "Egas Moniz - Cooperativa de Ensino Superior, CRL",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRL",
    "nct_id": "NCT07243535",
    "title": "Fractal vs Isochronous Cueing in Athletes After ACL Reconstruction",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Anterior Cruciate Ligament Reconstruction",
      "Anterior Cruciate Ligament Reconstruction Rehabilitation",
      "Athlete"
    ],
    "interventions": [
      "Fractal Cueing",
      "Isochronous Cueing"
    ],
    "primary_completion_date": "2026-02",
    "completion_date": "2026-02",
    "results_first_posted": null,
    "last_update_posted": "2025-11-24",
    "enrollment": null,
    "sponsor": "Egas Moniz - Cooperativa de Ensino Superior, CRL",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRL",
    "nct_id": "NCT06684912",
    "title": "Acute Effects of Aerobic Exercise on Flow Mediated Slowing and Flow Mediated Dilation in Adults with and Without Type 2 Diabetes",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes Mellitus, Type 2"
    ],
    "interventions": [
      "High-intensity interval exercise",
      "Moderate continuous exercise"
    ],
    "primary_completion_date": "2022-01-15",
    "completion_date": "2022-01-15",
    "results_first_posted": null,
    "last_update_posted": "2024-11-12",
    "enrollment": null,
    "sponsor": "Egas Moniz - Cooperativa de Ensino Superior, CRL",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRL",
    "nct_id": "NCT07079280",
    "title": "Comparing Vascular Responses to Aerobic Exercise With and Without Blood Flow Restriction in Young and Older Adults",
    "status": "NOT_YET_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ageing",
      "Blood Flow Restriction (BFR) Training Effects"
    ],
    "interventions": [
      "Low Intensity Aerobic Exercise with Blood Flow Restriction (LIAE+BFR)",
      "High Intensity Interval Exercise (HIIE)"
    ],
    "primary_completion_date": "2026-05-29",
    "completion_date": "2026-07-31",
    "results_first_posted": null,
    "last_update_posted": "2025-07-23",
    "enrollment": null,
    "sponsor": "Egas Moniz - Cooperativa de Ensino Superior, CRL",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRL",
    "nct_id": "NCT06532786",
    "title": "Neural Adaptations to Metronome-Paced Strength Training",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "Fractal Paced",
      "Isochronous Paced",
      "Self Paced"
    ],
    "primary_completion_date": "2026-08-30",
    "completion_date": "2026-12-31",
    "results_first_posted": null,
    "last_update_posted": "2026-01-16",
    "enrollment": null,
    "sponsor": "Egas Moniz - Cooperativa de Ensino Superior, CRL",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRL",
    "nct_id": "NCT05701943",
    "title": "Comparison of Home- vs. Gym-based Exercise Delivery Modes",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Vascular Stiffness",
      "Cardiorespiratory Fitness"
    ],
    "interventions": [
      "Home-Based",
      "Gym-Based"
    ],
    "primary_completion_date": "2021-07-30",
    "completion_date": "2021-07-30",
    "results_first_posted": null,
    "last_update_posted": "2023-01-27",
    "enrollment": null,
    "sponsor": "Egas Moniz - Cooperativa de Ensino Superior, CRL",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRL",
    "nct_id": "NCT06709560",
    "title": "Baroreflex Sensitivity Response to Exercise",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Sex"
    ],
    "interventions": [
      "Moderate Intensity Continuous Exercise",
      "Vigorous Intensity Continuous Exercise",
      "Moderate Intensity Continuous Exercise Matched for Blood Pressure",
      "Vigorous Intensity Continuous Exercise Matched for Blood Pressure"
    ],
    "primary_completion_date": "2023-07-28",
    "completion_date": "2023-07-28",
    "results_first_posted": null,
    "last_update_posted": "2024-11-29",
    "enrollment": null,
    "sponsor": "Egas Moniz - Cooperativa de Ensino Superior, CRL",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRL",
    "nct_id": "NCT05145673",
    "title": "Effect of Aqueous Cinnamon Extract on the Postprandial Glycaemia Levels in Type 2 Diabetes Mellitus",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 2 Diabetes"
    ],
    "interventions": [
      "Placebo (OGTT)",
      "Cinnamon (OGTT plus aqueous cinnamon extract)"
    ],
    "primary_completion_date": "2016-10-03",
    "completion_date": "2016-10-31",
    "results_first_posted": null,
    "last_update_posted": "2021-12-06",
    "enrollment": null,
    "sponsor": "Egas Moniz - Cooperativa de Ensino Superior, CRL",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRL",
    "nct_id": "NCT07021144",
    "title": "VA|PREVENTION: Randomized Controlled Trial of a Person-Centred Digital Intervention to Prevent Diabetes in High-Risk Adults",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pre-diabetes",
      "Pre-diabetic State"
    ],
    "interventions": [
      "VA|PREVENTION web application (digital intervention)",
      "Type 2 Diabetes Guidebook"
    ],
    "primary_completion_date": "2026-07-26",
    "completion_date": "2026-08-31",
    "results_first_posted": null,
    "last_update_posted": "2025-09-15",
    "enrollment": null,
    "sponsor": "Egas Moniz - Cooperativa de Ensino Superior, CRL",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRL",
    "nct_id": "NCT06371742",
    "title": "Study of the Fluid Intake Effect During Labour",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Labor Complication"
    ],
    "interventions": [
      "Liquid ingestion during labour"
    ],
    "primary_completion_date": "2017-07-14",
    "completion_date": "2017-09-14",
    "results_first_posted": null,
    "last_update_posted": "2024-04-17",
    "enrollment": null,
    "sponsor": "Egas Moniz - Cooperativa de Ensino Superior, CRL",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRL",
    "nct_id": "NCT07352384",
    "title": "Evaluation of the Efficacy of Neuromodulation in the Control of Chronic Orofacial Pain",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Orofacial Pain"
    ],
    "interventions": [
      "Active Neuromodulation (tDCS or TMS)",
      "Sham Neuromodulation (tDCS or TMS)"
    ],
    "primary_completion_date": "2026-02-01",
    "completion_date": "2026-08-01",
    "results_first_posted": null,
    "last_update_posted": "2026-01-20",
    "enrollment": null,
    "sponsor": "Egas Moniz - Cooperativa de Ensino Superior, CRL",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRL",
    "nct_id": "NCT07243548",
    "title": "Effect of Peripheral Magnetic Stimulation in Patients With Chronic Lower Back Pain",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Low Back Pain"
    ],
    "interventions": [
      "rPMS Intervention",
      "rPMS Controle"
    ],
    "primary_completion_date": "2025-11-01",
    "completion_date": "2025-11-27",
    "results_first_posted": null,
    "last_update_posted": "2025-12-04",
    "enrollment": null,
    "sponsor": "Egas Moniz - Cooperativa de Ensino Superior, CRL",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRL",
    "nct_id": "NCT07016048",
    "title": "Digital Technologies in Dental Rehabilitation Planning.",
    "status": "NOT_YET_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Digital Technologies in Dental Rehabilitation Planning"
    ],
    "interventions": [
      "Try-in of one crown test with a digital wax-up (per group)"
    ],
    "primary_completion_date": "2026-12",
    "completion_date": "2026-12",
    "results_first_posted": null,
    "last_update_posted": "2025-06-11",
    "enrollment": null,
    "sponsor": "Egas Moniz - Cooperativa de Ensino Superior, CRL",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRL",
    "nct_id": "NCT06813209",
    "title": "Effects of Transcranial Electrical Stimulation in Chronic Stress",
    "status": "NOT_YET_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Stress",
      "Sleep"
    ],
    "interventions": [
      "tDCS",
      "tVNS"
    ],
    "primary_completion_date": "2026-12",
    "completion_date": "2027-04",
    "results_first_posted": null,
    "last_update_posted": "2025-02-06",
    "enrollment": null,
    "sponsor": "Egas Moniz - Cooperativa de Ensino Superior, CRL",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRL",
    "nct_id": "NCT07191522",
    "title": "Efficacy of Photodynamic Therapy in the Non-Surgical Treatment of Peri-Implantitis",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Peri Implantitis"
    ],
    "interventions": [
      "Mechanical debridment with titanium curettes and ultrasounds",
      "Mechanical debridment with titanium curettes and ultrasounds + aPDT (antimicrobial photodynamic therapy)"
    ],
    "primary_completion_date": "2026-07-30",
    "completion_date": "2027-07-30",
    "results_first_posted": null,
    "last_update_posted": "2025-09-25",
    "enrollment": null,
    "sponsor": "Egas Moniz - Cooperativa de Ensino Superior, CRL",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRL",
    "nct_id": "NCT06616428",
    "title": "Acute Exercise Effects on Arterial Stiffness and Cardiovagal Modulation in Adults",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ageing",
      "Aerobic Exercise",
      "Resistance Exercise",
      "Combined Exercise"
    ],
    "interventions": [
      "Bike group fitness class",
      "Pump Power",
      "Global Training"
    ],
    "primary_completion_date": "2021-11-26",
    "completion_date": "2022-03-11",
    "results_first_posted": null,
    "last_update_posted": "2024-09-27",
    "enrollment": null,
    "sponsor": "Egas Moniz - Cooperativa de Ensino Superior, CRL",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRL",
    "nct_id": "NCT06617117",
    "title": "Central Vs Brachial BP, Exercise, and Coronary Artery Disease",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Coronary Arterial Disease (CAD)"
    ],
    "interventions": [
      "High-intensity combined exercise",
      "Moderate-intensity combined exercise"
    ],
    "primary_completion_date": "2020-03-15",
    "completion_date": "2020-03-15",
    "results_first_posted": null,
    "last_update_posted": "2024-09-27",
    "enrollment": null,
    "sponsor": "Egas Moniz - Cooperativa de Ensino Superior, CRL",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRL",
    "nct_id": "NCT06693401",
    "title": "Forensic Handwriting Analysis in People with Parkinson's Disease - Pilot Study",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Parkinson Disease"
    ],
    "interventions": [
      "Intervention group: PD rehabilitation complemented with Occupational Therapy programme",
      "Control Group: conventional physiotherapy programme"
    ],
    "primary_completion_date": "2023-07-21",
    "completion_date": "2023-12-20",
    "results_first_posted": null,
    "last_update_posted": "2024-11-18",
    "enrollment": null,
    "sponsor": "Egas Moniz - Cooperativa de Ensino Superior, CRL",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRL",
    "nct_id": "NCT07240233",
    "title": "Musical Intervention for Dental Anxiety",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dental Anxiety"
    ],
    "interventions": [
      "Music via headphones",
      "Headphones without audio"
    ],
    "primary_completion_date": "2026-11",
    "completion_date": "2027-04",
    "results_first_posted": null,
    "last_update_posted": "2025-12-04",
    "enrollment": null,
    "sponsor": "Egas Moniz - Cooperativa de Ensino Superior, CRL",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRL",
    "nct_id": "NCT04807725",
    "title": "Analysis of Genetic Variations in Patients With Peri-implantitis",
    "status": "UNKNOWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Peri-Implantitis"
    ],
    "interventions": [
      "Analysis of genetic polymorphisms",
      "Biochemical analysis"
    ],
    "primary_completion_date": "2022-07-29",
    "completion_date": "2022-07-29",
    "results_first_posted": null,
    "last_update_posted": "2022-03-23",
    "enrollment": null,
    "sponsor": "Egas Moniz - Cooperativa de Ensino Superior, CRL",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRL",
    "nct_id": "NCT05616715",
    "title": "Evaluation of Different Periodontal Plastic Surgery Techniques for Gummy Smile Treatment",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Gummy Smile"
    ],
    "interventions": [
      "Peek device",
      "Crown lengthening/gingivectomy"
    ],
    "primary_completion_date": "2023-09-15",
    "completion_date": "2023-12-15",
    "results_first_posted": null,
    "last_update_posted": "2023-01-06",
    "enrollment": null,
    "sponsor": "Egas Moniz - Cooperativa de Ensino Superior, CRL",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRL",
    "nct_id": "NCT05677620",
    "title": "Predictive Factors for Prescribing a Mandibular Advancement Device for the Treatment of Obstructive Sleep Apnea",
    "status": "UNKNOWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Sleep Apnea, Obstructive"
    ],
    "interventions": [
      "Pharyngeal Computed Tomography",
      "Drug-Induced Sleep Endoscopy (Propofol)",
      "Mandibular Advancement Device"
    ],
    "primary_completion_date": "2023-10",
    "completion_date": "2023-12",
    "results_first_posted": null,
    "last_update_posted": "2023-02-03",
    "enrollment": null,
    "sponsor": "Egas Moniz - Cooperativa de Ensino Superior, CRL",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRL",
    "nct_id": "NCT07070453",
    "title": "Effect of Photodynamic Therapy as an Adjunct to Non-Surgical Treatment of Periodontitis",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Periodontitis"
    ],
    "interventions": [
      "Non-surgical periodontal treatment",
      "Scaling and root planing + aPDT"
    ],
    "primary_completion_date": "2025-09-30",
    "completion_date": "2025-11-30",
    "results_first_posted": null,
    "last_update_posted": "2025-07-17",
    "enrollment": null,
    "sponsor": "Egas Moniz - Cooperativa de Ensino Superior, CRL",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRL",
    "nct_id": "NCT06539650",
    "title": "Neural Adaptations to a Single Session of Metronome-Paced Strength Training",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "Fractal Paced",
      "Isochronus Paced",
      "Self Paced"
    ],
    "primary_completion_date": "2025-06-30",
    "completion_date": "2025-07-31",
    "results_first_posted": null,
    "last_update_posted": "2026-01-16",
    "enrollment": null,
    "sponsor": "Egas Moniz - Cooperativa de Ensino Superior, CRL",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRL",
    "nct_id": "NCT07190456",
    "title": "Kinesiophobia vs. Task-Specific Fear: Defining Movement-Related Fear in ACL Reconstruction Patients",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "ACL Reconstruction"
    ],
    "interventions": [
      "Exposure to neutral images visualization",
      "Exposure to nocive images visualisation",
      "Exposure to anticipated realisation of a feared movement"
    ],
    "primary_completion_date": "2026-12-01",
    "completion_date": "2026-12-01",
    "results_first_posted": null,
    "last_update_posted": "2025-12-17",
    "enrollment": null,
    "sponsor": "Egas Moniz - Cooperativa de Ensino Superior, CRL",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRL",
    "nct_id": "NCT06596304",
    "title": "Comparing Vascular Responses to Resistance Exercise with and Without Blood Flow Restriction in Young and Older Adults",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ageing",
      "Blood Flow Restriction"
    ],
    "interventions": [
      "Low intensity-resistance training with lower limb blood flow restriction",
      "High Intensity Resistance Training"
    ],
    "primary_completion_date": "2025-05",
    "completion_date": "2025-07",
    "results_first_posted": null,
    "last_update_posted": "2024-10-23",
    "enrollment": null,
    "sponsor": "Egas Moniz - Cooperativa de Ensino Superior, CRL",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRL",
    "nct_id": "NCT05152745",
    "title": "Effect of Ginger Extract on Postprandial Glycaemia of Healthy Adults and Its Antioxidant Properties",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hyperglycemia, Postprandial"
    ],
    "interventions": [
      "Placebo OGGT",
      "Ginger aqueous extract"
    ],
    "primary_completion_date": "2017-07-30",
    "completion_date": "2017-10-30",
    "results_first_posted": null,
    "last_update_posted": "2021-12-10",
    "enrollment": null,
    "sponsor": "Egas Moniz - Cooperativa de Ensino Superior, CRL",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRL",
    "nct_id": "NCT06444490",
    "title": "Oral Hygiene Among Portuguese Older Adults",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Oral Hygiene",
      "Oral Health",
      "Older"
    ],
    "interventions": [
      "General Approach Instruction",
      "Personalised Technique Instruction"
    ],
    "primary_completion_date": "2023-05-29",
    "completion_date": "2023-05-29",
    "results_first_posted": null,
    "last_update_posted": "2024-06-05",
    "enrollment": null,
    "sponsor": "Egas Moniz - Cooperativa de Ensino Superior, CRL",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRL",
    "nct_id": "NCT06538766",
    "title": "The Effect of Different Focus of Attention Instructions on Resistance Training and Its Transfer to Gait Parameters in Older Adults",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Aging",
      "Healthy"
    ],
    "interventions": [
      "Strength training with an internal focus of attention",
      "Strength training with a proprioceptive external focus of attention",
      "Strength training with a visual external focus of attention"
    ],
    "primary_completion_date": "2026-04-30",
    "completion_date": "2026-04-30",
    "results_first_posted": null,
    "last_update_posted": "2025-09-18",
    "enrollment": null,
    "sponsor": "Egas Moniz - Cooperativa de Ensino Superior, CRL",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRL",
    "nct_id": "NCT05140629",
    "title": "Effect of Baobab Fruit on Postprandial Glycaemia in Healthy Adults",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hyperglycemia, Postprandial"
    ],
    "interventions": [
      "Baobab fruit aqueous extract",
      "Placebo OGTT"
    ],
    "primary_completion_date": "2018-07-30",
    "completion_date": "2018-10-30",
    "results_first_posted": null,
    "last_update_posted": "2021-12-01",
    "enrollment": null,
    "sponsor": "Egas Moniz - Cooperativa de Ensino Superior, CRL",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CTMX",
    "nct_id": "NCT03013491",
    "title": "PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor",
      "Lymphoma"
    ],
    "interventions": [
      "CX-072",
      "ipilimumab",
      "vemurafenib"
    ],
    "primary_completion_date": "2020-10-27",
    "completion_date": "2020-10-27",
    "results_first_posted": "2025-06-17",
    "last_update_posted": "2025-06-17",
    "enrollment": null,
    "sponsor": "CytomX Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CTMX",
    "nct_id": "NCT03706274",
    "title": "PROCLAIM-CX-188: A Trial to Find Safe and Active Doses of an Investigational Drug CX-188 for Patients With Solid Tumors",
    "status": "WITHDRAWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor, Adult"
    ],
    "interventions": [
      "CX-188"
    ],
    "primary_completion_date": "2020-12",
    "completion_date": "2022-12",
    "results_first_posted": null,
    "last_update_posted": "2021-05-05",
    "enrollment": null,
    "sponsor": "CytomX Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CTMX",
    "nct_id": "NCT03149549",
    "title": "PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor, Adult",
      "Breast Cancer",
      "Non Small Cell Lung Cancer",
      "Head and Neck Cancer",
      "Ovarian Cancer"
    ],
    "interventions": [
      "CX-2009"
    ],
    "primary_completion_date": "2020-09-10",
    "completion_date": "2020-09-10",
    "results_first_posted": "2024-01-05",
    "last_update_posted": "2024-01-05",
    "enrollment": null,
    "sponsor": "CytomX Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CTMX",
    "nct_id": "NCT03543813",
    "title": "PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor, Adult",
      "Head and Neck Cancer",
      "Non Small Cell Lung Cancer",
      "Diffuse Large B Cell Lymphoma",
      "Esophageal Cancer"
    ],
    "interventions": [
      "CX-2029"
    ],
    "primary_completion_date": "2023-06-01",
    "completion_date": "2023-06-01",
    "results_first_posted": null,
    "last_update_posted": "2024-01-23",
    "enrollment": null,
    "sponsor": "CytomX Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CTMX",
    "nct_id": "NCT03993379",
    "title": "PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor",
      "Unresectable or Metastatic Melanoma"
    ],
    "interventions": [
      "CX-072",
      "Ipilimumab"
    ],
    "primary_completion_date": "2020-05-21",
    "completion_date": "2020-05-21",
    "results_first_posted": "2021-12-01",
    "last_update_posted": "2025-12-26",
    "enrollment": null,
    "sponsor": "CytomX Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "DYN",
    "nct_id": "NCT05481879",
    "title": "Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Myotonic Dystrophy Type 1 (DM1)"
    ],
    "interventions": [
      "DYNE-101",
      "Placebo"
    ],
    "primary_completion_date": "2029-07",
    "completion_date": "2029-07",
    "results_first_posted": null,
    "last_update_posted": "2026-01-22",
    "enrollment": null,
    "sponsor": "Dyne Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "EBS",
    "nct_id": "NCT07268612",
    "title": "Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of Anthrax Disease.",
    "status": "NOT_YET_RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Anthrax"
    ],
    "interventions": [
      "CYFENDUS"
    ],
    "primary_completion_date": "2036-11",
    "completion_date": "2037-11",
    "results_first_posted": null,
    "last_update_posted": "2025-12-08",
    "enrollment": null,
    "sponsor": "Emergent BioSolutions",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "EBS",
    "nct_id": "NCT05935917",
    "title": "Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Smallpox"
    ],
    "interventions": [
      "Brincidofovir"
    ],
    "primary_completion_date": "2023-08-14",
    "completion_date": "2023-09-27",
    "results_first_posted": null,
    "last_update_posted": "2025-01-15",
    "enrollment": null,
    "sponsor": "Emergent BioSolutions",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "EBS",
    "nct_id": "NCT05155319",
    "title": "Universal Influenza A Vaccine in Healthy Adults",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Human Influenza"
    ],
    "interventions": [
      "UFluA 20 \u00b5g each antigen/dose",
      "UFluA 60 \u00b5g each antigen/dose",
      "Placebo"
    ],
    "primary_completion_date": "2023-10-10",
    "completion_date": "2023-10-10",
    "results_first_posted": null,
    "last_update_posted": "2025-01-20",
    "enrollment": null,
    "sponsor": "Emergent BioSolutions",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "EBS",
    "nct_id": "NCT05377255",
    "title": "Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adults",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Opioid Overdose"
    ],
    "interventions": [
      "16 mg naloxone AP003",
      "8 mg naloxone NARCAN Nasal Spray"
    ],
    "primary_completion_date": "2022-05-10",
    "completion_date": "2022-05-10",
    "results_first_posted": null,
    "last_update_posted": "2024-03-18",
    "enrollment": null,
    "sponsor": "Emergent BioSolutions",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "EBS",
    "nct_id": "NCT05194358",
    "title": "Study of SIAN Nasal Spray in Healthy Adults",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cyanide Poisoning"
    ],
    "interventions": [
      "Stabilized Isoamyl Nitrite (SIAN)"
    ],
    "primary_completion_date": "2023-09-29",
    "completion_date": "2023-10-13",
    "results_first_posted": null,
    "last_update_posted": "2025-06-03",
    "enrollment": null,
    "sponsor": "Emergent BioSolutions",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "EBS",
    "nct_id": "NCT05142306",
    "title": "A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected Adults",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "SARS-CoV-2 Infection"
    ],
    "interventions": [
      "COVID-HIG"
    ],
    "primary_completion_date": "2022-03-28",
    "completion_date": "2022-05-31",
    "results_first_posted": "2024-05-20",
    "last_update_posted": "2025-06-08",
    "enrollment": null,
    "sponsor": "Emergent BioSolutions",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "EBS",
    "nct_id": "NCT04661839",
    "title": "A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID-19"
    ],
    "interventions": [
      "COVID-HIGIV",
      "Placebo (saline)"
    ],
    "primary_completion_date": "2021-07-27",
    "completion_date": "2021-07-27",
    "results_first_posted": "2023-02-02",
    "last_update_posted": "2025-06-08",
    "enrollment": null,
    "sponsor": "Emergent BioSolutions",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "EBS",
    "nct_id": "NCT02177721",
    "title": "Clinical Benefit and Safety of Raxibacumab in Patients With Symptomatic Inhalational Anthrax in a Mass Exposure Scenario",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Infections, Bacterial"
    ],
    "interventions": [
      "Sample Collection"
    ],
    "primary_completion_date": "2035-05",
    "completion_date": "2035-12",
    "results_first_posted": null,
    "last_update_posted": "2025-07-23",
    "enrollment": null,
    "sponsor": "Emergent BioSolutions",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ERAS",
    "nct_id": "NCT06084871",
    "title": "Patient Blood Management in Cardiac Surgery in Turkiye",
    "status": "UNKNOWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Coronary Artery Disease",
      "Iron Deficiency Anemia"
    ],
    "interventions": [],
    "primary_completion_date": "2024-12-31",
    "completion_date": "2025-06-01",
    "results_first_posted": null,
    "last_update_posted": "2023-10-16",
    "enrollment": null,
    "sponsor": "ERAS Turkey Association",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GLUE",
    "nct_id": "NCT05546268",
    "title": "Study of Oral MRT-2359 in Selected Cancer Patients",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "NSCLC",
      "SCLC",
      "High Grade Neuroendocrine Cancer",
      "DLBCL",
      "L-MYC and N-MYC Amplified Solid Tumors",
      "NSCLC With High or Low L-MYC or N-MYC Expression",
      "HR-positive, HER2-negative Breast Cancer",
      "Prostate Cancer"
    ],
    "interventions": [
      "Oral MRT-2359",
      "Oral MRT-2359",
      "Oral MRT-2359",
      "Oral MRT-2359",
      "Oral MRT-2359",
      "Oral MRT-2359"
    ],
    "primary_completion_date": "2026-05",
    "completion_date": "2027-11",
    "results_first_posted": null,
    "last_update_posted": "2025-10-22",
    "enrollment": null,
    "sponsor": "Monte Rosa Therapeutics, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GPCR",
    "nct_id": "NCT00822341",
    "title": "Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of TG-0054 With Single IV Doses Escalation in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "TG-0054"
    ],
    "primary_completion_date": "2009-05",
    "completion_date": "2009-05",
    "results_first_posted": null,
    "last_update_posted": "2021-08-04",
    "enrollment": null,
    "sponsor": "GPCR Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GPCR",
    "nct_id": "NCT05561751",
    "title": "Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple Myeloma"
    ],
    "interventions": [
      "GPC-100",
      "Propranolol",
      "G-CSF"
    ],
    "primary_completion_date": "2025-08-31",
    "completion_date": "2025-09-30",
    "results_first_posted": null,
    "last_update_posted": "2025-06-22",
    "enrollment": null,
    "sponsor": "GPCR Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GPCR",
    "nct_id": "NCT02104427",
    "title": "PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple Myeloma",
      "Non-Hodgkin Lymphoma",
      "Hodgkin Disease"
    ],
    "interventions": [
      "TG-0054 combined with G-CSF"
    ],
    "primary_completion_date": "2015-11",
    "completion_date": "2015-11",
    "results_first_posted": "2017-12-13",
    "last_update_posted": "2021-04-19",
    "enrollment": null,
    "sponsor": "GPCR Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GPCR",
    "nct_id": "NCT01018979",
    "title": "Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple Myeloma",
      "Non-Hodgkin Lymphoma",
      "Hodgkin Disease"
    ],
    "interventions": [
      "TG-0054 (2.24 mg/kg)",
      "TG-0054 (3.14 mg/kg)"
    ],
    "primary_completion_date": "2011-10",
    "completion_date": "2011-10",
    "results_first_posted": "2015-01-15",
    "last_update_posted": "2021-05-11",
    "enrollment": null,
    "sponsor": "GPCR Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GPCR",
    "nct_id": "NCT01458288",
    "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple Myeloma",
      "Non-hodgkin's Lymphoma",
      "Hodgkin's Disease"
    ],
    "interventions": [
      "TG-0054"
    ],
    "primary_completion_date": "2013-07",
    "completion_date": "2013-07",
    "results_first_posted": "2015-01-08",
    "last_update_posted": "2021-04-19",
    "enrollment": null,
    "sponsor": "GPCR Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "HUMA",
    "nct_id": "NCT07073131",
    "title": "Comparison Between Maternal Complications of Chromic Catgut and Vicryl Rapid Sutures Used for Episiotomy Repair",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Episiotomy Extended by Laceration",
      "Episiotomy Wound"
    ],
    "interventions": [
      "Vicryl Rapide suturing",
      "Chromic catgut suturing"
    ],
    "primary_completion_date": "2024-12-31",
    "completion_date": "2024-12-31",
    "results_first_posted": null,
    "last_update_posted": "2025-07-18",
    "enrollment": null,
    "sponsor": "Huma Ijaz",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "IBRX",
    "nct_id": "NCT05976828",
    "title": "IBRX-042 In Participants With HPV-Associated Tumors",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HPV-Related Carcinoma"
    ],
    "interventions": [
      "IBRX-042"
    ],
    "primary_completion_date": "2027-09-02",
    "completion_date": "2033-08-14",
    "results_first_posted": null,
    "last_update_posted": "2025-10-20",
    "enrollment": null,
    "sponsor": "ImmunityBio, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ILMN",
    "nct_id": "NCT05049967",
    "title": "iKnow: A Prospective Study to Evaluate the Use of Multi-omics in Multi-System, Early Onset Disorders",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Genetic Disease"
    ],
    "interventions": [],
    "primary_completion_date": "2021-12-10",
    "completion_date": "2024-12-31",
    "results_first_posted": null,
    "last_update_posted": "2024-04-30",
    "enrollment": null,
    "sponsor": "Illumina, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "IOVA",
    "nct_id": "NCT03635424",
    "title": "Medtronic Transcatheter Aortic Valve Replacement (TAVR) Low Risk Bicuspid Study",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bicuspid Aortic Valve"
    ],
    "interventions": [
      "Medtronic TAVR Systems"
    ],
    "primary_completion_date": "2019-11-13",
    "completion_date": "2030-12",
    "results_first_posted": "2020-12-21",
    "last_update_posted": "2025-10-21",
    "enrollment": null,
    "sponsor": "Medtronic Cardiovascular",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "IRON",
    "nct_id": "NCT05646901",
    "title": "Involvement of the Gut Microbiota-brain Cross-talk in the Loss of Eating Control",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Obesity"
    ],
    "interventions": [],
    "primary_completion_date": "2026-08",
    "completion_date": "2026-08",
    "results_first_posted": null,
    "last_update_posted": "2025-12-12",
    "enrollment": null,
    "sponsor": "Institut d'Investigaci\u00f3 Biom\u00e8dica de Girona Dr. Josep Trueta",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "IRON",
    "nct_id": "NCT06784544",
    "title": "The Effects of Repeated Operational Stress and Limited Recovery on Resilience Capacity",
    "status": "NOT_YET_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Sleep, Inadequate",
      "Energy Deficit",
      "Iron Absorption",
      "High Physical Activity"
    ],
    "interventions": [
      "Operational Stressors"
    ],
    "primary_completion_date": "2025-11",
    "completion_date": "2025-11",
    "results_first_posted": null,
    "last_update_posted": "2025-01-20",
    "enrollment": null,
    "sponsor": "United States Army Research Institute of Environmental Medicine",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "IRON",
    "nct_id": "NCT07368972",
    "title": "Study of DISC-0974-201 in Participants With IBD and Anemia",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Inflammatory Bowel Disease (IBD)",
      "Anemia",
      "Inflammatory Bowel Disease (IBD); Anemia"
    ],
    "interventions": [
      "DISC-0974",
      "Placebo"
    ],
    "primary_completion_date": "2026-10",
    "completion_date": "2027-03",
    "results_first_posted": null,
    "last_update_posted": "2026-01-27",
    "enrollment": null,
    "sponsor": "Disc Medicine, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "IRON",
    "nct_id": "NCT04841668",
    "title": "Gut-Brain-axis: Targets for Improvement of Cognition in the Elderly",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Type 2 Diabetes Mellitus"
    ],
    "interventions": [
      "Metformin"
    ],
    "primary_completion_date": "2025-06-01",
    "completion_date": "2026-02",
    "results_first_posted": null,
    "last_update_posted": "2025-12-12",
    "enrollment": null,
    "sponsor": "Institut d'Investigaci\u00f3 Biom\u00e8dica de Girona Dr. Josep Trueta",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KURA",
    "nct_id": "NCT05738538",
    "title": "Expanded Access to Ziftomenib",
    "status": "AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Acute Lymphoblastic Leukemia, With Appropriate Mutations",
      "Acute Myeloid Leukemia, With NPM1 Mutations"
    ],
    "interventions": [
      "ziftomenib"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2025-06-04",
    "enrollment": null,
    "sponsor": "Kura Oncology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KURA",
    "nct_id": "NCT07007312",
    "title": "Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Myeloid Leukemia (AML)"
    ],
    "interventions": [
      "Ziftomenib",
      "Placebo",
      "Venetoclax",
      "Azacitidine (AZA)",
      "Daunorubicin",
      "Cytarabine (Ara-C)"
    ],
    "primary_completion_date": "2031-11",
    "completion_date": "2031-11",
    "results_first_posted": null,
    "last_update_posted": "2026-01-26",
    "enrollment": null,
    "sponsor": "Kura Oncology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KURA",
    "nct_id": "NCT04809233",
    "title": "Expanded Access to Tipifarnib",
    "status": "AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)"
    ],
    "interventions": [
      "Tipifarnib"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2025-06-04",
    "enrollment": null,
    "sponsor": "Kura Oncology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KURA",
    "nct_id": "NCT04997902",
    "title": "Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HNSCC"
    ],
    "interventions": [
      "Tipifarnib",
      "Alpelisib"
    ],
    "primary_completion_date": "2025-07-30",
    "completion_date": "2025-07-30",
    "results_first_posted": null,
    "last_update_posted": "2025-12-23",
    "enrollment": null,
    "sponsor": "Kura Oncology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KURA",
    "nct_id": "NCT06026410",
    "title": "KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumors With HRAS Alterations",
      "Non Small Cell Lung Cancer (NSCLC)",
      "Colorectal Cancer (CRC)",
      "Pancreatic Ductal Adenocarcinoma (PDAC)",
      "Clear Cell Renal Cell Carcinoma (ccRCC)",
      "Renal Cell Carcinoma (Kidney Cancer)",
      "Non Clear Cell Renal Cell Carcinoma (nccRCC)"
    ],
    "interventions": [
      "Darlifarnib",
      "Cabozantinib",
      "Adagrasib"
    ],
    "primary_completion_date": "2027-01",
    "completion_date": "2027-04",
    "results_first_posted": null,
    "last_update_posted": "2026-01-02",
    "enrollment": null,
    "sponsor": "Kura Oncology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KURA",
    "nct_id": "NCT02383927",
    "title": "Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Thyroid Cancer",
      "Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)",
      "HRAS Mutant Tumor",
      "Other Squamous Cell Carcinoma (SCC) With HRAS Mutant Tumor"
    ],
    "interventions": [
      "Tipifarnib"
    ],
    "primary_completion_date": "2020-12-14",
    "completion_date": "2020-12-14",
    "results_first_posted": "2024-07-11",
    "last_update_posted": "2024-07-11",
    "enrollment": null,
    "sponsor": "Kura Oncology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KURA",
    "nct_id": "NCT05693090",
    "title": "Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer",
    "status": "WITHDRAWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "NSCLC"
    ],
    "interventions": [
      "Tipifarnib",
      "Osimertinib"
    ],
    "primary_completion_date": "2027-07-27",
    "completion_date": "2027-07-27",
    "results_first_posted": null,
    "last_update_posted": "2023-03-06",
    "enrollment": null,
    "sponsor": "Kura Oncology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KURA",
    "nct_id": "NCT04067336",
    "title": "First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Malignant Neoplasm",
      "Acute Myeloid Leukemia",
      "Mixed Lineage Leukemia",
      "Mixed Lineage Acute Leukemia",
      "Acute Leukemia of Ambiguous Lineage",
      "Mixed Phenotype Acute Leukemia",
      "Acute Lymphoblastic Leukemia"
    ],
    "interventions": [
      "Ziftomenib",
      "Midazolam",
      "Itraconazole"
    ],
    "primary_completion_date": "2028-10-16",
    "completion_date": "2028-10-16",
    "results_first_posted": null,
    "last_update_posted": "2025-11-10",
    "enrollment": null,
    "sponsor": "Kura Oncology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KURA",
    "nct_id": "NCT04865159",
    "title": "Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumor"
    ],
    "interventions": [
      "Tipifarnib"
    ],
    "primary_completion_date": "2023-05-02",
    "completion_date": "2023-05-02",
    "results_first_posted": null,
    "last_update_posted": "2023-09-21",
    "enrollment": null,
    "sponsor": "Kura Oncology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KURA",
    "nct_id": "NCT06655246",
    "title": "A Study of Ziftomenib, an Oral Menin Inhibitor, in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Gastrointestinal Stromal Tumor (GIST)",
      "Gastrointestinal Stromal Tumor (GIST) of the Gastrointestinal Tract",
      "Gastrointestinal Stromal Cancer",
      "Gastrointestinal Stromal Neoplasm",
      "Gastrointestinal Stromal Tumor, Malignant",
      "Gastrointestinal Stromal Cell Tumors"
    ],
    "interventions": [
      "ziftomenib",
      "imatinib mesylate"
    ],
    "primary_completion_date": "2027-12",
    "completion_date": "2028-12",
    "results_first_posted": null,
    "last_update_posted": "2025-12-23",
    "enrollment": null,
    "sponsor": "Kura Oncology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KURA",
    "nct_id": "NCT03051035",
    "title": "First-in-Human Study of KO-947 in Non-Hematological Malignancies",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Malignant Neoplasm"
    ],
    "interventions": [
      "KO-947"
    ],
    "primary_completion_date": "2020-06-02",
    "completion_date": "2020-06-02",
    "results_first_posted": null,
    "last_update_posted": "2021-09-20",
    "enrollment": null,
    "sponsor": "Kura Oncology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KURA",
    "nct_id": "NCT05735184",
    "title": "A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Myeloid Leukemia",
      "Mixed Lineage Leukemia Gene Mutation",
      "Refractory AML",
      "AML With Mutated NPM1",
      "Acute Myeloid Leukemia Recurrent",
      "Acute Myeloid Leukemia, in Relapse",
      "NPM1 Mutation",
      "KMT2Ar",
      "Myeloid Sarcoma",
      "Nucleophosmin 1-mutated Acute Myeloid Leukemia"
    ],
    "interventions": [
      "Ziftomenib",
      "Venetoclax",
      "Azacitidine",
      "Daunorubicin",
      "Cytarabine",
      "Quizartinib"
    ],
    "primary_completion_date": "2030-04",
    "completion_date": "2030-04",
    "results_first_posted": null,
    "last_update_posted": "2025-10-09",
    "enrollment": null,
    "sponsor": "Kura Oncology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KURA",
    "nct_id": "NCT02464228",
    "title": "Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsed or Refractory Peripheral T-Cell Lymphoma"
    ],
    "interventions": [
      "Tipifarnib"
    ],
    "primary_completion_date": "2021-03-31",
    "completion_date": "2021-03-31",
    "results_first_posted": "2024-06-26",
    "last_update_posted": "2024-06-26",
    "enrollment": null,
    "sponsor": "Kura Oncology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KURA",
    "nct_id": "NCT02779777",
    "title": "Tipifarnib in Subjects With Myelodysplastic Syndromes",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Myelodysplastic Syndromes"
    ],
    "interventions": [
      "Tipifarnib"
    ],
    "primary_completion_date": "2018-08-28",
    "completion_date": "2018-08-28",
    "results_first_posted": "2024-07-31",
    "last_update_posted": "2024-07-31",
    "enrollment": null,
    "sponsor": "Kura Oncology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KURA",
    "nct_id": "NCT06001788",
    "title": "Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "AML",
      "AML With Mutated NPM1",
      "Hematologic Malignancy",
      "KMT2Ar",
      "NPM1 Mutation",
      "MLL Rearrangement",
      "Leukemia",
      "Acute Myeloid Leukemia",
      "Leukemia, Myeloid",
      "Leukemia, Myeloid, Acute",
      "Acute Leukemia",
      "Neoplasms by Histologic Type"
    ],
    "interventions": [
      "Ziftomenib",
      "Fludarabine",
      "Idarubicin",
      "Cytarabine",
      "Gilteritinib",
      "Granulocyte colony-stimulating factor"
    ],
    "primary_completion_date": "2026-08",
    "completion_date": "2027-08",
    "results_first_posted": null,
    "last_update_posted": "2025-12-03",
    "enrollment": null,
    "sponsor": "Kura Oncology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KURA",
    "nct_id": "NCT03719690",
    "title": "Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HRAS Gene Mutation",
      "HNSCC"
    ],
    "interventions": [
      "Tipifarnib",
      "HRAS Detection Assay"
    ],
    "primary_completion_date": "2023-05-02",
    "completion_date": "2023-05-02",
    "results_first_posted": "2024-06-21",
    "last_update_posted": "2024-06-21",
    "enrollment": null,
    "sponsor": "Kura Oncology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KURA",
    "nct_id": "NCT02807272",
    "title": "Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Leukemia, Myelomonocytic, Chronic"
    ],
    "interventions": [
      "Tipifarnib"
    ],
    "primary_completion_date": "2020-11-30",
    "completion_date": "2020-11-30",
    "results_first_posted": "2024-07-17",
    "last_update_posted": "2024-07-17",
    "enrollment": null,
    "sponsor": "Kura Oncology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LAB",
    "nct_id": "NCT00602381",
    "title": "Bioequivalency Study of 450 mg Lithium Carbonate Under Fasting Conditions",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bipolar Disorder"
    ],
    "interventions": [
      "Lithium"
    ],
    "primary_completion_date": "2002-11",
    "completion_date": "2002-11",
    "results_first_posted": null,
    "last_update_posted": "2018-01-23",
    "enrollment": null,
    "sponsor": "Roxane Laboratories",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LAB",
    "nct_id": "NCT06073600",
    "title": "Bioequivalence Study to Compare Metformin / Vildagliptin Versus Galvumet\u00ae",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fed Conditions"
    ],
    "interventions": [
      "Metformin / Vildagliptin Reference Film Coated Tablets (1000 mg / 50 mg) (Galvumet\u00ae)",
      "Metformin / Vildagliptin Test Film Coated Tablets (1000 mg / 50 mg)"
    ],
    "primary_completion_date": "2022-09-09",
    "completion_date": "2022-11-13",
    "results_first_posted": null,
    "last_update_posted": "2023-10-25",
    "enrollment": null,
    "sponsor": "Reseach Laboratory of Clinical and Experimental Pharmacology",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LAB",
    "nct_id": "NCT01513057",
    "title": "Bioequivalence Study of Mycophenolate Mofetil 250 mg Capsule, Under Fed Conditions",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "Mycophenolate Mofetil",
      "Mycophenolate Mofetil"
    ],
    "primary_completion_date": "2009-01",
    "completion_date": "2009-02",
    "results_first_posted": null,
    "last_update_posted": "2012-01-20",
    "enrollment": null,
    "sponsor": "Dr. Reddy's Laboratories Limited",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LAB",
    "nct_id": "NCT01937754",
    "title": "Study of the Effects of an Oral Nitric Oxide Supplement on Blood Pressure in Prehypertensive Adults",
    "status": "UNKNOWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Prehypertension"
    ],
    "interventions": [
      "Nitric Oxide supplement",
      "Placebo"
    ],
    "primary_completion_date": "2013-09",
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2013-09-10",
    "enrollment": null,
    "sponsor": "Neogenis Laboratories",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LAB",
    "nct_id": "NCT01269281",
    "title": "Bioequivalence Study of Sumatriptan Succinate Tablets 100 mg in Fed Conditions",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "Sumatriptan"
    ],
    "primary_completion_date": "2005-07",
    "completion_date": "2005-07",
    "results_first_posted": null,
    "last_update_posted": "2011-01-04",
    "enrollment": null,
    "sponsor": "Dr. Reddy's Laboratories Limited",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LAB",
    "nct_id": "NCT05977530",
    "title": "Teaching Young Children Swim Survival Skills",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Drowning"
    ],
    "interventions": [
      "self-rescue training"
    ],
    "primary_completion_date": "2024-11-01",
    "completion_date": "2024-11-23",
    "results_first_posted": "2025-02-28",
    "last_update_posted": "2025-02-28",
    "enrollment": null,
    "sponsor": "University of Alabama at Birmingham",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LAB",
    "nct_id": "NCT00618228",
    "title": "Bioequivalency Study of Balsalazide Capsules Under Fasting Conditions",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ulcerative Colitis"
    ],
    "interventions": [
      "Balsalazide"
    ],
    "primary_completion_date": "2004-01",
    "completion_date": "2004-01",
    "results_first_posted": null,
    "last_update_posted": "2018-01-23",
    "enrollment": null,
    "sponsor": "Roxane Laboratories",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LAB",
    "nct_id": "NCT02832583",
    "title": "Autologous Platelet Rich Plasma Combined to Hyaluronic Acid Obtained With Regen-Kit BCT-HA in Aesthetic Medicine",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Skin Wrinkling"
    ],
    "interventions": [
      "Regenkit BCT-HA Cellular Matrix"
    ],
    "primary_completion_date": "2015-12",
    "completion_date": "2016-06",
    "results_first_posted": null,
    "last_update_posted": "2016-10-03",
    "enrollment": null,
    "sponsor": "Regen Lab SA",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LAB",
    "nct_id": "NCT00153114",
    "title": "PolyethyleneGlycol3350 Laxative vs Placebo in Constipated Children",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Constipation"
    ],
    "interventions": [
      "polyethyleneglycol3350"
    ],
    "primary_completion_date": "2004-09",
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2013-02-07",
    "enrollment": null,
    "sponsor": "Braintree Laboratories",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LAB",
    "nct_id": "NCT01621750",
    "title": "Bioequivalence Study of Clopidogrel Tablets 300 mg Under Fasting Conditions",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fasting"
    ],
    "interventions": [
      "Clopidogrel"
    ],
    "primary_completion_date": "2008-09",
    "completion_date": "2008-09",
    "results_first_posted": null,
    "last_update_posted": "2012-06-18",
    "enrollment": null,
    "sponsor": "Dr. Reddy's Laboratories Limited",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LAB",
    "nct_id": "NCT01642914",
    "title": "Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Constipation",
      "Constipation"
    ],
    "interventions": [
      "Linaclotide 290 micrograms",
      "Linaclotide 145 micrograms",
      "Matching placebo"
    ],
    "primary_completion_date": "2013-05",
    "completion_date": "2013-08",
    "results_first_posted": "2016-04-26",
    "last_update_posted": "2016-04-26",
    "enrollment": null,
    "sponsor": "Forest Laboratories",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LAB",
    "nct_id": "NCT00778414",
    "title": "Bioequivalence Study of Amoxicillin-Clavulanic Acid 600 mg - 42.9 mg/ 5 mL Oral Suspension Under Fasting Conditions",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "Amoxicillin-Clavulanic acid 600mg - 42.9 mg/ 5 mL oral suspension"
    ],
    "primary_completion_date": "2006-07",
    "completion_date": "2006-09",
    "results_first_posted": null,
    "last_update_posted": "2008-10-23",
    "enrollment": null,
    "sponsor": "Ranbaxy Laboratories Limited",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LAB",
    "nct_id": "NCT03023085",
    "title": "A Pilot Evaluation of BLI4700 Bowel Preparation in Adult Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Colonoscopy"
    ],
    "interventions": [
      "BLI4700"
    ],
    "primary_completion_date": "2017-08",
    "completion_date": "2017-08",
    "results_first_posted": "2023-11-15",
    "last_update_posted": "2023-11-15",
    "enrollment": null,
    "sponsor": "Braintree Laboratories",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LAB",
    "nct_id": "NCT02819297",
    "title": "BLI400-302: A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Constipation",
      "Chronic Idiopathic Constipation",
      "CIC"
    ],
    "interventions": [
      "BLI400 Laxative",
      "BLI400 Placebo"
    ],
    "primary_completion_date": "2017-06",
    "completion_date": "2017-06",
    "results_first_posted": "2020-06-26",
    "last_update_posted": "2020-07-27",
    "enrollment": null,
    "sponsor": "Braintree Laboratories",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LAB",
    "nct_id": "NCT02756689",
    "title": "Outpatient Foley For Starting Induction of Labor at TErm",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pregnancy"
    ],
    "interventions": [
      "Inpatient cervical ripening",
      "Outpatient cervical ripening"
    ],
    "primary_completion_date": "2017-10",
    "completion_date": "2017-10",
    "results_first_posted": "2019-07-09",
    "last_update_posted": "2019-07-09",
    "enrollment": null,
    "sponsor": "University of Alabama at Birmingham",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LAB",
    "nct_id": "NCT01464476",
    "title": "Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Arrhythmias, Cardiac",
      "Heart Diseases",
      "Cardiovascular Diseases",
      "Implantable Cardioverter Defibrillator"
    ],
    "interventions": [
      "Azimilide Dihydrochloride",
      "Placebo"
    ],
    "primary_completion_date": "2013-05",
    "completion_date": "2013-06",
    "results_first_posted": null,
    "last_update_posted": "2013-05-06",
    "enrollment": null,
    "sponsor": "Forest Laboratories",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LAB",
    "nct_id": "NCT06682143",
    "title": "The Effects of Virtual Reality Greenspace on Stress Among Adults With Mobility Impairments",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Mobility Impairments"
    ],
    "interventions": [
      "Virtual Reality (VR)",
      "Control"
    ],
    "primary_completion_date": "2025-12-30",
    "completion_date": "2026-06-30",
    "results_first_posted": null,
    "last_update_posted": "2025-04-30",
    "enrollment": null,
    "sponsor": "University of Alabama at Birmingham",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LAB",
    "nct_id": "NCT04787653",
    "title": "Evaluation of the OtoBand as a Treatment to Reduce the Perceived Loudness of Tinnitus",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Tinnitus"
    ],
    "interventions": [
      "Otoband",
      "Placebo"
    ],
    "primary_completion_date": "2024-01-31",
    "completion_date": "2024-02-28",
    "results_first_posted": null,
    "last_update_posted": "2022-03-22",
    "enrollment": null,
    "sponsor": "Otolith Labs",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LAB",
    "nct_id": "NCT00797797",
    "title": "Study of Milnacipran Added to Pregabalin for Treatment of Fibromyalgia",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fibromyalgia"
    ],
    "interventions": [
      "No Treatment Added",
      "Milnacipran Added"
    ],
    "primary_completion_date": "2009-11",
    "completion_date": "2010-01",
    "results_first_posted": "2011-02-16",
    "last_update_posted": "2011-02-16",
    "enrollment": null,
    "sponsor": "Forest Laboratories",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LAB",
    "nct_id": "NCT01283061",
    "title": "Bioequivalence Study of Zafirlukast Tablets 20 mg of Dr. Reddy's Laboratories Limited Under Fasting Condition",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "Zafirlukast"
    ],
    "primary_completion_date": "2008-01",
    "completion_date": "2008-01",
    "results_first_posted": null,
    "last_update_posted": "2011-01-26",
    "enrollment": null,
    "sponsor": "Dr. Reddy's Laboratories Limited",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LENZ",
    "nct_id": "NCT03201562",
    "title": "A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Presbyopia"
    ],
    "interventions": [
      "Aceclidine+tropicamide combination",
      "Aceclidine",
      "Vehicle"
    ],
    "primary_completion_date": "2018-05-20",
    "completion_date": "2018-05-20",
    "results_first_posted": "2021-04-19",
    "last_update_posted": "2022-09-22",
    "enrollment": null,
    "sponsor": "LENZ Therapeutics, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LENZ",
    "nct_id": "NCT05753189",
    "title": "Phase 3 Safety Study for the Treatment of Presbyopia Subjects",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Presbyopia",
      "Near Vision",
      "Miosis",
      "Eye Diseases"
    ],
    "interventions": [
      "Aceclidine+Brimonidine combination ophthalmic solution",
      "Placebo",
      "Aceclidine Ophthalmic Solution"
    ],
    "primary_completion_date": "2024-02-09",
    "completion_date": "2024-02-09",
    "results_first_posted": null,
    "last_update_posted": "2024-12-18",
    "enrollment": null,
    "sponsor": "LENZ Therapeutics, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LENZ",
    "nct_id": "NCT05294328",
    "title": "Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Presbyopia",
      "Refractive Errors",
      "Eye Diseases"
    ],
    "interventions": [
      "Aceclidine+Brimonidine combination ophthalmic solution",
      "Aceclidine ophthalmic solution",
      "Vehicle Proprietary Ophthalmic Solution"
    ],
    "primary_completion_date": "2022-08-22",
    "completion_date": "2022-09-10",
    "results_first_posted": "2024-09-05",
    "last_update_posted": "2024-09-05",
    "enrollment": null,
    "sponsor": "LENZ Therapeutics, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LENZ",
    "nct_id": "NCT05431543",
    "title": "Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Presbyopia",
      "Refractive Errors",
      "Eye Diseases"
    ],
    "interventions": [
      "Aceclidine+Brimonidine combination ophthalmic solution",
      "Aceclidine ophthalmic solution",
      "Vehicle proprietary ophthalmic solution"
    ],
    "primary_completion_date": "2022-12-14",
    "completion_date": "2022-12-14",
    "results_first_posted": "2024-09-05",
    "last_update_posted": "2024-09-05",
    "enrollment": null,
    "sponsor": "LENZ Therapeutics, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LENZ",
    "nct_id": "NCT05936489",
    "title": "Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Eye Diseases",
      "Presbyopia",
      "Refractive Errors",
      "Brimonidine Tartrate",
      "Aceclidine",
      "Ophthalmic Solutions"
    ],
    "interventions": [
      "Aceclidine + Brimonidine",
      "Aceclidine"
    ],
    "primary_completion_date": "2023-10-03",
    "completion_date": "2023-10-03",
    "results_first_posted": null,
    "last_update_posted": "2023-10-16",
    "enrollment": null,
    "sponsor": "LENZ Therapeutics, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LENZ",
    "nct_id": "NCT05656027",
    "title": "Phase 3 Evaluation of the Safety and Efficacy of LNZ101 for the Treatment of Presbyopia",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Presbyopia",
      "Refractive Error",
      "Near Vision",
      "Miosis",
      "Eye Diseases"
    ],
    "interventions": [
      "Aceclidine + Brimonidine",
      "Aceclidine",
      "Brimonidine"
    ],
    "primary_completion_date": "2023-12-15",
    "completion_date": "2024-01-25",
    "results_first_posted": null,
    "last_update_posted": "2024-12-18",
    "enrollment": null,
    "sponsor": "LENZ Therapeutics, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LENZ",
    "nct_id": "NCT05728944",
    "title": "Phase 3 Efficacy Study of LNZ101 for the Treatment of Presbyopia",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Presbyopia",
      "Near Vision",
      "Miosis",
      "Eye Diseases"
    ],
    "interventions": [
      "Aceclidine+Brimonidine combination ophthalmic solution",
      "Aceclidine",
      "Vehicle"
    ],
    "primary_completion_date": "2023-12-14",
    "completion_date": "2024-01-24",
    "results_first_posted": null,
    "last_update_posted": "2024-12-18",
    "enrollment": null,
    "sponsor": "LENZ Therapeutics, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LENZ",
    "nct_id": "NCT02554396",
    "title": "Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Presbyopia"
    ],
    "interventions": [
      "PRX-100",
      "Placebo"
    ],
    "primary_completion_date": "2015-11",
    "completion_date": "2015-11",
    "results_first_posted": null,
    "last_update_posted": "2017-10-23",
    "enrollment": null,
    "sponsor": "LENZ Therapeutics, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MAZE",
    "nct_id": "NCT05249621",
    "title": "A Randomized Phase 1 of of MZE001 in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "MZE001",
      "Placebo"
    ],
    "primary_completion_date": "2022-12-21",
    "completion_date": "2022-12-21",
    "results_first_posted": null,
    "last_update_posted": "2023-02-06",
    "enrollment": null,
    "sponsor": "Maze Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MAZE",
    "nct_id": "NCT06830629",
    "title": "A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Proteinuric Kidney Disease"
    ],
    "interventions": [
      "MZE829"
    ],
    "primary_completion_date": "2026-09",
    "completion_date": "2026-09",
    "results_first_posted": null,
    "last_update_posted": "2025-11-12",
    "enrollment": null,
    "sponsor": "Maze Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MBX",
    "nct_id": "NCT07142707",
    "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Obesity"
    ],
    "interventions": [
      "MBX 4291",
      "Placebo"
    ],
    "primary_completion_date": "2026-05-30",
    "completion_date": "2026-05-30",
    "results_first_posted": null,
    "last_update_posted": "2025-12-15",
    "enrollment": null,
    "sponsor": "MBX Biosciences",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MBX",
    "nct_id": "NCT06465108",
    "title": "Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypoparathyroidism"
    ],
    "interventions": [
      "MBX 2109",
      "Placebo"
    ],
    "primary_completion_date": "2025-05-23",
    "completion_date": "2025-06-04",
    "results_first_posted": null,
    "last_update_posted": "2025-10-28",
    "enrollment": null,
    "sponsor": "MBX Biosciences",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MBX",
    "nct_id": "NCT06531941",
    "title": "Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypoparathyroidism"
    ],
    "interventions": [
      "400 \u00b5g of MBX 2109 once-weekly by subcutaneous injection",
      "200-1600 \u00b5g of MBX 2109 once-weekly by subcutaneous injection"
    ],
    "primary_completion_date": "2027-05-27",
    "completion_date": "2027-05-27",
    "results_first_posted": null,
    "last_update_posted": "2025-10-28",
    "enrollment": null,
    "sponsor": "MBX Biosciences",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MBX",
    "nct_id": "NCT05158335",
    "title": "Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of MBX 2109 in Healthy Adult Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "MBX 2109 (Part A)",
      "MBX 2109 (Part B)",
      "Placebo"
    ],
    "primary_completion_date": "2023-06-20",
    "completion_date": "2023-06-20",
    "results_first_posted": null,
    "last_update_posted": "2023-08-09",
    "enrollment": null,
    "sponsor": "MBX Biosciences",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MBX",
    "nct_id": "NCT06036784",
    "title": "Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Postbariatric Hypoglycemia"
    ],
    "interventions": [
      "MBX 1416 (Part A)",
      "MBX 1416 (Part B)",
      "Placebo",
      "MBX 1416 (Part C)"
    ],
    "primary_completion_date": "2024-11-14",
    "completion_date": "2024-12-05",
    "results_first_posted": null,
    "last_update_posted": "2024-12-12",
    "enrollment": null,
    "sponsor": "MBX Biosciences",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MBX",
    "nct_id": "NCT06496217",
    "title": "Safety and Pharmacokinetics Study of MBX 2109 in Adult Subjects With Normal and Impaired Renal Function",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Renal Impairment"
    ],
    "interventions": [
      "MBX 2109",
      "MBX 2109",
      "MBX 2109",
      "MBX 2109"
    ],
    "primary_completion_date": "2025-09-04",
    "completion_date": "2025-09-04",
    "results_first_posted": null,
    "last_update_posted": "2025-10-28",
    "enrollment": null,
    "sponsor": "MBX Biosciences",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MBX",
    "nct_id": "NCT07029412",
    "title": "Study to Evaluate Efficacy and Dose Response of Imapextide (STEADI)",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Postbariatric Hypoglycemia"
    ],
    "interventions": [
      "MBX 1416 (INN imapextide)"
    ],
    "primary_completion_date": "2025-12-22",
    "completion_date": "2026-01-26",
    "results_first_posted": null,
    "last_update_posted": "2025-12-17",
    "enrollment": null,
    "sponsor": "MBX Biosciences",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MESO",
    "nct_id": "NCT01089816",
    "title": "Rapid Diagnostic Test for Influenza",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Influenza"
    ],
    "interventions": [
      "Local/Regional Public Health Notification"
    ],
    "primary_completion_date": "2010-08",
    "completion_date": "2010-10",
    "results_first_posted": null,
    "last_update_posted": "2015-04-21",
    "enrollment": null,
    "sponsor": "Meso Scale Diagnostics, LLC.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MESO",
    "nct_id": "NCT00863343",
    "title": "Clinical Validation of the Point-of-Care MSD Influenza Test",
    "status": "TERMINATED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Influenza Human"
    ],
    "interventions": [
      "Public Health Notification"
    ],
    "primary_completion_date": "2010-07",
    "completion_date": "2010-08",
    "results_first_posted": "2012-03-01",
    "last_update_posted": "2012-03-01",
    "enrollment": null,
    "sponsor": "Meso Scale Diagnostics, LLC.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NBP",
    "nct_id": "NCT02905565",
    "title": "NBP in Adult Patients With Acute Ischemic Stroke (AIS)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "AIS"
    ],
    "interventions": [
      "NBP Softgel Capsules",
      "Placebo"
    ],
    "primary_completion_date": "2020-08-07",
    "completion_date": "2020-08-07",
    "results_first_posted": null,
    "last_update_posted": "2020-09-17",
    "enrollment": null,
    "sponsor": "CSPC-NBP Pharmaceutical Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NMRA",
    "nct_id": "NCT06058013",
    "title": "Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder"
    ],
    "interventions": [
      "NMRA-335140",
      "Placebo"
    ],
    "primary_completion_date": "2026-05",
    "completion_date": "2026-06",
    "results_first_posted": null,
    "last_update_posted": "2026-01-13",
    "enrollment": null,
    "sponsor": "Neumora Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NMRA",
    "nct_id": "NCT06029439",
    "title": "Study to Assess the Safety and Effectiveness of NMRA-335140-501",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder"
    ],
    "interventions": [
      "NMRA-335140"
    ],
    "primary_completion_date": "2027-06",
    "completion_date": "2027-06",
    "results_first_posted": null,
    "last_update_posted": "2026-01-14",
    "enrollment": null,
    "sponsor": "Neumora Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NMRA",
    "nct_id": "NCT06058039",
    "title": "Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder"
    ],
    "interventions": [
      "NMRA-335140",
      "Placebo"
    ],
    "primary_completion_date": "2026-02",
    "completion_date": "2026-03",
    "results_first_posted": null,
    "last_update_posted": "2026-01-13",
    "enrollment": null,
    "sponsor": "Neumora Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NMRA",
    "nct_id": "NCT06029426",
    "title": "Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder"
    ],
    "interventions": [
      "NMRA-335140",
      "Placebo"
    ],
    "primary_completion_date": "2024-12-03",
    "completion_date": "2025-01-15",
    "results_first_posted": null,
    "last_update_posted": "2025-11-26",
    "enrollment": null,
    "sponsor": "Neumora Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NMRA",
    "nct_id": "NCT06429722",
    "title": "To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Episode Associated With Bipolar II Disorder"
    ],
    "interventions": [
      "NMRA-335140 80 mg",
      "Placebo"
    ],
    "primary_completion_date": "2025-04-09",
    "completion_date": "2025-05-30",
    "results_first_posted": null,
    "last_update_posted": "2025-07-31",
    "enrollment": null,
    "sponsor": "Neumora Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ONC",
    "nct_id": "NCT04372433",
    "title": "IO-202 as Monotherapy and IO-202 Plus Azacitidine \u00b1 Venetoclax in Patients in AML and CMML",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "AML With Monocytic Differentiation",
      "CMML"
    ],
    "interventions": [
      "IO-202",
      "IO-202 and Azacitidine",
      "IO-202 and Azacitidine + Venetoclax",
      "IO-202 and Azacitidine"
    ],
    "primary_completion_date": "2025-01-31",
    "completion_date": "2025-01-31",
    "results_first_posted": null,
    "last_update_posted": "2025-02-14",
    "enrollment": null,
    "sponsor": "Immune-Onc Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ONC",
    "nct_id": "NCT05727176",
    "title": "Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Cholangiocarcinoma",
      "FGFR2 Fusions",
      "Gene Rearrangement"
    ],
    "interventions": [
      "TAS-120"
    ],
    "primary_completion_date": "2026-12",
    "completion_date": "2026-12",
    "results_first_posted": null,
    "last_update_posted": "2025-12-29",
    "enrollment": null,
    "sponsor": "Taiho Oncology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ONC",
    "nct_id": "NCT05054348",
    "title": "First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor, Adult"
    ],
    "interventions": [
      "IO-108",
      "IO-108 + pembrolizumab combination therapy",
      "IO-108 + cemiplimab combination therapy"
    ],
    "primary_completion_date": "2024-04-29",
    "completion_date": "2024-05-31",
    "results_first_posted": null,
    "last_update_posted": "2024-06-04",
    "enrollment": null,
    "sponsor": "Immune-Onc Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ONC",
    "nct_id": "NCT00248287",
    "title": "PhII ICb With/Without Erbitux in MBC Pts",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Breast Cancer"
    ],
    "interventions": [
      "Irinotecan + Carboplatin",
      "irinotecan + Carboplatin + erbitux"
    ],
    "primary_completion_date": "2025-12",
    "completion_date": "2026-12",
    "results_first_posted": "2016-11-03",
    "last_update_posted": "2025-01-29",
    "enrollment": null,
    "sponsor": "US Oncology Research",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ONC",
    "nct_id": "NCT03074032",
    "title": "Safety, Tolerability and Pharmacokinetics of ONC1-0013B in Patients With Progressive Metastatic Castration-resistant Prostate Cancer",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Castration-Resistant Prostate Cancer (mCRPC)"
    ],
    "interventions": [
      "ONC1-0013B"
    ],
    "primary_completion_date": "2017-04",
    "completion_date": "2017-04",
    "results_first_posted": null,
    "last_update_posted": "2017-07-11",
    "enrollment": null,
    "sponsor": "Avionco LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ONC",
    "nct_id": "NCT06352359",
    "title": "Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumor"
    ],
    "interventions": [
      "ONC-841"
    ],
    "primary_completion_date": "2025-09-30",
    "completion_date": "2027-09-30",
    "results_first_posted": null,
    "last_update_posted": "2025-03-05",
    "enrollment": null,
    "sponsor": "OncoC4, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ONC",
    "nct_id": "NCT00599313",
    "title": "Phase II Sunitinib Prog Met AIPC",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Prostate Cancer"
    ],
    "interventions": [
      "Sunitinib"
    ],
    "primary_completion_date": "2009-06",
    "completion_date": "2009-06",
    "results_first_posted": "2016-12-08",
    "last_update_posted": "2018-10-25",
    "enrollment": null,
    "sponsor": "US Oncology Research",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ONC",
    "nct_id": "NCT00493870",
    "title": "TAC Versus TC for Adjuvant Breast Cancer",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Cancer"
    ],
    "interventions": [
      "Docetaxel",
      "Doxorubicin",
      "Cyclophosphamide"
    ],
    "primary_completion_date": "2015-05-31",
    "completion_date": "2020-03-30",
    "results_first_posted": "2023-03-02",
    "last_update_posted": "2023-03-02",
    "enrollment": null,
    "sponsor": "US Oncology Research",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ONC",
    "nct_id": "NCT00303108",
    "title": "Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Breast Cancer"
    ],
    "interventions": [
      "Pegylated liposomal doxorubicin",
      "Carboplatin",
      "trastuzumab"
    ],
    "primary_completion_date": "2010-03",
    "completion_date": "2011-06",
    "results_first_posted": "2016-11-03",
    "last_update_posted": "2016-11-03",
    "enrollment": null,
    "sponsor": "US Oncology Research",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ONC",
    "nct_id": "NCT00470236",
    "title": "Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the Breast",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Carcinoma, Ductal, Breast"
    ],
    "interventions": [
      "Standard WB fractionation",
      "Shorter WB fractionation",
      "Standard WB fractionation+Boost",
      "Shorter WB fractionation + Boost"
    ],
    "primary_completion_date": "2024-06",
    "completion_date": "2024-06",
    "results_first_posted": null,
    "last_update_posted": "2023-03-22",
    "enrollment": null,
    "sponsor": "Trans Tasman Radiation Oncology Group",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ONC",
    "nct_id": "NCT05508100",
    "title": "Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumor"
    ],
    "interventions": [
      "IO-108",
      "IO-108 + pembrolizumab",
      "IO-108 + tislelizumab"
    ],
    "primary_completion_date": "2024-04-30",
    "completion_date": "2024-04-30",
    "results_first_posted": null,
    "last_update_posted": "2024-05-24",
    "enrollment": null,
    "sponsor": "Immune-Onc Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ONC",
    "nct_id": "NCT00661492",
    "title": "Mitoxantrone \u00b1 Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Androgen-independent Prostate Cancer"
    ],
    "interventions": [
      "cetuximab",
      "Mitoxantrone"
    ],
    "primary_completion_date": "2011-03",
    "completion_date": "2011-06",
    "results_first_posted": "2016-12-09",
    "last_update_posted": "2016-12-09",
    "enrollment": null,
    "sponsor": "US Oncology Research",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ONC",
    "nct_id": "NCT05309187",
    "title": "Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor, Adult"
    ],
    "interventions": [
      "IO-202",
      "IO-202 + pembrolizumab combination therapy",
      "RP2D of IO-202 + pembrolizumab combination therapy in multiple solid tumor types"
    ],
    "primary_completion_date": "2024-03-29",
    "completion_date": "2024-05-31",
    "results_first_posted": null,
    "last_update_posted": "2024-06-04",
    "enrollment": null,
    "sponsor": "Immune-Onc Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ONC",
    "nct_id": "NCT00493649",
    "title": "Adj TC + Herceptin Early Stage Breast Cancer",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Cancer"
    ],
    "interventions": [
      "Taxotere",
      "Cytoxan",
      "Herceptin"
    ],
    "primary_completion_date": "2013-04",
    "completion_date": "2013-04",
    "results_first_posted": "2016-11-03",
    "last_update_posted": "2016-11-03",
    "enrollment": null,
    "sponsor": "US Oncology Research",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ONC",
    "nct_id": "NCT00250861",
    "title": "Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's Lymphoma",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-Hodgkin's Lymphoma"
    ],
    "interventions": [
      "Rituximab",
      "Aldesleukin"
    ],
    "primary_completion_date": "2007-08",
    "completion_date": "2007-08",
    "results_first_posted": null,
    "last_update_posted": "2008-04-21",
    "enrollment": null,
    "sponsor": "US Oncology Research",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ONC",
    "nct_id": "NCT00517829",
    "title": "Docetaxel+Oxali+/-Cetux Met Gastric/GEJ",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Gastric Cancer Adenocarcinoma Metastatic"
    ],
    "interventions": [
      "Docetaxel",
      "cetuximab",
      "oxaliplatin"
    ],
    "primary_completion_date": "2012-04",
    "completion_date": "2012-04",
    "results_first_posted": "2016-02-11",
    "last_update_posted": "2016-11-28",
    "enrollment": null,
    "sponsor": "US Oncology Research",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ONC",
    "nct_id": "NCT02534922",
    "title": "Study of Prolanta\u2122 in Recurrent or Persistent Epithelial Ovarian Cancer",
    "status": "UNKNOWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ovarian Cancer",
      "Peritoneal Cancer",
      "Fallopian Tube Cancer"
    ],
    "interventions": [
      "Prolanta, a human prolactin receptor antagonist"
    ],
    "primary_completion_date": "2019-02",
    "completion_date": "2019-02",
    "results_first_posted": null,
    "last_update_posted": "2018-02-14",
    "enrollment": null,
    "sponsor": "Oncolix, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ONC",
    "nct_id": "NCT02294357",
    "title": "Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple Myeloma"
    ],
    "interventions": [
      "Carfilzomib",
      "Dexamethasone",
      "Prednisone",
      "Methylprednisolone",
      "Lenalidomide",
      "Pomalidomide"
    ],
    "primary_completion_date": "2020-09-21",
    "completion_date": "2020-09-22",
    "results_first_posted": null,
    "last_update_posted": "2023-11-01",
    "enrollment": null,
    "sponsor": "Oncotherapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OPK",
    "nct_id": "NCT03762408",
    "title": "Efficacy and Safety of a Intra-articular Injection, ENKO1, in Patients With Symptomatic Knee Osteoarthritis.",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Osteoarthritis, Knee"
    ],
    "interventions": [
      "ENKO 1",
      "Durolane"
    ],
    "primary_completion_date": "2020-05-29",
    "completion_date": "2020-05-29",
    "results_first_posted": null,
    "last_update_posted": "2021-03-23",
    "enrollment": null,
    "sponsor": "OPKO Health, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OPK",
    "nct_id": "NCT04063644",
    "title": "Quality of Life and Visual Acuity of Visglyc Eye Drops on Dry Eye Patients",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dry Eye Syndromes",
      "Cataract"
    ],
    "interventions": [
      "Vis Glyc Neo",
      "Physiological saline solution"
    ],
    "primary_completion_date": "2020-12-22",
    "completion_date": "2020-12-22",
    "results_first_posted": null,
    "last_update_posted": "2021-03-23",
    "enrollment": null,
    "sponsor": "OPKO Health, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OPK",
    "nct_id": "NCT03355651",
    "title": "Efficacy and Tolerability of a Nutritional Supplement, Plactive Progen, in ACL Reconstruction",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "ACL Reconstruction"
    ],
    "interventions": [
      "PROGEN"
    ],
    "primary_completion_date": "2017-02-01",
    "completion_date": "2017-03-03",
    "results_first_posted": null,
    "last_update_posted": "2017-11-30",
    "enrollment": null,
    "sponsor": "OPKO Health, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ORIC",
    "nct_id": "NCT05227144",
    "title": "Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsed or Refractory Multiple Myeloma"
    ],
    "interventions": [
      "ORIC-533"
    ],
    "primary_completion_date": "2025-03-03",
    "completion_date": "2025-03-03",
    "results_first_posted": null,
    "last_update_posted": "2025-03-20",
    "enrollment": null,
    "sponsor": "ORIC Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ORIC",
    "nct_id": "NCT06012721",
    "title": "Effect of Food on the Pharmacokinetics of ORIC-114",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Food Effect in Healthy Participants"
    ],
    "interventions": [
      "ORIC-114"
    ],
    "primary_completion_date": "2023-11-23",
    "completion_date": "2023-11-23",
    "results_first_posted": null,
    "last_update_posted": "2024-01-19",
    "enrollment": null,
    "sponsor": "ORIC Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ORIC",
    "nct_id": "NCT03835637",
    "title": "Single and Multiple Dose Study of ORIC-101 in Adult Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "ORIC-101"
    ],
    "primary_completion_date": "2018-07-04",
    "completion_date": "2018-07-04",
    "results_first_posted": null,
    "last_update_posted": "2019-02-08",
    "enrollment": null,
    "sponsor": "ORIC Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ORIC",
    "nct_id": "NCT05315700",
    "title": "Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumors"
    ],
    "interventions": [
      "ORIC-114",
      "Chemotherapy drug"
    ],
    "primary_completion_date": "2026-09",
    "completion_date": "2027-09",
    "results_first_posted": null,
    "last_update_posted": "2025-08-05",
    "enrollment": null,
    "sponsor": "ORIC Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ORIC",
    "nct_id": "NCT03928314",
    "title": "Study of ORIC-101 in Combination With Anticancer Therapy",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor"
    ],
    "interventions": [
      "ORIC-101",
      "Nab-paclitaxel"
    ],
    "primary_completion_date": "2022-09-22",
    "completion_date": "2023-12-04",
    "results_first_posted": null,
    "last_update_posted": "2023-12-15",
    "enrollment": null,
    "sponsor": "ORIC Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ORIC",
    "nct_id": "NCT05413421",
    "title": "Study of ORIC-944 in Patients With Metastatic Prostate Cancer",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Prostate Cancer"
    ],
    "interventions": [
      "ORIC-944",
      "Abiraterone acetate (Zytiga\u00ae) 250 mg or 500 mg tablets",
      "Apalutamide (Erleada\u2122) 60 mg or 240 mg tablets",
      "Darolutamide (Nubeqa\u00ae) 300 mg tablets",
      "Enzalutamide (Xtandi\u00ae) 40 mg capsules or 40 mg and 80 mg tablets"
    ],
    "primary_completion_date": "2025-12",
    "completion_date": "2026-09",
    "results_first_posted": null,
    "last_update_posted": "2025-08-11",
    "enrollment": null,
    "sponsor": "ORIC Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ORIC",
    "nct_id": "NCT03324555",
    "title": "Study of ORIC-101 in Healthy Adult Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "ORIC-101"
    ],
    "primary_completion_date": "2017-12-18",
    "completion_date": "2017-12-18",
    "results_first_posted": null,
    "last_update_posted": "2018-04-05",
    "enrollment": null,
    "sponsor": "ORIC Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ORIC",
    "nct_id": "NCT04033328",
    "title": "Study of ORIC-101 in Combination With Enzalutamide",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Prostatic Neoplasms"
    ],
    "interventions": [
      "ORIC-101",
      "enzalutamide 40 MG oral capsule [Xtandi]"
    ],
    "primary_completion_date": "2022-11-22",
    "completion_date": "2023-12-04",
    "results_first_posted": null,
    "last_update_posted": "2023-12-15",
    "enrollment": null,
    "sponsor": "ORIC Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ORIC",
    "nct_id": "NCT06816992",
    "title": "ORIC-114 in Combination with Subcutaneous Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumors",
      "EGFR Exon 20 Insertion Mutations",
      "NSCLC",
      "EGFR-mutated NSCLC"
    ],
    "interventions": [
      "ORIC-114 Dose 1 + amivantamab",
      "ORIC-114 Dose 2 + amivantamab",
      "ORIC-114 Dose 3 + amivantamab"
    ],
    "primary_completion_date": "2026-05",
    "completion_date": "2027-05",
    "results_first_posted": null,
    "last_update_posted": "2025-03-20",
    "enrollment": null,
    "sponsor": "ORIC Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PHAT",
    "nct_id": "NCT06989762",
    "title": "Intraabdominal Pressure Monitoring Urinary Catheter and Kidney Perfusion Pressure",
    "status": "NOT_YET_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Kidney Injury"
    ],
    "interventions": [
      "Conventional Foley Catheter(Medline)",
      "Accuryn Foley Catheter"
    ],
    "primary_completion_date": "2027-06-01",
    "completion_date": "2027-10-01",
    "results_first_posted": null,
    "last_update_posted": "2025-07-01",
    "enrollment": null,
    "sponsor": "Dang Tan Phat",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PRAX",
    "nct_id": "NCT06908356",
    "title": "An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Focal Onset Seizure",
      "Primary Generalized Epilepsy"
    ],
    "interventions": [
      "30mg PRAX-628"
    ],
    "primary_completion_date": "2025-07",
    "completion_date": "2025-07",
    "results_first_posted": null,
    "last_update_posted": "2025-04-03",
    "enrollment": null,
    "sponsor": "Praxis Precision Medicines",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PRAX",
    "nct_id": "NCT05021991",
    "title": "A Clinical Trial of 2 Doses of PRAX-944 in Participants With Essential Tremor",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Essential Tremor"
    ],
    "interventions": [
      "100 mg PRAX-944",
      "60 mg PRAX-944",
      "Placebo",
      "Flexibly dosed 20 mg to 100 mg PRAX-944"
    ],
    "primary_completion_date": "2023-02-09",
    "completion_date": "2024-02-29",
    "results_first_posted": null,
    "last_update_posted": "2024-03-13",
    "enrollment": null,
    "sponsor": "Praxis Precision Medicines",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PRAX",
    "nct_id": "NCT06840925",
    "title": "A Clinical Trial to Evaluate the Relative Bioavailability of PRAX-628",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "PRAX-628"
    ],
    "primary_completion_date": "2025-05-30",
    "completion_date": "2025-06-30",
    "results_first_posted": null,
    "last_update_posted": "2025-02-21",
    "enrollment": null,
    "sponsor": "Praxis Precision Medicines",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PRAX",
    "nct_id": "NCT06999902",
    "title": "Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1)",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Focal Seizure"
    ],
    "interventions": [
      "20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks",
      "Placebo"
    ],
    "primary_completion_date": "2025-11-24",
    "completion_date": "2025-12-08",
    "results_first_posted": null,
    "last_update_posted": "2025-05-31",
    "enrollment": null,
    "sponsor": "Praxis Precision Medicines",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "QURE",
    "nct_id": "NCT03765203",
    "title": "Utility of a Novel Dd-cfDNA Test to Detect Injury in Renal Post-Transplant Patients",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Transplant;Failure,Kidney"
    ],
    "interventions": [
      "Natera KidneyScan",
      "Clinical Performance and Value Vignettes"
    ],
    "primary_completion_date": "2019-01-07",
    "completion_date": "2019-01-07",
    "results_first_posted": null,
    "last_update_posted": "2020-09-16",
    "enrollment": null,
    "sponsor": "Qure Healthcare, LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "QURE",
    "nct_id": "NCT05702385",
    "title": "Clinical Utility Study for Exo-PDAC",
    "status": "WITHDRAWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pancreas Cancer"
    ],
    "interventions": [
      "Educational Materials for a new diagnostic test"
    ],
    "primary_completion_date": "2023-10-31",
    "completion_date": "2023-10-31",
    "results_first_posted": null,
    "last_update_posted": "2023-12-07",
    "enrollment": null,
    "sponsor": "Qure Healthcare, LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "QURE",
    "nct_id": "NCT03800901",
    "title": "Quality IQ Patient Simulation Physician Practice Measurement and Engagement",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes",
      "Hypertension",
      "Depression",
      "Osteoarthritis",
      "Asthma",
      "Pain",
      "Heart Failure"
    ],
    "interventions": [
      "Continuing Medical Education",
      "Quality IQ Patient Simulations"
    ],
    "primary_completion_date": "2019-03-11",
    "completion_date": "2019-04-15",
    "results_first_posted": null,
    "last_update_posted": "2020-03-03",
    "enrollment": null,
    "sponsor": "Qure Healthcare, LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "QURE",
    "nct_id": "NCT05910697",
    "title": "Clinical Utility of MyProstateScore 2.0 P2",
    "status": "TERMINATED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Prostate Cancer"
    ],
    "interventions": [
      "MyProstateScore 2.0 Results"
    ],
    "primary_completion_date": "2023-10-18",
    "completion_date": "2023-10-18",
    "results_first_posted": null,
    "last_update_posted": "2023-11-15",
    "enrollment": null,
    "sponsor": "Qure Healthcare, LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "QURE",
    "nct_id": "NCT04550416",
    "title": "Effects of a New Diagnostic Test on the Care of Prostate Cancer Patients: The ProMark\u2122 Clinical Utility Study",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Prostate Cancer"
    ],
    "interventions": [
      "ProMark Information and Test Results"
    ],
    "primary_completion_date": "2015-01",
    "completion_date": "2015-01",
    "results_first_posted": null,
    "last_update_posted": "2020-09-16",
    "enrollment": null,
    "sponsor": "Qure Healthcare, LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "QURE",
    "nct_id": "NCT05910684",
    "title": "Establishing Clinical Utility Evidence for Chronic Disease Management Testing Patient Study",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cardiometabolic Syndrome"
    ],
    "interventions": [
      "Aegis CDM Test and Educational Materials"
    ],
    "primary_completion_date": "2024-01-30",
    "completion_date": "2024-01-30",
    "results_first_posted": null,
    "last_update_posted": "2024-04-02",
    "enrollment": null,
    "sponsor": "Qure Healthcare, LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "QURE",
    "nct_id": "NCT05237271",
    "title": "Clinical Utility Trial for the SomaLogic CVD-T2D Test",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cardiovascular Diseases",
      "Type 2 Diabetes"
    ],
    "interventions": [
      "Educational Materials on the Cardiovascular Disease in Type 2 Diabetes (CVD-T2D)",
      "Educational Materials on the CVD-T2D and Bundled Metabolic Panel"
    ],
    "primary_completion_date": "2022-08-15",
    "completion_date": "2022-08-15",
    "results_first_posted": null,
    "last_update_posted": "2022-08-22",
    "enrollment": null,
    "sponsor": "Qure Healthcare, LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "QURE",
    "nct_id": "NCT04080037",
    "title": "Assessing Opioid Care Practices Using CPV Patient Simulation Modules",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pain",
      "Pain, Acute",
      "Pain, Chronic",
      "Pain, Neuropathic",
      "Opioid-use Disorder",
      "Opioid Abuse and Addiction",
      "Opioid Withdrawal"
    ],
    "interventions": [
      "Quality IQ Patient Simulations"
    ],
    "primary_completion_date": "2019-10-29",
    "completion_date": "2019-10-29",
    "results_first_posted": null,
    "last_update_posted": "2020-02-10",
    "enrollment": null,
    "sponsor": "Qure Healthcare, LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "QURE",
    "nct_id": "NCT02414438",
    "title": "Establishing the Clinical Utility of First StepDx PLUS and NextStepDx PLUS Study",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Intellectual Disability",
      "Developmental Delay"
    ],
    "interventions": [
      "FirstStepDX PLUS and NextStepDX PLUS Webinar",
      "FirstStepDX PLUS and NextStepDX PLUS Test Results"
    ],
    "primary_completion_date": "2015-01",
    "completion_date": "2015-01",
    "results_first_posted": null,
    "last_update_posted": "2015-04-10",
    "enrollment": null,
    "sponsor": "Qure Healthcare, LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "QURE",
    "nct_id": "NCT05200325",
    "title": "Clinical Utility Evidence for TissueCypher\u00ae",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Gastro-Intestinal Disorder",
      "Barrett Esophagus"
    ],
    "interventions": [
      "Educational materials for TissueCypher"
    ],
    "primary_completion_date": "2021-12-15",
    "completion_date": "2021-12-15",
    "results_first_posted": null,
    "last_update_posted": "2023-12-04",
    "enrollment": null,
    "sponsor": "Qure Healthcare, LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "QURE",
    "nct_id": "NCT03765164",
    "title": "Glucose Control Using 1,5-AG Testing",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes"
    ],
    "interventions": [
      "GlycoMark 1-5-AG",
      "Clinical Performance and Value Vignettes"
    ],
    "primary_completion_date": "2019-02-24",
    "completion_date": "2019-02-24",
    "results_first_posted": "2020-10-08",
    "last_update_posted": "2020-10-28",
    "enrollment": null,
    "sponsor": "Qure Healthcare, LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "QURE",
    "nct_id": "NCT04266821",
    "title": "Establishing Clinical Utility of a New Diagnostic Test for Patients Suffering From Pain: A CPV\u00ae Randomized Controlled Trial",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pain",
      "Pain, Chronic"
    ],
    "interventions": [
      "Experimental Arm"
    ],
    "primary_completion_date": "2020-05-04",
    "completion_date": "2020-05-31",
    "results_first_posted": null,
    "last_update_posted": "2020-09-16",
    "enrollment": null,
    "sponsor": "Qure Healthcare, LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "QURE",
    "nct_id": "NCT02915653",
    "title": "Adult Primary and Preventive Practice (APPP) Study",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Preventive Care"
    ],
    "interventions": [
      "Educational materials on a new diagnostic service"
    ],
    "primary_completion_date": "2016-11",
    "completion_date": "2017-11",
    "results_first_posted": null,
    "last_update_posted": "2018-06-20",
    "enrollment": null,
    "sponsor": "Qure Healthcare, LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "QURE",
    "nct_id": "NCT05525806",
    "title": "Clinical Utility Study for MyProstateScore+",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Prostate Cancer"
    ],
    "interventions": [
      "Education Materials for MyProstateScore"
    ],
    "primary_completion_date": "2023-06-04",
    "completion_date": "2023-06-04",
    "results_first_posted": null,
    "last_update_posted": "2023-06-13",
    "enrollment": null,
    "sponsor": "Qure Healthcare, LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "QURE",
    "nct_id": "NCT04266834",
    "title": "Establishing Clinical Utility of a New Diagnostic Test in Patients Undergoing Cardiac Catheterization",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "AKI",
      "Contrast-induced Nephropathy"
    ],
    "interventions": [
      "Experimental Arm"
    ],
    "primary_completion_date": "2020-06-01",
    "completion_date": "2020-06-30",
    "results_first_posted": null,
    "last_update_posted": "2020-09-16",
    "enrollment": null,
    "sponsor": "Qure Healthcare, LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "QURE",
    "nct_id": "NCT05192590",
    "title": "Establishing Clinical Utility Evidence for Chronic Disease Management Testing",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cardiometabolic Syndrome"
    ],
    "interventions": [
      "Educational Materials and Chronic Disease Management Test (CDMT)"
    ],
    "primary_completion_date": "2022-02-21",
    "completion_date": "2023-02-22",
    "results_first_posted": null,
    "last_update_posted": "2022-12-05",
    "enrollment": null,
    "sponsor": "Qure Healthcare, LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "QURE",
    "nct_id": "NCT04693793",
    "title": "Establishing Clinical Utility for a New Diagnostic Test for Patients With Shortness of Breath",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dyspnea",
      "Unexplained Chronic Dyspnea"
    ],
    "interventions": [
      "Education Materials and Janssen Test"
    ],
    "primary_completion_date": "2022-09-15",
    "completion_date": "2022-10-15",
    "results_first_posted": null,
    "last_update_posted": "2023-12-07",
    "enrollment": null,
    "sponsor": "Qure Healthcare, LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "QURE",
    "nct_id": "NCT05603299",
    "title": "Establishing Clinical Utility Evidence to Support Coverage and Reimbursement for Venn Biosciences' Dawn Test",
    "status": "WITHDRAWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non Small Cell Lung Cancer"
    ],
    "interventions": [
      "Educational Materials on the Dawn test"
    ],
    "primary_completion_date": "2023-12-18",
    "completion_date": "2023-12-18",
    "results_first_posted": null,
    "last_update_posted": "2023-06-15",
    "enrollment": null,
    "sponsor": "Qure Healthcare, LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "QURE",
    "nct_id": "NCT07099001",
    "title": "Establishing Clinical Utility Evidence for a Novel Alzheimer's Disease Blood-Based Biomarker Assay",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alzheimer Disease (AD)",
      "Cognitive Decline"
    ],
    "interventions": [
      "Educational materials on the Alzheimer's disease assay",
      "Alzheimer's disease assay results"
    ],
    "primary_completion_date": "2025-12-31",
    "completion_date": "2025-12-31",
    "results_first_posted": null,
    "last_update_posted": "2026-01-07",
    "enrollment": null,
    "sponsor": "Qure Healthcare, LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "QURE",
    "nct_id": "NCT03581994",
    "title": "DDI Effectiveness and Clinical Awareness",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Drug-Drug Interactions"
    ],
    "interventions": [
      "DDI Test Report"
    ],
    "primary_completion_date": "2018-07-19",
    "completion_date": "2018-08-28",
    "results_first_posted": null,
    "last_update_posted": "2019-03-20",
    "enrollment": null,
    "sponsor": "Qure Healthcare, LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "QURE",
    "nct_id": "NCT04204018",
    "title": "Measuring Practice Pattern Changes and Clinical Utility of a Novel Test for Preeclampsia",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pre-Eclampsia"
    ],
    "interventions": [
      "Experimental Arm"
    ],
    "primary_completion_date": "2019-12-23",
    "completion_date": "2019-12-23",
    "results_first_posted": null,
    "last_update_posted": "2020-02-10",
    "enrollment": null,
    "sponsor": "Qure Healthcare, LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "QURE",
    "nct_id": "NCT05658653",
    "title": "Clinical Utility of CDMT Among VillageMD Providers",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Disease",
      "Drug Drug Interaction",
      "Medication Adherence"
    ],
    "interventions": [
      "Educational Materials for Chronic Disease Management Test (CDMT)"
    ],
    "primary_completion_date": "2023-01-10",
    "completion_date": "2023-01-10",
    "results_first_posted": null,
    "last_update_posted": "2023-03-29",
    "enrollment": null,
    "sponsor": "Qure Healthcare, LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "QURE",
    "nct_id": "NCT04266860",
    "title": "Establishing Clinical Utility of a New Diagnostic Test for Rheumatology Patients",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lupus Nephritis",
      "Lupus Erythematosus, Systemic"
    ],
    "interventions": [
      "Experimental - Test Results and Education"
    ],
    "primary_completion_date": "2012-06-01",
    "completion_date": "2013-03-01",
    "results_first_posted": null,
    "last_update_posted": "2020-09-16",
    "enrollment": null,
    "sponsor": "Qure Healthcare, LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RAPT",
    "nct_id": "NCT02335814",
    "title": "First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Myeloid Leukemia"
    ],
    "interventions": [
      "FLX925"
    ],
    "primary_completion_date": "2017-05-03",
    "completion_date": "2017-05-03",
    "results_first_posted": null,
    "last_update_posted": "2018-02-09",
    "enrollment": null,
    "sponsor": "RAPT Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RAPT",
    "nct_id": "NCT04894994",
    "title": "FLX475 in Combination With Ipilimumab in Advanced Melanoma",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Melanoma"
    ],
    "interventions": [
      "FLX475",
      "Ipilimumab"
    ],
    "primary_completion_date": "2022-09-13",
    "completion_date": "2022-09-13",
    "results_first_posted": "2023-12-05",
    "last_update_posted": "2023-12-05",
    "enrollment": null,
    "sponsor": "RAPT Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RAPT",
    "nct_id": "NCT07220811",
    "title": "Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ig-E Mediated Food Allergy"
    ],
    "interventions": [
      "RPT904",
      "RPT904",
      "Placebo",
      "RPT904",
      "RPT904",
      "Placebo"
    ],
    "primary_completion_date": "2027-04",
    "completion_date": "2028-01",
    "results_first_posted": null,
    "last_update_posted": "2025-12-29",
    "enrollment": null,
    "sponsor": "RAPT Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RAPT",
    "nct_id": "NCT03674567",
    "title": "Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Cancer"
    ],
    "interventions": [
      "FLX475",
      "pembrolizumab (KEYTRUDA\u00ae)"
    ],
    "primary_completion_date": "2024-12-31",
    "completion_date": "2024-12-31",
    "results_first_posted": null,
    "last_update_posted": "2025-01-24",
    "enrollment": null,
    "sponsor": "RAPT Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RAPT",
    "nct_id": "NCT05935332",
    "title": "Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Asthma"
    ],
    "interventions": [
      "RPT193",
      "Placebo"
    ],
    "primary_completion_date": "2024-06-21",
    "completion_date": "2024-06-21",
    "results_first_posted": null,
    "last_update_posted": "2024-07-22",
    "enrollment": null,
    "sponsor": "RAPT Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RAPT",
    "nct_id": "NCT05399368",
    "title": "An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atopic Dermatitis"
    ],
    "interventions": [
      "RPT193",
      "Placebo"
    ],
    "primary_completion_date": "2024-05-24",
    "completion_date": "2024-05-24",
    "results_first_posted": null,
    "last_update_posted": "2024-06-14",
    "enrollment": null,
    "sponsor": "RAPT Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RAPT",
    "nct_id": "NCT06087978",
    "title": "Study of RPT193 in Healthy Adult Male Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Male Subjects"
    ],
    "interventions": [
      "14C RPT193"
    ],
    "primary_completion_date": "2023-10-12",
    "completion_date": "2023-10-12",
    "results_first_posted": null,
    "last_update_posted": "2023-11-29",
    "enrollment": null,
    "sponsor": "RAPT Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RAPT",
    "nct_id": "NCT04271514",
    "title": "A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atopic Dermatitis"
    ],
    "interventions": [
      "RPT193",
      "Placebo"
    ],
    "primary_completion_date": "2021-04-26",
    "completion_date": "2021-04-26",
    "results_first_posted": null,
    "last_update_posted": "2021-09-30",
    "enrollment": null,
    "sponsor": "RAPT Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "REGN",
    "nct_id": "NCT04519437",
    "title": "Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy",
      "Chronic Stable Illness"
    ],
    "interventions": [
      "REGN10933+REGN10987",
      "Placebo"
    ],
    "primary_completion_date": "2021-11-22",
    "completion_date": "2021-11-22",
    "results_first_posted": null,
    "last_update_posted": "2022-01-26",
    "enrollment": null,
    "sponsor": "Regeneron Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "REGN",
    "nct_id": "NCT04452318",
    "title": "COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants"
    ],
    "interventions": [
      "REGN10933 + REGN10987",
      "Placebo"
    ],
    "primary_completion_date": "2021-10-04",
    "completion_date": "2021-10-04",
    "results_first_posted": "2023-05-15",
    "last_update_posted": "2023-05-15",
    "enrollment": null,
    "sponsor": "Regeneron Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "REGN",
    "nct_id": "NCT05181683",
    "title": "COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy",
      "Chronic Stable Illness"
    ],
    "interventions": [
      "Casirivimab+Imdevimab"
    ],
    "primary_completion_date": "2022-06-03",
    "completion_date": "2022-06-03",
    "results_first_posted": null,
    "last_update_posted": "2025-10-14",
    "enrollment": null,
    "sponsor": "Regeneron Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "REGN",
    "nct_id": "NCT01197391",
    "title": "Ascending Dose Study of the Safety and Tolerability of REGN728 in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "REGN728"
    ],
    "primary_completion_date": "2012-03",
    "completion_date": "2012-03",
    "results_first_posted": null,
    "last_update_posted": "2012-11-12",
    "enrollment": null,
    "sponsor": "Regeneron Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "REGN",
    "nct_id": "NCT04506645",
    "title": "Study to Assess the Safety, Tolerability, and Pharmacokinetics of REGN5381 (an NPR1 Agonist) in Adult Humans",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "REGN5381",
      "Placebo"
    ],
    "primary_completion_date": "2022-12-14",
    "completion_date": "2022-12-14",
    "results_first_posted": null,
    "last_update_posted": "2022-12-20",
    "enrollment": null,
    "sponsor": "Regeneron Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "REGN",
    "nct_id": "NCT03576690",
    "title": "R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus Disease",
    "status": "AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Ebola Virus Disease"
    ],
    "interventions": [
      "REGN3470-3471-3479"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2025-11-24",
    "enrollment": null,
    "sponsor": "Regeneron Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "REGN",
    "nct_id": "NCT03088540",
    "title": "Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Carcinoma\uff0cNon-Small-Cell Lung",
      "Lung Carcinomas, Non-Small-Cell",
      "Non-small-cell Lung Carcinoma",
      "Nonsmall Cell Lung Cancer"
    ],
    "interventions": [
      "Pemetrexed",
      "Paclitaxel",
      "Gemcitabine",
      "Cisplatin",
      "Carboplatin",
      "cemiplimab"
    ],
    "primary_completion_date": "2025-04-18",
    "completion_date": "2025-04-18",
    "results_first_posted": null,
    "last_update_posted": "2025-05-04",
    "enrollment": null,
    "sponsor": "Regeneron Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "REGN",
    "nct_id": "NCT04426695",
    "title": "Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID-19"
    ],
    "interventions": [
      "REGN10933+REGN10987 combination therapy",
      "Placebo"
    ],
    "primary_completion_date": "2021-05-07",
    "completion_date": "2021-10-22",
    "results_first_posted": "2022-07-25",
    "last_update_posted": "2023-01-27",
    "enrollment": null,
    "sponsor": "Regeneron Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "REGN",
    "nct_id": "NCT05074433",
    "title": "A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Immunocompromised"
    ],
    "interventions": [
      "casirivimab+imdevimab",
      "Placebo"
    ],
    "primary_completion_date": "2022-05-18",
    "completion_date": "2022-05-18",
    "results_first_posted": "2023-07-24",
    "last_update_posted": "2025-10-20",
    "enrollment": null,
    "sponsor": "Regeneron Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "REGN",
    "nct_id": "NCT04425629",
    "title": "Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID-19"
    ],
    "interventions": [
      "casirivimab+imdevimab combination therapy"
    ],
    "primary_completion_date": "2022-01-21",
    "completion_date": "2022-06-09",
    "results_first_posted": "2023-12-21",
    "last_update_posted": "2023-12-21",
    "enrollment": null,
    "sponsor": "Regeneron Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "REGN",
    "nct_id": "NCT05092581",
    "title": "COVID-19 Study of Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) for the Treatment of Pediatric Patients Hospitalized Due to COVID-19",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID-19"
    ],
    "interventions": [
      "casirivimab+imdevimab"
    ],
    "primary_completion_date": "2022-06-09",
    "completion_date": "2022-06-09",
    "results_first_posted": null,
    "last_update_posted": "2025-10-14",
    "enrollment": null,
    "sponsor": "Regeneron Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "REGN",
    "nct_id": "NCT04617535",
    "title": "Compassionate Use of REGN-COV2 for the Treatment of COVID-19",
    "status": "NO_LONGER_AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "COVID-19"
    ],
    "interventions": [
      "REGN10933+REGN10987 combination therapy"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2023-10-03",
    "enrollment": null,
    "sponsor": "Regeneron Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "REGN",
    "nct_id": "NCT04992273",
    "title": "COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID-19"
    ],
    "interventions": [
      "casirivimab+imdevimab"
    ],
    "primary_completion_date": "2022-06-01",
    "completion_date": "2022-06-01",
    "results_first_posted": "2023-03-06",
    "last_update_posted": "2025-10-20",
    "enrollment": null,
    "sponsor": "Regeneron Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "REGN",
    "nct_id": "NCT05081388",
    "title": "COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "SARS-CoV-2"
    ],
    "interventions": [
      "REGN14256",
      "imdevimab",
      "casirivimab + imdevimab",
      "Placebo"
    ],
    "primary_completion_date": "2022-06-30",
    "completion_date": "2022-06-30",
    "results_first_posted": "2024-04-26",
    "last_update_posted": "2025-10-28",
    "enrollment": null,
    "sponsor": "Regeneron Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "REGN",
    "nct_id": "NCT05291546",
    "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9035 in Healthy Adult Volunteers and Mildly Hypertensive Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "REGN9035",
      "REGN5381",
      "Placebo"
    ],
    "primary_completion_date": "2024-04-02",
    "completion_date": "2024-04-02",
    "results_first_posted": null,
    "last_update_posted": "2024-04-15",
    "enrollment": null,
    "sponsor": "Regeneron Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "REGN",
    "nct_id": "NCT04666441",
    "title": "COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID-19"
    ],
    "interventions": [
      "REGN10933+REGN10987 combination therapy",
      "Placebo"
    ],
    "primary_completion_date": "2021-03-04",
    "completion_date": "2021-09-21",
    "results_first_posted": "2022-04-08",
    "last_update_posted": "2022-04-08",
    "enrollment": null,
    "sponsor": "Regeneron Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "REGN",
    "nct_id": "NCT04852978",
    "title": "COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy",
      "Chronic Stable Illness"
    ],
    "interventions": [
      "casirivimab+imdevimab",
      "Moderna mRNA-1273 vaccine"
    ],
    "primary_completion_date": "2022-11-21",
    "completion_date": "2022-11-21",
    "results_first_posted": "2024-08-20",
    "last_update_posted": "2025-10-20",
    "enrollment": null,
    "sponsor": "Regeneron Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SION",
    "nct_id": "NCT04034810",
    "title": "Safety and Efficacy of Silk Vista and Silk Vista Baby Flow Diverter for Intracranial Aneurysm Treatment",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Intracranial Aneurysm",
      "Flow Diverter"
    ],
    "interventions": [
      "Intracranial aneurysm treated with Silk vista and silk vista baby"
    ],
    "primary_completion_date": "2023-03-01",
    "completion_date": "2027-11-30",
    "results_first_posted": null,
    "last_update_posted": "2025-09-17",
    "enrollment": null,
    "sponsor": "Balt Extrusion",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SLN",
    "nct_id": "NCT05499013",
    "title": "Study to Assess SLN124 in Patients With Polycythemia Vera",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Polycythemia Vera"
    ],
    "interventions": [
      "SLN124",
      "Placebo"
    ],
    "primary_completion_date": "2026-09",
    "completion_date": "2030-03",
    "results_first_posted": null,
    "last_update_posted": "2025-12-19",
    "enrollment": null,
    "sponsor": "Silence Therapeutics plc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TEM",
    "nct_id": "NCT02379104",
    "title": "ROTEM\u00ae Sigma Performance Evaluation - Method Comparison With Predicate Device and Reference Intervals",
    "status": "UNKNOWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Blood Coagulation Disorders"
    ],
    "interventions": [
      "ROTEM sigma"
    ],
    "primary_completion_date": "2018-10",
    "completion_date": "2018-12",
    "results_first_posted": null,
    "last_update_posted": "2017-05-11",
    "enrollment": null,
    "sponsor": "Tem Innovations GmbH",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TEM",
    "nct_id": "NCT05093556",
    "title": "Interactive CBT for Headache And Relaxation Training",
    "status": "TERMINATED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Post-Traumatic Headache"
    ],
    "interventions": [
      "iCHART - Interactive CBT for Headache And Relaxation Training"
    ],
    "primary_completion_date": "2023-10-01",
    "completion_date": "2023-10-01",
    "results_first_posted": null,
    "last_update_posted": "2024-01-10",
    "enrollment": null,
    "sponsor": "VA Connecticut Healthcare System",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TERN",
    "nct_id": "NCT04897594",
    "title": "AVIATION Study: A Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "NASH - Nonalcoholic Steatohepatitis"
    ],
    "interventions": [
      "TERN-201",
      "Placebo"
    ],
    "primary_completion_date": "2022-09-02",
    "completion_date": "2022-09-02",
    "results_first_posted": "2024-06-07",
    "last_update_posted": "2024-06-07",
    "enrollment": null,
    "sponsor": "Terns, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TERN",
    "nct_id": "NCT05415722",
    "title": "DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic Steatohepatitis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "NASH - Nonalcoholic Steatohepatitis"
    ],
    "interventions": [
      "TERN-501",
      "TERN-101",
      "Placebo"
    ],
    "primary_completion_date": "2023-07-10",
    "completion_date": "2023-07-10",
    "results_first_posted": "2025-03-12",
    "last_update_posted": "2025-03-12",
    "enrollment": null,
    "sponsor": "Terns, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TERN",
    "nct_id": "NCT05791864",
    "title": "A First-in-Human, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With TTX-381 for the Ocular Manifestations Associated With Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) Disease",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Neuronal Ceroid Lipofuscinosis Type 2"
    ],
    "interventions": [
      "TTX-381"
    ],
    "primary_completion_date": "2026-07-30",
    "completion_date": "2031-07-30",
    "results_first_posted": null,
    "last_update_posted": "2025-12-18",
    "enrollment": null,
    "sponsor": "Tern Therapeutics, LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TERN",
    "nct_id": "NCT04328077",
    "title": "LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "NASH - Nonalcoholic Steatohepatitis"
    ],
    "interventions": [
      "TERN-101",
      "Placebo"
    ],
    "primary_completion_date": "2021-05-19",
    "completion_date": "2021-05-19",
    "results_first_posted": "2022-06-14",
    "last_update_posted": "2022-08-09",
    "enrollment": null,
    "sponsor": "Terns, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TVTX",
    "nct_id": "NCT05856760",
    "title": "A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Immunoglobulin A Nephropathy"
    ],
    "interventions": [
      "Sparsentan"
    ],
    "primary_completion_date": "2024-10-14",
    "completion_date": "2024-10-25",
    "results_first_posted": "2025-11-20",
    "last_update_posted": "2025-11-20",
    "enrollment": null,
    "sponsor": "Travere Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TVTX",
    "nct_id": "NCT07219121",
    "title": "Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis",
    "status": "RECRUITING",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Proteinuria",
      "Immunoglobulin A (IgA) Nephropathy",
      "Focal Segmental Glomerulosclerosis",
      "Kidney Transplant"
    ],
    "interventions": [
      "Sparsentan"
    ],
    "primary_completion_date": "2027-03",
    "completion_date": "2027-05",
    "results_first_posted": null,
    "last_update_posted": "2025-12-19",
    "enrollment": null,
    "sponsor": "Travere Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TVTX",
    "nct_id": "NCT06247085",
    "title": "A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants \u226512 to \u226465 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine Beta Synthase Deficiency Receiving Standard of Care Treatment",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Homocystinuria"
    ],
    "interventions": [
      "Pegtibatinase",
      "Placebo"
    ],
    "primary_completion_date": "2025-12",
    "completion_date": "2026-01",
    "results_first_posted": null,
    "last_update_posted": "2025-04-09",
    "enrollment": null,
    "sponsor": "Travere Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TVTX",
    "nct_id": "NCT06431893",
    "title": "A Phase 3 Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants \u22655 to \u226465 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE)",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Homocystinuria"
    ],
    "interventions": [
      "Pegtibatinase"
    ],
    "primary_completion_date": "2027-01",
    "completion_date": "2027-01",
    "results_first_posted": null,
    "last_update_posted": "2025-04-11",
    "enrollment": null,
    "sponsor": "Travere Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TVTX",
    "nct_id": "NCT05200871",
    "title": "Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy)",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Focal Segmental Glomerulosclerosis",
      "Immunoglobulin A Nephropathy"
    ],
    "interventions": [],
    "primary_completion_date": "2023-10-31",
    "completion_date": "2023-10-31",
    "results_first_posted": null,
    "last_update_posted": "2024-02-21",
    "enrollment": null,
    "sponsor": "Travere Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TYRA",
    "nct_id": "NCT07265947",
    "title": "Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Low Grade Upper Tract Urothelial Carcinoma"
    ],
    "interventions": [
      "Dabogratinib (TYRA-300) 60mg",
      "Dabogratinib (TYRA-300) 80mg",
      "Dabogratinib (TYRA-300) TBD"
    ],
    "primary_completion_date": "2030-10",
    "completion_date": "2030-11",
    "results_first_posted": null,
    "last_update_posted": "2026-01-16",
    "enrollment": null,
    "sponsor": "Tyra Biosciences, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TYRA",
    "nct_id": "NCT05544552",
    "title": "Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Locally Advanced Urothelial Carcinoma",
      "Metastatic Urothelial Carcinoma",
      "Solid Tumor",
      "Urothelial Carcinoma",
      "Solid Tumor, Adult",
      "Bladder Cancer",
      "Non-muscle-invasive Bladder Cancer",
      "FGFR3 Gene Mutation",
      "FGFR3 Gene Alteration",
      "Advanced Solid Tumor",
      "Advanced Urothelial Carcinoma",
      "Urinary Tract Cancer",
      "Urinary Tract Tumor",
      "Urinary Tract Carcinoma"
    ],
    "interventions": [
      "TYRA-300"
    ],
    "primary_completion_date": "2026-11",
    "completion_date": "2027-06",
    "results_first_posted": null,
    "last_update_posted": "2026-01-12",
    "enrollment": null,
    "sponsor": "Tyra Biosciences, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TYRA",
    "nct_id": "NCT06842355",
    "title": "A Study of TYRA-300 in Children With Achondroplasia: BEACH301",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Achondroplasia"
    ],
    "interventions": [
      "TYRA-300 0.125 mg/kg",
      "TYRA-300 0.25 mg/kg",
      "TYRA-300 0.375 mg/kg",
      "TYRA-300 0.50 mg/kg"
    ],
    "primary_completion_date": "2030-01",
    "completion_date": "2030-06",
    "results_first_posted": null,
    "last_update_posted": "2026-01-15",
    "enrollment": null,
    "sponsor": "Tyra Biosciences, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TYRA",
    "nct_id": "NCT06915753",
    "title": "Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Hepatocellular Carcinoma",
      "Solid Tumors",
      "Solid Tumor, Adult",
      "FGFR Gene Amplification",
      "FGFR Gene Alterations",
      "FGFR3 Gene Alteration",
      "FGFR3 Gene Mutation",
      "Advanced Solid Tumors",
      "FGFR4 Gene Mutation",
      "FGFR4 Gene Fusions",
      "FGF19 Gene Amplification",
      "FGF19 Gene Overexpression",
      "FGFR3 Gene Fusions",
      "Locally Advanced Unresectable Hepatocellular Carcinoma"
    ],
    "interventions": [
      "TYRA-430"
    ],
    "primary_completion_date": "2028-01",
    "completion_date": "2028-09",
    "results_first_posted": null,
    "last_update_posted": "2025-11-20",
    "enrollment": null,
    "sponsor": "Tyra Biosciences, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TYRA",
    "nct_id": "NCT06006702",
    "title": "A Relative Bioavailability and Food Effect Study of TYRA-300-B01 Capsule and Tablet Formulations in Healthy Adult Participants",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "TYRA-300-B01"
    ],
    "primary_completion_date": "2025-05",
    "completion_date": "2025-07",
    "results_first_posted": null,
    "last_update_posted": "2025-03-26",
    "enrollment": null,
    "sponsor": "Tyra Biosciences, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TYRA",
    "nct_id": "NCT06160752",
    "title": "Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Locally Advanced Cholangiocarcinoma",
      "Intrahepatic Cholangiocarcinoma",
      "Solid Tumor",
      "Metastatic Cholangiocarcinoma"
    ],
    "interventions": [
      "Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles",
      "Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles"
    ],
    "primary_completion_date": "2026-09",
    "completion_date": "2027-09",
    "results_first_posted": null,
    "last_update_posted": "2024-10-03",
    "enrollment": null,
    "sponsor": "Tyra Biosciences, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TYRA",
    "nct_id": "NCT06995677",
    "title": "Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Low-grade NMIBC",
      "FGFR Gene Amplification",
      "FGFR Gene Alterations",
      "FGFR3 Gene Alteration",
      "FGFR3 Gene Mutation",
      "FGFR3 Gene Fusions"
    ],
    "interventions": [
      "TYRA-300 60mg",
      "TYRA-300 50mg",
      "TYRA-300 Dose TBD"
    ],
    "primary_completion_date": "2028-02",
    "completion_date": "2028-09",
    "results_first_posted": null,
    "last_update_posted": "2026-01-09",
    "enrollment": null,
    "sponsor": "Tyra Biosciences, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "UPB",
    "nct_id": "NCT06196879",
    "title": "A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Severe Asthma"
    ],
    "interventions": [
      "Verekitug (UPB-101)",
      "Placebo"
    ],
    "primary_completion_date": "2026-02-19",
    "completion_date": "2026-06-11",
    "results_first_posted": null,
    "last_update_posted": "2025-06-12",
    "enrollment": null,
    "sponsor": "Upstream Bio Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "UPB",
    "nct_id": "NCT06164704",
    "title": "A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal Polyps",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Rhinosinusitis With Nasal Polyps"
    ],
    "interventions": [
      "Verekitug (UPB-101)",
      "Placebo"
    ],
    "primary_completion_date": "2025-07-07",
    "completion_date": "2025-07-22",
    "results_first_posted": null,
    "last_update_posted": "2025-08-15",
    "enrollment": null,
    "sponsor": "Upstream Bio Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "UPB",
    "nct_id": "NCT06981078",
    "title": "A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Obstructive Pulmonary Disease"
    ],
    "interventions": [
      "Verekitug",
      "Placebo"
    ],
    "primary_completion_date": "2028-04",
    "completion_date": "2028-07",
    "results_first_posted": null,
    "last_update_posted": "2025-10-14",
    "enrollment": null,
    "sponsor": "Upstream Bio Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "UPB",
    "nct_id": "NCT05653479",
    "title": "Safety and Blood Levels After a Single Injection of UPB-101 in Healthy Japanese and Non-Japanese Non-East Asian Adults",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "UPB-101"
    ],
    "primary_completion_date": "2023-04-07",
    "completion_date": "2023-05-13",
    "results_first_posted": "2024-09-03",
    "last_update_posted": "2024-09-03",
    "enrollment": null,
    "sponsor": "Upstream Bio Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "UPB",
    "nct_id": "NCT05448651",
    "title": "Safety and Biologic Impact (Pharmacodynamics) of Repeated Injections and Increasing Amounts of UPB-101 in Asthmatics",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Asthma"
    ],
    "interventions": [
      "UPB-101",
      "Placebo"
    ],
    "primary_completion_date": "2023-08-15",
    "completion_date": "2023-10-05",
    "results_first_posted": "2025-01-03",
    "last_update_posted": "2025-01-03",
    "enrollment": null,
    "sponsor": "Upstream Bio Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "UPB",
    "nct_id": "NCT06966479",
    "title": "A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Severe Asthma"
    ],
    "interventions": [
      "Verekitug",
      "Placebo"
    ],
    "primary_completion_date": "2027-09",
    "completion_date": "2027-09",
    "results_first_posted": null,
    "last_update_posted": "2026-01-12",
    "enrollment": null,
    "sponsor": "Upstream Bio Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VERA",
    "nct_id": "NCT06674577",
    "title": "A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "IgA Nephropathy (IgAN)",
      "Renal and Urinary Disorders",
      "Berger Disease"
    ],
    "interventions": [
      "Atacicept 150 mg"
    ],
    "primary_completion_date": "2028-05-31",
    "completion_date": "2028-05-31",
    "results_first_posted": null,
    "last_update_posted": "2025-04-08",
    "enrollment": null,
    "sponsor": "Vera Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VERA",
    "nct_id": "NCT04536363",
    "title": "Cri Analog PG1 Effectiveness and Safety in Covid-19",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Covid19"
    ],
    "interventions": [
      "Analogs, Prostaglandin E1",
      "Standard therapeutic protocol"
    ],
    "primary_completion_date": "2020-12-03",
    "completion_date": "2020-12-03",
    "results_first_posted": null,
    "last_update_posted": "2023-09-15",
    "enrollment": null,
    "sponsor": "Alonso Vera Torres",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VERA",
    "nct_id": "NCT05609812",
    "title": "Atacicept in Subjects With Active Lupus Nephritis (COMPASS)",
    "status": "WITHDRAWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lupus Nephritis (LN)"
    ],
    "interventions": [
      "Atacicept",
      "Placebo"
    ],
    "primary_completion_date": "2026-03-15",
    "completion_date": "2028-12-15",
    "results_first_posted": null,
    "last_update_posted": "2025-05-23",
    "enrollment": null,
    "sponsor": "Vera Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VERA",
    "nct_id": "NCT04294472",
    "title": "A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "BK Virus Infection"
    ],
    "interventions": [
      "MAU868",
      "Placebo"
    ],
    "primary_completion_date": "2022-02-10",
    "completion_date": "2022-02-10",
    "results_first_posted": "2023-05-24",
    "last_update_posted": "2023-06-07",
    "enrollment": null,
    "sponsor": "Vera Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VERA",
    "nct_id": "NCT02427945",
    "title": "Leveraging an Existing Large-scale Safe Water Program to Deliver Nutrition Messages at a Low Marginal Cost",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Child Malnutrition"
    ],
    "interventions": [
      "Provision of information on safe water",
      "Provision of information on safe water and child nutrition"
    ],
    "primary_completion_date": "2017-06",
    "completion_date": "2017-06",
    "results_first_posted": null,
    "last_update_posted": "2019-03-19",
    "enrollment": null,
    "sponsor": "Marcos Vera Hernandez",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VERA",
    "nct_id": "NCT03525990",
    "title": "Study Evaluating the Impact of Electronic Surveys on Patient-physician Communication and Quality of Life in Breast Cancer Patients",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Neoplasm Malignant Female"
    ],
    "interventions": [
      "Questionnaires"
    ],
    "primary_completion_date": "2022-04-30",
    "completion_date": "2022-04-30",
    "results_first_posted": null,
    "last_update_posted": "2023-04-21",
    "enrollment": null,
    "sponsor": "Dr. Vera Trommet",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VERA",
    "nct_id": "NCT07270445",
    "title": "Effect of Virtual Reality Use on Preoperative Anxiety",
    "status": "NOT_YET_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Anxiety"
    ],
    "interventions": [
      "Virtual reality glasses"
    ],
    "primary_completion_date": "2026-12-14",
    "completion_date": "2027-03-01",
    "results_first_posted": null,
    "last_update_posted": "2025-12-23",
    "enrollment": null,
    "sponsor": "Vera Guttenthaler",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VERA",
    "nct_id": "NCT07020923",
    "title": "Monthly Dosing of Atacicept in IgAN",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "IgA Nephropathy (IgAN)",
      "Berger Disease"
    ],
    "interventions": [
      "Atacicept"
    ],
    "primary_completion_date": "2026-09",
    "completion_date": "2027-09",
    "results_first_posted": null,
    "last_update_posted": "2025-06-24",
    "enrollment": null,
    "sponsor": "Vera Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VERA",
    "nct_id": "NCT04716231",
    "title": "Atacicept in Subjects With IgA Nephropathy",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "IgA Nephropathy",
      "Berger Disease"
    ],
    "interventions": [
      "Atacicept",
      "Placebo to match Atacicept"
    ],
    "primary_completion_date": "2025-05-15",
    "completion_date": "2028-07",
    "results_first_posted": null,
    "last_update_posted": "2025-09-30",
    "enrollment": null,
    "sponsor": "Vera Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VERA",
    "nct_id": "NCT03166527",
    "title": "Panzyga in CIDP Administered at Different Infusion Rates",
    "status": "UNKNOWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)"
    ],
    "interventions": [
      "Immune Globulin 10% Intravenous Solution"
    ],
    "primary_completion_date": "2018-12-15",
    "completion_date": "2018-12-15",
    "results_first_posted": null,
    "last_update_posted": "2017-05-25",
    "enrollment": null,
    "sponsor": "Vera Bril",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VERA",
    "nct_id": "NCT06983028",
    "title": "Atacicept in Multiple Glomerular Diseases",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "pMN",
      "IgAN",
      "Nephrotic Syndrome",
      "MCD",
      "FSGS"
    ],
    "interventions": [
      "Atacicept"
    ],
    "primary_completion_date": "2027-11",
    "completion_date": "2027-11",
    "results_first_posted": null,
    "last_update_posted": "2026-01-20",
    "enrollment": null,
    "sponsor": "Vera Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VERA",
    "nct_id": "NCT07291466",
    "title": "Assessment of Preoperative Anxiety and Evaluation of Calming Interventions: Anonymous Patient Survey",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Anxiety"
    ],
    "interventions": [],
    "primary_completion_date": "2026-01-15",
    "completion_date": "2026-01-30",
    "results_first_posted": null,
    "last_update_posted": "2025-12-26",
    "enrollment": null,
    "sponsor": "Vera Guttenthaler",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VERA",
    "nct_id": "NCT03060018",
    "title": "Transcutaneous Partial Oxygen and Carbon Dioxide Pressures Compared With Blood Gas Values",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Critical Illness"
    ],
    "interventions": [
      "Sentec (SenTec) Digital Monitoring System with OxiVenT Sensor"
    ],
    "primary_completion_date": "2018-12-31",
    "completion_date": "2018-12-31",
    "results_first_posted": null,
    "last_update_posted": "2019-02-05",
    "enrollment": null,
    "sponsor": "Vera Bernet, MD",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VERA",
    "nct_id": "NCT01761786",
    "title": "Cost-effectiveness of Genotype Guided Treatment With Antiplatelet Drugs in STEMI Patients: Optimization of Treatment (POPular Genetics)",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Myocardial Infarction",
      "STEMI"
    ],
    "interventions": [
      "CYP2C19 genotyping"
    ],
    "primary_completion_date": "2019-04-04",
    "completion_date": "2019-04-04",
    "results_first_posted": null,
    "last_update_posted": "2019-05-10",
    "enrollment": null,
    "sponsor": "Vera HM Deneer",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VIR",
    "nct_id": "NCT07142811",
    "title": "A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Viral Hepatitis"
    ],
    "interventions": [
      "Tobevibart",
      "Elebsiran",
      "Bulevirtide"
    ],
    "primary_completion_date": "2026-11",
    "completion_date": "2030-07",
    "results_first_posted": null,
    "last_update_posted": "2026-01-16",
    "enrollment": null,
    "sponsor": "Vir Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VIR",
    "nct_id": "NCT05484206",
    "title": "Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatic Impairment",
      "Cirrhosis"
    ],
    "interventions": [
      "VIR-2218",
      "VIR-3434"
    ],
    "primary_completion_date": "2026-09-25",
    "completion_date": "2027-04-30",
    "results_first_posted": null,
    "last_update_posted": "2025-06-13",
    "enrollment": null,
    "sponsor": "Vir Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VIR",
    "nct_id": "NCT04545060",
    "title": "VIR-7831 for the Early Treatment of COVID-19 in Outpatients",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Covid19"
    ],
    "interventions": [
      "VIR-7831 (sotrovimab)",
      "Placebo"
    ],
    "primary_completion_date": "2021-04-08",
    "completion_date": "2021-09-02",
    "results_first_posted": "2022-11-07",
    "last_update_posted": "2022-11-07",
    "enrollment": null,
    "sponsor": "Vir Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VIR",
    "nct_id": "NCT04856085",
    "title": "Study of VIR-2218, VIR-3434, and/or PEG-IFN\u03b1 in Subjects With Chronic Hepatitis B Virus Infection",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatitis B, Chronic"
    ],
    "interventions": [
      "VIR-2218",
      "VIR-3434",
      "PEG-IFN\u03b1"
    ],
    "primary_completion_date": "2026-03",
    "completion_date": "2026-03",
    "results_first_posted": null,
    "last_update_posted": "2025-10-21",
    "enrollment": null,
    "sponsor": "Vir Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VIR",
    "nct_id": "NCT05997615",
    "title": "Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hormone-refractory Prostate Cancer"
    ],
    "interventions": [
      "VIR-5500",
      "Enzalutamide",
      "Darolutamide"
    ],
    "primary_completion_date": "2027-09-29",
    "completion_date": "2027-09-29",
    "results_first_posted": null,
    "last_update_posted": "2025-09-24",
    "enrollment": null,
    "sponsor": "Vir Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VIR",
    "nct_id": "NCT05844228",
    "title": "A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Renal Impairment"
    ],
    "interventions": [
      "VIR-2218"
    ],
    "primary_completion_date": "2025-03-01",
    "completion_date": "2025-04-21",
    "results_first_posted": null,
    "last_update_posted": "2025-06-13",
    "enrollment": null,
    "sponsor": "Vir Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VIR",
    "nct_id": "NCT05280717",
    "title": "Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC)",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Covid19"
    ],
    "interventions": [
      "sotrovimab",
      "sotrovimab",
      "sotrovimab",
      "sotrovimab",
      "sotrovimab",
      "sotrovimab",
      "sotrovimab"
    ],
    "primary_completion_date": "2023-04-05",
    "completion_date": "2023-11-06",
    "results_first_posted": "2024-09-19",
    "last_update_posted": "2024-09-19",
    "enrollment": null,
    "sponsor": "Vir Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VIR",
    "nct_id": "NCT05567783",
    "title": "A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Influenza A"
    ],
    "interventions": [
      "VIR-2482 (450 mg)",
      "VIR-2482 (1200 mg)",
      "Placebo"
    ],
    "primary_completion_date": "2023-05-05",
    "completion_date": "2023-08-31",
    "results_first_posted": "2024-09-19",
    "last_update_posted": "2024-09-19",
    "enrollment": null,
    "sponsor": "Vir Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VIR",
    "nct_id": "NCT06070051",
    "title": "Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Hepatitis B"
    ],
    "interventions": [
      "VRON-0200-AdC6",
      "VRON-0200-AdC7",
      "VIR-2218",
      "VIR-3434"
    ],
    "primary_completion_date": "2026-03-31",
    "completion_date": "2026-03-31",
    "results_first_posted": null,
    "last_update_posted": "2025-05-30",
    "enrollment": null,
    "sponsor": "Virion Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VIR",
    "nct_id": "NCT05461170",
    "title": "SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatitis D, Chronic"
    ],
    "interventions": [
      "VIR-2218",
      "VIR-3434",
      "NRTI"
    ],
    "primary_completion_date": "2029-08",
    "completion_date": "2029-08",
    "results_first_posted": null,
    "last_update_posted": "2025-10-14",
    "enrollment": null,
    "sponsor": "Vir Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VIR",
    "nct_id": "NCT04988152",
    "title": "A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Covid19"
    ],
    "interventions": [
      "sotrovimab",
      "Placebo to Biologic",
      "sotrovimab",
      "Placebo to Biologic"
    ],
    "primary_completion_date": "2021-09-02",
    "completion_date": "2021-12-07",
    "results_first_posted": "2024-06-07",
    "last_update_posted": "2024-06-07",
    "enrollment": null,
    "sponsor": "Vir Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VIR",
    "nct_id": "NCT05235347",
    "title": "Sotrovimab Expanded Access Treatment Protocol (COVID-19)",
    "status": "NO_LONGER_AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Covid19"
    ],
    "interventions": [
      "Sotrovimab"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2022-11-10",
    "enrollment": null,
    "sponsor": "Vir Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VIR",
    "nct_id": "NCT04779879",
    "title": "Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Covid19"
    ],
    "interventions": [
      "Sotrovimab (Gen1)",
      "Sotrovimab (Gen2)",
      "Sotrovimab (Gen2)"
    ],
    "primary_completion_date": "2021-08-20",
    "completion_date": "2022-04-06",
    "results_first_posted": "2022-11-10",
    "last_update_posted": "2023-05-03",
    "enrollment": null,
    "sponsor": "Vir Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VIR",
    "nct_id": "NCT04913675",
    "title": "Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Covid19"
    ],
    "interventions": [
      "sotrovimab",
      "sotrovimab",
      "sotrovimab",
      "sotrovimab",
      "Sotrovimab",
      "Sotrovimab",
      "Sotrovimab"
    ],
    "primary_completion_date": "2022-07-19",
    "completion_date": "2023-03-24",
    "results_first_posted": "2023-05-26",
    "last_update_posted": "2024-03-07",
    "enrollment": null,
    "sponsor": "Vir Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VIR",
    "nct_id": "NCT04412863",
    "title": "Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Hepatitis B"
    ],
    "interventions": [
      "VIR-2218",
      "pegylated interferon-alfa 2a"
    ],
    "primary_completion_date": "2024-03-25",
    "completion_date": "2024-03-25",
    "results_first_posted": null,
    "last_update_posted": "2024-09-19",
    "enrollment": null,
    "sponsor": "Vir Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VIR",
    "nct_id": "NCT06960395",
    "title": "Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor Malignancies",
      "EGFR Positive Solid Tumors",
      "EGFR"
    ],
    "interventions": [
      "VIR-5525",
      "Pembrolizumab"
    ],
    "primary_completion_date": "2029-08",
    "completion_date": "2029-08",
    "results_first_posted": null,
    "last_update_posted": "2025-08-06",
    "enrollment": null,
    "sponsor": "Vir Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VIR",
    "nct_id": "NCT03672188",
    "title": "Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis B",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Hepatitis B"
    ],
    "interventions": [
      "VIR-2218",
      "Placebo"
    ],
    "primary_completion_date": "2020-09-03",
    "completion_date": "2020-09-03",
    "results_first_posted": "2021-12-13",
    "last_update_posted": "2021-12-13",
    "enrollment": null,
    "sponsor": "Vir Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VIR",
    "nct_id": "NCT05612581",
    "title": "A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatitis B, Chronic"
    ],
    "interventions": [
      "VIR-3434",
      "VIR-2218",
      "TDF",
      "PEG-IFN\u03b1"
    ],
    "primary_completion_date": "2024-10-15",
    "completion_date": "2025-08-19",
    "results_first_posted": "2025-11-26",
    "last_update_posted": "2025-11-26",
    "enrollment": null,
    "sponsor": "Vir Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VIR",
    "nct_id": "NCT04725877",
    "title": "VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HIV I Infection"
    ],
    "interventions": [
      "VIR-1111",
      "Placebo"
    ],
    "primary_completion_date": "2022-12-05",
    "completion_date": "2022-12-05",
    "results_first_posted": null,
    "last_update_posted": "2023-02-27",
    "enrollment": null,
    "sponsor": "Vir Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VIR",
    "nct_id": "NCT07128550",
    "title": "A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Viral Hepatitis"
    ],
    "interventions": [
      "Tobevibart",
      "Elebsiran",
      "Bulevirtide"
    ],
    "primary_completion_date": "2026-12",
    "completion_date": "2031-07",
    "results_first_posted": null,
    "last_update_posted": "2026-01-26",
    "enrollment": null,
    "sponsor": "Vir Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VIR",
    "nct_id": "NCT02158962",
    "title": "Empowered Sisters Project Making Choices Reducing Risks",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Domestic Violence",
      "Domestic Abuse"
    ],
    "interventions": [
      "Behavioral - Education"
    ],
    "primary_completion_date": "2017-01",
    "completion_date": "2017-03",
    "results_first_posted": null,
    "last_update_posted": "2014-12-30",
    "enrollment": null,
    "sponsor": "University of the Virgin Islands",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VIR",
    "nct_id": "NCT06903338",
    "title": "A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Viral Hepatitis"
    ],
    "interventions": [
      "Tobevibart",
      "Elebsiran"
    ],
    "primary_completion_date": "2026-12-31",
    "completion_date": "2031-05",
    "results_first_posted": null,
    "last_update_posted": "2025-11-14",
    "enrollment": null,
    "sponsor": "Vir Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VIR",
    "nct_id": "NCT05356741",
    "title": "To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Locally Advanced or Metastatic HER2-Expressing Cancers"
    ],
    "interventions": [
      "VIR-5818",
      "pembrolizumab"
    ],
    "primary_completion_date": "2027-08-16",
    "completion_date": "2027-08-16",
    "results_first_posted": null,
    "last_update_posted": "2025-09-24",
    "enrollment": null,
    "sponsor": "Vir Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VIR",
    "nct_id": "NCT04423393",
    "title": "Study of VIR-3434 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus Infection",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Hepatitis B"
    ],
    "interventions": [
      "VIR-3434",
      "Placebo"
    ],
    "primary_completion_date": "2022-10-24",
    "completion_date": "2022-11-25",
    "results_first_posted": "2024-10-08",
    "last_update_posted": "2024-10-08",
    "enrollment": null,
    "sponsor": "Vir Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VIR",
    "nct_id": "NCT04033406",
    "title": "Study of VIR-2482 in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Influenza A"
    ],
    "interventions": [
      "VIR-2482",
      "Placebo"
    ],
    "primary_completion_date": "2021-11-01",
    "completion_date": "2021-11-01",
    "results_first_posted": null,
    "last_update_posted": "2022-06-09",
    "enrollment": null,
    "sponsor": "Vir Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VYGR",
    "nct_id": "NCT06874621",
    "title": "VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alzheimer&#39;s Disease (AD)"
    ],
    "interventions": [
      "VY7523",
      "Placebo Comparator"
    ],
    "primary_completion_date": "2027-05",
    "completion_date": "2027-05",
    "results_first_posted": null,
    "last_update_posted": "2025-11-19",
    "enrollment": null,
    "sponsor": "Voyager Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "WVE",
    "nct_id": "NCT04906460",
    "title": "Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy"
    ],
    "interventions": [
      "WVE-N531"
    ],
    "primary_completion_date": "2026-06-27",
    "completion_date": "2027-04-24",
    "results_first_posted": null,
    "last_update_posted": "2025-12-15",
    "enrollment": null,
    "sponsor": "Wave Life Sciences Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "WVE",
    "nct_id": "NCT03907072",
    "title": "Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy"
    ],
    "interventions": [
      "WVE-210201 (suvodirsen)",
      "Placebo"
    ],
    "primary_completion_date": "2019-12-16",
    "completion_date": "2020-01-09",
    "results_first_posted": "2021-05-20",
    "last_update_posted": "2021-05-20",
    "enrollment": null,
    "sponsor": "Wave Life Sciences Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "WVE",
    "nct_id": "NCT04617860",
    "title": "Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Huntington Disease"
    ],
    "interventions": [
      "WVE-120102"
    ],
    "primary_completion_date": "2021-04-29",
    "completion_date": "2021-04-29",
    "results_first_posted": "2022-02-09",
    "last_update_posted": "2022-02-09",
    "enrollment": null,
    "sponsor": "Wave Life Sciences Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "WVE",
    "nct_id": "NCT04617847",
    "title": "Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Huntington Disease"
    ],
    "interventions": [
      "WVE-120101"
    ],
    "primary_completion_date": "2021-05-03",
    "completion_date": "2021-05-03",
    "results_first_posted": "2022-02-09",
    "last_update_posted": "2022-02-09",
    "enrollment": null,
    "sponsor": "Wave Life Sciences Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "WVE",
    "nct_id": "NCT03508947",
    "title": "Safety and Tolerability of WVE-210201 in Patients With Duchenne Muscular Dystrophy",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy"
    ],
    "interventions": [
      "WVE-210201",
      "Placebo"
    ],
    "primary_completion_date": "2019-03-06",
    "completion_date": "2019-03-06",
    "results_first_posted": null,
    "last_update_posted": "2019-04-08",
    "enrollment": null,
    "sponsor": "Wave Life Sciences Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "WVE",
    "nct_id": "NCT03225833",
    "title": "Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Huntington's Disease"
    ],
    "interventions": [
      "WVE-120101",
      "Placebo"
    ],
    "primary_completion_date": "2021-05-11",
    "completion_date": "2021-05-11",
    "results_first_posted": "2022-02-10",
    "last_update_posted": "2022-02-10",
    "enrollment": null,
    "sponsor": "Wave Life Sciences Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "WVE",
    "nct_id": "NCT03225846",
    "title": "Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Huntington's Disease"
    ],
    "interventions": [
      "WVE-120102",
      "Placebo"
    ],
    "primary_completion_date": "2021-05-10",
    "completion_date": "2021-05-10",
    "results_first_posted": "2022-04-25",
    "last_update_posted": "2022-04-25",
    "enrollment": null,
    "sponsor": "Wave Life Sciences Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "WVE",
    "nct_id": "NCT07209332",
    "title": "Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy"
    ],
    "interventions": [
      "WVE-N531"
    ],
    "primary_completion_date": "2029-03",
    "completion_date": "2029-03",
    "results_first_posted": null,
    "last_update_posted": "2025-10-07",
    "enrollment": null,
    "sponsor": "Wave Life Sciences Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GH",
    "nct_id": "NCT02139345",
    "title": "TC-A Registration Study",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Primary Osteoarthritis",
      "Rheumatoid Arthritis",
      "Post-traumatic Arthritis",
      "Avascular Necrosis"
    ],
    "interventions": [
      "TC-A PS Total Knee Replacement System",
      "TC-PLUS Solution PS Total Knee Replacement System"
    ],
    "primary_completion_date": "2016-11-23",
    "completion_date": "2016-11-23",
    "results_first_posted": null,
    "last_update_posted": "2017-11-14",
    "enrollment": null,
    "sponsor": "Smith & Nephew Medical (Shanghai) Ltd",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GH",
    "nct_id": "NCT05753956",
    "title": "Safety and Pharmacokinetics of GH002 in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "5 Methoxy N,N Dimethyltryptamine",
      "Placebo"
    ],
    "primary_completion_date": "2023-11-29",
    "completion_date": "2023-11-29",
    "results_first_posted": null,
    "last_update_posted": "2024-01-25",
    "enrollment": null,
    "sponsor": "GH Research Ireland Limited",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GH",
    "nct_id": "NCT05572008",
    "title": "ProteIn Nutrition in Crohn's Disease",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Crohn Disease"
    ],
    "interventions": [
      "Protein nutrition in paediatric Crohn's disease"
    ],
    "primary_completion_date": "2022-12-28",
    "completion_date": "2023-05-25",
    "results_first_posted": null,
    "last_update_posted": "2022-10-07",
    "enrollment": null,
    "sponsor": "University of Nottingham",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GH",
    "nct_id": "NCT05389059",
    "title": "Injectable Platelet Rich Fibrin With Collagen Matrix in Treatment of Multiple Gingival Recession.",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Gingival Diseases",
      "Traumatic Injury"
    ],
    "interventions": [
      "CAF+CM",
      "I-PRF"
    ],
    "primary_completion_date": "2023-03-30",
    "completion_date": "2023-09-01",
    "results_first_posted": null,
    "last_update_posted": "2022-05-24",
    "enrollment": null,
    "sponsor": "University of Baghdad",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GH",
    "nct_id": "NCT05804708",
    "title": "Phase 2 Clinical Trial of GH001 in Postpartum Depression",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Postpartum Depression",
      "Postnatal Depression"
    ],
    "interventions": [
      "GH001"
    ],
    "primary_completion_date": "2024-08-02",
    "completion_date": "2024-11-15",
    "results_first_posted": null,
    "last_update_posted": "2025-02-18",
    "enrollment": null,
    "sponsor": "GH Research Ireland Limited",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GH",
    "nct_id": "NCT05447208",
    "title": "Effect of GH on the Blastocyst Euploid Rate in AMA Patients",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Preimplantation Genetic Testing",
      "Growth Hormone",
      "Age, Parental"
    ],
    "interventions": [
      "Growth Hormone",
      "GnRH antagonist"
    ],
    "primary_completion_date": "2026-03-01",
    "completion_date": "2026-12-31",
    "results_first_posted": null,
    "last_update_posted": "2025-02-12",
    "enrollment": null,
    "sponsor": "ShangHai Ji Ai Genetics & IVF Institute",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GH",
    "nct_id": "NCT04698603",
    "title": "Clinical Study of GH001 in Depression",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Treatment Resistant Depression",
      "Major Depressive Disorder",
      "Depression"
    ],
    "interventions": [
      "5 Methoxy N,N Dimethyltryptamine"
    ],
    "primary_completion_date": "2021-11-06",
    "completion_date": "2021-11-06",
    "results_first_posted": null,
    "last_update_posted": "2023-08-15",
    "enrollment": null,
    "sponsor": "GH Research Ireland Limited",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GH",
    "nct_id": "NCT03740412",
    "title": "Study to Reduce Sitting in Older Adults Undergoing Hip or Knee Replacements",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Orthopedic Disorder",
      "Arthropathy of Knee",
      "Arthropathy of Hip",
      "Sedentary Lifestyle",
      "Physical Activity",
      "Osteoarthritis"
    ],
    "interventions": [
      "Sedentary behaviour reduction using motivational interviewing, education, individualised feedback, goal-setting, self-monitoring, environmental modification, and supportive phone calls"
    ],
    "primary_completion_date": "2019-04-15",
    "completion_date": "2019-04-15",
    "results_first_posted": null,
    "last_update_posted": "2019-07-05",
    "enrollment": null,
    "sponsor": "University of Birmingham",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GH",
    "nct_id": "NCT05979480",
    "title": "The Effects of Growth Hormone Treatment Discontinuation in Adults on Metabolic Profile, Body Composition and Quality Of Life (GAMBOL Study)",
    "status": "UNKNOWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Adult Growth Hormone Deficiency"
    ],
    "interventions": [
      "Dual energy X-ray absorptiometry (DXA)"
    ],
    "primary_completion_date": "2025-10-31",
    "completion_date": "2025-11-30",
    "results_first_posted": null,
    "last_update_posted": "2023-08-07",
    "enrollment": null,
    "sponsor": "University Hospital Birmingham",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GH",
    "nct_id": "NCT01395511",
    "title": "Acupuncture for Whiplash Associated Disorder",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Whiplash Associated Disorder (WAD)"
    ],
    "interventions": [
      "Acupuncture"
    ],
    "primary_completion_date": "2010-10",
    "completion_date": "2010-10",
    "results_first_posted": null,
    "last_update_posted": "2011-07-15",
    "enrollment": null,
    "sponsor": "Kyunghee University Medical Center",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GH",
    "nct_id": "NCT04355416",
    "title": "Clinical and Anti-inflammatory Effect of Curcumin Oral Gel as Adjuncts in Treatment of Periodontal Pocket",
    "status": "UNKNOWN",
    "phase": "EARLY_PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Periodontitis"
    ],
    "interventions": [
      "curcumin Oral gel",
      "subgingival scaling and root planing"
    ],
    "primary_completion_date": "2020-05-30",
    "completion_date": "2020-06-30",
    "results_first_posted": null,
    "last_update_posted": "2020-04-21",
    "enrollment": null,
    "sponsor": "University of Baghdad",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GH",
    "nct_id": "NCT07136415",
    "title": "Comparing Digital Therapy, Trazodone, and Daridorexant for Menopause-Related Insomnia Symptoms",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Menopausal Women",
      "Insomnia"
    ],
    "interventions": [
      "Cognitive behavioral therapy for insomnia (CBT-i)",
      "Trazodone",
      "Daridorexant"
    ],
    "primary_completion_date": "2031-02",
    "completion_date": "2031-02",
    "results_first_posted": null,
    "last_update_posted": "2025-12-31",
    "enrollment": null,
    "sponsor": "Brigham and Women's Hospital",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GH",
    "nct_id": "NCT05576870",
    "title": "Growth Study Using Else Toddler Nutritional Drink vs. a. Dairy Based Toddler Drink (Control) in Healthy Toddlers",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Weight Gain"
    ],
    "interventions": [
      "Plant based toddler nutrition",
      "Dairy based toddler nutrition"
    ],
    "primary_completion_date": "2023-05-31",
    "completion_date": "2023-05-31",
    "results_first_posted": null,
    "last_update_posted": "2022-10-13",
    "enrollment": null,
    "sponsor": "Else Nutrition GH Ltd",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GH",
    "nct_id": "NCT00993356",
    "title": "Preoperative Lanreotide Treatment in Acromegalic Patients With Macroadenomas",
    "status": "UNKNOWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acromegaly"
    ],
    "interventions": [
      "Preoperative lanreotide treatment",
      "Transsphenoidal surgery"
    ],
    "primary_completion_date": "2009-12",
    "completion_date": "2010-12",
    "results_first_posted": null,
    "last_update_posted": "2009-10-12",
    "enrollment": null,
    "sponsor": "Shanghai Jiao Tong University School of Medicine",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GH",
    "nct_id": "NCT05040243",
    "title": "Acupuncture Combined With Yanqing Zhitong Ointment Acupoint Application in Chronic Non-specific Low Back Pain",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-specific Low Back Pain"
    ],
    "interventions": [
      "Yanqing Zhitong Ointment Acupoint application",
      "placebo acupoint application"
    ],
    "primary_completion_date": "2022-12-30",
    "completion_date": "2022-12-30",
    "results_first_posted": null,
    "last_update_posted": "2022-08-02",
    "enrollment": null,
    "sponsor": "Shanghai University of Traditional Chinese Medicine",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GH",
    "nct_id": "NCT05838677",
    "title": "Pain at Work Toolkit in Employees With Chronic Pain",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Pain",
      "Pain, Chronic"
    ],
    "interventions": [
      "Pain at Work Toolkit",
      "Active control"
    ],
    "primary_completion_date": "2025-07-22",
    "completion_date": "2025-11-30",
    "results_first_posted": null,
    "last_update_posted": "2025-12-18",
    "enrollment": null,
    "sponsor": "University of Nottingham",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GH",
    "nct_id": "NCT00259610",
    "title": "Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rheumatoid Arthritis"
    ],
    "interventions": [
      "methotrexate",
      "sulfasalazine",
      "hydroxychloroquine",
      "etanercept"
    ],
    "primary_completion_date": "2009-06",
    "completion_date": "2009-06",
    "results_first_posted": "2014-07-17",
    "last_update_posted": "2014-07-17",
    "enrollment": null,
    "sponsor": "University of Alabama at Birmingham",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GH",
    "nct_id": "NCT04640831",
    "title": "Safety of GH001 in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "5 Methoxy N,N Dimethyltryptamine"
    ],
    "primary_completion_date": "2019-10-04",
    "completion_date": "2019-10-04",
    "results_first_posted": null,
    "last_update_posted": "2023-08-15",
    "enrollment": null,
    "sponsor": "GH Research Ireland Limited",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GH",
    "nct_id": "NCT06511947",
    "title": "Pharmacokinetics of GH001 Delivered Via a Proprietary Aerosol Delivery Device in Healthy Subjects",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "5 Methoxy N,N Dimethyltryptamine"
    ],
    "primary_completion_date": "2025-02",
    "completion_date": "2025-02",
    "results_first_posted": null,
    "last_update_posted": "2024-08-07",
    "enrollment": null,
    "sponsor": "GH Research Ireland Limited",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "INDV",
    "nct_id": "NCT03058237",
    "title": "A Phase 1 Bioavailability Study of Arbaclofen Placarbil Modified Release Formulations in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "Arbaclofen Placarbil SR",
      "Arbaclofen Placarbil MR Prototype A",
      "Arbaclofen Placarbil MR Prototype B",
      "Arbaclofen Placarbil IR"
    ],
    "primary_completion_date": "2017-07-05",
    "completion_date": "2017-07-05",
    "results_first_posted": null,
    "last_update_posted": "2018-01-17",
    "enrollment": null,
    "sponsor": "Indivior Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT04963582",
    "title": "LI4 Acupuncture for Analgesia in Intrauterine Device Insertion",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "IUD Insertion Complication",
      "Acute Pain"
    ],
    "interventions": [
      "Acupuncture"
    ],
    "primary_completion_date": "2021-10-01",
    "completion_date": "2021-10-01",
    "results_first_posted": null,
    "last_update_posted": "2021-10-05",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT04780997",
    "title": "The Effect of Virtual Reality Exercises on Balance in Patients With Osteoporosis",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Osteoporosis"
    ],
    "interventions": [
      "Virtual Reality"
    ],
    "primary_completion_date": "2021-08-30",
    "completion_date": "2021-10-01",
    "results_first_posted": null,
    "last_update_posted": "2021-03-04",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT03786393",
    "title": "Estrogen Receptor 1 Gene Polymorphism Frequency in Fibromyalgia Syndrome",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Fibromyalgia"
    ],
    "interventions": [
      "ACR 1990 fibromyalgia critters"
    ],
    "primary_completion_date": "2021-04-15",
    "completion_date": "2021-05-15",
    "results_first_posted": null,
    "last_update_posted": "2021-09-01",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT05278949",
    "title": "Re-fixating Dislocated Scleral Fixing Intra-ocular Lens",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Intraocular Lens Complication"
    ],
    "interventions": [
      "The surgical intervention"
    ],
    "primary_completion_date": "2023-03-21",
    "completion_date": "2023-03-21",
    "results_first_posted": null,
    "last_update_posted": "2023-03-24",
    "enrollment": null,
    "sponsor": "Omer Othman Abdullah",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT04702204",
    "title": "Efficacy of Denosumab Treatment in Bisphosphonate Unresponsive Patients",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Postmenopausal Osteoporosis"
    ],
    "interventions": [
      "Denosumab 60 MG/ML"
    ],
    "primary_completion_date": "2021-08-15",
    "completion_date": "2021-08-15",
    "results_first_posted": null,
    "last_update_posted": "2021-09-01",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT06758687",
    "title": "The Effect of Kinesio Taping Applied to Operating Room Nurses on Low Back Pain, Fatigue, and Sleep Quality",
    "status": "NOT_YET_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lower Back Pain",
      "Kinesio Taping"
    ],
    "interventions": [
      "Kinesiotape Application"
    ],
    "primary_completion_date": "2025-09",
    "completion_date": "2025-12",
    "results_first_posted": null,
    "last_update_posted": "2025-01-06",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT04960176",
    "title": "Validation of a Non-Invasive Sham Technique",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acupuncture"
    ],
    "interventions": [
      "Acupuncture",
      "Non-invasive Sham Acupuncture"
    ],
    "primary_completion_date": "2022-11-30",
    "completion_date": "2022-11-30",
    "results_first_posted": null,
    "last_update_posted": "2022-04-05",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT06866249",
    "title": "Investigation of the Development of Infants With a History of Colic",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Colic, Infantile",
      "Motor Development",
      "Sleep",
      "Sensory Integration Dysfunction"
    ],
    "interventions": [
      "Peabody Developmental Motor Scales-2",
      "Test Of Sensory Functions In Infants (Tsf\u0131)",
      "Brief Infant Sleep Questionnaire"
    ],
    "primary_completion_date": "2025-05-01",
    "completion_date": "2025-05-01",
    "results_first_posted": null,
    "last_update_posted": "2025-06-26",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT07319754",
    "title": "TENS for Pain and Sleep After Hernia Surgery",
    "status": "NOT_YET_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Inguinal Hernia",
      "Postoperative Pain",
      "Sleep Disturbance"
    ],
    "interventions": [
      "Transcutaneous Electrical Nerve Stimulation (TENS)",
      "Standard Postoperative Care"
    ],
    "primary_completion_date": "2026-10-01",
    "completion_date": "2026-10-10",
    "results_first_posted": null,
    "last_update_posted": "2026-01-06",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT06622785",
    "title": "Physical Activity of Participants in Different Age Groups",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Adults 18 Years and Older (no Other Exclusion Criteria)"
    ],
    "interventions": [
      "Physical activity",
      "Exercise Benefits"
    ],
    "primary_completion_date": "2024-06-01",
    "completion_date": "2024-06-01",
    "results_first_posted": null,
    "last_update_posted": "2024-10-03",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT07234435",
    "title": "Professionals Serving Individuals With Special Needs and Quality of Life",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Physiotherapist",
      "Teachers"
    ],
    "interventions": [
      "International Physical Activity Questionnaire",
      "The Nutrition Knowledge Level Scale",
      "Maslach Burnout Inventory",
      "Short Form-36 Health Survey"
    ],
    "primary_completion_date": "2026-01-01",
    "completion_date": "2026-01-15",
    "results_first_posted": null,
    "last_update_posted": "2025-11-21",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT04960189",
    "title": "GB34 Acupuncture in Acute Cholecystitis",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Cholecystitis"
    ],
    "interventions": [
      "Acupuncture"
    ],
    "primary_completion_date": "2025-12-10",
    "completion_date": "2025-12-10",
    "results_first_posted": null,
    "last_update_posted": "2026-01-08",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT05494242",
    "title": "Single Superior ILM/ERM Flap for the FTMH.",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ophthalmopathy"
    ],
    "interventions": [
      "Surgical intervention"
    ],
    "primary_completion_date": "2023-03-21",
    "completion_date": "2023-03-21",
    "results_first_posted": null,
    "last_update_posted": "2023-03-24",
    "enrollment": null,
    "sponsor": "Omer Othman Abdullah",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT06230939",
    "title": "Examination of Factors Associated With Fatigue in Individuals Diagnosed With Parkinson's Disease",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Parkinson Disease",
      "Fatigue"
    ],
    "interventions": [
      "Examination"
    ],
    "primary_completion_date": "2025-11-05",
    "completion_date": "2025-11-05",
    "results_first_posted": null,
    "last_update_posted": "2026-01-27",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT04730752",
    "title": "Validation and Comparison of the Appendicitis Inflammatory Response Score and Adult Appendicitis Score",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Acute Appendicitis",
      "Acute Appendicitis With Rupture"
    ],
    "interventions": [
      "Appendicitis Inflammatory Response",
      "Adult Appendicitis Score"
    ],
    "primary_completion_date": "2021-05-25",
    "completion_date": "2021-05-25",
    "results_first_posted": null,
    "last_update_posted": "2021-05-27",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT04559503",
    "title": "Progressive Relaxation Exercises in COPD",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Anxiety",
      "Dyspnea"
    ],
    "interventions": [
      "Progressive relaxation exercises"
    ],
    "primary_completion_date": "2016-11-15",
    "completion_date": "2017-09-15",
    "results_first_posted": null,
    "last_update_posted": "2020-09-23",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT05269563",
    "title": "Double Flap Technique for Macular Hole",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Macular Holes"
    ],
    "interventions": [
      "Surgical intervention"
    ],
    "primary_completion_date": "2023-03-23",
    "completion_date": "2023-03-23",
    "results_first_posted": null,
    "last_update_posted": "2023-03-24",
    "enrollment": null,
    "sponsor": "Omer Othman Abdullah",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT06884969",
    "title": "Late-onset Sepsis and Development",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Sepsis Newborn",
      "Motor Development",
      "Sensory Integration Dysfunction"
    ],
    "interventions": [
      "Test of Sensory Function in Infants",
      "Peabody Motor Development Scale-2"
    ],
    "primary_completion_date": "2025-05-15",
    "completion_date": "2025-05-15",
    "results_first_posted": null,
    "last_update_posted": "2025-06-26",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT06889441",
    "title": "Pacifier Use and Infant Development",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Pacifier",
      "Infant Development",
      "Sensory Processing Disorder"
    ],
    "interventions": [
      "Test of sensory function in infants",
      "The Peabody Developmental Motor Scales-Second Edition",
      "Infant/toddler sensory profile"
    ],
    "primary_completion_date": "2025-06-01",
    "completion_date": "2025-06-01",
    "results_first_posted": null,
    "last_update_posted": "2025-06-26",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT05349786",
    "title": "Physical Activity Program on Clinical Output in Heart Failure",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Heart Failure",
      "Nursing Caries"
    ],
    "interventions": [
      "Physical activity program"
    ],
    "primary_completion_date": "2018-12-03",
    "completion_date": "2021-07-16",
    "results_first_posted": null,
    "last_update_posted": "2022-04-27",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT05702164",
    "title": "Physiotherapy and Rehabilitation Students' Incontinence Knowledge Level",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Health Knowledge, Attitudes, Practice"
    ],
    "interventions": [],
    "primary_completion_date": "2023-06-06",
    "completion_date": "2024-12-06",
    "results_first_posted": null,
    "last_update_posted": "2024-01-22",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT06739096",
    "title": "Investigation of the Effectiveness of Short Wave Diathermy Treatment in Patients With Hand Osteoarthritis",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hand Osteoarthritis",
      "Osteoarthritis"
    ],
    "interventions": [
      "Short Wave Diathermy",
      "Exercise",
      "Sham Short Wave Diathermy"
    ],
    "primary_completion_date": "2025-02-18",
    "completion_date": "2026-02-28",
    "results_first_posted": null,
    "last_update_posted": "2025-11-26",
    "enrollment": null,
    "sponsor": "Omer Sezgin",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT06716346",
    "title": "Investigation of Posture, Postural Stability and Core Endurance in Adults with Forward Head Posture: a Controlled Study",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Forward Head Posture"
    ],
    "interventions": [],
    "primary_completion_date": "2025-01-08",
    "completion_date": "2025-01-08",
    "results_first_posted": null,
    "last_update_posted": "2025-02-10",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT04196946",
    "title": "Use of Intrathecal Analgesia in Appendectomy",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Anesthesia",
      "Analgesia"
    ],
    "interventions": [
      "25 mcg fentanyl",
      "250 mcg alfentanil"
    ],
    "primary_completion_date": "2015-09-02",
    "completion_date": "2019-09-02",
    "results_first_posted": null,
    "last_update_posted": "2019-12-12",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT05840523",
    "title": "Hip Abductor Strengthening With Proprioceptive Neuromuscular Facilitation",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Sports Physical Therapy"
    ],
    "interventions": [
      "Proprioceptive Neuromuscular Facilitation exercises",
      "The Range Of Motion exercises"
    ],
    "primary_completion_date": "2020-02-17",
    "completion_date": "2020-07-17",
    "results_first_posted": null,
    "last_update_posted": "2023-05-03",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT06258603",
    "title": "Oral Care of Intubated Intensive Care Patient",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pneumonia",
      "Mechanical Ventilation Complication",
      "Salivation",
      "Dry Mouth"
    ],
    "interventions": [
      "oral care bundle",
      "clinical oral care"
    ],
    "primary_completion_date": "2021-12-30",
    "completion_date": "2023-06-19",
    "results_first_posted": null,
    "last_update_posted": "2024-02-15",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT07280104",
    "title": "Infants With Primary Congenital Hypothyroidism and Development",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Congenital Hypothyroidism"
    ],
    "interventions": [
      "neurological status",
      "sensory processing functions",
      "Motor development"
    ],
    "primary_completion_date": "2026-12-15",
    "completion_date": "2026-12-20",
    "results_first_posted": null,
    "last_update_posted": "2025-12-12",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT07117734",
    "title": "Reliability and Quality of YouTube Videos Related to Balance Exercise",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Dynamic Balance",
      "Balance"
    ],
    "interventions": [
      "An Evaluation of the Quality and Informational Content of Balance Exercise Training Videos Published on YouTube."
    ],
    "primary_completion_date": "2025-09-01",
    "completion_date": "2025-09-01",
    "results_first_posted": null,
    "last_update_posted": "2025-09-09",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT06546033",
    "title": "Intermittent Fasting and Mediterranean Diet in Patient With Multiple Sclerosis",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple Sclerosis",
      "Intermittent Fasting"
    ],
    "interventions": [
      "application of different types of diet"
    ],
    "primary_completion_date": "2026-09-02",
    "completion_date": "2026-12-02",
    "results_first_posted": null,
    "last_update_posted": "2024-08-09",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT06766136",
    "title": "Effectiveness of Asthma Education Program Based on the Roy Adaptation Model",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Asthma Patients"
    ],
    "interventions": [
      "Asthma education program"
    ],
    "primary_completion_date": "2025-05-01",
    "completion_date": "2025-10-01",
    "results_first_posted": null,
    "last_update_posted": "2025-06-15",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT06581926",
    "title": "A Comparative Analysis of Healthy Young Adults Stratified by Gender.",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Healthy Young Adults"
    ],
    "interventions": [
      "Behavioral assessment"
    ],
    "primary_completion_date": "2024-10-30",
    "completion_date": "2024-11-30",
    "results_first_posted": null,
    "last_update_posted": "2024-12-03",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT06230926",
    "title": "Turkish Adaptation of \"Parkinson's Disease Quality of Life 7 (PDQoL7)\" Questionnaire",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Parkinson Disease",
      "Quality of Life"
    ],
    "interventions": [
      "Validity, Reliability and Adaptation"
    ],
    "primary_completion_date": "2025-11-11",
    "completion_date": "2025-11-11",
    "results_first_posted": null,
    "last_update_posted": "2026-01-27",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT07263750",
    "title": "Effect of Haptonomy on Prenatal Attachment and Fear of Childbirth in Primiparous Couples",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fear of Childbirth",
      "Prenatal Attachment"
    ],
    "interventions": [
      "Haptonomy"
    ],
    "primary_completion_date": "2025-12-27",
    "completion_date": "2026-03-01",
    "results_first_posted": null,
    "last_update_posted": "2025-12-04",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT07045116",
    "title": "Electronic vs. Conventional Syringes: Impact on Pediatric Pain and Anxiety",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dental Anxiety",
      "Pain Management"
    ],
    "interventions": [
      "Electronic anesthesia",
      "Conventional anesthesia"
    ],
    "primary_completion_date": "2025-07-31",
    "completion_date": "2025-08-30",
    "results_first_posted": null,
    "last_update_posted": "2025-07-31",
    "enrollment": null,
    "sponsor": "Randa Omer Ahmed Bashir",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT02391428",
    "title": "The Correlation Between Blood omega3 and ADHD",
    "status": "UNKNOWN",
    "phase": "EARLY_PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Attention Deficit Hyperactivity Disorder (ADHD)"
    ],
    "interventions": [
      "blood test",
      "omega3 capsules"
    ],
    "primary_completion_date": "2015-09",
    "completion_date": "2016-04",
    "results_first_posted": null,
    "last_update_posted": "2015-03-19",
    "enrollment": null,
    "sponsor": "Ayelet Omer Armon",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT06231030",
    "title": "Unidimensional Self-Efficacy Scale for Multiple Sclerosis (USE-MS) Turkish Adaptation",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Multiple Sclerosis",
      "Self Efficacy"
    ],
    "interventions": [
      "Validity, Reliability and Adaptation"
    ],
    "primary_completion_date": "2025-11-05",
    "completion_date": "2025-11-05",
    "results_first_posted": null,
    "last_update_posted": "2024-01-31",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT06583174",
    "title": "Evaluation of the Relationship Between Breastfeeding Attitudes and Nutrition Knowledge Levels",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Breastfeeding"
    ],
    "interventions": [
      "Breastfeeding Attitudes"
    ],
    "primary_completion_date": "2025-05-30",
    "completion_date": "2025-05-30",
    "results_first_posted": null,
    "last_update_posted": "2026-01-27",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT07094490",
    "title": "Comparison of Posture and Respiration in Adults With and Without Head Forward Posture",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Forward Head Posture"
    ],
    "interventions": [],
    "primary_completion_date": "2025-01-08",
    "completion_date": "2025-01-08",
    "results_first_posted": null,
    "last_update_posted": "2025-07-30",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT07242846",
    "title": "EFFECT OF INTRAARTICULAR TRIAMCINOLONE HEXACETONIDE AND BETAMETHASONE ON INTRAOCULAR PRESSURE",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Knee Osteoarthritis (Knee OA)",
      "Intraocular Pressure"
    ],
    "interventions": [
      "Diprospan",
      "artropan"
    ],
    "primary_completion_date": "2025-11-02",
    "completion_date": "2025-11-10",
    "results_first_posted": null,
    "last_update_posted": "2025-11-21",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT05073055",
    "title": "Spinal Anesthesia Versus Erector Spina Plane Block",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Inguinal Hernia Repair",
      "Postoperative Pain",
      "Peripheral Nerve Blocks"
    ],
    "interventions": [
      "\u0130nguinal Hernia Repair"
    ],
    "primary_completion_date": "2021-09-28",
    "completion_date": "2022-12-25",
    "results_first_posted": null,
    "last_update_posted": "2022-12-28",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT04910035",
    "title": "The Effect of Square Stepping Exercises Training on Lower Extremity",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Sedentary Healthy Young Individuals"
    ],
    "interventions": [
      "Exercises Training"
    ],
    "primary_completion_date": "2020-05-10",
    "completion_date": "2020-05-10",
    "results_first_posted": null,
    "last_update_posted": "2024-09-03",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT07359781",
    "title": "VALIDITY AND RELIABILITY OF THE BEHAVIORAL REGULATION IN EXERCISE QUESTIONNAIRE-2 (BREQ-2) IN ADOLESCENTS WITH IDIOPATHIC SCOLIOSIS",
    "status": "NOT_YET_RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Adolescence Idiopathic Scoliosis"
    ],
    "interventions": [
      "Questionnaire Assessment"
    ],
    "primary_completion_date": "2026-09",
    "completion_date": "2026-12",
    "results_first_posted": null,
    "last_update_posted": "2026-01-22",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT05967676",
    "title": "Psychological Readiness of Injured Athlete to Return to Sport",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Athletic Injuries"
    ],
    "interventions": [
      "Turkish adaptation, validity and reliability"
    ],
    "primary_completion_date": "2024-06-01",
    "completion_date": "2024-06-01",
    "results_first_posted": null,
    "last_update_posted": "2024-10-03",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT07014917",
    "title": "Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Lymphocytic Leukemia",
      "Small Lymphocytic Lymphoma",
      "CLL Variant"
    ],
    "interventions": [
      "Venetoclax",
      "Acalabrutinib",
      "Venetoclax",
      "Acalabrutinib"
    ],
    "primary_completion_date": "2028-06-05",
    "completion_date": "2032-06-05",
    "results_first_posted": null,
    "last_update_posted": "2026-01-06",
    "enrollment": null,
    "sponsor": "Zulfa Omer",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT04848922",
    "title": "Hot Showers on Postpartum Fatigue, Mood and Comfort In Women Giving Vaginal Birth",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fatigue",
      "Comfort",
      "Mood",
      "Postpartum Care"
    ],
    "interventions": [
      "Hot shower intervention"
    ],
    "primary_completion_date": "2019-02-13",
    "completion_date": "2019-11-25",
    "results_first_posted": null,
    "last_update_posted": "2025-05-21",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT05494229",
    "title": "Autologous Blood for Full-thickness Macular Hole",
    "status": "TERMINATED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ophthalmopathy"
    ],
    "interventions": [
      "Pars-plana vitrectomy"
    ],
    "primary_completion_date": "2023-03-01",
    "completion_date": "2023-03-01",
    "results_first_posted": null,
    "last_update_posted": "2023-03-27",
    "enrollment": null,
    "sponsor": "Omer Othman Abdullah",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT06343025",
    "title": "The Effects of Tai Chi and Pilates for Individuals With Prediabetes",
    "status": "NOT_YET_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "PreDiabetes"
    ],
    "interventions": [
      "Pilates Exercises Group",
      "Tai Chi Exercises Group"
    ],
    "primary_completion_date": "2025-06",
    "completion_date": "2025-09",
    "results_first_posted": null,
    "last_update_posted": "2024-04-02",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT04690218",
    "title": "Evaluation of Sleep Quality, Nutrition, Anxiety and Depression in Mastalgia",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Mastodynia"
    ],
    "interventions": [
      "Hospital anxiety and depression scale",
      "Pittsburgh Sleep Quality Index",
      "Nutritional Status Questionnaire"
    ],
    "primary_completion_date": "2021-12-31",
    "completion_date": "2021-12-31",
    "results_first_posted": null,
    "last_update_posted": "2022-01-04",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT05692479",
    "title": "Premenstrual Syndrome and Physical Activity Self-Worth",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Premenstrual Syndrome"
    ],
    "interventions": [
      "Premenstrual Syndrome Scale, Women's Physical Activity Self-Worth Inventory, Descriptive data"
    ],
    "primary_completion_date": "2023-02-28",
    "completion_date": "2023-02-28",
    "results_first_posted": null,
    "last_update_posted": "2023-03-23",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT05697523",
    "title": "Multiple Sclerosis and Respiratory and Functional Capacity",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Multiple Sclerosis"
    ],
    "interventions": [
      "Expanded Disability Status Scale, pulmonary function test, International Physical Activity Questionnaire - Short Form, 6 minute walk test"
    ],
    "primary_completion_date": "2021-01-01",
    "completion_date": "2021-01-01",
    "results_first_posted": null,
    "last_update_posted": "2023-01-26",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT06581913",
    "title": "Investigation of Eating Awareness,Eating Cravings, Wellness Awareness and Health Perception",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Healthy Young Adults"
    ],
    "interventions": [
      "Behavioral assessment"
    ],
    "primary_completion_date": "2025-09-30",
    "completion_date": "2025-09-30",
    "results_first_posted": null,
    "last_update_posted": "2026-01-27",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT05468086",
    "title": "VR Solace for Pain and Anxiety Using Survey and Biodata",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Pain"
    ],
    "interventions": [
      "VR Solace"
    ],
    "primary_completion_date": "2023-06-28",
    "completion_date": "2023-06-28",
    "results_first_posted": "2024-11-04",
    "last_update_posted": "2024-11-04",
    "enrollment": null,
    "sponsor": "Omer Liran",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT04866121",
    "title": "Acupuncture for Prevention of Postoperative Nausea and Vomiting",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "PONV"
    ],
    "interventions": [
      "Acupuncture"
    ],
    "primary_completion_date": "2022-05-01",
    "completion_date": "2022-05-01",
    "results_first_posted": null,
    "last_update_posted": "2021-05-03",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT04979117",
    "title": "Superb Microvascular Imaging Ultrasonography of Plantar Fasciitis",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Diagnose Disease",
      "Plantar Fasciitis"
    ],
    "interventions": [
      "Superb Microvascular Imaging (SMI) (Toshiba)"
    ],
    "primary_completion_date": "2022-12-27",
    "completion_date": "2022-12-27",
    "results_first_posted": null,
    "last_update_posted": "2022-12-28",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT05687799",
    "title": "Fatigue, Sleep and Quality of Life in Parkinson's Patients",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Idiopathic Parkinson's Disease"
    ],
    "interventions": [],
    "primary_completion_date": "2023-03-22",
    "completion_date": "2023-03-22",
    "results_first_posted": null,
    "last_update_posted": "2023-04-04",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT07108998",
    "title": "Study of Epcoritamab as a Consolidation Therapy in CLL/SLL",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "CLL/SLL",
      "CLL",
      "SLL",
      "Chronic Lymphocytic Leukemia",
      "Small Lymphocytic Lymphoma",
      "Small Lymphocytic Lymphoma Variant",
      "Chronic Lymphocytic Leukemia Variants"
    ],
    "interventions": [
      "Epcoritamab"
    ],
    "primary_completion_date": "2027-07-01",
    "completion_date": "2029-07-01",
    "results_first_posted": null,
    "last_update_posted": "2026-01-06",
    "enrollment": null,
    "sponsor": "Zulfa Omer",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT05278936",
    "title": "New Technique in Congenital/Pediatric Cataract Surgery",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pediatric Cataract",
      "Congenital Cataract"
    ],
    "interventions": [
      "The cataract surgery and the anterior vitrectomy"
    ],
    "primary_completion_date": "2021-08-01",
    "completion_date": "2021-10-01",
    "results_first_posted": null,
    "last_update_posted": "2022-05-02",
    "enrollment": null,
    "sponsor": "Omer Othman Abdullah",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT07121179",
    "title": "Sleep Characteristics in Infants With Joint Hypermobility",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Joint Hypermobility Syndrome",
      "Sleep",
      "Infant"
    ],
    "interventions": [
      "Beighton Scoring system",
      "Brief Infant Sleep Questionnaire"
    ],
    "primary_completion_date": "2026-01-15",
    "completion_date": "2026-01-15",
    "results_first_posted": null,
    "last_update_posted": "2025-09-03",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT06708585",
    "title": "Information and Progressive Relaxation Exercises",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Caesarean Section",
      "Fear",
      "Anxiety",
      "Pain"
    ],
    "interventions": [
      "progressive relaxation exercises and training"
    ],
    "primary_completion_date": "2025-02-20",
    "completion_date": "2025-03-30",
    "results_first_posted": null,
    "last_update_posted": "2024-11-27",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT07157930",
    "title": "Prenatal Hormonal Markers and Sleep Characteristics in Young Adults With Joint Hypermobility",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Joint Hypermobility",
      "Healty Controls",
      "Sleep",
      "Androgen Effect",
      "Hormonal"
    ],
    "interventions": [
      "The Beighton Scoring system",
      "2D:4D Digit Ratio"
    ],
    "primary_completion_date": "2025-12-17",
    "completion_date": "2025-12-17",
    "results_first_posted": null,
    "last_update_posted": "2025-12-24",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT06824337",
    "title": "Effect of Targeted Mobilization Program",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Caesarean Section",
      "Mobility",
      "Pain",
      "Breastfeeding"
    ],
    "interventions": [
      "mobilization training and targeted mobilization"
    ],
    "primary_completion_date": "2025-03-01",
    "completion_date": "2025-04-01",
    "results_first_posted": null,
    "last_update_posted": "2025-02-13",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT06978088",
    "title": "LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
      "Small Lymphocytic Lymphoma",
      "CLL/SLL",
      "Chronic Lymphocytic Leukemia"
    ],
    "interventions": [
      "LP-168",
      "Obinutuzumab"
    ],
    "primary_completion_date": "2029-06-01",
    "completion_date": "2034-06-01",
    "results_first_posted": null,
    "last_update_posted": "2025-08-14",
    "enrollment": null,
    "sponsor": "Zulfa Omer",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT05689749",
    "title": "Superb Microvascular Imaging Ultrasonography of Lacrimal Gland in Patients With Sj\u00f6gren Syndrome",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Inflammation",
      "Sjogren's Syndrome",
      "Gland; Inflammation"
    ],
    "interventions": [
      "Superb Microvascular Imaging (SMI) (Toshiba)"
    ],
    "primary_completion_date": "2023-01-03",
    "completion_date": "2023-06-01",
    "results_first_posted": null,
    "last_update_posted": "2023-06-26",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT07210853",
    "title": "Postural Stability Following Anterior Cruciate Ligament Reconstruction",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Anterior Cruciate Ligament (ACL)",
      "Postural Stability"
    ],
    "interventions": [],
    "primary_completion_date": "2024-12-15",
    "completion_date": "2024-12-15",
    "results_first_posted": null,
    "last_update_posted": "2025-10-07",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT07203703",
    "title": "Comparing Jaw Tracking and Traditional Methods for Measuring Bite Accuracy in Patients With Teeth",
    "status": "NOT_YET_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Jaw Tracking"
    ],
    "interventions": [
      "Jaw Tracking Device"
    ],
    "primary_completion_date": "2026-01-15",
    "completion_date": "2026-02-01",
    "results_first_posted": null,
    "last_update_posted": "2025-10-02",
    "enrollment": null,
    "sponsor": "Omer Abdelmagid",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT06436391",
    "title": "The Effectiveness of Two Different Methods in Heel Blood Collection",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Infant Behavior",
      "Pain"
    ],
    "interventions": [
      "Kinesio taping",
      "ShotBlocker"
    ],
    "primary_completion_date": "2024-08-31",
    "completion_date": "2024-09-20",
    "results_first_posted": null,
    "last_update_posted": "2024-12-12",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT07328698",
    "title": "Postoperative Ozonated Oil Dressing After Open Inguinal Hernia Repair: A Randomized Pilot Trial",
    "status": "NOT_YET_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Inguinal Hernia Unilateral",
      "Postoperative Wound Inflammation"
    ],
    "interventions": [
      "ozonated oil",
      "Standard Sterile Dressing"
    ],
    "primary_completion_date": "2026-04-30",
    "completion_date": "2026-05-31",
    "results_first_posted": null,
    "last_update_posted": "2026-01-09",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT05778890",
    "title": "Home Exercises Program Compared With Physiotherapy Program in TMD",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Temporomandibular Disorder"
    ],
    "interventions": [
      "Intervention Group: Physiotherapy program + home exercises program",
      "Control Group : Physiotherapy program"
    ],
    "primary_completion_date": "2018-02-20",
    "completion_date": "2018-05-02",
    "results_first_posted": null,
    "last_update_posted": "2023-03-21",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT07261696",
    "title": "The Effects of Inspiratory Muscle Training Female Patients With Fibromyalgia",
    "status": "NOT_YET_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fibromyalgia",
      "Autonomic Dysfunction"
    ],
    "interventions": [
      "Exercise"
    ],
    "primary_completion_date": "2026-12-05",
    "completion_date": "2026-12-05",
    "results_first_posted": null,
    "last_update_posted": "2025-12-03",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT03427437",
    "title": "Ultrasound-Guided Versus Conventional Method for Caudal Block",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ultrasound Therapy; Complications"
    ],
    "interventions": [
      "Bupivacaine",
      "Adrenalin",
      "Ultrasound"
    ],
    "primary_completion_date": "2017-11-01",
    "completion_date": "2018-01-01",
    "results_first_posted": null,
    "last_update_posted": "2018-02-09",
    "enrollment": null,
    "sponsor": "Omer Karaca",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT06436404",
    "title": "Hammock Position and Kangaroo Care",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Infant Development",
      "Premature"
    ],
    "interventions": [
      "Hammock intervention",
      "Kangaroo care intervention"
    ],
    "primary_completion_date": "2025-03-01",
    "completion_date": "2025-05-20",
    "results_first_posted": null,
    "last_update_posted": "2025-05-25",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT07027085",
    "title": "Investigation of the Effects of Virtual Reality Applications on Individuals Diagnosed With Schizophrenia",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia Disorders"
    ],
    "interventions": [
      "virtual reality"
    ],
    "primary_completion_date": "2025-10",
    "completion_date": "2025-12",
    "results_first_posted": null,
    "last_update_posted": "2025-06-18",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT07311837",
    "title": "Investigating the Relationships Between Body Composition, Peripheral Muscle Strength, and Cough Force in Healthy Young Adults",
    "status": "NOT_YET_RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Healthy Young Adults"
    ],
    "interventions": [],
    "primary_completion_date": "2026-03-01",
    "completion_date": "2026-03-15",
    "results_first_posted": null,
    "last_update_posted": "2025-12-31",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT05901922",
    "title": "The Effect of Social Skills Intervention on Praxis and Social Functioning in Individuals With Schizophrenia",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia"
    ],
    "interventions": [
      "Social skills training"
    ],
    "primary_completion_date": "2023-06-10",
    "completion_date": "2023-07-15",
    "results_first_posted": null,
    "last_update_posted": "2024-02-02",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT06519825",
    "title": "The Effect of Inspiratory Muscle Strength Training in Healthy Adults With Forward Head Posture",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Posture"
    ],
    "interventions": [
      "Exercise"
    ],
    "primary_completion_date": "2025-03-27",
    "completion_date": "2025-03-27",
    "results_first_posted": null,
    "last_update_posted": "2025-03-28",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT05385029",
    "title": "Fetal and Neonatal Thyroid in Pregnancies With Severe Acute Respiratory Syndrome Coronavirus 2 ( SARS- COV2 ) COVID-19",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Thyroid Dysfunction",
      "Hypothyroidism",
      "Hyperthyroidism"
    ],
    "interventions": [
      "Thyroxine"
    ],
    "primary_completion_date": "2021-09-30",
    "completion_date": "2021-09-30",
    "results_first_posted": null,
    "last_update_posted": "2022-05-23",
    "enrollment": null,
    "sponsor": "OMER B ABDELBASIT",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT05671341",
    "title": "Comparison of Balance, Activity-specific Balance Confidence and Quality of Life in Parkinson's Patients",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Idiopathic Parkinson's Disease"
    ],
    "interventions": [
      "Assessment"
    ],
    "primary_completion_date": "2023-02-28",
    "completion_date": "2023-02-28",
    "results_first_posted": null,
    "last_update_posted": "2024-09-03",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT06373315",
    "title": "The Effect of Smartphone and Hand Anthropometry on Pain and Upper Extremity Functions",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Upper Extremity Problem",
      "Smartphone Addiction"
    ],
    "interventions": [],
    "primary_completion_date": "2024-09-30",
    "completion_date": "2024-09-30",
    "results_first_posted": null,
    "last_update_posted": "2025-06-26",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT06428292",
    "title": "Fully Immersive Virtual Reality Applications in Children With Cerebral Palsy",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cerebral Palsy"
    ],
    "interventions": [
      "Virtual reality device branded ''Meta Quest 2''"
    ],
    "primary_completion_date": "2024-06-13",
    "completion_date": "2024-07-03",
    "results_first_posted": null,
    "last_update_posted": "2024-08-12",
    "enrollment": null,
    "sponsor": "Omer Ayhan",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT06979999",
    "title": "The Effects of Positive End-expiratory Pressure (PEEP) on Optic Nerve Sheath Diameter in Laparoscopic Cholecystectomy",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Positive End-expiratory Pressure (PEEP)",
      "Intracranial Pressure",
      "Optic Nerve Sheath Diameter",
      "Mechanical Ventilation"
    ],
    "interventions": [
      "Positive End-Expiratory Pressure (PEEP)"
    ],
    "primary_completion_date": "2025-05-29",
    "completion_date": "2025-07-29",
    "results_first_posted": null,
    "last_update_posted": "2025-05-20",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OMER",
    "nct_id": "NCT07307703",
    "title": "TENS for Anxiety, Pain, and Satisfaction After Laparoscopic Cholecystectomy",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Gallstone Disease",
      "Postoperative Pain",
      "Surgical Anxiety",
      "Patient Satisfaction After Laparoscopic Cholecystectomy"
    ],
    "interventions": [
      "Transcutaneous Electrical Nerve Stimulation (TENS)"
    ],
    "primary_completion_date": "2026-06-30",
    "completion_date": "2026-09-30",
    "results_first_posted": null,
    "last_update_posted": "2025-12-29",
    "enrollment": null,
    "sponsor": "Nigde Omer Halisdemir University",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RANI",
    "nct_id": "NCT05164614",
    "title": "Study Evaluating PK of PTH Administered Orally Via RaniPill\u2122 Capsule",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "RT-102 (80 \u03bcg)",
      "Forteo",
      "RT-102 (20 \u03bcg)"
    ],
    "primary_completion_date": "2022-10-10",
    "completion_date": "2022-10-17",
    "results_first_posted": null,
    "last_update_posted": "2022-10-31",
    "enrollment": null,
    "sponsor": "RANI Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RANI",
    "nct_id": "NCT06891287",
    "title": "An Early Phase Study of RT-114",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Obesity"
    ],
    "interventions": [
      "RT-114 is the RaniPill capsule with PG-102 for the treatment of obesity",
      "PG-102",
      "Placebo"
    ],
    "primary_completion_date": "2026-03-01",
    "completion_date": "2026-04-01",
    "results_first_posted": null,
    "last_update_posted": "2025-03-24",
    "enrollment": null,
    "sponsor": "RANI Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RANI",
    "nct_id": "NCT04911296",
    "title": "Pill Swallow Study",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Not Determined"
    ],
    "interventions": [
      "Mock-RP"
    ],
    "primary_completion_date": "2021-08-27",
    "completion_date": "2021-08-27",
    "results_first_posted": "2025-02-12",
    "last_update_posted": "2025-02-12",
    "enrollment": null,
    "sponsor": "RANI Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RANI",
    "nct_id": "NCT05890118",
    "title": "Study Evaluating PK of Ustekinumab Administered Orally Via RaniPill\u2122 Capsule",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "Stelara",
      "RT-111 (0.5mg)",
      "RT-111 (0.75mg)"
    ],
    "primary_completion_date": "2023-11-28",
    "completion_date": "2023-11-28",
    "results_first_posted": null,
    "last_update_posted": "2024-01-11",
    "enrollment": null,
    "sponsor": "RANI Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RANI",
    "nct_id": "NCT03798912",
    "title": "A First-in-Human Study of the RaniPill, an Oral Drug Delivery Platform",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "RaniPill capsule containing octreotide"
    ],
    "primary_completion_date": "2020-02-17",
    "completion_date": "2020-02-17",
    "results_first_posted": null,
    "last_update_posted": "2020-10-08",
    "enrollment": null,
    "sponsor": "RANI Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SIGA",
    "nct_id": "NCT04971109",
    "title": "Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Smallpox"
    ],
    "interventions": [
      "TPOXX",
      "TPOXX Placebo"
    ],
    "primary_completion_date": "2023-05-12",
    "completion_date": "2023-05-12",
    "results_first_posted": "2024-10-23",
    "last_update_posted": "2024-12-27",
    "enrollment": null,
    "sponsor": "SIGA Technologies",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SIGA",
    "nct_id": "NCT02474589",
    "title": "A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Smallpox"
    ],
    "interventions": [
      "tecovirimat",
      "Placebo"
    ],
    "primary_completion_date": "2016-08-24",
    "completion_date": "2016-08-24",
    "results_first_posted": "2017-11-28",
    "last_update_posted": "2017-11-28",
    "enrollment": null,
    "sponsor": "SIGA Technologies",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SIGA",
    "nct_id": "NCT04392739",
    "title": "Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KG",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Smallpox"
    ],
    "interventions": [
      "Tpoxx"
    ],
    "primary_completion_date": "2019-12-05",
    "completion_date": "2019-12-05",
    "results_first_posted": "2024-09-19",
    "last_update_posted": "2024-09-19",
    "enrollment": null,
    "sponsor": "SIGA Technologies",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SIGA",
    "nct_id": "NCT04957485",
    "title": "Study to Assess the Safety and Immunogenicity of TPOXX\u00ae When Administered Orally for 28 Days With JYNNEOS",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Smallpox"
    ],
    "interventions": [
      "Tecovirimat",
      "Smallpox and Mpox Vaccine",
      "Placebo"
    ],
    "primary_completion_date": "2026-01-01",
    "completion_date": "2026-01-01",
    "results_first_posted": null,
    "last_update_posted": "2025-05-15",
    "enrollment": null,
    "sponsor": "SIGA Technologies",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SIGA",
    "nct_id": "NCT00907803",
    "title": "Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Orthopoxviral Disease"
    ],
    "interventions": [
      "ST-246 400 mg",
      "ST-246 600 mg",
      "Placebo"
    ],
    "primary_completion_date": "2010-01",
    "completion_date": "2010-01",
    "results_first_posted": "2010-08-27",
    "last_update_posted": "2010-09-21",
    "enrollment": null,
    "sponsor": "SIGA Technologies",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SIGA",
    "nct_id": "NCT00728689",
    "title": "Phase I Trial of an Investigational Small Pox Medication",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Orthopoxviral Disease",
      "Smallpox",
      "Monkey Pox"
    ],
    "interventions": [
      "ST-246 Days 1 - 3",
      "ST-246 Days 11 - 13"
    ],
    "primary_completion_date": "2008-10",
    "completion_date": "2008-10",
    "results_first_posted": "2010-02-09",
    "last_update_posted": "2015-06-29",
    "enrollment": null,
    "sponsor": "SIGA Technologies",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SIGA",
    "nct_id": "NCT03972111",
    "title": "A Phase 4, Observational Field Study to Evaluate TPOXX in Patients With Smallpox",
    "status": "WITHDRAWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Smallpox"
    ],
    "interventions": [
      "TPOXX 200Mg Capsule"
    ],
    "primary_completion_date": "2024-09-30",
    "completion_date": "2024-09-30",
    "results_first_posted": null,
    "last_update_posted": "2022-10-03",
    "enrollment": null,
    "sponsor": "SIGA Technologies",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SIGA",
    "nct_id": "NCT00431951",
    "title": "Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "ST-246",
      "Placebo"
    ],
    "primary_completion_date": "2008-02",
    "completion_date": "2008-02",
    "results_first_posted": "2010-05-07",
    "last_update_posted": "2017-07-27",
    "enrollment": null,
    "sponsor": "SIGA Technologies",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SIGA",
    "nct_id": "NCT04485039",
    "title": "Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Smallpox"
    ],
    "interventions": [
      "Tecovirimat",
      "sevelamer carbonate oral tablet",
      "sucroferric oxyhydroxide chewable tablet",
      "calcium acetate oral tablet",
      "Lanthanum Carbonate Chewable Tablet"
    ],
    "primary_completion_date": "2022-12-15",
    "completion_date": "2023-04-23",
    "results_first_posted": "2024-10-09",
    "last_update_posted": "2024-12-27",
    "enrollment": null,
    "sponsor": "SIGA Technologies",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VOR",
    "nct_id": "NCT05984199",
    "title": "Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Leukemia, Myeloid, Acute"
    ],
    "interventions": [
      "VCAR33"
    ],
    "primary_completion_date": "2025-05-28",
    "completion_date": "2025-05-28",
    "results_first_posted": null,
    "last_update_posted": "2025-07-29",
    "enrollment": null,
    "sponsor": "Vor Biopharma",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VOR",
    "nct_id": "NCT05309733",
    "title": "A Long-term Follow-up Study of Patients Who Received VOR33",
    "status": "TERMINATED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Leukemia, Myeloid, Acute"
    ],
    "interventions": [
      "VOR33"
    ],
    "primary_completion_date": "2025-05-28",
    "completion_date": "2025-05-28",
    "results_first_posted": null,
    "last_update_posted": "2025-07-29",
    "enrollment": null,
    "sponsor": "Vor Biopharma",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VOR",
    "nct_id": "NCT06456580",
    "title": "A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (RemeMG)",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Generalized Myasthenia Gravis"
    ],
    "interventions": [
      "Telitacicept",
      "Placebo"
    ],
    "primary_completion_date": "2026-12",
    "completion_date": "2028-01",
    "results_first_posted": null,
    "last_update_posted": "2026-01-27",
    "enrollment": null,
    "sponsor": "Vor Biopharma",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VOR",
    "nct_id": "NCT04849910",
    "title": "Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Leukemia, Myeloid, Acute",
      "Myelodysplastic Syndromes"
    ],
    "interventions": [
      "VOR33",
      "Mylotarg"
    ],
    "primary_completion_date": "2025-05-28",
    "completion_date": "2025-05-28",
    "results_first_posted": null,
    "last_update_posted": "2025-07-29",
    "enrollment": null,
    "sponsor": "Vor Biopharma",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VOR",
    "nct_id": "NCT05306574",
    "title": "A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Systemic Lupus Erythematosus"
    ],
    "interventions": [
      "Telitacicept",
      "Placebo"
    ],
    "primary_completion_date": "2025-01-06",
    "completion_date": "2025-01-06",
    "results_first_posted": null,
    "last_update_posted": "2026-01-09",
    "enrollment": null,
    "sponsor": "Vor Biopharma",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VOR",
    "nct_id": "NCT06456567",
    "title": "A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)",
    "status": "WITHDRAWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Systemic Lupus Erythematosus"
    ],
    "interventions": [
      "Telitacicept",
      "Placebo"
    ],
    "primary_completion_date": "2025-01-02",
    "completion_date": "2025-01-06",
    "results_first_posted": null,
    "last_update_posted": "2026-01-09",
    "enrollment": null,
    "sponsor": "Vor Biopharma",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACLX",
    "nct_id": "NCT06626919",
    "title": "A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Muscular Diseases",
      "Neuromuscular Manifestations",
      "Autoimmune",
      "Autoimmune Diseases",
      "Autoimmune Diseases of the Nervous System",
      "Myasthenia Gravis",
      "Muscle Weakness"
    ],
    "interventions": [
      "anito-cel",
      "Standard Lymphodepletion regimen"
    ],
    "primary_completion_date": "2027-03",
    "completion_date": "2028-04",
    "results_first_posted": null,
    "last_update_posted": "2025-08-01",
    "enrollment": null,
    "sponsor": "Arcellx, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Arcellx"
  },
  {
    "ticker": "ACLX",
    "nct_id": "NCT05457010",
    "title": "Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS",
    "status": "UNKNOWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Myeloid Leukemia",
      "Myelodysplastic Syndromes"
    ],
    "interventions": [
      "SPRX002",
      "ARC-T Cells"
    ],
    "primary_completion_date": "2025-09-30",
    "completion_date": "2025-11-17",
    "results_first_posted": null,
    "last_update_posted": "2024-06-12",
    "enrollment": null,
    "sponsor": "Arcellx, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Arcellx"
  },
  {
    "ticker": "ADPT",
    "nct_id": "NCT05255354",
    "title": "Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Follicular Lymphoma",
      "Diffuse Large B Cell Lymphoma",
      "Mantle Cell Lymphoma"
    ],
    "interventions": [
      "ClonoSEQ"
    ],
    "primary_completion_date": "2025-09-01",
    "completion_date": "2026-12-31",
    "results_first_posted": null,
    "last_update_posted": "2024-08-22",
    "enrollment": null,
    "sponsor": "Adaptive Biotechnologies",
    "collected_at": "2026-01-27",
    "search_term": "Adaptive Biotechnologies"
  },
  {
    "ticker": "ADPT",
    "nct_id": "NCT04494893",
    "title": "ImmuneRACE - Immune Response Action to COVID-19 Events",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Covid19"
    ],
    "interventions": [],
    "primary_completion_date": "2021-03-23",
    "completion_date": "2021-04-23",
    "results_first_posted": null,
    "last_update_posted": "2022-02-16",
    "enrollment": null,
    "sponsor": "Adaptive Biotechnologies",
    "collected_at": "2026-01-27",
    "search_term": "Adaptive Biotechnologies"
  },
  {
    "ticker": "ADPT",
    "nct_id": "NCT05769829",
    "title": "ImmuneSense\u2122 IBD Study",
    "status": "TERMINATED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Inflammatory Bowel Diseases"
    ],
    "interventions": [],
    "primary_completion_date": "2023-08-14",
    "completion_date": "2023-08-14",
    "results_first_posted": null,
    "last_update_posted": "2023-10-05",
    "enrollment": null,
    "sponsor": "Adaptive Biotechnologies",
    "collected_at": "2026-01-27",
    "search_term": "Adaptive Biotechnologies"
  },
  {
    "ticker": "ADPT",
    "nct_id": "NCT04583982",
    "title": "ImmuneSense\u2122 COVID-19 Study",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Coronavirus Disease (COVID-19)",
      "SARS-CoV-2 Infection"
    ],
    "interventions": [
      "T-Detect\u2122 SARS-CoV-2 Assay"
    ],
    "primary_completion_date": "2020-12-04",
    "completion_date": "2020-12-04",
    "results_first_posted": null,
    "last_update_posted": "2022-04-15",
    "enrollment": null,
    "sponsor": "Adaptive Biotechnologies",
    "collected_at": "2026-01-27",
    "search_term": "Adaptive Biotechnologies"
  },
  {
    "ticker": "ADPT",
    "nct_id": "NCT05054088",
    "title": "ImmuneSense COVID-19 Variant Study",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Covid19"
    ],
    "interventions": [
      "T-Detect COVID test"
    ],
    "primary_completion_date": "2022-07-20",
    "completion_date": "2022-07-28",
    "results_first_posted": null,
    "last_update_posted": "2022-12-07",
    "enrollment": null,
    "sponsor": "Adaptive Biotechnologies",
    "collected_at": "2026-01-27",
    "search_term": "Adaptive Biotechnologies"
  },
  {
    "ticker": "ADPT",
    "nct_id": "NCT04545333",
    "title": "The clonoSEQ\u00ae Watch Registry",
    "status": "TERMINATED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Acute Lymphoblastic Leukemia, Adult B-Cell",
      "Chronic Lymphocytic Leukemia",
      "Multiple Myeloma",
      "Non-hodgkin Lymphoma"
    ],
    "interventions": [
      "clonoSEQ Assay"
    ],
    "primary_completion_date": "2023-10-01",
    "completion_date": "2023-10-01",
    "results_first_posted": null,
    "last_update_posted": "2024-08-01",
    "enrollment": null,
    "sponsor": "Adaptive Biotechnologies",
    "collected_at": "2026-01-27",
    "search_term": "Adaptive Biotechnologies"
  },
  {
    "ticker": "ADPT",
    "nct_id": "NCT04422314",
    "title": "ImmuneSense Lyme Study",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Lyme Disease"
    ],
    "interventions": [
      "T-Detect Lyme"
    ],
    "primary_completion_date": "2021-10-29",
    "completion_date": "2021-10-30",
    "results_first_posted": null,
    "last_update_posted": "2022-04-15",
    "enrollment": null,
    "sponsor": "Adaptive Biotechnologies",
    "collected_at": "2026-01-27",
    "search_term": "Adaptive Biotechnologies"
  },
  {
    "ticker": "ADPT",
    "nct_id": "NCT05112874",
    "title": "ImmuneSense\u2122 COVID-19 Cross-Reactivity Study",
    "status": "WITHDRAWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Coronavirus Disease",
      "SARS-CoV-2 Infection"
    ],
    "interventions": [],
    "primary_completion_date": "2023-05-17",
    "completion_date": "2023-05-17",
    "results_first_posted": null,
    "last_update_posted": "2023-07-27",
    "enrollment": null,
    "sponsor": "Adaptive Biotechnologies",
    "collected_at": "2026-01-27",
    "search_term": "Adaptive Biotechnologies"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT03934307",
    "title": "A Study to Evaluate ALN-AGT01 in Patients With Hypertension",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypertension"
    ],
    "interventions": [
      "ALN-AGT01",
      "ALN-AGT01-Matching Placebo",
      "Irbesartan",
      "Irbesartan-Matching Placebo"
    ],
    "primary_completion_date": "2022-04-20",
    "completion_date": "2023-01-04",
    "results_first_posted": null,
    "last_update_posted": "2023-01-17",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT05761301",
    "title": "A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 2 Diabetes Mellitus (T2DM)"
    ],
    "interventions": [
      "ALN-KHK",
      "Placebo"
    ],
    "primary_completion_date": "2025-04-03",
    "completion_date": "2025-04-03",
    "results_first_posted": null,
    "last_update_posted": "2025-05-07",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT04883905",
    "title": "ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Acute Hepatic Porphyria"
    ],
    "interventions": [],
    "primary_completion_date": "2027-04-01",
    "completion_date": "2027-04-01",
    "results_first_posted": null,
    "last_update_posted": "2025-12-19",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT02452372",
    "title": "A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Intermittent Porphyria"
    ],
    "interventions": [
      "givosiran (ALN-AS1)",
      "Sterile Normal Saline (0.9% NaCl)"
    ],
    "primary_completion_date": "2017-09-06",
    "completion_date": "2017-09-06",
    "results_first_posted": null,
    "last_update_posted": "2018-06-14",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT01961921",
    "title": "The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "TTR-mediated Amyloidosis"
    ],
    "interventions": [
      "ALN-TTR02 (patisiran) administered by intravenous (IV) infusion"
    ],
    "primary_completion_date": "2016-07",
    "completion_date": "2016-08",
    "results_first_posted": "2018-10-30",
    "last_update_posted": "2024-04-19",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT02797847",
    "title": "A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Transthyretin-mediated Amyloidosis (ATTR Amyloidosis)"
    ],
    "interventions": [
      "ALN-TTRSC02",
      "Sterile Normal Saline (0.9% NaCl)"
    ],
    "primary_completion_date": "2018-01-12",
    "completion_date": "2018-01-12",
    "results_first_posted": null,
    "last_update_posted": "2018-09-21",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT07052903",
    "title": "TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Transthyretin Amyloidosis With Cardiomyopathy"
    ],
    "interventions": [
      "Nucresiran",
      "Sterile Normal Saline (0.9% NaCl)"
    ],
    "primary_completion_date": "2030-05-28",
    "completion_date": "2032-11-30",
    "results_first_posted": null,
    "last_update_posted": "2025-12-19",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT01981837",
    "title": "Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "TTR-mediated Amyloidosis"
    ],
    "interventions": [
      "ALN-TTRSC (revusiran) for subcutaneous administration"
    ],
    "primary_completion_date": "2014-10",
    "completion_date": "2015-01",
    "results_first_posted": null,
    "last_update_posted": "2023-03-20",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT02503683",
    "title": "A Study of an Investigational Drug, ALN-AAT, in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Antitrypsin Deficiency Liver Disease"
    ],
    "interventions": [
      "ALN-AAT",
      "Sterile Normal Saline (0.9% NaCl)"
    ],
    "primary_completion_date": "2018-01-03",
    "completion_date": "2018-01-03",
    "results_first_posted": null,
    "last_update_posted": "2019-01-07",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT04936035",
    "title": "A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypertension"
    ],
    "interventions": [
      "Placebo",
      "ALN-AGT01"
    ],
    "primary_completion_date": "2023-04-04",
    "completion_date": "2024-12-05",
    "results_first_posted": "2024-12-27",
    "last_update_posted": "2025-12-23",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT02949830",
    "title": "A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Intermittent Porphyria"
    ],
    "interventions": [
      "Givosiran"
    ],
    "primary_completion_date": "2021-11-05",
    "completion_date": "2021-11-05",
    "results_first_posted": "2024-03-12",
    "last_update_posted": "2024-03-12",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT04056481",
    "title": "Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria",
    "status": "APPROVED_FOR_MARKETING",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Acute Hepatic Porphyria"
    ],
    "interventions": [
      "Givosiran"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2024-05-20",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT01158079",
    "title": "Multi-center, Open Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 Treatment",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumors"
    ],
    "interventions": [
      "ALN-VSP02"
    ],
    "primary_completion_date": "2012-08",
    "completion_date": "2012-09",
    "results_first_posted": null,
    "last_update_posted": "2012-10-12",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT06845202",
    "title": "A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Obese or Overweight Healthy Volunteers",
      "Type 2 Diabetes Mellitus (T2DM)"
    ],
    "interventions": [
      "ALN-4324",
      "Placebo"
    ],
    "primary_completion_date": "2027-08-31",
    "completion_date": "2027-08-31",
    "results_first_posted": null,
    "last_update_posted": "2025-12-19",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT01559077",
    "title": "Trial to Evaluate Safety, Tolerability, and Parmacokinetics of ALN-TTR02 in Healthy Volunteer Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "TTR-mediated Amyloidosis"
    ],
    "interventions": [
      "ALN-TTR02",
      "Sterile Normal Saline (0.9% NaCl)"
    ],
    "primary_completion_date": "2012-06",
    "completion_date": "2012-11",
    "results_first_posted": null,
    "last_update_posted": "2013-01-15",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT07181109",
    "title": "Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "High Risk Cardiovascular Disease",
      "Hypertension",
      "High Cardiovascular Risk"
    ],
    "interventions": [
      "Zilebesiran",
      "Placebo"
    ],
    "primary_completion_date": "2030-10-29",
    "completion_date": "2030-10-29",
    "results_first_posted": null,
    "last_update_posted": "2025-11-04",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT05505838",
    "title": "Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy",
    "status": "NO_LONGER_AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Transthyretin-mediated Amyloidosis With Cardiomyopathy",
      "ATTR Amyloidosis With Cardiomyopathy"
    ],
    "interventions": [
      "Patisiran"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2024-02-16",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT06393712",
    "title": "A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cerebral Amyloid Angiopathy"
    ],
    "interventions": [
      "Placebo",
      "ALN-APP"
    ],
    "primary_completion_date": "2027-07-01",
    "completion_date": "2029-11-01",
    "results_first_posted": null,
    "last_update_posted": "2025-12-19",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT04125472",
    "title": "Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1",
    "status": "APPROVED_FOR_MARKETING",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Primary Hyperoxaluria"
    ],
    "interventions": [
      "Lumasiran"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2024-02-16",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT03338816",
    "title": "ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Hepatic Porphyria",
      "Acute Intermittent Porphyria",
      "Porphyria, Acute Intermittent",
      "Acute Porphyria",
      "Hereditary Coproporphyria (HCP)",
      "Variegate Porphyria (VP)",
      "ALA Dehydratase Deficient Porphyria (ADP)"
    ],
    "interventions": [
      "Givosiran",
      "Placebo"
    ],
    "primary_completion_date": "2019-01-31",
    "completion_date": "2021-05-31",
    "results_first_posted": "2020-02-11",
    "last_update_posted": "2024-04-22",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT03505853",
    "title": "A Study to Investigate the Interaction Between Givosiran and a 5-probe Drug Cocktail in Patients With Acute Intermittent Porphyria (AIP)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Intermittent Porphyria (AIP)",
      "Acute Hepatic Porphyria (AHP)",
      "Porphyria, Acute Intermittent",
      "Acute Porphyria"
    ],
    "interventions": [
      "Givosiran",
      "5-probe cocktail"
    ],
    "primary_completion_date": "2018-11-16",
    "completion_date": "2019-01-10",
    "results_first_posted": null,
    "last_update_posted": "2019-03-12",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT03350451",
    "title": "An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "PH1",
      "Primary Hyperoxaluria",
      "RNAi Therapeutic",
      "siRNA",
      "AGT"
    ],
    "interventions": [
      "Lumasiran"
    ],
    "primary_completion_date": "2023-02-07",
    "completion_date": "2023-02-07",
    "results_first_posted": "2024-04-25",
    "last_update_posted": "2024-04-25",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT03997383",
    "title": "APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Transthyretin Amyloidosis (ATTR) With Cardiomyopathy"
    ],
    "interventions": [
      "Placebo",
      "Patisiran"
    ],
    "primary_completion_date": "2022-06-20",
    "completion_date": "2027-03-15",
    "results_first_posted": "2023-10-18",
    "last_update_posted": "2026-01-12",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT04153149",
    "title": "HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Transthyretin Amyloidosis (ATTR) With Cardiomyopathy"
    ],
    "interventions": [
      "Vutrisiran",
      "Sterile Normal Saline (0.9% NaCl)"
    ],
    "primary_completion_date": "2024-05-08",
    "completion_date": "2026-12-02",
    "results_first_posted": "2025-10-21",
    "last_update_posted": "2026-01-12",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT06585449",
    "title": "A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Huntington's Disease"
    ],
    "interventions": [
      "ALN-HTT02",
      "Placebo"
    ],
    "primary_completion_date": "2028-07-05",
    "completion_date": "2028-07-05",
    "results_first_posted": null,
    "last_update_posted": "2025-12-24",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT05256810",
    "title": "A Study to Evaluate ALN-XDH in Healthy Subjects and Patients With Gout",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Gout"
    ],
    "interventions": [
      "ALN-XDH",
      "Placebo"
    ],
    "primary_completion_date": "2023-01-25",
    "completion_date": "2023-01-25",
    "results_first_posted": null,
    "last_update_posted": "2024-03-29",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT03303313",
    "title": "A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atypical Hemolytic Uremic Syndrome"
    ],
    "interventions": [
      "Cemdisiran"
    ],
    "primary_completion_date": "2018-09-12",
    "completion_date": "2018-09-12",
    "results_first_posted": null,
    "last_update_posted": "2018-10-01",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT05661916",
    "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Transthyretin-Mediated Amyloidosis"
    ],
    "interventions": [
      "ALN-TTRSC04",
      "Placebo"
    ],
    "primary_completion_date": "2025-09-30",
    "completion_date": "2025-09-30",
    "results_first_posted": null,
    "last_update_posted": "2025-12-19",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT03905694",
    "title": "A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Primary Hyperoxaluria",
      "Primary Hyperoxaluria Type 1 (PH1)"
    ],
    "interventions": [
      "Lumasiran"
    ],
    "primary_completion_date": "2020-06-29",
    "completion_date": "2024-07-26",
    "results_first_posted": "2021-07-19",
    "last_update_posted": "2025-02-14",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT02240784",
    "title": "EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Acute Hepatic Porphyria"
    ],
    "interventions": [],
    "primary_completion_date": "2021-04-26",
    "completion_date": "2021-04-26",
    "results_first_posted": null,
    "last_update_posted": "2021-05-17",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT07223203",
    "title": "TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy",
      "hATTR-PN"
    ],
    "interventions": [
      "Nucresiran",
      "Vutrisiran"
    ],
    "primary_completion_date": "2027-12-27",
    "completion_date": "2031-06-12",
    "results_first_posted": null,
    "last_update_posted": "2026-01-14",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT03767829",
    "title": "A Study of ALN-AAT02 in Healthy Participants and Participants With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease"
    ],
    "interventions": [
      "ALN-AAT02",
      "Placebo",
      "ALN-AAT02"
    ],
    "primary_completion_date": "2020-06-25",
    "completion_date": "2020-06-25",
    "results_first_posted": null,
    "last_update_posted": "2021-04-27",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT04561518",
    "title": "ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Transthyretin-Mediated Amyloidosis",
      "ATTR Amyloidosis"
    ],
    "interventions": [],
    "primary_completion_date": "2030-09-01",
    "completion_date": "2030-09-01",
    "results_first_posted": null,
    "last_update_posted": "2025-12-24",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT03681184",
    "title": "A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Primary Hyperoxaluria Type 1 (PH1)"
    ],
    "interventions": [
      "Placebo",
      "Lumasiran"
    ],
    "primary_completion_date": "2019-11-05",
    "completion_date": "2024-01-12",
    "results_first_posted": "2021-01-19",
    "last_update_posted": "2024-08-12",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT02319005",
    "title": "ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)",
      "Amyloidosis, Hereditary",
      "Amyloid Neuropathies, Familial",
      "Amyloid Neuropathies",
      "Amyloidosis, Hereditary, Transthyretin-Related",
      "Familial Transthyretin Cardiac Amyloidosis"
    ],
    "interventions": [
      "Revusiran (ALN-TTRSC)",
      "Sterile Normal Saline (0.9% NaCl)"
    ],
    "primary_completion_date": "2017-03-30",
    "completion_date": "2017-03-30",
    "results_first_posted": "2018-07-18",
    "last_update_posted": "2018-07-18",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT06675565",
    "title": "A Study to Evaluate ALN-AGT01 RVR in Adult Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "ALN-AGT01 RVR",
      "Placebo"
    ],
    "primary_completion_date": "2025-09-08",
    "completion_date": "2025-09-08",
    "results_first_posted": null,
    "last_update_posted": "2025-09-19",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT02053454",
    "title": "A Study of the Safety, Tolerability and Pharmacokinetics of ALN-TTR02 in Japanese Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Transthyretin (TTR)-Mediated Amyloidosis"
    ],
    "interventions": [
      "patisiran (ALN-TTR02)",
      "Sterile Normal Saline (0.9% NaCl)"
    ],
    "primary_completion_date": "2014-03",
    "completion_date": "2014-06",
    "results_first_posted": null,
    "last_update_posted": "2015-05-25",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT06600321",
    "title": "A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Hepatocellular Carcinoma",
      "Metastatic Hepatocellular Carcinoma"
    ],
    "interventions": [
      "ALN-BCAT",
      "Pembrolizumab"
    ],
    "primary_completion_date": "2027-09-30",
    "completion_date": "2027-10-31",
    "results_first_posted": null,
    "last_update_posted": "2025-12-24",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT00882180",
    "title": "Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 In Patients With Advanced Solid Tumors With Liver Involvement",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumors"
    ],
    "interventions": [
      "ALN-VSP02"
    ],
    "primary_completion_date": "2011-07",
    "completion_date": "2011-08",
    "results_first_posted": null,
    "last_update_posted": "2011-08-24",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT07214727",
    "title": "A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alzheimer's Disease"
    ],
    "interventions": [
      "ALN-5288",
      "Placebo"
    ],
    "primary_completion_date": "2030-03-31",
    "completion_date": "2030-03-31",
    "results_first_posted": null,
    "last_update_posted": "2025-12-24",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT01437059",
    "title": "Trial to Evaluate Safety and Tolerability of ALN-PCS02 in Subjects With Elevated LDL-Cholesterol (LDL-C)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Elevated LDL-Cholesterol (LDL-C)"
    ],
    "interventions": [
      "ALN-PCS02",
      "Sterile Normal Saline (0.9% NaCl)"
    ],
    "primary_completion_date": "2012-03",
    "completion_date": "2012-09",
    "results_first_posted": null,
    "last_update_posted": "2012-10-12",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT04201418",
    "title": "A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Hereditary Transthyretin-mediated (ATTRv) Amyloidosis",
      "Polyneuropathy"
    ],
    "interventions": [
      "Patisiran"
    ],
    "primary_completion_date": "2022-05-24",
    "completion_date": "2022-05-24",
    "results_first_posted": null,
    "last_update_posted": "2022-06-06",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT05161936",
    "title": "A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Recurrent Calcium Oxalate Kidney Stone Disease",
      "Elevated Urinary Oxalate Levels"
    ],
    "interventions": [
      "Lumasiran",
      "Placebo"
    ],
    "primary_completion_date": "2022-11-01",
    "completion_date": "2022-11-01",
    "results_first_posted": "2024-05-22",
    "last_update_posted": "2024-05-22",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT01960348",
    "title": "APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "TTR-mediated Amyloidosis",
      "Amyloidosis, Hereditary",
      "Amyloid Neuropathies, Familial",
      "Familial Amyloid Polyneuropathies",
      "Amyloid Neuropathies",
      "Amyloidosis, Hereditary, Transthyretin-Related"
    ],
    "interventions": [
      "patisiran (ALN-TTR02)",
      "Sterile Normal Saline (0.9% NaCl)"
    ],
    "primary_completion_date": "2017-08",
    "completion_date": "2017-08",
    "results_first_posted": "2018-09-06",
    "last_update_posted": "2024-04-22",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT04982393",
    "title": "BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Primary Hyperoxaluria Type 1"
    ],
    "interventions": [],
    "primary_completion_date": "2028-09-01",
    "completion_date": "2028-09-01",
    "results_first_posted": null,
    "last_update_posted": "2025-12-24",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT06360289",
    "title": "Observational Study of Neurofilament Light Chain (NfL) as a Biomarker in Asymptomatic Carriers of the Transthyretin (TTR) Variants and Patients With Hereditary Transthyretin-mediated (hATTR) Amyloidosis With Polyneuropathy",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Hereditary Amyloidosis, Transthyretin-Related",
      "Asymptomatic Carrier State"
    ],
    "interventions": [
      "Standard of Care"
    ],
    "primary_completion_date": "2027-12-01",
    "completion_date": "2027-12-01",
    "results_first_posted": null,
    "last_update_posted": "2025-12-24",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT06679946",
    "title": "A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Transthyretin Amyloidosis (ATTR) With Cardiomyopathy"
    ],
    "interventions": [
      "Vutrisiran"
    ],
    "primary_completion_date": "2028-05-30",
    "completion_date": "2028-05-30",
    "results_first_posted": null,
    "last_update_posted": "2025-12-19",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT02314442",
    "title": "A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypercholesterolemia"
    ],
    "interventions": [
      "ALN-PCSSC",
      "Sterile Normal Saline (0.9% NaCl)"
    ],
    "primary_completion_date": "2015-05",
    "completion_date": "2015-11",
    "results_first_posted": null,
    "last_update_posted": "2015-12-17",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT03759379",
    "title": "HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Amyloidosis, Hereditary",
      "Transthyretin Amyloidosis"
    ],
    "interventions": [
      "Patisiran",
      "Vutrisiran"
    ],
    "primary_completion_date": "2020-11-10",
    "completion_date": "2025-11-05",
    "results_first_posted": "2022-08-11",
    "last_update_posted": "2026-01-12",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT07358078",
    "title": "DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Transthyretin Amyloidosis With Cardiomyopathy"
    ],
    "interventions": [],
    "primary_completion_date": "2030-10-23",
    "completion_date": "2030-10-23",
    "results_first_posted": null,
    "last_update_posted": "2026-01-22",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT05103332",
    "title": "Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypertension"
    ],
    "interventions": [
      "Indapamide",
      "Amlodipine",
      "Olmesartan",
      "Placebo",
      "Zilebesiran"
    ],
    "primary_completion_date": "2023-12-11",
    "completion_date": "2024-09-13",
    "results_first_posted": "2025-07-09",
    "last_update_posted": "2025-11-03",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT02252653",
    "title": "DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Familial Amyloidotic Cardiomyopathy (FAC)"
    ],
    "interventions": [],
    "primary_completion_date": "2016-01",
    "completion_date": "2016-03",
    "results_first_posted": null,
    "last_update_posted": "2016-07-20",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT07295717",
    "title": "A Study to Evaluate ALN-4285 in Adult Healthy Volunteers",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "ALN-4285",
      "Placebo"
    ],
    "primary_completion_date": "2026-12-29",
    "completion_date": "2027-03-23",
    "results_first_posted": null,
    "last_update_posted": "2025-12-22",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT02826018",
    "title": "A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatitis B",
      "Chronic Hepatitis B",
      "Hepatitis B, Chronic",
      "Hepatitis B Infection",
      "HBV"
    ],
    "interventions": [
      "ALN-HBV",
      "Sterile Normal Saline (0.9% NaCl)"
    ],
    "primary_completion_date": "2017-10",
    "completion_date": "2017-10",
    "results_first_posted": null,
    "last_update_posted": "2018-09-24",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT06423352",
    "title": "A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Mild to Moderate Hypertension"
    ],
    "interventions": [
      "Zilebesiran",
      "Placebo"
    ],
    "primary_completion_date": "2025-07-17",
    "completion_date": "2025-07-17",
    "results_first_posted": null,
    "last_update_posted": "2025-08-29",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT02352493",
    "title": "A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNH",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Paroxysmal Nocturnal Hemoglobinuria (PNH)"
    ],
    "interventions": [
      "ALN-CC5",
      "Sterile Normal Saline (0.9% NaCl)"
    ],
    "primary_completion_date": "2016-04",
    "completion_date": "2017-08",
    "results_first_posted": "2020-03-30",
    "last_update_posted": "2020-03-30",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT04152200",
    "title": "A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Primary Hyperoxaluria Type 1",
      "Primary Hyperoxaluria"
    ],
    "interventions": [
      "Lumasiran"
    ],
    "primary_completion_date": "2021-05-18",
    "completion_date": "2025-06-23",
    "results_first_posted": "2022-07-12",
    "last_update_posted": "2025-07-18",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT01617967",
    "title": "Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "TTR-mediated Amyloidosis"
    ],
    "interventions": [
      "Patisiran"
    ],
    "primary_completion_date": "2013-10",
    "completion_date": "2014-01",
    "results_first_posted": "2018-11-21",
    "last_update_posted": "2024-04-19",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT06272487",
    "title": "Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "High Cardiovascular Risk",
      "Hypertension"
    ],
    "interventions": [
      "Zilebesiran",
      "Placebo"
    ],
    "primary_completion_date": "2025-04-02",
    "completion_date": "2025-12-19",
    "results_first_posted": null,
    "last_update_posted": "2025-10-01",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT02510261",
    "title": "The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Amyloidosis"
    ],
    "interventions": [
      "Patisiran"
    ],
    "primary_completion_date": "2022-11-23",
    "completion_date": "2022-11-23",
    "results_first_posted": "2023-12-06",
    "last_update_posted": "2023-12-06",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT05231785",
    "title": "A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Early-Onset Alzheimer Disease"
    ],
    "interventions": [
      "ALN-APP",
      "Placebo"
    ],
    "primary_completion_date": "2029-03-28",
    "completion_date": "2029-03-28",
    "results_first_posted": null,
    "last_update_posted": "2025-12-19",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT01148953",
    "title": "Trial to Evaluate Safety and Tolerability of ALN-TTR01 in Transthyretin (TTR) Amyloidosis",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Transthyretin Mediated Amyloidosis (ATTR)"
    ],
    "interventions": [
      "ALN-TTR01",
      "Sterile Normal Saline (0.9% NaCl)"
    ],
    "primary_completion_date": "2012-01",
    "completion_date": "2012-02",
    "results_first_posted": null,
    "last_update_posted": "2012-05-24",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT03841448",
    "title": "A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "IgA Nephropathy (IgAN)",
      "Berger Disease",
      "Glomerulonephritis, IgA"
    ],
    "interventions": [
      "Placebo",
      "Cemdisiran"
    ],
    "primary_completion_date": "2022-03-17",
    "completion_date": "2023-06-27",
    "results_first_posted": "2023-12-08",
    "last_update_posted": "2024-08-09",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT00496821",
    "title": "Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Respiratory Syncytial Virus Infections"
    ],
    "interventions": [
      "ALN-RSV01"
    ],
    "primary_completion_date": null,
    "completion_date": "2007-11",
    "results_first_posted": null,
    "last_update_posted": "2007-11-30",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT05040373",
    "title": "Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Hereditary Transthyretin-mediated (hATTR) Amyloidosis",
      "Polyneuropathy"
    ],
    "interventions": [],
    "primary_completion_date": "2030-10-12",
    "completion_date": "2030-10-12",
    "results_first_posted": null,
    "last_update_posted": "2025-12-24",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT02292186",
    "title": "A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "TTR-mediated Amyloidosis"
    ],
    "interventions": [
      "Revusiran (ALN-TTRSC)"
    ],
    "primary_completion_date": "2017-02-22",
    "completion_date": "2017-02-22",
    "results_first_posted": "2018-06-15",
    "last_update_posted": "2020-07-09",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT02706886",
    "title": "Study of Lumasiran in Healthy Adults and Patients With Primary Hyperoxaluria Type 1",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Primary Hyperoxaluria Type 1 (PH1)"
    ],
    "interventions": [
      "Lumasiran",
      "Placebo"
    ],
    "primary_completion_date": "2019-01-23",
    "completion_date": "2019-01-23",
    "results_first_posted": "2020-01-30",
    "last_update_posted": "2020-01-30",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT02595983",
    "title": "The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Transthyretin (TTR)-Mediated Amyloidosis",
      "Familial Amyloidotic Polyneuropathy (FAP)",
      "ATTR Amyloidosis",
      "Familial Amyloid Neuropathies"
    ],
    "interventions": [
      "Revusiran"
    ],
    "primary_completion_date": "2017-02-06",
    "completion_date": "2017-02-06",
    "results_first_posted": "2019-03-28",
    "last_update_posted": "2019-03-28",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT02939820",
    "title": "Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)",
    "status": "APPROVED_FOR_MARKETING",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "TTR-mediated Amyloidosis",
      "Amyloidosis, Hereditary",
      "Amyloid Neuropathies, Familial",
      "Familial Amyloid Polyneuropathies",
      "Amyloid Neuropathies",
      "Amyloidosis, Hereditary, Transthyretin-Related"
    ],
    "interventions": [
      "patisiran (ALN-TTR02)"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2024-05-20",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT04565717",
    "title": "A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Nonalcoholic Steatohepatitis",
      "NASH"
    ],
    "interventions": [
      "ALN-HSD",
      "Placebo"
    ],
    "primary_completion_date": "2023-01-06",
    "completion_date": "2023-12-21",
    "results_first_posted": null,
    "last_update_posted": "2024-05-17",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT01065935",
    "title": "Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Respiratory Syncytial Virus Infections"
    ],
    "interventions": [
      "ALN-RSV01",
      "Normal Saline"
    ],
    "primary_completion_date": "2012-04",
    "completion_date": "2012-05",
    "results_first_posted": null,
    "last_update_posted": "2018-02-05",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT01814839",
    "title": "A Phase 1, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-TTRSC (Revusiran) in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "TTR-mediated Amyloidosis"
    ],
    "interventions": [
      "ALN-TTRSC (revusiran)",
      "Sterile Normal Saline (0.9% NaCl)"
    ],
    "primary_completion_date": "2015-04",
    "completion_date": "2015-05",
    "results_first_posted": null,
    "last_update_posted": "2016-02-05",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT03862807",
    "title": "Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Amyloidosis, Familial",
      "Transthyretin Amyloidosis"
    ],
    "interventions": [
      "Patisiran"
    ],
    "primary_completion_date": "2020-10-06",
    "completion_date": "2020-10-20",
    "results_first_posted": "2021-12-21",
    "last_update_posted": "2024-04-22",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "ALNY",
    "nct_id": "NCT00658086",
    "title": "Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Respiratory Syncytial Virus Infections"
    ],
    "interventions": [
      "ALN-RSV01",
      "normal saline"
    ],
    "primary_completion_date": "2009-04",
    "completion_date": "2009-06",
    "results_first_posted": null,
    "last_update_posted": "2018-01-29",
    "enrollment": null,
    "sponsor": "Alnylam Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Alnylam Pharmaceuticals"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT03106051",
    "title": "Study of Apremilast Use in Patients With Psoriatic Arthritic in Practice Conditions",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Arthritis, Psoriatic"
    ],
    "interventions": [],
    "primary_completion_date": "2018-07-31",
    "completion_date": "2020-08-12",
    "results_first_posted": null,
    "last_update_posted": "2025-09-03",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00115219",
    "title": "Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis (RA) Subjects Who Are Sub-Optimal Responders to Etanercept 50 mg Once Weekly (QW)",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rheumatoid Arthritis"
    ],
    "interventions": [
      "Etanercept"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2013-05-30",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00121030",
    "title": "Treatment for Patients With Gynecological Malignancies Who Suffer From Anemia Due to Chemotherapy",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Gynecological Malignancies",
      "Genital Neoplasms, Female",
      "Anemia"
    ],
    "interventions": [
      "darbepoetin alfa",
      "recombinant human erythropoietin (rHuEPO)"
    ],
    "primary_completion_date": null,
    "completion_date": "2003-12",
    "results_first_posted": null,
    "last_update_posted": "2007-12-24",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT03904069",
    "title": "Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML",
    "status": "WITHDRAWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsed/Refractory Acute Myeloid Leukemia"
    ],
    "interventions": [
      "AMG 553"
    ],
    "primary_completion_date": "2030-08-07",
    "completion_date": "2030-08-07",
    "results_first_posted": null,
    "last_update_posted": "2023-06-12",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00989092",
    "title": "Darbepoetin Alfa and Anemia of Cancer",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Anemia",
      "Anemia of Cancer",
      "Cancer",
      "Carcinoma",
      "Neoplasms",
      "Non-Myeloid Malignancies"
    ],
    "interventions": [
      "darbepoetin alfa"
    ],
    "primary_completion_date": "2004-01",
    "completion_date": "2004-06",
    "results_first_posted": "2014-01-29",
    "last_update_posted": "2014-01-29",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00454857",
    "title": "Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Idiopathic Thrombocytopenic Purpura",
      "Thrombocytopenia",
      "Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)",
      "Thrombocytopenic Purpura"
    ],
    "interventions": [
      "Retrospective Chart Review",
      "Patient-reported Outcome Questionnaires",
      "Physician Survey"
    ],
    "primary_completion_date": "2008-06",
    "completion_date": "2008-08",
    "results_first_posted": "2010-05-12",
    "last_update_posted": "2013-11-26",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT02954081",
    "title": "APremilast After FumaRic Acid Ester Treatment",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Psoriasis"
    ],
    "interventions": [
      "Phase I: Fumaric acid esters. Phase II: Apremilast"
    ],
    "primary_completion_date": "2022-08-15",
    "completion_date": "2022-08-15",
    "results_first_posted": null,
    "last_update_posted": "2023-01-26",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00115206",
    "title": "Neulasta\u00ae in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-Small Cell Lung Cancer"
    ],
    "interventions": [
      "Neulasta\u00ae (pegfilgrastim)"
    ],
    "primary_completion_date": null,
    "completion_date": "2004-07",
    "results_first_posted": null,
    "last_update_posted": "2009-04-06",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT02341417",
    "title": "Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on Dialysis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Secondary Hyperparathyroidism, Chronic Kidney Disease"
    ],
    "interventions": [
      "Cinacalcet"
    ],
    "primary_completion_date": "2017-03-15",
    "completion_date": "2017-03-15",
    "results_first_posted": "2018-05-18",
    "last_update_posted": "2020-06-29",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00293826",
    "title": "A Multiple Dose Study to Evaluate Subcutaneous AMG 108 in Subjects With Rheumatoid Arthritis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rheumatoid Arthritis"
    ],
    "interventions": [
      "AMG 108",
      "AMG 108",
      "AMG 108",
      "Placebo"
    ],
    "primary_completion_date": "2007-11",
    "completion_date": "2008-02",
    "results_first_posted": null,
    "last_update_posted": "2010-03-05",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00936988",
    "title": "A Multicenter, Open-label Extension Study to Assess the Long-term Safety and Efficacy of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hyperparathyroidism, Primary"
    ],
    "interventions": [
      "cinacalcet"
    ],
    "primary_completion_date": "2005-06",
    "completion_date": "2005-12",
    "results_first_posted": null,
    "last_update_posted": "2013-05-08",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01970488",
    "title": "Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA\u00ae) in Adults With Moderate to Severe Plaque Psoriasis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Psoriasis"
    ],
    "interventions": [
      "Adalimumab",
      "ABP 501"
    ],
    "primary_completion_date": "2014-08-14",
    "completion_date": "2015-03-18",
    "results_first_posted": "2016-12-13",
    "last_update_posted": "2019-04-03",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00120705",
    "title": "Treatment for Anemic Subjects With Non-Myeloid Malignancies Receiving Chemotherapy",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Neoplasms",
      "Anemia"
    ],
    "interventions": [
      "darbepoetin alfa"
    ],
    "primary_completion_date": null,
    "completion_date": "2003-09",
    "results_first_posted": null,
    "last_update_posted": "2009-03-25",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00115167",
    "title": "A Study of Darbepoetin Alfa in Anemic Subjects Not Receiving Chemotherapy Who Have Completed the 20010103 Study",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Anemia",
      "Cancer"
    ],
    "interventions": [
      "Placebo",
      "Darbepoetin alfa"
    ],
    "primary_completion_date": "2007-01",
    "completion_date": "2007-03",
    "results_first_posted": null,
    "last_update_posted": "2009-05-11",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00460265",
    "title": "Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Recurrent and/or Metastatic Head and Neck Cancer"
    ],
    "interventions": [
      "ARM 2",
      "ARM 1"
    ],
    "primary_completion_date": "2010-05",
    "completion_date": "2012-05",
    "results_first_posted": "2011-06-14",
    "last_update_posted": "2014-03-07",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00950911",
    "title": "Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bone Metastases in Men With Hormone-Refractory Prostate Cancer",
      "Bone Metastases in Subjects With Advanced Breast Cancer",
      "Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma"
    ],
    "interventions": [
      "amg 162"
    ],
    "primary_completion_date": "2012-02",
    "completion_date": "2012-04",
    "results_first_posted": "2014-02-11",
    "last_update_posted": "2014-02-11",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00872014",
    "title": "A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Hepatocellular Carcinoma",
      "Inoperable Hepatocellular Carcinoma"
    ],
    "interventions": [
      "AMG 386",
      "AMG 386",
      "Sorafenib"
    ],
    "primary_completion_date": "2011-10",
    "completion_date": "2015-06",
    "results_first_posted": null,
    "last_update_posted": "2016-04-04",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00117624",
    "title": "A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With a Non-Myeloid Malignancy",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Anemia"
    ],
    "interventions": [
      "darbepoetin alfa"
    ],
    "primary_completion_date": null,
    "completion_date": "2003-12",
    "results_first_posted": null,
    "last_update_posted": "2007-12-28",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01212757",
    "title": "PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Psoriatic Arthritis"
    ],
    "interventions": [
      "Apremilast 20mg",
      "Apremilast 30mg",
      "Placebo + 20 mg Apremilast",
      "Placebo + 30 mg Apremilast"
    ],
    "primary_completion_date": "2012-07-26",
    "completion_date": "2017-01-25",
    "results_first_posted": "2014-05-19",
    "last_update_posted": "2020-05-06",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT03439475",
    "title": "AMG 714 Expanded Access Program",
    "status": "NO_LONGER_AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Celiac Disease"
    ],
    "interventions": [
      "AMG 714"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2025-05-04",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT06502977",
    "title": "Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Extensive Stage Small Cell Lung Cancer"
    ],
    "interventions": [
      "Tarlatamab"
    ],
    "primary_completion_date": "2025-03-28",
    "completion_date": "2027-01-08",
    "results_first_posted": null,
    "last_update_posted": "2025-10-28",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT06333951",
    "title": "AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Thoracic Tumors",
      "Non-small Cell Lung Cancer"
    ],
    "interventions": [
      "AMG 193",
      "Carboplatin",
      "Paclitaxel",
      "Pembrolizumab",
      "Pemetrexed",
      "Sotorasib"
    ],
    "primary_completion_date": "2028-10-27",
    "completion_date": "2031-10-27",
    "results_first_posted": null,
    "last_update_posted": "2026-01-15",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT02624895",
    "title": "ObservationaL Study on the Qol of RAS Wild-type mCRC Patients Receiving Anti-EGFR MAbs + FOLFOX or FOLFIRI as 1st Line",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Metastatic Colorectal Cancer"
    ],
    "interventions": [],
    "primary_completion_date": "2020-12-31",
    "completion_date": "2020-12-31",
    "results_first_posted": null,
    "last_update_posted": "2021-01-22",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01235442",
    "title": "Evaluate Efficacy, and Safety of Topical Therapy and Etanercept in Subjects With Moderate to Severe Plaque Psoriasis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Psoriasis"
    ],
    "interventions": [
      "1=Etanercept",
      "2=Clobetasol propionate foam"
    ],
    "primary_completion_date": "2011-10",
    "completion_date": "2011-12",
    "results_first_posted": "2013-10-31",
    "last_update_posted": "2018-08-07",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01953341",
    "title": "Single-Ascending Dose Study of AMG 333 in Healthy Subjects and Subjects With Migraines",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Migraine"
    ],
    "interventions": [
      "AMG 333",
      "Placebo"
    ],
    "primary_completion_date": "2014-09",
    "completion_date": "2014-11",
    "results_first_posted": null,
    "last_update_posted": "2014-12-09",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT04057937",
    "title": "A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Japanese Subjects With Palmoplantar Pustulosis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Palmoplantaris Pustulosis"
    ],
    "interventions": [
      "Apremilast",
      "Placebo"
    ],
    "primary_completion_date": "2021-01-18",
    "completion_date": "2021-06-07",
    "results_first_posted": "2022-01-06",
    "last_update_posted": "2024-07-17",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01992341",
    "title": "AMG 386 Drug-Drug Interaction Study With Paclitaxel",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumors"
    ],
    "interventions": [
      "AMG 386",
      "Paclitaxel"
    ],
    "primary_completion_date": "2013-08",
    "completion_date": "2014-09",
    "results_first_posted": null,
    "last_update_posted": "2014-09-23",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT06590051",
    "title": "AMG 335 Expanded Access Program for IgG4-Related Disease",
    "status": "AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [],
    "interventions": [
      "UPLIZNA"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2024-09-19",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT03091127",
    "title": "Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Multiple Myeloma"
    ],
    "interventions": [],
    "primary_completion_date": "2020-03-17",
    "completion_date": "2020-03-17",
    "results_first_posted": null,
    "last_update_posted": "2022-12-12",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT06593522",
    "title": "A Phase 2 Study of AMG 193 in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "MTAP-deleted NSCLC"
    ],
    "interventions": [
      "AMG 193"
    ],
    "primary_completion_date": "2028-11-29",
    "completion_date": "2030-11-29",
    "results_first_posted": null,
    "last_update_posted": "2025-12-12",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01493518",
    "title": "Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Adults With Psoriasis",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Psoriasis"
    ],
    "interventions": [
      "AMG 557 or PLACEBO"
    ],
    "primary_completion_date": "2013-05",
    "completion_date": "2013-06",
    "results_first_posted": null,
    "last_update_posted": "2013-11-19",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00110903",
    "title": "Treatment for Subjects With Active Rheumatoid Arthritis (RA)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rheumatoid Arthritis"
    ],
    "interventions": [
      "Etanercept Liquid"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2013-04-26",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT03621605",
    "title": "A Phase1 Study of VIB9600",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Safety Issues"
    ],
    "interventions": [
      "VIB9600",
      "Placebos"
    ],
    "primary_completion_date": "2019-04-08",
    "completion_date": "2019-04-08",
    "results_first_posted": null,
    "last_update_posted": "2024-12-13",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01717989",
    "title": "Study to Evaluate the Prospective Payment System",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Chronic Kidney Disease"
    ],
    "interventions": [],
    "primary_completion_date": "2012-09",
    "completion_date": "2012-09",
    "results_first_posted": "2014-01-14",
    "last_update_posted": "2014-01-14",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00980174",
    "title": "Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Low Bone Mass",
      "Low Bone Mineral Density",
      "Males With Osteoporosis",
      "Osteopenia",
      "Osteoporosis"
    ],
    "interventions": [
      "60 mg denosumab",
      "Placebo"
    ],
    "primary_completion_date": "2011-06-21",
    "completion_date": "2012-05-23",
    "results_first_posted": "2012-11-29",
    "last_update_posted": "2018-10-17",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00125723",
    "title": "FIRST - Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Neutropenia"
    ],
    "interventions": [
      "PI Discretion"
    ],
    "primary_completion_date": "2005-12",
    "completion_date": "2005-12",
    "results_first_posted": null,
    "last_update_posted": "2010-12-23",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01668589",
    "title": "Observational Study of Denosumab (Prolia\u00ae) in Postmenopausal Women With Osteoporosis",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Postmenopausal Osteoporosis"
    ],
    "interventions": [],
    "primary_completion_date": "2015-08-31",
    "completion_date": "2015-08-31",
    "results_first_posted": "2016-09-20",
    "last_update_posted": "2018-01-30",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT03859427",
    "title": "A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsed or Refractory Multiple Myeloma"
    ],
    "interventions": [
      "Carfilzomib",
      "Carfilzomib",
      "Lenalidomide",
      "Dexamethasone"
    ],
    "primary_completion_date": "2023-03-31",
    "completion_date": "2023-03-31",
    "results_first_posted": "2024-04-18",
    "last_update_posted": "2024-08-13",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01410500",
    "title": "Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease",
    "status": "APPROVED_FOR_MARKETING",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Multiple Myeloma"
    ],
    "interventions": [
      "Carfilzomib"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2017-05-02",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT06229145",
    "title": "A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Gout"
    ],
    "interventions": [
      "Pegloticase",
      "Methotrexate"
    ],
    "primary_completion_date": "2025-07-30",
    "completion_date": "2026-03-12",
    "results_first_posted": null,
    "last_update_posted": "2026-01-02",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT07222553",
    "title": "Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Immunoglobulin G4-related Disease"
    ],
    "interventions": [
      "Inebilizumab"
    ],
    "primary_completion_date": "2031-06-10",
    "completion_date": "2031-06-10",
    "results_first_posted": null,
    "last_update_posted": "2025-12-22",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT07172919",
    "title": "A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumors"
    ],
    "interventions": [
      "Sotorasib",
      "Panitumumab"
    ],
    "primary_completion_date": "2027-12-12",
    "completion_date": "2027-12-12",
    "results_first_posted": null,
    "last_update_posted": "2025-12-02",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00124111",
    "title": "A Study of Cyclophosphamide/Methotrexate/5-Fluorouracil (CMF) With Pegfilgrastim in Subjects With Breast Cancer",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Cancer"
    ],
    "interventions": [
      "pegfilgrastim",
      "cyclophosphamide",
      "methotrexate",
      "5-fluorouracil"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2010-02-26",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT05899816",
    "title": "A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atopic Dermatitis",
      "Moderate-to-severe Atopic Dermatitis"
    ],
    "interventions": [
      "Rocatinlimab",
      "Placebo"
    ],
    "primary_completion_date": "2024-08-26",
    "completion_date": "2024-11-14",
    "results_first_posted": null,
    "last_update_posted": "2025-11-05",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT06747949",
    "title": "A Long-term Extension Study of Dazodalibep in Participants With Sj\u00f6gren's Syndrome (SS)",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Sj\u00f6gren's Syndrome"
    ],
    "interventions": [
      "Dazodalibep"
    ],
    "primary_completion_date": "2029-12-11",
    "completion_date": "2029-12-11",
    "results_first_posted": null,
    "last_update_posted": "2026-01-22",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00117104",
    "title": "Evaluating Aranesp\u00ae in Subjects With End Stage Renal Disease onChronic Hemodialysis",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "End Stage Renal Disease"
    ],
    "interventions": [
      "Aranesp\u00ae"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2009-10-16",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT03461211",
    "title": "Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Thyroid Eye Disease"
    ],
    "interventions": [
      "Teprotumumab"
    ],
    "primary_completion_date": "2020-06-08",
    "completion_date": "2021-02-17",
    "results_first_posted": "2021-07-19",
    "last_update_posted": "2024-06-28",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00114764",
    "title": "Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Myeloid Leukemia"
    ],
    "interventions": [
      "filgrastim",
      "pegfilgrastim"
    ],
    "primary_completion_date": "2004-04",
    "completion_date": "2004-08",
    "results_first_posted": null,
    "last_update_posted": "2008-10-31",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT02101164",
    "title": "Evaluate Time Associated With the Preparation & Administration of Denosumab/Pamidronate in Patients With Solid Tumors and Metastatic Bone Disease",
    "status": "WITHDRAWN",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor",
      "Metastatic Bone Disease"
    ],
    "interventions": [
      "denosumab",
      "pamidronate"
    ],
    "primary_completion_date": "2014-11",
    "completion_date": "2014-11",
    "results_first_posted": null,
    "last_update_posted": "2015-02-18",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01568216",
    "title": "20101299: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia"
    ],
    "interventions": [
      "AMG 747",
      "Placebo"
    ],
    "primary_completion_date": "2013-06",
    "completion_date": "2013-06",
    "results_first_posted": null,
    "last_update_posted": "2015-07-30",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT03774771",
    "title": "Safety, Pharmacokinetics, and Clinical Effects of Cinacalcet (AMG 073) in Primary Hyperparathyroidism",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Primary Hyperparathyroidism"
    ],
    "interventions": [
      "Cinacalcet",
      "Placebo"
    ],
    "primary_completion_date": "1999-12-13",
    "completion_date": "1999-12-13",
    "results_first_posted": null,
    "last_update_posted": "2018-12-13",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01143038",
    "title": "Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Idiopathic Thrombocytopenic Purpura"
    ],
    "interventions": [
      "Romiplostim"
    ],
    "primary_completion_date": "2013-09-20",
    "completion_date": "2013-12-26",
    "results_first_posted": "2016-02-24",
    "last_update_posted": "2022-09-21",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT03299244",
    "title": "Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Secondary Hyperparathyroidism",
      "Chronic Kidney Disease"
    ],
    "interventions": [
      "Etelcalcetide",
      "Cinacalcet"
    ],
    "primary_completion_date": "2020-04-08",
    "completion_date": "2020-04-08",
    "results_first_posted": "2021-04-30",
    "last_update_posted": "2021-04-30",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT06401044",
    "title": "A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Thyroid Eye Disease"
    ],
    "interventions": [
      "AMG 732",
      "Placebo"
    ],
    "primary_completion_date": "2027-02-22",
    "completion_date": "2027-08-13",
    "results_first_posted": null,
    "last_update_posted": "2026-01-22",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00117117",
    "title": "A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp\u00ae",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Anemia"
    ],
    "interventions": [
      "Aranesp"
    ],
    "primary_completion_date": null,
    "completion_date": "2003-12",
    "results_first_posted": null,
    "last_update_posted": "2009-03-25",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT07085117",
    "title": "Real World Study to Describe the Effectiveness and Safety of Teprotumumab Among Thyroid Eye Disease Patients",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Thyroid Eye Disease"
    ],
    "interventions": [
      "Teprotumumab"
    ],
    "primary_completion_date": "2025-08-10",
    "completion_date": "2025-08-10",
    "results_first_posted": null,
    "last_update_posted": "2025-09-08",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00111098",
    "title": "Treatment for Subjects With Chronic Kidney Disease (CKD) Not Receiving Dialysis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Kidney Disease"
    ],
    "interventions": [
      "Darbepoetin Alfa"
    ],
    "primary_completion_date": "2005-11",
    "completion_date": "2005-11",
    "results_first_posted": null,
    "last_update_posted": "2008-08-08",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00117247",
    "title": "A Study of Repeat-Dose Subcutaneous Darbepoetin Alfa in Subjects With Congestive Heart Failure and Anemia, and a Single Dose in Healthy Age- and Sex-Matched Control Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Anemia",
      "Congestive Heart Failure"
    ],
    "interventions": [
      "darbepoetin alfa"
    ],
    "primary_completion_date": null,
    "completion_date": "2004-07",
    "results_first_posted": null,
    "last_update_posted": "2009-10-16",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01242917",
    "title": "A Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rheumatoid Arthritis"
    ],
    "interventions": [
      "CCX-354-C",
      "Placebo",
      "CCX354-C"
    ],
    "primary_completion_date": "2011-07",
    "completion_date": "2011-07",
    "results_first_posted": null,
    "last_update_posted": "2025-03-06",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01285310",
    "title": "Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rheumatoid Arthritis"
    ],
    "interventions": [
      "Apremilast 30 mg",
      "Apremilast 20 mg",
      "Placebo"
    ],
    "primary_completion_date": "2012-02-21",
    "completion_date": "2012-09-10",
    "results_first_posted": "2014-08-15",
    "last_update_posted": "2020-05-08",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01447147",
    "title": "A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetic Nephropathy",
      "Type 2 Diabetes Mellitus"
    ],
    "interventions": [
      "Placebo",
      "CCX140-B",
      "CCX140-B"
    ],
    "primary_completion_date": "2014-08",
    "completion_date": "2014-12",
    "results_first_posted": null,
    "last_update_posted": "2025-02-27",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT04822298",
    "title": "Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-small Cell Lung Cancer",
      "NSCLC"
    ],
    "interventions": [
      "AMG 160"
    ],
    "primary_completion_date": "2021-12-08",
    "completion_date": "2022-01-26",
    "results_first_posted": "2024-07-05",
    "last_update_posted": "2024-07-05",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00002433",
    "title": "The Effects of r-metHuIFN-Gamma on the Lungs of Patients With AIDS",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HIV Infections"
    ],
    "interventions": [
      "Interferon gamma-1b"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2005-06-24",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT06761703",
    "title": "A Study to Determine the Feasibility of Online Recruitment of People Using an Anti-Obesity Medication for Weight Loss",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Obesity"
    ],
    "interventions": [
      "TAP\u00ae Micro Select Device (Touch Activated Phlebotomy)"
    ],
    "primary_completion_date": "2025-01-06",
    "completion_date": "2025-01-06",
    "results_first_posted": null,
    "last_update_posted": "2025-01-14",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00719550",
    "title": "AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Esophagogastric Junction Adenocarcinoma",
      "Gastric Cancer",
      "Esophageal Cancer"
    ],
    "interventions": [
      "Capecitabine",
      "Epirubicin",
      "AMG 102",
      "Cisplatin",
      "Placebo"
    ],
    "primary_completion_date": "2010-11",
    "completion_date": "2013-06",
    "results_first_posted": null,
    "last_update_posted": "2013-12-05",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT04987320",
    "title": "A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Olpasiran in Chinese Participants With Elevated Serum Lipoprotein(a)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Elevated Serum Lipoprotein(a)"
    ],
    "interventions": [
      "Olpasiran"
    ],
    "primary_completion_date": "2021-11-12",
    "completion_date": "2022-03-18",
    "results_first_posted": "2025-02-10",
    "last_update_posted": "2025-02-10",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00597909",
    "title": "Efficacy and Safety Study of Ammonul\u00ae in Patients With Grade 3 or 4 Hepatic Encephalopathy",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatic Encephalopathy"
    ],
    "interventions": [
      "sodium phenylacetate and sodium benzoate injection 10% / 10%",
      "sodium phenylacetate and sodium benzoate injection 10% / 10%",
      "placebo solution (10% dextrose)"
    ],
    "primary_completion_date": "2008-09",
    "completion_date": "2008-09",
    "results_first_posted": "2016-03-31",
    "last_update_posted": "2024-12-17",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT05368103",
    "title": "Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alopecia Areata"
    ],
    "interventions": [
      "Daxdilimab"
    ],
    "primary_completion_date": "2023-08-07",
    "completion_date": "2024-01-26",
    "results_first_posted": "2025-01-07",
    "last_update_posted": "2025-01-07",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT02634580",
    "title": "Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypercholesterolemia"
    ],
    "interventions": [
      "Evolocumab",
      "Ezetimibe",
      "Placebo to Evolocumab",
      "Placebo Ezetimibe"
    ],
    "primary_completion_date": "2017-08-10",
    "completion_date": "2018-05-26",
    "results_first_posted": "2018-08-31",
    "last_update_posted": "2020-11-10",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01466179",
    "title": "Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Lymphoblastic Leukemia"
    ],
    "interventions": [
      "Blinatumomab"
    ],
    "primary_completion_date": "2013-10",
    "completion_date": "2017-01",
    "results_first_posted": "2015-01-22",
    "last_update_posted": "2017-08-18",
    "enrollment": null,
    "sponsor": "Amgen Research (Munich) GmbH",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00861224",
    "title": "Effects of Long-term Dosing of AMG 531 on Bone Marrow Morphology",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Idiopathic Thrombocytopenic Purpura"
    ],
    "interventions": [
      "No Intervention for Observational Study"
    ],
    "primary_completion_date": "2006-10",
    "completion_date": "2007-05",
    "results_first_posted": null,
    "last_update_posted": "2010-07-16",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT02986139",
    "title": "Study to Assess the Injection Site Pain Associated With a New Etanercept Formulation in Adults With Rheumatoid Arthritis or Psoriatic Arthritis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Arthritis, Rheumatoid; Arthritis, Psoriatic"
    ],
    "interventions": [
      "Commercial Formulation Etanercept",
      "New Formulation Etanercept"
    ],
    "primary_completion_date": "2017-09-08",
    "completion_date": "2017-10-09",
    "results_first_posted": "2018-10-31",
    "last_update_posted": "2019-07-18",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00078819",
    "title": "Etanercept (Enbrel\u00ae) in Psoriasis - Pediatrics",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Psoriasis"
    ],
    "interventions": [
      "Etanercept",
      "Placebo"
    ],
    "primary_completion_date": "2006-02-01",
    "completion_date": "2007-06-01",
    "results_first_posted": "2019-07-29",
    "last_update_posted": "2019-07-29",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT05048784",
    "title": "A Study to Compare the Pharmacokinetics of Two Different Tablets of Sotorasib in Healthy Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants"
    ],
    "interventions": [
      "Sotorasib"
    ],
    "primary_completion_date": "2022-02-18",
    "completion_date": "2022-02-18",
    "results_first_posted": "2023-09-18",
    "last_update_posted": "2023-09-18",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01928368",
    "title": "A First-in-Human, Double Blind, Single Dose Study in Healthy Subjects and Subjects With Mild Atopic Asthma.",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Asthma"
    ],
    "interventions": [
      "AMG 282",
      "AMG 282 Matching Placebo"
    ],
    "primary_completion_date": "2016-03",
    "completion_date": "2016-03",
    "results_first_posted": null,
    "last_update_posted": "2016-12-14",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT02287610",
    "title": "A Non-Interventional Study of RAYOS in Adult Patients With Rheumatoid Arthritis",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Rheumatoid Arthritis"
    ],
    "interventions": [
      "RAYOS (delayed-release prednisone)"
    ],
    "primary_completion_date": "2015-10",
    "completion_date": "2015-10",
    "results_first_posted": "2017-02-03",
    "last_update_posted": "2024-12-18",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01207388",
    "title": "Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "B-cell Acute Lymphoblastic Leukemia"
    ],
    "interventions": [
      "Blinatumomab"
    ],
    "primary_completion_date": "2014-02",
    "completion_date": "2019-01-07",
    "results_first_posted": "2015-02-12",
    "last_update_posted": "2020-02-10",
    "enrollment": null,
    "sponsor": "Amgen Research (Munich) GmbH",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01875991",
    "title": "Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rheumatoid Arthritis",
      "Plaque Psoriasis"
    ],
    "interventions": [
      "Etanercept via Autoinjector A",
      "Etanercept via Autoinjector B"
    ],
    "primary_completion_date": "2014-03-04",
    "completion_date": "2014-03-04",
    "results_first_posted": "2015-05-20",
    "last_update_posted": "2018-09-04",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00005959",
    "title": "Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma",
    "status": "UNKNOWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lymphoma"
    ],
    "interventions": [
      "filgrastim",
      "rituximab",
      "cyclophosphamide",
      "doxorubicin hydrochloride",
      "prednisone",
      "vincristine sulfate"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2013-12-04",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01331941",
    "title": "A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumors",
      "Kidney Disease",
      "Renal Impairment"
    ],
    "interventions": [
      "AMG 386 + Paclitaxel",
      "AMG 386"
    ],
    "primary_completion_date": "2013-02-26",
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2017-11-06",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT04933695",
    "title": "A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-small Cell Lung Cancer"
    ],
    "interventions": [
      "Sotorasib"
    ],
    "primary_completion_date": "2025-05-27",
    "completion_date": "2025-05-27",
    "results_first_posted": null,
    "last_update_posted": "2025-10-22",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00322439",
    "title": "Observational Safety Study of Etanercept (Enbrel) for Treatment of Psoriasis",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Psoriasis"
    ],
    "interventions": [
      "Etanercept"
    ],
    "primary_completion_date": "2012-12-11",
    "completion_date": "2013-02-08",
    "results_first_posted": "2014-03-26",
    "last_update_posted": "2018-06-28",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00119600",
    "title": "A Study of AMG 114 Administered by Subcutaneous Injection for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies Receiving Multicycle Chemotherapy",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Anemia",
      "Cancer"
    ],
    "interventions": [
      "AMG 114"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2009-05-11",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT02373813",
    "title": "Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rheumatoid Arthritis"
    ],
    "interventions": [
      "etanercept pre-filled syringe subcutaneous injection",
      "Oral methotrexate",
      "Placebo for etanercept subcutaneous injection",
      "Placebo for methotrexate",
      "Folic acid (non-investigational product)"
    ],
    "primary_completion_date": "2019-12-06",
    "completion_date": "2019-12-06",
    "results_first_posted": "2020-12-19",
    "last_update_posted": "2023-01-11",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT02303821",
    "title": "Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Lymphoblastic Leukemia (ALL)"
    ],
    "interventions": [
      "Carfilzomib",
      "Dexamethasone",
      "Mitoxantrone",
      "PEG-asparaginase",
      "Vincristine",
      "Intrathecal (IT) Methotrexate",
      "Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate)",
      "6-Mercaptopurine",
      "Cyclophosphamide",
      "Cytarabine",
      "Daunorubicin"
    ],
    "primary_completion_date": "2024-06-28",
    "completion_date": "2024-06-28",
    "results_first_posted": "2025-06-04",
    "last_update_posted": "2025-06-04",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT07223190",
    "title": "A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia"
    ],
    "interventions": [
      "Blinatumomab",
      "Blinatumomab",
      "HyperCVAD"
    ],
    "primary_completion_date": "2029-12-31",
    "completion_date": "2033-03-30",
    "results_first_posted": null,
    "last_update_posted": "2025-10-31",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00503490",
    "title": "Safety, Pharmacokinetic and Pharmacodynamic Study of MP-376 in Patients With Cystic Fibrosis",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cystic Fibrosis"
    ],
    "interventions": [
      "MP-376 (Levofloxacin solution for Inhalation)",
      "placebo"
    ],
    "primary_completion_date": "2007-12",
    "completion_date": "2007-12",
    "results_first_posted": null,
    "last_update_posted": "2024-12-04",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT07293260",
    "title": "Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cardiovascular Disease"
    ],
    "interventions": [
      "Olpasiran",
      "Placebo"
    ],
    "primary_completion_date": "2028-06-02",
    "completion_date": "2028-06-02",
    "results_first_posted": null,
    "last_update_posted": "2025-12-19",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT07226778",
    "title": "Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Overweight",
      "Obesity"
    ],
    "interventions": [
      "Maridebart Cafraglutide"
    ],
    "primary_completion_date": "2026-05-12",
    "completion_date": "2026-05-12",
    "results_first_posted": null,
    "last_update_posted": "2025-12-03",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00425035",
    "title": "Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Renal Cell Carcinoma"
    ],
    "interventions": [
      "Panitumumab (ABX-EGF)"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2013-05-13",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01791374",
    "title": "Phase 1/1b Study of Rilotumumab in Japanese Subjects With Advanced Solid Tumors or Advanced or Metastatic Gastric or GEJ",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Part 1- Advanced Solid Tumors",
      "Part 2- Advanced or Metastatic Gastric Cancer",
      "Part 2- Advanced or Metastatic GEJ"
    ],
    "interventions": [
      "Rilotumumab",
      "Rilotumumab"
    ],
    "primary_completion_date": "2013-08",
    "completion_date": "2015-03",
    "results_first_posted": null,
    "last_update_posted": "2016-02-29",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT02780674",
    "title": "A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dermatomyositis, Polymyositis, Sjogren's, SLE, SSc"
    ],
    "interventions": [
      "MEDI7734",
      "Placebo"
    ],
    "primary_completion_date": "2017-10-23",
    "completion_date": "2017-11-27",
    "results_first_posted": null,
    "last_update_posted": "2024-12-13",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT03403374",
    "title": "Safety and Tolerability of Repatha\u00ae (Evolocumab) in Indian Participants With Homozygous Familial Hypercholesterolemia",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Homozygous Familial Hypercholesterolemia HoFH"
    ],
    "interventions": [
      "evolocumab"
    ],
    "primary_completion_date": "2019-11-27",
    "completion_date": "2019-11-27",
    "results_first_posted": "2020-11-03",
    "last_update_posted": "2024-05-29",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT02937701",
    "title": "Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Infliximab",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Arthritis, Rheumatoid"
    ],
    "interventions": [
      "ABP 710",
      "Infliximab"
    ],
    "primary_completion_date": "2018-04-16",
    "completion_date": "2018-08-13",
    "results_first_posted": "2019-08-28",
    "last_update_posted": "2019-08-28",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01253707",
    "title": "A Study of AMG 337 in Subjects With Advanced Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Malignancy",
      "Advanced Solid Tumors",
      "Cancer",
      "Oncology",
      "Oncology Patients",
      "Tumors"
    ],
    "interventions": [
      "AMG 337"
    ],
    "primary_completion_date": "2015-10-01",
    "completion_date": "2016-12-13",
    "results_first_posted": null,
    "last_update_posted": "2022-11-07",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT02253654",
    "title": "Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Renal Insufficiency, Chronic",
      "Anemia",
      "Renal Dialysis",
      "Erythrocyte Transfusion"
    ],
    "interventions": [
      "Epoetin alfa"
    ],
    "primary_completion_date": "2016-04-27",
    "completion_date": "2016-05-25",
    "results_first_posted": "2017-05-12",
    "last_update_posted": "2017-05-19",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT02010931",
    "title": "Retrospective Analysis of Survival in Adult MRD Positive Acute Lymphoblastic Leukemia Patients",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Acute Lymphoblastic Leukemia"
    ],
    "interventions": [],
    "primary_completion_date": "2014-03",
    "completion_date": "2014-06",
    "results_first_posted": null,
    "last_update_posted": "2022-09-15",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00101894",
    "title": "Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rectal Cancer",
      "Colon Cancer"
    ],
    "interventions": [
      "FOLFOX-4",
      "AMG 706",
      "Panitumumab (Part 1a only)",
      "FOLFIRI"
    ],
    "primary_completion_date": "2010-04",
    "completion_date": "2011-12",
    "results_first_posted": null,
    "last_update_posted": "2012-09-17",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00111995",
    "title": "Evaluating Aranesp\u00ae for the Treatment of Anemia in African-American Subjects With Chronic Renal Failure (CRF) Receiving Hemodialysis",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Renal Failure",
      "Anemia"
    ],
    "interventions": [
      "Aranesp\u00ae"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2008-08-08",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT05550129",
    "title": "Study to Evaluate the Drug-drug Interactions Between Metformin and AMG 510 in Healthy Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "AMG 510",
      "Metformin"
    ],
    "primary_completion_date": "2019-11-25",
    "completion_date": "2019-11-25",
    "results_first_posted": null,
    "last_update_posted": "2025-03-05",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00089661",
    "title": "AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Cancer",
      "Low Bone Mineral Density",
      "Osteopenia"
    ],
    "interventions": [
      "Placebo",
      "AMG 162 / Denosumab"
    ],
    "primary_completion_date": "2007-05-11",
    "completion_date": "2009-05-27",
    "results_first_posted": "2010-01-26",
    "last_update_posted": "2018-10-17",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT04804553",
    "title": "Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Active Juvenile Psoriatic Arthritis"
    ],
    "interventions": [
      "Apremilast",
      "Placebo"
    ],
    "primary_completion_date": "2028-03-21",
    "completion_date": "2028-12-29",
    "results_first_posted": null,
    "last_update_posted": "2026-01-22",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01755442",
    "title": "Investigate Effect of AMG 151 on 24-hour Ambulatory Blood Pressure & Glucose Levels in Type 2 Diabetes Mellitus Subjects",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes Mellitus"
    ],
    "interventions": [
      "Placebo",
      "AMG 151"
    ],
    "primary_completion_date": "2013-01",
    "completion_date": "2013-01",
    "results_first_posted": null,
    "last_update_posted": "2013-04-22",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT04772313",
    "title": "Pegloticase and Methotrexate Co-administered in Participants With Uncontrolled Gout Who Previously Failed Pegloticase Monotherapy",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Uncontrolled Gout"
    ],
    "interventions": [
      "Pegloticase",
      "Methotrexate (MTX)"
    ],
    "primary_completion_date": "2022-08-23",
    "completion_date": "2023-04-24",
    "results_first_posted": "2023-10-10",
    "last_update_posted": "2024-06-27",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00936897",
    "title": "A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Postmenopausal Osteoporosis"
    ],
    "interventions": [
      "Ibandronate",
      "Denosumab"
    ],
    "primary_completion_date": "2011-11",
    "completion_date": "2012-01",
    "results_first_posted": "2012-11-29",
    "last_update_posted": "2013-02-11",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00005960",
    "title": "Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy",
    "status": "UNKNOWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pain",
      "Prostate Cancer"
    ],
    "interventions": [
      "filgrastim",
      "cyclophosphamide",
      "docetaxel",
      "doxorubicin hydrochloride",
      "pain therapy"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2013-12-04",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00093873",
    "title": "Study Evaluating AMG 706 in Subjects With Advanced Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Tumors"
    ],
    "interventions": [
      "Anti-angiogenesis",
      "AMG 706"
    ],
    "primary_completion_date": "2006-02",
    "completion_date": "2006-12",
    "results_first_posted": null,
    "last_update_posted": "2013-05-15",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01575873",
    "title": "Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Steroid-induced Osteopor, Glucocorticoid-induced Ostepor"
    ],
    "interventions": [
      "Denosumab",
      "Placebo for risendronate",
      "Risendronate",
      "Placebo for denosumab"
    ],
    "primary_completion_date": "2016-06-21",
    "completion_date": "2017-06-29",
    "results_first_posted": "2018-07-27",
    "last_update_posted": "2018-07-27",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00858377",
    "title": "A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Malignancy",
      "Advanced Solid Tumors",
      "Cancer",
      "Solid Tumors",
      "Tumors"
    ],
    "interventions": [
      "Arm 1- Dose Escalation",
      "Arm 1- Dose Expansion"
    ],
    "primary_completion_date": "2014-12-31",
    "completion_date": "2019-04-03",
    "results_first_posted": null,
    "last_update_posted": "2019-05-06",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00101907",
    "title": "Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lung Cancer",
      "Pancreatic Cancer",
      "Esophageal Cancer"
    ],
    "interventions": [
      "AMG 706",
      "Panitumumab",
      "Gemcitabine",
      "Cisplatin"
    ],
    "primary_completion_date": "2007-06",
    "completion_date": "2008-04",
    "results_first_posted": "2014-03-20",
    "last_update_posted": "2014-03-20",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00433875",
    "title": "Phase 2 AMG 714 in Rheumatoid Arthritis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rheumatoid Arthritis"
    ],
    "interventions": [
      "AMG 714"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2007-12-28",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00111774",
    "title": "Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Colorectal Cancer",
      "Carcinoma"
    ],
    "interventions": [
      "ABX-EGF"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2013-05-14",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00339183",
    "title": "Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Colorectal Cancer"
    ],
    "interventions": [
      "Panitumumab",
      "FOLFIRI"
    ],
    "primary_completion_date": "2009-04-01",
    "completion_date": "2010-11-01",
    "results_first_posted": "2014-05-06",
    "last_update_posted": "2022-09-23",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT04040894",
    "title": "Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease",
    "status": "APPROVED_FOR_MARKETING",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Thyroid Eye Disease",
      "Graves' Orbitopathy"
    ],
    "interventions": [
      "Teprotumumab"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2024-06-20",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00680992",
    "title": "Study of Denosumab in Subjects With Giant Cell Tumor of Bone",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cancer",
      "Giant Cell Tumors",
      "Giant Cell Tumor of Bone",
      "Benign Giant Cell Tumors"
    ],
    "interventions": [
      "Denosumab"
    ],
    "primary_completion_date": "2018-05-17",
    "completion_date": "2018-05-17",
    "results_first_posted": "2018-12-10",
    "last_update_posted": "2022-09-22",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT05284747",
    "title": "EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cardiovascular Disease",
      "Myocardial Infarction",
      "Stroke",
      "Coronary Revascularization"
    ],
    "interventions": [
      "Evolocumab",
      "Routine Lipid Management"
    ],
    "primary_completion_date": "2027-05-29",
    "completion_date": "2027-05-29",
    "results_first_posted": null,
    "last_update_posted": "2025-10-06",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT05406115",
    "title": "Single and Multiple Ascending Dose Study to Evaluate AMG 786 in Healthy Participants and Participants With Obesity",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Obesity"
    ],
    "interventions": [
      "AMG 786",
      "Placebo"
    ],
    "primary_completion_date": "2023-08-21",
    "completion_date": "2023-08-21",
    "results_first_posted": null,
    "last_update_posted": "2025-10-27",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT02437916",
    "title": "Safety Study of AMG 228 to Treat Solid Tumors",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Malignancy",
      "Advanced Solid Tumors",
      "Cancer",
      "Oncology",
      "Oncology Patients",
      "Tumors",
      "Melanoma",
      "Non-small Cell Lung Cancer",
      "Squamous Cell Carcinoma of the Head and Neck",
      "Transitional Cell Carinoma of Bladder",
      "Colorectal Cancer"
    ],
    "interventions": [
      "AMG 228"
    ],
    "primary_completion_date": "2016-12-12",
    "completion_date": "2016-12-12",
    "results_first_posted": null,
    "last_update_posted": "2022-11-08",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01563185",
    "title": "Open-label Safety and Pharmacokinetic Study of DUEXIS\u00ae (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Juvenile Idiopathic Arthritis"
    ],
    "interventions": [
      "800 mg ibuprofen/26.6 mg famotidine"
    ],
    "primary_completion_date": "2015-03",
    "completion_date": "2015-03",
    "results_first_posted": "2015-12-23",
    "last_update_posted": "2024-12-16",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT04727554",
    "title": "Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumors"
    ],
    "interventions": [
      "AMG 994",
      "AMG 404"
    ],
    "primary_completion_date": "2023-06-05",
    "completion_date": "2023-06-05",
    "results_first_posted": "2025-01-06",
    "last_update_posted": "2025-01-06",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT07313761",
    "title": "A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Overweight and Obesity"
    ],
    "interventions": [
      "Maridebart Cafraglutide"
    ],
    "primary_completion_date": "2026-06-26",
    "completion_date": "2026-06-26",
    "results_first_posted": null,
    "last_update_posted": "2026-01-07",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT04631601",
    "title": "Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Castration-resistant Prostate Cancer"
    ],
    "interventions": [
      "Acapatamab",
      "Enzalutamide",
      "Abiraterone",
      "AMG 404"
    ],
    "primary_completion_date": "2023-10-23",
    "completion_date": "2023-10-23",
    "results_first_posted": null,
    "last_update_posted": "2025-10-07",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT02833857",
    "title": "A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Kidney Disease, Secondary Hyperparathyroidism"
    ],
    "interventions": [
      "Etelcalcetide"
    ],
    "primary_completion_date": "2018-10-31",
    "completion_date": "2018-10-31",
    "results_first_posted": "2019-07-10",
    "last_update_posted": "2019-07-10",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT02799498",
    "title": "Compare Actions in Healthy Volunteer of 50 mg Etanercept Injection Using an Auto-injector Device and Manual Injection",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Men and Women"
    ],
    "interventions": [
      "Auto-injector device",
      "Etanercept (ENBREL\u00ae) via Manual injection",
      "Etanercept (ENBREL\u00ae)"
    ],
    "primary_completion_date": "2004-01",
    "completion_date": "2004-01",
    "results_first_posted": null,
    "last_update_posted": "2016-06-15",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT05497557",
    "title": "A Study to Evaluate the Impact of Omeprazole on the Pharmacokinetics of Sotorasib Co-administered With an Acidic Beverage in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "Omeprazole",
      "Sotorasib"
    ],
    "primary_completion_date": "2022-09-08",
    "completion_date": "2022-09-08",
    "results_first_posted": "2024-01-19",
    "last_update_posted": "2024-01-19",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT02318407",
    "title": "A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 403 in Subjects With Osteoarthritis Knee Pain",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Osteoarthritis"
    ],
    "interventions": [
      "AMG 403",
      "Placebo"
    ],
    "primary_completion_date": "2008-01",
    "completion_date": "2008-03",
    "results_first_posted": null,
    "last_update_posted": "2014-12-17",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00141921",
    "title": "Pediatric Open-Label Extension Study of Etanercept in Patients With Plaque Psoriasis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pediatric Plaque Psoriasis"
    ],
    "interventions": [
      "Etanercept"
    ],
    "primary_completion_date": "2011-12-19",
    "completion_date": "2017-08-16",
    "results_first_posted": "2017-02-10",
    "last_update_posted": "2017-10-05",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00887965",
    "title": "A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal Women With Low Bone Mass or Osteoporosis Previously Treated With Denosumab",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Low Bone Mass",
      "Low Bone Mineral Density",
      "Osteoporosis",
      "Postmenopausal Osteoporosis"
    ],
    "interventions": [
      "Previous denosumab"
    ],
    "primary_completion_date": "2010-06",
    "completion_date": "2010-08",
    "results_first_posted": "2013-10-17",
    "last_update_posted": "2013-11-15",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT02003612",
    "title": "Historical Data Analysis of Hematological Remission and Survival in Adults With R/R Acute Lymphoblastic Leukemia",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Acute Lymphoblastic Leukemia"
    ],
    "interventions": [
      "Not applicable - observational study"
    ],
    "primary_completion_date": "2014-01-10",
    "completion_date": "2014-04-28",
    "results_first_posted": null,
    "last_update_posted": "2022-11-07",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT06563856",
    "title": "A Study of TEPEZZA Subcutaneous Administration in Healthy Adults",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bioavailability",
      "Bioequivalence"
    ],
    "interventions": [
      "TEPEZZA",
      "EDP"
    ],
    "primary_completion_date": "2021-05-27",
    "completion_date": "2021-05-27",
    "results_first_posted": null,
    "last_update_posted": "2024-08-21",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01071954",
    "title": "A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia Purpura",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Thrombocytopenia in Pediatric Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP"
    ],
    "interventions": [
      "Romiplostim"
    ],
    "primary_completion_date": "2017-01-12",
    "completion_date": "2017-01-12",
    "results_first_posted": "2019-01-29",
    "last_update_posted": "2020-01-18",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00111137",
    "title": "Treatment for Patients With Non-Myeloid Malignancies Receiving Chemotherapy",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cancer",
      "Non-Myeloid Malignancies"
    ],
    "interventions": [
      "rHuEPO",
      "Darbepoetin alfa"
    ],
    "primary_completion_date": "2003-11",
    "completion_date": "2004-04",
    "results_first_posted": null,
    "last_update_posted": "2008-02-28",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT05481411",
    "title": "A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic Impairment",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatic Impairment"
    ],
    "interventions": [
      "Olpasiran"
    ],
    "primary_completion_date": "2023-04-05",
    "completion_date": "2023-05-31",
    "results_first_posted": null,
    "last_update_posted": "2025-10-15",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT03064763",
    "title": "Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Unresectable Stage IIIB-IV Malignant Melanoma"
    ],
    "interventions": [
      "Talimogene laherparepvec"
    ],
    "primary_completion_date": "2020-08-03",
    "completion_date": "2023-01-12",
    "results_first_posted": "2021-06-14",
    "last_update_posted": "2023-08-09",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00975104",
    "title": "AMG 745 in Subjects With Age-associated Muscle Loss",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Age-associated Muscle Loss"
    ],
    "interventions": [
      "AMG 745 0.3 mg/kg",
      "AMG 745 1.0 mg/kg",
      "AMG 745 3.0 mg/kg",
      "Placebo"
    ],
    "primary_completion_date": "2011-05",
    "completion_date": "2011-08",
    "results_first_posted": null,
    "last_update_posted": "2018-10-04",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT05073315",
    "title": "A Comparative Study Between ABP 501 and Humira\u00ae in Participants With Moderate to Severe Plaque Psoriasis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Plaque Psoriasis"
    ],
    "interventions": [
      "Adalimumab",
      "ABP 501"
    ],
    "primary_completion_date": "2022-12-19",
    "completion_date": "2022-12-19",
    "results_first_posted": "2024-02-09",
    "last_update_posted": "2024-02-09",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01998607",
    "title": "Survey of XGEVA\u00ae Presrcibers in Europe to Evaluate Their Knowledge of the Summary of Product Characteristics Pertaining to Osteonecrosis of the Jaw",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Solid Tumours",
      "Bone Metastasis"
    ],
    "interventions": [
      "Physician Survey"
    ],
    "primary_completion_date": "2015-05-15",
    "completion_date": "2015-05-15",
    "results_first_posted": null,
    "last_update_posted": "2018-01-09",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00317499",
    "title": "Double-blind, Randomized, Placebo-controlled Phase 3 Study of Etanercept in the Treatment of Psoriatic Arthritis and Psoriasis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Psoriatic Arthritis",
      "Psoriasis"
    ],
    "interventions": [
      "Placebo",
      "Etanercept"
    ],
    "primary_completion_date": "2002-06",
    "completion_date": "2002-07",
    "results_first_posted": null,
    "last_update_posted": "2010-12-23",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01380730",
    "title": "LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hyperlipidemia"
    ],
    "interventions": [
      "Evolocumab",
      "Placebo to Evolocumab"
    ],
    "primary_completion_date": "2012-04-05",
    "completion_date": "2012-04-05",
    "results_first_posted": "2015-10-01",
    "last_update_posted": "2022-11-15",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT02366195",
    "title": "Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Unresected Stage IIIb to IVM1c Melanoma"
    ],
    "interventions": [
      "Talimogene Laherparepvec"
    ],
    "primary_completion_date": "2017-06-26",
    "completion_date": "2020-12-25",
    "results_first_posted": "2018-07-18",
    "last_update_posted": "2021-11-30",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01199302",
    "title": "Long-term Safety Study of Brodalumab in Adults With Crohn's Disease",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Crohn's Disease"
    ],
    "interventions": [
      "Brodalumab"
    ],
    "primary_completion_date": "2011-10-18",
    "completion_date": "2011-10-18",
    "results_first_posted": "2021-12-28",
    "last_update_posted": "2021-12-28",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00890981",
    "title": "A High-resolution Peripheral Quantitative Computed Tomography Study in Postmenopausal Women Previously Treated With Denosumab",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Low Bone Mass",
      "Low Bone Mineral Density",
      "Osteoporosis",
      "Postmenopausal Osteoporosis"
    ],
    "interventions": [
      "high-resolution peripheral quantitative computed tomography (HR-pQCT)",
      "Dual energy X-ray absorptiometry (DXA)",
      "Denosumab",
      "Placebo"
    ],
    "primary_completion_date": "2010-06",
    "completion_date": "2010-08",
    "results_first_posted": "2011-07-28",
    "last_update_posted": "2014-04-02",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00156962",
    "title": "Epoetin Alfa (EPO) in Subjects With Chronic Kidney Disease (CKD)",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Kidney Disease"
    ],
    "interventions": [
      "Epoetin alfa DT",
      "Epoetin alfa RB"
    ],
    "primary_completion_date": "2007-03",
    "completion_date": "2007-03",
    "results_first_posted": null,
    "last_update_posted": "2008-07-21",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT02520362",
    "title": "Denosumab Safety Assessment in Multiple Observational Databases",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Osteoporosis"
    ],
    "interventions": [
      "denosumab",
      "bisphosphonate"
    ],
    "primary_completion_date": "2023-07-21",
    "completion_date": "2023-07-21",
    "results_first_posted": null,
    "last_update_posted": "2024-11-04",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT05626751",
    "title": "An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc)",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diffuse Cutaneous Systemic Sclerosis",
      "Sclerosis, Systemic"
    ],
    "interventions": [
      "HZN-825"
    ],
    "primary_completion_date": "2025-02-24",
    "completion_date": "2025-02-24",
    "results_first_posted": "2026-01-05",
    "last_update_posted": "2026-01-05",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT02994927",
    "title": "A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "ANCA-Associated Vasculitis"
    ],
    "interventions": [
      "Avacopan",
      "Prednisone",
      "Cyclophosphamide",
      "Rituximab",
      "Azathioprine"
    ],
    "primary_completion_date": "2019-09-07",
    "completion_date": "2019-11-01",
    "results_first_posted": "2022-09-09",
    "last_update_posted": "2025-03-24",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01901146",
    "title": "Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HER2-positive Early Breast Cancer",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Cancer"
    ],
    "interventions": [
      "ABP 980",
      "Trastuzumab",
      "Paclitaxel",
      "Lumpectomy or Mastectomy with Sentinel Node or Axillary Node Dissection"
    ],
    "primary_completion_date": "2016-05-05",
    "completion_date": "2017-01-27",
    "results_first_posted": "2019-08-07",
    "last_update_posted": "2019-08-07",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00150462",
    "title": "Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Waldenstrom's Macroglobulinemia",
      "Non-Hodgkin's Lymphoma",
      "Hodgkin's Disease",
      "Multiple Myeloma"
    ],
    "interventions": [
      "Carfilzomib",
      "Dexamethasone"
    ],
    "primary_completion_date": "2009-10",
    "completion_date": "2009-10",
    "results_first_posted": "2015-12-03",
    "last_update_posted": "2017-05-02",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT02777554",
    "title": "A Study to Evaluate the Pharmacokinetic Exposure of 2 Formulations of Apremilast in Healthy Adults",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "Apremilast IR",
      "Apremilast XL"
    ],
    "primary_completion_date": "2016-11-22",
    "completion_date": "2016-11-22",
    "results_first_posted": "2021-07-22",
    "last_update_posted": "2021-07-22",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01683695",
    "title": "Safety Study of AMG 557 in Subjects With Lupus Arthritis",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lupus Arthritis, Systemic Lupus Erythematosus"
    ],
    "interventions": [
      "AMG 557",
      "Matching Placebo"
    ],
    "primary_completion_date": "2016-03",
    "completion_date": "2016-03",
    "results_first_posted": null,
    "last_update_posted": "2017-01-24",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00436670",
    "title": "Phase II Study to Evaluate the Efficacy of AMG 317",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Asthma"
    ],
    "interventions": [
      "AMG 317 75 mg",
      "AMG 317 150 mg",
      "AMG 317 300 mg",
      "Placebo"
    ],
    "primary_completion_date": "2008-09",
    "completion_date": "2009-02",
    "results_first_posted": null,
    "last_update_posted": "2016-03-23",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00527085",
    "title": "12-month Study of AMG 073 in Renal Osteodystrophy",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Renal Osteodystrophy"
    ],
    "interventions": [
      "AMG 073",
      "Placebo"
    ],
    "primary_completion_date": "2003-08",
    "completion_date": "2003-08",
    "results_first_posted": null,
    "last_update_posted": "2013-05-08",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00116727",
    "title": "Rheumatoid Arthritis DMARD Intervention and UtilizationStudy",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Rheumatoid Arthritis"
    ],
    "interventions": [
      "ENBREL\u00ae"
    ],
    "primary_completion_date": "2008-06",
    "completion_date": "2008-10",
    "results_first_posted": null,
    "last_update_posted": "2011-05-06",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00614523",
    "title": "Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "MDS",
      "Myelodysplastic Syndromes",
      "Thrombocytopenia"
    ],
    "interventions": [
      "Placebo",
      "Romiplostim"
    ],
    "primary_completion_date": "2011-03-31",
    "completion_date": "2015-11-30",
    "results_first_posted": "2013-08-13",
    "last_update_posted": "2022-11-07",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01634191",
    "title": "Effects of Age and Sex on the Pharmacokinetics of Apremilast in Healthy Adults",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteer"
    ],
    "interventions": [
      "Apremilast"
    ],
    "primary_completion_date": "2012-03-01",
    "completion_date": "2012-04-01",
    "results_first_posted": "2021-04-14",
    "last_update_posted": "2021-04-14",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00377819",
    "title": "Study of Transitioning From Alendronate to Denosumab",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Postmenopausal Osteoporosis"
    ],
    "interventions": [
      "alendronate",
      "Denosumab (AMG 162)"
    ],
    "primary_completion_date": "2008-03",
    "completion_date": "2008-07",
    "results_first_posted": "2010-08-03",
    "last_update_posted": "2011-07-11",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT06248619",
    "title": "A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Thyroid Eye Disease"
    ],
    "interventions": [
      "Teprotumumab",
      "Placebo"
    ],
    "primary_completion_date": "2026-02-10",
    "completion_date": "2026-09-29",
    "results_first_posted": null,
    "last_update_posted": "2025-09-29",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT04607980",
    "title": "A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Plaque Psoriasis"
    ],
    "interventions": [
      "ABP 654",
      "Ustekinumab"
    ],
    "primary_completion_date": "2022-01-13",
    "completion_date": "2022-06-03",
    "results_first_posted": "2023-12-15",
    "last_update_posted": "2024-12-12",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT02637141",
    "title": "A Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Celiac Disease",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Celiac Disease"
    ],
    "interventions": [
      "AMG 714",
      "Placebo",
      "Placebo Gluten Challenge",
      "Gluten Challenge"
    ],
    "primary_completion_date": "2017-02-15",
    "completion_date": "2017-03-14",
    "results_first_posted": "2019-12-03",
    "last_update_posted": "2019-12-03",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT02739984",
    "title": "Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypercholesterolemia",
      "Mixed Dyslipidemia",
      "Type 2 Diabetes"
    ],
    "interventions": [
      "Evolocumab",
      "Placebo to Evolocumab"
    ],
    "primary_completion_date": "2017-08-03",
    "completion_date": "2017-08-03",
    "results_first_posted": "2018-08-31",
    "last_update_posted": "2018-08-31",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT06660173",
    "title": "A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 2 Diabetes Mellitus (T2DM)"
    ],
    "interventions": [
      "Maridebart Cafraglutide",
      "Placebo"
    ],
    "primary_completion_date": "2025-10-06",
    "completion_date": "2026-11-10",
    "results_first_posted": null,
    "last_update_posted": "2025-11-25",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00117910",
    "title": "Treatment for Elderly Patients With High Risk Breast Cancer",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Cancer"
    ],
    "interventions": [
      "pegfilgrastim"
    ],
    "primary_completion_date": null,
    "completion_date": "2004-05",
    "results_first_posted": null,
    "last_update_posted": "2008-05-16",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00117442",
    "title": "A Study of Carboplatin/Paclitaxel With Pegfilgrastim Supported by Haematopoietic Progenitor Cell Re-Infusion in Whole Blood",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Cancer",
      "Lung Cancer",
      "Ovarian Cancer"
    ],
    "interventions": [
      "carboplatin",
      "paclitaxel",
      "pegfilgrastim"
    ],
    "primary_completion_date": "2004-08",
    "completion_date": "2004-12",
    "results_first_posted": null,
    "last_update_posted": "2013-05-13",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00604682",
    "title": "Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Psoriasis"
    ],
    "interventions": [
      "CC10004"
    ],
    "primary_completion_date": "2005-10-01",
    "completion_date": "2005-12-01",
    "results_first_posted": null,
    "last_update_posted": "2020-04-24",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01209286",
    "title": "Study of the BiTE\u00ae Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "B-ALL"
    ],
    "interventions": [
      "Blinatumomab"
    ],
    "primary_completion_date": "2012-03",
    "completion_date": "2016-10",
    "results_first_posted": "2015-01-07",
    "last_update_posted": "2017-03-06",
    "enrollment": null,
    "sponsor": "Amgen Research (Munich) GmbH",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00321620",
    "title": "Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bone Metastases"
    ],
    "interventions": [
      "zoledronic acid",
      "denosumab"
    ],
    "primary_completion_date": "2009-10-01",
    "completion_date": "2012-02-24",
    "results_first_posted": "2014-03-21",
    "last_update_posted": "2018-08-29",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT05565560",
    "title": "A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Plaque Psoriasis"
    ],
    "interventions": [
      "Apremilast"
    ],
    "primary_completion_date": "2025-11-20",
    "completion_date": "2026-09-06",
    "results_first_posted": null,
    "last_update_posted": "2025-12-19",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT02906124",
    "title": "Study to Evaluate the Safety of Repatha\u00ae in Pregnancy",
    "status": "TERMINATED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Hypercholesterolaemia",
      "Pregnancy"
    ],
    "interventions": [],
    "primary_completion_date": "2020-11-06",
    "completion_date": "2020-11-06",
    "results_first_posted": null,
    "last_update_posted": "2020-12-22",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00650078",
    "title": "Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra\u00ae) Therapy in Patients With Active Rheumatoid Arthritis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rheumatoid Arthritis"
    ],
    "interventions": [
      "MR prednisone",
      "Placebo"
    ],
    "primary_completion_date": "2009-05",
    "completion_date": "2009-05",
    "results_first_posted": "2012-12-13",
    "last_update_posted": "2024-12-18",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00049985",
    "title": "Heart Failure and Anemia",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Heart Failure",
      "Anemia"
    ],
    "interventions": [
      "Darbepoetin Alfa"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2009-08-07",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00104650",
    "title": "Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bone Metastases in Men With Hormone-Refractory Prostate Cancer",
      "Bone Metastases in Subjects With Advanced Breast Cancer",
      "Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma"
    ],
    "interventions": [
      "AMG 162 180 mg (SC) q 12 weeks",
      "IV Bisphosphonate q 4 weeks",
      "AMG 162- 180 mg q 4 weeks"
    ],
    "primary_completion_date": "2008-01",
    "completion_date": "2010-03",
    "results_first_posted": "2011-01-07",
    "last_update_posted": "2011-01-24",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00002126",
    "title": "A Randomized, Controlled, Multicenter Trial of Filgrastim (Recombinant-Methionyl Human Granulocyte Colony Stimulating Factor; G-CSF) for the Prevention of Grade 4 Neutropenia in Patients With HIV Infection.",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HIV Infections",
      "Cytopenias"
    ],
    "interventions": [
      "Filgrastim"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2005-06-24",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00658658",
    "title": "Panitumumab in Children With Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumors"
    ],
    "interventions": [
      "Panitumumab"
    ],
    "primary_completion_date": "2015-03",
    "completion_date": "2015-03",
    "results_first_posted": "2016-05-18",
    "last_update_posted": "2016-05-18",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00563316",
    "title": "Effect of Panitumumab on the Pharmacokinetics of Irinotecan",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Colorectal Cancer"
    ],
    "interventions": [
      "Panitumumab",
      "Irinotecan"
    ],
    "primary_completion_date": "2009-03",
    "completion_date": "2010-06",
    "results_first_posted": "2016-04-12",
    "last_update_posted": "2016-04-12",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT02791516",
    "title": "A Safety and Efficacy Study to Evaluate Romosozumab (AMG 785) in South Korean Women With Osteoporosis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Postmenopausal Osteoporosis"
    ],
    "interventions": [
      "Romosozumab",
      "Placebo"
    ],
    "primary_completion_date": "2018-02-12",
    "completion_date": "2018-12-21",
    "results_first_posted": "2019-07-05",
    "last_update_posted": "2019-10-07",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01018550",
    "title": "AMG 853 Phase 2 Study in Subjects With Inadequately Controlled Asthma",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Asthma"
    ],
    "interventions": [
      "AMG 853",
      "AMG 853",
      "AMG 853",
      "AMG 853",
      "Placebo"
    ],
    "primary_completion_date": "2010-12",
    "completion_date": "2011-03",
    "results_first_posted": null,
    "last_update_posted": "2016-03-23",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT03633708",
    "title": "A Study of Etelcalcetide in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Secondary Hyperparathyroidism",
      "Chronic Kidney Disease"
    ],
    "interventions": [
      "Etelcalcetide"
    ],
    "primary_completion_date": "2029-01-31",
    "completion_date": "2029-01-31",
    "results_first_posted": null,
    "last_update_posted": "2025-12-01",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01439880",
    "title": "Open Label Study of Long Term Evaluation Against LDL-C Trial",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypercholesterolemia"
    ],
    "interventions": [
      "Evolocumab",
      "Standard of care"
    ],
    "primary_completion_date": "2018-06-20",
    "completion_date": "2018-06-20",
    "results_first_posted": "2019-07-10",
    "last_update_posted": "2022-09-21",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00277160",
    "title": "A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Neutropenia",
      "Breast Cancer",
      "Lung Cancer",
      "Non-Hodgkin's Lymphoma",
      "Ovarian Cancer"
    ],
    "interventions": [
      "Neulasta (pegfilgrastim)"
    ],
    "primary_completion_date": "2004-11",
    "completion_date": "2005-01",
    "results_first_posted": null,
    "last_update_posted": "2010-10-08",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01575834",
    "title": "Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Postmenopausal Osteoporosis"
    ],
    "interventions": [
      "Romosozumab",
      "Placebo",
      "Denosumab"
    ],
    "primary_completion_date": "2015-12-14",
    "completion_date": "2016-12-28",
    "results_first_posted": "2018-11-08",
    "last_update_posted": "2024-08-28",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00379899",
    "title": "ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Kidney Disease",
      "End Stage Renal Disease",
      "Coronary Artery Calcification",
      "Vascular Calcification",
      "Calcification",
      "Cardiovascular Disease",
      "Chronic Renal Failure",
      "Hyperparathyroidism",
      "Kidney Disease",
      "Nephrology",
      "Secondary Hyperparathyroidism"
    ],
    "interventions": [
      "cinacalcet"
    ],
    "primary_completion_date": "2009-05",
    "completion_date": "2009-11",
    "results_first_posted": "2010-10-27",
    "last_update_posted": "2014-07-23",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00117234",
    "title": "Impact of Darbepoetin Alfa on Exercise Tolerance and Left Ventricular Structure in Subjects With Symptomatic Congestive Heart Failure (CHF) and Anemia",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Congestive Heart Failure",
      "Anemia"
    ],
    "interventions": [
      "darbepoetin alfa"
    ],
    "primary_completion_date": null,
    "completion_date": "2004-07",
    "results_first_posted": null,
    "last_update_posted": "2010-12-03",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00975221",
    "title": "Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Patients With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hyperparathyroidism, Primary",
      "Hypercalcemia"
    ],
    "interventions": [
      "Cinacalcet",
      "Placebo"
    ],
    "primary_completion_date": "2012-07-12",
    "completion_date": "2012-12-21",
    "results_first_posted": "2016-01-25",
    "last_update_posted": "2018-10-17",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01763918",
    "title": "Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hyperlipidemia"
    ],
    "interventions": [
      "Evolocumab",
      "Placebo"
    ],
    "primary_completion_date": "2013-11-27",
    "completion_date": "2013-12-19",
    "results_first_posted": "2015-12-22",
    "last_update_posted": "2019-06-17",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00006215",
    "title": "Docetaxel and Vinorelbine Plus Filgrastim in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer",
    "status": "UNKNOWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lung Cancer"
    ],
    "interventions": [
      "filgrastim",
      "docetaxel",
      "vinorelbine tartrate"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2013-12-19",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00448786",
    "title": "Effect of Different Doses of AMG 706 on the Gallbladder in Advanced Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumors"
    ],
    "interventions": [
      "AMG 706",
      "AMG 706",
      "AMG 706"
    ],
    "primary_completion_date": "2008-12",
    "completion_date": "2009-03",
    "results_first_posted": null,
    "last_update_posted": "2011-01-21",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01732770",
    "title": "Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Post Menopausal Osteoporosis"
    ],
    "interventions": [
      "Denosumab",
      "Zoledronic Acid",
      "Placebo to Denosumab",
      "Placebo to Zoledronic Acid"
    ],
    "primary_completion_date": "2015-01-07",
    "completion_date": "2015-01-07",
    "results_first_posted": "2016-01-25",
    "last_update_posted": "2020-03-10",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT03703908",
    "title": "A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Focal Segmental Glomerulosclerosis"
    ],
    "interventions": [
      "CCX140-B"
    ],
    "primary_completion_date": "2020-06-24",
    "completion_date": "2020-06-24",
    "results_first_posted": "2024-02-06",
    "last_update_posted": "2025-03-17",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT02429882",
    "title": "Study of Efficacy and Safety of Brodalumab Compared With Placebo in Subjects With Axial Spondyloarthritis",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Axial Spondyloarthritis"
    ],
    "interventions": [
      "Brodalumab 210 mg",
      "Placebo"
    ],
    "primary_completion_date": "2015-05",
    "completion_date": "2015-05",
    "results_first_posted": null,
    "last_update_posted": "2015-06-19",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT02633020",
    "title": "Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type II Refractory Celiac Disease (RCD-II)",
      "In-situ Small Bowel T-cell Lymphoma"
    ],
    "interventions": [
      "AMG 714",
      "Placebo"
    ],
    "primary_completion_date": "2017-04-11",
    "completion_date": "2017-05-02",
    "results_first_posted": "2019-12-27",
    "last_update_posted": "2019-12-27",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00356681",
    "title": "A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Neoplasms",
      "Breast Tumors",
      "Breast Cancer",
      "Locally Recurrent and Metastatic Breast Cancer"
    ],
    "interventions": [
      "AMG 706 placebo",
      "Bevacizumab",
      "AMG 706",
      "Paclitaxel"
    ],
    "primary_completion_date": "2009-02",
    "completion_date": "2012-08",
    "results_first_posted": null,
    "last_update_posted": "2015-10-15",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT06468826",
    "title": "A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "End-Stage Renal Disease (ESRD)"
    ],
    "interventions": [
      "Avacopan"
    ],
    "primary_completion_date": "2024-10-05",
    "completion_date": "2024-10-05",
    "results_first_posted": null,
    "last_update_posted": "2025-09-18",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01652690",
    "title": "Prospective Observational Study to Describe Characteristics and Management of Patients Treated With Denosumab (Prolia\u00ae) in Routine Clinical Practice",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Osteoporosis, Postmenopausal"
    ],
    "interventions": [
      "Denosumab"
    ],
    "primary_completion_date": "2015-05-15",
    "completion_date": "2015-05-15",
    "results_first_posted": "2016-05-26",
    "last_update_posted": "2019-03-06",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01375751",
    "title": "Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypercholesterolemia, Familial"
    ],
    "interventions": [
      "Evolocumab",
      "Placebo"
    ],
    "primary_completion_date": "2012-05-16",
    "completion_date": "2012-05-16",
    "results_first_posted": "2015-09-29",
    "last_update_posted": "2022-11-15",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00095277",
    "title": "Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Anemia"
    ],
    "interventions": [
      "Darbepoetin Alfa"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2009-03-13",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT02157948",
    "title": "A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Postmenopausal Osteoporosis"
    ],
    "interventions": [
      "Denosumab (CP2)",
      "Denosumab (CP4)"
    ],
    "primary_completion_date": "2015-07",
    "completion_date": "2015-07",
    "results_first_posted": "2017-08-16",
    "last_update_posted": "2017-08-16",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00950989",
    "title": "Brodalumab (AMG 827) in Rheumatoid Arthritis (RA) Participants With Inadequate Response to Methotrexate",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rheumatoid Arthritis"
    ],
    "interventions": [
      "Brodalumab",
      "Placebo",
      "Methotrexate",
      "folic acid"
    ],
    "primary_completion_date": "2011-02-11",
    "completion_date": "2011-02-11",
    "results_first_posted": "2021-12-21",
    "last_update_posted": "2021-12-21",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00527215",
    "title": "Phase 2 Study of Darbepoetin Alfa Extended Dosing",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pre-Dialysis"
    ],
    "interventions": [
      "darbepoetin alfa"
    ],
    "primary_completion_date": "2003-10",
    "completion_date": "2003-10",
    "results_first_posted": null,
    "last_update_posted": "2009-05-22",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT02345408",
    "title": "Phase 1b Study of CCX872-B in Patients With Pancreatic Adenocarcinoma",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pancreatic Cancer"
    ],
    "interventions": [
      "CCX872-B"
    ],
    "primary_completion_date": "2020-05-06",
    "completion_date": "2020-05-06",
    "results_first_posted": null,
    "last_update_posted": "2025-02-27",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT02499315",
    "title": "Study to Evaluate the Safety, Tolerability, and Action of AMG 357 in Females With Rheumatoid Arthritis",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rheumatoid Arthritis"
    ],
    "interventions": [
      "AMG 357",
      "Placebo"
    ],
    "primary_completion_date": "2016-02",
    "completion_date": "2016-02",
    "results_first_posted": null,
    "last_update_posted": "2016-05-06",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT06411860",
    "title": "A Study to Assess the Effect of Olpasiran on QT/QTc Intervals in Healthy Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Basic Science"
    ],
    "interventions": [
      "Placebo",
      "Olpasiran",
      "Moxifloxacin"
    ],
    "primary_completion_date": "2024-11-29",
    "completion_date": "2024-12-11",
    "results_first_posted": null,
    "last_update_posted": "2025-10-27",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT04825678",
    "title": "A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Migraine"
    ],
    "interventions": [
      "Erenumab"
    ],
    "primary_completion_date": "2023-09-28",
    "completion_date": "2023-09-28",
    "results_first_posted": "2024-09-19",
    "last_update_posted": "2024-09-19",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT04129164",
    "title": "A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sj\u00f6gren's Syndrome",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Sj\u00f6gren's Syndrome"
    ],
    "interventions": [
      "VIB4920",
      "Placebo"
    ],
    "primary_completion_date": "2022-09-01",
    "completion_date": "2023-03-10",
    "results_first_posted": "2025-04-30",
    "last_update_posted": "2025-04-30",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01405963",
    "title": "Double-blind, Multiple Dose Study of Tezepelumab (AMG 157) in Adults With Mild Atopic Asthma",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Asthma"
    ],
    "interventions": [
      "Placebo",
      "Tezepelumab"
    ],
    "primary_completion_date": "2013-04-05",
    "completion_date": "2013-04-05",
    "results_first_posted": "2022-10-17",
    "last_update_posted": "2022-10-17",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01235416",
    "title": "A Phase 1b, Open-label, Dose-finding Study of AMG 706 in Combination With Gemcitabine and Erlotinib to Treat Subjects With Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Histologically or Cytologically Documented Solid Tumors"
    ],
    "interventions": [
      "AMG 706"
    ],
    "primary_completion_date": "2008-04",
    "completion_date": "2010-02",
    "results_first_posted": null,
    "last_update_posted": "2011-01-21",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00121043",
    "title": "Evaluating Kineret\u00ae (Anakinra) in Rheumatoid Arthritis (RA) Subjects Using aSelf-Reported Questionnaire",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rheumatoid Arthritis"
    ],
    "interventions": [
      "SimpleJectTM",
      "Kineret\u00ae (Anakinra)"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2009-11-26",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00096915",
    "title": "Study Evaluating Darbepoetin Alfa in Subjects With Chronic Kidney Disease (CKD) Receiving Dialysis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Kidney Disease",
      "Chronic Kidney Disease"
    ],
    "interventions": [
      "Darbepoetin Alfa"
    ],
    "primary_completion_date": "2005-11",
    "completion_date": "2005-11",
    "results_first_posted": null,
    "last_update_posted": "2009-05-22",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT04925934",
    "title": "Study of VIB7734 for the Treatment of Moderate to Severely Active SLE",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lupus Erythematosus, Systemic"
    ],
    "interventions": [
      "VIB7734",
      "Placebo"
    ],
    "primary_completion_date": "2023-05-16",
    "completion_date": "2023-06-09",
    "results_first_posted": "2024-07-23",
    "last_update_posted": "2024-07-23",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT03776058",
    "title": "Safety, Tolerability, and Clinical Effects of Twice-daily Doses of Cinacalcet (AMG 073) in Adults With Primary Hyperparathyroidism (HPT)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Primary Hyperparathyroidism"
    ],
    "interventions": [
      "Cinacalcet",
      "Placebo"
    ],
    "primary_completion_date": "2000-12-26",
    "completion_date": "2000-12-26",
    "results_first_posted": null,
    "last_update_posted": "2018-12-14",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT03776032",
    "title": "A Novel Erythropoiesis Stimulating Protein (NESP; Darbopoetin Alfa) for the Treatment of Anemia in Lung Cancer Patients Receiving Multi-cycle Platinum-Containing Chemotherapy",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Anemia"
    ],
    "interventions": [
      "Darbepoetin alfa",
      "Placebo"
    ],
    "primary_completion_date": "2000-11-08",
    "completion_date": "2002-02-27",
    "results_first_posted": null,
    "last_update_posted": "2018-12-20",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00038298",
    "title": "A Rheumatoid Arthritis (RA) Study Treating Signs and Symptoms of RA in People With RA & Receiving Methotrexate",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rheumatoid Arthritis"
    ],
    "interventions": [
      "Placebo",
      "AMG 719",
      "AGM 719",
      "AMG 719",
      "placebo to AMG 719"
    ],
    "primary_completion_date": "2004-05",
    "completion_date": "2004-05",
    "results_first_posted": null,
    "last_update_posted": "2011-01-21",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT05060016",
    "title": "A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsed/Refractory Small Cell Lung Cancer"
    ],
    "interventions": [
      "Tarlatamab"
    ],
    "primary_completion_date": "2026-12-30",
    "completion_date": "2027-12-30",
    "results_first_posted": null,
    "last_update_posted": "2025-12-22",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01543204",
    "title": "Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab",
    "status": "TERMINATED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Psoriasis"
    ],
    "interventions": [
      "Etanercept"
    ],
    "primary_completion_date": "2015-05-29",
    "completion_date": "2015-05-29",
    "results_first_posted": "2016-06-27",
    "last_update_posted": "2017-12-29",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT07225686",
    "title": "Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Obesity",
      "Obstructive Sleep Apnea"
    ],
    "interventions": [
      "Maridebart cafraglutide",
      "Placebo"
    ],
    "primary_completion_date": "2027-09-29",
    "completion_date": "2028-09-13",
    "results_first_posted": null,
    "last_update_posted": "2026-01-15",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00086086",
    "title": "Subcutaneous (SC) Darbepoetin Alfa in Subjects With Symptomatic Congestive Heart Failure (CHF) & Anemia",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Congestive Heart Failure",
      "Anemia"
    ],
    "interventions": [
      "Darbepoetin Alfa"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2017-02-09",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00630786",
    "title": "Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Colon Cancer",
      "Colorectal Cancer",
      "Rectal Cancer",
      "Metastatic Colorectal Cancer",
      "Oncology"
    ],
    "interventions": [
      "Panitumumab",
      "Conatumumab"
    ],
    "primary_completion_date": "2009-05",
    "completion_date": "2010-11",
    "results_first_posted": "2014-02-06",
    "last_update_posted": "2014-02-06",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01737879",
    "title": "Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis",
    "status": "TERMINATED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Anemia"
    ],
    "interventions": [
      "Peginesatide",
      "Epoetin alfa"
    ],
    "primary_completion_date": "2013-03",
    "completion_date": "2013-07",
    "results_first_posted": "2014-04-21",
    "last_update_posted": "2014-04-21",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT06585462",
    "title": "Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cardiometabolic Disease"
    ],
    "interventions": [
      "AMG 513",
      "Placebo",
      "AMG 513",
      "Placebo"
    ],
    "primary_completion_date": "2026-07-22",
    "completion_date": "2026-07-22",
    "results_first_posted": null,
    "last_update_posted": "2025-08-13",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00002037",
    "title": "Evaluation of the Therapeutic Benefit of r-metHuIFN- Gamma in AIDS Patients With Disseminated Mycobacterium Avium-Intracellulare (MAI) Infection: A Multi-Centered Pilot Study",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Mycobacterium Avium-Intracellulare Infection",
      "HIV Infections"
    ],
    "interventions": [
      "Trifluridine"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2005-06-24",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT03608657",
    "title": "Study to Evaluate the Real-World Effectiveness, Safety and Tolerability of Treatment With Apremilast in Psoriatic Arthritis Patients Followed in Canadian Routine Care (APPRAISE)",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Arthritis, Psoriatic"
    ],
    "interventions": [
      "Apremilast"
    ],
    "primary_completion_date": "2021-04-12",
    "completion_date": "2022-03-30",
    "results_first_posted": null,
    "last_update_posted": "2024-06-05",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT02875184",
    "title": "A Study of Apremilast Use and Effectiveness in Patients With Psoriatic Arthritis in The Netherlands",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Arthritis, Psoriatic"
    ],
    "interventions": [],
    "primary_completion_date": "2022-06-30",
    "completion_date": "2022-06-30",
    "results_first_posted": null,
    "last_update_posted": "2023-10-10",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00094835",
    "title": "Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lung Cancer",
      "Non-Small Cell Lung Cancer"
    ],
    "interventions": [
      "Panitumumab",
      "Motesanib diphosphate",
      "Paclitaxel",
      "Carboplatin"
    ],
    "primary_completion_date": "2007-03",
    "completion_date": "2007-03",
    "results_first_posted": "2014-03-24",
    "last_update_posted": "2016-03-24",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01001208",
    "title": "The Efficacy and Safety of Adding Methotrexate to Etanercept in Psoriasis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Psoriasis"
    ],
    "interventions": [
      "Methotrexate",
      "Etanercept",
      "Placebo"
    ],
    "primary_completion_date": "2010-12",
    "completion_date": "2011-02",
    "results_first_posted": "2013-08-12",
    "last_update_posted": "2013-08-12",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01124279",
    "title": "Single-dose, Pharmacokinetics of AMG 853 in Healthy Adult Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "AMG 853"
    ],
    "primary_completion_date": "2010-08",
    "completion_date": "2010-10",
    "results_first_posted": null,
    "last_update_posted": "2011-01-07",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00261950",
    "title": "Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Secondary Hyperparathyroidism"
    ],
    "interventions": [
      "Sensipar (Cinacalcet HCl)"
    ],
    "primary_completion_date": "2011-05",
    "completion_date": "2011-05",
    "results_first_posted": "2013-12-04",
    "last_update_posted": "2014-07-21",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT02384317",
    "title": "Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Immunoglobulin A Nephropathy"
    ],
    "interventions": [
      "CCX168"
    ],
    "primary_completion_date": "2015-09-13",
    "completion_date": "2018-06-01",
    "results_first_posted": "2023-08-01",
    "last_update_posted": "2025-03-13",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00583674",
    "title": "Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin & Capecitabine in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Gastrointestinal Cancer"
    ],
    "interventions": [
      "AMG 386 placebo",
      "AMG 386 10mg/kg",
      "AMG 386 3mg/kg",
      "Cisplatin",
      "Capecitabine",
      "Cisplatin",
      "Capecitabine",
      "Cisplatin",
      "Capecitabine"
    ],
    "primary_completion_date": "2010-03",
    "completion_date": "2012-06",
    "results_first_posted": null,
    "last_update_posted": "2014-05-07",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT06312020",
    "title": "A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Sjogren's Syndrome"
    ],
    "interventions": [
      "HZN-1116",
      "Placebo"
    ],
    "primary_completion_date": "2026-03-19",
    "completion_date": "2026-11-24",
    "results_first_posted": null,
    "last_update_posted": "2025-10-24",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00101920",
    "title": "ABX-EGF as Second Line Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-small Cell Lung Cancer",
      "Neoplasm Metastasis",
      "Lung Cancer"
    ],
    "interventions": [
      "ABX-EGF"
    ],
    "primary_completion_date": "2004-12",
    "completion_date": "2004-12",
    "results_first_posted": null,
    "last_update_posted": "2010-10-15",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT02425826",
    "title": "A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis.",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Parapsoriasis"
    ],
    "interventions": [
      "Apremilast",
      "Placebo",
      "Placebo-Apremilast"
    ],
    "primary_completion_date": "2016-02-12",
    "completion_date": "2016-11-22",
    "results_first_posted": "2017-06-06",
    "last_update_posted": "2023-06-05",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01294397",
    "title": "Effects of Denosumab on the Pharmacokinetics of Etanercept",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Postmenopausal",
      "Osteopenia",
      "Rheumatoid Arthritis",
      "Osteoporosis"
    ],
    "interventions": [
      "Etanercept",
      "Denosumab"
    ],
    "primary_completion_date": "2016-01",
    "completion_date": "2016-01",
    "results_first_posted": "2017-06-20",
    "last_update_posted": "2017-06-20",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01901185",
    "title": "Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rheumatoid Arthritis",
      "Psoriatic Arthritis"
    ],
    "interventions": [
      "Etanercept / Autoinjector A"
    ],
    "primary_completion_date": "2013-12-18",
    "completion_date": "2013-12-30",
    "results_first_posted": "2014-11-21",
    "last_update_posted": "2018-09-04",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT06150781",
    "title": "Aimovig Pregnancy Exposure Registry",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Migraine"
    ],
    "interventions": [
      "erenumab-aooe"
    ],
    "primary_completion_date": "2027-10-28",
    "completion_date": "2027-10-28",
    "results_first_posted": null,
    "last_update_posted": "2025-11-04",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01588509",
    "title": "Transition From Alendronate to Romosozumab (AMG 785)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Osteoporosis"
    ],
    "interventions": [
      "Romosozumab"
    ],
    "primary_completion_date": "2012-11-21",
    "completion_date": "2012-11-21",
    "results_first_posted": "2019-03-04",
    "last_update_posted": "2019-03-26",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00102921",
    "title": "Safety and Activity Study of an Oral Medication to Treat Moderate to Severe Crohn's Disease",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Crohn Disease"
    ],
    "interventions": [
      "CCX282-B"
    ],
    "primary_completion_date": null,
    "completion_date": "2005-12",
    "results_first_posted": null,
    "last_update_posted": "2025-03-06",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01440257",
    "title": "A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetic Nephropathy",
      "Type 2 Diabetes Mellitus"
    ],
    "interventions": [
      "Placebo",
      "CCX140-B"
    ],
    "primary_completion_date": "2013-02",
    "completion_date": "2013-09",
    "results_first_posted": null,
    "last_update_posted": "2025-02-27",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT03721172",
    "title": "Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Psoriasis"
    ],
    "interventions": [
      "Apremilast",
      "Placebo"
    ],
    "primary_completion_date": "2020-03-06",
    "completion_date": "2020-07-24",
    "results_first_posted": "2021-05-17",
    "last_update_posted": "2024-05-29",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT02274792",
    "title": "Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Patients With Plaque Psoriasis",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Plaque Psoriasis"
    ],
    "interventions": [
      "Etanercept"
    ],
    "primary_completion_date": "2015-11",
    "completion_date": "2015-11",
    "results_first_posted": "2016-12-29",
    "last_update_posted": "2016-12-29",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT04191616",
    "title": "Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsed or Refractory Multiple Myeloma"
    ],
    "interventions": [
      "Carfilzomib",
      "Dexamethasone",
      "Pomalidomide"
    ],
    "primary_completion_date": "2022-11-30",
    "completion_date": "2024-10-01",
    "results_first_posted": "2023-11-08",
    "last_update_posted": "2025-09-04",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00537667",
    "title": "The SPECTRA Study",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rheumatoid Arthritis"
    ],
    "interventions": [
      "anakinra",
      "anakinra and PEG sTNF-R1"
    ],
    "primary_completion_date": "2003-03",
    "completion_date": "2003-06",
    "results_first_posted": null,
    "last_update_posted": "2009-11-26",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT03747939",
    "title": "Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Arthritis, Psoriatic"
    ],
    "interventions": [
      "Apremilast (CC-10004)",
      "Apremilast (CC-10004) Placebo"
    ],
    "primary_completion_date": "2022-12-19",
    "completion_date": "2023-07-05",
    "results_first_posted": "2024-01-05",
    "last_update_posted": "2024-10-22",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT06224192",
    "title": "A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atopic Dermatitis"
    ],
    "interventions": [
      "Rocatinlimab Prefilled Syringe",
      "Rocatinlimab AI"
    ],
    "primary_completion_date": "2025-04-11",
    "completion_date": "2026-03-15",
    "results_first_posted": null,
    "last_update_posted": "2025-10-08",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00986895",
    "title": "A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatic Encephalopathy",
      "Urea Cycle Disorders"
    ],
    "interventions": [
      "HPN-100"
    ],
    "primary_completion_date": null,
    "completion_date": "2007-06",
    "results_first_posted": null,
    "last_update_posted": "2024-06-20",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT02576678",
    "title": "A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Psoriasis"
    ],
    "interventions": [
      "Apremilast"
    ],
    "primary_completion_date": "2017-09-04",
    "completion_date": "2019-07-29",
    "results_first_posted": "2018-09-27",
    "last_update_posted": "2020-05-07",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00110916",
    "title": "Treatment for Patients With Osteoarthritis (OA) of the Knee",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Osteoarthritis"
    ],
    "interventions": [
      "Intra-articular metHuIL-1ra (anakinra)",
      "placebo"
    ],
    "primary_completion_date": "2005-02",
    "completion_date": "2005-02",
    "results_first_posted": null,
    "last_update_posted": "2008-02-22",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT06570798",
    "title": "A Phase 2a Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Systemic Lupus Erythematosus",
      "Active Refractory Rheumatoid Arthritis"
    ],
    "interventions": [
      "Inebilizumab",
      "Blinatumomab"
    ],
    "primary_completion_date": "2028-09-15",
    "completion_date": "2029-06-23",
    "results_first_posted": null,
    "last_update_posted": "2025-11-12",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01544114",
    "title": "A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Juvenile Idiopathic Arthritis (JIA)"
    ],
    "interventions": [
      "VIMOVO 250/20",
      "VIMOVO 375/20",
      "VIMOVO 500/20"
    ],
    "primary_completion_date": "2015-02",
    "completion_date": "2015-02",
    "results_first_posted": "2017-10-04",
    "last_update_posted": "2024-12-17",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT06122649",
    "title": "A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Plaque Psoriasis"
    ],
    "interventions": [
      "apremilast",
      "Placebo"
    ],
    "primary_completion_date": "2025-02-28",
    "completion_date": "2025-12-05",
    "results_first_posted": null,
    "last_update_posted": "2026-01-05",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00661141",
    "title": "Phase IIa Study of Fomepizole for Acetaldehyde Toxicity After Ethanol Exposure in Subjects With Altered Ethanol Metabolism",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Aldehyde Dehydrogenase-2 (ALDH2) Deficiency"
    ],
    "interventions": [
      "Antizol",
      "Placebo",
      "Ethanol"
    ],
    "primary_completion_date": "2008-06",
    "completion_date": "2008-06",
    "results_first_posted": "2017-09-15",
    "last_update_posted": "2024-12-27",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT02624869",
    "title": "Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Familial Hypercholesterolemia"
    ],
    "interventions": [
      "Evolocumab"
    ],
    "primary_completion_date": "2021-06-01",
    "completion_date": "2021-06-01",
    "results_first_posted": "2022-01-14",
    "last_update_posted": "2024-05-29",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT05891119",
    "title": "Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis",
    "status": "COMPLETED",
    "phase": "EARLY_PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atopic Dermatitis"
    ],
    "interventions": [
      "Caffeine",
      "Metoprolol",
      "Midazolam",
      "Warfarin",
      "Vitamin K",
      "Omeprazole",
      "Rocatinlimab"
    ],
    "primary_completion_date": "2024-08-28",
    "completion_date": "2025-02-12",
    "results_first_posted": null,
    "last_update_posted": "2025-12-23",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00992459",
    "title": "Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Urea Cycle Disorders"
    ],
    "interventions": [
      "HPN-100",
      "Buphenyl (NaPBA)"
    ],
    "primary_completion_date": "2010-09",
    "completion_date": "2010-09",
    "results_first_posted": "2013-08-12",
    "last_update_posted": "2024-07-09",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT06061523",
    "title": "A Clinical Trial to Evaluate Bioavailability and Effect of Food for Sotorasib in Healthy Participants",
    "status": "WITHDRAWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants"
    ],
    "interventions": [
      "Sotorasib"
    ],
    "primary_completion_date": "2024-09-09",
    "completion_date": "2024-09-09",
    "results_first_posted": null,
    "last_update_posted": "2024-04-12",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT03781375",
    "title": "Etanercept Plus Methotrexate Versus Methotrexate Alone in Children With Polyarticular Course Juvenile Rheumatoid Arthritis",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Juvenile Rheumatoid Arthritis"
    ],
    "interventions": [
      "Etanercept",
      "Placebo to Etanerceot",
      "Methotrexate"
    ],
    "primary_completion_date": "2002-06-20",
    "completion_date": "2002-06-24",
    "results_first_posted": "2019-08-02",
    "last_update_posted": "2019-08-02",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT02520427",
    "title": "A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsed/Refractory AML",
      "Minimal Residual Disease Positive AML",
      "Myelodysplastic Syndrome"
    ],
    "interventions": [
      "AMG 330"
    ],
    "primary_completion_date": "2022-01-09",
    "completion_date": "2022-01-09",
    "results_first_posted": "2024-07-31",
    "last_update_posted": "2024-07-31",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT01854918",
    "title": "Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hyperlipidemia and Mixed Dyslipidemia"
    ],
    "interventions": [
      "Evolocumab",
      "Standard of Care"
    ],
    "primary_completion_date": "2018-05-31",
    "completion_date": "2018-05-31",
    "results_first_posted": "2019-06-11",
    "last_update_posted": "2019-06-11",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT07094113",
    "title": "AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "KRAS Altered Advanced or Metastatic Solid Tumors"
    ],
    "interventions": [
      "AMG 410",
      "Pembrolizumab",
      "Panitumumab"
    ],
    "primary_completion_date": "2027-10-11",
    "completion_date": "2030-10-09",
    "results_first_posted": null,
    "last_update_posted": "2026-01-02",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT02797080",
    "title": "Long-Term Safety Extension Study of ACTIMMUNE\u00ae (Interferon \u03b3-1b) in Children and Young Adults With Friedreich's Ataxia",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Friedreich's Ataxia"
    ],
    "interventions": [
      "interferon \u03b3-1b"
    ],
    "primary_completion_date": "2017-03-31",
    "completion_date": "2017-03-31",
    "results_first_posted": "2018-05-01",
    "last_update_posted": "2024-12-10",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT00819780",
    "title": "PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Colon Cancer",
      "Colorectal Cancer",
      "Rectal Cancer",
      "Metastatic Colorectal Cancer"
    ],
    "interventions": [
      "Panitumumab",
      "Bevacizumab",
      "mFOLFOX6"
    ],
    "primary_completion_date": "2012-05-30",
    "completion_date": "2016-07-07",
    "results_first_posted": "2014-08-06",
    "last_update_posted": "2022-12-06",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMGN",
    "nct_id": "NCT05581992",
    "title": "Study to Evaluate the Drug-drug Interaction Effect of Omeprazole on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants"
    ],
    "interventions": [
      "AMG 510",
      "Omeprazole"
    ],
    "primary_completion_date": "2020-01-26",
    "completion_date": "2020-01-26",
    "results_first_posted": null,
    "last_update_posted": "2025-03-18",
    "enrollment": null,
    "sponsor": "Amgen",
    "collected_at": "2026-01-27",
    "search_term": "Amgen"
  },
  {
    "ticker": "AMLX",
    "nct_id": "NCT04516096",
    "title": "A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Amyotrophic Lateral Sclerosis"
    ],
    "interventions": [
      "AMX0035"
    ],
    "primary_completion_date": "2022-12-30",
    "completion_date": "2023-01-31",
    "results_first_posted": null,
    "last_update_posted": "2023-04-07",
    "enrollment": null,
    "sponsor": "Amylyx Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Amylyx Pharmaceuticals"
  },
  {
    "ticker": "AMLX",
    "nct_id": "NCT03533257",
    "title": "Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alzheimer Disease"
    ],
    "interventions": [
      "AMX0035",
      "Placebo"
    ],
    "primary_completion_date": "2020-10-22",
    "completion_date": "2020-11-06",
    "results_first_posted": "2025-03-07",
    "last_update_posted": "2025-03-07",
    "enrollment": null,
    "sponsor": "Amylyx Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Amylyx Pharmaceuticals"
  },
  {
    "ticker": "AMLX",
    "nct_id": "NCT05619783",
    "title": "Extension Study Evaluating The Safety And Tolerability of AMX0035",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Amyotrophic Lateral Sclerosis"
    ],
    "interventions": [
      "AMX0035"
    ],
    "primary_completion_date": "2024-10-16",
    "completion_date": "2024-10-30",
    "results_first_posted": null,
    "last_update_posted": "2025-01-13",
    "enrollment": null,
    "sponsor": "Amylyx Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Amylyx Pharmaceuticals"
  },
  {
    "ticker": "AMLX",
    "nct_id": "NCT03488524",
    "title": "Open Label Extension Study of AMX0035 in Patients With ALS",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Amyotrophic Lateral Sclerosis",
      "ALS"
    ],
    "interventions": [
      "AMX0035"
    ],
    "primary_completion_date": "2021-03-01",
    "completion_date": "2021-03-01",
    "results_first_posted": "2025-08-13",
    "last_update_posted": "2025-08-13",
    "enrollment": null,
    "sponsor": "Amylyx Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Amylyx Pharmaceuticals"
  },
  {
    "ticker": "AMLX",
    "nct_id": "NCT04987671",
    "title": "Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS",
    "status": "UNKNOWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "ALS"
    ],
    "interventions": [
      "AMX0035"
    ],
    "primary_completion_date": "2022-05-11",
    "completion_date": "2023-09",
    "results_first_posted": null,
    "last_update_posted": "2023-07-24",
    "enrollment": null,
    "sponsor": "Amylyx Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Amylyx Pharmaceuticals"
  },
  {
    "ticker": "AMLX",
    "nct_id": "NCT05676034",
    "title": "AMX0035 in Adult Patients With Wolfram Syndrome",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Wolfram Syndrome"
    ],
    "interventions": [
      "AMX0035"
    ],
    "primary_completion_date": "2024-07-23",
    "completion_date": "2026-12-31",
    "results_first_posted": null,
    "last_update_posted": "2025-04-02",
    "enrollment": null,
    "sponsor": "Amylyx Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Amylyx Pharmaceuticals"
  },
  {
    "ticker": "AMLX",
    "nct_id": "NCT06122662",
    "title": "AMX0035 and Progressive Supranuclear Palsy",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Progressive Supranuclear Palsy",
      "PSP",
      "Neurodegenerative Diseases",
      "Atypical Parkinsonism"
    ],
    "interventions": [
      "AMX0035",
      "Placebo"
    ],
    "primary_completion_date": "2026-04-01",
    "completion_date": "2029-11-30",
    "results_first_posted": null,
    "last_update_posted": "2024-12-20",
    "enrollment": null,
    "sponsor": "Amylyx Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Amylyx Pharmaceuticals"
  },
  {
    "ticker": "AMLX",
    "nct_id": "NCT03127514",
    "title": "AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Amyotrophic Lateral Sclerosis",
      "Motor Neuron Disease",
      "Neuromuscular Diseases",
      "Neurodegenerative Diseases",
      "Spinal Cord Diseases",
      "TDP-43 Proteinopathies",
      "Nervous System Diseases",
      "Central Nervous System Diseases"
    ],
    "interventions": [
      "AMX0035",
      "Placebo"
    ],
    "primary_completion_date": "2019-09-25",
    "completion_date": "2019-11-24",
    "results_first_posted": "2021-08-11",
    "last_update_posted": "2024-05-16",
    "enrollment": null,
    "sponsor": "Amylyx Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Amylyx Pharmaceuticals"
  },
  {
    "ticker": "AMLX",
    "nct_id": "NCT05021536",
    "title": "Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Amyotrophic Lateral Sclerosis"
    ],
    "interventions": [
      "Placebo",
      "AMX0035"
    ],
    "primary_completion_date": "2024-01-19",
    "completion_date": "2026-01-01",
    "results_first_posted": null,
    "last_update_posted": "2024-08-14",
    "enrollment": null,
    "sponsor": "Amylyx Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Amylyx Pharmaceuticals"
  },
  {
    "ticker": "ANNX",
    "nct_id": "NCT04188015",
    "title": "Study of ANX007 in Participants With Primary Open-angle Glaucoma",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Open Angle Glaucoma"
    ],
    "interventions": [
      "2.5mg ANX007",
      "5.0mg ANX007",
      "Sham Procedure"
    ],
    "primary_completion_date": "2019-06-03",
    "completion_date": "2019-06-03",
    "results_first_posted": null,
    "last_update_posted": "2020-08-20",
    "enrollment": null,
    "sponsor": "Annexon, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Annexon Biosciences"
  },
  {
    "ticker": "APGE",
    "nct_id": "NCT06395948",
    "title": "A Study Evaluating APG777 in Atopic Dermatitis",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atopic Dermatitis"
    ],
    "interventions": [
      "APG777",
      "Placebo"
    ],
    "primary_completion_date": "2026-11",
    "completion_date": "2028-06",
    "results_first_posted": null,
    "last_update_posted": "2025-12-17",
    "enrollment": null,
    "sponsor": "Apogee Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Apogee Therapeutics"
  },
  {
    "ticker": "APGE",
    "nct_id": "NCT06920901",
    "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Asthma"
    ],
    "interventions": [
      "APG777",
      "Placebo"
    ],
    "primary_completion_date": "2026-09",
    "completion_date": "2027-03",
    "results_first_posted": null,
    "last_update_posted": "2025-09-09",
    "enrollment": null,
    "sponsor": "Apogee Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Apogee Therapeutics"
  },
  {
    "ticker": "APGE",
    "nct_id": "NCT07027527",
    "title": "An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atopic Dermatitis"
    ],
    "interventions": [
      "APG777",
      "APG990",
      "Dupilumab"
    ],
    "primary_completion_date": "2026-12",
    "completion_date": "2027-12",
    "results_first_posted": null,
    "last_update_posted": "2026-01-21",
    "enrollment": null,
    "sponsor": "Apogee Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Apogee Therapeutics"
  },
  {
    "ticker": "APGE",
    "nct_id": "NCT07003425",
    "title": "A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atopic Dermatitis"
    ],
    "interventions": [
      "APG777",
      "APG777",
      "APG777"
    ],
    "primary_completion_date": "2029-12",
    "completion_date": "2029-12",
    "results_first_posted": null,
    "last_update_posted": "2026-01-14",
    "enrollment": null,
    "sponsor": "Apogee Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Apogee Therapeutics"
  },
  {
    "ticker": "ARVN",
    "nct_id": "NCT03888612",
    "title": "Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Prostate Cancer Metastatic"
    ],
    "interventions": [
      "ARV-110"
    ],
    "primary_completion_date": "2024-04-29",
    "completion_date": "2025-01-27",
    "results_first_posted": null,
    "last_update_posted": "2025-04-01",
    "enrollment": null,
    "sponsor": "Arvinas Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Arvinas"
  },
  {
    "ticker": "ARVN",
    "nct_id": "NCT05177042",
    "title": "Trial of ARV-110 and Abiraterone in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Prostate Cancer Metastatic"
    ],
    "interventions": [
      "ARV-110 in Combination with Abiraterone"
    ],
    "primary_completion_date": "2024-07-02",
    "completion_date": "2025-04-10",
    "results_first_posted": null,
    "last_update_posted": "2025-07-25",
    "enrollment": null,
    "sponsor": "Arvinas Androgen Receptor, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Arvinas"
  },
  {
    "ticker": "ARVN",
    "nct_id": "NCT05501769",
    "title": "ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Cancer"
    ],
    "interventions": [
      "ARV-471 in combination with Everolimus"
    ],
    "primary_completion_date": "2024-07-03",
    "completion_date": "2025-08-25",
    "results_first_posted": null,
    "last_update_posted": "2025-09-26",
    "enrollment": null,
    "sponsor": "Arvinas Estrogen Receptor, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Arvinas"
  },
  {
    "ticker": "ARVN",
    "nct_id": "NCT05549505",
    "title": "A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Cancer"
    ],
    "interventions": [
      "ARV-471",
      "Anastrozole",
      "Surgical resection of breast tumor"
    ],
    "primary_completion_date": "2024-07-13",
    "completion_date": "2024-07-25",
    "results_first_posted": "2025-08-29",
    "last_update_posted": "2025-08-29",
    "enrollment": null,
    "sponsor": "Arvinas Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Arvinas"
  },
  {
    "ticker": "ARVN",
    "nct_id": "NCT06393738",
    "title": "A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)",
      "Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)"
    ],
    "interventions": [
      "ARV-393"
    ],
    "primary_completion_date": "2025-12",
    "completion_date": "2025-12",
    "results_first_posted": null,
    "last_update_posted": "2025-06-04",
    "enrollment": null,
    "sponsor": "Arvinas Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Arvinas"
  },
  {
    "ticker": "ARVN",
    "nct_id": "NCT04072952",
    "title": "A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE\u00ae) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Cancer"
    ],
    "interventions": [
      "ARV-471",
      "ARV-471 in combination with palbociclib (IBRANCE\u00ae)"
    ],
    "primary_completion_date": "2024-09-13",
    "completion_date": "2025-11-30",
    "results_first_posted": null,
    "last_update_posted": "2025-10-08",
    "enrollment": null,
    "sponsor": "Arvinas Estrogen Receptor, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Arvinas"
  },
  {
    "ticker": "ARVN",
    "nct_id": "NCT07023731",
    "title": "A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "KRAS G12D Mutation",
      "Advanced Solid Cancer"
    ],
    "interventions": [
      "ARV-806"
    ],
    "primary_completion_date": "2027-11-30",
    "completion_date": "2029-04-02",
    "results_first_posted": null,
    "last_update_posted": "2025-08-11",
    "enrollment": null,
    "sponsor": "Arvinas Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Arvinas"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT06209177",
    "title": "Study of ARO-CFB in Adult Healthy Volunteers and Patients With Complement-Mediated Kidney Disease",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "IgA Nephropathy"
    ],
    "interventions": [
      "ARO-CFB",
      "Placebo"
    ],
    "primary_completion_date": "2025-03-31",
    "completion_date": "2026-03",
    "results_first_posted": null,
    "last_update_posted": "2025-12-17",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT04169711",
    "title": "Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Clear Cell Renal Cell Carcinoma"
    ],
    "interventions": [
      "ARO-HIF2"
    ],
    "primary_completion_date": "2022-01-24",
    "completion_date": "2022-07-22",
    "results_first_posted": null,
    "last_update_posted": "2025-10-09",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT01465516",
    "title": "Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir",
    "status": "TERMINATED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Hepatitis C Infection"
    ],
    "interventions": [
      "Boceprevir"
    ],
    "primary_completion_date": "2013-12",
    "completion_date": "2013-12",
    "results_first_posted": null,
    "last_update_posted": "2015-06-30",
    "enrollment": null,
    "sponsor": "Arrowhead Regional Medical Center",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT06937203",
    "title": "Study of ARO-ALK7 in Adult Volunteers With Obesity With and Without Type 2 Diabetes Mellitus",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Obesity",
      "Diabetes Mellitus, Type 2"
    ],
    "interventions": [
      "ARO-ALK7",
      "Placebo"
    ],
    "primary_completion_date": "2026-07",
    "completion_date": "2026-07",
    "results_first_posted": null,
    "last_update_posted": "2025-12-16",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT06131983",
    "title": "Study of ARO-DUX4 in Adult and Adolescent Patients With Facioscapulohumeral Muscular Dystrophy Type 1",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Facio-Scapulo-Humeral Dystrophy"
    ],
    "interventions": [
      "ARO-DUX4 for Injection",
      "Placebo"
    ],
    "primary_completion_date": "2026-12",
    "completion_date": "2026-12",
    "results_first_posted": null,
    "last_update_posted": "2025-10-07",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT05537025",
    "title": "Study of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Idiopathic Pulmonary Fibrosis"
    ],
    "interventions": [
      "ARO-MMP7 Inhalation Solution",
      "Placebo"
    ],
    "primary_completion_date": "2025-09-05",
    "completion_date": "2025-09-05",
    "results_first_posted": null,
    "last_update_posted": "2025-10-15",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT07223658",
    "title": "Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hyperlipidemia; Mixed"
    ],
    "interventions": [
      "ARO-DIMERPA",
      "Placebo"
    ],
    "primary_completion_date": "2026-06",
    "completion_date": "2027-07",
    "results_first_posted": null,
    "last_update_posted": "2026-01-09",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT06347003",
    "title": "Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Severe Hypertriglyceridemia"
    ],
    "interventions": [
      "Plozasiran Injection",
      "Placebo"
    ],
    "primary_completion_date": "2026-06",
    "completion_date": "2026-09",
    "results_first_posted": null,
    "last_update_posted": "2025-10-27",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT03469947",
    "title": "California Prehospital and In Hospital Antifibrinolytic Therapy Via TXA",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hemorrhagic Shock",
      "Trauma Injury"
    ],
    "interventions": [
      "Tranexamic Acid"
    ],
    "primary_completion_date": "2024-07-29",
    "completion_date": "2024-07-29",
    "results_first_posted": null,
    "last_update_posted": "2024-07-30",
    "enrollment": null,
    "sponsor": "Arrowhead Regional Medical Center",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT03362242",
    "title": "Study of ARO-AAT in Normal Adult Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alpha 1-Antitrypsin Deficiency"
    ],
    "interventions": [
      "ARO-AAT Injection",
      "Sterile Normal Saline (0.9% NaCl)"
    ],
    "primary_completion_date": "2018-10-23",
    "completion_date": "2020-03-21",
    "results_first_posted": null,
    "last_update_posted": "2025-12-24",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT04375514",
    "title": "Study of ARO-ENaC in Healthy Volunteers and in Patients With Cystic Fibrosis",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cystic Fibrosis, Pulmonary"
    ],
    "interventions": [
      "ARO-ENaC",
      "Placebo"
    ],
    "primary_completion_date": "2021-05-09",
    "completion_date": "2022-05-13",
    "results_first_posted": "2025-12-17",
    "last_update_posted": "2025-12-17",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT05292950",
    "title": "Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Asthma",
      "Chronic Obstructive Pulmonary Disease"
    ],
    "interventions": [
      "ARO-MUC5AC",
      "Placebo"
    ],
    "primary_completion_date": "2024-11-12",
    "completion_date": "2024-11-12",
    "results_first_posted": null,
    "last_update_posted": "2025-11-05",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT07037771",
    "title": "A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Homozygous Familial Hypercholesterolemia"
    ],
    "interventions": [
      "zodasiran Injection",
      "Placebo"
    ],
    "primary_completion_date": "2027-08-20",
    "completion_date": "2027-08-20",
    "results_first_posted": null,
    "last_update_posted": "2025-12-22",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT02065336",
    "title": "A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatitis B, Chronic"
    ],
    "interventions": [
      "ARC-520",
      "Placebo",
      "entecavir",
      "chlorpheniramine"
    ],
    "primary_completion_date": "2017-01",
    "completion_date": "2017-01",
    "results_first_posted": "2019-07-05",
    "last_update_posted": "2026-01-13",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT05888363",
    "title": "Management and Removal of Foreign Bodies in the Emergency Department",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Rectal Foreign Body",
      "Rectal Perforation",
      "Colonic Perforation"
    ],
    "interventions": [
      "No Intervention"
    ],
    "primary_completion_date": "2021-12-08",
    "completion_date": "2021-12-08",
    "results_first_posted": null,
    "last_update_posted": "2023-06-05",
    "enrollment": null,
    "sponsor": "Arrowhead Regional Medical Center",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT07221344",
    "title": "Study of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alzheimer Disease",
      "Alzheimer Disease, Early Onset"
    ],
    "interventions": [
      "ARO-MAPT-SC",
      "Placebo"
    ],
    "primary_completion_date": "2027-06",
    "completion_date": "2027-06",
    "results_first_posted": null,
    "last_update_posted": "2025-12-11",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT02900183",
    "title": "Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alpha-1 Antitrypsin Deficiency"
    ],
    "interventions": [
      "ARC-AAT Injection"
    ],
    "primary_completion_date": "2016-11",
    "completion_date": "2016-11",
    "results_first_posted": null,
    "last_update_posted": "2025-12-18",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT04998201",
    "title": "Study of ARO-APOC3 in Adults With Mixed Dyslipidemia",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Mixed Dyslipidemia"
    ],
    "interventions": [
      "ARO-APOC3",
      "Placebo"
    ],
    "primary_completion_date": "2023-02-10",
    "completion_date": "2023-08-14",
    "results_first_posted": null,
    "last_update_posted": "2025-10-03",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT02577029",
    "title": "Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatitis B",
      "Hepatitis D"
    ],
    "interventions": [
      "ARC-520",
      "entecavir",
      "pegylated interferon alpha 2a",
      "tenofovir disoproxil",
      "antihistamine"
    ],
    "primary_completion_date": "2016-12",
    "completion_date": "2016-12",
    "results_first_posted": "2019-04-12",
    "last_update_posted": "2026-01-13",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT05413135",
    "title": "Study of ARO-APOC3 in Adults With Dyslipidemia",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dyslipidemias"
    ],
    "interventions": [
      "ARO-APOC3"
    ],
    "primary_completion_date": "2025-09-18",
    "completion_date": "2025-09-18",
    "results_first_posted": null,
    "last_update_posted": "2025-12-17",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT03945292",
    "title": "Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alpha 1-Antitrypsin Deficiency"
    ],
    "interventions": [
      "Fazisiran Injection",
      "Placebo"
    ],
    "primary_completion_date": "2021-11-08",
    "completion_date": "2023-09-18",
    "results_first_posted": "2024-12-30",
    "last_update_posted": "2025-11-04",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT04202354",
    "title": "Study of ARO-HSD in Healthy Volunteers and Patients With Non-Alcoholic Steatohepatitis (NASH) or Suspected NASH",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-alcoholic Steatohepatitis"
    ],
    "interventions": [
      "ARO-HSD Injection",
      "sterile normal saline (0.9% NaCl)"
    ],
    "primary_completion_date": "2021-09-03",
    "completion_date": "2021-09-03",
    "results_first_posted": "2025-10-03",
    "last_update_posted": "2025-10-03",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT06822790",
    "title": "Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypertriglyceridemia"
    ],
    "interventions": [
      "Plozasiran Injection"
    ],
    "primary_completion_date": "2028-07",
    "completion_date": "2028-07",
    "results_first_posted": null,
    "last_update_posted": "2025-12-11",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT02535416",
    "title": "A Study of ARC-520 at Varying Infusion Rates in Healthy Adult Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "ARC-520",
      "cetirizine",
      "diphenhydramine"
    ],
    "primary_completion_date": "2016-08",
    "completion_date": "2016-08",
    "results_first_posted": "2018-02-26",
    "last_update_posted": "2026-01-13",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT02485262",
    "title": "Outcome of New Direct Acting Agents For Hepatitis C A Community Based Experience",
    "status": "UNKNOWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Hepatitis C"
    ],
    "interventions": [
      "Sofosbuvir and simeprevir"
    ],
    "primary_completion_date": "2016-11",
    "completion_date": "2016-11",
    "results_first_posted": null,
    "last_update_posted": "2015-06-30",
    "enrollment": null,
    "sponsor": "Arrowhead Regional Medical Center",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT04832971",
    "title": "Study of ARO-ANG3 in Adults With Mixed Dyslipidemia",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Mixed Dyslipidemia"
    ],
    "interventions": [
      "ARO-ANG3",
      "Placebo"
    ],
    "primary_completion_date": "2022-08-30",
    "completion_date": "2024-09-25",
    "results_first_posted": "2024-01-16",
    "last_update_posted": "2025-12-03",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT02363946",
    "title": "A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD)",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alpha-1 Antitrypsin Deficiency"
    ],
    "interventions": [
      "ARC-AAT Injection",
      "Placebo",
      "Diphenhydramine"
    ],
    "primary_completion_date": "2016-11",
    "completion_date": "2016-11",
    "results_first_posted": "2018-08-03",
    "last_update_posted": "2026-01-12",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT06700538",
    "title": "Study of ARO-INHBE in Adults With Obesity With and Without Diabetes Mellitus",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Obesity"
    ],
    "interventions": [
      "ARO-INHBE",
      "Placebo",
      "Tirzepatide"
    ],
    "primary_completion_date": "2026-05",
    "completion_date": "2026-05",
    "results_first_posted": null,
    "last_update_posted": "2025-12-17",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT03365947",
    "title": "Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatitis B"
    ],
    "interventions": [
      "ARO-HBV",
      "Sterile Normal Saline (0.9% NaCl)",
      "JNJ-56136379"
    ],
    "primary_completion_date": "2020-04-23",
    "completion_date": "2020-04-23",
    "results_first_posted": "2024-06-04",
    "last_update_posted": "2025-10-22",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT02349126",
    "title": "Study of ARC-520 in Patient With Chronic Hepatitis B Virus",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Hepatitis B"
    ],
    "interventions": [
      "ARC-520 Injection"
    ],
    "primary_completion_date": "2015-12",
    "completion_date": "2016-03",
    "results_first_posted": null,
    "last_update_posted": "2025-12-26",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT04720534",
    "title": "Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Severe Hypertriglyceridemia"
    ],
    "interventions": [
      "ARO-APOC3",
      "Placebo"
    ],
    "primary_completion_date": "2023-03-09",
    "completion_date": "2023-08-31",
    "results_first_posted": null,
    "last_update_posted": "2025-10-03",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT02604199",
    "title": "A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatitis B"
    ],
    "interventions": [
      "ARC-520 Injection",
      "placebo",
      "entecavir",
      "tenofovir",
      "antihistamine"
    ],
    "primary_completion_date": "2017-01",
    "completion_date": "2017-01",
    "results_first_posted": "2019-04-16",
    "last_update_posted": "2026-01-13",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT06880770",
    "title": "Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Severe Hypertriglyceridemia"
    ],
    "interventions": [
      "Plozasiran",
      "Placebo"
    ],
    "primary_completion_date": "2029-03",
    "completion_date": "2029-06",
    "results_first_posted": null,
    "last_update_posted": "2025-12-15",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT06796426",
    "title": "Treatment Protocol of Plozasiran in Adults and Adolescents With FCS",
    "status": "AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Familial Chylomicronemia"
    ],
    "interventions": [
      "Plozasiran"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2025-12-30",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT05083364",
    "title": "Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "C3 Glomerulopathy",
      "IgA Nephropathy"
    ],
    "interventions": [
      "ARO-C3",
      "Placebo"
    ],
    "primary_completion_date": "2025-05-05",
    "completion_date": "2025-10-31",
    "results_first_posted": null,
    "last_update_posted": "2025-12-16",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT02452528",
    "title": "Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Hepatitis B"
    ],
    "interventions": [
      "ARC-520",
      "Placebo",
      "Entecavir",
      "Tenofovir",
      "diphenhydramine"
    ],
    "primary_completion_date": "2016-12",
    "completion_date": "2016-12",
    "results_first_posted": "2017-11-01",
    "last_update_posted": "2025-11-03",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT05089084",
    "title": "Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Familial Chylomicronemia"
    ],
    "interventions": [
      "Plozasiran",
      "Placebo"
    ],
    "primary_completion_date": "2024-04-29",
    "completion_date": "2026-04",
    "results_first_posted": null,
    "last_update_posted": "2025-04-30",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT01872065",
    "title": "Safety and Tolerability Study of ARC-520 in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "ARC-520",
      "Placebo"
    ],
    "primary_completion_date": "2014-09",
    "completion_date": "2014-11",
    "results_first_posted": null,
    "last_update_posted": "2025-12-26",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT03783377",
    "title": "Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypertriglyceridemia",
      "Familial Chylomicronemia"
    ],
    "interventions": [
      "ARO-APOC3",
      "sterile normal saline (0.9% NaCl)"
    ],
    "primary_completion_date": "2021-02-11",
    "completion_date": "2021-02-11",
    "results_first_posted": null,
    "last_update_posted": "2025-12-24",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT06672445",
    "title": "Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Spinocerebellar Ataxia Type 2"
    ],
    "interventions": [
      "ARO-ATXN2 Injection",
      "Placebo"
    ],
    "primary_completion_date": "2026-12",
    "completion_date": "2026-12",
    "results_first_posted": null,
    "last_update_posted": "2025-12-19",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT02797522",
    "title": "A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatitis B"
    ],
    "interventions": [
      "ARC-521 Injection",
      "Placebo",
      "antihistamine",
      "acetaminophen",
      "entecavir",
      "tenofovir"
    ],
    "primary_completion_date": "2016-11",
    "completion_date": "2016-11",
    "results_first_posted": "2018-09-25",
    "last_update_posted": "2026-01-12",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT02604212",
    "title": "A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatitis B"
    ],
    "interventions": [
      "ARC-520",
      "Placebo",
      "entecavir",
      "antihistamine",
      "tenofovir"
    ],
    "primary_completion_date": "2016-12",
    "completion_date": "2016-12",
    "results_first_posted": "2019-04-16",
    "last_update_posted": "2026-01-13",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT06138743",
    "title": "Study of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Myotonic Dystrophy 1"
    ],
    "interventions": [
      "ARO-DM1 Intravenous (IV) Infusion",
      "Placebo Intravenous (IV) Infusion",
      "ARO-DM1 subcutaneous (SC) injection",
      "Placebo Subcutaneous (SC) Injection"
    ],
    "primary_completion_date": "2026-12",
    "completion_date": "2026-12",
    "results_first_posted": null,
    "last_update_posted": "2025-11-10",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT05533294",
    "title": "Study of ARO-RAGE in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Asthma"
    ],
    "interventions": [
      "ARO-RAGE Injection",
      "Placebo"
    ],
    "primary_completion_date": "2024-02-08",
    "completion_date": "2024-02-08",
    "results_first_posted": null,
    "last_update_posted": "2024-03-29",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT05949294",
    "title": "Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS)",
    "status": "WITHDRAWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Amyotrophic Lateral Sclerosis"
    ],
    "interventions": [
      "ARO-SOD1 Injection"
    ],
    "primary_completion_date": "2025-03",
    "completion_date": "2025-03",
    "results_first_posted": null,
    "last_update_posted": "2024-04-17",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT07241546",
    "title": "Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Asthma"
    ],
    "interventions": [
      "ARO-RAGE",
      "Placebo"
    ],
    "primary_completion_date": "2027-12",
    "completion_date": "2028-04",
    "results_first_posted": null,
    "last_update_posted": "2025-11-21",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT03747224",
    "title": "Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dyslipidemias",
      "Familial Hypercholesterolemia",
      "Hypertriglyceridemia"
    ],
    "interventions": [
      "ARO-ANG3",
      "sterile normal saline (0.9% NaCl)"
    ],
    "primary_completion_date": "2021-05-17",
    "completion_date": "2021-05-17",
    "results_first_posted": null,
    "last_update_posted": "2025-12-24",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT05276570",
    "title": "Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Asthma"
    ],
    "interventions": [
      "ARO-RAGE",
      "Placebo"
    ],
    "primary_completion_date": "2025-04-16",
    "completion_date": "2025-04-16",
    "results_first_posted": null,
    "last_update_posted": "2025-09-24",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT02738008",
    "title": "Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatitis B"
    ],
    "interventions": [
      "ARC-520 Injection",
      "entecavir",
      "tenofovir",
      "antihistamine"
    ],
    "primary_completion_date": "2016-12",
    "completion_date": "2016-12",
    "results_first_posted": "2019-04-16",
    "last_update_posted": "2026-01-13",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT05217667",
    "title": "Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Homozygous Familial Hypercholesterolemia"
    ],
    "interventions": [
      "ARO-ANG 3 Injection"
    ],
    "primary_completion_date": "2023-05-02",
    "completion_date": "2025-11",
    "results_first_posted": null,
    "last_update_posted": "2025-10-10",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT06347133",
    "title": "Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypertriglyceridemia"
    ],
    "interventions": [
      "Plozasiran Injection",
      "Placebo"
    ],
    "primary_completion_date": "2026-05",
    "completion_date": "2026-09",
    "results_first_posted": null,
    "last_update_posted": "2025-10-08",
    "enrollment": null,
    "sponsor": "Arrowhead Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ARWR",
    "nct_id": "NCT07056062",
    "title": "Oral Calcium Supplementation in Labor",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Uterine Contraction",
      "Labor Complication",
      "Labor Active Dilated Cm",
      "Labor Dystocia",
      "Labor Duration",
      "Labor",
      "Labor Delivery"
    ],
    "interventions": [
      "Calcium carbonate"
    ],
    "primary_completion_date": "2025-05-30",
    "completion_date": "2025-05-30",
    "results_first_posted": null,
    "last_update_posted": "2025-07-09",
    "enrollment": null,
    "sponsor": "Arrowhead Regional Medical Center",
    "collected_at": "2026-01-27",
    "search_term": "Arrowhead Pharmaceuticals"
  },
  {
    "ticker": "ATXS",
    "nct_id": "NCT05695248",
    "title": "A Study of STAR-0215 in Participants With Hereditary Angioedema",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hereditary Angioedema"
    ],
    "interventions": [
      "STAR-0215"
    ],
    "primary_completion_date": "2025-03-13",
    "completion_date": "2025-03-13",
    "results_first_posted": null,
    "last_update_posted": "2025-04-11",
    "enrollment": null,
    "sponsor": "Astria Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Astria Therapeutics"
  },
  {
    "ticker": "ATXS",
    "nct_id": "NCT05477160",
    "title": "A Study of STAR-0215 in Healthy Adult Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hereditary Angioedema"
    ],
    "interventions": [
      "STAR-0215 (SC)",
      "Placebo (SC)",
      "STAR-0215 (IV)",
      "Placebo (IV)"
    ],
    "primary_completion_date": "2023-11-17",
    "completion_date": "2023-11-17",
    "results_first_posted": null,
    "last_update_posted": "2024-01-11",
    "enrollment": null,
    "sponsor": "Astria Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Astria Therapeutics"
  },
  {
    "ticker": "ATXS",
    "nct_id": "NCT06842823",
    "title": "A Study of Navenibart in Participants With Hereditary Angioedema",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hereditary Angioedema (HAE)"
    ],
    "interventions": [
      "navenibart",
      "Placebo"
    ],
    "primary_completion_date": "2027-03",
    "completion_date": "2027-09",
    "results_first_posted": null,
    "last_update_posted": "2026-01-14",
    "enrollment": null,
    "sponsor": "Astria Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Astria Therapeutics"
  },
  {
    "ticker": "ATXS",
    "nct_id": "NCT06782477",
    "title": "A Study of STAR-0310 in Healthy Adult Participants",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants"
    ],
    "interventions": [
      "STAR-0310",
      "Placebo"
    ],
    "primary_completion_date": "2026-01",
    "completion_date": "2026-01",
    "results_first_posted": null,
    "last_update_posted": "2025-11-04",
    "enrollment": null,
    "sponsor": "Astria Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Astria Therapeutics"
  },
  {
    "ticker": "ATXS",
    "nct_id": "NCT06007677",
    "title": "A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hereditary Angioedema"
    ],
    "interventions": [
      "STAR-0215"
    ],
    "primary_completion_date": "2031-03",
    "completion_date": "2031-03",
    "results_first_posted": null,
    "last_update_posted": "2025-07-23",
    "enrollment": null,
    "sponsor": "Astria Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Astria Therapeutics"
  },
  {
    "ticker": "ATXS",
    "nct_id": "NCT07204938",
    "title": "A Long-Term Study of Navenibart in Participants With Hereditary Angioedema",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hereditary Angioedema (HAE)"
    ],
    "interventions": [
      "navenibart"
    ],
    "primary_completion_date": "2031-06",
    "completion_date": "2031-12",
    "results_first_posted": null,
    "last_update_posted": "2025-11-05",
    "enrollment": null,
    "sponsor": "Astria Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Astria Therapeutics"
  },
  {
    "ticker": "AUPH",
    "nct_id": "NCT01586845",
    "title": "Safety and Efficacy Study of Voclosporin and Tacrolimus in Transplantation",
    "status": "WITHDRAWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Renal Transplantation"
    ],
    "interventions": [
      "voclosporin",
      "tacrolimus"
    ],
    "primary_completion_date": "2015-12",
    "completion_date": "2015-12",
    "results_first_posted": null,
    "last_update_posted": "2014-01-20",
    "enrollment": null,
    "sponsor": "Aurinia Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Aurinia Pharmaceuticals"
  },
  {
    "ticker": "AUPH",
    "nct_id": "NCT05288855",
    "title": "Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Adolescent Lupus Nephritis",
      "Pediatric Lupus Nephritis"
    ],
    "interventions": [
      "Voclosporin",
      "Placebo Oral Capsule"
    ],
    "primary_completion_date": "2027-12",
    "completion_date": "2028-06",
    "results_first_posted": null,
    "last_update_posted": "2025-06-18",
    "enrollment": null,
    "sponsor": "Aurinia Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Aurinia Pharmaceuticals"
  },
  {
    "ticker": "AUPH",
    "nct_id": "NCT05337124",
    "title": "A Prospective Observational Registry of Patients Treated With LUPKYNIS\u00ae (Voclosporin) in the US",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Lupus Nephritis"
    ],
    "interventions": [
      "LUPKYNIS"
    ],
    "primary_completion_date": "2025-01-31",
    "completion_date": "2025-01-31",
    "results_first_posted": null,
    "last_update_posted": "2025-06-24",
    "enrollment": null,
    "sponsor": "Aurinia Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Aurinia Pharmaceuticals"
  },
  {
    "ticker": "AUPH",
    "nct_id": "NCT05306379",
    "title": "Drug-Drug Interaction Study to Investigate Effects of Voclosporin on Pharmacokinetics of Simvastatin",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Drug-drug Interaction"
    ],
    "interventions": [
      "Simvastatin",
      "Voclosporin"
    ],
    "primary_completion_date": "2022-04-05",
    "completion_date": "2022-04-05",
    "results_first_posted": null,
    "last_update_posted": "2022-04-20",
    "enrollment": null,
    "sponsor": "Aurinia Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Aurinia Pharmaceuticals"
  },
  {
    "ticker": "AUPH",
    "nct_id": "NCT03597139",
    "title": "Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis\u00ae in Subjects With Dry Eye Disease",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dry Eye"
    ],
    "interventions": [
      "Voclosporin Ophthalmic Solution",
      "Restasis\u00ae"
    ],
    "primary_completion_date": "2018-11-09",
    "completion_date": "2018-12-13",
    "results_first_posted": "2021-07-08",
    "last_update_posted": "2021-07-08",
    "enrollment": null,
    "sponsor": "Aurinia Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Aurinia Pharmaceuticals"
  },
  {
    "ticker": "AUPH",
    "nct_id": "NCT05962788",
    "title": "Long-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus Nephritis",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Adolescent Lupus Nephritis",
      "Pediatric Lupus Nephritis"
    ],
    "interventions": [
      "voclosporin"
    ],
    "primary_completion_date": "2028-12",
    "completion_date": "2029-06",
    "results_first_posted": null,
    "last_update_posted": "2025-06-18",
    "enrollment": null,
    "sponsor": "Aurinia Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Aurinia Pharmaceuticals"
  },
  {
    "ticker": "AUPH",
    "nct_id": "NCT00258713",
    "title": "A 36-Week Extension to Protocol ISA04-03",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Psoriasis"
    ],
    "interventions": [
      "voclosporin"
    ],
    "primary_completion_date": "2006-07",
    "completion_date": "2006-07",
    "results_first_posted": null,
    "last_update_posted": "2008-09-29",
    "enrollment": null,
    "sponsor": "Aurinia Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Aurinia Pharmaceuticals"
  },
  {
    "ticker": "AUPH",
    "nct_id": "NCT04147650",
    "title": "Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dry Eye Syndrome",
      "Keratoconjunctivitis Sicca"
    ],
    "interventions": [
      "0.05% Voclosporin Ophthalmic Solution (VOS)",
      "0.10% VOS",
      "0.20% VOS",
      "Vehicle Ophthalmic Solution"
    ],
    "primary_completion_date": "2020-09-17",
    "completion_date": "2020-10-08",
    "results_first_posted": "2021-12-10",
    "last_update_posted": "2021-12-10",
    "enrollment": null,
    "sponsor": "Aurinia Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Aurinia Pharmaceuticals"
  },
  {
    "ticker": "AUPH",
    "nct_id": "NCT00270634",
    "title": "Study of ISA247 (Voclosporin) in De Novo Renal Transplantation",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Kidney Diseases"
    ],
    "interventions": [
      "Voclosporin",
      "tacrolimus"
    ],
    "primary_completion_date": "2009-07",
    "completion_date": "2009-07",
    "results_first_posted": "2013-02-12",
    "last_update_posted": "2013-02-12",
    "enrollment": null,
    "sponsor": "Aurinia Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Aurinia Pharmaceuticals"
  },
  {
    "ticker": "AUPH",
    "nct_id": "NCT02949999",
    "title": "Voclosporin in Healthy Japanese Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Volunteers"
    ],
    "interventions": [
      "Voclosporin"
    ],
    "primary_completion_date": "2016-12",
    "completion_date": "2016-12",
    "results_first_posted": null,
    "last_update_posted": "2018-01-17",
    "enrollment": null,
    "sponsor": "Aurinia Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Aurinia Pharmaceuticals"
  },
  {
    "ticker": "AUPH",
    "nct_id": "NCT02949973",
    "title": "Aurinia Early Urinary Protein Reduction Predicts Response",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lupus Nephritis"
    ],
    "interventions": [
      "voclosporin"
    ],
    "primary_completion_date": "2016-12",
    "completion_date": "2017-02-17",
    "results_first_posted": "2021-03-19",
    "last_update_posted": "2021-03-19",
    "enrollment": null,
    "sponsor": "Aurinia Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Aurinia Pharmaceuticals"
  },
  {
    "ticker": "AUPH",
    "nct_id": "NCT00244842",
    "title": "Randomized Placebo-controlled Study of ISA247 in Plaque Psoriasis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Psoriasis"
    ],
    "interventions": [
      "voclosporin",
      "Placebo"
    ],
    "primary_completion_date": "2005-10",
    "completion_date": "2005-10",
    "results_first_posted": "2023-03-27",
    "last_update_posted": "2023-03-27",
    "enrollment": null,
    "sponsor": "Aurinia Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Aurinia Pharmaceuticals"
  },
  {
    "ticker": "AUPH",
    "nct_id": "NCT03597464",
    "title": "Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lupus Nephritis"
    ],
    "interventions": [
      "Voclosporin",
      "Placebo Oral Capsule"
    ],
    "primary_completion_date": "2021-10-07",
    "completion_date": "2021-10-07",
    "results_first_posted": "2022-12-14",
    "last_update_posted": "2022-12-14",
    "enrollment": null,
    "sponsor": "Aurinia Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Aurinia Pharmaceuticals"
  },
  {
    "ticker": "AUPH",
    "nct_id": "NCT00408187",
    "title": "Randomized, Placebo and Ciclosporin Controlled Study of ISA247 in Plaque Psoriasis Patients",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Psoriasis"
    ],
    "interventions": [
      "voclosporin",
      "Ciclosporin",
      "Placebo"
    ],
    "primary_completion_date": "2008-12",
    "completion_date": "2008-12",
    "results_first_posted": null,
    "last_update_posted": "2009-07-30",
    "enrollment": null,
    "sponsor": "Aurinia Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Aurinia Pharmaceuticals"
  },
  {
    "ticker": "AUTL",
    "nct_id": "NCT06799221",
    "title": "Expanded Access Program for OOS Obe-cel",
    "status": "AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Lymphoblastic Leukemia, Acute, Adult",
      "B Cell ALL"
    ],
    "interventions": [
      "Out-of-specification obecabtagene autoleucel"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2025-01-29",
    "enrollment": null,
    "sponsor": "Autolus Limited",
    "collected_at": "2026-01-27",
    "search_term": "Autolus Therapeutics"
  },
  {
    "ticker": "AUTL",
    "nct_id": "NCT07139743",
    "title": "Obe-cel in Refractory Progressive Forms of Multiple Sclerosis",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Progressive Multiple Sclerosis"
    ],
    "interventions": [
      "Obecabtagene autoleucel (obe-cel)"
    ],
    "primary_completion_date": "2029-08-15",
    "completion_date": "2029-08-15",
    "results_first_posted": null,
    "last_update_posted": "2025-09-04",
    "enrollment": null,
    "sponsor": "Autolus Limited",
    "collected_at": "2026-01-27",
    "search_term": "Autolus Therapeutics"
  },
  {
    "ticker": "AUTL",
    "nct_id": "NCT03590574",
    "title": "Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "T Cell Non-Hodgkin Lymphoma",
      "Peripheral T-Cell Lymphoma, Not Otherwise Specified",
      "Angioimmunoblastic T-cell Lymphoma",
      "Anaplastic Large Cell Lymphoma"
    ],
    "interventions": [
      "AUTO4"
    ],
    "primary_completion_date": "2024-12-12",
    "completion_date": "2024-12-12",
    "results_first_posted": null,
    "last_update_posted": "2025-05-14",
    "enrollment": null,
    "sponsor": "Autolus Limited",
    "collected_at": "2026-01-27",
    "search_term": "Autolus Therapeutics"
  },
  {
    "ticker": "AUTL",
    "nct_id": "NCT03287804",
    "title": "APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple Myeloma"
    ],
    "interventions": [
      "AUTO2"
    ],
    "primary_completion_date": "2019-09-05",
    "completion_date": "2019-09-05",
    "results_first_posted": "2020-10-23",
    "last_update_posted": "2020-10-23",
    "enrollment": null,
    "sponsor": "Autolus Limited",
    "collected_at": "2026-01-27",
    "search_term": "Autolus Therapeutics"
  },
  {
    "ticker": "AUTL",
    "nct_id": "NCT04404660",
    "title": "A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia"
    ],
    "interventions": [
      "AUTO1"
    ],
    "primary_completion_date": "2029-06-30",
    "completion_date": "2029-06-30",
    "results_first_posted": null,
    "last_update_posted": "2025-09-09",
    "enrollment": null,
    "sponsor": "Autolus Limited",
    "collected_at": "2026-01-27",
    "search_term": "Autolus Therapeutics"
  },
  {
    "ticker": "AUTL",
    "nct_id": "NCT06173518",
    "title": "A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia",
      "Relapsed or Refractory B Cell Non-Hodgkin Lymphoma"
    ],
    "interventions": [
      "AUTO1"
    ],
    "primary_completion_date": "2027-11",
    "completion_date": "2027-11",
    "results_first_posted": null,
    "last_update_posted": "2025-04-27",
    "enrollment": null,
    "sponsor": "Autolus Limited",
    "collected_at": "2026-01-27",
    "search_term": "Autolus Therapeutics"
  },
  {
    "ticker": "AUTL",
    "nct_id": "NCT07053800",
    "title": "Obe-cel in Severe, Refractory Systemic Lupus Erythematosus With Active Lupus Nephritis",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lupus Nephritis"
    ],
    "interventions": [
      "Obecabtagene autoleucel"
    ],
    "primary_completion_date": "2029-02",
    "completion_date": "2030-02",
    "results_first_posted": null,
    "last_update_posted": "2025-08-08",
    "enrollment": null,
    "sponsor": "Autolus Limited",
    "collected_at": "2026-01-27",
    "search_term": "Autolus Therapeutics"
  },
  {
    "ticker": "AUTL",
    "nct_id": "NCT03287817",
    "title": "Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)"
    ],
    "interventions": [
      "AUTO3"
    ],
    "primary_completion_date": "2023-10-19",
    "completion_date": "2023-10-19",
    "results_first_posted": "2025-07-14",
    "last_update_posted": "2025-07-14",
    "enrollment": null,
    "sponsor": "Autolus Limited",
    "collected_at": "2026-01-27",
    "search_term": "Autolus Therapeutics"
  },
  {
    "ticker": "AUTL",
    "nct_id": "NCT03628612",
    "title": "Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy",
      "Multiple Myeloma",
      "DLBCL",
      "ALL, Adult and Pediatric",
      "T Cell Lymphoma"
    ],
    "interventions": [
      "AUTO CAR T cell therapy"
    ],
    "primary_completion_date": "2043-07",
    "completion_date": "2043-12",
    "results_first_posted": null,
    "last_update_posted": "2025-08-07",
    "enrollment": null,
    "sponsor": "Autolus Limited",
    "collected_at": "2026-01-27",
    "search_term": "Autolus Therapeutics"
  },
  {
    "ticker": "AUTL",
    "nct_id": "NCT03289455",
    "title": "CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "B Acute Lymphoblastic Leukemia",
      "Recurrent Childhood Acute Lymphoblastic Leukemia",
      "Refractory Childhood Acute Lymphoblastic Leukemia",
      "B-cell Acute Lymphoblastic Leukemia"
    ],
    "interventions": [
      "AUTO3 (CD19/22 CAR T cells"
    ],
    "primary_completion_date": "2020-05-18",
    "completion_date": "2020-05-18",
    "results_first_posted": "2021-02-01",
    "last_update_posted": "2021-02-01",
    "enrollment": null,
    "sponsor": "Autolus Limited",
    "collected_at": "2026-01-27",
    "search_term": "Autolus Therapeutics"
  },
  {
    "ticker": "AVXL",
    "nct_id": "NCT02244541",
    "title": "Phase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of ANAVEX2-73 in Patients With Alzheimer's Disease",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alzheimer's Disease"
    ],
    "interventions": [
      "ANAVEX2-73 Oral",
      "ANAVEX2-73 Intravenous",
      "ANAVEX2-73 Oral",
      "ANAVEX2-73 Oral"
    ],
    "primary_completion_date": "2015-11",
    "completion_date": "2016-11",
    "results_first_posted": null,
    "last_update_posted": "2018-11-28",
    "enrollment": null,
    "sponsor": "Anavex Life Sciences Corp.",
    "collected_at": "2026-01-27",
    "search_term": "Anavex Life Sciences"
  },
  {
    "ticker": "AVXL",
    "nct_id": "NCT02756858",
    "title": "An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alzheimer's Disease"
    ],
    "interventions": [
      "ANAVEX2-73"
    ],
    "primary_completion_date": "2020-11",
    "completion_date": "2020-11",
    "results_first_posted": null,
    "last_update_posted": "2021-01-12",
    "enrollment": null,
    "sponsor": "Anavex Life Sciences Corp.",
    "collected_at": "2026-01-27",
    "search_term": "Anavex Life Sciences"
  },
  {
    "ticker": "AVXL",
    "nct_id": "NCT03774459",
    "title": "ANAVEX2-73 Study in Parkinson's Disease Dementia",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Parkinsons Disease With Dementia"
    ],
    "interventions": [
      "High dose ANAVEX2-73",
      "Mid dose ANAVEX2-73",
      "Placebo oral capsule"
    ],
    "primary_completion_date": "2020-09-30",
    "completion_date": "2020-09-30",
    "results_first_posted": null,
    "last_update_posted": "2020-10-22",
    "enrollment": null,
    "sponsor": "Anavex Life Sciences Corp.",
    "collected_at": "2026-01-27",
    "search_term": "Anavex Life Sciences"
  },
  {
    "ticker": "AVXL",
    "nct_id": "NCT04314934",
    "title": "OLE of Phase 2b/3 Study ANAVEX2-73-AD-004",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alzheimer Disease"
    ],
    "interventions": [
      "ANAVEX2-73"
    ],
    "primary_completion_date": "2024-06-14",
    "completion_date": "2024-06-14",
    "results_first_posted": null,
    "last_update_posted": "2024-08-12",
    "enrollment": null,
    "sponsor": "Anavex Life Sciences Corp.",
    "collected_at": "2026-01-27",
    "search_term": "Anavex Life Sciences"
  },
  {
    "ticker": "AVXL",
    "nct_id": "NCT06245213",
    "title": "A Study of ANAVEX3-71 in Adults With Schizophrenia",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia"
    ],
    "interventions": [
      "ANAVEX3-71 oral capsules",
      "Placebo oral capsules"
    ],
    "primary_completion_date": "2025-06-30",
    "completion_date": "2025-06-30",
    "results_first_posted": null,
    "last_update_posted": "2025-05-04",
    "enrollment": null,
    "sponsor": "Anavex Life Sciences Corp.",
    "collected_at": "2026-01-27",
    "search_term": "Anavex Life Sciences"
  },
  {
    "ticker": "AVXL",
    "nct_id": "NCT04304482",
    "title": "ANAVEX2-73 Study in Pediatric Patients With Rett Syndrome",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rett Syndrome"
    ],
    "interventions": [
      "ANAVEX2-73 oral liquid",
      "Placebo oral liquid"
    ],
    "primary_completion_date": "2023-06-01",
    "completion_date": "2023-06-30",
    "results_first_posted": null,
    "last_update_posted": "2023-08-21",
    "enrollment": null,
    "sponsor": "Anavex Life Sciences Corp.",
    "collected_at": "2026-01-27",
    "search_term": "Anavex Life Sciences"
  },
  {
    "ticker": "AVXL",
    "nct_id": "NCT04442945",
    "title": "Phase 1 Study of ANAVEX3-71",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "ANAVEX3-71",
      "Placebo"
    ],
    "primary_completion_date": "2021-09-30",
    "completion_date": "2021-10-30",
    "results_first_posted": null,
    "last_update_posted": "2022-01-19",
    "enrollment": null,
    "sponsor": "Anavex Life Sciences Corp.",
    "collected_at": "2026-01-27",
    "search_term": "Anavex Life Sciences"
  },
  {
    "ticker": "AVXL",
    "nct_id": "NCT03758924",
    "title": "Study of ANAVEX2-73 in Patients With Rett Syndrome",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rett Syndrome"
    ],
    "interventions": [
      "ANAVEX2-73",
      "Placebo"
    ],
    "primary_completion_date": "2020-10-30",
    "completion_date": "2020-10-30",
    "results_first_posted": null,
    "last_update_posted": "2021-01-12",
    "enrollment": null,
    "sponsor": "Anavex Life Sciences Corp.",
    "collected_at": "2026-01-27",
    "search_term": "Anavex Life Sciences"
  },
  {
    "ticker": "AVXL",
    "nct_id": "NCT04575259",
    "title": "OLE Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Parkinson Disease Dementia"
    ],
    "interventions": [
      "ANAVEX2-73"
    ],
    "primary_completion_date": "2022-05-31",
    "completion_date": "2022-06-30",
    "results_first_posted": null,
    "last_update_posted": "2022-08-01",
    "enrollment": null,
    "sponsor": "Anavex Life Sciences Corp.",
    "collected_at": "2026-01-27",
    "search_term": "Anavex Life Sciences"
  },
  {
    "ticker": "AVXL",
    "nct_id": "NCT03941444",
    "title": "ANAVEX2-73 Study in Patients With Rett Syndrome",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rett Syndrome"
    ],
    "interventions": [
      "ANAVEX2-73",
      "Placebo"
    ],
    "primary_completion_date": "2021-09-30",
    "completion_date": "2021-09-30",
    "results_first_posted": null,
    "last_update_posted": "2022-01-27",
    "enrollment": null,
    "sponsor": "Anavex Life Sciences Corp.",
    "collected_at": "2026-01-27",
    "search_term": "Anavex Life Sciences"
  },
  {
    "ticker": "AVXL",
    "nct_id": "NCT03790709",
    "title": "ANAVEX2-73 for Treatment of Early Alzheimer's Disease",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alzheimer Disease"
    ],
    "interventions": [
      "High dose ANAVEX2-73",
      "Mid dose ANAVEX2-73",
      "Placebo oral capsule"
    ],
    "primary_completion_date": "2022-06-30",
    "completion_date": "2022-06-30",
    "results_first_posted": null,
    "last_update_posted": "2022-07-14",
    "enrollment": null,
    "sponsor": "Anavex Life Sciences Corp.",
    "collected_at": "2026-01-27",
    "search_term": "Anavex Life Sciences"
  },
  {
    "ticker": "AXSM",
    "nct_id": "NCT04634669",
    "title": "Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Treatment Resistant Depression",
      "Major Depressive Disorder"
    ],
    "interventions": [
      "AXS-05 (dextromethorphan-bupropion)"
    ],
    "primary_completion_date": "2022-03-04",
    "completion_date": "2022-03-04",
    "results_first_posted": null,
    "last_update_posted": "2023-03-07",
    "enrollment": null,
    "sponsor": "Axsome Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Axsome Therapeutics"
  },
  {
    "ticker": "AXSM",
    "nct_id": "NCT06568367",
    "title": "Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Excessive Sleepiness",
      "Shift-work Disorder"
    ],
    "interventions": [
      "Solriamfetol 150 mg",
      "Solriamfetol 300 mg",
      "Placebo"
    ],
    "primary_completion_date": "2026-12",
    "completion_date": "2026-12",
    "results_first_posted": null,
    "last_update_posted": "2025-11-25",
    "enrollment": null,
    "sponsor": "Axsome Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Axsome Therapeutics"
  },
  {
    "ticker": "AXSM",
    "nct_id": "NCT04789174",
    "title": "Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Excessive Daytime Sleepiness",
      "Obstructive Sleep Apnea",
      "Impaired Cognitive Function"
    ],
    "interventions": [
      "Solriamfetol",
      "Placebo"
    ],
    "primary_completion_date": "2022-09-19",
    "completion_date": "2022-09-19",
    "results_first_posted": "2026-01-26",
    "last_update_posted": "2026-01-26",
    "enrollment": null,
    "sponsor": "Axsome Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Axsome Therapeutics"
  },
  {
    "ticker": "AXSM",
    "nct_id": "NCT05550207",
    "title": "Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Migraine"
    ],
    "interventions": [
      "AXS-07 (meloxicam-rizatriptan)"
    ],
    "primary_completion_date": "2024-11-27",
    "completion_date": "2024-11-27",
    "results_first_posted": null,
    "last_update_posted": "2025-12-02",
    "enrollment": null,
    "sponsor": "Axsome Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Axsome Therapeutics"
  },
  {
    "ticker": "AXSM",
    "nct_id": "NCT06736509",
    "title": "An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Agitation in Patients With Dementia of the Alzheimer's Type",
      "Alzheimer Disease",
      "Agitation, Psychomotor"
    ],
    "interventions": [
      "AXS-05 (dextromethorphan-bupropion)"
    ],
    "primary_completion_date": "2025-02-17",
    "completion_date": "2025-04-25",
    "results_first_posted": null,
    "last_update_posted": "2025-05-22",
    "enrollment": null,
    "sponsor": "Axsome Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Axsome Therapeutics"
  },
  {
    "ticker": "AXSM",
    "nct_id": "NCT06413420",
    "title": "SUNOSI\u00ae (Solriamfetol) Pregnancy Registry",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Narcolepsy",
      "Obstructive Sleep Apnea",
      "Pregnant Women and Their Offspring"
    ],
    "interventions": [
      "Sunosi (solriamfetol)",
      "Other prescription wake-promoting medications or stimulants",
      "No treatment"
    ],
    "primary_completion_date": "2029-09",
    "completion_date": "2029-09",
    "results_first_posted": null,
    "last_update_posted": "2024-05-14",
    "enrollment": null,
    "sponsor": "Axsome Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Axsome Therapeutics"
  },
  {
    "ticker": "AXSM",
    "nct_id": "NCT04947553",
    "title": "A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Agitation in Patients With Dementia of the Alzheimer's Type",
      "Alzheimer Disease",
      "Agitation, Psychomotor"
    ],
    "interventions": [
      "AXS-05 (dextromethorphan-bupropion)",
      "Placebo"
    ],
    "primary_completion_date": "2024-12-03",
    "completion_date": "2024-12-21",
    "results_first_posted": null,
    "last_update_posted": "2025-12-08",
    "enrollment": null,
    "sponsor": "Axsome Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Axsome Therapeutics"
  },
  {
    "ticker": "AXSM",
    "nct_id": "NCT03226522",
    "title": "Addressing Dementia Via Agitation-Centered Evaluation",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Agitation in Patients With Dementia of the Alzheimer's Type",
      "Alzheimer Disease",
      "Agitation,Psychomotor"
    ],
    "interventions": [
      "AXS-05",
      "Bupropion",
      "Placebo"
    ],
    "primary_completion_date": "2020-04-17",
    "completion_date": "2020-04-17",
    "results_first_posted": "2023-09-13",
    "last_update_posted": "2023-09-13",
    "enrollment": null,
    "sponsor": "Axsome Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Axsome Therapeutics"
  },
  {
    "ticker": "AXSM",
    "nct_id": "NCT05972044",
    "title": "A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "ADHD"
    ],
    "interventions": [
      "Solriamfetol 150 mg",
      "Solriamfetol 300 mg",
      "Placebo"
    ],
    "primary_completion_date": "2025-02-07",
    "completion_date": "2025-03-14",
    "results_first_posted": null,
    "last_update_posted": "2025-04-03",
    "enrollment": null,
    "sponsor": "Axsome Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Axsome Therapeutics"
  },
  {
    "ticker": "AXSM",
    "nct_id": "NCT02504008",
    "title": "CREATE-1: A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-1",
    "status": "UNKNOWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Complex Regional Pain Syndrome",
      "Reflex Sympathetic Dystrophy"
    ],
    "interventions": [
      "AXS-02 (oral zoledronate)",
      "Placebo"
    ],
    "primary_completion_date": "2019-01",
    "completion_date": "2019-01",
    "results_first_posted": null,
    "last_update_posted": "2018-03-23",
    "enrollment": null,
    "sponsor": "Axsome Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Axsome Therapeutics"
  },
  {
    "ticker": "AXSM",
    "nct_id": "NCT04068051",
    "title": "Multimechanistic Treatment Over Time of Migraine Symptoms (MOVEMENT)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Migraine"
    ],
    "interventions": [
      "AXS-07"
    ],
    "primary_completion_date": "2020-09-22",
    "completion_date": "2020-09-22",
    "results_first_posted": "2023-10-10",
    "last_update_posted": "2023-10-10",
    "enrollment": null,
    "sponsor": "Axsome Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Axsome Therapeutics"
  },
  {
    "ticker": "AXSM",
    "nct_id": "NCT05113745",
    "title": "A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Narcolepsy",
      "Cataplexy",
      "Excessive Daytime Sleepiness"
    ],
    "interventions": [
      "AXS-12 (reboxetine)",
      "Placebo"
    ],
    "primary_completion_date": "2024-11-15",
    "completion_date": "2024-11-15",
    "results_first_posted": null,
    "last_update_posted": "2025-11-13",
    "enrollment": null,
    "sponsor": "Axsome Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Axsome Therapeutics"
  },
  {
    "ticker": "AXSM",
    "nct_id": "NCT04019704",
    "title": "A Trial of AXS-05 in Patients With Major Depressive Disorder",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Depression",
      "Major Depressive Disorder"
    ],
    "interventions": [
      "AXS-05",
      "Placebo"
    ],
    "primary_completion_date": "2019-11-26",
    "completion_date": "2019-12-05",
    "results_first_posted": "2022-10-12",
    "last_update_posted": "2022-10-12",
    "enrollment": null,
    "sponsor": "Axsome Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Axsome Therapeutics"
  },
  {
    "ticker": "AXSM",
    "nct_id": "NCT05008341",
    "title": "Evaluate Sunosi\u00ae PK in Breast Milk and Plasma of Healthy Postpartum Women Following Single Dose Oral Administration",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Narcolepsy",
      "Obstructive Sleep Apnea",
      "Excessive Daytime Somnolence",
      "Excessive Sleepiness",
      "Postpartum"
    ],
    "interventions": [
      "Solriamfetol 150 mg Oral Tablet"
    ],
    "primary_completion_date": "2022-04-15",
    "completion_date": "2022-04-15",
    "results_first_posted": null,
    "last_update_posted": "2023-04-14",
    "enrollment": null,
    "sponsor": "Axsome Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Axsome Therapeutics"
  },
  {
    "ticker": "AXSM",
    "nct_id": "NCT06413433",
    "title": "Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Binge-Eating Disorder"
    ],
    "interventions": [
      "Solriamfetol 150 mg",
      "Solriamfetol 300 mg",
      "Placebo"
    ],
    "primary_completion_date": "2025-12",
    "completion_date": "2025-12",
    "results_first_posted": null,
    "last_update_posted": "2025-11-21",
    "enrollment": null,
    "sponsor": "Axsome Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Axsome Therapeutics"
  },
  {
    "ticker": "AXSM",
    "nct_id": "NCT06223880",
    "title": "A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms",
    "status": "RECRUITING",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder"
    ],
    "interventions": [
      "AXS-05",
      "Bupropion"
    ],
    "primary_completion_date": "2026-03",
    "completion_date": "2026-03",
    "results_first_posted": null,
    "last_update_posted": "2025-01-23",
    "enrollment": null,
    "sponsor": "Axsome Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Axsome Therapeutics"
  },
  {
    "ticker": "AXSM",
    "nct_id": "NCT03881852",
    "title": "Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Narcolepsy",
      "Cataplexy Narcolepsy",
      "Excessive Sleepiness"
    ],
    "interventions": [
      "AXS-12 (Reboxetine)",
      "Placebo"
    ],
    "primary_completion_date": "2019-11-27",
    "completion_date": "2019-11-27",
    "results_first_posted": "2023-08-24",
    "last_update_posted": "2023-08-24",
    "enrollment": null,
    "sponsor": "Axsome Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Axsome Therapeutics"
  },
  {
    "ticker": "AXSM",
    "nct_id": "NCT04971291",
    "title": "An Evaluation of AXS-05 for the Treatment of TRD in Treatment-Adherent Patients",
    "status": "UNKNOWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder",
      "Treatment Resistant Depression"
    ],
    "interventions": [
      "AXS-05",
      "Bupropion SR"
    ],
    "primary_completion_date": "2021-07",
    "completion_date": "2021-07",
    "results_first_posted": null,
    "last_update_posted": "2021-07-26",
    "enrollment": null,
    "sponsor": "Axsome Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Axsome Therapeutics"
  },
  {
    "ticker": "AXSM",
    "nct_id": "NCT06878976",
    "title": "Open-Label Safety Study of Solriamfetol in Subjects With Binge Eating Disorder",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Binge-Eating Disorder"
    ],
    "interventions": [
      "Solriamfetol 75mg, 150 mg, or 300 mg"
    ],
    "primary_completion_date": "2026-12",
    "completion_date": "2026-12",
    "results_first_posted": null,
    "last_update_posted": "2025-11-25",
    "enrollment": null,
    "sponsor": "Axsome Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Axsome Therapeutics"
  },
  {
    "ticker": "AXSM",
    "nct_id": "NCT02741791",
    "title": "A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Treatment Resistant Major Depressive Disorder"
    ],
    "interventions": [
      "AXS-05",
      "Bupropion"
    ],
    "primary_completion_date": "2020-03-20",
    "completion_date": "2020-03-20",
    "results_first_posted": null,
    "last_update_posted": "2021-03-24",
    "enrollment": null,
    "sponsor": "Axsome Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Axsome Therapeutics"
  },
  {
    "ticker": "AXSM",
    "nct_id": "NCT02746068",
    "title": "A Study to Assess the Efficacy and Safety of AXS-02 in Subjects With Knee OA Associated With Bone Marrow Lesions",
    "status": "UNKNOWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Osteoarthritis, Knee"
    ],
    "interventions": [
      "AXS-02",
      "Placebo"
    ],
    "primary_completion_date": "2020-12",
    "completion_date": "2020-12",
    "results_first_posted": null,
    "last_update_posted": "2019-01-10",
    "enrollment": null,
    "sponsor": "Axsome Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Axsome Therapeutics"
  },
  {
    "ticker": "AXSM",
    "nct_id": "NCT05557409",
    "title": "A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Agitation in Patients With Dementia of the Alzheimer's Type",
      "Alzheimer Disease",
      "Agitation"
    ],
    "interventions": [
      "AXS-05",
      "Placebo"
    ],
    "primary_completion_date": "2024-11-21",
    "completion_date": "2024-12-21",
    "results_first_posted": null,
    "last_update_posted": "2025-11-26",
    "enrollment": null,
    "sponsor": "Axsome Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Axsome Therapeutics"
  },
  {
    "ticker": "AXSM",
    "nct_id": "NCT04797715",
    "title": "Assessing Clinical Outcomes in Alzheimer's Disease Agitation",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Agitation in Patients With Dementia of the Alzheimer's Type",
      "Alzheimer Disease",
      "Agitation,Psychomotor"
    ],
    "interventions": [
      "AXS-05",
      "Placebo"
    ],
    "primary_completion_date": "2022-11-21",
    "completion_date": "2022-11-21",
    "results_first_posted": null,
    "last_update_posted": "2023-11-29",
    "enrollment": null,
    "sponsor": "Axsome Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Axsome Therapeutics"
  },
  {
    "ticker": "AXSM",
    "nct_id": "NCT05059223",
    "title": "A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Narcolepsy",
      "Cataplexy",
      "Excessive Daytime Sleepiness"
    ],
    "interventions": [
      "AXS-12 (reboxetine)",
      "Placebo"
    ],
    "primary_completion_date": "2024-03-15",
    "completion_date": "2024-03-15",
    "results_first_posted": null,
    "last_update_posted": "2025-03-19",
    "enrollment": null,
    "sponsor": "Axsome Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Axsome Therapeutics"
  },
  {
    "ticker": "AXSM",
    "nct_id": "NCT06360419",
    "title": "Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder"
    ],
    "interventions": [
      "Solriamfetol 300 mg",
      "Placebo"
    ],
    "primary_completion_date": "2024-12-31",
    "completion_date": "2025-03-26",
    "results_first_posted": null,
    "last_update_posted": "2026-01-05",
    "enrollment": null,
    "sponsor": "Axsome Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Axsome Therapeutics"
  },
  {
    "ticker": "AXSM",
    "nct_id": "NCT03595579",
    "title": "Assessing Symptomatic Clinical Episodes in Depression",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder"
    ],
    "interventions": [
      "AXS-05",
      "Bupropion"
    ],
    "primary_completion_date": "2019-01-07",
    "completion_date": "2019-01-07",
    "results_first_posted": "2021-09-24",
    "last_update_posted": "2021-09-24",
    "enrollment": null,
    "sponsor": "Axsome Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Axsome Therapeutics"
  },
  {
    "ticker": "AXSM",
    "nct_id": "NCT04608396",
    "title": "Mechanistic Evaluation of Response in TRD (MERIT)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Treatment Resistant Depression",
      "Major Depressive Disorder"
    ],
    "interventions": [
      "AXS-05",
      "Placebo"
    ],
    "primary_completion_date": "2021-07-30",
    "completion_date": "2021-07-30",
    "results_first_posted": null,
    "last_update_posted": "2022-07-12",
    "enrollment": null,
    "sponsor": "Axsome Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Axsome Therapeutics"
  },
  {
    "ticker": "AXSM",
    "nct_id": "NCT04039022",
    "title": "Open-Label Safety Study of AXS-05 in Subjects With Depression",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder",
      "Treatment Resistant Depression",
      "Depression"
    ],
    "interventions": [
      "AXS-05 (dextromethorphan and bupropion) oral tablets"
    ],
    "primary_completion_date": "2020-10-23",
    "completion_date": "2020-10-23",
    "results_first_posted": "2022-10-12",
    "last_update_posted": "2022-10-12",
    "enrollment": null,
    "sponsor": "Axsome Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Axsome Therapeutics"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT02303626",
    "title": "12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hereditary Angioedema",
      "HAE"
    ],
    "interventions": [
      "BCX4161",
      "Placebo"
    ],
    "primary_completion_date": "2016-01",
    "completion_date": "2016-01",
    "results_first_posted": "2025-11-17",
    "last_update_posted": "2025-11-17",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT06100900",
    "title": "Dose Escalation of BCX10013 in Participants with Paroxysmal Nocturnal Hemoglobinuria (PNH)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Paroxysmal Nocturnal Hemoglobinuria"
    ],
    "interventions": [
      "BCX10013"
    ],
    "primary_completion_date": "2024-12-11",
    "completion_date": "2024-12-11",
    "results_first_posted": null,
    "last_update_posted": "2025-01-08",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT05453968",
    "title": "Berotralstat Treatment in Children With Hereditary Angioedema",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hereditary Angioedema",
      "Pediatric"
    ],
    "interventions": [
      "Berotralstat"
    ],
    "primary_completion_date": "2024-09-11",
    "completion_date": "2027-02",
    "results_first_posted": null,
    "last_update_posted": "2025-09-10",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT01407874",
    "title": "A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Gout",
      "Hyperuricemia",
      "Arthritis",
      "Joint Disease",
      "Renal Insufficiency"
    ],
    "interventions": [
      "Placebo",
      "Ulodesine (BCX4208) 5 mg",
      "Ulodesine (BCX4208) 10 mg"
    ],
    "primary_completion_date": "2012-07",
    "completion_date": "2012-07",
    "results_first_posted": null,
    "last_update_posted": "2013-11-20",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT02670720",
    "title": "Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary Angioedema",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hereditary Angioedema",
      "HAE"
    ],
    "interventions": [
      "avoralstat"
    ],
    "primary_completion_date": "2016-02",
    "completion_date": "2016-02",
    "results_first_posted": null,
    "last_update_posted": "2016-02-17",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT02870972",
    "title": "Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hereditary Angioedema (HAE)"
    ],
    "interventions": [
      "BCX7353",
      "Placebo"
    ],
    "primary_completion_date": "2017-08",
    "completion_date": "2017-08",
    "results_first_posted": "2021-03-04",
    "last_update_posted": "2021-03-23",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT00419263",
    "title": "Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza.",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Influenza"
    ],
    "interventions": [
      "Peramivir 150 mg",
      "Peramivir 300 mg",
      "Placebo"
    ],
    "primary_completion_date": "2007-09",
    "completion_date": "2007-09",
    "results_first_posted": "2015-02-12",
    "last_update_posted": "2015-02-12",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT01129648",
    "title": "Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/Gout",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Gout"
    ],
    "interventions": [
      "Placebo",
      "Allopurinol",
      "Allopurinol",
      "Allopurinol",
      "BCX4208",
      "Allopurinol",
      "Allopurinol",
      "Allopurinol",
      "BCX4208",
      "Allopurinol",
      "Allopurinol",
      "Allopurinol",
      "BCX4208",
      "Allopurinol",
      "Allopurinol",
      "Allopurinol",
      "BCX4208"
    ],
    "primary_completion_date": "2010-11",
    "completion_date": "2010-11",
    "results_first_posted": null,
    "last_update_posted": "2012-01-23",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT00035022",
    "title": "Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Leukemia, Lymphocytic",
      "Lymphoma"
    ],
    "interventions": [
      "BCX-1777"
    ],
    "primary_completion_date": null,
    "completion_date": "2004-03",
    "results_first_posted": null,
    "last_update_posted": "2006-01-13",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT00957996",
    "title": "Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Seasonal Influenza",
      "Cough",
      "Sore Throat",
      "Nasal Congestion",
      "Myalgia",
      "Headache",
      "Fatigue"
    ],
    "interventions": [
      "Peramivir",
      "Peramivir"
    ],
    "primary_completion_date": "2010-10",
    "completion_date": "2011-08",
    "results_first_posted": "2015-02-12",
    "last_update_posted": "2015-02-12",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT00419081",
    "title": "Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Leukemia",
      "Lymphoma"
    ],
    "interventions": [
      "Forodesine Hydrochloride Sterile Solution, 5 mg/mL",
      "Forodesine Hydrochloride Capsules (100 mg)"
    ],
    "primary_completion_date": "2007-03",
    "completion_date": "2007-03",
    "results_first_posted": null,
    "last_update_posted": "2012-01-23",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT03472040",
    "title": "A Long Term Safety Study of BCX7353 in Hereditary Angioedema",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hereditary Angioedema",
      "HAE",
      "Prophylaxis"
    ],
    "interventions": [
      "BCX7353"
    ],
    "primary_completion_date": "2022-04-27",
    "completion_date": "2022-04-27",
    "results_first_posted": "2023-06-18",
    "last_update_posted": "2023-06-18",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT06539507",
    "title": "A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Netherton Syndrome"
    ],
    "interventions": [
      "BCX17725",
      "Placebo"
    ],
    "primary_completion_date": "2026-10",
    "completion_date": "2026-12",
    "results_first_posted": null,
    "last_update_posted": "2026-01-13",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT00705406",
    "title": "A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute, Uncomplicated Human Influenza"
    ],
    "interventions": [
      "Peramivir",
      "Placebo"
    ],
    "primary_completion_date": "2009-04",
    "completion_date": "2009-10",
    "results_first_posted": "2015-02-16",
    "last_update_posted": "2015-02-16",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT00985127",
    "title": "Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Gout"
    ],
    "interventions": [
      "placebo",
      "BCX4208"
    ],
    "primary_completion_date": "2010-09",
    "completion_date": "2010-09",
    "results_first_posted": null,
    "last_update_posted": "2012-01-23",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT07228559",
    "title": "A Study of Avoralstat In Participants With Diabetic Macular Edema",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetic Macular Edema (DME)"
    ],
    "interventions": [
      "avoralstat"
    ],
    "primary_completion_date": "2026-05",
    "completion_date": "2026-09",
    "results_first_posted": null,
    "last_update_posted": "2025-11-14",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT03800173",
    "title": "A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Marburg Virus Disease"
    ],
    "interventions": [
      "galidesivir",
      "placebo"
    ],
    "primary_completion_date": "2019-04-30",
    "completion_date": "2019-04-30",
    "results_first_posted": "2021-07-23",
    "last_update_posted": "2021-07-23",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT00002237",
    "title": "A Study of Peldesine (BCX-34) in HIV-Infected Patients",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HIV Infections"
    ],
    "interventions": [
      "Peldesine"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2005-06-24",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT04428632",
    "title": "Oral Berotralstat Expanded Access Program",
    "status": "APPROVED_FOR_MARKETING",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Hereditary Angioedema",
      "HAE",
      "Prophylaxis"
    ],
    "interventions": [
      "Berotralstat"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2020-12-11",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT05116774",
    "title": "BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor Therapy",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Paroxysmal Nocturnal Hemoglobinuria (PNH)"
    ],
    "interventions": [
      "Eculizumab",
      "Ravulizumab",
      "BCX9930"
    ],
    "primary_completion_date": "2023-09-14",
    "completion_date": "2023-09-14",
    "results_first_posted": "2025-03-07",
    "last_update_posted": "2025-03-07",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT01984788",
    "title": "Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hereditary Angioedema"
    ],
    "interventions": [
      "BCX4161",
      "Placebo"
    ],
    "primary_completion_date": "2014-05",
    "completion_date": "2014-05",
    "results_first_posted": null,
    "last_update_posted": "2014-08-18",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT03873116",
    "title": "Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in Japan",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hereditary Angioedema, HAE"
    ],
    "interventions": [
      "BCX7353 capsules",
      "BCX7353 capsules",
      "Placebo oral capsule"
    ],
    "primary_completion_date": "2021-07-08",
    "completion_date": "2021-07-08",
    "results_first_posted": "2021-03-04",
    "last_update_posted": "2024-07-19",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT01265264",
    "title": "Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to Allopurinol",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Gout",
      "Hyperuricemia",
      "Arthritis",
      "Joint Disease"
    ],
    "interventions": [
      "ulodesine",
      "Placebo"
    ],
    "primary_completion_date": "2012-07",
    "completion_date": "2013-02",
    "results_first_posted": null,
    "last_update_posted": "2013-11-20",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT03485911",
    "title": "Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hereditary Angioedema",
      "HAE"
    ],
    "interventions": [
      "BCX7353 capsules",
      "Placebo oral capsule"
    ],
    "primary_completion_date": "2019-04-10",
    "completion_date": "2022-04-06",
    "results_first_posted": "2021-03-02",
    "last_update_posted": "2023-06-26",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT04933721",
    "title": "Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hereditary Angioedema",
      "HAE"
    ],
    "interventions": [
      "berotralstat"
    ],
    "primary_completion_date": "2031-08",
    "completion_date": "2031-08",
    "results_first_posted": null,
    "last_update_posted": "2025-12-23",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT05741346",
    "title": "Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Paroxysmal Nocturnal Hemoglobinuria"
    ],
    "interventions": [
      "BCX9930"
    ],
    "primary_completion_date": "2025-01-31",
    "completion_date": "2025-01-31",
    "results_first_posted": "2025-10-24",
    "last_update_posted": "2025-10-24",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT00098332",
    "title": "Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lymphoma"
    ],
    "interventions": [
      "forodesine hydrochloride"
    ],
    "primary_completion_date": "2010-12",
    "completion_date": "2011-07",
    "results_first_posted": null,
    "last_update_posted": "2013-07-10",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT05116787",
    "title": "BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants Not Receiving Other Complement Inhibitor Therapy",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Paroxysmal Nocturnal Hemoglobinuria (PNH)"
    ],
    "interventions": [
      "Placebo",
      "BCX9930 monotherapy"
    ],
    "primary_completion_date": "2023-09-18",
    "completion_date": "2023-09-18",
    "results_first_posted": "2025-01-03",
    "last_update_posted": "2025-01-03",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT00453999",
    "title": "Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Influenza"
    ],
    "interventions": [
      "Peramivir 200 mg",
      "Peramivir 400 mg",
      "Oseltamivir"
    ],
    "primary_completion_date": "2008-09",
    "completion_date": "2009-08",
    "results_first_posted": "2015-02-12",
    "last_update_posted": "2015-02-12",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT00289549",
    "title": "Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Leukemia, Lymphocytic, Chronic"
    ],
    "interventions": [
      "forodesine hydrochloride (BCX-1777)"
    ],
    "primary_completion_date": "2009-01",
    "completion_date": "2009-01",
    "results_first_posted": null,
    "last_update_posted": "2012-02-08",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT04702568",
    "title": "A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Paroxysmal Nocturnal Hemoglobinuria",
      "PNH"
    ],
    "interventions": [
      "BCX9930",
      "Eculizumab",
      "Ravulizumab"
    ],
    "primary_completion_date": "2023-10-04",
    "completion_date": "2023-10-04",
    "results_first_posted": "2024-12-13",
    "last_update_posted": "2025-04-13",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT00289562",
    "title": "Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "B-cell Acute Lymphoblastic Leukemia"
    ],
    "interventions": [
      "forodesine hydrochloride (BCX-1777)"
    ],
    "primary_completion_date": "2007-12",
    "completion_date": "2007-12",
    "results_first_posted": null,
    "last_update_posted": "2012-01-20",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT00095381",
    "title": "Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Leukemia, T-Cell"
    ],
    "interventions": [
      "forodesine hydrochloride (BCX-1777)"
    ],
    "primary_completion_date": "2007-03",
    "completion_date": "2007-12",
    "results_first_posted": null,
    "last_update_posted": "2012-01-19",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT02819102",
    "title": "An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzyme Activity Using Probe Substrates",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hereditary Angioedema"
    ],
    "interventions": [
      "BCX7353 and probes"
    ],
    "primary_completion_date": "2016-06",
    "completion_date": "2016-06",
    "results_first_posted": null,
    "last_update_posted": "2017-01-31",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT02218294",
    "title": "Study to Determine How BCX4161 is Metabolized and Eliminated by the Body",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hereditary Angioedema"
    ],
    "interventions": [
      "BCX4161"
    ],
    "primary_completion_date": "2014-09",
    "completion_date": "2014-09",
    "results_first_posted": null,
    "last_update_posted": "2014-10-29",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT00610935",
    "title": "Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Influenza"
    ],
    "interventions": [
      "Peramivir",
      "Placebo"
    ],
    "primary_completion_date": "2008-02",
    "completion_date": "2008-02",
    "results_first_posted": "2021-03-17",
    "last_update_posted": "2021-03-17",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT02319772",
    "title": "A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BCX4430",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Filovirus Infections",
      "Ebola Virus Infection"
    ],
    "interventions": [
      "BCX4430",
      "Placebo"
    ],
    "primary_completion_date": "2016-03",
    "completion_date": "2016-04",
    "results_first_posted": null,
    "last_update_posted": "2016-07-07",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT05162066",
    "title": "Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Complement 3 Glomerulopathy",
      "Immunoglobulin A Nephropathy",
      "Membranous Nephropathy"
    ],
    "interventions": [
      "BCX9930"
    ],
    "primary_completion_date": "2022-09-23",
    "completion_date": "2022-09-23",
    "results_first_posted": "2024-05-02",
    "last_update_posted": "2024-05-02",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT00061880",
    "title": "BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lymphoma"
    ],
    "interventions": [
      "forodesine hydrochloride"
    ],
    "primary_completion_date": "2005-01",
    "completion_date": "2008-01",
    "results_first_posted": null,
    "last_update_posted": "2013-05-30",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT00501735",
    "title": "Forodesine in the Treatment of Cutaneous T-Cell Lymphoma",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cutaneous T-cell Lymphoma (CTCL),"
    ],
    "interventions": [
      "Forodesine 200 mg"
    ],
    "primary_completion_date": "2010-07",
    "completion_date": "2011-12",
    "results_first_posted": null,
    "last_update_posted": "2012-01-23",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT02448264",
    "title": "First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BCX7353 in Healthy Western and Japanese Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hereditary Angioedema"
    ],
    "interventions": [
      "BCX7353",
      "Placebo to match BCX7353"
    ],
    "primary_completion_date": "2015-11",
    "completion_date": "2015-12",
    "results_first_posted": null,
    "last_update_posted": "2016-01-13",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT04330534",
    "title": "First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNH",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Paroxysmal Nocturnal Hemoglobinuria"
    ],
    "interventions": [
      "BCX9930",
      "Placebo"
    ],
    "primary_completion_date": "2020-11-11",
    "completion_date": "2021-01-25",
    "results_first_posted": null,
    "last_update_posted": "2022-02-17",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT03202784",
    "title": "A Relative Bioavailability Study of Two Formulations of BCX7353",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hereditary Angioedema"
    ],
    "interventions": [
      "BCX7353"
    ],
    "primary_completion_date": "2017-08-01",
    "completion_date": "2017-09-30",
    "results_first_posted": null,
    "last_update_posted": "2020-01-27",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT03240133",
    "title": "Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hereditary Angioedema (HAE)"
    ],
    "interventions": [
      "BCX7353",
      "Placebo"
    ],
    "primary_completion_date": "2019-01-29",
    "completion_date": "2019-01-29",
    "results_first_posted": "2021-04-01",
    "last_update_posted": "2021-04-01",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT03891420",
    "title": "A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID-19",
      "Yellow Fever"
    ],
    "interventions": [
      "Galidesivir",
      "Placebo"
    ],
    "primary_completion_date": "2021-01-31",
    "completion_date": "2021-04-30",
    "results_first_posted": null,
    "last_update_posted": "2021-05-27",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT02125162",
    "title": "A Study of the Relative Bioavailability of a New Formulation of BCX4161 and the Effect of Food on BCX4161",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hereditary Angioedema"
    ],
    "interventions": [
      "BCX4161"
    ],
    "primary_completion_date": "2014-07",
    "completion_date": "2014-07",
    "results_first_posted": null,
    "last_update_posted": "2014-08-15",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT02369159",
    "title": "Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Influenza"
    ],
    "interventions": [
      "Peramivir",
      "Oseltamivir"
    ],
    "primary_completion_date": "2019-10-28",
    "completion_date": "2020-05-14",
    "results_first_posted": "2021-03-23",
    "last_update_posted": "2021-03-23",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT00486980",
    "title": "Intramuscular Peramivir for the Treatment of Uncomplicated Influenza",
    "status": "WITHDRAWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Influenza"
    ],
    "interventions": [
      "Peramivir 150mg",
      "Peramivir 300mg"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2008-01-30",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT02635724",
    "title": "Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Influenza"
    ],
    "interventions": [
      "Peramivir"
    ],
    "primary_completion_date": "2018-04",
    "completion_date": "2018-09",
    "results_first_posted": "2021-03-23",
    "last_update_posted": "2021-03-23",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT00640523",
    "title": "Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Lymphocytic Leukemia (CLL)"
    ],
    "interventions": [
      "forodesine HCl"
    ],
    "primary_completion_date": "2010-11",
    "completion_date": "2011-11",
    "results_first_posted": null,
    "last_update_posted": "2012-01-23",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT01224795",
    "title": "A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Influenza"
    ],
    "interventions": [
      "Peramivir",
      "Placebo Comparator"
    ],
    "primary_completion_date": "2010-11",
    "completion_date": "2010-11",
    "results_first_posted": null,
    "last_update_posted": "2015-01-06",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BCRX",
    "nct_id": "NCT03136237",
    "title": "A Drug-Drug Interaction Study to Evaluate Drug Transporter Interactions",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hereditary Angioedema"
    ],
    "interventions": [
      "BCX7353",
      "Digoxin",
      "BCX7353 + digoxin",
      "Rosuvastatin",
      "rosuvastatin + BCX7353",
      "Cyclosporine + BCX7353"
    ],
    "primary_completion_date": "2017-08-15",
    "completion_date": "2017-08-15",
    "results_first_posted": null,
    "last_update_posted": "2017-10-26",
    "enrollment": null,
    "sponsor": "BioCryst Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "BioCryst"
  },
  {
    "ticker": "BDTX",
    "nct_id": "NCT07326566",
    "title": "Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Glioblastoma (GBM)",
      "Newly Diagnosed Glioblastoma",
      "GBM",
      "Glioblastoma Multiforme (GBM)",
      "Glioma",
      "Central Nervous System Diseases",
      "Brain Cancer"
    ],
    "interventions": [
      "silevertinib in combination with temozolomide",
      "temozolomide (TMZ)"
    ],
    "primary_completion_date": "2028-11",
    "completion_date": "2029-03",
    "results_first_posted": null,
    "last_update_posted": "2026-01-08",
    "enrollment": null,
    "sponsor": "Black Diamond Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Black Diamond Therapeutics"
  },
  {
    "ticker": "BDTX",
    "nct_id": "NCT04209465",
    "title": "A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor"
    ],
    "interventions": [
      "BDTX-189"
    ],
    "primary_completion_date": "2022-09-02",
    "completion_date": "2022-09-16",
    "results_first_posted": "2025-04-17",
    "last_update_posted": "2025-04-17",
    "enrollment": null,
    "sponsor": "Black Diamond Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Black Diamond Therapeutics"
  },
  {
    "ticker": "BHVN",
    "nct_id": "NCT06423781",
    "title": "Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder"
    ],
    "interventions": [
      "BHV-7000"
    ],
    "primary_completion_date": "2027-11",
    "completion_date": "2027-11",
    "results_first_posted": null,
    "last_update_posted": "2025-07-11",
    "enrollment": null,
    "sponsor": "Biohaven Therapeutics Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Biohaven"
  },
  {
    "ticker": "BHVN",
    "nct_id": "NCT04634435",
    "title": "Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple Myeloma"
    ],
    "interventions": [
      "BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2"
    ],
    "primary_completion_date": "2025-01-10",
    "completion_date": "2025-01-10",
    "results_first_posted": null,
    "last_update_posted": "2025-01-20",
    "enrollment": null,
    "sponsor": "Biohaven Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Biohaven"
  },
  {
    "ticker": "BHVN",
    "nct_id": "NCT06874335",
    "title": "A Phase 1 Study of BHV-1530 in Advanced Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor"
    ],
    "interventions": [
      "BHV-1530"
    ],
    "primary_completion_date": "2029-03",
    "completion_date": "2029-03",
    "results_first_posted": null,
    "last_update_posted": "2025-11-18",
    "enrollment": null,
    "sponsor": "Biohaven Therapeutics Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Biohaven"
  },
  {
    "ticker": "BHVN",
    "nct_id": "NCT06976268",
    "title": "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Parkinson Disease"
    ],
    "interventions": [
      "BHV-8000",
      "BHV-8000",
      "Placebo"
    ],
    "primary_completion_date": "2027-08",
    "completion_date": "2027-09",
    "results_first_posted": null,
    "last_update_posted": "2026-01-14",
    "enrollment": null,
    "sponsor": "Biohaven Therapeutics Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Biohaven"
  },
  {
    "ticker": "BHVN",
    "nct_id": "NCT04693351",
    "title": "Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Obsessive-Compulsive Disorder"
    ],
    "interventions": [
      "Troriluzole",
      "Placebo"
    ],
    "primary_completion_date": "2025-04-29",
    "completion_date": "2025-04-29",
    "results_first_posted": null,
    "last_update_posted": "2025-08-19",
    "enrollment": null,
    "sponsor": "Biohaven Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Biohaven"
  },
  {
    "ticker": "BHVN",
    "nct_id": "NCT03299166",
    "title": "Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Obsessive-Compulsive Disorder"
    ],
    "interventions": [
      "Troriluzole",
      "Placebo"
    ],
    "primary_completion_date": "2020-06-02",
    "completion_date": "2025-12-08",
    "results_first_posted": "2023-06-02",
    "last_update_posted": "2026-01-22",
    "enrollment": null,
    "sponsor": "Biohaven Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Biohaven"
  },
  {
    "ticker": "BHVN",
    "nct_id": "NCT04708834",
    "title": "Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Obsessive Compulsive Disorder"
    ],
    "interventions": [
      "Troriluzole (BHV-4157)"
    ],
    "primary_completion_date": "2026-06",
    "completion_date": "2026-06",
    "results_first_posted": null,
    "last_update_posted": "2026-01-20",
    "enrollment": null,
    "sponsor": "Biohaven Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Biohaven"
  },
  {
    "ticker": "BHVN",
    "nct_id": "NCT06384807",
    "title": "A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor"
    ],
    "interventions": [
      "BHV-1510",
      "Cemiplimab",
      "BHV-1510",
      "BHV-1510",
      "Cemiplimab"
    ],
    "primary_completion_date": "2028-02",
    "completion_date": "2028-02",
    "results_first_posted": null,
    "last_update_posted": "2025-11-17",
    "enrollment": null,
    "sponsor": "Biohaven Therapeutics Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Biohaven"
  },
  {
    "ticker": "BHVN",
    "nct_id": "NCT06980649",
    "title": "Study of BHV-1300 in Graves' Disease",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Graves Disease"
    ],
    "interventions": [
      "BHV-1300"
    ],
    "primary_completion_date": "2026-03",
    "completion_date": "2026-03",
    "results_first_posted": null,
    "last_update_posted": "2025-11-24",
    "enrollment": null,
    "sponsor": "Biohaven Therapeutics Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Biohaven"
  },
  {
    "ticker": "BHVN",
    "nct_id": "NCT07262268",
    "title": "A Phase 1b Study of BHV-7000 in Participants With Inherited Erythromelalgia",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Familial Erythromelalgia"
    ],
    "interventions": [
      "BHV-7000",
      "Placebo"
    ],
    "primary_completion_date": "2026-06",
    "completion_date": "2026-07",
    "results_first_posted": null,
    "last_update_posted": "2026-01-20",
    "enrollment": null,
    "sponsor": "Biohaven Therapeutics Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Biohaven"
  },
  {
    "ticker": "BHVN",
    "nct_id": "NCT06419608",
    "title": "Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder"
    ],
    "interventions": [
      "BHV-7000",
      "Placebo"
    ],
    "primary_completion_date": "2025-11-07",
    "completion_date": "2025-11-07",
    "results_first_posted": null,
    "last_update_posted": "2026-01-07",
    "enrollment": null,
    "sponsor": "Biohaven Therapeutics Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Biohaven"
  },
  {
    "ticker": "BHVN",
    "nct_id": "NCT05086094",
    "title": "Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)",
    "status": "NO_LONGER_AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Multiple System Atrophy (MSA)"
    ],
    "interventions": [
      "BHV3241, verdiperstat"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2022-10-06",
    "enrollment": null,
    "sponsor": "Biohaven Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Biohaven"
  },
  {
    "ticker": "BHVN",
    "nct_id": "NCT06423794",
    "title": "BHV-7000 Open-Label Extension Bipolar Mania Study",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bipolar Disorder"
    ],
    "interventions": [
      "BHV-7000"
    ],
    "primary_completion_date": "2025-04-25",
    "completion_date": "2025-04-25",
    "results_first_posted": null,
    "last_update_posted": "2025-12-16",
    "enrollment": null,
    "sponsor": "Biohaven Therapeutics Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Biohaven"
  },
  {
    "ticker": "BHVN",
    "nct_id": "NCT03605667",
    "title": "Study of BHV-4157 in Alzheimer's Disease",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alzheimer Disease"
    ],
    "interventions": [
      "troriluzole",
      "Placebo oral capsule"
    ],
    "primary_completion_date": "2020-12-15",
    "completion_date": "2021-12-23",
    "results_first_posted": "2023-12-06",
    "last_update_posted": "2023-12-06",
    "enrollment": null,
    "sponsor": "Biohaven Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Biohaven"
  },
  {
    "ticker": "BHVN",
    "nct_id": "NCT03520517",
    "title": "Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Amyotrophic Lateral Sclerosis",
      "ALS",
      "Lou Gehrig Disease",
      "Lou Gehrig's Disease",
      "Lou-Gehrigs Disease",
      "Motor Neuron Disease, Amyotrophic Lateral Sclerosis"
    ],
    "interventions": [
      "BHV-0223"
    ],
    "primary_completion_date": "2018-10-08",
    "completion_date": "2018-10-08",
    "results_first_posted": null,
    "last_update_posted": "2022-10-06",
    "enrollment": null,
    "sponsor": "Biohaven Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Biohaven"
  },
  {
    "ticker": "BHVN",
    "nct_id": "NCT03829241",
    "title": "Randomized Trial of Adult Participants With Generalized Anxiety Disorder",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Generalized Anxiety Disorder"
    ],
    "interventions": [
      "Troriluzole",
      "Placebo"
    ],
    "primary_completion_date": "2020-01-14",
    "completion_date": "2020-05-08",
    "results_first_posted": "2022-12-28",
    "last_update_posted": "2024-05-08",
    "enrollment": null,
    "sponsor": "Biohaven Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Biohaven"
  },
  {
    "ticker": "BHVN",
    "nct_id": "NCT06425159",
    "title": "A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Generalized Epilepsy"
    ],
    "interventions": [
      "BHV-7000",
      "Placebo"
    ],
    "primary_completion_date": "2026-07",
    "completion_date": "2027-07",
    "results_first_posted": null,
    "last_update_posted": "2026-01-20",
    "enrollment": null,
    "sponsor": "Biohaven Therapeutics Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Biohaven"
  },
  {
    "ticker": "BHVN",
    "nct_id": "NCT03537807",
    "title": "Expanded Access Protocol of BHV-0223 for Patients With Amyotrophic Lateral Sclerosis (ALS)",
    "status": "NO_LONGER_AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Amyotrophic Lateral Sclerosis",
      "ALS",
      "Lou Gehrig Disease",
      "Lou Gehrig's Disease",
      "Lou-Gehrigs Disease",
      "Motor Neuron Disease, Amyotrophic Lateral Sclerosis"
    ],
    "interventions": [
      "Riluzole"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2019-07-26",
    "enrollment": null,
    "sponsor": "Biohaven Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Biohaven"
  },
  {
    "ticker": "BHVN",
    "nct_id": "NCT04641143",
    "title": "Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Obsessive-Compulsive Disorder"
    ],
    "interventions": [
      "Troriluzole",
      "Placebo"
    ],
    "primary_completion_date": "2025-10-27",
    "completion_date": "2025-10-27",
    "results_first_posted": null,
    "last_update_posted": "2026-01-07",
    "enrollment": null,
    "sponsor": "Biohaven Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Biohaven"
  },
  {
    "ticker": "BHVN",
    "nct_id": "NCT06603623",
    "title": "Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Migraine"
    ],
    "interventions": [
      "BHV-2100",
      "BHV-2100",
      "Placebo"
    ],
    "primary_completion_date": "2025-03-24",
    "completion_date": "2025-03-28",
    "results_first_posted": null,
    "last_update_posted": "2025-07-08",
    "enrollment": null,
    "sponsor": "Biohaven Therapeutics Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Biohaven"
  },
  {
    "ticker": "BHVN",
    "nct_id": "NCT03701399",
    "title": "Troriluzole in Adult Participants With Spinocerebellar Ataxia",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Spinocerebellar Ataxias",
      "Spinocerebellar Ataxia Type 1",
      "Spinocerebellar Ataxia Type 2",
      "Spinocerebellar Ataxia Type 3",
      "Spinocerebellar Ataxia Type 6",
      "Spinocerebellar Ataxia Type 7",
      "Spinocerebellar Ataxia Type 8",
      "Spinocerebellar Ataxia Type 10"
    ],
    "interventions": [
      "troriluzole",
      "Placebo"
    ],
    "primary_completion_date": "2022-02-18",
    "completion_date": "2026-06",
    "results_first_posted": "2025-02-10",
    "last_update_posted": "2025-11-04",
    "enrollment": null,
    "sponsor": "Biohaven Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Biohaven"
  },
  {
    "ticker": "BHVN",
    "nct_id": "NCT05337553",
    "title": "A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Spinal Muscular Atrophy",
      "Neuromuscular Diseases",
      "SMA"
    ],
    "interventions": [
      "taldefgrobep alfa",
      "Placebo",
      "taldefgrobep alfa"
    ],
    "primary_completion_date": "2024-09-25",
    "completion_date": "2026-01",
    "results_first_posted": null,
    "last_update_posted": "2025-08-26",
    "enrollment": null,
    "sponsor": "Biohaven Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Biohaven"
  },
  {
    "ticker": "BHVN",
    "nct_id": "NCT07281495",
    "title": "Taldefgrobep Alfa in Adults With Overweight and Obesity",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Obesity",
      "Overweight"
    ],
    "interventions": [
      "Taldefgrobep Alfa",
      "Placebo",
      "Taldefgrobep Alfa",
      "Placebo"
    ],
    "primary_completion_date": "2026-09",
    "completion_date": "2026-09",
    "results_first_posted": null,
    "last_update_posted": "2026-01-12",
    "enrollment": null,
    "sponsor": "Biohaven Therapeutics Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Biohaven"
  },
  {
    "ticker": "BHVN",
    "nct_id": "NCT07054684",
    "title": "Study of BHV-1400 in IgA Nephropathy",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "IgA Nephropathy"
    ],
    "interventions": [
      "BHV-1400"
    ],
    "primary_completion_date": "2026-07",
    "completion_date": "2026-07",
    "results_first_posted": null,
    "last_update_posted": "2026-01-12",
    "enrollment": null,
    "sponsor": "Biohaven Therapeutics Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Biohaven"
  },
  {
    "ticker": "BHVN",
    "nct_id": "NCT02960893",
    "title": "Trial in Adult Participants With Spinocerebellar Ataxia (SCA)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Spinocerebellar Ataxias",
      "Spinocerebellar Ataxia Genotype Type 1",
      "Spinocerebellar Ataxia Genotype Type 2",
      "Spinocerebellar Ataxia Genotype Type 3",
      "Spinocerebellar Ataxia Genotype Type 6",
      "Spinocerebellar Ataxia Genotype Type 7",
      "Spinocerebellar Ataxia Genotype Type 8",
      "Spinocerebellar Ataxia Genotype Type 10"
    ],
    "interventions": [
      "Troriluzole",
      "Placebo",
      "Troriluzole"
    ],
    "primary_completion_date": "2017-08-18",
    "completion_date": "2024-09-20",
    "results_first_posted": "2020-08-14",
    "last_update_posted": "2025-10-08",
    "enrollment": null,
    "sponsor": "Biohaven Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Biohaven"
  },
  {
    "ticker": "BHVN",
    "nct_id": "NCT06034886",
    "title": "Expanded Access Protocol of Troriluzole in Patients With Spinocerebellar Ataxia (SCA)",
    "status": "AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "SCA",
      "Spinocerebellar Ataxias"
    ],
    "interventions": [
      "Troriluzole"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2026-01-09",
    "enrollment": null,
    "sponsor": "Biohaven Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Biohaven"
  },
  {
    "ticker": "BHVN",
    "nct_id": "NCT06309966",
    "title": "Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Focal Epilepsy"
    ],
    "interventions": [
      "BHV-7000",
      "BHV-7000",
      "Placebo"
    ],
    "primary_completion_date": "2026-05",
    "completion_date": "2026-05",
    "results_first_posted": null,
    "last_update_posted": "2026-01-27",
    "enrollment": null,
    "sponsor": "Biohaven Therapeutics Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Biohaven"
  },
  {
    "ticker": "BHVN",
    "nct_id": "NCT03952806",
    "title": "Study of BHV-3241 in Participants With Multiple System Atrophy",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple System Atrophy"
    ],
    "interventions": [
      "Verdiperstat",
      "Placebo"
    ],
    "primary_completion_date": "2021-07-29",
    "completion_date": "2022-06-30",
    "results_first_posted": "2023-09-29",
    "last_update_posted": "2023-09-29",
    "enrollment": null,
    "sponsor": "Biohaven Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Biohaven"
  },
  {
    "ticker": "BHVN",
    "nct_id": "NCT06419582",
    "title": "BHV-7000 Acute Treatment of Bipolar Mania",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bipolar Disorder"
    ],
    "interventions": [
      "BHV-7000",
      "Placebo"
    ],
    "primary_completion_date": "2025-01-15",
    "completion_date": "2025-01-30",
    "results_first_posted": null,
    "last_update_posted": "2025-12-16",
    "enrollment": null,
    "sponsor": "Biohaven Therapeutics Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Biohaven"
  },
  {
    "ticker": "BHVN",
    "nct_id": "NCT06529146",
    "title": "Real-World Data Study of Troriluzole-Treated Patients With Spinocerebellar Ataxia (SCA) Compared to a Matched Natural History Control",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Spinocerebellar Ataxias"
    ],
    "interventions": [
      "BHV-4157"
    ],
    "primary_completion_date": "2024-09-06",
    "completion_date": "2026-06",
    "results_first_posted": null,
    "last_update_posted": "2026-01-09",
    "enrollment": null,
    "sponsor": "Biohaven Therapeutics Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Biohaven"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT06449209",
    "title": "Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Extensive-stage Small-cell Lung Cancer",
      "Small-cell Lung Cancer"
    ],
    "interventions": [
      "BNT327 Dose Level 1 (DL1)",
      "BNT327 Dose Level 2 (DL2)",
      "Etoposide",
      "Carboplatin",
      "Paclitaxel",
      "Topotecan"
    ],
    "primary_completion_date": "2027-06",
    "completion_date": "2028-05",
    "results_first_posted": null,
    "last_update_posted": "2025-12-05",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT04625205",
    "title": "A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Unresectable Melanoma",
      "Metastatic Melanoma"
    ],
    "interventions": [
      "NEO-PTC-01",
      "IL-2",
      "PD-1 Inhibitors"
    ],
    "primary_completion_date": "2025-03-26",
    "completion_date": "2025-03-26",
    "results_first_posted": null,
    "last_update_posted": "2025-04-06",
    "enrollment": null,
    "sponsor": "BioNTech US Inc.",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT04503278",
    "title": "A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor"
    ],
    "interventions": [
      "CLDN6 CAR-T",
      "CLDN6 uRNA-LPX/CLDN6 modRNA-LPX"
    ],
    "primary_completion_date": "2028-12",
    "completion_date": "2041-01",
    "results_first_posted": null,
    "last_update_posted": "2025-12-23",
    "enrollment": null,
    "sponsor": "BioNTech Cell & Gene Therapies GmbH",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT02316457",
    "title": "RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uID",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Cancer (Triple Negative Breast Cancer (TNBC))"
    ],
    "interventions": [
      "IVAC_W_bre1_uID",
      "IVAC_W_bre1_uID/IVAC_M_uID"
    ],
    "primary_completion_date": "2020-05-13",
    "completion_date": "2023-05-17",
    "results_first_posted": null,
    "last_update_posted": "2023-07-19",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT04813627",
    "title": "Epidemiological Study to Monitor Study Participants With Resected Stage II (High Risk) or Stage III Colorectal Cancer for Circulating Tumor DNA Before, During and After Their Treatment With Adjuvant Chemotherapy",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Colorectal Cancer Stage II",
      "Colorectal Cancer Stage III"
    ],
    "interventions": [
      "Regular blood sample collection for ctDNA assessment"
    ],
    "primary_completion_date": "2025-04-23",
    "completion_date": "2026-04",
    "results_first_posted": null,
    "last_update_posted": "2025-05-29",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT05988203",
    "title": "A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Monkeypox"
    ],
    "interventions": [
      "BNT166a"
    ],
    "primary_completion_date": "2025-08-25",
    "completion_date": "2026-03",
    "results_first_posted": null,
    "last_update_posted": "2025-10-22",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT07079631",
    "title": "A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Colorectal Cancer"
    ],
    "interventions": [
      "BNT314",
      "BNT327",
      "SoC chemotherapy treatment 1",
      "SoC chemotherapy treatment 2",
      "Bevacizumab"
    ],
    "primary_completion_date": "2030-12",
    "completion_date": "2031-05",
    "results_first_posted": null,
    "last_update_posted": "2025-12-01",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT04526899",
    "title": "A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Melanoma Stage III",
      "Melanoma Stage IV",
      "Unresectable Melanoma"
    ],
    "interventions": [
      "BNT111",
      "Cemiplimab"
    ],
    "primary_completion_date": "2024-01-25",
    "completion_date": "2025-11-24",
    "results_first_posted": "2025-12-15",
    "last_update_posted": "2026-01-08",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT06150183",
    "title": "Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Malignant Solid Tumor"
    ],
    "interventions": [
      "BNT314"
    ],
    "primary_completion_date": "2027-06",
    "completion_date": "2028-03",
    "results_first_posted": null,
    "last_update_posted": "2026-01-23",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT05630352",
    "title": "A Study to Learn About Bivalent COVID-19 RNA Vaccine Candidate(s) in Healthy Infants and Children",
    "status": "WITHDRAWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID-19"
    ],
    "interventions": [
      "Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose",
      "Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose",
      "Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose",
      "Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 1 microgram dose"
    ],
    "primary_completion_date": "2026-07-13",
    "completion_date": "2026-07-13",
    "results_first_posted": null,
    "last_update_posted": "2024-03-18",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT06178991",
    "title": "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Influenza",
      "COVID-19"
    ],
    "interventions": [
      "Influenza and COVID-19 Combination A",
      "Licensed influenza vaccine",
      "COVID-19 Vaccine",
      "Influenza and COVID-19 Combination B",
      "Placebo",
      "Investigational influenza vaccine"
    ],
    "primary_completion_date": "2024-11-26",
    "completion_date": "2024-11-26",
    "results_first_posted": "2025-12-04",
    "last_update_posted": "2025-12-04",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT06821061",
    "title": "A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Influenza",
      "COVID-19 (Coronavirus Disease 2019)"
    ],
    "interventions": [
      "Investigational Influenza Vaccine",
      "Investigational COVID-19 Vaccine",
      "Investigational Influenza and COVID-19 Combination Vaccine",
      "Licensed Influenza Vaccine 1",
      "Licensed Influenza Vaccine 2",
      "Licensed Influenza Vaccine 3",
      "Licensed COVID-19 Vaccine"
    ],
    "primary_completion_date": "2025-12-17",
    "completion_date": "2025-12-17",
    "results_first_posted": null,
    "last_update_posted": "2026-01-26",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT02410733",
    "title": "Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Melanoma"
    ],
    "interventions": [
      "Lipo-MERIT"
    ],
    "primary_completion_date": "2023-06-20",
    "completion_date": "2023-06-20",
    "results_first_posted": null,
    "last_update_posted": "2023-07-19",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT02672917",
    "title": "Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pancreatic Cancer"
    ],
    "interventions": [
      "MVT-5873",
      "modified FOLFIRINOX (mFOLFIRINOX)",
      "gemcitabine + nab-paclitaxel"
    ],
    "primary_completion_date": "2024-08-07",
    "completion_date": "2025-01-14",
    "results_first_posted": null,
    "last_update_posted": "2025-01-28",
    "enrollment": null,
    "sponsor": "BioNTech Research & Development, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT06750185",
    "title": "Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumor"
    ],
    "interventions": [
      "BNT317 DL1",
      "BNT317 DL2",
      "BNT317 DL3",
      "BNT317 DL4",
      "BNT317 DL5 (intermediate)",
      "BNT317 DL6 (intermediate)",
      "BNT317 DL7 (additional)"
    ],
    "primary_completion_date": "2028-06",
    "completion_date": "2028-06",
    "results_first_posted": null,
    "last_update_posted": "2025-07-01",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT05537038",
    "title": "Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Tuberculosis"
    ],
    "interventions": [
      "BNT164a1",
      "BNT164b1",
      "Placebo"
    ],
    "primary_completion_date": "2025-06-06",
    "completion_date": "2025-12-08",
    "results_first_posted": null,
    "last_update_posted": "2025-12-22",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT03380871",
    "title": "A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Carcinoma, Non-Small-Cell Lung",
      "Lung Cancer",
      "Nonsquamous Nonsmall Cell Neoplasm of Lung"
    ],
    "interventions": [
      "NEO-PV-01",
      "Pembrolizumab",
      "Adjuvant",
      "Carboplatin",
      "Pemetrexed"
    ],
    "primary_completion_date": "2019-10-31",
    "completion_date": "2021-02-05",
    "results_first_posted": null,
    "last_update_posted": "2021-02-26",
    "enrollment": null,
    "sponsor": "BioNTech US Inc.",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT06340568",
    "title": "A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Endometrial Cancer"
    ],
    "interventions": [
      "BNT323/DB-1303",
      "Doxorubicin",
      "Paclitaxel"
    ],
    "primary_completion_date": "2028-03",
    "completion_date": "2029-11",
    "results_first_posted": null,
    "last_update_posted": "2025-12-15",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT06827236",
    "title": "A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Locally Advanced Breast Cancer",
      "Unresectable Breast Carcinoma",
      "Metastatic Breast Cancer"
    ],
    "interventions": [
      "BNT323",
      "BNT327"
    ],
    "primary_completion_date": "2028-05",
    "completion_date": "2029-05",
    "results_first_posted": null,
    "last_update_posted": "2026-01-14",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT01684241",
    "title": "RBL001/RBL002 Phase I Clinical Trial",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Melanoma"
    ],
    "interventions": [
      "RBL001/RBL002"
    ],
    "primary_completion_date": "2015-05",
    "completion_date": "2015-07",
    "results_first_posted": null,
    "last_update_posted": "2020-01-18",
    "enrollment": null,
    "sponsor": "BioNTech RNA Pharmaceuticals GmbH",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT02035956",
    "title": "IVAC MUTANOME Phase I Clinical Trial",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Melanoma"
    ],
    "interventions": [
      "IVAC MUTANOME, RBL001/RBL002"
    ],
    "primary_completion_date": "2017-02-14",
    "completion_date": "2019-10",
    "results_first_posted": null,
    "last_update_posted": "2020-01-18",
    "enrollment": null,
    "sponsor": "BioNTech RNA Pharmaceuticals GmbH",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT06683352",
    "title": "A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Influenza,Human",
      "COVID-19"
    ],
    "interventions": [
      "Investigational Influenza Vaccine",
      "COVID-19 Vaccine",
      "Influenza and COVID Combination Vaccine",
      "Licensed Influenza Vaccine 1",
      "Licensed Influenza Vaccine 2",
      "Placebo"
    ],
    "primary_completion_date": "2025-07-15",
    "completion_date": "2025-07-15",
    "results_first_posted": null,
    "last_update_posted": "2025-08-15",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT06469164",
    "title": "A First-in-human Safety Trial of BNT331 Administered as Single Ascending Doses in Healthy Women and as Multiple Ascending Doses in Women Diagnosed With Bacterial Vaginosis",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bacterial Vaginosis"
    ],
    "interventions": [
      "BNT331",
      "Placebo"
    ],
    "primary_completion_date": "2025-07-31",
    "completion_date": "2025-07-31",
    "results_first_posted": null,
    "last_update_posted": "2025-08-07",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT06712355",
    "title": "Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Extensive-stage Small-cell Lung Cancer"
    ],
    "interventions": [
      "Pumitamig",
      "Atezolizumab",
      "Etoposide",
      "Carboplatin (or cisplatin if carboplatin is not tolerated)"
    ],
    "primary_completion_date": "2028-12",
    "completion_date": "2029-03",
    "results_first_posted": null,
    "last_update_posted": "2026-01-27",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT07297212",
    "title": "A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works in Patients With Recurrent Glioblastoma",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Recurrent Glioblastoma"
    ],
    "interventions": [
      "Pumitamig",
      "Bevacizumab",
      "Temozolomide"
    ],
    "primary_completion_date": "2028-01",
    "completion_date": "2029-07",
    "results_first_posted": null,
    "last_update_posted": "2025-12-22",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT06069778",
    "title": "Safety, Tolerability, and Efficacy of mFOLFIRINOX \u00b1 BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pancreatic Cancer"
    ],
    "interventions": [
      "BNT321 0.5 mg/kg",
      "BNT321 DL 2",
      "mFOLFIRINOX",
      "BNT321 RP2D"
    ],
    "primary_completion_date": "2024-09-18",
    "completion_date": "2024-09-18",
    "results_first_posted": "2025-10-31",
    "last_update_posted": "2025-10-31",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT07186842",
    "title": "A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Cancers"
    ],
    "interventions": [
      "BNT329",
      "CA19-9-targeting monoclonal antibody"
    ],
    "primary_completion_date": "2030-05",
    "completion_date": "2030-05",
    "results_first_posted": null,
    "last_update_posted": "2025-12-03",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT03597282",
    "title": "A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Melanoma"
    ],
    "interventions": [
      "NEO-PV-01",
      "Nivolumab",
      "Adjuvant",
      "APX005M",
      "ipilimumab"
    ],
    "primary_completion_date": "2020-05-05",
    "completion_date": "2020-08-11",
    "results_first_posted": null,
    "last_update_posted": "2020-09-03",
    "enrollment": null,
    "sponsor": "BioNTech US Inc.",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT03118349",
    "title": "Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pancreatic Carcinoma",
      "Tumors That Express CA 19-9"
    ],
    "interventions": [
      "MVT-1075",
      "MVT-5873"
    ],
    "primary_completion_date": "2018-04-11",
    "completion_date": "2018-04-11",
    "results_first_posted": null,
    "last_update_posted": "2023-04-21",
    "enrollment": null,
    "sponsor": "BioNTech Research & Development, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT06892548",
    "title": "A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Lung Cancer"
    ],
    "interventions": [
      "BNT324",
      "BNT327"
    ],
    "primary_completion_date": "2027-08",
    "completion_date": "2031-06",
    "results_first_posted": null,
    "last_update_posted": "2026-01-21",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT07300839",
    "title": "A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID-19",
      "SARS-COV-2 Infection"
    ],
    "interventions": [
      "BNT162b2 Vaccine",
      "Placebo"
    ],
    "primary_completion_date": "2026-07-31",
    "completion_date": "2026-07-31",
    "results_first_posted": null,
    "last_update_posted": "2025-12-24",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT04955626",
    "title": "To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants \u226512 Years of Age.",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "SARS-CoV-2 Infection",
      "COVID-19"
    ],
    "interventions": [
      "BNT162b2",
      "Placebo",
      "BNT162b2 OMI",
      "Combination BNT162b2 and BNT162b2 OMI",
      "Combination (Bivalent) BNT162b2 and BNT162b2 OMI"
    ],
    "primary_completion_date": "2023-05-25",
    "completion_date": "2023-05-25",
    "results_first_posted": "2025-11-10",
    "last_update_posted": "2025-11-10",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT02687230",
    "title": "Phase 1 Imaging Study of 89Zr-DFO-HuMab-5B1 With HuMab-5B1",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pancreatic Carcinoma",
      "Tumors That Express CA19-9"
    ],
    "interventions": [
      "MVT-2163",
      "MVT-5873"
    ],
    "primary_completion_date": "2017-05-05",
    "completion_date": "2017-05-05",
    "results_first_posted": null,
    "last_update_posted": "2021-08-31",
    "enrollment": null,
    "sponsor": "BioNTech Research & Development, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT04754594",
    "title": "To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "SARS-CoV-2 Infection",
      "COVID-19",
      "Maternal Immunization"
    ],
    "interventions": [
      "BNT162b2",
      "Placebo"
    ],
    "primary_completion_date": "2022-07-15",
    "completion_date": "2022-07-15",
    "results_first_posted": "2024-12-06",
    "last_update_posted": "2024-12-06",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT04816669",
    "title": "A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "SARS-CoV-2 Infection",
      "COVID-19"
    ],
    "interventions": [
      "BNT162b2"
    ],
    "primary_completion_date": "2021-12-01",
    "completion_date": "2021-12-02",
    "results_first_posted": "2022-12-23",
    "last_update_posted": "2022-12-23",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT07255404",
    "title": "A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pancreatic Ductal Adenocarcinoma (PDAC)"
    ],
    "interventions": [
      "Pumitamig",
      "Nab-paclitaxel",
      "Gemcitabine",
      "mFOLFIRINOX"
    ],
    "primary_completion_date": "2027-12",
    "completion_date": "2028-08",
    "results_first_posted": null,
    "last_update_posted": "2026-01-09",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT04588480",
    "title": "Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "SARS-CoV-2 Infection",
      "COVID-19"
    ],
    "interventions": [
      "BNT162b2",
      "Placebo"
    ],
    "primary_completion_date": "2021-11-25",
    "completion_date": "2021-11-25",
    "results_first_posted": "2023-02-01",
    "last_update_posted": "2023-02-01",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT07070232",
    "title": "A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumor"
    ],
    "interventions": [
      "BNT326",
      "Pumitamig",
      "Itraconazole",
      "Paroxetine"
    ],
    "primary_completion_date": "2028-02",
    "completion_date": "2029-10",
    "results_first_posted": null,
    "last_update_posted": "2026-01-27",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT05004181",
    "title": "Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "SARS-CoV-2 Infection",
      "COVID-19",
      "SARS-CoV-2 Acute Respiratory Disease",
      "SARS (Disease)"
    ],
    "interventions": [
      "BNT162b2",
      "Multivalent BNT162b2 (B.1.1.7 + B.1.617.2)",
      "Monovalent BNT162b2 (B.1.1.7)",
      "Monovalent BNT162b2 (B.1.617.2)",
      "Monovalent BNT162b2 (B.1.1.529.1)",
      "Observational"
    ],
    "primary_completion_date": "2023-08-16",
    "completion_date": "2023-10-04",
    "results_first_posted": "2024-11-22",
    "last_update_posted": "2024-11-22",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT07111520",
    "title": "A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-small Cell Lung Cancer"
    ],
    "interventions": [
      "BNT326",
      "BNT327",
      "Pembrolizumab",
      "SoC"
    ],
    "primary_completion_date": "2029-01",
    "completion_date": "2030-01",
    "results_first_posted": null,
    "last_update_posted": "2025-10-22",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT06841055",
    "title": "Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy Following Chemoimmunotherapy",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-small Cell Lung Cancer"
    ],
    "interventions": [
      "Pumitamig",
      "Docetaxel"
    ],
    "primary_completion_date": "2028-10",
    "completion_date": "2028-10",
    "results_first_posted": null,
    "last_update_posted": "2025-11-25",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT05142189",
    "title": "Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-Small Cell Lung Cancer"
    ],
    "interventions": [
      "BNT116",
      "Cemiplimab",
      "Docetaxel",
      "Carboplatin",
      "Paclitaxel",
      "BNT316",
      "anti-B7-H3 antibody conjugated to topoisomerase I inhibitor",
      "anti-HER3 antibody conjugated to topoisomerase I inhibitor",
      "Bispecific antibody for PD-L1 and VEGF-A"
    ],
    "primary_completion_date": "2030-02",
    "completion_date": "2031-11",
    "results_first_posted": null,
    "last_update_posted": "2025-11-12",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT04523571",
    "title": "Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "SARS-CoV-2"
    ],
    "interventions": [
      "BNT162b1",
      "Placebo"
    ],
    "primary_completion_date": "2020-09-30",
    "completion_date": "2021-08-10",
    "results_first_posted": "2023-09-18",
    "last_update_posted": "2023-09-18",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT04949490",
    "title": "A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial Subjects",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID-19",
      "SARS-CoV-2 Infection"
    ],
    "interventions": [
      "BNT162b2s01",
      "BNT162b2"
    ],
    "primary_completion_date": "2022-04-14",
    "completion_date": "2022-09-16",
    "results_first_posted": "2024-09-19",
    "last_update_posted": "2024-09-19",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT06449222",
    "title": "Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Locally Advanced Breast Cancer",
      "Triple Negative Breast Cancer",
      "Metastatic Triple Negative Breast Cancers"
    ],
    "interventions": [
      "BNT327 Dose Level 1 (DL1)",
      "BNT327 Dose Level 1 (DL2)",
      "Nab-placlitaxel",
      "Carboplatin",
      "Gemcitabine",
      "Paclitaxel",
      "Eribulin",
      "BNT327 Optimized Dose",
      "BNT327 Equivalent Q3W Dose"
    ],
    "primary_completion_date": "2028-08",
    "completion_date": "2029-06",
    "results_first_posted": null,
    "last_update_posted": "2025-12-11",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT07173751",
    "title": "ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Neoplasms"
    ],
    "interventions": [
      "Pumitamig",
      "Nab-paclitaxel/Paclitaxel",
      "Gemcitabine",
      "Carboplatin",
      "Eribulin",
      "Matching placebo"
    ],
    "primary_completion_date": "2029-12",
    "completion_date": "2030-09",
    "results_first_posted": null,
    "last_update_posted": "2026-01-13",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT02897765",
    "title": "A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Urinary Bladder Cancer",
      "Bladder Tumors",
      "Transitional Cell Carcinoma of the Bladder",
      "Malignant Melanoma",
      "Melanoma",
      "Skin Cancer",
      "Carcinoma, Non-Small-Cell Lung",
      "Lung Cancer"
    ],
    "interventions": [
      "NEO-PV-01",
      "Nivolumab",
      "Adjuvant"
    ],
    "primary_completion_date": "2019-02",
    "completion_date": "2020-05",
    "results_first_posted": null,
    "last_update_posted": "2021-02-25",
    "enrollment": null,
    "sponsor": "BioNTech US Inc.",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT07365995",
    "title": "A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Castration-resistant Prostate Cancer"
    ],
    "interventions": [
      "BNT324",
      "Docetaxel",
      "Prednisone/prednisolone"
    ],
    "primary_completion_date": "2031-02",
    "completion_date": "2031-02",
    "results_first_posted": null,
    "last_update_posted": "2026-01-26",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT04710043",
    "title": "Dose Escalation Trial of BNT152+153 in Patients With Cancer",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor"
    ],
    "interventions": [
      "BNT152",
      "BNT153"
    ],
    "primary_completion_date": "2025-09-10",
    "completion_date": "2025-09-10",
    "results_first_posted": null,
    "last_update_posted": "2025-09-25",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT05596734",
    "title": "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Influenza, Human",
      "COVID-19"
    ],
    "interventions": [
      "bivalent BNT162b2 (original/Omi BA.4/BA.5)",
      "qIRV (22/23)",
      "QIV",
      "bIRV",
      "tIRV"
    ],
    "primary_completion_date": "2023-12-28",
    "completion_date": "2023-12-28",
    "results_first_posted": "2025-07-23",
    "last_update_posted": "2025-07-23",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT04486378",
    "title": "A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Colorectal Cancer Stage II",
      "Colorectal Cancer Stage III"
    ],
    "interventions": [
      "RO7198457 intravenous (IV)",
      "Observational group (no intervention)"
    ],
    "primary_completion_date": "2026-11",
    "completion_date": "2030-08",
    "results_first_posted": null,
    "last_update_posted": "2026-01-14",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT05541861",
    "title": "Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "SARS-CoV-2 Infection",
      "COVID-19"
    ],
    "interventions": [
      "BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg",
      "BNT162b4 5 mcg",
      "BNT162b4 10 mcg",
      "BNT162b4 15 mcg",
      "BNT162b4 30 mcg",
      "BNT162b2 Monovalent (OMI XBB.1.5) 30 mcg"
    ],
    "primary_completion_date": "2024-11-22",
    "completion_date": "2024-11-22",
    "results_first_posted": "2026-01-13",
    "last_update_posted": "2026-01-13",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT07069309",
    "title": "A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages \u226565 Years",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID-19",
      "SARS-COV-2 Infection"
    ],
    "interventions": [
      "BNT162b2 (2025/2026 recommended SARS-CoV-2 strain)"
    ],
    "primary_completion_date": "2026-05-05",
    "completion_date": "2026-05-05",
    "results_first_posted": null,
    "last_update_posted": "2025-12-22",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT06069544",
    "title": "A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Malaria"
    ],
    "interventions": [
      "BNT165e",
      "Placebo"
    ],
    "primary_completion_date": "2025-05-28",
    "completion_date": "2026-03",
    "results_first_posted": null,
    "last_update_posted": "2025-06-06",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT07147348",
    "title": "A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumor"
    ],
    "interventions": [
      "BNT3212",
      "BNT327"
    ],
    "primary_completion_date": "2027-12",
    "completion_date": "2028-03",
    "results_first_posted": null,
    "last_update_posted": "2025-10-01",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT05310084",
    "title": "Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "SARS-CoV-2 Infection",
      "COVID-19"
    ],
    "interventions": [
      "BNT162b2",
      "Placebo",
      "Seasonal Inactivated Influenza Vaccine"
    ],
    "primary_completion_date": "2022-10-05",
    "completion_date": "2022-10-05",
    "results_first_posted": "2023-11-24",
    "last_update_posted": "2024-06-12",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT05543616",
    "title": "A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "SARS-CoV-2 Virus",
      "Severe Acute Respiratory Syndrome Coronavirus 2",
      "COVID-19"
    ],
    "interventions": [
      "Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose",
      "Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose",
      "Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose",
      "Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose",
      "Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose",
      "Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose",
      "Variant-adapted BNT162b2 (Omicron KP.2) 10 microgram dose"
    ],
    "primary_completion_date": "2026-06-16",
    "completion_date": "2026-06-16",
    "results_first_posted": null,
    "last_update_posted": "2025-09-10",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT04537949",
    "title": "A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Covid-19",
      "Protection Against COVID-19"
    ],
    "interventions": [
      "BNT162b3"
    ],
    "primary_completion_date": "2021-03-12",
    "completion_date": "2022-02-07",
    "results_first_posted": "2022-03-24",
    "last_update_posted": "2024-01-05",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT04101357",
    "title": "Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor",
      "Extensive-stage Small Cell Lung Cancer"
    ],
    "interventions": [
      "BNT411",
      "Atezolizumab",
      "Carboplatin",
      "Etoposide"
    ],
    "primary_completion_date": "2024-01-19",
    "completion_date": "2024-05-23",
    "results_first_posted": "2025-03-18",
    "last_update_posted": "2025-03-18",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT04455620",
    "title": "BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor"
    ],
    "interventions": [
      "BNT151"
    ],
    "primary_completion_date": "2024-05-28",
    "completion_date": "2024-05-28",
    "results_first_posted": "2025-07-02",
    "last_update_posted": "2025-07-02",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT05581641",
    "title": "Safety and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Malaria"
    ],
    "interventions": [
      "BNT165b1",
      "Placebo"
    ],
    "primary_completion_date": "2024-02-23",
    "completion_date": "2024-09-06",
    "results_first_posted": "2025-09-03",
    "last_update_posted": "2025-09-03",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT05432583",
    "title": "A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Genital Herpes Simplex Type 2"
    ],
    "interventions": [
      "BNT163",
      "Placebo"
    ],
    "primary_completion_date": "2026-10",
    "completion_date": "2026-10",
    "results_first_posted": null,
    "last_update_posted": "2025-10-20",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT02244580",
    "title": "Re-Evaluation of Tumor Samples From Women With Breast Cancer With the in Vitro Diagnostic Kit \"MammaTyperTM\"",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Invasive Breast Cancer"
    ],
    "interventions": [
      "MammaTyper\u2122"
    ],
    "primary_completion_date": "2014-08",
    "completion_date": "2014-08",
    "results_first_posted": "2016-11-07",
    "last_update_posted": "2016-11-07",
    "enrollment": null,
    "sponsor": "BioNTech Diagnostics GmbH",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT05547464",
    "title": "Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Tuberculosis"
    ],
    "interventions": [
      "BNT164a1",
      "BNT164b1",
      "Placebo"
    ],
    "primary_completion_date": "2026-03",
    "completion_date": "2026-12",
    "results_first_posted": null,
    "last_update_posted": "2026-01-13",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "BNTX",
    "nct_id": "NCT05262530",
    "title": "Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor"
    ],
    "interventions": [
      "BNT142"
    ],
    "primary_completion_date": "2025-12-22",
    "completion_date": "2025-12-22",
    "results_first_posted": null,
    "last_update_posted": "2026-01-21",
    "enrollment": null,
    "sponsor": "BioNTech SE",
    "collected_at": "2026-01-27",
    "search_term": "BioNTech"
  },
  {
    "ticker": "CATX",
    "nct_id": "NCT06710756",
    "title": "Lead-212 PSV359 Therapy for Patients With Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pancreatic Ductal Adenocarcinoma",
      "Gastric Cancer",
      "Esophageal Cancer",
      "Colorectal Cancer",
      "Ovarian Cancer",
      "Head and Neck Cancer",
      "Sarcoma",
      "Mesothelioma"
    ],
    "interventions": [
      "[203Pb]Pb-PSV359",
      "[212Pb]Pb-PSV359"
    ],
    "primary_completion_date": "2028-01-31",
    "completion_date": "2032-05-28",
    "results_first_posted": null,
    "last_update_posted": "2026-01-16",
    "enrollment": null,
    "sponsor": "Perspective Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Perspective Therapeutics"
  },
  {
    "ticker": "CDXS",
    "nct_id": "NCT03577886",
    "title": "Safety and Tolerability of CDX-6114 in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "CDX-6114",
      "Placebo"
    ],
    "primary_completion_date": "2018-08-21",
    "completion_date": "2018-09-04",
    "results_first_posted": null,
    "last_update_posted": "2018-09-20",
    "enrollment": null,
    "sponsor": "Codexis Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Codexis"
  },
  {
    "ticker": "CDXS",
    "nct_id": "NCT03797664",
    "title": "A Study of the Safety and Tolerability of CDX-6114 in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "CDX-6114",
      "Placebo"
    ],
    "primary_completion_date": "2019-04-12",
    "completion_date": "2019-04-12",
    "results_first_posted": null,
    "last_update_posted": "2021-08-04",
    "enrollment": null,
    "sponsor": "Codexis Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Codexis"
  },
  {
    "ticker": "CGEM",
    "nct_id": "NCT04036682",
    "title": "A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non Small Cell Lung Cancer",
      "EGFR Exon 20 Mutation"
    ],
    "interventions": [
      "CLN-081"
    ],
    "primary_completion_date": "2026-01-31",
    "completion_date": "2026-03-31",
    "results_first_posted": null,
    "last_update_posted": "2025-03-13",
    "enrollment": null,
    "sponsor": "Cullinan Therapeutics Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Cullinan Oncology"
  },
  {
    "ticker": "CGEM",
    "nct_id": "NCT06381141",
    "title": "A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple Myeloma"
    ],
    "interventions": [
      "CLN-619"
    ],
    "primary_completion_date": "2026-09",
    "completion_date": "2027-03",
    "results_first_posted": null,
    "last_update_posted": "2025-09-18",
    "enrollment": null,
    "sponsor": "Cullinan Therapeutics Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Cullinan Oncology"
  },
  {
    "ticker": "CGEM",
    "nct_id": "NCT05143996",
    "title": "CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsed/Refractory Acute Myeloid Leukemia (AML)",
      "Myelodysplastic Syndrome (MDS)"
    ],
    "interventions": [
      "CLN-049"
    ],
    "primary_completion_date": "2027-01",
    "completion_date": "2027-06",
    "results_first_posted": null,
    "last_update_posted": "2026-01-16",
    "enrollment": null,
    "sponsor": "Cullinan Therapeutics Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Cullinan Oncology"
  },
  {
    "ticker": "CGEM",
    "nct_id": "NCT06035744",
    "title": "CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumor"
    ],
    "interventions": [
      "CLN-617",
      "Pembrolizumab"
    ],
    "primary_completion_date": "2028-06",
    "completion_date": "2028-06",
    "results_first_posted": null,
    "last_update_posted": "2025-03-03",
    "enrollment": null,
    "sponsor": "Cullinan Therapeutics Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Cullinan Oncology"
  },
  {
    "ticker": "CGEM",
    "nct_id": "NCT05879744",
    "title": "A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "NHL",
      "NHL, Relapsed, Adult"
    ],
    "interventions": [
      "CLN-978"
    ],
    "primary_completion_date": "2026-11",
    "completion_date": "2027-04",
    "results_first_posted": null,
    "last_update_posted": "2024-05-02",
    "enrollment": null,
    "sponsor": "Cullinan Therapeutics Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Cullinan Oncology"
  },
  {
    "ticker": "CGEM",
    "nct_id": "NCT05117476",
    "title": "A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumor",
      "NSCLC"
    ],
    "interventions": [
      "CLN-619",
      "Pembrolizumab",
      "Paclitaxel",
      "Carboplatin AUC 6",
      "pemetrexed",
      "Datopotamab deruxtecan-dlnk (Dato-DXd)"
    ],
    "primary_completion_date": "2026-03",
    "completion_date": "2026-06",
    "results_first_posted": null,
    "last_update_posted": "2025-11-24",
    "enrollment": null,
    "sponsor": "Cullinan Therapeutics Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Cullinan Oncology"
  },
  {
    "ticker": "CGEM",
    "nct_id": "NCT03682055",
    "title": "Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Nasopharyngeal Carcinoma",
      "Nasopharyngeal Cancer"
    ],
    "interventions": [
      "VK-2019"
    ],
    "primary_completion_date": "2020-06-23",
    "completion_date": "2020-08-08",
    "results_first_posted": "2023-08-15",
    "last_update_posted": "2023-08-15",
    "enrollment": null,
    "sponsor": "Cullinan Therapeutics Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Cullinan Oncology"
  },
  {
    "ticker": "CLDX",
    "nct_id": "NCT05368285",
    "title": "A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Spontaneous Urticaria"
    ],
    "interventions": [
      "barzolvolimab",
      "Matching Placebo"
    ],
    "primary_completion_date": "2023-09-28",
    "completion_date": "2024-12-20",
    "results_first_posted": null,
    "last_update_posted": "2025-03-26",
    "enrollment": null,
    "sponsor": "Celldex Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Celldex Therapeutics"
  },
  {
    "ticker": "CLDX",
    "nct_id": "NCT04440943",
    "title": "A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-small Cell Lung Cancer",
      "Breast Cancer",
      "Gastric Cancer",
      "Renal Cell Carcinoma",
      "Ovarian Cancer",
      "Primary Peritoneal Carcinoma",
      "Fallopian Tube Cancer",
      "Cholangiocarcinoma",
      "Bladder Urothelial Carcinoma",
      "MSI-H Colorectal Cancer",
      "Esophageal Cancer",
      "Hepatic Cancer",
      "Head and Neck Cancer",
      "Other Solid Tumors"
    ],
    "interventions": [
      "CDX-527"
    ],
    "primary_completion_date": "2023-04-06",
    "completion_date": "2023-04-06",
    "results_first_posted": null,
    "last_update_posted": "2023-06-18",
    "enrollment": null,
    "sponsor": "Celldex Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Celldex Therapeutics"
  },
  {
    "ticker": "CLDX",
    "nct_id": "NCT05031624",
    "title": "A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Subjects"
    ],
    "interventions": [
      "CDX-0159",
      "Normal saline"
    ],
    "primary_completion_date": "2022-01-14",
    "completion_date": "2022-01-14",
    "results_first_posted": null,
    "last_update_posted": "2022-01-21",
    "enrollment": null,
    "sponsor": "Celldex Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Celldex Therapeutics"
  },
  {
    "ticker": "CLDX",
    "nct_id": "NCT01465139",
    "title": "A Study to Evaluate CDX-301 (rhuFlt3L) in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "CDX-301"
    ],
    "primary_completion_date": "2012-11",
    "completion_date": "2013-01",
    "results_first_posted": null,
    "last_update_posted": "2017-06-27",
    "enrollment": null,
    "sponsor": "Celldex Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Celldex Therapeutics"
  },
  {
    "ticker": "CLDX",
    "nct_id": "NCT03254927",
    "title": "A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Head and Neck Squamous Cell Carcinoma"
    ],
    "interventions": [
      "CDX-3379 and cetuximab"
    ],
    "primary_completion_date": "2020-09-16",
    "completion_date": "2020-12-16",
    "results_first_posted": "2023-04-03",
    "last_update_posted": "2023-04-03",
    "enrollment": null,
    "sponsor": "Celldex Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Celldex Therapeutics"
  },
  {
    "ticker": "CLDX",
    "nct_id": "NCT04146129",
    "title": "A Phase 1 Study of CDX-0159",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Subjects"
    ],
    "interventions": [
      "CDX-0159",
      "Normal saline"
    ],
    "primary_completion_date": "2020-04-06",
    "completion_date": "2020-06-26",
    "results_first_posted": null,
    "last_update_posted": "2020-07-07",
    "enrollment": null,
    "sponsor": "Celldex Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Celldex Therapeutics"
  },
  {
    "ticker": "CLDX",
    "nct_id": "NCT06366750",
    "title": "A Study of Barzolvolimab in Patients With Prurigo Nodularis",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Prurigo Nodularis"
    ],
    "interventions": [
      "barzolvolimab",
      "Matching Placebo"
    ],
    "primary_completion_date": "2026-06",
    "completion_date": "2027-03",
    "results_first_posted": null,
    "last_update_posted": "2025-12-18",
    "enrollment": null,
    "sponsor": "Celldex Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Celldex Therapeutics"
  },
  {
    "ticker": "CLDX",
    "nct_id": "NCT00709462",
    "title": "A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Cancer",
      "Colorectal Cancer",
      "Pancreatic Cancer",
      "Bladder Cancer",
      "Ovarian Cancer"
    ],
    "interventions": [
      "CDX1307"
    ],
    "primary_completion_date": "2010-05",
    "completion_date": "2010-06",
    "results_first_posted": null,
    "last_update_posted": "2010-07-26",
    "enrollment": null,
    "sponsor": "Celldex Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Celldex Therapeutics"
  },
  {
    "ticker": "CLDX",
    "nct_id": "NCT06650761",
    "title": "A Phase I Study of CDX-622",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants"
    ],
    "interventions": [
      "CDX-622",
      "Normal Saline"
    ],
    "primary_completion_date": "2026-04",
    "completion_date": "2026-04",
    "results_first_posted": null,
    "last_update_posted": "2025-09-10",
    "enrollment": null,
    "sponsor": "Celldex Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Celldex Therapeutics"
  },
  {
    "ticker": "CLDX",
    "nct_id": "NCT02014909",
    "title": "A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Cancer"
    ],
    "interventions": [
      "KTN3379"
    ],
    "primary_completion_date": "2017-05-25",
    "completion_date": "2017-06-05",
    "results_first_posted": null,
    "last_update_posted": "2017-07-24",
    "enrollment": null,
    "sponsor": "Celldex Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Celldex Therapeutics"
  },
  {
    "ticker": "CLDX",
    "nct_id": "NCT05788484",
    "title": "A Study of CDX-585 in Patients With Advanced Malignancies",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-small Cell Lung Cancer",
      "Gastric Cancer",
      "Head and Neck Cancer",
      "Ovarian Cancer",
      "Primary Peritoneal Carcinoma",
      "Fallopian Tube Cancer",
      "Bladder Urothelial Carcinoma",
      "Colorectal Cancer",
      "Esophageal Cancer",
      "Hepatic Cancer",
      "Renal Cell Carcinoma",
      "Cholangiocarcinoma",
      "Pancreatic Cancer",
      "Other Solid Tumors"
    ],
    "interventions": [
      "CDX-585"
    ],
    "primary_completion_date": "2025-05-21",
    "completion_date": "2025-05-21",
    "results_first_posted": null,
    "last_update_posted": "2025-06-15",
    "enrollment": null,
    "sponsor": "Celldex Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Celldex Therapeutics"
  },
  {
    "ticker": "CLDX",
    "nct_id": "NCT02837991",
    "title": "A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Renal Cell Carcinoma (RCC)",
      "Clear-cell Renal Cell Carcinoma",
      "Papillary Renal Cell Carcinoma",
      "Kidney Neoplasms",
      "Metastatic Renal Cell Carcinoma",
      "Ovarian Clear Cell Carcinoma"
    ],
    "interventions": [
      "CDX-014"
    ],
    "primary_completion_date": "2018-11-16",
    "completion_date": "2018-11-16",
    "results_first_posted": null,
    "last_update_posted": "2020-06-04",
    "enrollment": null,
    "sponsor": "Celldex Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Celldex Therapeutics"
  },
  {
    "ticker": "CLDX",
    "nct_id": "NCT07256392",
    "title": "Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Spontaneous Urticaria"
    ],
    "interventions": [
      "barzolvolimab",
      "Standard of Care"
    ],
    "primary_completion_date": "2028-09",
    "completion_date": "2028-09",
    "results_first_posted": null,
    "last_update_posted": "2025-12-24",
    "enrollment": null,
    "sponsor": "Celldex Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Celldex Therapeutics"
  },
  {
    "ticker": "CLDX",
    "nct_id": "NCT01094496",
    "title": "A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The \"N-ABLE\" Study)",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bladder Cancer"
    ],
    "interventions": [
      "CDX-1307 Vaccine Regimen",
      "Chemotherapy"
    ],
    "primary_completion_date": "2011-07",
    "completion_date": "2011-07",
    "results_first_posted": null,
    "last_update_posted": "2020-02-13",
    "enrollment": null,
    "sponsor": "Celldex Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Celldex Therapeutics"
  },
  {
    "ticker": "CLDX",
    "nct_id": "NCT00948961",
    "title": "A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Malignancies"
    ],
    "interventions": [
      "CDX-1401 in combination with Resiquimod and/or Poly-ICLC",
      "CDX-1401",
      "Resiquimod",
      "poly-ICLC"
    ],
    "primary_completion_date": "2012-06",
    "completion_date": "2014-02",
    "results_first_posted": null,
    "last_update_posted": "2016-06-27",
    "enrollment": null,
    "sponsor": "Celldex Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Celldex Therapeutics"
  },
  {
    "ticker": "CLDX",
    "nct_id": "NCT04548869",
    "title": "A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cold Urticaria",
      "Cold Contact Urticaria",
      "Symptomatic Dermographism",
      "Symptomatic Dermatographism",
      "Cholinergic Urticaria"
    ],
    "interventions": [
      "CDX-0159"
    ],
    "primary_completion_date": "2022-12-16",
    "completion_date": "2023-05-12",
    "results_first_posted": null,
    "last_update_posted": "2023-05-17",
    "enrollment": null,
    "sponsor": "Celldex Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Celldex Therapeutics"
  },
  {
    "ticker": "CLDX",
    "nct_id": "NCT02386111",
    "title": "A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Carcinoma, Renal Cell",
      "Kidney Diseases",
      "Kidney Neoplasms",
      "Urogenital Neoplasms",
      "Urologic Diseases",
      "Urologic Neoplasms",
      "Neoplasms",
      "Neoplasms by Histologic Type",
      "Clear-cell Metastatic Renal Cell Carcinoma"
    ],
    "interventions": [
      "Combination of varlilumab and sunitinib"
    ],
    "primary_completion_date": "2017-08",
    "completion_date": "2017-11-03",
    "results_first_posted": null,
    "last_update_posted": "2018-07-26",
    "enrollment": null,
    "sponsor": "Celldex Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Celldex Therapeutics"
  },
  {
    "ticker": "CLDX",
    "nct_id": "NCT00648102",
    "title": "Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Cancer",
      "Colorectal Cancer",
      "Pancreatic Cancer",
      "Bladder Cancer",
      "Ovarian Cancer"
    ],
    "interventions": [
      "CDX-1307"
    ],
    "primary_completion_date": "2009-05",
    "completion_date": "2009-12",
    "results_first_posted": null,
    "last_update_posted": "2010-07-26",
    "enrollment": null,
    "sponsor": "Celldex Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Celldex Therapeutics"
  },
  {
    "ticker": "CLDX",
    "nct_id": "NCT07330778",
    "title": "A Study of CDX-622 in Participants With Mild to Moderate Asthma",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Mild to Moderate Asthma"
    ],
    "interventions": [
      "CDX-622"
    ],
    "primary_completion_date": "2027-03",
    "completion_date": "2027-03",
    "results_first_posted": null,
    "last_update_posted": "2026-01-22",
    "enrollment": null,
    "sponsor": "Celldex Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Celldex Therapeutics"
  },
  {
    "ticker": "CLDX",
    "nct_id": "NCT03067935",
    "title": "Individual Patient Expanded Access-Glembatumumab Vedotin",
    "status": "NO_LONGER_AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Metastatic gpNMB Expressing Triple Negative Breast Cancer"
    ],
    "interventions": [
      "glembatumumab vedotin"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2018-05-21",
    "enrollment": null,
    "sponsor": "Celldex Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Celldex Therapeutics"
  },
  {
    "ticker": "CLDX",
    "nct_id": "NCT02302339",
    "title": "A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Melanoma"
    ],
    "interventions": [
      "glembatumumab vedotin",
      "glembatumumab vedotin and varlilumab",
      "glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab)",
      "glembatumumab vedotin and CDX-301"
    ],
    "primary_completion_date": "2018-06-14",
    "completion_date": "2018-10-03",
    "results_first_posted": "2019-09-06",
    "last_update_posted": "2019-09-06",
    "enrollment": null,
    "sponsor": "Celldex Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Celldex Therapeutics"
  },
  {
    "ticker": "CLDX",
    "nct_id": "NCT01156753",
    "title": "A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Cancer"
    ],
    "interventions": [
      "CDX-011",
      "\"Investigator's Choice\" chemotherapy"
    ],
    "primary_completion_date": "2012-10",
    "completion_date": "2012-11",
    "results_first_posted": null,
    "last_update_posted": "2017-07-02",
    "enrollment": null,
    "sponsor": "Celldex Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Celldex Therapeutics"
  },
  {
    "ticker": "CLDX",
    "nct_id": "NCT01791686",
    "title": "Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dense Deposit Disease",
      "Membranoproliferative Glomerulonephritis Type II",
      "C3 Glomerulonephritis"
    ],
    "interventions": [
      "CDX-1135"
    ],
    "primary_completion_date": "2014-03",
    "completion_date": "2014-03",
    "results_first_posted": null,
    "last_update_posted": "2014-03-07",
    "enrollment": null,
    "sponsor": "Celldex Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Celldex Therapeutics"
  },
  {
    "ticker": "CLDX",
    "nct_id": "NCT06727552",
    "title": "A Study of Barzolvolimab in Patients With Atopic Dermatitis",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atopic Dermatitis"
    ],
    "interventions": [
      "Barzolvolimab",
      "Matching placebo"
    ],
    "primary_completion_date": "2026-10",
    "completion_date": "2027-05",
    "results_first_posted": null,
    "last_update_posted": "2025-11-14",
    "enrollment": null,
    "sponsor": "Celldex Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Celldex Therapeutics"
  },
  {
    "ticker": "CLDX",
    "nct_id": "NCT03329950",
    "title": "A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Melanoma",
      "Non-small Cell Lung Cancer",
      "Breast Cancer",
      "Gastric Cancer",
      "Renal Cell Carcinoma",
      "Ovarian Cancer",
      "Cholangiocarcinoma",
      "Bladder Urothelial Carcinoma",
      "Pancreatic Adenocarcinoma",
      "Colorectal Cancer",
      "Esophageal Cancer",
      "Hepatic Cancer",
      "Head and Neck Cancer",
      "Primary Peritoneal Cancer",
      "Fallopian Tube Cancer",
      "Other Solid Tumors",
      "Diffuse Large B-cell Lymphoma (DLBCL)",
      "Mantle Cell Lymphoma",
      "Indolent B-cell Lymphomas",
      "Non-Hodgkin Lymphoma",
      "Follicular Lymphoma",
      "Lymphoplasmacytic Lymphoma",
      "Waldenstrom's Disease",
      "Marginal Zone Lymphoma",
      "Mucosa Associated Lymphoid Tissue",
      "Small Lymphocytic Leukemia"
    ],
    "interventions": [
      "CDX-1140",
      "CDX-301",
      "pembrolizumab",
      "Chemotherapy"
    ],
    "primary_completion_date": "2022-09-13",
    "completion_date": "2022-09-13",
    "results_first_posted": null,
    "last_update_posted": "2024-03-28",
    "enrollment": null,
    "sponsor": "Celldex Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Celldex Therapeutics"
  },
  {
    "ticker": "CLDX",
    "nct_id": "NCT03068650",
    "title": "Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut",
    "status": "NO_LONGER_AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Recurrent GBM"
    ],
    "interventions": [
      "rindopepimut"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2017-10-18",
    "enrollment": null,
    "sponsor": "Celldex Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Celldex Therapeutics"
  },
  {
    "ticker": "CLDX",
    "nct_id": "NCT00458601",
    "title": "Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Malignant Glioma"
    ],
    "interventions": [
      "CDX-110 with GM-CSF",
      "Temozolomide"
    ],
    "primary_completion_date": "2010-11",
    "completion_date": "2016-05",
    "results_first_posted": null,
    "last_update_posted": "2018-01-16",
    "enrollment": null,
    "sponsor": "Celldex Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Celldex Therapeutics"
  },
  {
    "ticker": "CLDX",
    "nct_id": "NCT05405660",
    "title": "A Study of CDX-0159 in Patients With Chronic Inducible Urticaria",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Inducible Urticaria"
    ],
    "interventions": [
      "barzolvolimab",
      "Matching Placebo"
    ],
    "primary_completion_date": "2024-06-12",
    "completion_date": "2025-09-12",
    "results_first_posted": null,
    "last_update_posted": "2025-11-06",
    "enrollment": null,
    "sponsor": "Celldex Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Celldex Therapeutics"
  },
  {
    "ticker": "CLDX",
    "nct_id": "NCT04944862",
    "title": "A Study of CDX-0159 in Patients With Prurigo Nodularis",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Prurigo Nodularis"
    ],
    "interventions": [
      "CDX-0159",
      "Normal saline"
    ],
    "primary_completion_date": "2023-07-31",
    "completion_date": "2023-07-31",
    "results_first_posted": null,
    "last_update_posted": "2023-08-14",
    "enrollment": null,
    "sponsor": "Celldex Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Celldex Therapeutics"
  },
  {
    "ticker": "CLDX",
    "nct_id": "NCT01460134",
    "title": "A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma",
      "Chronic Lymphocytic Leukemia",
      "Mantle Cell Lymphoma",
      "Marginal Zone B Cell Lymphoma)",
      "Any T-cell Malignancy",
      "Solid Tumors (Metastatic Melanoma, Renal (Clear) Cell Carcinoma",
      "Hormone-refractory Prostate Adenocarcinoma, Ovarian Cancer",
      "Colorectal Adenocarcinoma, Non-small Cell Lung Cancer)",
      "Burkett's Lymphoma",
      "Primary Lymphoma of the Central Nervous System"
    ],
    "interventions": [
      "CDX-1127",
      "CDX-1127",
      "CDX-1127"
    ],
    "primary_completion_date": "2015-12",
    "completion_date": "2017-10-16",
    "results_first_posted": null,
    "last_update_posted": "2018-01-31",
    "enrollment": null,
    "sponsor": "Celldex Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Celldex Therapeutics"
  },
  {
    "ticker": "CLDX",
    "nct_id": "NCT04538794",
    "title": "A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Spontaneous Urticaria"
    ],
    "interventions": [
      "CDX-0159",
      "Normal Saline"
    ],
    "primary_completion_date": "2023-01-17",
    "completion_date": "2023-01-17",
    "results_first_posted": null,
    "last_update_posted": "2023-07-19",
    "enrollment": null,
    "sponsor": "Celldex Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Celldex Therapeutics"
  },
  {
    "ticker": "CLDX",
    "nct_id": "NCT02413827",
    "title": "A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Unresectable Stage III or Stage IV Melanoma"
    ],
    "interventions": [
      "Combination of varlilumab and ipilimumab",
      "Cohort A: varlilumab & ipilimumab; Cohort B: varlilumab, ipilimumab, CDX-1401 & poly-ICLC"
    ],
    "primary_completion_date": "2016-11-02",
    "completion_date": "2016-11-09",
    "results_first_posted": null,
    "last_update_posted": "2017-04-07",
    "enrollment": null,
    "sponsor": "Celldex Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Celldex Therapeutics"
  },
  {
    "ticker": "CLDX",
    "nct_id": "NCT01498328",
    "title": "A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Glioblastoma",
      "Small Cell Glioblastoma",
      "Giant Cell Glioblastoma",
      "Gliosarcoma",
      "Glioblastoma With Oligodendroglial Component",
      "Recurrent Glioblastoma",
      "Relapsed Glioblastoma"
    ],
    "interventions": [
      "Bevacizumab",
      "Rindopepimut (CDX-110) with GM-CSF",
      "KLH"
    ],
    "primary_completion_date": "2015-04",
    "completion_date": "2016-05-17",
    "results_first_posted": null,
    "last_update_posted": "2020-02-17",
    "enrollment": null,
    "sponsor": "Celldex Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Celldex Therapeutics"
  },
  {
    "ticker": "CLDX",
    "nct_id": "NCT02473731",
    "title": "A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Squamous Cell Carcinoma of the Head and Neck"
    ],
    "interventions": [
      "KTN3379"
    ],
    "primary_completion_date": "2016-09-22",
    "completion_date": "2016-10-10",
    "results_first_posted": null,
    "last_update_posted": "2019-08-01",
    "enrollment": null,
    "sponsor": "Celldex Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Celldex Therapeutics"
  },
  {
    "ticker": "CLDX",
    "nct_id": "NCT05774184",
    "title": "A Study of CDX-0159 in Patients With Eosinophilic Esophagitis",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Eosinophilic Esophagitis"
    ],
    "interventions": [
      "barzolvolimab",
      "Matching Placebo"
    ],
    "primary_completion_date": "2025-06-04",
    "completion_date": "2026-01",
    "results_first_posted": null,
    "last_update_posted": "2026-01-21",
    "enrollment": null,
    "sponsor": "Celldex Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Celldex Therapeutics"
  },
  {
    "ticker": "CLDX",
    "nct_id": "NCT01997333",
    "title": "Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic gpNMB Over-expressing Triple Negative Breast Cancer"
    ],
    "interventions": [
      "CDX-011",
      "Capecitabine"
    ],
    "primary_completion_date": "2017-11-30",
    "completion_date": "2018-08-07",
    "results_first_posted": "2019-03-08",
    "last_update_posted": "2019-03-08",
    "enrollment": null,
    "sponsor": "Celldex Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Celldex Therapeutics"
  },
  {
    "ticker": "CLDX",
    "nct_id": "NCT02456701",
    "title": "Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Thyroid Cancer"
    ],
    "interventions": [
      "KTN3379",
      "vemurafenib"
    ],
    "primary_completion_date": "2016-10-13",
    "completion_date": "2016-10-13",
    "results_first_posted": null,
    "last_update_posted": "2017-09-05",
    "enrollment": null,
    "sponsor": "Celldex Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Celldex Therapeutics"
  },
  {
    "ticker": "CLDX",
    "nct_id": "NCT07266402",
    "title": "A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Inducible Urticaria",
      "Cold Urticaria",
      "Cold-Induced Urticaria",
      "Symptomatic Dermographism"
    ],
    "interventions": [
      "Barzolvolimab",
      "Matching Placebo"
    ],
    "primary_completion_date": "2028-06",
    "completion_date": "2028-10",
    "results_first_posted": null,
    "last_update_posted": "2026-01-12",
    "enrollment": null,
    "sponsor": "Celldex Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Celldex Therapeutics"
  },
  {
    "ticker": "CLDX",
    "nct_id": "NCT01480479",
    "title": "Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Glioblastoma",
      "Small Cell Glioblastoma",
      "Giant Cell Glioblastoma",
      "Gliosarcoma",
      "Glioblastoma With Oligodendroglial Component"
    ],
    "interventions": [
      "Rindopepimut (CDX-110) with GM-CSF",
      "Temozolomide",
      "KLH"
    ],
    "primary_completion_date": "2016-11",
    "completion_date": "2016-11",
    "results_first_posted": null,
    "last_update_posted": "2018-01-16",
    "enrollment": null,
    "sponsor": "Celldex Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Celldex Therapeutics"
  },
  {
    "ticker": "CLDX",
    "nct_id": "NCT06455202",
    "title": "A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Spontaneous Urticaria"
    ],
    "interventions": [
      "barzolvolimab",
      "Matching placebo"
    ],
    "primary_completion_date": "2026-10",
    "completion_date": "2027-04",
    "results_first_posted": null,
    "last_update_posted": "2025-12-18",
    "enrollment": null,
    "sponsor": "Celldex Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Celldex Therapeutics"
  },
  {
    "ticker": "CLDX",
    "nct_id": "NCT02642016",
    "title": "A Study to Evaluate the Safety and Pharmacokinetics of CDX-0158 in Adult Patients With Advanced Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Cancer"
    ],
    "interventions": [
      "CDX-0158 (formerly known as KTN-0158)"
    ],
    "primary_completion_date": "2018-01-30",
    "completion_date": "2019-06-04",
    "results_first_posted": null,
    "last_update_posted": "2019-06-12",
    "enrollment": null,
    "sponsor": "Celldex Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Celldex Therapeutics"
  },
  {
    "ticker": "CRBU",
    "nct_id": "NCT05332054",
    "title": "Long-Term Follow-up Study",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Lymphoma, Non-Hodgkin",
      "Relapsed Non-Hodgkin Lymphoma",
      "Refractory B-Cell Non-Hodgkin Lymphoma",
      "Non-Hodgkin Lymphoma",
      "Lymphoma",
      "B Cell Lymphoma",
      "B-Cell Non-Hodgkin's Lymphoma",
      "Hematologic Malignancy",
      "Relapsed/Refractory Multiple Myeloma",
      "Relapsed/Refractory Acute Myeloid Leukemia"
    ],
    "interventions": [
      "Caribou-sponsored investigational therapy"
    ],
    "primary_completion_date": "2041-12",
    "completion_date": "2041-12",
    "results_first_posted": null,
    "last_update_posted": "2025-07-11",
    "enrollment": null,
    "sponsor": "Caribou Biosciences, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Caribou Biosciences"
  },
  {
    "ticker": "CRBU",
    "nct_id": "NCT06128044",
    "title": "CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Myeloid Leukemia, in Relapse",
      "Acute Myeloid Leukemia Refractory"
    ],
    "interventions": [
      "CB-012"
    ],
    "primary_completion_date": "2025-05-30",
    "completion_date": "2025-05-30",
    "results_first_posted": null,
    "last_update_posted": "2025-06-11",
    "enrollment": null,
    "sponsor": "Caribou Biosciences, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Caribou Biosciences"
  },
  {
    "ticker": "CRBU",
    "nct_id": "NCT06752876",
    "title": "CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)",
    "status": "WITHDRAWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Systemic Lupus Erythematosus",
      "Lupus",
      "Lupus Erythematosus",
      "Lupus Nephritis"
    ],
    "interventions": [
      "CB-010"
    ],
    "primary_completion_date": "2029-04",
    "completion_date": "2029-04",
    "results_first_posted": null,
    "last_update_posted": "2025-09-19",
    "enrollment": null,
    "sponsor": "Caribou Biosciences, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Caribou Biosciences"
  },
  {
    "ticker": "CRNX",
    "nct_id": "NCT07221084",
    "title": "A Study to Assess Pharmacokinetics, Safety, and Tolerability of Atumelnant in Healthy Japanese and Caucasian Participants",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "Atumelnant",
      "Placebo"
    ],
    "primary_completion_date": "2026-02",
    "completion_date": "2026-02",
    "results_first_posted": null,
    "last_update_posted": "2025-10-27",
    "enrollment": null,
    "sponsor": "Crinetics Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Crinetics Pharmaceuticals"
  },
  {
    "ticker": "CRNX",
    "nct_id": "NCT07087054",
    "title": "Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Carcinoid Syndrome",
      "Carcinoid",
      "Carcinoid Tumor",
      "Carcinoid Tumor of Ileum",
      "Carcinoid Tumor of Cecum",
      "Carcinoid Tumor of Liver",
      "Carcinoid Tumor of Pancreas",
      "Carcinoid Syndrome Diarrhea",
      "Carcinoid Intestine Tumor"
    ],
    "interventions": [
      "Paltusotine",
      "Placebo"
    ],
    "primary_completion_date": "2027-08",
    "completion_date": "2030-01",
    "results_first_posted": null,
    "last_update_posted": "2025-11-28",
    "enrollment": null,
    "sponsor": "Crinetics Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Crinetics Pharmaceuticals"
  },
  {
    "ticker": "CRNX",
    "nct_id": "NCT06048887",
    "title": "Single and Multiple-Ascending Dose Study of CRN04894 in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "CRN04894 Oral Solution",
      "Placebo Oral Solution"
    ],
    "primary_completion_date": "2022-04-11",
    "completion_date": "2022-04-11",
    "results_first_posted": null,
    "last_update_posted": "2023-09-21",
    "enrollment": null,
    "sponsor": "Crinetics Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Crinetics Pharmaceuticals"
  },
  {
    "ticker": "CRNX",
    "nct_id": "NCT07144163",
    "title": "A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Congenital Adrenal Hyperplasia",
      "Classic Congenital Adrenal Hyperplasia"
    ],
    "interventions": [
      "Atumelnant",
      "Placebo"
    ],
    "primary_completion_date": "2027-05",
    "completion_date": "2027-05",
    "results_first_posted": null,
    "last_update_posted": "2025-12-17",
    "enrollment": null,
    "sponsor": "Crinetics Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Crinetics Pharmaceuticals"
  },
  {
    "ticker": "CRNX",
    "nct_id": "NCT04246749",
    "title": "Mass Balance and Pharmacokinetics of [14C]-CRN00808 in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "[14C]-CRN00808",
      "CRN00808"
    ],
    "primary_completion_date": "2019-10-25",
    "completion_date": "2019-10-25",
    "results_first_posted": null,
    "last_update_posted": "2020-01-29",
    "enrollment": null,
    "sponsor": "Crinetics Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Crinetics Pharmaceuticals"
  },
  {
    "ticker": "CRNX",
    "nct_id": "NCT05907291",
    "title": "Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Congenital Adrenal Hyperplasia",
      "Classic Congenital Adrenal Hyperplasia"
    ],
    "interventions": [
      "atumelnant (CRN04894)"
    ],
    "primary_completion_date": "2025-08-22",
    "completion_date": "2025-08-22",
    "results_first_posted": null,
    "last_update_posted": "2025-09-23",
    "enrollment": null,
    "sponsor": "Crinetics Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Crinetics Pharmaceuticals"
  },
  {
    "ticker": "CRNX",
    "nct_id": "NCT05804669",
    "title": "A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cushing Syndrome",
      "Cushing Disease",
      "Ectopic ACTH Syndrome"
    ],
    "interventions": [
      "atumelnant"
    ],
    "primary_completion_date": "2026-10",
    "completion_date": "2026-10",
    "results_first_posted": null,
    "last_update_posted": "2025-04-10",
    "enrollment": null,
    "sponsor": "Crinetics Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Crinetics Pharmaceuticals"
  },
  {
    "ticker": "CRNX",
    "nct_id": "NCT07159841",
    "title": "A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Congenital Adrenal Hyperplasia",
      "Classic Congenital Adrenal Hyperplasia"
    ],
    "interventions": [
      "Atumelnant",
      "Placebo"
    ],
    "primary_completion_date": "2030-03",
    "completion_date": "2030-03",
    "results_first_posted": null,
    "last_update_posted": "2026-01-26",
    "enrollment": null,
    "sponsor": "Crinetics Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Crinetics Pharmaceuticals"
  },
  {
    "ticker": "CRNX",
    "nct_id": "NCT03936166",
    "title": "A Single and Multiple-Ascending Dose Study of CRN01941 in Healthy Adult Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "CRN01941 Oral Solution",
      "CRN01941 Oral Capsule",
      "Placebo Oral Solution",
      "Placebo Oral Capsule"
    ],
    "primary_completion_date": "2019-12-16",
    "completion_date": "2019-12-16",
    "results_first_posted": null,
    "last_update_posted": "2020-11-04",
    "enrollment": null,
    "sponsor": "Crinetics Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Crinetics Pharmaceuticals"
  },
  {
    "ticker": "CRNX",
    "nct_id": "NCT07129252",
    "title": "A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "SST2-positive Neuroendocrine Neoplasms",
      "Neuroendocrine Tumors",
      "Neuroendocrine Neoplasm"
    ],
    "interventions": [
      "CRN09682"
    ],
    "primary_completion_date": "2027-08",
    "completion_date": "2029-08",
    "results_first_posted": null,
    "last_update_posted": "2026-01-22",
    "enrollment": null,
    "sponsor": "Crinetics Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Crinetics Pharmaceuticals"
  },
  {
    "ticker": "CRNX",
    "nct_id": "NCT06712823",
    "title": "An Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Congenital Adrenal Hyperplasia",
      "Classic Congenital Adrenal Hyperplasia"
    ],
    "interventions": [
      "atumelnant (CRN04894)"
    ],
    "primary_completion_date": "2027-11",
    "completion_date": "2027-11",
    "results_first_posted": null,
    "last_update_posted": "2025-09-23",
    "enrollment": null,
    "sponsor": "Crinetics Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Crinetics Pharmaceuticals"
  },
  {
    "ticker": "CRNX",
    "nct_id": "NCT03789656",
    "title": "An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acromegaly"
    ],
    "interventions": [
      "Paltusotine"
    ],
    "primary_completion_date": "2020-08-03",
    "completion_date": "2020-08-31",
    "results_first_posted": "2025-02-17",
    "last_update_posted": "2025-02-17",
    "enrollment": null,
    "sponsor": "Crinetics Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Crinetics Pharmaceuticals"
  },
  {
    "ticker": "CYTK",
    "nct_id": "NCT03759392",
    "title": "Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Heart Failure With Reduced Ejection Fraction"
    ],
    "interventions": [
      "Omecamtiv Mecarbil",
      "Placebo"
    ],
    "primary_completion_date": "2021-11-08",
    "completion_date": "2022-01-06",
    "results_first_posted": "2023-03-07",
    "last_update_posted": "2023-03-07",
    "enrollment": null,
    "sponsor": "Cytokinetics",
    "collected_at": "2026-01-27",
    "search_term": "Cytokinetics"
  },
  {
    "ticker": "CYTK",
    "nct_id": "NCT05662215",
    "title": "A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult Participants",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants"
    ],
    "interventions": [
      "CK-3828136",
      "Placebo for CK-3828136"
    ],
    "primary_completion_date": "2023-08-08",
    "completion_date": "2023-08-08",
    "results_first_posted": null,
    "last_update_posted": "2024-10-17",
    "enrollment": null,
    "sponsor": "Cytokinetics",
    "collected_at": "2026-01-27",
    "search_term": "Cytokinetics"
  },
  {
    "ticker": "CYTK",
    "nct_id": "NCT01380223",
    "title": "A Pharmacokinetic and Pharmacodynamic Study of Omecamtiv Mecarbil in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Heart Failure"
    ],
    "interventions": [
      "placebo",
      "omecamtiv mecarbil",
      "omecamtiv mecarbil",
      "omecamtiv mecarbil",
      "omecamtiv mecarbil",
      "omecamtiv mecarbil",
      "omecamtiv mecarbil",
      "omecamtiv mecarbil",
      "omecamtiv mecarbil",
      "omecamtiv mecarbil",
      "omecamtiv mecarbil"
    ],
    "primary_completion_date": "2006-04",
    "completion_date": "2006-04",
    "results_first_posted": null,
    "last_update_posted": "2015-10-14",
    "enrollment": null,
    "sponsor": "Cytokinetics",
    "collected_at": "2026-01-27",
    "search_term": "Cytokinetics"
  },
  {
    "ticker": "CYTK",
    "nct_id": "NCT00682565",
    "title": "PK and Tolerability of IV and Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Heart Failure",
      "Myocardial Ischemia",
      "Angina Pectoris"
    ],
    "interventions": [
      "CK-1827452 24mg and 6 mg iv infusion",
      "CK-1827452 12.5mg capsule",
      "CK-1827452 48 mg and 11 mg iv infusion",
      "CK-1827452 25mg capsule",
      "Placebo iv infusion",
      "Placebo capsule"
    ],
    "primary_completion_date": "2008-11",
    "completion_date": "2009-03",
    "results_first_posted": "2010-02-25",
    "last_update_posted": "2018-08-21",
    "enrollment": null,
    "sponsor": "Cytokinetics",
    "collected_at": "2026-01-27",
    "search_term": "Cytokinetics"
  },
  {
    "ticker": "CYTK",
    "nct_id": "NCT05442775",
    "title": "A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Amyotrophic Lateral Sclerosis"
    ],
    "interventions": [
      "Reldesemtiv"
    ],
    "primary_completion_date": "2023-06-07",
    "completion_date": "2023-06-07",
    "results_first_posted": "2024-08-13",
    "last_update_posted": "2024-08-13",
    "enrollment": null,
    "sponsor": "Cytokinetics",
    "collected_at": "2026-01-27",
    "search_term": "Cytokinetics"
  },
  {
    "ticker": "CYTK",
    "nct_id": "NCT01378676",
    "title": "A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Amyotrophic Lateral Sclerosis"
    ],
    "interventions": [
      "Placebo (Part A)",
      "CK-2017357 (Part A)",
      "CK-2017357 (Part A)",
      "CK-2017357 (Part A)",
      "Riluzole 50 MG (Part B)",
      "Placebo (Part B)",
      "CK-2017357 (Part B)",
      "CK-2017357 (Part B)",
      "CK-2017357 (Part B)"
    ],
    "primary_completion_date": "2012-03",
    "completion_date": "2012-03",
    "results_first_posted": null,
    "last_update_posted": "2019-05-07",
    "enrollment": null,
    "sponsor": "Cytokinetics",
    "collected_at": "2026-01-27",
    "search_term": "Cytokinetics"
  },
  {
    "ticker": "CYTK",
    "nct_id": "NCT00748579",
    "title": "Phase II Study of the Effect of CK-1827452 Injection on Myocardial Efficiency",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Heart Failure"
    ],
    "interventions": [
      "CK-1827452",
      "CK-1827452"
    ],
    "primary_completion_date": "2008-11",
    "completion_date": "2009-07",
    "results_first_posted": "2010-08-23",
    "last_update_posted": "2020-01-21",
    "enrollment": null,
    "sponsor": "Cytokinetics",
    "collected_at": "2026-01-27",
    "search_term": "Cytokinetics"
  },
  {
    "ticker": "CYTK",
    "nct_id": "NCT01786512",
    "title": "COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Modified Release Oral Formulation",
      "Left Ventricular Systolic Dysfunction",
      "Chronic Heart Failure",
      "History of Chronic Heart Failure",
      "Left Ventricular Ejection Fraction",
      "Pharmacokinetics",
      "Echocardiogram"
    ],
    "interventions": [
      "Omecamtiv Mecarbil Matrix F1 Formulation",
      "Omecamtiv Mecarbil Matrix F2 Formulation",
      "Placebo",
      "Omecamtiv Mecarbil Swellable Core Technology F2"
    ],
    "primary_completion_date": "2015-07-22",
    "completion_date": "2015-08-19",
    "results_first_posted": "2021-05-17",
    "last_update_posted": "2021-08-12",
    "enrollment": null,
    "sponsor": "Cytokinetics",
    "collected_at": "2026-01-27",
    "search_term": "Cytokinetics"
  },
  {
    "ticker": "CYTK",
    "nct_id": "NCT00343564",
    "title": "A Study of SB-743921 in Non-Hodgkin Lymphoma and Hodgkin Lymphoma",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-Hodgkin's Lymphoma",
      "Hodgkin's Disease"
    ],
    "interventions": [
      "SB-743921",
      "SB-743921"
    ],
    "primary_completion_date": "2010-07",
    "completion_date": "2010-07",
    "results_first_posted": "2016-10-04",
    "last_update_posted": "2020-01-13",
    "enrollment": null,
    "sponsor": "Cytokinetics",
    "collected_at": "2026-01-27",
    "search_term": "Cytokinetics"
  },
  {
    "ticker": "CYTK",
    "nct_id": "NCT05924815",
    "title": "Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants"
    ],
    "interventions": [
      "Aficamten",
      "Aficamten-matching Placebo",
      "Moxifloxacin"
    ],
    "primary_completion_date": "2023-11-14",
    "completion_date": "2023-11-14",
    "results_first_posted": null,
    "last_update_posted": "2023-12-19",
    "enrollment": null,
    "sponsor": "Cytokinetics",
    "collected_at": "2026-01-27",
    "search_term": "Cytokinetics"
  },
  {
    "ticker": "CYTK",
    "nct_id": "NCT01077167",
    "title": "Pharmacokinetic Study of Omecamtiv Mecarbil in Heart Failure Patients",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Heart Failure"
    ],
    "interventions": [
      "Omecamtiv mecarbil"
    ],
    "primary_completion_date": "2011-05",
    "completion_date": "2011-05",
    "results_first_posted": null,
    "last_update_posted": "2021-07-30",
    "enrollment": null,
    "sponsor": "Cytokinetics",
    "collected_at": "2026-01-27",
    "search_term": "Cytokinetics"
  },
  {
    "ticker": "CYTK",
    "nct_id": "NCT01089010",
    "title": "A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Amyotrophic Lateral Sclerosis"
    ],
    "interventions": [
      "Placebo",
      "250 mg CK-2017357",
      "500 mg CK-2017357"
    ],
    "primary_completion_date": "2010-11",
    "completion_date": "2010-11",
    "results_first_posted": null,
    "last_update_posted": "2019-05-10",
    "enrollment": null,
    "sponsor": "Cytokinetics",
    "collected_at": "2026-01-27",
    "search_term": "Cytokinetics"
  },
  {
    "ticker": "CYTK",
    "nct_id": "NCT02496767",
    "title": "Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Amyotrophic Lateral Sclerosis"
    ],
    "interventions": [
      "Tirasemtiv",
      "Placebo tablets"
    ],
    "primary_completion_date": "2017-03-09",
    "completion_date": "2017-09-27",
    "results_first_posted": "2020-06-19",
    "last_update_posted": "2020-09-09",
    "enrollment": null,
    "sponsor": "Cytokinetics",
    "collected_at": "2026-01-27",
    "search_term": "Cytokinetics"
  },
  {
    "ticker": "CYTK",
    "nct_id": "NCT02644668",
    "title": "A Study of CK-2127107 in Patients With Spinal Muscular Atrophy",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Spinal Muscular Atrophy"
    ],
    "interventions": [
      "Placebo",
      "Reldesemtiv 150 mg",
      "Reldesemtiv 450 mg"
    ],
    "primary_completion_date": "2018-05-31",
    "completion_date": "2018-05-31",
    "results_first_posted": "2020-08-31",
    "last_update_posted": "2020-08-31",
    "enrollment": null,
    "sponsor": "Cytokinetics",
    "collected_at": "2026-01-27",
    "search_term": "Cytokinetics"
  },
  {
    "ticker": "CYTK",
    "nct_id": "NCT02601001",
    "title": "Pharmacokinetics and Safety Study of Omecamtiv Mecarbil in Healthy Japanese Adults",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteer"
    ],
    "interventions": [
      "Omecamtiv mecarbil",
      "Placebo"
    ],
    "primary_completion_date": "2016-01-06",
    "completion_date": "2016-01-06",
    "results_first_posted": "2021-05-18",
    "last_update_posted": "2021-07-27",
    "enrollment": null,
    "sponsor": "Cytokinetics",
    "collected_at": "2026-01-27",
    "search_term": "Cytokinetics"
  },
  {
    "ticker": "CYTK",
    "nct_id": "NCT03767855",
    "title": "A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Symptomatic Obstructive Hypertrophic Cardiomyopathy",
      "Healthy Subjects"
    ],
    "interventions": [
      "CK-3773274 - Granules in Capsule",
      "Placebo - Granules in Capsule",
      "CK-3773274 - Tablets"
    ],
    "primary_completion_date": "2020-01-03",
    "completion_date": "2020-01-03",
    "results_first_posted": null,
    "last_update_posted": "2025-01-24",
    "enrollment": null,
    "sponsor": "Cytokinetics",
    "collected_at": "2026-01-27",
    "search_term": "Cytokinetics"
  },
  {
    "ticker": "CYTK",
    "nct_id": "NCT04944784",
    "title": "A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Amyotrophic Lateral Sclerosis"
    ],
    "interventions": [
      "Reldesemtiv",
      "Placebo"
    ],
    "primary_completion_date": "2023-07-18",
    "completion_date": "2023-07-18",
    "results_first_posted": "2024-12-05",
    "last_update_posted": "2024-12-05",
    "enrollment": null,
    "sponsor": "Cytokinetics",
    "collected_at": "2026-01-27",
    "search_term": "Cytokinetics"
  },
  {
    "ticker": "CYTK",
    "nct_id": "NCT06793371",
    "title": "AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)"
    ],
    "interventions": [
      "CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)",
      "Placebo to match CK-4021586"
    ],
    "primary_completion_date": "2026-09",
    "completion_date": "2026-09",
    "results_first_posted": null,
    "last_update_posted": "2026-01-12",
    "enrollment": null,
    "sponsor": "Cytokinetics",
    "collected_at": "2026-01-27",
    "search_term": "Cytokinetics"
  },
  {
    "ticker": "CYTK",
    "nct_id": "NCT01268280",
    "title": "Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Myasthenia Gravis"
    ],
    "interventions": [
      "Placebo",
      "250 mg CK-2017357",
      "500 mg CK-2017357"
    ],
    "primary_completion_date": "2012-10",
    "completion_date": "2012-10",
    "results_first_posted": null,
    "last_update_posted": "2019-09-24",
    "enrollment": null,
    "sponsor": "Cytokinetics",
    "collected_at": "2026-01-27",
    "search_term": "Cytokinetics"
  },
  {
    "ticker": "CYTK",
    "nct_id": "NCT01131013",
    "title": "A Study of CK-2017357 in Patients With Peripheral Artery Disease and Symptomatic Claudication",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Intermittent Claudication",
      "Peripheral Artery Disease"
    ],
    "interventions": [
      "Placebo",
      "375 mg CK-2017357",
      "500 mg CK-2017357"
    ],
    "primary_completion_date": "2011-03",
    "completion_date": "2011-03",
    "results_first_posted": null,
    "last_update_posted": "2019-05-14",
    "enrollment": null,
    "sponsor": "Cytokinetics",
    "collected_at": "2026-01-27",
    "search_term": "Cytokinetics"
  },
  {
    "ticker": "CYTK",
    "nct_id": "NCT01486849",
    "title": "Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Amyotrophic Lateral Sclerosis"
    ],
    "interventions": [
      "CK-2017357",
      "Placebo",
      "Riluzole 50 MG"
    ],
    "primary_completion_date": "2012-03",
    "completion_date": "2012-03",
    "results_first_posted": null,
    "last_update_posted": "2019-05-03",
    "enrollment": null,
    "sponsor": "Cytokinetics",
    "collected_at": "2026-01-27",
    "search_term": "Cytokinetics"
  },
  {
    "ticker": "CYTK",
    "nct_id": "NCT04175808",
    "title": "Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Adults",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "QT Intervals Changes",
      "QTc Intervals Changes"
    ],
    "interventions": [
      "Omecamtiv Mecarbil (OM)",
      "Placebo",
      "Moxifloxacin"
    ],
    "primary_completion_date": "2020-03-04",
    "completion_date": "2020-03-04",
    "results_first_posted": "2021-07-20",
    "last_update_posted": "2025-03-30",
    "enrollment": null,
    "sponsor": "Cytokinetics",
    "collected_at": "2026-01-27",
    "search_term": "Cytokinetics"
  },
  {
    "ticker": "CYTK",
    "nct_id": "NCT06736574",
    "title": "Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Heart Failure",
      "Heart Failure With Reduced Ejection Fraction"
    ],
    "interventions": [
      "Omecamtiv Mecarbil (OM)",
      "Placebo"
    ],
    "primary_completion_date": "2027-09",
    "completion_date": "2027-12",
    "results_first_posted": null,
    "last_update_posted": "2026-01-23",
    "enrollment": null,
    "sponsor": "Cytokinetics",
    "collected_at": "2026-01-27",
    "search_term": "Cytokinetics"
  },
  {
    "ticker": "CYTK",
    "nct_id": "NCT04848506",
    "title": "Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Symptomatic Hypertrophic Cardiomyopathy (HCM)"
    ],
    "interventions": [
      "Aficamten (5 - 20 mg)"
    ],
    "primary_completion_date": "2028-03",
    "completion_date": "2028-03",
    "results_first_posted": null,
    "last_update_posted": "2026-01-22",
    "enrollment": null,
    "sponsor": "Cytokinetics",
    "collected_at": "2026-01-27",
    "search_term": "Cytokinetics"
  },
  {
    "ticker": "CYTK",
    "nct_id": "NCT04219826",
    "title": "Dose-finding Study to Evaluate the Safety, Tolerability, PK, and PD of CK-3773274 in Adults With HCM",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypertrophic Cardiomyopathy (HCM)"
    ],
    "interventions": [
      "CK-3773274 (5 - 15 mg)",
      "CK-3773274 (10 - 30 mg)",
      "Placebo for CK-3773274"
    ],
    "primary_completion_date": "2023-02-28",
    "completion_date": "2023-02-28",
    "results_first_posted": null,
    "last_update_posted": "2025-02-05",
    "enrollment": null,
    "sponsor": "Cytokinetics",
    "collected_at": "2026-01-27",
    "search_term": "Cytokinetics"
  },
  {
    "ticker": "CYTK",
    "nct_id": "NCT00941681",
    "title": "Pharmacokinetics of Oral CK-1827452 in Patients With Stable Heart Failure",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Heart Failure"
    ],
    "interventions": [
      "CK-1827452",
      "CK-1827452",
      "CK-1827452"
    ],
    "primary_completion_date": "2009-10",
    "completion_date": "2009-10",
    "results_first_posted": "2010-12-21",
    "last_update_posted": "2013-02-12",
    "enrollment": null,
    "sponsor": "Cytokinetics",
    "collected_at": "2026-01-27",
    "search_term": "Cytokinetics"
  },
  {
    "ticker": "CYTK",
    "nct_id": "NCT04464525",
    "title": "Omecamtiv Mecarbil Post-trial Access Study",
    "status": "WITHDRAWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Heart Failure With Reduced Ejection Fraction"
    ],
    "interventions": [
      "Omecamtiv mecarbil"
    ],
    "primary_completion_date": "2026-11-27",
    "completion_date": "2026-11-27",
    "results_first_posted": null,
    "last_update_posted": "2021-07-30",
    "enrollment": null,
    "sponsor": "Cytokinetics",
    "collected_at": "2026-01-27",
    "search_term": "Cytokinetics"
  },
  {
    "ticker": "CYTK",
    "nct_id": "NCT02936635",
    "title": "A Study for Patients Who Completed VITALITY-ALS (CY 4031)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Amyotrophic Lateral Sclerosis (ALS)"
    ],
    "interventions": [
      "tirasemtiv"
    ],
    "primary_completion_date": "2018-10-26",
    "completion_date": "2018-10-26",
    "results_first_posted": "2021-05-12",
    "last_update_posted": "2021-06-15",
    "enrollment": null,
    "sponsor": "Cytokinetics",
    "collected_at": "2026-01-27",
    "search_term": "Cytokinetics"
  },
  {
    "ticker": "CYTK",
    "nct_id": "NCT05767346",
    "title": "Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Obstructive Hypertrophic Cardiomyopathy (oHCM)"
    ],
    "interventions": [
      "Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)",
      "Placebo to match aficamten",
      "Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg)",
      "Placebo to match metoprolol succinate"
    ],
    "primary_completion_date": "2025-02-28",
    "completion_date": "2025-03-28",
    "results_first_posted": null,
    "last_update_posted": "2025-05-02",
    "enrollment": null,
    "sponsor": "Cytokinetics",
    "collected_at": "2026-01-27",
    "search_term": "Cytokinetics"
  },
  {
    "ticker": "CYTK",
    "nct_id": "NCT06081894",
    "title": "Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy"
    ],
    "interventions": [
      "Aficamten",
      "Placebo"
    ],
    "primary_completion_date": "2026-06",
    "completion_date": "2026-09",
    "results_first_posted": null,
    "last_update_posted": "2025-10-29",
    "enrollment": null,
    "sponsor": "Cytokinetics",
    "collected_at": "2026-01-27",
    "search_term": "Cytokinetics"
  },
  {
    "ticker": "CYTK",
    "nct_id": "NCT00624442",
    "title": "A Study of CK-1827452 Infusion in Stable Heart Failure",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Heart Failure"
    ],
    "interventions": [
      "CK-1827452",
      "CK-1827452",
      "CK-1827452",
      "CK-1827452",
      "CK-1827452",
      "CK-1827452",
      "CK-1827452",
      "CK-1827452",
      "Placebo",
      "Placebo",
      "CK-1827452",
      "Placebo",
      "CK-1827452",
      "CK-1827452",
      "CK-1827452",
      "CK-1827452"
    ],
    "primary_completion_date": "2009-02",
    "completion_date": "2009-02",
    "results_first_posted": "2010-08-16",
    "last_update_posted": "2021-05-14",
    "enrollment": null,
    "sponsor": "Cytokinetics",
    "collected_at": "2026-01-27",
    "search_term": "Cytokinetics"
  },
  {
    "ticker": "CYTK",
    "nct_id": "NCT00607841",
    "title": "A Study of Ispinesib in Metastatic Breast Cancer",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Neoplasms"
    ],
    "interventions": [
      "Ispinesib",
      "Ispinesib",
      "Ispinesib"
    ],
    "primary_completion_date": "2009-11",
    "completion_date": "2009-11",
    "results_first_posted": null,
    "last_update_posted": "2019-05-06",
    "enrollment": null,
    "sponsor": "Cytokinetics",
    "collected_at": "2026-01-27",
    "search_term": "Cytokinetics"
  },
  {
    "ticker": "CYTK",
    "nct_id": "NCT05186818",
    "title": "Aficamten vs Placebo in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Obstructive Hypertrophic Cardiomyopathy (oHCM)"
    ],
    "interventions": [
      "Aficamten (5 mg, 10 mg, 15 mg, and 20 mg)",
      "Placebo to match aficamten"
    ],
    "primary_completion_date": "2023-11-10",
    "completion_date": "2023-12-18",
    "results_first_posted": null,
    "last_update_posted": "2025-02-27",
    "enrollment": null,
    "sponsor": "Cytokinetics",
    "collected_at": "2026-01-27",
    "search_term": "Cytokinetics"
  },
  {
    "ticker": "CYTK",
    "nct_id": "NCT05877053",
    "title": "A Single and Multiple Ascending Dose Study of CK-4021586 in Healthy Adult Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants"
    ],
    "interventions": [
      "CK-4021586",
      "Placebo for CK-4021586"
    ],
    "primary_completion_date": "2024-11-20",
    "completion_date": "2024-11-20",
    "results_first_posted": null,
    "last_update_posted": "2025-05-01",
    "enrollment": null,
    "sponsor": "Cytokinetics",
    "collected_at": "2026-01-27",
    "search_term": "Cytokinetics"
  },
  {
    "ticker": "CYTK",
    "nct_id": "NCT03160898",
    "title": "A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Amyotrophic Lateral Sclerosis"
    ],
    "interventions": [
      "Reldesemtiv",
      "Placebo"
    ],
    "primary_completion_date": "2019-03-07",
    "completion_date": "2019-03-07",
    "results_first_posted": "2020-09-11",
    "last_update_posted": "2020-09-11",
    "enrollment": null,
    "sponsor": "Cytokinetics",
    "collected_at": "2026-01-27",
    "search_term": "Cytokinetics"
  },
  {
    "ticker": "DRMA",
    "nct_id": "NCT02949960",
    "title": "DMT210 Topical Gel in the Treatment of Atopic Dermatitis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atopic Dermatitis"
    ],
    "interventions": [
      "DMT210 Topical Gel",
      "Vehicle Control"
    ],
    "primary_completion_date": "2017-07-14",
    "completion_date": "2017-07-14",
    "results_first_posted": null,
    "last_update_posted": "2018-04-18",
    "enrollment": null,
    "sponsor": "Dermata Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Dermata Therapeutics"
  },
  {
    "ticker": "DRMA",
    "nct_id": "NCT04106778",
    "title": "DMT310-003 Topical in the Treatment of Acne Vulgaris",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acne Vulgaris"
    ],
    "interventions": [
      "DMT310",
      "Placebo"
    ],
    "primary_completion_date": "2020-05-04",
    "completion_date": "2020-05-04",
    "results_first_posted": null,
    "last_update_posted": "2020-07-22",
    "enrollment": null,
    "sponsor": "Dermata Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Dermata Therapeutics"
  },
  {
    "ticker": "DRMA",
    "nct_id": "NCT06090721",
    "title": "DMT310-009 Topical in the Treatment of Acne Vulgaris",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acne Vulgaris"
    ],
    "interventions": [
      "DMT310",
      "Placebo"
    ],
    "primary_completion_date": "2025-03-31",
    "completion_date": "2025-04-30",
    "results_first_posted": null,
    "last_update_posted": "2025-08-22",
    "enrollment": null,
    "sponsor": "Dermata Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Dermata Therapeutics"
  },
  {
    "ticker": "DRMA",
    "nct_id": "NCT03003104",
    "title": "DMT210 Topical Gel in the Treatment of Acne Rosacea",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acne Rosacea"
    ],
    "interventions": [
      "DMT210 Topical Gel 5%",
      "Vehicle Control"
    ],
    "primary_completion_date": "2017-08-30",
    "completion_date": "2017-08-30",
    "results_first_posted": null,
    "last_update_posted": "2018-04-18",
    "enrollment": null,
    "sponsor": "Dermata Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Dermata Therapeutics"
  },
  {
    "ticker": "DRMA",
    "nct_id": "NCT05108025",
    "title": "DMT310-005 Topical in the Treatment of Acne Rosacea",
    "status": "UNKNOWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acne Rosacea"
    ],
    "interventions": [
      "Topical Powder",
      "Placebo Topical Powder"
    ],
    "primary_completion_date": "2022-12",
    "completion_date": "2022-12",
    "results_first_posted": null,
    "last_update_posted": "2022-12-08",
    "enrollment": null,
    "sponsor": "Dermata Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Dermata Therapeutics"
  },
  {
    "ticker": "DVAX",
    "nct_id": "NCT05245838",
    "title": "Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix\u00ae in Healthy Adult Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Shingles",
      "Herpes Zoster",
      "Vaccine-Preventable Diseases"
    ],
    "interventions": [
      "Z-1018",
      "Z-1018",
      "Z-1018",
      "Z-1018",
      "Shingrix"
    ],
    "primary_completion_date": "2022-10-20",
    "completion_date": "2022-10-20",
    "results_first_posted": null,
    "last_update_posted": "2022-11-07",
    "enrollment": null,
    "sponsor": "Dynavax Technologies Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Dynavax"
  },
  {
    "ticker": "DVAX",
    "nct_id": "NCT00823862",
    "title": "Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Hepatitis C"
    ],
    "interventions": [
      "SD-101",
      "ribavirin"
    ],
    "primary_completion_date": "2009-12",
    "completion_date": "2010-02",
    "results_first_posted": null,
    "last_update_posted": "2019-04-16",
    "enrollment": null,
    "sponsor": "Dynavax Technologies Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Dynavax"
  },
  {
    "ticker": "DVAX",
    "nct_id": "NCT01282762",
    "title": "Long-Term Study on Safety and Immunogenicity of HEPLISAV\u2122 and Engerix-B\u00ae in Adults With Chronic Kidney Disease",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Chronic Kidney Disease"
    ],
    "interventions": [
      "HEPLISAV",
      "Engerix-B"
    ],
    "primary_completion_date": "2013-08",
    "completion_date": "2013-08",
    "results_first_posted": null,
    "last_update_posted": "2019-03-20",
    "enrollment": null,
    "sponsor": "Dynavax Technologies Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Dynavax"
  },
  {
    "ticker": "DVAX",
    "nct_id": "NCT02266147",
    "title": "Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "B-cell Lymphoma"
    ],
    "interventions": [
      "SD-101",
      "Radiation therapy"
    ],
    "primary_completion_date": "2017-04",
    "completion_date": "2017-04",
    "results_first_posted": "2020-09-04",
    "last_update_posted": "2020-09-04",
    "enrollment": null,
    "sponsor": "Dynavax Technologies Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Dynavax"
  },
  {
    "ticker": "DVAX",
    "nct_id": "NCT03934736",
    "title": "HEPLISAV-B\u00ae in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "End Stage Renal Disease on Hemodialysis (Diagnosis)"
    ],
    "interventions": [
      "HEPLISAV-B\u00ae"
    ],
    "primary_completion_date": "2020-10-23",
    "completion_date": "2021-09-15",
    "results_first_posted": "2024-08-09",
    "last_update_posted": "2024-08-09",
    "enrollment": null,
    "sponsor": "Dynavax Technologies Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Dynavax"
  },
  {
    "ticker": "DVAX",
    "nct_id": "NCT00435812",
    "title": "Safety and Efficacy of HEPLISAV\u2122 Hepatitis B Virus Vaccine Compared With Engerix-B\u00ae Vaccine",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatitis B"
    ],
    "interventions": [
      "HEPLISAV and/or Placebo",
      "Engerix-B"
    ],
    "primary_completion_date": "2008-02",
    "completion_date": "2008-03",
    "results_first_posted": "2018-02-13",
    "last_update_posted": "2019-03-20",
    "enrollment": null,
    "sponsor": "Dynavax Technologies Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Dynavax"
  },
  {
    "ticker": "DVAX",
    "nct_id": "NCT00511095",
    "title": "Open-Label Study of the Safety and Immunogenicity of HEPLISAV\u2122 Hepatitis B Virus Vaccine",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatitis B"
    ],
    "interventions": [
      "HEPLISAV"
    ],
    "primary_completion_date": "2007-10",
    "completion_date": "2008-03",
    "results_first_posted": "2017-04-12",
    "last_update_posted": "2019-04-30",
    "enrollment": null,
    "sponsor": "Dynavax Technologies Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Dynavax"
  },
  {
    "ticker": "DVAX",
    "nct_id": "NCT03326752",
    "title": "Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Non Small Cell Lung Cancer"
    ],
    "interventions": [
      "DV281",
      "Breath Actuated Nebulizer",
      "DV281 (RP2D)",
      "Approved Anti-PD-1 Inhibitor"
    ],
    "primary_completion_date": "2019-09-19",
    "completion_date": "2019-09-19",
    "results_first_posted": null,
    "last_update_posted": "2020-06-17",
    "enrollment": null,
    "sponsor": "Dynavax Technologies Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Dynavax"
  },
  {
    "ticker": "DVAX",
    "nct_id": "NCT01023230",
    "title": "A Study to Assess DV-601 in Subjects With Chronic Hepatitis B",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatitis B, Chronic"
    ],
    "interventions": [
      "DV-601",
      "Entecavir"
    ],
    "primary_completion_date": "2011-05",
    "completion_date": "2011-05",
    "results_first_posted": null,
    "last_update_posted": "2019-04-16",
    "enrollment": null,
    "sponsor": "Dynavax Technologies Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Dynavax"
  },
  {
    "ticker": "DVAX",
    "nct_id": "NCT01999699",
    "title": "A Study of the Immune Response to Heplisav in Healthy Older Adults",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatitis B"
    ],
    "interventions": [
      "HEPLISAV"
    ],
    "primary_completion_date": "2015-02",
    "completion_date": "2015-03",
    "results_first_posted": null,
    "last_update_posted": "2019-03-20",
    "enrollment": null,
    "sponsor": "Dynavax Technologies Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Dynavax"
  },
  {
    "ticker": "DVAX",
    "nct_id": "NCT02521870",
    "title": "A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Melanoma",
      "Head Neck Cancer"
    ],
    "interventions": [
      "SD-101(1)",
      "Pembrolizumab",
      "SD-101(2)",
      "Pembrolizumab",
      "SD-101(3)",
      "Pembrolizumab"
    ],
    "primary_completion_date": "2020-04",
    "completion_date": "2020-04",
    "results_first_posted": "2021-08-03",
    "last_update_posted": "2021-08-03",
    "enrollment": null,
    "sponsor": "Dynavax Technologies Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Dynavax"
  },
  {
    "ticker": "DVAX",
    "nct_id": "NCT07207408",
    "title": "Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis"
    ],
    "interventions": [
      "rF1V-1018",
      "rF1V-1018",
      "rF1V-1018",
      "rF1V-1018",
      "rF1V-1018",
      "rF1V-1018"
    ],
    "primary_completion_date": "2026-05-29",
    "completion_date": "2026-10-16",
    "results_first_posted": null,
    "last_update_posted": "2025-10-06",
    "enrollment": null,
    "sponsor": "Dynavax Technologies Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Dynavax"
  },
  {
    "ticker": "DVAX",
    "nct_id": "NCT01005407",
    "title": "Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "HEPLISAV and/or Placebo",
      "Engerix-B"
    ],
    "primary_completion_date": "2011-01",
    "completion_date": "2011-05",
    "results_first_posted": "2018-01-11",
    "last_update_posted": "2019-03-20",
    "enrollment": null,
    "sponsor": "Dynavax Technologies Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Dynavax"
  },
  {
    "ticker": "DVAX",
    "nct_id": "NCT00498212",
    "title": "A Safety and Efficacy Study of a Single or Double Dose of HEPLISAV\u2122 Hepatitis B Vaccine in Adults With End-Stage Renal Disease",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatitis B"
    ],
    "interventions": [
      "1018 ISS-HBsAg-Single",
      "1018 ISS-HBsAg-Double"
    ],
    "primary_completion_date": "2008-08",
    "completion_date": "2008-10",
    "results_first_posted": null,
    "last_update_posted": "2019-03-26",
    "enrollment": null,
    "sponsor": "Dynavax Technologies Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Dynavax"
  },
  {
    "ticker": "DVAX",
    "nct_id": "NCT01195246",
    "title": "Safety and Immunogenicity of HEPLISAV\u2122 a Hepatitis B Virus Vaccine in Adults on Hemodialysis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "End Stage Renal Disease"
    ],
    "interventions": [
      "HEPLISAV",
      "Engerix-B",
      "Fendrix"
    ],
    "primary_completion_date": "2012-02",
    "completion_date": "2012-08",
    "results_first_posted": null,
    "last_update_posted": "2019-03-20",
    "enrollment": null,
    "sponsor": "Dynavax Technologies Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Dynavax"
  },
  {
    "ticker": "DVAX",
    "nct_id": "NCT00985426",
    "title": "Comparing Safety and Immunogenicity of HEPLISAV-B\u00ae to Engerix-B\u00ae in Chronic Kidney Disease (CKD) Patients",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Kidney Disease"
    ],
    "interventions": [
      "HEPLISAV-B",
      "Engerix-B",
      "Placebo"
    ],
    "primary_completion_date": "2012-01",
    "completion_date": "2012-01",
    "results_first_posted": "2020-12-16",
    "last_update_posted": "2021-05-19",
    "enrollment": null,
    "sponsor": "Dynavax Technologies Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Dynavax"
  },
  {
    "ticker": "DVAX",
    "nct_id": "NCT02117934",
    "title": "Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV\u2122, Compared to Engerix-B\u00ae Vaccine",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "HEPLISAV",
      "Engerix-B"
    ],
    "primary_completion_date": "2015-10",
    "completion_date": "2015-10",
    "results_first_posted": "2018-01-10",
    "last_update_posted": "2019-03-20",
    "enrollment": null,
    "sponsor": "Dynavax Technologies Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Dynavax"
  },
  {
    "ticker": "DVAX",
    "nct_id": "NCT00599001",
    "title": "Safety, Pharmacokinetics, and Pharmacodynamics of SD-101 in Healthy Normal Males",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "SD-101",
      "placebo"
    ],
    "primary_completion_date": "2008-03",
    "completion_date": "2008-03",
    "results_first_posted": null,
    "last_update_posted": "2019-04-16",
    "enrollment": null,
    "sponsor": "Dynavax Technologies Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Dynavax"
  },
  {
    "ticker": "DVAX",
    "nct_id": "NCT00426712",
    "title": "Safety of HEPLISAV\u2122 Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatitis B"
    ],
    "interventions": [
      "1018 ISS immunostimulatory oligonucleotide with HBV surface antigen",
      "Hepatitis B Vaccine (Recombinant)"
    ],
    "primary_completion_date": "2008-03",
    "completion_date": "2008-03",
    "results_first_posted": null,
    "last_update_posted": "2019-03-20",
    "enrollment": null,
    "sponsor": "Dynavax Technologies Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Dynavax"
  },
  {
    "ticker": "DVAX",
    "nct_id": "NCT00403052",
    "title": "A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Colorectal Neoplasms"
    ],
    "interventions": [
      "1018 ISS immunostimulatory oligonucleotide"
    ],
    "primary_completion_date": "2007-12",
    "completion_date": "2007-12",
    "results_first_posted": null,
    "last_update_posted": "2019-04-16",
    "enrollment": null,
    "sponsor": "Dynavax Technologies Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Dynavax"
  },
  {
    "ticker": "DVAX",
    "nct_id": "NCT00387738",
    "title": "Efficacy and Safety Study of TOLAMBA\u2122 in Ragweed-Allergic Adults",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rhinitis, Allergic, Seasonal"
    ],
    "interventions": [
      "Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate",
      "Histamine base"
    ],
    "primary_completion_date": "2007-05",
    "completion_date": "2008-03",
    "results_first_posted": null,
    "last_update_posted": "2019-04-16",
    "enrollment": null,
    "sponsor": "Dynavax Technologies Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Dynavax"
  },
  {
    "ticker": "DVAX",
    "nct_id": "NCT06569823",
    "title": "Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix\u00ae in Healthy Adults 50 Years of Age and Over",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Shingles",
      "Herpes Zoster",
      "Vaccine-Preventable Diseases"
    ],
    "interventions": [
      "Z-1018",
      "Shingrix"
    ],
    "primary_completion_date": "2027-11",
    "completion_date": "2031-11",
    "results_first_posted": null,
    "last_update_posted": "2025-11-06",
    "enrollment": null,
    "sponsor": "Dynavax Technologies Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Dynavax"
  },
  {
    "ticker": "DVAX",
    "nct_id": "NCT03664648",
    "title": "DV2-HBV-27: Observational Pregnancy Registry",
    "status": "UNKNOWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Pregnant"
    ],
    "interventions": [
      "HEPLISAV-B"
    ],
    "primary_completion_date": "2024-09",
    "completion_date": "2024-12",
    "results_first_posted": null,
    "last_update_posted": "2023-09-18",
    "enrollment": null,
    "sponsor": "Dynavax Technologies Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Dynavax"
  },
  {
    "ticker": "DVAX",
    "nct_id": "NCT05506969",
    "title": "Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018\u00ae Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Plague, Pneumonic",
      "Plague",
      "Vaccine-Preventable Diseases"
    ],
    "interventions": [
      "rF1V-1018",
      "rF1V vaccine"
    ],
    "primary_completion_date": "2023-10-03",
    "completion_date": "2024-04-26",
    "results_first_posted": "2025-07-29",
    "last_update_posted": "2025-07-29",
    "enrollment": null,
    "sponsor": "Dynavax Technologies Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Dynavax"
  },
  {
    "ticker": "DVAX",
    "nct_id": "NCT00537355",
    "title": "An Evaluation of the Efficacy and Safety of TOLAMBA\u2122 for Ragweed-Allergic Rhinitis in an Environmental Exposure Chamber",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rhinitis, Allergic, Seasonal"
    ],
    "interventions": [
      "Amb a 1 Immunostimulatory Oligoribonucleotide Conjugate",
      "Histamine"
    ],
    "primary_completion_date": "2008-03",
    "completion_date": "2008-05",
    "results_first_posted": null,
    "last_update_posted": "2019-04-16",
    "enrollment": null,
    "sponsor": "Dynavax Technologies Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Dynavax"
  },
  {
    "ticker": "ELVN",
    "nct_id": "NCT06787144",
    "title": "ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "CML (Chronic Myelogenous Leukemia)",
      "Chronic Phase CML"
    ],
    "interventions": [
      "ELVN-001"
    ],
    "primary_completion_date": "2028-01",
    "completion_date": "2028-01",
    "results_first_posted": null,
    "last_update_posted": "2025-07-01",
    "enrollment": null,
    "sponsor": "Enliven Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Enliven Therapeutics"
  },
  {
    "ticker": "ELVN",
    "nct_id": "NCT06328738",
    "title": "ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HER2-positive Breast Cancer",
      "HER2-positive Gastric Cancer",
      "HER2 Positive Solid Tumors",
      "HER2 Amplification",
      "Colorectal Cancer"
    ],
    "interventions": [
      "ELVN-002",
      "Trastuzumab",
      "5-Fluorouracil",
      "Oxaliplatin",
      "Capecitabine",
      "Eribulin",
      "paclitaxel",
      "Leucovorin"
    ],
    "primary_completion_date": "2027-01",
    "completion_date": "2028-07",
    "results_first_posted": null,
    "last_update_posted": "2025-11-19",
    "enrollment": null,
    "sponsor": "Enliven Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Enliven Therapeutics"
  },
  {
    "ticker": "ELVN",
    "nct_id": "NCT05650879",
    "title": "ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HER2 Mutant Non-small Cell Lung Cancer",
      "HER2-positive Metastatic Breast Cancer",
      "HER2 Gene Mutation",
      "HER2 Amplification"
    ],
    "interventions": [
      "ELVN-002",
      "Fam-Trastuzumab Deruxtecan-Nxki",
      "Trastuzumab emtansine"
    ],
    "primary_completion_date": "2026-07",
    "completion_date": "2026-07",
    "results_first_posted": null,
    "last_update_posted": "2025-07-15",
    "enrollment": null,
    "sponsor": "Enliven Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Enliven Therapeutics"
  },
  {
    "ticker": "EPRX",
    "nct_id": "NCT04120402",
    "title": "Study to Evaluate the Efficacy and Safety of EP-104IAR in Patients With Osteoarthritis of the Knee",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Osteoarthritis, Knee"
    ],
    "interventions": [
      "EP-104IAR 25 mg",
      "Vehicle"
    ],
    "primary_completion_date": "2023-05-17",
    "completion_date": "2023-06-01",
    "results_first_posted": "2024-06-25",
    "last_update_posted": "2024-06-25",
    "enrollment": null,
    "sponsor": "Eupraxia Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Eupraxia Pharmaceuticals"
  },
  {
    "ticker": "EPRX",
    "nct_id": "NCT05608681",
    "title": "A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Eosinophilic Esophagitis"
    ],
    "interventions": [
      "EP-104GI",
      "Matching vehicle control"
    ],
    "primary_completion_date": "2026-12",
    "completion_date": "2026-12",
    "results_first_posted": null,
    "last_update_posted": "2025-12-10",
    "enrollment": null,
    "sponsor": "Eupraxia Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Eupraxia Pharmaceuticals"
  },
  {
    "ticker": "EPRX",
    "nct_id": "NCT02609126",
    "title": "Safety Study of a Long-Acting Injectable Steroid to Treat Knee Osteoarthritis",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Osteoarthritis, Knee"
    ],
    "interventions": [
      "EP-104IAR",
      "Vehicle"
    ],
    "primary_completion_date": "2017-12-28",
    "completion_date": "2017-12-28",
    "results_first_posted": null,
    "last_update_posted": "2021-09-01",
    "enrollment": null,
    "sponsor": "Eupraxia Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Eupraxia Pharmaceuticals"
  },
  {
    "ticker": "EWTX",
    "nct_id": "NCT05730842",
    "title": "Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteer",
      "Muscular Dystrophies",
      "Muscular Disorders, Atrophic",
      "Muscular Diseases",
      "Musculoskeletal Diseases",
      "Neuromuscular Diseases",
      "Nervous System Diseases",
      "Genetic Diseases, Inborn"
    ],
    "interventions": [
      "EDG-5506 Tablet",
      "Radiolabeled EDG-5506 Suspension",
      "Radiolabeled EDG-5506 Intravenous"
    ],
    "primary_completion_date": "2023-04-06",
    "completion_date": "2023-04-06",
    "results_first_posted": null,
    "last_update_posted": "2023-04-18",
    "enrollment": null,
    "sponsor": "Edgewise Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Edgewise Therapeutics"
  },
  {
    "ticker": "EWTX",
    "nct_id": "NCT07177066",
    "title": "A Study of EDG-15400 in Healthy Adults",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Adults"
    ],
    "interventions": [
      "EDG-15400",
      "Placebo"
    ],
    "primary_completion_date": "2026-05",
    "completion_date": "2026-05",
    "results_first_posted": null,
    "last_update_posted": "2025-09-16",
    "enrollment": null,
    "sponsor": "Edgewise Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Edgewise Therapeutics"
  },
  {
    "ticker": "EWTX",
    "nct_id": "NCT06347159",
    "title": "A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypertrophic Cardiomyopathy"
    ],
    "interventions": [
      "EDG-7500",
      "EDG-7500"
    ],
    "primary_completion_date": "2026-06",
    "completion_date": "2026-12",
    "results_first_posted": null,
    "last_update_posted": "2025-11-24",
    "enrollment": null,
    "sponsor": "Edgewise Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Edgewise Therapeutics"
  },
  {
    "ticker": "EWTX",
    "nct_id": "NCT05540860",
    "title": "A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy"
    ],
    "interventions": [
      "Sevasemten Dose 1",
      "Sevasemten Dose 2",
      "Sevasemten Dose 3",
      "Sevasemten Dose 4",
      "Sevasemten Dose 5",
      "Placebo"
    ],
    "primary_completion_date": "2027-01",
    "completion_date": "2027-01",
    "results_first_posted": null,
    "last_update_posted": "2025-11-12",
    "enrollment": null,
    "sponsor": "Edgewise Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Edgewise Therapeutics"
  },
  {
    "ticker": "EWTX",
    "nct_id": "NCT07324616",
    "title": "A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatic Impairment (HI)"
    ],
    "interventions": [
      "EDG-7500"
    ],
    "primary_completion_date": "2026-05",
    "completion_date": "2026-05",
    "results_first_posted": null,
    "last_update_posted": "2026-01-07",
    "enrollment": null,
    "sponsor": "Edgewise Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Edgewise Therapeutics"
  },
  {
    "ticker": "EWTX",
    "nct_id": "NCT05160415",
    "title": "A Study of EDG-5506 in Adult Males With Becker Muscular Dystrophy",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Becker Muscular Dystrophy"
    ],
    "interventions": [
      "Sevasemten"
    ],
    "primary_completion_date": "2024-03-01",
    "completion_date": "2024-03-01",
    "results_first_posted": "2025-06-24",
    "last_update_posted": "2025-06-24",
    "enrollment": null,
    "sponsor": "Edgewise Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Edgewise Therapeutics"
  },
  {
    "ticker": "EWTX",
    "nct_id": "NCT05492734",
    "title": "A Study to Assess the Feasibility of Non-invasive Dried Blood Sampling",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Muscular Dystrophies"
    ],
    "interventions": [
      "EDG-5506"
    ],
    "primary_completion_date": "2022-08-19",
    "completion_date": "2022-08-19",
    "results_first_posted": null,
    "last_update_posted": "2022-09-02",
    "enrollment": null,
    "sponsor": "Edgewise Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Edgewise Therapeutics"
  },
  {
    "ticker": "EWTX",
    "nct_id": "NCT05291091",
    "title": "Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Becker Muscular Dystrophy"
    ],
    "interventions": [
      "Sevasemten 10 mg",
      "Sevasemten 5 mg",
      "Sevasemten 12.5 mg",
      "Placebo"
    ],
    "primary_completion_date": "2026-09",
    "completion_date": "2026-09",
    "results_first_posted": null,
    "last_update_posted": "2025-12-01",
    "enrollment": null,
    "sponsor": "Edgewise Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Edgewise Therapeutics"
  },
  {
    "ticker": "EWTX",
    "nct_id": "NCT07034768",
    "title": "A Study to Evaluate EDG-7500 in People With Renal Impairment",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Renal Impairments"
    ],
    "interventions": [
      "EDG-7500"
    ],
    "primary_completion_date": "2025-12-31",
    "completion_date": "2025-12-31",
    "results_first_posted": null,
    "last_update_posted": "2025-08-20",
    "enrollment": null,
    "sponsor": "Edgewise Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Edgewise Therapeutics"
  },
  {
    "ticker": "EWTX",
    "nct_id": "NCT06100887",
    "title": "Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy"
    ],
    "interventions": [
      "Sevasemten Dose 1",
      "Sevasemten Dose 2",
      "Sevasemten Dose 3",
      "Placebo"
    ],
    "primary_completion_date": "2027-03",
    "completion_date": "2027-03",
    "results_first_posted": null,
    "last_update_posted": "2025-11-06",
    "enrollment": null,
    "sponsor": "Edgewise Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Edgewise Therapeutics"
  },
  {
    "ticker": "EWTX",
    "nct_id": "NCT06738836",
    "title": "A Study to Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C]-EDG-7500",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteer"
    ],
    "interventions": [
      "[14C]-EDG-7500"
    ],
    "primary_completion_date": "2025-01-17",
    "completion_date": "2025-01-17",
    "results_first_posted": null,
    "last_update_posted": "2025-04-16",
    "enrollment": null,
    "sponsor": "Edgewise Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Edgewise Therapeutics"
  },
  {
    "ticker": "EWTX",
    "nct_id": "NCT06011317",
    "title": "A Study of EDG-7500 in Healthy Adults",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Subjects"
    ],
    "interventions": [
      "EDG-7500",
      "Placebo"
    ],
    "primary_completion_date": "2024-05-23",
    "completion_date": "2024-06-20",
    "results_first_posted": null,
    "last_update_posted": "2024-07-16",
    "enrollment": null,
    "sponsor": "Edgewise Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Edgewise Therapeutics"
  },
  {
    "ticker": "EWTX",
    "nct_id": "NCT06916897",
    "title": "A Study to Evaluate Effect of Verapamil and Food of Sevasemten in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Subjects"
    ],
    "interventions": [
      "sevasemten",
      "Verapamil"
    ],
    "primary_completion_date": "2025-02-22",
    "completion_date": "2025-02-22",
    "results_first_posted": null,
    "last_update_posted": "2025-04-08",
    "enrollment": null,
    "sponsor": "Edgewise Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Edgewise Therapeutics"
  },
  {
    "ticker": "EWTX",
    "nct_id": "NCT04585464",
    "title": "A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteers and Becker Muscular Dystrophy Adults",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteer",
      "Becker Muscular Dystrophy"
    ],
    "interventions": [
      "EDG-5506",
      "Placebo"
    ],
    "primary_completion_date": "2021-11-15",
    "completion_date": "2021-12-27",
    "results_first_posted": null,
    "last_update_posted": "2022-06-28",
    "enrollment": null,
    "sponsor": "Edgewise Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Edgewise Therapeutics"
  },
  {
    "ticker": "FDMT",
    "nct_id": "NCT05930561",
    "title": "4D-150 in Patients With Diabetic Macular Edema",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetic Macular Edema",
      "Diabetic Retinopathy"
    ],
    "interventions": [
      "4D-150 IVT",
      "Aflibercept IVT"
    ],
    "primary_completion_date": "2029-02-28",
    "completion_date": "2029-02-28",
    "results_first_posted": null,
    "last_update_posted": "2025-09-22",
    "enrollment": null,
    "sponsor": "4D Molecular Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "4D Molecular Therapeutics"
  },
  {
    "ticker": "FDMT",
    "nct_id": "NCT07064759",
    "title": "Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Neovascular Age-Related Macular Degeneration (nAMD)"
    ],
    "interventions": [
      "4D-150 IVT (3E10 vg/eye)",
      "EYLEA\u00ae (aflibercept) Injection 2 mg (0.05mL)"
    ],
    "primary_completion_date": "2028-11",
    "completion_date": "2029-02",
    "results_first_posted": null,
    "last_update_posted": "2025-10-20",
    "enrollment": null,
    "sponsor": "4D Molecular Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "4D Molecular Therapeutics"
  },
  {
    "ticker": "FDMT",
    "nct_id": "NCT05629559",
    "title": "4D-310 in Adults With Fabry Disease and Cardiac Involvement",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fabry Disease"
    ],
    "interventions": [
      "4D-310"
    ],
    "primary_completion_date": "2026-06",
    "completion_date": "2030-06",
    "results_first_posted": null,
    "last_update_posted": "2025-02-21",
    "enrollment": null,
    "sponsor": "4D Molecular Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "4D Molecular Therapeutics"
  },
  {
    "ticker": "FDMT",
    "nct_id": "NCT04519749",
    "title": "An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fabry Disease"
    ],
    "interventions": [
      "4D-310"
    ],
    "primary_completion_date": "2026-01",
    "completion_date": "2030-06",
    "results_first_posted": null,
    "last_update_posted": "2024-04-08",
    "enrollment": null,
    "sponsor": "4D Molecular Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "4D Molecular Therapeutics"
  },
  {
    "ticker": "FDMT",
    "nct_id": "NCT04517149",
    "title": "4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "X-Linked Retinitis Pigmentosa"
    ],
    "interventions": [
      "4D-125 IVT Injection",
      "Observational"
    ],
    "primary_completion_date": "2026-06",
    "completion_date": "2029-05",
    "results_first_posted": null,
    "last_update_posted": "2025-03-21",
    "enrollment": null,
    "sponsor": "4D Molecular Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "4D Molecular Therapeutics"
  },
  {
    "ticker": "FDMT",
    "nct_id": "NCT02994368",
    "title": "\"Natural History\" Study of Choroideremia",
    "status": "TERMINATED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Choroideremia"
    ],
    "interventions": [
      "Observation"
    ],
    "primary_completion_date": "2021-10",
    "completion_date": "2021-10",
    "results_first_posted": null,
    "last_update_posted": "2022-01-06",
    "enrollment": null,
    "sponsor": "4D Molecular Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "4D Molecular Therapeutics"
  },
  {
    "ticker": "FDMT",
    "nct_id": "NCT04483440",
    "title": "Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Choroideremia"
    ],
    "interventions": [
      "4D-110"
    ],
    "primary_completion_date": "2027-05-26",
    "completion_date": "2027-08-31",
    "results_first_posted": null,
    "last_update_posted": "2025-05-22",
    "enrollment": null,
    "sponsor": "4D Molecular Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "4D Molecular Therapeutics"
  },
  {
    "ticker": "FDMT",
    "nct_id": "NCT06864988",
    "title": "4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Macular Neovascularization Secondary to Age-Related Macular Degeneration"
    ],
    "interventions": [
      "4D-150 IVT (3E10 vg/eye)",
      "EYLEA\u00ae (aflibercept) Injection 2 mg (0.05mL)"
    ],
    "primary_completion_date": "2027-06",
    "completion_date": "2028-06",
    "results_first_posted": null,
    "last_update_posted": "2026-01-07",
    "enrollment": null,
    "sponsor": "4D Molecular Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "4D Molecular Therapeutics"
  },
  {
    "ticker": "FHTX",
    "nct_id": "NCT04891757",
    "title": "FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Hematologic Malignancy",
      "Relapsed Acute Myeloid Leukemia",
      "Refractory Acute Myeloid Leukemia",
      "Relapsed Myelodysplastic Syndromes",
      "Refractory Myelodysplastic Syndromes",
      "Relapsed Chronic Myelomonocytic Leukemia",
      "Refractory Chronic Myelomonocytic Leukemia"
    ],
    "interventions": [
      "FHD-286",
      "Low Dose Cytarabine",
      "Decitabine"
    ],
    "primary_completion_date": "2025-09",
    "completion_date": "2027-06",
    "results_first_posted": null,
    "last_update_posted": "2025-07-10",
    "enrollment": null,
    "sponsor": "Foghorn Therapeutics Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Foghorn Therapeutics"
  },
  {
    "ticker": "FHTX",
    "nct_id": "NCT04879017",
    "title": "FHD-286 in Subjects With Metastatic Uveal Melanoma",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Uveal Melanoma"
    ],
    "interventions": [
      "FHD-286"
    ],
    "primary_completion_date": "2023-11-30",
    "completion_date": "2023-11-30",
    "results_first_posted": null,
    "last_update_posted": "2024-04-25",
    "enrollment": null,
    "sponsor": "Foghorn Therapeutics Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Foghorn Therapeutics"
  },
  {
    "ticker": "FHTX",
    "nct_id": "NCT04965753",
    "title": "FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Synovial Sarcoma"
    ],
    "interventions": [
      "FHD-609"
    ],
    "primary_completion_date": "2023-12-04",
    "completion_date": "2023-12-04",
    "results_first_posted": null,
    "last_update_posted": "2025-03-04",
    "enrollment": null,
    "sponsor": "Foghorn Therapeutics Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Foghorn Therapeutics"
  },
  {
    "ticker": "FULC",
    "nct_id": "NCT05002231",
    "title": "Relative Bioavailability and Food Effect Study of Losmapimod 15 mg Tablets",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Adult Subjects"
    ],
    "interventions": [
      "Losmapimod 15 mg oral tablet",
      "Losmapimod two 7.5 mg oral tablets",
      "Losmapimod one 15 mg oral tablet"
    ],
    "primary_completion_date": "2021-10-05",
    "completion_date": "2021-10-22",
    "results_first_posted": null,
    "last_update_posted": "2021-11-12",
    "enrollment": null,
    "sponsor": "Fulcrum Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Fulcrum Therapeutics"
  },
  {
    "ticker": "FULC",
    "nct_id": "NCT04003974",
    "title": "Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Facioscapulohumeral Muscular Dystrophy (FSHD)"
    ],
    "interventions": [
      "Losmapimod oral tablet",
      "Placebo oral tablet"
    ],
    "primary_completion_date": "2021-01-28",
    "completion_date": "2021-01-28",
    "results_first_posted": "2024-07-10",
    "last_update_posted": "2024-07-10",
    "enrollment": null,
    "sponsor": "Fulcrum Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Fulcrum Therapeutics"
  },
  {
    "ticker": "FULC",
    "nct_id": "NCT04586985",
    "title": "Safety, Tolerability and Pharmacokinetics of FTX-6058",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Adult Subjects",
      "Sickle Cell Disease"
    ],
    "interventions": [
      "FTX-6058/placebo oral capsule(s)",
      "FTX-6058/placebo oral capsule(s)",
      "FTX-6058 - Two Dosing Periods",
      "FTX-6058 / Midazolam Syrup",
      "FTX-6058/placebo oral capsule(s)"
    ],
    "primary_completion_date": "2022-11-15",
    "completion_date": "2022-11-15",
    "results_first_posted": null,
    "last_update_posted": "2022-12-12",
    "enrollment": null,
    "sponsor": "Fulcrum Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Fulcrum Therapeutics"
  },
  {
    "ticker": "FULC",
    "nct_id": "NCT04264442",
    "title": "Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Facioscapulohumeral Muscular Dystrophy (FSHD)"
    ],
    "interventions": [
      "Losmapimod"
    ],
    "primary_completion_date": "2024-11-07",
    "completion_date": "2024-11-07",
    "results_first_posted": "2025-09-30",
    "last_update_posted": "2025-09-30",
    "enrollment": null,
    "sponsor": "Fulcrum Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Fulcrum Therapeutics"
  },
  {
    "ticker": "FULC",
    "nct_id": "NCT04511819",
    "title": "Losmapimod Safety and Efficacy in COVID-19",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID-19"
    ],
    "interventions": [
      "Losmapimod oral tablet",
      "Placebo oral tablet"
    ],
    "primary_completion_date": "2021-03-31",
    "completion_date": "2021-03-31",
    "results_first_posted": "2024-03-13",
    "last_update_posted": "2024-03-13",
    "enrollment": null,
    "sponsor": "Fulcrum Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Fulcrum Therapeutics"
  },
  {
    "ticker": "FULC",
    "nct_id": "NCT05397470",
    "title": "Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Facioscapulohumeral Muscular Dystrophy (FSHD)"
    ],
    "interventions": [
      "Losmapimod",
      "Placebo oral tablet"
    ],
    "primary_completion_date": "2024-11-19",
    "completion_date": "2024-11-19",
    "results_first_posted": "2025-11-10",
    "last_update_posted": "2025-11-10",
    "enrollment": null,
    "sponsor": "Fulcrum Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Fulcrum Therapeutics"
  },
  {
    "ticker": "FULC",
    "nct_id": "NCT05169580",
    "title": "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pociredir",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Sickle Cell Disease",
      "Sickle Cell Anemia"
    ],
    "interventions": [
      "Pociredir oral capsule(s)"
    ],
    "primary_completion_date": "2025-12",
    "completion_date": "2026-01",
    "results_first_posted": null,
    "last_update_posted": "2025-10-27",
    "enrollment": null,
    "sponsor": "Fulcrum Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Fulcrum Therapeutics"
  },
  {
    "ticker": "FULC",
    "nct_id": "NCT04004000",
    "title": "Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Losmapimod for FSHD1 With Extension",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Facioscapulohumeral Muscular Dystrophy 1"
    ],
    "interventions": [
      "Losmapimod"
    ],
    "primary_completion_date": "2024-10-31",
    "completion_date": "2024-10-31",
    "results_first_posted": "2025-12-02",
    "last_update_posted": "2025-12-02",
    "enrollment": null,
    "sponsor": "Fulcrum Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Fulcrum Therapeutics"
  },
  {
    "ticker": "IDYA",
    "nct_id": "NCT05787587",
    "title": "A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced or Metastatic Solid Tumors",
      "Breast Cancer",
      "Ovarian Cancer",
      "Prostate Cancer",
      "Endometrial Cancer",
      "Colorectal Cancer",
      "Head and Neck Cancers",
      "Extensive Stage Small Cell Lung Cancer (ES-SCLC)",
      "NSCLC"
    ],
    "interventions": [
      "IDE-161",
      "Pembrolizumab"
    ],
    "primary_completion_date": "2026-10",
    "completion_date": "2027-05",
    "results_first_posted": null,
    "last_update_posted": "2026-01-23",
    "enrollment": null,
    "sponsor": "IDEAYA Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "IDEAYA Biosciences"
  },
  {
    "ticker": "IDYA",
    "nct_id": "NCT04794699",
    "title": "Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor"
    ],
    "interventions": [
      "IDE397",
      "Docetaxel",
      "Paclitaxel",
      "Sacituzumab govitecan"
    ],
    "primary_completion_date": "2026-12-31",
    "completion_date": "2027-03-30",
    "results_first_posted": null,
    "last_update_posted": "2025-11-12",
    "enrollment": null,
    "sponsor": "IDEAYA Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "IDEAYA Biosciences"
  },
  {
    "ticker": "IDYA",
    "nct_id": "NCT07174583",
    "title": "A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Small-cell Lung Cancer",
      "Neuroendocrine Carcinomas",
      "Solid Tumor Show to Express DLL3"
    ],
    "interventions": [
      "IDE849",
      "durvalumab",
      "IDE161"
    ],
    "primary_completion_date": "2029-05",
    "completion_date": "2029-05",
    "results_first_posted": null,
    "last_update_posted": "2026-01-23",
    "enrollment": null,
    "sponsor": "IDEAYA Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "IDEAYA Biosciences"
  },
  {
    "ticker": "IDYA",
    "nct_id": "NCT05907954",
    "title": "(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Uveal Melanoma"
    ],
    "interventions": [
      "Darovasertib"
    ],
    "primary_completion_date": "2027-04-30",
    "completion_date": "2030-04-30",
    "results_first_posted": null,
    "last_update_posted": "2025-10-22",
    "enrollment": null,
    "sponsor": "IDEAYA Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "IDEAYA Biosciences"
  },
  {
    "ticker": "IDYA",
    "nct_id": "NCT07277413",
    "title": "A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "NSCLC Adenocarcinoma",
      "Gastroesophageal Cancer (GC)",
      "Gastric Adenocarcinoma",
      "Adenocarcinoma of Esophagus",
      "Squamous Cell Car. - Esophagus",
      "Urothelial Carcinoma (UC)",
      "Bladder Cancer",
      "Mesothelioma",
      "Pleural Mesothelioma",
      "Peritoneal Mesothelioma",
      "Non-Small Cell Lung Cancer NSCLC"
    ],
    "interventions": [
      "IDE892",
      "IDE397"
    ],
    "primary_completion_date": "2028-04-30",
    "completion_date": "2028-04-30",
    "results_first_posted": null,
    "last_update_posted": "2026-01-20",
    "enrollment": null,
    "sponsor": "IDEAYA Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "IDEAYA Biosciences"
  },
  {
    "ticker": "IDYA",
    "nct_id": "NCT03947385",
    "title": "Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Uveal Melanoma",
      "Cutaneous Melanoma",
      "Colorectal Cancer",
      "Other Solid Tumors"
    ],
    "interventions": [
      "IDE196",
      "Binimetinib",
      "Crizotinib"
    ],
    "primary_completion_date": "2027-01-29",
    "completion_date": "2027-06-15",
    "results_first_posted": null,
    "last_update_posted": "2026-01-27",
    "enrollment": null,
    "sponsor": "IDEAYA Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "IDEAYA Biosciences"
  },
  {
    "ticker": "IMRX",
    "nct_id": "NCT06208124",
    "title": "A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumor (Phase 1)",
      "Pancreas Adenocarcinoma",
      "Non-small Cell Lung Cancer",
      "Malignant Melanoma (Cutaneous)"
    ],
    "interventions": [
      "IMM-6-415"
    ],
    "primary_completion_date": "2025-04-30",
    "completion_date": "2025-04-30",
    "results_first_posted": null,
    "last_update_posted": "2025-05-28",
    "enrollment": null,
    "sponsor": "Immuneering Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Immuneering"
  },
  {
    "ticker": "IMRX",
    "nct_id": "NCT05585320",
    "title": "A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumor",
      "Pancreatic Adenocarcinoma",
      "Malignant Melanoma (Cutaneous)",
      "Non-small Cell Lung Cancer (NSCLC)"
    ],
    "interventions": [
      "IMM-1-104 Monotherapy (Treatment Group A)",
      "IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B)",
      "IMM-1-104 + modified FOLFIRINOX (Treatment Group C)",
      "IMM-1-104 + dabrafenib (Treatment Group D)",
      "IMM-1-104 + pembrolizumab (Treatment Group E)"
    ],
    "primary_completion_date": "2026-06",
    "completion_date": "2027-06",
    "results_first_posted": null,
    "last_update_posted": "2025-09-02",
    "enrollment": null,
    "sponsor": "Immuneering Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Immuneering"
  },
  {
    "ticker": "INBX",
    "nct_id": "NCT06295731",
    "title": "INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS\u226520 HNSCC",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Head and Neck Squamous Cell Carcinoma (HNSCC)"
    ],
    "interventions": [
      "INBRX-106",
      "Pembrolizumab"
    ],
    "primary_completion_date": "2029-05",
    "completion_date": "2029-05",
    "results_first_posted": null,
    "last_update_posted": "2025-11-17",
    "enrollment": null,
    "sponsor": "Inhibrx Biosciences, Inc",
    "collected_at": "2026-01-27",
    "search_term": "Inhibrx"
  },
  {
    "ticker": "INBX",
    "nct_id": "NCT03715933",
    "title": "Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ewing Sarcoma"
    ],
    "interventions": [
      "INBRX-109",
      "Irinotecan",
      "Temozolomide",
      "carboplatin",
      "pemetrexed",
      "Leucovorin",
      "Fluorouracil"
    ],
    "primary_completion_date": "2026-06",
    "completion_date": "2026-12",
    "results_first_posted": null,
    "last_update_posted": "2025-12-09",
    "enrollment": null,
    "sponsor": "Inhibrx Biosciences, Inc",
    "collected_at": "2026-01-27",
    "search_term": "Inhibrx"
  },
  {
    "ticker": "INBX",
    "nct_id": "NCT03809624",
    "title": "Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Solid Tumors",
      "Non-small Cell Lung Cancer",
      "Melanoma",
      "Head and Neck Squamous Cell Carcinoma",
      "Gastric Adenocarcinoma",
      "Renal Cell Carcinoma",
      "Esophageal Adenocarcinoma",
      "Nasopharyngeal Carcinoma",
      "Oropharyngeal Carcinoma"
    ],
    "interventions": [
      "INBRX-105 - PDL1x41BB antibody",
      "Pembrolizumab"
    ],
    "primary_completion_date": "2024-10-03",
    "completion_date": "2024-10-03",
    "results_first_posted": null,
    "last_update_posted": "2024-10-23",
    "enrollment": null,
    "sponsor": "Inhibrx Biosciences, Inc",
    "collected_at": "2026-01-27",
    "search_term": "Inhibrx"
  },
  {
    "ticker": "INBX",
    "nct_id": "NCT04950075",
    "title": "Study of INBRX-109 in Conventional Chondrosarcoma",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Conventional Chondrosarcoma"
    ],
    "interventions": [
      "INBRX-109",
      "Placebo"
    ],
    "primary_completion_date": "2025-09-30",
    "completion_date": "2026-12",
    "results_first_posted": null,
    "last_update_posted": "2026-01-09",
    "enrollment": null,
    "sponsor": "Inhibrx Biosciences, Inc",
    "collected_at": "2026-01-27",
    "search_term": "Inhibrx"
  },
  {
    "ticker": "INBX",
    "nct_id": "NCT04198766",
    "title": "Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor",
      "Non-Small Cell Lung Cancer",
      "Head and Neck Cancer",
      "Melanoma",
      "Gastric Cancer",
      "Renal Cell Carcinoma",
      "Urothelial Carcinoma"
    ],
    "interventions": [
      "INBRX-106 - Hexavalent OX40 agonist antibody",
      "pembrolizumab 200 mg",
      "pembrolizumab 400 mg",
      "Carboplatin AUC-5",
      "Carboplatin AUC-6",
      "Pemetrexed 500 mg/m2",
      "Cisplatin 75mg/m2",
      "Paclitaxel 200mg/m2",
      "Nab paclitaxel 100mg/m2"
    ],
    "primary_completion_date": "2026-10-30",
    "completion_date": "2027-05-12",
    "results_first_posted": null,
    "last_update_posted": "2025-12-18",
    "enrollment": null,
    "sponsor": "Inhibrx Biosciences, Inc",
    "collected_at": "2026-01-27",
    "search_term": "Inhibrx"
  },
  {
    "ticker": "INBX",
    "nct_id": "NCT03815396",
    "title": "Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alpha-1 Antitrypsin Deficiency",
      "AATD"
    ],
    "interventions": [
      "INBRX-101/rhAAT-Fc"
    ],
    "primary_completion_date": "2022-08-18",
    "completion_date": "2022-08-18",
    "results_first_posted": null,
    "last_update_posted": "2022-09-13",
    "enrollment": null,
    "sponsor": "Inhibrx Biosciences, Inc",
    "collected_at": "2026-01-27",
    "search_term": "Inhibrx"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03627065",
    "title": "A Study of INCB050465 in Primary Sj\u00f6gren's Syndrome",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Primary Sj\u00f6gren's Syndrome"
    ],
    "interventions": [
      "Parsaclisib"
    ],
    "primary_completion_date": "2019-12-07",
    "completion_date": "2020-01-02",
    "results_first_posted": "2021-03-24",
    "last_update_posted": "2021-08-13",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT06505265",
    "title": "A Study to Evaluate Skin and Plasma Pharmacokinetic of Multiple Doses of Povorcitinib After Oral Administration in Healthy Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants"
    ],
    "interventions": [
      "Povorcitinib"
    ],
    "primary_completion_date": "2024-09-18",
    "completion_date": "2024-09-18",
    "results_first_posted": null,
    "last_update_posted": "2024-09-26",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT04796922",
    "title": "To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)",
    "status": "WITHDRAWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Follicular Lymphoma ( FL)",
      "Marginal Zone Lymphoma (MZL)"
    ],
    "interventions": [
      "parsaclisib",
      "rituximab",
      "obinutuzumab"
    ],
    "primary_completion_date": "2028-12-20",
    "completion_date": "2032-08-25",
    "results_first_posted": null,
    "last_update_posted": "2022-07-18",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT06555081",
    "title": "A Study to Evaluate the Bioequivalence of Ruxolitinib Extended Release (XR) Tablets With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants"
    ],
    "interventions": [
      "Ruxolitinib IR",
      "Ruxolitinib XR"
    ],
    "primary_completion_date": "2024-10-25",
    "completion_date": "2024-11-07",
    "results_first_posted": null,
    "last_update_posted": "2025-02-13",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03745651",
    "title": "TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atopic Dermatitis"
    ],
    "interventions": [
      "Ruxolitinib cream",
      "Vehicle cream"
    ],
    "primary_completion_date": "2019-11-18",
    "completion_date": "2020-11-09",
    "results_first_posted": "2021-12-17",
    "last_update_posted": "2023-09-28",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT02178722",
    "title": "Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Microsatellite-instability (MSI) High Colorectal Cancer (CRC)",
      "Endometrial Cancer",
      "Head and Neck Cancer",
      "Hepatocellular Carcinoma (HCC)",
      "Gastric Cancer",
      "Lung Cancer",
      "Lymphoma",
      "Renal Cell Carcinoma (RCC)",
      "Ovarian Cancer",
      "Solid Tumors",
      "UC (Urothelial Cancer)",
      "Melanoma",
      "Bladder Cancer",
      "Triple Negative Breast Cancer (TNBC)"
    ],
    "interventions": [
      "MK-3475",
      "INCB024360"
    ],
    "primary_completion_date": "2018-11-26",
    "completion_date": "2020-11-06",
    "results_first_posted": "2019-12-19",
    "last_update_posted": "2022-02-14",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT04839380",
    "title": "The Purpose of the Study is to Evaluate the Effect of Ruxolitinib Cream on Itch in Participants With Atopic Dermatitis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atopic Dermatitis"
    ],
    "interventions": [
      "ruxolitinib cream"
    ],
    "primary_completion_date": "2022-11-18",
    "completion_date": "2022-11-18",
    "results_first_posted": "2023-10-31",
    "last_update_posted": "2023-10-31",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT05936567",
    "title": "Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Urticaria",
      "Chronic Spontaneous Urticaria",
      "Chronic Idiopathic Urticaria",
      "Hives",
      "Angioedema",
      "Pruritis"
    ],
    "interventions": [
      "Povorcitinib",
      "Placebo"
    ],
    "primary_completion_date": "2025-02-28",
    "completion_date": "2025-10-09",
    "results_first_posted": null,
    "last_update_posted": "2025-10-15",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03257644",
    "title": "A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atopic Dermatitis"
    ],
    "interventions": [
      "Ruxolitinib phosphate cream"
    ],
    "primary_completion_date": "2020-10-07",
    "completion_date": "2020-10-07",
    "results_first_posted": null,
    "last_update_posted": "2020-11-10",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT04434937",
    "title": "Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lymphoma"
    ],
    "interventions": [
      "parsaclisib"
    ],
    "primary_completion_date": "2023-02-16",
    "completion_date": "2023-10-13",
    "results_first_posted": "2024-01-03",
    "last_update_posted": "2024-10-23",
    "enrollment": null,
    "sponsor": "Incyte Biosciences Japan GK",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT05127421",
    "title": "Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atopic Dermatitis"
    ],
    "interventions": [
      "Ruxolitinib cream",
      "Vehicle"
    ],
    "primary_completion_date": "2023-08-03",
    "completion_date": "2023-09-29",
    "results_first_posted": "2024-08-15",
    "last_update_posted": "2024-08-15",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03837509",
    "title": "INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsed or Refractory Multiple Myeloma"
    ],
    "interventions": [
      "INCB001158",
      "Daratumumab SC"
    ],
    "primary_completion_date": "2022-04-05",
    "completion_date": "2022-04-05",
    "results_first_posted": "2023-03-20",
    "last_update_posted": "2025-11-04",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT01254136",
    "title": "Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Cancer"
    ],
    "interventions": [
      "INCB007839 300mg BID",
      "Trastuzumab",
      "Vinorelbine"
    ],
    "primary_completion_date": "2011-09",
    "completion_date": "2011-10",
    "results_first_posted": null,
    "last_update_posted": "2012-01-25",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT04530344",
    "title": "Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Vitiligo"
    ],
    "interventions": [
      "ruxolitinib",
      "Vehicle"
    ],
    "primary_completion_date": "2022-11-14",
    "completion_date": "2022-11-14",
    "results_first_posted": "2023-07-19",
    "last_update_posted": "2025-08-14",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT02903914",
    "title": "Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Cancer",
      "Solid Tumors",
      "Colorectal Cancer (CRC)",
      "Gastric Cancer",
      "Head and Neck Cancer",
      "Lung Cancer",
      "Renal Cell Carcinoma (RCC)",
      "Bladder Cancer",
      "UC (Urothelial Cancer)",
      "Mesothelioma"
    ],
    "interventions": [
      "INCB001158",
      "Pembrolizumab"
    ],
    "primary_completion_date": "2020-04-30",
    "completion_date": "2022-08-15",
    "results_first_posted": "2021-09-30",
    "last_update_posted": "2025-08-05",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT06039384",
    "title": "A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumors"
    ],
    "interventions": [
      "INCB099280",
      "adagrasib"
    ],
    "primary_completion_date": "2025-04-11",
    "completion_date": "2025-07-11",
    "results_first_posted": null,
    "last_update_posted": "2025-08-03",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03241173",
    "title": "A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Malignancies"
    ],
    "interventions": [
      "INCAGN01949",
      "Nivolumab",
      "Ipilimumab"
    ],
    "primary_completion_date": "2019-09-17",
    "completion_date": "2019-09-17",
    "results_first_posted": "2022-09-27",
    "last_update_posted": "2022-09-27",
    "enrollment": null,
    "sponsor": "Incyte Biosciences International S\u00e0rl",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03126019",
    "title": "A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lymphoma"
    ],
    "interventions": [
      "Parsaclisib"
    ],
    "primary_completion_date": "2021-02-26",
    "completion_date": "2024-06-07",
    "results_first_posted": "2022-02-10",
    "last_update_posted": "2025-03-14",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT04629339",
    "title": "Study of INCB086550 in Select Solid Tumors",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non Small Cell Lung Cancer",
      "Urothelial Cancer",
      "Renal Cell Carcinoma",
      "Hepatocellular Carcinoma",
      "Melanoma"
    ],
    "interventions": [
      "INCB086550"
    ],
    "primary_completion_date": "2024-03-26",
    "completion_date": "2024-03-26",
    "results_first_posted": "2025-03-13",
    "last_update_posted": "2025-03-13",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03314935",
    "title": "A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Biliary Tract Cancer (BTC)",
      "Colorectal Cancer (CRC)",
      "Endometrial Cancer",
      "Gastroesophageal Cancer (GC)",
      "Ovarian Cancer",
      "Solid Tumors"
    ],
    "interventions": [
      "INCB001158",
      "Oxaliplatin",
      "Leucovorin",
      "5-Fluorouracil",
      "Gemcitabine",
      "Cisplatin",
      "Paclitaxel"
    ],
    "primary_completion_date": "2022-11-28",
    "completion_date": "2022-11-28",
    "results_first_posted": "2023-12-07",
    "last_update_posted": "2025-08-12",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03132324",
    "title": "A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Sickle Cell Disease"
    ],
    "interventions": [
      "INCB059872"
    ],
    "primary_completion_date": "2018-10-03",
    "completion_date": "2018-10-03",
    "results_first_posted": null,
    "last_update_posted": "2019-10-28",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT05101369",
    "title": "A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB086550",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "INCB086550"
    ],
    "primary_completion_date": "2022-03-25",
    "completion_date": "2022-03-25",
    "results_first_posted": null,
    "last_update_posted": "2025-08-21",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT06934980",
    "title": "A Study to Evaluate Microneedle-based Collection of Dermal Interstitial Skin Fluid in Healthy Participants and Atopic Dermatitis Participants",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Atopic Dermatitis",
      "Healthy Volunteers"
    ],
    "interventions": [
      "Microneedle Device"
    ],
    "primary_completion_date": "2025-12-19",
    "completion_date": "2025-12-19",
    "results_first_posted": null,
    "last_update_posted": "2026-01-16",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT06873789",
    "title": "A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumors",
      "Advanced Solid Tumors",
      "Metastatic Solid Tumors"
    ],
    "interventions": [
      "INCB177054",
      "Retifanlimab"
    ],
    "primary_completion_date": "2028-10-30",
    "completion_date": "2028-10-30",
    "results_first_posted": null,
    "last_update_posted": "2025-10-15",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03059823",
    "title": "A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Locally Advanced Solid Tumors",
      "Metastatic Solid Tumors"
    ],
    "interventions": [
      "retifanlimab"
    ],
    "primary_completion_date": "2024-05-22",
    "completion_date": "2024-05-22",
    "results_first_posted": null,
    "last_update_posted": "2025-08-03",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03314922",
    "title": "A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lymphoma"
    ],
    "interventions": [
      "Parsaclisib"
    ],
    "primary_completion_date": "2020-05-05",
    "completion_date": "2023-03-09",
    "results_first_posted": null,
    "last_update_posted": "2023-08-14",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT06380205",
    "title": "A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants"
    ],
    "interventions": [
      "Povorcitinib",
      "Levonorgestrel/Ethinyl estradiol"
    ],
    "primary_completion_date": "2024-06-07",
    "completion_date": "2024-06-07",
    "results_first_posted": null,
    "last_update_posted": "2024-07-03",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT06441318",
    "title": "A Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants"
    ],
    "interventions": [
      "Povorcitinib",
      "Placebo",
      "Moxifloxacin"
    ],
    "primary_completion_date": "2024-09-10",
    "completion_date": "2024-09-10",
    "results_first_posted": null,
    "last_update_posted": "2024-09-25",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT04896385",
    "title": "A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Vitiligo"
    ],
    "interventions": [
      "Ruxolitinib cream",
      "Vehicle Cream"
    ],
    "primary_completion_date": "2022-11-17",
    "completion_date": "2023-07-10",
    "results_first_posted": "2023-12-07",
    "last_update_posted": "2025-08-05",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT04370704",
    "title": "Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Melanoma"
    ],
    "interventions": [
      "INCAGN02385",
      "INCAGN02390",
      "INCMGA00012."
    ],
    "primary_completion_date": "2025-08-25",
    "completion_date": "2025-08-25",
    "results_first_posted": null,
    "last_update_posted": "2025-10-03",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03085914",
    "title": "A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor"
    ],
    "interventions": [
      "Epacadostat",
      "Pembrolizumab",
      "Oxaliplatin",
      "Leucovorin",
      "5-Fluorouracil",
      "Gemcitabine",
      "nab-Paclitaxel",
      "Carboplatin",
      "Paclitaxel",
      "Pemetrexed",
      "Cyclophosphamide",
      "Carboplatin",
      "Cisplatin",
      "5-Fluorouracil",
      "Investigator's choice of platinum agent"
    ],
    "primary_completion_date": "2019-01-25",
    "completion_date": "2020-07-13",
    "results_first_posted": "2020-05-07",
    "last_update_posted": "2022-09-23",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT02119650",
    "title": "Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "NSCLC (Non-small Cell Lung Carcinoma)"
    ],
    "interventions": [
      "Ruxolitinib",
      "Placebo",
      "Pemetrexed",
      "Cisplatin"
    ],
    "primary_completion_date": "2016-02-11",
    "completion_date": "2016-06-21",
    "results_first_posted": "2017-06-14",
    "last_update_posted": "2018-02-13",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT02093429",
    "title": "Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "MDS (Myelodysplastic Syndrome)"
    ],
    "interventions": [
      "INCB047986"
    ],
    "primary_completion_date": "2014-09",
    "completion_date": "2014-09",
    "results_first_posted": null,
    "last_update_posted": "2018-01-17",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT04674748",
    "title": "To Assess the Safety, Tolerability and Pharmacokinetics of INCB086550",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumors"
    ],
    "interventions": [
      "INCB086550"
    ],
    "primary_completion_date": "2022-05-13",
    "completion_date": "2022-05-13",
    "results_first_posted": null,
    "last_update_posted": "2025-09-24",
    "enrollment": null,
    "sponsor": "Incyte Biosciences Japan GK",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT02917993",
    "title": "An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lung Cancer"
    ],
    "interventions": [
      "Itacitinib",
      "Osimertinib"
    ],
    "primary_completion_date": "2025-12-31",
    "completion_date": "2025-12-31",
    "results_first_posted": null,
    "last_update_posted": "2025-12-10",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT07195916",
    "title": "A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumors",
      "Hematologic Malignancies"
    ],
    "interventions": [
      "INCA036873"
    ],
    "primary_completion_date": "2028-08-18",
    "completion_date": "2028-08-18",
    "results_first_posted": null,
    "last_update_posted": "2026-01-23",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03910530",
    "title": "A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumors",
      "Metastatic Solid Tumors"
    ],
    "interventions": [
      "Retifanlimab",
      "INCB001158",
      "Retifanlimab + INCB001158"
    ],
    "primary_completion_date": "2021-12-14",
    "completion_date": "2021-12-14",
    "results_first_posted": null,
    "last_update_posted": "2022-02-25",
    "enrollment": null,
    "sponsor": "Incyte Biosciences Japan GK",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT00820950",
    "title": "A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Psoriasis"
    ],
    "interventions": [
      "Ruxolitinib phosphate cream",
      "Dovonex\u00ae calcipotriene 0.005%",
      "Diprolene\u00ae AF betamethasone dipropionate 0.05% cream.",
      "Placebo cream",
      "Ruxolitinib phosphate cream",
      "Ruxolitinib phosphate cream"
    ],
    "primary_completion_date": "2009-01-31",
    "completion_date": "2009-04-30",
    "results_first_posted": "2022-02-08",
    "last_update_posted": "2022-02-08",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT06179160",
    "title": "A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumors"
    ],
    "interventions": [
      "INCB161734",
      "Cetuximab",
      "Retifanlimab",
      "GEMNabP",
      "mFOLFIRINOX",
      "FOLFOX",
      "FOLFIRI",
      "INCA33890"
    ],
    "primary_completion_date": "2027-01-01",
    "completion_date": "2027-01-01",
    "results_first_posted": null,
    "last_update_posted": "2026-01-26",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT01604889",
    "title": "A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Melanoma"
    ],
    "interventions": [
      "Epacadostat",
      "Placebo",
      "ipilimumab",
      "ipilimumab"
    ],
    "primary_completion_date": "2016-12-27",
    "completion_date": "2016-12-27",
    "results_first_posted": null,
    "last_update_posted": "2019-03-26",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT05755438",
    "title": "A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Prurigo"
    ],
    "interventions": [
      "Ruxolitinib Cream",
      "Vehicle Cream"
    ],
    "primary_completion_date": "2024-10-07",
    "completion_date": "2025-08-13",
    "results_first_posted": "2025-11-14",
    "last_update_posted": "2025-11-14",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT02559492",
    "title": "Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumors"
    ],
    "interventions": [
      "Itacitinib",
      "Epacadostat",
      "Itacitinib",
      "INCB050465"
    ],
    "primary_completion_date": "2018-09-10",
    "completion_date": "2019-08-18",
    "results_first_posted": null,
    "last_update_posted": "2019-09-25",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03039114",
    "title": "Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lymphoma"
    ],
    "interventions": [
      "Parsaclisib",
      "Hexal",
      "Gazyvaro"
    ],
    "primary_completion_date": "2021-03-30",
    "completion_date": "2021-03-30",
    "results_first_posted": null,
    "last_update_posted": "2025-08-21",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03126110",
    "title": "Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Malignancies",
      "Metastatic Cancer"
    ],
    "interventions": [
      "INCAGN01876",
      "Nivolumab",
      "Ipilimumab"
    ],
    "primary_completion_date": "2021-11-09",
    "completion_date": "2021-11-09",
    "results_first_posted": "2022-12-28",
    "last_update_posted": "2025-08-14",
    "enrollment": null,
    "sponsor": "Incyte Biosciences International S\u00e0rl",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT02431260",
    "title": "An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumors and Hematologic Malignancy"
    ],
    "interventions": [
      "INCB054329 Monotherapy"
    ],
    "primary_completion_date": "2018-01-31",
    "completion_date": "2018-01-31",
    "results_first_posted": "2019-06-14",
    "last_update_posted": "2019-06-14",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT00820560",
    "title": "Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumors and Hematologic Malignancy"
    ],
    "interventions": [
      "INCB007839"
    ],
    "primary_completion_date": "2009-01",
    "completion_date": "2009-01",
    "results_first_posted": null,
    "last_update_posted": "2018-01-17",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT06310304",
    "title": "A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants.",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants"
    ],
    "interventions": [
      "Ruxolitinib IR",
      "Ruxolitinib XR"
    ],
    "primary_completion_date": "2024-04-16",
    "completion_date": "2024-05-15",
    "results_first_posted": null,
    "last_update_posted": "2024-06-05",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT02393248",
    "title": "Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lung Cancer",
      "Solid Tumor",
      "Gastric Cancer",
      "Urothelial Cancer",
      "Endometrial Cancer",
      "Multiple Myeloma",
      "Myeloproliferative Neoplasms",
      "Breast Cancer",
      "Cholangiocarcinoma",
      "UC",
      "MPN"
    ],
    "interventions": [
      "Pemigatinib",
      "Gemcitabine",
      "Pembrolizumab",
      "Docetaxel",
      "Trastuzumab",
      "Retifanlimab",
      "Cisplatin"
    ],
    "primary_completion_date": "2021-12-17",
    "completion_date": "2021-12-17",
    "results_first_posted": "2023-01-06",
    "last_update_posted": "2023-01-06",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT06713590",
    "title": "A Study to Evaluate a Single-Dose Subcutaneous Axatilimab Compared With Intravenous Axatilimab in Healthy Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants"
    ],
    "interventions": [
      "Axatilimab"
    ],
    "primary_completion_date": "2025-06-06",
    "completion_date": "2025-06-10",
    "results_first_posted": null,
    "last_update_posted": "2025-06-25",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT04377620",
    "title": "Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID-19"
    ],
    "interventions": [
      "Placebo",
      "Ruxolitinib"
    ],
    "primary_completion_date": "2021-02-26",
    "completion_date": "2021-02-26",
    "results_first_posted": "2022-01-19",
    "last_update_posted": "2022-01-19",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT05949632",
    "title": "A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumors"
    ],
    "interventions": [
      "INCB099280",
      "axitinib"
    ],
    "primary_completion_date": "2025-06-06",
    "completion_date": "2025-06-06",
    "results_first_posted": null,
    "last_update_posted": "2025-08-03",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT06843408",
    "title": "A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Graft-versus-host-disease"
    ],
    "interventions": [
      "INCA034176"
    ],
    "primary_completion_date": "2026-07-03",
    "completion_date": "2027-12-31",
    "results_first_posted": null,
    "last_update_posted": "2026-01-12",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03647215",
    "title": "CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Chronic Phase Chronic Myelogenous Leukemia",
      "Accelerated Phase Chronic Myelogenous Leukemia",
      "Blastic Phase Chronic Myelogenous Leukemia",
      "Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia"
    ],
    "interventions": [],
    "primary_completion_date": "2021-03-31",
    "completion_date": "2021-06-30",
    "results_first_posted": null,
    "last_update_posted": "2021-08-16",
    "enrollment": null,
    "sponsor": "Incyte Biosciences UK",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT02959437",
    "title": "Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumors",
      "Advanced Malignancies",
      "Metastatic Cancer"
    ],
    "interventions": [
      "Azacitidine",
      "Pembrolizumab",
      "Epacadostat",
      "INCB057643",
      "Pembrolizumab",
      "Epacadostat",
      "INCB059872"
    ],
    "primary_completion_date": "2019-02-15",
    "completion_date": "2020-03-02",
    "results_first_posted": "2020-03-05",
    "last_update_posted": "2025-10-21",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT06465433",
    "title": "Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hematologic Malignancies"
    ],
    "interventions": [
      "Tafasitamab"
    ],
    "primary_completion_date": "2027-08-29",
    "completion_date": "2027-08-29",
    "results_first_posted": null,
    "last_update_posted": "2025-12-10",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT00698230",
    "title": "Safety and Efficacy of INCB013739 Plus Metformin Compared to Metformin Alone on Glycemic Control in Type 2 Diabetics",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 2 Diabetes"
    ],
    "interventions": [
      "INCB013739",
      "INCB013739",
      "INCB013739",
      "INCB013739",
      "INCB013739",
      "Placebo comparator matching INCB013739",
      "Metformin"
    ],
    "primary_completion_date": "2009-04",
    "completion_date": "2009-05",
    "results_first_posted": null,
    "last_update_posted": "2018-02-14",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT02456675",
    "title": "INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Refractory Hodgkin Lymphoma",
      "Recurrent Adult Hodgkin's Lymphoma"
    ],
    "interventions": [
      "INCB040093 Monotherapy",
      "INCB040093",
      "itacitinib"
    ],
    "primary_completion_date": "2016-12-16",
    "completion_date": "2016-12-16",
    "results_first_posted": null,
    "last_update_posted": "2018-01-12",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03277352",
    "title": "INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Malignancies",
      "Metastatic Cancer"
    ],
    "interventions": [
      "INCAGN01876",
      "Epacadostat",
      "Pembrolizumab"
    ],
    "primary_completion_date": "2020-07-01",
    "completion_date": "2020-07-01",
    "results_first_posted": "2021-07-22",
    "last_update_posted": "2021-07-22",
    "enrollment": null,
    "sponsor": "Incyte Biosciences International S\u00e0rl",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03896815",
    "title": "Expanded Access Use of INCB054329 to Treat a Single Patient With Metastatic Renal Cell Carcinoma",
    "status": "NO_LONGER_AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [],
    "interventions": [
      "INCB054329"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2019-04-01",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT06832618",
    "title": "A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atopic Dermatitis"
    ],
    "interventions": [
      "Ruxolitinib",
      "Vehicle Cream"
    ],
    "primary_completion_date": "2026-07-13",
    "completion_date": "2028-05-18",
    "results_first_posted": null,
    "last_update_posted": "2025-12-18",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03144687",
    "title": "A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "MPN (Myeloproliferative Neoplasms)"
    ],
    "interventions": [
      "Itacitinib",
      "Ruxolitinib"
    ],
    "primary_completion_date": "2020-03-14",
    "completion_date": "2021-06-01",
    "results_first_posted": "2021-07-02",
    "last_update_posted": "2022-06-16",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT04661007",
    "title": "To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non Hodgkins Lymphoma",
      "Diffuse Large B-cell Lymphoma"
    ],
    "interventions": [
      "tafasitamab",
      "lenalidomide",
      "parsaclisib",
      "R-CHOP"
    ],
    "primary_completion_date": "2026-12-31",
    "completion_date": "2026-12-31",
    "results_first_posted": null,
    "last_update_posted": "2025-12-18",
    "enrollment": null,
    "sponsor": "Incyte Biosciences Japan GK",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT04203511",
    "title": "INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301)",
    "status": "WITHDRAWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-small Cell Lung Cancer"
    ],
    "interventions": [
      "Retifanlimab",
      "Placebo",
      "Pemetrexed",
      "Cisplatin",
      "Carboplatin",
      "Paclitaxel",
      "Etoposide",
      "Radiotherapy"
    ],
    "primary_completion_date": "2023-11-30",
    "completion_date": "2025-01-31",
    "results_first_posted": null,
    "last_update_posted": "2020-06-09",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT07018635",
    "title": "A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants"
    ],
    "interventions": [
      "INCB161734",
      "Itraconazole",
      "Rifampin",
      "Esomeprazole",
      "Famotidine"
    ],
    "primary_completion_date": "2025-09-29",
    "completion_date": "2025-09-29",
    "results_first_posted": null,
    "last_update_posted": "2025-11-26",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT06909162",
    "title": "A Study to Evaluate the Effect of Food on the Single-Dose Pharmacokinetics and a Drug-Drug Interaction Evaluation of Itraconazole and Rifampin on INCB123667 When Administered Orally to Healthy Adult Participants",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants"
    ],
    "interventions": [
      "INCB123667",
      "itraconazole",
      "rifampin"
    ],
    "primary_completion_date": "2026-02-03",
    "completion_date": "2026-03-01",
    "results_first_posted": null,
    "last_update_posted": "2025-11-04",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03721965",
    "title": "Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Graft-versus-host Disease"
    ],
    "interventions": [
      "Itacitinib",
      "Corticosteroids"
    ],
    "primary_completion_date": "2020-02-17",
    "completion_date": "2020-02-17",
    "results_first_posted": "2023-02-21",
    "last_update_posted": "2025-11-04",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT00393120",
    "title": "Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HIV Infections"
    ],
    "interventions": [
      "INCB009471",
      "INCB009471",
      "Placebo comparator"
    ],
    "primary_completion_date": "2007-09",
    "completion_date": "2007-09",
    "results_first_posted": null,
    "last_update_posted": "2018-03-26",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03538028",
    "title": "A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cervical Cancer",
      "Microsatellite Instability (MSI)-High Endometrial Cancer",
      "Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ])",
      "Esophageal Cancer",
      "Hepatocellular Carcinoma",
      "Melanoma (Uveal Melanoma Excluded)",
      "Merkel Cell Carcinoma",
      "Mesothelioma",
      "MSI-high Colorectal Cancer",
      "Non-small Cell Lung Cancer (NSCLC)",
      "Ovarian Cancer",
      "Squamous Cell Carcinoma of the Head and Neck (SCCHN)",
      "Small Cell Lung Cancer (SCLC)",
      "Renal Cell Carcinoma (RCC)",
      "Triple-negative Breast Cancer",
      "Urothelial Carcinoma",
      "Diffuse Large B-cell Lymphoma"
    ],
    "interventions": [
      "INCAGN02385"
    ],
    "primary_completion_date": "2020-10-07",
    "completion_date": "2020-10-07",
    "results_first_posted": null,
    "last_update_posted": "2020-10-30",
    "enrollment": null,
    "sponsor": "Incyte Biosciences International S\u00e0rl",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03348904",
    "title": "Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lung Cancer"
    ],
    "interventions": [
      "Nivolumab",
      "Epacadostat",
      "Placebo",
      "Carboplatin",
      "Cisplatin",
      "Gemcitabine",
      "Paclitaxel",
      "Pemetrexed"
    ],
    "primary_completion_date": "2018-05-22",
    "completion_date": "2018-05-22",
    "results_first_posted": "2019-06-13",
    "last_update_posted": "2019-06-13",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT01626573",
    "title": "A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rheumatoid Arthritis"
    ],
    "interventions": [
      "Itacitinib",
      "Itacitinib Placebo"
    ],
    "primary_completion_date": "2013-07",
    "completion_date": "2013-10",
    "results_first_posted": null,
    "last_update_posted": "2019-03-12",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT05287113",
    "title": "Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS \u2265 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Head and Neck Cancer"
    ],
    "interventions": [
      "Retifanlimab",
      "INCAGN02385",
      "INCAGN02390",
      "Placebo"
    ],
    "primary_completion_date": "2025-03-14",
    "completion_date": "2026-07-10",
    "results_first_posted": null,
    "last_update_posted": "2026-01-07",
    "enrollment": null,
    "sponsor": "Incyte Biosciences International S\u00e0rl",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03920839",
    "title": "INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)",
    "status": "WITHDRAWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced and/or Metastatic Solid Tumors",
      "Stage IIIB Not Amenable to Curative Therapy to Stage IV Non-small Cell Lung Cancer",
      "Advanced/Metastatic Unresectable Malignant Pleural Mesothelioma"
    ],
    "interventions": [
      "Retifanlimab",
      "Gemcitabine",
      "Cisplatin",
      "Pemetrexed",
      "Carboplatin",
      "Paclitaxel"
    ],
    "primary_completion_date": "2019-11-04",
    "completion_date": "2019-11-04",
    "results_first_posted": null,
    "last_update_posted": "2020-04-24",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT01195311",
    "title": "A Dose-escalation Study in Subjects With Advanced Malignancies",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumors and Hematologic Malignancy"
    ],
    "interventions": [
      "INCB024360"
    ],
    "primary_completion_date": "2013-05",
    "completion_date": "2013-07",
    "results_first_posted": null,
    "last_update_posted": "2018-01-17",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT00300573",
    "title": "Randomized, Double-Blind Study Comparing Dexelvucitabine (DFC) to Lamivudine (3TC) in Subjects With Resistance to NRTIs, PIs, and NNRTIs",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HIV Infections",
      "Human Immunodeficiency Virus"
    ],
    "interventions": [
      "Dexelvucitabine"
    ],
    "primary_completion_date": null,
    "completion_date": "2006-04",
    "results_first_posted": null,
    "last_update_posted": "2018-08-23",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT05906628",
    "title": "Topical Ruxolitinib Evaluation in Chronic Hand Eczema",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hand Eczema"
    ],
    "interventions": [
      "Ruxolitinib cream",
      "Vehicle"
    ],
    "primary_completion_date": "2024-07-15",
    "completion_date": "2024-12-13",
    "results_first_posted": "2025-07-31",
    "last_update_posted": "2025-07-31",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03011372",
    "title": "A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "MPN (Myeloproliferative Neoplasms)"
    ],
    "interventions": [
      "Pemigatinib"
    ],
    "primary_completion_date": "2024-10-30",
    "completion_date": "2024-10-30",
    "results_first_posted": "2025-11-18",
    "last_update_posted": "2025-11-18",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT06212999",
    "title": "A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hidradenitis Suppurativa (HS)"
    ],
    "interventions": [
      "Povorcitinib"
    ],
    "primary_completion_date": "2026-12-26",
    "completion_date": "2026-12-26",
    "results_first_posted": null,
    "last_update_posted": "2025-11-04",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03679767",
    "title": "A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Non-small Cell Lung Cancer",
      "Locally Advanced Urothelial Cancer",
      "Metastatic Urothelial Cancer",
      "Unresectable Melanoma",
      "Metastatic Melanoma",
      "Locally Advanced Renal Cell Carcinoma",
      "Metastatic Clear-Cell Renal Cell Carcinoma"
    ],
    "interventions": [
      "Retifanlimab"
    ],
    "primary_completion_date": "2021-04-15",
    "completion_date": "2022-06-28",
    "results_first_posted": "2022-05-10",
    "last_update_posted": "2023-07-21",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03906344",
    "title": "Expanded Access Use of INCB052793 to Treat a Single Patient With Myelofibrosis",
    "status": "NO_LONGER_AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [],
    "interventions": [
      "INCB052793"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2019-04-08",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT05359692",
    "title": "INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Head and Neck Squamous Cell Carcinoma",
      "Advanced Malignancies",
      "Recurrent Head and Neck Squamous Cell Carcinoma"
    ],
    "interventions": [
      "INCAGN01876",
      "retifanlimab"
    ],
    "primary_completion_date": "2024-04-20",
    "completion_date": "2025-01-11",
    "results_first_posted": null,
    "last_update_posted": "2023-09-15",
    "enrollment": null,
    "sponsor": "Incyte Biosciences International S\u00e0rl",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT06855498",
    "title": "Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hidradenitis Suppurativa (HS)"
    ],
    "interventions": [
      "povorcitinib"
    ],
    "primary_completion_date": "2028-02-28",
    "completion_date": "2028-02-28",
    "results_first_posted": null,
    "last_update_posted": "2026-01-26",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT00398619",
    "title": "A Study of the Effect of INCB013739 on Cortisone Reducing Enzyme Activity in Obese People Predisposed to Diabetes",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Insulin Resistance",
      "Obesity"
    ],
    "interventions": [
      "INCB13739"
    ],
    "primary_completion_date": "2007-03",
    "completion_date": "2007-03",
    "results_first_posted": null,
    "last_update_posted": "2012-01-23",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT01858883",
    "title": "Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumors",
      "Pancreatic Cancer"
    ],
    "interventions": [
      "itacitinib",
      "Gemcitabine",
      "nab-paclitaxel",
      "filgrastim"
    ],
    "primary_completion_date": "2016-02",
    "completion_date": "2016-03",
    "results_first_posted": null,
    "last_update_posted": "2019-07-18",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT05073458",
    "title": "Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Warm Autoimmune Hemolytic Anemia (wAIHA)"
    ],
    "interventions": [
      "parsaclisinib",
      "placebo"
    ],
    "primary_completion_date": "2023-10-17",
    "completion_date": "2024-04-29",
    "results_first_posted": "2025-01-15",
    "last_update_posted": "2025-11-03",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03112603",
    "title": "A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Graft-versus-host Disease (GVHD)"
    ],
    "interventions": [
      "Ruxolitinib",
      "Extracorporeal photopheresis (ECP)",
      "Low-dose methotrexate (MTX)",
      "Mycophenolate mofetil (MMF)",
      "mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus)",
      "Infliximab",
      "Rituximab",
      "Pentostatin",
      "Imatinib",
      "Ibrutinib"
    ],
    "primary_completion_date": "2020-05-08",
    "completion_date": "2022-12-15",
    "results_first_posted": "2022-04-15",
    "last_update_posted": "2025-08-12",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT05238922",
    "title": "Study of INCB123667 in Subjects With Advanced Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumors"
    ],
    "interventions": [
      "INCB0123667",
      "Palbociclib",
      "Bevacizumab",
      "Olaparib",
      "Paclitaxel",
      "Ribociclib",
      "Fulvestrant"
    ],
    "primary_completion_date": "2027-07-27",
    "completion_date": "2027-08-31",
    "results_first_posted": null,
    "last_update_posted": "2025-12-31",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03011892",
    "title": "A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atopic Dermatitis"
    ],
    "interventions": [
      "Ruxolitinib 0.15% Cream QD",
      "Ruxolitinib 0.5% Cream QD",
      "Ruxolitinib 1.5% Cream QD",
      "Ruxolitinib 1.5% Cream BID",
      "Triamcinolone 0.1% Cream BID",
      "Vehicle Cream BID"
    ],
    "primary_completion_date": "2018-01-10",
    "completion_date": "2018-03-12",
    "results_first_posted": "2021-04-09",
    "last_update_posted": "2021-04-09",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT02646748",
    "title": "Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Colorectal Cancer (CRC)",
      "Endometrial Cancer",
      "Melanoma",
      "Head and Neck Cancer",
      "Lung Cancer",
      "MMR-deficient Tumors",
      "Breast Cancer",
      "Pancreatic Cancer",
      "Renal Cell Carcinoma (RCC)",
      "Solid Tumors",
      "UC (Urothelial Cancer)"
    ],
    "interventions": [
      "Pembrolizumab",
      "itacitinib",
      "INCB050465"
    ],
    "primary_completion_date": "2019-11-07",
    "completion_date": "2020-11-20",
    "results_first_posted": null,
    "last_update_posted": "2022-03-31",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT02355431",
    "title": "Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumors and Hematologic Malignancy",
      "NSCLC (Non-small Cell Lung Carcinoma)"
    ],
    "interventions": [
      "Itacitinib",
      "erlotinib",
      "placebo"
    ],
    "primary_completion_date": "2015-09",
    "completion_date": "2015-09",
    "results_first_posted": null,
    "last_update_posted": "2019-03-08",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT02760485",
    "title": "A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lymphoma"
    ],
    "interventions": [
      "itacitinib",
      "ibrutinib"
    ],
    "primary_completion_date": "2022-06-06",
    "completion_date": "2022-06-06",
    "results_first_posted": "2023-06-15",
    "last_update_posted": "2023-06-15",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT06585774",
    "title": "A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Graft-versus-host-disease"
    ],
    "interventions": [
      "INCA034176",
      "Placebo",
      "Corticosteroids"
    ],
    "primary_completion_date": "2027-09-28",
    "completion_date": "2030-03-31",
    "results_first_posted": null,
    "last_update_posted": "2026-01-12",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT01423604",
    "title": "Study of Ruxolitinib in Pancreatic Cancer Patients",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pancreatic Cancer"
    ],
    "interventions": [
      "Capecitabine",
      "Ruxolitinib",
      "Placebo"
    ],
    "primary_completion_date": "2013-06",
    "completion_date": "2016-11",
    "results_first_posted": "2016-08-29",
    "last_update_posted": "2018-02-12",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03342352",
    "title": "Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)",
    "status": "WITHDRAWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Head and Neck Cancer"
    ],
    "interventions": [
      "Nivolumab",
      "Epacadostat",
      "Placebo",
      "Carboplatin",
      "Cisplatin",
      "Cetuximab",
      "5-Fluorouracil"
    ],
    "primary_completion_date": "2018-04-20",
    "completion_date": "2018-04-20",
    "results_first_posted": null,
    "last_update_posted": "2019-12-20",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT04680052",
    "title": "A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Follicular Lymphoma",
      "Marginal Zone Lymphoma"
    ],
    "interventions": [
      "tafasitamab",
      "rituximab",
      "lenalidomide",
      "placebo"
    ],
    "primary_completion_date": "2024-02-23",
    "completion_date": "2028-08-09",
    "results_first_posted": "2025-04-04",
    "last_update_posted": "2025-12-22",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT02953678",
    "title": "A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Graft-versus-host Disease (GVHD)"
    ],
    "interventions": [
      "Ruxolitinib",
      "Prednisone or methylprednisolone"
    ],
    "primary_completion_date": "2018-01-31",
    "completion_date": "2019-08-14",
    "results_first_posted": "2019-08-20",
    "last_update_posted": "2021-11-24",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT04921969",
    "title": "A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atopic Dermatitis"
    ],
    "interventions": [
      "Ruxolitinib",
      "Vehicle Cream"
    ],
    "primary_completion_date": "2023-05-10",
    "completion_date": "2024-04-08",
    "results_first_posted": "2024-06-10",
    "last_update_posted": "2025-03-28",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT02723994",
    "title": "A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Leukemia"
    ],
    "interventions": [
      "Ruxolitinib",
      "Asparaginase Erwinia Chrysanthemi",
      "Cyclophosphamide",
      "Cytarabine",
      "Dexamethasone",
      "Doxorubicin",
      "Leucovorin Calcium",
      "Mercaptopurine",
      "Methotrexate",
      "Pegaspargase",
      "Prednisone",
      "Thioguanine",
      "Vincristine Sulfate"
    ],
    "primary_completion_date": "2026-02-01",
    "completion_date": "2026-02-01",
    "results_first_posted": null,
    "last_update_posted": "2025-10-20",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT05620823",
    "title": "A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hidradenitis Suppurativa (HS)"
    ],
    "interventions": [
      "Povorcitinib",
      "Placebo"
    ],
    "primary_completion_date": "2025-02-03",
    "completion_date": "2025-12-23",
    "results_first_posted": null,
    "last_update_posted": "2026-01-27",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT06910137",
    "title": "An Early Access Program Guideline to Provide Access to Retifanlimab (INCMGA00012) Together With Carboplatin and Paclitaxel for Squamous Carcinoma of the Anal Canal (SCAC)",
    "status": "AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Squamous Cell Carcinoma of the Anal Canal"
    ],
    "interventions": [
      "retifanlimab"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2026-01-08",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT06309394",
    "title": "A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]INCB099280 in Healthy Male Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants"
    ],
    "interventions": [
      "INCB099280"
    ],
    "primary_completion_date": "2024-06-04",
    "completion_date": "2024-06-04",
    "results_first_posted": "2025-09-11",
    "last_update_posted": "2025-09-11",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03934372",
    "title": "Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Myeloid Leukemia",
      "Accelerated Phase Chronic Myeloid Leukemia",
      "Blast Phase Chronic Myeloid Leukemia",
      "Chronic Phase Chronic Myeloid Leukemia",
      "Acute Lymphoblastic Leukemia",
      "Acute Lymphocytic Leukemia",
      "Leukemia",
      "Lymphoma",
      "Solid Tumors"
    ],
    "interventions": [
      "Ponatinib"
    ],
    "primary_completion_date": "2028-02-01",
    "completion_date": "2028-02-01",
    "results_first_posted": null,
    "last_update_posted": "2025-12-17",
    "enrollment": null,
    "sponsor": "Incyte Biosciences International S\u00e0rl",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT05696392",
    "title": "The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.",
    "status": "TERMINATED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atopic Dermatitis"
    ],
    "interventions": [
      "ruxolitinib cream"
    ],
    "primary_completion_date": "2025-01-22",
    "completion_date": "2025-01-22",
    "results_first_posted": "2025-12-19",
    "last_update_posted": "2025-12-19",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03607487",
    "title": "A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hidradenitis Suppurativa"
    ],
    "interventions": [
      "INCB054707",
      "Placebo"
    ],
    "primary_completion_date": "2019-08-13",
    "completion_date": "2019-08-13",
    "results_first_posted": "2020-09-21",
    "last_update_posted": "2025-08-21",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT02998476",
    "title": "A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lymphoma"
    ],
    "interventions": [
      "Parsaclisib"
    ],
    "primary_completion_date": "2019-02-22",
    "completion_date": "2021-02-05",
    "results_first_posted": "2020-04-24",
    "last_update_posted": "2025-08-22",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT05593432",
    "title": "A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cutaneous Lichen Planus"
    ],
    "interventions": [
      "Ruxolitinib cream",
      "Vehicle cream"
    ],
    "primary_completion_date": "2023-10-02",
    "completion_date": "2024-02-26",
    "results_first_posted": "2024-10-24",
    "last_update_posted": "2024-10-24",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03597295",
    "title": "A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Squamous Cell Carcinoma of Anal Canal"
    ],
    "interventions": [
      "Retifanlimab"
    ],
    "primary_completion_date": "2020-06-08",
    "completion_date": "2021-11-10",
    "results_first_posted": "2021-08-23",
    "last_update_posted": "2025-08-21",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03656536",
    "title": "A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Unresectable Cholangiocarcinoma",
      "Metastatic Cholangiocarcinoma"
    ],
    "interventions": [
      "Pemigatinib",
      "Gemcitabine",
      "Cisplatin"
    ],
    "primary_completion_date": "2025-07-07",
    "completion_date": "2025-07-07",
    "results_first_posted": null,
    "last_update_posted": "2025-08-24",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03569371",
    "title": "A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hidradenitis Suppurativa"
    ],
    "interventions": [
      "INCB054707"
    ],
    "primary_completion_date": "2019-04-22",
    "completion_date": "2019-04-22",
    "results_first_posted": "2020-05-20",
    "last_update_posted": "2022-09-26",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT01634087",
    "title": "A Study of Escalating Doses of Itacitinib Administered Orally in Patients With Plaque Psoriasis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Plaque Psoriasis"
    ],
    "interventions": [
      "Itacitinib",
      "Placebo"
    ],
    "primary_completion_date": "2013-01",
    "completion_date": "2013-02",
    "results_first_posted": null,
    "last_update_posted": "2019-03-12",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT05099445",
    "title": "Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Renal Impairment",
      "Hemodialysis"
    ],
    "interventions": [
      "INCB000928"
    ],
    "primary_completion_date": "2023-02-19",
    "completion_date": "2023-02-27",
    "results_first_posted": null,
    "last_update_posted": "2023-05-15",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT05233410",
    "title": "Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2",
    "status": "WITHDRAWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Hand Eczema (CHE)"
    ],
    "interventions": [
      "Ruxolitinib cream",
      "Vehicle"
    ],
    "primary_completion_date": "2024-04-25",
    "completion_date": "2024-09-22",
    "results_first_posted": null,
    "last_update_posted": "2022-11-10",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT00639002",
    "title": "A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple Myeloma"
    ],
    "interventions": [
      "Ruxolitinib 25 mg",
      "Dexamethasone 40 mg"
    ],
    "primary_completion_date": "2010-07",
    "completion_date": "2010-07",
    "results_first_posted": "2012-01-23",
    "last_update_posted": "2018-02-13",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT04476043",
    "title": "To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hidradenitis Suppurativa",
      "Acne Inversa"
    ],
    "interventions": [
      "INCB054707",
      "Placebo"
    ],
    "primary_completion_date": "2021-12-15",
    "completion_date": "2023-08-16",
    "results_first_posted": "2023-01-26",
    "last_update_posted": "2025-08-12",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT07124078",
    "title": "A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Graft-versus-host-disease"
    ],
    "interventions": [
      "INCA034176",
      "Best available Treatment (BAT)"
    ],
    "primary_completion_date": "2029-01-31",
    "completion_date": "2029-07-31",
    "results_first_posted": null,
    "last_update_posted": "2026-01-26",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT00698789",
    "title": "Evaluate the Safety and Tolerability of INCB019602 When Administered With Metformin in Patients With Type 2 Diabetes",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 2 Diabetes"
    ],
    "interventions": [
      "INCB019602",
      "INCB019602",
      "INCB019602",
      "INCB019602",
      "INCB019602",
      "Placebo",
      "Metformin"
    ],
    "primary_completion_date": "2009-02",
    "completion_date": "2009-06",
    "results_first_posted": null,
    "last_update_posted": "2012-10-30",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT04849715",
    "title": "A Study of Parsaclisib, a PI3K\u03b4 Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma",
    "status": "WITHDRAWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Mantle Cell Lymphoma"
    ],
    "interventions": [
      "parsaclisib",
      "rituximab",
      "bendamustine",
      "Placebo"
    ],
    "primary_completion_date": "2030-08-15",
    "completion_date": "2034-07-07",
    "results_first_posted": null,
    "last_update_posted": "2022-04-29",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03515785",
    "title": "A Study to Evaluate Effectiveness and Safety of Ponatinib in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - \"POSEIDON\"",
    "status": "WITHDRAWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "BCR-ABL Positive Acute Lymphoblastic Leukemia"
    ],
    "interventions": [],
    "primary_completion_date": "2021-03",
    "completion_date": "2021-03",
    "results_first_posted": null,
    "last_update_posted": "2018-12-14",
    "enrollment": null,
    "sponsor": "Incyte Biosciences International S\u00e0rl",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT02923349",
    "title": "A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Malignancies",
      "Metastatic Cancer"
    ],
    "interventions": [
      "INCAGN01949"
    ],
    "primary_completion_date": "2019-03-26",
    "completion_date": "2019-03-26",
    "results_first_posted": "2020-05-12",
    "last_update_posted": "2025-08-24",
    "enrollment": null,
    "sponsor": "Incyte Biosciences International S\u00e0rl",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT02587598",
    "title": "Study of INCB053914 in Subjects With Advanced Malignancies",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumors"
    ],
    "interventions": [
      "INCB053914",
      "I-DAC (Intermediate dose cytarabine)",
      "Azacitidine",
      "Ruxolitinib"
    ],
    "primary_completion_date": "2020-08-11",
    "completion_date": "2020-08-11",
    "results_first_posted": "2021-12-08",
    "last_update_posted": "2021-12-08",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT00902486",
    "title": "INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rheumatoid Arthritis"
    ],
    "interventions": [
      "INCB028050",
      "INCB028050",
      "INCB028050",
      "Placebo"
    ],
    "primary_completion_date": "2010-06",
    "completion_date": "2010-07",
    "results_first_posted": "2018-09-04",
    "last_update_posted": "2018-09-04",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT02711137",
    "title": "Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumors"
    ],
    "interventions": [
      "INCB057643",
      "Gemcitabine",
      "Paclitaxel",
      "Rucaparib",
      "Abiraterone",
      "Ruxolitinib",
      "Azacitidine"
    ],
    "primary_completion_date": "2019-02-13",
    "completion_date": "2019-02-13",
    "results_first_posted": "2022-04-28",
    "last_update_posted": "2025-10-21",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT05061693",
    "title": "A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Prurigo Nodularis"
    ],
    "interventions": [
      "INCB054707",
      "Placebo"
    ],
    "primary_completion_date": "2023-08-11",
    "completion_date": "2024-02-28",
    "results_first_posted": "2024-08-27",
    "last_update_posted": "2025-07-11",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT04048564",
    "title": "Observational Study on CML Patients in Any Phase of the Disease Treated With Ponatinib (Iclusig\u00ae)",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Chronic Myeloid Leukemia"
    ],
    "interventions": [],
    "primary_completion_date": "2022-12-31",
    "completion_date": "2023-07-03",
    "results_first_posted": null,
    "last_update_posted": "2023-09-28",
    "enrollment": null,
    "sponsor": "Incyte BioSciences France",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT05620836",
    "title": "A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hidradenitis Suppurativa (HS)"
    ],
    "interventions": [
      "Povorcitinib",
      "Placebo"
    ],
    "primary_completion_date": "2025-01-07",
    "completion_date": "2025-11-21",
    "results_first_posted": null,
    "last_update_posted": "2026-01-09",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT06804811",
    "title": "A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "NonSegmental Vitiligo"
    ],
    "interventions": [
      "Ruxolitinib Cream",
      "Vehicle Cream"
    ],
    "primary_completion_date": "2027-04-30",
    "completion_date": "2027-12-01",
    "results_first_posted": null,
    "last_update_posted": "2025-12-17",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT04205812",
    "title": "Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Squamous Non-Small Cell Lung Cancer",
      "Metastatic Nonsquamous Non-Small Cell Lung Cancer"
    ],
    "interventions": [
      "Retifanlimab",
      "Placebo",
      "Pemetrexed",
      "Cisplatin",
      "Carboplatin",
      "Paclitaxel",
      "nab-Paclitaxel"
    ],
    "primary_completion_date": "2023-12-15",
    "completion_date": "2026-08-28",
    "results_first_posted": "2025-02-06",
    "last_update_posted": "2025-09-25",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT07049575",
    "title": "Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hidradenitis Suppurativa"
    ],
    "interventions": [
      "Ruxolitinib Cream"
    ],
    "primary_completion_date": "2026-12-09",
    "completion_date": "2026-12-09",
    "results_first_posted": null,
    "last_update_posted": "2025-12-31",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT05593445",
    "title": "A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lichen Sclerosus"
    ],
    "interventions": [
      "Ruxolitinib cream",
      "Vehicle cream"
    ],
    "primary_completion_date": "2023-09-01",
    "completion_date": "2023-12-21",
    "results_first_posted": "2024-09-24",
    "last_update_posted": "2024-09-24",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03322566",
    "title": "A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lung Cancer"
    ],
    "interventions": [
      "Pembrolizumab",
      "Epacadostat",
      "Platinum-based chemotherapy",
      "Placebo"
    ],
    "primary_completion_date": "2018-12-13",
    "completion_date": "2020-10-16",
    "results_first_posted": "2020-01-29",
    "last_update_posted": "2022-01-24",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT04355793",
    "title": "Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection",
    "status": "NO_LONGER_AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "COVID-19"
    ],
    "interventions": [
      "Ruxolitinib"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2021-12-15",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT02872714",
    "title": "A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "UC (Urothelial Cancer)"
    ],
    "interventions": [
      "pemigatinib",
      "pemigatinib"
    ],
    "primary_completion_date": "2022-02-01",
    "completion_date": "2022-02-01",
    "results_first_posted": "2023-03-24",
    "last_update_posted": "2025-08-14",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT02955940",
    "title": "An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pancreatic Cancer",
      "Colorectal Cancer (CRC)",
      "Breast Cancer",
      "Lung Cancer"
    ],
    "interventions": [
      "Ruxolitinib",
      "Capecitabine",
      "Regorafenib"
    ],
    "primary_completion_date": "2027-09-30",
    "completion_date": "2027-09-30",
    "results_first_posted": null,
    "last_update_posted": "2025-12-17",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT06627335",
    "title": "An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Pregnancy Related",
      "Atopic Dermatitis"
    ],
    "interventions": [
      "Ruxolitinib Cream",
      "TCS"
    ],
    "primary_completion_date": "2027-08-15",
    "completion_date": "2028-08-15",
    "results_first_posted": null,
    "last_update_posted": "2025-12-11",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT02265510",
    "title": "An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumors",
      "Advanced Malignancies",
      "Metastatic Cancer"
    ],
    "interventions": [
      "INCB052793",
      "gemcitabine",
      "nab-paclitaxel",
      "dexamethasone",
      "Carfilzomib",
      "bortezomib",
      "lenalidomide",
      "azacitidine",
      "INCB052793",
      "pomalidomide",
      "INCB050465",
      "INCB039110"
    ],
    "primary_completion_date": "2019-02-27",
    "completion_date": "2019-02-27",
    "results_first_posted": "2020-04-17",
    "last_update_posted": "2020-04-17",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT06775327",
    "title": "Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, & Food Effect of Oral INCB000631 to Healthy Adult Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants"
    ],
    "interventions": [
      "INCB000631",
      "Placebo"
    ],
    "primary_completion_date": "2025-05-28",
    "completion_date": "2025-05-28",
    "results_first_posted": null,
    "last_update_posted": "2025-06-11",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03978637",
    "title": "Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bronchiolitis Obliterans Syndrome"
    ],
    "interventions": [
      "Itacitinib"
    ],
    "primary_completion_date": "2023-10-13",
    "completion_date": "2023-10-13",
    "results_first_posted": "2025-01-29",
    "last_update_posted": "2025-10-20",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT06034002",
    "title": "A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Myeloproliferative Neoplasms"
    ],
    "interventions": [
      "INCA033989",
      "Ruxolitinib"
    ],
    "primary_completion_date": "2028-10-29",
    "completion_date": "2028-10-29",
    "results_first_posted": null,
    "last_update_posted": "2025-10-30",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03906318",
    "title": "Expanded Access Use of Itacitinib to Treat a Single Patient With Aplastic Anemia",
    "status": "NO_LONGER_AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Aplastic Anemia"
    ],
    "interventions": [
      "Iticitinib"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2022-09-30",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT06238817",
    "title": "A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atopic Dermatitis"
    ],
    "interventions": [
      "Ruxolitinib Cream",
      "Vehicle Cream"
    ],
    "primary_completion_date": "2025-05-21",
    "completion_date": "2025-10-17",
    "results_first_posted": null,
    "last_update_posted": "2025-10-28",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03599713",
    "title": "A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Merkel Cell Carcinoma"
    ],
    "interventions": [
      "Retifanlimab"
    ],
    "primary_completion_date": "2022-01-21",
    "completion_date": "2024-06-28",
    "results_first_posted": "2023-05-03",
    "last_update_posted": "2025-08-05",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03584516",
    "title": "GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Graft-versus-host Disease"
    ],
    "interventions": [
      "Itacitinib",
      "Placebo",
      "Methylprednisolone",
      "Prednisone"
    ],
    "primary_completion_date": "2023-11-03",
    "completion_date": "2023-11-03",
    "results_first_posted": "2025-01-27",
    "last_update_posted": "2025-10-20",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT04824092",
    "title": "Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diffuse Large B-cell Lymphoma"
    ],
    "interventions": [
      "Tafasitamab",
      "Lenalidomide",
      "Rituximab",
      "Cyclophosphamide",
      "Doxorubicin",
      "Vincristine",
      "Prednisone",
      "Tafasitamab placebo",
      "Lenalidomide placebo"
    ],
    "primary_completion_date": "2026-09-01",
    "completion_date": "2027-11-01",
    "results_first_posted": null,
    "last_update_posted": "2025-09-08",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03347123",
    "title": "A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumors"
    ],
    "interventions": [
      "Epacadostat",
      "Nivolumab",
      "Ipilimumab",
      "Lirilumab"
    ],
    "primary_completion_date": "2021-01-29",
    "completion_date": "2021-01-29",
    "results_first_posted": "2022-02-28",
    "last_update_posted": "2022-02-28",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT02117479",
    "title": "Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pancreatic Cancer"
    ],
    "interventions": [
      "Ruxolitinib",
      "Placebo",
      "Capecitabine"
    ],
    "primary_completion_date": "2016-02",
    "completion_date": "2016-12",
    "results_first_posted": "2017-07-11",
    "last_update_posted": "2019-03-26",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT06959225",
    "title": "Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hidradenitis Suppurativa"
    ],
    "interventions": [
      "Ruxolitinib Cream",
      "Vehicle Cream"
    ],
    "primary_completion_date": "2026-10-09",
    "completion_date": "2027-07-11",
    "results_first_posted": null,
    "last_update_posted": "2025-12-18",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT06958211",
    "title": "Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hidradenitis Suppurativa"
    ],
    "interventions": [
      "Ruxolitinib Cream",
      "Vehicle Cream"
    ],
    "primary_completion_date": "2026-10-09",
    "completion_date": "2027-07-11",
    "results_first_posted": null,
    "last_update_posted": "2025-12-18",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03762447",
    "title": "A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumors"
    ],
    "interventions": [
      "INCB086550"
    ],
    "primary_completion_date": "2023-11-17",
    "completion_date": "2023-11-17",
    "results_first_posted": null,
    "last_update_posted": "2025-08-11",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03361228",
    "title": "A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumors"
    ],
    "interventions": [
      "INCB001158",
      "Epacadostat",
      "Pembrolizumab"
    ],
    "primary_completion_date": "2019-03-30",
    "completion_date": "2019-03-30",
    "results_first_posted": "2020-05-21",
    "last_update_posted": "2020-05-21",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT07218744",
    "title": "Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB123667 in Healthy Male Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants"
    ],
    "interventions": [
      "INCB123667"
    ],
    "primary_completion_date": "2025-12-10",
    "completion_date": "2025-12-10",
    "results_first_posted": null,
    "last_update_posted": "2026-01-07",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT06263478",
    "title": "A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Graft-versus-host-disease"
    ],
    "interventions": [
      "INCA034176"
    ],
    "primary_completion_date": "2025-08-06",
    "completion_date": "2027-03-30",
    "results_first_posted": null,
    "last_update_posted": "2026-01-07",
    "enrollment": null,
    "sponsor": "Incyte Biosciences Japan GK",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT05219864",
    "title": "Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1",
    "status": "WITHDRAWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hand Eczema"
    ],
    "interventions": [
      "Ruxolitinib cream",
      "Vehicle"
    ],
    "primary_completion_date": "2024-04-25",
    "completion_date": "2024-09-22",
    "results_first_posted": null,
    "last_update_posted": "2022-11-17",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT01641107",
    "title": "Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia.",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Philadelphia Positive",
      "BCR-ABL Positive",
      "Acute Lymphoblastic Leukemia"
    ],
    "interventions": [
      "Ponatinib"
    ],
    "primary_completion_date": "2020-04-24",
    "completion_date": "2021-09-30",
    "results_first_posted": null,
    "last_update_posted": "2021-11-30",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT01685255",
    "title": "A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ovarian Cancer",
      "Genitourinary (GU) Tumors"
    ],
    "interventions": [
      "Epacadostat",
      "tamoxifen"
    ],
    "primary_completion_date": "2014-10-23",
    "completion_date": "2014-10-23",
    "results_first_posted": null,
    "last_update_posted": "2019-03-11",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT04586244",
    "title": "An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Urothelial Carcinoma"
    ],
    "interventions": [
      "retifanlimab",
      "epacadostat",
      "INCAGN02385",
      "INCAGN02390"
    ],
    "primary_completion_date": "2024-01-29",
    "completion_date": "2024-01-29",
    "results_first_posted": "2025-03-10",
    "last_update_posted": "2025-10-30",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT05429268",
    "title": "Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Large B-Cell Lymphoma",
      "Diffuse Large B-Cell Lymphoma"
    ],
    "interventions": [
      "Tafasitamab",
      "Lenalidomide"
    ],
    "primary_completion_date": "2026-04-01",
    "completion_date": "2027-04-01",
    "results_first_posted": null,
    "last_update_posted": "2025-12-10",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03906357",
    "title": "Expanded Access of Pemigatinib to Treat a Single Patient With Metastatic Pancreatic Cancer",
    "status": "NO_LONGER_AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [],
    "interventions": [
      "Pemigatinib"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2022-04-19",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT06416800",
    "title": "A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants"
    ],
    "interventions": [
      "Digoxin",
      "Rosuvastatin",
      "Metformin",
      "Povorcitinib",
      "Probenecid"
    ],
    "primary_completion_date": "2025-01-15",
    "completion_date": "2025-01-15",
    "results_first_posted": null,
    "last_update_posted": "2025-02-06",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03361865",
    "title": "Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "UC (Urothelial Cancer)"
    ],
    "interventions": [
      "Pembrolizumab",
      "Epacadostat",
      "Placebo"
    ],
    "primary_completion_date": "2018-08-09",
    "completion_date": "2020-08-04",
    "results_first_posted": "2019-08-29",
    "last_update_posted": "2025-08-22",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT02953704",
    "title": "Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "MPN (Myeloproliferative Neoplasms)"
    ],
    "interventions": [],
    "primary_completion_date": "2022-03-29",
    "completion_date": "2022-03-29",
    "results_first_posted": null,
    "last_update_posted": "2022-05-13",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT05090891",
    "title": "To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fibrodysplasia Ossificans Progressiva (FOP)"
    ],
    "interventions": [
      "INCB000928",
      "Placebo"
    ],
    "primary_completion_date": "2027-07-30",
    "completion_date": "2033-01-20",
    "results_first_posted": null,
    "last_update_posted": "2025-12-05",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT05577182",
    "title": "Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Malignancies"
    ],
    "interventions": [
      "INCA32459-101"
    ],
    "primary_completion_date": "2025-10-13",
    "completion_date": "2025-10-13",
    "results_first_posted": null,
    "last_update_posted": "2025-11-03",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT05624723",
    "title": "Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Renal Insufficiency",
      "Kidney Diseases"
    ],
    "interventions": [
      "INCB054707"
    ],
    "primary_completion_date": "2024-02-07",
    "completion_date": "2024-02-07",
    "results_first_posted": null,
    "last_update_posted": "2024-02-13",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03652077",
    "title": "A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cervical Cancer",
      "Gastric Cancer",
      "Stomach Cancer",
      "Gastroesophageal Junction Cancer",
      "Esophageal Cancer",
      "Hepatocellular Carcinoma",
      "Melanoma",
      "Uveal Melanoma",
      "Merkel Cell Carcinoma",
      "Mesothelioma",
      "MSI",
      "Non-small Cell Lung Cancer",
      "NSCLC",
      "Ovarian Cancer",
      "Squamous Cell Carcinoma of the Head and Neck",
      "Small Cell Lung Cancer",
      "Renal Cell Carcinoma",
      "RCC",
      "Triple-negative Breast Cancer",
      "Urothelial Carcinoma",
      "Mismatch Repair Deficiency"
    ],
    "interventions": [
      "INCAGN02390"
    ],
    "primary_completion_date": "2021-08-18",
    "completion_date": "2021-08-18",
    "results_first_posted": null,
    "last_update_posted": "2021-11-15",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT02614612",
    "title": "Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Graft-versus-host Disease (GVHD)"
    ],
    "interventions": [
      "Itacitinib (200 mg)",
      "Itacitinib (300 mg)",
      "prednisone or methylprednisolone (corticosteroids)"
    ],
    "primary_completion_date": "2016-06",
    "completion_date": "2018-08",
    "results_first_posted": null,
    "last_update_posted": "2019-03-08",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT04818346",
    "title": "A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "NonSegmental Vitiligo"
    ],
    "interventions": [
      "INCB054707",
      "Placebo"
    ],
    "primary_completion_date": "2022-05-24",
    "completion_date": "2023-05-24",
    "results_first_posted": "2023-07-05",
    "last_update_posted": "2024-04-11",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT02318277",
    "title": "A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumors",
      "Head and Neck Cancer",
      "Lung Cancer",
      "UC (Urothelial Cancer)"
    ],
    "interventions": [
      "MEDI4736",
      "INCB024360"
    ],
    "primary_completion_date": "2019-08-28",
    "completion_date": "2020-10-16",
    "results_first_posted": "2020-12-29",
    "last_update_posted": "2022-01-13",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT05750823",
    "title": "A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Nonsegmental Vitiligo With Genital Involvement"
    ],
    "interventions": [
      "Ruxolitinib Cream"
    ],
    "primary_completion_date": "2025-03-06",
    "completion_date": "2025-03-06",
    "results_first_posted": null,
    "last_update_posted": "2025-07-11",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT07104565",
    "title": "Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Immune Thrombocytopenia"
    ],
    "interventions": [
      "INCA000585"
    ],
    "primary_completion_date": "2027-09-23",
    "completion_date": "2028-03-09",
    "results_first_posted": null,
    "last_update_posted": "2026-01-27",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03235544",
    "title": "A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lymphoma"
    ],
    "interventions": [
      "Parsaclisib"
    ],
    "primary_completion_date": "2024-04-30",
    "completion_date": "2024-04-30",
    "results_first_posted": "2022-02-10",
    "last_update_posted": "2025-03-18",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT04582539",
    "title": "To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Myelodysplastic Syndromes",
      "Multiple Myeloma",
      "Anemia"
    ],
    "interventions": [
      "INCB000928"
    ],
    "primary_completion_date": "2024-08-15",
    "completion_date": "2024-08-15",
    "results_first_posted": "2025-10-22",
    "last_update_posted": "2025-10-22",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03260894",
    "title": "Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Renal Cell Carcinoma (RCC)"
    ],
    "interventions": [
      "Pembrolizumab",
      "Epacadostat",
      "Sunitinib",
      "Pazopanib"
    ],
    "primary_completion_date": "2018-08-22",
    "completion_date": "2025-06-04",
    "results_first_posted": "2019-09-10",
    "last_update_posted": "2025-07-29",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT06299553",
    "title": "Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "DLBCL - Diffuse Large B Cell Lymphoma"
    ],
    "interventions": [],
    "primary_completion_date": "2025-06-30",
    "completion_date": "2027-06-30",
    "results_first_posted": null,
    "last_update_posted": "2024-05-22",
    "enrollment": null,
    "sponsor": "Incyte Biosciences Italy S.r.l",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT04809467",
    "title": "A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Lymphocytic Leukemia",
      "Non Hodgkin Lymphoma"
    ],
    "interventions": [
      "tafasitamab",
      "parsaclisib"
    ],
    "primary_completion_date": "2024-10-22",
    "completion_date": "2024-10-22",
    "results_first_posted": null,
    "last_update_posted": "2025-08-03",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT05888844",
    "title": "A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cutaneous Squamous Cell Carcinoma"
    ],
    "interventions": [
      "INCB099280"
    ],
    "primary_completion_date": "2025-12-31",
    "completion_date": "2026-12-31",
    "results_first_posted": null,
    "last_update_posted": "2025-12-10",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT04981795",
    "title": "realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Diffuse Large B-cell Lymphoma"
    ],
    "interventions": [
      "Tafasitamab"
    ],
    "primary_completion_date": "2025-10-31",
    "completion_date": "2026-08-31",
    "results_first_posted": null,
    "last_update_posted": "2024-12-10",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT04949191",
    "title": "The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Malignancies"
    ],
    "interventions": [
      "Pemigatinib",
      "Retifanlimab",
      "Pembrolizumab"
    ],
    "primary_completion_date": "2024-04-11",
    "completion_date": "2024-04-11",
    "results_first_posted": "2024-09-19",
    "last_update_posted": "2024-09-19",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT06821542",
    "title": "A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Graft-versus-host-disease"
    ],
    "interventions": [
      "INCA034176",
      "Best Available Therapy (BAT)"
    ],
    "primary_completion_date": "2028-05-31",
    "completion_date": "2032-11-30",
    "results_first_posted": null,
    "last_update_posted": "2025-09-08",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03144674",
    "title": "A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lymphoma"
    ],
    "interventions": [
      "Parsaclisib"
    ],
    "primary_completion_date": "2021-01-15",
    "completion_date": "2024-05-29",
    "results_first_posted": "2022-02-10",
    "last_update_posted": "2025-07-11",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03522142",
    "title": "A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumors"
    ],
    "interventions": [
      "INCB081776",
      "INCMGA00012"
    ],
    "primary_completion_date": "2025-09-10",
    "completion_date": "2025-09-10",
    "results_first_posted": null,
    "last_update_posted": "2025-10-09",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03144661",
    "title": "An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatocellular Carcinoma (HCC)",
      "Cholangiocarcinoma",
      "Esophageal Cancer",
      "Nasopharyngeal Cancer",
      "Ovarian Cancer",
      "Solid Tumors"
    ],
    "interventions": [
      "INCB062079"
    ],
    "primary_completion_date": "2020-06-10",
    "completion_date": "2020-06-10",
    "results_first_posted": null,
    "last_update_posted": "2025-10-21",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT06213831",
    "title": "A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Prurigo Nodularis"
    ],
    "interventions": [
      "Ruxolitinib Cream 1.5%"
    ],
    "primary_completion_date": "2025-07-17",
    "completion_date": "2025-07-17",
    "results_first_posted": null,
    "last_update_posted": "2025-08-13",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03099304",
    "title": "A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Vitiligo"
    ],
    "interventions": [
      "Ruxolitinib cream",
      "Vehicle cream"
    ],
    "primary_completion_date": "2018-09-12",
    "completion_date": "2021-09-08",
    "results_first_posted": "2021-12-10",
    "last_update_posted": "2022-11-17",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT02119663",
    "title": "A Study of Ruxolitinib in Pancreatic Cancer Patients",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pancreatic Cancer"
    ],
    "interventions": [
      "Ruxolitinib",
      "Placebo",
      "Capecitabine"
    ],
    "primary_completion_date": "2016-02",
    "completion_date": "2016-10",
    "results_first_posted": "2017-06-06",
    "last_update_posted": "2018-02-13",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT06213818",
    "title": "A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of INCB160058 When Administered Orally to Healthy Adult Participant",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants"
    ],
    "interventions": [
      "INCB160058",
      "Placebo",
      "Esomeprazole",
      "Famotidine"
    ],
    "primary_completion_date": "2025-08-19",
    "completion_date": "2025-08-19",
    "results_first_posted": null,
    "last_update_posted": "2025-10-14",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT04580485",
    "title": "INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ovarian Cancer",
      "Bladder Cancer",
      "Non Small Cell Lung Cancer",
      "Squamous Cell Carcinoma of Head and Neck",
      "Triple Negative Breast Cancer",
      "Castration Resistant Prostate Cancer",
      "Colorectal Cancer",
      "Gastric/ Gastroesophageal Junction",
      "Hepatocellular Carcinoma",
      "Pancreatic Ductal Adenocarcinoma",
      "Squamous Carcinoma of the Anal Canal"
    ],
    "interventions": [
      "INCB106385",
      "INCMGA00012"
    ],
    "primary_completion_date": "2024-01-22",
    "completion_date": "2024-01-22",
    "results_first_posted": null,
    "last_update_posted": "2025-07-11",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT02119676",
    "title": "Study of Ruxolitinib in Colorectal Cancer Patients",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "CRC (Colorectal Cancer)"
    ],
    "interventions": [
      "Ruxolitinib",
      "Regorafenib",
      "Placebo"
    ],
    "primary_completion_date": "2016-02",
    "completion_date": "2016-12",
    "results_first_posted": "2017-06-14",
    "last_update_posted": "2018-02-13",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03627052",
    "title": "A Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Moderate to Severe Ulcerative Colitis"
    ],
    "interventions": [
      "Itacitinib",
      "Placebo"
    ],
    "primary_completion_date": "2019-11-13",
    "completion_date": "2019-11-13",
    "results_first_posted": null,
    "last_update_posted": "2019-12-06",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT04640025",
    "title": "A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Myelofibrosis",
      "Postlung Transplant (Bronchiolitis Obliterans)",
      "Chronic Graft Versus Host Disease"
    ],
    "interventions": [
      "itacitinib"
    ],
    "primary_completion_date": "2026-06-22",
    "completion_date": "2026-06-22",
    "results_first_posted": null,
    "last_update_posted": "2025-12-10",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT05635838",
    "title": "Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hidradenitis Suppurativa"
    ],
    "interventions": [
      "Ruxolitinib cream",
      "Vehicle cream"
    ],
    "primary_completion_date": "2023-10-19",
    "completion_date": "2024-03-14",
    "results_first_posted": "2024-11-01",
    "last_update_posted": "2024-11-01",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT02553330",
    "title": "A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alopecia Areata"
    ],
    "interventions": [
      "Placebo Cream",
      "Ruxolitinib Phosphate Cream"
    ],
    "primary_completion_date": "2017-10-03",
    "completion_date": "2017-10-03",
    "results_first_posted": "2020-12-16",
    "last_update_posted": "2020-12-16",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT06516965",
    "title": "A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Prurigo Nodularis"
    ],
    "interventions": [
      "Povorcitinib",
      "Placebo"
    ],
    "primary_completion_date": "2026-10-19",
    "completion_date": "2027-05-03",
    "results_first_posted": null,
    "last_update_posted": "2026-01-16",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT00550043",
    "title": "A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid Arthritis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rheumatoid Arthritis"
    ],
    "interventions": [
      "INCB018424",
      "Placebo"
    ],
    "primary_completion_date": "2008-09",
    "completion_date": "2008-09",
    "results_first_posted": "2015-03-23",
    "last_update_posted": "2015-03-23",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT02151474",
    "title": "INCB047986 in Rheumatoid Arthritis",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rheumatoid Arthritis"
    ],
    "interventions": [
      "INCB047986",
      "Placebo"
    ],
    "primary_completion_date": "2014-08",
    "completion_date": "2014-08",
    "results_first_posted": null,
    "last_update_posted": "2015-02-23",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT07213973",
    "title": "Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hidradenitis Suppurativa (HS)"
    ],
    "interventions": [
      "Povorcitinib"
    ],
    "primary_completion_date": "2028-03-25",
    "completion_date": "2028-03-25",
    "results_first_posted": null,
    "last_update_posted": "2025-12-05",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT05624710",
    "title": "A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Renal Insufficiency",
      "Kidney Diseases"
    ],
    "interventions": [
      "INCB054707"
    ],
    "primary_completion_date": "2023-06-30",
    "completion_date": "2023-06-30",
    "results_first_posted": null,
    "last_update_posted": "2025-08-03",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT00864175",
    "title": "Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast Cancer",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Cancer"
    ],
    "interventions": [
      "INCB007839",
      "INCB007839",
      "INCB007839",
      "INCB007839",
      "trastuzumab",
      "Docetaxel"
    ],
    "primary_completion_date": "2011-06",
    "completion_date": "2011-10",
    "results_first_posted": null,
    "last_update_posted": "2018-01-18",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03538041",
    "title": "A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Autoimmune Hemolytic Anemia"
    ],
    "interventions": [
      "Parsaclisib"
    ],
    "primary_completion_date": "2021-08-05",
    "completion_date": "2024-04-02",
    "results_first_posted": "2022-09-22",
    "last_update_posted": "2025-07-11",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT05267106",
    "title": "Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Glioblastoma",
      "Adult-type Diffuse Gliomas"
    ],
    "interventions": [
      "Pemigatinib"
    ],
    "primary_completion_date": "2024-12-17",
    "completion_date": "2024-12-17",
    "results_first_posted": "2025-12-30",
    "last_update_posted": "2025-12-30",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT06388564",
    "title": "A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Graft-versus-host-disease"
    ],
    "interventions": [
      "Axatilimab",
      "Ruxolitinib",
      "Corticosteroids"
    ],
    "primary_completion_date": "2027-06-01",
    "completion_date": "2029-12-01",
    "results_first_posted": null,
    "last_update_posted": "2025-12-05",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT05851443",
    "title": "A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Moderate to Severe Asthma"
    ],
    "interventions": [
      "povorcitinib",
      "placebo",
      "ICS-LABA"
    ],
    "primary_completion_date": "2026-06-15",
    "completion_date": "2027-01-31",
    "results_first_posted": null,
    "last_update_posted": "2025-12-17",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT00478322",
    "title": "Pharmacodynamic Study of the Effect of INCB013739 on Insulin Sensitivity in Obese, Type 2 Diabetic Subjects",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes Mellitus, Type 2",
      "Obesity"
    ],
    "interventions": [
      "Placebo",
      "INCB013739"
    ],
    "primary_completion_date": "2007-11",
    "completion_date": "2008-02",
    "results_first_posted": null,
    "last_update_posted": "2016-12-06",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT04472429",
    "title": "Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Squamous Cell Carcinoma of the Anal Canal"
    ],
    "interventions": [
      "carboplatin",
      "paclitaxel",
      "retifanlimab"
    ],
    "primary_completion_date": "2024-04-15",
    "completion_date": "2025-09-26",
    "results_first_posted": "2025-05-23",
    "last_update_posted": "2025-11-03",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT06941077",
    "title": "A Study to Evaluate the Relative Bioavailability of New Formulations of INCB057643 Tablets Administered Orally in Healthy Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "INCB057643"
    ],
    "primary_completion_date": "2025-06-03",
    "completion_date": "2025-06-03",
    "results_first_posted": null,
    "last_update_posted": "2025-06-11",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT05909995",
    "title": "Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Melanoma",
      "Hepatocellular Carcinoma (HCC)",
      "Renal Cell Carcinoma (RCC)",
      "Microsatellite Instability - High (MSI-H)",
      "Mismatch Repair Deficient (dMMR)",
      "Colorectal Carcinoma (CRC)"
    ],
    "interventions": [
      "INCB 99280 with Ipilimumab"
    ],
    "primary_completion_date": "2024-09-19",
    "completion_date": "2024-11-11",
    "results_first_posted": null,
    "last_update_posted": "2025-02-18",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03497273",
    "title": "Safety of Itacitinib in Combination With Corticosteroids for Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Japanese Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Graft-versus-host Disease"
    ],
    "interventions": [
      "Itacitinib",
      "Corticosteroid"
    ],
    "primary_completion_date": "2019-11-30",
    "completion_date": "2020-02-17",
    "results_first_posted": null,
    "last_update_posted": "2020-03-03",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT02712905",
    "title": "An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumors and Hematologic Malignancy"
    ],
    "interventions": [
      "INCB059872",
      "all-trans retinoic acid (ATRA)",
      "azacitidine",
      "nivolumab"
    ],
    "primary_completion_date": "2022-04-14",
    "completion_date": "2022-04-14",
    "results_first_posted": "2023-06-12",
    "last_update_posted": "2025-11-04",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03424122",
    "title": "INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "B-cell Lymphoma"
    ],
    "interventions": [
      "Parsaclisib",
      "Rituximab",
      "Bendamustine",
      "Ibrutinib"
    ],
    "primary_completion_date": "2022-06-27",
    "completion_date": "2022-06-27",
    "results_first_posted": null,
    "last_update_posted": "2025-08-21",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT05068466",
    "title": "A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of INCB054707",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants"
    ],
    "interventions": [
      "INCB054707",
      "Placebo"
    ],
    "primary_completion_date": "2022-01-25",
    "completion_date": "2022-01-25",
    "results_first_posted": null,
    "last_update_posted": "2022-09-16",
    "enrollment": null,
    "sponsor": "Incyte Biosciences Japan GK",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT02257619",
    "title": "Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "NSCLC (Non-small Cell Lung Carcinoma)"
    ],
    "interventions": [
      "Itacitinib",
      "docetaxel"
    ],
    "primary_completion_date": "2016-02",
    "completion_date": "2016-04",
    "results_first_posted": null,
    "last_update_posted": "2018-01-25",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03358472",
    "title": "Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Head and Neck Cancer"
    ],
    "interventions": [
      "Pembrolizumab",
      "Epacadostat",
      "Cetuximab",
      "Cisplatin",
      "Carboplatin",
      "5-Fluorouracil"
    ],
    "primary_completion_date": "2018-07-19",
    "completion_date": "2025-10-30",
    "results_first_posted": "2019-09-10",
    "last_update_posted": "2025-12-03",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT06548360",
    "title": "A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "NonSegmental Vitiligo"
    ],
    "interventions": [
      "Ruxolitinib Cream",
      "Vehicle Cream"
    ],
    "primary_completion_date": "2026-08-10",
    "completion_date": "2027-03-13",
    "results_first_posted": null,
    "last_update_posted": "2025-12-18",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT04003623",
    "title": "Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced or Metastatic Solid Tumors",
      "FGFR Mutations",
      "FGFR Translocations"
    ],
    "interventions": [
      "Pemigatinib"
    ],
    "primary_completion_date": "2020-06-12",
    "completion_date": "2020-06-12",
    "results_first_posted": "2022-04-21",
    "last_update_posted": "2022-05-10",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT00778700",
    "title": "A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Psoriasis"
    ],
    "interventions": [
      "Placebo Cream",
      "Ruxolitinib Phosphate"
    ],
    "primary_completion_date": "2009-06-26",
    "completion_date": "2009-06-26",
    "results_first_posted": "2022-02-09",
    "last_update_posted": "2022-02-09",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03688152",
    "title": "A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsed Diffuse Large B-Cell Lymphoma",
      "Refractory Diffuse Large B-Cell Lymphoma"
    ],
    "interventions": [
      "INCB053914",
      "INCB050465"
    ],
    "primary_completion_date": "2020-09-01",
    "completion_date": "2020-09-01",
    "results_first_posted": null,
    "last_update_posted": "2020-11-10",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03745638",
    "title": "Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atopic Dermatitis"
    ],
    "interventions": [
      "Ruxolitinib Cream",
      "Vehicle Cream"
    ],
    "primary_completion_date": "2019-12-23",
    "completion_date": "2020-12-01",
    "results_first_posted": "2021-12-17",
    "last_update_posted": "2023-09-28",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT06818812",
    "title": "A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumors"
    ],
    "interventions": [
      "INCB186748",
      "Cetuximab",
      "GEMNabP",
      "mFOLFIRINOX"
    ],
    "primary_completion_date": "2027-03-27",
    "completion_date": "2027-03-27",
    "results_first_posted": null,
    "last_update_posted": "2025-09-22",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT06259669",
    "title": "Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Pregnancy Related",
      "Atopic Dermatitis"
    ],
    "interventions": [
      "Ruxolitinib Cream"
    ],
    "primary_completion_date": "2032-08-01",
    "completion_date": "2033-08-01",
    "results_first_posted": null,
    "last_update_posted": "2025-12-11",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT01822756",
    "title": "An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumors",
      "Pancreatic Cancer"
    ],
    "interventions": [
      "ruxolitinib",
      "gemcitabine",
      "nab-paclitaxel",
      "filgrastim"
    ],
    "primary_completion_date": "2015-09",
    "completion_date": "2016-08",
    "results_first_posted": "2017-04-13",
    "last_update_posted": "2018-02-12",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT05456529",
    "title": "Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atopic Dermatitis (AD)"
    ],
    "interventions": [
      "Ruxolitinib Cream"
    ],
    "primary_completion_date": "2024-05-17",
    "completion_date": "2024-05-17",
    "results_first_posted": "2025-06-25",
    "last_update_posted": "2025-06-25",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT07284849",
    "title": "A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "CRC (Colorectal Cancer)"
    ],
    "interventions": [
      "INCA33890",
      "Placebo",
      "Bevacizumab",
      "FOLFOX"
    ],
    "primary_completion_date": "2028-12-29",
    "completion_date": "2029-09-28",
    "results_first_posted": null,
    "last_update_posted": "2025-12-18",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT05919511",
    "title": "Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "cGVHD"
    ],
    "interventions": [
      "Non-Interventional"
    ],
    "primary_completion_date": "2027-10-15",
    "completion_date": "2027-10-15",
    "results_first_posted": null,
    "last_update_posted": "2025-08-29",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03374488",
    "title": "Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "UC (Urothelial Cancer)"
    ],
    "interventions": [
      "Pembrolizumab",
      "Epacadostat",
      "Placebo"
    ],
    "primary_completion_date": "2018-07-27",
    "completion_date": "2020-07-23",
    "results_first_posted": "2019-08-28",
    "last_update_posted": "2025-08-22",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03678454",
    "title": "Iclusig\u00ae (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Chronic Myeloid Leukemia",
      "CML",
      "Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia",
      "Ph+ ALL"
    ],
    "interventions": [],
    "primary_completion_date": "2022-03-31",
    "completion_date": "2022-03-31",
    "results_first_posted": null,
    "last_update_posted": "2022-04-12",
    "enrollment": null,
    "sponsor": "Incyte Biosciences Benelux",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03957070",
    "title": "The Sonic Incytes Liver Incyte System, Assessment of Liver Fibrosis and Steatosis",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Liver Fibrosis",
      "Liver Steatosis"
    ],
    "interventions": [
      "Liver Incyte"
    ],
    "primary_completion_date": "2021-04-01",
    "completion_date": "2021-04-01",
    "results_first_posted": null,
    "last_update_posted": "2021-11-08",
    "enrollment": null,
    "sponsor": "Sonic Incytes",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT01929941",
    "title": "An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor",
      "Hodgkin's Lymphoma",
      "NHL (Non-Hodgkin Lymphoma)",
      "Pancreatic Cancer",
      "Breast Cancer",
      "UC (Ureter and Urethera)",
      "Advanced Cancer",
      "Metastatic Cancer"
    ],
    "interventions": [
      "INCB047986",
      "INCB047986",
      "Gemcitabine",
      "nab-paclitaxel"
    ],
    "primary_completion_date": "2014-08",
    "completion_date": "2014-08",
    "results_first_posted": null,
    "last_update_posted": "2018-01-17",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT05936359",
    "title": "A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Myeloproliferative Neoplasms"
    ],
    "interventions": [
      "INCA033989",
      "Ruxolitinib"
    ],
    "primary_completion_date": "2028-02-29",
    "completion_date": "2028-02-29",
    "results_first_posted": null,
    "last_update_posted": "2025-11-18",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03920852",
    "title": "A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic Dermatitis",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atopic Dermatitis"
    ],
    "interventions": [
      "Ruxolitinib cream"
    ],
    "primary_completion_date": "2019-12-26",
    "completion_date": "2019-12-26",
    "results_first_posted": null,
    "last_update_posted": "2020-02-17",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT04831996",
    "title": "To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Malignancies"
    ],
    "interventions": [
      "parsaclisib"
    ],
    "primary_completion_date": "2022-07-08",
    "completion_date": "2022-07-08",
    "results_first_posted": null,
    "last_update_posted": "2022-08-17",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT05561985",
    "title": "Expanded Access Use of Itacitinib to Treat a Single Patient With STAT1 Gain of Function (GOF) Disease",
    "status": "AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "STAT1 Gain-of-Function Disease"
    ],
    "interventions": [
      "Itacitinib"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2025-06-08",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT02327078",
    "title": "A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "B-cell Malignancies",
      "Colorectal Cancer (CRC)",
      "Head and Neck Cancer",
      "Lung Cancer",
      "Lymphoma",
      "Melanoma",
      "Ovarian Cancer",
      "Glioblastoma"
    ],
    "interventions": [
      "Nivolumab",
      "Epacadostat",
      "Chemotherapy"
    ],
    "primary_completion_date": "2020-06-16",
    "completion_date": "2020-06-16",
    "results_first_posted": "2023-04-26",
    "last_update_posted": "2025-08-14",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT05247489",
    "title": "A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Vitiligo"
    ],
    "interventions": [
      "Ruxolitinib 1.5% cream",
      "NB-UVB phototherapy"
    ],
    "primary_completion_date": "2023-12-19",
    "completion_date": "2023-12-19",
    "results_first_posted": "2025-02-20",
    "last_update_posted": "2025-02-20",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03589651",
    "title": "INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Unresectable or Metastatic Solid Tumors"
    ],
    "interventions": [
      "Retifanlimab",
      "Epacadostat",
      "INCB050465"
    ],
    "primary_completion_date": "2022-11-21",
    "completion_date": "2022-11-21",
    "results_first_posted": null,
    "last_update_posted": "2023-02-21",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT04071366",
    "title": "A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cytokine Release Syndrome"
    ],
    "interventions": [
      "Itacitinib",
      "Immune effector cell therapy",
      "Placebo",
      "Yescarta"
    ],
    "primary_completion_date": "2023-02-23",
    "completion_date": "2023-08-22",
    "results_first_posted": "2024-03-26",
    "last_update_posted": "2024-03-26",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT04052425",
    "title": "Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-segmental Vitiligo"
    ],
    "interventions": [
      "Ruxolitinib cream",
      "Vehicle"
    ],
    "primary_completion_date": "2021-03-18",
    "completion_date": "2021-10-21",
    "results_first_posted": "2022-09-21",
    "last_update_posted": "2025-08-22",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT02120417",
    "title": "A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Cancer"
    ],
    "interventions": [
      "Ruxolitinib",
      "Capecitabine",
      "Placebo"
    ],
    "primary_completion_date": "2016-02",
    "completion_date": "2017-01",
    "results_first_posted": "2017-07-12",
    "last_update_posted": "2018-02-13",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT02697591",
    "title": "A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Malignancies",
      "Metastatic Cancer"
    ],
    "interventions": [
      "INCAGN01876"
    ],
    "primary_completion_date": "2019-12-16",
    "completion_date": "2019-12-16",
    "results_first_posted": "2021-02-26",
    "last_update_posted": "2021-02-26",
    "enrollment": null,
    "sponsor": "Incyte Biosciences International S\u00e0rl",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT04057573",
    "title": "Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-segmental Vitiligo"
    ],
    "interventions": [
      "Ruxolitinib cream",
      "Vehicle"
    ],
    "primary_completion_date": "2021-03-15",
    "completion_date": "2021-10-01",
    "results_first_posted": "2022-09-21",
    "last_update_posted": "2025-08-22",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT05034822",
    "title": "Study of Ruxolitinib Cream in Children With Atopic Dermatitis",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atopic Dermatitis"
    ],
    "interventions": [
      "Ruxolitinib cream"
    ],
    "primary_completion_date": "2023-08-07",
    "completion_date": "2023-08-07",
    "results_first_posted": null,
    "last_update_posted": "2023-09-15",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03235570",
    "title": "A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumors"
    ],
    "interventions": [
      "Pemigatinib"
    ],
    "primary_completion_date": "2020-03-04",
    "completion_date": "2020-03-04",
    "results_first_posted": null,
    "last_update_posted": "2020-05-29",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT02752074",
    "title": "A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Melanoma"
    ],
    "interventions": [
      "pembrolizumab + epacadostat",
      "pembrolizumab + placebo"
    ],
    "primary_completion_date": "2018-01-08",
    "completion_date": "2019-08-16",
    "results_first_posted": "2019-05-15",
    "last_update_posted": "2025-08-24",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT05836324",
    "title": "A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumors",
      "Advanced Solid Tumors",
      "Metastatic Solid Tumors"
    ],
    "interventions": [
      "INCA33890",
      "bevacizumab",
      "FOLFIRI",
      "FOLFOX",
      "Cetuximab"
    ],
    "primary_completion_date": "2027-01-13",
    "completion_date": "2027-01-13",
    "results_first_posted": null,
    "last_update_posted": "2025-12-18",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT04242199",
    "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumor",
      "MSI-H/dMMR Tumors",
      "Cutaneous Squamous Cell Carcinoma",
      "Urothelial Carcinoma",
      "Cervical Cancer",
      "HepatoCellular Carcinoma",
      "Esophageal Squamous Cell Carcinoma",
      "Merkel Cell Carcinoma",
      "Small-cell Lung Cancer",
      "Mesothelioma",
      "PD-L1 Amplified Tumor (9p24.1)",
      "Nasopharyngeal Carcinoma"
    ],
    "interventions": [
      "INCB099280"
    ],
    "primary_completion_date": "2024-08-29",
    "completion_date": "2024-11-21",
    "results_first_posted": null,
    "last_update_posted": "2025-07-14",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT05544032",
    "title": "Expanded Access of Axatilimab to Treat a Single Patient With Chronic Graft Versus Host Disease (GVHD)",
    "status": "AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Chronic Graft Vs. Host Disease"
    ],
    "interventions": [
      "axatilimab"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2025-10-08",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT00617994",
    "title": "Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Psoriasis"
    ],
    "interventions": [
      "Ruxolitinib"
    ],
    "primary_completion_date": "2009-04-30",
    "completion_date": "2009-05-31",
    "results_first_posted": "2022-02-08",
    "last_update_posted": "2022-02-08",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT07008118",
    "title": "A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Myeloproliferative Neoplasms"
    ],
    "interventions": [
      "INCA035784"
    ],
    "primary_completion_date": "2028-03-14",
    "completion_date": "2029-12-14",
    "results_first_posted": null,
    "last_update_posted": "2026-01-23",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT00638378",
    "title": "Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Prostate Cancer"
    ],
    "interventions": [
      "Ruxolitinib"
    ],
    "primary_completion_date": "2009-01",
    "completion_date": "2009-01",
    "results_first_posted": "2012-01-20",
    "last_update_posted": "2018-02-12",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT04989387",
    "title": "Study of INCA 0186 in Subjects With Advanced Solid Tumors",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumors",
      "Squamous Cell Carcinoma of the Head and Neck (SCCHN)",
      "Gastrointestinal (GI) Malignancies"
    ],
    "interventions": [
      "INCA00186",
      "Retifanlimab",
      "INCB106385"
    ],
    "primary_completion_date": "2024-09-19",
    "completion_date": "2024-09-19",
    "results_first_posted": null,
    "last_update_posted": "2025-09-02",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT04831944",
    "title": "To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment.",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Malignancies"
    ],
    "interventions": [
      "parsaclisib"
    ],
    "primary_completion_date": "2022-03-10",
    "completion_date": "2022-03-11",
    "results_first_posted": null,
    "last_update_posted": "2022-08-26",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03514407",
    "title": "A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsed Ewing Sarcoma"
    ],
    "interventions": [
      "INCB059872"
    ],
    "primary_completion_date": "2020-06-25",
    "completion_date": "2020-06-25",
    "results_first_posted": null,
    "last_update_posted": "2025-10-21",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT01072266",
    "title": "A Dose-escalation Study in Subjects With Advanced Malignancies",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor",
      "Advanced Cancer",
      "Metastatic Cancer"
    ],
    "interventions": [
      "INCB028060"
    ],
    "primary_completion_date": "2012-07",
    "completion_date": "2013-01",
    "results_first_posted": null,
    "last_update_posted": "2017-11-22",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT03780166",
    "title": "A Study of the Safety and Tolerability of INCB050465 in Pemphigus Vulgaris",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pemphigus Vulgaris"
    ],
    "interventions": [
      "Parsaclisib"
    ],
    "primary_completion_date": "2020-11",
    "completion_date": "2020-11",
    "results_first_posted": null,
    "last_update_posted": "2019-09-13",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT05253807",
    "title": "Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-Small Cell Lung Cancer (NSCLC)"
    ],
    "interventions": [
      "Pemigatinib"
    ],
    "primary_completion_date": "2023-08-16",
    "completion_date": "2023-08-16",
    "results_first_posted": "2024-08-06",
    "last_update_posted": "2025-08-05",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT04463771",
    "title": "Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Endometrial Cancer"
    ],
    "interventions": [
      "retifanlimab",
      "epacadostat",
      "pemigatinib",
      "INCAGN02385",
      "INCAGN02390"
    ],
    "primary_completion_date": "2026-04-14",
    "completion_date": "2026-07-10",
    "results_first_posted": null,
    "last_update_posted": "2025-12-10",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT07039929",
    "title": "Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB000631 When Administered Orally to Healthy Adult Participants",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants"
    ],
    "interventions": [
      "INCB000631",
      "Placebo"
    ],
    "primary_completion_date": "2025-10-11",
    "completion_date": "2025-10-11",
    "results_first_posted": null,
    "last_update_posted": "2025-10-29",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT04272034",
    "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumors",
      "MSI-H/dMMR Tumors",
      "Cutaneous Squamous Cell Carcinoma",
      "Urothelial Carcinoma, HCC",
      "Cervical Cancer",
      "Esophageal Squamous Cell Carcinoma",
      "Merkel Cell Carcinoma",
      "Small-cell Lung Cancer",
      "Mesothelioma",
      "PD-L1 Amplified Tumor (9p24.1)",
      "Nasopharyngeal Carcinoma",
      "Cyclin-dependent Kinase 12 Mutated Tumors",
      "Basal Cell Carcinoma (Unresectable or Metastatic)",
      "Sarcomatoid Renal Cell Carcinoma",
      "Clear Cell Ovarian or Endometrial Carcinoma",
      "Anal Carcinoma",
      "Squamous Cell Penile Carcinoma",
      "DNA Polymerase Epsilon Mutated Tumors (P286R and V411L)"
    ],
    "interventions": [
      "INCB099318"
    ],
    "primary_completion_date": "2024-08-16",
    "completion_date": "2024-08-16",
    "results_first_posted": null,
    "last_update_posted": "2025-10-16",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INCY",
    "nct_id": "NCT02298153",
    "title": "A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "NSCLC (Non-small Cell Lung Carcinoma)",
      "UC (Urothelial Cancer)"
    ],
    "interventions": [
      "atezolizumab",
      "epacadostat"
    ],
    "primary_completion_date": "2017-11-08",
    "completion_date": "2017-11-08",
    "results_first_posted": null,
    "last_update_posted": "2017-12-11",
    "enrollment": null,
    "sponsor": "Incyte Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Incyte"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT06178783",
    "title": "A Study of the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "Brensocatib"
    ],
    "primary_completion_date": "2024-01-04",
    "completion_date": "2024-01-04",
    "results_first_posted": null,
    "last_update_posted": "2024-01-22",
    "enrollment": null,
    "sponsor": "Insmed Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT00777296",
    "title": "Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE\u2122)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cystic Fibrosis"
    ],
    "interventions": [
      "ARIKACE\u2122",
      "Placebo"
    ],
    "primary_completion_date": "2008-02-27",
    "completion_date": "2008-02-27",
    "results_first_posted": "2019-07-16",
    "last_update_posted": "2020-07-30",
    "enrollment": null,
    "sponsor": "Insmed Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT05826574",
    "title": "A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "Brensocatib",
      "Rifampin",
      "Esomeprazole"
    ],
    "primary_completion_date": "2023-07-16",
    "completion_date": "2023-07-16",
    "results_first_posted": null,
    "last_update_posted": "2023-08-21",
    "enrollment": null,
    "sponsor": "Insmed Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT04677543",
    "title": "Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Mycobacterium Infections, Nontuberculous"
    ],
    "interventions": [
      "ALIS",
      "Azithromycin",
      "Ethambutol",
      "ELC"
    ],
    "primary_completion_date": "2023-05-09",
    "completion_date": "2023-05-09",
    "results_first_posted": "2024-06-28",
    "last_update_posted": "2024-06-28",
    "enrollment": null,
    "sponsor": "Insmed Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT06817382",
    "title": "A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (DMD)",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy"
    ],
    "interventions": [
      "INS1201"
    ],
    "primary_completion_date": "2028-01-31",
    "completion_date": "2028-03-31",
    "results_first_posted": null,
    "last_update_posted": "2026-01-15",
    "enrollment": null,
    "sponsor": "Insmed Gene Therapy LLC",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT00102531",
    "title": "Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Osteosarcoma Metastatic"
    ],
    "interventions": [
      "Cisplatin liposomal"
    ],
    "primary_completion_date": "2008-03",
    "completion_date": "2008-03-17",
    "results_first_posted": "2017-08-01",
    "last_update_posted": "2017-08-01",
    "enrollment": null,
    "sponsor": "Insmed Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT05649722",
    "title": "An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pulmonary Hypertension",
      "Interstitial Lung Disease"
    ],
    "interventions": [
      "Treprostinil Palmitil Inhalation Powder",
      "Placebo"
    ],
    "primary_completion_date": "2026-03-14",
    "completion_date": "2026-03-14",
    "results_first_posted": null,
    "last_update_posted": "2025-12-31",
    "enrollment": null,
    "sponsor": "Insmed Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT05999942",
    "title": "A Study to Investigate Lung Deposition of Inhaled Amikacin-loaded Liposomes in Healthy Male Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "Liposomal Amikacin for Inhalation"
    ],
    "primary_completion_date": "2004-06-29",
    "completion_date": "2004-06-29",
    "results_first_posted": null,
    "last_update_posted": "2023-08-21",
    "enrollment": null,
    "sponsor": "Insmed Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT01315236",
    "title": "Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Mycobacterium Infections, Nontuberculous"
    ],
    "interventions": [
      "Liposomal amikacin for inhalation (LAI)",
      "placebo"
    ],
    "primary_completion_date": "2014-08-18",
    "completion_date": "2015-06-18",
    "results_first_posted": "2019-08-21",
    "last_update_posted": "2019-08-21",
    "enrollment": null,
    "sponsor": "Insmed Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT06939647",
    "title": "An Expanded Access Study to Assess Treprostinil Palmitil Inhalation Powder (TPIP) for Participants With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)",
    "status": "AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Pulmonary Arterial Hypertension",
      "Pulmonary Hypertension, Interstitial Lung Disease"
    ],
    "interventions": [
      "Treprostinil Palmitil"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2025-12-24",
    "enrollment": null,
    "sponsor": "Insmed Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT05652257",
    "title": "A Study of the Absorption, Metabolism, and Excretion of [14C]-Brensocatib Following a Single Oral Administration in Healthy Male Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "[14C]-brensocatib"
    ],
    "primary_completion_date": "2021-09-14",
    "completion_date": "2021-09-14",
    "results_first_posted": null,
    "last_update_posted": "2023-03-23",
    "enrollment": null,
    "sponsor": "Insmed Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT05673603",
    "title": "A Study of Brensocatib Following a Single Oral Administration in Participants With or Without Renal Impairment",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Renal Impairment"
    ],
    "interventions": [
      "Brensocatib"
    ],
    "primary_completion_date": "2023-02-14",
    "completion_date": "2023-02-14",
    "results_first_posted": null,
    "last_update_posted": "2023-04-18",
    "enrollment": null,
    "sponsor": "Insmed Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT05344508",
    "title": "An Expanded Access Study to Assess Brensocatib for Participants With Non-Cystic Fibrosis Bronchiectasis",
    "status": "APPROVED_FOR_MARKETING",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Non-Cystic Fibrosis Bronchiectasis"
    ],
    "interventions": [
      "Brensocatib"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2025-11-04",
    "enrollment": null,
    "sponsor": "Insmed Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT07234032",
    "title": "An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pulmonary Hypertension",
      "Interstitial Lung Disease"
    ],
    "interventions": [
      "Treprostinil Palmitil Inhalation Powder",
      "Placebo"
    ],
    "primary_completion_date": "2031-01-22",
    "completion_date": "2031-01-22",
    "results_first_posted": null,
    "last_update_posted": "2025-11-18",
    "enrollment": null,
    "sponsor": "Insmed Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT00368173",
    "title": "IGF-I/IGFBP-3 Therapy in Children and Adolescents With Growth Hormone Insenitivity Syndrome (GHIS) Such as Laron Syndrome",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Growth Hormone Insensitivity Syndrome (GHIS)",
      "Laron Syndrome"
    ],
    "interventions": [
      "rhIGF-I/rhIGFBP-3"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2012-09-13",
    "enrollment": null,
    "sponsor": "Insmed Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT06193031",
    "title": "A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of C16TR for Inhalation With Tyvaso\u00ae Cohort in Healthy Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "C16TR",
      "Placebo",
      "Tyvaso\u00ae"
    ],
    "primary_completion_date": "2015-12-18",
    "completion_date": "2015-12-18",
    "results_first_posted": null,
    "last_update_posted": "2024-01-05",
    "enrollment": null,
    "sponsor": "Insmed Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT06238856",
    "title": "Single Dose Escalation Study of TR02 (Sustained Lipid Inhalation Technology [SLIT\u2122] Amikacin) in Participants With Cystic Fibrosis (CF) Having Chronic Infections of Pseudomonas Aeruginosa",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cystic Fibrosis"
    ],
    "interventions": [
      "SLIT\u2122 Amikacin",
      "Placebo"
    ],
    "primary_completion_date": "2005-02-08",
    "completion_date": "2005-02-08",
    "results_first_posted": null,
    "last_update_posted": "2024-02-02",
    "enrollment": null,
    "sponsor": "Insmed Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT04677569",
    "title": "Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Mycobacterium Infections, Nontuberculous"
    ],
    "interventions": [
      "ALIS",
      "Azithromycin",
      "Ethambutol",
      "ELC (matching placebo for ALIS)"
    ],
    "primary_completion_date": "2025-11-21",
    "completion_date": "2026-01-15",
    "results_first_posted": null,
    "last_update_posted": "2025-12-24",
    "enrollment": null,
    "sponsor": "Insmed Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT01316276",
    "title": "Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cystic Fibrosis"
    ],
    "interventions": [
      "Liposomal amikacin for inhalation"
    ],
    "primary_completion_date": "2015-07-16",
    "completion_date": "2015-07-16",
    "results_first_posted": "2019-07-26",
    "last_update_posted": "2020-06-17",
    "enrollment": null,
    "sponsor": "Insmed Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT07179380",
    "title": "Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pulmonary Hypertension",
      "Interstitial Lung Disease"
    ],
    "interventions": [
      "Treprostinil Palmitil Inhalation Powder",
      "Placebo"
    ],
    "primary_completion_date": "2028-12-30",
    "completion_date": "2028-12-30",
    "results_first_posted": null,
    "last_update_posted": "2026-01-12",
    "enrollment": null,
    "sponsor": "Insmed Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT05176951",
    "title": "A Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pulmonary Hypertension"
    ],
    "interventions": [
      "Treprostinil Palmitil",
      "Placebo"
    ],
    "primary_completion_date": "2024-03-14",
    "completion_date": "2024-03-14",
    "results_first_posted": null,
    "last_update_posted": "2025-03-17",
    "enrollment": null,
    "sponsor": "Insmed Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT06091579",
    "title": "A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "Treprostinil Palmitil Inhalation Powder",
      "Placebo"
    ],
    "primary_completion_date": "2021-01-12",
    "completion_date": "2021-01-12",
    "results_first_posted": null,
    "last_update_posted": "2023-10-19",
    "enrollment": null,
    "sponsor": "Insmed Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT05649748",
    "title": "An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pulmonary Arterial Hypertension"
    ],
    "interventions": [
      "Treprostinil Palmitil",
      "Placebo"
    ],
    "primary_completion_date": "2026-12-31",
    "completion_date": "2026-12-31",
    "results_first_posted": null,
    "last_update_posted": "2025-12-24",
    "enrollment": null,
    "sponsor": "Insmed Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT04791514",
    "title": "A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pulmonary Arterial Hypertension"
    ],
    "interventions": [
      "Treprostinil Palmitil"
    ],
    "primary_completion_date": "2022-08-26",
    "completion_date": "2022-08-26",
    "results_first_posted": "2023-09-22",
    "last_update_posted": "2023-09-22",
    "enrollment": null,
    "sponsor": "Insmed Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT01315691",
    "title": "Study to Evaluate Arikace\u2122 in CF Patients With Chronic Infection Due to Pseudomonas Aeruginosa",
    "status": "WITHDRAWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cystic Fibrosis"
    ],
    "interventions": [
      "Liposomal amikacin for inhalation",
      "Placebo for liposomal amikacin for inhalation"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2018-07-31",
    "enrollment": null,
    "sponsor": "Insmed Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT06344728",
    "title": "A Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Tablets in Healthy Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants"
    ],
    "interventions": [
      "Brensocatib Oral Solution",
      "Brensocatib Oral Tablet"
    ],
    "primary_completion_date": "2024-05-24",
    "completion_date": "2024-05-24",
    "results_first_posted": null,
    "last_update_posted": "2024-06-13",
    "enrollment": null,
    "sponsor": "Insmed Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT02344004",
    "title": "Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Mycobacterium Infections, Nontuberculous"
    ],
    "interventions": [
      "LAI (Liposomal Amikacin for Inhalation) 590 mg"
    ],
    "primary_completion_date": "2018-07-03",
    "completion_date": "2019-04-03",
    "results_first_posted": "2018-11-20",
    "last_update_posted": "2020-05-07",
    "enrollment": null,
    "sponsor": "Insmed Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT06013241",
    "title": "A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Rhinosinusitis Without Nasal Polyps"
    ],
    "interventions": [
      "Brensocatib",
      "Placebo",
      "Mometasone furoate nasal spray (MFNS)"
    ],
    "primary_completion_date": "2025-09-30",
    "completion_date": "2025-10-30",
    "results_first_posted": null,
    "last_update_posted": "2025-11-10",
    "enrollment": null,
    "sponsor": "Insmed Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT05517525",
    "title": "A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatic Impairment"
    ],
    "interventions": [
      "Brensocatib"
    ],
    "primary_completion_date": "2023-06-01",
    "completion_date": "2023-06-01",
    "results_first_posted": null,
    "last_update_posted": "2023-07-19",
    "enrollment": null,
    "sponsor": "Insmed Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT00558844",
    "title": "Safety/Tolerability Study of Arikayce\u2122 in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cystic Fibrosis"
    ],
    "interventions": [
      "Arikayce\u2122 560 mg",
      "Placebo for 560 mg",
      "Arikayce\u2122 70 mg",
      "Arikayce\u2122 140 mg",
      "Placebo for 70 mg / 140 mg"
    ],
    "primary_completion_date": "2009-06",
    "completion_date": "2009-06",
    "results_first_posted": "2019-06-04",
    "last_update_posted": "2019-06-04",
    "enrollment": null,
    "sponsor": "Insmed Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT00351221",
    "title": "Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 for Children With Noonan Syndrome",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Noonan Syndrome"
    ],
    "interventions": [
      "rhIGF-1/rhIGFBP-3"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2007-03-30",
    "enrollment": null,
    "sponsor": "Insmed Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT04594369",
    "title": "A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-Cystic Fibrosis Bronchiectasis"
    ],
    "interventions": [
      "Brensocatib 10 mg",
      "Brensocatib 25 mg",
      "Placebo"
    ],
    "primary_completion_date": "2024-10-28",
    "completion_date": "2024-10-28",
    "results_first_posted": "2025-12-16",
    "last_update_posted": "2025-12-16",
    "enrollment": null,
    "sponsor": "Insmed Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT05927597",
    "title": "A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of INS1007 in Healthy Japanese and Caucasian Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "INS1007",
      "Placebo"
    ],
    "primary_completion_date": "2019-08-01",
    "completion_date": "2019-08-01",
    "results_first_posted": null,
    "last_update_posted": "2023-07-03",
    "enrollment": null,
    "sponsor": "Insmed Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT03905642",
    "title": "Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKAYCE\u2122) - Extension Phase",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cystic Fibrosis"
    ],
    "interventions": [
      "Arikayce\u2122"
    ],
    "primary_completion_date": "2010-11-02",
    "completion_date": "2010-11-02",
    "results_first_posted": "2019-05-14",
    "last_update_posted": "2020-07-30",
    "enrollment": null,
    "sponsor": "Insmed Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT07290062",
    "title": "A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Amyotrophic Lateral Sclerosis"
    ],
    "interventions": [
      "INS1202"
    ],
    "primary_completion_date": "2030-03-31",
    "completion_date": "2030-03-31",
    "results_first_posted": null,
    "last_update_posted": "2025-12-17",
    "enrollment": null,
    "sponsor": "Insmed Gene Therapy LLC",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT07102316",
    "title": "A Study to Assess the Relative Bioavailability After a Single Inhalation Administration of Treprostinil Palmitil Inhalation Powder (TPIP) Formulation 2 (F2) to TPIP Formulation 3 (F3) in Healthy Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "TPIP F2",
      "TPIP F3"
    ],
    "primary_completion_date": "2025-10-25",
    "completion_date": "2025-11-03",
    "results_first_posted": null,
    "last_update_posted": "2025-11-21",
    "enrollment": null,
    "sponsor": "Insmed Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT02628600",
    "title": "Open-label Safety Extension Study Assessing Safety and Tolerability of LAI in Patients Who Participated in Study INS-212",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "NTM Lung Infection Due to MAC"
    ],
    "interventions": [
      "LAI 590 mg",
      "Multi-drug regimen"
    ],
    "primary_completion_date": "2018-10-17",
    "completion_date": "2018-10-17",
    "results_first_posted": "2019-11-19",
    "last_update_posted": "2020-02-10",
    "enrollment": null,
    "sponsor": "Insmed Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT06685835",
    "title": "A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hidradenitis Suppurativa"
    ],
    "interventions": [
      "Brensocatib",
      "Placebo"
    ],
    "primary_completion_date": "2026-05-22",
    "completion_date": "2027-01-28",
    "results_first_posted": null,
    "last_update_posted": "2025-11-12",
    "enrollment": null,
    "sponsor": "Insmed Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT01315678",
    "title": "Study to Evaluate Arikayce\u2122 in CF Patients With Chronic Pseudomonas Aeruginosa Infections",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pseudomonas Aeruginosa Infection"
    ],
    "interventions": [
      "Liposomal amikacin for inhalation (Arikayce\u2122) using the PARI Investigational eFlow\u00ae Nebulizer.",
      "Tobramycin inhalation solution using a PARI LC\u00ae Plus nebulizer."
    ],
    "primary_completion_date": "2013-06",
    "completion_date": "2013-09-18",
    "results_first_posted": "2019-06-24",
    "last_update_posted": "2020-06-16",
    "enrollment": null,
    "sponsor": "Insmed Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT05147805",
    "title": "A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pulmonary Arterial Hypertension"
    ],
    "interventions": [
      "Treprostinil Palmitil",
      "Placebo"
    ],
    "primary_completion_date": "2025-03-27",
    "completion_date": "2025-03-27",
    "results_first_posted": null,
    "last_update_posted": "2025-04-10",
    "enrollment": null,
    "sponsor": "Insmed Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT05965570",
    "title": "A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "Brensocatib",
      "Clarithromycin"
    ],
    "primary_completion_date": "2023-09-22",
    "completion_date": "2023-09-22",
    "results_first_posted": null,
    "last_update_posted": "2023-12-11",
    "enrollment": null,
    "sponsor": "Insmed Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT00577577",
    "title": "Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Myotonic Dystrophy Type 1"
    ],
    "interventions": [
      "rhIGF-I/rhIGFBP-3",
      "placebo"
    ],
    "primary_completion_date": "2008-12-29",
    "completion_date": "2008-12-29",
    "results_first_posted": "2022-01-06",
    "last_update_posted": "2022-01-06",
    "enrollment": null,
    "sponsor": "Insmed Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT05090904",
    "title": "A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cystic Fibrosis"
    ],
    "interventions": [
      "Brensocatib",
      "Placebo"
    ],
    "primary_completion_date": "2022-11-01",
    "completion_date": "2022-11-01",
    "results_first_posted": null,
    "last_update_posted": "2023-11-01",
    "enrollment": null,
    "sponsor": "Insmed Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT00775138",
    "title": "Safety and Tolerability Study of 2 Dose Level of Arikayce\u2122 in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa.",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bronchiectasis"
    ],
    "interventions": [
      "280 mg Arikayce\u2122",
      "Matching Placebo for Cohort 1",
      "560 mg Arikayce\u2122",
      "Matching Placebo for Cohort 2"
    ],
    "primary_completion_date": "2009-05-11",
    "completion_date": "2009-05-11",
    "results_first_posted": "2019-07-10",
    "last_update_posted": "2019-07-10",
    "enrollment": null,
    "sponsor": "Insmed Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "INSM",
    "nct_id": "NCT05355935",
    "title": "A Study to Investigate the Effects of Brensocatib on QT Interval in Healthy Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteer"
    ],
    "interventions": [
      "Brensocatib",
      "Moxifloxacin",
      "Placebo"
    ],
    "primary_completion_date": "2022-10-07",
    "completion_date": "2022-10-07",
    "results_first_posted": null,
    "last_update_posted": "2023-03-27",
    "enrollment": null,
    "sponsor": "Insmed Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Insmed"
  },
  {
    "ticker": "IRWD",
    "nct_id": "NCT02291679",
    "title": "Trial of Linaclotide in Patients With Chronic Idiopathic Constipation",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Idiopathic Constipation"
    ],
    "interventions": [
      "Linaclotide",
      "Matching Placebo"
    ],
    "primary_completion_date": "2015-08",
    "completion_date": "2015-08",
    "results_first_posted": "2017-05-19",
    "last_update_posted": "2017-06-15",
    "enrollment": null,
    "sponsor": "Ironwood Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ironwood Pharmaceuticals"
  },
  {
    "ticker": "IRWD",
    "nct_id": "NCT02837783",
    "title": "A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation (IBS-C)",
    "status": "TERMINATED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Irritable Bowel Syndrome Characterized by Constipation"
    ],
    "interventions": [
      "Linaclotide",
      "Placebo"
    ],
    "primary_completion_date": "2018-10-31",
    "completion_date": "2018-10-31",
    "results_first_posted": "2021-12-06",
    "last_update_posted": "2021-12-06",
    "enrollment": null,
    "sponsor": "Ironwood Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ironwood Pharmaceuticals"
  },
  {
    "ticker": "IRWD",
    "nct_id": "NCT02559206",
    "title": "Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Irritable Bowel Syndrome With Constipation"
    ],
    "interventions": [
      "Linaclotide",
      "Matching Placebo"
    ],
    "primary_completion_date": "2016-09-30",
    "completion_date": "2016-09-30",
    "results_first_posted": "2020-04-24",
    "last_update_posted": "2020-04-24",
    "enrollment": null,
    "sponsor": "Ironwood Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ironwood Pharmaceuticals"
  },
  {
    "ticker": "IRWD",
    "nct_id": "NCT05740007",
    "title": "A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Interstitial Cystitis",
      "Bladder Pain Syndrome"
    ],
    "interventions": [
      "IW-3300 rectal foam",
      "Placebo"
    ],
    "primary_completion_date": "2025-01-23",
    "completion_date": "2025-02-06",
    "results_first_posted": null,
    "last_update_posted": "2025-02-28",
    "enrollment": null,
    "sponsor": "Ironwood Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ironwood Pharmaceuticals"
  },
  {
    "ticker": "IRWD",
    "nct_id": "NCT02030925",
    "title": "Ph2a Study to Evaluate IW-3718 in Patients With Gastroesophageal Reflux Not Completely Responsive to Proton Pump Inhibitors",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Gastroesophageal Reflux"
    ],
    "interventions": [
      "IW-3718",
      "Matching Placebo"
    ],
    "primary_completion_date": "2014-12",
    "completion_date": "2014-12",
    "results_first_posted": null,
    "last_update_posted": "2016-08-01",
    "enrollment": null,
    "sponsor": "Ironwood Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ironwood Pharmaceuticals"
  },
  {
    "ticker": "IRWD",
    "nct_id": "NCT00730171",
    "title": "An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Irritable Bowel Syndrome With Constipation",
      "Chronic Constipation"
    ],
    "interventions": [
      "Linaclotide"
    ],
    "primary_completion_date": "2012-03",
    "completion_date": "2012-03",
    "results_first_posted": "2018-02-19",
    "last_update_posted": "2018-02-19",
    "enrollment": null,
    "sponsor": "Ironwood Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ironwood Pharmaceuticals"
  },
  {
    "ticker": "IRWD",
    "nct_id": "NCT00258193",
    "title": "Phase 2 Study of MD-1100 Acetate on Gastrointestinal Transit in Patients With C-IBS",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Irritable Bowel Syndrome"
    ],
    "interventions": [
      "MD-1100 Acetate"
    ],
    "primary_completion_date": null,
    "completion_date": "2006-09",
    "results_first_posted": null,
    "last_update_posted": "2006-10-20",
    "enrollment": null,
    "sponsor": "Ironwood Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ironwood Pharmaceuticals"
  },
  {
    "ticker": "IRWD",
    "nct_id": "NCT00938717",
    "title": "Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Irritable Bowel Syndrome With Constipation"
    ],
    "interventions": [
      "Linaclotide or Matching Placebo"
    ],
    "primary_completion_date": "2010-09",
    "completion_date": "2010-09",
    "results_first_posted": "2013-01-30",
    "last_update_posted": "2013-11-05",
    "enrollment": null,
    "sponsor": "Ironwood Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ironwood Pharmaceuticals"
  },
  {
    "ticker": "IRWD",
    "nct_id": "NCT00402337",
    "title": "Dose-range-finding, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic Constipation",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Constipation"
    ],
    "interventions": [
      "linaclotide acetate",
      "Matching placebo"
    ],
    "primary_completion_date": "2007-12",
    "completion_date": "2008-02",
    "results_first_posted": "2013-03-05",
    "last_update_posted": "2013-03-05",
    "enrollment": null,
    "sponsor": "Ironwood Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ironwood Pharmaceuticals"
  },
  {
    "ticker": "IRWD",
    "nct_id": "NCT00730015",
    "title": "Trial of Linaclotide in Patients With Chronic Constipation",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Constipation"
    ],
    "interventions": [
      "Matching Placebo",
      "Linaclotide"
    ],
    "primary_completion_date": "2009-08",
    "completion_date": "2009-10",
    "results_first_posted": "2013-01-30",
    "last_update_posted": "2013-01-30",
    "enrollment": null,
    "sponsor": "Ironwood Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ironwood Pharmaceuticals"
  },
  {
    "ticker": "IRWD",
    "nct_id": "NCT00404001",
    "title": "Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypercholesterolemia"
    ],
    "interventions": [
      "MD-0727"
    ],
    "primary_completion_date": null,
    "completion_date": "2007-07",
    "results_first_posted": null,
    "last_update_posted": "2007-10-01",
    "enrollment": null,
    "sponsor": "Ironwood Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ironwood Pharmaceuticals"
  },
  {
    "ticker": "IRWD",
    "nct_id": "NCT00306748",
    "title": "Phase 2 Study of MD-1100 Acetate Administered for 14 Days to Patients Meeting Criteria for Chronic Constipation",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Constipation"
    ],
    "interventions": [
      "MD-1100 Acetate"
    ],
    "primary_completion_date": null,
    "completion_date": "2006-08",
    "results_first_posted": null,
    "last_update_posted": "2009-03-24",
    "enrollment": null,
    "sponsor": "Ironwood Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ironwood Pharmaceuticals"
  },
  {
    "ticker": "IRWD",
    "nct_id": "NCT03226899",
    "title": "A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment",
    "status": "TERMINATED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Gout",
      "Chronic Kidney Disease (CKD)"
    ],
    "interventions": [
      "Lesinurad",
      "XOI",
      "Placebo",
      "colchicine",
      "corticosteroids"
    ],
    "primary_completion_date": "2019-02-25",
    "completion_date": "2019-02-25",
    "results_first_posted": "2021-11-04",
    "last_update_posted": "2021-11-04",
    "enrollment": null,
    "sponsor": "Ironwood Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ironwood Pharmaceuticals"
  },
  {
    "ticker": "IRWD",
    "nct_id": "NCT00460811",
    "title": "Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Irritable Bowel Syndrome With Constipation"
    ],
    "interventions": [
      "Linaclotide Acetate",
      "Matching placebo"
    ],
    "primary_completion_date": "2008-02",
    "completion_date": "2008-04",
    "results_first_posted": "2013-01-30",
    "last_update_posted": "2013-02-04",
    "enrollment": null,
    "sponsor": "Ironwood Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ironwood Pharmaceuticals"
  },
  {
    "ticker": "IRWD",
    "nct_id": "NCT02637557",
    "title": "A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Gastroesophageal Reflux Disease"
    ],
    "interventions": [
      "IW-3718",
      "Matching Placebo",
      "PPI"
    ],
    "primary_completion_date": "2017-04-26",
    "completion_date": "2017-04-26",
    "results_first_posted": "2019-10-15",
    "last_update_posted": "2019-10-15",
    "enrollment": null,
    "sponsor": "Ironwood Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ironwood Pharmaceuticals"
  },
  {
    "ticker": "IRWD",
    "nct_id": "NCT03573908",
    "title": "A Trial of Linaclotide 290 \u03bcg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Irritable Bowel Syndrome Characterized by Constipation"
    ],
    "interventions": [
      "Linaclotide",
      "Placebo"
    ],
    "primary_completion_date": "2019-03-13",
    "completion_date": "2019-04-10",
    "results_first_posted": "2020-11-16",
    "last_update_posted": "2020-12-01",
    "enrollment": null,
    "sponsor": "Ironwood Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ironwood Pharmaceuticals"
  },
  {
    "ticker": "IRWD",
    "nct_id": "NCT03931785",
    "title": "A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Irritable Bowel Syndrome With Diarrhea (IBS-D)"
    ],
    "interventions": [
      "MD-7246",
      "Placebo"
    ],
    "primary_completion_date": "2020-02-26",
    "completion_date": "2020-03-11",
    "results_first_posted": "2021-03-12",
    "last_update_posted": "2021-03-12",
    "enrollment": null,
    "sponsor": "Ironwood Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ironwood Pharmaceuticals"
  },
  {
    "ticker": "IRWD",
    "nct_id": "NCT01712412",
    "title": "Phase 2a Study of IW-9179 to Treat Functional Dyspepsia",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dyspepsia",
      "Functional Gastrointestinal Disorders"
    ],
    "interventions": [
      "IW-9179",
      "Placebo"
    ],
    "primary_completion_date": "2014-02",
    "completion_date": "2014-03",
    "results_first_posted": null,
    "last_update_posted": "2014-03-19",
    "enrollment": null,
    "sponsor": "Ironwood Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ironwood Pharmaceuticals"
  },
  {
    "ticker": "IRWD",
    "nct_id": "NCT02289846",
    "title": "Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetic Gastroparesis"
    ],
    "interventions": [
      "IW-9179",
      "Matching Placebo"
    ],
    "primary_completion_date": "2015-12",
    "completion_date": "2015-12",
    "results_first_posted": null,
    "last_update_posted": "2016-12-05",
    "enrollment": null,
    "sponsor": "Ironwood Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ironwood Pharmaceuticals"
  },
  {
    "ticker": "IRWD",
    "nct_id": "NCT03856970",
    "title": "Study to Evaluate the Effect of IW-3718 on the Pharmacokinetics of Oral Contraceptive, Levothyroxine, Glyburide, and Digoxin in Healthy Adult Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "Microgestin\u00ae",
      "Levothyroxine",
      "Glyburide",
      "Digoxin",
      "IW-3718"
    ],
    "primary_completion_date": "2019-06-25",
    "completion_date": "2019-07-03",
    "results_first_posted": null,
    "last_update_posted": "2019-07-29",
    "enrollment": null,
    "sponsor": "Ironwood Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ironwood Pharmaceuticals"
  },
  {
    "ticker": "IRWD",
    "nct_id": "NCT01107236",
    "title": "Study to Evaluate Efficacy and Safety of IW-6118 in Patients Undergoing Third Molar Extraction",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "IW-6118",
      "Matching Placebo",
      "Naproxen Sodium"
    ],
    "primary_completion_date": "2010-08",
    "completion_date": "2010-08",
    "results_first_posted": null,
    "last_update_posted": "2022-08-11",
    "enrollment": null,
    "sponsor": "Ironwood Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ironwood Pharmaceuticals"
  },
  {
    "ticker": "IRWD",
    "nct_id": "NCT05188261",
    "title": "A Study of Single Ascending Doses of IW-3300 in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "IW-3300",
      "Placebo"
    ],
    "primary_completion_date": "2022-03-09",
    "completion_date": "2022-03-21",
    "results_first_posted": "2023-12-08",
    "last_update_posted": "2023-12-08",
    "enrollment": null,
    "sponsor": "Ironwood Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ironwood Pharmaceuticals"
  },
  {
    "ticker": "IRWD",
    "nct_id": "NCT05362695",
    "title": "A Study of Multiple-ascending Doses of IW-3300 in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "IW-3300",
      "Placebo"
    ],
    "primary_completion_date": "2022-06-30",
    "completion_date": "2022-07-13",
    "results_first_posted": "2024-02-02",
    "last_update_posted": "2024-02-02",
    "enrollment": null,
    "sponsor": "Ironwood Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ironwood Pharmaceuticals"
  },
  {
    "ticker": "JANX",
    "nct_id": "NCT05519449",
    "title": "Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Prostate Cancer",
      "Metastatic Castration-resistant Prostate Cancer",
      "Castration Resistant Prostatic Cancer"
    ],
    "interventions": [
      "JANX007",
      "Darolutamide"
    ],
    "primary_completion_date": "2027-07",
    "completion_date": "2028-12",
    "results_first_posted": null,
    "last_update_posted": "2026-01-20",
    "enrollment": null,
    "sponsor": "Janux Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Janux Therapeutics"
  },
  {
    "ticker": "JANX",
    "nct_id": "NCT07291323",
    "title": "Study of JANX011 in Healthy Adult Volunteers to Assess Safety and Tolerability.",
    "status": "NOT_YET_RECRUITING",
    "phase": "EARLY_PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Autoimmune"
    ],
    "interventions": [
      "JANX011"
    ],
    "primary_completion_date": "2026-10",
    "completion_date": "2026-12",
    "results_first_posted": null,
    "last_update_posted": "2025-12-18",
    "enrollment": null,
    "sponsor": "Janux Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Janux Therapeutics"
  },
  {
    "ticker": "JANX",
    "nct_id": "NCT05783622",
    "title": "Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-Small Cell Lung Cancer",
      "Renal Cell Carcinoma",
      "Squamous Cell Carcinoma of the Head and Neck",
      "Colorectal Carcinoma",
      "Small Cell Lung Cancer",
      "Pancreatic Ductal Adenocarcinoma",
      "Triple-negative Breast Cancer"
    ],
    "interventions": [
      "JANX008"
    ],
    "primary_completion_date": "2026-01",
    "completion_date": "2027-10",
    "results_first_posted": null,
    "last_update_posted": "2025-10-14",
    "enrollment": null,
    "sponsor": "Janux Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Janux Therapeutics"
  },
  {
    "ticker": "KNSA",
    "nct_id": "NCT05198310",
    "title": "Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Arthritis, Rheumatoid"
    ],
    "interventions": [
      "KPL-404",
      "Placebo"
    ],
    "primary_completion_date": "2024-02-08",
    "completion_date": "2024-05-06",
    "results_first_posted": "2025-07-22",
    "last_update_posted": "2025-07-22",
    "enrollment": null,
    "sponsor": "Kiniksa Pharmaceuticals, Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Kiniksa Pharmaceuticals"
  },
  {
    "ticker": "KNSA",
    "nct_id": "NCT04497662",
    "title": "Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of KPL-404 in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "KPL-404",
      "Matching Placebo"
    ],
    "primary_completion_date": "2021-01-21",
    "completion_date": "2021-03-02",
    "results_first_posted": null,
    "last_update_posted": "2021-05-04",
    "enrollment": null,
    "sponsor": "Kiniksa Pharmaceuticals, Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Kiniksa Pharmaceuticals"
  },
  {
    "ticker": "KNSA",
    "nct_id": "NCT07010159",
    "title": "Phase 2/3 Study of KPL-387 in Recurrent Pericarditis",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pericarditis",
      "Pericarditis Acute",
      "Recurrent Pericarditis"
    ],
    "interventions": [
      "KPL-387",
      "Placebo"
    ],
    "primary_completion_date": "2027-12-31",
    "completion_date": "2029-12-31",
    "results_first_posted": null,
    "last_update_posted": "2026-01-21",
    "enrollment": null,
    "sponsor": "Kiniksa Pharmaceuticals International, plc",
    "collected_at": "2026-01-27",
    "search_term": "Kiniksa Pharmaceuticals"
  },
  {
    "ticker": "KNSA",
    "nct_id": "NCT04447469",
    "title": "Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID"
    ],
    "interventions": [
      "mavrilimumab",
      "Placebo"
    ],
    "primary_completion_date": "2021-11-12",
    "completion_date": "2022-01-14",
    "results_first_posted": "2025-01-22",
    "last_update_posted": "2025-01-22",
    "enrollment": null,
    "sponsor": "Kiniksa Pharmaceuticals International, plc",
    "collected_at": "2026-01-27",
    "search_term": "Kiniksa Pharmaceuticals"
  },
  {
    "ticker": "KNSA",
    "nct_id": "NCT07288216",
    "title": "Transition to KPL-387 Monotherapy Dosing & Administration Study",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Recurrent Pericarditis",
      "Heart Diseases",
      "Pericarditis"
    ],
    "interventions": [
      "KPL-387"
    ],
    "primary_completion_date": "2027-12-31",
    "completion_date": "2029-12-31",
    "results_first_posted": null,
    "last_update_posted": "2026-01-26",
    "enrollment": null,
    "sponsor": "Kiniksa Pharmaceuticals International, plc",
    "collected_at": "2026-01-27",
    "search_term": "Kiniksa Pharmaceuticals"
  },
  {
    "ticker": "KNSA",
    "nct_id": "NCT03980522",
    "title": "A Pilot Study of KPL-914 in Recurrent Pericarditis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Recurrent Pericarditis"
    ],
    "interventions": [
      "KPL-914"
    ],
    "primary_completion_date": "2019-05-17",
    "completion_date": "2019-05-17",
    "results_first_posted": "2021-05-27",
    "last_update_posted": "2021-05-27",
    "enrollment": null,
    "sponsor": "Kiniksa Pharmaceuticals (UK), Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Kiniksa Pharmaceuticals"
  },
  {
    "ticker": "KNSA",
    "nct_id": "NCT06531395",
    "title": "A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sj\u00f6gren's Disease",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Sj\u00f6grens Disease"
    ],
    "interventions": [
      "Abiprubart",
      "Placebo"
    ],
    "primary_completion_date": "2025-03-06",
    "completion_date": "2025-05-01",
    "results_first_posted": null,
    "last_update_posted": "2025-05-21",
    "enrollment": null,
    "sponsor": "Kiniksa Pharmaceuticals International, plc",
    "collected_at": "2026-01-27",
    "search_term": "Kiniksa Pharmaceuticals"
  },
  {
    "ticker": "KNSA",
    "nct_id": "NCT03737110",
    "title": "Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Recurrent Pericarditis"
    ],
    "interventions": [
      "Rilonacept",
      "Placebo"
    ],
    "primary_completion_date": "2020-05-29",
    "completion_date": "2022-06-30",
    "results_first_posted": "2021-07-13",
    "last_update_posted": "2023-09-06",
    "enrollment": null,
    "sponsor": "Kiniksa Pharmaceuticals (UK), Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Kiniksa Pharmaceuticals"
  },
  {
    "ticker": "KNSA",
    "nct_id": "NCT04687358",
    "title": "REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult Patients",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Recurrent Pericarditis"
    ],
    "interventions": [],
    "primary_completion_date": "2026-02",
    "completion_date": "2026-02",
    "results_first_posted": null,
    "last_update_posted": "2025-04-29",
    "enrollment": null,
    "sponsor": "Kiniksa Pharmaceuticals International, plc",
    "collected_at": "2026-01-27",
    "search_term": "Kiniksa Pharmaceuticals"
  },
  {
    "ticker": "KNSA",
    "nct_id": "NCT03827018",
    "title": "KPL-301 for Subjects With Giant Cell Arteritis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Giant Cell Arteritis"
    ],
    "interventions": [
      "mavrilimumab",
      "placebo",
      "prednisone"
    ],
    "primary_completion_date": "2020-08-13",
    "completion_date": "2020-11-25",
    "results_first_posted": "2023-10-17",
    "last_update_posted": "2023-10-23",
    "enrollment": null,
    "sponsor": "Kiniksa Pharmaceuticals, Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Kiniksa Pharmaceuticals"
  },
  {
    "ticker": "KYMR",
    "nct_id": "NCT06673667",
    "title": "First-in-human Study of Orally Administered KT-621 in Healthy Adult Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants Study"
    ],
    "interventions": [
      "KT-621",
      "Placebo"
    ],
    "primary_completion_date": "2025-04-23",
    "completion_date": "2025-04-23",
    "results_first_posted": null,
    "last_update_posted": "2025-10-02",
    "enrollment": null,
    "sponsor": "Kymera Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Kymera Therapeutics"
  },
  {
    "ticker": "KYMR",
    "nct_id": "NCT07217015",
    "title": "A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atopic Dermatitis"
    ],
    "interventions": [
      "KT-621",
      "Placebo"
    ],
    "primary_completion_date": "2027-06",
    "completion_date": "2028-06",
    "results_first_posted": null,
    "last_update_posted": "2026-01-14",
    "enrollment": null,
    "sponsor": "Kymera Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Kymera Therapeutics"
  },
  {
    "ticker": "KYMR",
    "nct_id": "NCT05233033",
    "title": "Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non Hodgkin Lymphoma",
      "Diffuse Large B Cell Lymphoma",
      "DLBCL",
      "MYD88 Gene Mutation"
    ],
    "interventions": [
      "KT-413"
    ],
    "primary_completion_date": "2023-07-28",
    "completion_date": "2023-07-28",
    "results_first_posted": null,
    "last_update_posted": "2024-12-10",
    "enrollment": null,
    "sponsor": "Kymera Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Kymera Therapeutics"
  },
  {
    "ticker": "KYMR",
    "nct_id": "NCT05775406",
    "title": "Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Myeloid Malignancies",
      "Acute Lymphocytic Leukemia",
      "Lymphomas",
      "Advanced Solid Tumors"
    ],
    "interventions": [
      "KT-253"
    ],
    "primary_completion_date": "2024-12-18",
    "completion_date": "2024-12-18",
    "results_first_posted": null,
    "last_update_posted": "2025-01-27",
    "enrollment": null,
    "sponsor": "Kymera Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Kymera Therapeutics"
  },
  {
    "ticker": "KYMR",
    "nct_id": "NCT05225584",
    "title": "Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non Hodgkin Lymphoma (NHL)",
      "Peripheral T-cell Lymphoma (PTCL)",
      "Cutaneous T-Cell Lymphoma (CTCL)",
      "Large Granular Lymphocytic Leukemia (LGL-L)",
      "T-cell Prolymphocytic Leukemia (T-PLL)",
      "Solid Tumors"
    ],
    "interventions": [
      "KT-333"
    ],
    "primary_completion_date": "2025-03-03",
    "completion_date": "2025-03-03",
    "results_first_posted": null,
    "last_update_posted": "2025-03-19",
    "enrollment": null,
    "sponsor": "Kymera Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Kymera Therapeutics"
  },
  {
    "ticker": "KYMR",
    "nct_id": "NCT04772885",
    "title": "A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteer",
      "Atopic Dermatitis",
      "Hidradenitis Suppurativa"
    ],
    "interventions": [
      "KT-474/Placebo",
      "KT-474"
    ],
    "primary_completion_date": "2022-10-20",
    "completion_date": "2022-10-20",
    "results_first_posted": null,
    "last_update_posted": "2022-10-24",
    "enrollment": null,
    "sponsor": "Kymera Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Kymera Therapeutics"
  },
  {
    "ticker": "KYMR",
    "nct_id": "NCT07323654",
    "title": "A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Eosinophilic Asthma"
    ],
    "interventions": [
      "KT-621",
      "Placebo"
    ],
    "primary_completion_date": "2027-12",
    "completion_date": "2027-12",
    "results_first_posted": null,
    "last_update_posted": "2026-01-07",
    "enrollment": null,
    "sponsor": "Kymera Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Kymera Therapeutics"
  },
  {
    "ticker": "KYMR",
    "nct_id": "NCT06945458",
    "title": "Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atopic Dermatitis"
    ],
    "interventions": [
      "KT-621"
    ],
    "primary_completion_date": "2025-11-10",
    "completion_date": "2025-11-10",
    "results_first_posted": null,
    "last_update_posted": "2026-01-26",
    "enrollment": null,
    "sponsor": "Kymera Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Kymera Therapeutics"
  },
  {
    "ticker": "KYMR",
    "nct_id": "NCT04440410",
    "title": "Evaluation of Cutaneous and Circulating Inflammatory Biomarkers in Hidradenitis Suppurativa and Atopic Dermatitis",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Hidradenitis Suppurativa",
      "Dermatitis, Atopic"
    ],
    "interventions": [],
    "primary_completion_date": "2021-03-24",
    "completion_date": "2021-03-24",
    "results_first_posted": null,
    "last_update_posted": "2021-04-13",
    "enrollment": null,
    "sponsor": "Kymera Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Kymera Therapeutics"
  },
  {
    "ticker": "LCTX",
    "nct_id": "NCT01217008",
    "title": "Safety Study of GRNOPC1 in Spinal Cord Injury",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Spinal Cord Injury"
    ],
    "interventions": [
      "GRNOPC1"
    ],
    "primary_completion_date": "2013-07",
    "completion_date": "2013-07",
    "results_first_posted": null,
    "last_update_posted": "2020-06-18",
    "enrollment": null,
    "sponsor": "Lineage Cell Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Lineage Cell Therapeutics"
  },
  {
    "ticker": "LCTX",
    "nct_id": "NCT05975424",
    "title": "LTFU Study of Subjects With Cervical SCI Who Received AST-OPC1",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Spinal Cord Injuries"
    ],
    "interventions": [
      "Magnetic Resonance Imaging (MRI)"
    ],
    "primary_completion_date": "2033-01-14",
    "completion_date": "2033-01-14",
    "results_first_posted": null,
    "last_update_posted": "2024-08-21",
    "enrollment": null,
    "sponsor": "Lineage Cell Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Lineage Cell Therapeutics"
  },
  {
    "ticker": "LCTX",
    "nct_id": "NCT02302157",
    "title": "Dose Escalation Study of AST-OPC1 in Spinal Cord Injury",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cervical Spinal Cord Injury",
      "Spine Injury",
      "Spinal Cord Trauma"
    ],
    "interventions": [
      "AST-OPC1"
    ],
    "primary_completion_date": "2018-12",
    "completion_date": "2018-12",
    "results_first_posted": "2021-07-13",
    "last_update_posted": "2021-07-14",
    "enrollment": null,
    "sponsor": "Lineage Cell Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Lineage Cell Therapeutics"
  },
  {
    "ticker": "LCTX",
    "nct_id": "NCT05919563",
    "title": "LTFU Study of Subjects Who Received GRNOPC1",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Spinal Cord Injuries"
    ],
    "interventions": [
      "Magnetic Resonance Imaging (MRI)"
    ],
    "primary_completion_date": "2026-12-12",
    "completion_date": "2026-12-12",
    "results_first_posted": null,
    "last_update_posted": "2024-08-21",
    "enrollment": null,
    "sponsor": "Lineage Cell Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Lineage Cell Therapeutics"
  },
  {
    "ticker": "LCTX",
    "nct_id": "NCT06841770",
    "title": "A Study to Evaluate the Safety of a Delivery Device for Administering LCTOPC1 in Participants With Spinal Cord Injury",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Spinal Cord Injury Cervical",
      "Spinal Cord Injury Thoracic",
      "Spinal Cord Injury, Acute",
      "Spinal Cord Injury",
      "Spinal Cord Injury, Chronic"
    ],
    "interventions": [
      "OPC1"
    ],
    "primary_completion_date": "2027-08-10",
    "completion_date": "2037-06-30",
    "results_first_posted": null,
    "last_update_posted": "2025-06-12",
    "enrollment": null,
    "sponsor": "Lineage Cell Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Lineage Cell Therapeutics"
  },
  {
    "ticker": "LGND",
    "nct_id": "NCT00623324",
    "title": "The Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson's Disease",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Early Stage Parkinson's Disease"
    ],
    "interventions": [
      "Aplindore",
      "Placebo"
    ],
    "primary_completion_date": "2008-07",
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2011-10-03",
    "enrollment": null,
    "sponsor": "Ligand Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Ligand Pharmaceuticals"
  },
  {
    "ticker": "LGND",
    "nct_id": "NCT00879112",
    "title": "Study of MB07811 in Subjects With Hypercholesterolemia",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypercholesterolemia"
    ],
    "interventions": [
      "MB07811",
      "Placebo"
    ],
    "primary_completion_date": "2009-12",
    "completion_date": "2009-12",
    "results_first_posted": null,
    "last_update_posted": "2011-08-12",
    "enrollment": null,
    "sponsor": "Ligand Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Ligand Pharmaceuticals"
  },
  {
    "ticker": "LGND",
    "nct_id": "NCT02672839",
    "title": "A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 2 Diabetes Mellitus (T2DM)"
    ],
    "interventions": [
      "LGD-6972 Solution",
      "LGD-6972 Capsules"
    ],
    "primary_completion_date": "2016-05",
    "completion_date": "2016-05",
    "results_first_posted": null,
    "last_update_posted": "2016-05-18",
    "enrollment": null,
    "sponsor": "Ligand Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Ligand Pharmaceuticals"
  },
  {
    "ticker": "LGND",
    "nct_id": "NCT00006345",
    "title": "Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Drug/Agent Toxicity by Tissue/Organ",
      "Lymphoma"
    ],
    "interventions": [
      "denileukin diftitox",
      "dexamethasone"
    ],
    "primary_completion_date": null,
    "completion_date": "2004-03",
    "results_first_posted": null,
    "last_update_posted": "2013-05-30",
    "enrollment": null,
    "sponsor": "Ligand Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Ligand Pharmaceuticals"
  },
  {
    "ticker": "LGND",
    "nct_id": "NCT04627831",
    "title": "Comparison of Captisol-Enabled\u2122 Iohexol and Omnipaque\u2122 in Patients With Impaired Renal Function Undergoing Coronary Angiography",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Contrast-induced Nephropathy"
    ],
    "interventions": [
      "CE-Iohexol",
      "Iohexol"
    ],
    "primary_completion_date": "2023-03",
    "completion_date": "2023-04",
    "results_first_posted": null,
    "last_update_posted": "2022-04-11",
    "enrollment": null,
    "sponsor": "Ligand Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Ligand Pharmaceuticals"
  },
  {
    "ticker": "LGND",
    "nct_id": "NCT00674453",
    "title": "The Prevention Of Postmenopausal Osteoporosis With Lasofoxifene And Cytokine Evaluation",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bone Loss"
    ],
    "interventions": [
      "Lasofoxifene",
      "Placebo"
    ],
    "primary_completion_date": null,
    "completion_date": "2007-09",
    "results_first_posted": null,
    "last_update_posted": "2011-08-10",
    "enrollment": null,
    "sponsor": "Ligand Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Ligand Pharmaceuticals"
  },
  {
    "ticker": "LGND",
    "nct_id": "NCT00163137",
    "title": "Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone Loss",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Osteoporosis"
    ],
    "interventions": [
      "lasofoxifene",
      "raloxifene",
      "Placebo"
    ],
    "primary_completion_date": "2005-10",
    "completion_date": "2005-10",
    "results_first_posted": null,
    "last_update_posted": "2011-08-12",
    "enrollment": null,
    "sponsor": "Ligand Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Ligand Pharmaceuticals"
  },
  {
    "ticker": "LQDA",
    "nct_id": "NCT07285655",
    "title": "A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pulmonary Hypertension Due to Lung Disease (Disorder)"
    ],
    "interventions": [
      "L606",
      "Placebo"
    ],
    "primary_completion_date": "2029-07",
    "completion_date": "2031-12",
    "results_first_posted": null,
    "last_update_posted": "2025-12-17",
    "enrollment": null,
    "sponsor": "Liquidia Technologies, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Liquidia"
  },
  {
    "ticker": "LQDA",
    "nct_id": "NCT04691154",
    "title": "A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pulmonary Arterial Hypertension",
      "Pulmonary Hypertension Due to Lung Diseases"
    ],
    "interventions": [
      "L606 inhalation suspension"
    ],
    "primary_completion_date": "2025-03-20",
    "completion_date": "2031-03-31",
    "results_first_posted": null,
    "last_update_posted": "2025-12-15",
    "enrollment": null,
    "sponsor": "Liquidia Technologies, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Liquidia"
  },
  {
    "ticker": "LQDA",
    "nct_id": "NCT06129240",
    "title": "An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Pulmonary Hypertension",
      "Interstitial Lung Disease"
    ],
    "interventions": [
      "LIQ861"
    ],
    "primary_completion_date": "2026-07-30",
    "completion_date": "2026-10-31",
    "results_first_posted": null,
    "last_update_posted": "2025-05-31",
    "enrollment": null,
    "sponsor": "Liquidia Technologies, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Liquidia"
  },
  {
    "ticker": "LQDA",
    "nct_id": "NCT02982889",
    "title": "Single Ascending Dose Study of Two Liquidia Bupivacaine Formulations",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Pain"
    ],
    "interventions": [
      "LIQ865A bupivacaine formulation",
      "LIQ865B bupivacaine formulation",
      "Diluent for LIQ865",
      "0.5% bupivacaine hydrochoride"
    ],
    "primary_completion_date": "2017-03-23",
    "completion_date": "2017-04-26",
    "results_first_posted": null,
    "last_update_posted": "2017-08-24",
    "enrollment": null,
    "sponsor": "Liquidia Technologies, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Liquidia"
  },
  {
    "ticker": "LQDA",
    "nct_id": "NCT01224262",
    "title": "A Study Evaluating the Safety and Tolerability of a Seasonal Influenza Vaccine Containing LIQ001",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Influenza"
    ],
    "interventions": [
      "Fluzone\u00ae (2010/2011 Inactivated Trivalent Influenza Vaccine)",
      "LIQ001 (0.45mg)",
      "LIQ001 (1.8mg)"
    ],
    "primary_completion_date": "2011-12",
    "completion_date": "2011-12",
    "results_first_posted": null,
    "last_update_posted": "2013-03-01",
    "enrollment": null,
    "sponsor": "Liquidia Technologies, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Liquidia"
  },
  {
    "ticker": "LQDA",
    "nct_id": "NCT03884465",
    "title": "Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pulmonary Arterial Hypertension"
    ],
    "interventions": [
      "Inhaled dry powder treprostinil (LIQ861)"
    ],
    "primary_completion_date": "2020-12-23",
    "completion_date": "2020-12-23",
    "results_first_posted": null,
    "last_update_posted": "2021-09-13",
    "enrollment": null,
    "sponsor": "Liquidia Technologies, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Liquidia"
  },
  {
    "ticker": "LQDA",
    "nct_id": "NCT03399604",
    "title": "Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Primary Pulmonary Hypertension"
    ],
    "interventions": [
      "LIQ861 Inhaled Treprostinil"
    ],
    "primary_completion_date": "2019-05-06",
    "completion_date": "2019-11-25",
    "results_first_posted": "2024-07-30",
    "last_update_posted": "2024-07-30",
    "enrollment": null,
    "sponsor": "Liquidia Technologies, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Liquidia"
  },
  {
    "ticker": "LQDA",
    "nct_id": "NCT03992755",
    "title": "Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Primary Pulmonary Hypertension"
    ],
    "interventions": [
      "LIQ861 Inhaled Treprostinil"
    ],
    "primary_completion_date": "2025-05-31",
    "completion_date": "2025-05-31",
    "results_first_posted": null,
    "last_update_posted": "2025-01-29",
    "enrollment": null,
    "sponsor": "Liquidia Technologies, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Liquidia"
  },
  {
    "ticker": "MDGL",
    "nct_id": "NCT04671069",
    "title": "Drug Interaction Study of MGL-3196 With Clopidogrel",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "MGL-3196",
      "Clopidogrel"
    ],
    "primary_completion_date": "2019-08-30",
    "completion_date": "2019-09-14",
    "results_first_posted": null,
    "last_update_posted": "2020-12-28",
    "enrollment": null,
    "sponsor": "Madrigal Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Madrigal Pharmaceuticals"
  },
  {
    "ticker": "MDGL",
    "nct_id": "NCT04643795",
    "title": "Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatic Impairment",
      "NASH - Nonalcoholic Steatohepatitis",
      "Cirrhosis, Liver"
    ],
    "interventions": [
      "MGL-3196"
    ],
    "primary_completion_date": "2021-08-04",
    "completion_date": "2021-08-04",
    "results_first_posted": null,
    "last_update_posted": "2023-10-05",
    "enrollment": null,
    "sponsor": "Madrigal Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Madrigal Pharmaceuticals"
  },
  {
    "ticker": "MDGL",
    "nct_id": "NCT02749578",
    "title": "Drug Interaction Study of MGL-3196 With Atorvastatin",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "Atorvastatin",
      "MGL-3196"
    ],
    "primary_completion_date": "2016-05",
    "completion_date": "2016-05",
    "results_first_posted": null,
    "last_update_posted": "2016-08-30",
    "enrollment": null,
    "sponsor": "Madrigal Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Madrigal Pharmaceuticals"
  },
  {
    "ticker": "MDGL",
    "nct_id": "NCT02912260",
    "title": "Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-alcoholic Steatohepatitis"
    ],
    "interventions": [
      "MGL-3196",
      "Placebo"
    ],
    "primary_completion_date": "2017-10-25",
    "completion_date": "2021-11-23",
    "results_first_posted": "2025-12-23",
    "last_update_posted": "2025-12-23",
    "enrollment": null,
    "sponsor": "Madrigal Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Madrigal Pharmaceuticals"
  },
  {
    "ticker": "MDGL",
    "nct_id": "NCT04671056",
    "title": "Drug Interaction Study of MGL-3196 With Pioglitazone",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "MGL-3196",
      "Pioglitazone 15mg"
    ],
    "primary_completion_date": "2018-12-11",
    "completion_date": "2019-01-05",
    "results_first_posted": null,
    "last_update_posted": "2020-12-17",
    "enrollment": null,
    "sponsor": "Madrigal Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Madrigal Pharmaceuticals"
  },
  {
    "ticker": "MDGL",
    "nct_id": "NCT06397872",
    "title": "A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Renal Impairment"
    ],
    "interventions": [
      "100 mg Resmetirom Tablet"
    ],
    "primary_completion_date": "2024-09-16",
    "completion_date": "2024-12-31",
    "results_first_posted": null,
    "last_update_posted": "2025-10-14",
    "enrollment": null,
    "sponsor": "Madrigal Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Madrigal Pharmaceuticals"
  },
  {
    "ticker": "MDGL",
    "nct_id": "NCT04951219",
    "title": "A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-Alcoholic Fatty Liver Disease"
    ],
    "interventions": [
      "Resmetirom"
    ],
    "primary_completion_date": "2026-03",
    "completion_date": "2026-04",
    "results_first_posted": null,
    "last_update_posted": "2025-08-03",
    "enrollment": null,
    "sponsor": "Madrigal Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Madrigal Pharmaceuticals"
  },
  {
    "ticker": "MDGL",
    "nct_id": "NCT03413124",
    "title": "Bioavailability Study of MGL-3196 Tablets Compared to Capsules",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "MGL-3196 Tablet",
      "MGL-3196 Capsule"
    ],
    "primary_completion_date": "2018-02-17",
    "completion_date": "2018-03-13",
    "results_first_posted": null,
    "last_update_posted": "2019-09-18",
    "enrollment": null,
    "sponsor": "Madrigal Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Madrigal Pharmaceuticals"
  },
  {
    "ticker": "MDGL",
    "nct_id": "NCT04197479",
    "title": "A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-Alcoholic Fatty Liver Disease"
    ],
    "interventions": [
      "Placebo",
      "Resmetirom"
    ],
    "primary_completion_date": "2023-01-06",
    "completion_date": "2023-01-06",
    "results_first_posted": null,
    "last_update_posted": "2023-09-05",
    "enrollment": null,
    "sponsor": "Madrigal Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Madrigal Pharmaceuticals"
  },
  {
    "ticker": "MDGL",
    "nct_id": "NCT03900429",
    "title": "A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "NASH - Nonalcoholic Steatohepatitis"
    ],
    "interventions": [
      "MGL-3196",
      "Placebo",
      "Liver Biopsy"
    ],
    "primary_completion_date": "2028-01",
    "completion_date": "2028-01",
    "results_first_posted": null,
    "last_update_posted": "2024-02-20",
    "enrollment": null,
    "sponsor": "Madrigal Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Madrigal Pharmaceuticals"
  },
  {
    "ticker": "MDGL",
    "nct_id": "NCT01367873",
    "title": "Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Drug Safety"
    ],
    "interventions": [
      "Placebo",
      "VIA-3196"
    ],
    "primary_completion_date": "2011-10",
    "completion_date": "2011-10",
    "results_first_posted": null,
    "last_update_posted": "2023-08-22",
    "enrollment": null,
    "sponsor": "Madrigal Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Madrigal Pharmaceuticals"
  },
  {
    "ticker": "MDGL",
    "nct_id": "NCT02542969",
    "title": "Drug Interaction Study of MGL-3196 With Rosuvastatin and Simvastatin",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "Simvastatin",
      "Rosuvastatin",
      "MGL-3196"
    ],
    "primary_completion_date": "2015-10",
    "completion_date": "2015-10",
    "results_first_posted": null,
    "last_update_posted": "2022-09-02",
    "enrollment": null,
    "sponsor": "Madrigal Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Madrigal Pharmaceuticals"
  },
  {
    "ticker": "MDGL",
    "nct_id": "NCT03038022",
    "title": "Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Heterozygous Familial Hypercholesterolemia"
    ],
    "interventions": [
      "MGL-3196 (resmetirom)",
      "Placebo"
    ],
    "primary_completion_date": "2018-01-15",
    "completion_date": "2018-01-15",
    "results_first_posted": "2025-12-23",
    "last_update_posted": "2025-12-23",
    "enrollment": null,
    "sponsor": "Madrigal Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Madrigal Pharmaceuticals"
  },
  {
    "ticker": "MDGL",
    "nct_id": "NCT01519531",
    "title": "Ascending Multiple-Dose Study to Evaluate VIA-3196 in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Drug Safety"
    ],
    "interventions": [
      "Placebo",
      "VIA-3196"
    ],
    "primary_completion_date": "2012-11",
    "completion_date": "2012-11",
    "results_first_posted": null,
    "last_update_posted": "2012-12-06",
    "enrollment": null,
    "sponsor": "Madrigal Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Madrigal Pharmaceuticals"
  },
  {
    "ticker": "MDGL",
    "nct_id": "NCT03220165",
    "title": "Radiolabeled Study to Determine the Mass Balance of [14C] MGL-3196",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "MGL-3196"
    ],
    "primary_completion_date": "2017-09-03",
    "completion_date": "2017-09-03",
    "results_first_posted": null,
    "last_update_posted": "2017-12-19",
    "enrollment": null,
    "sponsor": "Madrigal Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Madrigal Pharmaceuticals"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT07224321",
    "title": "INHALE-1st: Afrezza\u00ae For Youth With Newly-Diagnosed Type 1 Diabetes",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 1 Diabetes Mellitus"
    ],
    "interventions": [
      "Technosphere Insulin",
      "Technosphere Insulin",
      "Basal insulin"
    ],
    "primary_completion_date": "2026-10",
    "completion_date": "2027-06",
    "results_first_posted": null,
    "last_update_posted": "2026-01-26",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT01196104",
    "title": "Clinical Trial Evaluating the Efficacy and Safety of Technosphere\u00ae Inhalation Insulin (TI) Inhalation Powder Using the Gen2 Inhaler",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 2 Diabetes"
    ],
    "interventions": [
      "Technosphere\u00ae Insulin Inhalation Powder",
      "Insulin Aspart",
      "Insulin Glargine"
    ],
    "primary_completion_date": "2011-08",
    "completion_date": "2012-03",
    "results_first_posted": "2014-10-21",
    "last_update_posted": "2014-10-30",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT00757367",
    "title": "A Trial to Determine How Long Insulin and FDKP (the Molecule That Forms Technosphere Particles) Stays in the Lungs of Healthy Individuals After Inhalation of Technosphere\u00ae Insulin (TI) Powder Using Bronchoalveolar Lavage (BAL)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Subjects"
    ],
    "interventions": [
      "TI Inhalation Powder"
    ],
    "primary_completion_date": "2008-10",
    "completion_date": "2008-10",
    "results_first_posted": null,
    "last_update_posted": "2013-12-17",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT02527265",
    "title": "Afrezza Safety and Pharmacokinetics Study in Pediatric Patients",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 1 Diabetes Mellitus"
    ],
    "interventions": [
      "Afrezza"
    ],
    "primary_completion_date": "2020-03-17",
    "completion_date": "2020-06-25",
    "results_first_posted": "2021-04-06",
    "last_update_posted": "2021-04-06",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT00688090",
    "title": "Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma.",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Melanoma",
      "Stage III and IV Melanoma"
    ],
    "interventions": [
      "Biological: MKC1106-MT",
      "Biological: MKCC1106-MT"
    ],
    "primary_completion_date": "2009-12",
    "completion_date": "2010-05",
    "results_first_posted": null,
    "last_update_posted": "2010-08-03",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT01365117",
    "title": "Pharmacokinetic Study in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "Technosphere\u00ae Insulin Inhalation Powder",
      "Technosphere\u00ae Insulin Inhalation Powder"
    ],
    "primary_completion_date": "2011-02",
    "completion_date": "2011-04",
    "results_first_posted": null,
    "last_update_posted": "2012-06-14",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT00309244",
    "title": "Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes Type 2"
    ],
    "interventions": [
      "Technosphere\u00ae Insulin Inhalation Powder",
      "70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)"
    ],
    "primary_completion_date": "2008-08",
    "completion_date": "2008-09",
    "results_first_posted": "2014-10-16",
    "last_update_posted": "2014-10-16",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT00023647",
    "title": "Vaccine Therapy in Treating Patients With Stage IV Melanoma",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Melanoma (Skin)"
    ],
    "interventions": [
      "Synchrotope TA2M",
      "Synchrotope TA2M",
      "Synchrotope TA2M"
    ],
    "primary_completion_date": "2002-04",
    "completion_date": "2002-11",
    "results_first_posted": null,
    "last_update_posted": "2012-07-10",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT01021891",
    "title": "A Study to Evaluate Insulin in the Blood After Inhalation of a Dry Powder Insulin Formulation (Called Technosphere\u00ae/Insulin) in Non-diabetic Patients With & Without Chronic Obstructive Pulmonary Disease (COPD)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Obstructive Pulmonary Disease (COPD)"
    ],
    "interventions": [
      "Technosphere\u00ae/Insulin"
    ],
    "primary_completion_date": "2008-08",
    "completion_date": "2008-11",
    "results_first_posted": null,
    "last_update_posted": "2013-12-17",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT01798914",
    "title": "Patient Transitioning From Exubera\u00ae Inhalation Powder to Technosphere\u00ae Insulin Inhalation Powder",
    "status": "NO_LONGER_AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Type 1 Diabetes",
      "Type 2 Diabetes"
    ],
    "interventions": [
      "Technosphere Insulin Inhalation Powder"
    ],
    "primary_completion_date": "2015-04",
    "completion_date": "2015-05",
    "results_first_posted": null,
    "last_update_posted": "2016-01-20",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT01902121",
    "title": "Compare the Same Dosage of Insulin Using a Combination of Cartridges, 30 Units as 2 Cartridges vs. 1 Cartridge",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "Technosphere\u00ae Insulin 10U + 20U",
      "Technosphere\u00ae Insulin 30U"
    ],
    "primary_completion_date": "2013-11",
    "completion_date": "2014-08",
    "results_first_posted": null,
    "last_update_posted": "2014-12-12",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT00662857",
    "title": "A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes Mellitus: Type 1"
    ],
    "interventions": [
      "Technosphere\u00ae Insulin Inhalation Powder",
      "Technosphere Insulin\u00ae Inhalation Powder",
      "RAA Population"
    ],
    "primary_completion_date": "2008-11",
    "completion_date": "2008-12",
    "results_first_posted": "2014-10-16",
    "last_update_posted": "2014-10-16",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT00642538",
    "title": "A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes Mellitus",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes Mellitus, Type 2"
    ],
    "interventions": [
      "MKC253 Inhalation Powder",
      "Technosphere Inhalation Powder",
      "subcutaneous injection"
    ],
    "primary_completion_date": "2008-09",
    "completion_date": "2008-09",
    "results_first_posted": null,
    "last_update_posted": "2012-06-14",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT00511602",
    "title": "Study of the Efficacy and Safety of Inhaled Technosphere Insulin in Patients With Type 2 Diabetes",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 2 Diabetes Mellitus"
    ],
    "interventions": [
      "Technosphere Insulin",
      "Technosphere Placebo"
    ],
    "primary_completion_date": "2004-11",
    "completion_date": "2005-12",
    "results_first_posted": null,
    "last_update_posted": "2012-04-30",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT00700622",
    "title": "Safety and Efficacy of Technosphere\u00ae Insulin Inhalation Powder and Lantus\u00ae Compared to Humalog\u00ae and Lantus\u00ae Over 16-Weeks",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes, Type 1"
    ],
    "interventions": [
      "Technosphere Insulin",
      "Insulin glargine",
      "Insulin lispro"
    ],
    "primary_completion_date": "2009-11",
    "completion_date": "2010-03",
    "results_first_posted": "2014-10-16",
    "last_update_posted": "2014-10-16",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT01201928",
    "title": "Pulmonary Function Substudy for Subjects Enrolled in Studies MKC-TI-161, MKC-TI-162 or MKC-TI-166",
    "status": "TERMINATED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Type 1 Diabetes Mellitus",
      "Type 2 Diabetes Mellitus"
    ],
    "interventions": [
      "Comparator administered in parent trial",
      "Technosphere Insulin Inhalation Powder"
    ],
    "primary_completion_date": "2011-03",
    "completion_date": "2012-03",
    "results_first_posted": null,
    "last_update_posted": "2012-12-06",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT01445951",
    "title": "Clinical Trial Evaluating Technosphere\u00ae Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 1 Diabetes Mellitus"
    ],
    "interventions": [
      "Technosphere\u00ae Insulin with MedTone C Inhaler",
      "Technosphere \u00aeInsulin with Gen2 Inhaler",
      "Insulin Aspart in combination with a basal insulin"
    ],
    "primary_completion_date": "2013-05",
    "completion_date": "2013-06",
    "results_first_posted": "2014-10-22",
    "last_update_posted": "2014-10-22",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT00721344",
    "title": "A Study to Determine if Technosphere\u00ae Inhalation Powder (FDKP) Causes ECG Changes (QTc) Following the Medication's Inhaled Administration.",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Subjects"
    ],
    "interventions": [
      "Technosphere Inhalation Powder (FDKP)",
      "Moxifloxacin",
      "Technosphere Inhalation Powder (FDKP)",
      "Placebo"
    ],
    "primary_completion_date": "2008-08",
    "completion_date": "2008-10",
    "results_first_posted": null,
    "last_update_posted": "2012-06-13",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT04849845",
    "title": "Afrezza\u00ae Dosing Optimization Study",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes Mellitus, Type 1",
      "Diabetes Mellitus, Type 2"
    ],
    "interventions": [
      "Afrezza Dose 1",
      "Afrezza Dose 2"
    ],
    "primary_completion_date": "2021-05-28",
    "completion_date": "2021-05-28",
    "results_first_posted": "2023-09-18",
    "last_update_posted": "2023-09-18",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT02470637",
    "title": "Single Dose Clamp Study to Evaluate Concentration-time Profile and Metabolic Activity of 3 Dose Levels of Afrezza and 3 Dose Levels of Insulin Lispro in Patients With Type 1 Diabetes Mellitus",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 1 Diabetes Mellitus"
    ],
    "interventions": [
      "SAR439065",
      "Insulin lispro"
    ],
    "primary_completion_date": "2015-09",
    "completion_date": "2015-09",
    "results_first_posted": null,
    "last_update_posted": "2017-04-13",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT00754624",
    "title": "An Open-label, Multi-center, International, Three-year, Safety and Tolerability 'Follow on' Trial",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 2 Diabetes Mellitus"
    ],
    "interventions": [
      "Technosphere\u00ae Insulin Inhalation Powder and MedTone\u2122 Inhaler"
    ],
    "primary_completion_date": "2008-06",
    "completion_date": "2008-10",
    "results_first_posted": "2014-10-16",
    "last_update_posted": "2014-10-16",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT00332826",
    "title": "Inhaled Technosphere Insulin in Subjects With Diabetes Mellitus and Asthma",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes Mellitus, Type 1",
      "Diabetes Mellitus, Type 2",
      "Asthma"
    ],
    "interventions": [
      "Technosphere Insulin"
    ],
    "primary_completion_date": "2007-10",
    "completion_date": "2007-10",
    "results_first_posted": null,
    "last_update_posted": "2012-05-04",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT00419302",
    "title": "To Compare the Effect of Inhaled Insulin With Subcutaneously Injected Insulin in Subjects With Type 2 Diabetes Mellitus.",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes Mellitus, Type 2"
    ],
    "interventions": [
      "Technosphere/Insulin"
    ],
    "primary_completion_date": null,
    "completion_date": "2004-04",
    "results_first_posted": null,
    "last_update_posted": "2009-10-14",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT00674050",
    "title": "A Study Designed to Determine if the Drugs Albuterol (Salbutamol) and Fluticasone Have an Effect on the Pharmacokinetics of the Investigational Product Technosphere\u00ae Insulin Inhalation Powder in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes Mellitus",
      "Healthy Subjects"
    ],
    "interventions": [
      "Technosphere Insulin (TI) Inhalation Powder",
      "Albuterol (Salbutamol)",
      "Fluticasone"
    ],
    "primary_completion_date": "2008-09",
    "completion_date": "2008-10",
    "results_first_posted": null,
    "last_update_posted": "2012-06-13",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT00511979",
    "title": "Comparison of the Effect on the Glucose Infusion Rates Between Inhaled Technosphere Insulin and a Subcutaneous Injection of Regular Human Insulin",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "Technosphere Insulin",
      "Technosphere insulin",
      "Technosphere insulin",
      "Regular human insulin"
    ],
    "primary_completion_date": "2000-02",
    "completion_date": "2000-06",
    "results_first_posted": null,
    "last_update_posted": "2012-06-26",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT06532942",
    "title": "A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MKND-201 in Healthy Volunteers",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "(Part A) MKND-201",
      "Placebo",
      "(Part B) MKND-201"
    ],
    "primary_completion_date": "2024-10-31",
    "completion_date": "2024-10-31",
    "results_first_posted": null,
    "last_update_posted": "2024-08-06",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT00741429",
    "title": "A 2-Month Safety Follow-Up Trial",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Type 1 Diabetes",
      "Type 2 Diabetes"
    ],
    "interventions": [
      "Technosphere Insulin Inhalation Powder",
      "Comparator"
    ],
    "primary_completion_date": "2008-09",
    "completion_date": "2008-09",
    "results_first_posted": null,
    "last_update_posted": "2014-12-03",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT01490762",
    "title": "Healthy Normal Volunteers Looking at Exposure and Effects of Multiple Doses of Technosphere\u00ae Insulin (TI) Using the Gen2C Inhaler",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "Technosphere Insulin Inhalation Powder using the Gen2C inhaler",
      "Regular Human Insulin"
    ],
    "primary_completion_date": "2012-05",
    "completion_date": "2012-07",
    "results_first_posted": null,
    "last_update_posted": "2012-09-07",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT00747006",
    "title": "Safety and Efficacy of Technosphere\u00ae Insulin Inhalation Powder (TI Inhalation Powder)When an Optimal Dose is Taken With Varied Carbohydrate Intake",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes Mellitus, Type 2",
      "Diabetes Mellitus, Type 1"
    ],
    "interventions": [
      "TI Inhalation Powder and Humalog (Amendment 1)",
      "TI Inhalation Powder (original protocol)"
    ],
    "primary_completion_date": "2011-02",
    "completion_date": "2011-05",
    "results_first_posted": "2014-10-21",
    "last_update_posted": "2014-10-30",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT00934414",
    "title": "Clamp Study Comparing Inhalation of Technosphere\u00ae/Insulin in Smokers and Non-Smokers With Type 2 Diabetes",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes Type 2"
    ],
    "interventions": [
      "Technosphere Insulin Inhalation Powder"
    ],
    "primary_completion_date": "2006-08",
    "completion_date": "2006-09",
    "results_first_posted": null,
    "last_update_posted": "2009-07-08",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT01982604",
    "title": "Comparison of 30 Units of TI (Technosphere\u00ae Insulin) Prepared With Insulin From Two Different Suppliers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "TI-Inhalation Powder A",
      "TI-Inhalation Powder B"
    ],
    "primary_completion_date": "2014-02",
    "completion_date": "2014-08",
    "results_first_posted": null,
    "last_update_posted": "2014-10-02",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT00673621",
    "title": "A Study Designed to Determine if the Pharmacokinetic Disposition of Inhaled Insulin Exposure is the Same for Asthmatics and Non-asthmatics",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Asthma",
      "Diabetes Mellitus"
    ],
    "interventions": [
      "Technosphere Insulin Inhalation Powder",
      "Salbutamol (Albuterol)",
      "Methacholine chloride"
    ],
    "primary_completion_date": "2008-11",
    "completion_date": "2008-12",
    "results_first_posted": null,
    "last_update_posted": "2012-06-13",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT07344558",
    "title": "A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Idiopathic Pulmonary Fibrosis (IPF)"
    ],
    "interventions": [
      "MNKD-201(Nintenadib DPI)",
      "Placebo"
    ],
    "primary_completion_date": "2026-04-01",
    "completion_date": "2026-04-01",
    "results_first_posted": null,
    "last_update_posted": "2026-01-15",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT00642681",
    "title": "Effects of URI on Diabetic Subjects Utilizing Technosphere Insulin After a Meal Challenge",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Diabetes Mellitus",
      "Upper Respiratory Infection"
    ],
    "interventions": [
      "Technosphere Insulin"
    ],
    "primary_completion_date": "2008-07",
    "completion_date": "2008-08",
    "results_first_posted": null,
    "last_update_posted": "2014-12-03",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT00511719",
    "title": "Bioavailability of Technosphere\u00ae Insulin Versus Subcutaneous Regular Human Insulin in Type 2 Diabetes",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 2 Diabetes Mellitus"
    ],
    "interventions": [
      "Technosphere Insulin",
      "Actrapid"
    ],
    "primary_completion_date": "2004-04",
    "completion_date": "2005-03",
    "results_first_posted": null,
    "last_update_posted": "2011-06-29",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT01451398",
    "title": "Comparison of Technosphere\u00ae Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 2 Diabetes"
    ],
    "interventions": [
      "Technosphere\u00ae Insulin",
      "Technosphere Powder"
    ],
    "primary_completion_date": "2013-06",
    "completion_date": "2013-07",
    "results_first_posted": "2014-10-17",
    "last_update_posted": "2014-10-17",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT00308737",
    "title": "Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes, Type 1",
      "Diabetes, Type 2"
    ],
    "interventions": [
      "Technosphere\u00ae Insulin Inhalation Powder",
      "Usual Care"
    ],
    "primary_completion_date": "2008-09",
    "completion_date": "2008-10",
    "results_first_posted": "2014-10-16",
    "last_update_posted": "2014-10-16",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT01026051",
    "title": "Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Stage III Melanoma",
      "Stage IV Melanoma"
    ],
    "interventions": [
      "MKC1106-MT"
    ],
    "primary_completion_date": "2011-09",
    "completion_date": "2012-07",
    "results_first_posted": null,
    "last_update_posted": "2012-05-15",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT00033228",
    "title": "Vaccine Therapy in Treating Patients With Stage IV Melanoma",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Melanoma (Skin)"
    ],
    "interventions": [
      "MKC1106-MT",
      "MKC1106-MT",
      "MKC1106-MT"
    ],
    "primary_completion_date": "2003-03",
    "completion_date": "2003-04",
    "results_first_posted": null,
    "last_update_posted": "2011-05-12",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT00511732",
    "title": "18-Week, Randomized, Double-blind, Placebo Controlled, Forced Titration Study of Patients With Type 2 Diabetes",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 2 Diabetes Mellitus"
    ],
    "interventions": [
      "Technosphere Insulin",
      "Technosphere Placebo"
    ],
    "primary_completion_date": "2005-08",
    "completion_date": "2007-08",
    "results_first_posted": null,
    "last_update_posted": "2012-04-30",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT00539890",
    "title": "Comparison Between Technosphere/Insulin Inhalation Powder Versus Rapid Acting Insulin in Subjects With Type 2 Diabetes Mellitus",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes Type 2"
    ],
    "interventions": [
      "Technosphere Insulin"
    ],
    "primary_completion_date": null,
    "completion_date": "2006-07",
    "results_first_posted": null,
    "last_update_posted": "2009-10-14",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT00475371",
    "title": "A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult Males",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes Mellitus, Type 2",
      "Healthy Males"
    ],
    "interventions": [
      "MKC253 Inhalation Powder"
    ],
    "primary_completion_date": "2007-06",
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2012-06-14",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT00642616",
    "title": "Evaluate Safety of Technosphere\u00ae Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 1 Diabetes Mellitus",
      "Type 2 Diabetes Mellitus",
      "Moderate Chronic Obstructive Pulmonary Disease",
      "Asthma"
    ],
    "interventions": [
      "Technosphere\u00ae Insulin",
      "Usual Care"
    ],
    "primary_completion_date": "2014-11",
    "completion_date": "2014-11",
    "results_first_posted": "2016-02-15",
    "last_update_posted": "2017-04-14",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT05904743",
    "title": "INHALE-3: Afrezza\u00ae Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes Mellitus, Type 1"
    ],
    "interventions": [
      "Afrezza",
      "insulin degludec",
      "Rapid-acting Insulin Analog",
      "Basal Insulin"
    ],
    "primary_completion_date": "2024-03-26",
    "completion_date": "2024-06-24",
    "results_first_posted": null,
    "last_update_posted": "2024-08-09",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT00539396",
    "title": "A 3 Month, Randomized, Open Label, Multi-center Study of Technosphere/Insulin Compared to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Receiving Insulin Glargine",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes Mellitus, Type 1"
    ],
    "interventions": [
      "Technosphere Insulin"
    ],
    "primary_completion_date": null,
    "completion_date": "2005-12",
    "results_first_posted": null,
    "last_update_posted": "2009-10-14",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT00332488",
    "title": "Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes Mellitus, Type 2"
    ],
    "interventions": [
      "Technosphere Insulin",
      "Metformin & Secretagogues",
      "Technosphere Insulin & Metformin"
    ],
    "primary_completion_date": "2008-03",
    "completion_date": null,
    "results_first_posted": "2014-10-16",
    "last_update_posted": "2014-10-16",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT06418711",
    "title": "ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "MAC Lung Disease",
      "Treatment Refractory MAC Lung Disease",
      "Mycobacterium Infections, Nontuberculous"
    ],
    "interventions": [
      "Clofazimine Inhalation Suspension",
      "Placebo"
    ],
    "primary_completion_date": "2025-11-10",
    "completion_date": "2025-11-10",
    "results_first_posted": null,
    "last_update_posted": "2025-11-12",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT02485327",
    "title": "PK and PD Within-Subject Variability of a Single Dose of Afrezza Inhaled Technosphere Insulin in Patients With Diabetes Mellitus Type 1 (T1DM)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 1 Diabetes Mellitus"
    ],
    "interventions": [
      "Technosphere Insulin SAR439065 Afrezza\u00ae"
    ],
    "primary_completion_date": "2015-11",
    "completion_date": "2015-11",
    "results_first_posted": null,
    "last_update_posted": "2017-03-15",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT00423254",
    "title": "Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ovarian",
      "Melanoma",
      "Renal",
      "Prostate",
      "Colorectal",
      "Endometrial Carcinoma",
      "Cervical Carcinoma",
      "Testicular Cancer",
      "Thyroid Cancer",
      "Small Cell Lung Carcinoma",
      "Mesothelioma",
      "Breast Carcinoma",
      "Esophageal Carcinoma",
      "Gastric Cancer",
      "Pancreatic Carcinoma",
      "Neuroendocrine Cancer",
      "Liver Cancer",
      "Gallbladder Cancer",
      "Biliary Tract Cancer",
      "Anal Carcinoma",
      "Bone Sarcomas",
      "Soft Tissue Sarcomas",
      "Carcinoma of Unknown Origin, Primary"
    ],
    "interventions": [
      "PSMA/PRAME",
      "PSMA/PRAME"
    ],
    "primary_completion_date": "2009-09",
    "completion_date": "2009-11",
    "results_first_posted": null,
    "last_update_posted": "2010-08-03",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT00626249",
    "title": "Single Dose, Single Administration Study of Technosphere Inhalation Powder in Diabetic Subjects With Mild or Moderate Kidney Disease Compared to Diabetic Subjects With Normal Kidney Function",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Mild Nephropathy",
      "Moderate Nephropathy",
      "Diabetes Mellitus"
    ],
    "interventions": [
      "Technosphere Inhalation Powder"
    ],
    "primary_completion_date": "2008-09",
    "completion_date": "2008-10",
    "results_first_posted": null,
    "last_update_posted": "2013-12-17",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT00570687",
    "title": "A Study Comparing Subcutaneous Rapid Acting Insulin and One Formulation of Inhaled Insulin in Subjects With Type 2 Diabetes",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes Mellitus, Type 2"
    ],
    "interventions": [
      "Technosphere Insulin"
    ],
    "primary_completion_date": "2009-01",
    "completion_date": "2009-01",
    "results_first_posted": "2014-10-16",
    "last_update_posted": "2014-10-16",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT01544881",
    "title": "Comparison of Technosphere Insulin Inhalation Powder & Subcutaneous Rapid-Acting Analog in Subjects With Type 1 Diabetes",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 1 Diabetes Mellitus"
    ],
    "interventions": [
      "Technosphere Insulin Inhalation Powder",
      "Rapid Acting Analog"
    ],
    "primary_completion_date": "2012-09",
    "completion_date": "2013-01",
    "results_first_posted": null,
    "last_update_posted": "2013-01-25",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MNKD",
    "nct_id": "NCT03464864",
    "title": "Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pulmonary Arterial Hypertension"
    ],
    "interventions": [
      "Treprostinil Inhalation Powder"
    ],
    "primary_completion_date": "2018-06-05",
    "completion_date": "2018-06-05",
    "results_first_posted": null,
    "last_update_posted": "2018-10-30",
    "enrollment": null,
    "sponsor": "Mannkind Corporation",
    "collected_at": "2026-01-27",
    "search_term": "MannKind"
  },
  {
    "ticker": "MRSN",
    "nct_id": "NCT05329545",
    "title": "Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "High Grade Serous Ovarian Cancer",
      "Fallopian Tube Cancer",
      "Primary Peritoneal Cancer"
    ],
    "interventions": [
      "Upifitimab rilsodotin",
      "Placebo"
    ],
    "primary_completion_date": "2023-09-29",
    "completion_date": "2023-09-29",
    "results_first_posted": null,
    "last_update_posted": "2023-10-26",
    "enrollment": null,
    "sponsor": "Mersana Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Mersana Therapeutics"
  },
  {
    "ticker": "MRSN",
    "nct_id": "NCT02952729",
    "title": "Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Breast Cancer",
      "Advanced Nonsmall Cell Lung Cancer",
      "Advanced Gastric Cancer"
    ],
    "interventions": [
      "XMT-1522"
    ],
    "primary_completion_date": "2019-01-28",
    "completion_date": "2019-01-28",
    "results_first_posted": null,
    "last_update_posted": "2021-02-24",
    "enrollment": null,
    "sponsor": "Mersana Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Mersana Therapeutics"
  },
  {
    "ticker": "MRSN",
    "nct_id": "NCT00455052",
    "title": "A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Small Cell Lung Cancer",
      "Non-small Cell Lung Cancer"
    ],
    "interventions": [
      "XMT-1001"
    ],
    "primary_completion_date": "2011-12",
    "completion_date": "2011-12",
    "results_first_posted": null,
    "last_update_posted": "2018-01-31",
    "enrollment": null,
    "sponsor": "Mersana Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Mersana Therapeutics"
  },
  {
    "ticker": "MRSN",
    "nct_id": "NCT06517433",
    "title": "First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Platinum Resistant Ovarian Cancer",
      "Non Small Cell Lung Cancer Metastatic"
    ],
    "interventions": [
      "upifitamab rilsodotin"
    ],
    "primary_completion_date": "2021-07-09",
    "completion_date": "2021-07-09",
    "results_first_posted": null,
    "last_update_posted": "2024-07-24",
    "enrollment": null,
    "sponsor": "Mersana Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Mersana Therapeutics"
  },
  {
    "ticker": "MRSN",
    "nct_id": "NCT05377996",
    "title": "A Study of XMT-1660 in Participants With Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Triple Negative Breast Cancer",
      "Breast Cancer",
      "Endometrial Cancer",
      "Ovarian Cancer",
      "Fallopian Tube Cancer",
      "Primary Peritoneal Cavity Cancer",
      "Adenoid Cystic Carcinoma"
    ],
    "interventions": [
      "XMT-1660"
    ],
    "primary_completion_date": "2026-12",
    "completion_date": "2027-05",
    "results_first_posted": null,
    "last_update_posted": "2025-10-28",
    "enrollment": null,
    "sponsor": "Mersana Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Mersana Therapeutics"
  },
  {
    "ticker": "MRSN",
    "nct_id": "NCT01011972",
    "title": "A Study of Intravenous XMT-1107 in Patients With Advanced Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Neoplasm Metastasis"
    ],
    "interventions": [
      "XMT-1107"
    ],
    "primary_completion_date": "2013-09",
    "completion_date": "2013-09",
    "results_first_posted": null,
    "last_update_posted": "2018-01-31",
    "enrollment": null,
    "sponsor": "Mersana Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Mersana Therapeutics"
  },
  {
    "ticker": "MRSN",
    "nct_id": "NCT04396340",
    "title": "First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ovarian Cancer",
      "Nonsmall Cell Lung Cancer"
    ],
    "interventions": [
      "XMT-1592"
    ],
    "primary_completion_date": "2022-09-30",
    "completion_date": "2022-09-30",
    "results_first_posted": null,
    "last_update_posted": "2024-03-15",
    "enrollment": null,
    "sponsor": "Mersana Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Mersana Therapeutics"
  },
  {
    "ticker": "MRSN",
    "nct_id": "NCT06517485",
    "title": "First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Platinum Resistant Ovarian Cancer",
      "Non-Small Cell Adenocarcinoma"
    ],
    "interventions": [
      "upifitamab rilsodotin"
    ],
    "primary_completion_date": "2022-05-31",
    "completion_date": "2022-08-03",
    "results_first_posted": null,
    "last_update_posted": "2024-07-24",
    "enrollment": null,
    "sponsor": "Mersana Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Mersana Therapeutics"
  },
  {
    "ticker": "MRSN",
    "nct_id": "NCT04907968",
    "title": "Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Platinum-sensitive Ovarian Cancer (UPGRADE-A)"
    ],
    "interventions": [
      "XMT-1536 (Upifitamab Rilsodotin)",
      "Carboplatin"
    ],
    "primary_completion_date": "2023-10-03",
    "completion_date": "2023-10-03",
    "results_first_posted": null,
    "last_update_posted": "2023-10-10",
    "enrollment": null,
    "sponsor": "Mersana Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Mersana Therapeutics"
  },
  {
    "ticker": "MRSN",
    "nct_id": "NCT03319628",
    "title": "First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Platinum Resistant Ovarian Cancer",
      "Non Small Cell Lung Cancer Metastatic"
    ],
    "interventions": [
      "upifitamab rilsodotin"
    ],
    "primary_completion_date": "2023-05-31",
    "completion_date": "2024-10-31",
    "results_first_posted": null,
    "last_update_posted": "2023-11-13",
    "enrollment": null,
    "sponsor": "Mersana Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Mersana Therapeutics"
  },
  {
    "ticker": "MRSN",
    "nct_id": "NCT05514717",
    "title": "A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HER2-positive Breast Cancer",
      "HER2-positive Gastric Cancer",
      "HER2-positive Non-Small Cell Lung Cancer",
      "HER2-positive Colorectal Cancer",
      "HER2-positive Tumors",
      "HER2 Low Breast Cancer"
    ],
    "interventions": [
      "XMT-2056"
    ],
    "primary_completion_date": "2027-04",
    "completion_date": "2027-04",
    "results_first_posted": null,
    "last_update_posted": "2025-07-11",
    "enrollment": null,
    "sponsor": "Mersana Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Mersana Therapeutics"
  },
  {
    "ticker": "MYGN",
    "nct_id": "NCT01468623",
    "title": "Study Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer Patients Treated With mFOLFOX6",
    "status": "TERMINATED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Colorectal Cancer, Metastatic"
    ],
    "interventions": [
      "Pharmacokinetic 5-FU dose adjustment using OnDose\u00ae assay",
      "Standard of care"
    ],
    "primary_completion_date": "2012-08",
    "completion_date": "2012-08",
    "results_first_posted": null,
    "last_update_posted": "2023-07-19",
    "enrollment": null,
    "sponsor": "Myriad Genetic Laboratories, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Myriad Genetics"
  },
  {
    "ticker": "MYGN",
    "nct_id": "NCT03511235",
    "title": "Clinical Outcomes in Men With Prostate Cancer Who Selected Active Surveillance Using Prolaris\u00ae Testing",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Prostate Cancer"
    ],
    "interventions": [],
    "primary_completion_date": "2018-07-31",
    "completion_date": "2018-07-31",
    "results_first_posted": null,
    "last_update_posted": "2020-10-06",
    "enrollment": null,
    "sponsor": "Myriad Genetic Laboratories, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Myriad Genetics"
  },
  {
    "ticker": "MYGN",
    "nct_id": "NCT02121899",
    "title": "Registry Measuring Impact of RNA Expression Testing on Treatment Decisions in Early Stage Lung Cancer and Assessing the Disease-free Survival With Long-term Follow-up (ONC006)",
    "status": "TERMINATED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Lung Cancer",
      "NSCLC",
      "NSCLC Adenocarcinoma"
    ],
    "interventions": [],
    "primary_completion_date": "2017-06-30",
    "completion_date": "2017-07-31",
    "results_first_posted": null,
    "last_update_posted": "2017-09-05",
    "enrollment": null,
    "sponsor": "Myriad Genetic Laboratories, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Myriad Genetics"
  },
  {
    "ticker": "MYGN",
    "nct_id": "NCT04015102",
    "title": "A Registry for Hereditary Cancer Risk Assessment and Genetic Testing",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Prostate Cancer"
    ],
    "interventions": [],
    "primary_completion_date": "2020-10-21",
    "completion_date": "2020-10-30",
    "results_first_posted": null,
    "last_update_posted": "2020-11-05",
    "enrollment": null,
    "sponsor": "Myriad Genetic Laboratories, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Myriad Genetics"
  },
  {
    "ticker": "MYGN",
    "nct_id": "NCT02454595",
    "title": "Registry to Measure the Impact of Adding Genomic Testing",
    "status": "TERMINATED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Prostate Cancer"
    ],
    "interventions": [
      "Registry"
    ],
    "primary_completion_date": "2017-07-03",
    "completion_date": "2017-07-03",
    "results_first_posted": null,
    "last_update_posted": "2017-09-05",
    "enrollment": null,
    "sponsor": "Myriad Genetic Laboratories, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Myriad Genetics"
  },
  {
    "ticker": "MYGN",
    "nct_id": "NCT02121925",
    "title": "Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions in Early Stage Lung Cancer Patients and Assessing the Disease-free Survival With Long-term Follow-up",
    "status": "TERMINATED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Lung Cancer",
      "NSCLC",
      "Lung Adenocarcinoma"
    ],
    "interventions": [],
    "primary_completion_date": "2017-06-30",
    "completion_date": "2017-07-31",
    "results_first_posted": null,
    "last_update_posted": "2017-09-05",
    "enrollment": null,
    "sponsor": "Myriad Genetic Laboratories, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Myriad Genetics"
  },
  {
    "ticker": "MYGN",
    "nct_id": "NCT03067389",
    "title": "Combined Breast Cancer Risk Study",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Hereditary Cancer"
    ],
    "interventions": [
      "Diagnostic test"
    ],
    "primary_completion_date": "2019-01-08",
    "completion_date": "2019-01-08",
    "results_first_posted": null,
    "last_update_posted": "2019-01-15",
    "enrollment": null,
    "sponsor": "Myriad Genetic Laboratories, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Myriad Genetics"
  },
  {
    "ticker": "MYGN",
    "nct_id": "NCT01954004",
    "title": "Open Registry Measuring Impact of Genomic Testing on Treatment of Prostate Cancer Patients",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Prostate Cancer"
    ],
    "interventions": [],
    "primary_completion_date": "2014-09",
    "completion_date": "2014-09",
    "results_first_posted": null,
    "last_update_posted": "2015-06-02",
    "enrollment": null,
    "sponsor": "Myriad Genetic Laboratories, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Myriad Genetics"
  },
  {
    "ticker": "MYGN",
    "nct_id": "NCT02209584",
    "title": "Open Registry Measuring Impact of Genomic Testing on Treatment Decision After Biopsy in Newly Diagnosed Prostate Cancer Patients",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Prostate Cancer"
    ],
    "interventions": [],
    "primary_completion_date": "2015-04-15",
    "completion_date": "2015-12-08",
    "results_first_posted": null,
    "last_update_posted": "2017-09-05",
    "enrollment": null,
    "sponsor": "Myriad Genetic Laboratories, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Myriad Genetics"
  },
  {
    "ticker": "MYGN",
    "nct_id": "NCT03152448",
    "title": "Prospective Prolaris Value and Efficacy",
    "status": "TERMINATED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Prostate Cancer"
    ],
    "interventions": [
      "Prolaris"
    ],
    "primary_completion_date": "2022-03-21",
    "completion_date": "2022-03-21",
    "results_first_posted": null,
    "last_update_posted": "2022-06-13",
    "enrollment": null,
    "sponsor": "Myriad Genetic Laboratories, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Myriad Genetics"
  },
  {
    "ticker": "MYGN",
    "nct_id": "NCT03081455",
    "title": "Impact of a Process Intervention on Screening and Testing Outcomes for Common Hereditary Cancer Syndromes",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Hereditary Cancer"
    ],
    "interventions": [
      "Diagnostic Test"
    ],
    "primary_completion_date": "2017-07-07",
    "completion_date": "2017-08-04",
    "results_first_posted": null,
    "last_update_posted": "2017-08-08",
    "enrollment": null,
    "sponsor": "Myriad Genetic Laboratories, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Myriad Genetics"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT03706469",
    "title": "A Study to Evaluate the Relative Bioavailability (BA) and Effect of Food on TAK-831 Tablet Formulations in Healthy Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "TAK-831 T2",
      "TAK-831 T3"
    ],
    "primary_completion_date": "2018-12-11",
    "completion_date": "2018-12-22",
    "results_first_posted": "2019-12-23",
    "last_update_posted": "2021-06-14",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT07105098",
    "title": "NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia"
    ],
    "interventions": [
      "NBI-1117568",
      "Placebo"
    ],
    "primary_completion_date": "2027-11",
    "completion_date": "2027-11",
    "results_first_posted": null,
    "last_update_posted": "2025-09-23",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT05493293",
    "title": "Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure Medications in Adults With Focal Onset Seizures",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Focal Onset Seizure",
      "Focal Onset Epilepsy"
    ],
    "interventions": [
      "NBI-921352"
    ],
    "primary_completion_date": "2024-03-11",
    "completion_date": "2024-03-11",
    "results_first_posted": null,
    "last_update_posted": "2024-04-12",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT05159908",
    "title": "A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti-seizure Medications in Adults With Focal Onset Seizures",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Focal Onset Seizure",
      "Focal Onset Epilepsy"
    ],
    "interventions": [
      "NBI-921352",
      "Placebo"
    ],
    "primary_completion_date": "2023-08-21",
    "completion_date": "2023-08-21",
    "results_first_posted": null,
    "last_update_posted": "2024-09-26",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT05206513",
    "title": "Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dyskinesia",
      "Cerebral Palsy"
    ],
    "interventions": [
      "Placebo",
      "Valbenazine"
    ],
    "primary_completion_date": "2025-12",
    "completion_date": "2026-06",
    "results_first_posted": null,
    "last_update_posted": "2025-08-01",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT07227818",
    "title": "Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia"
    ],
    "interventions": [
      "NBI-1117568",
      "Placebo"
    ],
    "primary_completion_date": "2029-07",
    "completion_date": "2029-07",
    "results_first_posted": null,
    "last_update_posted": "2025-11-13",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT03062033",
    "title": "Real-World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents",
    "status": "UNKNOWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Tardive Dyskinesia"
    ],
    "interventions": [],
    "primary_completion_date": "2018-08",
    "completion_date": "2018-08",
    "results_first_posted": null,
    "last_update_posted": "2017-11-22",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT04873869",
    "title": "Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "SCN8A Developmental and Epileptic Encephalopathy Syndrome"
    ],
    "interventions": [
      "NBI-921352",
      "Placebo"
    ],
    "primary_completion_date": "2023-03-17",
    "completion_date": "2023-03-17",
    "results_first_posted": "2025-10-16",
    "last_update_posted": "2025-10-16",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT05226780",
    "title": "Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "SCN8A Developmental and Epileptic Encephalopathy Syndrome"
    ],
    "interventions": [
      "NBI-921352"
    ],
    "primary_completion_date": "2026-03",
    "completion_date": "2026-03",
    "results_first_posted": null,
    "last_update_posted": "2025-07-17",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT03065192",
    "title": "Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Idiopathic Parkinson's Disease",
      "Parkinson's Disease",
      "Basal Ganglia Disease",
      "Brain Diseases",
      "Central Nervous System Diseases",
      "Movement Disorders",
      "Nervous System Diseases",
      "Neurodegenerative Diseases",
      "Parkinsonian Disorders"
    ],
    "interventions": [
      "VY-AADC01"
    ],
    "primary_completion_date": "2021-08-10",
    "completion_date": "2021-08-10",
    "results_first_posted": null,
    "last_update_posted": "2022-03-21",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT05859698",
    "title": "Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia",
      "Schizoaffective Disorder",
      "Bipolar Disorder",
      "Major Depressive Disorder",
      "Tardive Dyskinesia"
    ],
    "interventions": [
      "Valbenazine"
    ],
    "primary_completion_date": "2024-12-27",
    "completion_date": "2024-12-27",
    "results_first_posted": "2026-01-16",
    "last_update_posted": "2026-01-16",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT00014677",
    "title": "NBI-3001 Followed by Surgery in Treating Patients With Recurrent Glioblastoma Multiforme",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Brain and Central Nervous System Tumors"
    ],
    "interventions": [
      "interleukin-4 PE38KDEL cytotoxin",
      "conventional surgery"
    ],
    "primary_completion_date": "2002-09",
    "completion_date": "2008-07",
    "results_first_posted": null,
    "last_update_posted": "2013-07-18",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT01733121",
    "title": "NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Tardive Dyskinesia"
    ],
    "interventions": [
      "NBI-98854",
      "NBI-98854",
      "Placebo"
    ],
    "primary_completion_date": "2013-12",
    "completion_date": "2013-12",
    "results_first_posted": "2017-08-10",
    "last_update_posted": "2017-08-10",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT00873561",
    "title": "A Study to Evaluate NBI-6024 in Adult and Adolescent Patients With New Onset of Type 1 Diabetes Mellitus",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 1 Diabetes Mellitus"
    ],
    "interventions": [
      "NBI-6024"
    ],
    "primary_completion_date": "2006-04",
    "completion_date": "2006-07",
    "results_first_posted": null,
    "last_update_posted": "2009-04-01",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT01916993",
    "title": "Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild,Moderate, or Severe Hepatic Insufficiency",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects"
    ],
    "interventions": [
      "NBI-98854 50 mg capsule"
    ],
    "primary_completion_date": "2013-12",
    "completion_date": "2013-12",
    "results_first_posted": null,
    "last_update_posted": "2014-01-16",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT01393600",
    "title": "NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Tardive Dyskinesia"
    ],
    "interventions": [
      "NBI-98854",
      "NBI-98854",
      "Placebo"
    ],
    "primary_completion_date": "2012-02",
    "completion_date": "2012-02",
    "results_first_posted": "2017-08-10",
    "last_update_posted": "2017-08-10",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT06966401",
    "title": "Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder"
    ],
    "interventions": [
      "NBI-1065845"
    ],
    "primary_completion_date": "2029-05",
    "completion_date": "2030-05",
    "results_first_posted": null,
    "last_update_posted": "2025-08-01",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT06963034",
    "title": "NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia"
    ],
    "interventions": [
      "NBI-1117568",
      "Placebo"
    ],
    "primary_completion_date": "2027-10",
    "completion_date": "2027-10",
    "results_first_posted": null,
    "last_update_posted": "2025-12-15",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT04787965",
    "title": "Opicapone Treatment Initiation Open-Label Study",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Parkinson Disease"
    ],
    "interventions": [
      "Opicapone"
    ],
    "primary_completion_date": "2022-08-04",
    "completion_date": "2022-08-04",
    "results_first_posted": null,
    "last_update_posted": "2022-11-28",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT04880616",
    "title": "Safety, Efficacy, and Tolerability of NBI-827104 for the Treatment of Essential Tremor",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Essential Tremor"
    ],
    "interventions": [
      "NBI-827104",
      "Placebo"
    ],
    "primary_completion_date": "2022-05-25",
    "completion_date": "2022-06-08",
    "results_first_posted": null,
    "last_update_posted": "2022-07-12",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT03687684",
    "title": "Phase 1 Study of TAK-831 in Healthy Adult Asian Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "TAK-831",
      "Placebo"
    ],
    "primary_completion_date": "2019-06-09",
    "completion_date": "2019-06-19",
    "results_first_posted": "2020-06-29",
    "last_update_posted": "2021-06-14",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT02561156",
    "title": "TAK-653 Escalating Single and Multiple Dose Study in Healthy Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Depressive Disorder"
    ],
    "interventions": [
      "TAK-653 Placebo",
      "TAK-653"
    ],
    "primary_completion_date": "2017-09-11",
    "completion_date": "2017-09-23",
    "results_first_posted": "2019-02-08",
    "last_update_posted": "2021-03-03",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT02736955",
    "title": "Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Tardive Dyskinesia"
    ],
    "interventions": [
      "Valbenazine"
    ],
    "primary_completion_date": "2017-06-30",
    "completion_date": "2017-06-30",
    "results_first_posted": "2018-12-19",
    "last_update_posted": "2018-12-19",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT02581865",
    "title": "Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Tourette Syndrome"
    ],
    "interventions": [
      "NBI-98854",
      "Placebo"
    ],
    "primary_completion_date": "2016-12",
    "completion_date": "2016-12",
    "results_first_posted": "2020-05-07",
    "last_update_posted": "2020-05-07",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT05203341",
    "title": "Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder"
    ],
    "interventions": [
      "Placebo",
      "NBI-1065845"
    ],
    "primary_completion_date": "2024-01-10",
    "completion_date": "2024-02-21",
    "results_first_posted": null,
    "last_update_posted": "2025-01-15",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT06267846",
    "title": "A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder"
    ],
    "interventions": [
      "NBI-1070770",
      "Placebo"
    ],
    "primary_completion_date": "2025-07-25",
    "completion_date": "2025-09-11",
    "results_first_posted": null,
    "last_update_posted": "2025-10-29",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT03444038",
    "title": "Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Tourette Syndrome"
    ],
    "interventions": [
      "Valbenazine"
    ],
    "primary_completion_date": "2019-07-12",
    "completion_date": "2019-07-12",
    "results_first_posted": "2022-02-23",
    "last_update_posted": "2022-02-23",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT05301894",
    "title": "Extension Study to Evaluate NBI-827104 in Pediatric Participants With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Epileptic Encephalopathy",
      "Continuous Spike and Wave During Sleep"
    ],
    "interventions": [
      "NBI-827104"
    ],
    "primary_completion_date": "2025-01-27",
    "completion_date": "2025-01-27",
    "results_first_posted": null,
    "last_update_posted": "2025-02-28",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT03525886",
    "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adults With Congenital Adrenal Hyperplasia",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "CAH - Congenital Adrenal Hyperplasia"
    ],
    "interventions": [
      "NBI-74788"
    ],
    "primary_completion_date": "2020-04-07",
    "completion_date": "2020-04-07",
    "results_first_posted": "2022-05-03",
    "last_update_posted": "2022-05-03",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT03382639",
    "title": "A Study to Evaluate 3 Dose Levels of Luvadaxistat of Adults With Negative Symptoms of Schizophrenia",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia"
    ],
    "interventions": [
      "Luvadaxistat",
      "Placebo"
    ],
    "primary_completion_date": "2020-12-29",
    "completion_date": "2021-01-12",
    "results_first_posted": "2024-02-28",
    "last_update_posted": "2024-02-28",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT01688037",
    "title": "NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Tardive Dyskinesia"
    ],
    "interventions": [
      "NBI-98854",
      "NBI-98854",
      "Placebo"
    ],
    "primary_completion_date": "2013-09",
    "completion_date": "2013-10",
    "results_first_posted": "2017-11-08",
    "last_update_posted": "2017-11-08",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT07114874",
    "title": "NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia"
    ],
    "interventions": [
      "NBI-1117568"
    ],
    "primary_completion_date": "2031-12",
    "completion_date": "2031-12",
    "results_first_posted": null,
    "last_update_posted": "2025-10-22",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT03359785",
    "title": "A Study to Evaluate Multiple Oral Doses of Luvadaxistat in Adults With Schizophrenia",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia"
    ],
    "interventions": [
      "Luvadaxistat",
      "Matching Placebo"
    ],
    "primary_completion_date": "2020-12-21",
    "completion_date": "2020-12-21",
    "results_first_posted": "2024-02-28",
    "last_update_posted": "2024-02-28",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT02349503",
    "title": "Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia",
    "status": "WITHDRAWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Congenital Adrenal Hyperplasia"
    ],
    "interventions": [
      "NBI-77860",
      "NBI-77860",
      "NBI-77860"
    ],
    "primary_completion_date": "2015-10",
    "completion_date": "2015-10",
    "results_first_posted": null,
    "last_update_posted": "2015-06-11",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT00525941",
    "title": "An Exploratory Study of NBI-34060 Capsules and Next Day Functioning",
    "status": "WITHDRAWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Insomnia"
    ],
    "interventions": [
      "NBI-34060"
    ],
    "primary_completion_date": "2008-01",
    "completion_date": "2008-01",
    "results_first_posted": null,
    "last_update_posted": "2015-05-12",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT07196501",
    "title": "A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder"
    ],
    "interventions": [
      "NBI-1065845",
      "Placebo"
    ],
    "primary_completion_date": "2028-07",
    "completion_date": "2028-07",
    "results_first_posted": null,
    "last_update_posted": "2026-01-14",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT05165394",
    "title": "Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Anhedonia",
      "Major Depressive Disorder"
    ],
    "interventions": [
      "Placebo",
      "NBI-1065846"
    ],
    "primary_completion_date": "2023-07-07",
    "completion_date": "2023-09-13",
    "results_first_posted": "2024-07-31",
    "last_update_posted": "2024-07-31",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT03319953",
    "title": "A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Stable Schizophrenia"
    ],
    "interventions": [
      "TAK-041",
      "Placebo",
      "Second Generation Antipsychotics (SGA)"
    ],
    "primary_completion_date": "2019-09-11",
    "completion_date": "2019-11-06",
    "results_first_posted": "2021-02-09",
    "last_update_posted": "2021-03-19",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT07365462",
    "title": "Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Tardive Dyskinesia"
    ],
    "interventions": [
      "NBI-1065890",
      "Placebo"
    ],
    "primary_completion_date": "2027-02",
    "completion_date": "2027-03",
    "results_first_posted": null,
    "last_update_posted": "2026-01-26",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT03891862",
    "title": "Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Tardive Dyskinesia (TD)"
    ],
    "interventions": [
      "Valbenazine",
      "Placebo oral capsule"
    ],
    "primary_completion_date": "2019-12-23",
    "completion_date": "2020-01-30",
    "results_first_posted": "2021-03-10",
    "last_update_posted": "2021-04-20",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT02879578",
    "title": "Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Tourette Syndrome"
    ],
    "interventions": [
      "Valbenazine"
    ],
    "primary_completion_date": "2017-11-01",
    "completion_date": "2017-11-01",
    "results_first_posted": "2021-04-29",
    "last_update_posted": "2021-04-29",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT03530293",
    "title": "Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Tourette Syndrome"
    ],
    "interventions": [
      "Valbenazine",
      "Placebo oral capsule"
    ],
    "primary_completion_date": "2019-07-16",
    "completion_date": "2019-07-16",
    "results_first_posted": "2022-05-17",
    "last_update_posted": "2022-05-17",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT03214588",
    "title": "Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Friedreich Ataxia"
    ],
    "interventions": [
      "TAK-831",
      "TAK-831 Placebo"
    ],
    "primary_completion_date": "2018-12-27",
    "completion_date": "2018-12-27",
    "results_first_posted": "2019-12-19",
    "last_update_posted": "2021-06-14",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT03732534",
    "title": "Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Tourette Syndrome"
    ],
    "interventions": [
      "NBI-98854"
    ],
    "primary_completion_date": "2019-02-18",
    "completion_date": "2019-02-18",
    "results_first_posted": "2022-04-19",
    "last_update_posted": "2022-04-19",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT04234672",
    "title": "A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]TAK-831 in Male Healthy Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "TAK-831 Oral Tablet",
      "[14C]TAK-831 IV Infusion",
      "[14C]TAK-831 Oral Suspension"
    ],
    "primary_completion_date": "2020-04-04",
    "completion_date": "2020-04-04",
    "results_first_posted": "2021-04-28",
    "last_update_posted": "2021-06-30",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT00039052",
    "title": "Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Cancer",
      "Kidney Cancer",
      "Lung Cancer"
    ],
    "interventions": [
      "interleukin-4 PE38KDEL cytotoxin"
    ],
    "primary_completion_date": "2003-05",
    "completion_date": "2008-07",
    "results_first_posted": null,
    "last_update_posted": "2013-07-18",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT07105111",
    "title": "A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor",
    "status": "RECRUITING",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia",
      "Schizoaffective Disorder",
      "Bipolar Disorder",
      "Major Depressive Disorder",
      "Tardive Dyskinesia"
    ],
    "interventions": [
      "Valbenazine"
    ],
    "primary_completion_date": "2027-04",
    "completion_date": "2027-04",
    "results_first_posted": null,
    "last_update_posted": "2025-10-22",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT03325010",
    "title": "Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Tourette Syndrome"
    ],
    "interventions": [
      "Valbenazine",
      "Placebo oral capsule"
    ],
    "primary_completion_date": "2018-11-01",
    "completion_date": "2018-11-16",
    "results_first_posted": "2021-06-28",
    "last_update_posted": "2021-06-28",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT02405091",
    "title": "Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Tardive Dyskinesia"
    ],
    "interventions": [
      "NBI-98854"
    ],
    "primary_completion_date": "2017-03",
    "completion_date": "2017-03",
    "results_first_posted": "2018-11-30",
    "last_update_posted": "2018-11-30",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT02566759",
    "title": "A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia, Cerebellar Ataxia"
    ],
    "interventions": [
      "TAK-831 Oral Suspension",
      "TAK-831 Placebo",
      "TAK-831 Tablet"
    ],
    "primary_completion_date": "2016-06-09",
    "completion_date": "2016-07-12",
    "results_first_posted": "2018-02-06",
    "last_update_posted": "2021-06-14",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT04806451",
    "title": "Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Congenital Adrenal Hyperplasia"
    ],
    "interventions": [
      "Crinecerfont",
      "Placebo"
    ],
    "primary_completion_date": "2023-03-10",
    "completion_date": "2027-08",
    "results_first_posted": "2025-02-05",
    "last_update_posted": "2025-02-05",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT03698331",
    "title": "The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Tardive Dyskinesia (TD)"
    ],
    "interventions": [
      "Valbenazine",
      "Placebo oral capsule"
    ],
    "primary_completion_date": "2019-04-03",
    "completion_date": "2019-04-03",
    "results_first_posted": "2020-06-04",
    "last_update_posted": "2020-06-04",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT06911112",
    "title": "NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder"
    ],
    "interventions": [
      "NBI-1065845",
      "Placebo"
    ],
    "primary_completion_date": "2027-07",
    "completion_date": "2027-07",
    "results_first_posted": null,
    "last_update_posted": "2025-12-01",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT02274558",
    "title": "A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Tardive Dyskinesia"
    ],
    "interventions": [
      "NBI-98854",
      "Placebo"
    ],
    "primary_completion_date": "2015-09",
    "completion_date": "2016-07",
    "results_first_posted": "2017-07-11",
    "last_update_posted": "2017-07-11",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT01973543",
    "title": "Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's Disease",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Parkinson's Disease"
    ],
    "interventions": [
      "VY-AADC01"
    ],
    "primary_completion_date": "2020-01-24",
    "completion_date": "2020-01-24",
    "results_first_posted": null,
    "last_update_posted": "2020-03-03",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT06312189",
    "title": "Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chorea, Huntington"
    ],
    "interventions": [
      "Valbenazine"
    ],
    "primary_completion_date": "2026-04",
    "completion_date": "2026-04",
    "results_first_posted": null,
    "last_update_posted": "2024-05-16",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT05110157",
    "title": "Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia"
    ],
    "interventions": [
      "Placebo",
      "Valbenazine"
    ],
    "primary_completion_date": "2025-02-04",
    "completion_date": "2025-02-18",
    "results_first_posted": null,
    "last_update_posted": "2025-07-10",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT04400331",
    "title": "Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chorea, Huntington"
    ],
    "interventions": [
      "Valbenazine"
    ],
    "primary_completion_date": "2026-03",
    "completion_date": "2026-03",
    "results_first_posted": null,
    "last_update_posted": "2024-12-24",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT02679079",
    "title": "Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Tourette Syndrome"
    ],
    "interventions": [
      "NBI-98854",
      "Placebo"
    ],
    "primary_completion_date": "2017-04-14",
    "completion_date": "2017-04-14",
    "results_first_posted": "2021-01-15",
    "last_update_posted": "2021-01-15",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT02256475",
    "title": "Safety, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Tourette Syndrome"
    ],
    "interventions": [
      "NBI-98854"
    ],
    "primary_completion_date": "2015-11",
    "completion_date": "2015-12",
    "results_first_posted": null,
    "last_update_posted": "2016-01-07",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT03562494",
    "title": "VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Parkinson's Disease"
    ],
    "interventions": [
      "VY-AADC02",
      "Sham (Placebo) Surgery"
    ],
    "primary_completion_date": "2024-10-30",
    "completion_date": "2024-10-30",
    "results_first_posted": null,
    "last_update_posted": "2024-12-10",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT03101293",
    "title": "A Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 Tablet Formulation",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "TAK-831"
    ],
    "primary_completion_date": "2017-05-19",
    "completion_date": "2017-05-26",
    "results_first_posted": "2019-03-18",
    "last_update_posted": "2021-06-14",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT04102579",
    "title": "Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chorea, Huntington"
    ],
    "interventions": [
      "Valbenazine",
      "Placebo"
    ],
    "primary_completion_date": "2021-10-15",
    "completion_date": "2021-10-26",
    "results_first_posted": "2023-10-11",
    "last_update_posted": "2023-10-11",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT03496870",
    "title": "A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Parkinson Disease"
    ],
    "interventions": [
      "Opicapone",
      "Carbidopa Levodopa"
    ],
    "primary_completion_date": "2018-07-02",
    "completion_date": "2018-07-02",
    "results_first_posted": null,
    "last_update_posted": "2019-03-22",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT07288320",
    "title": "An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bipolar I Disorder",
      "Mania"
    ],
    "interventions": [
      "NBI-1117568",
      "Placebo"
    ],
    "primary_completion_date": "2028-02",
    "completion_date": "2028-02",
    "results_first_posted": null,
    "last_update_posted": "2025-12-17",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT06786624",
    "title": "Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder"
    ],
    "interventions": [
      "NBI-1065845",
      "Placebo"
    ],
    "primary_completion_date": "2027-07",
    "completion_date": "2027-07",
    "results_first_posted": null,
    "last_update_posted": "2025-10-29",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT05545111",
    "title": "Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia"
    ],
    "interventions": [
      "NBI-1117568",
      "Placebo"
    ],
    "primary_completion_date": "2024-07-10",
    "completion_date": "2024-07-10",
    "results_first_posted": null,
    "last_update_posted": "2025-07-11",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT00232167",
    "title": "Study Of Indiplon/Placebo With Sertraline In Insomnia Co-Existing With Depression",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Insomnia",
      "Depression"
    ],
    "interventions": [
      "Indiplon",
      "Sertraline"
    ],
    "primary_completion_date": null,
    "completion_date": "2006-04",
    "results_first_posted": null,
    "last_update_posted": "2007-10-02",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT07187375",
    "title": "Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Congenital Adrenal Hyperplasia"
    ],
    "interventions": [
      "Crinecerfont"
    ],
    "primary_completion_date": "2029-09-06",
    "completion_date": "2029-10-04",
    "results_first_posted": null,
    "last_update_posted": "2025-11-03",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT01910480",
    "title": "Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of NBI-98854 in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Effect of Ketoconazole on the PK of NBI-98854 in Healthy Subjects"
    ],
    "interventions": [
      "NBI-98854 50 mg capsule once daily",
      "Ketoconazole 400 mg (200 mg twice daily)"
    ],
    "primary_completion_date": "2013-08",
    "completion_date": "2013-08",
    "results_first_posted": null,
    "last_update_posted": "2013-09-05",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT04045145",
    "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Participants With Congenital Adrenal Hyperplasia",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "CAH - Congenital Adrenal Hyperplasia"
    ],
    "interventions": [
      "Crinecerfont"
    ],
    "primary_completion_date": "2021-07-02",
    "completion_date": "2021-07-02",
    "results_first_posted": "2024-07-18",
    "last_update_posted": "2024-07-18",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT01267188",
    "title": "Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Tardive Dyskinesia"
    ],
    "interventions": [
      "NBI-98854"
    ],
    "primary_completion_date": "2011-03",
    "completion_date": "2011-03",
    "results_first_posted": null,
    "last_update_posted": "2011-04-20",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT07288333",
    "title": "Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia"
    ],
    "interventions": [
      "NBI-1117570",
      "Placebo"
    ],
    "primary_completion_date": "2027-08",
    "completion_date": "2027-08",
    "results_first_posted": null,
    "last_update_posted": "2025-12-17",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT02748694",
    "title": "Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers",
      "Schizophrenia"
    ],
    "interventions": [
      "TAK-041",
      "TAK-041 Placebo"
    ],
    "primary_completion_date": "2019-09-22",
    "completion_date": "2019-09-22",
    "results_first_posted": "2021-03-01",
    "last_update_posted": "2021-03-19",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT05654870",
    "title": "Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia"
    ],
    "interventions": [
      "Valbenazine",
      "Placebo"
    ],
    "primary_completion_date": "2023-11-08",
    "completion_date": "2023-11-08",
    "results_first_posted": null,
    "last_update_posted": "2024-11-12",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT05182476",
    "title": "Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia"
    ],
    "interventions": [
      "Placebo",
      "Luvadaxistat"
    ],
    "primary_completion_date": "2024-06-28",
    "completion_date": "2024-10-14",
    "results_first_posted": null,
    "last_update_posted": "2025-07-02",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT03733496",
    "title": "Observational, Long-term Extension Study for Participants of Prior VY-AADC01 Studies",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Parkinson's Disease"
    ],
    "interventions": [],
    "primary_completion_date": "2023-07-18",
    "completion_date": "2023-07-18",
    "results_first_posted": null,
    "last_update_posted": "2023-12-22",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT04490915",
    "title": "Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Congenital Adrenal Hyperplasia"
    ],
    "interventions": [
      "Crinecerfont",
      "Placebo"
    ],
    "primary_completion_date": "2023-07-19",
    "completion_date": "2027-08",
    "results_first_posted": "2025-02-05",
    "last_update_posted": "2025-02-05",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT03792672",
    "title": "A Study to Evaluate Central Nervous System (CNS) Pharmacodynamic Activity of TAK-653 in Healthy Participants Using Transcranial Magnetic Stimulation (TMS)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "TAK-653",
      "Placebo",
      "Ketamine"
    ],
    "primary_completion_date": "2019-05-15",
    "completion_date": "2019-06-18",
    "results_first_posted": "2020-07-02",
    "last_update_posted": "2021-03-19",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT06963021",
    "title": "NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder"
    ],
    "interventions": [
      "NBI-1065845",
      "Placebo"
    ],
    "primary_completion_date": "2027-07",
    "completion_date": "2027-07",
    "results_first_posted": null,
    "last_update_posted": "2025-12-22",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NBIX",
    "nct_id": "NCT04625101",
    "title": "Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Epileptic Encephalopathy",
      "Continuous Spike and Wave During Sleep"
    ],
    "interventions": [
      "NBI-827104",
      "Placebo"
    ],
    "primary_completion_date": "2022-08-08",
    "completion_date": "2022-10-11",
    "results_first_posted": "2025-09-05",
    "last_update_posted": "2025-09-05",
    "enrollment": null,
    "sponsor": "Neurocrine Biosciences",
    "collected_at": "2026-01-27",
    "search_term": "Neurocrine Biosciences"
  },
  {
    "ticker": "NGNE",
    "nct_id": "NCT04659629",
    "title": "NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor",
      "Advanced Solid Tumor"
    ],
    "interventions": [
      "NL-201",
      "Pembrolizumab Injection [Keytruda]"
    ],
    "primary_completion_date": "2022-12-15",
    "completion_date": "2024-08-15",
    "results_first_posted": null,
    "last_update_posted": "2024-10-01",
    "enrollment": null,
    "sponsor": "Neurogene Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Neurogene"
  },
  {
    "ticker": "NGNE",
    "nct_id": "NCT03853876",
    "title": "A Natural History Study of Aspartylglucosaminuria",
    "status": "TERMINATED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Aspartylglucosaminuria",
      "Aspartylglucosamidase (AGA) Deficiency",
      "Lysosomal Storage Diseases"
    ],
    "interventions": [],
    "primary_completion_date": "2020-10-15",
    "completion_date": "2022-03-17",
    "results_first_posted": null,
    "last_update_posted": "2022-04-12",
    "enrollment": null,
    "sponsor": "Neurogene Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Neurogene"
  },
  {
    "ticker": "NGNE",
    "nct_id": "NCT03822650",
    "title": "A Natural History Study of Neuronal Ceroid Lipofuscinosis Type 5 (CLN5)",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Ceroid Lipofuscinosis, Neuronal 5"
    ],
    "interventions": [],
    "primary_completion_date": "2024-05-30",
    "completion_date": "2024-05-30",
    "results_first_posted": null,
    "last_update_posted": "2024-06-27",
    "enrollment": null,
    "sponsor": "Neurogene Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Neurogene"
  },
  {
    "ticker": "NGNE",
    "nct_id": "NCT05898620",
    "title": "A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rett Syndrome"
    ],
    "interventions": [
      "NGN-401"
    ],
    "primary_completion_date": "2029-12",
    "completion_date": "2029-12",
    "results_first_posted": null,
    "last_update_posted": "2026-01-13",
    "enrollment": null,
    "sponsor": "Neurogene Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Neurogene"
  },
  {
    "ticker": "NRIX",
    "nct_id": "NCT06593457",
    "title": "A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in Healthy Adult Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "IP",
      "Matching Placebo"
    ],
    "primary_completion_date": "2024-10-29",
    "completion_date": "2024-11-14",
    "results_first_posted": null,
    "last_update_posted": "2025-03-14",
    "enrollment": null,
    "sponsor": "Nurix Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Nurix Therapeutics"
  },
  {
    "ticker": "NRIX",
    "nct_id": "NCT06717269",
    "title": "Relative Bioavailability of NX-5948 Tablets vs Capsules and the Effect of Covariates on the PK of NX-5948 Tablets",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteer"
    ],
    "interventions": [
      "NX-5948",
      "Esomeprazole"
    ],
    "primary_completion_date": "2025-11-30",
    "completion_date": "2025-12-31",
    "results_first_posted": null,
    "last_update_posted": "2025-12-02",
    "enrollment": null,
    "sponsor": "Nurix Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Nurix Therapeutics"
  },
  {
    "ticker": "NRIX",
    "nct_id": "NCT07221500",
    "title": "A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Lymphocytic Leukemia (CLL)",
      "Small Lymphocytic Lymphoma (SLL)"
    ],
    "interventions": [
      "NX-5948"
    ],
    "primary_completion_date": "2028-01",
    "completion_date": "2030-10",
    "results_first_posted": null,
    "last_update_posted": "2025-12-17",
    "enrollment": null,
    "sponsor": "Nurix Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Nurix Therapeutics"
  },
  {
    "ticker": "NRIX",
    "nct_id": "NCT06691828",
    "title": "Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance Study of [14C] NX-5948",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteer"
    ],
    "interventions": [
      "NX-5948"
    ],
    "primary_completion_date": "2024-11-28",
    "completion_date": "2024-12-05",
    "results_first_posted": null,
    "last_update_posted": "2025-03-12",
    "enrollment": null,
    "sponsor": "Nurix Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Nurix Therapeutics"
  },
  {
    "ticker": "NRIX",
    "nct_id": "NCT05131022",
    "title": "A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Lymphocytic Leukemia (CLL)",
      "Small Lymphocytic Lymphoma (SLL)",
      "Diffuse Large B Cell Lymphoma (DLBCL)",
      "Follicular Lymphoma (FL)",
      "Mantle Cell Lymphoma (MCL)",
      "Marginal Zone Lymphoma (MZL)",
      "Waldenstrom Macroglobulinemia (WM)",
      "Primary Central Nervous System Lymphoma (PCNSL)",
      "Secondary Central Nervous System Lymphoma (SCNSL)"
    ],
    "interventions": [
      "NX-5948"
    ],
    "primary_completion_date": "2027-01",
    "completion_date": "2028-01",
    "results_first_posted": null,
    "last_update_posted": "2025-12-09",
    "enrollment": null,
    "sponsor": "Nurix Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Nurix Therapeutics"
  },
  {
    "ticker": "NRIX",
    "nct_id": "NCT05107739",
    "title": "A Study of DeTIL-0255 in Adults With Advanced Malignancies",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Platinum-resistant Ovarian Cancer",
      "Endometrial Cancer",
      "Cervical Cancer"
    ],
    "interventions": [
      "Drug Product De-TIL-0255"
    ],
    "primary_completion_date": "2023-05-09",
    "completion_date": "2023-05-09",
    "results_first_posted": null,
    "last_update_posted": "2024-05-03",
    "enrollment": null,
    "sponsor": "Nurix Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Nurix Therapeutics"
  },
  {
    "ticker": "NUVL",
    "nct_id": "NCT05384626",
    "title": "A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Locally Advanced Solid Tumor",
      "Metastatic Solid Tumor"
    ],
    "interventions": [
      "Neladalkib (NVL-655)"
    ],
    "primary_completion_date": "2027-12",
    "completion_date": "2028-01",
    "results_first_posted": null,
    "last_update_posted": "2025-10-30",
    "enrollment": null,
    "sponsor": "Nuvalent Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Nuvalent"
  },
  {
    "ticker": "NUVL",
    "nct_id": "NCT06834074",
    "title": "Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors",
    "status": "AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Non Small Cell Lung Cancer",
      "ALK-positive Non-small Cell Lung Cancer (NSCLC)"
    ],
    "interventions": [
      "NVL-655"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2026-01-23",
    "enrollment": null,
    "sponsor": "Nuvalent Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Nuvalent"
  },
  {
    "ticker": "NUVL",
    "nct_id": "NCT06797362",
    "title": "Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors",
    "status": "AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Non Small Cell Lung Cancer",
      "ROS1-positive Non-Small Cell Lung Cancer (NSCLC)"
    ],
    "interventions": [
      "NVL-520"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2026-01-15",
    "enrollment": null,
    "sponsor": "Nuvalent Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Nuvalent"
  },
  {
    "ticker": "NUVL",
    "nct_id": "NCT05118789",
    "title": "A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Locally Advanced Solid Tumor",
      "Metastatic Solid Tumor"
    ],
    "interventions": [
      "Zidesamtinib (NVL-520)"
    ],
    "primary_completion_date": "2027-12-31",
    "completion_date": "2028-12-31",
    "results_first_posted": null,
    "last_update_posted": "2025-10-24",
    "enrollment": null,
    "sponsor": "Nuvalent Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Nuvalent"
  },
  {
    "ticker": "NUVL",
    "nct_id": "NCT06765109",
    "title": "Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-small Cell Lung Cancer",
      "Anaplastic Lymphoma Kinase-positive"
    ],
    "interventions": [
      "Neladalkib (NVL-655)",
      "Alectinib"
    ],
    "primary_completion_date": "2029-12",
    "completion_date": "2029-12",
    "results_first_posted": null,
    "last_update_posted": "2026-01-12",
    "enrollment": null,
    "sponsor": "Nuvalent Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Nuvalent"
  },
  {
    "ticker": "NUVL",
    "nct_id": "NCT06521554",
    "title": "A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Locally Advanced Solid Tumor",
      "Metastatic Solid Tumor"
    ],
    "interventions": [
      "NVL-330"
    ],
    "primary_completion_date": "2026-03",
    "completion_date": "2026-03",
    "results_first_posted": null,
    "last_update_posted": "2025-09-16",
    "enrollment": null,
    "sponsor": "Nuvalent Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Nuvalent"
  },
  {
    "ticker": "NVCR",
    "nct_id": "NCT04892472",
    "title": "EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-small Cell Lung Cancer"
    ],
    "interventions": [
      "NovoTTF-200T",
      "Pembrolizumab (MK-3475) 200 mg"
    ],
    "primary_completion_date": "2025-01-10",
    "completion_date": "2025-01-10",
    "results_first_posted": null,
    "last_update_posted": "2025-04-23",
    "enrollment": null,
    "sponsor": "NovoCure GmbH",
    "collected_at": "2026-01-27",
    "search_term": "NovoCure"
  },
  {
    "ticker": "NVCR",
    "nct_id": "NCT01971281",
    "title": "Safety Feasibility and Effect of TTFields (150 kHz) Concomitant With Gemcitabine or Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma (PANOVA)",
    "status": "UNKNOWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pancreatic Adenocarcinoma"
    ],
    "interventions": [
      "NovoTTF-100L",
      "Gemcitabine",
      "nab-Paclitaxel"
    ],
    "primary_completion_date": "2017-12",
    "completion_date": "2017-12",
    "results_first_posted": null,
    "last_update_posted": "2017-09-13",
    "enrollment": null,
    "sponsor": "NovoCure Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "NovoCure"
  },
  {
    "ticker": "NVCR",
    "nct_id": "NCT01755624",
    "title": "Effect of TTFields (150kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-5 Brain Metastases Following Optimal Standard Local Treatment (COMET)",
    "status": "UNKNOWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "1-5 Brain Metastases From Non-Small Cell Lung Cancer"
    ],
    "interventions": [
      "NovoTTF-100A device",
      "Best Standard of Care"
    ],
    "primary_completion_date": "2017-07",
    "completion_date": "2017-07",
    "results_first_posted": null,
    "last_update_posted": "2016-09-21",
    "enrollment": null,
    "sponsor": "NovoCure Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "NovoCure"
  },
  {
    "ticker": "NVCR",
    "nct_id": "NCT07319910",
    "title": "Continued Access Program for Tumor Treating Fields (TTFields) Used With Chemotherapy (Gemcitabine and Nab-Paclitaxel) in Adults With Locally Advanced Pancreatic Cancer (PANOVA-3CA)",
    "status": "TEMPORARILY_NOT_AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Locally Advanced Pancreatic Adenocarcinoma"
    ],
    "interventions": [
      "TTFields",
      "Gemcitabine",
      "Nab paclitaxel"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2026-01-06",
    "enrollment": null,
    "sponsor": "NovoCure GmbH",
    "collected_at": "2026-01-27",
    "search_term": "NovoCure"
  },
  {
    "ticker": "NVCR",
    "nct_id": "NCT00916409",
    "title": "Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Glioblastoma Multiforme"
    ],
    "interventions": [
      "NovoTTF-100A device",
      "Temozolomide"
    ],
    "primary_completion_date": "2016-12",
    "completion_date": "2017-03",
    "results_first_posted": null,
    "last_update_posted": "2017-04-10",
    "enrollment": null,
    "sponsor": "NovoCure Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "NovoCure"
  },
  {
    "ticker": "NVCR",
    "nct_id": "NCT02397928",
    "title": "Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Malignant Pleural Mesothelioma"
    ],
    "interventions": [
      "NovoTTF-100L device",
      "Pemetrexed",
      "Cisplatin or Carboplatin"
    ],
    "primary_completion_date": "2018-04",
    "completion_date": "2018-04",
    "results_first_posted": null,
    "last_update_posted": "2018-09-25",
    "enrollment": null,
    "sponsor": "NovoCure Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "NovoCure"
  },
  {
    "ticker": "NVCR",
    "nct_id": "NCT04281576",
    "title": "Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Gastric Cancer",
      "GastroEsophageal Cancer"
    ],
    "interventions": [
      "NovoTTF-100L(P)",
      "Oxaliplatin",
      "Capecitabine",
      "Trastuzumab"
    ],
    "primary_completion_date": "2024-06-07",
    "completion_date": "2024-06-07",
    "results_first_posted": null,
    "last_update_posted": "2024-11-14",
    "enrollment": null,
    "sponsor": "NovoCure Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "NovoCure"
  },
  {
    "ticker": "NVCR",
    "nct_id": "NCT06558799",
    "title": "LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-Small Cell Lung Cancer (NSCLC)"
    ],
    "interventions": [
      "NovoTTF-200T",
      "Pembrolizumab"
    ],
    "primary_completion_date": "2026-01-31",
    "completion_date": "2026-01-31",
    "results_first_posted": null,
    "last_update_posted": "2025-10-28",
    "enrollment": null,
    "sponsor": "NovoCure GmbH",
    "collected_at": "2026-01-27",
    "search_term": "NovoCure"
  },
  {
    "ticker": "NVCR",
    "nct_id": "NCT03606590",
    "title": "Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatocellular Carcinoma"
    ],
    "interventions": [
      "NovoTTF-100L(P) device",
      "Sorafenib"
    ],
    "primary_completion_date": "2021-01-14",
    "completion_date": "2021-01-14",
    "results_first_posted": null,
    "last_update_posted": "2024-11-14",
    "enrollment": null,
    "sponsor": "NovoCure Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "NovoCure"
  },
  {
    "ticker": "NVCR",
    "nct_id": "NCT02831959",
    "title": "Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Brain Metastases From Non-small Cell Lung Cancer (NSCLC)"
    ],
    "interventions": [
      "NovoTTF-200M device",
      "Best Standard of Care"
    ],
    "primary_completion_date": "2024-11-29",
    "completion_date": "2024-11-29",
    "results_first_posted": null,
    "last_update_posted": "2025-10-31",
    "enrollment": null,
    "sponsor": "NovoCure GmbH",
    "collected_at": "2026-01-27",
    "search_term": "NovoCure"
  },
  {
    "ticker": "NVCR",
    "nct_id": "NCT01756729",
    "title": "Post-approval Study of NovoTTF-100A in Recurrent GBM Patients",
    "status": "TERMINATED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Recurrent Glioblastoma Multiforme"
    ],
    "interventions": [
      "NovoTTF-100A"
    ],
    "primary_completion_date": "2018-01",
    "completion_date": "2018-01",
    "results_first_posted": null,
    "last_update_posted": "2016-03-02",
    "enrollment": null,
    "sponsor": "NovoCure Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "NovoCure"
  },
  {
    "ticker": "NVCR",
    "nct_id": "NCT06390059",
    "title": "EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Pancreatic Ductal Adenocarcinoma"
    ],
    "interventions": [
      "Tumor Treating Fields",
      "Atezolizumab",
      "Gemcitabine",
      "nab-paclitaxel"
    ],
    "primary_completion_date": "2025-11-27",
    "completion_date": "2025-11-27",
    "results_first_posted": null,
    "last_update_posted": "2025-04-30",
    "enrollment": null,
    "sponsor": "NovoCure Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "NovoCure"
  },
  {
    "ticker": "NVCR",
    "nct_id": "NCT06556563",
    "title": "EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Glioblastoma"
    ],
    "interventions": [
      "Optune\u00ae device",
      "Temozolomide",
      "Pembrolizumab",
      "Placebo"
    ],
    "primary_completion_date": "2029-04",
    "completion_date": "2029-04",
    "results_first_posted": null,
    "last_update_posted": "2026-01-21",
    "enrollment": null,
    "sponsor": "NovoCure GmbH",
    "collected_at": "2026-01-27",
    "search_term": "NovoCure"
  },
  {
    "ticker": "NVCR",
    "nct_id": "NCT06924099",
    "title": "TTFields General Routine Clinical Care in ndGBM Patients: a French Prospective Non-Interventional Study (TIGER France)",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Glioblastoma"
    ],
    "interventions": [],
    "primary_completion_date": "2029-01-31",
    "completion_date": "2029-01-31",
    "results_first_posted": null,
    "last_update_posted": "2025-04-11",
    "enrollment": null,
    "sponsor": "NovoCure Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "NovoCure"
  },
  {
    "ticker": "NVCR",
    "nct_id": "NCT06216301",
    "title": "LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Non-small Cell Lung Cancer"
    ],
    "interventions": [
      "NovoTTF-200T",
      "Pembrolizumab",
      "Platinum based chemotherapy"
    ],
    "primary_completion_date": "2028-10",
    "completion_date": "2028-10",
    "results_first_posted": null,
    "last_update_posted": "2025-12-17",
    "enrollment": null,
    "sponsor": "NovoCure GmbH",
    "collected_at": "2026-01-27",
    "search_term": "NovoCure"
  },
  {
    "ticker": "NVCR",
    "nct_id": "NCT03258021",
    "title": "TTFields In GErmany in Routine Clinical Care",
    "status": "UNKNOWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Glioblastoma"
    ],
    "interventions": [
      "TTFields"
    ],
    "primary_completion_date": "2021-06",
    "completion_date": "2021-07",
    "results_first_posted": null,
    "last_update_posted": "2021-01-28",
    "enrollment": null,
    "sponsor": "NovoCure Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "NovoCure"
  },
  {
    "ticker": "NVCR",
    "nct_id": "NCT04492163",
    "title": "Open-Label Pilot Study of OPTUNE\u00ae With High Density Transducer Arrays for the Treatment of Recurrent GBM",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Glioblastoma Multiforme"
    ],
    "interventions": [
      "TTFields"
    ],
    "primary_completion_date": "2023-06-20",
    "completion_date": "2023-06-20",
    "results_first_posted": null,
    "last_update_posted": "2024-08-16",
    "enrollment": null,
    "sponsor": "NovoCure GmbH",
    "collected_at": "2026-01-27",
    "search_term": "NovoCure"
  },
  {
    "ticker": "NVCR",
    "nct_id": "NCT00379470",
    "title": "Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Recurrent Glioblastoma Multiforme"
    ],
    "interventions": [
      "NovoTTF-100A"
    ],
    "primary_completion_date": "2009-11",
    "completion_date": "2011-01",
    "results_first_posted": null,
    "last_update_posted": "2012-05-01",
    "enrollment": null,
    "sponsor": "NovoCure Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "NovoCure"
  },
  {
    "ticker": "NVCR",
    "nct_id": "NCT03780569",
    "title": "TTFields Together With Temozolomide and Radiotherapy in Patients With Newly Diagnosed GBM",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Glioblastoma Multiforme"
    ],
    "interventions": [
      "NovoTTF-200A",
      "Radiotherapy",
      "Temozolomide"
    ],
    "primary_completion_date": "2019-01",
    "completion_date": "2019-01",
    "results_first_posted": null,
    "last_update_posted": "2018-12-20",
    "enrollment": null,
    "sponsor": "NovoCure Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "NovoCure"
  },
  {
    "ticker": "NVCR",
    "nct_id": "NCT03940196",
    "title": "Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ovarian Cancer"
    ],
    "interventions": [
      "NovoTTF-100L(O)",
      "Paclitaxel"
    ],
    "primary_completion_date": "2023-05-18",
    "completion_date": "2023-05-18",
    "results_first_posted": null,
    "last_update_posted": "2024-03-29",
    "enrollment": null,
    "sponsor": "NovoCure Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "NovoCure"
  },
  {
    "ticker": "OCGN",
    "nct_id": "NCT05956626",
    "title": "A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Stargardt Disease"
    ],
    "interventions": [
      "OCU410ST"
    ],
    "primary_completion_date": "2026-09-28",
    "completion_date": "2026-09-28",
    "results_first_posted": null,
    "last_update_posted": "2025-10-16",
    "enrollment": null,
    "sponsor": "Ocugen",
    "collected_at": "2026-01-27",
    "search_term": "Ocugen"
  },
  {
    "ticker": "OCGN",
    "nct_id": "NCT03418727",
    "title": "Dry Eye Disease Study With Brimonidine",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dry Eye"
    ],
    "interventions": [
      "Brimonidine",
      "Brimonidine Mono Therapy",
      "sodium carboxymethylcellulose",
      "Corticosteroid Eye Drop"
    ],
    "primary_completion_date": "2018-03-29",
    "completion_date": "2018-03-29",
    "results_first_posted": "2022-07-06",
    "last_update_posted": "2022-07-06",
    "enrollment": null,
    "sponsor": "Ocugen",
    "collected_at": "2026-01-27",
    "search_term": "Ocugen"
  },
  {
    "ticker": "OCGN",
    "nct_id": "NCT06018558",
    "title": "Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Geographic Atrophy"
    ],
    "interventions": [
      "OCU410"
    ],
    "primary_completion_date": "2026-02-17",
    "completion_date": "2026-05-29",
    "results_first_posted": null,
    "last_update_posted": "2025-12-05",
    "enrollment": null,
    "sponsor": "Ocugen",
    "collected_at": "2026-01-27",
    "search_term": "Ocugen"
  },
  {
    "ticker": "OCGN",
    "nct_id": "NCT05541289",
    "title": "Expanded Access Program of Whole, Inactivated COVID-19 Vaccine COVAXIN\u2122 (BBV152) in Adults Aged 18 Years and Older",
    "status": "NO_LONGER_AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "COVID-19"
    ],
    "interventions": [
      "BBV152"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2022-09-22",
    "enrollment": null,
    "sponsor": "Ocugen",
    "collected_at": "2026-01-27",
    "search_term": "Ocugen"
  },
  {
    "ticker": "OCGN",
    "nct_id": "NCT03785340",
    "title": "Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dry Eye"
    ],
    "interventions": [
      "Brimonidine Tartrate",
      "Placebos"
    ],
    "primary_completion_date": "2019-02-25",
    "completion_date": "2019-02-25",
    "results_first_posted": "2022-06-06",
    "last_update_posted": "2022-07-18",
    "enrollment": null,
    "sponsor": "Ocugen",
    "collected_at": "2026-01-27",
    "search_term": "Ocugen"
  },
  {
    "ticker": "OCGN",
    "nct_id": "NCT03591874",
    "title": "Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Graft Versus Host Disease",
      "Ocular Surface Disease",
      "oGVHD",
      "Ocular Graft vs Host Disease",
      "Brimonidine Tartrate",
      "Lubricant Eye Drops",
      "Ophthalmic Solutions",
      "Graft vs Host Disease"
    ],
    "interventions": [
      "Brimonidine Tartrate",
      "Placebos"
    ],
    "primary_completion_date": "2020-04-30",
    "completion_date": "2020-04-30",
    "results_first_posted": "2022-07-06",
    "last_update_posted": "2022-07-06",
    "enrollment": null,
    "sponsor": "Ocugen",
    "collected_at": "2026-01-27",
    "search_term": "Ocugen"
  },
  {
    "ticker": "PCRX",
    "nct_id": "NCT03955458",
    "title": "EXPAREL Facia Iliaca Compartment Block for Intertrochanteric Hip Fracture",
    "status": "WITHDRAWN",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hip Fractures",
      "Intertrochanteric Fractures"
    ],
    "interventions": [
      "EXPAREL",
      "Ropivacaine",
      "Bupivacaine Hydrochloride"
    ],
    "primary_completion_date": "2020-05",
    "completion_date": "2020-05",
    "results_first_posted": null,
    "last_update_posted": "2020-02-27",
    "enrollment": null,
    "sponsor": "Pacira Pharmaceuticals, Inc",
    "collected_at": "2026-01-27",
    "search_term": "Pacira BioSciences"
  },
  {
    "ticker": "PCVX",
    "nct_id": "NCT05297578",
    "title": "Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pneumococcal Vaccines"
    ],
    "interventions": [
      "24-Valent Pneumococcal Conjugate Vaccine",
      "Pneumococcal 20-valent Conjugate Vaccine"
    ],
    "primary_completion_date": "2023-02-15",
    "completion_date": "2023-02-15",
    "results_first_posted": "2024-04-16",
    "last_update_posted": "2024-10-09",
    "enrollment": null,
    "sponsor": "Vaxcyte, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Vaxcyte"
  },
  {
    "ticker": "PCVX",
    "nct_id": "NCT06151288",
    "title": "Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pneumococcal Vaccines"
    ],
    "interventions": [
      "31 valent pneumococcal conjugate vaccine",
      "20 valent pneumococcal conjugate vaccine"
    ],
    "primary_completion_date": "2024-07-17",
    "completion_date": "2024-07-17",
    "results_first_posted": "2025-07-28",
    "last_update_posted": "2025-07-28",
    "enrollment": null,
    "sponsor": "Vaxcyte, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Vaxcyte"
  },
  {
    "ticker": "PCVX",
    "nct_id": "NCT06720038",
    "title": "A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pneumococcal Vaccines"
    ],
    "interventions": [
      "0.5 mL of the low dose VAX-31",
      "0.5 mL of the mid dose VAX-31",
      "0.5 mL of the high dose VAX-31",
      "0.5 mL dose of PCV20",
      "0.5 mL of the High-PFS dose VAX-31"
    ],
    "primary_completion_date": "2027-12",
    "completion_date": "2027-12",
    "results_first_posted": null,
    "last_update_posted": "2026-01-26",
    "enrollment": null,
    "sponsor": "Vaxcyte, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Vaxcyte"
  },
  {
    "ticker": "PCVX",
    "nct_id": "NCT07284654",
    "title": "Safety, Tolerability, and Immunogenicity of VAX-31 in Adults \u226550 Years With Immunobridging to Adults 18-49",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pneumococcal Vaccines"
    ],
    "interventions": [
      "31 valent pneumococcal conjugate vaccine",
      "PCV20",
      "PCV21"
    ],
    "primary_completion_date": "2027-01",
    "completion_date": "2027-01",
    "results_first_posted": null,
    "last_update_posted": "2025-12-16",
    "enrollment": null,
    "sponsor": "Vaxcyte, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Vaxcyte"
  },
  {
    "ticker": "PCVX",
    "nct_id": "NCT05844423",
    "title": "Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pneumococcal Vaccines"
    ],
    "interventions": [
      "0.5 ml dose of 1.1 mcg VAX-24",
      "0.5 ml dose of PCV20",
      "0.5 ml dose of 2.2 mcg VAX-24",
      "0.5 ml dose of 2.2/4.4 mcg VAX-24"
    ],
    "primary_completion_date": "2025-08-25",
    "completion_date": "2025-08-25",
    "results_first_posted": null,
    "last_update_posted": "2025-09-11",
    "enrollment": null,
    "sponsor": "Vaxcyte, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Vaxcyte"
  },
  {
    "ticker": "PCVX",
    "nct_id": "NCT05266456",
    "title": "Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pneumococcal Vaccines"
    ],
    "interventions": [
      "24 valent pneumococcal conjugate vaccine",
      "20 valent pneumococcal conjugate vaccine"
    ],
    "primary_completion_date": "2023-01-10",
    "completion_date": "2023-01-10",
    "results_first_posted": "2024-04-18",
    "last_update_posted": "2024-04-18",
    "enrollment": null,
    "sponsor": "Vaxcyte, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Vaxcyte"
  },
  {
    "ticker": "PCVX",
    "nct_id": "NCT07365826",
    "title": "A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults \u2265 50 Years of Age",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pneumococcal Vaccines"
    ],
    "interventions": [
      "31-valent pneumococcal conjugate vaccine",
      "Seasonal Influenza Vaccine (SIV) (Flublok)",
      "Placebo"
    ],
    "primary_completion_date": "2027-03",
    "completion_date": "2027-03",
    "results_first_posted": null,
    "last_update_posted": "2026-01-26",
    "enrollment": null,
    "sponsor": "Vaxcyte, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Vaxcyte"
  },
  {
    "ticker": "PEPG",
    "nct_id": "NCT06079736",
    "title": "A Study Of PGN-EDO51 In Participants With Duchenne Muscular Dystrophy Amenable To Exon 51-Skipping Treatment",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy"
    ],
    "interventions": [
      "PGN-EDO51"
    ],
    "primary_completion_date": "2025-08-28",
    "completion_date": "2025-08-28",
    "results_first_posted": null,
    "last_update_posted": "2025-12-02",
    "enrollment": null,
    "sponsor": "PepGen Inc",
    "collected_at": "2026-01-27",
    "search_term": "PepGen"
  },
  {
    "ticker": "PEPG",
    "nct_id": "NCT06204809",
    "title": "Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Myotonic Dystrophy 1"
    ],
    "interventions": [
      "PGN-EDODM1 for infusion",
      "Placebo"
    ],
    "primary_completion_date": "2025-10",
    "completion_date": "2025-10",
    "results_first_posted": null,
    "last_update_posted": "2025-10-06",
    "enrollment": null,
    "sponsor": "PepGen Inc",
    "collected_at": "2026-01-27",
    "search_term": "PepGen"
  },
  {
    "ticker": "PEPG",
    "nct_id": "NCT07220603",
    "title": "An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Myotonic Dystrophy 1"
    ],
    "interventions": [
      "PGN-EDODM1"
    ],
    "primary_completion_date": "2029-01",
    "completion_date": "2029-01",
    "results_first_posted": null,
    "last_update_posted": "2026-01-12",
    "enrollment": null,
    "sponsor": "PepGen Inc",
    "collected_at": "2026-01-27",
    "search_term": "PepGen"
  },
  {
    "ticker": "PEPG",
    "nct_id": "NCT06667453",
    "title": "A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Myotonic Dystrophy 1"
    ],
    "interventions": [
      "PGN-EDODM1",
      "Placebo"
    ],
    "primary_completion_date": "2026-08",
    "completion_date": "2026-08",
    "results_first_posted": null,
    "last_update_posted": "2025-12-22",
    "enrollment": null,
    "sponsor": "PepGen Inc",
    "collected_at": "2026-01-27",
    "search_term": "PepGen"
  },
  {
    "ticker": "PEPG",
    "nct_id": "NCT06833931",
    "title": "A Study of PGN-EDO51 or Placebo in People With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy (DMD)"
    ],
    "interventions": [
      "IV infusion",
      "Placebo"
    ],
    "primary_completion_date": "2025-05-28",
    "completion_date": "2025-05-28",
    "results_first_posted": null,
    "last_update_posted": "2025-06-24",
    "enrollment": null,
    "sponsor": "PepGen Inc",
    "collected_at": "2026-01-27",
    "search_term": "PepGen"
  },
  {
    "ticker": "PRTA",
    "nct_id": "NCT01707264",
    "title": "Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Primary Amyloidosis"
    ],
    "interventions": [
      "NEOD001"
    ],
    "primary_completion_date": "2016-08-09",
    "completion_date": "2016-08-09",
    "results_first_posted": null,
    "last_update_posted": "2018-08-28",
    "enrollment": null,
    "sponsor": "Prothena Biosciences Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Prothena"
  },
  {
    "ticker": "PRTA",
    "nct_id": "NCT02630901",
    "title": "Multiple Ascending Dose Study of PRX003 in Subjects With Psoriasis",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Psoriasis"
    ],
    "interventions": [
      "PRX003",
      "Placebo"
    ],
    "primary_completion_date": "2018-02-28",
    "completion_date": "2018-02-28",
    "results_first_posted": null,
    "last_update_posted": "2018-05-04",
    "enrollment": null,
    "sponsor": "Prothena Biosciences Limited",
    "collected_at": "2026-01-27",
    "search_term": "Prothena"
  },
  {
    "ticker": "PRTA",
    "nct_id": "NCT03336580",
    "title": "A Study of PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Amyloidogenic Transthyretin (ATTR) Amyloidosis"
    ],
    "interventions": [
      "PRX004"
    ],
    "primary_completion_date": "2020-07-23",
    "completion_date": "2020-07-23",
    "results_first_posted": null,
    "last_update_posted": "2020-08-20",
    "enrollment": null,
    "sponsor": "Prothena Biosciences Limited",
    "collected_at": "2026-01-27",
    "search_term": "Prothena"
  },
  {
    "ticker": "PRTA",
    "nct_id": "NCT03154047",
    "title": "Study in Subjects With Light Chain (AL) Amyloidosis",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "AL Amyloidosis"
    ],
    "interventions": [
      "NEOD001"
    ],
    "primary_completion_date": "2018-05-30",
    "completion_date": "2018-05-30",
    "results_first_posted": "2018-12-12",
    "last_update_posted": "2019-03-26",
    "enrollment": null,
    "sponsor": "Prothena Biosciences Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Prothena"
  },
  {
    "ticker": "PRTA",
    "nct_id": "NCT02095171",
    "title": "Single Ascending Dose Study of PRX002 in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Parkinson's Disease"
    ],
    "interventions": [
      "PRX002",
      "Placebo"
    ],
    "primary_completion_date": "2014-12",
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2015-02-10",
    "enrollment": null,
    "sponsor": "Prothena Biosciences Limited",
    "collected_at": "2026-01-27",
    "search_term": "Prothena"
  },
  {
    "ticker": "PRTA",
    "nct_id": "NCT02458677",
    "title": "Single Ascending Dose Study of PRX003 in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Psoriasis"
    ],
    "interventions": [
      "PRX003",
      "Placebo"
    ],
    "primary_completion_date": "2016-02",
    "completion_date": "2016-02",
    "results_first_posted": null,
    "last_update_posted": "2016-03-16",
    "enrollment": null,
    "sponsor": "Prothena Biosciences Limited",
    "collected_at": "2026-01-27",
    "search_term": "Prothena"
  },
  {
    "ticker": "PRTA",
    "nct_id": "NCT02574676",
    "title": "Quality of Life (QOL) Registry for Patients With AL Amyloidosis",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "AL Amyloidosis",
      "Amyloidosis"
    ],
    "interventions": [
      "non-interventional"
    ],
    "primary_completion_date": "2018-07",
    "completion_date": "2018-07",
    "results_first_posted": null,
    "last_update_posted": "2019-04-09",
    "enrollment": null,
    "sponsor": "Prothena Biosciences Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Prothena"
  },
  {
    "ticker": "PRTA",
    "nct_id": "NCT06699680",
    "title": "Phase 1 Study of PRX019 in Healthy Adult Volunteers",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants Study"
    ],
    "interventions": [
      "PRX019",
      "Placebo"
    ],
    "primary_completion_date": "2026-01-23",
    "completion_date": "2026-01-23",
    "results_first_posted": null,
    "last_update_posted": "2024-11-21",
    "enrollment": null,
    "sponsor": "Prothena Biosciences Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Prothena"
  },
  {
    "ticker": "PRTA",
    "nct_id": "NCT02632786",
    "title": "The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "AL Amyloidosis"
    ],
    "interventions": [
      "NEOD001",
      "Placebo"
    ],
    "primary_completion_date": "2018-03",
    "completion_date": "2018-03",
    "results_first_posted": "2019-04-05",
    "last_update_posted": "2019-04-05",
    "enrollment": null,
    "sponsor": "Prothena Biosciences Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Prothena"
  },
  {
    "ticker": "PRTA",
    "nct_id": "NCT02613182",
    "title": "Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "AL Amyloidosis"
    ],
    "interventions": [
      "NEOD001"
    ],
    "primary_completion_date": "2018-05",
    "completion_date": "2018-05",
    "results_first_posted": "2019-05-16",
    "last_update_posted": "2019-05-16",
    "enrollment": null,
    "sponsor": "Prothena Biosciences Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Prothena"
  },
  {
    "ticker": "PRTA",
    "nct_id": "NCT04973137",
    "title": "A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Light Chain (AL) Amyloidosis"
    ],
    "interventions": [
      "Birtamimab",
      "Placebo",
      "Standard of Care Chemotherapy"
    ],
    "primary_completion_date": "2025-04-02",
    "completion_date": "2025-06-20",
    "results_first_posted": "2025-12-16",
    "last_update_posted": "2025-12-16",
    "enrollment": null,
    "sponsor": "Prothena Biosciences Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Prothena"
  },
  {
    "ticker": "PRTA",
    "nct_id": "NCT02157714",
    "title": "Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Parkinson's Disease"
    ],
    "interventions": [
      "PRX002",
      "Placebo"
    ],
    "primary_completion_date": "2016-09",
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2016-10-21",
    "enrollment": null,
    "sponsor": "Prothena Biosciences Limited",
    "collected_at": "2026-01-27",
    "search_term": "Prothena"
  },
  {
    "ticker": "PRTA",
    "nct_id": "NCT02312206",
    "title": "The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Primary Systemic (AL) Amyloidosis"
    ],
    "interventions": [
      "NEOD001",
      "Placebo"
    ],
    "primary_completion_date": "2018-05",
    "completion_date": "2018-05",
    "results_first_posted": "2019-05-29",
    "last_update_posted": "2023-11-14",
    "enrollment": null,
    "sponsor": "Prothena Biosciences Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Prothena"
  },
  {
    "ticker": "PSNL",
    "nct_id": "NCT06230185",
    "title": "CtDNA Based MRD Testing for NAC Monitoring in TNBC",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "TNBC - Triple-Negative Breast Cancer",
      "Minimal Residual Disease"
    ],
    "interventions": [],
    "primary_completion_date": "2025-08-30",
    "completion_date": "2025-12-31",
    "results_first_posted": null,
    "last_update_posted": "2025-01-07",
    "enrollment": null,
    "sponsor": "Personalis Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Personalis"
  },
  {
    "ticker": "PTCT",
    "nct_id": "NCT00911248",
    "title": "PTC299 for Treatment of Neurofibromatosis Type 2",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Neurofibromatosis 2"
    ],
    "interventions": [
      "PTC299"
    ],
    "primary_completion_date": "2012-03-31",
    "completion_date": "2012-03-31",
    "results_first_posted": null,
    "last_update_posted": "2019-04-12",
    "enrollment": null,
    "sponsor": "PTC Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "PTC Therapeutics"
  },
  {
    "ticker": "PTCT",
    "nct_id": "NCT03796637",
    "title": "A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Who Have Been Treated With Ataluren",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy"
    ],
    "interventions": [
      "Ataluren"
    ],
    "primary_completion_date": "2019-06-03",
    "completion_date": "2019-06-03",
    "results_first_posted": "2022-04-05",
    "last_update_posted": "2022-04-05",
    "enrollment": null,
    "sponsor": "PTC Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "PTC Therapeutics"
  },
  {
    "ticker": "PTCT",
    "nct_id": "NCT04117880",
    "title": "A Phase 2 Open Label Extension Study in Participants With Nonsense Mutation Aniridia",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Aniridia"
    ],
    "interventions": [
      "Ataluren"
    ],
    "primary_completion_date": "2021-01-31",
    "completion_date": "2021-01-31",
    "results_first_posted": null,
    "last_update_posted": "2019-10-07",
    "enrollment": null,
    "sponsor": "PTC Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "PTC Therapeutics"
  },
  {
    "ticker": "PTCT",
    "nct_id": "NCT02404480",
    "title": "PTC596 in Patients With Advanced Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cancer"
    ],
    "interventions": [
      "PTC596"
    ],
    "primary_completion_date": "2017-02-06",
    "completion_date": "2017-02-06",
    "results_first_posted": null,
    "last_update_posted": "2017-12-08",
    "enrollment": null,
    "sponsor": "PTC Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "PTC Therapeutics"
  },
  {
    "ticker": "PTCT",
    "nct_id": "NCT02286609",
    "title": "A Single Dose Evaluation of the Effects of Moderate Hepatic Impairment on Deflazacort Pharmacokinetics",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatic Impairment"
    ],
    "interventions": [
      "Deflazacort"
    ],
    "primary_completion_date": "2015-02",
    "completion_date": "2015-02",
    "results_first_posted": null,
    "last_update_posted": "2017-08-18",
    "enrollment": null,
    "sponsor": "PTC Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "PTC Therapeutics"
  },
  {
    "ticker": "PTCT",
    "nct_id": "NCT02592941",
    "title": "Deflazacort Expanded Access Program for Children, Adolescents and Adults With Duchenne Muscular Dystrophy",
    "status": "APPROVED_FOR_MARKETING",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Duchenne Muscular Dystrophy"
    ],
    "interventions": [
      "Deflazacort"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2018-02-28",
    "enrollment": null,
    "sponsor": "PTC Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "PTC Therapeutics"
  },
  {
    "ticker": "PTCT",
    "nct_id": "NCT05358717",
    "title": "A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Huntington Disease"
    ],
    "interventions": [
      "PTC518",
      "Placebo"
    ],
    "primary_completion_date": "2025-02-07",
    "completion_date": "2025-07-31",
    "results_first_posted": "2026-01-13",
    "last_update_posted": "2026-01-13",
    "enrollment": null,
    "sponsor": "PTC Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "PTC Therapeutics"
  },
  {
    "ticker": "PTCT",
    "nct_id": "NCT00508586",
    "title": "PTC299 and Hormonal Agent for Treatment of Metastatic Breast Cancer",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Breast Cancer"
    ],
    "interventions": [
      "PTC299"
    ],
    "primary_completion_date": "2012-03",
    "completion_date": "2012-03",
    "results_first_posted": null,
    "last_update_posted": "2016-03-03",
    "enrollment": null,
    "sponsor": "PTC Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "PTC Therapeutics"
  },
  {
    "ticker": "PTCT",
    "nct_id": "NCT05099640",
    "title": "A Study of PTC923 in Participants With Phenylketonuria",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Phenylketonuria"
    ],
    "interventions": [
      "PTC923",
      "Placebo"
    ],
    "primary_completion_date": "2023-04-03",
    "completion_date": "2023-05-03",
    "results_first_posted": "2024-01-10",
    "last_update_posted": "2024-01-10",
    "enrollment": null,
    "sponsor": "PTC Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "PTC Therapeutics"
  },
  {
    "ticker": "PTCT",
    "nct_id": "NCT03761095",
    "title": "A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Leiomyosarcoma"
    ],
    "interventions": [
      "Unesbulin",
      "Dacarbazine"
    ],
    "primary_completion_date": "2024-02-05",
    "completion_date": "2024-02-05",
    "results_first_posted": null,
    "last_update_posted": "2024-03-15",
    "enrollment": null,
    "sponsor": "PTC Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "PTC Therapeutics"
  },
  {
    "ticker": "PTCT",
    "nct_id": "NCT02409004",
    "title": "Effects of Rifampin on the Pharmacokinetics of Ataluren",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "Ataluren",
      "Rifampin"
    ],
    "primary_completion_date": "2015-03",
    "completion_date": "2015-03",
    "results_first_posted": null,
    "last_update_posted": "2017-12-22",
    "enrollment": null,
    "sponsor": "PTC Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "PTC Therapeutics"
  },
  {
    "ticker": "PTCT",
    "nct_id": "NCT00947193",
    "title": "Study of Ataluren (PTC124) in Hemophilia A and B",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hemophilia A",
      "Hemophilia B"
    ],
    "interventions": [
      "Ataluren"
    ],
    "primary_completion_date": "2011-08-30",
    "completion_date": "2011-08-30",
    "results_first_posted": "2020-06-16",
    "last_update_posted": "2020-06-16",
    "enrollment": null,
    "sponsor": "PTC Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "PTC Therapeutics"
  },
  {
    "ticker": "PTCT",
    "nct_id": "NCT00759876",
    "title": "Phase 2a Extension Study of Ataluren (PTC124) in Duchenne Muscular Dystrophy (DMD)",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy"
    ],
    "interventions": [
      "Ataluren"
    ],
    "primary_completion_date": "2010-05-17",
    "completion_date": "2010-05-17",
    "results_first_posted": "2020-10-29",
    "last_update_posted": "2020-10-29",
    "enrollment": null,
    "sponsor": "PTC Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "PTC Therapeutics"
  },
  {
    "ticker": "PTCT",
    "nct_id": "NCT00704821",
    "title": "PTC299 for Treatment of Advanced Cancer",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Cancer"
    ],
    "interventions": [
      "PTC299",
      "Docetaxel"
    ],
    "primary_completion_date": "2012-02-24",
    "completion_date": "2012-02-24",
    "results_first_posted": null,
    "last_update_posted": "2019-05-10",
    "enrollment": null,
    "sponsor": "PTC Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "PTC Therapeutics"
  },
  {
    "ticker": "PTCT",
    "nct_id": "NCT03648827",
    "title": "A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy"
    ],
    "interventions": [
      "Ataluren"
    ],
    "primary_completion_date": "2020-10-23",
    "completion_date": "2020-10-23",
    "results_first_posted": "2022-04-05",
    "last_update_posted": "2022-04-05",
    "enrollment": null,
    "sponsor": "PTC Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "PTC Therapeutics"
  },
  {
    "ticker": "PTCT",
    "nct_id": "NCT02456103",
    "title": "Extension Study of Ataluren in Participants With Nonsense Mutation Cystic Fibrosis",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cystic Fibrosis"
    ],
    "interventions": [
      "Ataluren"
    ],
    "primary_completion_date": "2017-06-02",
    "completion_date": "2017-06-02",
    "results_first_posted": "2020-04-15",
    "last_update_posted": "2020-04-27",
    "enrollment": null,
    "sponsor": "PTC Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "PTC Therapeutics"
  },
  {
    "ticker": "PTCT",
    "nct_id": "NCT05218655",
    "title": "A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Inherited Mitochondrial Disease"
    ],
    "interventions": [
      "Vatiquinone"
    ],
    "primary_completion_date": "2025-04-15",
    "completion_date": "2025-04-15",
    "results_first_posted": "2025-12-22",
    "last_update_posted": "2025-12-22",
    "enrollment": null,
    "sponsor": "PTC Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "PTC Therapeutics"
  },
  {
    "ticker": "PTCT",
    "nct_id": "NCT01557400",
    "title": "Study of Ataluren for Previously Treated Participants With Nonsense Mutation Duchenne/Becker Muscular Dystrophy (nmDBMD) in Europe, Israel, Australia, and Canada",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy",
      "Becker Muscular Dystrophy",
      "Dystrophinopathy"
    ],
    "interventions": [
      "Ataluren"
    ],
    "primary_completion_date": "2018-01-19",
    "completion_date": "2018-01-19",
    "results_first_posted": "2020-11-25",
    "last_update_posted": "2020-11-25",
    "enrollment": null,
    "sponsor": "PTC Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "PTC Therapeutics"
  },
  {
    "ticker": "PTCT",
    "nct_id": "NCT03761069",
    "title": "Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Leukemia, Myeloid, Acute",
      "AML"
    ],
    "interventions": [
      "PTC299"
    ],
    "primary_completion_date": "2021-12-28",
    "completion_date": "2021-12-28",
    "results_first_posted": null,
    "last_update_posted": "2022-02-02",
    "enrollment": null,
    "sponsor": "PTC Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "PTC Therapeutics"
  },
  {
    "ticker": "PTCT",
    "nct_id": "NCT01370447",
    "title": "EPI-743 for Mitochondrial Respiratory Chain Diseases",
    "status": "NO_LONGER_AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Mitochondrial Diseases"
    ],
    "interventions": [
      "EPI-743"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2024-01-23",
    "enrollment": null,
    "sponsor": "PTC Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "PTC Therapeutics"
  },
  {
    "ticker": "PTCT",
    "nct_id": "NCT05269355",
    "title": "A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Leiomyosarcoma"
    ],
    "interventions": [
      "Unesbulin",
      "Dacarbazine",
      "Placebo"
    ],
    "primary_completion_date": "2024-06-17",
    "completion_date": "2024-07-17",
    "results_first_posted": "2025-06-13",
    "last_update_posted": "2025-06-13",
    "enrollment": null,
    "sponsor": "PTC Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "PTC Therapeutics"
  },
  {
    "ticker": "PTCT",
    "nct_id": "NCT01826487",
    "title": "Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Muscular Dystrophy, Duchenne",
      "Muscular Dystrophies",
      "Muscular Disorders, Atrophic",
      "Muscular Diseases",
      "Musculoskeletal Diseases",
      "Neuromuscular Diseases",
      "Nervous System Diseases",
      "Genetic Diseases, X-Linked",
      "Genetic Diseases, Inborn"
    ],
    "interventions": [
      "Ataluren",
      "Placebo"
    ],
    "primary_completion_date": "2015-08-20",
    "completion_date": "2015-08-20",
    "results_first_posted": "2020-08-04",
    "last_update_posted": "2020-08-04",
    "enrollment": null,
    "sponsor": "PTC Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "PTC Therapeutics"
  },
  {
    "ticker": "PTCT",
    "nct_id": "NCT01009294",
    "title": "Study of Ataluren (PTC124) in Nonambulatory Participants With Nonsense-Mutation-Mediated Duchenne/Becker Muscular Dystrophy (nmDMD/BMD)",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy",
      "Becker Muscular Dystrophy"
    ],
    "interventions": [
      "Ataluren",
      "Chronic Corticosteroid Therapy"
    ],
    "primary_completion_date": "2010-03-23",
    "completion_date": "2010-03-23",
    "results_first_posted": "2020-07-29",
    "last_update_posted": "2020-07-29",
    "enrollment": null,
    "sponsor": "PTC Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "PTC Therapeutics"
  },
  {
    "ticker": "PTCT",
    "nct_id": "NCT00803205",
    "title": "Study of Ataluren (PTC124\u2122) in Cystic Fibrosis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cystic Fibrosis"
    ],
    "interventions": [
      "Ataluren",
      "Placebo"
    ],
    "primary_completion_date": "2011-11-12",
    "completion_date": "2011-11-12",
    "results_first_posted": "2020-05-14",
    "last_update_posted": "2020-05-14",
    "enrollment": null,
    "sponsor": "PTC Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "PTC Therapeutics"
  },
  {
    "ticker": "PTCT",
    "nct_id": "NCT04336826",
    "title": "A Study to Evaluate the Safety and Pharmacokinetics of Ataluren in Participants From \u22656 Months to <2 Years of Age With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Nonsene Mutation Duchenne Muscular Dystrophy"
    ],
    "interventions": [
      "Ataluren"
    ],
    "primary_completion_date": "2023-08-07",
    "completion_date": "2023-08-07",
    "results_first_posted": "2024-04-01",
    "last_update_posted": "2024-04-01",
    "enrollment": null,
    "sponsor": "PTC Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "PTC Therapeutics"
  },
  {
    "ticker": "PTCT",
    "nct_id": "NCT02286635",
    "title": "Evaluate Effects of Multiple Doses of Rifampin and Clarithromycin on the Single Dose Pharmacokinetics of Deflazacort",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "Deflazacort and rifampin",
      "Deflazacort and Clarithromycin"
    ],
    "primary_completion_date": "2014-12",
    "completion_date": "2014-12",
    "results_first_posted": null,
    "last_update_posted": "2017-08-18",
    "enrollment": null,
    "sponsor": "PTC Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "PTC Therapeutics"
  },
  {
    "ticker": "PTCT",
    "nct_id": "NCT01721733",
    "title": "Safety and Efficacy Study of EPI-743 in Children With Leigh Syndrome",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Leigh Syndrome"
    ],
    "interventions": [
      "Placebo",
      "EPI-743 15 mg/kg",
      "EPI-743 5 mg/kg"
    ],
    "primary_completion_date": "2015-02-28",
    "completion_date": "2015-05-31",
    "results_first_posted": null,
    "last_update_posted": "2020-08-31",
    "enrollment": null,
    "sponsor": "PTC Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "PTC Therapeutics"
  },
  {
    "ticker": "PTCT",
    "nct_id": "NCT02819557",
    "title": "Study of Ataluren in \u22652 to <5 Year-Old Male Participants With Duchenne Muscular Dystrophy",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy"
    ],
    "interventions": [
      "Ataluren"
    ],
    "primary_completion_date": "2018-02-09",
    "completion_date": "2018-02-09",
    "results_first_posted": "2020-08-28",
    "last_update_posted": "2020-08-28",
    "enrollment": null,
    "sponsor": "PTC Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "PTC Therapeutics"
  },
  {
    "ticker": "PTCT",
    "nct_id": "NCT00351078",
    "title": "PTC124 for the Treatment of Cystic Fibrosis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cystic Fibrosis"
    ],
    "interventions": [
      "PTC124"
    ],
    "primary_completion_date": "2007-07",
    "completion_date": "2007-07",
    "results_first_posted": null,
    "last_update_posted": "2017-12-13",
    "enrollment": null,
    "sponsor": "PTC Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "PTC Therapeutics"
  },
  {
    "ticker": "PTCT",
    "nct_id": "NCT04378075",
    "title": "A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Mitochondrial Diseases",
      "Drug Resistant Epilepsy",
      "Leigh Disease",
      "Leigh Syndrome",
      "Mitochondrial Encephalopathy (MELAS)",
      "Pontocerebellar Hypoplasia Type 6 (PCH6)",
      "Alpers Disease",
      "Alpers Syndrome"
    ],
    "interventions": [
      "Vatiquinone",
      "Placebo"
    ],
    "primary_completion_date": "2023-03-18",
    "completion_date": "2023-12-27",
    "results_first_posted": null,
    "last_update_posted": "2024-08-27",
    "enrollment": null,
    "sponsor": "PTC Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "PTC Therapeutics"
  },
  {
    "ticker": "PTCT",
    "nct_id": "NCT00847379",
    "title": "Phase 2B Extension Study of Ataluren (PTC124) in Duchenne/Becker Muscular Dystrophy (DMD/BMD)",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy",
      "Becker Muscular Dystrophy"
    ],
    "interventions": [
      "Ataluren"
    ],
    "primary_completion_date": "2010-05-24",
    "completion_date": "2010-05-24",
    "results_first_posted": "2020-07-15",
    "last_update_posted": "2020-07-15",
    "enrollment": null,
    "sponsor": "PTC Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "PTC Therapeutics"
  },
  {
    "ticker": "PTCT",
    "nct_id": "NCT02647359",
    "title": "Study of Ataluren in Participants With Nonsense Mutation Aniridia",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Aniridia"
    ],
    "interventions": [
      "Ataluren",
      "Placebo"
    ],
    "primary_completion_date": "2021-01-22",
    "completion_date": "2021-01-22",
    "results_first_posted": "2022-05-27",
    "last_update_posted": "2022-05-27",
    "enrollment": null,
    "sponsor": "PTC Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "PTC Therapeutics"
  },
  {
    "ticker": "PTGX",
    "nct_id": "NCT04504383",
    "title": "PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ulcerative Colitis Chronic Moderate",
      "Ulcerative Colitis Chronic Severe"
    ],
    "interventions": [
      "PN-943",
      "Placebo"
    ],
    "primary_completion_date": "2023-02-16",
    "completion_date": "2023-02-16",
    "results_first_posted": null,
    "last_update_posted": "2023-04-25",
    "enrollment": null,
    "sponsor": "Protagonist Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Protagonist Therapeutics"
  },
  {
    "ticker": "PTGX",
    "nct_id": "NCT04621630",
    "title": "Pharmacokinetics of PN-235 in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "PN-235",
      "Placebo"
    ],
    "primary_completion_date": "2021-09-19",
    "completion_date": "2021-10-13",
    "results_first_posted": null,
    "last_update_posted": "2022-02-18",
    "enrollment": null,
    "sponsor": "Protagonist Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Protagonist Therapeutics"
  },
  {
    "ticker": "PTGX",
    "nct_id": "NCT03802201",
    "title": "Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "\u03b2-thalassemia",
      "Ineffective Erythropoiesis",
      "Chronic Anemia"
    ],
    "interventions": [
      "PTG-300"
    ],
    "primary_completion_date": "2020-07-31",
    "completion_date": "2020-07-31",
    "results_first_posted": null,
    "last_update_posted": "2021-07-16",
    "enrollment": null,
    "sponsor": "Protagonist Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Protagonist Therapeutics"
  },
  {
    "ticker": "PTGX",
    "nct_id": "NCT07153146",
    "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PN-881 in Healthy Subjects.",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteer"
    ],
    "interventions": [
      "PN-881 Oral Solution",
      "PN-881 Oral Tablet",
      "Placebo"
    ],
    "primary_completion_date": "2026-06-15",
    "completion_date": "2026-06-15",
    "results_first_posted": null,
    "last_update_posted": "2025-12-16",
    "enrollment": null,
    "sponsor": "Protagonist Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Protagonist Therapeutics"
  },
  {
    "ticker": "PTGX",
    "nct_id": "NCT04054921",
    "title": "Safety Study for Beta Thalassemia Subjects on PTG-300",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "\u03b2-thalassemia",
      "Ineffective Erythropoiesis"
    ],
    "interventions": [
      "PTG-300"
    ],
    "primary_completion_date": "2020-07-31",
    "completion_date": "2020-07-31",
    "results_first_posted": null,
    "last_update_posted": "2021-07-16",
    "enrollment": null,
    "sponsor": "Protagonist Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Protagonist Therapeutics"
  },
  {
    "ticker": "PTGX",
    "nct_id": "NCT04819620",
    "title": "Pharmacokinetics of PN-232 in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Subjects"
    ],
    "interventions": [
      "PN-232",
      "Placebo"
    ],
    "primary_completion_date": "2021-12-17",
    "completion_date": "2022-06-16",
    "results_first_posted": null,
    "last_update_posted": "2022-10-03",
    "enrollment": null,
    "sponsor": "Protagonist Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Protagonist Therapeutics"
  },
  {
    "ticker": "PTGX",
    "nct_id": "NCT02895100",
    "title": "Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative Colitis",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ulcerative Colitis"
    ],
    "interventions": [
      "PTG-100",
      "Placebo"
    ],
    "primary_completion_date": "2018-03-26",
    "completion_date": "2018-03-26",
    "results_first_posted": "2021-03-22",
    "last_update_posted": "2025-08-21",
    "enrollment": null,
    "sponsor": "Protagonist Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Protagonist Therapeutics"
  },
  {
    "ticker": "PYXS",
    "nct_id": "NCT05718557",
    "title": "Study of PYX-106 in Solid Tumors",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor"
    ],
    "interventions": [
      "PYX-106"
    ],
    "primary_completion_date": "2026-05",
    "completion_date": "2026-05",
    "results_first_posted": null,
    "last_update_posted": "2025-08-03",
    "enrollment": null,
    "sponsor": "Pyxis Oncology, Inc",
    "collected_at": "2026-01-27",
    "search_term": "Pyxis Oncology"
  },
  {
    "ticker": "PYXS",
    "nct_id": "NCT05720117",
    "title": "Study of PYX-201 in Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor",
      "Advanced Solid Tumor"
    ],
    "interventions": [
      "PYX-201"
    ],
    "primary_completion_date": "2026-07",
    "completion_date": "2027-05",
    "results_first_posted": null,
    "last_update_posted": "2025-08-01",
    "enrollment": null,
    "sponsor": "Pyxis Oncology, Inc",
    "collected_at": "2026-01-27",
    "search_term": "Pyxis Oncology"
  },
  {
    "ticker": "PYXS",
    "nct_id": "NCT06795412",
    "title": "Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumours"
    ],
    "interventions": [
      "PYX-201",
      "pembrolizumab"
    ],
    "primary_completion_date": "2027-12-06",
    "completion_date": "2027-12-06",
    "results_first_posted": null,
    "last_update_posted": "2025-10-01",
    "enrollment": null,
    "sponsor": "Pyxis Oncology, Inc",
    "collected_at": "2026-01-27",
    "search_term": "Pyxis Oncology"
  },
  {
    "ticker": "RCKT",
    "nct_id": "NCT04525352",
    "title": "A Trial to Evaluate Safety and Efficacy of RP-L401-0120 in Subjects With Infantile Malignant Osteopetrosis",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Infantile Malignant Osteopetrosis"
    ],
    "interventions": [
      "RP-L401"
    ],
    "primary_completion_date": "2021-05-21",
    "completion_date": "2021-05-21",
    "results_first_posted": null,
    "last_update_posted": "2022-07-13",
    "enrollment": null,
    "sponsor": "Rocket Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Rocket Pharmaceuticals"
  },
  {
    "ticker": "RCKT",
    "nct_id": "NCT06282432",
    "title": "Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Leukocyte Adhesion Deficiency"
    ],
    "interventions": [],
    "primary_completion_date": "2036-10-04",
    "completion_date": "2036-10-04",
    "results_first_posted": null,
    "last_update_posted": "2025-12-18",
    "enrollment": null,
    "sponsor": "Rocket Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Rocket Pharmaceuticals"
  },
  {
    "ticker": "RCKT",
    "nct_id": "NCT06644742",
    "title": "PKP2-ACM Natural History Study",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Cardiomyopathies",
      "Heart Diseases",
      "Cardiovascular Diseases",
      "Genetic Diseases"
    ],
    "interventions": [],
    "primary_completion_date": "2028-12",
    "completion_date": "2028-12",
    "results_first_posted": null,
    "last_update_posted": "2025-09-22",
    "enrollment": null,
    "sponsor": "Rocket Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Rocket Pharmaceuticals"
  },
  {
    "ticker": "RCKT",
    "nct_id": "NCT06422351",
    "title": "Clinical Trial to Evaluate the Efficacy of Gene Therapy for Pyruvate Kinase Deficiency",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pyruvate Kinase Deficiency"
    ],
    "interventions": [
      "RP-L301"
    ],
    "primary_completion_date": "2026-11",
    "completion_date": "2029-01",
    "results_first_posted": null,
    "last_update_posted": "2024-05-22",
    "enrollment": null,
    "sponsor": "Rocket Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Rocket Pharmaceuticals"
  },
  {
    "ticker": "RCKT",
    "nct_id": "NCT06214507",
    "title": "Danon Disease Natural History Study",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Danon Disease"
    ],
    "interventions": [
      "No intervention"
    ],
    "primary_completion_date": "2029-12",
    "completion_date": "2030-03",
    "results_first_posted": null,
    "last_update_posted": "2026-01-08",
    "enrollment": null,
    "sponsor": "Rocket Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Rocket Pharmaceuticals"
  },
  {
    "ticker": "RCKT",
    "nct_id": "NCT03825783",
    "title": "A Gene Therapy Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I",
    "status": "WITHDRAWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Leukocyte Adhesion Defect - Type I"
    ],
    "interventions": [
      "RP-L201"
    ],
    "primary_completion_date": "2021-10",
    "completion_date": "2021-10",
    "results_first_posted": null,
    "last_update_posted": "2021-12-07",
    "enrollment": null,
    "sponsor": "Rocket Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Rocket Pharmaceuticals"
  },
  {
    "ticker": "RCKT",
    "nct_id": "NCT04069533",
    "title": "Lentiviral-mediated Gene Therapy for Pediatric Patients With Fanconi Anemia Subtype A",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fanconi Anemia Complementation Group A"
    ],
    "interventions": [
      "RP-L102"
    ],
    "primary_completion_date": "2025-02",
    "completion_date": "2025-02",
    "results_first_posted": null,
    "last_update_posted": "2024-05-22",
    "enrollment": null,
    "sponsor": "Rocket Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Rocket Pharmaceuticals"
  },
  {
    "ticker": "RCKT",
    "nct_id": "NCT03812263",
    "title": "A Clinical Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Leukocyte Adhesion Defect - Type I"
    ],
    "interventions": [
      "RP-L201"
    ],
    "primary_completion_date": "2023-09-12",
    "completion_date": "2023-09-12",
    "results_first_posted": null,
    "last_update_posted": "2023-11-15",
    "enrollment": null,
    "sponsor": "Rocket Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Rocket Pharmaceuticals"
  },
  {
    "ticker": "RCKT",
    "nct_id": "NCT05885412",
    "title": "A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM)",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM)"
    ],
    "interventions": [
      "RP-A601"
    ],
    "primary_completion_date": "2025-09",
    "completion_date": "2026-09",
    "results_first_posted": null,
    "last_update_posted": "2024-10-04",
    "enrollment": null,
    "sponsor": "Rocket Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Rocket Pharmaceuticals"
  },
  {
    "ticker": "RCKT",
    "nct_id": "NCT05548855",
    "title": "Natural History of Danon Disease",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Danon Disease"
    ],
    "interventions": [
      "Heart Transplant",
      "Cardiac Assistive Device"
    ],
    "primary_completion_date": "2023-10-31",
    "completion_date": "2023-10-31",
    "results_first_posted": null,
    "last_update_posted": "2023-11-21",
    "enrollment": null,
    "sponsor": "Rocket Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Rocket Pharmaceuticals"
  },
  {
    "ticker": "RCKT",
    "nct_id": "NCT04437771",
    "title": "Long-Term Follow-up of Subjects With Fanconi Anaemia Subtype A Treated With ex Vivo Gene Therapy",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Fanconi Anemia Complementation Group A",
      "Fanconi Anemia"
    ],
    "interventions": [
      "Safety and efficacy assessments"
    ],
    "primary_completion_date": "2034-10-30",
    "completion_date": "2035-01-30",
    "results_first_posted": null,
    "last_update_posted": "2020-06-22",
    "enrollment": null,
    "sponsor": "Rocket Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Rocket Pharmaceuticals"
  },
  {
    "ticker": "RCKT",
    "nct_id": "NCT03814408",
    "title": "A Clinical Trial to Evaluate the Safety of RP-L102 in Pediatric Subjects With Fanconi Anemia Subtype A",
    "status": "UNKNOWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fanconi Anemia Complementation Group A"
    ],
    "interventions": [
      "RP-L102"
    ],
    "primary_completion_date": "2020-12",
    "completion_date": "2022-03",
    "results_first_posted": null,
    "last_update_posted": "2020-11-24",
    "enrollment": null,
    "sponsor": "Rocket Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Rocket Pharmaceuticals"
  },
  {
    "ticker": "RCKT",
    "nct_id": "NCT04248439",
    "title": "Gene Therapy for Fanconi Anemia, Complementation Group A",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fanconi Anemia Complementation Group A"
    ],
    "interventions": [
      "RP-L102"
    ],
    "primary_completion_date": "2026-05-05",
    "completion_date": "2026-05-05",
    "results_first_posted": null,
    "last_update_posted": "2025-12-22",
    "enrollment": null,
    "sponsor": "Rocket Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Rocket Pharmaceuticals"
  },
  {
    "ticker": "RCKT",
    "nct_id": "NCT03882437",
    "title": "Gene Therapy for Male Patients With Danon Disease (DD) Using RP-A501; AAV9.LAMP2B",
    "status": "UNKNOWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Danon Disease"
    ],
    "interventions": [
      "RP-A501"
    ],
    "primary_completion_date": "2025-03-24",
    "completion_date": "2025-03-24",
    "results_first_posted": null,
    "last_update_posted": "2023-03-03",
    "enrollment": null,
    "sponsor": "Rocket Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Rocket Pharmaceuticals"
  },
  {
    "ticker": "RCKT",
    "nct_id": "NCT06092034",
    "title": "A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Danon Disease"
    ],
    "interventions": [
      "RP-A501"
    ],
    "primary_completion_date": "2028-04",
    "completion_date": "2032-04",
    "results_first_posted": null,
    "last_update_posted": "2025-10-07",
    "enrollment": null,
    "sponsor": "Rocket Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Rocket Pharmaceuticals"
  },
  {
    "ticker": "RCKT",
    "nct_id": "NCT07137338",
    "title": "A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dilated Cardiomyopathy (DCM)"
    ],
    "interventions": [
      "RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, BCL2-associated Athanogene 3 (BAG3)"
    ],
    "primary_completion_date": "2029-06",
    "completion_date": "2029-06",
    "results_first_posted": null,
    "last_update_posted": "2025-08-22",
    "enrollment": null,
    "sponsor": "Rocket Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Rocket Pharmaceuticals"
  },
  {
    "ticker": "REPL",
    "nct_id": "NCT06887348",
    "title": "A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Melanoma",
      "Metastatic Melanoma",
      "Advanced Solid Tumor",
      "Hepatocellular Carcinoma"
    ],
    "interventions": [
      "Observational study with no interventions"
    ],
    "primary_completion_date": "2030-12",
    "completion_date": "2035-12",
    "results_first_posted": null,
    "last_update_posted": "2026-01-12",
    "enrollment": null,
    "sponsor": "Replimune Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Replimune"
  },
  {
    "ticker": "REPL",
    "nct_id": "NCT04735978",
    "title": "Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumor"
    ],
    "interventions": [
      "RP3",
      "Nivolumab"
    ],
    "primary_completion_date": "2026-11-30",
    "completion_date": "2026-11-30",
    "results_first_posted": null,
    "last_update_posted": "2025-09-09",
    "enrollment": null,
    "sponsor": "Replimune Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Replimune"
  },
  {
    "ticker": "REPL",
    "nct_id": "NCT05733598",
    "title": "Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatocellular Carcinoma",
      "Biliary Tract Cancer"
    ],
    "interventions": [
      "RP2",
      "Bevacizumab",
      "Atezolizumab",
      "Durvalumab",
      "RP2 Monotherapy"
    ],
    "primary_completion_date": "2027-12-01",
    "completion_date": "2028-07-01",
    "results_first_posted": null,
    "last_update_posted": "2025-12-15",
    "enrollment": null,
    "sponsor": "Replimune Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Replimune"
  },
  {
    "ticker": "REPL",
    "nct_id": "NCT03767348",
    "title": "Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-Small Cell Lung Cancer (NSCLC)",
      "Microsatellite Instability-High (MSI-H)",
      "Non-melanoma Skin Cancer (NMSC)",
      "Cutaneous Melanoma"
    ],
    "interventions": [
      "RP1",
      "nivolumab"
    ],
    "primary_completion_date": "2025-12",
    "completion_date": "2028-12",
    "results_first_posted": null,
    "last_update_posted": "2025-12-17",
    "enrollment": null,
    "sponsor": "Replimune Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Replimune"
  },
  {
    "ticker": "REPL",
    "nct_id": "NCT06581406",
    "title": "A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Na\u00efve Adult Patients With Metastatic Uveal Melanoma",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Uveal Melanoma"
    ],
    "interventions": [
      "RP2",
      "Ipilimumab",
      "Nivolumab"
    ],
    "primary_completion_date": "2030-01",
    "completion_date": "2031-10",
    "results_first_posted": null,
    "last_update_posted": "2026-01-09",
    "enrollment": null,
    "sponsor": "Replimune Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Replimune"
  },
  {
    "ticker": "REPL",
    "nct_id": "NCT04349436",
    "title": "A Phase 1B/2 Study of RP1 in Solid Organ Transplant Patients With Advanced Cutaneous Malignancies",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cutaneous Squamous Cell Carcinoma",
      "Merkel Cell Carcinoma",
      "Basal Cell Carcinoma",
      "Melanoma"
    ],
    "interventions": [
      "RP1, intra-tumoral injection, oncolytic virus"
    ],
    "primary_completion_date": "2027-09",
    "completion_date": "2028-01",
    "results_first_posted": null,
    "last_update_posted": "2025-10-31",
    "enrollment": null,
    "sponsor": "Replimune Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Replimune"
  },
  {
    "ticker": "REPL",
    "nct_id": "NCT06590480",
    "title": "An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced Melanoma",
    "status": "NO_LONGER_AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Advanced Melanoma"
    ],
    "interventions": [
      "RP1",
      "Nivolumab"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2025-12-18",
    "enrollment": null,
    "sponsor": "Replimune Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Replimune"
  },
  {
    "ticker": "REPL",
    "nct_id": "NCT04050436",
    "title": "Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cutaneous Squamous Cell Carcinoma",
      "Advanced Cutaneous Squamous Cell Carcinoma",
      "Metastatic Cutaneous Squamous Cell Carcinoma"
    ],
    "interventions": [
      "Cemiplimab",
      "RP1"
    ],
    "primary_completion_date": "2025-09",
    "completion_date": "2025-09",
    "results_first_posted": null,
    "last_update_posted": "2025-01-27",
    "enrollment": null,
    "sponsor": "Replimune Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Replimune"
  },
  {
    "ticker": "REPL",
    "nct_id": "NCT06264180",
    "title": "VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Melanoma"
    ],
    "interventions": [
      "Vusolimogene Oderparepvec",
      "Nivolumab",
      "Nivolumab + Relatlimab",
      "Pembrolizumab",
      "Single-agent chemotherapy"
    ],
    "primary_completion_date": "2029-01-01",
    "completion_date": "2034-08-31",
    "results_first_posted": null,
    "last_update_posted": "2025-12-23",
    "enrollment": null,
    "sponsor": "Replimune Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Replimune"
  },
  {
    "ticker": "REPL",
    "nct_id": "NCT04336241",
    "title": "Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cancer"
    ],
    "interventions": [
      "RP2",
      "nivolumab"
    ],
    "primary_completion_date": "2026-10-31",
    "completion_date": "2028-04-30",
    "results_first_posted": null,
    "last_update_posted": "2025-09-09",
    "enrollment": null,
    "sponsor": "Replimune Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Replimune"
  },
  {
    "ticker": "REPL",
    "nct_id": "NCT05733611",
    "title": "RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Refractory Metastatic Colorectal Cancer",
      "pMMR",
      "MSS"
    ],
    "interventions": [
      "RP2",
      "RP3",
      "atezolizumab",
      "bevacizumab"
    ],
    "primary_completion_date": "2027-01-01",
    "completion_date": "2027-03-01",
    "results_first_posted": null,
    "last_update_posted": "2025-01-16",
    "enrollment": null,
    "sponsor": "Replimune Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Replimune"
  },
  {
    "ticker": "RGEN",
    "nct_id": "NCT00660335",
    "title": "Safety and Efficacy of Synthetic Human Secretin-Enhanced MRCP in Subjects With Abnormalities of the Pancreas",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pancreatitis"
    ],
    "interventions": [
      "RG1068 (synthetic human secretin)"
    ],
    "primary_completion_date": "2009-10",
    "completion_date": "2009-10",
    "results_first_posted": null,
    "last_update_posted": "2009-12-03",
    "enrollment": null,
    "sponsor": "Repligen Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Repligen"
  },
  {
    "ticker": "RGEN",
    "nct_id": "NCT00060515",
    "title": "RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Mitochondrial Diseases"
    ],
    "interventions": [
      "RG2133 (2',3',5'-tri-O-acetyluridine)"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2005-08-05",
    "enrollment": null,
    "sponsor": "Repligen Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Repligen"
  },
  {
    "ticker": "RGEN",
    "nct_id": "NCT00322764",
    "title": "Phase II Study to Assess RG2417 in the Treatment of Bipolar I Depression",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bipolar Depression"
    ],
    "interventions": [
      "Uridine"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2007-11-09",
    "enrollment": null,
    "sponsor": "Repligen Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Repligen"
  },
  {
    "ticker": "RGEN",
    "nct_id": "NCT00812058",
    "title": "A Study to Assess the Safety, Tolerability and Efficacy of RG2417 in Bipolar I Depression",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bipolar I Depression"
    ],
    "interventions": [
      "RG2417",
      "Placebo"
    ],
    "primary_completion_date": "2010-12",
    "completion_date": "2010-12",
    "results_first_posted": null,
    "last_update_posted": "2011-01-17",
    "enrollment": null,
    "sponsor": "Repligen Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Repligen"
  },
  {
    "ticker": "RGEN",
    "nct_id": "NCT00036244",
    "title": "Synthetic Human Secretin in Children With Autism",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Autism"
    ],
    "interventions": [
      "RG1068 (Synthetic Human Secretin)"
    ],
    "primary_completion_date": null,
    "completion_date": "2004-01",
    "results_first_posted": null,
    "last_update_posted": "2005-08-05",
    "enrollment": null,
    "sponsor": "Repligen Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Repligen"
  },
  {
    "ticker": "RGEN",
    "nct_id": "NCT00036231",
    "title": "Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Autism"
    ],
    "interventions": [
      "RG1068 (Synthetic Human Secretin)"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2005-11-21",
    "enrollment": null,
    "sponsor": "Repligen Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Repligen"
  },
  {
    "ticker": "RGNX",
    "nct_id": "NCT04462692",
    "title": "An Observational Study in Children With CLN2 Batten Disease",
    "status": "WITHDRAWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Neuronal Ceroid Lipofuscinosis Type 2 (CLN2)"
    ],
    "interventions": [],
    "primary_completion_date": "2023-10",
    "completion_date": "2023-10",
    "results_first_posted": null,
    "last_update_posted": "2021-11-01",
    "enrollment": null,
    "sponsor": "REGENXBIO Inc.",
    "collected_at": "2026-01-27",
    "search_term": "REGENXBIO"
  },
  {
    "ticker": "RGNX",
    "nct_id": "NCT04480476",
    "title": "A Retrospective, Natural History Study in Children With CLN2",
    "status": "WITHDRAWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Late-infantile Neuronal Ceroid Lipofuscinosis Type 2 (CLN2)"
    ],
    "interventions": [],
    "primary_completion_date": "2022-04",
    "completion_date": "2022-04",
    "results_first_posted": null,
    "last_update_posted": "2021-11-01",
    "enrollment": null,
    "sponsor": "REGENXBIO Inc.",
    "collected_at": "2026-01-27",
    "search_term": "REGENXBIO"
  },
  {
    "ticker": "RGNX",
    "nct_id": "NCT06103487",
    "title": "Long Term Follow-Up for RGX-111",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Mucopolysaccharidosis I"
    ],
    "interventions": [
      "No Intervention"
    ],
    "primary_completion_date": "2027-09",
    "completion_date": "2027-09",
    "results_first_posted": null,
    "last_update_posted": "2024-07-03",
    "enrollment": null,
    "sponsor": "REGENXBIO Inc.",
    "collected_at": "2026-01-27",
    "search_term": "REGENXBIO"
  },
  {
    "ticker": "RGNX",
    "nct_id": "NCT07236606",
    "title": "RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome)",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "MPS II",
      "Hunter Syndrome (MPS II)"
    ],
    "interventions": [
      "RGX-121-3102"
    ],
    "primary_completion_date": "2028-04-30",
    "completion_date": "2031-05-30",
    "results_first_posted": null,
    "last_update_posted": "2025-11-26",
    "enrollment": null,
    "sponsor": "REGENXBIO Inc.",
    "collected_at": "2026-01-27",
    "search_term": "REGENXBIO"
  },
  {
    "ticker": "RGNX",
    "nct_id": "NCT05683379",
    "title": "AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Males With DMD",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy"
    ],
    "interventions": [
      "AAV8 DetectCDx"
    ],
    "primary_completion_date": "2026-09",
    "completion_date": "2026-09",
    "results_first_posted": null,
    "last_update_posted": "2025-11-25",
    "enrollment": null,
    "sponsor": "REGENXBIO Inc.",
    "collected_at": "2026-01-27",
    "search_term": "REGENXBIO"
  },
  {
    "ticker": "RGNX",
    "nct_id": "NCT03566043",
    "title": "CAMPSIITE\u2122 RGX-121 Gene Therapy in Subjects With MPS II (Hunter Syndrome)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Mucopolysaccharidosis Type II (MPS II)"
    ],
    "interventions": [
      "RGX-121"
    ],
    "primary_completion_date": "2023-11-27",
    "completion_date": "2025-08",
    "results_first_posted": null,
    "last_update_posted": "2025-01-28",
    "enrollment": null,
    "sponsor": "REGENXBIO Inc.",
    "collected_at": "2026-01-27",
    "search_term": "REGENXBIO"
  },
  {
    "ticker": "RGNX",
    "nct_id": "NCT04597385",
    "title": "Long-term Follow-Up for RGX-121",
    "status": "UNKNOWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Mucopolysaccharidosis II"
    ],
    "interventions": [
      "Long-term Follow-Up"
    ],
    "primary_completion_date": "2025-09",
    "completion_date": "2025-09",
    "results_first_posted": null,
    "last_update_posted": "2021-08-10",
    "enrollment": null,
    "sponsor": "REGENXBIO Inc.",
    "collected_at": "2026-01-27",
    "search_term": "REGENXBIO"
  },
  {
    "ticker": "RGNX",
    "nct_id": "NCT04080050",
    "title": "A Long-term Follow-up Study to Evaluate the Safety and Efficacy of RGX-501",
    "status": "UNKNOWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Homozygous Familial Hypercholesterolemia (HoFH)"
    ],
    "interventions": [
      "Single intravenous (IV) dose of human Low Density Lipoprotein Receptor (LDLR) Gene Therapy"
    ],
    "primary_completion_date": "2024-09-29",
    "completion_date": "2025-09-29",
    "results_first_posted": null,
    "last_update_posted": "2023-03-09",
    "enrollment": null,
    "sponsor": "REGENXBIO Inc.",
    "collected_at": "2026-01-27",
    "search_term": "REGENXBIO"
  },
  {
    "ticker": "RGNX",
    "nct_id": "NCT05693142",
    "title": "AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy"
    ],
    "interventions": [
      "RGX-202"
    ],
    "primary_completion_date": "2026-02",
    "completion_date": "2028-08",
    "results_first_posted": null,
    "last_update_posted": "2025-12-17",
    "enrollment": null,
    "sponsor": "REGENXBIO Inc.",
    "collected_at": "2026-01-27",
    "search_term": "REGENXBIO"
  },
  {
    "ticker": "RGNX",
    "nct_id": "NCT03066258",
    "title": "Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Neovascular Age-related Macular Degeneration",
      "Wet Age-related Macular Degeneration"
    ],
    "interventions": [
      "RGX-314"
    ],
    "primary_completion_date": "2019-11-24",
    "completion_date": "2021-06-17",
    "results_first_posted": "2023-05-16",
    "last_update_posted": "2023-05-16",
    "enrollment": null,
    "sponsor": "REGENXBIO Inc.",
    "collected_at": "2026-01-27",
    "search_term": "REGENXBIO"
  },
  {
    "ticker": "RGNX",
    "nct_id": "NCT04148001",
    "title": "Identifying and Genotyping Homozygous Familial Hypercholesterolemia (HoFH) Patients",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Homozygous Familial Hypercholesterolemia (HoFH)"
    ],
    "interventions": [],
    "primary_completion_date": "2020-04-08",
    "completion_date": "2020-04-08",
    "results_first_posted": null,
    "last_update_posted": "2021-02-02",
    "enrollment": null,
    "sponsor": "REGENXBIO Inc.",
    "collected_at": "2026-01-27",
    "search_term": "REGENXBIO"
  },
  {
    "ticker": "RGNX",
    "nct_id": "NCT06491927",
    "title": "Long Term Follow-up for RGX-202",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy"
    ],
    "interventions": [
      "No Intervention"
    ],
    "primary_completion_date": "2029-12-01",
    "completion_date": "2029-12-01",
    "results_first_posted": null,
    "last_update_posted": "2025-05-13",
    "enrollment": null,
    "sponsor": "REGENXBIO Inc.",
    "collected_at": "2026-01-27",
    "search_term": "REGENXBIO"
  },
  {
    "ticker": "RGNX",
    "nct_id": "NCT04571970",
    "title": "RGX-121 Gene Therapy in Children 5 Years of Age and Over With MPS II (Hunter Syndrome)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Mucopolysaccharidosis Type II (MPS II)"
    ],
    "interventions": [
      "RGX-121"
    ],
    "primary_completion_date": "2023-05-09",
    "completion_date": "2024-05-23",
    "results_first_posted": null,
    "last_update_posted": "2025-01-28",
    "enrollment": null,
    "sponsor": "REGENXBIO Inc.",
    "collected_at": "2026-01-27",
    "search_term": "REGENXBIO"
  },
  {
    "ticker": "RGNX",
    "nct_id": "NCT03580083",
    "title": "RGX-111 Gene Therapy in Patients With MPS I",
    "status": "UNKNOWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Mucopolysaccharidosis Type I (MPS I)",
      "Hurler Syndrome",
      "Hurler-Scheie Syndrome"
    ],
    "interventions": [
      "RGX-111"
    ],
    "primary_completion_date": "2023-03-01",
    "completion_date": "2024-10",
    "results_first_posted": null,
    "last_update_posted": "2023-12-06",
    "enrollment": null,
    "sponsor": "REGENXBIO Inc.",
    "collected_at": "2026-01-27",
    "search_term": "REGENXBIO"
  },
  {
    "ticker": "RGNX",
    "nct_id": "NCT04591834",
    "title": "Mucopolysaccharidosis Type II Observational",
    "status": "WITHDRAWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Mucopolysaccharidosis II"
    ],
    "interventions": [
      "Observational"
    ],
    "primary_completion_date": "2025-07",
    "completion_date": "2025-07",
    "results_first_posted": null,
    "last_update_posted": "2022-10-10",
    "enrollment": null,
    "sponsor": "REGENXBIO Inc.",
    "collected_at": "2026-01-27",
    "search_term": "REGENXBIO"
  },
  {
    "ticker": "RIGL",
    "nct_id": "NCT02076399",
    "title": "A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Immune Thrombocytopenic Purpura"
    ],
    "interventions": [
      "Fostamatinib disodium",
      "Placebo"
    ],
    "primary_completion_date": "2016-04-21",
    "completion_date": "2016-04-21",
    "results_first_posted": "2019-01-11",
    "last_update_posted": "2019-02-12",
    "enrollment": null,
    "sponsor": "Rigel Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Rigel Pharmaceuticals"
  },
  {
    "ticker": "RIGL",
    "nct_id": "NCT00115089",
    "title": "7 Day Study of Mast Cell Inhibitor, R926112, in Patients With Symptomatic Seasonal Allergic Rhinitis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rhinitis, Allergic, Seasonal"
    ],
    "interventions": [
      "R926112",
      "Beclomethasone dipropionate"
    ],
    "primary_completion_date": null,
    "completion_date": "2005-09",
    "results_first_posted": null,
    "last_update_posted": "2005-11-11",
    "enrollment": null,
    "sponsor": "Rigel Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Rigel Pharmaceuticals"
  },
  {
    "ticker": "RIGL",
    "nct_id": "NCT02612558",
    "title": "A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Warm Antibody Autoimmune Hemolytic Anemia"
    ],
    "interventions": [
      "Fostamatinib 150 mg bid"
    ],
    "primary_completion_date": "2019-12",
    "completion_date": "2019-12",
    "results_first_posted": null,
    "last_update_posted": "2021-07-21",
    "enrollment": null,
    "sponsor": "Rigel Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Rigel Pharmaceuticals"
  },
  {
    "ticker": "RIGL",
    "nct_id": "NCT02077192",
    "title": "Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Immune Thrombocytopenic Purpura"
    ],
    "interventions": [
      "Fostamatinib Disodium"
    ],
    "primary_completion_date": "2020-06-02",
    "completion_date": "2020-06-02",
    "results_first_posted": "2023-12-11",
    "last_update_posted": "2023-12-11",
    "enrollment": null,
    "sponsor": "Rigel Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Rigel Pharmaceuticals"
  },
  {
    "ticker": "RIGL",
    "nct_id": "NCT00706342",
    "title": "Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Purpura, Thrombocytopenic, Idiopathic"
    ],
    "interventions": [
      "Fostamatinib Disodium / R935788"
    ],
    "primary_completion_date": "2010-04",
    "completion_date": "2010-04",
    "results_first_posted": "2014-08-13",
    "last_update_posted": "2016-06-03",
    "enrollment": null,
    "sponsor": "Rigel Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Rigel Pharmaceuticals"
  },
  {
    "ticker": "RIGL",
    "nct_id": "NCT00798096",
    "title": "Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "T Cell Lymphoma"
    ],
    "interventions": [
      "Fostamatinib Disodium"
    ],
    "primary_completion_date": "2010-04",
    "completion_date": "2010-04",
    "results_first_posted": "2014-06-12",
    "last_update_posted": "2016-09-19",
    "enrollment": null,
    "sponsor": "Rigel Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Rigel Pharmaceuticals"
  },
  {
    "ticker": "RIGL",
    "nct_id": "NCT06161974",
    "title": "Study of Olutasidenib and Temozolomide in HGG",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "High Grade Glioma",
      "Astrocytoma",
      "Astrocytoma, Grade III",
      "Astrocytoma, Grade IV",
      "Diffuse Intrinsic Pontine Glioma",
      "WHO Grade III Glioma",
      "WHO Grade IV Glioma",
      "Metastatic Brain Tumor",
      "Diffuse Midline Glioma, H3 K27M-Mutant",
      "Thalamus Tumor",
      "Spinal Tumor",
      "IDH1 Mutation",
      "IDH1 R132",
      "IDH1 R132C",
      "IDH1 R132H",
      "IDH1 R132S",
      "IDH1 R132G",
      "IDH1 R132L",
      "Oligodendroglioma"
    ],
    "interventions": [
      "Olutasidenib + TMZ"
    ],
    "primary_completion_date": "2029-06",
    "completion_date": "2035-06",
    "results_first_posted": null,
    "last_update_posted": "2025-02-21",
    "enrollment": null,
    "sponsor": "Rigel Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Rigel Pharmaceuticals"
  },
  {
    "ticker": "RIGL",
    "nct_id": "NCT00446095",
    "title": "Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell Lymphoma",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lymphoma"
    ],
    "interventions": [
      "fostamatinib"
    ],
    "primary_completion_date": "2010-04",
    "completion_date": "2010-10",
    "results_first_posted": "2014-12-18",
    "last_update_posted": "2016-09-19",
    "enrollment": null,
    "sponsor": "Rigel Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Rigel Pharmaceuticals"
  },
  {
    "ticker": "RIGL",
    "nct_id": "NCT01591044",
    "title": "A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Asthma"
    ],
    "interventions": [
      "Placebo",
      "R940343 1mg",
      "R940343 2mg"
    ],
    "primary_completion_date": "2013-07",
    "completion_date": "2013-07",
    "results_first_posted": "2016-09-29",
    "last_update_posted": "2016-09-29",
    "enrollment": null,
    "sponsor": "Rigel Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Rigel Pharmaceuticals"
  },
  {
    "ticker": "RIGL",
    "nct_id": "NCT01733992",
    "title": "A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Keratoconjunctivitis Sicca"
    ],
    "interventions": [
      "R348 Ophthalmic Solution, 0.2%",
      "R348 Ophthalmic Solution, 0.5%",
      "R348 Ophthalmic Solution, 1.0%",
      "Placebo"
    ],
    "primary_completion_date": "2013-02",
    "completion_date": "2013-02",
    "results_first_posted": null,
    "last_update_posted": "2014-08-04",
    "enrollment": null,
    "sponsor": "Rigel Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Rigel Pharmaceuticals"
  },
  {
    "ticker": "RIGL",
    "nct_id": "NCT00752999",
    "title": "Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus Erythematosus",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Systemic Lupus Erythematosus"
    ],
    "interventions": [
      "Fostamatinib Disodium (R935788)",
      "Placebo"
    ],
    "primary_completion_date": "2009-11",
    "completion_date": "2010-03",
    "results_first_posted": null,
    "last_update_posted": "2012-04-30",
    "enrollment": null,
    "sponsor": "Rigel Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Rigel Pharmaceuticals"
  },
  {
    "ticker": "RIGL",
    "nct_id": "NCT00326339",
    "title": "Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rheumatoid Arthritis"
    ],
    "interventions": [
      "R788",
      "Placebo"
    ],
    "primary_completion_date": "2007-10",
    "completion_date": "2007-12",
    "results_first_posted": null,
    "last_update_posted": "2009-04-20",
    "enrollment": null,
    "sponsor": "Rigel Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Rigel Pharmaceuticals"
  },
  {
    "ticker": "RIGL",
    "nct_id": "NCT01900249",
    "title": "To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Keratoconjunctivitis Sicca"
    ],
    "interventions": [
      "R348 Ophthalmic Solution, 0.2%",
      "R348 Ophthalmic Solution, 0.5%",
      "Placebo"
    ],
    "primary_completion_date": "2014-07",
    "completion_date": "2014-07",
    "results_first_posted": "2016-10-03",
    "last_update_posted": "2016-10-03",
    "enrollment": null,
    "sponsor": "Rigel Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Rigel Pharmaceuticals"
  },
  {
    "ticker": "RIGL",
    "nct_id": "NCT00665626",
    "title": "Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rheumatoid Arthritis"
    ],
    "interventions": [
      "Fostamatinib disodium (R935788)",
      "Placebo"
    ],
    "primary_completion_date": "2009-06",
    "completion_date": "2009-06",
    "results_first_posted": "2016-07-15",
    "last_update_posted": "2017-05-01",
    "enrollment": null,
    "sponsor": "Rigel Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Rigel Pharmaceuticals"
  },
  {
    "ticker": "RIGL",
    "nct_id": "NCT02112838",
    "title": "Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "IGA Nephropathy"
    ],
    "interventions": [
      "Fostamatinib 150 mg",
      "Fostamatinib 100 mg",
      "Placebo"
    ],
    "primary_completion_date": "2018-03-23",
    "completion_date": "2018-11-12",
    "results_first_posted": "2019-06-27",
    "last_update_posted": "2019-06-27",
    "enrollment": null,
    "sponsor": "Rigel Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Rigel Pharmaceuticals"
  },
  {
    "ticker": "RIGL",
    "nct_id": "NCT02076412",
    "title": "A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Immune Thrombocytopenic Purpura"
    ],
    "interventions": [
      "Fostamatinib Disodium",
      "Placebo"
    ],
    "primary_completion_date": "2016-08",
    "completion_date": "2016-08",
    "results_first_posted": "2019-01-25",
    "last_update_posted": "2019-01-25",
    "enrollment": null,
    "sponsor": "Rigel Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Rigel Pharmaceuticals"
  },
  {
    "ticker": "RIGL",
    "nct_id": "NCT02433236",
    "title": "Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "IGA Nephropathy"
    ],
    "interventions": [
      "Fostamatinib Disodium tablet 100 mg",
      "Fostamatinib Disodium tablet 150 mg"
    ],
    "primary_completion_date": "2015-09",
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2015-10-23",
    "enrollment": null,
    "sponsor": "Rigel Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Rigel Pharmaceuticals"
  },
  {
    "ticker": "RIGL",
    "nct_id": "NCT04904276",
    "title": "Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy",
    "status": "TERMINATED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "ITP",
      "Immune Thrombocytopenia"
    ],
    "interventions": [
      "Fostamatinib"
    ],
    "primary_completion_date": "2022-11-17",
    "completion_date": "2022-11-17",
    "results_first_posted": null,
    "last_update_posted": "2024-03-15",
    "enrollment": null,
    "sponsor": "Rigel Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Rigel Pharmaceuticals"
  },
  {
    "ticker": "RIGL",
    "nct_id": "NCT01597050",
    "title": "Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lupus Erythematosus, Discoid",
      "Lupus Erythematosus, Systemic"
    ],
    "interventions": [
      "R932333",
      "Placebo"
    ],
    "primary_completion_date": "2013-09",
    "completion_date": "2013-09",
    "results_first_posted": "2016-06-08",
    "last_update_posted": "2016-07-14",
    "enrollment": null,
    "sponsor": "Rigel Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Rigel Pharmaceuticals"
  },
  {
    "ticker": "RIGL",
    "nct_id": "NCT00665925",
    "title": "Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rheumatoid Arthritis"
    ],
    "interventions": [
      "Fostamatinib disodium (R935788)",
      "Fostamatinib disodium (R935788)",
      "Placebo"
    ],
    "primary_completion_date": "2009-06",
    "completion_date": "2009-06",
    "results_first_posted": "2016-06-13",
    "last_update_posted": "2016-09-16",
    "enrollment": null,
    "sponsor": "Rigel Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Rigel Pharmaceuticals"
  },
  {
    "ticker": "RIGL",
    "nct_id": "NCT02040623",
    "title": "Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Graft-versus-host Disease"
    ],
    "interventions": [
      "R348 Ophthalmic Solution, 0.2%",
      "R348 Ophthalmic Solution, 0.5%",
      "Placebo Ophthalmic Solution"
    ],
    "primary_completion_date": "2016-07",
    "completion_date": "2016-07",
    "results_first_posted": "2016-10-10",
    "last_update_posted": "2016-10-10",
    "enrollment": null,
    "sponsor": "Rigel Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Rigel Pharmaceuticals"
  },
  {
    "ticker": "RIGL",
    "nct_id": "NCT03764618",
    "title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Warm Antibody Autoimmune Hemolytic Anemia"
    ],
    "interventions": [
      "Fostamatinib disodium",
      "Placebo"
    ],
    "primary_completion_date": "2022-04-11",
    "completion_date": "2022-04-11",
    "results_first_posted": "2023-05-25",
    "last_update_posted": "2023-05-25",
    "enrollment": null,
    "sponsor": "Rigel Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Rigel Pharmaceuticals"
  },
  {
    "ticker": "RIGL",
    "nct_id": "NCT04629703",
    "title": "Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Covid19",
      "SARS (Severe Acute Respiratory Syndrome)",
      "SARS Pneumonia",
      "SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere",
      "Pneumonia",
      "Pneumonia, Viral"
    ],
    "interventions": [
      "Fostamatinib",
      "Placebo"
    ],
    "primary_completion_date": "2022-09-05",
    "completion_date": "2022-09-05",
    "results_first_posted": null,
    "last_update_posted": "2023-08-18",
    "enrollment": null,
    "sponsor": "Rigel Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Rigel Pharmaceuticals"
  },
  {
    "ticker": "RIGL",
    "nct_id": "NCT03363334",
    "title": "Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP",
    "status": "NO_LONGER_AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Immune Thrombocytopenic Purpura"
    ],
    "interventions": [
      "Fostamatinib disodium 100 mg",
      "Fostamatinib disodium 150 mg"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2018-08-01",
    "enrollment": null,
    "sponsor": "Rigel Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Rigel Pharmaceuticals"
  },
  {
    "ticker": "RLAY",
    "nct_id": "NCT05759949",
    "title": "First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "PIK3CA Mutation",
      "Solid Tumor, Adult",
      "HER2-negative Breast Cancer",
      "Breast Cancer",
      "Metastatic Breast Cancer",
      "Advanced Breast Cancer",
      "Unresectable Solid Tumor",
      "Hormone Receptor Positive Tumor"
    ],
    "interventions": [
      "RLY-5836",
      "Fulvestrant",
      "Palbociclib",
      "Ribociclib",
      "Abemaciclib"
    ],
    "primary_completion_date": "2025-03-18",
    "completion_date": "2025-04-11",
    "results_first_posted": null,
    "last_update_posted": "2025-05-16",
    "enrollment": null,
    "sponsor": "Relay Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Relay Therapeutics"
  },
  {
    "ticker": "RLAY",
    "nct_id": "NCT06789913",
    "title": "A Phase 2 Study of Mutant-selective PI3K\u03b1 Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "PIK3CA-Related Overgrowth Spectrum (PROS)",
      "Lymphatic Malformations",
      "Vascular Malformations",
      "PIK3CA Mutation",
      "CLOVES Syndrome",
      "Klippel Trenaunay Syndrome",
      "Megalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP)"
    ],
    "interventions": [
      "RLY-2608",
      "Placebo"
    ],
    "primary_completion_date": "2031-07",
    "completion_date": "2031-10",
    "results_first_posted": null,
    "last_update_posted": "2026-01-08",
    "enrollment": null,
    "sponsor": "Relay Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Relay Therapeutics"
  },
  {
    "ticker": "RLAY",
    "nct_id": "NCT05216432",
    "title": "First-in-Human Study of Mutant-selective PI3K\u03b1 Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "PIK3CA Mutation",
      "Solid Tumor, Adult",
      "HER2-negative Breast Cancer",
      "Breast Cancer",
      "Metastatic Breast Cancer",
      "Advanced Breast Cancer",
      "Unresectable Solid Tumor"
    ],
    "interventions": [
      "RLY-2608",
      "Fulvestrant",
      "Palbociclib 125mg",
      "Ribociclib 400mg",
      "Ribociclib 600mg",
      "PF-07220060 100mg",
      "PF-07220060 300 mg"
    ],
    "primary_completion_date": "2027-04-30",
    "completion_date": "2027-04-30",
    "results_first_posted": null,
    "last_update_posted": "2025-09-22",
    "enrollment": null,
    "sponsor": "Relay Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Relay Therapeutics"
  },
  {
    "ticker": "RLAY",
    "nct_id": "NCT06982521",
    "title": "Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "PIK3CA Mutation",
      "HER2- Negative Breast Cancer",
      "Hormone Receptor Positive Tumor",
      "Breast Cancer",
      "Metastatic Breast Cancer",
      "Advanced Breast Cancer"
    ],
    "interventions": [
      "RLY-2608",
      "Capivasertib",
      "Fulvestrant"
    ],
    "primary_completion_date": "2028-04-30",
    "completion_date": "2031-12-31",
    "results_first_posted": null,
    "last_update_posted": "2025-12-31",
    "enrollment": null,
    "sponsor": "Relay Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Relay Therapeutics"
  },
  {
    "ticker": "RVMD",
    "nct_id": "NCT06162221",
    "title": "Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-Small Cell Lung Cancer, NSCLC",
      "KRAS, NRAS, HRAS-mutated NSCLC",
      "KRAS G12C-mutated Solid Tumors, Lung Cancer",
      "Lung Cancer Stage IV, Advanced Solid Tumor, Cancer",
      "RAS G12D-mutated NSCLC"
    ],
    "interventions": [
      "RMC-6291",
      "RMC-6236",
      "Pembrolizumab",
      "Cisplatin",
      "Carboplatin",
      "Pemetrexed",
      "RMC-9805"
    ],
    "primary_completion_date": "2027-06",
    "completion_date": "2028-12",
    "results_first_posted": null,
    "last_update_posted": "2026-01-12",
    "enrollment": null,
    "sponsor": "Revolution Medicines, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Revolution Medicines"
  },
  {
    "ticker": "RVMD",
    "nct_id": "NCT05379985",
    "title": "Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-small Cell Lung Cancer (NSCLC)",
      "Colorectal Cancer (CRC)",
      "Pancreatic Ductal Adenocarcinoma (PDAC)",
      "Advanced Solid Tumors"
    ],
    "interventions": [
      "RMC-6236"
    ],
    "primary_completion_date": "2027-05-31",
    "completion_date": "2027-07-26",
    "results_first_posted": null,
    "last_update_posted": "2025-11-12",
    "enrollment": null,
    "sponsor": "Revolution Medicines, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Revolution Medicines"
  },
  {
    "ticker": "RVMD",
    "nct_id": "NCT06625320",
    "title": "Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pancreatic Cancer",
      "PDAC",
      "PDAC - Pancreatic Ductal Adenocarcinoma"
    ],
    "interventions": [
      "RMC-6236",
      "Gemcitabine",
      "nab-paclitaxel",
      "Irinotecan",
      "Liposomal irinotecan",
      "5-fluorouracil",
      "leucovorin",
      "Oxaliplatin"
    ],
    "primary_completion_date": "2026-06",
    "completion_date": "2027-12",
    "results_first_posted": null,
    "last_update_posted": "2025-12-12",
    "enrollment": null,
    "sponsor": "Revolution Medicines, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Revolution Medicines"
  },
  {
    "ticker": "RVMD",
    "nct_id": "NCT04774952",
    "title": "Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumors"
    ],
    "interventions": [
      "RMC-5552"
    ],
    "primary_completion_date": "2024-05-06",
    "completion_date": "2024-06-28",
    "results_first_posted": null,
    "last_update_posted": "2025-04-15",
    "enrollment": null,
    "sponsor": "Revolution Medicines, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Revolution Medicines"
  },
  {
    "ticker": "RVMD",
    "nct_id": "NCT03989115",
    "title": "Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor"
    ],
    "interventions": [
      "RMC-4630",
      "Cobimetinib",
      "Drug: Osimertinib"
    ],
    "primary_completion_date": "2022-02-08",
    "completion_date": "2022-02-08",
    "results_first_posted": "2023-06-26",
    "last_update_posted": "2023-06-26",
    "enrollment": null,
    "sponsor": "Revolution Medicines, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Revolution Medicines"
  },
  {
    "ticker": "RVMD",
    "nct_id": "NCT06128551",
    "title": "Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRAS G12C Mutant Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-Small Cell Lung Cancer (NSCLC)",
      "Colorectal Cancer",
      "Pancreatic Ductal Adenocarcinoma"
    ],
    "interventions": [
      "Assigned interventions"
    ],
    "primary_completion_date": "2026-11-30",
    "completion_date": "2026-11-30",
    "results_first_posted": null,
    "last_update_posted": "2025-03-27",
    "enrollment": null,
    "sponsor": "Revolution Medicines, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Revolution Medicines"
  },
  {
    "ticker": "RVMD",
    "nct_id": "NCT07349537",
    "title": "Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-small Cell Lung Cancer (NSCLC)",
      "Colorectal Cancer (CRC)",
      "Pancreatic Adenocarcinoma",
      "Pancreatic Ductal Adenocarcinoma (PDAC)",
      "PDAC",
      "CRC",
      "NSCLC",
      "Pancreatic Cancer",
      "Lung Cancer (NSCLC)",
      "Advanced Solid Tumors"
    ],
    "interventions": [
      "RMC-5127",
      "daraxonrasib",
      "cetuximab"
    ],
    "primary_completion_date": "2028-04",
    "completion_date": "2028-10",
    "results_first_posted": null,
    "last_update_posted": "2026-01-26",
    "enrollment": null,
    "sponsor": "Revolution Medicines, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Revolution Medicines"
  },
  {
    "ticker": "RVMD",
    "nct_id": "NCT05462717",
    "title": "Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-Small Cell Lung Cancer (NSCLC)",
      "Colorectal Cancer (CRC)",
      "Pancreatic Ductal Adenocarcinoma",
      "Advanced Solid Tumor"
    ],
    "interventions": [
      "RMC-6291"
    ],
    "primary_completion_date": "2024-11",
    "completion_date": "2025-12",
    "results_first_posted": null,
    "last_update_posted": "2024-11-07",
    "enrollment": null,
    "sponsor": "Revolution Medicines, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Revolution Medicines"
  },
  {
    "ticker": "RXRX",
    "nct_id": "NCT06005974",
    "title": "A Study of REC-4881 in Participants with Cancers Which Have an AXIN1 or APC Mutation",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "AXIN1 Gene Mutation",
      "APC Gene Mutation",
      "Solid Tumor"
    ],
    "interventions": [
      "REC-4881"
    ],
    "primary_completion_date": "2027-01",
    "completion_date": "2027-01",
    "results_first_posted": null,
    "last_update_posted": "2024-11-29",
    "enrollment": null,
    "sponsor": "Recursion Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Recursion Pharmaceuticals"
  },
  {
    "ticker": "RXRX",
    "nct_id": "NCT06536465",
    "title": "The Clostridioides Difficile Trial of REC-3964",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Recurrent Clostridioides Difficile Infection"
    ],
    "interventions": [
      "REC-3964"
    ],
    "primary_completion_date": "2025-05-06",
    "completion_date": "2025-05-06",
    "results_first_posted": "2025-11-17",
    "last_update_posted": "2025-11-17",
    "enrollment": null,
    "sponsor": "Recursion Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Recursion Pharmaceuticals"
  },
  {
    "ticker": "RXRX",
    "nct_id": "NCT06678659",
    "title": "A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Unresectable",
      "Locally Advanced",
      "Metastatic Cancers",
      "Relapsed/Refractory Lymphomas"
    ],
    "interventions": [
      "REC-1245"
    ],
    "primary_completion_date": "2028-10-30",
    "completion_date": "2028-10-30",
    "results_first_posted": null,
    "last_update_posted": "2025-12-05",
    "enrollment": null,
    "sponsor": "Recursion Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Recursion Pharmaceuticals"
  },
  {
    "ticker": "RXRX",
    "nct_id": "NCT05130866",
    "title": "Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Neurofibromatosis Type 2"
    ],
    "interventions": [
      "REC-2282",
      "Placebo"
    ],
    "primary_completion_date": "2025-08-18",
    "completion_date": "2025-08-18",
    "results_first_posted": null,
    "last_update_posted": "2025-10-07",
    "enrollment": null,
    "sponsor": "Recursion Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Recursion Pharmaceuticals"
  },
  {
    "ticker": "RXRX",
    "nct_id": "NCT05985655",
    "title": "Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumor",
      "Head and Neck Squamous Cell Carcinoma (HNSCC)",
      "Pancreatic Adenocarcinoma",
      "Non-small Cell Lung Cancer (NSCLC)",
      "Breast Carcinoma",
      "High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)",
      "Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma"
    ],
    "interventions": [
      "GTAEXS617",
      "SoC"
    ],
    "primary_completion_date": "2028-01",
    "completion_date": "2028-05",
    "results_first_posted": null,
    "last_update_posted": "2025-09-05",
    "enrollment": null,
    "sponsor": "Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Recursion Pharmaceuticals"
  },
  {
    "ticker": "RXRX",
    "nct_id": "NCT05552755",
    "title": "Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Familial Adenomatous Polyposis"
    ],
    "interventions": [
      "REC-4881",
      "Placebo"
    ],
    "primary_completion_date": "2026-07",
    "completion_date": "2026-07",
    "results_first_posted": null,
    "last_update_posted": "2025-12-04",
    "enrollment": null,
    "sponsor": "Recursion Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Recursion Pharmaceuticals"
  },
  {
    "ticker": "RXRX",
    "nct_id": "NCT05085561",
    "title": "The Symptomatic Cerebral Cavernous Malformation Trial of REC-994",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cerebral Cavernous Malformation"
    ],
    "interventions": [
      "REC-994",
      "Placebo"
    ],
    "primary_completion_date": "2025-06-30",
    "completion_date": "2025-06-30",
    "results_first_posted": null,
    "last_update_posted": "2025-08-06",
    "enrollment": null,
    "sponsor": "Recursion Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Recursion Pharmaceuticals"
  },
  {
    "ticker": "RXRX",
    "nct_id": "NCT06980116",
    "title": "Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsed or Refractory B-cell Malignancies"
    ],
    "interventions": [
      "EXS73565"
    ],
    "primary_completion_date": "2028-06",
    "completion_date": "2028-12",
    "results_first_posted": null,
    "last_update_posted": "2025-12-03",
    "enrollment": null,
    "sponsor": "Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Recursion Pharmaceuticals"
  },
  {
    "ticker": "SEPN",
    "nct_id": "NCT07069036",
    "title": "A Study to Evaluate Single and Multiple Doses of SEP-631 in Healthy Adult Volunteers",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "SEP-631",
      "Placebo"
    ],
    "primary_completion_date": "2026-03",
    "completion_date": "2026-04",
    "results_first_posted": null,
    "last_update_posted": "2025-07-16",
    "enrollment": null,
    "sponsor": "Septerna, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Septerna"
  },
  {
    "ticker": "SGMO",
    "nct_id": "NCT00400634",
    "title": "Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Idiopathic Parkinson's Disease"
    ],
    "interventions": [
      "CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])",
      "Sham Surgery"
    ],
    "primary_completion_date": "2008-11",
    "completion_date": "2008-11",
    "results_first_posted": "2012-08-14",
    "last_update_posted": "2022-11-10",
    "enrollment": null,
    "sponsor": "Sangamo Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Sangamo Therapeutics"
  },
  {
    "ticker": "SGMO",
    "nct_id": "NCT00665145",
    "title": "Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes Mellitus, Type 1",
      "Diabetes Mellitus, Type 2",
      "Diabetic Polyneuropathy"
    ],
    "interventions": [
      "SB-509",
      "SB-509",
      "Placebo",
      "SB-509"
    ],
    "primary_completion_date": "2009-10",
    "completion_date": "2009-10",
    "results_first_posted": null,
    "last_update_posted": "2012-11-01",
    "enrollment": null,
    "sponsor": "Sangamo Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Sangamo Therapeutics"
  },
  {
    "ticker": "SGMO",
    "nct_id": "NCT01044654",
    "title": "Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HIV Infection",
      "HIV Infections"
    ],
    "interventions": [
      "SB-728-T"
    ],
    "primary_completion_date": "2014-12",
    "completion_date": "2014-12",
    "results_first_posted": null,
    "last_update_posted": "2015-03-13",
    "enrollment": null,
    "sponsor": "Sangamo Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Sangamo Therapeutics"
  },
  {
    "ticker": "SGMO",
    "nct_id": "NCT01543152",
    "title": "Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HIV"
    ],
    "interventions": [
      "SB-728-T",
      "SB-728-T",
      "SB-728-T",
      "SB-728-T",
      "SB-728-T"
    ],
    "primary_completion_date": "2017-07-07",
    "completion_date": "2017-07-07",
    "results_first_posted": "2021-04-21",
    "last_update_posted": "2021-05-24",
    "enrollment": null,
    "sponsor": "Sangamo Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Sangamo Therapeutics"
  },
  {
    "ticker": "SGMO",
    "nct_id": "NCT00876863",
    "title": "Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alzheimer's Disease"
    ],
    "interventions": [
      "CERE-110: Adeno-Associated Virus injection Surgery",
      "Placebo Surgery"
    ],
    "primary_completion_date": "2015-08-13",
    "completion_date": "2015-08-13",
    "results_first_posted": null,
    "last_update_posted": "2020-12-21",
    "enrollment": null,
    "sponsor": "Sangamo Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Sangamo Therapeutics"
  },
  {
    "ticker": "SGMO",
    "nct_id": "NCT00476931",
    "title": "Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes Mellitus, Type 1",
      "Diabetes Mellitus, Type 2",
      "Diabetic Polyneuropathy"
    ],
    "interventions": [
      "SB-509",
      "Placebo"
    ],
    "primary_completion_date": "2010-07",
    "completion_date": "2010-12",
    "results_first_posted": null,
    "last_update_posted": "2012-11-01",
    "enrollment": null,
    "sponsor": "Sangamo Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Sangamo Therapeutics"
  },
  {
    "ticker": "SGMO",
    "nct_id": "NCT00406458",
    "title": "Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes Mellitus, Type 1",
      "Diabetes Mellitus, Type 2",
      "Diabetic Polyneuropathy"
    ],
    "interventions": [
      "SB-509",
      "Normal Saline"
    ],
    "primary_completion_date": "2008-12",
    "completion_date": "2009-05",
    "results_first_posted": null,
    "last_update_posted": "2012-11-01",
    "enrollment": null,
    "sponsor": "Sangamo Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Sangamo Therapeutics"
  },
  {
    "ticker": "SGMO",
    "nct_id": "NCT00087789",
    "title": "CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alzheimer's Disease"
    ],
    "interventions": [
      "CERE-110: Adeno-Associated Virus Delivery of NGF"
    ],
    "primary_completion_date": "2010-05",
    "completion_date": "2010-05",
    "results_first_posted": null,
    "last_update_posted": "2022-11-10",
    "enrollment": null,
    "sponsor": "Sangamo Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Sangamo Therapeutics"
  },
  {
    "ticker": "SGMO",
    "nct_id": "NCT04817774",
    "title": "Safety & Tolerability Study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal Transplant Recipients",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Kidney Transplant Rejection",
      "End Stage Renal Disease"
    ],
    "interventions": [
      "TX200-TR101"
    ],
    "primary_completion_date": "2024-07-11",
    "completion_date": "2025-10-29",
    "results_first_posted": null,
    "last_update_posted": "2025-02-10",
    "enrollment": null,
    "sponsor": "Sangamo Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Sangamo Therapeutics"
  },
  {
    "ticker": "SGMO",
    "nct_id": "NCT01252641",
    "title": "Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HIV",
      "HIV Infection"
    ],
    "interventions": [
      "SB-728-T"
    ],
    "primary_completion_date": "2014-12",
    "completion_date": "2015-05",
    "results_first_posted": null,
    "last_update_posted": "2019-09-20",
    "enrollment": null,
    "sponsor": "Sangamo Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Sangamo Therapeutics"
  },
  {
    "ticker": "SGMO",
    "nct_id": "NCT00748501",
    "title": "Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Amyotrophic Lateral Sclerosis"
    ],
    "interventions": [
      "SB-509"
    ],
    "primary_completion_date": "2010-06",
    "completion_date": "2010-06",
    "results_first_posted": null,
    "last_update_posted": "2012-11-01",
    "enrollment": null,
    "sponsor": "Sangamo Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Sangamo Therapeutics"
  },
  {
    "ticker": "SGMO",
    "nct_id": "NCT05145062",
    "title": "Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400.",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Blood and Lymphatic Diseases"
    ],
    "interventions": [
      "BIVV003",
      "ST-400"
    ],
    "primary_completion_date": "2038-07-14",
    "completion_date": "2038-07-14",
    "results_first_posted": null,
    "last_update_posted": "2025-11-12",
    "enrollment": null,
    "sponsor": "Sangamo Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Sangamo Therapeutics"
  },
  {
    "ticker": "SGMO",
    "nct_id": "NCT00252850",
    "title": "Safety of CERE-120 (AAV2-NTN) in Subjects With Idiopathic Parkinson's Disease",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Parkinson's Disease"
    ],
    "interventions": [
      "CERE-120: AAV2-NTN"
    ],
    "primary_completion_date": "2007-03",
    "completion_date": "2007-03",
    "results_first_posted": null,
    "last_update_posted": "2022-11-10",
    "enrollment": null,
    "sponsor": "Sangamo Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Sangamo Therapeutics"
  },
  {
    "ticker": "SGMO",
    "nct_id": "NCT06980948",
    "title": "Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Neuropathic Pain"
    ],
    "interventions": [
      "ST-503",
      "Sham (No Treatment)"
    ],
    "primary_completion_date": "2027-07",
    "completion_date": "2028-07",
    "results_first_posted": null,
    "last_update_posted": "2025-10-28",
    "enrollment": null,
    "sponsor": "Sangamo Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Sangamo Therapeutics"
  },
  {
    "ticker": "SGMO",
    "nct_id": "NCT05039866",
    "title": "Long-Term Follow-up of Subjects Who Were Treated With ST-920",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Fabry Disease",
      "Fabry Disease, Cardiac Variant"
    ],
    "interventions": [
      "ST-920"
    ],
    "primary_completion_date": "2029-03",
    "completion_date": "2039-03",
    "results_first_posted": null,
    "last_update_posted": "2025-05-25",
    "enrollment": null,
    "sponsor": "Sangamo Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Sangamo Therapeutics"
  },
  {
    "ticker": "SGMO",
    "nct_id": "NCT01079325",
    "title": "Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes Mellitus, Type 1",
      "Diabetes Mellitus, Type 2",
      "Diabetic Polyneuropathy"
    ],
    "interventions": [
      "SB-509",
      "Saline"
    ],
    "primary_completion_date": "2015-05",
    "completion_date": "2016-04",
    "results_first_posted": null,
    "last_update_posted": "2022-05-23",
    "enrollment": null,
    "sponsor": "Sangamo Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Sangamo Therapeutics"
  },
  {
    "ticker": "SGMO",
    "nct_id": "NCT05987527",
    "title": "Long-Term Follow-Up of TX200-TR101 (STEADFAST Long Term)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Kidney Transplant Rejection",
      "End Stage Renal Disease"
    ],
    "interventions": [
      "Blood sample"
    ],
    "primary_completion_date": "2039-06-11",
    "completion_date": "2039-06-11",
    "results_first_posted": null,
    "last_update_posted": "2025-12-04",
    "enrollment": null,
    "sponsor": "Sangamo Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Sangamo Therapeutics"
  },
  {
    "ticker": "SGMO",
    "nct_id": "NCT03653247",
    "title": "A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Sickle Cell Disease"
    ],
    "interventions": [
      "Plerixafor",
      "Busulfan",
      "BIVV003"
    ],
    "primary_completion_date": "2025-07-17",
    "completion_date": "2025-07-17",
    "results_first_posted": null,
    "last_update_posted": "2025-09-12",
    "enrollment": null,
    "sponsor": "Sangamo Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Sangamo Therapeutics"
  },
  {
    "ticker": "SGMO",
    "nct_id": "NCT00985517",
    "title": "Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Idiopathic Parkinson's Disease"
    ],
    "interventions": [
      "CERE-120: Adeno-Associated Virus Delivery of Neurturin",
      "Sham Surgery"
    ],
    "primary_completion_date": "2014-11-09",
    "completion_date": "2017-11-16",
    "results_first_posted": "2020-03-26",
    "last_update_posted": "2020-04-16",
    "enrollment": null,
    "sponsor": "Sangamo Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Sangamo Therapeutics"
  },
  {
    "ticker": "SRRK",
    "nct_id": "NCT04291079",
    "title": "SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cancer"
    ],
    "interventions": [
      "SRK-181",
      "anti-PD-(L)1 antibody therapy"
    ],
    "primary_completion_date": "2025-04-14",
    "completion_date": "2025-04-14",
    "results_first_posted": null,
    "last_update_posted": "2025-04-29",
    "enrollment": null,
    "sponsor": "Scholar Rock, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Scholar Rock"
  },
  {
    "ticker": "SRRK",
    "nct_id": "NCT06445075",
    "title": "Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Overweight and Obesity"
    ],
    "interventions": [
      "Apitegromab",
      "Placebo",
      "Tirzepatide"
    ],
    "primary_completion_date": "2025-03-04",
    "completion_date": "2025-06-17",
    "results_first_posted": null,
    "last_update_posted": "2026-01-23",
    "enrollment": null,
    "sponsor": "Scholar Rock, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Scholar Rock"
  },
  {
    "ticker": "SRRK",
    "nct_id": "NCT07047144",
    "title": "A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Spinal Muscular Atrophy",
      "SMA",
      "Spinal Muscular Atrophy Type 2",
      "Spinal Muscular Atrophy Type 3",
      "Neuromuscular Manifestations",
      "Anti-myostatin"
    ],
    "interventions": [
      "Apitegromab",
      "Nusinersen",
      "Risdiplam"
    ],
    "primary_completion_date": "2028-11",
    "completion_date": "2029-03",
    "results_first_posted": null,
    "last_update_posted": "2026-01-26",
    "enrollment": null,
    "sponsor": "Scholar Rock, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Scholar Rock"
  },
  {
    "ticker": "SRRK",
    "nct_id": "NCT05626855",
    "title": "Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Spinal Muscular Atrophy",
      "Spinal Muscular Atrophy Type 3",
      "Spinal Muscular Atrophy Type 2",
      "SMA",
      "Neuromuscular Diseases",
      "Muscular Atrophy",
      "Atrophy",
      "Muscular Atrophy, Spinal",
      "Neuromuscular Manifestations",
      "Anti-myostatin"
    ],
    "interventions": [
      "Apitegromab"
    ],
    "primary_completion_date": "2026-11-01",
    "completion_date": "2029-05-02",
    "results_first_posted": null,
    "last_update_posted": "2025-05-25",
    "enrollment": null,
    "sponsor": "Scholar Rock, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Scholar Rock"
  },
  {
    "ticker": "SRRK",
    "nct_id": "NCT05156320",
    "title": "Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Spinal Muscular Atrophy",
      "Spinal Muscular Atrophy Type 3",
      "Spinal Muscular Atrophy Type 2",
      "SMA",
      "Neuromuscular Diseases",
      "Muscular Atrophy",
      "Atrophy",
      "Muscular Atrophy, Spinal",
      "Neuromuscular Manifestations",
      "Anti-myostatin"
    ],
    "interventions": [
      "Apitegromab",
      "Placebo"
    ],
    "primary_completion_date": "2024-12-18",
    "completion_date": "2024-12-18",
    "results_first_posted": null,
    "last_update_posted": "2026-01-22",
    "enrollment": null,
    "sponsor": "Scholar Rock, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Scholar Rock"
  },
  {
    "ticker": "SRRK",
    "nct_id": "NCT03921528",
    "title": "An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Spinal Muscular Atrophy",
      "Spinal Muscular Atrophy Type 3",
      "Spinal Muscular Atrophy Type 2",
      "SMA",
      "Neuromuscular Diseases",
      "Muscular Atrophy",
      "Atrophy",
      "Muscular Atrophy, Spinal",
      "Neuromuscular Manifestations"
    ],
    "interventions": [
      "SRK-015"
    ],
    "primary_completion_date": "2021-01-19",
    "completion_date": "2024-02-28",
    "results_first_posted": "2022-11-17",
    "last_update_posted": "2024-12-02",
    "enrollment": null,
    "sponsor": "Scholar Rock, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Scholar Rock"
  },
  {
    "ticker": "SRRK",
    "nct_id": "NCT06877689",
    "title": "EAP of Apitegromab for Patients With Spinal Muscular Atrophy",
    "status": "AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "SMA"
    ],
    "interventions": [
      "Apitegromab"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2025-03-14",
    "enrollment": null,
    "sponsor": "Scholar Rock, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Scholar Rock"
  },
  {
    "ticker": "STRO",
    "nct_id": "NCT07227168",
    "title": "A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Head and Neck Squamous Cell Carcinoma HNSCC",
      "Non-Small Cell Lung Cancer NSCLC",
      "Esophageal Cancer",
      "Gastric Cancer",
      "Colorectal Cancer",
      "Pancreatic Ductal Adenocarcinoma (PDAC)",
      "Cervical Cancer",
      "Endometrial Cancer",
      "Urothelial Cancer"
    ],
    "interventions": [
      "STRO-004",
      "Pembrolizumab"
    ],
    "primary_completion_date": "2027-12",
    "completion_date": "2028-04",
    "results_first_posted": null,
    "last_update_posted": "2026-01-22",
    "enrollment": null,
    "sponsor": "Sutro Biopharma, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Sutro Biopharma"
  },
  {
    "ticker": "STRO",
    "nct_id": "NCT06555263",
    "title": "Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lung Cancer",
      "Lung Cancer Metastatic",
      "Lung Cancer, Nonsmall Cell",
      "Lung Cancer Non-Small Cell Stage IIIB",
      "Lung Cancer Non-small Cell Stage IV",
      "Lung Cancer, Non-small Cell"
    ],
    "interventions": [
      "Luveltamab tazevibulin"
    ],
    "primary_completion_date": "2025-05-01",
    "completion_date": "2025-05-01",
    "results_first_posted": null,
    "last_update_posted": "2025-08-22",
    "enrollment": null,
    "sponsor": "Sutro Biopharma, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Sutro Biopharma"
  },
  {
    "ticker": "STRO",
    "nct_id": "NCT03748186",
    "title": "Study of STRO-002, an Anti-Folate Receptor Alpha (FolR\u03b1) Antibody Drug Conjugate in Ovarian & Endometrial Cancers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ovarian Cancer",
      "Ovarian Carcinoma",
      "Ovary Cancer",
      "Endometrial Cancer",
      "Endometrioid Adenocarcinoma",
      "Fallopian Tube Cancer",
      "Primary Peritoneal Carcinoma"
    ],
    "interventions": [
      "STRO-002"
    ],
    "primary_completion_date": "2024-06-04",
    "completion_date": "2024-06-04",
    "results_first_posted": null,
    "last_update_posted": "2025-08-20",
    "enrollment": null,
    "sponsor": "Sutro Biopharma, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Sutro Biopharma"
  },
  {
    "ticker": "STRO",
    "nct_id": "NCT06679582",
    "title": "Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Myeloid Leukemia (AML)"
    ],
    "interventions": [
      "Luveltamab tazevibulin"
    ],
    "primary_completion_date": "2025-06-01",
    "completion_date": "2025-06-01",
    "results_first_posted": null,
    "last_update_posted": "2025-08-24",
    "enrollment": null,
    "sponsor": "Sutro Biopharma, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Sutro Biopharma"
  },
  {
    "ticker": "STRO",
    "nct_id": "NCT05200364",
    "title": "A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ovarian Cancer",
      "Ovarian Carcinoma",
      "Ovary Cancer",
      "Fallopian Tube Cancer",
      "Primary Peritoneal Carcinoma"
    ],
    "interventions": [
      "STRO-002",
      "Bevacizumab"
    ],
    "primary_completion_date": "2025-06-01",
    "completion_date": "2025-06-01",
    "results_first_posted": null,
    "last_update_posted": "2025-09-22",
    "enrollment": null,
    "sponsor": "Sutro Biopharma, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Sutro Biopharma"
  },
  {
    "ticker": "STRO",
    "nct_id": "NCT03424603",
    "title": "Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "B-cell Lymphoma",
      "Non Hodgkin Lymphoma",
      "Multiple Myeloma",
      "Follicular Lymphoma",
      "Mantle Cell Lymphoma",
      "Diffuse Large B Cell Lymphoma",
      "Indolent Lymphoma",
      "B Cells--Tumors"
    ],
    "interventions": [
      "STRO-001"
    ],
    "primary_completion_date": "2024-02-15",
    "completion_date": "2024-03-15",
    "results_first_posted": null,
    "last_update_posted": "2024-06-11",
    "enrollment": null,
    "sponsor": "Sutro Biopharma, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Sutro Biopharma"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT00772603",
    "title": "Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Epilepsies, Partial"
    ],
    "interventions": [
      "Placebo",
      "2400mg SPN-804",
      "1200mg SPN-804"
    ],
    "primary_completion_date": "2010-04",
    "completion_date": "2010-11",
    "results_first_posted": "2014-02-11",
    "last_update_posted": "2014-02-11",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT03597503",
    "title": "Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Attention Deficit Hyperactivity Disorder"
    ],
    "interventions": [
      "SPN-810",
      "Placebo"
    ],
    "primary_completion_date": "2020-01-22",
    "completion_date": "2020-01-22",
    "results_first_posted": "2024-02-20",
    "last_update_posted": "2024-04-24",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT03787758",
    "title": "A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part B",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Huntington Disease"
    ],
    "interventions": [
      "SAGE-718"
    ],
    "primary_completion_date": "2019-10-07",
    "completion_date": "2019-10-07",
    "results_first_posted": null,
    "last_update_posted": "2025-09-17",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT00918424",
    "title": "Long Term Study of the Safety of OXC XR as in Pediatric Epilepsy Subjects",
    "status": "APPROVED_FOR_MARKETING",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Epilepsy"
    ],
    "interventions": [
      "Oxcarbazepine Extended Release"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2017-05-09",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT02942017",
    "title": "A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Postpartum Depression"
    ],
    "interventions": [
      "Placebo",
      "SAGE-547 90 \u03bcg/kg/h"
    ],
    "primary_completion_date": "2017-09-17",
    "completion_date": "2017-10-11",
    "results_first_posted": "2019-06-13",
    "last_update_posted": "2025-09-15",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT01364662",
    "title": "A Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Impulsive Aggression Comorbid With ADHD"
    ],
    "interventions": [
      "SPN-810",
      "Placebo"
    ],
    "primary_completion_date": "2012-10",
    "completion_date": "2012-10",
    "results_first_posted": null,
    "last_update_posted": "2021-02-11",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT02942004",
    "title": "A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Postpartum Depression"
    ],
    "interventions": [
      "Placebo",
      "SAGE-547 60 \u03bcg/kg/h",
      "SAGE-547 90 \u03bcg/kg/h"
    ],
    "primary_completion_date": "2017-09-24",
    "completion_date": "2017-10-19",
    "results_first_posted": "2019-06-13",
    "last_update_posted": "2025-10-14",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT07141329",
    "title": "SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Focal Onset Seizures"
    ],
    "interventions": [
      "SPN-817"
    ],
    "primary_completion_date": "2027-12-31",
    "completion_date": "2027-12-31",
    "results_first_posted": null,
    "last_update_posted": "2025-10-10",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT06259331",
    "title": "Evaluation of Viloxazine and Its Metabolite 5-Hydroxy-viloxazine Glucuronide Into Breast Milk in Healthy Lactating Women",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Lactating Women"
    ],
    "interventions": [
      "SPN-812 (600mg, QD)"
    ],
    "primary_completion_date": "2023-09-20",
    "completion_date": "2023-09-20",
    "results_first_posted": "2024-06-06",
    "last_update_posted": "2024-06-06",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT05518578",
    "title": "Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy",
    "status": "UNKNOWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Epilepsy",
      "Seizures, Epileptic"
    ],
    "interventions": [
      "SPN-817"
    ],
    "primary_completion_date": "2024-10",
    "completion_date": "2025-01",
    "results_first_posted": null,
    "last_update_posted": "2023-03-20",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT03474770",
    "title": "BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Focal Impaired Awareness Seizures"
    ],
    "interventions": [
      "BIS-001ER"
    ],
    "primary_completion_date": "2026-12-30",
    "completion_date": "2026-12-30",
    "results_first_posted": null,
    "last_update_posted": "2022-08-30",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT05107128",
    "title": "A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Huntington's Disease"
    ],
    "interventions": [
      "SAGE-718",
      "Placebo"
    ],
    "primary_completion_date": "2024-09-04",
    "completion_date": "2024-10-03",
    "results_first_posted": "2025-09-05",
    "last_update_posted": "2025-09-15",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT02633527",
    "title": "Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Attention-Deficit/Hyperactivity Disorder (ADHD)"
    ],
    "interventions": [
      "Placebo",
      "100mg SPN-812",
      "200mg SPN-812",
      "300mg SPN-812",
      "400mg SPN-812"
    ],
    "primary_completion_date": "2016-07-25",
    "completion_date": "2016-07-25",
    "results_first_posted": "2021-10-27",
    "last_update_posted": "2021-10-27",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT00626236",
    "title": "Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Attention Deficit Disorder With Hyperactivity",
      "Conduct Disorder"
    ],
    "interventions": [
      "SPN-810",
      "SPN-810",
      "SPN-810",
      "SPN-810"
    ],
    "primary_completion_date": "2009-09-23",
    "completion_date": "2009-09-23",
    "results_first_posted": "2025-09-16",
    "last_update_posted": "2025-12-09",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT02339064",
    "title": "Infusion of Apomorphine: Long-term Safety Study",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Idiopathic Parkinson's Disease"
    ],
    "interventions": [
      "apomorphine infusion"
    ],
    "primary_completion_date": "2018-12",
    "completion_date": "2025-12",
    "results_first_posted": null,
    "last_update_posted": "2025-06-19",
    "enrollment": null,
    "sponsor": "MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT02610868",
    "title": "Open-Label and Single-Arm Study of MYOBLOC\u00ae in the Treatment of Troublesome Sialorrhea in Adults",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Sialorrhea"
    ],
    "interventions": [
      "MYOBLOC"
    ],
    "primary_completion_date": "2017-06",
    "completion_date": "2017-06",
    "results_first_posted": "2019-11-04",
    "last_update_posted": "2021-07-13",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT00918047",
    "title": "Study of PK and Safety of OXC (Oxcarbazepine) XR (Extended Release) as Adjunctive Therapy in Pediatric Epilepsy Patients",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Epilepsies, Partial"
    ],
    "interventions": [
      "SPN-804O"
    ],
    "primary_completion_date": "2010-07",
    "completion_date": "2010-11",
    "results_first_posted": null,
    "last_update_posted": "2017-07-02",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT05318937",
    "title": "A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Parkinson Disease",
      "Cognitive Dysfunction"
    ],
    "interventions": [
      "SAGE-718-matching placebo",
      "SAGE-718"
    ],
    "primary_completion_date": "2024-01-17",
    "completion_date": "2024-02-23",
    "results_first_posted": "2025-02-06",
    "last_update_posted": "2025-09-12",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT01770145",
    "title": "Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Parkinson's Disease",
      "Motor Symptoms",
      "Akinesia",
      "Hypomobility",
      "Delayed Levodopa Onset"
    ],
    "interventions": [
      "APOKYN",
      "L-dopa",
      "Trimethobenzamide"
    ],
    "primary_completion_date": "2014-04",
    "completion_date": "2014-04",
    "results_first_posted": "2015-09-07",
    "last_update_posted": "2023-08-14",
    "enrollment": null,
    "sponsor": "MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT02618434",
    "title": "Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Attention Deficit Hyperactivity Disorder (ADHD)"
    ],
    "interventions": [
      "SPN-810 (18 mg)",
      "SPN-810 (36 mg)",
      "Placebo"
    ],
    "primary_completion_date": "2019-11-15",
    "completion_date": "2020-02-14",
    "results_first_posted": "2024-03-18",
    "last_update_posted": "2024-03-18",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT02477618",
    "title": "A Study With SAGE-547 for Super-Refractory Status Epilepticus",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Super-Refractory Status Epilepticus"
    ],
    "interventions": [
      "SAGE-547",
      "Placebo"
    ],
    "primary_completion_date": "2017-07-18",
    "completion_date": "2017-08-11",
    "results_first_posted": "2019-05-02",
    "last_update_posted": "2025-10-14",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT05655520",
    "title": "A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Huntington's Disease"
    ],
    "interventions": [
      "SAGE-718"
    ],
    "primary_completion_date": "2025-01-20",
    "completion_date": "2025-01-20",
    "results_first_posted": "2025-12-17",
    "last_update_posted": "2025-12-17",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT03615703",
    "title": "Functional MRI Study in Healthy Children Engaged in Aggressive Behaviors",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Impulsive Aggression"
    ],
    "interventions": [],
    "primary_completion_date": "2019-03-15",
    "completion_date": "2019-03-15",
    "results_first_posted": null,
    "last_update_posted": "2019-06-10",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT02691182",
    "title": "Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Attention Deficit Hyperactivity Disorder (ADHD)"
    ],
    "interventions": [
      "SPN-810"
    ],
    "primary_completion_date": "2021-05",
    "completion_date": "2021-05",
    "results_first_posted": "2024-05-16",
    "last_update_posted": "2024-05-16",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT03247530",
    "title": "Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHD",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "ADHD"
    ],
    "interventions": [
      "Placebo",
      "100mg SPN-812",
      "200mg SPN-812"
    ],
    "primary_completion_date": "2018-09-12",
    "completion_date": "2018-09-12",
    "results_first_posted": "2021-06-02",
    "last_update_posted": "2021-07-02",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT04050293",
    "title": "Therapy for Migraine Prevention in Children 6-11 Years of Age",
    "status": "TERMINATED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Migraine Disorders",
      "Headache Disorders"
    ],
    "interventions": [
      "SPN-538",
      "Placebo"
    ],
    "primary_completion_date": "2023-03-01",
    "completion_date": "2023-03-01",
    "results_first_posted": "2025-11-21",
    "last_update_posted": "2026-01-22",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT02052739",
    "title": "Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Super-refractory Status Epilepticus"
    ],
    "interventions": [
      "SAGE-547"
    ],
    "primary_completion_date": "2015-05-03",
    "completion_date": "2015-05-03",
    "results_first_posted": "2022-05-03",
    "last_update_posted": "2025-09-15",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT04781140",
    "title": "Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD",
    "status": "RECRUITING",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Attention-Deficit/Hyperactivity Disorder"
    ],
    "interventions": [
      "100mg SPN-812",
      "Placebo"
    ],
    "primary_completion_date": "2026-06",
    "completion_date": "2026-06",
    "results_first_posted": null,
    "last_update_posted": "2026-01-08",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT03924492",
    "title": "Expanded Access Protocol of ZULRESSO\u2122 (Brexanolone) Injection for Adult Patients With Postpartum Depression",
    "status": "APPROVED_FOR_MARKETING",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Postpartum Depression"
    ],
    "interventions": [
      "ZULRESSO (brexanolone) injection"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2025-09-15",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT04016792",
    "title": "Classroom Study of SPN-812 in Children With ADHD",
    "status": "WITHDRAWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "ADHD"
    ],
    "interventions": [
      "Placebo",
      "200 mg SPN-812"
    ],
    "primary_completion_date": "2020-09",
    "completion_date": "2020-11",
    "results_first_posted": null,
    "last_update_posted": "2019-09-18",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT05049343",
    "title": "Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteer"
    ],
    "interventions": [
      "SAGE-904",
      "Placebo",
      "Ketamine"
    ],
    "primary_completion_date": "2021-11-20",
    "completion_date": "2021-12-03",
    "results_first_posted": null,
    "last_update_posted": "2025-09-17",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT02618408",
    "title": "Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Attention Deficit Hyperactivity Disorder (ADHD)"
    ],
    "interventions": [
      "SPN-810 (18 mg)",
      "SPN-810 (36 mg)",
      "Placebo"
    ],
    "primary_completion_date": "2019-09-04",
    "completion_date": "2019-10-24",
    "results_first_posted": "2022-11-01",
    "last_update_posted": "2024-01-02",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT03771586",
    "title": "A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteer"
    ],
    "interventions": [
      "SAGE-718",
      "Placebo"
    ],
    "primary_completion_date": "2018-12-17",
    "completion_date": "2019-01-02",
    "results_first_posted": null,
    "last_update_posted": "2025-09-17",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT04602624",
    "title": "A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alzheimer Disease",
      "Cognitive Dysfunction",
      "Mild Dementia"
    ],
    "interventions": [
      "SAGE-718"
    ],
    "primary_completion_date": "2021-09-28",
    "completion_date": "2021-09-28",
    "results_first_posted": "2024-10-10",
    "last_update_posted": "2025-09-15",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT03247543",
    "title": "Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "ADHD"
    ],
    "interventions": [
      "Placebo",
      "200mg SPN-812",
      "400mg SPN-812"
    ],
    "primary_completion_date": "2018-10-17",
    "completion_date": "2018-10-17",
    "results_first_posted": "2021-07-08",
    "last_update_posted": "2021-07-08",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT06185985",
    "title": "Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood Symptoms",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Attention-Deficit/Hyperactivity Disorder"
    ],
    "interventions": [
      "SPN-812"
    ],
    "primary_completion_date": "2025-01",
    "completion_date": "2025-01",
    "results_first_posted": null,
    "last_update_posted": "2025-01-13",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT02433314",
    "title": "An Open Label, Expanded Access Protocol With SAGE-547 for Super-Refractory Status Epilepticus",
    "status": "NO_LONGER_AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Super-Refractory Status Epilepticus"
    ],
    "interventions": [
      "SAGE-547"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2025-09-15",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT02023606",
    "title": "Phase I Study to Assess the Absorption, Metabolism, and Excretion of [14C] Labeled SPN-810M",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Impulsive Aggression Comorbid With ADHD"
    ],
    "interventions": [
      "SPN-810M"
    ],
    "primary_completion_date": "2013-12",
    "completion_date": "2013-12",
    "results_first_posted": null,
    "last_update_posted": "2016-05-13",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT03844906",
    "title": "A Study to Assess Electrophysiology, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of SAGE-718 Using Ketamine Challenge in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteer"
    ],
    "interventions": [
      "SAGE-718",
      "Placebo"
    ],
    "primary_completion_date": "2019-03-18",
    "completion_date": "2019-04-01",
    "results_first_posted": null,
    "last_update_posted": "2025-09-17",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT03665038",
    "title": "A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Post Partum Depression"
    ],
    "interventions": [
      "Brexanolone"
    ],
    "primary_completion_date": "2021-01-08",
    "completion_date": "2021-01-08",
    "results_first_posted": "2022-08-11",
    "last_update_posted": "2025-09-15",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT03247556",
    "title": "Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "ADHD"
    ],
    "interventions": [
      "Placebo",
      "400mg SPN-812",
      "600mg SPN-812"
    ],
    "primary_completion_date": "2019-02-14",
    "completion_date": "2019-02-14",
    "results_first_posted": "2021-07-02",
    "last_update_posted": "2021-07-02",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT04016779",
    "title": "Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Attention-Deficit/Hyperactivity Disorder (ADHD)"
    ],
    "interventions": [
      "Placebo",
      "SPN-812"
    ],
    "primary_completion_date": "2020-10-10",
    "completion_date": "2020-10-10",
    "results_first_posted": "2022-07-12",
    "last_update_posted": "2022-07-12",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT02614547",
    "title": "A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Severe Postpartum Depression"
    ],
    "interventions": [
      "SAGE-547",
      "Placebo"
    ],
    "primary_completion_date": "2016-06-22",
    "completion_date": "2016-06-22",
    "results_first_posted": "2021-09-13",
    "last_update_posted": "2025-09-15",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT04815967",
    "title": "Efficacy and Safety Study of MYOBLOC\u00ae in the Treatment of Adult Upper Limb Spasticity",
    "status": "UNKNOWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Spasticity",
      "Cerebrovascular Accident",
      "Multiple Sclerosis",
      "Traumatic Brain Injury",
      "Cervical Spinal Cord Injury",
      "Cerebral Palsy"
    ],
    "interventions": [
      "Phase 2; Low Dose MYOBLOC",
      "Phase 2; High Dose MYOBLOC",
      "Phase 2; Placebo",
      "Phase 3; MYOBLOC",
      "Phase 3; Placebo"
    ],
    "primary_completion_date": "2023-07-01",
    "completion_date": "2024-07-01",
    "results_first_posted": null,
    "last_update_posted": "2023-03-07",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT04786990",
    "title": "Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Attention-Deficit/Hyperactivity Disorder (ADHD)"
    ],
    "interventions": [
      "SPN-812"
    ],
    "primary_completion_date": "2023-05-23",
    "completion_date": "2023-07-26",
    "results_first_posted": "2024-05-01",
    "last_update_posted": "2024-05-01",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT03247517",
    "title": "Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "ADHD"
    ],
    "interventions": [
      "Placebo",
      "200mg SPN-812",
      "400mg SPN-812"
    ],
    "primary_completion_date": "2018-10-17",
    "completion_date": "2018-10-17",
    "results_first_posted": "2021-06-18",
    "last_update_posted": "2021-06-18",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT01416064",
    "title": "Open-Label, Extension Study to 810P202",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Impulsive Aggression Comorbid With ADHD in Children"
    ],
    "interventions": [
      "Molindone"
    ],
    "primary_completion_date": "2013-01",
    "completion_date": "2013-02",
    "results_first_posted": null,
    "last_update_posted": "2017-05-02",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT04476017",
    "title": "A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Parkinson Disease",
      "Cognitive Dysfunction"
    ],
    "interventions": [
      "SAGE-718"
    ],
    "primary_completion_date": "2022-03-25",
    "completion_date": "2022-03-25",
    "results_first_posted": "2023-06-06",
    "last_update_posted": "2025-09-15",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT05358821",
    "title": "28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Huntington Disease"
    ],
    "interventions": [
      "SAGE-718",
      "Placebo"
    ],
    "primary_completion_date": "2024-02-29",
    "completion_date": "2024-04-10",
    "results_first_posted": "2025-05-06",
    "last_update_posted": "2025-09-15",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT05102552",
    "title": "Evaluating the Safety and Relative Bioavailability of Three SPN-817 Treatments (A, B and C) in Healthy Adult Subjects",
    "status": "COMPLETED",
    "phase": "EARLY_PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteer"
    ],
    "interventions": [
      "SPN-817, Treatment B",
      "SPN-817, Treatment C",
      "BIS-001, Treatment A"
    ],
    "primary_completion_date": "2022-03-25",
    "completion_date": "2022-08-15",
    "results_first_posted": null,
    "last_update_posted": "2022-08-30",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT03944785",
    "title": "Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Idiopathic Parkinson Disease"
    ],
    "interventions": [
      "XADAGO (safinamide)"
    ],
    "primary_completion_date": "2019-12-23",
    "completion_date": "2020-01-10",
    "results_first_posted": "2021-02-18",
    "last_update_posted": "2023-06-07",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT01994109",
    "title": "Efficacy and Safety Study of MYOBLOC\u00ae Followed by Open-Label Multiple-Treatment With MYOBLOC\u00ae in the Treatment of Troublesome Sialorrhea in Adult Subjects",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Sialorrhea"
    ],
    "interventions": [
      "MYOBLOC",
      "PLACEBO"
    ],
    "primary_completion_date": "2016-01",
    "completion_date": "2017-01",
    "results_first_posted": "2019-08-15",
    "last_update_posted": "2021-07-13",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT01284530",
    "title": "Evaluation of the Pharmacokinetics, Safety, and Tolerability of TPM XR as Adjunctive Therapy in Pediatric Subjects With Epilepsy",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Epilepsy"
    ],
    "interventions": [
      "TPM XR"
    ],
    "primary_completion_date": "2012-06",
    "completion_date": "2012-06",
    "results_first_posted": null,
    "last_update_posted": "2016-06-02",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT07226661",
    "title": "Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder (MDD)"
    ],
    "interventions": [
      "SPN-821 2400 mg",
      "Placebo"
    ],
    "primary_completion_date": "2026-12-31",
    "completion_date": "2027-01-31",
    "results_first_posted": null,
    "last_update_posted": "2025-11-10",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT04143217",
    "title": "Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Attention-Deficit/Hyperactivity Disorder"
    ],
    "interventions": [
      "SPN-812"
    ],
    "primary_completion_date": "2022-07-26",
    "completion_date": "2022-12-14",
    "results_first_posted": "2024-02-13",
    "last_update_posted": "2024-02-13",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT03770780",
    "title": "A Study to Assess the Electrophysiology, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response Using Magnetic Resonance Imaging of SAGE-718 Using a Ketamine Challenge in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteer"
    ],
    "interventions": [
      "SAGE-718",
      "Placebo"
    ],
    "primary_completion_date": "2019-03-08",
    "completion_date": "2019-03-22",
    "results_first_posted": null,
    "last_update_posted": "2025-09-17",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT05384977",
    "title": "Mass Balance Study of NV-5138 in Healthy Male Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "[14C]-NV-5138"
    ],
    "primary_completion_date": "2021-12-09",
    "completion_date": "2021-12-09",
    "results_first_posted": null,
    "last_update_posted": "2022-05-23",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT06798896",
    "title": "RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults with Focal Onset Seizures",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Focal Onset Seizures"
    ],
    "interventions": [
      "SPN-817",
      "Placebo"
    ],
    "primary_completion_date": "2026-10",
    "completion_date": "2026-10",
    "results_first_posted": null,
    "last_update_posted": "2025-02-06",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT05619692",
    "title": "A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Mild Cognitive Impairment",
      "Mild Dementia",
      "Alzheimer's Disease"
    ],
    "interventions": [
      "SAGE-718",
      "SAGE-718-matching Placebo"
    ],
    "primary_completion_date": "2024-06-05",
    "completion_date": "2024-07-09",
    "results_first_posted": "2025-06-18",
    "last_update_posted": "2025-09-15",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT00908349",
    "title": "Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Partial Epilepsy"
    ],
    "interventions": [
      "Oxcarbazepine XR"
    ],
    "primary_completion_date": "2011-11",
    "completion_date": "2011-11",
    "results_first_posted": "2017-05-31",
    "last_update_posted": "2017-05-31",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT02549573",
    "title": "Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN\u00ae",
    "status": "TERMINATED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Parkinson's Disease",
      "Motor Symptoms"
    ],
    "interventions": [
      "APOKYN",
      "Physical Therapy"
    ],
    "primary_completion_date": "2016-12",
    "completion_date": "2016-12",
    "results_first_posted": "2018-01-12",
    "last_update_posted": "2023-09-01",
    "enrollment": null,
    "sponsor": "MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT07219927",
    "title": "Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States:",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Parkinson Disease"
    ],
    "interventions": [
      "Observational study"
    ],
    "primary_completion_date": "2027-08-01",
    "completion_date": "2027-08-01",
    "results_first_posted": null,
    "last_update_posted": "2025-10-22",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT01107496",
    "title": "Evaluation of Immediate-Release Viloxazine in Adults With ADHD",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Attention-Deficit/Hyperactivity Disorder (ADHD)"
    ],
    "interventions": [
      "IR Viloxazine",
      "Placebo"
    ],
    "primary_completion_date": "2010-12",
    "completion_date": "2010-12",
    "results_first_posted": "2024-10-15",
    "last_update_posted": "2024-10-15",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT01114854",
    "title": "A Conversion Study of Immediate Release (IR) and Modified Release (MR) Forms of Topiramate (TPM)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Epilepsy"
    ],
    "interventions": [
      "Topiramate IR",
      "Topiramate ER"
    ],
    "primary_completion_date": "2010-12",
    "completion_date": "2011-01",
    "results_first_posted": null,
    "last_update_posted": "2017-05-18",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT04099667",
    "title": "Efficacy and Safety Study of MYOBLOC\u00ae in the Treatment of Adult Lower Limb Spasticity",
    "status": "UNKNOWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Spasticity"
    ],
    "interventions": [
      "Phase 2; Low Dose MYOBLOC",
      "Phase 2; High Dose MYOBLOC",
      "Phase 2; Placebo",
      "Phase 3; MYOBLOC",
      "Phase 3; Placebo"
    ],
    "primary_completion_date": "2023-04",
    "completion_date": "2024-07",
    "results_first_posted": null,
    "last_update_posted": "2023-03-07",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT02736656",
    "title": "Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Attention-Deficit/Hyperactivity Disorder"
    ],
    "interventions": [
      "SPN-812"
    ],
    "primary_completion_date": "2026-09",
    "completion_date": "2026-09",
    "results_first_posted": null,
    "last_update_posted": "2025-06-25",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT03156439",
    "title": "Bioavailability, Safety, and Tolerability of BIS-001 ER",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Epilepsy, Complex Partial"
    ],
    "interventions": [
      "BIS-001 ER"
    ],
    "primary_completion_date": "2017-09-30",
    "completion_date": "2017-09-30",
    "results_first_posted": null,
    "last_update_posted": "2018-01-18",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT05645432",
    "title": "An Open-Label Study Evaluating Brexanolone in Adults With Tinnitus",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Tinnitus"
    ],
    "interventions": [
      "Brexanolone"
    ],
    "primary_completion_date": "2023-11-21",
    "completion_date": "2023-11-21",
    "results_first_posted": "2024-12-12",
    "last_update_posted": "2025-09-15",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT03638466",
    "title": "Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHD",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Attention Deficit Hyperactivity Disorder (ADHD)",
      "Impulsive Aggression"
    ],
    "interventions": [
      "Functional Magnetic Resonance Imaging (fMRI)",
      "Magnetic Resonance Spectroscopy (MRS)",
      "Point Subtraction Aggression Paradigm (PSAP) Task",
      "SPN-810",
      "Placebo"
    ],
    "primary_completion_date": "2019-11-07",
    "completion_date": "2019-11-07",
    "results_first_posted": "2025-05-02",
    "last_update_posted": "2025-05-02",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "SUPN",
    "nct_id": "NCT05059600",
    "title": "A Study To Assess The Safe-Use Conditions For Administration of ZULRESSO\u00ae in a Home Setting",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Postpartum Depression"
    ],
    "interventions": [
      "ZULRESSO\u00ae"
    ],
    "primary_completion_date": "2022-07-14",
    "completion_date": "2022-07-14",
    "results_first_posted": "2023-07-19",
    "last_update_posted": "2025-09-15",
    "enrollment": null,
    "sponsor": "Supernus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Supernus Pharmaceuticals"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT01791049",
    "title": "TD-1607 SAD Study in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Serious Infections Due to Known or Suspected Gram-positive Pathogens"
    ],
    "interventions": [
      "TD-1607",
      "Placebo"
    ],
    "primary_completion_date": "2013-08",
    "completion_date": "2013-10",
    "results_first_posted": null,
    "last_update_posted": "2021-01-19",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT02705755",
    "title": "TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Neurogenic Orthostatic Hypotension",
      "Multiple System Atrophy (MSA) With Orthostatic Hypotension",
      "Pure Autonomic Failure",
      "Parkinson Disease",
      "Hypotension, Orthostatic",
      "Orthostatic Hypotension",
      "Pure Autonomic Failure With Orthostatic Hypotension",
      "Parkinson Disease With Orthostatic Hypotension"
    ],
    "interventions": [
      "TD-9855",
      "Placebo"
    ],
    "primary_completion_date": "2018-07-24",
    "completion_date": "2018-11-28",
    "results_first_posted": "2022-09-26",
    "last_update_posted": "2022-09-26",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT01333540",
    "title": "A Study to Assess the Safety, Tolerability and Clinical Activity of TD-1211 in Patients With Opioid-Induced Constipation",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Opioid-induced Constipation (OIC)"
    ],
    "interventions": [
      "TD-1211",
      "Placebo"
    ],
    "primary_completion_date": "2012-05",
    "completion_date": "2012-06",
    "results_first_posted": null,
    "last_update_posted": "2021-01-25",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT03555617",
    "title": "Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Inflammatory Bowel Disease"
    ],
    "interventions": [
      "TD-1473",
      "Itraconazole"
    ],
    "primary_completion_date": "2018-07-15",
    "completion_date": "2018-07-15",
    "results_first_posted": null,
    "last_update_posted": "2021-01-14",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT01040637",
    "title": "A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced Constipation",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy",
      "Opioid-induced Constipation"
    ],
    "interventions": [
      "TD-1211",
      "TD-1211",
      "TD-1211",
      "TD-1211",
      "TD-1211",
      "TD-1211",
      "TD-1211",
      "TD-1211",
      "TD-1211",
      "Placebo"
    ],
    "primary_completion_date": "2010-10",
    "completion_date": "2010-10",
    "results_first_posted": null,
    "last_update_posted": "2021-01-20",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT00687700",
    "title": "A Study to Investigate the Pharmacology of a Dual Pharmacophore in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pulmonary Disease, Chronic Obstructive"
    ],
    "interventions": [
      "GSK961081",
      "GSK961081 matching placebo",
      "Propranolol",
      "Propranolol matching placebo"
    ],
    "primary_completion_date": "2008-05-27",
    "completion_date": "2008-05-27",
    "results_first_posted": null,
    "last_update_posted": "2021-10-06",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT03103412",
    "title": "TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects"
    ],
    "interventions": [
      "TD-3504",
      "15N2-tofacitinib",
      "Placebo"
    ],
    "primary_completion_date": "2017-11-08",
    "completion_date": "2017-11-08",
    "results_first_posted": null,
    "last_update_posted": "2021-01-14",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT01401985",
    "title": "A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Opioid Induced Constipation"
    ],
    "interventions": [
      "TD-1211",
      "Placebo"
    ],
    "primary_completion_date": "2012-05",
    "completion_date": "2012-08",
    "results_first_posted": null,
    "last_update_posted": "2021-05-25",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT03432793",
    "title": "Drug-Drug Interaction (DDI) Study for TD-9855",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Drug Drug Interaction (DDI)"
    ],
    "interventions": [
      "TD-9855",
      "Fluvoxamine",
      "Itraconazole",
      "Caffeine"
    ],
    "primary_completion_date": "2018-04-21",
    "completion_date": "2018-04-21",
    "results_first_posted": null,
    "last_update_posted": "2021-01-14",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT01458340",
    "title": "A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Attention-Deficit/Hyperactivity Disorder",
      "ADHD"
    ],
    "interventions": [
      "TD-9855",
      "TD-9855",
      "Placebo"
    ],
    "primary_completion_date": "2013-10",
    "completion_date": "2013-11",
    "results_first_posted": "2022-03-14",
    "last_update_posted": "2022-04-04",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT01702194",
    "title": "TD-1211 IV/Oral Mass Balance Study",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "OIC"
    ],
    "interventions": [
      "TD-1211 IV [C14]",
      "TD-1211 PO [C14]"
    ],
    "primary_completion_date": "2013-02",
    "completion_date": "2013-03",
    "results_first_posted": null,
    "last_update_posted": "2021-01-20",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT01568411",
    "title": "A Fixed-Sequence, Two-Period, Open-Label Drug-Drug Interaction Study to Assess the Effect of an Inhibitor of Cytochrome P450 Isoenzyme 3A4 and Permeability Glycoprotein 1 on the Pharmacokinetics of TD-1211",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "TD-1211",
      "TD-1211+ itraconazole"
    ],
    "primary_completion_date": "2012-06",
    "completion_date": "2012-06",
    "results_first_posted": null,
    "last_update_posted": "2021-01-20",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT03750565",
    "title": "Multiple Dose Ethnobridging PK Study in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Inflammatory Bowel Diseases",
      "IBD"
    ],
    "interventions": [
      "TD-1473 - Dose A",
      "TD-1473 - Dose B",
      "TD-1473 - Dose C",
      "Placebo"
    ],
    "primary_completion_date": "2019-02-13",
    "completion_date": "2019-02-13",
    "results_first_posted": null,
    "last_update_posted": "2021-01-14",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT02903095",
    "title": "Single Ascending Dose Study of TD-1439 in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Subjects"
    ],
    "interventions": [
      "TD-1439",
      "Placebo"
    ],
    "primary_completion_date": "2016-12",
    "completion_date": "2017-02",
    "results_first_posted": null,
    "last_update_posted": "2021-01-19",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT04350736",
    "title": "First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Lung Injury (ALI) Associated With COVID-19",
      "Inflammatory Lung Conditions Associated With COVID-19"
    ],
    "interventions": [
      "TD-0903",
      "Placebo"
    ],
    "primary_completion_date": "2020-06-24",
    "completion_date": "2020-07-01",
    "results_first_posted": null,
    "last_update_posted": "2021-07-01",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT05091723",
    "title": "TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental Oxygenation",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19)"
    ],
    "interventions": [
      "Nezulcitinib (TD-0903) Dose A",
      "Nezulcitinib (TD-0903) Dose B"
    ],
    "primary_completion_date": "2021-11-24",
    "completion_date": "2021-11-24",
    "results_first_posted": null,
    "last_update_posted": "2021-12-10",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT04200573",
    "title": "Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Symptomatic Neurogenic Orthostatic Hypertension",
      "nOH"
    ],
    "interventions": [
      "Ampreloxetine"
    ],
    "primary_completion_date": "2021-08-19",
    "completion_date": "2021-08-19",
    "results_first_posted": null,
    "last_update_posted": "2021-09-08",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT04044339",
    "title": "Single and Multiple Ascending Dose, First-in- Human Study in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "TD-5202",
      "Placebo"
    ],
    "primary_completion_date": "2019-11-27",
    "completion_date": "2019-11-27",
    "results_first_posted": null,
    "last_update_posted": "2021-01-14",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT01644240",
    "title": "A Phase 1, Multiple Intravenous Dose Study to Examine Safety, Tolerability, and PK of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy Subjects",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Gastrointestinal Motility Disorder"
    ],
    "interventions": [
      "TD-8954",
      "Placebo - saline"
    ],
    "primary_completion_date": "2012-11",
    "completion_date": "2012-12",
    "results_first_posted": "2017-08-02",
    "last_update_posted": "2017-08-02",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT05165485",
    "title": "Phase 4 COPD and Suboptimal Inspiratory Flow Rate",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Obstructive Pulmonary Disease"
    ],
    "interventions": [
      "Revefenacin",
      "Tiotropium",
      "Revefenacin Placebo",
      "Tiotropium Placebo"
    ],
    "primary_completion_date": "2023-11-13",
    "completion_date": "2023-11-20",
    "results_first_posted": "2024-12-20",
    "last_update_posted": "2024-12-20",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT02709928",
    "title": "Multiple Ascending Dose Study of TD-0714 in Healthy and Elderly Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Adults, Elderly Subjects"
    ],
    "interventions": [
      "TD-0714",
      "Placebo"
    ],
    "primary_completion_date": "2016-11",
    "completion_date": "2016-12",
    "results_first_posted": null,
    "last_update_posted": "2021-01-19",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT01693692",
    "title": "Phase 2 Study of TD-9855 to Treat Fibromyalgia",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fibromyalgia"
    ],
    "interventions": [
      "TD-9855 Group 1",
      "TD-9855 Group 2",
      "Placebo"
    ],
    "primary_completion_date": "2014-01",
    "completion_date": "2014-04",
    "results_first_posted": "2022-03-04",
    "last_update_posted": "2022-03-04",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT01655771",
    "title": "TD-1211 Single-Dose Study in Elderly and Young Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Constipation"
    ],
    "interventions": [
      "TD-1211 Dose 1",
      "TD-1211 Dose 2"
    ],
    "primary_completion_date": "2013-02",
    "completion_date": "2013-03",
    "results_first_posted": null,
    "last_update_posted": "2021-01-14",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT02818686",
    "title": "TD-1473 for Active Ulcerative Colitis (UC)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ulcerative Colitis, Active Moderate",
      "Ulcerative Colitis, Active Severe"
    ],
    "interventions": [
      "TD-1473",
      "Placebo"
    ],
    "primary_completion_date": "2018-03-29",
    "completion_date": "2018-03-29",
    "results_first_posted": null,
    "last_update_posted": "2021-09-30",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT00887406",
    "title": "Study of GSK961081 in Healthy Volunteer Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pulmonary Disease, Chronic Obstructive"
    ],
    "interventions": [
      "GSK961081 15mcg SD",
      "GSK961081 3mcg SD",
      "GSK961081 50mcg SD",
      "Placebo SD",
      "GSK961081 100mcg SD",
      "GSK961081 200mcg SD",
      "GSK961081 300mcg SD",
      "GSK961081 100mcg RD",
      "GSK961081 300mcg RD",
      "Placebo RD"
    ],
    "primary_completion_date": "2006-10-04",
    "completion_date": "2006-10-04",
    "results_first_posted": null,
    "last_update_posted": "2021-10-06",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT04681079",
    "title": "Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "COVID-19"
    ],
    "interventions": [
      "albuterol sulfate (MDI)",
      "albuterol sulfate (nebulizer)"
    ],
    "primary_completion_date": "2021-11-22",
    "completion_date": "2022-01-18",
    "results_first_posted": null,
    "last_update_posted": "2022-01-28",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT01718938",
    "title": "Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Gastroparesis"
    ],
    "interventions": [
      "velusetrag dose 1",
      "velusetrag dose 2",
      "velusetrag dose 3",
      "placebo"
    ],
    "primary_completion_date": "2013-12",
    "completion_date": "2014-02",
    "results_first_posted": null,
    "last_update_posted": "2018-02-26",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT02267525",
    "title": "The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) Study",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Gastroparesis"
    ],
    "interventions": [
      "Velusetrag",
      "Placebo"
    ],
    "primary_completion_date": "2017-06",
    "completion_date": "2017-06",
    "results_first_posted": null,
    "last_update_posted": "2018-04-17",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT03920254",
    "title": "TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ulcerative Colitis (UC)"
    ],
    "interventions": [
      "TD-1473 Dose A",
      "TD-1473 Dose B",
      "TD-1473 Dose C"
    ],
    "primary_completion_date": "2021-10-27",
    "completion_date": "2021-10-27",
    "results_first_posted": "2022-11-02",
    "last_update_posted": "2022-11-02",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT01949103",
    "title": "TD-1607 MAD Study in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Infections",
      "Bacterial Infections"
    ],
    "interventions": [
      "TD-1607",
      "Placebo"
    ],
    "primary_completion_date": "2014-06",
    "completion_date": "2014-07",
    "results_first_posted": null,
    "last_update_posted": "2021-01-19",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT00442832",
    "title": "TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Staphylococcal Skin Infection"
    ],
    "interventions": [
      "TD-1792",
      "Vancomycin"
    ],
    "primary_completion_date": "2007-05",
    "completion_date": "2007-05",
    "results_first_posted": null,
    "last_update_posted": "2021-01-20",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT01924143",
    "title": "TD-9855 Mass Balance Study",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "ADHD",
      "Fibromyalgia"
    ],
    "interventions": [
      "TD-9855"
    ],
    "primary_completion_date": "2013-11",
    "completion_date": "2013-12",
    "results_first_posted": null,
    "last_update_posted": "2021-01-19",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT04587713",
    "title": "Single Dose Bioavailability and Ethnobridging PK Study in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Intestinal Disorder",
      "Bowel Diseases, Inflammatory"
    ],
    "interventions": [
      "TD-1473 [Tablet A]",
      "TD-1473 [Tablet B]"
    ],
    "primary_completion_date": "2020-12-24",
    "completion_date": "2020-12-27",
    "results_first_posted": null,
    "last_update_posted": "2021-04-09",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT04589260",
    "title": "TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Idiopathic Pulmonary Fibrosis (IPF)"
    ],
    "interventions": [
      "TD-1058",
      "Placebo"
    ],
    "primary_completion_date": "2021-05-06",
    "completion_date": "2021-10-04",
    "results_first_posted": null,
    "last_update_posted": "2022-02-23",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT03408470",
    "title": "TD-1473 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Intestinal Disorders",
      "Bowel Diseases, Inflammatory"
    ],
    "interventions": [
      "TD-1473 oral capsule",
      "[14C]-TD-1473 IV bolus",
      "[14C]-TD-1473 Oral Capsule"
    ],
    "primary_completion_date": "2018-02-21",
    "completion_date": "2018-02-21",
    "results_first_posted": null,
    "last_update_posted": "2021-01-14",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT00674817",
    "title": "An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And Anti-Muscarinic Drugs.",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pulmonary Disease, Chronic Obstructive"
    ],
    "interventions": [
      "400 microgrammes GSK961081",
      "1200 microgrammes GSK961081"
    ],
    "primary_completion_date": "2008-10-01",
    "completion_date": "2008-10-19",
    "results_first_posted": "2017-03-27",
    "last_update_posted": "2021-10-20",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT03758443",
    "title": "Efficacy & Safety of TD-1473 in Ulcerative Colitis",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ulcerative Colitis (UC)"
    ],
    "interventions": [
      "TD-1473 Dose A",
      "TD-1473 Dose B",
      "TD-1473 Dose C",
      "Placebo"
    ],
    "primary_completion_date": "2021-10-20",
    "completion_date": "2021-10-20",
    "results_first_posted": "2022-11-15",
    "last_update_posted": "2022-11-15",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT03652038",
    "title": "Single and Multiple Ascending Dose Study of TD-8236 by Inhalation",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Asthma"
    ],
    "interventions": [
      "TD-8236",
      "Placebo"
    ],
    "primary_completion_date": "2020-07-13",
    "completion_date": "2020-07-13",
    "results_first_posted": null,
    "last_update_posted": "2021-09-30",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT02022306",
    "title": "TD-6450 SAD and MAD in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatitis C"
    ],
    "interventions": [
      "TD-6450",
      "Placebo"
    ],
    "primary_completion_date": "2014-08",
    "completion_date": "2014-09",
    "results_first_posted": null,
    "last_update_posted": "2021-01-14",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT04402866",
    "title": "TD-0903 for ALI Associated With COVID-19",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Lung Injury (ALI) Associated With COVID-19",
      "Lung Inflammation Associated With COVID-19"
    ],
    "interventions": [
      "TD-0903",
      "Placebo"
    ],
    "primary_completion_date": "2021-04-21",
    "completion_date": "2021-04-21",
    "results_first_posted": "2022-03-17",
    "last_update_posted": "2022-03-17",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT02954263",
    "title": "Multiple Ascending Dose Study of TD-1439 in Healthy Adult and Elderly Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Adults, Elderly Subjects"
    ],
    "interventions": [
      "TD-1439",
      "Placebo"
    ],
    "primary_completion_date": "2017-02",
    "completion_date": "2017-04",
    "results_first_posted": null,
    "last_update_posted": "2021-01-20",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT02639078",
    "title": "Single Ascending Dose Study of TD-0714 in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "TD-0714",
      "Placebo Comparator"
    ],
    "primary_completion_date": "2016-02",
    "completion_date": "2016-02",
    "results_first_posted": null,
    "last_update_posted": "2021-10-13",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT04688632",
    "title": "Thorough QT Study to Evaluate Ampreloxetine in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Symptomatic Neurogenic Orthostatic Hypertension",
      "nOH"
    ],
    "interventions": [
      "Ampreloxetine <Dose A>",
      "Ampreloxetine <Dose B>",
      "Ampreloxetine Placebo",
      "Moxifloxacin",
      "Moxifloxacin Placebo"
    ],
    "primary_completion_date": "2021-03-13",
    "completion_date": "2021-03-26",
    "results_first_posted": null,
    "last_update_posted": "2021-04-20",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT00550225",
    "title": "Succinate Salt Version of GSK961081 for Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pulmonary Disease, Chronic Obstructive"
    ],
    "interventions": [
      "GSK961081",
      "GSK961081 matching placebo"
    ],
    "primary_completion_date": "2008-01-08",
    "completion_date": "2008-01-08",
    "results_first_posted": null,
    "last_update_posted": "2021-10-06",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT04150341",
    "title": "Effect of Inhaled TD-8236 on Allergen-induced Asthmatic Response",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Asthma"
    ],
    "interventions": [
      "TD-8236",
      "Placebo"
    ],
    "primary_completion_date": "2020-08-28",
    "completion_date": "2020-09-03",
    "results_first_posted": "2022-03-18",
    "last_update_posted": "2022-03-18",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT02663089",
    "title": "A Phase 1 (Ph1), Single Dose (SD), GSK961081 Absorption, Distribution, Metabolism, and Excretion (ADME) Study in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pulmonary Disease, Chronic Obstructive"
    ],
    "interventions": [
      "[14C]-GSK961081 solution for IV infusion",
      "[14C]-GSK961081 oral solution",
      "GSK961081 dry powder for inhalation"
    ],
    "primary_completion_date": "2016-03-17",
    "completion_date": "2016-03-17",
    "results_first_posted": null,
    "last_update_posted": "2021-10-06",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT02116543",
    "title": "TD-6450 MAD Study in HCV Infected Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatitis C",
      "HCV"
    ],
    "interventions": [
      "TD-6450",
      "Placebo"
    ],
    "primary_completion_date": "2014-10",
    "completion_date": "2014-11",
    "results_first_posted": null,
    "last_update_posted": "2021-01-19",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT02657122",
    "title": "SAD and MAD Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of TD-1473 in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "TD-1473 for SAD",
      "Placebo for SAD",
      "TD-1473 for MAD",
      "Placebo for MAD"
    ],
    "primary_completion_date": "2016-04",
    "completion_date": "2016-04",
    "results_first_posted": null,
    "last_update_posted": "2021-01-19",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TBPH",
    "nct_id": "NCT01459926",
    "title": "A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced Constipation",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Opioid Induced Constipation"
    ],
    "interventions": [
      "TD-1211",
      "TD-1211",
      "TD-1211",
      "Placebo"
    ],
    "primary_completion_date": "2012-05",
    "completion_date": "2012-06",
    "results_first_posted": null,
    "last_update_posted": "2021-01-22",
    "enrollment": null,
    "sponsor": "Theravance Biopharma",
    "collected_at": "2026-01-27",
    "search_term": "Theravance Biopharma"
  },
  {
    "ticker": "TNGX",
    "nct_id": "NCT06065059",
    "title": "Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Cancer",
      "Ovarian Cancer",
      "Pancreas Cancer",
      "Prostate Cancer",
      "BRCA1 Mutation",
      "BRCA-Mutated Ovarian Carcinoma",
      "BRCA-Associated Breast Carcinoma",
      "HRD Positive Advanced Ovarian Cancer"
    ],
    "interventions": [
      "TNG348",
      "Olaparib"
    ],
    "primary_completion_date": "2024-05-22",
    "completion_date": "2024-05-22",
    "results_first_posted": null,
    "last_update_posted": "2024-08-13",
    "enrollment": null,
    "sponsor": "Tango Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Tango Therapeutics"
  },
  {
    "ticker": "TNGX",
    "nct_id": "NCT05732831",
    "title": "Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Locally Advanced Solid Tumor"
    ],
    "interventions": [
      "TNG462",
      "Pembrolizumab"
    ],
    "primary_completion_date": "2026-05",
    "completion_date": "2026-09",
    "results_first_posted": null,
    "last_update_posted": "2025-11-14",
    "enrollment": null,
    "sponsor": "Tango Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Tango Therapeutics"
  },
  {
    "ticker": "TNGX",
    "nct_id": "NCT06922591",
    "title": "Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "PDAC",
      "PDAC - Pancreatic Ductal Adenocarcinoma",
      "NSCLC",
      "RAS Mutation",
      "MTAP Deletion",
      "Lung Cancer",
      "Pancreatic Cancer Metastatic",
      "Thoracic Cancer"
    ],
    "interventions": [
      "TNG462",
      "RMC-9805",
      "RMC-6236",
      "mFOLFIRINOX",
      "gemcitabine/nab-paclitaxel"
    ],
    "primary_completion_date": "2027-06",
    "completion_date": "2027-12",
    "results_first_posted": null,
    "last_update_posted": "2025-12-11",
    "enrollment": null,
    "sponsor": "Tango Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Tango Therapeutics"
  },
  {
    "ticker": "TNGX",
    "nct_id": "NCT05887492",
    "title": "Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non Small Cell Lung Cancer",
      "Solid Tumors, Adult",
      "Lung Cancer",
      "Lung Adenocarcinoma"
    ],
    "interventions": [
      "TNG260",
      "Pembrolizumab"
    ],
    "primary_completion_date": "2026-01",
    "completion_date": "2026-06",
    "results_first_posted": null,
    "last_update_posted": "2025-11-18",
    "enrollment": null,
    "sponsor": "Tango Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Tango Therapeutics"
  },
  {
    "ticker": "TNGX",
    "nct_id": "NCT06810544",
    "title": "Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non Small Cell Lung Cancer",
      "Glioma Glioblastoma Multiforme",
      "Glioma, Malignant",
      "Solid Tumor",
      "Non-Small Cell Adenocarcinoma",
      "Lung Cancer",
      "Brain Tumor"
    ],
    "interventions": [
      "TNG456",
      "abemaciclib"
    ],
    "primary_completion_date": "2027-03-31",
    "completion_date": "2027-09-30",
    "results_first_posted": null,
    "last_update_posted": "2025-11-06",
    "enrollment": null,
    "sponsor": "Tango Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Tango Therapeutics"
  },
  {
    "ticker": "TNGX",
    "nct_id": "NCT05275478",
    "title": "Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Locally Advanced Solid Tumor"
    ],
    "interventions": [
      "TNG908"
    ],
    "primary_completion_date": "2025-12",
    "completion_date": "2025-12",
    "results_first_posted": null,
    "last_update_posted": "2025-11-14",
    "enrollment": null,
    "sponsor": "Tango Therapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Tango Therapeutics"
  },
  {
    "ticker": "TNYA",
    "nct_id": "NCT06228924",
    "title": "Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Arrhythmogenic Right Ventricular Cardiomyopathy"
    ],
    "interventions": [
      "TN-401"
    ],
    "primary_completion_date": "2026-05-01",
    "completion_date": "2029-10-01",
    "results_first_posted": null,
    "last_update_posted": "2025-02-06",
    "enrollment": null,
    "sponsor": "Tenaya Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Tenaya Therapeutics"
  },
  {
    "ticker": "TNYA",
    "nct_id": "NCT05112237",
    "title": "Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Cardiomyopathy"
    ],
    "interventions": [],
    "primary_completion_date": "2028-06",
    "completion_date": "2028-06",
    "results_first_posted": null,
    "last_update_posted": "2024-11-13",
    "enrollment": null,
    "sponsor": "Tenaya Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Tenaya Therapeutics"
  },
  {
    "ticker": "TNYA",
    "nct_id": "NCT06311708",
    "title": "Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Arrhythmogenic Right Ventricular Cardiomyopathy"
    ],
    "interventions": [],
    "primary_completion_date": "2030-03-29",
    "completion_date": "2030-07-11",
    "results_first_posted": null,
    "last_update_posted": "2024-11-01",
    "enrollment": null,
    "sponsor": "Tenaya Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Tenaya Therapeutics"
  },
  {
    "ticker": "TNYA",
    "nct_id": "NCT05836259",
    "title": "Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypertrophic Cardiomyopathy"
    ],
    "interventions": [
      "TN-201"
    ],
    "primary_completion_date": "2027-08",
    "completion_date": "2032-08",
    "results_first_posted": null,
    "last_update_posted": "2025-07-15",
    "enrollment": null,
    "sponsor": "Tenaya Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Tenaya Therapeutics"
  },
  {
    "ticker": "TSHA",
    "nct_id": "NCT05277363",
    "title": "A Study of the Natural Course of SURF1 Deficiency",
    "status": "WITHDRAWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Leigh Syndrome"
    ],
    "interventions": [
      "None (Observational study)"
    ],
    "primary_completion_date": "2022-05-04",
    "completion_date": "2022-05-04",
    "results_first_posted": null,
    "last_update_posted": "2022-05-20",
    "enrollment": null,
    "sponsor": "Taysha Gene Therapies, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Taysha Gene Therapies"
  },
  {
    "ticker": "TSHA",
    "nct_id": "NCT05606614",
    "title": "A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study)",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rett Syndrome"
    ],
    "interventions": [
      "TSHA-102"
    ],
    "primary_completion_date": "2031-06",
    "completion_date": "2031-06",
    "results_first_posted": null,
    "last_update_posted": "2025-12-30",
    "enrollment": null,
    "sponsor": "Taysha Gene Therapies, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Taysha Gene Therapies"
  },
  {
    "ticker": "TSHA",
    "nct_id": "NCT06152237",
    "title": "Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rett Syndrome"
    ],
    "interventions": [
      "TSHA-102"
    ],
    "primary_completion_date": "2028-11-02",
    "completion_date": "2031-11-02",
    "results_first_posted": null,
    "last_update_posted": "2025-10-15",
    "enrollment": null,
    "sponsor": "Taysha Gene Therapies, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Taysha Gene Therapies"
  },
  {
    "ticker": "URGN",
    "nct_id": "NCT02674269",
    "title": "Safety and Efficacy Study of Intravesical Instillations of BotuGelTM, Slow Release RTGel Based Botox\u00ae Formulations, in Idiopathic OAB Patients With Urinary Incontinence (\"INTIMO2\")",
    "status": "WITHDRAWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Overactive Bladder"
    ],
    "interventions": [
      "300 IU of BotuGelTM (60ml)",
      "400 IU of BotuGelTM (60ml)",
      "TC-3 Gel"
    ],
    "primary_completion_date": "2016-10",
    "completion_date": "2016-10",
    "results_first_posted": null,
    "last_update_posted": "2017-06-16",
    "enrollment": null,
    "sponsor": "UroGen Pharma Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "UroGen Pharma"
  },
  {
    "ticker": "URGN",
    "nct_id": "NCT05494411",
    "title": "Named Patient Program for Mitomycin for Pyelocalyceal Solution",
    "status": "AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Urothelial Cancer of Renal Pelvis",
      "Urothelial Carcinoma of the Renal Pelvis and Ureter",
      "Urothelial Carcinoma Ureter",
      "Urothelial Carcinoma Ureter Recurrent",
      "Urothelial Carcinoma",
      "Urothelial Carcinoma Recurrent"
    ],
    "interventions": [
      "Mitomycin for pyelocalyceal solution"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2025-02-28",
    "enrollment": null,
    "sponsor": "UroGen Pharma Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "UroGen Pharma"
  },
  {
    "ticker": "URGN",
    "nct_id": "NCT02307487",
    "title": "Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bladder Cancer",
      "Neoplasms",
      "Urinary Bladder Diseases",
      "Urologic Diseases"
    ],
    "interventions": [
      "120 mg MMC in 90ml gel",
      "140 mg MMC in 90ml gel",
      "160 mg MMC in 90ml gel",
      "120 mg MMC in 60ml gel",
      "140 mg MMC in 60ml gel",
      "160 mg MMC in 60ml gel"
    ],
    "primary_completion_date": "2016-04",
    "completion_date": "2017-06",
    "results_first_posted": null,
    "last_update_posted": "2017-06-16",
    "enrollment": null,
    "sponsor": "UroGen Pharma Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "UroGen Pharma"
  },
  {
    "ticker": "URGN",
    "nct_id": "NCT06774131",
    "title": "A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Upper Urinary Tract Urothelial Carcinoma",
      "Urothelial Carcinoma"
    ],
    "interventions": [
      "UGN-104"
    ],
    "primary_completion_date": "2026-10",
    "completion_date": "2027-10",
    "results_first_posted": null,
    "last_update_posted": "2026-01-16",
    "enrollment": null,
    "sponsor": "UroGen Pharma Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "UroGen Pharma"
  },
  {
    "ticker": "URGN",
    "nct_id": "NCT01997983",
    "title": "Efficacy and Safety of Intravesical Instillations of Botulinum Toxin in TC-3 Gel in IC Patients",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Interstitial Cystitis",
      "IC"
    ],
    "interventions": [
      "TC-3 Gel mixed with Botox (BTX)"
    ],
    "primary_completion_date": "2014-04",
    "completion_date": "2015-08",
    "results_first_posted": null,
    "last_update_posted": "2016-04-12",
    "enrollment": null,
    "sponsor": "UroGen Pharma Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "UroGen Pharma"
  },
  {
    "ticker": "URGN",
    "nct_id": "NCT01803295",
    "title": "Pre-TURBT TC-3 Gel Intravesical Instillation in NMIBC",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Carcinoma of Urinary Bladder, Superficial"
    ],
    "interventions": [
      "40 mg MMC gel",
      "Standard of care MMC mixed with water",
      "80 mg MMC gel"
    ],
    "primary_completion_date": "2016-07",
    "completion_date": "2017-06",
    "results_first_posted": null,
    "last_update_posted": "2017-06-16",
    "enrollment": null,
    "sponsor": "UroGen Pharma Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "UroGen Pharma"
  },
  {
    "ticker": "URGN",
    "nct_id": "NCT01799499",
    "title": "A Prospective Open Label Comparative Dose Ranging Study Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC)",
    "status": "WITHDRAWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non Muscle Invasive Bladder Cancer"
    ],
    "interventions": [
      "TC-3 hydrogel",
      "TC-3 hydrogel",
      "TC-3 hydrogel"
    ],
    "primary_completion_date": "2013-03",
    "completion_date": "2013-03",
    "results_first_posted": null,
    "last_update_posted": "2015-09-01",
    "enrollment": null,
    "sponsor": "UroGen Pharma Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "UroGen Pharma"
  },
  {
    "ticker": "URGN",
    "nct_id": "NCT06331299",
    "title": "A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bladder Cancer",
      "Urothelial Carcinoma",
      "Urothelial Carcinoma Bladder"
    ],
    "interventions": [
      "UGN-103"
    ],
    "primary_completion_date": "2025-09-11",
    "completion_date": "2026-09",
    "results_first_posted": null,
    "last_update_posted": "2026-01-15",
    "enrollment": null,
    "sponsor": "UroGen Pharma Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "UroGen Pharma"
  },
  {
    "ticker": "URGN",
    "nct_id": "NCT05136898",
    "title": "Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bladder Cancer",
      "Urothelial Carcinoma",
      "Urothelial Carcinoma Bladder"
    ],
    "interventions": [
      "UGN-102"
    ],
    "primary_completion_date": "2023-02-02",
    "completion_date": "2023-02-02",
    "results_first_posted": "2024-09-19",
    "last_update_posted": "2024-09-19",
    "enrollment": null,
    "sponsor": "UroGen Pharma Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "UroGen Pharma"
  },
  {
    "ticker": "URGN",
    "nct_id": "NCT05375903",
    "title": "A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-muscle Invasive Bladder Cancer",
      "NMIBC",
      "Carcinoma in Situ of Bladder",
      "Bladder Cancer",
      "Urothelial Carcinoma Bladder",
      "Urothelial Carcinoma Recurrent"
    ],
    "interventions": [
      "UGN-301",
      "UGN-201",
      "Gemcitabine"
    ],
    "primary_completion_date": "2026-01-09",
    "completion_date": "2026-01-09",
    "results_first_posted": null,
    "last_update_posted": "2026-01-14",
    "enrollment": null,
    "sponsor": "UroGen Pharma Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "UroGen Pharma"
  },
  {
    "ticker": "URGN",
    "nct_id": "NCT01648010",
    "title": "Safety and Tolerability Study Which Evaluate Intravesical Instillation With Mitomycin C Mixed With TC-3 Drug Retaining Hydrogel Device In Patients With Muscle Invasive Bladder Cancer",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Carcinoma of Urinary Bladder, Invasive"
    ],
    "interventions": [
      "TC-3 gel",
      "TC-3 gel mixed with Mitomycin C (MMC)"
    ],
    "primary_completion_date": "2013-05",
    "completion_date": "2013-05",
    "results_first_posted": null,
    "last_update_posted": "2013-05-07",
    "enrollment": null,
    "sponsor": "UroGen Pharma Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "UroGen Pharma"
  },
  {
    "ticker": "URGN",
    "nct_id": "NCT04006691",
    "title": "Efficacy and Safety of UGN-101 in Recurrent Patients",
    "status": "WITHDRAWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Carcinoma",
      "Transitional Cell Carcinoma",
      "Transitional Cell Cancer of the Renal Pelvis and Ureter"
    ],
    "interventions": [
      "UGN-101 instillations"
    ],
    "primary_completion_date": "2020-03-31",
    "completion_date": "2020-03-31",
    "results_first_posted": null,
    "last_update_posted": "2020-05-07",
    "enrollment": null,
    "sponsor": "UroGen Pharma Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "UroGen Pharma"
  },
  {
    "ticker": "URGN",
    "nct_id": "NCT02179099",
    "title": "Safety and Efficacy of Intravesical Botulinum Toxin in TC-3 Gel in OAB Patients",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Overactive Bladder"
    ],
    "interventions": [
      "BTX mixed with TC-3 Gel"
    ],
    "primary_completion_date": "2015-11",
    "completion_date": "2016-02",
    "results_first_posted": null,
    "last_update_posted": "2016-03-01",
    "enrollment": null,
    "sponsor": "UroGen Pharma Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "UroGen Pharma"
  },
  {
    "ticker": "URGN",
    "nct_id": "NCT05874921",
    "title": "uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Urothelial Carcinoma",
      "Urothelial Carcinoma Recurrent",
      "Urothelial Carcinoma Ureter",
      "Urothelial Carcinoma Ureter Recurrent",
      "Urothelial Cancer of Renal Pelvis",
      "Urothelial Carcinoma of the Renal Pelvis and Ureter",
      "Carcinoma, Transitional Cell",
      "Transitional Cell Carcinoma of Renal Pelvis"
    ],
    "interventions": [
      "Jelmyto (mitomycin) for pyelocalyceal solution"
    ],
    "primary_completion_date": "2026-04",
    "completion_date": "2028-01",
    "results_first_posted": null,
    "last_update_posted": "2025-02-28",
    "enrollment": null,
    "sponsor": "UroGen Pharma Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "UroGen Pharma"
  },
  {
    "ticker": "URGN",
    "nct_id": "NCT03558503",
    "title": "A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bladder Cancer",
      "Urothelial Carcinoma",
      "Urothelial Carcinoma Bladder"
    ],
    "interventions": [
      "UGN-102"
    ],
    "primary_completion_date": "2020-01-03",
    "completion_date": "2020-10-21",
    "results_first_posted": "2022-07-25",
    "last_update_posted": "2022-09-16",
    "enrollment": null,
    "sponsor": "UroGen Pharma Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "UroGen Pharma"
  },
  {
    "ticker": "URGN",
    "nct_id": "NCT05243550",
    "title": "A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bladder Cancer",
      "Urothelial Carcinoma",
      "Urothelial Carcinoma Bladder"
    ],
    "interventions": [
      "UGN-102"
    ],
    "primary_completion_date": "2023-04-26",
    "completion_date": "2028-02",
    "results_first_posted": "2024-11-04",
    "last_update_posted": "2024-11-04",
    "enrollment": null,
    "sponsor": "UroGen Pharma Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "UroGen Pharma"
  },
  {
    "ticker": "URGN",
    "nct_id": "NCT02891460",
    "title": "Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NMIBC Patients",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Urinary Bladder Neoplasms",
      "Urologic Neoplasms",
      "Neoplasms",
      "Urinary Bladder Diseases",
      "Urologic Diseases"
    ],
    "interventions": [
      "40 mg MMC in 40 mL TC-3.",
      "80 mg MMC in 40 mL TC-3."
    ],
    "primary_completion_date": "2014-02",
    "completion_date": "2015-03",
    "results_first_posted": null,
    "last_update_posted": "2016-09-08",
    "enrollment": null,
    "sponsor": "UroGen Pharma Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "UroGen Pharma"
  },
  {
    "ticker": "VCEL",
    "nct_id": "NCT00797550",
    "title": "Use of TRC Autologous Bone Marrow Cells in Posterolateral Lumbar Spine Fusion",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Single Level Posterolateral Spinal Fusion"
    ],
    "interventions": [
      "Bone Repair Cells (BRCs)",
      "Autologous bone graft"
    ],
    "primary_completion_date": "2006-08",
    "completion_date": "2008-10",
    "results_first_posted": null,
    "last_update_posted": "2021-05-11",
    "enrollment": null,
    "sponsor": "Vericel Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Vericel"
  },
  {
    "ticker": "VCEL",
    "nct_id": "NCT06915233",
    "title": "A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chondral Defect",
      "Articular Cartilage Defect"
    ],
    "interventions": [
      "autologous cultured chondrocytes on porcine collagen membrane",
      "Bone Marrow Stimulation"
    ],
    "primary_completion_date": "2030-07",
    "completion_date": "2030-07",
    "results_first_posted": null,
    "last_update_posted": "2025-12-18",
    "enrollment": null,
    "sponsor": "Vericel Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Vericel"
  },
  {
    "ticker": "VCEL",
    "nct_id": "NCT00424567",
    "title": "Feasibility Study of Aastrom Tissue Repair Cells to Treat Non-Union Fractures.",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fracture, Ununited",
      "Pseudarthrosis"
    ],
    "interventions": [
      "Fracture surgery",
      "Cultured Bone Marrow Tissue"
    ],
    "primary_completion_date": null,
    "completion_date": "2007-06",
    "results_first_posted": null,
    "last_update_posted": "2021-05-11",
    "enrollment": null,
    "sponsor": "Vericel Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Vericel"
  },
  {
    "ticker": "VCEL",
    "nct_id": "NCT01483898",
    "title": "An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia (CLI)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Critical Limb Ischemia"
    ],
    "interventions": [
      "Ixmyelocel-T",
      "Placebo"
    ],
    "primary_completion_date": "2014-03-25",
    "completion_date": "2014-03-25",
    "results_first_posted": null,
    "last_update_posted": "2021-05-27",
    "enrollment": null,
    "sponsor": "Vericel Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Vericel"
  },
  {
    "ticker": "VCEL",
    "nct_id": "NCT00468000",
    "title": "Use of Ixmyelocel-T (Formerly Vascular Repair Cells [VRC]) in Patients With Peripheral Arterial Disease to Treat Critical Limb Ischemia",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Peripheral Arterial Disease"
    ],
    "interventions": [
      "Ixmyelocel-T",
      "Placebo"
    ],
    "primary_completion_date": "2011-03",
    "completion_date": "2011-03",
    "results_first_posted": null,
    "last_update_posted": "2020-05-20",
    "enrollment": null,
    "sponsor": "Vericel Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Vericel"
  },
  {
    "ticker": "VCEL",
    "nct_id": "NCT00719576",
    "title": "Superiority of MACI\u00ae Versus Microfracture Treatment in Patients With Symptomatic Articular Cartilage Defects in the Knee",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Articular Cartilage Defect"
    ],
    "interventions": [
      "autologous cultured chondrocytes on porcine collagen membrane",
      "Microfracture"
    ],
    "primary_completion_date": "2012-03",
    "completion_date": "2012-03",
    "results_first_posted": "2017-12-14",
    "last_update_posted": "2021-05-12",
    "enrollment": null,
    "sponsor": "Vericel Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Vericel"
  },
  {
    "ticker": "VCEL",
    "nct_id": "NCT01251588",
    "title": "Extension Study for Participants of MACI00206 Study of MACI\u00ae for the Treatment of Symptomatic Articular Cartilage Defects of the Knee",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Articular Cartilage Defects"
    ],
    "interventions": [
      "autologous cultured chondrocytes on porcine collagen membrane",
      "Microfracture"
    ],
    "primary_completion_date": "2015-03",
    "completion_date": "2015-03",
    "results_first_posted": "2017-04-27",
    "last_update_posted": "2021-05-12",
    "enrollment": null,
    "sponsor": "Vericel Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Vericel"
  },
  {
    "ticker": "VCEL",
    "nct_id": "NCT00140634",
    "title": "The Objectives of the Cartilage Repair Registry is to Report Long Term Efficacy and Safety of Cartilage Repair Procedures in Registry Patients",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Articular Cartilage",
      "Cartilage Diseases"
    ],
    "interventions": [
      "Carticel (autologous cultured chondrocyte) implantation"
    ],
    "primary_completion_date": "2009-01",
    "completion_date": "2009-01",
    "results_first_posted": null,
    "last_update_posted": "2021-05-11",
    "enrollment": null,
    "sponsor": "Vericel Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Vericel"
  },
  {
    "ticker": "VCEL",
    "nct_id": "NCT00158613",
    "title": "Study of the Treatment of Articular Repair (STAR)",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Articular Cartilage"
    ],
    "interventions": [
      "Carticel (autologous cultured chondrocyte) implantation"
    ],
    "primary_completion_date": "2005-11",
    "completion_date": "2005-11",
    "results_first_posted": null,
    "last_update_posted": "2021-05-11",
    "enrollment": null,
    "sponsor": "Vericel Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Vericel"
  },
  {
    "ticker": "VCEL",
    "nct_id": "NCT01020968",
    "title": "Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dilated Cardiomyopathy"
    ],
    "interventions": [
      "Ixmyelocel-T",
      "Vehicle Control"
    ],
    "primary_completion_date": "2012-01-11",
    "completion_date": "2013-12-05",
    "results_first_posted": null,
    "last_update_posted": "2021-05-27",
    "enrollment": null,
    "sponsor": "Vericel Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Vericel"
  },
  {
    "ticker": "VCEL",
    "nct_id": "NCT00765518",
    "title": "Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dilated Cardiomyopathy"
    ],
    "interventions": [
      "Ixmyelocel-T",
      "Standard of Care"
    ],
    "primary_completion_date": "2012-09-05",
    "completion_date": "2012-09-05",
    "results_first_posted": null,
    "last_update_posted": "2021-05-27",
    "enrollment": null,
    "sponsor": "Vericel Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Vericel"
  },
  {
    "ticker": "VCEL",
    "nct_id": "NCT00505219",
    "title": "Ixmyelocel-T Treatment of Patients With Osteonecrosis of the Femoral Head",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Osteonecrosis"
    ],
    "interventions": [
      "Ixmyelocel-T",
      "Standard of Care Only"
    ],
    "primary_completion_date": "2010-09",
    "completion_date": "2010-12",
    "results_first_posted": null,
    "last_update_posted": "2019-10-21",
    "enrollment": null,
    "sponsor": "Vericel Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Vericel"
  },
  {
    "ticker": "VCEL",
    "nct_id": "NCT01670981",
    "title": "An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ischemic Dilated Cardiomyopathy (IDCM)"
    ],
    "interventions": [
      "ixmyelocel-T",
      "Placebo"
    ],
    "primary_completion_date": "2016-02-01",
    "completion_date": "2018-03-07",
    "results_first_posted": null,
    "last_update_posted": "2021-05-27",
    "enrollment": null,
    "sponsor": "Vericel Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Vericel"
  },
  {
    "ticker": "VCEL",
    "nct_id": "NCT03588975",
    "title": "A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chondral Defect",
      "Osteochondritis Dissecans (OCD)",
      "Articular Cartilage Defect",
      "Articular Cartilage Disorder of Knee"
    ],
    "interventions": [
      "MACI",
      "microfracture"
    ],
    "primary_completion_date": "2027-06",
    "completion_date": "2027-06",
    "results_first_posted": null,
    "last_update_posted": "2024-12-02",
    "enrollment": null,
    "sponsor": "Vericel Corporation",
    "collected_at": "2026-01-27",
    "search_term": "Vericel"
  },
  {
    "ticker": "VCYT",
    "nct_id": "NCT06426628",
    "title": "Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Pulmonary Nodule, Solitary",
      "Lung Cancer"
    ],
    "interventions": [],
    "primary_completion_date": "2024-12-31",
    "completion_date": "2027-03-31",
    "results_first_posted": null,
    "last_update_posted": "2024-11-13",
    "enrollment": null,
    "sponsor": "Veracyte, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Veracyte"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT01428661",
    "title": "Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder"
    ],
    "interventions": [
      "tasimelteon",
      "placebo"
    ],
    "primary_completion_date": "2013-01",
    "completion_date": "2013-05",
    "results_first_posted": "2015-06-19",
    "last_update_posted": "2015-06-19",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT03154697",
    "title": "Development of Clinical Database of Individuals With Smith-Magenis Syndrome and Sleep Disturbances",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Sleep Disturbances in Smith-Magenis Syndrome"
    ],
    "interventions": [
      "Data collection of sleep disturbances in individuals with SMS"
    ],
    "primary_completion_date": "2030-12",
    "completion_date": "2030-12",
    "results_first_posted": null,
    "last_update_posted": "2024-03-20",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT06323655",
    "title": "Evaluation of Next-Day Residual Effects of Tasimelteon Compared With Placebo and Active Control in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "Tasimelteon",
      "Active Control Placebo",
      "Tasimelteon Placebo",
      "Active Control"
    ],
    "primary_completion_date": "2018-08-28",
    "completion_date": "2018-08-28",
    "results_first_posted": null,
    "last_update_posted": "2024-03-21",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT01477619",
    "title": "Effects of Smoking, Age and Body Size on Pharmacokinetics, Safety and Tolerability on Tasimelteon in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "Tasimelteon"
    ],
    "primary_completion_date": "2012-01",
    "completion_date": "2012-01",
    "results_first_posted": null,
    "last_update_posted": "2014-02-17",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT00291187",
    "title": "VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Insomnia"
    ],
    "interventions": [
      "20 mg VEC-162",
      "50 mg VEC-162",
      "100 mg VEC-162",
      "Placebo"
    ],
    "primary_completion_date": "2006-08",
    "completion_date": "2006-08",
    "results_first_posted": "2014-10-15",
    "last_update_posted": "2014-10-15",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT05572281",
    "title": "Bioequivalence Study Between Tasimelteon Capsule Formulation and Liquid Suspension Formulation in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "Tasimelteon Oral Capsule",
      "Tasimelteon Oral Suspension"
    ],
    "primary_completion_date": "2022-06-15",
    "completion_date": "2022-06-15",
    "results_first_posted": null,
    "last_update_posted": "2024-03-21",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT04800237",
    "title": "Evaluating the Effects of VQW-765 vs. Placebo in Performance Anxiety",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Performance Anxiety"
    ],
    "interventions": [
      "VQW-765",
      "Placebo"
    ],
    "primary_completion_date": "2022-08-02",
    "completion_date": "2022-08-02",
    "results_first_posted": null,
    "last_update_posted": "2024-03-20",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT04028492",
    "title": "Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Idiopathic Gastroparesis",
      "Diabetic Gastroparesis",
      "Gastroparesis"
    ],
    "interventions": [
      "Tradipitant",
      "Placebo",
      "Open Label Tradipitant"
    ],
    "primary_completion_date": "2025-02-21",
    "completion_date": "2025-02-21",
    "results_first_posted": null,
    "last_update_posted": "2025-07-24",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT06296966",
    "title": "A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dry Eye"
    ],
    "interventions": [
      "VSJ-110",
      "Placebo"
    ],
    "primary_completion_date": "2024-07",
    "completion_date": "2024-07",
    "results_first_posted": null,
    "last_update_posted": "2024-03-06",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT04326426",
    "title": "ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Coronavirus Infection"
    ],
    "interventions": [
      "Tradipitant",
      "Placebo"
    ],
    "primary_completion_date": "2020-08-01",
    "completion_date": "2020-08-31",
    "results_first_posted": null,
    "last_update_posted": "2020-04-20",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT01578057",
    "title": "Evaluation of the Pharmacodynamic and Pharmacokinetic Interactions of Tasimelteon and Ethanol",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pharmacodyamics and Pharmacokinetics of Tasimelteon Alone and in Combination With Ethanol"
    ],
    "interventions": [
      "tasimelteon",
      "Ethanol",
      "Placebo tasimelteon",
      "Placebo ethanol"
    ],
    "primary_completion_date": "2012-06",
    "completion_date": "2012-06",
    "results_first_posted": null,
    "last_update_posted": "2014-02-17",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT03633396",
    "title": "A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Palmoplantar Pustulosis"
    ],
    "interventions": [
      "Imsidolimab",
      "Placebo"
    ],
    "primary_completion_date": "2021-04-23",
    "completion_date": "2021-04-23",
    "results_first_posted": "2022-05-31",
    "last_update_posted": "2025-09-15",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT02970968",
    "title": "Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of Gastroparesis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Gastroparesis"
    ],
    "interventions": [
      "VLY-686 (Tradipitant)",
      "Placebo"
    ],
    "primary_completion_date": "2018-11",
    "completion_date": "2018-12",
    "results_first_posted": "2024-08-06",
    "last_update_posted": "2024-08-06",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT04652882",
    "title": "Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Sleep Wake Disorders",
      "Sleep Disorders, Circadian Rhythm",
      "Chronobiology Disorders"
    ],
    "interventions": [
      "Tasimelteon",
      "Placebo"
    ],
    "primary_completion_date": "2026-06",
    "completion_date": "2026-06",
    "results_first_posted": null,
    "last_update_posted": "2025-12-02",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT02560103",
    "title": "An Observational Study to Investigate the Effects of Rapid Transmeridian Travel",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Jet Lag Disorder"
    ],
    "interventions": [
      "Transmeridian travel across multiple time zones"
    ],
    "primary_completion_date": "2017-10",
    "completion_date": "2017-10",
    "results_first_posted": null,
    "last_update_posted": "2018-06-26",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT01218789",
    "title": "Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light Perception",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non 24 Hour Sleep Wake Disorder"
    ],
    "interventions": [
      "tasimelteon"
    ],
    "primary_completion_date": "2024-12-05",
    "completion_date": "2024-12-05",
    "results_first_posted": null,
    "last_update_posted": "2024-04-03",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT03772340",
    "title": "Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Motion Sickness"
    ],
    "interventions": [
      "Tradipitant",
      "Placebo"
    ],
    "primary_completion_date": "2019-06-06",
    "completion_date": "2019-06-27",
    "results_first_posted": "2025-05-09",
    "last_update_posted": "2025-05-09",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT06803290",
    "title": "Food Effect Study of VHX-896 in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "VHX-896"
    ],
    "primary_completion_date": "2022-12-27",
    "completion_date": "2022-12-27",
    "results_first_posted": null,
    "last_update_posted": "2025-01-31",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT01429116",
    "title": "Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-24-Hour Sleep-Wake Disorder"
    ],
    "interventions": [
      "tasimelteon"
    ],
    "primary_completion_date": "2015-01",
    "completion_date": "2015-01",
    "results_first_posted": null,
    "last_update_posted": "2015-04-21",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT03838926",
    "title": "Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsed or Refractory Hematologic Malignancies"
    ],
    "interventions": [
      "Trichostatin A"
    ],
    "primary_completion_date": "2025-12",
    "completion_date": "2025-12",
    "results_first_posted": null,
    "last_update_posted": "2025-07-17",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT05361707",
    "title": "Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Autism Spectrum Disorder",
      "Sleep Disorder",
      "Neurological Disorder",
      "Sleep Disturbance"
    ],
    "interventions": [
      "Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension"
    ],
    "primary_completion_date": "2025-07",
    "completion_date": "2025-07",
    "results_first_posted": null,
    "last_update_posted": "2024-03-21",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT02130999",
    "title": "Open Label Study to Assess the Absolute Bioavailability of Tasimelteon (HETLIOZ\u2122)",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-24-Hour-Sleep-Wake Disorder"
    ],
    "interventions": [
      "tasimelteon 20 mg capsule",
      "tasimelteon 2 mg I.V."
    ],
    "primary_completion_date": "2014-05",
    "completion_date": "2014-05",
    "results_first_posted": "2016-07-22",
    "last_update_posted": "2016-08-22",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT07179055",
    "title": "An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dry Eye"
    ],
    "interventions": [
      "VSJ-110",
      "Placebo"
    ],
    "primary_completion_date": "2026-09",
    "completion_date": "2026-09",
    "results_first_posted": null,
    "last_update_posted": "2025-09-17",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT06961968",
    "title": "Randomized Withdrawal Study in Patients With Schizophrenia",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia"
    ],
    "interventions": [
      "iloperidone",
      "placebo"
    ],
    "primary_completion_date": "2027-11",
    "completion_date": "2027-11",
    "results_first_posted": null,
    "last_update_posted": "2026-01-12",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT06138613",
    "title": "Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Motion Sickness"
    ],
    "interventions": [
      "Tradipitant"
    ],
    "primary_completion_date": "2026-05-30",
    "completion_date": "2026-06-30",
    "results_first_posted": null,
    "last_update_posted": "2025-11-21",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT04819776",
    "title": "Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bipolar I Disorder"
    ],
    "interventions": [
      "Iloperidone",
      "Iloperidone Placebo"
    ],
    "primary_completion_date": "2022-09-07",
    "completion_date": "2023-08-16",
    "results_first_posted": "2024-04-16",
    "last_update_posted": "2024-04-18",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT01291511",
    "title": "Relapse Prevention Study in Patients With Schizophrenia",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia"
    ],
    "interventions": [
      "Iloperidone",
      "Placebo"
    ],
    "primary_completion_date": "2014-03",
    "completion_date": "2015-03",
    "results_first_posted": "2023-07-17",
    "last_update_posted": "2023-07-17",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT01195558",
    "title": "Patient Registry of Blind Subjects With Sleep-related Problems",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Sleep-wake Disorder in Blind Individuals"
    ],
    "interventions": [
      "Data collection on blindness and sleep problems"
    ],
    "primary_completion_date": "2030-04",
    "completion_date": "2030-04",
    "results_first_posted": null,
    "last_update_posted": "2020-06-24",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT06836557",
    "title": "Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Idiopathic Gastroparesis",
      "Diabetic Gastroparesis",
      "Gastroparesis"
    ],
    "interventions": [
      "Tradipitant"
    ],
    "primary_completion_date": "2025-12",
    "completion_date": "2025-12",
    "results_first_posted": null,
    "last_update_posted": "2025-02-20",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT02621385",
    "title": "Study to Assess the Effect of Multiple Doses of Tradipitant on CYP3A4 Using Midazolam as a Substrate in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "tradipitant",
      "Midazolam"
    ],
    "primary_completion_date": "2016-02",
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2016-04-27",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT01540500",
    "title": "Pharmacokinetics of Tasimelteon Alone and in Combination With CYP1A2 Inhibitor, Fluvoxamine",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "Tasimelteon",
      "Fluvoxamine"
    ],
    "primary_completion_date": "2012-03",
    "completion_date": "2012-03",
    "results_first_posted": null,
    "last_update_posted": "2014-02-17",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT05903924",
    "title": "Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Motion Sickness"
    ],
    "interventions": [
      "Tradipitant",
      "Placebo"
    ],
    "primary_completion_date": "2024-04-06",
    "completion_date": "2024-04-24",
    "results_first_posted": "2025-04-04",
    "last_update_posted": "2025-04-04",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT05352893",
    "title": "Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Generalized Pustular Psoriasis"
    ],
    "interventions": [
      "Imsidolimab high dose",
      "Imsidolimab low dose",
      "Placebo"
    ],
    "primary_completion_date": "2023-08-17",
    "completion_date": "2023-08-17",
    "results_first_posted": null,
    "last_update_posted": "2025-09-09",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT02231008",
    "title": "Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMS",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Smith-Magenis Syndrome",
      "Circadian"
    ],
    "interventions": [
      "tasimelteon",
      "placebo"
    ],
    "primary_completion_date": "2018-11-19",
    "completion_date": "2022-01",
    "results_first_posted": null,
    "last_update_posted": "2022-11-18",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT04353401",
    "title": "WGS Analysis of COVID-19 Positive Patients",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Coronavirus Infection",
      "COVID-19"
    ],
    "interventions": [],
    "primary_completion_date": "2022-03-09",
    "completion_date": "2022-03-09",
    "results_first_posted": null,
    "last_update_posted": "2024-03-22",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT04856930",
    "title": "A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Hidradenitis Suppurativa",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hidradenitis Suppurativa"
    ],
    "interventions": [
      "Imsidolimab",
      "Placebo"
    ],
    "primary_completion_date": "2022-07-15",
    "completion_date": "2022-12-14",
    "results_first_posted": "2025-09-22",
    "last_update_posted": "2025-09-22",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT00467441",
    "title": "VSF-173 Study in Healthy Adult Volunteers for Treatment of Induced Excessive Sleepiness",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Excessive Somnolence"
    ],
    "interventions": [
      "VSF-173"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2007-11-02",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT06953869",
    "title": "Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Insomnia Disorder"
    ],
    "interventions": [
      "Tasimelteon Oral Suspension",
      "Placebo"
    ],
    "primary_completion_date": "2027-11",
    "completion_date": "2028-01",
    "results_first_posted": null,
    "last_update_posted": "2025-05-01",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT02776215",
    "title": "Study of the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Circadian Rhythm Sleep Disorders",
      "Non-24 Hour Sleep-Wake Disorder",
      "Autism Spectrum Disorder",
      "Smith-Magenis Syndrome"
    ],
    "interventions": [
      "tasimelteon"
    ],
    "primary_completion_date": "2017-12-20",
    "completion_date": "2017-12-20",
    "results_first_posted": null,
    "last_update_posted": "2024-03-21",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT01402076",
    "title": "A Study to Assess the Effect Tasimelteon on the Cytochrome P450 3A4 and 2C8 Enzymes in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "Tasimelteon",
      "Rosiglitazone",
      "Midazolam"
    ],
    "primary_completion_date": "2011-08",
    "completion_date": "2011-08",
    "results_first_posted": null,
    "last_update_posted": "2014-02-17",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT01271387",
    "title": "Pharmacokinetics of Tasimelteon in Subjects With Mild or Moderate Hepatic Impairment",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatic Impairment"
    ],
    "interventions": [
      "tasimelteon"
    ],
    "primary_completion_date": "2011-08",
    "completion_date": "2011-08",
    "results_first_posted": null,
    "last_update_posted": "2014-02-17",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT01430754",
    "title": "Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-24-Hour Sleep-Wake Disorder"
    ],
    "interventions": [
      "tasimelteon",
      "Placebo"
    ],
    "primary_completion_date": "2012-12",
    "completion_date": "2012-12",
    "results_first_posted": "2014-10-10",
    "last_update_posted": "2014-10-10",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT06830044",
    "title": "Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder (MDD)"
    ],
    "interventions": [
      "Milsaperidone",
      "Placebo"
    ],
    "primary_completion_date": "2028-03",
    "completion_date": "2028-03",
    "results_first_posted": null,
    "last_update_posted": "2025-11-12",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT03373201",
    "title": "Evaluating the Effects of Tasimelteon vs. Placebo on Jet Lag Type Insomnia",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Jet Lag Type Insomnia"
    ],
    "interventions": [
      "Tasimelteon",
      "Placebo"
    ],
    "primary_completion_date": "2018-03-05",
    "completion_date": "2018-03-05",
    "results_first_posted": "2023-09-15",
    "last_update_posted": "2023-09-15",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT04697056",
    "title": "A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ichthyosis"
    ],
    "interventions": [
      "Imsidolimab",
      "placebo"
    ],
    "primary_completion_date": "2021-11-19",
    "completion_date": "2021-11-19",
    "results_first_posted": "2023-03-02",
    "last_update_posted": "2025-09-16",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT01163032",
    "title": "Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-24-Hour Sleep-Wake Disorder"
    ],
    "interventions": [
      "tasimelteon",
      "Placebo"
    ],
    "primary_completion_date": "2012-11",
    "completion_date": "2012-11",
    "results_first_posted": "2014-10-16",
    "last_update_posted": "2014-10-16",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT00254202",
    "title": "Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia"
    ],
    "interventions": [
      "Iloperidone",
      "Ziprasidone",
      "Placebo"
    ],
    "primary_completion_date": "2006-09-26",
    "completion_date": "2007-03-21",
    "results_first_posted": "2024-12-13",
    "last_update_posted": "2024-12-13",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT04474990",
    "title": "Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With Gastroparesis",
    "status": "AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Gastroparesis",
      "Diabetic Gastroparesis"
    ],
    "interventions": [
      "Tradipitant"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2025-08-24",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT04849559",
    "title": "Effects of Tradipitant on Satiation, Gastric Volume, Gastric Accommodation, and Gastric Emptying in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteer"
    ],
    "interventions": [
      "Tradipitant",
      "Placebo"
    ],
    "primary_completion_date": "2021-09-24",
    "completion_date": "2021-09-24",
    "results_first_posted": "2024-04-16",
    "last_update_posted": "2024-04-16",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT04327661",
    "title": "Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Motion Sickness"
    ],
    "interventions": [
      "Tradipitant",
      "Placebo"
    ],
    "primary_completion_date": "2023-04-01",
    "completion_date": "2023-04-12",
    "results_first_posted": "2024-12-11",
    "last_update_posted": "2024-12-11",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT02180451",
    "title": "Observational Study to Investigate the Melatonin and Cortisol Circadian Rhythms of Individuals With Smith-Magenis Syndrome (SMS)",
    "status": "UNKNOWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Smith Magenis Syndrome"
    ],
    "interventions": [],
    "primary_completion_date": "2017-01",
    "completion_date": "2017-01",
    "results_first_posted": null,
    "last_update_posted": "2016-03-25",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT07090161",
    "title": "Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypertension",
      "Uncontrolled Hypertension"
    ],
    "interventions": [
      "iloperidone",
      "Placebo"
    ],
    "primary_completion_date": "2026-10",
    "completion_date": "2026-11",
    "results_first_posted": null,
    "last_update_posted": "2026-01-23",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT06701396",
    "title": "Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1\u039411 Variant",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Sleep Wake Disorders",
      "Sleep Disorders, Circadian Rhythm",
      "Chronobiology Disorders",
      "Gene Mutations and Other Alterations Nec"
    ],
    "interventions": [
      "Tasimelteon",
      "Placebo"
    ],
    "primary_completion_date": "2025-06-30",
    "completion_date": "2025-06-30",
    "results_first_posted": null,
    "last_update_posted": "2024-11-22",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT03568331",
    "title": "Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atopic Dermatitis"
    ],
    "interventions": [
      "Tradipitant",
      "Placebo"
    ],
    "primary_completion_date": "2019-12-27",
    "completion_date": "2019-12-27",
    "results_first_posted": "2024-05-13",
    "last_update_posted": "2024-05-13",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT04712734",
    "title": "A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of Schizophrenia",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia"
    ],
    "interventions": [
      "Iloperidone"
    ],
    "primary_completion_date": "2022-08-30",
    "completion_date": "2022-08-30",
    "results_first_posted": null,
    "last_update_posted": "2023-06-29",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT04127058",
    "title": "Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bipolar I Disorder",
      "Schizophrenia"
    ],
    "interventions": [
      "Iloperidone"
    ],
    "primary_completion_date": "2019-11-27",
    "completion_date": "2019-11-27",
    "results_first_posted": null,
    "last_update_posted": "2020-04-13",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT02004041",
    "title": "Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Treatment-resistant Pruritus Associated With Atopic Dermatitis"
    ],
    "interventions": [
      "VLY-686",
      "Placebo"
    ],
    "primary_completion_date": "2015-02-19",
    "completion_date": "2015-02-19",
    "results_first_posted": "2024-06-11",
    "last_update_posted": "2024-06-11",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT01919944",
    "title": "Study of Itch Control by VLY-686 in Healthy Volunteers After Intradermal Injections of Substance P",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pruritus"
    ],
    "interventions": [
      "VLY-686",
      "Placebo"
    ],
    "primary_completion_date": "2013-11",
    "completion_date": "2013-11",
    "results_first_posted": null,
    "last_update_posted": "2015-06-03",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT04969211",
    "title": "Bioequivalence Study Between VHX-896 Tablets and Iloperidone Tablets in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "VHX-896 and iloperidone",
      "Iloperidone and VHX-896"
    ],
    "primary_completion_date": "2021-10-13",
    "completion_date": "2021-10-13",
    "results_first_posted": null,
    "last_update_posted": "2022-07-11",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT07223632",
    "title": "Treatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual Patient",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Charcot Marie Tooth Disease (CMT)",
      "Neuromuscular Diseases (NMD)"
    ],
    "interventions": [
      "VCA-894A"
    ],
    "primary_completion_date": "2026-03",
    "completion_date": "2026-03",
    "results_first_posted": null,
    "last_update_posted": "2025-11-03",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT04140695",
    "title": "Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atopic Dermatitis"
    ],
    "interventions": [
      "Tradipitant",
      "Placebo"
    ],
    "primary_completion_date": "2020-10-14",
    "completion_date": "2020-10-14",
    "results_first_posted": "2024-05-14",
    "last_update_posted": "2024-05-14",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT06494397",
    "title": "Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia",
      "Bipolar I Disorder"
    ],
    "interventions": [
      "VHX-896 and iloperidone",
      "Iloperidone and VHX-896"
    ],
    "primary_completion_date": "2024-10-24",
    "completion_date": "2024-10-24",
    "results_first_posted": null,
    "last_update_posted": "2025-09-19",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT04697069",
    "title": "A Study to Evaluate of the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Acneiform Rash",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acneiform Eruptions"
    ],
    "interventions": [
      "Imsidolimab",
      "Placebo"
    ],
    "primary_completion_date": "2021-12-13",
    "completion_date": "2021-12-13",
    "results_first_posted": "2023-01-09",
    "last_update_posted": "2025-09-22",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT01637636",
    "title": "Pharmacokinetics of Tasimelteon Alone and in Combination With a CYP3A4 Inhibitor, Ketoconazole, or a CYP3A4 Inducer, Rifampin.",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "tasimelteon",
      "tasimelteon",
      "Rifampin",
      "Ketoconazole"
    ],
    "primary_completion_date": "2012-08",
    "completion_date": "2012-08",
    "results_first_posted": null,
    "last_update_posted": "2014-02-17",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT07221578",
    "title": "Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Social Anxiety Disorder (SAD)"
    ],
    "interventions": [
      "VQW-765",
      "Placebo"
    ],
    "primary_completion_date": "2026-12",
    "completion_date": "2027-04",
    "results_first_posted": null,
    "last_update_posted": "2026-01-14",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT07065773",
    "title": "Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Onychomycosis of Toenail"
    ],
    "interventions": [
      "Trichostatin A"
    ],
    "primary_completion_date": "2026-03",
    "completion_date": "2026-05",
    "results_first_posted": null,
    "last_update_posted": "2025-09-19",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT02651714",
    "title": "Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atopic Dermatitis"
    ],
    "interventions": [
      "Tradipitant",
      "Placebo"
    ],
    "primary_completion_date": "2017-08-04",
    "completion_date": "2017-08-04",
    "results_first_posted": "2024-06-13",
    "last_update_posted": "2024-06-13",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT05344365",
    "title": "A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Parkinson Disease Psychosis"
    ],
    "interventions": [
      "Iloperidone"
    ],
    "primary_completion_date": "2023-11",
    "completion_date": "2023-11",
    "results_first_posted": null,
    "last_update_posted": "2024-03-21",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT03619902",
    "title": "A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Generalized Pustular Psoriasis"
    ],
    "interventions": [
      "Imsidolimab"
    ],
    "primary_completion_date": "2021-01-20",
    "completion_date": "2021-01-20",
    "results_first_posted": "2022-03-29",
    "last_update_posted": "2025-09-16",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT00490945",
    "title": "Safety and Efficacy of VEC-162 on Circadian Rhythm in Healthy Adult Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Circadian Rhythm Sleep Disorders"
    ],
    "interventions": [
      "VEC-162"
    ],
    "primary_completion_date": "2005-03",
    "completion_date": "2005-03",
    "results_first_posted": "2014-08-26",
    "last_update_posted": "2014-08-26",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT04856917",
    "title": "A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acne Vulgaris"
    ],
    "interventions": [
      "Imsidolimab",
      "Placebo"
    ],
    "primary_completion_date": "2022-02-01",
    "completion_date": "2022-03-29",
    "results_first_posted": "2023-06-15",
    "last_update_posted": "2025-09-22",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT06804603",
    "title": "A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Obesity"
    ],
    "interventions": [
      "Tradipitant",
      "Placebo"
    ],
    "primary_completion_date": "2025-10-06",
    "completion_date": "2025-10-06",
    "results_first_posted": null,
    "last_update_posted": "2025-11-12",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT03291041",
    "title": "A Proof of Concept Study to Evaluate the Effects of Tasimelteon and Placebo in Travelers With Jet Lag Disorder",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Jet Lag Disorder"
    ],
    "interventions": [
      "Tasimelteon",
      "Placebo"
    ],
    "primary_completion_date": "2017-11",
    "completion_date": "2017-11",
    "results_first_posted": "2021-11-03",
    "last_update_posted": "2021-11-03",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT01495169",
    "title": "Tolerability and Pharmacokinetics of Iloperidone in Adolescent Patients",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Safety and Tolerability of Iloperidone"
    ],
    "interventions": [
      "iloperidone (oral tablet)"
    ],
    "primary_completion_date": "2015-02",
    "completion_date": "2015-02",
    "results_first_posted": null,
    "last_update_posted": "2016-06-13",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT07362017",
    "title": "Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Moderate-to-severe Chronic Plaque Psoriasis"
    ],
    "interventions": [
      "Ponesimod"
    ],
    "primary_completion_date": "2028-08",
    "completion_date": "2028-12",
    "results_first_posted": null,
    "last_update_posted": "2026-01-23",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT05648591",
    "title": "Safety and Tolerability of Open-Labeled Iloperidone in Adolescents",
    "status": "RECRUITING",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia",
      "Bipolar I Disorder"
    ],
    "interventions": [
      "Iloperidone"
    ],
    "primary_completion_date": "2026-03-31",
    "completion_date": "2026-11-30",
    "results_first_posted": null,
    "last_update_posted": "2025-03-04",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT00548340",
    "title": "VEC-162 Study in Adult Patients With Primary Insomnia",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Primary Insomnia"
    ],
    "interventions": [
      "VEC-162 20 mg",
      "Placebo",
      "VEC-162 50 mg"
    ],
    "primary_completion_date": "2008-02",
    "completion_date": "2008-06",
    "results_first_posted": "2014-10-15",
    "last_update_posted": "2014-10-15",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT05366855",
    "title": "Long-Term Safety and Efficacy of Imsidolimab (ANB019) in Subjects With Generalized Pustular Psoriasis",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Generalized Pustular Psoriasis"
    ],
    "interventions": [
      "Imsidolimab",
      "Placebo"
    ],
    "primary_completion_date": "2024-02-08",
    "completion_date": "2024-07-17",
    "results_first_posted": null,
    "last_update_posted": "2025-09-09",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT04622345",
    "title": "Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Allergic Conjunctivitis"
    ],
    "interventions": [
      "VSJ-110",
      "Placebo"
    ],
    "primary_completion_date": "2021-05-22",
    "completion_date": "2021-06-28",
    "results_first_posted": "2025-09-11",
    "last_update_posted": "2025-09-11",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VNDA",
    "nct_id": "NCT01526746",
    "title": "Pharmacokinetics of Tasimelteon in Subjects With Renal Impairment and Matched Control Subjects With Relatively Normal Renal Function",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Renal Impairment"
    ],
    "interventions": [
      "Tasimelteon",
      "Tasimelteon"
    ],
    "primary_completion_date": "2012-06",
    "completion_date": "2012-06",
    "results_first_posted": null,
    "last_update_posted": "2014-02-17",
    "enrollment": null,
    "sponsor": "Vanda Pharmaceuticals",
    "collected_at": "2026-01-27",
    "search_term": "Vanda Pharmaceuticals"
  },
  {
    "ticker": "VRTX",
    "nct_id": "NCT05791201",
    "title": "A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 1 Diabetes"
    ],
    "interventions": [
      "VX-264"
    ],
    "primary_completion_date": "2026-05-29",
    "completion_date": "2026-05-29",
    "results_first_posted": null,
    "last_update_posted": "2025-08-11",
    "enrollment": null,
    "sponsor": "Vertex Pharmaceuticals Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Vertex Pharmaceuticals"
  },
  {
    "ticker": "VRTX",
    "nct_id": "NCT06820307",
    "title": "Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pain"
    ],
    "interventions": [
      "Suzetrigine",
      "DRSP/EE",
      "NGM/EE"
    ],
    "primary_completion_date": "2025-04-29",
    "completion_date": "2025-04-29",
    "results_first_posted": null,
    "last_update_posted": "2025-05-29",
    "enrollment": null,
    "sponsor": "Vertex Pharmaceuticals Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Vertex Pharmaceuticals"
  },
  {
    "ticker": "VRTX",
    "nct_id": "NCT04537793",
    "title": "Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cystic Fibrosis"
    ],
    "interventions": [
      "ELX/TEZ/IVA",
      "IVA"
    ],
    "primary_completion_date": "2022-06-03",
    "completion_date": "2022-06-03",
    "results_first_posted": "2023-06-28",
    "last_update_posted": "2023-06-28",
    "enrollment": null,
    "sponsor": "Vertex Pharmaceuticals Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Vertex Pharmaceuticals"
  },
  {
    "ticker": "VRTX",
    "nct_id": "NCT06926621",
    "title": "A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Myotonic Dystrophy Type 1 (DM1)"
    ],
    "interventions": [
      "VX-670"
    ],
    "primary_completion_date": "2028-07-24",
    "completion_date": "2028-07-24",
    "results_first_posted": null,
    "last_update_posted": "2026-01-13",
    "enrollment": null,
    "sponsor": "Vertex Pharmaceuticals Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Vertex Pharmaceuticals"
  },
  {
    "ticker": "VRTX",
    "nct_id": "NCT00205465",
    "title": "Phase 2 Clinical Study in Psoriasis With Oral Investigational Drug VX-765",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Psoriasis"
    ],
    "interventions": [
      "VX-765"
    ],
    "primary_completion_date": null,
    "completion_date": "2005-09",
    "results_first_posted": null,
    "last_update_posted": "2007-12-05",
    "enrollment": null,
    "sponsor": "Vertex Pharmaceuticals Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Vertex Pharmaceuticals"
  },
  {
    "ticker": "VRTX",
    "nct_id": "NCT05865171",
    "title": "A Study to Evaluate Pharmacokinetics (PK) and Safety of Inaxaplin in Participants With Renal Impairment",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Renal Impairment"
    ],
    "interventions": [
      "IXP"
    ],
    "primary_completion_date": "2024-06-12",
    "completion_date": "2024-06-12",
    "results_first_posted": null,
    "last_update_posted": "2024-07-12",
    "enrollment": null,
    "sponsor": "Vertex Pharmaceuticals Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Vertex Pharmaceuticals"
  },
  {
    "ticker": "VRTX",
    "nct_id": "NCT01153542",
    "title": "Study of VX-770 on Desipramine",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "In Development for Cystic Fibrosis"
    ],
    "interventions": [
      "VX-770",
      "VX-770"
    ],
    "primary_completion_date": "2010-08",
    "completion_date": "2010-08",
    "results_first_posted": null,
    "last_update_posted": "2010-12-09",
    "enrollment": null,
    "sponsor": "Vertex Pharmaceuticals Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Vertex Pharmaceuticals"
  },
  {
    "ticker": "VRTX",
    "nct_id": "NCT04702360",
    "title": "ELX/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients With at Least One F508del Mutation",
    "status": "APPROVED_FOR_MARKETING",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Cystic Fibrosis"
    ],
    "interventions": [
      "ELX/TEZ/IVA",
      "IVA"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2021-07-15",
    "enrollment": null,
    "sponsor": "Vertex Pharmaceuticals Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Vertex Pharmaceuticals"
  },
  {
    "ticker": "VRTX",
    "nct_id": "NCT06619860",
    "title": "Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetic Peripheral Neuropathic Pain"
    ],
    "interventions": [
      "VX-993",
      "Pregabalin",
      "Placebo (matched to pregabalin)",
      "Placebo (matched to VX-993)"
    ],
    "primary_completion_date": "2026-04-30",
    "completion_date": "2026-05-30",
    "results_first_posted": null,
    "last_update_posted": "2025-10-27",
    "enrollment": null,
    "sponsor": "Vertex Pharmaceuticals Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Vertex Pharmaceuticals"
  },
  {
    "ticker": "VRTX",
    "nct_id": "NCT06394167",
    "title": "A Phase 1 Dose Escalation Study of Intravenous VX-993 in Healthy Adults",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pain"
    ],
    "interventions": [
      "VX-993",
      "Placebo"
    ],
    "primary_completion_date": "2025-02-18",
    "completion_date": "2025-02-18",
    "results_first_posted": null,
    "last_update_posted": "2025-03-20",
    "enrollment": null,
    "sponsor": "Vertex Pharmaceuticals Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Vertex Pharmaceuticals"
  },
  {
    "ticker": "VRTX",
    "nct_id": "NCT05518734",
    "title": "A Phase 1 Dose Escalation Study of VX-708 in Healthy Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pain"
    ],
    "interventions": [
      "VX-708",
      "Itraconazole",
      "Midazolam",
      "Placebo"
    ],
    "primary_completion_date": "2023-03-07",
    "completion_date": "2023-03-07",
    "results_first_posted": null,
    "last_update_posted": "2023-03-30",
    "enrollment": null,
    "sponsor": "Vertex Pharmaceuticals Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Vertex Pharmaceuticals"
  },
  {
    "ticker": "VRTX",
    "nct_id": "NCT05727800",
    "title": "A Phase 1, First-in-human Study of VX-668",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alpha-1 Antitrypsin Deficiency"
    ],
    "interventions": [
      "VX-668",
      "Placebo"
    ],
    "primary_completion_date": "2023-09-12",
    "completion_date": "2024-02-13",
    "results_first_posted": null,
    "last_update_posted": "2024-03-15",
    "enrollment": null,
    "sponsor": "Vertex Pharmaceuticals Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Vertex Pharmaceuticals"
  },
  {
    "ticker": "VRTX",
    "nct_id": "NCT01381289",
    "title": "VX-770 Expanded Access Program",
    "status": "APPROVED_FOR_MARKETING",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Cystic Fibrosis"
    ],
    "interventions": [
      "VX-770"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2012-02-09",
    "enrollment": null,
    "sponsor": "Vertex Pharmaceuticals Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Vertex Pharmaceuticals"
  },
  {
    "ticker": "VRTX",
    "nct_id": "NCT06460506",
    "title": "Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cystic Fibrosis"
    ],
    "interventions": [
      "ELX/TEZ/IVA",
      "IVA"
    ],
    "primary_completion_date": "2027-09-30",
    "completion_date": "2027-09-30",
    "results_first_posted": null,
    "last_update_posted": "2025-10-06",
    "enrollment": null,
    "sponsor": "Vertex Pharmaceuticals Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Vertex Pharmaceuticals"
  },
  {
    "ticker": "VRTX",
    "nct_id": "NCT06506773",
    "title": "Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fibrosis (CF)",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Cystic Fibrosis"
    ],
    "interventions": [],
    "primary_completion_date": "2025-11-27",
    "completion_date": "2025-11-27",
    "results_first_posted": null,
    "last_update_posted": "2025-12-31",
    "enrollment": null,
    "sponsor": "Vertex Pharmaceuticals Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Vertex Pharmaceuticals"
  },
  {
    "ticker": "VRTX",
    "nct_id": "NCT01910415",
    "title": "Phase 1, QT/QTC Interval Study in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cystic Fibrosis"
    ],
    "interventions": [
      "Lumacaftor",
      "Lumacaftor Placebo",
      "Ivacaftor",
      "Ivacaftor Placebo",
      "moxifloxacin hydrochloride"
    ],
    "primary_completion_date": "2014-03",
    "completion_date": "2014-03",
    "results_first_posted": null,
    "last_update_posted": "2014-08-11",
    "enrollment": null,
    "sponsor": "Vertex Pharmaceuticals Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Vertex Pharmaceuticals"
  },
  {
    "ticker": "VRTX",
    "nct_id": "NCT06832410",
    "title": "An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 1 Diabetes",
      "Kidney Transplant"
    ],
    "interventions": [
      "Biological/Vaccine"
    ],
    "primary_completion_date": "2026-09-17",
    "completion_date": "2027-09-17",
    "results_first_posted": null,
    "last_update_posted": "2025-08-21",
    "enrollment": null,
    "sponsor": "Vertex Pharmaceuticals Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Vertex Pharmaceuticals"
  },
  {
    "ticker": "VRTX",
    "nct_id": "NCT00273936",
    "title": "Trial of AVN-944 in Patients With Advanced Hematologic Malignancies",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Leukemia",
      "Chronic Leukemia",
      "Multiple Myeloma",
      "Hodgkin's Lymphoma",
      "Non-Hodgkin's Lymphoma",
      "Waldenstrom's Macroglobulinemia"
    ],
    "interventions": [
      "AVN-944 capsules for oral administration"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2011-08-04",
    "enrollment": null,
    "sponsor": "Vertex Pharmaceuticals Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Vertex Pharmaceuticals"
  },
  {
    "ticker": "VRTX",
    "nct_id": "NCT07283770",
    "title": "Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cystic Fibrosis"
    ],
    "interventions": [
      "VX-581",
      "Placebo"
    ],
    "primary_completion_date": "2026-11-19",
    "completion_date": "2026-11-19",
    "results_first_posted": null,
    "last_update_posted": "2025-12-29",
    "enrollment": null,
    "sponsor": "Vertex Pharmaceuticals Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Vertex Pharmaceuticals"
  },
  {
    "ticker": "VRTX",
    "nct_id": "NCT02742519",
    "title": "A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cystic Fibrosis"
    ],
    "interventions": [
      "ivacaftor",
      "Placebo"
    ],
    "primary_completion_date": "2017-08",
    "completion_date": "2017-08",
    "results_first_posted": "2018-11-19",
    "last_update_posted": "2018-11-19",
    "enrollment": null,
    "sponsor": "Vertex Pharmaceuticals Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Vertex Pharmaceuticals"
  },
  {
    "ticker": "VRTX",
    "nct_id": "NCT06696443",
    "title": "Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetic Peripheral Neuropathic Pain"
    ],
    "interventions": [
      "Suzetrigine"
    ],
    "primary_completion_date": "2027-01-25",
    "completion_date": "2027-01-25",
    "results_first_posted": null,
    "last_update_posted": "2025-12-02",
    "enrollment": null,
    "sponsor": "Vertex Pharmaceuticals Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Vertex Pharmaceuticals"
  },
  {
    "ticker": "VRTX",
    "nct_id": "NCT05535959",
    "title": "A Study to Evaluate the Relative Bioavailability of a Fixed-dose Combination Tablet of VX-121/Tezacaftor/Deutivacaftor",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cystic Fibrosis"
    ],
    "interventions": [
      "VX-121/TEZ/D-IVA"
    ],
    "primary_completion_date": "2022-11-09",
    "completion_date": "2022-11-09",
    "results_first_posted": null,
    "last_update_posted": "2022-12-12",
    "enrollment": null,
    "sponsor": "Vertex Pharmaceuticals Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Vertex Pharmaceuticals"
  },
  {
    "ticker": "VRTX",
    "nct_id": "NCT01516918",
    "title": "A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Hepatitis C Virus"
    ],
    "interventions": [
      "VX-222",
      "telaprevir",
      "ribavirin",
      "peginterferon-alfa-2a"
    ],
    "primary_completion_date": "2013-09",
    "completion_date": "2013-12",
    "results_first_posted": null,
    "last_update_posted": "2014-10-20",
    "enrollment": null,
    "sponsor": "Vertex Pharmaceuticals Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Vertex Pharmaceuticals"
  },
  {
    "ticker": "VRTX",
    "nct_id": "NCT06529796",
    "title": "Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic Impairment",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Focal Segmental Glomerulosclerosis (FSGS)"
    ],
    "interventions": [
      "IXP"
    ],
    "primary_completion_date": "2024-12-20",
    "completion_date": "2024-12-20",
    "results_first_posted": null,
    "last_update_posted": "2025-01-20",
    "enrollment": null,
    "sponsor": "Vertex Pharmaceuticals Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Vertex Pharmaceuticals"
  },
  {
    "ticker": "VRTX",
    "nct_id": "NCT06345755",
    "title": "A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Autosomal Dominant Polycystic Kidney Disease (ADPKD)"
    ],
    "interventions": [
      "VX-407",
      "Placebo",
      "Midazolam",
      "VX-407"
    ],
    "primary_completion_date": "2025-01-27",
    "completion_date": "2025-06-13",
    "results_first_posted": null,
    "last_update_posted": "2025-07-14",
    "enrollment": null,
    "sponsor": "Vertex Pharmaceuticals Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Vertex Pharmaceuticals"
  },
  {
    "ticker": "VRTX",
    "nct_id": "NCT01614470",
    "title": "Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cystic Fibrosis"
    ],
    "interventions": [
      "Ivacaftor",
      "Placebo"
    ],
    "primary_completion_date": "2013-10",
    "completion_date": "2013-10",
    "results_first_posted": "2014-10-29",
    "last_update_posted": "2014-10-29",
    "enrollment": null,
    "sponsor": "Vertex Pharmaceuticals Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Vertex Pharmaceuticals"
  },
  {
    "ticker": "VRTX",
    "nct_id": "NCT05477563",
    "title": "Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent \u03b2-Thalassemia and Severe Sickle Cell Disease",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Beta-Thalassemia",
      "Thalassemia",
      "Hematologic Diseases",
      "Genetic Diseases, Inborn",
      "Hemoglobinopathies",
      "Sickle Cell Disease",
      "Sickle Cell Anemia"
    ],
    "interventions": [
      "CTX001"
    ],
    "primary_completion_date": "2027-06-09",
    "completion_date": "2027-06-09",
    "results_first_posted": null,
    "last_update_posted": "2025-11-06",
    "enrollment": null,
    "sponsor": "Vertex Pharmaceuticals Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Vertex Pharmaceuticals"
  },
  {
    "ticker": "VRTX",
    "nct_id": "NCT01080222",
    "title": "A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Na\u00efve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Hepatitis C Virus Infection"
    ],
    "interventions": [
      "telaprevir",
      "VX-222",
      "ribavirin",
      "peginterferon-alfa-2a",
      "VX-222"
    ],
    "primary_completion_date": "2013-10",
    "completion_date": "2013-11",
    "results_first_posted": null,
    "last_update_posted": "2020-09-30",
    "enrollment": null,
    "sponsor": "Vertex Pharmaceuticals Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Vertex Pharmaceuticals"
  },
  {
    "ticker": "VRTX",
    "nct_id": "NCT03277196",
    "title": "A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Participants With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cystic Fibrosis"
    ],
    "interventions": [
      "IVA"
    ],
    "primary_completion_date": "2023-10-02",
    "completion_date": "2023-10-02",
    "results_first_posted": "2024-10-23",
    "last_update_posted": "2024-10-23",
    "enrollment": null,
    "sponsor": "Vertex Pharmaceuticals Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Vertex Pharmaceuticals"
  },
  {
    "ticker": "VRTX",
    "nct_id": "NCT05455502",
    "title": "A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-548",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pain"
    ],
    "interventions": [
      "VX-548"
    ],
    "primary_completion_date": "2022-09-17",
    "completion_date": "2022-09-17",
    "results_first_posted": null,
    "last_update_posted": "2024-03-20",
    "enrollment": null,
    "sponsor": "Vertex Pharmaceuticals Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Vertex Pharmaceuticals"
  },
  {
    "ticker": "VRTX",
    "nct_id": "NCT05111145",
    "title": "A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cystic Fibrosis"
    ],
    "interventions": [
      "ELX/TEZ/IVA",
      "IVA"
    ],
    "primary_completion_date": "2022-12-20",
    "completion_date": "2022-12-20",
    "results_first_posted": "2023-07-11",
    "last_update_posted": "2023-07-11",
    "enrollment": null,
    "sponsor": "Vertex Pharmaceuticals Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Vertex Pharmaceuticals"
  },
  {
    "ticker": "VRTX",
    "nct_id": "NCT01501383",
    "title": "A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Epilepsy"
    ],
    "interventions": [
      "VX-765 Part A",
      "Placebo",
      "VX-765 Part B"
    ],
    "primary_completion_date": "2013-08",
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2020-09-30",
    "enrollment": null,
    "sponsor": "Vertex Pharmaceuticals Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Vertex Pharmaceuticals"
  },
  {
    "ticker": "VRTX",
    "nct_id": "NCT05553366",
    "title": "Evaluation of Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Pain"
    ],
    "interventions": [
      "SUZ",
      "HB/APAP",
      "Placebo (matched to SUZ)",
      "Placebo (matched to HB/APAP)"
    ],
    "primary_completion_date": "2023-12-15",
    "completion_date": "2023-12-15",
    "results_first_posted": "2025-08-01",
    "last_update_posted": "2025-08-01",
    "enrollment": null,
    "sponsor": "Vertex Pharmaceuticals Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Vertex Pharmaceuticals"
  },
  {
    "ticker": "VRTX",
    "nct_id": "NCT06508762",
    "title": "A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-993",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pain"
    ],
    "interventions": [
      "VX-993"
    ],
    "primary_completion_date": "2024-09-10",
    "completion_date": "2024-09-10",
    "results_first_posted": null,
    "last_update_posted": "2024-10-10",
    "enrollment": null,
    "sponsor": "Vertex Pharmaceuticals Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Vertex Pharmaceuticals"
  },
  {
    "ticker": "VRTX",
    "nct_id": "NCT01726946",
    "title": "A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Na\u00efve Subjects With Chronic Hepatitis C",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Hepatitis C"
    ],
    "interventions": [
      "VX-135",
      "ribavirin"
    ],
    "primary_completion_date": "2014-02",
    "completion_date": "2014-02",
    "results_first_posted": null,
    "last_update_posted": "2015-04-16",
    "enrollment": null,
    "sponsor": "Vertex Pharmaceuticals Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Vertex Pharmaceuticals"
  },
  {
    "ticker": "VRTX",
    "nct_id": "NCT06420765",
    "title": "A Microneurography Study of NaV1.8 Inhibition in Healthy Adults",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pain"
    ],
    "interventions": [
      "VX-150",
      "VX-548",
      "VX-993",
      "Placebo"
    ],
    "primary_completion_date": "2025-03-22",
    "completion_date": "2025-04-04",
    "results_first_posted": null,
    "last_update_posted": "2025-04-20",
    "enrollment": null,
    "sponsor": "Vertex Pharmaceuticals Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Vertex Pharmaceuticals"
  },
  {
    "ticker": "VRTX",
    "nct_id": "NCT01581138",
    "title": "VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Hepatitis C Virus"
    ],
    "interventions": [
      "VX-222",
      "telaprevir",
      "ribavirin"
    ],
    "primary_completion_date": "2013-06",
    "completion_date": "2013-12",
    "results_first_posted": null,
    "last_update_posted": "2014-07-04",
    "enrollment": null,
    "sponsor": "Vertex Pharmaceuticals Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Vertex Pharmaceuticals"
  },
  {
    "ticker": "VRTX",
    "nct_id": "NCT02730208",
    "title": "A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cystic Fibrosis"
    ],
    "interventions": [
      "Tezacaftor/Ivacaftor",
      "Ivacaftor",
      "Placebo",
      "Placebo"
    ],
    "primary_completion_date": "2018-07",
    "completion_date": "2018-07",
    "results_first_posted": "2019-08-21",
    "last_update_posted": "2019-10-23",
    "enrollment": null,
    "sponsor": "Vertex Pharmaceuticals Incorporated",
    "collected_at": "2026-01-27",
    "search_term": "Vertex Pharmaceuticals"
  },
  {
    "ticker": "VTYX",
    "nct_id": "NCT05688852",
    "title": "VTX958 for the Treatment of Moderately to Severely Active Crohn's Disease",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Crohn Disease"
    ],
    "interventions": [
      "VTX958",
      "VTX958",
      "VTX958 Placebo"
    ],
    "primary_completion_date": "2024-06-27",
    "completion_date": "2024-12-20",
    "results_first_posted": null,
    "last_update_posted": "2025-07-03",
    "enrollment": null,
    "sponsor": "Ventyx Biosciences, Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ventyx Biosciences"
  },
  {
    "ticker": "VTYX",
    "nct_id": "NCT05715125",
    "title": "VTX958 Versus Placebo for the Treatment of Active Psoriatic Arthritis (Tranquility-PsA)",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Psoriatic Arthritis"
    ],
    "interventions": [
      "Dose A VTX958",
      "Dose B VTX958",
      "Placebo"
    ],
    "primary_completion_date": "2024-01-02",
    "completion_date": "2024-01-02",
    "results_first_posted": null,
    "last_update_posted": "2024-12-27",
    "enrollment": null,
    "sponsor": "Ventyx Biosciences, Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ventyx Biosciences"
  },
  {
    "ticker": "VTYX",
    "nct_id": "NCT05655299",
    "title": "VTX958 Versus Placebo for the Treatment of Moderate to Severe Psoriasis",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Psoriasis"
    ],
    "interventions": [
      "VTX958 Dose A",
      "VTX958 Dose B",
      "VTX958 Dose C",
      "VTX958 Dose D",
      "Placebo"
    ],
    "primary_completion_date": "2023-09-25",
    "completion_date": "2023-12-20",
    "results_first_posted": null,
    "last_update_posted": "2024-09-19",
    "enrollment": null,
    "sponsor": "Ventyx Biosciences, Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ventyx Biosciences"
  },
  {
    "ticker": "XENE",
    "nct_id": "NCT06775379",
    "title": "A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder"
    ],
    "interventions": [
      "Azetukalner",
      "Placebo"
    ],
    "primary_completion_date": "2026-08",
    "completion_date": "2026-10",
    "results_first_posted": null,
    "last_update_posted": "2025-10-22",
    "enrollment": null,
    "sponsor": "Xenon Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xenon Pharmaceuticals"
  },
  {
    "ticker": "XENE",
    "nct_id": "NCT07172516",
    "title": "A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bipolar Disorder",
      "Bipolar Depression",
      "Bipolar I Disorder",
      "Bipolar II Disorder"
    ],
    "interventions": [
      "Azetukalner",
      "Placebo"
    ],
    "primary_completion_date": "2028-06",
    "completion_date": "2028-08",
    "results_first_posted": null,
    "last_update_posted": "2025-12-19",
    "enrollment": null,
    "sponsor": "Xenon Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xenon Pharmaceuticals"
  },
  {
    "ticker": "XENE",
    "nct_id": "NCT04952467",
    "title": "Single-dose Mass Balance Recovery and Metabolite Profile and Identification of 14C-XEN1101",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "14C-XEN1101"
    ],
    "primary_completion_date": "2021-10-04",
    "completion_date": "2021-10-04",
    "results_first_posted": null,
    "last_update_posted": "2022-01-14",
    "enrollment": null,
    "sponsor": "Xenon Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xenon Pharmaceuticals"
  },
  {
    "ticker": "XENE",
    "nct_id": "NCT07217860",
    "title": "An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bipolar Depression",
      "Bipolar I Disorder",
      "Bipolar Disorder",
      "Bipolar II Disorder"
    ],
    "interventions": [
      "Azetukalner"
    ],
    "primary_completion_date": "2029-06",
    "completion_date": "2029-08",
    "results_first_posted": null,
    "last_update_posted": "2025-12-19",
    "enrollment": null,
    "sponsor": "Xenon Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xenon Pharmaceuticals"
  },
  {
    "ticker": "XENE",
    "nct_id": "NCT01090622",
    "title": "Study of XPF-001 in the Treatment of Pain From Primary/Inherited Erythromelalgia (IEM)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Primary Erythromelalgia",
      "Inherited Erythromelalgia"
    ],
    "interventions": [
      "XPF-001",
      "Placebo"
    ],
    "primary_completion_date": "2010-08",
    "completion_date": "2010-09",
    "results_first_posted": null,
    "last_update_posted": "2012-03-16",
    "enrollment": null,
    "sponsor": "Xenon Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xenon Pharmaceuticals"
  },
  {
    "ticker": "XENE",
    "nct_id": "NCT02656043",
    "title": "A Safety, Tolerability, Efficacy and Exposure Study of XEN801 Topical Gel",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acne Vulgaris"
    ],
    "interventions": [
      "XPF-005",
      "Placebo"
    ],
    "primary_completion_date": "2017-02-16",
    "completion_date": "2017-03-17",
    "results_first_posted": null,
    "last_update_posted": "2019-01-22",
    "enrollment": null,
    "sponsor": "Xenon Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xenon Pharmaceuticals"
  },
  {
    "ticker": "XENE",
    "nct_id": "NCT06922110",
    "title": "An Open-Label Study of Azetukalner in Major Depressive Disorder",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder"
    ],
    "interventions": [
      "Azetukalner"
    ],
    "primary_completion_date": "2027-01",
    "completion_date": "2027-03",
    "results_first_posted": null,
    "last_update_posted": "2025-09-09",
    "enrollment": null,
    "sponsor": "Xenon Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xenon Pharmaceuticals"
  },
  {
    "ticker": "XENE",
    "nct_id": "NCT03340220",
    "title": "Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of XEN1101.",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "XPF-008",
      "Microcrystalline Cellulose",
      "XPF-010",
      "Itraconazole 400mg"
    ],
    "primary_completion_date": "2021-11-26",
    "completion_date": "2021-11-26",
    "results_first_posted": null,
    "last_update_posted": "2023-05-11",
    "enrollment": null,
    "sponsor": "Xenon Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xenon Pharmaceuticals"
  },
  {
    "ticker": "XENE",
    "nct_id": "NCT07076407",
    "title": "A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder"
    ],
    "interventions": [
      "Azetukalner",
      "Placebo"
    ],
    "primary_completion_date": "2027-05",
    "completion_date": "2027-07",
    "results_first_posted": null,
    "last_update_posted": "2025-12-09",
    "enrollment": null,
    "sponsor": "Xenon Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xenon Pharmaceuticals"
  },
  {
    "ticker": "XENE",
    "nct_id": "NCT04639310",
    "title": "XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Epilepsy",
      "Epilepsy in Children",
      "Epilepsy; Seizure",
      "Disease",
      "Brain Diseases",
      "Central Nervous System Diseases",
      "Nervous System Diseases",
      "Epileptic Syndromes"
    ],
    "interventions": [
      "XEN496",
      "Placebo"
    ],
    "primary_completion_date": "2023-05-16",
    "completion_date": "2023-05-16",
    "results_first_posted": "2024-08-23",
    "last_update_posted": "2024-08-23",
    "enrollment": null,
    "sponsor": "Xenon Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xenon Pharmaceuticals"
  },
  {
    "ticker": "XENE",
    "nct_id": "NCT03467100",
    "title": "Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XEN901",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "XEN901",
      "Inert Ingredients Oral Product"
    ],
    "primary_completion_date": "2018-12-19",
    "completion_date": "2018-12-19",
    "results_first_posted": null,
    "last_update_posted": "2019-07-22",
    "enrollment": null,
    "sponsor": "Xenon Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xenon Pharmaceuticals"
  },
  {
    "ticker": "XENE",
    "nct_id": "NCT03468725",
    "title": "Safety, Tolerability, Pharmacokinetics and Effects on Transcranial Magnetic Stimulation of Oral Doses of XEN1101",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Male Volunteers"
    ],
    "interventions": [
      "XPF-008",
      "Microcrystalline Cellulose"
    ],
    "primary_completion_date": "2018-07-31",
    "completion_date": "2018-07-31",
    "results_first_posted": null,
    "last_update_posted": "2018-09-18",
    "enrollment": null,
    "sponsor": "Xenon Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xenon Pharmaceuticals"
  },
  {
    "ticker": "XENE",
    "nct_id": "NCT01195636",
    "title": "A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Postherpetic Neuralgia"
    ],
    "interventions": [
      "XPF-002",
      "Placebo"
    ],
    "primary_completion_date": "2011-03",
    "completion_date": "2011-03",
    "results_first_posted": "2013-11-25",
    "last_update_posted": "2013-11-25",
    "enrollment": null,
    "sponsor": "Xenon Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xenon Pharmaceuticals"
  },
  {
    "ticker": "XENE",
    "nct_id": "NCT00954356",
    "title": "Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extraction",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dental Pain"
    ],
    "interventions": [
      "XPF-001",
      "placebo"
    ],
    "primary_completion_date": "2009-11",
    "completion_date": "2009-12",
    "results_first_posted": "2012-06-29",
    "last_update_posted": "2012-07-16",
    "enrollment": null,
    "sponsor": "Xenon Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xenon Pharmaceuticals"
  },
  {
    "ticker": "XENE",
    "nct_id": "NCT00813670",
    "title": "Single and Multiple Ascending Dose Safety Study of XPF-001 in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Human Volunteers"
    ],
    "interventions": [
      "XPF-001"
    ],
    "primary_completion_date": "2009-05",
    "completion_date": "2009-07",
    "results_first_posted": null,
    "last_update_posted": "2009-09-14",
    "enrollment": null,
    "sponsor": "Xenon Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xenon Pharmaceuticals"
  },
  {
    "ticker": "XENE",
    "nct_id": "NCT05718817",
    "title": "An Open-label Study of XEN1101 in Epilepsy",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Focal Epilepsy",
      "Tonic-Clonic Seizures"
    ],
    "interventions": [
      "XEN1101"
    ],
    "primary_completion_date": "2028-07",
    "completion_date": "2028-09",
    "results_first_posted": null,
    "last_update_posted": "2025-12-18",
    "enrollment": null,
    "sponsor": "Xenon Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xenon Pharmaceuticals"
  },
  {
    "ticker": "XENE",
    "nct_id": "NCT04912856",
    "title": "An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Epilepsy",
      "Epilepsy in Children",
      "Epilepsy; Seizure",
      "Disease",
      "Brain Diseases",
      "Central Nervous System Diseases",
      "Nervous System Diseases",
      "Epileptic Syndromes"
    ],
    "interventions": [
      "XEN496"
    ],
    "primary_completion_date": "2023-11-17",
    "completion_date": "2023-11-17",
    "results_first_posted": "2025-02-14",
    "last_update_posted": "2025-02-14",
    "enrollment": null,
    "sponsor": "Xenon Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xenon Pharmaceuticals"
  },
  {
    "ticker": "XENE",
    "nct_id": "NCT01486446",
    "title": "Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Primary Erythromelalgia",
      "Inherited Erythromelalgia"
    ],
    "interventions": [
      "XPF-002",
      "Placebo"
    ],
    "primary_completion_date": "2012-04",
    "completion_date": "2012-05",
    "results_first_posted": "2014-04-14",
    "last_update_posted": "2014-04-14",
    "enrollment": null,
    "sponsor": "Xenon Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xenon Pharmaceuticals"
  },
  {
    "ticker": "XENE",
    "nct_id": "NCT05716100",
    "title": "A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Focal Onset Seizures"
    ],
    "interventions": [
      "XEN1101",
      "Placebo"
    ],
    "primary_completion_date": "2026-10",
    "completion_date": "2026-12",
    "results_first_posted": null,
    "last_update_posted": "2025-12-19",
    "enrollment": null,
    "sponsor": "Xenon Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xenon Pharmaceuticals"
  },
  {
    "ticker": "XENE",
    "nct_id": "NCT03796962",
    "title": "A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Focal Epilepsy"
    ],
    "interventions": [
      "XEN1101"
    ],
    "primary_completion_date": "2021-09-02",
    "completion_date": "2028-10",
    "results_first_posted": "2024-09-24",
    "last_update_posted": "2024-09-24",
    "enrollment": null,
    "sponsor": "Xenon Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xenon Pharmaceuticals"
  },
  {
    "ticker": "XENE",
    "nct_id": "NCT05376150",
    "title": "A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder"
    ],
    "interventions": [
      "XEN1101 10 mg",
      "XEN1101 20 mg",
      "Placebo"
    ],
    "primary_completion_date": "2023-09-18",
    "completion_date": "2023-10-16",
    "results_first_posted": null,
    "last_update_posted": "2024-09-19",
    "enrollment": null,
    "sponsor": "Xenon Pharmaceuticals Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xenon Pharmaceuticals"
  },
  {
    "ticker": "XNCR",
    "nct_id": "NCT07284797",
    "title": "A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Idiopathic Inflammatory Myopathy (IIM)",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy",
      "Idiopathic Inflammatory Myopathies"
    ],
    "interventions": [
      "XmAb13676"
    ],
    "primary_completion_date": "2027-02",
    "completion_date": "2027-02",
    "results_first_posted": null,
    "last_update_posted": "2025-12-16",
    "enrollment": null,
    "sponsor": "Xencor, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xencor"
  },
  {
    "ticker": "XNCR",
    "nct_id": "NCT02148744",
    "title": "Safety and Tolerability of XmAb\u00ae7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Allergic Rhinitis",
      "Allergic Conjunctivitis",
      "Atopic Dermatitis"
    ],
    "interventions": [
      "XmAb7195",
      "Placebo"
    ],
    "primary_completion_date": "2015-09-21",
    "completion_date": "2015-09-21",
    "results_first_posted": null,
    "last_update_posted": "2017-01-24",
    "enrollment": null,
    "sponsor": "Xencor, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xencor"
  },
  {
    "ticker": "XNCR",
    "nct_id": "NCT02725515",
    "title": "A Study of the Effect of XmAb\u00ae5871 in Patients With Systemic Lupus Erythematosus",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Systemic Lupus Erythematosus"
    ],
    "interventions": [
      "XmAb5871",
      "Placebo to match XmAb5871"
    ],
    "primary_completion_date": "2018-07-17",
    "completion_date": "2018-07-17",
    "results_first_posted": "2019-08-09",
    "last_update_posted": "2019-08-20",
    "enrollment": null,
    "sponsor": "Xencor, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xencor"
  },
  {
    "ticker": "XNCR",
    "nct_id": "NCT02730312",
    "title": "PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Myelogenous Leukemia",
      "B-cell Acute Lymphoblastic Leukemia",
      "Blastic Plasmacytoid Dendritic Cell Neoplasm",
      "Chronic Myeloid Leukemia, Blast Crisis"
    ],
    "interventions": [
      "XmAb14045"
    ],
    "primary_completion_date": "2021-09",
    "completion_date": "2021-09",
    "results_first_posted": null,
    "last_update_posted": "2022-03-08",
    "enrollment": null,
    "sponsor": "Xencor, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xencor"
  },
  {
    "ticker": "XNCR",
    "nct_id": "NCT05328102",
    "title": "Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diffuse Large-cell B-cell Lymphoma"
    ],
    "interventions": [
      "Plamotamab",
      "Tafasitamab",
      "Lenalidomide"
    ],
    "primary_completion_date": "2023-02-21",
    "completion_date": "2023-02-21",
    "results_first_posted": "2024-04-30",
    "last_update_posted": "2024-04-30",
    "enrollment": null,
    "sponsor": "Xencor, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xencor"
  },
  {
    "ticker": "XNCR",
    "nct_id": "NCT04857866",
    "title": "Safety, Tolerability and PK of a Single Subcutaneous Injection of XmAb27564 in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Safety in Healthy Volunteers"
    ],
    "interventions": [
      "XmAb27564",
      "Placebo"
    ],
    "primary_completion_date": "2022-11-10",
    "completion_date": "2022-11-10",
    "results_first_posted": null,
    "last_update_posted": "2023-03-01",
    "enrollment": null,
    "sponsor": "Xencor, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xencor"
  },
  {
    "ticker": "XNCR",
    "nct_id": "NCT02867098",
    "title": "XmAb5871 Bioavailability Study",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "XmAb5871"
    ],
    "primary_completion_date": "2016-10-21",
    "completion_date": "2016-10-21",
    "results_first_posted": null,
    "last_update_posted": "2017-12-08",
    "enrollment": null,
    "sponsor": "Xencor, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xencor"
  },
  {
    "ticker": "XNCR",
    "nct_id": "NCT03752398",
    "title": "A Study of XmAb\u00ae23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Melanoma (Excluding Uveal Melanoma)",
      "Cervical Carcinoma",
      "Pancreatic Carcinoma",
      "Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative",
      "Hepatocellular Carcinoma",
      "Urothelial Carcinoma",
      "Squamous Cell Carcinoma of the Head and Neck",
      "Nasopharyngeal Carcinoma",
      "Renal Cell Carcinoma",
      "Colorectal Carcinoma",
      "Endometrial Carcinoma",
      "Non-small Cell Lung Carcinoma",
      "Small Cell Lung Cancer",
      "Gastric or Gastroesophageal Junction Adenocarcinoma",
      "Advanced Solid Tumors",
      "Undifferentiated Pleomorphic Sarcoma"
    ],
    "interventions": [
      "XmAb\u00ae23104",
      "Yervoy\u00ae (ipilimumab)"
    ],
    "primary_completion_date": "2024-02-15",
    "completion_date": "2024-02-15",
    "results_first_posted": null,
    "last_update_posted": "2024-07-05",
    "enrollment": null,
    "sponsor": "Xencor, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xencor"
  },
  {
    "ticker": "XNCR",
    "nct_id": "NCT03517488",
    "title": "A Study of XmAb\u00ae20717 in Subjects With Selected Advanced Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Melanoma",
      "Breast Carcinoma",
      "Hepatocellular Carcinoma",
      "Urothelial Carcinoma",
      "Squamous Cell Carcinoma of the Head and Neck",
      "Renal Cell Carcinoma",
      "Colorectal Carcinoma",
      "Non-small Cell Lung Carcinoma",
      "Gastric or Gastroesophageal Junction Adenocarcinoma",
      "Endometrial Carcinoma",
      "Mesothelioma",
      "Neuroendocrine Carcinoma",
      "Cervical Cancer",
      "Small Cell Lung Carcinoma",
      "Squamous Cell Carcinoma of the Anus",
      "Castration-Resistant Prostate Carcinoma",
      "Nasopharyngeal Carcinoma",
      "Cholangiocarcinoma",
      "Basal Cell Carcinoma",
      "Ovarian Carcinoma",
      "Fallopian Tube Carcinoma",
      "Thymoma",
      "Thymic Carcinoma",
      "Squamous Cell Carcinoma of the Penis",
      "Vulvar Carcinoma",
      "Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy",
      "Malignant Adnexal Neoplasms",
      "Non-squamous Cell Salivary Gland Carcinoma"
    ],
    "interventions": [
      "XmAb20717"
    ],
    "primary_completion_date": "2022-06-01",
    "completion_date": "2022-09-06",
    "results_first_posted": null,
    "last_update_posted": "2022-12-01",
    "enrollment": null,
    "sponsor": "Xencor, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xencor"
  },
  {
    "ticker": "XNCR",
    "nct_id": "NCT05585034",
    "title": "Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb\u00ae808 in Combination With Pembrolizumab in Advanced Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Head and Neck Squamous Cell Carcinoma",
      "Melanoma Excluding Uveal Melanoma",
      "Non-small Cell Lung Cancer, Squamous or Non-squamous",
      "Urothelial Carcinoma",
      "Renal Cell Carcinoma, Clear Cell",
      "Castration-resistant Prostate Cancer",
      "Ovarian Cancer, Epithelial",
      "TNBC - Triple-Negative Breast Cancer",
      "Colorectal Cancer"
    ],
    "interventions": [
      "XmAb\u00ae808",
      "Keytruda\u00ae (pembrolizumab)"
    ],
    "primary_completion_date": "2025-05-20",
    "completion_date": "2025-05-20",
    "results_first_posted": null,
    "last_update_posted": "2025-08-07",
    "enrollment": null,
    "sponsor": "Xencor, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xencor"
  },
  {
    "ticker": "XNCR",
    "nct_id": "NCT03411915",
    "title": "A Study of XmAb\u00ae18087 in Subjects With NET and GIST",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Neuroendocrine Tumor",
      "Gastrointestinal Neoplasm"
    ],
    "interventions": [
      "XmAb18087"
    ],
    "primary_completion_date": "2021-10-26",
    "completion_date": "2021-10-26",
    "results_first_posted": null,
    "last_update_posted": "2022-05-10",
    "enrollment": null,
    "sponsor": "Xencor, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xencor"
  },
  {
    "ticker": "XNCR",
    "nct_id": "NCT06619990",
    "title": "Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ulcerative Colitis (UC)"
    ],
    "interventions": [
      "XmAb942",
      "Placebo"
    ],
    "primary_completion_date": "2028-04",
    "completion_date": "2029-01",
    "results_first_posted": null,
    "last_update_posted": "2025-12-12",
    "enrollment": null,
    "sponsor": "Xencor, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xencor"
  },
  {
    "ticker": "XNCR",
    "nct_id": "NCT03445663",
    "title": "Study Evaluating AMG 424 in Subjects With Multiple Myeloma",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsed/ Refractory Multiple Myeloma"
    ],
    "interventions": [
      "AMG 424"
    ],
    "primary_completion_date": "2020-06-19",
    "completion_date": "2020-06-19",
    "results_first_posted": null,
    "last_update_posted": "2023-03-07",
    "enrollment": null,
    "sponsor": "Xencor, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xencor"
  },
  {
    "ticker": "XNCR",
    "nct_id": "NCT06276491",
    "title": "Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ovarian Cancer",
      "Endometrial Cancer",
      "Germ Cell Tumor",
      "Testicular Germ Cell Tumor",
      "Ovarian Germ Cell Tumor"
    ],
    "interventions": [
      "XmAb541"
    ],
    "primary_completion_date": "2027-12",
    "completion_date": "2028-12",
    "results_first_posted": null,
    "last_update_posted": "2025-08-07",
    "enrollment": null,
    "sponsor": "Xencor, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xencor"
  },
  {
    "ticker": "XNCR",
    "nct_id": "NCT05996445",
    "title": "A Study of XmAb\u00ae662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumors"
    ],
    "interventions": [
      "XmAb662",
      "Keytruda\u00ae (pembrolizumab)"
    ],
    "primary_completion_date": "2024-05-21",
    "completion_date": "2024-05-21",
    "results_first_posted": null,
    "last_update_posted": "2024-08-23",
    "enrollment": null,
    "sponsor": "Xencor, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xencor"
  },
  {
    "ticker": "XNCR",
    "nct_id": "NCT06005792",
    "title": "Multiple Ascending-Dose Study of XmAb\u00ae27564 in Patients With Psoriasis or Atopic Dermatitis",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Psoriasis",
      "Atopic Dermatitis"
    ],
    "interventions": [
      "XmAb27564",
      "Placebo"
    ],
    "primary_completion_date": "2024-03-22",
    "completion_date": "2024-11-22",
    "results_first_posted": null,
    "last_update_posted": "2025-12-02",
    "enrollment": null,
    "sponsor": "Xencor, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xencor"
  },
  {
    "ticker": "XNCR",
    "nct_id": "NCT05433142",
    "title": "Study of XmAb\u00ae819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Clear Cell Renal Cell Carcinoma"
    ],
    "interventions": [
      "XmAb819"
    ],
    "primary_completion_date": "2026-02",
    "completion_date": "2027-11",
    "results_first_posted": null,
    "last_update_posted": "2025-07-31",
    "enrollment": null,
    "sponsor": "Xencor, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xencor"
  },
  {
    "ticker": "XNCR",
    "nct_id": "NCT02881853",
    "title": "Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb\u00ae7195",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers",
      "Atopic Disease"
    ],
    "interventions": [
      "XmAb7195",
      "Placebo"
    ],
    "primary_completion_date": "2017-02-24",
    "completion_date": "2017-02-24",
    "results_first_posted": null,
    "last_update_posted": "2017-07-11",
    "enrollment": null,
    "sponsor": "Xencor, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xencor"
  },
  {
    "ticker": "XNCR",
    "nct_id": "NCT02725476",
    "title": "Study to Evaluate the Effect of XmAb\u00ae5871 on Disease Activity in Patients With IgG4-Related Disease (RD)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "IgG4-RD"
    ],
    "interventions": [
      "XmAb5871"
    ],
    "primary_completion_date": "2017-12",
    "completion_date": "2017-12",
    "results_first_posted": "2018-12-07",
    "last_update_posted": "2018-12-07",
    "enrollment": null,
    "sponsor": "Xencor, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xencor"
  },
  {
    "ticker": "XNCR",
    "nct_id": "NCT07230353",
    "title": "A Phase 1b Open-label Study to Evaluate Safety in Participants With Rheumatoid Arthritis",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rheumatoid Arthritis"
    ],
    "interventions": [
      "XmAb13676"
    ],
    "primary_completion_date": "2028-06",
    "completion_date": "2028-06",
    "results_first_posted": null,
    "last_update_posted": "2025-11-17",
    "enrollment": null,
    "sponsor": "Xencor, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xencor"
  },
  {
    "ticker": "XNCR",
    "nct_id": "NCT01161511",
    "title": "Safety and Tolerability of XmAb\u00ae5574 in Chronic Lymphocytic Leukemia",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Lymphocytic Leukemia",
      "Small Lymphocytic Lymphoma"
    ],
    "interventions": [
      "XmAb5574"
    ],
    "primary_completion_date": "2013-01",
    "completion_date": "2013-01",
    "results_first_posted": null,
    "last_update_posted": "2014-04-21",
    "enrollment": null,
    "sponsor": "Xencor, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xencor"
  },
  {
    "ticker": "XNCR",
    "nct_id": "NCT00606645",
    "title": "Safety Study of XmAb\u00ae2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hodgkin Lymphoma",
      "Anaplastic Large Cell Lymphoma"
    ],
    "interventions": [
      "XmAb2513"
    ],
    "primary_completion_date": "2010-04",
    "completion_date": "2010-04",
    "results_first_posted": null,
    "last_update_posted": "2014-04-21",
    "enrollment": null,
    "sponsor": "Xencor, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xencor"
  },
  {
    "ticker": "XNCR",
    "nct_id": "NCT05032040",
    "title": "A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ovarian Cancer",
      "Clear Cell Carcinoma",
      "Endometrial Cancer",
      "Cervical Carcinoma",
      "Metastatic Castration-Resistant Prostate Cancer (mCRPC)"
    ],
    "interventions": [
      "vudalimab"
    ],
    "primary_completion_date": "2025-10-15",
    "completion_date": "2025-12-30",
    "results_first_posted": null,
    "last_update_posted": "2025-02-07",
    "enrollment": null,
    "sponsor": "Xencor, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xencor"
  },
  {
    "ticker": "XNCR",
    "nct_id": "NCT03849469",
    "title": "A Study of XmAb\u00ae22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Melanoma",
      "Cervical Carcinoma",
      "Pancreatic Carcinoma",
      "Triple Negative Breast Cancer",
      "Hepatocellular Carcinoma",
      "Urothelial Carcinoma",
      "Squamous Cell Carcinoma of the Head and Neck",
      "Nasopharyngeal Carcinoma",
      "Renal Cell Carcinoma",
      "Non-small Cell Lung Carcinoma",
      "Small Cell Lung Carcinoma",
      "Gastric or Gastroesophageal Junction Adenocarcinoma",
      "Advanced or Metastatic Solid Tumors",
      "Prostate Carcinoma",
      "Epithelial Ovarian Cancer",
      "Fallopian Tube Cancer",
      "Primary Peritoneal Carcinoma",
      "Intrahepatic Cholangiocarcinoma",
      "Squamous Cell Anal Cancer",
      "Squamous Cell Penile Carcinoma",
      "Squamous Cell Vulvar Carcinoma",
      "Colorectal Carcinoma",
      "Endometrial Carcinoma"
    ],
    "interventions": [
      "XmAb\u00ae22841",
      "Pembrolizumab (Keytruda\u00ae)"
    ],
    "primary_completion_date": "2023-02-16",
    "completion_date": "2023-02-16",
    "results_first_posted": null,
    "last_update_posted": "2023-03-30",
    "enrollment": null,
    "sponsor": "Xencor, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xencor"
  },
  {
    "ticker": "XNCR",
    "nct_id": "NCT06173505",
    "title": "Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Nonsquamous Non-small Cell Lung Cancer"
    ],
    "interventions": [
      "Vudalimab + Carboplatin + Pemetrexed",
      "Pembrolizumab + Carboplatin + Pemetrexed"
    ],
    "primary_completion_date": "2026-10",
    "completion_date": "2027-10",
    "results_first_posted": null,
    "last_update_posted": "2024-12-04",
    "enrollment": null,
    "sponsor": "Xencor, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Xencor"
  },
  {
    "ticker": "ZLAB",
    "nct_id": "NCT06885281",
    "title": "A Study of ZL-1310 in Participants With Selected Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumors"
    ],
    "interventions": [
      "ZL-1310"
    ],
    "primary_completion_date": "2026-12",
    "completion_date": "2027-06",
    "results_first_posted": null,
    "last_update_posted": "2025-12-15",
    "enrollment": null,
    "sponsor": "Zai Lab (Shanghai) Co., Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Zai Lab"
  },
  {
    "ticker": "ZLAB",
    "nct_id": "NCT06179069",
    "title": "A Study of ZL-1310 in Subjects With Small Cell Lung Cancer",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "SCLC"
    ],
    "interventions": [
      "ZL-1310",
      "Atezolizumab",
      "Carboplatin"
    ],
    "primary_completion_date": "2027-05-30",
    "completion_date": "2027-07-31",
    "results_first_posted": null,
    "last_update_posted": "2025-08-15",
    "enrollment": null,
    "sponsor": "Zai Lab (Shanghai) Co., Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Zai Lab"
  },
  {
    "ticker": "ZLAB",
    "nct_id": "NCT05866354",
    "title": "To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Malignancies"
    ],
    "interventions": [
      "Tisotumab Vedotin"
    ],
    "primary_completion_date": "2023-11-02",
    "completion_date": "2023-11-02",
    "results_first_posted": null,
    "last_update_posted": "2023-11-27",
    "enrollment": null,
    "sponsor": "Zai Lab (Shanghai) Co., Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Zai Lab"
  },
  {
    "ticker": "ZLAB",
    "nct_id": "NCT04392102",
    "title": "A Study of Niraparib in Patients With Relapsed Ovarian Cancer",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ovarian Cancer"
    ],
    "interventions": [
      "ZL-2306(Niraparib\uff09"
    ],
    "primary_completion_date": "2021-04-08",
    "completion_date": "2022-08-11",
    "results_first_posted": null,
    "last_update_posted": "2022-08-29",
    "enrollment": null,
    "sponsor": "Zai Lab (Shanghai) Co., Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Zai Lab"
  },
  {
    "ticker": "ZLAB",
    "nct_id": "NCT03705156",
    "title": "Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) in Ovarian Cancer Patient",
    "status": "UNKNOWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Platinum-sensitive Relapsed Ovarian Cancer"
    ],
    "interventions": [
      "ZL-2306(nirapairb)",
      "Placebos"
    ],
    "primary_completion_date": "2020-02-01",
    "completion_date": "2024-08-24",
    "results_first_posted": null,
    "last_update_posted": "2023-04-13",
    "enrollment": null,
    "sponsor": "Zai Lab (Shanghai) Co., Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Zai Lab"
  },
  {
    "ticker": "ZLAB",
    "nct_id": "NCT04262804",
    "title": "A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC",
    "status": "UNKNOWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Cancer Metastatic"
    ],
    "interventions": [
      "Margetuximab",
      "Trastuzumab",
      "Chosen Chemotherapy (Capecitabine)",
      "Chosen Chemotherapy (Vinorelbine )",
      "Chosen Chemotherapy (Gemcitabine )"
    ],
    "primary_completion_date": "2021-09-03",
    "completion_date": "2023-12",
    "results_first_posted": null,
    "last_update_posted": "2023-08-22",
    "enrollment": null,
    "sponsor": "Zai Lab (Shanghai) Co., Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Zai Lab"
  },
  {
    "ticker": "ZLAB",
    "nct_id": "NCT06380907",
    "title": "A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Plaque Psoriasis"
    ],
    "interventions": [
      "ZL-1102 1% w/w gel BID for 16 weeks",
      "ZL-1102 3% w/w gel BID for 16 weeks",
      "ZL-1102 3% w/w gel QD for 16 weeks",
      "Placebo ZL-1102 0% w/w gel BID for 16 weeks",
      "Placebo ZL-1102 0% w/w gel QD for 16 weeks"
    ],
    "primary_completion_date": "2026-02-28",
    "completion_date": "2026-03",
    "results_first_posted": null,
    "last_update_posted": "2024-11-05",
    "enrollment": null,
    "sponsor": "Zai Lab (Hong Kong), Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Zai Lab"
  },
  {
    "ticker": "ZLAB",
    "nct_id": "NCT04398108",
    "title": "A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HER2 Positive Metastatic Breast Cancer"
    ],
    "interventions": [
      "Margetuximab Margetuximab-IV"
    ],
    "primary_completion_date": "2021-04-27",
    "completion_date": "2021-04-27",
    "results_first_posted": null,
    "last_update_posted": "2021-06-14",
    "enrollment": null,
    "sponsor": "Zai Lab (Shanghai) Co., Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Zai Lab"
  },
  {
    "ticker": "ZLAB",
    "nct_id": "NCT03516084",
    "title": "A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Extensive-stage Small Cell Lung Cancer"
    ],
    "interventions": [
      "ZL-2306(nirapairb)",
      "Placebo"
    ],
    "primary_completion_date": "2020-02-21",
    "completion_date": "2020-03-20",
    "results_first_posted": null,
    "last_update_posted": "2020-12-21",
    "enrollment": null,
    "sponsor": "Zai Lab (Shanghai) Co., Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Zai Lab"
  },
  {
    "ticker": "ZLAB",
    "nct_id": "NCT04653038",
    "title": "A Study to Evaluate the Safety and Efficacy of MGD013 in Patients With Melanoma",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Unresectable, Recurrent or Metastatic Melanoma",
      "Untreated Mucosal or Acral Lentiginous Melanoma"
    ],
    "interventions": [
      "MGD013"
    ],
    "primary_completion_date": "2022-03-02",
    "completion_date": "2022-03-02",
    "results_first_posted": null,
    "last_update_posted": "2024-01-29",
    "enrollment": null,
    "sponsor": "Zai Lab (Shanghai) Co., Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Zai Lab"
  },
  {
    "ticker": "ZLAB",
    "nct_id": "NCT03134352",
    "title": "Study to Evaluate the Efficacy and Safety of ZL-3101 in Subjects With Subacute Eczema",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Eczema"
    ],
    "interventions": [
      "ZL-3101",
      "Placebo"
    ],
    "primary_completion_date": "2018-05-25",
    "completion_date": "2018-09-10",
    "results_first_posted": null,
    "last_update_posted": "2019-01-24",
    "enrollment": null,
    "sponsor": "Zai Lab Pty. Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Zai Lab"
  },
  {
    "ticker": "ZLAB",
    "nct_id": "NCT02397005",
    "title": "Study of the Tolerability and Pharmacokinetic of ZL-2102 With an Investigation of Food Effect in Healthy Male Subjects",
    "status": "UNKNOWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Obstructive Pulmonary Disease",
      "Asthma",
      "Idiopathic Pulmonary Fibrosis"
    ],
    "interventions": [
      "ZL-2102",
      "Placebo matching ZL-2102"
    ],
    "primary_completion_date": "2016-04",
    "completion_date": "2019-08",
    "results_first_posted": null,
    "last_update_posted": "2019-01-24",
    "enrollment": null,
    "sponsor": "Zai Lab Pty. Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Zai Lab"
  },
  {
    "ticker": "ZLAB",
    "nct_id": "NCT07211776",
    "title": "A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Thyroid Eye Disease (TED)"
    ],
    "interventions": [
      "ZL-1109 (VRDN-003)",
      "Placebo"
    ],
    "primary_completion_date": "2027-03-14",
    "completion_date": "2028-01-29",
    "results_first_posted": null,
    "last_update_posted": "2025-12-29",
    "enrollment": null,
    "sponsor": "Zai Lab (Shanghai) Co., Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Zai Lab"
  },
  {
    "ticker": "ZLAB",
    "nct_id": "NCT07235384",
    "title": "A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atopic Dermatitis (AD)"
    ],
    "interventions": [
      "ZL-1503",
      "Placebo",
      "ZL-1503",
      "Placebo"
    ],
    "primary_completion_date": "2027-12-28",
    "completion_date": "2027-12-28",
    "results_first_posted": null,
    "last_update_posted": "2025-12-19",
    "enrollment": null,
    "sponsor": "Zai Lab (Shanghai) Co., Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Zai Lab"
  },
  {
    "ticker": "ZLAB",
    "nct_id": "NCT03709316",
    "title": "A Study of ZL-2306 (Niraparib) as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer",
    "status": "UNKNOWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ovarian Cancer"
    ],
    "interventions": [
      "ZL-2306 (Nirapairb)",
      "Placebo Comparator"
    ],
    "primary_completion_date": "2022-01-29",
    "completion_date": "2023-12-30",
    "results_first_posted": null,
    "last_update_posted": "2021-06-02",
    "enrollment": null,
    "sponsor": "Zai Lab (Shanghai) Co., Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Zai Lab"
  },
  {
    "ticker": "ZLAB",
    "nct_id": "NCT05859464",
    "title": "A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Malignant Solid Tumor"
    ],
    "interventions": [
      "ZL-1218",
      "Pembrolizumab"
    ],
    "primary_completion_date": "2025-08-28",
    "completion_date": "2025-08-28",
    "results_first_posted": null,
    "last_update_posted": "2025-10-20",
    "enrollment": null,
    "sponsor": "Zai Lab (Hong Kong), Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Zai Lab"
  },
  {
    "ticker": "ZLAB",
    "nct_id": "NCT03516071",
    "title": "A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatocellular Carcinoma (HCC)"
    ],
    "interventions": [
      "Brivanib 800 mg, QD",
      "Brivanib 400 mg, BID"
    ],
    "primary_completion_date": "2018-11-09",
    "completion_date": "2019-07-19",
    "results_first_posted": null,
    "last_update_posted": "2019-09-04",
    "enrollment": null,
    "sponsor": "Zai Lab (Shanghai) Co., Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Zai Lab"
  },
  {
    "ticker": "ZLAB",
    "nct_id": "NCT04633122",
    "title": "A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Gastrointestinal Stromal Tumor(GIST)"
    ],
    "interventions": [
      "Ripretinib",
      "Sunitinib"
    ],
    "primary_completion_date": "2022-07-20",
    "completion_date": "2022-07-20",
    "results_first_posted": "2025-01-15",
    "last_update_posted": "2025-02-10",
    "enrollment": null,
    "sponsor": "Zai Lab (Shanghai) Co., Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Zai Lab"
  },
  {
    "ticker": "ZLAB",
    "nct_id": "NCT04257617",
    "title": "A Trial of ZL-1201 in Subjects With Advanced Cancer",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Cancer"
    ],
    "interventions": [
      "ZL-1201"
    ],
    "primary_completion_date": "2022-05-17",
    "completion_date": "2023-01-19",
    "results_first_posted": null,
    "last_update_posted": "2023-08-22",
    "enrollment": null,
    "sponsor": "Zai Lab (Shanghai) Co., Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Zai Lab"
  },
  {
    "ticker": "ZLAB",
    "nct_id": "NCT03551171",
    "title": "The Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-2306 (Niraparib) in Patients With Ovarian Cancer",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ovarian Cancer"
    ],
    "interventions": [
      "ZL-2306 (niraparib)"
    ],
    "primary_completion_date": "2018-05-03",
    "completion_date": "2018-07-10",
    "results_first_posted": null,
    "last_update_posted": "2019-01-24",
    "enrollment": null,
    "sponsor": "Zai Lab (Shanghai) Co., Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Zai Lab"
  },
  {
    "ticker": "ZLAB",
    "nct_id": "NCT06462326",
    "title": "A Study to Compare the Effect of Omadacycline Versus Moxifloxacin in Healthy Adult Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteer"
    ],
    "interventions": [
      "Moxifloxacin Oral Tablet",
      "Omadacycline Oral Tablet"
    ],
    "primary_completion_date": "2024-09-29",
    "completion_date": "2024-09-29",
    "results_first_posted": null,
    "last_update_posted": "2024-11-01",
    "enrollment": null,
    "sponsor": "Zai Lab (Hong Kong), Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Zai Lab"
  },
  {
    "ticker": "ZLAB",
    "nct_id": "NCT04178460",
    "title": "A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Gastric Cancer",
      "Triple Negative Breast Cancer",
      "Biliary Tract Carcinoma",
      "Endometrial Carcinoma"
    ],
    "interventions": [
      "Niraparib combined with MGD013"
    ],
    "primary_completion_date": "2022-03-02",
    "completion_date": "2022-03-02",
    "results_first_posted": null,
    "last_update_posted": "2022-06-01",
    "enrollment": null,
    "sponsor": "Zai Lab (Shanghai) Co., Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Zai Lab"
  },
  {
    "ticker": "ZLAB",
    "nct_id": "NCT04282980",
    "title": "A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Gastrointestinal Stromal Tumors"
    ],
    "interventions": [
      "DCC-2618"
    ],
    "primary_completion_date": "2021-02-26",
    "completion_date": "2022-08-23",
    "results_first_posted": "2025-03-03",
    "last_update_posted": "2025-03-03",
    "enrollment": null,
    "sponsor": "Zai Lab (Shanghai) Co., Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Zai Lab"
  },
  {
    "ticker": "ZLAB",
    "nct_id": "NCT04212221",
    "title": "MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Hepatocellular Carcinoma (HCC)"
    ],
    "interventions": [
      "MGD013 monotherapy",
      "MGD013 in combination with Brivanib Alaninate"
    ],
    "primary_completion_date": "2022-04-27",
    "completion_date": "2022-04-27",
    "results_first_posted": "2024-07-23",
    "last_update_posted": "2024-07-23",
    "enrollment": null,
    "sponsor": "Zai Lab (Shanghai) Co., Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Zai Lab"
  },
  {
    "ticker": "ZLAB",
    "nct_id": "NCT07218146",
    "title": "A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Small-cell Lung Cancer"
    ],
    "interventions": [
      "ZL-1310",
      "Investigator's Choice of Therapy"
    ],
    "primary_completion_date": "2028-06-30",
    "completion_date": "2028-11-30",
    "results_first_posted": null,
    "last_update_posted": "2026-01-15",
    "enrollment": null,
    "sponsor": "Zai Lab (Shanghai) Co., Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Zai Lab"
  },
  {
    "ticker": "ZLAB",
    "nct_id": "NCT05263986",
    "title": "The Clinical Trial to Evaluate the Pharmacokinetics and Safety of MRTX849 in Patients With Advanced Solid Tumors",
    "status": "UNKNOWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced or Metastatic Solid Tumor"
    ],
    "interventions": [
      "MRTX849"
    ],
    "primary_completion_date": "2023-10-31",
    "completion_date": "2023-10-31",
    "results_first_posted": null,
    "last_update_posted": "2023-02-27",
    "enrollment": null,
    "sponsor": "Zai Lab (Shanghai) Co., Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Zai Lab"
  },
  {
    "ticker": "ZLAB",
    "nct_id": "NCT05065710",
    "title": "A Study of ZL-1211 in Patients With Advanced Solid Tumor",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumor"
    ],
    "interventions": [
      "ZL-1211"
    ],
    "primary_completion_date": "2024-03-09",
    "completion_date": "2024-04-09",
    "results_first_posted": null,
    "last_update_posted": "2024-09-03",
    "enrollment": null,
    "sponsor": "Zai Biopharmaceutical (Suzhou) Co., Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Zai Lab"
  },
  {
    "ticker": "ZLAB",
    "nct_id": "NCT06162286",
    "title": "A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline to Moxifloxacin for Treating Adult Subjects With CABP",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Community-acquired Bacterial Pneumonia"
    ],
    "interventions": [
      "Omadacycline",
      "Moxifloxacin"
    ],
    "primary_completion_date": "2025-01-01",
    "completion_date": "2025-11-30",
    "results_first_posted": null,
    "last_update_posted": "2024-06-14",
    "enrollment": null,
    "sponsor": "Zai Lab (Hong Kong), Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Zai Lab"
  },
  {
    "ticker": "ZVRA",
    "nct_id": "NCT04316637",
    "title": "Early Access Program With Arimoclomol in US Patients With NPC",
    "status": "AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Niemann-Pick Disease, Type C"
    ],
    "interventions": [
      "Arimoclomol"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2024-08-16",
    "enrollment": null,
    "sponsor": "ZevraDenmark",
    "collected_at": "2026-01-27",
    "search_term": "Zevra Therapeutics"
  },
  {
    "ticker": "ZVRA",
    "nct_id": "NCT03460652",
    "title": "KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "ADHD"
    ],
    "interventions": [
      "KP415 oral capsule"
    ],
    "primary_completion_date": "2019-06-20",
    "completion_date": "2019-07-09",
    "results_first_posted": "2021-07-19",
    "last_update_posted": "2021-07-19",
    "enrollment": null,
    "sponsor": "Zevra Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Zevra Therapeutics"
  },
  {
    "ticker": "ZVRA",
    "nct_id": "NCT03292952",
    "title": "KP415 Classroom Study in Children (6-12 Years of Age) With ADHD",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "ADHD"
    ],
    "interventions": [
      "KP415 oral capsule",
      "Placebo oral capsule"
    ],
    "primary_completion_date": "2018-05-16",
    "completion_date": "2018-05-16",
    "results_first_posted": "2021-06-30",
    "last_update_posted": "2021-06-30",
    "enrollment": null,
    "sponsor": "Zevra Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Zevra Therapeutics"
  },
  {
    "ticker": "ZVRA",
    "nct_id": "NCT05668754",
    "title": "Placebo-Controlled, Double-Blind, Study to Determine the Safety and Efficacy of SDX in Patients With IH",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Idiopathic Hypersomnia"
    ],
    "interventions": [
      "Serdexmethylphenidate",
      "Placebo"
    ],
    "primary_completion_date": "2024-02-28",
    "completion_date": "2024-03-21",
    "results_first_posted": null,
    "last_update_posted": "2025-02-03",
    "enrollment": null,
    "sponsor": "Zevra Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Zevra Therapeutics"
  },
  {
    "ticker": "FOLD",
    "nct_id": "NCT06904261",
    "title": "A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fabry Disease"
    ],
    "interventions": [
      "Migalastat HCl 20 mg"
    ],
    "primary_completion_date": "2027-12",
    "completion_date": "2028-12",
    "results_first_posted": null,
    "last_update_posted": "2026-01-15",
    "enrollment": null,
    "sponsor": "Amicus Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Amicus Therapeutics"
  },
  {
    "ticker": "FOLD",
    "nct_id": "NCT03911505",
    "title": "ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pompe Disease (Late-onset)"
    ],
    "interventions": [
      "Cipaglucosidase Alfa",
      "Miglustat"
    ],
    "primary_completion_date": "2026-06",
    "completion_date": "2026-06",
    "results_first_posted": null,
    "last_update_posted": "2025-10-27",
    "enrollment": null,
    "sponsor": "Amicus Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Amicus Therapeutics"
  },
  {
    "ticker": "FOLD",
    "nct_id": "NCT01458119",
    "title": "Open-Label Phase 3 Long-Term Safety Study of Migalastat",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fabry Disease"
    ],
    "interventions": [
      "migalastat hydrochloride"
    ],
    "primary_completion_date": "2016-02-17",
    "completion_date": "2016-02-17",
    "results_first_posted": "2018-10-02",
    "last_update_posted": "2018-10-02",
    "enrollment": null,
    "sponsor": "Amicus Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Amicus Therapeutics"
  },
  {
    "ticker": "FOLD",
    "nct_id": "NCT04252066",
    "title": "A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Fabry Disease"
    ],
    "interventions": [
      "migalastat"
    ],
    "primary_completion_date": "2029-08",
    "completion_date": "2030-02",
    "results_first_posted": null,
    "last_update_posted": "2025-07-08",
    "enrollment": null,
    "sponsor": "Amicus Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Amicus Therapeutics"
  },
  {
    "ticker": "FOLD",
    "nct_id": "NCT01476163",
    "title": "Physician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry Disease",
    "status": "AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Fabry Disease"
    ],
    "interventions": [
      "migalastat HCl 150 mg",
      "migalastat HCl 20 mg"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2025-07-03",
    "enrollment": null,
    "sponsor": "Amicus Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Amicus Therapeutics"
  },
  {
    "ticker": "FOLD",
    "nct_id": "NCT00283933",
    "title": "A 24-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fabry Disease"
    ],
    "interventions": [
      "migalastat HCl"
    ],
    "primary_completion_date": "2008-03-12",
    "completion_date": "2008-03-12",
    "results_first_posted": "2018-09-07",
    "last_update_posted": "2018-09-07",
    "enrollment": null,
    "sponsor": "Amicus Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Amicus Therapeutics"
  },
  {
    "ticker": "FOLD",
    "nct_id": "NCT01489995",
    "title": "Migalastat Food Effect Study",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fabry Disease"
    ],
    "interventions": [
      "A (migalastat)",
      "B (migalastat)",
      "C (migalastat)",
      "D (migalastat)",
      "E (migalastat)"
    ],
    "primary_completion_date": "2011-12",
    "completion_date": "2011-12",
    "results_first_posted": null,
    "last_update_posted": "2013-12-18",
    "enrollment": null,
    "sponsor": "Amicus Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Amicus Therapeutics"
  },
  {
    "ticker": "FOLD",
    "nct_id": "NCT00304512",
    "title": "A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Female Participants With Fabry Disease",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fabry Disease"
    ],
    "interventions": [
      "migalastat HCl"
    ],
    "primary_completion_date": "2008-05-09",
    "completion_date": "2008-05-09",
    "results_first_posted": "2018-09-07",
    "last_update_posted": "2018-10-03",
    "enrollment": null,
    "sponsor": "Amicus Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Amicus Therapeutics"
  },
  {
    "ticker": "FOLD",
    "nct_id": "NCT03865836",
    "title": "Expanded Access for ATB200/AT2221 for the Treatment of Pompe Disease",
    "status": "AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Pompe Disease"
    ],
    "interventions": [
      "ATB200",
      "AT2221"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2025-09-15",
    "enrollment": null,
    "sponsor": "Amicus Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Amicus Therapeutics"
  },
  {
    "ticker": "FOLD",
    "nct_id": "NCT04808505",
    "title": "A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Glycogen Storage Disease Type II Infantile Onset"
    ],
    "interventions": [
      "Cipaglucosidase alfa",
      "Miglustat"
    ],
    "primary_completion_date": "2027-07",
    "completion_date": "2027-07",
    "results_first_posted": null,
    "last_update_posted": "2026-01-22",
    "enrollment": null,
    "sponsor": "Amicus Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Amicus Therapeutics"
  },
  {
    "ticker": "FOLD",
    "nct_id": "NCT04043273",
    "title": "Treatment-related Benefit and Satisfaction in Fabry Patients. Insight in Patients Expectations and Preferences",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Fabry Disease",
      "Anderson Fabry Disease"
    ],
    "interventions": [
      "Noninterventional characterization of patients expectations and preferences regarding their treatment"
    ],
    "primary_completion_date": "2023-01-30",
    "completion_date": "2023-01-30",
    "results_first_posted": null,
    "last_update_posted": "2024-05-23",
    "enrollment": null,
    "sponsor": "Amicus Therapeutics France SAS",
    "collected_at": "2026-01-27",
    "search_term": "Amicus Therapeutics"
  },
  {
    "ticker": "FOLD",
    "nct_id": "NCT00515398",
    "title": "A Study to Evaluate the Effects of Pharmacological Chaperones in Cells From Patients With Pompe Disease",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Pompe Disease",
      "Glycogen Storage Disease Type II"
    ],
    "interventions": [
      "Observation"
    ],
    "primary_completion_date": "2008-01",
    "completion_date": "2008-01",
    "results_first_posted": null,
    "last_update_posted": "2008-06-05",
    "enrollment": null,
    "sponsor": "Amicus Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Amicus Therapeutics"
  },
  {
    "ticker": "FOLD",
    "nct_id": "NCT01218659",
    "title": "Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fabry Disease"
    ],
    "interventions": [
      "migalastat hydrochloride",
      "agalsidase"
    ],
    "primary_completion_date": "2014-05-27",
    "completion_date": "2015-05-28",
    "results_first_posted": "2018-11-01",
    "last_update_posted": "2018-11-01",
    "enrollment": null,
    "sponsor": "Amicus Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Amicus Therapeutics"
  },
  {
    "ticker": "FOLD",
    "nct_id": "NCT01380743",
    "title": "Drug-drug Interaction Study",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pompe Disease"
    ],
    "interventions": [
      "duvoglustat",
      "rhGAA"
    ],
    "primary_completion_date": "2013-01-04",
    "completion_date": "2013-01-04",
    "results_first_posted": "2018-08-17",
    "last_update_posted": "2025-06-26",
    "enrollment": null,
    "sponsor": "Amicus Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Amicus Therapeutics"
  },
  {
    "ticker": "FOLD",
    "nct_id": "NCT00446550",
    "title": "A Study of Oral AT2101 (Afegostat Tartrate) in Treatment-naive Patients With Gaucher Disease",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Gaucher Disease",
      "Type 1 Gaucher Disease",
      "Gaucher Disease, Type 1"
    ],
    "interventions": [
      "afegostat tartrate"
    ],
    "primary_completion_date": "2009-08-20",
    "completion_date": "2009-08-20",
    "results_first_posted": "2018-08-15",
    "last_update_posted": "2018-08-15",
    "enrollment": null,
    "sponsor": "Amicus Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Amicus Therapeutics"
  },
  {
    "ticker": "FOLD",
    "nct_id": "NCT02675465",
    "title": "First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pompe Disease"
    ],
    "interventions": [
      "ATB200",
      "AT2221"
    ],
    "primary_completion_date": "2024-08-22",
    "completion_date": "2024-08-22",
    "results_first_posted": "2025-10-23",
    "last_update_posted": "2025-10-23",
    "enrollment": null,
    "sponsor": "Amicus Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Amicus Therapeutics"
  },
  {
    "ticker": "FOLD",
    "nct_id": "NCT04020055",
    "title": "A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fabry Disease"
    ],
    "interventions": [
      "migalastat HCl 150 mg"
    ],
    "primary_completion_date": "2026-12-31",
    "completion_date": "2026-12-31",
    "results_first_posted": null,
    "last_update_posted": "2026-01-14",
    "enrollment": null,
    "sponsor": "Amicus Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Amicus Therapeutics"
  },
  {
    "ticker": "FOLD",
    "nct_id": "NCT04281537",
    "title": "A Study to Describe the Experience of Both Patients and Their Clinicians in the Treatment of Fabry Disease With Enzyme Replacement Therapy.",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Fabry Disease"
    ],
    "interventions": [
      "Enzyme Replacement Therapy (ERT)"
    ],
    "primary_completion_date": "2022-05-18",
    "completion_date": "2022-05-18",
    "results_first_posted": "2024-11-04",
    "last_update_posted": "2024-11-04",
    "enrollment": null,
    "sponsor": "Amicus Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Amicus Therapeutics"
  },
  {
    "ticker": "FOLD",
    "nct_id": "NCT03158662",
    "title": "Survey to Identify Burdens and Unmet Needs of Patients With Epidermolysis Bullosa",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Epidermolysis Bullosa"
    ],
    "interventions": [
      "Survey"
    ],
    "primary_completion_date": "2017-06-30",
    "completion_date": "2017-06-30",
    "results_first_posted": null,
    "last_update_posted": "2017-08-24",
    "enrollment": null,
    "sponsor": "Amicus Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Amicus Therapeutics"
  },
  {
    "ticker": "FOLD",
    "nct_id": "NCT00283959",
    "title": "A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fabry Disease"
    ],
    "interventions": [
      "migalastat HCl"
    ],
    "primary_completion_date": "2008-05-08",
    "completion_date": "2008-05-08",
    "results_first_posted": "2018-09-07",
    "last_update_posted": "2018-10-31",
    "enrollment": null,
    "sponsor": "Amicus Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Amicus Therapeutics"
  },
  {
    "ticker": "FOLD",
    "nct_id": "NCT02194985",
    "title": "Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fabry Disease"
    ],
    "interventions": [
      "migalastat HCl 150 mg"
    ],
    "primary_completion_date": "2019-10-23",
    "completion_date": "2019-10-23",
    "results_first_posted": "2020-12-21",
    "last_update_posted": "2020-12-21",
    "enrollment": null,
    "sponsor": "Amicus Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Amicus Therapeutics"
  },
  {
    "ticker": "FOLD",
    "nct_id": "NCT06906367",
    "title": "A Study of Patients With Fabry Disease (US Specific)",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Fabry Disease"
    ],
    "interventions": [
      "migalastat HCl",
      "ERT"
    ],
    "primary_completion_date": "2032-06",
    "completion_date": "2032-06",
    "results_first_posted": null,
    "last_update_posted": "2026-01-14",
    "enrollment": null,
    "sponsor": "Amicus Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Amicus Therapeutics"
  },
  {
    "ticker": "FOLD",
    "nct_id": "NCT00214500",
    "title": "A Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fabry Disease"
    ],
    "interventions": [
      "migalastat HCl"
    ],
    "primary_completion_date": "2008-01-29",
    "completion_date": "2008-01-29",
    "results_first_posted": "2018-09-07",
    "last_update_posted": "2018-10-30",
    "enrollment": null,
    "sponsor": "Amicus Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Amicus Therapeutics"
  },
  {
    "ticker": "FOLD",
    "nct_id": "NCT04138277",
    "title": "A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With LOPD",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pompe Disease (Late-onset)"
    ],
    "interventions": [
      "AT2221",
      "ATB200"
    ],
    "primary_completion_date": "2024-12-31",
    "completion_date": "2024-12-31",
    "results_first_posted": "2026-01-12",
    "last_update_posted": "2026-01-12",
    "enrollment": null,
    "sponsor": "Amicus Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Amicus Therapeutics"
  },
  {
    "ticker": "FOLD",
    "nct_id": "NCT00813865",
    "title": "A Long-Term Extension Study of AT2101 (Afegostat Tartrate) in Type 1 Gaucher Patients",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Gaucher Disease",
      "Type 1 Gaucher Disease",
      "Gaucher Disease, Type 1"
    ],
    "interventions": [
      "afegostat tartrate"
    ],
    "primary_completion_date": "2012-05-01",
    "completion_date": "2012-05-01",
    "results_first_posted": "2018-08-15",
    "last_update_posted": "2018-08-15",
    "enrollment": null,
    "sponsor": "Amicus Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Amicus Therapeutics"
  },
  {
    "ticker": "FOLD",
    "nct_id": "NCT00351156",
    "title": "Study to Evaluate Blood Cell Lines From Patients With Gaucher Disease",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Gaucher Disease"
    ],
    "interventions": [
      "Blood sample"
    ],
    "primary_completion_date": "2007-03",
    "completion_date": "2007-03",
    "results_first_posted": null,
    "last_update_posted": "2010-08-19",
    "enrollment": null,
    "sponsor": "Amicus Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Amicus Therapeutics"
  },
  {
    "ticker": "FOLD",
    "nct_id": "NCT01196871",
    "title": "Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fabry Disease"
    ],
    "interventions": [
      "Migalastat HCl",
      "Agalsidase Beta",
      "Agalsidase Alfa"
    ],
    "primary_completion_date": "2012-10-09",
    "completion_date": "2012-10-09",
    "results_first_posted": "2018-11-01",
    "last_update_posted": "2018-12-19",
    "enrollment": null,
    "sponsor": "Amicus Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Amicus Therapeutics"
  },
  {
    "ticker": "FOLD",
    "nct_id": "NCT04049760",
    "title": "Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fabry Disease"
    ],
    "interventions": [
      "migalastat HCl 150 mg"
    ],
    "primary_completion_date": "2024-11-29",
    "completion_date": "2024-11-29",
    "results_first_posted": "2025-06-17",
    "last_update_posted": "2025-06-17",
    "enrollment": null,
    "sponsor": "Amicus Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Amicus Therapeutics"
  },
  {
    "ticker": "FOLD",
    "nct_id": "NCT04327973",
    "title": "Expanded Access for ATB200/AT2221 for the Treatment of IOPD",
    "status": "AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Pompe Disease Infantile-Onset"
    ],
    "interventions": [
      "ATB200",
      "AT2221"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2025-09-10",
    "enrollment": null,
    "sponsor": "Amicus Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Amicus Therapeutics"
  },
  {
    "ticker": "FOLD",
    "nct_id": "NCT04804566",
    "title": "Understanding Fabry Disease Therapy Choices Through the Eyes of the Patients",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Fabry Disease"
    ],
    "interventions": [
      "This is a non-interventional study"
    ],
    "primary_completion_date": "2023-11-01",
    "completion_date": "2023-11-01",
    "results_first_posted": null,
    "last_update_posted": "2024-04-03",
    "enrollment": null,
    "sponsor": "Amicus Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Amicus Therapeutics"
  },
  {
    "ticker": "FOLD",
    "nct_id": "NCT03729362",
    "title": "A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pompe Disease (Late-onset)"
    ],
    "interventions": [
      "Cipaglucosidase Alfa",
      "Miglustat",
      "Alglucosidase Alfa",
      "Placebo"
    ],
    "primary_completion_date": "2020-12-15",
    "completion_date": "2021-01-15",
    "results_first_posted": "2023-09-11",
    "last_update_posted": "2025-09-11",
    "enrollment": null,
    "sponsor": "Amicus Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Amicus Therapeutics"
  },
  {
    "ticker": "FOLD",
    "nct_id": "NCT01853852",
    "title": "A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fabry Disease"
    ],
    "interventions": [
      "GR181413A/AT1001 solution",
      "GR181413A/AT1001 capsule",
      "Potable water",
      "Placebo capsule"
    ],
    "primary_completion_date": "2011-12",
    "completion_date": "2011-12",
    "results_first_posted": null,
    "last_update_posted": "2013-12-18",
    "enrollment": null,
    "sponsor": "Amicus Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Amicus Therapeutics"
  },
  {
    "ticker": "FOLD",
    "nct_id": "NCT03500094",
    "title": "Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fabry Disease"
    ],
    "interventions": [
      "Migalastat HCl 150 mg"
    ],
    "primary_completion_date": "2021-02-02",
    "completion_date": "2021-02-06",
    "results_first_posted": "2021-11-30",
    "last_update_posted": "2021-11-30",
    "enrollment": null,
    "sponsor": "Amicus Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Amicus Therapeutics"
  },
  {
    "ticker": "FOLD",
    "nct_id": "NCT00925301",
    "title": "Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fabry Disease"
    ],
    "interventions": [
      "migalastat hydrochloride",
      "Placebo"
    ],
    "primary_completion_date": "2012-06-12",
    "completion_date": "2014-01-29",
    "results_first_posted": "2018-10-30",
    "last_update_posted": "2018-10-30",
    "enrollment": null,
    "sponsor": "Amicus Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Amicus Therapeutics"
  },
  {
    "ticker": "FOLD",
    "nct_id": "NCT00433147",
    "title": "A Study of AT2101 (Afegostat Tartrate) in Adult Patients With Type 1 Gaucher Disease Currently Receiving Enzyme Replacement Therapy",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Gaucher Disease, Type 1",
      "Type 1 Gaucher Disease",
      "Gaucher Disease"
    ],
    "interventions": [
      "Afegostat tartrate"
    ],
    "primary_completion_date": "2008-02-19",
    "completion_date": "2008-02-19",
    "results_first_posted": "2018-08-15",
    "last_update_posted": "2018-09-25",
    "enrollment": null,
    "sponsor": "Amicus Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Amicus Therapeutics"
  },
  {
    "ticker": "FOLD",
    "nct_id": "NCT00875160",
    "title": "A Study in Type 1 Gaucher Patients to Evaluate the Pharmacokinetics, Safety and Pharmacodynamics of AT2101",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 1 Gaucher Disease"
    ],
    "interventions": [
      "AT2101"
    ],
    "primary_completion_date": "2009-07",
    "completion_date": "2009-07",
    "results_first_posted": null,
    "last_update_posted": "2010-08-19",
    "enrollment": null,
    "sponsor": "Amicus Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Amicus Therapeutics"
  },
  {
    "ticker": "FOLD",
    "nct_id": "NCT00526071",
    "title": "Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fabry Disease"
    ],
    "interventions": [
      "migalastat HCl"
    ],
    "primary_completion_date": "2012-09-08",
    "completion_date": "2012-09-08",
    "results_first_posted": "2018-10-03",
    "last_update_posted": "2018-10-03",
    "enrollment": null,
    "sponsor": "Amicus Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Amicus Therapeutics"
  },
  {
    "ticker": "FOLD",
    "nct_id": "NCT02082327",
    "title": "A Phase 1 Study To Evaluate the Safety of Migalastat Hydrochloride Given Intravenously to Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fabry Disease"
    ],
    "interventions": [
      "IV migalastat HCl",
      "IV placebo",
      "oral migalastat HCl"
    ],
    "primary_completion_date": "2014-06",
    "completion_date": "2014-06",
    "results_first_posted": null,
    "last_update_posted": "2014-06-18",
    "enrollment": null,
    "sponsor": "Amicus Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Amicus Therapeutics"
  },
  {
    "ticker": "FOLD",
    "nct_id": "NCT01730469",
    "title": "Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fabry Disease"
    ],
    "interventions": [
      "AT1001 150 mg"
    ],
    "primary_completion_date": "2012-04",
    "completion_date": "2012-04",
    "results_first_posted": null,
    "last_update_posted": "2017-08-03",
    "enrollment": null,
    "sponsor": "Amicus Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Amicus Therapeutics"
  },
  {
    "ticker": "FOLD",
    "nct_id": "NCT00688597",
    "title": "Study to Evaluate the Safety of AT2220 (Duvoglustat) in Pompe Disease",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pompe Disease"
    ],
    "interventions": [
      "Duvoglustat"
    ],
    "primary_completion_date": "2009-12-14",
    "completion_date": "2009-12-14",
    "results_first_posted": "2018-08-17",
    "last_update_posted": "2025-09-11",
    "enrollment": null,
    "sponsor": "Amicus Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Amicus Therapeutics"
  },
  {
    "ticker": "FOLD",
    "nct_id": "NCT01730482",
    "title": "A Study to Assess the Absorption, Metabolism and Excretion of Migalastat Hydrochloride (AT1001-014)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fabry Disease"
    ],
    "interventions": [
      "[14C] AT1001"
    ],
    "primary_completion_date": "2011-09",
    "completion_date": "2011-09",
    "results_first_posted": null,
    "last_update_posted": "2013-12-18",
    "enrollment": null,
    "sponsor": "Amicus Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Amicus Therapeutics"
  },
  {
    "ticker": "FOLD",
    "nct_id": "NCT03347253",
    "title": "STRIDE Study - A Study in Subjects With LOPD Who Are Currently Being Treated With ERT",
    "status": "TERMINATED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Late-onset Pompe Disease"
    ],
    "interventions": [],
    "primary_completion_date": "2018-11-30",
    "completion_date": "2018-11-30",
    "results_first_posted": null,
    "last_update_posted": "2025-07-08",
    "enrollment": null,
    "sponsor": "Amicus Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Amicus Therapeutics"
  },
  {
    "ticker": "FOLD",
    "nct_id": "NCT04602364",
    "title": "French Prospective, Observational Cohort Study of Patients With Fabry Disease Treated With Migalastat",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Fabry Disease"
    ],
    "interventions": [
      "Noninterventional"
    ],
    "primary_completion_date": "2023-06-30",
    "completion_date": "2023-06-30",
    "results_first_posted": null,
    "last_update_posted": "2024-05-23",
    "enrollment": null,
    "sponsor": "Amicus Therapeutics France SAS",
    "collected_at": "2026-01-27",
    "search_term": "Amicus Therapeutics"
  },
  {
    "ticker": "FOLD",
    "nct_id": "NCT06121011",
    "title": "A Global Prospective Observational Registry of Patients With Pompe Disease",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Pompe Disease"
    ],
    "interventions": [
      "Cipaglucosidase alfa",
      "Miglustat",
      "Alglucosidase alfa or Avalglucosidase alfa",
      "Untreated"
    ],
    "primary_completion_date": "2034-12-20",
    "completion_date": "2034-12-20",
    "results_first_posted": null,
    "last_update_posted": "2025-12-22",
    "enrollment": null,
    "sponsor": "Amicus Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Amicus Therapeutics"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT00276172",
    "title": "Open-Label Natalizumab Safety Extension Study",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple Sclerosis"
    ],
    "interventions": [
      "Natalizumab"
    ],
    "primary_completion_date": "2005-10",
    "completion_date": "2006-01",
    "results_first_posted": null,
    "last_update_posted": "2009-06-22",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT05764122",
    "title": "A Study to Evaluate the Efficacy and Safety of BIIB131 for Participants With Ischemic Stroke Between 4.5 and 24 Hours After Last Known Well",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ischemic Stroke"
    ],
    "interventions": [
      "BIIB131",
      "Placebo"
    ],
    "primary_completion_date": "2025-07-07",
    "completion_date": "2025-07-07",
    "results_first_posted": null,
    "last_update_posted": "2024-02-12",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT06064929",
    "title": "A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lupus Nephritis"
    ],
    "interventions": [
      "Felzartamab"
    ],
    "primary_completion_date": "2026-06-30",
    "completion_date": "2026-06-30",
    "results_first_posted": null,
    "last_update_posted": "2025-12-31",
    "enrollment": null,
    "sponsor": "HI-Bio, A Biogen Company",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT00102024",
    "title": "Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Colorectal Cancer",
      "Metastases"
    ],
    "interventions": [
      "Unconjugated IDEC-159",
      "111In-IDEC-159",
      "90Y-IDEC-159"
    ],
    "primary_completion_date": "2006-01",
    "completion_date": "2006-01",
    "results_first_posted": null,
    "last_update_posted": "2010-08-27",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT06454721",
    "title": "A Study to Determine the Biodistribution, Safety, and Tolerability of a Microdose of Radiolabeled BIIB080 Co-administered With BIIB080 in Healthy Adults",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteer"
    ],
    "interventions": [
      "[89Zr]Zr-DFO-BIIB080",
      "BIIB080"
    ],
    "primary_completion_date": "2026-02-16",
    "completion_date": "2026-07-30",
    "results_first_posted": null,
    "last_update_posted": "2025-10-10",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT04948606",
    "title": "Exploring Diroximel Fumarate Real-world Experience in Canada and Israel",
    "status": "TERMINATED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Relapsing Forms of MS"
    ],
    "interventions": [
      "Diroximel Fumarate"
    ],
    "primary_completion_date": "2023-04-14",
    "completion_date": "2023-04-14",
    "results_first_posted": null,
    "last_update_posted": "2023-05-10",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT00451451",
    "title": "Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsing-Remitting Multiple Sclerosis"
    ],
    "interventions": [
      "BG00012",
      "Placebo",
      "Glatiramer Acetate"
    ],
    "primary_completion_date": "2011-08",
    "completion_date": "2011-08",
    "results_first_posted": "2014-06-02",
    "last_update_posted": "2015-01-26",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT04729907",
    "title": "A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Muscular Atrophy, Spinal"
    ],
    "interventions": [
      "Nusinersen"
    ],
    "primary_completion_date": "2026-07-31",
    "completion_date": "2026-07-31",
    "results_first_posted": null,
    "last_update_posted": "2025-02-03",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT02359344",
    "title": "PK & Tolerability of CNV1014802 in Young and Elderly Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Trigeminal Neuralgia"
    ],
    "interventions": [
      "CNV1014802",
      "Placebo"
    ],
    "primary_completion_date": "2015-04-20",
    "completion_date": "2015-04-20",
    "results_first_posted": null,
    "last_update_posted": "2017-10-12",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT00168727",
    "title": "Zevalin\u00ae Followed by Rituxan\u00ae Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lymphoma, Non-Hodgkin",
      "Lymphoma, Low-Grade"
    ],
    "interventions": [
      "ibritumomab tiuxetan (Zevalin\u00ae)"
    ],
    "primary_completion_date": null,
    "completion_date": "2005-10-31",
    "results_first_posted": null,
    "last_update_posted": "2023-08-23",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT02855411",
    "title": "A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cognitive Impairment Associated With Schizophrenia (CIAS)"
    ],
    "interventions": [
      "PF-04958242",
      "placebo"
    ],
    "primary_completion_date": "2016-09-26",
    "completion_date": "2016-09-26",
    "results_first_posted": "2017-10-04",
    "last_update_posted": "2020-01-09",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT02137109",
    "title": "Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Multiple Sclerosis"
    ],
    "interventions": [
      "natalizumab"
    ],
    "primary_completion_date": "2015-10",
    "completion_date": "2015-10",
    "results_first_posted": null,
    "last_update_posted": "2015-10-20",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT01864148",
    "title": "Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple Sclerosis"
    ],
    "interventions": [
      "BIIB033",
      "Placebo",
      "Avonex"
    ],
    "primary_completion_date": "2015-12",
    "completion_date": "2016-03",
    "results_first_posted": "2017-05-03",
    "last_update_posted": "2017-05-03",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT00811889",
    "title": "Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Kidney Disease",
      "Type 2 Diabetes",
      "Diabetic Nephropathy"
    ],
    "interventions": [
      "Placebo",
      "Bardoxolone Methyl (RTA 402)"
    ],
    "primary_completion_date": "2010-05-31",
    "completion_date": "2010-12-31",
    "results_first_posted": null,
    "last_update_posted": "2025-05-29",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT04056689",
    "title": "Study to Evaluate DNL151 in Subjects With Parkinson's Disease",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Parkinson's Disease"
    ],
    "interventions": [
      "DNL151",
      "Placebo"
    ],
    "primary_completion_date": "2020-12-02",
    "completion_date": "2020-12-02",
    "results_first_posted": null,
    "last_update_posted": "2023-04-18",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT00575068",
    "title": "Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-Hodgkin's Lymphoma"
    ],
    "interventions": [
      "IDEC-114"
    ],
    "primary_completion_date": "2002-09",
    "completion_date": "2010-11",
    "results_first_posted": null,
    "last_update_posted": "2012-06-08",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT00529438",
    "title": "RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumors",
      "Lymphoid Malignancies"
    ],
    "interventions": [
      "Bardoxolone methyl"
    ],
    "primary_completion_date": "2008-12-01",
    "completion_date": "2008-12-01",
    "results_first_posted": null,
    "last_update_posted": "2025-05-28",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT03926637",
    "title": "Feasibility of the Multiple Sclerosis Performance Test in Participants With Multiple Sclerosis",
    "status": "TERMINATED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Multiple Sclerosis"
    ],
    "interventions": [
      "Multiple Sclerosis Performance Test (MSPT)"
    ],
    "primary_completion_date": "2022-12-05",
    "completion_date": "2022-12-05",
    "results_first_posted": null,
    "last_update_posted": "2023-01-30",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT00493077",
    "title": "Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple Sclerosis"
    ],
    "interventions": [
      "low immunogenic interferon-beta-1a"
    ],
    "primary_completion_date": "2006-05",
    "completion_date": "2006-05",
    "results_first_posted": null,
    "last_update_posted": "2008-01-30",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT05265728",
    "title": "A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple Sclerosis, Relapsing-Remitting"
    ],
    "interventions": [
      "Natalizumab"
    ],
    "primary_completion_date": "2024-01-18",
    "completion_date": "2024-05-27",
    "results_first_posted": "2025-11-25",
    "last_update_posted": "2025-11-25",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT01955707",
    "title": "Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Ischemic Stroke"
    ],
    "interventions": [
      "natalizumab",
      "Placebo"
    ],
    "primary_completion_date": "2015-02",
    "completion_date": "2015-04",
    "results_first_posted": "2016-07-01",
    "last_update_posted": "2016-07-01",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT00492765",
    "title": "Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple Sclerosis"
    ],
    "interventions": [
      "Interferon-beta-1a",
      "Simvastatin",
      "Placebo"
    ],
    "primary_completion_date": "2010-04",
    "completion_date": "2010-04",
    "results_first_posted": null,
    "last_update_posted": "2010-10-15",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT00168714",
    "title": "Pregnancy Exposure Registry for Avonex (Interferon Beta-1a)",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Prenatal Exposure Delayed Effects",
      "Multiple Sclerosis",
      "Pregnancy"
    ],
    "interventions": [
      "BG9418 (interferon beta-1a)"
    ],
    "primary_completion_date": "2011-09",
    "completion_date": "2011-09",
    "results_first_posted": null,
    "last_update_posted": "2014-06-09",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT05065970",
    "title": "Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Immunoglobulin A (IgA) Nephropathy"
    ],
    "interventions": [
      "Felzartamab",
      "Placebo"
    ],
    "primary_completion_date": "2023-02-06",
    "completion_date": "2024-05-06",
    "results_first_posted": null,
    "last_update_posted": "2025-02-07",
    "enrollment": null,
    "sponsor": "HI-Bio, A Biogen Company",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT05532163",
    "title": "A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)",
    "status": "TERMINATED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple Sclerosis, Relapsing-Remitting"
    ],
    "interventions": [
      "Natalizumab"
    ],
    "primary_completion_date": "2023-10-09",
    "completion_date": "2023-10-09",
    "results_first_posted": null,
    "last_update_posted": "2024-06-21",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT02666963",
    "title": "A Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of RTA 901 in Healthy Adults",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "RTA 901 Capsules, 10 or 40 mg",
      "Placebo"
    ],
    "primary_completion_date": "2017-07-23",
    "completion_date": "2017-07-23",
    "results_first_posted": null,
    "last_update_posted": "2025-05-29",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT01884935",
    "title": "PK and PD Study of Natalizumab in Pediatric Subjects With RRMS",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsing-Remitting Multiple Sclerosis"
    ],
    "interventions": [
      "Natalizumab"
    ],
    "primary_completion_date": "2014-09",
    "completion_date": "2014-09",
    "results_first_posted": null,
    "last_update_posted": "2016-06-23",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT00438607",
    "title": "Dose-Finding Safety Study of BIIB014 in Combination With Levodopa in Moderate to Late Stage Parkinson's Disease",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Parkinson's Disease"
    ],
    "interventions": [
      "BIIB014",
      "Placebo"
    ],
    "primary_completion_date": "2009-04",
    "completion_date": "2009-04",
    "results_first_posted": null,
    "last_update_posted": "2009-07-13",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT02228707",
    "title": "Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "BIIB061",
      "Placebo"
    ],
    "primary_completion_date": "2016-05",
    "completion_date": "2016-05",
    "results_first_posted": null,
    "last_update_posted": "2016-06-15",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT04476030",
    "title": "A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Depressive Disorder, Major"
    ],
    "interventions": [
      "SAGE-217",
      "Matching Placebo",
      "Sertraline",
      "Escitalopram",
      "Citalopram",
      "Duloxetine",
      "Desvenlafaxine"
    ],
    "primary_completion_date": "2021-10-25",
    "completion_date": "2021-12-22",
    "results_first_posted": "2023-11-07",
    "last_update_posted": "2023-12-22",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT05310071",
    "title": "A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alzheimer's Disease"
    ],
    "interventions": [
      "Aducanumab",
      "Placebo"
    ],
    "primary_completion_date": "2024-08-12",
    "completion_date": "2024-08-12",
    "results_first_posted": "2025-04-23",
    "last_update_posted": "2025-04-23",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT01235221",
    "title": "Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple Sclerosis"
    ],
    "interventions": [
      "BIIB041 (Fampridine-SR)"
    ],
    "primary_completion_date": "2012-06",
    "completion_date": "2012-06",
    "results_first_posted": null,
    "last_update_posted": "2014-07-04",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT01873404",
    "title": "BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Participants With Painful Lumbar Radiculopathy",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Painful Lumbar Radiculopathy",
      "Sciatica",
      "Radiculopathy"
    ],
    "interventions": [
      "BG00010",
      "Placebo"
    ],
    "primary_completion_date": "2015-03",
    "completion_date": "2015-03",
    "results_first_posted": null,
    "last_update_posted": "2015-09-10",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT05655507",
    "title": "Zuranolone Pharmacokinetics (PK) and Safety Study Adolescent Participants With Major Depressive Disorder (MDD)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder"
    ],
    "interventions": [
      "Zuranolone"
    ],
    "primary_completion_date": "2024-10-18",
    "completion_date": "2024-10-18",
    "results_first_posted": null,
    "last_update_posted": "2025-03-26",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT00664716",
    "title": "Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) Participants",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rheumatoid Arthritis"
    ],
    "interventions": [
      "Baminercept alfa 1",
      "Placebo",
      "Baminercept alfa 2",
      "Baminercept alfa 3",
      "Baminercept alfa 4",
      "Baminercept alfa 5"
    ],
    "primary_completion_date": "2008-10",
    "completion_date": "2008-10",
    "results_first_posted": null,
    "last_update_posted": "2016-01-21",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT03100734",
    "title": "Observational Study to Evaluate the Real-Life Effectiveness of Benepali Following Transition From Enbrel",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Rheumatoid Arthritis",
      "Axial Spondyloarthritis"
    ],
    "interventions": [
      "Benepali",
      "Enbrel"
    ],
    "primary_completion_date": "2018-11-30",
    "completion_date": "2018-11-30",
    "results_first_posted": null,
    "last_update_posted": "2021-02-05",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT00674947",
    "title": "A Phase I Study of BIIB015 in Relapsed/Refractory Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumors"
    ],
    "interventions": [
      "BIIB015"
    ],
    "primary_completion_date": "2011-06",
    "completion_date": "2011-06",
    "results_first_posted": null,
    "last_update_posted": "2013-09-16",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT01051349",
    "title": "Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsing-Remitting Multiple Sclerosis"
    ],
    "interventions": [
      "BIIB019 (Daclizumab)",
      "trivalent seasonal influenza vaccine"
    ],
    "primary_completion_date": "2016-08-25",
    "completion_date": "2016-08-25",
    "results_first_posted": "2018-11-09",
    "last_update_posted": "2018-11-09",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT04593121",
    "title": "Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIIB107 in Healthy Adult Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "BIIB107",
      "Placebo"
    ],
    "primary_completion_date": "2024-03-05",
    "completion_date": "2024-03-05",
    "results_first_posted": null,
    "last_update_posted": "2024-04-15",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT01943526",
    "title": "Ireland Natalizumab (TYSABRI) Observational Program",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Relapsing-Remitting Multiple Sclerosis"
    ],
    "interventions": [
      "natalizumab"
    ],
    "primary_completion_date": "2017-12-31",
    "completion_date": "2017-12-31",
    "results_first_posted": null,
    "last_update_posted": "2018-05-04",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT01873417",
    "title": "Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsing Forms of Multiple Sclerosis"
    ],
    "interventions": [
      "BG00012 (DMF)"
    ],
    "primary_completion_date": "2013-11",
    "completion_date": "2013-11",
    "results_first_posted": "2014-11-11",
    "last_update_posted": "2017-03-21",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT03070132",
    "title": "802NP301 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia",
    "status": "WITHDRAWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Trigeminal Neuralgia"
    ],
    "interventions": [
      "BIIB074",
      "Placebo"
    ],
    "primary_completion_date": "2025-10-14",
    "completion_date": "2026-08-21",
    "results_first_posted": null,
    "last_update_posted": "2023-05-06",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT02611674",
    "title": "Methodology Study of Novel Outcome Measures to Assess Progression of ALS",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Amyotrophic Lateral Sclerosis"
    ],
    "interventions": [],
    "primary_completion_date": "2018-07-27",
    "completion_date": "2019-08-01",
    "results_first_posted": null,
    "last_update_posted": "2019-10-24",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT03716570",
    "title": "A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson's Disease",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Parkinson's Disease"
    ],
    "interventions": [
      "BIIB054",
      "Placebo"
    ],
    "primary_completion_date": "2021-04-23",
    "completion_date": "2021-04-23",
    "results_first_posted": null,
    "last_update_posted": "2021-05-25",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT01064401",
    "title": "Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon \u03b2 1a in Participants With Relapsing-Remitting Multiple Sclerosis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsing-Remitting Multiple Sclerosis"
    ],
    "interventions": [
      "BIIB019 (Daclizumab High Yield Process)",
      "Interferon beta-1a Placebo",
      "Interferon beta-1a",
      "Daclizumab High Yield Process Placebo"
    ],
    "primary_completion_date": "2014-03",
    "completion_date": "2014-07",
    "results_first_posted": "2016-07-11",
    "last_update_posted": "2016-07-11",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT05106465",
    "title": "A Study to Explore Association Patterns Between Digital Outcome Assessments From the Konectom\u2122 Platform and Magnetic Resonance Imaging (MRI) Measures of Brain Tissue Damage",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Multiple Sclerosis (MS)"
    ],
    "interventions": [
      "Konectom platform"
    ],
    "primary_completion_date": "2024-04-03",
    "completion_date": "2024-04-03",
    "results_first_posted": null,
    "last_update_posted": "2024-05-17",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT01416207",
    "title": "A Multiple-Dose, Open-Label, Phase 1, Pharmacokinetic, Pharmacodynamic, and Safety Study of Avonex\u00ae in Chinese Healthy Volunteer Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "Avonex"
    ],
    "primary_completion_date": "2011-10",
    "completion_date": "2011-10",
    "results_first_posted": null,
    "last_update_posted": "2011-11-04",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT01405833",
    "title": "Study of the Safety, Tolerability, Pharmacokinetics and Safety of BG00010 (Neublastin) in Subjects With Sciatica.",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Sciatica"
    ],
    "interventions": [
      "BG00010 (Neublastin)",
      "Placebo"
    ],
    "primary_completion_date": "2012-09",
    "completion_date": "2012-09",
    "results_first_posted": null,
    "last_update_posted": "2014-09-09",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT02641041",
    "title": "Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Central Nervous System (CNS) Demyelinating Disease",
      "Multiple Sclerosis"
    ],
    "interventions": [
      "BIIB033",
      "Placebo"
    ],
    "primary_completion_date": "2016-09",
    "completion_date": "2016-09",
    "results_first_posted": null,
    "last_update_posted": "2016-10-10",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT01540630",
    "title": "A Phase IIa Withdrawal Study of CNV1014802 in Patients With Trigeminal Neuralgia",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Trigeminal Neuralgia"
    ],
    "interventions": [
      "CNV1014802",
      "Placebo"
    ],
    "primary_completion_date": "2014-03-31",
    "completion_date": "2014-06-30",
    "results_first_posted": null,
    "last_update_posted": "2019-01-10",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT06264440",
    "title": "A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteer"
    ],
    "interventions": [
      "BIIB122",
      "Rabeprazole"
    ],
    "primary_completion_date": "2024-06-18",
    "completion_date": "2024-06-18",
    "results_first_posted": null,
    "last_update_posted": "2024-07-19",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT00168740",
    "title": "Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma"
    ],
    "interventions": [
      "rituximab"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2005-09-15",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT00424788",
    "title": "A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)",
    "status": "COMPLETED",
    "phase": "EARLY_PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsing Forms of Multiple Sclerosis"
    ],
    "interventions": [
      "Plasma exchange",
      "natalizumab treatment"
    ],
    "primary_completion_date": "2007-10",
    "completion_date": "2007-10",
    "results_first_posted": null,
    "last_update_posted": "2009-09-04",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT01930890",
    "title": "BIIB023 Long-Term Extension Study in Subjects With Lupus Nephritis",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lupus Nephritis"
    ],
    "interventions": [
      "BIIB023",
      "mycophenolate mofetil",
      "oral corticosteroids"
    ],
    "primary_completion_date": "2016-01",
    "completion_date": "2016-01",
    "results_first_posted": "2017-01-18",
    "last_update_posted": "2017-01-18",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT01780246",
    "title": "An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy Who Previously Participated in ISIS 396443-CS1 (NCT01494701)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Spinal Muscular Atrophy"
    ],
    "interventions": [
      "nusinersen"
    ],
    "primary_completion_date": "2014-02-28",
    "completion_date": "2014-02-28",
    "results_first_posted": null,
    "last_update_posted": "2021-02-16",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT02090413",
    "title": "Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsing-Remitting Multiple Sclerosis"
    ],
    "interventions": [
      "dimethyl fumarate",
      "acetylsalicylic acid",
      "ASA-Placebo"
    ],
    "primary_completion_date": "2015-02",
    "completion_date": "2015-11",
    "results_first_posted": "2016-12-28",
    "last_update_posted": "2016-12-28",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT00801060",
    "title": "Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Lymphocytic Leukemia"
    ],
    "interventions": [
      "Lumiliximab + FCR",
      "FCR"
    ],
    "primary_completion_date": "2010-06",
    "completion_date": "2010-09",
    "results_first_posted": null,
    "last_update_posted": "2015-10-02",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT02664324",
    "title": "MSPT Device Usability Study",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Multiple Sclerosis"
    ],
    "interventions": [],
    "primary_completion_date": "2016-04",
    "completion_date": "2016-04",
    "results_first_posted": null,
    "last_update_posted": "2016-05-04",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT02428231",
    "title": "Tecfidera Slow-Titration Study",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple Sclerosis"
    ],
    "interventions": [
      "dimethyl fumarate"
    ],
    "primary_completion_date": "2015-12",
    "completion_date": "2016-01",
    "results_first_posted": "2017-05-05",
    "last_update_posted": "2017-05-05",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT04733040",
    "title": "Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R+ Membranous Nephropathy (aMN) (NewPLACE)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Glomerulonephritis",
      "Membranous Nephropathy",
      "antiPLA2R Positive"
    ],
    "interventions": [
      "MOR202"
    ],
    "primary_completion_date": "2023-12-14",
    "completion_date": "2023-12-14",
    "results_first_posted": null,
    "last_update_posted": "2025-02-07",
    "enrollment": null,
    "sponsor": "HI-Bio, A Biogen Company",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT05058950",
    "title": "An Observational Study Using Multimodal Sensors to Measure Cognitive Health in Adults and Distinguish Mild Cognitive Impairment From Normal Aging",
    "status": "TERMINATED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Mild Cognitive Impairment",
      "Normal Aging"
    ],
    "interventions": [],
    "primary_completion_date": "2023-09-19",
    "completion_date": "2023-09-19",
    "results_first_posted": null,
    "last_update_posted": "2023-09-21",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT02193074",
    "title": "A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Spinal Muscular Atrophy"
    ],
    "interventions": [
      "nusinersen",
      "Sham procedure"
    ],
    "primary_completion_date": "2016-11-21",
    "completion_date": "2016-11-21",
    "results_first_posted": "2017-07-28",
    "last_update_posted": "2021-02-17",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT04746976",
    "title": "Study of Diroximel Fumarate in the Real-World Setting",
    "status": "TERMINATED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Relapsing Forms of MS"
    ],
    "interventions": [
      "Diroximel Fumarate"
    ],
    "primary_completion_date": "2023-04-14",
    "completion_date": "2023-04-14",
    "results_first_posted": null,
    "last_update_posted": "2023-05-26",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT06044337",
    "title": "A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Subacute Cutaneous Lupus Erythematosus",
      "Chronic Cutaneous Lupus Erythematosus"
    ],
    "interventions": [
      "BIIB059 (litifilimab)"
    ],
    "primary_completion_date": "2029-06-26",
    "completion_date": "2029-12-11",
    "results_first_posted": null,
    "last_update_posted": "2026-01-26",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT03943056",
    "title": "A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of BIIB091, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Healthy Adult Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteer"
    ],
    "interventions": [
      "BIIB091",
      "Placebo"
    ],
    "primary_completion_date": "2020-01-10",
    "completion_date": "2020-01-10",
    "results_first_posted": null,
    "last_update_posted": "2021-03-22",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT00908154",
    "title": "Safety, Tolerability and Pharmacokinetics of Repeat Doses of GSK1014802.",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bipolar Depression",
      "Bipolar Disorder"
    ],
    "interventions": [
      "Placebo",
      "GSK1014802"
    ],
    "primary_completion_date": "2008-12-31",
    "completion_date": "2008-12-31",
    "results_first_posted": null,
    "last_update_posted": "2017-10-30",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT00107861",
    "title": "Interferon-Beta Gene Transfer (Ad.hIFN-\u03b2) as Treatment for Refractory Colorectal Carcinoma With Liver Metastases",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Colorectal Carcinoma",
      "Metastases"
    ],
    "interventions": [
      "Ad.hIFN-\u03b2 (BG00001, IDEC-201)"
    ],
    "primary_completion_date": null,
    "completion_date": "2006-09",
    "results_first_posted": null,
    "last_update_posted": "2009-07-14",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT02234869",
    "title": "Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy",
    "status": "WITHDRAWN",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsing Multiple Sclerosis"
    ],
    "interventions": [
      "Interferon Beta",
      "BIIB017 (Peginterferon beta-1a)"
    ],
    "primary_completion_date": "2017-02",
    "completion_date": "2018-03",
    "results_first_posted": null,
    "last_update_posted": "2014-11-17",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT00097760",
    "title": "Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple Sclerosis, Relapsing-Remitting"
    ],
    "interventions": [
      "Natalizumab",
      "Natalizumab",
      "Placebo"
    ],
    "primary_completion_date": "2004-03",
    "completion_date": "2004-03",
    "results_first_posted": null,
    "last_update_posted": "2009-06-18",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT00031083",
    "title": "Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Glioblastoma Multiforme",
      "Anaplastic Astrocytoma",
      "Oligoastrocytoma, Mixed",
      "Gliosarcoma"
    ],
    "interventions": [
      "Interferon-beta"
    ],
    "primary_completion_date": null,
    "completion_date": "2003-10-10",
    "results_first_posted": null,
    "last_update_posted": "2020-11-17",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT03749447",
    "title": "An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Kidney Diseases",
      "Alport Syndrome",
      "Autosomal Dominant Polycystic Kidney"
    ],
    "interventions": [
      "Bardoxolone methyl"
    ],
    "primary_completion_date": "2023-08-23",
    "completion_date": "2023-08-23",
    "results_first_posted": "2024-03-19",
    "last_update_posted": "2025-06-03",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT05058729",
    "title": "MS PATHS COVID-19 Questionnaire Data Linkage Sub-Study",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Multiple Sclerosis (MS)"
    ],
    "interventions": [],
    "primary_completion_date": "2021-10-08",
    "completion_date": "2021-10-08",
    "results_first_posted": null,
    "last_update_posted": "2023-04-18",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT00090038",
    "title": "Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-Hodgkin's Lymphoma"
    ],
    "interventions": [
      "rituximab"
    ],
    "primary_completion_date": "2007-06",
    "completion_date": "2007-11",
    "results_first_posted": null,
    "last_update_posted": "2009-10-20",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT04926129",
    "title": "Natural History of the Progression of X-Linked Retinitis Pigmentosa",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "X-Linked Retinitis Pigmentosa"
    ],
    "interventions": [
      "Other: Assessments"
    ],
    "primary_completion_date": "2022-12-16",
    "completion_date": "2022-12-16",
    "results_first_posted": null,
    "last_update_posted": "2023-02-10",
    "enrollment": null,
    "sponsor": "NightstaRx Ltd, a Biogen Company",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT03579030",
    "title": "Safety and PK/PD of RTA 1701 in Healthy Adults",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "Placebo oral capsule",
      "RTA 1701 capsules"
    ],
    "primary_completion_date": "2019-06-28",
    "completion_date": "2019-06-28",
    "results_first_posted": null,
    "last_update_posted": "2025-05-29",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT01721161",
    "title": "BIIB033 In Acute Optic Neuritis (AON)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Optic Neuritis"
    ],
    "interventions": [
      "BIIB033 (anti-LINGO-1 mAb)",
      "Placebo"
    ],
    "primary_completion_date": "2014-10",
    "completion_date": "2014-10",
    "results_first_posted": "2016-06-30",
    "last_update_posted": "2016-06-30",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT00707512",
    "title": "CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring",
    "status": "TERMINATED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Crohn's Disease"
    ],
    "interventions": [
      "natalizumab"
    ],
    "primary_completion_date": "2015-05-28",
    "completion_date": "2015-05-28",
    "results_first_posted": null,
    "last_update_posted": "2024-06-03",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT04079101",
    "title": "Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "BIIB104",
      "Placebo"
    ],
    "primary_completion_date": "2019-12-27",
    "completion_date": "2019-12-27",
    "results_first_posted": null,
    "last_update_posted": "2021-03-24",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT04756687",
    "title": "Real World Analysis on Lymphocyte Reconstitution After Lymphopenia in Participants Treated by Tecfidera",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Multiple Sclerosis",
      "Multiple Sclerosis, Relapsing-Remitting"
    ],
    "interventions": [
      "Dimethyl fumarate"
    ],
    "primary_completion_date": "2021-06-15",
    "completion_date": "2021-06-15",
    "results_first_posted": null,
    "last_update_posted": "2023-10-23",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT01568112",
    "title": "Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "BG00012 (dimethyl fumarate)",
      "BG00012 placebo",
      "ASA",
      "ASA placebo"
    ],
    "primary_completion_date": "2012-10",
    "completion_date": "2012-10",
    "results_first_posted": "2016-06-13",
    "last_update_posted": "2016-06-13",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT04068532",
    "title": "A Study to Explore Pharmacodynamic Effects of BIIB104 on Brain Circuitry in Healthy Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "Placebo",
      "BIIB104"
    ],
    "primary_completion_date": "2020-11-11",
    "completion_date": "2020-11-11",
    "results_first_posted": null,
    "last_update_posted": "2021-03-22",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT00390221",
    "title": "Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsing-Remitting Multiple Sclerosis"
    ],
    "interventions": [
      "BIIB019 (Daclizumab High Yield Process)",
      "Placebo"
    ],
    "primary_completion_date": "2011-05",
    "completion_date": "2011-08",
    "results_first_posted": "2016-07-11",
    "last_update_posted": "2016-07-11",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT01494701",
    "title": "An Open-label Safety, Tolerability, and Dose-range Finding Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Spinal Muscular Atrophy"
    ],
    "interventions": [
      "nusinersen"
    ],
    "primary_completion_date": "2013-01-31",
    "completion_date": "2013-01-31",
    "results_first_posted": null,
    "last_update_posted": "2021-02-18",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT05067790",
    "title": "A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Spinal Muscular Atrophy"
    ],
    "interventions": [
      "Nusinersen"
    ],
    "primary_completion_date": "2027-06-14",
    "completion_date": "2027-06-14",
    "results_first_posted": null,
    "last_update_posted": "2025-05-06",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT01017198",
    "title": "Effect of Food and Antacid on BIIB021 With Advanced Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumors"
    ],
    "interventions": [
      "BIIB021 and Food",
      "BIIB0121 and Antacid"
    ],
    "primary_completion_date": "2010-08",
    "completion_date": "2011-01",
    "results_first_posted": null,
    "last_update_posted": "2013-09-16",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT02623699",
    "title": "An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Amyotrophic Lateral Sclerosis"
    ],
    "interventions": [
      "Tofersen",
      "Placebo"
    ],
    "primary_completion_date": "2021-07-16",
    "completion_date": "2021-07-16",
    "results_first_posted": "2023-07-28",
    "last_update_posted": "2023-07-28",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT01313364",
    "title": "A Safety Study in Healthy Volunteers of the Single-Use Autoinjector Containing Placebo of BG9418 Interferon Beta-1a With a 25-Gauge \u00d7 1-Inch Needle",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "25G x 1\" Needle Autoinjector"
    ],
    "primary_completion_date": "2011-04",
    "completion_date": "2011-04",
    "results_first_posted": null,
    "last_update_posted": "2011-08-12",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT00492570",
    "title": "GER-009-06-AVX Early Therapy in Multiple Sclerosis",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Relapsing-Remitting Multiple Sclerosis"
    ],
    "interventions": [],
    "primary_completion_date": "2007-10",
    "completion_date": "2008-12",
    "results_first_posted": null,
    "last_update_posted": "2009-06-16",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT01549769",
    "title": "Pharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Renal Insufficiency, Chronic",
      "Diabetes Mellitus, Type 2"
    ],
    "interventions": [
      "Bardoxolone Methyl"
    ],
    "primary_completion_date": "2012-11-30",
    "completion_date": "2013-10-31",
    "results_first_posted": null,
    "last_update_posted": "2025-05-29",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT07221669",
    "title": "A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Muscular Atrophy, Spinal"
    ],
    "interventions": [
      "Salanersen"
    ],
    "primary_completion_date": "2028-11-28",
    "completion_date": "2032-05-29",
    "results_first_posted": null,
    "last_update_posted": "2026-01-15",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT00105170",
    "title": "Safety and Tolerability of hCBE-11 in Subjects With Advanced Solid Tumors",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Tumors"
    ],
    "interventions": [
      "hCBE-11"
    ],
    "primary_completion_date": "2006-08",
    "completion_date": "2006-08",
    "results_first_posted": null,
    "last_update_posted": "2013-04-26",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT03672175",
    "title": "A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive Disorder",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder"
    ],
    "interventions": [
      "SAGE-217",
      "Placebo"
    ],
    "primary_completion_date": "2019-09-24",
    "completion_date": "2020-03-17",
    "results_first_posted": "2022-11-10",
    "last_update_posted": "2023-11-29",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT00664027",
    "title": "Phase IIa Trial to Determine the Effects of Bardoxolone Methyl on Renal Function in Patients With Diabetic Nephropathy",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetic Nephropathy"
    ],
    "interventions": [
      "RTA 402 (Bardoxolone Methyl)"
    ],
    "primary_completion_date": "2009-05-31",
    "completion_date": "2009-05-31",
    "results_first_posted": null,
    "last_update_posted": "2025-05-29",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT03945279",
    "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Amyotrophic Lateral Sclerosis"
    ],
    "interventions": [
      "BIIB100",
      "Placebo"
    ],
    "primary_completion_date": "2021-06-21",
    "completion_date": "2021-06-21",
    "results_first_posted": null,
    "last_update_posted": "2023-04-18",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT02128113",
    "title": "RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Corneal Endothelial Cell Loss",
      "Ocular Pain",
      "Ocular Inflammation",
      "Cataract Surgery"
    ],
    "interventions": [
      "Vehicle Ophthalmic Solution",
      "Omaveloxolone Ophthalmic Suspension 0.5%",
      "Omaveloxolone Ophthalmic Suspension 1%"
    ],
    "primary_completion_date": "2015-02-28",
    "completion_date": "2015-04-30",
    "results_first_posted": "2023-05-26",
    "last_update_posted": "2025-06-03",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT02443740",
    "title": "Safety, Tolerability and Pharmacokinetics of BIIB118 (PF-05251749)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "BIIB118",
      "BIIB118",
      "BIIB118"
    ],
    "primary_completion_date": "2015-10-31",
    "completion_date": "2015-10-31",
    "results_first_posted": "2018-05-17",
    "last_update_posted": "2021-02-17",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT01070836",
    "title": "JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Relapsing Multiple Sclerosis"
    ],
    "interventions": [
      "natalizumab"
    ],
    "primary_completion_date": "2015-11",
    "completion_date": "2015-11",
    "results_first_posted": null,
    "last_update_posted": "2016-09-29",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT03662919",
    "title": "One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Arthritis, Rheumatoid",
      "Spondylitis, Ankylosing",
      "Arthritis, Psoriatic",
      "Crohn's Disease",
      "Colitis, Ulcerative"
    ],
    "interventions": [
      "Infliximab",
      "Adalimumab"
    ],
    "primary_completion_date": "2022-06-30",
    "completion_date": "2022-06-30",
    "results_first_posted": null,
    "last_update_posted": "2022-10-18",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT03000530",
    "title": "A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depressive Disorder",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depression"
    ],
    "interventions": [
      "SAGE-217",
      "Placebo"
    ],
    "primary_completion_date": "2017-10-04",
    "completion_date": "2017-11-08",
    "results_first_posted": "2020-12-02",
    "last_update_posted": "2023-11-28",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "BIIB",
    "nct_id": "NCT01052506",
    "title": "BIIB033 Single Ascending Dose Study in Healthy Volunteer Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "BIIB033",
      "Placebo"
    ],
    "primary_completion_date": "2011-10",
    "completion_date": "2011-10",
    "results_first_posted": null,
    "last_update_posted": "2017-01-09",
    "enrollment": null,
    "sponsor": "Biogen",
    "collected_at": "2026-01-27",
    "search_term": "Biogen"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT01849003",
    "title": "Study of the Effect of GS-6615 in Subjects With LQT-3",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Long QT Syndrome"
    ],
    "interventions": [
      "GS-6615"
    ],
    "primary_completion_date": "2014-11",
    "completion_date": "2014-11",
    "results_first_posted": null,
    "last_update_posted": "2014-11-17",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT02955602",
    "title": "Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Primary Biliary Cirrhosis"
    ],
    "interventions": [
      "MBX-8025 2 mg Capsule",
      "MBX-8025 5 mg Capsule",
      "MBX-8025 10 mg Capsule"
    ],
    "primary_completion_date": "2018-09-07",
    "completion_date": "2019-07-08",
    "results_first_posted": "2022-07-14",
    "last_update_posted": "2022-07-14",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT01497366",
    "title": "Phase 3 Study of Sofosbuvir and Ribavirin",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatitis C"
    ],
    "interventions": [
      "Sofosbuvir",
      "PEG",
      "RBV"
    ],
    "primary_completion_date": "2013-01",
    "completion_date": "2013-04",
    "results_first_posted": "2014-04-02",
    "last_update_posted": "2014-04-02",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT00597129",
    "title": "Safety and Efficacy Study of 90Y-hPAM4 at Different Doses",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pancreatic Cancer"
    ],
    "interventions": [
      "90Y-hPAM4"
    ],
    "primary_completion_date": "2007-10",
    "completion_date": "2007-10",
    "results_first_posted": null,
    "last_update_posted": "2021-08-19",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT01362231",
    "title": "A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Idiopathic Pulmonary Fibrosis"
    ],
    "interventions": [
      "GS-6624"
    ],
    "primary_completion_date": "2012-12",
    "completion_date": "2012-12",
    "results_first_posted": null,
    "last_update_posted": "2015-07-09",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT00617305",
    "title": "Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pulmonary Arterial Hypertension"
    ],
    "interventions": [
      "Ambrisentan",
      "Placebo",
      "Sildenafil",
      "Tadalafil"
    ],
    "primary_completion_date": "2011-02",
    "completion_date": "2011-07",
    "results_first_posted": "2012-07-30",
    "last_update_posted": "2012-07-30",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT05633654",
    "title": "Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Triple Negative Breast Cancer"
    ],
    "interventions": [
      "Sacituzumab govitecan-hziy (SG)",
      "Pembrolizumab",
      "Capecitabine"
    ],
    "primary_completion_date": "2027-06",
    "completion_date": "2031-08",
    "results_first_posted": null,
    "last_update_posted": "2026-01-20",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT02868242",
    "title": "Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatitis C Virus Infection"
    ],
    "interventions": [
      "LDV/SOF"
    ],
    "primary_completion_date": "2018-11-12",
    "completion_date": "2019-02-03",
    "results_first_posted": "2019-08-20",
    "last_update_posted": "2020-03-02",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT02914522",
    "title": "Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ulcerative Colitis"
    ],
    "interventions": [
      "Filgotinib",
      "PTM filgotinib"
    ],
    "primary_completion_date": "2020-03-31",
    "completion_date": "2020-03-31",
    "results_first_posted": "2021-04-21",
    "last_update_posted": "2021-04-21",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT00772902",
    "title": "ROCKET II - Randomized Open Label Switch for Cholesterol Elevation on Kivexa + Kaletra Evaluation Trial",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HIV-1"
    ],
    "interventions": [
      "Truvada + Kaletra",
      "Kivexa + Kaletra"
    ],
    "primary_completion_date": "2009-09",
    "completion_date": "2009-10",
    "results_first_posted": null,
    "last_update_posted": "2011-11-21",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT01221272",
    "title": "Effect of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Myocardial Perfusion Imaging",
      "Myocardial Ischemia"
    ],
    "interventions": [
      "Ranolazine",
      "Placebo to match ranolazine",
      "SPECT MPI",
      "Exercise"
    ],
    "primary_completion_date": "2012-09",
    "completion_date": "2012-09",
    "results_first_posted": "2014-09-03",
    "last_update_posted": "2014-09-03",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT01851330",
    "title": "Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination \u00b1 Ribavirin for the Treatment of HCV (ION-3)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Hepatitis C Virus"
    ],
    "interventions": [
      "LDV/SOF",
      "RBV"
    ],
    "primary_completion_date": "2013-12",
    "completion_date": "2014-03",
    "results_first_posted": "2014-12-30",
    "last_update_posted": "2018-11-16",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT00007436",
    "title": "The Safety of Tenofovir Disoproxil Fumarate Taken With Other Anti-HIV Drugs to Treat HIV-Infected Patients",
    "status": "UNKNOWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HIV Infections"
    ],
    "interventions": [
      "Tenofovir disoproxil fumarate"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2005-06-24",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT01066611",
    "title": "Study to Investigate Effects of CAL-263 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Allergic Rhinitis"
    ],
    "interventions": [
      "CAL-263",
      "Placebo"
    ],
    "primary_completion_date": "2010-04",
    "completion_date": "2010-04",
    "results_first_posted": null,
    "last_update_posted": "2011-05-05",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT00158704",
    "title": "Continued Access Study of Adefovir Dipivoxil (ADV) for Patients w/Chronic HBV Infection.",
    "status": "TERMINATED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatitis B"
    ],
    "interventions": [
      "Hepsera"
    ],
    "primary_completion_date": null,
    "completion_date": "2005-01",
    "results_first_posted": null,
    "last_update_posted": "2007-03-08",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT02063997",
    "title": "Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Gout"
    ],
    "interventions": [
      "Arhalofenate 600 mg",
      "Allopurinol 300 mg",
      "Colchicine 0.6 mg",
      "Placebo",
      "Arhalofenate 800 mg"
    ],
    "primary_completion_date": "2015-01",
    "completion_date": "2015-01",
    "results_first_posted": null,
    "last_update_posted": "2018-01-29",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT00208299",
    "title": "ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan\u00ae in Patients Undergoing Myocardial Perfusion Imaging (MPI)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Coronary Artery Disease"
    ],
    "interventions": [
      "Regadenoson",
      "Adenosine"
    ],
    "primary_completion_date": "2006-08",
    "completion_date": "2006-08",
    "results_first_posted": null,
    "last_update_posted": "2009-11-26",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT04994509",
    "title": "Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pre-Exposure Prophylaxis of HIV Infection"
    ],
    "interventions": [
      "Oral Lenacapavir (LEN)",
      "Subcutaneous (SC) Lenacapavir (LEN)",
      "F/TAF",
      "F/TDF",
      "Placebo SC LEN",
      "PTM Oral LEN",
      "PTM F/TAF",
      "PTM F/TDF"
    ],
    "primary_completion_date": "2024-05-27",
    "completion_date": "2028-01",
    "results_first_posted": "2025-06-19",
    "last_update_posted": "2025-07-17",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT01728207",
    "title": "Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-hodgkin's Lymphoma",
      "Follicular Lymphoma",
      "Mantle Cell Lymphoma",
      "Marginal Zone Lymphoma",
      "Chronic Lymphocytic Leukemia",
      "Small Lymphocytic Lymphoma"
    ],
    "interventions": [
      "IMMU-114"
    ],
    "primary_completion_date": "2017-03",
    "completion_date": "2017-03",
    "results_first_posted": null,
    "last_update_posted": "2021-08-19",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT01675973",
    "title": "A Phase 1 Study to Assess the Effect of Severe Renal Impairment on the Pharmacokinetics, as Well as Safety/Tolerability, of Ranolazine",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Severe Renal Impairment"
    ],
    "interventions": [
      "RANEXA"
    ],
    "primary_completion_date": "2012-08",
    "completion_date": "2012-08",
    "results_first_posted": null,
    "last_update_posted": "2012-12-06",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT03960645",
    "title": "Study to Evaluate the Pharmacokinetics (PK), Safety, and Efficacy of B/F/TAF in Human Immunodeficiency Virus (HIV)-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third Trimesters",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HIV-1-infection"
    ],
    "interventions": [
      "B/F/TAF"
    ],
    "primary_completion_date": "2022-07-21",
    "completion_date": "2022-08-18",
    "results_first_posted": "2024-05-28",
    "last_update_posted": "2024-06-14",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT02296853",
    "title": "Study to Evaluate the Pharmacokinetics of Tenofovir Alafenamide (TAF) in Adults With Normal Hepatic Function and Adults With Severe Hepatic Impairment",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatitis B Virus"
    ],
    "interventions": [
      "TAF"
    ],
    "primary_completion_date": "2015-04-17",
    "completion_date": "2015-04-17",
    "results_first_posted": "2020-12-09",
    "last_update_posted": "2020-12-09",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT02562742",
    "title": "Use-Results Surveillance Study of Sovaldi\u00ae Plus Rebetol\u00ae in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Hepatitis C"
    ],
    "interventions": [
      "SOF",
      "REB"
    ],
    "primary_completion_date": "2017-06-12",
    "completion_date": "2017-06-12",
    "results_first_posted": null,
    "last_update_posted": "2017-08-01",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT02104583",
    "title": "Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ventricular Arrhythmia"
    ],
    "interventions": [
      "Eleclazine",
      "Placebo to match eleclazine"
    ],
    "primary_completion_date": "2016-09",
    "completion_date": "2016-10",
    "results_first_posted": "2019-04-09",
    "last_update_posted": "2019-04-09",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT02021656",
    "title": "Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Participants With Chronic Genotype 1 HCV Infection",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic HCV Infection"
    ],
    "interventions": [
      "LDV/SOF"
    ],
    "primary_completion_date": "2017-07-08",
    "completion_date": "2017-09-29",
    "results_first_posted": "2018-12-28",
    "last_update_posted": "2020-03-05",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT01282424",
    "title": "Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Follicular Lymphoma",
      "Small Lymphocytic Lymphoma",
      "Lymphoplasmacytic Lymphoma",
      "Marginal Zone Lymphoma"
    ],
    "interventions": [
      "Idelalisib"
    ],
    "primary_completion_date": "2018-05-02",
    "completion_date": "2018-05-16",
    "results_first_posted": "2014-09-04",
    "last_update_posted": "2019-07-11",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT01909804",
    "title": "Safety and Efficacy of Sofosbuvir Plus Velpatasvir With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV Infection",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatitis C"
    ],
    "interventions": [
      "SOF",
      "VEL",
      "RBV"
    ],
    "primary_completion_date": "2014-05",
    "completion_date": "2014-08",
    "results_first_posted": "2016-09-16",
    "last_update_posted": "2018-11-15",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT01772121",
    "title": "Observational Study on Prevalence of Host and Viral Genotypes in Chronic Hepatitis B and Hepatitis C Patients in India",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Hepatitis B",
      "Hepatitis C"
    ],
    "interventions": [],
    "primary_completion_date": "2012-10",
    "completion_date": "2012-10",
    "results_first_posted": null,
    "last_update_posted": "2015-07-09",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT00353587",
    "title": "Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Suboptimally Controlled on Insulin",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 2 Diabetes"
    ],
    "interventions": [
      "MBX-102",
      "MBX-102",
      "MBX-102",
      "Placebo",
      "Actos"
    ],
    "primary_completion_date": "2007-11",
    "completion_date": "2007-11",
    "results_first_posted": null,
    "last_update_posted": "2015-05-01",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT00712166",
    "title": "Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cystic Fibrosis",
      "Lung Infection",
      "Pseudomonas Aeruginosa"
    ],
    "interventions": [
      "AZLI 75 mg three times daily (TID)",
      "Placebo three times daily (TID)"
    ],
    "primary_completion_date": "2009-06",
    "completion_date": "2009-08",
    "results_first_posted": "2010-12-20",
    "last_update_posted": "2010-12-20",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT02177786",
    "title": "Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetic Kidney Disease"
    ],
    "interventions": [
      "Selonsertib",
      "Placebo to match selonsertib"
    ],
    "primary_completion_date": "2016-07",
    "completion_date": "2016-08",
    "results_first_posted": "2019-06-11",
    "last_update_posted": "2019-11-05",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT05502341",
    "title": "Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HIV-1-infection"
    ],
    "interventions": [
      "Bictegravir",
      "Lenacapavir",
      "BIC/LEN FDC",
      "Stable Baseline Regimen"
    ],
    "primary_completion_date": "2025-09-29",
    "completion_date": "2028-07",
    "results_first_posted": null,
    "last_update_posted": "2025-10-14",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT00650949",
    "title": "Efficacy Study of CYT997 in Combination With Carboplatin in Glioblastoma",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Glioblastoma Multiforme"
    ],
    "interventions": [
      "CYT997",
      "Carboplatin"
    ],
    "primary_completion_date": "2011-06",
    "completion_date": "2011-06",
    "results_first_posted": null,
    "last_update_posted": "2013-05-03",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT00003338",
    "title": "Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma",
    "status": "UNKNOWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lymphoma"
    ],
    "interventions": [
      "immunoscintigraphy",
      "technetium Tc 99m epratuzumab"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2021-08-16",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT04971785",
    "title": "Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Nonalcoholic Steatohepatitis"
    ],
    "interventions": [
      "Semaglutide (SEMA)",
      "Cilofexor (CILO)/Firsocostat (FIR)",
      "PTM SEMA",
      "PTM CILO/FIR"
    ],
    "primary_completion_date": "2024-11-12",
    "completion_date": "2024-12-09",
    "results_first_posted": "2025-11-26",
    "last_update_posted": "2025-11-26",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT01965535",
    "title": "Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination \u00b1 Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HCV Infection"
    ],
    "interventions": [
      "LDV/SOF",
      "RBV",
      "Placebo to match LDV/SOF",
      "Placebo to match RBV"
    ],
    "primary_completion_date": "2014-08",
    "completion_date": "2014-11",
    "results_first_posted": "2015-09-28",
    "last_update_posted": "2018-11-16",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT00158717",
    "title": "Observational Study of the Durability of Seroconversion Chronic HBV Patients Who Seroconverted in a Previous Gilead-Sponsored Study of ADV.",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Hepatitis B"
    ],
    "interventions": [
      "Hepsera"
    ],
    "primary_completion_date": "2006-04",
    "completion_date": "2006-04",
    "results_first_posted": null,
    "last_update_posted": "2014-01-07",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT00061425",
    "title": "Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-Hodgkin's Lymphoma",
      "Lymphoma, B-Cell"
    ],
    "interventions": [
      "radiolabeled epratuzumab"
    ],
    "primary_completion_date": "2007-11",
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2021-08-19",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT00002396",
    "title": "The Safety and Effectiveness of PMPA Prodrug in HIV-Infected Patients",
    "status": "UNKNOWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HIV Infections"
    ],
    "interventions": [
      "Tenofovir disoproxil fumarate"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2005-06-24",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT01980888",
    "title": "Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Lymphocytic Leukemia"
    ],
    "interventions": [
      "Idelalisib",
      "Bendamustine",
      "Rituximab",
      "Placebo"
    ],
    "primary_completion_date": "2016-05-30",
    "completion_date": "2016-06-16",
    "results_first_posted": "2017-10-11",
    "last_update_posted": "2018-11-19",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT01672866",
    "title": "Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Liver Fibrosis Due to NASH"
    ],
    "interventions": [
      "Placebo",
      "SIM"
    ],
    "primary_completion_date": "2016-08-02",
    "completion_date": "2016-12-29",
    "results_first_posted": "2019-03-27",
    "last_update_posted": "2019-03-27",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT00002453",
    "title": "A Compassionate Use Study of Tenofovir Disoproxil Fumarate as Treatment for HIV Infection",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HIV Infections"
    ],
    "interventions": [
      "Tenofovir disoproxil fumarate"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2005-06-24",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT02242045",
    "title": "Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Lymphocytic Leukemia",
      "Indolent Non-Hodgkin Lymphoma",
      "Follicular Lymphoma",
      "Small Lymphocytic Lymphoma",
      "Lymphoplasmacytic Lymphoma (With or Without Waldenstrom Macroglobulinemia)",
      "Marginal Zone Lymphoma"
    ],
    "interventions": [
      "Idelalisib"
    ],
    "primary_completion_date": "2014-12-25",
    "completion_date": "2017-10-17",
    "results_first_posted": "2021-03-19",
    "last_update_posted": "2021-03-19",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT00757237",
    "title": "Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cystic Fibrosis"
    ],
    "interventions": [
      "Aztreonam for Inhalation Solution (AZLI)",
      "Tobramycin Inhalation Solution (TIS)"
    ],
    "primary_completion_date": "2010-05",
    "completion_date": "2010-11",
    "results_first_posted": "2011-07-04",
    "last_update_posted": "2011-07-04",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT00499239",
    "title": "A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-Hodgkin's Lymphoma",
      "Chronic Lymphocytic Leukemia",
      "Multiple Myeloma"
    ],
    "interventions": [
      "GS-9219"
    ],
    "primary_completion_date": "2010-07",
    "completion_date": "2010-10",
    "results_first_posted": null,
    "last_update_posted": "2014-02-04",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT02468557",
    "title": "Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Previously Untreated Pancreatic Ductal Adenocarcinoma",
      "Relapsed/Refractory Pancreatic Ductal Adenocarcinoma"
    ],
    "interventions": [
      "Idelalisib",
      "Nab-paclitaxel",
      "mFOLFOX6"
    ],
    "primary_completion_date": "2016-04-27",
    "completion_date": "2016-04-27",
    "results_first_posted": "2021-03-22",
    "last_update_posted": "2021-04-02",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT03077412",
    "title": "Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fistulizing Crohn's Disease"
    ],
    "interventions": [
      "Filgotinib",
      "Placebo to match filgotinib"
    ],
    "primary_completion_date": "2021-01-20",
    "completion_date": "2021-02-17",
    "results_first_posted": "2022-04-08",
    "last_update_posted": "2022-04-08",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT02258555",
    "title": "Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Follicular Lymphoma",
      "Chronic Lymphocytic Leukemia",
      "Small Lymphocytic Lymphoma",
      "Marginal Zone Lymphoma"
    ],
    "interventions": [
      "GS-9901"
    ],
    "primary_completion_date": "2015-08",
    "completion_date": "2015-08",
    "results_first_posted": null,
    "last_update_posted": "2015-10-19",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT01840735",
    "title": "Phase 1b Safety, Tolerability, and PK Study to Assess GS-5737 in Subjects With CF",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cystic Fibrosis"
    ],
    "interventions": [
      "GS-5737",
      "Placebo"
    ],
    "primary_completion_date": "2013-07",
    "completion_date": "2013-08",
    "results_first_posted": null,
    "last_update_posted": "2014-08-12",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT02943447",
    "title": "Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Primary Biliary Cholangitis"
    ],
    "interventions": [
      "Cilofexor",
      "Placebo to match cilofexor"
    ],
    "primary_completion_date": "2019-09-04",
    "completion_date": "2019-09-04",
    "results_first_posted": "2020-01-13",
    "last_update_posted": "2020-09-22",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT02781571",
    "title": "Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatitis C Virus Infection"
    ],
    "interventions": [
      "SOF/VEL"
    ],
    "primary_completion_date": "2017-07-28",
    "completion_date": "2017-07-28",
    "results_first_posted": "2018-08-21",
    "last_update_posted": "2018-11-14",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT01472198",
    "title": "A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pancreatic Cancer"
    ],
    "interventions": [
      "Simtuzumab",
      "Gemcitabine",
      "Placebo to match simtuzumab"
    ],
    "primary_completion_date": "2013-10",
    "completion_date": "2015-02",
    "results_first_posted": null,
    "last_update_posted": "2015-03-10",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT02862548",
    "title": "Efficacy and Safety of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF)-Containing Regimens in Participants With Chronic Hepatitis B Virus (HBV) Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver Transplant",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Hepatitis B"
    ],
    "interventions": [
      "TAF",
      "TDF",
      "Other approved antivirals"
    ],
    "primary_completion_date": "2018-02-08",
    "completion_date": "2021-05-05",
    "results_first_posted": "2019-02-26",
    "last_update_posted": "2022-06-08",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT02613871",
    "title": "Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatitis C Virus Infection"
    ],
    "interventions": [
      "LDV/SOF"
    ],
    "primary_completion_date": "2017-01-04",
    "completion_date": "2018-11-07",
    "results_first_posted": "2018-02-13",
    "last_update_posted": "2020-03-06",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT01270698",
    "title": "Study of IMMU-130 in Patients With Relapsed/Refractory Colorectal Cancer",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Colorectal Cancer"
    ],
    "interventions": [
      "IMMU-130"
    ],
    "primary_completion_date": "2014-12",
    "completion_date": "2014-12",
    "results_first_posted": null,
    "last_update_posted": "2021-08-19",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT01625338",
    "title": "Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Hepatitis C"
    ],
    "interventions": [
      "SOF",
      "RBV",
      "Peg-IFN"
    ],
    "primary_completion_date": "2014-10",
    "completion_date": "2014-12",
    "results_first_posted": "2015-11-09",
    "last_update_posted": "2015-11-09",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT02457598",
    "title": "Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "B-cell Malignancies"
    ],
    "interventions": [
      "Tirabrutinib",
      "Idelalisib",
      "Entospletinib",
      "Obinutuzumab"
    ],
    "primary_completion_date": "2024-09-25",
    "completion_date": "2024-09-25",
    "results_first_posted": "2025-06-17",
    "last_update_posted": "2025-06-17",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT02520284",
    "title": "Safety and Efficacy of Andecaliximab (GS-5745) in Adults With Moderately to Severely Active Ulcerative Colitis",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ulcerative Colitis"
    ],
    "interventions": [
      "Andecaliximab",
      "Placebo"
    ],
    "primary_completion_date": "2016-09",
    "completion_date": "2016-11",
    "results_first_posted": "2019-04-10",
    "last_update_posted": "2019-04-10",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT02246998",
    "title": "Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HIV-1 Infection"
    ],
    "interventions": [
      "STB",
      "TVD",
      "ATR",
      "RTV",
      "ATV",
      "ABC/3TC",
      "Iohexol"
    ],
    "primary_completion_date": "2016-01-20",
    "completion_date": "2016-02-17",
    "results_first_posted": "2018-01-03",
    "last_update_posted": "2018-01-03",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT04049617",
    "title": "Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Evixapodlin (Formerly GS-4224) in Participants With Advanced Solid Tumors",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumors"
    ],
    "interventions": [
      "Evixapodlin"
    ],
    "primary_completion_date": "2021-03-30",
    "completion_date": "2021-03-30",
    "results_first_posted": "2022-08-10",
    "last_update_posted": "2022-10-06",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT01956812",
    "title": "Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Pancreatic Cancer",
      "Pancreatic Cancer"
    ],
    "interventions": [
      "IMMU-107",
      "placebo",
      "Gemcitabine"
    ],
    "primary_completion_date": "2016-11",
    "completion_date": "2016-11",
    "results_first_posted": null,
    "last_update_posted": "2021-08-16",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT01369498",
    "title": "Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Myelofibrosis"
    ],
    "interventions": [
      "Simtuzumab",
      "Ruxolitinib"
    ],
    "primary_completion_date": "2014-06-05",
    "completion_date": "2014-09-24",
    "results_first_posted": "2020-07-01",
    "last_update_posted": "2020-07-01",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT03820258",
    "title": "Study to Investigate Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) Fixed Dose Combination (FDC) in Adolescents and Children With Chronic Hepatitis C Virus (HCV) Infection",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatitis C Virus Infection"
    ],
    "interventions": [
      "SOF/VEL/VOX"
    ],
    "primary_completion_date": "2019-12-04",
    "completion_date": "2020-02-19",
    "results_first_posted": "2020-08-31",
    "last_update_posted": "2020-10-23",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT00298350",
    "title": "Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART.",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HIV",
      "HIV-1",
      "Human Immunodeficiency Virus"
    ],
    "interventions": [
      "GS-9137 - A Novel HIV-1 Integrase Inhibitor"
    ],
    "primary_completion_date": "2007-06",
    "completion_date": "2007-07",
    "results_first_posted": null,
    "last_update_posted": "2008-07-29",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT05458102",
    "title": "Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Human Immunodeficiency Virus Type 1 (HIV-1) Infection"
    ],
    "interventions": [
      "Vesatolimod",
      "Cobicistat",
      "Voriconazole",
      "Rifabutin"
    ],
    "primary_completion_date": "2023-05-01",
    "completion_date": "2023-05-01",
    "results_first_posted": "2024-12-03",
    "last_update_posted": "2024-12-03",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT02254408",
    "title": "Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Respiratory Syncytial Virus"
    ],
    "interventions": [
      "Presatovir",
      "Placebo"
    ],
    "primary_completion_date": "2017-07-14",
    "completion_date": "2017-07-14",
    "results_first_posted": "2018-08-06",
    "last_update_posted": "2018-08-06",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT01565889",
    "title": "Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatitis C",
      "HIV"
    ],
    "interventions": [
      "SOF",
      "EFV/FTC/TDF",
      "EFV",
      "ZDV/3TC",
      "ATV",
      "Ritonavir",
      "FTC/TDF",
      "DRV",
      "RAL",
      "PEG",
      "RBV"
    ],
    "primary_completion_date": "2013-08",
    "completion_date": "2013-11",
    "results_first_posted": "2014-10-01",
    "last_update_posted": "2014-10-01",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT06630286",
    "title": "Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HIV-1-infection"
    ],
    "interventions": [
      "ISL/LEN",
      "B/F/TAF",
      "PTM B/F/TAF",
      "PTM ISL/LEN"
    ],
    "primary_completion_date": "2026-04",
    "completion_date": "2030-08",
    "results_first_posted": null,
    "last_update_posted": "2025-11-13",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT00330369",
    "title": "DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypertension"
    ],
    "interventions": [
      "Darusentan",
      "Darusentan Placebo"
    ],
    "primary_completion_date": "2009-01",
    "completion_date": "2009-01",
    "results_first_posted": null,
    "last_update_posted": "2014-03-18",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT05585307",
    "title": "Study of Novel Antiretrovirals in Participants With HIV-1",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HIV-1-infection"
    ],
    "interventions": [
      "Bavtavirine",
      "B/F/TAF",
      "Standard of Care (Substudy 01)",
      "GS-1720",
      "Standard of Care (Substudy 02)",
      "GS-6212",
      "Standard of Care (Substudy 03)"
    ],
    "primary_completion_date": "2024-02-17",
    "completion_date": "2024-03-18",
    "results_first_posted": "2025-05-08",
    "last_update_posted": "2025-05-08",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT02538614",
    "title": "Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Lymphocytic Leukemia (CLL)"
    ],
    "interventions": [
      "Idelalisib",
      "BI 836826"
    ],
    "primary_completion_date": "2017-07-05",
    "completion_date": "2017-07-05",
    "results_first_posted": "2020-11-25",
    "last_update_posted": "2020-11-25",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT03547908",
    "title": "Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HIV-1/HBV Co-Infection"
    ],
    "interventions": [
      "B/F/TAF",
      "Placebo to match DTG",
      "Placebo to match F/TDF",
      "DTG",
      "F/TDF",
      "Placebo to match B/F/TAF"
    ],
    "primary_completion_date": "2022-02-25",
    "completion_date": "2024-03-07",
    "results_first_posted": "2023-03-15",
    "last_update_posted": "2025-03-19",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT01095796",
    "title": "Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HIV",
      "HIV Infections"
    ],
    "interventions": [
      "Stribild",
      "Atripla",
      "Stribild Placebo",
      "Atripla Placebo"
    ],
    "primary_completion_date": "2011-08",
    "completion_date": "2014-09",
    "results_first_posted": "2012-10-22",
    "last_update_posted": "2015-11-11",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT02533427",
    "title": "Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HCV Infection"
    ],
    "interventions": [
      "SOF/VEL/VOX",
      "VOX",
      "Norgestimate/ethinyl estradiol"
    ],
    "primary_completion_date": "2016-03-18",
    "completion_date": "2016-03-18",
    "results_first_posted": "2020-09-02",
    "last_update_posted": "2020-09-02",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT02121795",
    "title": "Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HIV-1 Infection"
    ],
    "interventions": [
      "FTC/TDF",
      "F/TAF",
      "Allowed third antiretroviral agent",
      "FTC/TDF Placebo",
      "F/TAF Placebo"
    ],
    "primary_completion_date": "2015-08-12",
    "completion_date": "2019-03-01",
    "results_first_posted": "2016-11-30",
    "last_update_posted": "2020-03-12",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT04431453",
    "title": "Study of Remdesivir in Participants Below 18 Years Old With COVID-19",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID-19"
    ],
    "interventions": [
      "Remdesivir"
    ],
    "primary_completion_date": "2023-02-10",
    "completion_date": "2023-02-10",
    "results_first_posted": "2023-12-22",
    "last_update_posted": "2024-02-06",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT01088048",
    "title": "Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Indolent Non-Hodgkin's Lymphoma",
      "Chronic Lymphocytic Leukemia",
      "Mantle Cell Lymphoma"
    ],
    "interventions": [
      "Idelalisib",
      "Rituximab",
      "Bendamustine",
      "Ofatumumab",
      "Fludarabine",
      "Everolimus",
      "Bortezomib",
      "Chlorambucil",
      "Lenalidomide"
    ],
    "primary_completion_date": "2015-04-28",
    "completion_date": "2015-04-28",
    "results_first_posted": "2021-03-18",
    "last_update_posted": "2021-03-18",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT01799889",
    "title": "Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Lymphocytic Leukemia",
      "Mantle Cell Lymphoma",
      "Diffuse Large B-cell Lymphoma",
      "Non-FL Indolent Non-Hodgkin's Lymphoma",
      "Follicular Lymphoma"
    ],
    "interventions": [
      "Entospletinib MM",
      "Entospletinib SDD"
    ],
    "primary_completion_date": "2017-09-14",
    "completion_date": "2020-01-30",
    "results_first_posted": "2020-09-23",
    "last_update_posted": "2020-11-19",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT01452308",
    "title": "Pilot Study of Simtuzumab in the Treatment of Liver Fibrosis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Liver Fibrosis"
    ],
    "interventions": [
      "Simtuzumab"
    ],
    "primary_completion_date": "2013-01",
    "completion_date": "2013-08",
    "results_first_posted": null,
    "last_update_posted": "2014-02-03",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT02251717",
    "title": "Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatitis C Virus Infection"
    ],
    "interventions": [
      "LDV/SOF"
    ],
    "primary_completion_date": "2016-03-24",
    "completion_date": "2016-06-16",
    "results_first_posted": "2017-11-17",
    "last_update_posted": "2018-11-19",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT02876796",
    "title": "Study to Evaluate the Pharmacodynamic Effects of a Single Oral Dose of GS-0976 (NDI-010976) in Healthy Adult Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "PD Effects of GS-0976 (NDI-010976) on Fractional DNL"
    ],
    "interventions": [
      "GS-0976",
      "Placebo",
      "1-13C acetate",
      "Fructose solution"
    ],
    "primary_completion_date": "2015-09",
    "completion_date": "2015-10",
    "results_first_posted": null,
    "last_update_posted": "2016-08-24",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT00664378",
    "title": "Efficacy Study of CYT997 in Multiple Myeloma",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsed and Refractory Multiple Myeloma"
    ],
    "interventions": [
      "CYT997"
    ],
    "primary_completion_date": "2011-02",
    "completion_date": "2011-02",
    "results_first_posted": null,
    "last_update_posted": "2018-06-08",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT01641640",
    "title": "Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Hepatitis C"
    ],
    "interventions": [
      "Sofosbuvir",
      "RBV",
      "PEG"
    ],
    "primary_completion_date": "2013-01",
    "completion_date": "2013-04",
    "results_first_posted": "2014-05-08",
    "last_update_posted": "2014-05-08",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT00104520",
    "title": "Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cystic Fibrosis"
    ],
    "interventions": [
      "AZLI 75 mg two times a day (BID)/three times a day (TID)",
      "Placebo two times a day (BID)/three times a day (TID)"
    ],
    "primary_completion_date": "2006-09",
    "completion_date": "2006-09",
    "results_first_posted": "2011-03-11",
    "last_update_posted": "2011-03-11",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT02378935",
    "title": "Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatitis C Virus Infection"
    ],
    "interventions": [
      "VOX",
      "SOF/VEL",
      "RBV"
    ],
    "primary_completion_date": "2016-02-01",
    "completion_date": "2016-04-12",
    "results_first_posted": "2017-12-08",
    "last_update_posted": "2020-03-06",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT03053050",
    "title": "Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Nonalcoholic Steatohepatitis"
    ],
    "interventions": [
      "SEL",
      "Placebo to match SEL 6 mg",
      "Placebo to match SEL 18 mg"
    ],
    "primary_completion_date": "2019-06-19",
    "completion_date": "2019-06-19",
    "results_first_posted": "2020-06-29",
    "last_update_posted": "2020-06-29",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT06486441",
    "title": "Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Endometrial Cancer"
    ],
    "interventions": [
      "Sacituzumab govitecan-hziy",
      "Doxorubicin",
      "Paclitaxel"
    ],
    "primary_completion_date": "2029-06",
    "completion_date": "2029-06",
    "results_first_posted": null,
    "last_update_posted": "2026-01-15",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT00423748",
    "title": "Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pulmonary Arterial Hypertension"
    ],
    "interventions": [
      "ambrisentan"
    ],
    "primary_completion_date": null,
    "completion_date": "2006-02",
    "results_first_posted": null,
    "last_update_posted": "2009-04-16",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT02759562",
    "title": "Effect of Andecaliximab on FEV1 in Adults With Cystic Fibrosis",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cystic Fibrosis"
    ],
    "interventions": [
      "Andecaliximab",
      "Placebo"
    ],
    "primary_completion_date": "2017-07-06",
    "completion_date": "2017-07-21",
    "results_first_posted": "2018-07-05",
    "last_update_posted": "2018-08-17",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT02176876",
    "title": "Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Rheumatoid Arthritis",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rheumatoid Arthritis"
    ],
    "interventions": [
      "GS-5745",
      "Placebo to match GS-5745"
    ],
    "primary_completion_date": "2015-04",
    "completion_date": "2015-06",
    "results_first_posted": null,
    "last_update_posted": "2015-06-29",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT01108510",
    "title": "Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HIV",
      "HIV Infections"
    ],
    "interventions": [
      "COBI",
      "RTV",
      "ATV",
      "FTC/TDF",
      "COBI placebo",
      "RTV placebo"
    ],
    "primary_completion_date": "2011-11",
    "completion_date": "2015-04",
    "results_first_posted": "2014-10-28",
    "last_update_posted": "2016-05-23",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT01732926",
    "title": "Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Indolent Non-Hodgkin's Lymphomas"
    ],
    "interventions": [
      "Idelalisib",
      "Rituximab",
      "Bendamustine",
      "Placebo"
    ],
    "primary_completion_date": "2016-05-17",
    "completion_date": "2016-05-17",
    "results_first_posted": "2017-05-11",
    "last_update_posted": "2018-11-16",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT03417778",
    "title": "Study to Evaluate the Pharmacokinetics of Filgotinib in Participants With Impaired Hepatic Function",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rheumatoid Arthritis"
    ],
    "interventions": [
      "Filgotinib"
    ],
    "primary_completion_date": "2018-08-09",
    "completion_date": "2018-08-09",
    "results_first_posted": "2021-01-15",
    "last_update_posted": "2021-01-15",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT01495702",
    "title": "Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acquired Immunodeficiency Syndrome",
      "HIV Infections"
    ],
    "interventions": [
      "NNRTI",
      "FTC/TDF",
      "Stribild"
    ],
    "primary_completion_date": "2013-11",
    "completion_date": "2014-12",
    "results_first_posted": "2015-01-26",
    "last_update_posted": "2016-01-07",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT00547066",
    "title": "Study of Veltuzumab (hA20) at Different Doses in Patients With ITP",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Purpura, Thrombocytopenic, Idiopathic",
      "Autoimmune Thrombocytopenic Purpura",
      "Purpura, Thrombocytopenic, Autoimmune"
    ],
    "interventions": [
      "veltuzumab"
    ],
    "primary_completion_date": "2011-11",
    "completion_date": "2011-11",
    "results_first_posted": null,
    "last_update_posted": "2021-08-16",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT01705574",
    "title": "Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acquired Immunodeficiency Syndrome",
      "HIV Infections"
    ],
    "interventions": [
      "E/C/F/TDF",
      "ATV",
      "RTV",
      "FTC/TDF",
      "E/C/F/TDF Placebo",
      "ATV Placebo",
      "RTV Placebo",
      "FTC/TDF Placebo",
      "E/C/F/TAF"
    ],
    "primary_completion_date": "2015-02-09",
    "completion_date": "2018-09-06",
    "results_first_posted": "2016-03-10",
    "last_update_posted": "2019-09-20",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT02161679",
    "title": "Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Triple-negative Breast Cancer"
    ],
    "interventions": [
      "IMMU-132 infusion is administered to participants in one arm for the study",
      "IMMU-132 plus Carboplatin infusion"
    ],
    "primary_completion_date": "2016-08",
    "completion_date": "2016-08",
    "results_first_posted": null,
    "last_update_posted": "2021-08-19",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT02378961",
    "title": "Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatitis C Virus Infection"
    ],
    "interventions": [
      "VOX",
      "SOF/VEL"
    ],
    "primary_completion_date": "2015-09-21",
    "completion_date": "2016-01-26",
    "results_first_posted": "2017-09-15",
    "last_update_posted": "2020-03-03",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT01035879",
    "title": "Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 Diabetes",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes"
    ],
    "interventions": [
      "MBX-2982",
      "MBX-2982",
      "MBX-2982",
      "Sitagliptin",
      "placebo"
    ],
    "primary_completion_date": "2010-08",
    "completion_date": "2010-08",
    "results_first_posted": null,
    "last_update_posted": "2015-04-17",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "GILD",
    "nct_id": "NCT02071082",
    "title": "Efficacy and Safety of E/C/F/TAF (Genvoya\u00ae) in HIV-1/Hepatitis B Co-infected Adults",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HIV",
      "HBV"
    ],
    "interventions": [
      "E/C/F/TAF"
    ],
    "primary_completion_date": "2015-01-23",
    "completion_date": "2016-10-26",
    "results_first_posted": "2016-04-04",
    "last_update_posted": "2018-11-16",
    "enrollment": null,
    "sponsor": "Gilead Sciences",
    "collected_at": "2026-01-27",
    "search_term": "Gilead Sciences"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT00522574",
    "title": "A Safety Study of XL019 in Adults With Myelofibrosis",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Myeloproliferative Disorders",
      "Myelofibrosis",
      "Polycythemia Vera",
      "Thrombocythemia, Essential"
    ],
    "interventions": [
      "XL019"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2011-04-05",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT01493869",
    "title": "Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy",
      "Hepatic Impairment"
    ],
    "interventions": [
      "cabozantinib"
    ],
    "primary_completion_date": "2014-05",
    "completion_date": "2014-08",
    "results_first_posted": null,
    "last_update_posted": "2014-09-22",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT06952010",
    "title": "A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor",
      "Advanced Solid Tumor",
      "Metastatic Solid Tumor",
      "Immune Sensitive Tumor"
    ],
    "interventions": [
      "XB628"
    ],
    "primary_completion_date": "2027-05",
    "completion_date": "2027-11",
    "results_first_posted": null,
    "last_update_posted": "2025-12-26",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT00704392",
    "title": "Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors",
    "status": "WITHDRAWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cancer",
      "Non-small-cell Lung Cancer",
      "Breast Cancer"
    ],
    "interventions": [
      "XL647",
      "XL147"
    ],
    "primary_completion_date": "2009-12",
    "completion_date": "2009-12",
    "results_first_posted": null,
    "last_update_posted": "2015-08-20",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT00129571",
    "title": "Study of XL820 in Adults With Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cancer"
    ],
    "interventions": [
      "XL820"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2008-06-04",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT00796484",
    "title": "Safety Study of Pharmacokinetics of XL888 in Adults With Solid Tumors",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cancer"
    ],
    "interventions": [
      "XL888"
    ],
    "primary_completion_date": "2010-11",
    "completion_date": "2010-11",
    "results_first_posted": null,
    "last_update_posted": "2015-08-21",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT06082167",
    "title": "Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Head and Neck Squamous Cell Carcinoma"
    ],
    "interventions": [
      "Zanzalintinib",
      "Zanzalintinib-matched Placebo",
      "Pembrolizumab"
    ],
    "primary_completion_date": "2028-08",
    "completion_date": "2029-03",
    "results_first_posted": null,
    "last_update_posted": "2025-08-17",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT01605227",
    "title": "Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Prostate Cancer",
      "Castration Resistant Prostate Cancer",
      "Pain",
      "Prostatic Neoplasms"
    ],
    "interventions": [
      "cabozantinib",
      "prednisone"
    ],
    "primary_completion_date": "2014-09",
    "completion_date": "2015-03",
    "results_first_posted": "2018-03-14",
    "last_update_posted": "2018-03-14",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT00595829",
    "title": "A Phase 1 Study of XL019 in Adults With Polycythemia Vera",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Polycythemia Vera"
    ],
    "interventions": [
      "XL019"
    ],
    "primary_completion_date": "2009-02",
    "completion_date": "2009-02",
    "results_first_posted": null,
    "last_update_posted": "2015-08-21",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT05932862",
    "title": "A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumor"
    ],
    "interventions": [
      "XL309",
      "Olaparib"
    ],
    "primary_completion_date": "2029-01-03",
    "completion_date": "2029-08-03",
    "results_first_posted": null,
    "last_update_posted": "2025-09-05",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT00464113",
    "title": "Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Myeloid Leukemia",
      "Leukemia, Lymphoblastic, Acute, Philadelphia-Positive"
    ],
    "interventions": [
      "XL228"
    ],
    "primary_completion_date": "2010-12",
    "completion_date": "2011-04",
    "results_first_posted": null,
    "last_update_posted": "2015-08-21",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT00940225",
    "title": "Study of Cabozantinib (XL184) in Adults With Advanced Malignancies",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumors",
      "Cancer"
    ],
    "interventions": [
      "Cabozantinib",
      "Placebo"
    ],
    "primary_completion_date": "2013-05",
    "completion_date": "2014-06",
    "results_first_posted": "2024-04-25",
    "last_update_posted": "2024-04-25",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT00960492",
    "title": "Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Glioblastoma",
      "Giant Cell Glioblastoma",
      "Gliosarcoma"
    ],
    "interventions": [
      "XL184",
      "temozolomide",
      "temozolomide",
      "Radiation Therapy",
      "temozolomide"
    ],
    "primary_completion_date": "2012-11",
    "completion_date": "2013-10",
    "results_first_posted": null,
    "last_update_posted": "2014-09-22",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT00596648",
    "title": "A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Carcinoma, Non-Small-Cell Lung"
    ],
    "interventions": [
      "XL184",
      "erlotinib"
    ],
    "primary_completion_date": "2012-08-02",
    "completion_date": "2012-08-02",
    "results_first_posted": "2026-01-13",
    "last_update_posted": "2026-01-13",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT00350831",
    "title": "Study of XL820 Given Orally Daily to Subjects With Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cancer"
    ],
    "interventions": [
      "XL820"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2008-08-18",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT00526838",
    "title": "Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cancer",
      "Lymphoma"
    ],
    "interventions": [
      "XL228"
    ],
    "primary_completion_date": "2010-12",
    "completion_date": "2010-12",
    "results_first_posted": null,
    "last_update_posted": "2015-08-21",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT01865747",
    "title": "A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Renal Cell Carcinoma"
    ],
    "interventions": [
      "Cabozantinib tablets",
      "Everolimus (Afinitor) tablets"
    ],
    "primary_completion_date": "2015-05-22",
    "completion_date": "2021-01-15",
    "results_first_posted": "2017-07-18",
    "last_update_posted": "2021-04-27",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT05144347",
    "title": "Study of XL114 in Subjects With Non-Hodgkin's Lymphoma",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-Hodgkin's Lymphoma (NHL)",
      "Activated B-Cell Type Diffuse Large B-Cell Lymphoma (ABC-DLBCL)",
      "Mantle Cell Lymphoma (MCL)",
      "Chronic Lymphocytic Leukemia (CLL)",
      "Small Lymphocytic Lymphoma (SLL)"
    ],
    "interventions": [
      "XL114"
    ],
    "primary_completion_date": "2022-11-01",
    "completion_date": "2022-11-01",
    "results_first_posted": null,
    "last_update_posted": "2023-07-11",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT00234481",
    "title": "Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Lymphocytic Leukemia",
      "Small Lymphocytic Lymphoma"
    ],
    "interventions": [
      "XL844"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2008-06-04",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT05176483",
    "title": "Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Renal Cell Carcinoma (RCC)",
      "Metastatic Castration-Resistant Prostate Cancer (mCRPC)",
      "Urothelial Carcinoma (UC)",
      "Solid Tumor",
      "Hepatocellular Carcinoma (HCC)",
      "Non-small Cell Lung Cancer (NSCLC)",
      "Colorectal Cancer (CRC)",
      "Head and Neck Squamous Cell Carcinoma (HNSCC)",
      "Clear Cell Renal Cell Carcinoma (ccRCC)",
      "Non-Clear Cell Renal Cell Carcinoma (nccRCC)"
    ],
    "interventions": [
      "Zanzalintinib",
      "Nivolumab",
      "Ipilimumab",
      "Nivolumab",
      "Nivolumab",
      "Nivolumab + Relatlimab"
    ],
    "primary_completion_date": "2030-06-28",
    "completion_date": "2030-06-28",
    "results_first_posted": null,
    "last_update_posted": "2026-01-20",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT07123103",
    "title": "A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumors"
    ],
    "interventions": [
      "XB371"
    ],
    "primary_completion_date": "2027-11",
    "completion_date": "2028-02",
    "results_first_posted": null,
    "last_update_posted": "2025-10-30",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT04726332",
    "title": "Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Neoplasm Malignant",
      "Epithelial Ovarian Cancer",
      "Triple Negative Breast Cancer",
      "Hormone Receptor Positive Breast Carcinoma",
      "Metastatic Castration-resistant Prostate Cancer"
    ],
    "interventions": [
      "XL102",
      "Fulvestrant",
      "Abiraterone",
      "Prednisone"
    ],
    "primary_completion_date": "2024-05-02",
    "completion_date": "2024-05-02",
    "results_first_posted": null,
    "last_update_posted": "2024-05-14",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT01522443",
    "title": "Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Prostate Cancer",
      "Castration Resistant Prostate Cancer",
      "Pain",
      "Prostatic Neoplasms"
    ],
    "interventions": [
      "cabozantinib",
      "mitoxantrone",
      "prednisone"
    ],
    "primary_completion_date": "2014-10",
    "completion_date": "2015-01-13",
    "results_first_posted": "2018-05-23",
    "last_update_posted": "2018-05-23",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT01908426",
    "title": "Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatocellular Carcinoma"
    ],
    "interventions": [
      "Cabozantinib tablets",
      "Placebo tablets"
    ],
    "primary_completion_date": "2017-10-16",
    "completion_date": "2021-01-12",
    "results_first_posted": "2019-03-01",
    "last_update_posted": "2021-05-06",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT01761773",
    "title": "A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy",
      "Renal Impairment"
    ],
    "interventions": [
      "cabozantinib"
    ],
    "primary_completion_date": "2013-04",
    "completion_date": "2014-07",
    "results_first_posted": null,
    "last_update_posted": "2014-09-22",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT03690388",
    "title": "A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Differentiated Thyroid Cancer"
    ],
    "interventions": [
      "Cabozantinib",
      "Placebo"
    ],
    "primary_completion_date": "2020-08-19",
    "completion_date": "2026-07-31",
    "results_first_posted": "2023-05-18",
    "last_update_posted": "2025-09-25",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT01683110",
    "title": "Expanded Access of Cabozantinib in Medullary Thyroid Cancer",
    "status": "APPROVED_FOR_MARKETING",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Medullary Thyroid Cancer"
    ],
    "interventions": [
      "cabozantinib"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2013-01-16",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT03937219",
    "title": "Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Renal Cell Carcinoma"
    ],
    "interventions": [
      "Cabozantinib",
      "Nivolumab",
      "Ipilimumab",
      "Cabozantinib-matched placebo"
    ],
    "primary_completion_date": "2022-01-31",
    "completion_date": "2027-01-31",
    "results_first_posted": "2025-09-10",
    "last_update_posted": "2025-09-10",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT00704288",
    "title": "Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Glioblastoma Multiforme"
    ],
    "interventions": [
      "XL184"
    ],
    "primary_completion_date": "2012-06",
    "completion_date": "2012-12",
    "results_first_posted": "2024-02-05",
    "last_update_posted": "2024-02-05",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT01995058",
    "title": "Combo of Cabozantinib With Abiraterone in Chemotherapy-Na\u00efve Subjects With Bone-Metastatic CRPC",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Prostate Cancer",
      "Castration Resistant Prostate Cancer",
      "Prostatic Neoplasms"
    ],
    "interventions": [
      "cabozantinib",
      "abiraterone",
      "prednisone"
    ],
    "primary_completion_date": "2014-11",
    "completion_date": "2014-11",
    "results_first_posted": "2026-01-08",
    "last_update_posted": "2026-01-08",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT01100619",
    "title": "A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Papillary Thyroid Cancer",
      "Follicular Thyroid Cancer",
      "Huerthle Cell Thyroid Cancer",
      "Renal Cell Carcinoma"
    ],
    "interventions": [
      "rosiglitazone",
      "XL184"
    ],
    "primary_completion_date": "2012-08",
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2013-09-19",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT00460278",
    "title": "Study of XL418 in Adults With Solid Tumors",
    "status": "SUSPENDED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cancer",
      "Solid Tumors"
    ],
    "interventions": [
      "XL418"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2008-06-04",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT00215605",
    "title": "Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lymphoma",
      "Cancer",
      "Thyroid Carcinoma"
    ],
    "interventions": [
      "XL184"
    ],
    "primary_completion_date": "2011-04",
    "completion_date": "2012-07",
    "results_first_posted": null,
    "last_update_posted": "2013-02-27",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT01553656",
    "title": "Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumors",
      "Cancer",
      "NSCLC"
    ],
    "interventions": [
      "cabozantinib capsules",
      "cabozantinib tablets"
    ],
    "primary_completion_date": "2015-05",
    "completion_date": "2015-07",
    "results_first_posted": null,
    "last_update_posted": "2015-08-20",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT05425940",
    "title": "Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Colorectal Cancer"
    ],
    "interventions": [
      "XL092",
      "Atezolizumab",
      "Regorafenib"
    ],
    "primary_completion_date": "2026-05",
    "completion_date": "2027-01",
    "results_first_posted": null,
    "last_update_posted": "2025-10-23",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT01896479",
    "title": "A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Medullary Thyroid Cancer"
    ],
    "interventions": [
      "Cabozantinib (XL184) 140 mg",
      "Cabozantinib (XL184) 60 mg",
      "Placebo tablet",
      "Placebo capsule"
    ],
    "primary_completion_date": "2020-07-15",
    "completion_date": "2035-01",
    "results_first_posted": "2025-09-02",
    "last_update_posted": "2025-09-02",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT00451880",
    "title": "Study of XL281 in Adults With Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cancer",
      "Non-small-cell Lung Cancer",
      "Colorectal Cancer",
      "Papillary Thyroid Cancer",
      "Melanoma"
    ],
    "interventions": [
      "XL281",
      "famotidine"
    ],
    "primary_completion_date": "2011-10",
    "completion_date": "2011-10",
    "results_first_posted": null,
    "last_update_posted": "2011-10-13",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT06545331",
    "title": "Study of XB010 in Subjects With Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Locally Advanced or Metastatic Solid Tumors",
      "Esophageal Squamous Cell Cancer",
      "Head and Neck Squamous Cell Cancer",
      "NSCLC (Non-small Cell Lung Cancer)",
      "Hormone-receptor-positive Breast Cancer",
      "Triple Negative Breast Cancer (TNBC)"
    ],
    "interventions": [
      "XB010",
      "Pembrolizumab"
    ],
    "primary_completion_date": "2026-11-23",
    "completion_date": "2027-10-20",
    "results_first_posted": null,
    "last_update_posted": "2026-01-20",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT04446117",
    "title": "Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Prostate Cancer",
      "Prostate Adenocarcinoma"
    ],
    "interventions": [
      "Cabozantinib",
      "Atezolizumab",
      "Abiraterone Acetate",
      "Enzalutamide",
      "Prednisone"
    ],
    "primary_completion_date": "2024-04-19",
    "completion_date": "2026-10-16",
    "results_first_posted": "2025-12-18",
    "last_update_posted": "2025-12-18",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT06191796",
    "title": "Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors"
    ],
    "interventions": [
      "zanzalintinib",
      "AB521",
      "Nivolumab"
    ],
    "primary_completion_date": "2025-05-12",
    "completion_date": "2025-05-12",
    "results_first_posted": null,
    "last_update_posted": "2025-06-12",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT06630247",
    "title": "A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Cancers",
      "Solid Tumor Cancer",
      "Solid Tumor Malignancy",
      "Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)",
      "Metastatic Solid Tumor",
      "Locally Advanced Solid Tumor",
      "Urothelial Cancer of Renal Pelvis"
    ],
    "interventions": [
      "XL495",
      "ADC cytotoxic agents"
    ],
    "primary_completion_date": "2025-05-07",
    "completion_date": "2025-05-07",
    "results_first_posted": null,
    "last_update_posted": "2025-06-25",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT04925284",
    "title": "Study of XB002 in Subjects With Solid Tumors (JEWEL-101)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non Small Cell Lung Cancer",
      "Cervical Cancer",
      "SCCHN",
      "Pancreatic Cancer",
      "Esophageal SCC",
      "Metastatic Castration-resistant Prostate Cancer",
      "Triple Negative Breast Cancer",
      "Hormone Receptor-positive Breast Cancer",
      "Epithelial Ovarian Cancer",
      "Endometrial Cancer",
      "Tissue Factor-Expressing Solid Tumors"
    ],
    "interventions": [
      "XB002",
      "Nivolumab",
      "Bevacizumab"
    ],
    "primary_completion_date": "2025-03-10",
    "completion_date": "2025-03-10",
    "results_first_posted": null,
    "last_update_posted": "2025-04-04",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT06962332",
    "title": "Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatic Impairment",
      "Moderate Hepatic Impairment"
    ],
    "interventions": [
      "Zanzalintinib"
    ],
    "primary_completion_date": "2025-12",
    "completion_date": "2026-04",
    "results_first_posted": null,
    "last_update_posted": "2025-06-22",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT05678673",
    "title": "Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-Clear Cell Renal Cell Carcinoma"
    ],
    "interventions": [
      "XL092",
      "Nivolumab",
      "Sunitinib Malate"
    ],
    "primary_completion_date": "2025-07",
    "completion_date": "2028-06",
    "results_first_posted": null,
    "last_update_posted": "2025-07-14",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT00570635",
    "title": "A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Gastrointestinal Stromal Tumors",
      "Gastrointestinal Neoplasms"
    ],
    "interventions": [
      "XL820",
      "XL820"
    ],
    "primary_completion_date": "2009-05",
    "completion_date": "2009-05",
    "results_first_posted": null,
    "last_update_posted": "2013-06-07",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT03170960",
    "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Urothelial Carcinoma",
      "Renal Cell Carcinoma",
      "Non-Small Cell Lung Cancer",
      "Castration-resistant Prostate Cancer",
      "Triple Negative Breast Cancer",
      "Ovarian Cancer",
      "Endometrial Cancer",
      "Hepatocellular Carcinoma",
      "Gastric Cancer",
      "Gastroesophageal Junction Adenocarcinoma",
      "Colorectal Cancer",
      "Head and Neck Cancer",
      "Differentiated Thyroid Cancer",
      "Lower Esophageal Cancer"
    ],
    "interventions": [
      "cabozantinib",
      "atezolizumab",
      "cabozantinib",
      "cabozantinib"
    ],
    "primary_completion_date": "2023-02-21",
    "completion_date": "2027-09-30",
    "results_first_posted": null,
    "last_update_posted": "2025-08-17",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT06943755",
    "title": "Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pancreatic Neuroendocrine Tumor (pNET)",
      "Extra-Pancreatic Neuroendocrine Tumor (epNET)"
    ],
    "interventions": [
      "Zanzalintinib",
      "Everolimus"
    ],
    "primary_completion_date": "2029-06",
    "completion_date": "2029-06",
    "results_first_posted": null,
    "last_update_posted": "2026-01-20",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT00475917",
    "title": "A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cancer",
      "Lymphoma"
    ],
    "interventions": [
      "XL844",
      "Gemcitabine"
    ],
    "primary_completion_date": "2008-12",
    "completion_date": "2008-12",
    "results_first_posted": null,
    "last_update_posted": "2015-08-21",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT01068782",
    "title": "Study of Multiple Doses and Regimens of XL184 (Cabozantinib) in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Astrocytic Tumors"
    ],
    "interventions": [
      "XL184"
    ],
    "primary_completion_date": "2011-05",
    "completion_date": "2013-10",
    "results_first_posted": null,
    "last_update_posted": "2014-07-30",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT03755791",
    "title": "Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatocellular Carcinoma"
    ],
    "interventions": [
      "Cabozantinib",
      "Cabozantinib",
      "Sorafenib",
      "Atezolizumab"
    ],
    "primary_completion_date": "2021-11-30",
    "completion_date": "2026-07-31",
    "results_first_posted": "2025-12-11",
    "last_update_posted": "2025-12-11",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT03845166",
    "title": "A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Neoplasm Malignant",
      "Renal Cell Carcinoma",
      "Hormone Receptor Positive Breast Carcinoma",
      "Metastatic Castration-resistant Prostate Cancer",
      "Colorectal Cancer"
    ],
    "interventions": [
      "XL092",
      "Atezolizumab",
      "Avelumab"
    ],
    "primary_completion_date": "2026-08-31",
    "completion_date": "2027-05-31",
    "results_first_posted": null,
    "last_update_posted": "2024-11-19",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "EXEL",
    "nct_id": "NCT00704730",
    "title": "Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Thyroid Cancer"
    ],
    "interventions": [
      "XL184",
      "Placebo"
    ],
    "primary_completion_date": "2011-10",
    "completion_date": "2020-09",
    "results_first_posted": "2014-09-09",
    "last_update_posted": "2021-04-20",
    "enrollment": null,
    "sponsor": "Exelixis",
    "collected_at": "2026-01-27",
    "search_term": "Exelixis"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT04059406",
    "title": "Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx)",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Beta Thalassemia Intermedia"
    ],
    "interventions": [
      "sapablursen"
    ],
    "primary_completion_date": "2023-03-28",
    "completion_date": "2023-03-28",
    "results_first_posted": "2025-02-18",
    "last_update_posted": "2025-02-18",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT02900027",
    "title": "Safety, Tolerability, PK, and Pharmacodynamics(PD) of IONIS APOCIII-LRx in Healthy Volunteers With Elevated Triglycerides",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Elevated Triglycerides (TG)"
    ],
    "interventions": [
      "APOC-III-L-Rx",
      "Placebo Comparator"
    ],
    "primary_completion_date": "2018-04-30",
    "completion_date": "2018-04-30",
    "results_first_posted": null,
    "last_update_posted": "2018-05-22",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT01041222",
    "title": "Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Familial Amyotrophic Lateral Sclerosis"
    ],
    "interventions": [
      "ISIS 333611"
    ],
    "primary_completion_date": "2011-12",
    "completion_date": "2012-01",
    "results_first_posted": null,
    "last_update_posted": "2012-04-13",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT02414594",
    "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS APO(a)-LRx in Healthy Volunteers With Elevated Lipoprotein(a)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Elevated Lipoprotein(a)"
    ],
    "interventions": [
      "IONIS-APO(a)-LRx",
      "Sterile Normal Saline (0.9% NaCl)"
    ],
    "primary_completion_date": "2016-02",
    "completion_date": "2016-02",
    "results_first_posted": null,
    "last_update_posted": "2018-12-05",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT05659901",
    "title": "Rocket Study: A Study to Characterize Biomarkers and Disease Progression in Participants With Pelizaeus-Merzbacher Disease",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Pelizaeus-Merzbacher Disease"
    ],
    "interventions": [],
    "primary_completion_date": "2029-03",
    "completion_date": "2029-03",
    "results_first_posted": null,
    "last_update_posted": "2026-01-16",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT04932512",
    "title": "A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ION224",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Steatohepatitis, Nonalcoholic"
    ],
    "interventions": [
      "ION224",
      "Placebo"
    ],
    "primary_completion_date": "2024-01-10",
    "completion_date": "2024-02-28",
    "results_first_posted": null,
    "last_update_posted": "2024-11-27",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT06153966",
    "title": "PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION717",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Prion Disease"
    ],
    "interventions": [
      "ION717",
      "Placebo"
    ],
    "primary_completion_date": "2025-07",
    "completion_date": "2027-07",
    "results_first_posted": null,
    "last_update_posted": "2024-12-27",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT01234038",
    "title": "Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-small Cell Lung Cancer"
    ],
    "interventions": [
      "ISIS EIF4E Rx",
      "ISIS EIF4E Rx",
      "ISIS EIF4E Rx",
      "Paclitaxel",
      "Carboplatin"
    ],
    "primary_completion_date": "2012-10",
    "completion_date": "2013-01",
    "results_first_posted": null,
    "last_update_posted": "2018-06-27",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT00734240",
    "title": "Safety and Tolerability of Single and Multiple Doses of ISIS 353512 in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Inflammatory Diseases"
    ],
    "interventions": [
      "ISIS 353512",
      "ISIS 353512",
      "ISIS 353512",
      "ISIS 353512",
      "ISIS 353512",
      "ISIS 353512",
      "ISIS 353512",
      "ISIS 353512",
      "ISIS 353512",
      "ISIS 353512",
      "ISIS 353512",
      "ISIS 353512",
      "ISIS 353512",
      "ISIS 353512",
      "ISIS 353512",
      "ISIS 353512"
    ],
    "primary_completion_date": "2010-02",
    "completion_date": "2010-03",
    "results_first_posted": null,
    "last_update_posted": "2010-07-29",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT04014335",
    "title": "A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA Nephropathy",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Primary IgA Nephropathy"
    ],
    "interventions": [
      "IONIS-FB-LRx"
    ],
    "primary_completion_date": "2024-02-08",
    "completion_date": "2024-04-11",
    "results_first_posted": null,
    "last_update_posted": "2025-01-23",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT04836182",
    "title": "A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection Fraction",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Heart Failure With Reduced Ejection Fraction"
    ],
    "interventions": [
      "IONIS-AGT-LRx",
      "Placebo"
    ],
    "primary_completion_date": "2022-10-19",
    "completion_date": "2023-01-11",
    "results_first_posted": null,
    "last_update_posted": "2023-09-11",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT00048295",
    "title": "Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Crohn's Disease"
    ],
    "interventions": [
      "Alicaforsen"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2022-08-15",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT01918865",
    "title": "Safety, Tolerability, and Efficacy of ISIS-PTP1BRx in Type 2 Diabetes",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 2 Diabetes Mellitus",
      "Obese"
    ],
    "interventions": [
      "ISIS-PTP1BRx",
      "Placebo",
      "daily OAD (metformin and/or sulfonylurea)"
    ],
    "primary_completion_date": "2014-10",
    "completion_date": "2015-02",
    "results_first_posted": null,
    "last_update_posted": "2015-03-03",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT06430385",
    "title": "ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome"
    ],
    "interventions": [
      "ION440",
      "Sham procedure"
    ],
    "primary_completion_date": "2027-09",
    "completion_date": "2030-04",
    "results_first_posted": null,
    "last_update_posted": "2025-12-05",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT03263507",
    "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Donidalorsen (IONIS-PKK-LRx) Administered Subcutaneously to Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "Placebo",
      "Donidalorsen"
    ],
    "primary_completion_date": "2018-10-09",
    "completion_date": "2018-10-09",
    "results_first_posted": null,
    "last_update_posted": "2022-08-04",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT00365781",
    "title": "Examination of Dermatologic Effects From Subcutaneous Injections of ISIS 113715",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 2 Diabetes Mellitus"
    ],
    "interventions": [
      "ISIS 113715"
    ],
    "primary_completion_date": null,
    "completion_date": "2006-09",
    "results_first_posted": null,
    "last_update_posted": "2007-10-17",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT04307381",
    "title": "An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary Angioedema",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hereditary Angioedema"
    ],
    "interventions": [
      "Donidalorsen"
    ],
    "primary_completion_date": "2025-01-24",
    "completion_date": "2025-01-24",
    "results_first_posted": null,
    "last_update_posted": "2025-03-24",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT04441788",
    "title": "A Study to Assess the Safety, Tolerability, and Efficacy of ION-827359 in Participants With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis (CB)",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Bronchitis",
      "Chronic Obstructive Pulmonary Disease"
    ],
    "interventions": [
      "ION-827359",
      "Placebo",
      "ION-827359"
    ],
    "primary_completion_date": "2021-04-27",
    "completion_date": "2021-08-09",
    "results_first_posted": "2022-12-20",
    "last_update_posted": "2022-12-20",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT04849741",
    "title": "A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Disease (AxD)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alexander Disease"
    ],
    "interventions": [
      "zilganersen",
      "Placebo"
    ],
    "primary_completion_date": "2025-08-22",
    "completion_date": "2029-09",
    "results_first_posted": null,
    "last_update_posted": "2025-11-28",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT01737398",
    "title": "Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "FAP",
      "Familial Amyloid Polyneuropathy",
      "TTR",
      "Transthyretin",
      "Amyloidosis"
    ],
    "interventions": [
      "Inotersen",
      "Placebo"
    ],
    "primary_completion_date": "2017-03-03",
    "completion_date": "2017-11-07",
    "results_first_posted": "2019-01-23",
    "last_update_posted": "2019-07-17",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT00330330",
    "title": "Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Who Have Not Received Prior Treatment",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 2 Diabetes Mellitus"
    ],
    "interventions": [
      "ISIS 113715"
    ],
    "primary_completion_date": null,
    "completion_date": "2006-08",
    "results_first_posted": null,
    "last_update_posted": "2008-02-06",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT00063414",
    "title": "ISIS 2302-CS22, A 6-Week, Active-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ulcerative Colitis"
    ],
    "interventions": [
      "Alicaforsen"
    ],
    "primary_completion_date": "2005-03-24",
    "completion_date": "2005-03-24",
    "results_first_posted": null,
    "last_update_posted": "2022-12-05",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT00836225",
    "title": "Safety, Tolerability and Activity Study of Multiple Doses of ISIS-SGLT2Rx in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 2 Diabetes Mellitus"
    ],
    "interventions": [
      "ISIS 388626"
    ],
    "primary_completion_date": "2011-10",
    "completion_date": "2012-01",
    "results_first_posted": null,
    "last_update_posted": "2012-02-03",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT04165486",
    "title": "Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple System Atrophy"
    ],
    "interventions": [
      "ION464",
      "Placebo"
    ],
    "primary_completion_date": "2027-09",
    "completion_date": "2027-09",
    "results_first_posted": null,
    "last_update_posted": "2025-12-08",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT02519036",
    "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington's Disease",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Huntington's Disease"
    ],
    "interventions": [
      "ISIS 443139 10 mg",
      "ISIS 443139 30 mg",
      "ISIS 443139 60 mg",
      "ISIS 443139 90 mg",
      "ISIS 443139 120 mg",
      "Placebo"
    ],
    "primary_completion_date": "2017-11-08",
    "completion_date": "2017-11-08",
    "results_first_posted": "2019-05-31",
    "last_update_posted": "2019-05-31",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT03101878",
    "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ionis AGT-LRx in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "Ionis AGT-LRx",
      "Placebo"
    ],
    "primary_completion_date": "2018-03-29",
    "completion_date": "2018-08-01",
    "results_first_posted": null,
    "last_update_posted": "2018-08-21",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT04136171",
    "title": "CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)"
    ],
    "interventions": [
      "Eplontersen",
      "Placebo"
    ],
    "primary_completion_date": "2026-04",
    "completion_date": "2026-08",
    "results_first_posted": null,
    "last_update_posted": "2025-08-08",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT03334214",
    "title": "Safety, Tolerability, and Pharmacodynamics of IONIS-DGAT2Rx in Adult Patients With Type 2 Diabetes",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatic Steatosis"
    ],
    "interventions": [
      "IONIS DGAT2Rx",
      "Placebo"
    ],
    "primary_completion_date": "2018-11-28",
    "completion_date": "2018-11-28",
    "results_first_posted": "2020-01-27",
    "last_update_posted": "2020-01-27",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT00002355",
    "title": "A Comparison of ISIS 2922 Used Immediately or Later in Patients With Cytomegalovirus (CMV) of the Eyes",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cytomegalovirus Retinitis",
      "HIV Infections"
    ],
    "interventions": [
      "Fomivirsen sodium"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2005-06-24",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT07298447",
    "title": "Donidalorsen Treatment in Children With Hereditary Angioedema",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hereditary Angioedema (HAE)"
    ],
    "interventions": [
      "Donidalorsen"
    ],
    "primary_completion_date": "2029-06",
    "completion_date": "2029-06",
    "results_first_posted": null,
    "last_update_posted": "2025-12-23",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT03446144",
    "title": "Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Geographic Atrophy",
      "Age Related Macular Degeneration"
    ],
    "interventions": [
      "IONIS-FB-Lrx",
      "Placebo (sterline saline 0.9%)"
    ],
    "primary_completion_date": "2018-10-10",
    "completion_date": "2018-10-10",
    "results_first_posted": null,
    "last_update_posted": "2019-08-13",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT01647308",
    "title": "Mechanistic Study of ISIS ISIS-APOCIIIRX in Type 2 Diabetes",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 2 Diabetes"
    ],
    "interventions": [
      "ISIS-APOCIIIRX",
      "Placebo"
    ],
    "primary_completion_date": "2014-01",
    "completion_date": "2014-03",
    "results_first_posted": null,
    "last_update_posted": "2022-01-18",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT00519727",
    "title": "Safety Study of ISIS 325568 in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 2 Diabetes Mellitus"
    ],
    "interventions": [
      "ISIS 325568"
    ],
    "primary_completion_date": "2008-04",
    "completion_date": "2008-06",
    "results_first_posted": null,
    "last_update_posted": "2008-08-19",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT00048321",
    "title": "ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthritis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rheumatoid Arthritis"
    ],
    "interventions": [
      "ISIS 104838"
    ],
    "primary_completion_date": "2003-02-01",
    "completion_date": "2003-02-01",
    "results_first_posted": null,
    "last_update_posted": "2022-12-05",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT02312011",
    "title": "A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Myotonic Dystrophy Type 1"
    ],
    "interventions": [
      "IONIS-DMPKRx",
      "Placebo"
    ],
    "primary_completion_date": "2016-07",
    "completion_date": "2016-08",
    "results_first_posted": null,
    "last_update_posted": "2022-12-06",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT05610280",
    "title": "A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypertriglyceridemia",
      "Cardiovascular Diseases",
      "Atherosclerosis"
    ],
    "interventions": [
      "Olezarsen",
      "Placebo"
    ],
    "primary_completion_date": "2024-08-08",
    "completion_date": "2025-06-09",
    "results_first_posted": null,
    "last_update_posted": "2025-07-11",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT03967249",
    "title": "Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acromegaly"
    ],
    "interventions": [
      "IONIS GHR-LRx",
      "Somatostatin Receptor Ligand (SRL)"
    ],
    "primary_completion_date": "2022-03-31",
    "completion_date": "2022-07-07",
    "results_first_posted": null,
    "last_update_posted": "2023-03-22",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT02211209",
    "title": "The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Familial Chylomicronemia Syndrome"
    ],
    "interventions": [
      "Volanesorsen",
      "Placebo"
    ],
    "primary_completion_date": "2016-12-19",
    "completion_date": "2017-03-28",
    "results_first_posted": "2022-04-13",
    "last_update_posted": "2022-04-13",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT03186989",
    "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Mild Alzheimer's Disease"
    ],
    "interventions": [
      "IONIS MAPTRx",
      "Placebo"
    ],
    "primary_completion_date": "2022-05-12",
    "completion_date": "2022-05-12",
    "results_first_posted": "2025-04-08",
    "last_update_posted": "2025-04-08",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT06014541",
    "title": "Observational Study to Characterize Biomarkers and Disease Progression in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome"
    ],
    "interventions": [],
    "primary_completion_date": "2026-06",
    "completion_date": "2026-06",
    "results_first_posted": null,
    "last_update_posted": "2025-06-22",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT05667493",
    "title": "An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)"
    ],
    "interventions": [
      "Eplontersen"
    ],
    "primary_completion_date": "2029-08",
    "completion_date": "2029-08",
    "results_first_posted": null,
    "last_update_posted": "2025-12-12",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT06415448",
    "title": "Donidalorsen Expanded Access Program for Patients With Hereditary Angioedema",
    "status": "AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Hereditary Angioedema"
    ],
    "interventions": [
      "Donidalorsen"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2025-07-11",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT02553889",
    "title": "A Study of Safety, PK, & PD of ISIS 416858 Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "End-stage Renal Disease (ESRD)"
    ],
    "interventions": [
      "ISIS 416858",
      "Placebo"
    ],
    "primary_completion_date": "2016-11",
    "completion_date": "2016-11",
    "results_first_posted": null,
    "last_update_posted": "2016-12-13",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT01968265",
    "title": "Safety, Tolerability and Efficacy of ISIS-GCCRRx in Type 2 Diabetes",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 2 Diabetes Mellitus"
    ],
    "interventions": [
      "ISIS-GCCRRx",
      "Placebo"
    ],
    "primary_completion_date": "2015-01",
    "completion_date": "2015-05",
    "results_first_posted": null,
    "last_update_posted": "2015-05-13",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT05314439",
    "title": "A Study to Assess the Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of ION904 in Participants With Uncontrolled Hypertension",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypertension"
    ],
    "interventions": [
      "ION904",
      "Placebo"
    ],
    "primary_completion_date": "2023-01-31",
    "completion_date": "2023-02-15",
    "results_first_posted": null,
    "last_update_posted": "2023-12-22",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT02175004",
    "title": "Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "FAP",
      "Familial Amyloid Polyneuropathy",
      "TTR",
      "Transthyretin",
      "Amyloidosis"
    ],
    "interventions": [
      "Inotersen"
    ],
    "primary_completion_date": "2020-09-11",
    "completion_date": "2021-01-07",
    "results_first_posted": "2023-02-09",
    "last_update_posted": "2023-11-18",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT03582462",
    "title": "A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of IONIS FXI-LRx in up to 84 Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants"
    ],
    "interventions": [
      "IONIS FXI-LRx",
      "Placebo"
    ],
    "primary_completion_date": "2019-04-26",
    "completion_date": "2019-04-26",
    "results_first_posted": null,
    "last_update_posted": "2022-01-18",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT03815825",
    "title": "GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Macular Degeneration",
      "Geographic Atrophy"
    ],
    "interventions": [
      "IONIS-FB-LRx",
      "Placebo"
    ],
    "primary_completion_date": "2024-04-18",
    "completion_date": "2024-06-12",
    "results_first_posted": null,
    "last_update_posted": "2025-03-07",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT05143957",
    "title": "A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Phlebotomy Dependent Polycythemia Vera"
    ],
    "interventions": [
      "sapablursen"
    ],
    "primary_completion_date": "2025-06-26",
    "completion_date": "2026-06",
    "results_first_posted": null,
    "last_update_posted": "2026-01-16",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT00002356",
    "title": "The Safety and Effectiveness of ISIS 2922 in Patients With AIDS Who Have Cytomegalovirus (CMV) of the Eyes",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cytomegalovirus Retinitis",
      "HIV Infections"
    ],
    "interventions": [
      "Fomivirsen sodium"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2005-06-24",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT03358030",
    "title": "A Study of ISIS 416858 Administered Subcutaneously to Participants With End-Stage Renal Disease (ESRD) on Hemodialysis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "End-stage Renal Disease (ESRD)"
    ],
    "interventions": [
      "ISIS 416858",
      "Placebo"
    ],
    "primary_completion_date": "2019-07-10",
    "completion_date": "2019-07-10",
    "results_first_posted": "2023-01-20",
    "last_update_posted": "2023-01-20",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT04302064",
    "title": "A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending and Multiple Doses of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Healthy Japanese Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants"
    ],
    "interventions": [
      "Eplontersen",
      "Placebo"
    ],
    "primary_completion_date": "2020-09-10",
    "completion_date": "2020-09-10",
    "results_first_posted": null,
    "last_update_posted": "2022-03-31",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT03647228",
    "title": "A Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of IONIS-ENaCRx in Healthy Volunteers and Patients With Cystic Fibrosis",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Subjects",
      "Cystic Fibrosis"
    ],
    "interventions": [
      "IONIS-ENaCRx",
      "Placebo"
    ],
    "primary_completion_date": "2020-10-13",
    "completion_date": "2020-10-13",
    "results_first_posted": null,
    "last_update_posted": "2021-02-04",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT05071300",
    "title": "A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hereditary Transthyretin-Mediated Amyloid Polyneuropathy"
    ],
    "interventions": [
      "Eplontersen"
    ],
    "primary_completion_date": "2029-08",
    "completion_date": "2029-08",
    "results_first_posted": null,
    "last_update_posted": "2025-12-04",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT01529424",
    "title": "Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypertriglyceridemia"
    ],
    "interventions": [
      "ISIS apoC-III Rx",
      "ISIS apoC-III Rx",
      "ISIS apoC-III Rx",
      "Placebo",
      "Placebo",
      "Placebo"
    ],
    "primary_completion_date": "2014-01",
    "completion_date": "2014-01",
    "results_first_posted": null,
    "last_update_posted": "2022-01-27",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT05681351",
    "title": "CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Severe Hypertriglyceridemia"
    ],
    "interventions": [
      "Olezarsen"
    ],
    "primary_completion_date": "2027-03",
    "completion_date": "2027-03",
    "results_first_posted": null,
    "last_update_posted": "2025-12-01",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT06150716",
    "title": "Orbit Study: A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Intrathecally Administered ION356 in Participants With Pelizaeus Merzbacher Disease (PMD)",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pelizaeus-Merzbacher Disease"
    ],
    "interventions": [
      "ION356"
    ],
    "primary_completion_date": "2028-06",
    "completion_date": "2028-06",
    "results_first_posted": null,
    "last_update_posted": "2025-12-12",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT05130450",
    "title": "A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Familial Chylomicronemia Syndrome"
    ],
    "interventions": [
      "Olezarsen"
    ],
    "primary_completion_date": "2028-02",
    "completion_date": "2028-02",
    "results_first_posted": null,
    "last_update_posted": "2025-12-12",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT00002187",
    "title": "A Study of ISIS 2922 in the Treatment of Advanced Cytomegalovirus Retinitis",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cytomegalovirus Retinitis",
      "HIV Infections"
    ],
    "interventions": [
      "Fomivirsen sodium"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2005-06-24",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT02476019",
    "title": "A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obese Patients",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Obesity"
    ],
    "interventions": [
      "ISIS-FGFR4RX",
      "Placebo"
    ],
    "primary_completion_date": "2016-07",
    "completion_date": "2016-09",
    "results_first_posted": null,
    "last_update_posted": "2018-06-25",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT00327626",
    "title": "Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 2 Diabetes Mellitus"
    ],
    "interventions": [
      "ISIS 113715"
    ],
    "primary_completion_date": "2007-02-01",
    "completion_date": "2007-03-01",
    "results_first_posted": null,
    "last_update_posted": "2022-12-05",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT06073587",
    "title": "The CARDIO-TTRansform Scintigraphy Sub-study",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)"
    ],
    "interventions": [
      "Scintigraphy scan"
    ],
    "primary_completion_date": "2026-03",
    "completion_date": "2026-03",
    "results_first_posted": null,
    "last_update_posted": "2025-11-28",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT04030598",
    "title": "A Study to Assess the Clinical Efficacy of Donidalorsen (Also Known as IONIS-PKK-LRx and ISIS 721744) in Participants With Hereditary Angioedema",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hereditary Angioedema"
    ],
    "interventions": [
      "Donidalorsen",
      "Placebo"
    ],
    "primary_completion_date": "2021-01-04",
    "completion_date": "2021-03-01",
    "results_first_posted": "2022-09-28",
    "last_update_posted": "2023-04-03",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT03400098",
    "title": "ATTR Expanded Access Program (EAP) by Ionis",
    "status": "APPROVED_FOR_MARKETING",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Amyloidosis, Hereditary"
    ],
    "interventions": [
      "Inotersen"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2019-08-05",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT05392114",
    "title": "A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hereditary Angioedema"
    ],
    "interventions": [
      "Donidalorsen"
    ],
    "primary_completion_date": "2026-12",
    "completion_date": "2027-03",
    "results_first_posted": null,
    "last_update_posted": "2025-12-12",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT02300233",
    "title": "The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypertriglyceridemia"
    ],
    "interventions": [
      "Volanesorsen",
      "Placebo"
    ],
    "primary_completion_date": "2016-07-27",
    "completion_date": "2017-01-24",
    "results_first_posted": "2022-04-13",
    "last_update_posted": "2022-04-13",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT04714320",
    "title": "A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood Pressure",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypertension"
    ],
    "interventions": [
      "Placebo",
      "IONIS-AGT-LRx"
    ],
    "primary_completion_date": "2022-06-29",
    "completion_date": "2022-10-03",
    "results_first_posted": "2025-02-18",
    "last_update_posted": "2025-02-18",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT00002156",
    "title": "A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR )",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cytomegalovirus Retinitis",
      "HIV Infections"
    ],
    "interventions": [
      "Fomivirsen sodium",
      "Ganciclovir"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2005-06-24",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT05355402",
    "title": "A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypertriglyceridemia",
      "Atherosclerotic Cardiovascular Disease",
      "Severe Hypertriglyceridemia"
    ],
    "interventions": [
      "Olezarsen",
      "Placebo"
    ],
    "primary_completion_date": "2023-03-22",
    "completion_date": "2023-12-21",
    "results_first_posted": null,
    "last_update_posted": "2024-11-27",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT06073574",
    "title": "CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)"
    ],
    "interventions": [
      "Cardiac MRI"
    ],
    "primary_completion_date": "2026-03",
    "completion_date": "2026-04",
    "results_first_posted": null,
    "last_update_posted": "2025-11-28",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT01713361",
    "title": "Active Comparator-Controlled Study to Assess Safety and Efficacy of ISIS-FXIRx in Total Knee Arthroplasty",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Venous Thromboembolism"
    ],
    "interventions": [
      "ISIS-FXIRx Dose #2",
      "ISIS-FXIRx Dose #3",
      "Enoxaparin"
    ],
    "primary_completion_date": "2014-05",
    "completion_date": "2014-08",
    "results_first_posted": null,
    "last_update_posted": "2014-08-27",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT00062816",
    "title": "Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic Hepatitis C (HCV) Patients Not Responding Adequately to the Two Drugs",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatitis C, Chronic"
    ],
    "interventions": [
      "ISIS 14803, peginterferon alfa, ribavirin"
    ],
    "primary_completion_date": "2004-01",
    "completion_date": "2004-01",
    "results_first_posted": null,
    "last_update_posted": "2022-12-05",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT03976349",
    "title": "A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Parkinson's Disease"
    ],
    "interventions": [
      "BIIB094",
      "Placebo"
    ],
    "primary_completion_date": "2024-08-12",
    "completion_date": "2024-08-12",
    "results_first_posted": null,
    "last_update_posted": "2025-09-23",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT05127226",
    "title": "HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Angelman Syndrome"
    ],
    "interventions": [
      "ION582"
    ],
    "primary_completion_date": "2029-03",
    "completion_date": "2029-03",
    "results_first_posted": null,
    "last_update_posted": "2025-11-14",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT03876522",
    "title": "Natural History and Functional Status Study of Patients With Lafora Disease",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Lafora Disease"
    ],
    "interventions": [],
    "primary_completion_date": "2022-04-01",
    "completion_date": "2022-04-01",
    "results_first_posted": null,
    "last_update_posted": "2022-09-28",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT01710852",
    "title": "Antiarrhythmic and Symptomatic Effect of ISIS CRP Rx Targeting CRP in Paroxysmal Atrial Fibrillation",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Paroxysmal Atrial Fibrillation"
    ],
    "interventions": [
      "ISIS CRP Rx",
      "Placebo"
    ],
    "primary_completion_date": "2014-04",
    "completion_date": "2014-04",
    "results_first_posted": null,
    "last_update_posted": "2015-08-26",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT03165864",
    "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered Subcutaneously to Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Thalassemia"
    ],
    "interventions": [
      "IONIS TMPRSS6-Lrx",
      "Placebo"
    ],
    "primary_completion_date": "2018-09-25",
    "completion_date": "2018-09-25",
    "results_first_posted": null,
    "last_update_posted": "2019-01-22",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT04522180",
    "title": "A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients With Acromegaly",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acromegaly"
    ],
    "interventions": [
      "GHR-LRX"
    ],
    "primary_completion_date": "2022-07-15",
    "completion_date": "2023-05-04",
    "results_first_posted": "2024-10-03",
    "last_update_posted": "2024-10-03",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT00330200",
    "title": "Effects of ISIS 113715 on Insulin Sensitivity, Glucose, and Lipid Metabolism and Energy Expenditure in Type 2 Diabetics",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 2 Diabetes Mellitus"
    ],
    "interventions": [
      "ISIS 113715"
    ],
    "primary_completion_date": "2007-03-01",
    "completion_date": "2007-03-01",
    "results_first_posted": null,
    "last_update_posted": "2022-12-05",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT02160899",
    "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS-APO(a)Rx in Participants With High Lipoprotein(a)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Elevated Lipoprotein(a)"
    ],
    "interventions": [
      "ISIS-APO(a)Rx",
      "Placebo"
    ],
    "primary_completion_date": "2015-11",
    "completion_date": "2015-11",
    "results_first_posted": "2019-12-20",
    "last_update_posted": "2019-12-20",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT05337878",
    "title": "A Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pelacarsen (ISIS 681257) in Healthy Japanese Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants"
    ],
    "interventions": [
      "Placebo",
      "Pelacarsen"
    ],
    "primary_completion_date": "2019-12-18",
    "completion_date": "2019-12-18",
    "results_first_posted": null,
    "last_update_posted": "2022-04-20",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT04398485",
    "title": "A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsed Multiple Myeloma",
      "Refractory Multiple Myeloma"
    ],
    "interventions": [
      "ION251"
    ],
    "primary_completion_date": "2024-09-30",
    "completion_date": "2024-09-30",
    "results_first_posted": null,
    "last_update_posted": "2024-10-31",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT01414101",
    "title": "Safety, Tolerability, and Pharmacodynamic Study of ISIS CRP Rx in Rheumatoid Arthritis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rheumatoid Arthritis"
    ],
    "interventions": [
      "ISIS CRP Rx or Placebo"
    ],
    "primary_completion_date": "2013-05",
    "completion_date": "2013-05",
    "results_first_posted": null,
    "last_update_posted": "2013-05-17",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT00455598",
    "title": "Placebo Controlled, Dose Escalation Study in Subjects With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 2 Diabetes Mellitus"
    ],
    "interventions": [
      "ISIS 113715"
    ],
    "primary_completion_date": "2009-03",
    "completion_date": "2009-05",
    "results_first_posted": null,
    "last_update_posted": "2009-08-28",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT03728634",
    "title": "Evaluate the Safety and Tolerability, as Well as the Pharmacokinetic and Pharmacodynamic Profiles of Single and Multiple Doses of Eplontersen Administered Subcutaneously to Healthy Volunteers and Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR ).",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers",
      "hATTR Amyloidosis"
    ],
    "interventions": [
      "ION-682884",
      "Placebo",
      "Vitamin A"
    ],
    "primary_completion_date": "2020-02-20",
    "completion_date": "2020-02-20",
    "results_first_posted": "2022-12-19",
    "last_update_posted": "2022-12-19",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT04083222",
    "title": "A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypertension"
    ],
    "interventions": [
      "Placebo",
      "ISIS 757456"
    ],
    "primary_completion_date": "2020-07-20",
    "completion_date": "2020-07-20",
    "results_first_posted": "2023-01-18",
    "last_update_posted": "2023-01-18",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT05579860",
    "title": "A Study Comparing Two Subcutaneous Formulations: Vial and Autoinjector (AI) With Olezarsen, at Two Dose Levels, in Healthy Adult Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants"
    ],
    "interventions": [
      "Olezarsen"
    ],
    "primary_completion_date": "2023-05-22",
    "completion_date": "2023-05-22",
    "results_first_posted": null,
    "last_update_posted": "2024-05-10",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT06914609",
    "title": "REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Angelman Syndrome"
    ],
    "interventions": [
      "ION582",
      "Placebo"
    ],
    "primary_completion_date": "2027-08",
    "completion_date": "2030-04",
    "results_first_posted": null,
    "last_update_posted": "2025-12-22",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT03548415",
    "title": "Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acromegaly"
    ],
    "interventions": [
      "IONIS-GHR-LRx",
      "Placebo"
    ],
    "primary_completion_date": "2021-02-18",
    "completion_date": "2021-04-02",
    "results_first_posted": "2022-11-14",
    "last_update_posted": "2022-11-14",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT06360237",
    "title": "Olezarsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)",
    "status": "APPROVED_FOR_MARKETING",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Familial Chylomicronemia Syndrome"
    ],
    "interventions": [
      "Olezarsen"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2024-12-27",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT06673069",
    "title": "Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alzheimer Disease",
      "Down Syndrome"
    ],
    "interventions": [
      "ION269"
    ],
    "primary_completion_date": "2027-02",
    "completion_date": "2027-03",
    "results_first_posted": null,
    "last_update_posted": "2025-09-09",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT04768972",
    "title": "FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Amyotrophic Lateral Sclerosis"
    ],
    "interventions": [
      "ION363",
      "Placebo"
    ],
    "primary_completion_date": "2026-06",
    "completion_date": "2028-03",
    "results_first_posted": null,
    "last_update_posted": "2026-01-27",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT04568434",
    "title": "A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Familial Chylomicronemia Syndrome"
    ],
    "interventions": [
      "Olezarsen",
      "Placebo"
    ],
    "primary_completion_date": "2023-07-14",
    "completion_date": "2023-10-17",
    "results_first_posted": "2025-03-06",
    "last_update_posted": "2025-03-06",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT00017407",
    "title": "Carboplatin and Paclitaxel With or Without ISIS 3521 in Treating Patients With Non-Small Cell Lung Cancer",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lung Cancer"
    ],
    "interventions": [
      "ISIS 3521",
      "carboplatin",
      "paclitaxel"
    ],
    "primary_completion_date": "2002-09-09",
    "completion_date": "2002-09-09",
    "results_first_posted": null,
    "last_update_posted": "2022-12-05",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT02824003",
    "title": "Study to Evaluate the Effect of ISIS GCGRRx on Hepatic Lipid and Glycogen Content in Type 2 Diabetes",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 2 Diabetes"
    ],
    "interventions": [
      "ISIS-GCGRRx",
      "Placebo"
    ],
    "primary_completion_date": "2016-12-15",
    "completion_date": "2017-05-22",
    "results_first_posted": null,
    "last_update_posted": "2018-05-08",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT01885260",
    "title": "Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 2 Diabetes Mellitus"
    ],
    "interventions": [
      "ISIS-GCGRRx - Dose Level 1",
      "ISIS-GCGRRx - Dose Level 2",
      "Placebo"
    ],
    "primary_completion_date": "2014-05",
    "completion_date": "2014-11",
    "results_first_posted": null,
    "last_update_posted": "2016-07-04",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT04659096",
    "title": "A Study of ION537 in Patients With Molecularly Selected Advanced Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumors"
    ],
    "interventions": [
      "ION537"
    ],
    "primary_completion_date": "2022-10-19",
    "completion_date": "2022-10-19",
    "results_first_posted": null,
    "last_update_posted": "2022-12-21",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT05139810",
    "title": "OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hereditary Angioedema"
    ],
    "interventions": [
      "Donidalorsen",
      "Placebo"
    ],
    "primary_completion_date": "2023-11-09",
    "completion_date": "2023-11-09",
    "results_first_posted": "2025-03-06",
    "last_update_posted": "2025-03-06",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT05185843",
    "title": "A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Familial Chylomicronemia Syndrome"
    ],
    "interventions": [
      "Olezarsen"
    ],
    "primary_completion_date": "2027-06",
    "completion_date": "2027-06",
    "results_first_posted": null,
    "last_update_posted": "2025-12-12",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "IONS",
    "nct_id": "NCT02709850",
    "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS ANGPTL3-LRx in Healthy Volunteers With Elevated Triglycerides and Participants With Familial Hypercholesterolemia",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypertriglyceridemia",
      "Familial Hypercholesterolemia"
    ],
    "interventions": [
      "IONIS ANGPTL3-LRx",
      "Placebo"
    ],
    "primary_completion_date": "2017-04-12",
    "completion_date": "2017-06-26",
    "results_first_posted": null,
    "last_update_posted": "2020-11-19",
    "enrollment": null,
    "sponsor": "Ionis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Ionis Pharmaceuticals"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT01417091",
    "title": "Safety, Pharmacokinetics and Pharmacodynamics of BPS804 in Osteogenesis Imperfecta",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Osteogenesis Imperfecta"
    ],
    "interventions": [
      "BPS804"
    ],
    "primary_completion_date": "2012-12",
    "completion_date": "2012-12",
    "results_first_posted": null,
    "last_update_posted": "2021-05-11",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT03651505",
    "title": "X-linked Hypophosphatemia Disease Monitoring Program",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "X-linked Hypophosphatemia",
      "Hypophosphatemic Rickets"
    ],
    "interventions": [
      "No intervention"
    ],
    "primary_completion_date": "2032-12",
    "completion_date": "2032-12",
    "results_first_posted": null,
    "last_update_posted": "2025-10-31",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT06636071",
    "title": "Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imperfecta",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Osteogenesis Imperfecta"
    ],
    "interventions": [
      "setrusumab"
    ],
    "primary_completion_date": "2027-01",
    "completion_date": "2028-01",
    "results_first_posted": null,
    "last_update_posted": "2025-12-15",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT02377921",
    "title": "Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sialic Acid in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hereditary Inclusion Body Myopathy",
      "Distal Myopathy With Rimmed Vacuoles",
      "Distal Myopathy, Nonaka Type",
      "GNE Myopathy"
    ],
    "interventions": [
      "aceneuramic acid extended-release (Ace-ER)",
      "Placebo"
    ],
    "primary_completion_date": "2017-06-09",
    "completion_date": "2017-06-09",
    "results_first_posted": "2018-07-09",
    "last_update_posted": "2019-06-27",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT02931682",
    "title": "Observational Study of Males With Creatine Transporter Deficiency",
    "status": "TERMINATED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Creatine Deficiency, X-linked"
    ],
    "interventions": [],
    "primary_completion_date": "2022-10-24",
    "completion_date": "2022-10-24",
    "results_first_posted": null,
    "last_update_posted": "2022-11-14",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT05933200",
    "title": "A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAOD",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)"
    ],
    "interventions": [
      "Triheptanoin",
      "MCT Oil"
    ],
    "primary_completion_date": "2027-08",
    "completion_date": "2027-08",
    "results_first_posted": null,
    "last_update_posted": "2026-01-13",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT02599961",
    "title": "Study to Assess the Long Term Safety and Efficacy of UX007 in Participants With Glucose Type 1 Deficiency Syndrome (Glut1 DS)",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Glucose Transporter Type 1 Deficiency Syndrome"
    ],
    "interventions": [
      "UX007"
    ],
    "primary_completion_date": "2019-10-22",
    "completion_date": "2019-10-22",
    "results_first_posted": "2020-04-30",
    "last_update_posted": "2020-06-11",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT04088734",
    "title": "Gene Transfer Study of ABO-102 in Patients With Middle and Advanced Phases of MPS IIIA Disease",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "MPS IIIA",
      "Sanfilippo Syndrome",
      "Sanfilippo A",
      "Mucopolysaccharidosis III"
    ],
    "interventions": [
      "ABO-102"
    ],
    "primary_completion_date": "2022-03-10",
    "completion_date": "2022-03-10",
    "results_first_posted": "2023-07-25",
    "last_update_posted": "2023-07-25",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT06636383",
    "title": "Glycogen Storage Disease Type Ia (GSDIa) Disease Monitoring Program",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Glycogen Storage Disease Type Ia"
    ],
    "interventions": [
      "No Intervention"
    ],
    "primary_completion_date": "2036-12",
    "completion_date": "2036-12",
    "results_first_posted": null,
    "last_update_posted": "2026-01-07",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT03773770",
    "title": "Expanded Access to Triheptanoin",
    "status": "AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Long Chain Fatty Acid Oxidation Disorders"
    ],
    "interventions": [
      "Triheptanoin"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2026-01-12",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT04812106",
    "title": "Long-Chain Fatty Acid Oxidation Disorders Online Disease Monitoring Program",
    "status": "TERMINATED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)"
    ],
    "interventions": [
      "No Intervention"
    ],
    "primary_completion_date": "2022-10-27",
    "completion_date": "2022-10-27",
    "results_first_posted": null,
    "last_update_posted": "2022-11-18",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT02731690",
    "title": "A Study to Evaluate the Safety of Aceneuramic Acid Extended Release (Ace-ER; UX001) Tablets in Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE) Myopathy (GNEM) (Also Known as Hereditary Inclusion Body Myopathy [HIBM]) Patients With Severe Ambulatory Impairment",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hereditary Inclusion Body Myopathy",
      "Distal Myopathy With Rimmed Vacuoles",
      "Distal Myopathy, Nonaka Type",
      "GNE Myopathy",
      "Quadriceps Sparing Myopathy",
      "Inclusion Body Myopathy 2"
    ],
    "interventions": [
      "Aceneuramic Acid Extended-Release"
    ],
    "primary_completion_date": "2018-01-10",
    "completion_date": "2018-01-10",
    "results_first_posted": "2019-02-19",
    "last_update_posted": "2019-02-19",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT01993186",
    "title": "Phase 2 Study of Triheptanoin (UX007) for the Treatment of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)"
    ],
    "interventions": [
      "UX007",
      "Placebo"
    ],
    "primary_completion_date": "2017-09-20",
    "completion_date": "2017-09-20",
    "results_first_posted": "2020-05-29",
    "last_update_posted": "2020-06-19",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT04884815",
    "title": "A Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson Disease",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Wilson Disease"
    ],
    "interventions": [
      "UX701",
      "Standard of Care (SOC)"
    ],
    "primary_completion_date": "2029-03",
    "completion_date": "2034-03",
    "results_first_posted": null,
    "last_update_posted": "2025-12-12",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT04717453",
    "title": "Study to Characterize Rate of Ureagenesis in Patients With Ornithine Transcarbamylase (OTC) Deficiency",
    "status": "TERMINATED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Ornithine Transcarbamylase Deficiency"
    ],
    "interventions": [
      "No Intervention"
    ],
    "primary_completion_date": "2021-12-15",
    "completion_date": "2021-12-15",
    "results_first_posted": null,
    "last_update_posted": "2022-02-18",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT02960217",
    "title": "Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)"
    ],
    "interventions": [
      "UX007",
      "Placebo"
    ],
    "primary_completion_date": "2019-10-09",
    "completion_date": "2019-10-09",
    "results_first_posted": "2020-04-24",
    "last_update_posted": "2020-06-16",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT04574830",
    "title": "Study to Evaluate Biomarkers and Clinical Manifestations in Individuals With Glycogen Storage Disease Type III (GSD III)",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Glycogen Storage Disease Type III"
    ],
    "interventions": [
      "No Intervention"
    ],
    "primary_completion_date": "2022-06-30",
    "completion_date": "2022-06-30",
    "results_first_posted": null,
    "last_update_posted": "2022-09-13",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT02736188",
    "title": "Study to Evaluate the Safety and Efficacy of Aceneuramic Acid Extended-Release (Ace-ER) Tablets in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hereditary Inclusion Body Myopathy",
      "Distal Myopathy With Rimmed Vacuoles",
      "Distal Myopathy, Nonaka Type",
      "GNE Myopathy",
      "Quadriceps Sparing Myopathy"
    ],
    "interventions": [
      "Aceneuramic Acid Extended-Release Tablets"
    ],
    "primary_completion_date": "2018-01-10",
    "completion_date": "2018-01-10",
    "results_first_posted": "2019-02-19",
    "last_update_posted": "2023-03-24",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT03604835",
    "title": "Mucopolysaccharidosis VII Disease Monitoring Program",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Mucopolysaccharidosis VII",
      "MPS VII",
      "MPS 7",
      "Sly Syndrome"
    ],
    "interventions": [
      "No Intervention"
    ],
    "primary_completion_date": "2033-05",
    "completion_date": "2033-05",
    "results_first_posted": null,
    "last_update_posted": "2026-01-12",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT06415344",
    "title": "Long-term Extension of GTX-102 in Angelman Syndrome",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Angelman Syndrome"
    ],
    "interventions": [
      "GTX-102"
    ],
    "primary_completion_date": "2029-02",
    "completion_date": "2029-02",
    "results_first_posted": null,
    "last_update_posted": "2026-01-07",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT04360265",
    "title": "Follow-up Study of AAV-Mediated Gene Transfer (UX111; Previously Known as ABO-102) for MPS Type IIIA",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Mucopolysaccharidosis IIIA",
      "MPS IIIA",
      "Sanfilippo Syndrome",
      "Sanfilippo A"
    ],
    "interventions": [
      "No Investigational Product",
      "Adjuvant Immunomodulatory (IM) Therapy"
    ],
    "primary_completion_date": "2027-08",
    "completion_date": "2027-08",
    "results_first_posted": null,
    "last_update_posted": "2026-01-21",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT01784679",
    "title": "GNE-Myopathy Disease Monitoring Program (GNEM-DMP): A Registry and Prospective Observational Natural History Study to Assess GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Hereditary Inclusion Body Myopathy",
      "GNE Myopathy",
      "Nonaka Disease",
      "Quadriceps Sparing Myopathy (QSM)",
      "Distal Myopathy With Rimmed Vacuoles (DMRV)"
    ],
    "interventions": [],
    "primary_completion_date": "2017-11-30",
    "completion_date": "2017-11-30",
    "results_first_posted": null,
    "last_update_posted": "2018-04-27",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT04990388",
    "title": "Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III)",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Glycogen Storage Disease Type III"
    ],
    "interventions": [
      "UX053",
      "Placebo",
      "Antipyretic",
      "H2 Blocker",
      "H1 Blocker"
    ],
    "primary_completion_date": "2023-03-20",
    "completion_date": "2023-03-20",
    "results_first_posted": "2024-04-16",
    "last_update_posted": "2024-04-16",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT02716246",
    "title": "Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "MPS IIIA",
      "Sanfilippo Syndrome",
      "Sanfilippo A",
      "Mucopolysaccharidosis III"
    ],
    "interventions": [
      "UX111",
      "Prophylactic Immunomodulatory (IM) Therapy",
      "Optimized Prophylactic IM Therapy",
      "Adjuvant IM Therapy"
    ],
    "primary_completion_date": "2027-07",
    "completion_date": "2027-07",
    "results_first_posted": null,
    "last_update_posted": "2025-12-17",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT01856218",
    "title": "An Open-Label Phase 1/2 Study to Assess the Safety, Efficacy and Dose of Study Drug UX003 Recombinant Human Beta-glucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Mucopolysaccharidosis Type 7"
    ],
    "interventions": [
      "UX003"
    ],
    "primary_completion_date": "2016-07",
    "completion_date": "2016-07",
    "results_first_posted": "2018-01-05",
    "last_update_posted": "2019-01-04",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT04259281",
    "title": "A Study of the Safety and Tolerability of GTX-102 in Children With Angelman Syndrome",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Angelman Syndrome"
    ],
    "interventions": [
      "GTX-102"
    ],
    "primary_completion_date": "2025-01-08",
    "completion_date": "2025-01-08",
    "results_first_posted": null,
    "last_update_posted": "2026-01-09",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT05345171",
    "title": "Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "OTC Deficiency"
    ],
    "interventions": [
      "DTX301",
      "Placebo",
      "Oral Corticosteroids",
      "Placebo for oral corticosteroids",
      "Sodium Acetate"
    ],
    "primary_completion_date": "2025-02-19",
    "completion_date": "2031-03",
    "results_first_posted": null,
    "last_update_posted": "2025-12-15",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT05196165",
    "title": "Clinical Survey Study to Assess Physical Function and the Incidence of Hypoglycemia in Participants With Glycogen Storage Disease Type III",
    "status": "TERMINATED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Glycogen Storage Disease Type III"
    ],
    "interventions": [
      "No Intervention"
    ],
    "primary_completion_date": "2023-03-02",
    "completion_date": "2023-03-02",
    "results_first_posted": null,
    "last_update_posted": "2023-09-28",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT02618915",
    "title": "Safety and Dose Finding Study of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hemophilia B"
    ],
    "interventions": [
      "DTX101"
    ],
    "primary_completion_date": "2017-10-18",
    "completion_date": "2017-10-18",
    "results_first_posted": "2018-11-14",
    "last_update_posted": "2018-11-14",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT03775174",
    "title": "Expanded Access to Mepsevii",
    "status": "AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "MPS VII",
      "Mucopolysaccharidosis VII",
      "Sly Syndrome"
    ],
    "interventions": [
      "Mepsevii"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2026-01-12",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT06617429",
    "title": "Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Angelman Syndrome"
    ],
    "interventions": [
      "GTX-102",
      "Sham-LP"
    ],
    "primary_completion_date": "2026-07",
    "completion_date": "2027-11",
    "results_first_posted": null,
    "last_update_posted": "2025-11-06",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT04708015",
    "title": "Retrospective Study of Glucose Monitoring for Glycemic Control in Patients With GSDIa",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Glycogen Storage Disease Type IA"
    ],
    "interventions": [
      "No Intervention"
    ],
    "primary_completion_date": "2022-03-04",
    "completion_date": "2022-03-04",
    "results_first_posted": null,
    "last_update_posted": "2024-05-29",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT04632953",
    "title": "Long-Chain Fatty Acid Oxidation Disorders In-Clinic Disease Monitoring Program",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)"
    ],
    "interventions": [
      "No Intervention"
    ],
    "primary_completion_date": "2035-12",
    "completion_date": "2035-12",
    "results_first_posted": null,
    "last_update_posted": "2025-12-02",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT01517880",
    "title": "A Phase 2 Study to Evaluate the Dose and Pharmacodynamic Efficacy of Sialic Acid-Extended Release (SA-ER) Tablets in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "GNE Myopathy",
      "Hereditary Inclusion Body Myopathy"
    ],
    "interventions": [
      "Sialic Acid Extended Release (SA-ER)",
      "Placebo"
    ],
    "primary_completion_date": "2013-11",
    "completion_date": "2013-11",
    "results_first_posted": null,
    "last_update_posted": "2016-06-16",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT03118570",
    "title": "A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Osteogenesis Imperfecta, Type I",
      "Osteogenesis Imperfecta Type III",
      "Osteogenesis Imperfecta Type IV"
    ],
    "interventions": [
      "setrusumab",
      "Calcium",
      "Vitamin D",
      "zoledronic acid (optional)"
    ],
    "primary_completion_date": "2019-10-01",
    "completion_date": "2020-11-12",
    "results_first_posted": "2022-03-02",
    "last_update_posted": "2023-07-05",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT02230566",
    "title": "A Phase 3 Study of UX003 Recombinant Human Betaglucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "MPS 7",
      "Sly Syndrome",
      "Mucopolysaccharidosis",
      "MPS VII"
    ],
    "interventions": [
      "UX003",
      "Placebo"
    ],
    "primary_completion_date": "2016-05",
    "completion_date": "2016-05",
    "results_first_posted": "2018-02-19",
    "last_update_posted": "2020-07-30",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT01886378",
    "title": "A Study of UX007 (Triheptanoin) in Participants With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)",
      "Carnitine Palmitoyltransferase (CPT II) Deficiency",
      "Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency",
      "Longchain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency",
      "Trifunctional Protein (TFP) Deficiency"
    ],
    "interventions": [
      "UX007"
    ],
    "primary_completion_date": "2016-08-25",
    "completion_date": "2016-08-25",
    "results_first_posted": "2021-02-11",
    "last_update_posted": "2021-02-11",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT05125809",
    "title": "Setrusumab vs Placebo for Osteogenesis Imperfecta",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Osteogenesis Imperfecta"
    ],
    "interventions": [
      "Setrusumab",
      "Placebo"
    ],
    "primary_completion_date": "2025-10-20",
    "completion_date": "2027-04",
    "results_first_posted": null,
    "last_update_posted": "2025-12-02",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT02214160",
    "title": "Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Extension Study for Subjects Previously Enrolled in Triheptanoin Studies",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Carnitine Palmitoyltransferase (CPT I or CPT II) Deficiency",
      "Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency",
      "Long-chain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency",
      "Trifunctional Protein (TFP) Deficiency",
      "Carnitine-acylcarnitine Translocase (CACT) Deficiency"
    ],
    "interventions": [
      "UX007"
    ],
    "primary_completion_date": "2020-12-03",
    "completion_date": "2020-12-03",
    "results_first_posted": "2021-12-08",
    "last_update_posted": "2023-08-01",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT03970278",
    "title": "Study of Long-Term Safety and Efficacy on Gene Therapy in Glycogen Storage Disease Type Ia",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Glycogen Storage Disease Type IA",
      "Von Gierke's Disease (GSD Type Ia)"
    ],
    "interventions": [
      "No intervention"
    ],
    "primary_completion_date": "2025-02-25",
    "completion_date": "2025-02-25",
    "results_first_posted": null,
    "last_update_posted": "2025-03-06",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT02991144",
    "title": "Safety and Dose-Finding Study of DTX301 (scAAV8OTC) in Adults With Late-Onset Ornithine Transcarbamylase (OTC) Deficiency",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ornithine Transcarbamylase (OTC) Deficiency"
    ],
    "interventions": [
      "scAAV8OTC",
      "Reactive Corticosteroid Taper Regimen",
      "Prophylactic Corticosteroid Taper Regimen"
    ],
    "primary_completion_date": "2021-12-16",
    "completion_date": "2021-12-16",
    "results_first_posted": "2022-12-23",
    "last_update_posted": "2023-01-26",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT03636438",
    "title": "Long Term Follow Up to Evaluate DTX301 in Adults With Late-Onset OTC Deficiency",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Ornithine Transcarbamylase (OTC) Deficiency"
    ],
    "interventions": [
      "No Intervention"
    ],
    "primary_completion_date": "2029-12",
    "completion_date": "2029-12",
    "results_first_posted": null,
    "last_update_posted": "2025-11-17",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT03517085",
    "title": "Safety and Dose-Finding Study of DTX401 (AAV8G6PC) in Adults With Glycogen Storage Disease Type Ia (GSDIa)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "GSD1"
    ],
    "interventions": [
      "DTX401",
      "steroid regimen"
    ],
    "primary_completion_date": "2021-11-02",
    "completion_date": "2021-11-02",
    "results_first_posted": "2022-11-18",
    "last_update_posted": "2022-11-18",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT05312697",
    "title": "Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Osteogenesis Imperfecta"
    ],
    "interventions": [
      "Setrusumab"
    ],
    "primary_completion_date": "2022-07-07",
    "completion_date": "2022-07-07",
    "results_first_posted": "2025-07-23",
    "last_update_posted": "2025-07-23",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT03768817",
    "title": "Clinical Outcome of Triheptanoin Treatment in Patients With Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) Treated Under Expanded Access Program",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)"
    ],
    "interventions": [
      "No Intervention"
    ],
    "primary_completion_date": "2020-06-08",
    "completion_date": "2020-06-08",
    "results_first_posted": null,
    "last_update_posted": "2020-08-28",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT04269122",
    "title": "A Study to Assess Plasma Ammonia Time-Normalized Area Under the Curve and Rate of Ureagenesis in Healthy Adult Subjects",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Ornithine Transcarbamylase Deficiency"
    ],
    "interventions": [
      "No Intervention"
    ],
    "primary_completion_date": "2020-02-20",
    "completion_date": "2020-02-20",
    "results_first_posted": null,
    "last_update_posted": "2020-03-30",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT01806610",
    "title": "Study of Safety and Tolerability of BPS804 in Patients With Late-stage Chronic Kidney Disease",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic-kidney Disease Stage 5D on Stable Hemodialysis"
    ],
    "interventions": [
      "BPS804",
      "Placebo"
    ],
    "primary_completion_date": "2014-04",
    "completion_date": "2014-04",
    "results_first_posted": null,
    "last_update_posted": "2022-09-14",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT01359319",
    "title": "Safety and Pharmacokinetics of Sialic Acid Tables in Patients With Hereditary Inclusion Body Myopathy (HIBM)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hereditary Inclusion Body Myopathy (HIBM)"
    ],
    "interventions": [
      "Sialic Acid Extended Release (SA-ER) Tablets",
      "Sialic Acid Extended Release (SA-ER) Tables",
      "Sialic Acid Extended Release (SA-ER) Tablets",
      "Sialic Acid Extended Release (SA-ER) Tablets",
      "Sialic Acid Extended Release (SA-ER) Tablets"
    ],
    "primary_completion_date": "2012-04",
    "completion_date": "2012-05",
    "results_first_posted": null,
    "last_update_posted": "2012-05-21",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT01406977",
    "title": "Dose Escalation Study to Evaluate the Safety and Tolerability of Multiple Infusions of BPS804 in Adults With Hypophosphatasia (HPP)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypophosphatasia"
    ],
    "interventions": [
      "BPS804"
    ],
    "primary_completion_date": "2012-09",
    "completion_date": "2012-09",
    "results_first_posted": null,
    "last_update_posted": "2022-09-16",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT01830972",
    "title": "An Open Label Phase 2 Extension Study of Higher Dose Sialic Acid-Extended Release (SA-ER) Tablets and Sialic Acid-Immediate Release (SA-IR) Capsules in Patients With Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE) Myopathy",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "GNE Myopathy",
      "Hereditary Inclusion Body Myopathy (HIBM)"
    ],
    "interventions": [
      "SA-ER 500 mg",
      "SA-IR 500 mg"
    ],
    "primary_completion_date": "2017-02-14",
    "completion_date": "2017-02-14",
    "results_first_posted": "2018-03-13",
    "last_update_posted": "2018-04-11",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT02971969",
    "title": "Long-Term Safety, Tolerability, and Efficacy of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Hemophilia B"
    ],
    "interventions": [],
    "primary_completion_date": "2021-11-06",
    "completion_date": "2021-11-06",
    "results_first_posted": null,
    "last_update_posted": "2022-01-06",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT04909346",
    "title": "Adeno-Associated Virus (AAV) Antibody Study in Subjects OTC Deficiency, GSDIa, and Wilson Disease",
    "status": "TERMINATED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Ornithine Transcarbamylase Deficiency",
      "Wilson Disease",
      "Glycogen Storage Disease Type IA"
    ],
    "interventions": [],
    "primary_completion_date": "2022-11-17",
    "completion_date": "2022-11-17",
    "results_first_posted": null,
    "last_update_posted": "2023-06-12",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT03216486",
    "title": "An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Osteogenesis Imperfecta"
    ],
    "interventions": [
      "BPS804"
    ],
    "primary_completion_date": "2018-11-01",
    "completion_date": "2018-11-01",
    "results_first_posted": null,
    "last_update_posted": "2023-07-03",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT05768854",
    "title": "Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Osteogenesis Imperfecta"
    ],
    "interventions": [
      "Bisphosphonate",
      "Setrusumab"
    ],
    "primary_completion_date": "2025-10-23",
    "completion_date": "2027-04",
    "results_first_posted": null,
    "last_update_posted": "2025-12-02",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT02418455",
    "title": "Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Treatment in Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7) Patients Less Than 5 Years of Age",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Sly Syndrome",
      "MPS VII",
      "Mucopolysaccharidosis",
      "Mucopolysaccharidosis VII"
    ],
    "interventions": [
      "UX003"
    ],
    "primary_completion_date": "2019-03-26",
    "completion_date": "2019-03-26",
    "results_first_posted": "2019-10-16",
    "last_update_posted": "2019-10-30",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT04531189",
    "title": "Clinical Evaluation and Assessment of Instruments and Biomarkers in Subjects With Wilson Disease",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Wilson Disease"
    ],
    "interventions": [],
    "primary_completion_date": "2022-03-25",
    "completion_date": "2022-03-25",
    "results_first_posted": null,
    "last_update_posted": "2022-04-29",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT05139316",
    "title": "A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Glycogen Storage Disease Type IA"
    ],
    "interventions": [
      "DTX401",
      "Placebo",
      "Oral prednisolone",
      "Placebo for oral prednisolone"
    ],
    "primary_completion_date": "2024-02-20",
    "completion_date": "2026-02",
    "results_first_posted": null,
    "last_update_posted": "2025-11-19",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT01406548",
    "title": "Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Osteopenia",
      "Osteoporosis"
    ],
    "interventions": [
      "BPS804 20mg/Kg",
      "Placebo to 20mg/Kg BPS804"
    ],
    "primary_completion_date": "2013-10",
    "completion_date": "2013-10",
    "results_first_posted": null,
    "last_update_posted": "2022-09-15",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "RARE",
    "nct_id": "NCT04783428",
    "title": "Tumor-induced Osteomalacia Disease Monitoring Program",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Tumor-induced Osteomalacia (TIO)"
    ],
    "interventions": [
      "No intervention"
    ],
    "primary_completion_date": "2032-02-28",
    "completion_date": "2032-02-28",
    "results_first_posted": null,
    "last_update_posted": "2026-01-21",
    "enrollment": null,
    "sponsor": "Ultragenyx Pharmaceutical Inc",
    "collected_at": "2026-01-27",
    "search_term": "Ultragenyx"
  },
  {
    "ticker": "HALO",
    "nct_id": "NCT03267940",
    "title": "Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cholangiocarcinoma Non-resectable",
      "Cholangiocarcinoma, Intrahepatic",
      "Cholangiocarcinoma, Extrahepatic",
      "Gallbladder Adenocarcinoma"
    ],
    "interventions": [
      "PEGPH20",
      "CIS",
      "GEM",
      "Atezolizumab"
    ],
    "primary_completion_date": "2019-11-11",
    "completion_date": "2019-11-11",
    "results_first_posted": "2020-02-07",
    "last_update_posted": "2020-02-07",
    "enrollment": null,
    "sponsor": "Halozyme Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Halozyme"
  },
  {
    "ticker": "HALO",
    "nct_id": "NCT01194245",
    "title": "Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes Mellitus, Type 1"
    ],
    "interventions": [
      "Insulin lispro",
      "recombinant human hyaluronidase PH20",
      "Insulin aspart",
      "Insulin glulisine",
      "Insulin glargine"
    ],
    "primary_completion_date": "2011-08",
    "completion_date": "2011-08",
    "results_first_posted": "2014-08-19",
    "last_update_posted": "2019-02-26",
    "enrollment": null,
    "sponsor": "Halozyme Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Halozyme"
  },
  {
    "ticker": "HALO",
    "nct_id": "NCT01194258",
    "title": "Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes Mellitus, Type II"
    ],
    "interventions": [
      "Insulin lispro",
      "Insulin aspart",
      "Recombinant human hyaluronidase PH20",
      "Insulin glulisine",
      "Insulin glargine"
    ],
    "primary_completion_date": "2011-08",
    "completion_date": "2011-08",
    "results_first_posted": "2014-08-20",
    "last_update_posted": "2014-08-20",
    "enrollment": null,
    "sponsor": "Halozyme Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Halozyme"
  },
  {
    "ticker": "HALO",
    "nct_id": "NCT00593281",
    "title": "INFUSE Morphine Study",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pain"
    ],
    "interventions": [
      "Hylenex"
    ],
    "primary_completion_date": "2006-10",
    "completion_date": "2006-10",
    "results_first_posted": null,
    "last_update_posted": "2008-01-14",
    "enrollment": null,
    "sponsor": "Halozyme Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Halozyme"
  },
  {
    "ticker": "HALO",
    "nct_id": "NCT00435604",
    "title": "A Study of the Subcutaneous Injection of a Viscous Antibody Solution With Recombinant Human Hyaluronidase",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "Hylenex"
    ],
    "primary_completion_date": null,
    "completion_date": "2007-05",
    "results_first_posted": null,
    "last_update_posted": "2011-10-17",
    "enrollment": null,
    "sponsor": "Halozyme Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Halozyme"
  },
  {
    "ticker": "HALO",
    "nct_id": "NCT00782587",
    "title": "Study of Immediate Post-Operative Intravesical Instillation of Chemophase\u00ae in Patients With Superficial Bladder Cancer",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Superficial Bladder Cancer"
    ],
    "interventions": [
      "Chemophase"
    ],
    "primary_completion_date": "2009-03",
    "completion_date": "2009-08",
    "results_first_posted": null,
    "last_update_posted": "2010-02-08",
    "enrollment": null,
    "sponsor": "Halozyme Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Halozyme"
  },
  {
    "ticker": "HALO",
    "nct_id": "NCT01453153",
    "title": "Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Stage IV Pancreatic Cancer"
    ],
    "interventions": [
      "Gemcitabine",
      "PEGPH20",
      "Placebo"
    ],
    "primary_completion_date": "2014-02",
    "completion_date": "2015-05",
    "results_first_posted": "2018-11-30",
    "last_update_posted": "2018-11-30",
    "enrollment": null,
    "sponsor": "Halozyme Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Halozyme"
  },
  {
    "ticker": "HALO",
    "nct_id": "NCT01839487",
    "title": "PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Pancreatic Cancer"
    ],
    "interventions": [
      "PEGPH20",
      "Nab-paclitaxel",
      "Gemcitabine",
      "Dexamethasone",
      "Enoxaparin"
    ],
    "primary_completion_date": "2018-05-01",
    "completion_date": "2018-09-26",
    "results_first_posted": "2020-07-20",
    "last_update_posted": "2020-07-20",
    "enrollment": null,
    "sponsor": "Halozyme Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Halozyme"
  },
  {
    "ticker": "HALO",
    "nct_id": "NCT00369187",
    "title": "Study of a Large Protein Molecule Administered With Escalating Doses of Recombinant Human Hyaluronidase",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rheumatoid Arthritis"
    ],
    "interventions": [
      "large protein molecule"
    ],
    "primary_completion_date": null,
    "completion_date": "2006-10",
    "results_first_posted": null,
    "last_update_posted": "2008-01-10",
    "enrollment": null,
    "sponsor": "Halozyme Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Halozyme"
  },
  {
    "ticker": "HALO",
    "nct_id": "NCT00803972",
    "title": "Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "rHuPH20",
      "Insulin Human Injection",
      "Insulin Lispro Injection"
    ],
    "primary_completion_date": "2009-08-28",
    "completion_date": "2009-08-28",
    "results_first_posted": null,
    "last_update_posted": "2018-08-15",
    "enrollment": null,
    "sponsor": "Halozyme Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Halozyme"
  },
  {
    "ticker": "HALO",
    "nct_id": "NCT01275131",
    "title": "Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 1 Diabetes Mellitus"
    ],
    "interventions": [
      "Insulin aspart",
      "Recombinant human hyaluronidase PH20 (rHuPH20)"
    ],
    "primary_completion_date": "2011-12",
    "completion_date": "2011-12",
    "results_first_posted": "2014-07-25",
    "last_update_posted": "2014-07-25",
    "enrollment": null,
    "sponsor": "Halozyme Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Halozyme"
  },
  {
    "ticker": "HALO",
    "nct_id": "NCT00311519",
    "title": "A Phase IIIB Dose Comparison Study of Subcutaneous Hydration With and Without Human Recombinant Hyaluronidase (HYLENEX) in Volunteer Subjects",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "Hylenex"
    ],
    "primary_completion_date": null,
    "completion_date": "2006-01",
    "results_first_posted": null,
    "last_update_posted": "2006-04-06",
    "enrollment": null,
    "sponsor": "Halozyme Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Halozyme"
  },
  {
    "ticker": "HALO",
    "nct_id": "NCT00862849",
    "title": "Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to Insulin Lispro Alone",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes Mellitus"
    ],
    "interventions": [
      "Insulin Lispro",
      "Regular Human Insulin",
      "rHuPH20"
    ],
    "primary_completion_date": "2009-06",
    "completion_date": "2009-08",
    "results_first_posted": "2014-07-11",
    "last_update_posted": "2014-07-22",
    "enrollment": null,
    "sponsor": "Halozyme Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Halozyme"
  },
  {
    "ticker": "HALO",
    "nct_id": "NCT00928447",
    "title": "Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact Dermatitis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dermatitis, Allergic Contact"
    ],
    "interventions": [
      "rHuPH20",
      "Placebo"
    ],
    "primary_completion_date": "2009-09-13",
    "completion_date": "2009-09-13",
    "results_first_posted": "2021-12-17",
    "last_update_posted": "2021-12-17",
    "enrollment": null,
    "sponsor": "Halozyme Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Halozyme"
  },
  {
    "ticker": "HALO",
    "nct_id": "NCT00773175",
    "title": "Subcutaneous Rehydration Compared to Intravenous Rehydration",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dehydration"
    ],
    "interventions": [
      "recombinant human hyaluronidase"
    ],
    "primary_completion_date": "2009-11",
    "completion_date": "2009-12",
    "results_first_posted": "2018-11-07",
    "last_update_posted": "2018-11-07",
    "enrollment": null,
    "sponsor": "Halozyme Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Halozyme"
  },
  {
    "ticker": "HALO",
    "nct_id": "NCT01170897",
    "title": "Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor"
    ],
    "interventions": [
      "PEGPH20"
    ],
    "primary_completion_date": "2013-10",
    "completion_date": "2014-01",
    "results_first_posted": null,
    "last_update_posted": "2014-01-29",
    "enrollment": null,
    "sponsor": "Halozyme Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Halozyme"
  },
  {
    "ticker": "HALO",
    "nct_id": "NCT00705536",
    "title": "Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog\u00ae With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R\u00ae With and Without rHuPH20",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes Mellitus"
    ],
    "interventions": [
      "Humalog",
      "Humulin-R",
      "Recombinant human hyaluronidase PH20 (rHuPH20)"
    ],
    "primary_completion_date": "2008-02",
    "completion_date": "2008-02",
    "results_first_posted": "2014-07-14",
    "last_update_posted": "2019-02-26",
    "enrollment": null,
    "sponsor": "Halozyme Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Halozyme"
  },
  {
    "ticker": "HALO",
    "nct_id": "NCT00979875",
    "title": "A Pharmacokinetic and Glucodynamic Study of Subcutaneously Administered Insulin Analogs With rHuPH20 Compared to Insulin Analogs Alone",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "Recombinant human hyaluronidase PH20 (rHuPH20)",
      "Insulin lispro",
      "Insulin glulisine",
      "Insulin aspart"
    ],
    "primary_completion_date": "2010-02",
    "completion_date": "2010-05",
    "results_first_posted": "2014-07-14",
    "last_update_posted": "2014-07-14",
    "enrollment": null,
    "sponsor": "Halozyme Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Halozyme"
  },
  {
    "ticker": "HALO",
    "nct_id": "NCT00834704",
    "title": "Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor"
    ],
    "interventions": [
      "PEGPH20"
    ],
    "primary_completion_date": "2012-06",
    "completion_date": "2012-11",
    "results_first_posted": null,
    "last_update_posted": "2013-03-26",
    "enrollment": null,
    "sponsor": "Halozyme Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Halozyme"
  },
  {
    "ticker": "HALO",
    "nct_id": "NCT06689085",
    "title": "52 Week Study of Safety, PK, & Efficacy of XYOSTED\u00ae for Testosterone Replacement in Male Adolescents With Hypogonadism",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypogonadism, Male"
    ],
    "interventions": [
      "Testosterone enanthate"
    ],
    "primary_completion_date": "2027-10",
    "completion_date": "2027-12",
    "results_first_posted": null,
    "last_update_posted": "2025-11-26",
    "enrollment": null,
    "sponsor": "Halozyme Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Halozyme"
  },
  {
    "ticker": "HALO",
    "nct_id": "NCT02715804",
    "title": "A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pancreatic Ductal Carcinoma"
    ],
    "interventions": [
      "Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20)",
      "Placebo",
      "nab-Paclitaxel",
      "Gemcitabine"
    ],
    "primary_completion_date": "2019-11-04",
    "completion_date": "2019-11-04",
    "results_first_posted": "2020-07-14",
    "last_update_posted": "2020-07-14",
    "enrollment": null,
    "sponsor": "Halozyme Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Halozyme"
  },
  {
    "ticker": "HALO",
    "nct_id": "NCT00774800",
    "title": "Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 1 Diabetes Mellitus"
    ],
    "interventions": [
      "Humalog",
      "Humulin-R",
      "Recombinant human hyaluronidase PH20 (rHuPH20)",
      "Liquid meal"
    ],
    "primary_completion_date": "2009-03",
    "completion_date": "2009-03",
    "results_first_posted": "2014-09-05",
    "last_update_posted": "2019-02-26",
    "enrollment": null,
    "sponsor": "Halozyme Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Halozyme"
  },
  {
    "ticker": "HALO",
    "nct_id": "NCT00807963",
    "title": "Pharmacokinetic, Safety and Tolerability Study of SC Administered Bisphosphonate With rHuPH20 vs Bisphosphonate Alone",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Risk Factors for or a Diagnosis of Osteoporosis"
    ],
    "interventions": [
      "rHuPH20",
      "zoledronic acid"
    ],
    "primary_completion_date": "2009-09-21",
    "completion_date": "2009-09-21",
    "results_first_posted": null,
    "last_update_posted": "2018-08-15",
    "enrollment": null,
    "sponsor": "Halozyme Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Halozyme"
  },
  {
    "ticker": "HALO",
    "nct_id": "NCT00318643",
    "title": "Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bladder Cancer"
    ],
    "interventions": [
      "Mitomycin C",
      "Chemophase"
    ],
    "primary_completion_date": "2009-08-11",
    "completion_date": "2009-08-11",
    "results_first_posted": "2021-10-29",
    "last_update_posted": "2021-10-29",
    "enrollment": null,
    "sponsor": "Halozyme Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Halozyme"
  },
  {
    "ticker": "HALO",
    "nct_id": "NCT00656370",
    "title": "Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hylenex)",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "recombinant human hyaluronidase"
    ],
    "primary_completion_date": "2008-01-30",
    "completion_date": "2008-01-30",
    "results_first_posted": "2010-05-14",
    "last_update_posted": "2018-10-17",
    "enrollment": null,
    "sponsor": "Halozyme Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Halozyme"
  },
  {
    "ticker": "HALO",
    "nct_id": "NCT00883558",
    "title": "Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes Mellitus, Type 1"
    ],
    "interventions": [
      "Insulin Lispro",
      "regular human insulin",
      "recombinant human hyaluronidase PH20",
      "Insulin glargine"
    ],
    "primary_completion_date": "2010-02",
    "completion_date": "2010-04",
    "results_first_posted": "2014-09-08",
    "last_update_posted": "2014-09-08",
    "enrollment": null,
    "sponsor": "Halozyme Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Halozyme"
  },
  {
    "ticker": "HALO",
    "nct_id": "NCT02563548",
    "title": "A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "NSCLC",
      "Gastric Cancer"
    ],
    "interventions": [
      "PEGPH20",
      "Pembrolizumab"
    ],
    "primary_completion_date": "2019-03-26",
    "completion_date": "2019-03-26",
    "results_first_posted": "2020-02-07",
    "last_update_posted": "2020-02-07",
    "enrollment": null,
    "sponsor": "Halozyme Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Halozyme"
  },
  {
    "ticker": "HALO",
    "nct_id": "NCT01848990",
    "title": "CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 1 Diabetes Mellitus"
    ],
    "interventions": [
      "Commercial Hylenex\u00ae recombinant (hyaluronidase human injection)",
      "Precommercial Hylenex recombinant (hyaluronidase human injection)",
      "Insulin lispro",
      "Insulin aspart",
      "Insulin glulisine"
    ],
    "primary_completion_date": "2014-02",
    "completion_date": "2014-09",
    "results_first_posted": "2014-10-29",
    "last_update_posted": "2018-11-07",
    "enrollment": null,
    "sponsor": "Halozyme Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Halozyme"
  },
  {
    "ticker": "HALO",
    "nct_id": "NCT01572012",
    "title": "Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "Ondansetron",
      "Ondansetron + Hylenex",
      "Zofran ODT",
      "Ondansetron solution"
    ],
    "primary_completion_date": "2013-11",
    "completion_date": "2013-11",
    "results_first_posted": null,
    "last_update_posted": "2014-01-24",
    "enrollment": null,
    "sponsor": "Halozyme Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Halozyme"
  },
  {
    "ticker": "HALO",
    "nct_id": "NCT01526733",
    "title": "Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 1 Diabetes Mellitus"
    ],
    "interventions": [
      "Sham Injection",
      "Recombinant human hyaluronidase PH20",
      "Insulin aspart",
      "Insulin lispro"
    ],
    "primary_completion_date": "2012-08",
    "completion_date": "2013-09",
    "results_first_posted": "2014-09-29",
    "last_update_posted": "2019-02-26",
    "enrollment": null,
    "sponsor": "Halozyme Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Halozyme"
  },
  {
    "ticker": "HALO",
    "nct_id": "NCT02346370",
    "title": "A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-small Cell Lung Cancer"
    ],
    "interventions": [
      "PEGylated recombinant human hyaluronidase PH20",
      "Docetaxel"
    ],
    "primary_completion_date": "2016-08-09",
    "completion_date": "2016-11-14",
    "results_first_posted": "2019-02-08",
    "last_update_posted": "2019-02-08",
    "enrollment": null,
    "sponsor": "Halozyme Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Halozyme"
  },
  {
    "ticker": "HALO",
    "nct_id": "NCT00916357",
    "title": "Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes Mellitus, Type 2"
    ],
    "interventions": [
      "Humalog",
      "Humulin-R",
      "Recombinant human hyaluronidase PH20 (rHuPH20)"
    ],
    "primary_completion_date": "2009-11",
    "completion_date": "2009-11",
    "results_first_posted": "2014-08-18",
    "last_update_posted": "2014-08-18",
    "enrollment": null,
    "sponsor": "Halozyme Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Halozyme"
  },
  {
    "ticker": "HALO",
    "nct_id": "NCT03662334",
    "title": "A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20)",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 1 Diabetes Mellitus"
    ],
    "interventions": [
      "Rapid Acting insulin with pre-treatment of rHuPH20",
      "Sham injection"
    ],
    "primary_completion_date": "2014-02-27",
    "completion_date": "2014-02-27",
    "results_first_posted": "2019-02-01",
    "last_update_posted": "2019-02-01",
    "enrollment": null,
    "sponsor": "Halozyme Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Halozyme"
  },
  {
    "ticker": "EDIT",
    "nct_id": "NCT04853576",
    "title": "A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Sickle Cell Disease",
      "Hemoglobinopathies"
    ],
    "interventions": [
      "EDIT-301"
    ],
    "primary_completion_date": "2025-08",
    "completion_date": "2025-08",
    "results_first_posted": null,
    "last_update_posted": "2025-01-31",
    "enrollment": null,
    "sponsor": "Editas Medicine, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Editas Medicine"
  },
  {
    "ticker": "EDIT",
    "nct_id": "NCT03872479",
    "title": "Single Ascending Dose Study in Participants With LCA10",
    "status": "UNKNOWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Leber Congenital Amaurosis 10",
      "Inherited Retinal Dystrophies",
      "Eye Diseases, Hereditary",
      "Retinal Disease",
      "Retinal Degeneration",
      "Vision Disorders",
      "Eye Disorders Congenital"
    ],
    "interventions": [
      "EDIT-101"
    ],
    "primary_completion_date": "2025-05-23",
    "completion_date": "2025-05-23",
    "results_first_posted": null,
    "last_update_posted": "2022-12-05",
    "enrollment": null,
    "sponsor": "Editas Medicine, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Editas Medicine"
  },
  {
    "ticker": "EDIT",
    "nct_id": "NCT05444894",
    "title": "EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Transfusion Dependent Beta Thalassemia",
      "Hemoglobinopathies",
      "Thalassemia Major",
      "Thalassemia Intermedia"
    ],
    "interventions": [
      "EDIT-301"
    ],
    "primary_completion_date": "2025-09",
    "completion_date": "2025-12",
    "results_first_posted": null,
    "last_update_posted": "2025-04-02",
    "enrollment": null,
    "sponsor": "Editas Medicine, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Editas Medicine"
  },
  {
    "ticker": "EDIT",
    "nct_id": "NCT06363760",
    "title": "A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent \u03b2-Thalassemia Who Received EDIT-301",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Sickle Cell Disease",
      "Transfusion-dependent Beta-Thalassemia",
      "Hemoglobinopathies"
    ],
    "interventions": [
      "Safety and efficacy assessments"
    ],
    "primary_completion_date": "2040-08",
    "completion_date": "2040-08",
    "results_first_posted": null,
    "last_update_posted": "2025-04-02",
    "enrollment": null,
    "sponsor": "Editas Medicine, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Editas Medicine"
  },
  {
    "ticker": "BEAM",
    "nct_id": "NCT05521243",
    "title": "An Exploratory Investigation of a Supplement to Enhance Sleep Quality and Quantity",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Sleep",
      "Sleep Disturbance",
      "Sleep Hygiene"
    ],
    "interventions": [
      "Beam Organics Dream Powder",
      "Beam Organics Dream Powder Extra Strength",
      "Placebo"
    ],
    "primary_completion_date": "2022-09-30",
    "completion_date": "2022-09-30",
    "results_first_posted": null,
    "last_update_posted": "2022-11-08",
    "enrollment": null,
    "sponsor": "Beam",
    "collected_at": "2026-01-27",
    "search_term": "Beam Therapeutics"
  },
  {
    "ticker": "BEAM",
    "nct_id": "NCT07183735",
    "title": "A Crossover Trial to Examine the Efficacy of a Powder to Improve Sleep Quality and Performance",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Sleep",
      "Sleep Disorder"
    ],
    "interventions": [
      "BEAM Dream Powder",
      "Placebo Control"
    ],
    "primary_completion_date": "2024-10-17",
    "completion_date": "2024-10-17",
    "results_first_posted": null,
    "last_update_posted": "2025-09-19",
    "enrollment": null,
    "sponsor": "Beam",
    "collected_at": "2026-01-27",
    "search_term": "Beam Therapeutics"
  },
  {
    "ticker": "BEAM",
    "nct_id": "NCT05885464",
    "title": "A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lymphoblastic Lymphoma",
      "T-Cell Lymphoblastic Leukemia/Lymphoma",
      "Lymphoblastic Leukemia"
    ],
    "interventions": [
      "BEAM-201"
    ],
    "primary_completion_date": "2026-12",
    "completion_date": "2026-12",
    "results_first_posted": null,
    "last_update_posted": "2025-01-13",
    "enrollment": null,
    "sponsor": "Beam Therapeutics Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Beam Therapeutics"
  },
  {
    "ticker": "BEAM",
    "nct_id": "NCT06735755",
    "title": "A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa)",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Glycogen Storage Disease Type Ia"
    ],
    "interventions": [
      "BEAM-301: Single dose of BEAM-301 administered by IV"
    ],
    "primary_completion_date": "2027-12-30",
    "completion_date": "2027-12-30",
    "results_first_posted": null,
    "last_update_posted": "2025-12-15",
    "enrollment": null,
    "sponsor": "Beam Therapeutics Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Beam Therapeutics"
  },
  {
    "ticker": "BEAM",
    "nct_id": "NCT06389877",
    "title": "A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alpha 1-Antitrypsin Deficiency"
    ],
    "interventions": [
      "BEAM-302"
    ],
    "primary_completion_date": "2027-06",
    "completion_date": "2027-08",
    "results_first_posted": null,
    "last_update_posted": "2025-06-10",
    "enrollment": null,
    "sponsor": "Beam Therapeutics Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Beam Therapeutics"
  },
  {
    "ticker": "BEAM",
    "nct_id": "NCT07153094",
    "title": "Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS\u00ae PLUS (Shenzhen)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor, Adult"
    ],
    "interventions": [
      "Proton Beam Therapy (PBT)"
    ],
    "primary_completion_date": "2026-10",
    "completion_date": "2031-07",
    "results_first_posted": null,
    "last_update_posted": "2026-01-16",
    "enrollment": null,
    "sponsor": "Ion Beam Applications",
    "collected_at": "2026-01-27",
    "search_term": "Beam Therapeutics"
  },
  {
    "ticker": "ALLO",
    "nct_id": "NCT04696731",
    "title": "Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced/Metastatic Clear Cell Renal Cell Carcinoma"
    ],
    "interventions": [
      "ALLO-316",
      "ALLO-647",
      "Fludarabine",
      "Cyclophosphamide"
    ],
    "primary_completion_date": "2025-10",
    "completion_date": "2025-12",
    "results_first_posted": null,
    "last_update_posted": "2025-09-25",
    "enrollment": null,
    "sponsor": "Allogene Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Allogene Therapeutics"
  },
  {
    "ticker": "ALLO",
    "nct_id": "NCT03939026",
    "title": "Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsed/Refractory Large B Cell Lymphoma",
      "Relapsed/Refractory Follicular Lymphoma"
    ],
    "interventions": [
      "ALLO-501",
      "ALLO-647",
      "Fludarabine",
      "Cyclophosphamide"
    ],
    "primary_completion_date": "2021-10-23",
    "completion_date": "2025-01-28",
    "results_first_posted": null,
    "last_update_posted": "2025-11-04",
    "enrollment": null,
    "sponsor": "Allogene Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Allogene Therapeutics"
  },
  {
    "ticker": "ALLO",
    "nct_id": "NCT04416984",
    "title": "Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults with Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma"
    ],
    "interventions": [
      "ALLO-501A",
      "ALLO-647",
      "Fludarabine",
      "Cyclophosphamide"
    ],
    "primary_completion_date": "2025-08",
    "completion_date": "2029-05",
    "results_first_posted": null,
    "last_update_posted": "2025-01-24",
    "enrollment": null,
    "sponsor": "Allogene Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Allogene Therapeutics"
  },
  {
    "ticker": "ALLO",
    "nct_id": "NCT05000450",
    "title": "Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsed/Refractory Multiple Myeloma"
    ],
    "interventions": [
      "ALLO-605",
      "ALLO-647",
      "Fludarabine",
      "Cyclophosphamide"
    ],
    "primary_completion_date": "2023-10-11",
    "completion_date": "2023-10-11",
    "results_first_posted": null,
    "last_update_posted": "2024-06-28",
    "enrollment": null,
    "sponsor": "Allogene Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Allogene Therapeutics"
  },
  {
    "ticker": "ALLO",
    "nct_id": "NCT04093596",
    "title": "Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsed/Refractory Multiple Myeloma"
    ],
    "interventions": [
      "ALLO-715",
      "ALLO-647",
      "Fludarabine",
      "Cyclophosphamide",
      "Nirogacestat"
    ],
    "primary_completion_date": "2027-09",
    "completion_date": "2027-09",
    "results_first_posted": null,
    "last_update_posted": "2023-08-14",
    "enrollment": null,
    "sponsor": "Allogene Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Allogene Therapeutics"
  },
  {
    "ticker": "ALLO",
    "nct_id": "NCT05714345",
    "title": "Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsed/Refractory Large B Cell Lymphoma"
    ],
    "interventions": [
      "ALLO-647",
      "Fludarabine",
      "Cyclophosphamide",
      "ALLO-501A"
    ],
    "primary_completion_date": "2024-02-20",
    "completion_date": "2024-10-28",
    "results_first_posted": "2025-12-31",
    "last_update_posted": "2025-12-31",
    "enrollment": null,
    "sponsor": "Allogene Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Allogene Therapeutics"
  },
  {
    "ticker": "ALLO",
    "nct_id": "NCT07085104",
    "title": "A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Systemic Lupus Erythematosus (With and Without Nephritis)",
      "Idiopathic Inflammatory Myopathy",
      "Systemic Sclerosis",
      "Lupus Nephritis"
    ],
    "interventions": [
      "ALLO-329",
      "Cyclophophamide"
    ],
    "primary_completion_date": "2028-02",
    "completion_date": "2032-10",
    "results_first_posted": null,
    "last_update_posted": "2025-07-25",
    "enrollment": null,
    "sponsor": "Allogene Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Allogene Therapeutics"
  },
  {
    "ticker": "ALLO",
    "nct_id": "NCT06500273",
    "title": "Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Large B-cell Lymphoma"
    ],
    "interventions": [
      "cemacabtagene ansegedleucel",
      "Fludarabine",
      "Cyclophosphamide",
      "Foresight CLARITY\u2122 IUO MRD test, powered by PhasED-Seq\u2122"
    ],
    "primary_completion_date": "2027-08-24",
    "completion_date": "2031-08-24",
    "results_first_posted": null,
    "last_update_posted": "2025-12-22",
    "enrollment": null,
    "sponsor": "Allogene Therapeutics",
    "collected_at": "2026-01-27",
    "search_term": "Allogene Therapeutics"
  },
  {
    "ticker": "IOVA",
    "nct_id": "NCT05361174",
    "title": "A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Unresectable Melanoma",
      "Metastatic Melanoma",
      "Stage III Non-small Cell Lung Cancer",
      "Stage IV Non-small Cell Lung Cancer"
    ],
    "interventions": [
      "IOV-4001"
    ],
    "primary_completion_date": "2025-06",
    "completion_date": "2027-06",
    "results_first_posted": null,
    "last_update_posted": "2024-12-05",
    "enrollment": null,
    "sponsor": "Iovance Biotherapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Iovance Biotherapeutics"
  },
  {
    "ticker": "IOVA",
    "nct_id": "NCT03645928",
    "title": "Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Melanoma",
      "Squamous Cell Carcinoma of the Head and Neck",
      "Non-small Cell Lung Cancer"
    ],
    "interventions": [
      "Lifileucel",
      "LN-145",
      "Pembrolizumab",
      "LN-145-S1",
      "Ipilimumab",
      "Nivolumab",
      "Nivolumab-relatlimab",
      "Cisplatin",
      "Carboplatin",
      "Paclitaxel",
      "Nab-Paclitaxel",
      "Pemetrexed"
    ],
    "primary_completion_date": "2029-08-09",
    "completion_date": "2029-08-09",
    "results_first_posted": null,
    "last_update_posted": "2025-06-19",
    "enrollment": null,
    "sponsor": "Iovance Biotherapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Iovance Biotherapeutics"
  },
  {
    "ticker": "IOVA",
    "nct_id": "NCT07288203",
    "title": "A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Melanoma (Skin Cancer)",
      "Unresectable Melanoma",
      "Metastatic Melanoma"
    ],
    "interventions": [
      "Lifileucel"
    ],
    "primary_completion_date": "2032-12",
    "completion_date": "2033-12",
    "results_first_posted": null,
    "last_update_posted": "2026-01-12",
    "enrollment": null,
    "sponsor": "Iovance Biotherapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Iovance Biotherapeutics"
  },
  {
    "ticker": "IOVA",
    "nct_id": "NCT03083873",
    "title": "Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Squamous Cell Carcinoma of the Head and Neck"
    ],
    "interventions": [
      "LN-145",
      "LN-145-S1"
    ],
    "primary_completion_date": "2022-08-08",
    "completion_date": "2022-08-08",
    "results_first_posted": "2023-10-12",
    "last_update_posted": "2023-10-12",
    "enrollment": null,
    "sponsor": "Iovance Biotherapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Iovance Biotherapeutics"
  },
  {
    "ticker": "IOVA",
    "nct_id": "NCT06566092",
    "title": "Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Soft Tissue Sarcoma",
      "Primary Central Nervous System Carcinoma",
      "Melanoma",
      "Rhabdomyosarcoma",
      "Ewing Sarcoma"
    ],
    "interventions": [
      "LN-145/LN-144"
    ],
    "primary_completion_date": "2026-07",
    "completion_date": "2028-07",
    "results_first_posted": null,
    "last_update_posted": "2025-06-29",
    "enrollment": null,
    "sponsor": "Iovance Biotherapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Iovance Biotherapeutics"
  },
  {
    "ticker": "IOVA",
    "nct_id": "NCT06940739",
    "title": "A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Unresectable Melanoma",
      "Metastatic Melanoma",
      "Ocular Melanoma"
    ],
    "interventions": [
      "IOV-3001"
    ],
    "primary_completion_date": "2032-06",
    "completion_date": "2032-07",
    "results_first_posted": null,
    "last_update_posted": "2025-12-03",
    "enrollment": null,
    "sponsor": "Iovance Biotherapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Iovance Biotherapeutics"
  },
  {
    "ticker": "IOVA",
    "nct_id": "NCT04614103",
    "title": "Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Non Small Cell Lung Cancer"
    ],
    "interventions": [
      "LN-145",
      "LN-145"
    ],
    "primary_completion_date": "2030-12",
    "completion_date": "2031-12",
    "results_first_posted": null,
    "last_update_posted": "2025-11-12",
    "enrollment": null,
    "sponsor": "Iovance Biotherapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Iovance Biotherapeutics"
  },
  {
    "ticker": "IOVA",
    "nct_id": "NCT03108495",
    "title": "Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cervical Carcinoma"
    ],
    "interventions": [
      "LN-145",
      "LN-145 + pembrolizumab"
    ],
    "primary_completion_date": "2025-08-22",
    "completion_date": "2025-08-22",
    "results_first_posted": null,
    "last_update_posted": "2025-09-17",
    "enrollment": null,
    "sponsor": "Iovance Biotherapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Iovance Biotherapeutics"
  },
  {
    "ticker": "IOVA",
    "nct_id": "NCT04155710",
    "title": "Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Lymphocytic Leukemia",
      "Small Lymphocytic Lymphoma"
    ],
    "interventions": [
      "IOV-2001",
      "Low dose IL-2",
      "High dose IL-2",
      "IL-2"
    ],
    "primary_completion_date": "2024-11-11",
    "completion_date": "2024-12-02",
    "results_first_posted": null,
    "last_update_posted": "2025-12-24",
    "enrollment": null,
    "sponsor": "Iovance Biotherapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Iovance Biotherapeutics"
  },
  {
    "ticker": "IOVA",
    "nct_id": "NCT03419559",
    "title": "Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non Small Cell Lung Cancer"
    ],
    "interventions": [
      "LN-145",
      "Durvalumab"
    ],
    "primary_completion_date": "2021-12",
    "completion_date": "2024-12",
    "results_first_posted": null,
    "last_update_posted": "2019-04-16",
    "enrollment": null,
    "sponsor": "Iovance Biotherapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Iovance Biotherapeutics"
  },
  {
    "ticker": "IOVA",
    "nct_id": "NCT06481592",
    "title": "A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Endometrial Cancer"
    ],
    "interventions": [
      "Lifileucel"
    ],
    "primary_completion_date": "2028-05",
    "completion_date": "2029-11",
    "results_first_posted": null,
    "last_update_posted": "2025-10-30",
    "enrollment": null,
    "sponsor": "Iovance Biotherapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Iovance Biotherapeutics"
  },
  {
    "ticker": "IOVA",
    "nct_id": "NCT02360579",
    "title": "Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Melanoma"
    ],
    "interventions": [
      "Lifileucel"
    ],
    "primary_completion_date": "2024-10-24",
    "completion_date": "2024-10-24",
    "results_first_posted": "2025-12-09",
    "last_update_posted": "2025-12-09",
    "enrollment": null,
    "sponsor": "Iovance Biotherapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Iovance Biotherapeutics"
  },
  {
    "ticker": "IOVA",
    "nct_id": "NCT05398640",
    "title": "Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release",
    "status": "AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Unresectable Melanoma",
      "Metastatic Melanoma"
    ],
    "interventions": [
      "OOS AMTAGVI"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2025-06-17",
    "enrollment": null,
    "sponsor": "Iovance Biotherapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Iovance Biotherapeutics"
  },
  {
    "ticker": "IOVA",
    "nct_id": "NCT05727904",
    "title": "Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Melanoma",
      "Unresectable Melanoma",
      "Melanoma"
    ],
    "interventions": [
      "Lifileucel plus Pembrolizumab",
      "Pembrolizumab with Optional Crossover Period"
    ],
    "primary_completion_date": "2028-03-01",
    "completion_date": "2030-03-01",
    "results_first_posted": null,
    "last_update_posted": "2025-07-08",
    "enrollment": null,
    "sponsor": "Iovance Biotherapeutics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Iovance Biotherapeutics"
  },
  {
    "ticker": "CABA",
    "nct_id": "NCT06359041",
    "title": "RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Generalized Myasthenia Gravis (gMG)"
    ],
    "interventions": [
      "CABA-201"
    ],
    "primary_completion_date": "2029-09",
    "completion_date": "2029-09",
    "results_first_posted": null,
    "last_update_posted": "2026-01-15",
    "enrollment": null,
    "sponsor": "Cabaletta Bio",
    "collected_at": "2026-01-27",
    "search_term": "Cabaletta Bio"
  },
  {
    "ticker": "CABA",
    "nct_id": "NCT05451212",
    "title": "Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "MuSK Myasthenia Gravis"
    ],
    "interventions": [
      "MuSK-CAART"
    ],
    "primary_completion_date": "2025-07-24",
    "completion_date": "2025-07-24",
    "results_first_posted": null,
    "last_update_posted": "2025-11-10",
    "enrollment": null,
    "sponsor": "Cabaletta Bio",
    "collected_at": "2026-01-27",
    "search_term": "Cabaletta Bio"
  },
  {
    "ticker": "CABA",
    "nct_id": "NCT04422912",
    "title": "A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pemphigus Vulgaris"
    ],
    "interventions": [
      "DSG3-CAART",
      "CABA-201"
    ],
    "primary_completion_date": "2029-01",
    "completion_date": "2029-01",
    "results_first_posted": null,
    "last_update_posted": "2025-12-17",
    "enrollment": null,
    "sponsor": "Cabaletta Bio",
    "collected_at": "2026-01-27",
    "search_term": "Cabaletta Bio"
  },
  {
    "ticker": "CABA",
    "nct_id": "NCT06328777",
    "title": "RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Systemic Sclerosis",
      "Scleroderma"
    ],
    "interventions": [
      "CABA-201"
    ],
    "primary_completion_date": "2029-07",
    "completion_date": "2029-07",
    "results_first_posted": null,
    "last_update_posted": "2025-09-29",
    "enrollment": null,
    "sponsor": "Cabaletta Bio",
    "collected_at": "2026-01-27",
    "search_term": "Cabaletta Bio"
  },
  {
    "ticker": "CABA",
    "nct_id": "NCT07006805",
    "title": "RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsing Multiple Sclerosis (RMS)",
      "Progressive Multiple Sclerosis (PMS)",
      "Multiple Sclerosis - Relapsing Remitting",
      "Multiple Sclerosis",
      "Multiple Sclerosis (Relapsing Remitting)",
      "Multiple Sclerosis (MS) - Relapsing-remitting",
      "Progressive Multiple Sclerosis"
    ],
    "interventions": [
      "CABA-201"
    ],
    "primary_completion_date": "2028-09",
    "completion_date": "2029-10",
    "results_first_posted": null,
    "last_update_posted": "2025-10-31",
    "enrollment": null,
    "sponsor": "Cabaletta Bio",
    "collected_at": "2026-01-27",
    "search_term": "Cabaletta Bio"
  },
  {
    "ticker": "CABA",
    "nct_id": "NCT06121297",
    "title": "RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Systemic Lupus Erythematosus",
      "Lupus Nephritis"
    ],
    "interventions": [
      "CABA-201",
      "CABA-201"
    ],
    "primary_completion_date": "2029-12",
    "completion_date": "2029-12",
    "results_first_posted": null,
    "last_update_posted": "2025-12-11",
    "enrollment": null,
    "sponsor": "Cabaletta Bio",
    "collected_at": "2026-01-27",
    "search_term": "Cabaletta Bio"
  },
  {
    "ticker": "CABA",
    "nct_id": "NCT06154252",
    "title": "RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Idiopathic Inflammatory Myopathy",
      "Dermatomyositis",
      "Anti-Synthetase Syndrome",
      "Immune-Mediated Necrotizing Myopathy",
      "Juvenile Dermatomyositis",
      "Juvenile Polymyositis",
      "Juvenile Idiopathic Inflammatory Myopathy (JIIM)",
      "Juvenile Myositis"
    ],
    "interventions": [
      "CABA-201 following preconditioning with fludarabine and cyclophosphamide"
    ],
    "primary_completion_date": "2028-07",
    "completion_date": "2028-07",
    "results_first_posted": null,
    "last_update_posted": "2025-10-22",
    "enrollment": null,
    "sponsor": "Cabaletta Bio",
    "collected_at": "2026-01-27",
    "search_term": "Cabaletta Bio"
  },
  {
    "ticker": "CDNA",
    "nct_id": "NCT05459181",
    "title": "HeartCare Immuno-optimization in Cardiac Allografts (MOSAIC)",
    "status": "NOT_YET_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Heart Transplant",
      "Immunosuppression",
      "Allograft"
    ],
    "interventions": [
      "HeartCare"
    ],
    "primary_completion_date": "2026-09",
    "completion_date": "2026-09",
    "results_first_posted": null,
    "last_update_posted": "2024-10-23",
    "enrollment": null,
    "sponsor": "CareDx",
    "collected_at": "2026-01-27",
    "search_term": "CareDx"
  },
  {
    "ticker": "CDNA",
    "nct_id": "NCT04566055",
    "title": "Assessing AlloSure Dd-cfDNA Monitoring Insights of Renal Allografts With Longitudinal Surveillance",
    "status": "UNKNOWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Kidney Transplant Rejection"
    ],
    "interventions": [
      "AlloSure"
    ],
    "primary_completion_date": "2020-10-01",
    "completion_date": "2020-10-01",
    "results_first_posted": null,
    "last_update_posted": "2020-10-05",
    "enrollment": null,
    "sponsor": "CareDx",
    "collected_at": "2026-01-27",
    "search_term": "CareDx"
  },
  {
    "ticker": "CDNA",
    "nct_id": "NCT02178943",
    "title": "Utility of Donor-Derived Cell Free DNA in Association With Gene Expression Profiling",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Cardiac Transplant Failure",
      "Cardiac Transplant Rejection",
      "Heart Diseases"
    ],
    "interventions": [],
    "primary_completion_date": "2019-12",
    "completion_date": "2020-02",
    "results_first_posted": null,
    "last_update_posted": "2024-10-29",
    "enrollment": null,
    "sponsor": "CareDx",
    "collected_at": "2026-01-27",
    "search_term": "CareDx"
  },
  {
    "ticker": "CDNA",
    "nct_id": "NCT05423496",
    "title": "KidneyCare Immuno-optimization in Renal Allografts (KIRA)",
    "status": "WITHDRAWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Kidney Transplant",
      "Immunosuppression",
      "Allograft"
    ],
    "interventions": [
      "KidneyCare",
      "steroid",
      "MMF"
    ],
    "primary_completion_date": "2023-02-23",
    "completion_date": "2023-02-23",
    "results_first_posted": null,
    "last_update_posted": "2023-03-27",
    "enrollment": null,
    "sponsor": "CareDx",
    "collected_at": "2026-01-27",
    "search_term": "CareDx"
  },
  {
    "ticker": "CDNA",
    "nct_id": "NCT04601155",
    "title": "Transition of Renal Patients Using AlloSure Into Community Kidney Care",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Kidney Transplant Rejection"
    ],
    "interventions": [
      "AlloSure"
    ],
    "primary_completion_date": "2023-03-24",
    "completion_date": "2023-10-06",
    "results_first_posted": null,
    "last_update_posted": "2023-11-03",
    "enrollment": null,
    "sponsor": "CareDx",
    "collected_at": "2026-01-27",
    "search_term": "CareDx"
  },
  {
    "ticker": "CDNA",
    "nct_id": "NCT03695601",
    "title": "Surveillance HeartCare\u00ae Outcomes Registry",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Heart Transplant Rejection"
    ],
    "interventions": [
      "Standard of Care"
    ],
    "primary_completion_date": "2026-11",
    "completion_date": "2026-11",
    "results_first_posted": null,
    "last_update_posted": "2026-01-21",
    "enrollment": null,
    "sponsor": "CareDx",
    "collected_at": "2026-01-27",
    "search_term": "CareDx"
  },
  {
    "ticker": "CDNA",
    "nct_id": "NCT05050955",
    "title": "AlloSure Lung Assessment and Metagenomics Outcomes Study",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Lung Transplant Infection",
      "Lung Transplant; Complications",
      "Lung Transplant Failure and Rejection"
    ],
    "interventions": [],
    "primary_completion_date": "2028-12-31",
    "completion_date": "2028-12-31",
    "results_first_posted": null,
    "last_update_posted": "2025-10-20",
    "enrollment": null,
    "sponsor": "CareDx",
    "collected_at": "2026-01-27",
    "search_term": "CareDx"
  },
  {
    "ticker": "CDNA",
    "nct_id": "NCT05033548",
    "title": "Technology Enabled And Molecular Monitoring of the Allograft and Transplant rEcipient",
    "status": "TERMINATED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Transplant"
    ],
    "interventions": [],
    "primary_completion_date": "2023-02-02",
    "completion_date": "2023-07-31",
    "results_first_posted": null,
    "last_update_posted": "2023-08-30",
    "enrollment": null,
    "sponsor": "CareDx",
    "collected_at": "2026-01-27",
    "search_term": "CareDx"
  },
  {
    "ticker": "CDNA",
    "nct_id": "NCT01833195",
    "title": "Outcomes AlloMap Registry: the Long-term Management and Outcomes of Heart Transplant Recipients With AlloMap Testing",
    "status": "UNKNOWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Cardiac Transplant Failure",
      "Cardiac Transplant Rejection",
      "Heart Diseases"
    ],
    "interventions": [],
    "primary_completion_date": "2020-02",
    "completion_date": "2020-02",
    "results_first_posted": null,
    "last_update_posted": "2020-02-05",
    "enrollment": null,
    "sponsor": "CareDx",
    "collected_at": "2026-01-27",
    "search_term": "CareDx"
  },
  {
    "ticker": "CDNA",
    "nct_id": "NCT04793360",
    "title": "Molecular Assessment and Profiling of Liver Transplant Recipients",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Liver Transplantation",
      "Biomarkers"
    ],
    "interventions": [
      "LiverCare"
    ],
    "primary_completion_date": "2027-12-31",
    "completion_date": "2028-03-31",
    "results_first_posted": null,
    "last_update_posted": "2026-01-13",
    "enrollment": null,
    "sponsor": "CareDx",
    "collected_at": "2026-01-27",
    "search_term": "CareDx"
  },
  {
    "ticker": "CDNA",
    "nct_id": "NCT02424227",
    "title": "Non Invasive Blood Test To Diagnose Acute Rejection After Kidney Transplantation",
    "status": "UNKNOWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Kidney Transplant Recipients"
    ],
    "interventions": [],
    "primary_completion_date": "2018-08-30",
    "completion_date": "2019-01-31",
    "results_first_posted": null,
    "last_update_posted": "2018-12-17",
    "enrollment": null,
    "sponsor": "CareDx",
    "collected_at": "2026-01-27",
    "search_term": "CareDx"
  },
  {
    "ticker": "CDNA",
    "nct_id": "NCT04341103",
    "title": "AlloSure Guided Immuno-Optimization for COVID-19: An Early Experience",
    "status": "UNKNOWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Solid Organ Transplant Rejection",
      "COVID-19"
    ],
    "interventions": [],
    "primary_completion_date": "2020-12-01",
    "completion_date": "2021-03-01",
    "results_first_posted": null,
    "last_update_posted": "2020-04-10",
    "enrollment": null,
    "sponsor": "CareDx",
    "collected_at": "2026-01-27",
    "search_term": "CareDx"
  },
  {
    "ticker": "CDNA",
    "nct_id": "NCT03326076",
    "title": "Evaluation of Patient Outcomes From the Kidney Allograft Outcomes AlloSure Registry",
    "status": "UNKNOWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Kidney Transplant Rejection"
    ],
    "interventions": [
      "Donor-derived cell-free DNA (AlloSure\u00ae)",
      "Standard care",
      "Peripheral blood gene expression profiling (AlloMap Kidney)",
      "Analytic platform (IBox)"
    ],
    "primary_completion_date": "2025-06-30",
    "completion_date": "2025-12-31",
    "results_first_posted": null,
    "last_update_posted": "2023-06-27",
    "enrollment": null,
    "sponsor": "CareDx",
    "collected_at": "2026-01-27",
    "search_term": "CareDx"
  },
  {
    "ticker": "CDNA",
    "nct_id": "NCT04635384",
    "title": "Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme Test",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Acute Myeloid Leukemia",
      "Acute Lymphoblastic Leukemia",
      "Myelodysplastic Syndrome"
    ],
    "interventions": [],
    "primary_completion_date": "2025-10-31",
    "completion_date": "2025-12-31",
    "results_first_posted": null,
    "last_update_posted": "2024-10-26",
    "enrollment": null,
    "sponsor": "CareDx",
    "collected_at": "2026-01-27",
    "search_term": "CareDx"
  },
  {
    "ticker": "IRON",
    "nct_id": "NCT07187973",
    "title": "A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Sickle Cell Disease"
    ],
    "interventions": [
      "DISC-3405"
    ],
    "primary_completion_date": "2027-06",
    "completion_date": "2027-10",
    "results_first_posted": null,
    "last_update_posted": "2025-12-04",
    "enrollment": null,
    "sponsor": "Disc Medicine, Inc",
    "collected_at": "2026-01-27",
    "search_term": "Disc Medicine"
  },
  {
    "ticker": "IRON",
    "nct_id": "NCT06910358",
    "title": "Study of Bitopertin in Participants With EPP or XLP (APOLLO)",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Erythropoietic Protoporphyria (EPP)",
      "X-Linked Protoporphyria (XLP)"
    ],
    "interventions": [
      "Placebo",
      "DISC-1459"
    ],
    "primary_completion_date": "2026-10",
    "completion_date": "2026-11",
    "results_first_posted": null,
    "last_update_posted": "2026-01-20",
    "enrollment": null,
    "sponsor": "Disc Medicine, Inc",
    "collected_at": "2026-01-27",
    "search_term": "Disc Medicine"
  },
  {
    "ticker": "IRON",
    "nct_id": "NCT04877470",
    "title": "Baseline-characteristics of Patients Referred to a Secondary Spine Centre",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Spine Disease",
      "Characteristics Disease",
      "Spinal Disease",
      "Demography"
    ],
    "interventions": [
      "Consultation at spine-centre"
    ],
    "primary_completion_date": "2023-03-01",
    "completion_date": "2023-05-01",
    "results_first_posted": null,
    "last_update_posted": "2024-02-02",
    "enrollment": null,
    "sponsor": "Zuyderland Medisch Centrum",
    "collected_at": "2026-01-27",
    "search_term": "Disc Medicine"
  },
  {
    "ticker": "IRON",
    "nct_id": "NCT06127745",
    "title": "Discure Technologies Feasibility Study for DDD",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Degenerative Disc Disease",
      "Chronic Low-back Pain",
      "Discogenic Pain"
    ],
    "interventions": [
      "Discure System"
    ],
    "primary_completion_date": "2024-11",
    "completion_date": "2024-12",
    "results_first_posted": null,
    "last_update_posted": "2023-11-14",
    "enrollment": null,
    "sponsor": "Discure Technologies Ltd.",
    "collected_at": "2026-01-27",
    "search_term": "Disc Medicine"
  },
  {
    "ticker": "IRON",
    "nct_id": "NCT06050915",
    "title": "A Study of DISC-3405 in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteer"
    ],
    "interventions": [
      "DISC-3405",
      "DISC-3405",
      "Placebo",
      "Placebo"
    ],
    "primary_completion_date": "2024-07-09",
    "completion_date": "2024-07-09",
    "results_first_posted": null,
    "last_update_posted": "2024-12-18",
    "enrollment": null,
    "sponsor": "Disc Medicine, Inc",
    "collected_at": "2026-01-27",
    "search_term": "Disc Medicine"
  },
  {
    "ticker": "IRON",
    "nct_id": "NCT05883748",
    "title": "HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Erythropoietic Protoporphyria"
    ],
    "interventions": [
      "DISC-1459",
      "DISC-1459"
    ],
    "primary_completion_date": "2028-06",
    "completion_date": "2028-06",
    "results_first_posted": null,
    "last_update_posted": "2025-12-18",
    "enrollment": null,
    "sponsor": "Disc Medicine, Inc",
    "collected_at": "2026-01-27",
    "search_term": "Disc Medicine"
  },
  {
    "ticker": "IRON",
    "nct_id": "NCT05320198",
    "title": "Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Myelofibrosis; Anemia",
      "Anemia",
      "Myelofibrosis",
      "Myelofibrosis Due to and Following Polycythemia Vera",
      "Primary Myelofibrosis",
      "Post-essential Thrombocythemia Myelofibrosis",
      "Myelodysplastic Syndromes"
    ],
    "interventions": [
      "DISC-0974"
    ],
    "primary_completion_date": "2026-09",
    "completion_date": "2026-09",
    "results_first_posted": null,
    "last_update_posted": "2026-01-23",
    "enrollment": null,
    "sponsor": "Disc Medicine, Inc",
    "collected_at": "2026-01-27",
    "search_term": "Disc Medicine"
  },
  {
    "ticker": "IRON",
    "nct_id": "NCT06985147",
    "title": "A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Polycythemia Vera (PV)"
    ],
    "interventions": [
      "DISC-3405"
    ],
    "primary_completion_date": "2027-02",
    "completion_date": "2029-02",
    "results_first_posted": null,
    "last_update_posted": "2025-12-04",
    "enrollment": null,
    "sponsor": "Disc Medicine, Inc",
    "collected_at": "2026-01-27",
    "search_term": "Disc Medicine"
  },
  {
    "ticker": "IRON",
    "nct_id": "NCT07254806",
    "title": "A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to Moderate Lumbar Degenerative Disc Disease",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Degenerative Disc Disease"
    ],
    "interventions": [
      "IDCT (rebonuputemcel)",
      "Sham (No Treatment)"
    ],
    "primary_completion_date": "2027-11-24",
    "completion_date": "2028-11-24",
    "results_first_posted": null,
    "last_update_posted": "2026-01-22",
    "enrollment": null,
    "sponsor": "DiscGenics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Disc Medicine"
  },
  {
    "ticker": "IRON",
    "nct_id": "NCT05308472",
    "title": "Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants With EPP",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Erythropoietic Protoporphyria"
    ],
    "interventions": [
      "DISC-1459",
      "DISC-1459",
      "Placebo"
    ],
    "primary_completion_date": "2024-02-20",
    "completion_date": "2024-08-23",
    "results_first_posted": "2026-01-08",
    "last_update_posted": "2026-01-08",
    "enrollment": null,
    "sponsor": "Disc Medicine, Inc",
    "collected_at": "2026-01-27",
    "search_term": "Disc Medicine"
  },
  {
    "ticker": "IRON",
    "nct_id": "NCT03347708",
    "title": "Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Degenerative Disc Disease"
    ],
    "interventions": [
      "IDCT",
      "Saline Solution",
      "Sodium Hyaluronate"
    ],
    "primary_completion_date": "2022-02-01",
    "completion_date": "2022-11-10",
    "results_first_posted": null,
    "last_update_posted": "2023-01-25",
    "enrollment": null,
    "sponsor": "DiscGenics, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Disc Medicine"
  },
  {
    "ticker": "IRON",
    "nct_id": "NCT05745883",
    "title": "Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants With CKD and Anemia",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Kidney Diseases",
      "Anemia of Chronic Kidney Disease"
    ],
    "interventions": [
      "DISC-0974",
      "Placebo"
    ],
    "primary_completion_date": "2026-01",
    "completion_date": "2026-05",
    "results_first_posted": null,
    "last_update_posted": "2025-12-18",
    "enrollment": null,
    "sponsor": "Disc Medicine, Inc",
    "collected_at": "2026-01-27",
    "search_term": "Disc Medicine"
  },
  {
    "ticker": "IRON",
    "nct_id": "NCT04999527",
    "title": "Study to Evaluate the Safety, Tolerability, PK and PD of DISC-0974 in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteer"
    ],
    "interventions": [
      "DISC-0974",
      "Placebo"
    ],
    "primary_completion_date": "2022-06-30",
    "completion_date": "2022-06-30",
    "results_first_posted": null,
    "last_update_posted": "2022-07-19",
    "enrollment": null,
    "sponsor": "Disc Medicine, Inc",
    "collected_at": "2026-01-27",
    "search_term": "Disc Medicine"
  },
  {
    "ticker": "GH",
    "nct_id": "NCT05059444",
    "title": "ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Bladder Carcinoma",
      "Ureter Carcinoma",
      "Renal Pelvis Carcinoma",
      "Non-small Cell Lung Cancer",
      "Invasive Breast Carcinoma",
      "Cutaneous Melanoma",
      "Esophageal Carcinoma",
      "Gastroesophageal Junction Carcinoma",
      "Gastric Adenocarcinoma",
      "Pancreatic Adenocarcinoma",
      "Squamous Cell Carcinoma of the Head and Neck",
      "Epithelial Ovarian Carcinoma",
      "Fallopian Tube Carcinoma",
      "Endometrial Carcinoma",
      "Renal Cell Carcinoma",
      "Rectal Adenocarcinoma"
    ],
    "interventions": [
      "Guardant Reveal"
    ],
    "primary_completion_date": "2029-08",
    "completion_date": "2029-08",
    "results_first_posted": null,
    "last_update_posted": "2025-08-22",
    "enrollment": null,
    "sponsor": "Guardant Health, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Guardant Health"
  },
  {
    "ticker": "GH",
    "nct_id": "NCT03477474",
    "title": "Registry of Guardant360\u00ae Use and Outcomes In People With Advanced Cancer",
    "status": "TERMINATED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Non-small Cell Lung Cancer Metastatic"
    ],
    "interventions": [],
    "primary_completion_date": "2019-09-01",
    "completion_date": "2019-09-01",
    "results_first_posted": null,
    "last_update_posted": "2019-10-10",
    "enrollment": null,
    "sponsor": "Guardant Health, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Guardant Health"
  },
  {
    "ticker": "GH",
    "nct_id": "NCT05117840",
    "title": "Screening for High Frequency Malignant Disease",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Lung Cancer"
    ],
    "interventions": [
      "Low-dose CT scan"
    ],
    "primary_completion_date": "2026-04-30",
    "completion_date": "2026-04-30",
    "results_first_posted": null,
    "last_update_posted": "2026-01-12",
    "enrollment": null,
    "sponsor": "Guardant Health, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Guardant Health"
  },
  {
    "ticker": "GH",
    "nct_id": "NCT04436393",
    "title": "Guardant360\u00ae Related Clinical Outcomes in Patients Who Share Medical Records-Breast Cancer",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Advanced Breast Cancer"
    ],
    "interventions": [
      "Guardant360 test"
    ],
    "primary_completion_date": "2022-03-17",
    "completion_date": "2022-03-17",
    "results_first_posted": null,
    "last_update_posted": "2022-06-22",
    "enrollment": null,
    "sponsor": "Guardant Health, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Guardant Health"
  },
  {
    "ticker": "GH",
    "nct_id": "NCT03625557",
    "title": "Guardant360\u00ae Test-Related Clinical Outcomes in Patients Who Share Medical Records",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Non-Hematologic Malignancy"
    ],
    "interventions": [],
    "primary_completion_date": "2020-02-01",
    "completion_date": "2020-04-16",
    "results_first_posted": null,
    "last_update_posted": "2020-04-17",
    "enrollment": null,
    "sponsor": "Guardant Health, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Guardant Health"
  },
  {
    "ticker": "GH",
    "nct_id": "NCT06880055",
    "title": "Shield Post-Approval Study Protocol",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Colo-rectal Cancer"
    ],
    "interventions": [
      "Shield Blood Test for colo-rectal cancer Screening"
    ],
    "primary_completion_date": "2030-09-01",
    "completion_date": "2030-12-01",
    "results_first_posted": null,
    "last_update_posted": "2025-12-24",
    "enrollment": null,
    "sponsor": "Guardant Health, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Guardant Health"
  },
  {
    "ticker": "GH",
    "nct_id": "NCT03615443",
    "title": "Noninvasive vs. Invasive Lung Evaluation",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Non-Small Cell Lung Cancer"
    ],
    "interventions": [
      "Guardant360"
    ],
    "primary_completion_date": "2020-11-23",
    "completion_date": "2020-11-23",
    "results_first_posted": null,
    "last_update_posted": "2021-05-03",
    "enrollment": null,
    "sponsor": "Guardant Health, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Guardant Health"
  },
  {
    "ticker": "GH",
    "nct_id": "NCT05935384",
    "title": "SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Non-small Cell Lung Cancer",
      "Colorectal Cancer",
      "Breast Cancer"
    ],
    "interventions": [
      "Guardant360"
    ],
    "primary_completion_date": "2030-12-30",
    "completion_date": "2030-12-30",
    "results_first_posted": null,
    "last_update_posted": "2025-08-22",
    "enrollment": null,
    "sponsor": "Guardant Health, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Guardant Health"
  },
  {
    "ticker": "GH",
    "nct_id": "NCT04136002",
    "title": "Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Colorectal Cancer"
    ],
    "interventions": [],
    "primary_completion_date": "2024-03-20",
    "completion_date": "2025-08-05",
    "results_first_posted": null,
    "last_update_posted": "2025-08-11",
    "enrollment": null,
    "sponsor": "Guardant Health, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Guardant Health"
  },
  {
    "ticker": "RNA",
    "nct_id": "NCT07038200",
    "title": "A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Facioscapulohumeral Muscular Dystrophy",
      "FSHD",
      "FSHD - Facioscapulohumeral Muscular Dystrophy",
      "FSHD1",
      "FSHD2",
      "Fascioscapulohumeral Muscular Dystrophy",
      "Fascioscapulohumeral Muscular Dystrophy Type 1",
      "Fascioscapulohumeral Muscular Dystrophy Type 2",
      "Facioscapulohumeral Muscular Dystrophy 1",
      "Facioscapulohumeral Dystrophy",
      "Facio-Scapulo-Humeral Dystrophy",
      "Facioscapulohumeral Muscular Dystrophy 2",
      "Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1)",
      "FSH Muscular Dystrophy",
      "Landouzy Dejerine Dystrophy",
      "Landouzy-Dejerine Muscular Dystrophy",
      "Landouzy-Dejerine Syndrome"
    ],
    "interventions": [
      "AOC-1020",
      "Placebo"
    ],
    "primary_completion_date": "2028-05",
    "completion_date": "2028-07",
    "results_first_posted": null,
    "last_update_posted": "2026-01-20",
    "enrollment": null,
    "sponsor": "Avidity Biosciences, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Avidity Biosciences"
  },
  {
    "ticker": "RNA",
    "nct_id": "NCT05670730",
    "title": "Study of AOC 1044 in Healthy Adult Volunteers and Participants With Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 Skipping",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy",
      "Exon 44"
    ],
    "interventions": [
      "AOC 1044",
      "Placebo"
    ],
    "primary_completion_date": "2024-11-25",
    "completion_date": "2024-11-25",
    "results_first_posted": null,
    "last_update_posted": "2025-07-14",
    "enrollment": null,
    "sponsor": "Avidity Biosciences, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Avidity Biosciences"
  },
  {
    "ticker": "RNA",
    "nct_id": "NCT05027269",
    "title": "Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "DM1",
      "Myotonic Dystrophy 1",
      "Myotonic Dystrophy",
      "Myotonic Dystrophy Type 1 (DM1)",
      "Dystrophy Myotonic",
      "Myotonic Disorders",
      "Steinert Disease",
      "Myotonic Muscular Dystrophy"
    ],
    "interventions": [
      "AOC 1001",
      "Placebo"
    ],
    "primary_completion_date": "2023-02-14",
    "completion_date": "2023-02-14",
    "results_first_posted": null,
    "last_update_posted": "2024-02-05",
    "enrollment": null,
    "sponsor": "Avidity Biosciences, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Avidity Biosciences"
  },
  {
    "ticker": "RNA",
    "nct_id": "NCT05479981",
    "title": "Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "DM1",
      "Muscular Dystrophies",
      "Myotonic Dystrophy",
      "Myotonic Dystrophy 1",
      "Myotonic Disorders",
      "Muscular Disorders, Atrophic",
      "Muscular Diseases",
      "Musculoskeletal Diseases",
      "Neuromuscular Diseases",
      "Nervous System Diseases",
      "Genetic Diseases, Inborn",
      "Heredodegenerative Disorders, Nervous System",
      "Neurodegenerative Diseases"
    ],
    "interventions": [
      "Placebo",
      "AOC 1001"
    ],
    "primary_completion_date": "2025-09-05",
    "completion_date": "2025-09-10",
    "results_first_posted": null,
    "last_update_posted": "2025-10-08",
    "enrollment": null,
    "sponsor": "Avidity Biosciences, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Avidity Biosciences"
  },
  {
    "ticker": "RNA",
    "nct_id": "NCT05747924",
    "title": "Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "FSHD",
      "FSHD1",
      "FSHD2",
      "FMD",
      "FMD2",
      "Fascioscapulohumeral Muscular Dystrophy",
      "Fascioscapulohumeral Muscular Dystrophy Type 1",
      "Fascioscapulohumeral Muscular Dystrophy Type 2",
      "Dystrophies, Facioscapulohumeral Muscular",
      "Dystrophy, Facioscapulohumeral Muscular",
      "Facioscapulohumeral Muscular Dystrophy 1",
      "Facioscapulohumeral Muscular Dystrophy 2",
      "Facio-Scapulo-Humeral Dystrophy",
      "Atrophy, Facioscapulohumeral",
      "Atrophies, Facioscapulohumeral",
      "Facioscapulohumeral Atrophy",
      "Muscular Dystrophies",
      "Muscular Dystrophy, Facioscapulohumeral",
      "FSH Muscular Dystrophy",
      "Landouzy Dejerine Dystrophy",
      "Landouzy-Dejerine Muscular Dystrophy",
      "Dystrophies, Landouzy-Dejerine",
      "Dystrophy, Landouzy-Dejerine",
      "Landouzy-Dejerine Syndrome",
      "Muscular Dystrophy, Landouzy Dejerine",
      "Progressive Muscular Dystrophy",
      "FSH"
    ],
    "interventions": [
      "AOC 1020",
      "Placebo"
    ],
    "primary_completion_date": "2026-10",
    "completion_date": "2027-04",
    "results_first_posted": null,
    "last_update_posted": "2025-04-01",
    "enrollment": null,
    "sponsor": "Avidity Biosciences, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Avidity Biosciences"
  },
  {
    "ticker": "RNA",
    "nct_id": "NCT07250737",
    "title": "Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping",
    "status": "AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Muscular Disorders, Atrophic",
      "Muscular Diseases",
      "Musculoskeletal Diseases",
      "Neuromuscular Diseases",
      "Nervous System Diseases",
      "Genetic Diseases, Inborn",
      "Genetic Diseases, X-Linked",
      "Muscular Dystrophies",
      "Muscular Dystrophy, Duchenne"
    ],
    "interventions": [
      "delpacibart zotadirsen"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2025-11-26",
    "enrollment": null,
    "sponsor": "Avidity Biosciences, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Avidity Biosciences"
  },
  {
    "ticker": "RNA",
    "nct_id": "NCT06411288",
    "title": "Global Study of Del-desiran for the Treatment of DM1",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "DM1",
      "Myotonic Dystrophy",
      "Myotonic Dystrophy 1",
      "Myotonia",
      "Myotonic Dystrophy Type 1 (DM1)",
      "Dystrophy Myotonic",
      "Myotonic Disorders",
      "Steinert Disease",
      "Steinert",
      "Myotonic Muscular Dystrophy"
    ],
    "interventions": [
      "AOC 1001 (del-desiran)",
      "Placebo"
    ],
    "primary_completion_date": "2026-08",
    "completion_date": "2026-09",
    "results_first_posted": null,
    "last_update_posted": "2026-01-22",
    "enrollment": null,
    "sponsor": "Avidity Biosciences, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Avidity Biosciences"
  },
  {
    "ticker": "RNA",
    "nct_id": "NCT07008469",
    "title": "Global Open-Label Extension Study of Del-desiran for the Treatment of DM1",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Myotonic Dystrophy Type 1",
      "DM1",
      "Myotonic Dystrophy",
      "Myotonia",
      "Myotonic Dystrophy 1",
      "Myotonic Disorders",
      "Steinert Myotonic Dystrophy",
      "Steinert Disease"
    ],
    "interventions": [
      "Del-desiran (AOC 1001)"
    ],
    "primary_completion_date": "2030-08",
    "completion_date": "2030-10",
    "results_first_posted": null,
    "last_update_posted": "2025-12-22",
    "enrollment": null,
    "sponsor": "Avidity Biosciences, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Avidity Biosciences"
  },
  {
    "ticker": "RNA",
    "nct_id": "NCT06244082",
    "title": "Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "DMD",
      "Duchenne Muscular Dystrophy",
      "Duchenne",
      "Exon 44"
    ],
    "interventions": [
      "AOC 1044"
    ],
    "primary_completion_date": "2027-04-30",
    "completion_date": "2027-07-31",
    "results_first_posted": null,
    "last_update_posted": "2025-05-14",
    "enrollment": null,
    "sponsor": "Avidity Biosciences, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Avidity Biosciences"
  },
  {
    "ticker": "RNA",
    "nct_id": "NCT06547216",
    "title": "Phase 2 Open-label Extension Study of AOC 1020 in Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "FSHD",
      "FSHD1",
      "FSHD2",
      "FMD",
      "FMD2",
      "Fascioscapulohumeral Muscular Dystrophy",
      "Fascioscapulohumeral Muscular Dystrophy Type 1",
      "Fascioscapulohumeral Muscular Dystrophy Type 2",
      "Dystrophies, Facioscapulohumeral Muscular",
      "Dystrophy, Facioscapulohumeral Muscular",
      "Facioscapulohumeral Muscular Dystrophy 1",
      "Facioscapulohumeral Muscular Dystrophy 2",
      "Facio-Scapulo-Humeral Dystrophy",
      "Atrophy, Facioscapulohumeral",
      "Atrophies, Facioscapulohumeral",
      "Facioscapulohumeral Atrophy",
      "Muscular Dystrophies",
      "Muscular Dystrophy, Facioscapulohumeral",
      "FSH Muscular Dystrophy",
      "Landouzy Dejerine Dystrophy",
      "Landouzy-Dejerine Muscular Dystrophy",
      "Dystrophies, Landouzy-Dejerine",
      "Dystrophy, Landouzy-Dejerine",
      "Landouzy-Dejerine Syndrome",
      "Muscular Dystrophy, Landouzy Dejerine",
      "Progressive Muscular Dystrophy",
      "FSH"
    ],
    "interventions": [
      "AOC 1020"
    ],
    "primary_completion_date": "2028-04",
    "completion_date": "2028-04",
    "results_first_posted": null,
    "last_update_posted": "2024-12-20",
    "enrollment": null,
    "sponsor": "Avidity Biosciences, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Avidity Biosciences"
  },
  {
    "ticker": "SLN",
    "nct_id": "NCT00938574",
    "title": "Study With Atu027 in Patients With Advanced Solid Cancer",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumors"
    ],
    "interventions": [
      "Atu027"
    ],
    "primary_completion_date": "2012-07",
    "completion_date": "2012-09",
    "results_first_posted": null,
    "last_update_posted": "2013-04-09",
    "enrollment": null,
    "sponsor": "Silence Therapeutics GmbH",
    "collected_at": "2026-01-27",
    "search_term": "Silence Therapeutics"
  },
  {
    "ticker": "SLN",
    "nct_id": "NCT01808638",
    "title": "Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Carcinoma, Pancreatic Ductal"
    ],
    "interventions": [
      "Atu027 & gemcitabine in lead in safety period",
      "Atu027 & gemcitabine in treatment arm 1",
      "Atu027 & gemcitabine in treatment arm 2"
    ],
    "primary_completion_date": "2015-08",
    "completion_date": "2016-01",
    "results_first_posted": null,
    "last_update_posted": "2016-03-11",
    "enrollment": null,
    "sponsor": "Silence Therapeutics GmbH",
    "collected_at": "2026-01-27",
    "search_term": "Silence Therapeutics"
  },
  {
    "ticker": "SLN",
    "nct_id": "NCT05537571",
    "title": "Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cardiovascular Diseases",
      "Atherosclerosis",
      "Lipoprotein(a)"
    ],
    "interventions": [
      "SLN360",
      "Placebo"
    ],
    "primary_completion_date": "2024-01-11",
    "completion_date": "2024-07-01",
    "results_first_posted": "2025-07-01",
    "last_update_posted": "2025-07-01",
    "enrollment": null,
    "sponsor": "Silence Therapeutics plc",
    "collected_at": "2026-01-27",
    "search_term": "Silence Therapeutics"
  },
  {
    "ticker": "SLN",
    "nct_id": "NCT04718844",
    "title": "A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-transfusion-dependent Thalassemia",
      "Low Risk Myelodysplastic Syndrome",
      "Very-Low Risk Myelodysplastic Syndrome"
    ],
    "interventions": [
      "SLN124",
      "Placebo"
    ],
    "primary_completion_date": "2023-05-23",
    "completion_date": "2023-05-23",
    "results_first_posted": null,
    "last_update_posted": "2024-01-03",
    "enrollment": null,
    "sponsor": "Silence Therapeutics plc",
    "collected_at": "2026-01-27",
    "search_term": "Silence Therapeutics"
  },
  {
    "ticker": "SLN",
    "nct_id": "NCT04176653",
    "title": "Study in Beta-thalassaemia or Myelodysplastic Syndrome Patients to Investigate the Safety and Tolerability of SLN124",
    "status": "WITHDRAWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-transfusion-dependent Thalassemia",
      "Low Risk Myelodysplastic Syndrome"
    ],
    "interventions": [
      "SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as Placebo"
    ],
    "primary_completion_date": "2021-09-30",
    "completion_date": "2021-10-14",
    "results_first_posted": null,
    "last_update_posted": "2020-04-27",
    "enrollment": null,
    "sponsor": "Silence Therapeutics plc",
    "collected_at": "2026-01-27",
    "search_term": "Silence Therapeutics"
  },
  {
    "ticker": "SLN",
    "nct_id": "NCT04559971",
    "title": "A Phase 1 Study to Evaluate the Safety, Tolerability, PK and PD of SLN124 in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "EARLY_PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "SLN124",
      "Placebo"
    ],
    "primary_completion_date": "2021-03-23",
    "completion_date": "2021-03-23",
    "results_first_posted": null,
    "last_update_posted": "2023-04-21",
    "enrollment": null,
    "sponsor": "Silence Therapeutics plc",
    "collected_at": "2026-01-27",
    "search_term": "Silence Therapeutics"
  },
  {
    "ticker": "SLN",
    "nct_id": "NCT04606602",
    "title": "Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hyperlipidemias",
      "Dyslipidemias",
      "Elevated Lp(a)"
    ],
    "interventions": [
      "SLN360",
      "Placebo"
    ],
    "primary_completion_date": "2023-08-23",
    "completion_date": "2023-08-23",
    "results_first_posted": null,
    "last_update_posted": "2024-08-12",
    "enrollment": null,
    "sponsor": "Silence Therapeutics plc",
    "collected_at": "2026-01-27",
    "search_term": "Silence Therapeutics"
  },
  {
    "ticker": "ERAS",
    "nct_id": "NCT04959981",
    "title": "A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Non-squamous Non-small-cell Lung Cancer"
    ],
    "interventions": [
      "ERAS-007",
      "ERAS-601",
      "Osimertinib",
      "Sotorasib"
    ],
    "primary_completion_date": "2023-04-27",
    "completion_date": "2023-04-27",
    "results_first_posted": null,
    "last_update_posted": "2023-07-25",
    "enrollment": null,
    "sponsor": "Erasca, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Erasca"
  },
  {
    "ticker": "ERAS",
    "nct_id": "NCT05039177",
    "title": "A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Colorectal Cancer",
      "Metastatic Pancreatic Ductal Adenocarcinoma"
    ],
    "interventions": [
      "ERAS-007",
      "Encorafenib",
      "Cetuximab",
      "Palbociclib"
    ],
    "primary_completion_date": "2025-08",
    "completion_date": "2025-12",
    "results_first_posted": null,
    "last_update_posted": "2025-02-11",
    "enrollment": null,
    "sponsor": "Erasca, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Erasca"
  },
  {
    "ticker": "ERAS",
    "nct_id": "NCT04866134",
    "title": "A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced or Metastatic Solid Tumors"
    ],
    "interventions": [
      "ERAS-007",
      "ERAS-601"
    ],
    "primary_completion_date": "2025-05-01",
    "completion_date": "2025-11-01",
    "results_first_posted": null,
    "last_update_posted": "2024-08-27",
    "enrollment": null,
    "sponsor": "Erasca, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Erasca"
  },
  {
    "ticker": "ERAS",
    "nct_id": "NCT05907304",
    "title": "A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced or Metastatic Solid Tumors"
    ],
    "interventions": [
      "Naporafenib",
      "Trametinib"
    ],
    "primary_completion_date": "2025-07",
    "completion_date": "2025-11",
    "results_first_posted": null,
    "last_update_posted": "2025-05-22",
    "enrollment": null,
    "sponsor": "Erasca, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Erasca"
  },
  {
    "ticker": "ERAS",
    "nct_id": "NCT04670679",
    "title": "A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced or Metastatic Solid Tumors"
    ],
    "interventions": [
      "ERAS-601",
      "Cetuximab",
      "Pembrolizumab"
    ],
    "primary_completion_date": "2025-11",
    "completion_date": "2026-02",
    "results_first_posted": null,
    "last_update_posted": "2025-02-12",
    "enrollment": null,
    "sponsor": "Erasca, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Erasca"
  },
  {
    "ticker": "ERAS",
    "nct_id": "NCT05279859",
    "title": "A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies",
    "status": "WITHDRAWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Myeloid Leukemia"
    ],
    "interventions": [
      "ERAS-007",
      "ERAS-601",
      "Gilteritinib"
    ],
    "primary_completion_date": "2025-03-01",
    "completion_date": "2025-06-01",
    "results_first_posted": null,
    "last_update_posted": "2022-06-15",
    "enrollment": null,
    "sponsor": "Erasca, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Erasca"
  },
  {
    "ticker": "ERAS",
    "nct_id": "NCT06983743",
    "title": "A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Solid Tumors"
    ],
    "interventions": [
      "ERAS-0015",
      "ERAS-0015 in combination"
    ],
    "primary_completion_date": "2028-05-01",
    "completion_date": "2028-12-01",
    "results_first_posted": null,
    "last_update_posted": "2025-09-11",
    "enrollment": null,
    "sponsor": "Erasca, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Erasca"
  },
  {
    "ticker": "ERAS",
    "nct_id": "NCT06346067",
    "title": "A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced or Metastatic NRAS-mutant Melanoma"
    ],
    "interventions": [
      "Naporafenib",
      "Dacarbazine",
      "Temozolomide",
      "Trametinib"
    ],
    "primary_completion_date": "2028-04",
    "completion_date": "2028-12",
    "results_first_posted": null,
    "last_update_posted": "2025-01-17",
    "enrollment": null,
    "sponsor": "Erasca, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Erasca"
  },
  {
    "ticker": "ERAS",
    "nct_id": "NCT07021898",
    "title": "A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Solid Tumors"
    ],
    "interventions": [
      "ERAS-4001",
      "ERAS-4001 in combination"
    ],
    "primary_completion_date": "2028-08",
    "completion_date": "2028-12",
    "results_first_posted": null,
    "last_update_posted": "2025-12-03",
    "enrollment": null,
    "sponsor": "Erasca, Inc.",
    "collected_at": "2026-01-27",
    "search_term": "Erasca"
  },
  {
    "ticker": "CLLS",
    "nct_id": "NCT04106076",
    "title": "Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia",
    "status": "WITHDRAWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Myeloid Leukaemia"
    ],
    "interventions": [
      "UCART123"
    ],
    "primary_completion_date": "2019-12-05",
    "completion_date": "2019-12-05",
    "results_first_posted": null,
    "last_update_posted": "2020-07-14",
    "enrollment": null,
    "sponsor": "Cellectis S.A.",
    "collected_at": "2026-01-27",
    "search_term": "Cellectis"
  },
  {
    "ticker": "CLLS",
    "nct_id": "NCT04150497",
    "title": "Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "B-cell Acute Lymphoblastic Leukemia"
    ],
    "interventions": [
      "UCART22",
      "CLLS52"
    ],
    "primary_completion_date": "2026-06-30",
    "completion_date": "2026-06-30",
    "results_first_posted": null,
    "last_update_posted": "2025-09-09",
    "enrollment": null,
    "sponsor": "Cellectis S.A.",
    "collected_at": "2026-01-27",
    "search_term": "Cellectis"
  },
  {
    "ticker": "CLLS",
    "nct_id": "NCT03190278",
    "title": "Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsed/Refractory Acute Myeloid Leukemia"
    ],
    "interventions": [
      "UCART123v1.2"
    ],
    "primary_completion_date": "2024-12-24",
    "completion_date": "2025-12",
    "results_first_posted": null,
    "last_update_posted": "2025-08-07",
    "enrollment": null,
    "sponsor": "Cellectis S.A.",
    "collected_at": "2026-01-27",
    "search_term": "Cellectis"
  },
  {
    "ticker": "CLLS",
    "nct_id": "NCT04142619",
    "title": "Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsed/Refractory Multiple Myeloma"
    ],
    "interventions": [
      "UCARTCS1A"
    ],
    "primary_completion_date": "2023-06-18",
    "completion_date": "2023-06-18",
    "results_first_posted": null,
    "last_update_posted": "2023-09-22",
    "enrollment": null,
    "sponsor": "Cellectis S.A.",
    "collected_at": "2026-01-27",
    "search_term": "Cellectis"
  },
  {
    "ticker": "CLLS",
    "nct_id": "NCT03203369",
    "title": "Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)"
    ],
    "interventions": [
      "UCART123"
    ],
    "primary_completion_date": "2019-06-27",
    "completion_date": "2019-06-27",
    "results_first_posted": null,
    "last_update_posted": "2019-07-31",
    "enrollment": null,
    "sponsor": "Cellectis S.A.",
    "collected_at": "2026-01-27",
    "search_term": "Cellectis"
  },
  {
    "ticker": "CLLS",
    "nct_id": "NCT05607420",
    "title": "Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "B-cell Non-Hodgkin Lymphoma (B-NHL)"
    ],
    "interventions": [
      "UCART20x22",
      "CLLS52"
    ],
    "primary_completion_date": "2027-08",
    "completion_date": "2027-08",
    "results_first_posted": null,
    "last_update_posted": "2025-08-24",
    "enrollment": null,
    "sponsor": "Cellectis S.A.",
    "collected_at": "2026-01-27",
    "search_term": "Cellectis"
  },
  {
    "ticker": "SION",
    "nct_id": "NCT03720418",
    "title": "Study of OXB-102 (AXO-Lenti-PD) in Patients With Bilateral, Idiopathic Parkinson's Disease",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Parkinson Disease"
    ],
    "interventions": [
      "OXB-102",
      "Imitation Surgical Procedure (ISP)"
    ],
    "primary_completion_date": "2022-04-12",
    "completion_date": "2022-04-12",
    "results_first_posted": null,
    "last_update_posted": "2022-05-03",
    "enrollment": null,
    "sponsor": "Sio Gene Therapies",
    "collected_at": "2026-01-27",
    "search_term": "Sio Gene Therapies"
  },
  {
    "ticker": "AARD",
    "nct_id": "NCT07197034",
    "title": "The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) Trial",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hyperphagia",
      "Prader-Willi Syndrome",
      "Hyperphagia in Prader-Willi Syndrome"
    ],
    "interventions": [
      "ARD-101"
    ],
    "primary_completion_date": "2027-03",
    "completion_date": "2027-04",
    "results_first_posted": null,
    "last_update_posted": "2026-01-08",
    "enrollment": null,
    "sponsor": "Aardvark Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AARD",
    "nct_id": "NCT05121441",
    "title": "Study to Evaluate ARD-101 in Adults With Obesity",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Obesity"
    ],
    "interventions": [
      "ARD-101",
      "Placebo"
    ],
    "primary_completion_date": "2022-11-09",
    "completion_date": "2022-11-09",
    "results_first_posted": "2025-01-22",
    "last_update_posted": "2025-01-22",
    "enrollment": null,
    "sponsor": "Aardvark Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AARD",
    "nct_id": "NCT06828861",
    "title": "ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hyperphagia",
      "Prader-Willi Syndrome"
    ],
    "interventions": [
      "Placebo",
      "ARD-101"
    ],
    "primary_completion_date": "2026-03",
    "completion_date": "2026-04",
    "results_first_posted": null,
    "last_update_posted": "2026-01-08",
    "enrollment": null,
    "sponsor": "Aardvark Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AARD",
    "nct_id": "NCT05153434",
    "title": "A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Prader-Willi Syndrome"
    ],
    "interventions": [
      "ARD-101"
    ],
    "primary_completion_date": "2024-09-24",
    "completion_date": "2024-09-24",
    "results_first_posted": null,
    "last_update_posted": "2025-05-09",
    "enrollment": null,
    "sponsor": "Aardvark Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AARD",
    "nct_id": "NCT01129765",
    "title": "Home Usability of a Nasal Lavage System in Children",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Nasal Congestion",
      "Respiratory Tract Infection",
      "Sinusitis",
      "Allergic Rhinitis"
    ],
    "interventions": [
      "Use of an automatic nasal irrigator/aspirator"
    ],
    "primary_completion_date": "2009-08",
    "completion_date": "2009-08",
    "results_first_posted": "2010-07-05",
    "last_update_posted": "2010-08-03",
    "enrollment": null,
    "sponsor": "Aardvark Medical Company",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AARD",
    "nct_id": "NCT06126653",
    "title": "A Study to Evaluate ARD-501 in Patients With Autism Spectrum Disorder",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Autism Spectrum Disorder"
    ],
    "interventions": [
      "Low Dose ARD-501",
      "High Dose ARD-501",
      "Placebo"
    ],
    "primary_completion_date": "2025-01-13",
    "completion_date": "2025-01-13",
    "results_first_posted": null,
    "last_update_posted": "2025-05-09",
    "enrollment": null,
    "sponsor": "Aardvark Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AARD",
    "nct_id": "NCT05215847",
    "title": "Study to Evaluate ARD-101 in Adults Receiving Bariatric Surgery",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bariatric Surgery",
      "Obesity",
      "Weight Gain"
    ],
    "interventions": [
      "ARD-101"
    ],
    "primary_completion_date": "2023-02-03",
    "completion_date": "2023-02-03",
    "results_first_posted": "2024-11-14",
    "last_update_posted": "2025-02-11",
    "enrollment": null,
    "sponsor": "Aardvark Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ABCL",
    "nct_id": "NCT07118891",
    "title": "Study Evaluating ABCL635 for Vasomotor Symptoms of Menopause",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Vasomotor Symptoms Associated With Menopause",
      "Healthy Volunteers"
    ],
    "interventions": [
      "ABCL635",
      "Placebo"
    ],
    "primary_completion_date": "2027-02",
    "completion_date": "2027-02",
    "results_first_posted": null,
    "last_update_posted": "2026-01-27",
    "enrollment": null,
    "sponsor": "AbCellera Biologics Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ABCL",
    "nct_id": "NCT07108894",
    "title": "A First-in-Human Phase 1 Single-Ascending Dose Study of ABCL575 in Healthy Participants",
    "status": "RECRUITING",
    "phase": "EARLY_PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "ABCL575",
      "Placebo (Normal Saline 0.9%)"
    ],
    "primary_completion_date": "2026-11",
    "completion_date": "2026-11",
    "results_first_posted": null,
    "last_update_posted": "2025-08-15",
    "enrollment": null,
    "sponsor": "AbCellera Biologics Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACIU",
    "nct_id": "NCT04445831",
    "title": "A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's Disease",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alzheimer's Disease",
      "Cognitive Impairment",
      "Tauopathies",
      "Mild Cognitive Impairment",
      "Dementia",
      "Brain Diseases",
      "Central Nervous System Diseases"
    ],
    "interventions": [
      "ACI-35.030",
      "ACI-35.030",
      "ACI-35.030",
      "Placebo",
      "JACI-35.054",
      "JACI-35.054"
    ],
    "primary_completion_date": "2023-09-05",
    "completion_date": "2023-09-05",
    "results_first_posted": "2025-02-14",
    "last_update_posted": "2025-02-14",
    "enrollment": null,
    "sponsor": "AC Immune SA",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACIU",
    "nct_id": "NCT04373616",
    "title": "A Study of ACI-24 in Adults With Down Syndrome",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Down Syndrome"
    ],
    "interventions": [
      "ACI-24",
      "Placebo"
    ],
    "primary_completion_date": "2024-04",
    "completion_date": "2024-10",
    "results_first_posted": null,
    "last_update_posted": "2021-10-22",
    "enrollment": null,
    "sponsor": "AC Immune SA",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACIU",
    "nct_id": "NCT06891716",
    "title": "[18F]ACI-19626 PET in TDP-43 Proteinopathies",
    "status": "RECRUITING",
    "phase": "EARLY_PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Frontotemporal Dementia (FTD)",
      "Amyotrophic Lateral Sclerosis (ALS)",
      "TDP-43 Proteinopathies",
      "Suspected Limbic Predominant Age-related TDP-43 Encephalopathy (LATE)",
      "Alzheimer's Disease (AD)"
    ],
    "interventions": [
      "[18F]ACI-19626"
    ],
    "primary_completion_date": "2026-11",
    "completion_date": "2026-11",
    "results_first_posted": null,
    "last_update_posted": "2025-03-24",
    "enrollment": null,
    "sponsor": "AC Immune SA",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACIU",
    "nct_id": "NCT05462106",
    "title": "A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Amyloid Plaque",
      "Beta-Amyloid",
      "DSAD",
      "Prodromal Alzheimer's Disease",
      "Alzheimer's Disease"
    ],
    "interventions": [
      "Placebo",
      "ACI-24.060 at Dose A",
      "ACI-24.060 at Dose B",
      "ACI-24.060 at Dose C",
      "ACI-24.060 at Dose D",
      "Placebo",
      "ACI-24.060 at Dose A",
      "ACI-24.060 at Dose B",
      "ACI-24.060 at Dose C"
    ],
    "primary_completion_date": "2026-06",
    "completion_date": "2026-06",
    "results_first_posted": null,
    "last_update_posted": "2025-12-15",
    "enrollment": null,
    "sponsor": "AC Immune SA",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACIU",
    "nct_id": "NCT02738450",
    "title": "Safety, Tolerability and Immunogenicity of ACI-24 Vaccine in Adults With Down Syndrome",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Down Syndrome"
    ],
    "interventions": [
      "ACI-24 low dose",
      "ACI-24 high dose",
      "Placebo"
    ],
    "primary_completion_date": "2020-06",
    "completion_date": "2020-06",
    "results_first_posted": "2021-09-21",
    "last_update_posted": "2021-10-15",
    "enrollment": null,
    "sponsor": "AC Immune SA",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACIU",
    "nct_id": "NCT06015841",
    "title": "A Study to Evaluate the Effects of ACI-7104.056 in Patients With Early Stages of Parkinson's Disease",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Parkinson Disease",
      "Parkinson Disease 6, Early-Onset"
    ],
    "interventions": [
      "Placebo",
      "ACI-7104.056 at Dose A",
      "ACI-7104.056 at Dose B (optional)",
      "ACI-7104.056 at Dose C (optional)"
    ],
    "primary_completion_date": "2028-01",
    "completion_date": "2028-01",
    "results_first_posted": null,
    "last_update_posted": "2025-11-21",
    "enrollment": null,
    "sponsor": "AC Immune SA",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACIU",
    "nct_id": "NCT06891703",
    "title": "[18F]ACI-15916 PET in \u03b1-synucleinopathies",
    "status": "RECRUITING",
    "phase": "EARLY_PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Parkinson's Disease (PD)",
      "Multiple System Atrophy (MSA)",
      "Dementia With Lewy Bodies (DLB)"
    ],
    "interventions": [
      "[18F]ACI-15916"
    ],
    "primary_completion_date": "2026-03",
    "completion_date": "2026-03",
    "results_first_posted": null,
    "last_update_posted": "2025-11-19",
    "enrollment": null,
    "sponsor": "AC Immune SA",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACRS",
    "nct_id": "NCT03315689",
    "title": "Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alopecia Universalis (AU)",
      "Alopecia Totalis (AT)"
    ],
    "interventions": [
      "Vehicle",
      "ATI-50002"
    ],
    "primary_completion_date": "2019-06-20",
    "completion_date": "2019-06-20",
    "results_first_posted": "2020-07-02",
    "last_update_posted": "2020-07-02",
    "enrollment": null,
    "sponsor": "Aclaris Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACRS",
    "nct_id": "NCT02160626",
    "title": "Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Seborrheic Keratosis"
    ],
    "interventions": [
      "A-101 Vehicle",
      "A-101 (40) Topical Solution",
      "A-101 (32.5) Topical Solution"
    ],
    "primary_completion_date": "2014-12",
    "completion_date": "2014-12",
    "results_first_posted": "2018-12-07",
    "last_update_posted": "2019-01-03",
    "enrollment": null,
    "sponsor": "Aclaris Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACRS",
    "nct_id": "NCT05216224",
    "title": "ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hidradenitis Suppurativa"
    ],
    "interventions": [
      "ATI-450",
      "Placebo oral tablet"
    ],
    "primary_completion_date": "2022-12-23",
    "completion_date": "2023-01-24",
    "results_first_posted": "2026-01-07",
    "last_update_posted": "2026-01-07",
    "enrollment": null,
    "sponsor": "Aclaris Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACRS",
    "nct_id": "NCT04247815",
    "title": "Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rheumatoid Arthritis"
    ],
    "interventions": [
      "ATI-450",
      "Placebo oral tablet",
      "Methotrexate"
    ],
    "primary_completion_date": "2021-02-04",
    "completion_date": "2021-02-04",
    "results_first_posted": "2023-03-29",
    "last_update_posted": "2023-03-29",
    "enrollment": null,
    "sponsor": "Aclaris Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACRS",
    "nct_id": "NCT02667236",
    "title": "A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Seborrheic Keratosis"
    ],
    "interventions": [
      "A-101 Solution",
      "Vehicle Solution"
    ],
    "primary_completion_date": "2016-10",
    "completion_date": "2016-10",
    "results_first_posted": "2017-11-13",
    "last_update_posted": "2018-02-06",
    "enrollment": null,
    "sponsor": "Aclaris Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACRS",
    "nct_id": "NCT03812510",
    "title": "Safety Study of A-101 Topical Solution for the Treatment of Common Warts",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Common Wart"
    ],
    "interventions": [
      "A-101"
    ],
    "primary_completion_date": "2019-11-27",
    "completion_date": "2019-12-20",
    "results_first_posted": "2020-11-23",
    "last_update_posted": "2020-11-23",
    "enrollment": null,
    "sponsor": "Aclaris Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACRS",
    "nct_id": "NCT02669862",
    "title": "A Study of A-101 Solution in Subjects With Common Warts.",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Common Warts"
    ],
    "interventions": [
      "A-101 Solution 40",
      "A-101 Solution 45",
      "Vehicle Solution"
    ],
    "primary_completion_date": "2016-09-16",
    "completion_date": "2016-09-16",
    "results_first_posted": "2018-12-07",
    "last_update_posted": "2018-12-07",
    "enrollment": null,
    "sponsor": "Aclaris Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACRS",
    "nct_id": "NCT03354637",
    "title": "A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alopecia Areata"
    ],
    "interventions": [
      "ATI-50002 high dose",
      "ATI-50002 low dose",
      "Placebo"
    ],
    "primary_completion_date": "2019-04-18",
    "completion_date": "2019-09-10",
    "results_first_posted": "2020-06-05",
    "last_update_posted": "2020-06-05",
    "enrollment": null,
    "sponsor": "Aclaris Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACRS",
    "nct_id": "NCT03594227",
    "title": "ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alopecia"
    ],
    "interventions": [
      "ATI-501 400mg BID (Low dose)",
      "ATI-501 600mg BID (Mid dose)",
      "ATI-501 800mg BID (High dose)",
      "Placebo"
    ],
    "primary_completion_date": "2019-06-06",
    "completion_date": "2019-06-18",
    "results_first_posted": "2020-09-16",
    "last_update_posted": "2020-09-16",
    "enrollment": null,
    "sponsor": "Aclaris Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACRS",
    "nct_id": "NCT05279417",
    "title": "ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rheumatoid Arthritis"
    ],
    "interventions": [
      "ATI-450 50 mg oral tablet BID",
      "Placebo oral tablet",
      "Methotrexate",
      "ATI-450 20 mg oral tablet BID"
    ],
    "primary_completion_date": "2023-09-05",
    "completion_date": "2023-10-11",
    "results_first_posted": null,
    "last_update_posted": "2024-09-05",
    "enrollment": null,
    "sponsor": "Aclaris Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACRS",
    "nct_id": "NCT03380390",
    "title": "Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rosacea"
    ],
    "interventions": [
      "Oxymetazoline HCL 1.0% Cream",
      "Energy-Based Therapy"
    ],
    "primary_completion_date": "2018-06-15",
    "completion_date": "2018-06-15",
    "results_first_posted": "2019-06-28",
    "last_update_posted": "2019-09-04",
    "enrollment": null,
    "sponsor": "Aclaris Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACRS",
    "nct_id": "NCT03210337",
    "title": "A Phase2 of A-101 Topical Solution in Subjects With Common Warts",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Common Wart"
    ],
    "interventions": [
      "A-101 Topical Solution",
      "A-101 Vehicle Solution"
    ],
    "primary_completion_date": "2018-03-16",
    "completion_date": "2018-03-16",
    "results_first_posted": "2019-05-01",
    "last_update_posted": "2019-05-01",
    "enrollment": null,
    "sponsor": "Aclaris Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACRS",
    "nct_id": "NCT03278028",
    "title": "A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Common Wart"
    ],
    "interventions": [
      "A-101 Topical Solution",
      "A-101 Vehicle Solution"
    ],
    "primary_completion_date": "2018-03-01",
    "completion_date": "2018-03-01",
    "results_first_posted": "2019-03-29",
    "last_update_posted": "2019-04-09",
    "enrollment": null,
    "sponsor": "Aclaris Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACRS",
    "nct_id": "NCT02667288",
    "title": "An Open-Label Safety Study of A-101 Solution",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Seborrheic Keratosis"
    ],
    "interventions": [
      "A-101 Solution"
    ],
    "primary_completion_date": "2016-10",
    "completion_date": "2016-10",
    "results_first_posted": "2017-11-17",
    "last_update_posted": "2018-02-07",
    "enrollment": null,
    "sponsor": "Aclaris Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACRS",
    "nct_id": "NCT03585296",
    "title": "A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atopic Dermatitis"
    ],
    "interventions": [
      "ATI-502"
    ],
    "primary_completion_date": "2019-04-25",
    "completion_date": "2019-04-25",
    "results_first_posted": "2020-02-06",
    "last_update_posted": "2020-02-17",
    "enrollment": null,
    "sponsor": "Aclaris Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACRS",
    "nct_id": "NCT03551821",
    "title": "Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alopecia Areata",
      "Alopecia Totalis",
      "Alopecia Universalis"
    ],
    "interventions": [
      "ATI-50002"
    ],
    "primary_completion_date": "2018-11-06",
    "completion_date": "2018-11-06",
    "results_first_posted": "2019-12-11",
    "last_update_posted": "2019-12-11",
    "enrollment": null,
    "sponsor": "Aclaris Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACRS",
    "nct_id": "NCT03487588",
    "title": "An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Seborrheic Keratosis"
    ],
    "interventions": [
      "A-101 Topical Solution"
    ],
    "primary_completion_date": "2018-11-14",
    "completion_date": "2018-11-14",
    "results_first_posted": "2019-10-02",
    "last_update_posted": "2019-10-02",
    "enrollment": null,
    "sponsor": "Aclaris Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACRS",
    "nct_id": "NCT03468855",
    "title": "A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Vitiligo"
    ],
    "interventions": [
      "ATI-50002 topical solution"
    ],
    "primary_completion_date": "2019-10-16",
    "completion_date": "2019-10-16",
    "results_first_posted": "2020-11-30",
    "last_update_posted": "2020-11-30",
    "enrollment": null,
    "sponsor": "Aclaris Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACRS",
    "nct_id": "NCT05432596",
    "title": "Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atopic Dermatitis"
    ],
    "interventions": [
      "ATI-1777 2.0% w/w",
      "ATI-1777 1.0% w/w",
      "ATI-1777 0.5% w/w",
      "Vehicle"
    ],
    "primary_completion_date": "2023-10-26",
    "completion_date": "2023-11-14",
    "results_first_posted": null,
    "last_update_posted": "2024-10-26",
    "enrollment": null,
    "sponsor": "Aclaris Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACRS",
    "nct_id": "NCT03691831",
    "title": "A Study of A-101 Topical Solution for the Treatment of Common Warts",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Common Wart"
    ],
    "interventions": [
      "Active",
      "Vehicle"
    ],
    "primary_completion_date": "2019-04-21",
    "completion_date": "2019-07-09",
    "results_first_posted": "2020-10-05",
    "last_update_posted": "2020-10-27",
    "enrollment": null,
    "sponsor": "Aclaris Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACRS",
    "nct_id": "NCT03148691",
    "title": "A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic Keratosis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Seborrheic Keratosis"
    ],
    "interventions": [
      "A-101"
    ],
    "primary_completion_date": "2018-02-28",
    "completion_date": "2018-04-03",
    "results_first_posted": "2019-05-06",
    "last_update_posted": "2019-05-06",
    "enrollment": null,
    "sponsor": "Aclaris Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACRS",
    "nct_id": "NCT04524858",
    "title": "Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cryopyrin-Associated Periodic Syndrome"
    ],
    "interventions": [
      "ATI-450"
    ],
    "primary_completion_date": "2021-02-25",
    "completion_date": "2021-02-25",
    "results_first_posted": "2023-09-21",
    "last_update_posted": "2023-09-21",
    "enrollment": null,
    "sponsor": "Aclaris Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACRS",
    "nct_id": "NCT07011706",
    "title": "ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atopic Dermatitis",
      "Atopic",
      "Dermatitis",
      "AD",
      "Eczema"
    ],
    "interventions": [
      "ATI-045",
      "Placebo"
    ],
    "primary_completion_date": "2026-08",
    "completion_date": "2026-10",
    "results_first_posted": null,
    "last_update_posted": "2026-01-13",
    "enrollment": null,
    "sponsor": "Aclaris Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACRS",
    "nct_id": "NCT03495817",
    "title": "A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Androgenetic Alopecia"
    ],
    "interventions": [
      "ATI-50002"
    ],
    "primary_completion_date": "2019-10-15",
    "completion_date": "2019-10-30",
    "results_first_posted": "2020-12-09",
    "last_update_posted": "2020-12-09",
    "enrollment": null,
    "sponsor": "Aclaris Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACRS",
    "nct_id": "NCT01986920",
    "title": "Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Seborrheic Keratosis (SK)"
    ],
    "interventions": [
      "A-101 25%",
      "A-101 32.5%",
      "A-101 40%",
      "A-101 Vehicle"
    ],
    "primary_completion_date": "2014-02-25",
    "completion_date": "2014-02-25",
    "results_first_posted": "2018-12-11",
    "last_update_posted": "2018-12-11",
    "enrollment": null,
    "sponsor": "Aclaris Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACRS",
    "nct_id": "NCT06585202",
    "title": "Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atopic Dermatitis"
    ],
    "interventions": [
      "ATI-2138"
    ],
    "primary_completion_date": "2025-03-13",
    "completion_date": "2025-03-27",
    "results_first_posted": null,
    "last_update_posted": "2025-04-29",
    "enrollment": null,
    "sponsor": "Aclaris Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACRS",
    "nct_id": "NCT02260180",
    "title": "Study of A-101 for the Treatment of Seborrheic Keratosis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Seborrheic Keratosis"
    ],
    "interventions": [
      "A-101"
    ],
    "primary_completion_date": "2015-03",
    "completion_date": "2015-03",
    "results_first_posted": "2018-12-06",
    "last_update_posted": "2020-12-02",
    "enrollment": null,
    "sponsor": "Aclaris Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACRS",
    "nct_id": "NCT03759340",
    "title": "ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alopecia Areata",
      "Alopecia Universalis",
      "Alopecia Totalis"
    ],
    "interventions": [
      "ATI 502 0.46% Topical Solution"
    ],
    "primary_completion_date": "2019-09-11",
    "completion_date": "2019-09-11",
    "results_first_posted": "2020-09-17",
    "last_update_posted": "2020-10-06",
    "enrollment": null,
    "sponsor": "Aclaris Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACRS",
    "nct_id": "NCT05511519",
    "title": "Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Psoriatic Arthritis"
    ],
    "interventions": [
      "ATI-450",
      "Placebo Oral Tablet"
    ],
    "primary_completion_date": "2023-12-06",
    "completion_date": "2024-01-03",
    "results_first_posted": null,
    "last_update_posted": "2024-11-27",
    "enrollment": null,
    "sponsor": "Aclaris Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACRS",
    "nct_id": "NCT04598269",
    "title": "Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atopic Dermatitis"
    ],
    "interventions": [
      "ATI-1777",
      "Vehicle"
    ],
    "primary_completion_date": "2021-04-08",
    "completion_date": "2021-04-22",
    "results_first_posted": "2023-09-28",
    "last_update_posted": "2023-09-28",
    "enrollment": null,
    "sponsor": "Aclaris Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACRS",
    "nct_id": "NCT02667275",
    "title": "A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Seborrheic Keratosis"
    ],
    "interventions": [
      "A-101 Solution",
      "Vehicle Solution"
    ],
    "primary_completion_date": "2016-10",
    "completion_date": "2016-10",
    "results_first_posted": "2017-11-13",
    "last_update_posted": "2018-02-06",
    "enrollment": null,
    "sponsor": "Aclaris Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACRS",
    "nct_id": "NCT03224598",
    "title": "A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dermatosis Papulosa Nigra"
    ],
    "interventions": [
      "A-101 Topical Solution 40%"
    ],
    "primary_completion_date": "2019-01-08",
    "completion_date": "2019-01-08",
    "results_first_posted": "2020-03-17",
    "last_update_posted": "2020-03-30",
    "enrollment": null,
    "sponsor": "Aclaris Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ACRS",
    "nct_id": "NCT03687372",
    "title": "Study of A-101 Topical Solution for the Treatment of Common Warts",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Common Wart"
    ],
    "interventions": [
      "A-101",
      "vehicle"
    ],
    "primary_completion_date": "2019-06-20",
    "completion_date": "2019-09-06",
    "results_first_posted": "2020-10-05",
    "last_update_posted": "2020-10-05",
    "enrollment": null,
    "sponsor": "Aclaris Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AGIO",
    "nct_id": "NCT04565678",
    "title": "A Study to Assess the Relative Bioavailability and Effect of Food on the Coated Granule Formulation of Mitapivat in Healthy Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "Mitapivat tablets",
      "Mitapivat coated granules"
    ],
    "primary_completion_date": "2020-12-03",
    "completion_date": "2020-12-03",
    "results_first_posted": null,
    "last_update_posted": "2020-12-10",
    "enrollment": null,
    "sponsor": "Agios Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AGIO",
    "nct_id": "NCT02492737",
    "title": "Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Myeloid Leukemia (AML)",
      "Myelodysplastic Syndrome",
      "Hematologic Malignancies"
    ],
    "interventions": [
      "AG881"
    ],
    "primary_completion_date": "2018-03-21",
    "completion_date": "2018-03-21",
    "results_first_posted": null,
    "last_update_posted": "2019-03-08",
    "enrollment": null,
    "sponsor": "Agios Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AGIO",
    "nct_id": "NCT03559699",
    "title": "A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pyruvate Kinase Deficiency",
      "Anemia, Hemolytic"
    ],
    "interventions": [
      "AG-348"
    ],
    "primary_completion_date": "2020-11-12",
    "completion_date": "2020-11-12",
    "results_first_posted": "2021-12-10",
    "last_update_posted": "2022-01-04",
    "enrollment": null,
    "sponsor": "Agios Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AGIO",
    "nct_id": "NCT03834584",
    "title": "A Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lymphoma"
    ],
    "interventions": [
      "AG-636"
    ],
    "primary_completion_date": "2020-06-17",
    "completion_date": "2020-06-17",
    "results_first_posted": null,
    "last_update_posted": "2020-08-25",
    "enrollment": null,
    "sponsor": "Agios Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AGIO",
    "nct_id": "NCT04472832",
    "title": "A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Mitapivat (AG-348) in Healthy Adult Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "Placebo for Treatment A",
      "Mitapivat 100 mg",
      "Placebo for Treatment B",
      "Mitapivat 300 mg",
      "Placebo for Treatment C"
    ],
    "primary_completion_date": "2020-11-23",
    "completion_date": "2020-11-23",
    "results_first_posted": null,
    "last_update_posted": "2021-02-18",
    "enrollment": null,
    "sponsor": "Agios Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AGIO",
    "nct_id": "NCT06286046",
    "title": "A Study of Mitapivat in Participants With Sickle Cell Disease and Nephropathy",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Sickle Cell Disease",
      "Nephropathy"
    ],
    "interventions": [
      "Mitapivat"
    ],
    "primary_completion_date": "2027-05",
    "completion_date": "2028-12",
    "results_first_posted": null,
    "last_update_posted": "2025-12-26",
    "enrollment": null,
    "sponsor": "Agios Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AGIO",
    "nct_id": "NCT06648824",
    "title": "Study of How Mitapivat Affects Midazolam Blood Levels in Healthy Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants"
    ],
    "interventions": [
      "Mitapivat",
      "Midazolam"
    ],
    "primary_completion_date": "2024-12-03",
    "completion_date": "2024-12-03",
    "results_first_posted": null,
    "last_update_posted": "2025-01-28",
    "enrollment": null,
    "sponsor": "Agios Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AGIO",
    "nct_id": "NCT02831972",
    "title": "Drug-Drug Interaction Study of AG120 in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "AG120",
      "Itraconazole"
    ],
    "primary_completion_date": "2016-09",
    "completion_date": "2016-10",
    "results_first_posted": null,
    "last_update_posted": "2017-06-27",
    "enrollment": null,
    "sponsor": "Agios Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AGIO",
    "nct_id": "NCT03397329",
    "title": "Study to Evaluate the Relative Bioavailability and Safety of the AG-348 Tablet and Capsule Formulations in Healthy Adults",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "AG-348 Sequence A",
      "AG-348 Sequence B"
    ],
    "primary_completion_date": "2017-11-13",
    "completion_date": "2017-11-13",
    "results_first_posted": null,
    "last_update_posted": "2018-01-12",
    "enrollment": null,
    "sponsor": "Agios Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AGIO",
    "nct_id": "NCT03692052",
    "title": "A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent Thalassemia",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Thalassemia"
    ],
    "interventions": [
      "AG-348"
    ],
    "primary_completion_date": "2020-08-20",
    "completion_date": "2030-09-30",
    "results_first_posted": "2021-11-15",
    "last_update_posted": "2026-01-16",
    "enrollment": null,
    "sponsor": "Agios Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AGIO",
    "nct_id": "NCT06286033",
    "title": "Single and Multiple Ascending Dose Study and Food Effect Study for AG181",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "AG-181",
      "Placebo"
    ],
    "primary_completion_date": "2025-10-09",
    "completion_date": "2025-10-09",
    "results_first_posted": null,
    "last_update_posted": "2025-12-23",
    "enrollment": null,
    "sponsor": "Agios Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AGIO",
    "nct_id": "NCT05610657",
    "title": "A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Moderate Hepatic Impairment"
    ],
    "interventions": [
      "Mitapivat"
    ],
    "primary_completion_date": "2023-07-21",
    "completion_date": "2023-07-21",
    "results_first_posted": null,
    "last_update_posted": "2023-09-21",
    "enrollment": null,
    "sponsor": "Agios Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AGIO",
    "nct_id": "NCT03960502",
    "title": "A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C] AG-881 and Concomitant Intravenous Microdose of [13C315N3] AG-881",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Male Participants"
    ],
    "interventions": [
      "AG-881",
      "[13C315N3]AG-881"
    ],
    "primary_completion_date": "2019-09-07",
    "completion_date": "2019-09-07",
    "results_first_posted": null,
    "last_update_posted": "2019-10-23",
    "enrollment": null,
    "sponsor": "Agios Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AGIO",
    "nct_id": "NCT03481738",
    "title": "Pyruvate Kinase Deficiency Global Longitudinal Registry",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Pyruvate Kinase Deficiency"
    ],
    "interventions": [],
    "primary_completion_date": "2027-05-31",
    "completion_date": "2027-05-31",
    "results_first_posted": null,
    "last_update_posted": "2025-12-31",
    "enrollment": null,
    "sponsor": "Agios Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AGIO",
    "nct_id": "NCT04696393",
    "title": "A Study to Compare the Pharmacokinetics and Safety of Mitapivat 100 mg Tablet Formulation With Mitapivat 2 \u00d7 50 mg Tablet Formulation in Healthy Adult Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "Mitapivat tablet"
    ],
    "primary_completion_date": "2021-03-19",
    "completion_date": "2021-03-19",
    "results_first_posted": null,
    "last_update_posted": "2021-04-13",
    "enrollment": null,
    "sponsor": "Agios Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AGIO",
    "nct_id": "NCT01234350",
    "title": "A Safety Study in Patients With Advanced Prostate Cancer Treated With FIRMAGON",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Prostate Cancer"
    ],
    "interventions": [],
    "primary_completion_date": "2018-03-27",
    "completion_date": "2018-03-27",
    "results_first_posted": "2019-05-20",
    "last_update_posted": "2019-06-25",
    "enrollment": null,
    "sponsor": "Ferring Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AGIO",
    "nct_id": "NCT07241234",
    "title": "A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Participants With Phenylketonuria",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Phenylketonuria"
    ],
    "interventions": [
      "AG-181"
    ],
    "primary_completion_date": "2028-01-17",
    "completion_date": "2028-01-17",
    "results_first_posted": null,
    "last_update_posted": "2025-12-31",
    "enrollment": null,
    "sponsor": "Agios Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AGIO",
    "nct_id": "NCT02579707",
    "title": "Food Effect Study of AG120 in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "AG120"
    ],
    "primary_completion_date": "2016-02",
    "completion_date": "2016-06",
    "results_first_posted": null,
    "last_update_posted": "2016-11-29",
    "enrollment": null,
    "sponsor": "Agios Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AGIO",
    "nct_id": "NCT02108106",
    "title": "A Phase I Study of AG-348 in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteer"
    ],
    "interventions": [
      "AG-348",
      "Placebo"
    ],
    "primary_completion_date": "2014-08",
    "completion_date": "2014-08",
    "results_first_posted": null,
    "last_update_posted": "2014-10-22",
    "enrollment": null,
    "sponsor": "Agios Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AGIO",
    "nct_id": "NCT03853798",
    "title": "Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pyruvate Kinase Deficiency"
    ],
    "interventions": [
      "Mitapivat"
    ],
    "primary_completion_date": "2024-07-03",
    "completion_date": "2024-07-03",
    "results_first_posted": "2025-11-18",
    "last_update_posted": "2025-11-18",
    "enrollment": null,
    "sponsor": "Agios Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALMS",
    "nct_id": "NCT05431634",
    "title": "Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Safety and Tolerability"
    ],
    "interventions": [
      "Experimental drug: ESK-001",
      "Placebo"
    ],
    "primary_completion_date": "2022-12-01",
    "completion_date": "2022-12-31",
    "results_first_posted": null,
    "last_update_posted": "2023-05-09",
    "enrollment": null,
    "sponsor": "Alumis Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALMS",
    "nct_id": "NCT06588738",
    "title": "A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Plaque Psoriasis"
    ],
    "interventions": [
      "ESK-001",
      "Placebo",
      "Apremilast"
    ],
    "primary_completion_date": "2025-09-23",
    "completion_date": "2025-12",
    "results_first_posted": null,
    "last_update_posted": "2025-12-09",
    "enrollment": null,
    "sponsor": "Alumis Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALMS",
    "nct_id": "NCT05953688",
    "title": "POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIU",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Uveitis Posterior Non-Infectious",
      "Uveitis, Intermediate",
      "Noninfectious Panuveitis"
    ],
    "interventions": [
      "ESK-001"
    ],
    "primary_completion_date": "2024-08-13",
    "completion_date": "2024-08-13",
    "results_first_posted": null,
    "last_update_posted": "2024-08-28",
    "enrollment": null,
    "sponsor": "Alumis Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALMS",
    "nct_id": "NCT05739435",
    "title": "Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Plaque Psoriasis"
    ],
    "interventions": [
      "ESK-001"
    ],
    "primary_completion_date": "2026-12-01",
    "completion_date": "2026-12-30",
    "results_first_posted": null,
    "last_update_posted": "2025-10-27",
    "enrollment": null,
    "sponsor": "Alumis Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALMS",
    "nct_id": "NCT06586112",
    "title": "A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Plaque Psoriasis"
    ],
    "interventions": [
      "ESK-001",
      "Apremilast",
      "Placebo"
    ],
    "primary_completion_date": "2025-09-19",
    "completion_date": "2025-12",
    "results_first_posted": null,
    "last_update_posted": "2025-12-09",
    "enrollment": null,
    "sponsor": "Alumis Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALMS",
    "nct_id": "NCT06962774",
    "title": "An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Renal Impairment"
    ],
    "interventions": [
      "ESK-001"
    ],
    "primary_completion_date": "2025-08-01",
    "completion_date": "2025-08-01",
    "results_first_posted": null,
    "last_update_posted": "2025-12-10",
    "enrollment": null,
    "sponsor": "Alumis Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALMS",
    "nct_id": "NCT06846541",
    "title": "Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Plaque Psoriasis",
      "Psoriasis (PsO)",
      "Psoriasis",
      "Moderate Psoriasis",
      "Severe Psoriasis"
    ],
    "interventions": [
      "Open-Label ESK-001",
      "Blinded ESK-001",
      "Placebo"
    ],
    "primary_completion_date": "2028-11",
    "completion_date": "2028-11",
    "results_first_posted": null,
    "last_update_posted": "2025-10-28",
    "enrollment": null,
    "sponsor": "Alumis Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALMS",
    "nct_id": "NCT05600036",
    "title": "A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Plaque Psoriasis"
    ],
    "interventions": [
      "ESK-001",
      "Placebo"
    ],
    "primary_completion_date": "2023-06-29",
    "completion_date": "2023-07-25",
    "results_first_posted": "2024-07-23",
    "last_update_posted": "2025-06-18",
    "enrollment": null,
    "sponsor": "Alumis Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALMS",
    "nct_id": "NCT06952634",
    "title": "An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatic Impairment"
    ],
    "interventions": [
      "ESK-001"
    ],
    "primary_completion_date": "2025-12",
    "completion_date": "2025-12",
    "results_first_posted": null,
    "last_update_posted": "2025-05-01",
    "enrollment": null,
    "sponsor": "Alumis Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALMS",
    "nct_id": "NCT05330858",
    "title": "Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pharmacokinetics"
    ],
    "interventions": [
      "ESK-001",
      "Rabeprazole"
    ],
    "primary_completion_date": "2022-06-30",
    "completion_date": "2022-09-20",
    "results_first_posted": null,
    "last_update_posted": "2023-05-09",
    "enrollment": null,
    "sponsor": "Alumis Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALMS",
    "nct_id": "NCT05966480",
    "title": "Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "SLE"
    ],
    "interventions": [
      "ESK-001",
      "Placebo"
    ],
    "primary_completion_date": "2026-07-01",
    "completion_date": "2027-09-01",
    "results_first_posted": null,
    "last_update_posted": "2025-08-01",
    "enrollment": null,
    "sponsor": "Alumis Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALVO",
    "nct_id": "NCT06400719",
    "title": "Pilot Study of AVT16 in Healthy Adult Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "AVT16"
    ],
    "primary_completion_date": "2024-11-06",
    "completion_date": "2024-11-06",
    "results_first_posted": null,
    "last_update_posted": "2025-03-11",
    "enrollment": null,
    "sponsor": "Alvotech Swiss AG",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALVO",
    "nct_id": "NCT06570772",
    "title": "Study to Investigate Comparative Efficacy, Safety and Immunogenicity Between AVT16 and Entyvio",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ulcerative Colitis"
    ],
    "interventions": [
      "AVT16",
      "Vedolizumab"
    ],
    "primary_completion_date": "2025-11-25",
    "completion_date": "2025-11-25",
    "results_first_posted": null,
    "last_update_posted": "2025-12-26",
    "enrollment": null,
    "sponsor": "Alvotech Swiss AG",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALVO",
    "nct_id": "NCT03849404",
    "title": "Efficacy, Safety, and Immunogenicity of AVT02 With Moderate-to-Severe Chronic Plaque Psoriasis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Plaque Psoriasis"
    ],
    "interventions": [
      "Adalimumab"
    ],
    "primary_completion_date": "2019-12-23",
    "completion_date": "2020-07-20",
    "results_first_posted": null,
    "last_update_posted": "2020-07-28",
    "enrollment": null,
    "sponsor": "Alvotech Swiss AG",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALVO",
    "nct_id": "NCT05986786",
    "title": "Clinical Study to Evaluate the Handling and Safety of AVT06 PFS in Subjects With Chorioretinal Vascular Disease",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chorioretinal Vascular Disease"
    ],
    "interventions": [
      "Patients will receive 1 IVT injection of AVT06 PFS depending on their chorioretinal vascular disease schedule"
    ],
    "primary_completion_date": "2024-04-19",
    "completion_date": "2025-03-21",
    "results_first_posted": null,
    "last_update_posted": "2025-04-22",
    "enrollment": null,
    "sponsor": "Alvotech Swiss AG",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALVO",
    "nct_id": "NCT05876949",
    "title": "AVT03 With Xgeva in Healthy Male Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "This is a Phase I Study Conducted in Healthy Volunteers"
    ],
    "interventions": [
      "AVT03",
      "Denosumab"
    ],
    "primary_completion_date": "2024-04-15",
    "completion_date": "2024-04-15",
    "results_first_posted": "2025-05-15",
    "last_update_posted": "2025-05-15",
    "enrollment": null,
    "sponsor": "Alvotech Swiss AG",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALVO",
    "nct_id": "NCT03579823",
    "title": "Comparative Safety, Tolerability, Pharmacokinetic Study of AVT02 (100MG/ML) and Humira (100MG/ML) in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "Adalimumab 100 MG/ML [Humira]",
      "AVT02 100MG/ML"
    ],
    "primary_completion_date": "2018-08-24",
    "completion_date": "2018-08-24",
    "results_first_posted": null,
    "last_update_posted": "2019-01-18",
    "enrollment": null,
    "sponsor": "Alvotech Swiss AG",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALVO",
    "nct_id": "NCT04744363",
    "title": "Pharmacokinetics, Safety and Tolerability Study of AVT04 to EU Approved and US Licensed Stelara (Ustekinumab)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Psoriasis"
    ],
    "interventions": [
      "Stelara PFS"
    ],
    "primary_completion_date": "2022-03-19",
    "completion_date": "2022-03-19",
    "results_first_posted": null,
    "last_update_posted": "2022-05-23",
    "enrollment": null,
    "sponsor": "Alvotech Swiss AG",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALVO",
    "nct_id": "NCT04930042",
    "title": "Efficacy, Safety, and Immunogenicity of AVT04 With Moderate-to-Severe Chronic Plaque Psoriasis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Psoriasis"
    ],
    "interventions": [
      "Stelara",
      "AVT04"
    ],
    "primary_completion_date": "2021-12-28",
    "completion_date": "2022-10-11",
    "results_first_posted": null,
    "last_update_posted": "2023-02-02",
    "enrollment": null,
    "sponsor": "Alvotech Swiss AG",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALVO",
    "nct_id": "NCT03849313",
    "title": "Pharmacokinetics, Safety and Tolerability Study of AVT02 to EU-approved and US-licensed Humira (Adalimumab)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "Adalimumab"
    ],
    "primary_completion_date": "2020-02-17",
    "completion_date": "2020-02-17",
    "results_first_posted": null,
    "last_update_posted": "2022-05-04",
    "enrollment": null,
    "sponsor": "Alvotech Swiss AG",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALVO",
    "nct_id": "NCT04453137",
    "title": "Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Plaque Psoriasis"
    ],
    "interventions": [
      "Adalimumab originator",
      "Adalimumab biosimilar"
    ],
    "primary_completion_date": "2021-05-31",
    "completion_date": "2021-11-16",
    "results_first_posted": null,
    "last_update_posted": "2022-05-04",
    "enrollment": null,
    "sponsor": "Alvotech Swiss AG",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALVO",
    "nct_id": "NCT05126784",
    "title": "AVT03 With Prolia in Healthy Male Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Male Subjects"
    ],
    "interventions": [
      "AVT03",
      "Prolia"
    ],
    "primary_completion_date": "2023-10-16",
    "completion_date": "2023-10-16",
    "results_first_posted": null,
    "last_update_posted": "2024-05-29",
    "enrollment": null,
    "sponsor": "Alvotech Swiss AG",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALVO",
    "nct_id": "NCT05395091",
    "title": "Multicenter Study in Postmenopausal Women With Osteoporosis, ALVOBOND",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Osteoporosis, Postmenopausal"
    ],
    "interventions": [
      "AVT03",
      "Denosumab"
    ],
    "primary_completion_date": "2024-05-07",
    "completion_date": "2024-10-28",
    "results_first_posted": "2025-05-29",
    "last_update_posted": "2025-05-29",
    "enrollment": null,
    "sponsor": "Alvotech Swiss AG",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALVO",
    "nct_id": "NCT05842213",
    "title": "Comparative, Multicenter Study in Subjects with Rheumatoid Arthritis, ALVOFLEX",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rheumatoid Arthritis"
    ],
    "interventions": [
      "AVT05 (proposed biosimilar to golimumab)",
      "Simponi (Golimumab)"
    ],
    "primary_completion_date": "2024-03-04",
    "completion_date": "2024-09-24",
    "results_first_posted": null,
    "last_update_posted": "2024-10-02",
    "enrollment": null,
    "sponsor": "Alvotech Swiss AG",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALVO",
    "nct_id": "NCT05632211",
    "title": "A Study to Investigate the PK, Safety, and Tolerability Between AVT05, US and EU Simponi\u00ae in Healthy Adult Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Adult Subjects"
    ],
    "interventions": [
      "AVT05",
      "Simponi"
    ],
    "primary_completion_date": "2023-10-03",
    "completion_date": "2023-10-03",
    "results_first_posted": "2025-05-28",
    "last_update_posted": "2025-05-28",
    "enrollment": null,
    "sponsor": "Alvotech Swiss AG",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALVO",
    "nct_id": "NCT06732804",
    "title": "Study to Investigate Comparative Pharmacokinetics, Safety, Immunogenicity and Tolerability Between AVT80 and Entyvio",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Male and Female Subjects"
    ],
    "interventions": [
      "AVT80",
      "Geographical region 1 Entyvio",
      "Geographical region 2 Entyvio"
    ],
    "primary_completion_date": "2026-01-08",
    "completion_date": "2026-01-08",
    "results_first_posted": null,
    "last_update_posted": "2026-01-20",
    "enrollment": null,
    "sponsor": "Alvotech Swiss AG",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALVO",
    "nct_id": "NCT05155293",
    "title": "Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Neovascular (Wet) AMD"
    ],
    "interventions": [
      "AVT06 (proposed aflibercept biosimilar)",
      "Eylea\u00ae (Aflibercept)"
    ],
    "primary_completion_date": "2023-11-17",
    "completion_date": "2024-09-23",
    "results_first_posted": null,
    "last_update_posted": "2024-09-27",
    "enrollment": null,
    "sponsor": "Alvotech Swiss AG",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALVO",
    "nct_id": "NCT03983876",
    "title": "PK, Safety and Tolerability Study of AVT02 (Adalimumab) Pre-filled Syringe (PFS) vs, AVT02 Autoinjector (AI)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Phase 1"
    ],
    "interventions": [
      "Adalimumab"
    ],
    "primary_completion_date": "2019-12-03",
    "completion_date": "2019-12-03",
    "results_first_posted": null,
    "last_update_posted": "2022-05-04",
    "enrollment": null,
    "sponsor": "Alvotech Swiss AG",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ALVO",
    "nct_id": "NCT04224194",
    "title": "Auto-injector Real Life Handling in Patients",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "RA"
    ],
    "interventions": [
      "Adalimumab"
    ],
    "primary_completion_date": "2020-07-08",
    "completion_date": "2021-02-26",
    "results_first_posted": null,
    "last_update_posted": "2022-05-05",
    "enrollment": null,
    "sponsor": "Alvotech Swiss AG",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AMPH",
    "nct_id": "NCT01357642",
    "title": "Epinephrine Inhalation Aerosol USP: For Evaluation Of Efficacy And Safety In Asthma Patients",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Asthma"
    ],
    "interventions": [
      "Epinephrine inhalation aerosol",
      "Placebo",
      "epinephrine inhalation aerosol"
    ],
    "primary_completion_date": "2011-11",
    "completion_date": "2011-12",
    "results_first_posted": null,
    "last_update_posted": "2016-03-11",
    "enrollment": null,
    "sponsor": "Amphastar Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AMPH",
    "nct_id": "NCT02271334",
    "title": "Evaluation of Pharmacokinetics and Safety of A006 in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Asthma"
    ],
    "interventions": [
      "A006 DPI",
      "A006 DPI",
      "Proventil\u00ae MDI",
      "Proventil\u00ae MDI"
    ],
    "primary_completion_date": "2014-10",
    "completion_date": "2015-03",
    "results_first_posted": null,
    "last_update_posted": "2017-04-19",
    "enrollment": null,
    "sponsor": "Amphastar Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AMPH",
    "nct_id": "NCT01581177",
    "title": "Albuterol DPI (A006) Clinical Study-B2: Efficacy, Dose-Ranging and Initial Safety Evaluation",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Asthma"
    ],
    "interventions": [
      "Albuterol DPI 25 mcg/inh",
      "Albuterol DPI 90 mcg/inh",
      "Placebo DPI",
      "Albuterol MDI 90 mcg/inh"
    ],
    "primary_completion_date": "2012-07",
    "completion_date": "2012-08",
    "results_first_posted": null,
    "last_update_posted": "2017-05-19",
    "enrollment": null,
    "sponsor": "Amphastar Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AMPH",
    "nct_id": "NCT01476904",
    "title": "Safety Study in Adolescent and Adult Patients With Asthma",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Asthma"
    ],
    "interventions": [
      "Placebo",
      "Primatene Mist",
      "Epinephrine inhalation"
    ],
    "primary_completion_date": "2012-04",
    "completion_date": "2012-07",
    "results_first_posted": null,
    "last_update_posted": "2017-02-13",
    "enrollment": null,
    "sponsor": "Amphastar Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AMPH",
    "nct_id": "NCT01737905",
    "title": "Evaluation of Efficacy and Safety for Single Dose of E004 in Children With Asthma",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Asthma"
    ],
    "interventions": [
      "Epinephrine HFA-MDI (E004)",
      "Placebo-HFA"
    ],
    "primary_completion_date": "2013-03",
    "completion_date": "2013-12",
    "results_first_posted": null,
    "last_update_posted": "2016-03-11",
    "enrollment": null,
    "sponsor": "Amphastar Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AMPH",
    "nct_id": "NCT00634829",
    "title": "Single-Dose Cross-Over Study of the Effects of Albuterol-HFA in Exercise Induced Bronchoconstriction",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Asthma",
      "Bronchospasm"
    ],
    "interventions": [
      "albuterol (Armstrong Albuterol HFA)",
      "Albuterol Sulfate (Provenetil-HFA)",
      "Placebo-HFA"
    ],
    "primary_completion_date": "2008-10",
    "completion_date": "2008-10",
    "results_first_posted": null,
    "last_update_posted": "2013-07-15",
    "enrollment": null,
    "sponsor": "Amphastar Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AMPH",
    "nct_id": "NCT04207840",
    "title": "Study of Drug Exposure in Systemic Circulation of Primatene Mist by Oral Inhalation, Versus Epinephrine Injection by Intramuscular Injection and ProAir by Oral Inhalation in Healthy Individuals",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pharmacokinetics",
      "Epinephrine",
      "Albuterol",
      "Asthma",
      "Anaphylaxis"
    ],
    "interventions": [
      "Epinephrine (0.125 mg/inhalation)",
      "Epinephrine Injection Auto-Injector (0.3mg/0.3mL)",
      "Albuterol Sulfate (0.09 mg/inhalation)"
    ],
    "primary_completion_date": "2019-12-20",
    "completion_date": "2019-12-23",
    "results_first_posted": "2021-03-30",
    "last_update_posted": "2021-03-30",
    "enrollment": null,
    "sponsor": "Amphastar Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AMPH",
    "nct_id": "NCT01174732",
    "title": "Dose-Ranging Study of A006 DPI, in Adult Asthma Patients",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Asthma",
      "Bronchospasm"
    ],
    "interventions": [
      "albuterol inhalation powder",
      "albuterol inhalation powder",
      "albuterol inhalation powder",
      "albuterol inhalation powder",
      "Placebo",
      "albuterol inhalation aerosol",
      "albuterol inhalation aerosol"
    ],
    "primary_completion_date": "2010-10",
    "completion_date": "2011-01",
    "results_first_posted": null,
    "last_update_posted": "2017-04-19",
    "enrollment": null,
    "sponsor": "Amphastar Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AMPH",
    "nct_id": "NCT01188577",
    "title": "Epinephrine Inhalation Aerosol USP, a HFA-MDI Study for Assessment of Pharmacokinetics",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Asthma",
      "Bronchospasm",
      "Wheezing",
      "Shortness of Breath"
    ],
    "interventions": [
      "Epinephrine Inhalation Aerosol, HFA",
      "Epinephrine Inhalation Aerosol"
    ],
    "primary_completion_date": "2010-09",
    "completion_date": "2011-01",
    "results_first_posted": "2014-10-24",
    "last_update_posted": "2017-07-25",
    "enrollment": null,
    "sponsor": "Amphastar Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AMPH",
    "nct_id": "NCT01737892",
    "title": "Assessment and Evaluation of Pharmacokinetic Profile of E004 in Healthy Adults",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Asthma"
    ],
    "interventions": [
      "Arm T Epinephrine Inhalation Aerosol HFA, 125 mcg, 1 inhalation",
      "Arm C-Epinephrine Inhalation Aerosol CFC"
    ],
    "primary_completion_date": "2012-11",
    "completion_date": "2012-11",
    "results_first_posted": null,
    "last_update_posted": "2016-03-17",
    "enrollment": null,
    "sponsor": "Amphastar Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AMPH",
    "nct_id": "NCT01189396",
    "title": "Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Asthma",
      "Bronchospasm",
      "Chronic Obstructive Pulmonary Disease (COPD)"
    ],
    "interventions": [
      "A006",
      "Placebo DPI",
      "Proventil-HFA"
    ],
    "primary_completion_date": "2010-12",
    "completion_date": "2011-01",
    "results_first_posted": null,
    "last_update_posted": "2017-07-02",
    "enrollment": null,
    "sponsor": "Amphastar Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AMPH",
    "nct_id": "NCT01689363",
    "title": "Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Allergic Skin Reaction"
    ],
    "interventions": [
      "Hyaluronidase",
      "Histamine",
      "Saline"
    ],
    "primary_completion_date": "2012-11",
    "completion_date": "2012-12",
    "results_first_posted": "2017-01-20",
    "last_update_posted": "2017-01-20",
    "enrollment": null,
    "sponsor": "Amphastar Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AMPH",
    "nct_id": "NCT00635505",
    "title": "Controlled, 12-Week Study of Albuterol HFA Versus the Active Control, Proventil(R)-HFA in Asthmatic Patients",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Asthma"
    ],
    "interventions": [
      "albuterol HFA (Armstrong's)",
      "albuterol HFA (Proventil HFA)",
      "HFA placebo"
    ],
    "primary_completion_date": "2008-08",
    "completion_date": "2008-08",
    "results_first_posted": null,
    "last_update_posted": "2013-07-15",
    "enrollment": null,
    "sponsor": "Amphastar Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AMPH",
    "nct_id": "NCT02210806",
    "title": "Albuterol DPI (A006) Clinical Study-B3:Efficacy, Dose-ranging and Safety Evaluation",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Asthma"
    ],
    "interventions": [
      "A006 DPI",
      "A006 DPI",
      "Placebo DPI",
      "Proventil\u00ae MDI",
      "Proventil\u00ae MDI"
    ],
    "primary_completion_date": "2014-09",
    "completion_date": "2014-10",
    "results_first_posted": null,
    "last_update_posted": "2017-04-19",
    "enrollment": null,
    "sponsor": "Amphastar Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AMPH",
    "nct_id": "NCT00634517",
    "title": "4-Week Study of Efficacy, Safety and PK of Albuterol-HFA Versus Proventil-HFA in Pediatric Asthma",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Asthma"
    ],
    "interventions": [
      "Armstrong Albuterol Sulfate Inhalation Aerosol",
      "Albuterol Sulfate Inhalation Aerosol"
    ],
    "primary_completion_date": "2008-12",
    "completion_date": "2008-12",
    "results_first_posted": null,
    "last_update_posted": "2013-07-15",
    "enrollment": null,
    "sponsor": "Amphastar Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AMPH",
    "nct_id": "NCT01460511",
    "title": "Evaluation of Efficacy and Safety of E004 in Children With Asthma",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Asthma"
    ],
    "interventions": [
      "E004 (Epinephrine Inhalation Aerosol) HFA-MDI",
      "Placebo-HFA"
    ],
    "primary_completion_date": "2012-03",
    "completion_date": "2012-07",
    "results_first_posted": null,
    "last_update_posted": "2018-07-31",
    "enrollment": null,
    "sponsor": "Amphastar Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AMPH",
    "nct_id": "NCT01255709",
    "title": "Epinephrine Inhalation Aerosol USP, CLINICAL STUDY-B3 FOR ASSESSMENT OF PHARMACOKINETICS",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Asthma"
    ],
    "interventions": [
      "Arm T1: Primatene Mist HFA",
      "Arm T2: Primatene Mist HFA",
      "Arm C: Primatene Mist (epinephrine inhalation aerosol, USP)"
    ],
    "primary_completion_date": "2011-01",
    "completion_date": "2011-01",
    "results_first_posted": null,
    "last_update_posted": "2016-03-17",
    "enrollment": null,
    "sponsor": "Amphastar Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AMPH",
    "nct_id": "NCT01143051",
    "title": "Pharmacokinetics (PK) Study of Epinephrine Inhalation Aerosol in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Asthma"
    ],
    "interventions": [
      "epinephrine inhalation aerosol",
      "epinephrine inhalation aerosol",
      "epinephrine inhalation aerosol"
    ],
    "primary_completion_date": "2010-06",
    "completion_date": "2010-06",
    "results_first_posted": "2014-07-15",
    "last_update_posted": "2018-09-25",
    "enrollment": null,
    "sponsor": "Amphastar Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AMPH",
    "nct_id": "NCT01025648",
    "title": "Randomized, Placebo/Active Crossover Dose-ranging Study for Safety and Efficacy in Asthma Patients.",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Asthma"
    ],
    "interventions": [
      "E004 (epinephrine inhalation aerosol), 90 mcg/actuation",
      "E004 Placebo",
      "E004 (epinephrine inhalation aerosol), 125 mcg",
      "E004 (epinephrine inhalation aerosol), 220 mcg",
      "epinephrine inhalation aerosol, CFC propelled",
      "E004 (epinephrine inhalation aerosol), 160 mcg"
    ],
    "primary_completion_date": "2009-12",
    "completion_date": "2009-12",
    "results_first_posted": null,
    "last_update_posted": "2018-05-16",
    "enrollment": null,
    "sponsor": "Amphastar Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AMPH",
    "nct_id": "NCT05539872",
    "title": "Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pharmacokinetics",
      "Pharmacodynamics"
    ],
    "interventions": [
      "I004",
      "NovoLog"
    ],
    "primary_completion_date": "2023-01-29",
    "completion_date": "2023-01-30",
    "results_first_posted": null,
    "last_update_posted": "2024-01-29",
    "enrollment": null,
    "sponsor": "Amphastar Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AMRX",
    "nct_id": "NCT06267274",
    "title": "A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Open-angle Glaucoma",
      "Ocular Hypertension"
    ],
    "interventions": [
      "Bimatoprost Ophthalmic Solution, 0.01%",
      "LUMIGAN\u00ae (bimatoprost ophthalmic solution) 0.01%"
    ],
    "primary_completion_date": "2025-03-01",
    "completion_date": "2025-05-01",
    "results_first_posted": null,
    "last_update_posted": "2024-08-06",
    "enrollment": null,
    "sponsor": "Amneal Pharmaceuticals, LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AMRX",
    "nct_id": "NCT01067001",
    "title": "Minocycline HCl Extended Release Tablets 135 mg Oral Bioequivalence Study",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Fasting"
    ],
    "interventions": [],
    "primary_completion_date": "2009-10",
    "completion_date": "2009-11",
    "results_first_posted": null,
    "last_update_posted": "2010-02-11",
    "enrollment": null,
    "sponsor": "Amneal Pharmaceuticals Co. India Private Limited",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AMRX",
    "nct_id": "NCT03562923",
    "title": "A Study to Compare Fluticasone Propionate 100mcg/Salmeterol 50 mcg Inhalation Powder to Advair Discus 100/50",
    "status": "UNKNOWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Asthma"
    ],
    "interventions": [
      "Test Product",
      "Reference Product",
      "Placebo"
    ],
    "primary_completion_date": "2019-05",
    "completion_date": "2019-06",
    "results_first_posted": null,
    "last_update_posted": "2018-06-20",
    "enrollment": null,
    "sponsor": "Amneal Ireland Limited",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AMRX",
    "nct_id": "NCT03562949",
    "title": "A BE Study to Compare Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg and QVAR\u00ae 40 mcg, Inhalation Aerosol",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Asthma"
    ],
    "interventions": [
      "Test Product",
      "Reference Product",
      "Placebo"
    ],
    "primary_completion_date": "2019-08-02",
    "completion_date": "2019-08-02",
    "results_first_posted": null,
    "last_update_posted": "2020-01-13",
    "enrollment": null,
    "sponsor": "Amneal Ireland Limited",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AMRX",
    "nct_id": "NCT02940561",
    "title": "BE Study in Patients - Methotrexate Tablets",
    "status": "UNKNOWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Psoriasis",
      "Rheumatoid Arthritis"
    ],
    "interventions": [
      "Methotrexate - Amneal",
      "Methotrexate - DAVA"
    ],
    "primary_completion_date": "2016-10",
    "completion_date": "2016-10",
    "results_first_posted": null,
    "last_update_posted": "2016-10-21",
    "enrollment": null,
    "sponsor": "Amneal Pharmaceuticals, LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AMRX",
    "nct_id": "NCT01650051",
    "title": "Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg as an Analgesic for Short-Term Treatment in Female Subjects Suffering From Moderate-to-Severe Pain and Burning Upon Urination Associated With Uncomplicated Urinary Tract Infections (uUTI)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Uncomplicated Urinary Tract Infections"
    ],
    "interventions": [
      "Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg",
      "Phenazopyridine Hydrochloride Tables, USP 200 mg"
    ],
    "primary_completion_date": "2013-02",
    "completion_date": "2014-02",
    "results_first_posted": null,
    "last_update_posted": "2014-06-26",
    "enrollment": null,
    "sponsor": "Amneal Pharmaceuticals, LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AMRX",
    "nct_id": "NCT01779947",
    "title": "Study to Evaluate the Safety and Bioequivalence of Estradiol Vaginal Inserts, 10 mcg and Vagifem\u00ae 10 mcg and Compare to Placebo",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atrophic Vaginitis Due to Menopause"
    ],
    "interventions": [
      "Estradiol Vaginal Tablets 10 mcg",
      "placebo"
    ],
    "primary_completion_date": "2012-09",
    "completion_date": "2012-12",
    "results_first_posted": null,
    "last_update_posted": "2014-06-26",
    "enrollment": null,
    "sponsor": "Amneal Pharmaceuticals, LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AMRX",
    "nct_id": "NCT02103322",
    "title": "Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed Conditions",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Myeloid Leukemia",
      "Gastrointestinal Stromal Tumor"
    ],
    "interventions": [
      "Imatinib Mesylate Tablets, 400 mg",
      "Imatinib Mesylate Tablets, 400 mg"
    ],
    "primary_completion_date": "2014-03",
    "completion_date": "2014-06",
    "results_first_posted": null,
    "last_update_posted": "2014-06-27",
    "enrollment": null,
    "sponsor": "Amneal Pharmaceuticals, LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AMRX",
    "nct_id": "NCT02110368",
    "title": "Bioequivalence Study of Test and Reference Testosterone Topical Gel, 1.62% Metered Pump in Testosterone Deficient Adult Male Subjects Under Fasting Conditions",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Primary Hypogonadism",
      "Hypogonadotropic Hypogonadism"
    ],
    "interventions": [
      "Testosterone Topical Gel, 1.62% Metered Pump",
      "AndroGel (testosterone gel) 1.62% Metered-Dose Pump"
    ],
    "primary_completion_date": "2014-03",
    "completion_date": "2014-05",
    "results_first_posted": null,
    "last_update_posted": "2014-06-26",
    "enrollment": null,
    "sponsor": "Amneal Pharmaceuticals, LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AMRX",
    "nct_id": "NCT03549897",
    "title": "Bronchoprovocation Study to Evaluate the Pharmacodynamics of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base",
    "status": "UNKNOWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Asthma"
    ],
    "interventions": [
      "Placebo",
      "90 mcg Reference Product",
      "180 mcg Reference Product",
      "90 mcg Test Product"
    ],
    "primary_completion_date": "2018-08",
    "completion_date": "2018-09",
    "results_first_posted": null,
    "last_update_posted": "2018-06-14",
    "enrollment": null,
    "sponsor": "Amneal Ireland Limited",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AMRX",
    "nct_id": "NCT05401357",
    "title": "Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN\u00ae in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Glaucoma, Open-Angle",
      "Ocular Hypertension"
    ],
    "interventions": [
      "Test - Bimatoprost 0.01% Ophthalmic Solution",
      "Reference - LUMIGAN\u00ae (Bimatoprost 0.01% Ophthalmic Solution)"
    ],
    "primary_completion_date": "2022-12",
    "completion_date": "2022-12",
    "results_first_posted": null,
    "last_update_posted": "2022-08-10",
    "enrollment": null,
    "sponsor": "Amneal Pharmaceuticals, LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AMRX",
    "nct_id": "NCT02121002",
    "title": "Study Comparing a Generic Diclofenac Sodium Topical Gel, 1% to Voltaren in the Treatment of Subjects With Osteoarthritis of the Knee",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Osteoarthritis"
    ],
    "interventions": [
      "Diclofenac Sodium Topical Gel, 1%",
      "Voltaren Topical Gel, 1%",
      "Vehicle Diclofenac Sodium Topical Gel"
    ],
    "primary_completion_date": "2014-10",
    "completion_date": "2014-12",
    "results_first_posted": "2021-06-16",
    "last_update_posted": "2021-06-16",
    "enrollment": null,
    "sponsor": "Amneal Pharmaceuticals, LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AMRX",
    "nct_id": "NCT02072954",
    "title": "Bioequivalence Fasting Study in Patients",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia"
    ],
    "interventions": [
      "Asenapine Sublingual Tablets 10 mg",
      "Asenapine Sublingual Tablets 10 mg"
    ],
    "primary_completion_date": "2014-02",
    "completion_date": "2014-06",
    "results_first_posted": null,
    "last_update_posted": "2014-06-27",
    "enrollment": null,
    "sponsor": "Amneal Pharmaceuticals, LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AMRX",
    "nct_id": "NCT02125253",
    "title": "Study to Compare the Therapeutic Equivalence of Mometasone Furoate Nasal Spray, 50 mcg With Nasonex Nasal Spray in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Seasonal Allergic Rhinitis"
    ],
    "interventions": [
      "Mometasone Furoate Nasal Spray, 50 mcg",
      "Nasonex Nasal Spray, 50 mcg",
      "Placebo Nasal Spray"
    ],
    "primary_completion_date": "2014-03",
    "completion_date": "2014-06",
    "results_first_posted": null,
    "last_update_posted": "2015-11-02",
    "enrollment": null,
    "sponsor": "Amneal Pharmaceuticals, LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AMRX",
    "nct_id": "NCT01064024",
    "title": "Evaluate the Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg vs. Placebo",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pain",
      "Urinary Tract Infections"
    ],
    "interventions": [
      "Phenazopyridine Hydrochloride",
      "Placebo"
    ],
    "primary_completion_date": "2010-12",
    "completion_date": "2010-12",
    "results_first_posted": null,
    "last_update_posted": "2013-01-29",
    "enrollment": null,
    "sponsor": "Amneal Pharmaceuticals, LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ANAB",
    "nct_id": "NCT05935085",
    "title": "This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD).",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atopic Dermatitis Eczema"
    ],
    "interventions": [
      "ANB032",
      "Placebo"
    ],
    "primary_completion_date": "2024-10-16",
    "completion_date": "2025-01-07",
    "results_first_posted": null,
    "last_update_posted": "2025-02-14",
    "enrollment": null,
    "sponsor": "AnaptysBio, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ANAB",
    "nct_id": "NCT03469934",
    "title": "Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic Asthma",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Eosinophilic Asthma"
    ],
    "interventions": [
      "Etokimab",
      "Placebo"
    ],
    "primary_completion_date": "2018-10-30",
    "completion_date": "2018-10-30",
    "results_first_posted": "2023-08-16",
    "last_update_posted": "2023-08-16",
    "enrollment": null,
    "sponsor": "AnaptysBio, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ANAB",
    "nct_id": "NCT03614923",
    "title": "Etokimab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Rhinosinusitis"
    ],
    "interventions": [
      "Etokimab",
      "Placebo",
      "Mometasone Furoate Nasal Spray"
    ],
    "primary_completion_date": "2020-09-02",
    "completion_date": "2020-10-26",
    "results_first_posted": "2022-01-24",
    "last_update_posted": "2022-01-24",
    "enrollment": null,
    "sponsor": "AnaptysBio, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ANAB",
    "nct_id": "NCT05205070",
    "title": "A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia Areata",
    "status": "UNKNOWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alopecia Areata"
    ],
    "interventions": [
      "Rosnilimab",
      "Placebo"
    ],
    "primary_completion_date": "2023-01-19",
    "completion_date": "2023-03-19",
    "results_first_posted": null,
    "last_update_posted": "2022-05-10",
    "enrollment": null,
    "sponsor": "AnaptysBio, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ANAB",
    "nct_id": "NCT03533751",
    "title": "Efficacy, Safety, and Pharmacokinetic Profile of Etokimab (ANB020) in Adult Participants With Moderate-to-Severe Atopic Dermatitis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atopic Dermatitis"
    ],
    "interventions": [
      "Etokimab",
      "Placebo"
    ],
    "primary_completion_date": "2019-12-03",
    "completion_date": "2019-12-03",
    "results_first_posted": "2023-05-24",
    "last_update_posted": "2023-05-24",
    "enrollment": null,
    "sponsor": "AnaptysBio, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ANAB",
    "nct_id": "NCT06127043",
    "title": "A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ulcerative Colitis"
    ],
    "interventions": [
      "Rosnilimab",
      "Placebo"
    ],
    "primary_completion_date": "2026-01",
    "completion_date": "2026-05",
    "results_first_posted": null,
    "last_update_posted": "2025-10-03",
    "enrollment": null,
    "sponsor": "AnaptysBio, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ANAB",
    "nct_id": "NCT02920021",
    "title": "Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Peanut Allergy",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Peanut Allergy"
    ],
    "interventions": [
      "Etokimab",
      "Placebo"
    ],
    "primary_completion_date": "2018-03-30",
    "completion_date": "2018-03-30",
    "results_first_posted": "2023-07-27",
    "last_update_posted": "2023-07-27",
    "enrollment": null,
    "sponsor": "AnaptysBio, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ANAB",
    "nct_id": "NCT06041269",
    "title": "A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rheumatoid Arthritis"
    ],
    "interventions": [
      "Rosnilimab",
      "Placebo"
    ],
    "primary_completion_date": "2024-11-29",
    "completion_date": "2025-05-30",
    "results_first_posted": null,
    "last_update_posted": "2024-11-25",
    "enrollment": null,
    "sponsor": "AnaptysBio, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ANRO",
    "nct_id": "NCT06502964",
    "title": "Study of ALTO-101 in Patients With Schizophrenia",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia",
      "Cognitive Impairment"
    ],
    "interventions": [
      "ALTO-101",
      "ALTO-101 Transdermal Delivery System",
      "Placebo",
      "Placebo Transdermal Delivery System"
    ],
    "primary_completion_date": "2026-02",
    "completion_date": "2026-03",
    "results_first_posted": null,
    "last_update_posted": "2025-12-26",
    "enrollment": null,
    "sponsor": "Alto Neuroscience",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ANRO",
    "nct_id": "NCT05712187",
    "title": "Phase 2b Study of ALTO-100 in MDD",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder"
    ],
    "interventions": [
      "ALTO-100",
      "Placebo"
    ],
    "primary_completion_date": "2024-09-05",
    "completion_date": "2024-10-24",
    "results_first_posted": null,
    "last_update_posted": "2025-09-08",
    "enrollment": null,
    "sponsor": "Alto Neuroscience",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ANRO",
    "nct_id": "NCT05157945",
    "title": "ALTO-300 in Depression (ALTO-300-004)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder"
    ],
    "interventions": [
      "ALTO-300 PO Tablet"
    ],
    "primary_completion_date": "2023-04-26",
    "completion_date": "2023-05-05",
    "results_first_posted": null,
    "last_update_posted": "2024-04-26",
    "enrollment": null,
    "sponsor": "Alto Neuroscience",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ANRO",
    "nct_id": "NCT05419869",
    "title": "Pilot Decentralized Trial",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder"
    ],
    "interventions": [
      "ALTO-100 PO Tablet"
    ],
    "primary_completion_date": "2023-01-13",
    "completion_date": "2023-01-26",
    "results_first_posted": null,
    "last_update_posted": "2024-01-18",
    "enrollment": null,
    "sponsor": "Alto Neuroscience",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ANRO",
    "nct_id": "NCT04388189",
    "title": "Leveraging EEG for Antidepressant Prediction With Duloxetine and Bupropion",
    "status": "WITHDRAWN",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder"
    ],
    "interventions": [
      "Duloxetine",
      "Bupropion"
    ],
    "primary_completion_date": "2023-05-30",
    "completion_date": "2023-05-30",
    "results_first_posted": null,
    "last_update_posted": "2020-10-19",
    "enrollment": null,
    "sponsor": "Alto Neuroscience",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ANRO",
    "nct_id": "NCT05922878",
    "title": "Study of ALTO-300 in MDD",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder"
    ],
    "interventions": [
      "ALTO-300",
      "Placebo"
    ],
    "primary_completion_date": "2026-12",
    "completion_date": "2026-12",
    "results_first_posted": null,
    "last_update_posted": "2025-07-24",
    "enrollment": null,
    "sponsor": "Alto Neuroscience",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ANRO",
    "nct_id": "NCT06391593",
    "title": "PD, PK, and Safety of ALTO-203 in Patients With MDD",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder",
      "Anhedonia"
    ],
    "interventions": [
      "ALTO-203 25 \u03bcg",
      "ALTO-203 75 \u03bcg",
      "Placebo"
    ],
    "primary_completion_date": "2025-04-14",
    "completion_date": "2025-04-21",
    "results_first_posted": null,
    "last_update_posted": "2025-10-20",
    "enrollment": null,
    "sponsor": "Alto Neuroscience",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ANRO",
    "nct_id": "NCT06656416",
    "title": "ALTO-100 in Bipolar Disorder With Depression (BD-D)",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bipolar Disorder I or II With a Major Depressive Episode"
    ],
    "interventions": [
      "ALTO-100",
      "Placebo"
    ],
    "primary_completion_date": "2026-08",
    "completion_date": "2026-10",
    "results_first_posted": null,
    "last_update_posted": "2025-07-16",
    "enrollment": null,
    "sponsor": "Alto Neuroscience",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ANRO",
    "nct_id": "NCT04388202",
    "title": "Leveraging EEG for Antidepressant Prediction With Sertraline and Escitalopram",
    "status": "WITHDRAWN",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder"
    ],
    "interventions": [
      "Sertraline",
      "Escitalopram"
    ],
    "primary_completion_date": "2023-05-30",
    "completion_date": "2023-05-30",
    "results_first_posted": null,
    "last_update_posted": "2020-10-19",
    "enrollment": null,
    "sponsor": "Alto Neuroscience",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ANRO",
    "nct_id": "NCT05118750",
    "title": "ALTO-300 in Depression",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder"
    ],
    "interventions": [
      "ALTO-300 oral (PO) tablet"
    ],
    "primary_completion_date": "2023-05-05",
    "completion_date": "2023-05-09",
    "results_first_posted": null,
    "last_update_posted": "2024-04-30",
    "enrollment": null,
    "sponsor": "Alto Neuroscience",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ANRO",
    "nct_id": "NCT02378025",
    "title": "Treating Chronic Pain in Gulf War Illness",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Pain",
      "Gulf War Illness",
      "Chronic Illness"
    ],
    "interventions": [
      "Yoga Group",
      "Pain Management Wellness Group"
    ],
    "primary_completion_date": "2018-03",
    "completion_date": "2018-03",
    "results_first_posted": "2020-06-11",
    "last_update_posted": "2020-06-11",
    "enrollment": null,
    "sponsor": "Palo Alto Veterans Institute for Research",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ANRO",
    "nct_id": "NCT05117632",
    "title": "ALTO-100 in MDD and/or PTSD",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder",
      "Post Traumatic Stress Disorder"
    ],
    "interventions": [
      "ALTO-100 PO tablet"
    ],
    "primary_completion_date": "2022-12-01",
    "completion_date": "2022-12-09",
    "results_first_posted": null,
    "last_update_posted": "2023-12-01",
    "enrollment": null,
    "sponsor": "Alto Neuroscience",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "APLS",
    "nct_id": "NCT03777332",
    "title": "Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Geographic Atrophy"
    ],
    "interventions": [
      "PEGCETACOPLAN (APL-2)"
    ],
    "primary_completion_date": "2021-04-01",
    "completion_date": "2021-04-01",
    "results_first_posted": null,
    "last_update_posted": "2021-11-10",
    "enrollment": null,
    "sponsor": "Apellis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "APLS",
    "nct_id": "NCT03465709",
    "title": "Pegcetacoplan (APL-2) in Neovascular AMD",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Neovascular Age-related Macular Degeneration"
    ],
    "interventions": [
      "Pegcetacoplan"
    ],
    "primary_completion_date": "2019-04-05",
    "completion_date": "2019-04-05",
    "results_first_posted": "2020-09-16",
    "last_update_posted": "2020-09-16",
    "enrollment": null,
    "sponsor": "Apellis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "APLS",
    "nct_id": "NCT06161584",
    "title": "A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Geographic Atrophy"
    ],
    "interventions": [
      "Pegcetacoplan"
    ],
    "primary_completion_date": "2028-06",
    "completion_date": "2028-06",
    "results_first_posted": null,
    "last_update_posted": "2025-11-04",
    "enrollment": null,
    "sponsor": "Apellis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "APLS",
    "nct_id": "NCT04770545",
    "title": "An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Geographic Atrophy Secondary to Age-related Macular Degeneration"
    ],
    "interventions": [
      "PEGCETACOPLAN (APL-2)"
    ],
    "primary_completion_date": "2025-09-05",
    "completion_date": "2025-09-05",
    "results_first_posted": null,
    "last_update_posted": "2025-10-24",
    "enrollment": null,
    "sponsor": "Apellis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "APLS",
    "nct_id": "NCT04729062",
    "title": "C3G/Primary IC-MPGN EAP",
    "status": "APPROVED_FOR_MARKETING",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "C3G",
      "IC-MPGN",
      "C3 Glomerulopathy",
      "C3 Glomerulonephritis",
      "Complement 3 Glomerulopathy",
      "Complement 3 Glomerulopathy (C3G)",
      "Complement 3 Glomerulonephritis",
      "Dense Deposit Disease",
      "DDD",
      "Membranoproliferative Glomerulonephritis",
      "Membranoproliferative Glomerulonephritis (MPGN)",
      "Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)"
    ],
    "interventions": [
      "Pegcetacoplan"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2025-11-06",
    "enrollment": null,
    "sponsor": "Apellis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "APLS",
    "nct_id": "NCT04572854",
    "title": "Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "C3G",
      "IC-MPGN",
      "Renal Transplant",
      "Complement 3 Glomerulopathy",
      "Complement 3 Glomerulopathy (C3G)",
      "Dense Deposit Disease (DDD)",
      "Membranoproliferative Glomerulonephritis",
      "Membranoproliferative Glomerulonephritis (MPGN)",
      "Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)",
      "C3 Glomerulopathy",
      "C3 Glomerulonephritis",
      "Complement 3 Glomerulonephritis"
    ],
    "interventions": [
      "Pegcetacoplan"
    ],
    "primary_completion_date": "2023-02-27",
    "completion_date": "2026-01",
    "results_first_posted": "2025-02-07",
    "last_update_posted": "2025-03-30",
    "enrollment": null,
    "sponsor": "Apellis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "APLS",
    "nct_id": "NCT03531255",
    "title": "Pegcetacoplan Long Term Safety and Efficacy Extension Study",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "PNH"
    ],
    "interventions": [
      "Pegcetacoplan"
    ],
    "primary_completion_date": "2025-06",
    "completion_date": "2025-06",
    "results_first_posted": null,
    "last_update_posted": "2025-03-28",
    "enrollment": null,
    "sponsor": "Apellis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "APLS",
    "nct_id": "NCT02503332",
    "title": "Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Geographic Atrophy"
    ],
    "interventions": [
      "Pegcetacoplan",
      "Sham Procedure"
    ],
    "primary_completion_date": "2017-07-14",
    "completion_date": "2018-01-17",
    "results_first_posted": "2020-10-06",
    "last_update_posted": "2020-10-06",
    "enrollment": null,
    "sponsor": "Apellis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "APLS",
    "nct_id": "NCT03500549",
    "title": "Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Paroxysmal Nocturnal Hemoglobinuria"
    ],
    "interventions": [
      "Pegcetacoplan",
      "Soliris"
    ],
    "primary_completion_date": "2019-11-14",
    "completion_date": "2020-08-13",
    "results_first_posted": "2022-03-25",
    "last_update_posted": "2022-03-25",
    "enrollment": null,
    "sponsor": "Apellis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "APLS",
    "nct_id": "NCT03593200",
    "title": "A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "PNH"
    ],
    "interventions": [
      "Pegcetacoplan"
    ],
    "primary_completion_date": "2019-10-22",
    "completion_date": "2019-10-22",
    "results_first_posted": "2020-12-22",
    "last_update_posted": "2020-12-22",
    "enrollment": null,
    "sponsor": "Apellis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "APLS",
    "nct_id": "NCT07213960",
    "title": "A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "FSGS"
    ],
    "interventions": [
      "APL2",
      "Placebo"
    ],
    "primary_completion_date": "2029-10",
    "completion_date": "2029-12",
    "results_first_posted": null,
    "last_update_posted": "2025-10-09",
    "enrollment": null,
    "sponsor": "Apellis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "APLS",
    "nct_id": "NCT07214740",
    "title": "Study to Evaluate a Pegcetacoplan (Syfovre\u00ae) Prefilled Syringe",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Geographic Atrophy Secondary to Age-related Macular Degeneration"
    ],
    "interventions": [
      "APL-2, Pegcetacoplan"
    ],
    "primary_completion_date": "2025-12-12",
    "completion_date": "2025-12-12",
    "results_first_posted": null,
    "last_update_posted": "2025-12-17",
    "enrollment": null,
    "sponsor": "Apellis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "APLS",
    "nct_id": "NCT02461771",
    "title": "Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Neovascular Age-Related Macular Degeneration"
    ],
    "interventions": [
      "Pegcetacoplan"
    ],
    "primary_completion_date": "2016-03-08",
    "completion_date": "2016-03-08",
    "results_first_posted": "2020-10-06",
    "last_update_posted": "2020-10-06",
    "enrollment": null,
    "sponsor": "Apellis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "APLS",
    "nct_id": "NCT03453619",
    "title": "Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "IgA Nephropathy",
      "Lupus Nephritis",
      "Membranous Nephropathy",
      "C3 Glomerulonephritis",
      "Dense Deposit Disease"
    ],
    "interventions": [
      "APL-2"
    ],
    "primary_completion_date": "2020-04-16",
    "completion_date": "2023-08-26",
    "results_first_posted": "2025-02-13",
    "last_update_posted": "2025-02-13",
    "enrollment": null,
    "sponsor": "Apellis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "APLS",
    "nct_id": "NCT07215390",
    "title": "A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Geographic Atrophy Secondary to Age-related Macular Degeneration"
    ],
    "interventions": [
      "APL-3007, pegcetacoplan (APL-2)",
      "APL-3007, pegcetacoplan (APL-2)",
      "Placebo, Syfovre"
    ],
    "primary_completion_date": "2027-06",
    "completion_date": "2027-11",
    "results_first_posted": null,
    "last_update_posted": "2026-01-15",
    "enrollment": null,
    "sponsor": "Apellis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "APLS",
    "nct_id": "NCT03226678",
    "title": "Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Warm Autoimmune Hemolytic Anemia",
      "Cold Agglutinin Disease"
    ],
    "interventions": [
      "APL-2"
    ],
    "primary_completion_date": "2022-09-12",
    "completion_date": "2022-09-12",
    "results_first_posted": "2024-12-12",
    "last_update_posted": "2024-12-12",
    "enrollment": null,
    "sponsor": "Apellis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "APLS",
    "nct_id": "NCT06499571",
    "title": "Geographic Atrophy Long-Terms Outcomes Study",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Geographic Atrophy"
    ],
    "interventions": [],
    "primary_completion_date": "2023-07-31",
    "completion_date": "2023-07-31",
    "results_first_posted": null,
    "last_update_posted": "2024-07-12",
    "enrollment": null,
    "sponsor": "Apellis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "APLS",
    "nct_id": "NCT05809531",
    "title": "An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "C3G",
      "IC-MPGN",
      "C3 Glomerulopathy",
      "C3 Glomerulonephritis",
      "Complement 3 Glomerulopathy",
      "Complement 3 Glomerulopathy (C3G)",
      "Complement 3 Glomerulonephritis",
      "Dense Deposit Disease",
      "DDD",
      "Membranoproliferative Glomerulonephritis",
      "Membranoproliferative Glomerulonephritis (MPGN)",
      "Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)"
    ],
    "interventions": [
      "Pegcetacoplan"
    ],
    "primary_completion_date": "2027-07",
    "completion_date": "2027-07",
    "results_first_posted": null,
    "last_update_posted": "2025-03-28",
    "enrollment": null,
    "sponsor": "Apellis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "APLS",
    "nct_id": "NCT03525600",
    "title": "Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Geographic Atrophy"
    ],
    "interventions": [
      "APL-2",
      "APL-2",
      "Sham Procedure",
      "Sham Procedure"
    ],
    "primary_completion_date": "2021-06-21",
    "completion_date": "2022-06-20",
    "results_first_posted": "2023-06-18",
    "last_update_posted": "2023-06-18",
    "enrollment": null,
    "sponsor": "Apellis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "APLS",
    "nct_id": "NCT04402060",
    "title": "A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID",
      "Covid-19",
      "Coronavirus",
      "Coronavirus Infection",
      "Severe Acute Respiratory Syndrome",
      "Severe Acute Respiratory Syndrome Coronavirus 2",
      "Sars-CoV2",
      "Ards",
      "Acute Respiratory Distress Syndrome"
    ],
    "interventions": [
      "APL-9",
      "Vehicle Control"
    ],
    "primary_completion_date": "2021-02-13",
    "completion_date": "2021-02-13",
    "results_first_posted": "2022-03-23",
    "last_update_posted": "2022-03-23",
    "enrollment": null,
    "sponsor": "Apellis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "APLS",
    "nct_id": "NCT02264639",
    "title": "A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Paroxysmal Nocturnal Hemoglobinuria (PNH)"
    ],
    "interventions": [
      "Pegcetacoplan"
    ],
    "primary_completion_date": "2018-10-22",
    "completion_date": "2018-10-22",
    "results_first_posted": "2021-01-08",
    "last_update_posted": "2021-01-08",
    "enrollment": null,
    "sponsor": "Apellis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "APLS",
    "nct_id": "NCT04901936",
    "title": "A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Paroxysmal Nocturnal Hemoglobinuria (PNH)",
      "Paroxysmal Hemoglobinuria"
    ],
    "interventions": [
      "Pegcetacoplan"
    ],
    "primary_completion_date": "2028-12",
    "completion_date": "2028-12",
    "results_first_posted": null,
    "last_update_posted": "2025-06-11",
    "enrollment": null,
    "sponsor": "Apellis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "APLS",
    "nct_id": "NCT07020832",
    "title": "A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Delayed Graft Function",
      "End Stage Renal Disease",
      "Deceased Donor Kidney Transplant"
    ],
    "interventions": [
      "Pegcetacoplan",
      "Placebo"
    ],
    "primary_completion_date": "2027-08",
    "completion_date": "2028-08",
    "results_first_posted": null,
    "last_update_posted": "2025-06-13",
    "enrollment": null,
    "sponsor": "Apellis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "APLS",
    "nct_id": "NCT03525613",
    "title": "A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Geographic Atrophy"
    ],
    "interventions": [
      "APL-2",
      "APL-2",
      "Sham Procedure",
      "Sham Procedure"
    ],
    "primary_completion_date": "2021-06-28",
    "completion_date": "2022-06-28",
    "results_first_posted": "2023-07-06",
    "last_update_posted": "2023-07-06",
    "enrollment": null,
    "sponsor": "Apellis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "APLS",
    "nct_id": "NCT05067127",
    "title": "Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "C3G",
      "IC-MPGN",
      "C3 Glomerulopathy",
      "C3 Glomerulonephritis",
      "Complement 3 Glomerulopathy",
      "Complement 3 Glomerulopathy (C3G)",
      "Complement 3 Glomerulonephritis",
      "Dense Deposit Disease",
      "DDD",
      "Membranoproliferative Glomerulonephritis",
      "Membranoproliferative Glomerulonephritis (MPGN)",
      "Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)"
    ],
    "interventions": [
      "Pegcetacoplan",
      "Placebo"
    ],
    "primary_completion_date": "2024-06-26",
    "completion_date": "2025-01-14",
    "results_first_posted": "2025-08-06",
    "last_update_posted": "2025-08-06",
    "enrollment": null,
    "sponsor": "Apellis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "APLS",
    "nct_id": "NCT02588833",
    "title": "Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. Pegcetacoplan (APL-2) in PNH Subjects.",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Paroxysmal Nocturnal Hemoglobinuria"
    ],
    "interventions": [
      "Pegcetacoplan"
    ],
    "primary_completion_date": "2019-08-26",
    "completion_date": "2019-08-26",
    "results_first_posted": "2021-01-11",
    "last_update_posted": "2021-01-11",
    "enrollment": null,
    "sponsor": "Apellis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "APLS",
    "nct_id": "NCT04085601",
    "title": "A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With PNH",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Paroxysmal Nocturnal Hemoglobinuria"
    ],
    "interventions": [
      "APL-2"
    ],
    "primary_completion_date": "2021-06-23",
    "completion_date": "2021-06-23",
    "results_first_posted": "2022-10-21",
    "last_update_posted": "2022-10-21",
    "enrollment": null,
    "sponsor": "Apellis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "APLS",
    "nct_id": "NCT04579666",
    "title": "MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Amyotrophic Lateral Sclerosis",
      "Motor Neuron Disease"
    ],
    "interventions": [
      "Pegcetacoplan (APL-2)",
      "Placebo"
    ],
    "primary_completion_date": "2023-03-31",
    "completion_date": "2023-07-13",
    "results_first_posted": "2025-04-24",
    "last_update_posted": "2025-04-24",
    "enrollment": null,
    "sponsor": "Apellis Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AQST",
    "nct_id": "NCT01220167",
    "title": "Three-way Crossover Study Comparing Ondansetron ODFS Administered With and Without Water to Zofran ODT Without Water",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants"
    ],
    "interventions": [
      "Ondansetron 8 mg ODFS without water",
      "Ondansetron 8 mg ODFS with water",
      "Zofran ODT (ondansetron 8 mg) without water"
    ],
    "primary_completion_date": "2008-08",
    "completion_date": "2008-08",
    "results_first_posted": "2020-08-18",
    "last_update_posted": "2020-08-18",
    "enrollment": null,
    "sponsor": "Aquestive Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AQST",
    "nct_id": "NCT03679975",
    "title": "Riluzole Oral Soluble Film (ROSF) Swallowing Safety in Amyotrophic Lateral Sclerosis (ALS)",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Amyotrophic Lateral Sclerosis"
    ],
    "interventions": [
      "Riluzole Oral Soluble film (ROSF) 50 mg"
    ],
    "primary_completion_date": "2018-09-26",
    "completion_date": "2018-12-21",
    "results_first_posted": "2020-08-10",
    "last_update_posted": "2020-08-18",
    "enrollment": null,
    "sponsor": "Aquestive Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AQST",
    "nct_id": "NCT06527937",
    "title": "Pharmacokinetics Study of DESF in Adults With Oral Allergy Syndrome",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Allergic Reaction"
    ],
    "interventions": [
      "DESF",
      "Epinephrine Injection"
    ],
    "primary_completion_date": "2024-10-10",
    "completion_date": "2024-10-13",
    "results_first_posted": null,
    "last_update_posted": "2025-09-26",
    "enrollment": null,
    "sponsor": "Aquestive Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AQST",
    "nct_id": "NCT03953820",
    "title": "Diazepam Buccal Film (DBF) - Diastat Rectal Gel (DRG) Crossover Study",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Epilepsy"
    ],
    "interventions": [
      "Diazepam Buccal Film",
      "Diastat\u00ae Rectal Gel (Valeant Pharmaceuticals USA)"
    ],
    "primary_completion_date": "2019-07-31",
    "completion_date": "2019-07-31",
    "results_first_posted": "2020-08-18",
    "last_update_posted": "2020-08-18",
    "enrollment": null,
    "sponsor": "Aquestive Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AQST",
    "nct_id": "NCT03222349",
    "title": "Pharmacokinetics and Safety Study of Diazepam Buccal Film (DBF) in Pediatric Subjects With Epilepsy",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Epilepsy"
    ],
    "interventions": [
      "Diazepam Buccal Film"
    ],
    "primary_completion_date": "2020-01-28",
    "completion_date": "2020-03-11",
    "results_first_posted": "2021-05-26",
    "last_update_posted": "2021-05-26",
    "enrollment": null,
    "sponsor": "Aquestive Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AQST",
    "nct_id": "NCT03457753",
    "title": "Riluzole Oral Soluble Film Safety and Tolerability in Amyotrophic Lateral Sclerosis",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "ALS"
    ],
    "interventions": [
      "Riluzole Oral Soluble Film"
    ],
    "primary_completion_date": "2018-03-27",
    "completion_date": "2018-03-27",
    "results_first_posted": null,
    "last_update_posted": "2019-05-13",
    "enrollment": null,
    "sponsor": "Aquestive Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AQST",
    "nct_id": "NCT03428360",
    "title": "Safety and Tolerability Study of Diazepam Buccal Film (DBF) in Subjects With Epilepsy",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Epilepsy"
    ],
    "interventions": [
      "Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category"
    ],
    "primary_completion_date": "2020-06-25",
    "completion_date": "2020-06-25",
    "results_first_posted": "2021-08-05",
    "last_update_posted": "2021-08-05",
    "enrollment": null,
    "sponsor": "Aquestive Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AQST",
    "nct_id": "NCT03179891",
    "title": "Study of Diazepam Buccal Film Administered in the Interictal and in the Ictal-Periictal States to Adults With Epilepsy",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Epilepsy"
    ],
    "interventions": [
      "Diazepam Buccal Film 12.5 mg"
    ],
    "primary_completion_date": "2018-07-25",
    "completion_date": "2018-12-21",
    "results_first_posted": "2020-09-18",
    "last_update_posted": "2020-09-18",
    "enrollment": null,
    "sponsor": "Aquestive Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARDX",
    "nct_id": "NCT03018067",
    "title": "A Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hyperkalemia"
    ],
    "interventions": [
      "RDX227675",
      "Placebo"
    ],
    "primary_completion_date": "2017-05",
    "completion_date": "2017-05",
    "results_first_posted": null,
    "last_update_posted": "2019-12-26",
    "enrollment": null,
    "sponsor": "Ardelyx",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARDX",
    "nct_id": "NCT01923428",
    "title": "The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Constipation Predominant Irritable Bowel Syndrome"
    ],
    "interventions": [
      "AZD1722",
      "Placebo"
    ],
    "primary_completion_date": "2014-10",
    "completion_date": "2014-10",
    "results_first_posted": "2020-01-10",
    "last_update_posted": "2020-04-08",
    "enrollment": null,
    "sponsor": "Ardelyx",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARDX",
    "nct_id": "NCT02249936",
    "title": "A Phase 1 Study to Examine the Pharmacodynamics of Different AZD1722 Formulations",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "AZD1722",
      "Omeprazole"
    ],
    "primary_completion_date": "2013-02",
    "completion_date": "2013-02",
    "results_first_posted": null,
    "last_update_posted": "2014-09-26",
    "enrollment": null,
    "sponsor": "Ardelyx",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARDX",
    "nct_id": "NCT01764854",
    "title": "Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "End Stage Renal Disease",
      "Chronic Kidney Disease Stage 5",
      "ESRD"
    ],
    "interventions": [
      "AZD1722 (in-patient)",
      "Placebo (in-patient)",
      "AZD1722 (out-patient)",
      "Placebo"
    ],
    "primary_completion_date": "2013-10",
    "completion_date": "2013-10",
    "results_first_posted": "2020-08-10",
    "last_update_posted": "2020-08-10",
    "enrollment": null,
    "sponsor": "Ardelyx",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARDX",
    "nct_id": "NCT02621892",
    "title": "A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Constipation Predominant Irritable Bowel Syndrome"
    ],
    "interventions": [
      "Tenapanor",
      "Placebo"
    ],
    "primary_completion_date": "2017-03",
    "completion_date": "2017-04",
    "results_first_posted": "2020-04-21",
    "last_update_posted": "2020-04-21",
    "enrollment": null,
    "sponsor": "Ardelyx",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARDX",
    "nct_id": "NCT02796131",
    "title": "Safety, Tolerability, and Pharmacodynamics of RDX5791 in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "RDX5791",
      "Placebo"
    ],
    "primary_completion_date": "2011-10",
    "completion_date": "2012-04",
    "results_first_posted": null,
    "last_update_posted": "2016-06-10",
    "enrollment": null,
    "sponsor": "Ardelyx",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARDX",
    "nct_id": "NCT03427125",
    "title": "A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hyperphosphatemia"
    ],
    "interventions": [
      "Tenapanor",
      "Placebo",
      "Sevelamer Carbonate"
    ],
    "primary_completion_date": "2019-11-15",
    "completion_date": "2020-02-27",
    "results_first_posted": "2023-06-29",
    "last_update_posted": "2023-06-29",
    "enrollment": null,
    "sponsor": "Ardelyx",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARDX",
    "nct_id": "NCT02176252",
    "title": "Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of AZD1722 in Healthy Male and Female Japanese Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteer"
    ],
    "interventions": [
      "AZD1722",
      "Placebo"
    ],
    "primary_completion_date": "2013-12",
    "completion_date": "2013-12",
    "results_first_posted": null,
    "last_update_posted": "2014-06-27",
    "enrollment": null,
    "sponsor": "Ardelyx",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARDX",
    "nct_id": "NCT03824587",
    "title": "Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hyperphosphatemia"
    ],
    "interventions": [
      "Tenapanor",
      "Placebo",
      "Phosphate Binder Agents"
    ],
    "primary_completion_date": "2019-07-17",
    "completion_date": "2019-07-17",
    "results_first_posted": "2023-03-06",
    "last_update_posted": "2023-03-06",
    "enrollment": null,
    "sponsor": "Ardelyx",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARDX",
    "nct_id": "NCT05643534",
    "title": "Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Irritable Bowel Syndrome With Constipation (IBS-C)"
    ],
    "interventions": [
      "Tenapanor 50 MG",
      "Tenapanor 25 mg bid",
      "Placebo"
    ],
    "primary_completion_date": "2026-06-01",
    "completion_date": "2026-06-01",
    "results_first_posted": null,
    "last_update_posted": "2026-01-12",
    "enrollment": null,
    "sponsor": "Ardelyx",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARDX",
    "nct_id": "NCT02140281",
    "title": "To Assess the Effect of AZD1722 on the Pharmacokinetics of Cefadroxil in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "Treatment A (cefadroxil alone)",
      "Treatment B - AZD1722 followed by cefadroxil"
    ],
    "primary_completion_date": "2014-08",
    "completion_date": "2014-08",
    "results_first_posted": null,
    "last_update_posted": "2015-09-22",
    "enrollment": null,
    "sponsor": "Ardelyx",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARDX",
    "nct_id": "NCT06553547",
    "title": "4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Irritable Bowel Syndrome With Constipation (IBS-C)"
    ],
    "interventions": [
      "Tenapanor",
      "Placebo"
    ],
    "primary_completion_date": "2026-06",
    "completion_date": "2026-06",
    "results_first_posted": null,
    "last_update_posted": "2026-01-12",
    "enrollment": null,
    "sponsor": "Ardelyx",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARDX",
    "nct_id": "NCT01847092",
    "title": "A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Kidney Disease",
      "Type 2 Diabetes Mellitus"
    ],
    "interventions": [
      "AZD1722",
      "Placebo"
    ],
    "primary_completion_date": "2015-03",
    "completion_date": "2015-04",
    "results_first_posted": "2020-05-27",
    "last_update_posted": "2020-05-27",
    "enrollment": null,
    "sponsor": "Ardelyx",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARDX",
    "nct_id": "NCT04780841",
    "title": "A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hyperkalemia"
    ],
    "interventions": [
      "RDX013",
      "Placebo"
    ],
    "primary_completion_date": "2021-12-28",
    "completion_date": "2022-03-03",
    "results_first_posted": null,
    "last_update_posted": "2022-05-04",
    "enrollment": null,
    "sponsor": "Ardelyx",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARDX",
    "nct_id": "NCT04549597",
    "title": "Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Kidney Disease Requiring Chronic Dialysis",
      "Hyperphosphatemia"
    ],
    "interventions": [
      "Tenapanor"
    ],
    "primary_completion_date": "2021-10-13",
    "completion_date": "2021-12-01",
    "results_first_posted": "2023-03-29",
    "last_update_posted": "2023-03-29",
    "enrollment": null,
    "sponsor": "Ardelyx",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARDX",
    "nct_id": "NCT06203444",
    "title": "An Open-label Study to Evaluate the Pharmacokinetics of Oral Tenapanor in Breast Milk of Lactating Females",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lactation"
    ],
    "interventions": [
      "Tenapanor"
    ],
    "primary_completion_date": "2024-05-30",
    "completion_date": "2024-05-30",
    "results_first_posted": null,
    "last_update_posted": "2024-07-11",
    "enrollment": null,
    "sponsor": "Ardelyx",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARDX",
    "nct_id": "NCT02675998",
    "title": "An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hyperphosphatemia"
    ],
    "interventions": [
      "Tenapanor",
      "Placebo"
    ],
    "primary_completion_date": "2016-12",
    "completion_date": "2018-01-17",
    "results_first_posted": "2020-08-10",
    "last_update_posted": "2020-08-10",
    "enrollment": null,
    "sponsor": "Ardelyx",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARDX",
    "nct_id": "NCT02063386",
    "title": "AZD1722 Open Label, Absorption Distribution Metabolism and Excretion Study",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "AZD1722"
    ],
    "primary_completion_date": "2014-05",
    "completion_date": "2014-05",
    "results_first_posted": null,
    "last_update_posted": "2015-09-22",
    "enrollment": null,
    "sponsor": "Ardelyx",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARDX",
    "nct_id": "NCT02686138",
    "title": "A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Constipation Predominant Irritable Bowel Syndrome"
    ],
    "interventions": [
      "Tenapanor",
      "Placebo"
    ],
    "primary_completion_date": "2017-08",
    "completion_date": "2017-10",
    "results_first_posted": "2020-04-13",
    "last_update_posted": "2020-04-22",
    "enrollment": null,
    "sponsor": "Ardelyx",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARDX",
    "nct_id": "NCT02727751",
    "title": "A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Constipation Predominant Irritable Bowel Syndrome"
    ],
    "interventions": [
      "Tenapanor"
    ],
    "primary_completion_date": "2017-10",
    "completion_date": "2017-10",
    "results_first_posted": "2020-04-24",
    "last_update_posted": "2020-09-09",
    "enrollment": null,
    "sponsor": "Ardelyx",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARDX",
    "nct_id": "NCT01340053",
    "title": "A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Constipation Predominant Irritable Bowel Syndrome"
    ],
    "interventions": [
      "RDX5791"
    ],
    "primary_completion_date": "2011-12",
    "completion_date": "2012-02",
    "results_first_posted": "2019-10-15",
    "last_update_posted": "2019-10-15",
    "enrollment": null,
    "sponsor": "Ardelyx",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARDX",
    "nct_id": "NCT02081534",
    "title": "Dose Finding Study to Treat High Phosphate Levels in the Blood.",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hyperphosphatemia"
    ],
    "interventions": [
      "AZD1722",
      "Placebo"
    ],
    "primary_completion_date": "2014-11",
    "completion_date": "2014-11",
    "results_first_posted": "2020-09-14",
    "last_update_posted": "2020-09-14",
    "enrollment": null,
    "sponsor": "Ardelyx",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARDX",
    "nct_id": "NCT02819687",
    "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RDX5791 in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "RDX5791",
      "Placebo"
    ],
    "primary_completion_date": "2011-03",
    "completion_date": "2011-08",
    "results_first_posted": null,
    "last_update_posted": "2016-06-30",
    "enrollment": null,
    "sponsor": "Ardelyx",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARDX",
    "nct_id": "NCT05905926",
    "title": "Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Irritable Bowel Syndrome With Constipation (IBS-C)"
    ],
    "interventions": [
      "Tenapanor"
    ],
    "primary_completion_date": "2031-07",
    "completion_date": "2031-10",
    "results_first_posted": null,
    "last_update_posted": "2026-01-12",
    "enrollment": null,
    "sponsor": "Ardelyx",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARDX",
    "nct_id": "NCT02346890",
    "title": "A Phase 1 Study to Examine the Effect of Renvela on the Pharmacodynamics of AZD1722",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "AZD1722",
      "Renvela"
    ],
    "primary_completion_date": "2013-04",
    "completion_date": "2013-04",
    "results_first_posted": null,
    "last_update_posted": "2015-01-27",
    "enrollment": null,
    "sponsor": "Ardelyx",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARDX",
    "nct_id": "NCT02226783",
    "title": "D5611C00003 - Food Interaction Study With AZD1722 Tablet in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers Food Interaction Study"
    ],
    "interventions": [
      "AZD1722 salt tablet",
      "AZD1722 free base tablet",
      "AZD1722 free base tablet + Omeprazole"
    ],
    "primary_completion_date": "2013-10",
    "completion_date": "2013-10",
    "results_first_posted": null,
    "last_update_posted": "2015-09-22",
    "enrollment": null,
    "sponsor": "Ardelyx",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARDX",
    "nct_id": "NCT03988920",
    "title": "A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hyperphosphatemia",
      "End Stage Renal Disease"
    ],
    "interventions": [
      "Tenapanor",
      "Sevelamer Carbonate"
    ],
    "primary_completion_date": "2021-06-26",
    "completion_date": "2021-07-31",
    "results_first_posted": "2023-03-29",
    "last_update_posted": "2023-03-29",
    "enrollment": null,
    "sponsor": "Ardelyx",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARDX",
    "nct_id": "NCT02140268",
    "title": "To Evaluate the Effect of AZD1722 on the Pharmacokinetics of Oral Midazolam in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "Midazolam",
      "AZD1722",
      "AZD1722 and Midazolam"
    ],
    "primary_completion_date": "2014-08",
    "completion_date": "2014-08",
    "results_first_posted": null,
    "last_update_posted": "2015-09-22",
    "enrollment": null,
    "sponsor": "Ardelyx",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARQT",
    "nct_id": "NCT04655313",
    "title": "Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Psoriasis",
      "Plaque Psoriasis"
    ],
    "interventions": [
      "ARQ-151 cream 0.3%"
    ],
    "primary_completion_date": "2022-01-12",
    "completion_date": "2022-01-12",
    "results_first_posted": "2023-12-15",
    "last_update_posted": "2023-12-15",
    "enrollment": null,
    "sponsor": "Arcutis Biotherapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARQT",
    "nct_id": "NCT04773600",
    "title": "Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atopic Dermatitis Eczema"
    ],
    "interventions": [
      "Roflumilast Cream",
      "Vehicle cream"
    ],
    "primary_completion_date": "2022-09-29",
    "completion_date": "2022-09-29",
    "results_first_posted": "2024-10-04",
    "last_update_posted": "2024-10-04",
    "enrollment": null,
    "sponsor": "Arcutis Biotherapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARQT",
    "nct_id": "NCT04286607",
    "title": "Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Plaque Psoriasis"
    ],
    "interventions": [
      "Topical roflumilast"
    ],
    "primary_completion_date": "2024-01-22",
    "completion_date": "2024-01-22",
    "results_first_posted": null,
    "last_update_posted": "2025-01-07",
    "enrollment": null,
    "sponsor": "Arcutis Biotherapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARQT",
    "nct_id": "NCT04279119",
    "title": "Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Adolescents and Adults With Chronic Plaque Psoriasis",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Plaque Psoriasis"
    ],
    "interventions": [
      "ARQ-151- cream 0.3%"
    ],
    "primary_completion_date": "2021-03-25",
    "completion_date": "2021-03-25",
    "results_first_posted": null,
    "last_update_posted": "2022-08-03",
    "enrollment": null,
    "sponsor": "Arcutis Biotherapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARQT",
    "nct_id": "NCT07340216",
    "title": "Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Psoriasis"
    ],
    "interventions": [
      "ARQ-154 Foam 0.3%"
    ],
    "primary_completion_date": "2026-12",
    "completion_date": "2027-02",
    "results_first_posted": null,
    "last_update_posted": "2026-01-14",
    "enrollment": null,
    "sponsor": "Arcutis Biotherapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARQT",
    "nct_id": "NCT04128007",
    "title": "Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Plaque Psoriasis"
    ],
    "interventions": [
      "Roflumilast foam 0.3%",
      "Vehicle foam"
    ],
    "primary_completion_date": "2020-09-23",
    "completion_date": "2020-09-25",
    "results_first_posted": "2022-09-30",
    "last_update_posted": "2022-10-26",
    "enrollment": null,
    "sponsor": "Arcutis Biotherapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARQT",
    "nct_id": "NCT04378569",
    "title": "Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Hand Eczema"
    ],
    "interventions": [
      "ARQ-252 cream 0.3%",
      "ARQ-252 cream 0.1%",
      "ARQ-252 Vehicle Cream"
    ],
    "primary_completion_date": "2021-02-24",
    "completion_date": "2021-02-24",
    "results_first_posted": "2024-04-05",
    "last_update_posted": "2024-04-05",
    "enrollment": null,
    "sponsor": "Arcutis Biotherapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARQT",
    "nct_id": "NCT04211389",
    "title": "Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Plaque Psoriasis"
    ],
    "interventions": [
      "ARQ-151 0.3% cream",
      "ARQ-151 vehicle cream"
    ],
    "primary_completion_date": "2020-11-23",
    "completion_date": "2020-11-23",
    "results_first_posted": "2022-10-18",
    "last_update_posted": "2022-12-07",
    "enrollment": null,
    "sponsor": "Arcutis Biotherapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARQT",
    "nct_id": "NCT06998056",
    "title": "Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atopic Dermatitis (Eczema)"
    ],
    "interventions": [
      "ARQ-151 cream 0.05%"
    ],
    "primary_completion_date": "2025-12-04",
    "completion_date": "2025-12-04",
    "results_first_posted": null,
    "last_update_posted": "2025-12-10",
    "enrollment": null,
    "sponsor": "Arcutis Biotherapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARQT",
    "nct_id": "NCT04811131",
    "title": "Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Vitiligo"
    ],
    "interventions": [
      "ARQ-252 cream 0.3%",
      "ARQ-252 Vehicle cream",
      "NB-UVB phototherapy active treatment",
      "NB-UVB phototherapy sham treatment"
    ],
    "primary_completion_date": "2021-08-09",
    "completion_date": "2021-08-09",
    "results_first_posted": "2024-07-12",
    "last_update_posted": "2024-07-12",
    "enrollment": null,
    "sponsor": "Arcutis Biotherapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARQT",
    "nct_id": "NCT04746911",
    "title": "Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Psoriasis",
      "Plaque Psoriasis"
    ],
    "interventions": [
      "ARQ-151 cream 0.3%"
    ],
    "primary_completion_date": "2022-05-11",
    "completion_date": "2022-05-11",
    "results_first_posted": null,
    "last_update_posted": "2023-03-10",
    "enrollment": null,
    "sponsor": "Arcutis Biotherapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARQT",
    "nct_id": "NCT04211363",
    "title": "Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Plaque Psoriasis"
    ],
    "interventions": [
      "Roflumilast 0.3% cream",
      "Vehicle Cream"
    ],
    "primary_completion_date": "2020-11-16",
    "completion_date": "2020-11-16",
    "results_first_posted": "2022-11-03",
    "last_update_posted": "2022-12-07",
    "enrollment": null,
    "sponsor": "Arcutis Biotherapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARQT",
    "nct_id": "NCT04445987",
    "title": "Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Seborrheic Dermatitis"
    ],
    "interventions": [
      "ARQ-154"
    ],
    "primary_completion_date": "2022-11-19",
    "completion_date": "2022-11-19",
    "results_first_posted": "2024-06-11",
    "last_update_posted": "2024-06-11",
    "enrollment": null,
    "sponsor": "Arcutis Biotherapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARQT",
    "nct_id": "NCT03392168",
    "title": "Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque Psoriasis",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Psoriasis"
    ],
    "interventions": [
      "ARQ-151 cream 0.5%",
      "ARQ-151 cream 0.15%",
      "ARQ-151 vehicle cream"
    ],
    "primary_completion_date": "2018-05-02",
    "completion_date": "2018-05-02",
    "results_first_posted": "2021-07-08",
    "last_update_posted": "2022-08-04",
    "enrollment": null,
    "sponsor": "Arcutis Biotherapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARQT",
    "nct_id": "NCT04773587",
    "title": "Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atopic Dermatitis Eczema"
    ],
    "interventions": [
      "Roflumilast Cream 0.15%",
      "Vehicle Cream"
    ],
    "primary_completion_date": "2022-08-30",
    "completion_date": "2022-08-30",
    "results_first_posted": "2024-10-09",
    "last_update_posted": "2024-10-09",
    "enrollment": null,
    "sponsor": "Arcutis Biotherapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARQT",
    "nct_id": "NCT03638258",
    "title": "The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Plaque Psoriasis"
    ],
    "interventions": [
      "Roflumilast Cream 0.3%",
      "Roflumilast Cream 0.15%",
      "Vehicle Cream"
    ],
    "primary_completion_date": "2019-05-29",
    "completion_date": "2019-05-29",
    "results_first_posted": "2022-08-10",
    "last_update_posted": "2022-09-02",
    "enrollment": null,
    "sponsor": "Arcutis Biotherapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARQT",
    "nct_id": "NCT03764475",
    "title": "Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psoriasis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Plaque Psoriasis"
    ],
    "interventions": [
      "Roflumilast"
    ],
    "primary_completion_date": "2020-10-08",
    "completion_date": "2020-10-08",
    "results_first_posted": "2022-08-18",
    "last_update_posted": "2022-09-02",
    "enrollment": null,
    "sponsor": "Arcutis Biotherapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARQT",
    "nct_id": "NCT04804605",
    "title": "Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atopic Dermatitis Eczema"
    ],
    "interventions": [
      "ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%"
    ],
    "primary_completion_date": "2024-05-28",
    "completion_date": "2024-05-28",
    "results_first_posted": "2025-12-23",
    "last_update_posted": "2025-12-23",
    "enrollment": null,
    "sponsor": "Arcutis Biotherapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARQT",
    "nct_id": "NCT05028582",
    "title": "Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Scalp Psoriasis"
    ],
    "interventions": [
      "Roflumilast Foam 0.3%",
      "Vehicle Foam"
    ],
    "primary_completion_date": "2022-06-03",
    "completion_date": "2022-06-03",
    "results_first_posted": "2025-07-17",
    "last_update_posted": "2025-07-17",
    "enrollment": null,
    "sponsor": "Arcutis Biotherapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARQT",
    "nct_id": "NCT04973228",
    "title": "Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Seborrheic Dermatitis"
    ],
    "interventions": [
      "Roflumilast Foam",
      "Vehicle Foam"
    ],
    "primary_completion_date": "2022-04-06",
    "completion_date": "2022-04-06",
    "results_first_posted": "2024-03-12",
    "last_update_posted": "2024-03-12",
    "enrollment": null,
    "sponsor": "Arcutis Biotherapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARQT",
    "nct_id": "NCT04845620",
    "title": "Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atopic Dermatitis Eczema"
    ],
    "interventions": [
      "Roflumilast Cream 0.05%",
      "Vehicle Cream"
    ],
    "primary_completion_date": "2023-06-01",
    "completion_date": "2023-06-01",
    "results_first_posted": "2025-12-23",
    "last_update_posted": "2025-12-23",
    "enrollment": null,
    "sponsor": "Arcutis Biotherapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARQT",
    "nct_id": "NCT04156191",
    "title": "Pharmacokinetics (PK), Safety, Efficacy and Maximal Use PK of ARQ-151 in Adolescents/Children With Mild/Moderate Eczema",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atopic Dermatitis (Eczema)"
    ],
    "interventions": [
      "ARQ-151 cream 0.15%",
      "ARQ-151 cream 0.05%"
    ],
    "primary_completion_date": "2023-05-02",
    "completion_date": "2023-05-02",
    "results_first_posted": null,
    "last_update_posted": "2023-07-24",
    "enrollment": null,
    "sponsor": "Arcutis Biotherapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARQT",
    "nct_id": "NCT03916081",
    "title": "Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atopic Dermatitis"
    ],
    "interventions": [
      "Roflumilast Cream 0.05%",
      "Roflumilast Cream 0.15%",
      "Vehicle Cream"
    ],
    "primary_completion_date": "2019-11-04",
    "completion_date": "2019-11-04",
    "results_first_posted": "2023-02-13",
    "last_update_posted": "2023-02-13",
    "enrollment": null,
    "sponsor": "Arcutis Biotherapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ARQT",
    "nct_id": "NCT04091646",
    "title": "Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Seborrheic Dermatitis"
    ],
    "interventions": [
      "Roflumilast Foam 0.3%",
      "Vehicle foam"
    ],
    "primary_completion_date": "2020-08-18",
    "completion_date": "2020-08-21",
    "results_first_posted": "2023-07-03",
    "last_update_posted": "2023-07-03",
    "enrollment": null,
    "sponsor": "Arcutis Biotherapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ASND",
    "nct_id": "NCT01247675",
    "title": "A Safety, Pharmacokinetic and Pharmacodynamic Study of ACP-001 (TransCon hGH) in Adults With Growth Hormone Deficiency",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Adult Growth Hormone Deficiency"
    ],
    "interventions": [
      "ACP-001 (TransCon hGH)",
      "ACP-001 (TransCon hGH)",
      "ACP-001 (TransCon hGH)",
      "Omnitrope"
    ],
    "primary_completion_date": "2011-05",
    "completion_date": "2011-05",
    "results_first_posted": "2017-03-09",
    "last_update_posted": "2017-03-09",
    "enrollment": null,
    "sponsor": "Ascendis Pharma A/S",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ASND",
    "nct_id": "NCT06732895",
    "title": "A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Achondroplasia"
    ],
    "interventions": [
      "Navepegritide",
      "Placebo for navepegritide"
    ],
    "primary_completion_date": "2026-12",
    "completion_date": "2027-01",
    "results_first_posted": null,
    "last_update_posted": "2025-12-17",
    "enrollment": null,
    "sponsor": "Ascendis Pharma A/S",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ASND",
    "nct_id": "NCT04085523",
    "title": "A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With Achondroplasia",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Achondroplasia"
    ],
    "interventions": [
      "TransCon CNP",
      "Placebo for TransCon CNP"
    ],
    "primary_completion_date": "2022-09-27",
    "completion_date": "2024-10-01",
    "results_first_posted": "2024-03-07",
    "last_update_posted": "2025-05-22",
    "enrollment": null,
    "sponsor": "Ascendis Pharma A/S",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ASND",
    "nct_id": "NCT05775523",
    "title": "A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Growth Hormone Deficiency"
    ],
    "interventions": [
      "No intervention"
    ],
    "primary_completion_date": "2033-03",
    "completion_date": "2033-03",
    "results_first_posted": null,
    "last_update_posted": "2025-10-27",
    "enrollment": null,
    "sponsor": "Ascendis Pharma Endocrinology Division A/S",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ASND",
    "nct_id": "NCT05598320",
    "title": "A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With Achondroplasia",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Achondroplasia"
    ],
    "interventions": [
      "TransCon CNP",
      "Placebo for TransCon CNP"
    ],
    "primary_completion_date": "2024-08-09",
    "completion_date": "2025-08-13",
    "results_first_posted": null,
    "last_update_posted": "2026-01-15",
    "enrollment": null,
    "sponsor": "Ascendis Pharma Growth Disorders A/S",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ASND",
    "nct_id": "NCT07081997",
    "title": "A Phase 3 Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 \u03bcg/Day in Adult Participants With Hypoparathyroidism",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypoparathyroidism",
      "Endocrine System Diseases",
      "Parathyroid Diseases"
    ],
    "interventions": [
      "Palopegteriparatide"
    ],
    "primary_completion_date": "2026-12",
    "completion_date": "2027-12",
    "results_first_posted": null,
    "last_update_posted": "2025-10-27",
    "enrollment": null,
    "sponsor": "Ascendis Pharma Bone Diseases A/S",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ASND",
    "nct_id": "NCT03344458",
    "title": "A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Growth Hormone Deficiency, Pediatric",
      "Endocrine System Diseases",
      "Hormone Deficiency",
      "Pituitary Diseases"
    ],
    "interventions": [
      "TransCon hGH"
    ],
    "primary_completion_date": "2023-02-21",
    "completion_date": "2023-02-21",
    "results_first_posted": "2024-05-08",
    "last_update_posted": "2024-05-08",
    "enrollment": null,
    "sponsor": "Ascendis Pharma A/S",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ASND",
    "nct_id": "NCT06079398",
    "title": "A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Achondroplasia"
    ],
    "interventions": [
      "Navepegritide",
      "Placebo for Navepegritide"
    ],
    "primary_completion_date": "2026-03",
    "completion_date": "2027-03",
    "results_first_posted": null,
    "last_update_posted": "2025-11-26",
    "enrollment": null,
    "sponsor": "Ascendis Pharma A/S",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ASND",
    "nct_id": "NCT05081609",
    "title": "A Study to Investigate Safety and Tolerability of TransCon IL-2 \u03b2/\u03b3 Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumor",
      "Locally Advanced Solid Tumor",
      "Metastatic Solid Tumor",
      "Platinum-resistant Ovarian Cancer",
      "Post Anti-PD-1 Melanoma",
      "2L+ Cervical Cancer",
      "Neoadjuvant Melanoma",
      "Neoadjuvant Non-Small Cell Lung Cancer",
      "Post Anti-PD-(L)1 Non-Small Cell Lung Cancer",
      "Post Anti-PD-(L)1 Small Cell Lung Cancer",
      "Third Line or Later (3L+) HER2+ Breast Cancer",
      "Second or Third Line (2L/3L) Cervical Cancer",
      "Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC)"
    ],
    "interventions": [
      "TransCon IL-2 \u03b2/\u03b3",
      "Pembrolizumab",
      "Chemotherapy drug",
      "TransCon TLR7/8 Agonist",
      "Surgery",
      "Trastuzumab",
      "Trastuzumab emtansine (T-DM1)"
    ],
    "primary_completion_date": "2027-08",
    "completion_date": "2029-08",
    "results_first_posted": null,
    "last_update_posted": "2025-07-08",
    "enrollment": null,
    "sponsor": "Ascendis Pharma Oncology Division A/S",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ASND",
    "nct_id": "NCT01010425",
    "title": "Pharmacokinetics and Pharmacodynamics of ACP-001 (TransCon PEG hGH)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "ACP-001 (TransCon PEG hGH)",
      "ACP-001 (TransCon PEG hGH)",
      "ACP-001 (TransCon PEG hGH)",
      "ACP-001 (TransCon PEG hGH)",
      "Placebo",
      "Human Growth Hormone"
    ],
    "primary_completion_date": "2010-02",
    "completion_date": "2010-05",
    "results_first_posted": null,
    "last_update_posted": "2010-06-08",
    "enrollment": null,
    "sponsor": "Ascendis Pharma A/S",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ASND",
    "nct_id": "NCT07264634",
    "title": "A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH\u00ae (Palopegteriparatide)",
    "status": "NOT_YET_RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Hypoparathyroidism"
    ],
    "interventions": [
      "Palopegteriparatide"
    ],
    "primary_completion_date": "2028-01",
    "completion_date": "2028-01",
    "results_first_posted": null,
    "last_update_posted": "2025-12-04",
    "enrollment": null,
    "sponsor": "Ascendis Pharma A/S",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ASND",
    "nct_id": "NCT03875534",
    "title": "A Multi-center, Longitudinal, Observational Study of Children With Achondroplasia",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Achondroplasia"
    ],
    "interventions": [],
    "primary_completion_date": "2024-01-12",
    "completion_date": "2024-01-12",
    "results_first_posted": null,
    "last_update_posted": "2024-03-19",
    "enrollment": null,
    "sponsor": "Ascendis Pharma A/S",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ASND",
    "nct_id": "NCT03305016",
    "title": "A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Growth Hormone Deficiency, Pediatric",
      "Endocrine System Diseases",
      "Hormone Deficiency",
      "Pituitary Diseases"
    ],
    "interventions": [
      "TransCon hGH"
    ],
    "primary_completion_date": "2019-03-19",
    "completion_date": "2019-03-19",
    "results_first_posted": "2022-01-04",
    "last_update_posted": "2022-01-04",
    "enrollment": null,
    "sponsor": "Ascendis Pharma Endocrinology Division A/S",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ASND",
    "nct_id": "NCT06433557",
    "title": "A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With Achondroplasia",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Achondroplasia"
    ],
    "interventions": [
      "Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections"
    ],
    "primary_completion_date": "2025-09",
    "completion_date": "2027-09",
    "results_first_posted": null,
    "last_update_posted": "2025-07-02",
    "enrollment": null,
    "sponsor": "Ascendis Pharma Growth Disorders A/S",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ASND",
    "nct_id": "NCT05980598",
    "title": "TransCon (TC) TLR7/8 Agonist, TC IL-2 \u03b2/\u03b3, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Head and Neck Neoplasms"
    ],
    "interventions": [
      "TransCon TLR7/8 Agonist",
      "Pembrolizumab",
      "TransCon IL-2 \u03b2/\u03b3"
    ],
    "primary_completion_date": "2025-03-28",
    "completion_date": "2025-03-28",
    "results_first_posted": null,
    "last_update_posted": "2025-08-01",
    "enrollment": null,
    "sponsor": "Ascendis Pharma A/S",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ASND",
    "nct_id": "NCT05820672",
    "title": "A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Growth Hormone Deficiency"
    ],
    "interventions": [
      "No intervention"
    ],
    "primary_completion_date": "2033-03",
    "completion_date": "2033-03",
    "results_first_posted": null,
    "last_update_posted": "2025-10-27",
    "enrollment": null,
    "sponsor": "Ascendis Pharma Endocrinology Division A/S",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ASND",
    "nct_id": "NCT04009291",
    "title": "A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypoparathyroidism",
      "Endocrine System Diseases",
      "Parathyroid Diseases"
    ],
    "interventions": [
      "TransCon PTH",
      "Placebo for TransCon PTH"
    ],
    "primary_completion_date": "2020-03-06",
    "completion_date": "2025-04-17",
    "results_first_posted": "2023-09-01",
    "last_update_posted": "2025-05-08",
    "enrollment": null,
    "sponsor": "Ascendis Pharma A/S",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ASND",
    "nct_id": "NCT04799054",
    "title": "A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumor",
      "Locally Advanced Solid Tumor",
      "Metastatic Solid Tumor",
      "Head and Neck Squamous Cell Carcinoma HNSCC",
      "HPV-associated Cancers",
      "Neoadjuvant Melanoma",
      "Neoadjuvant Cutaneous Squamous Cell Carcinoma (cSCC)"
    ],
    "interventions": [
      "TransCon TLR7/8 Agonist",
      "Pembrolizumab"
    ],
    "primary_completion_date": "2025-12-02",
    "completion_date": "2025-12-02",
    "results_first_posted": null,
    "last_update_posted": "2026-01-20",
    "enrollment": null,
    "sponsor": "Ascendis Pharma Oncology Division A/S",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ASND",
    "nct_id": "NCT04701203",
    "title": "A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypoparathyroidism",
      "Endocrine System Diseases",
      "Parathyroid Diseases"
    ],
    "interventions": [
      "TransCon PTH",
      "Placebo"
    ],
    "primary_completion_date": "2022-01-12",
    "completion_date": "2025-01-21",
    "results_first_posted": "2025-02-28",
    "last_update_posted": "2025-03-18",
    "enrollment": null,
    "sponsor": "Ascendis Pharma Bone Diseases A/S",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ASND",
    "nct_id": "NCT05690386",
    "title": "A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Turner Syndrome"
    ],
    "interventions": [
      "Lonapegsomatropin",
      "Somatropin"
    ],
    "primary_completion_date": "2024-10-18",
    "completion_date": "2027-12",
    "results_first_posted": null,
    "last_update_posted": "2026-01-12",
    "enrollment": null,
    "sponsor": "Ascendis Pharma Endocrinology Division A/S",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ASND",
    "nct_id": "NCT02781727",
    "title": "A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Growth Hormone Deficiency, Pediatric",
      "hGH (Human Growth Hormone)",
      "Endocrine System Diseases",
      "Hormones",
      "Pituitary Diseases"
    ],
    "interventions": [
      "Once weekly subcutaneous injection of TransCon hGH",
      "Once daily subcutaneous injection of Genotropin"
    ],
    "primary_completion_date": "2019-01-17",
    "completion_date": "2019-01-17",
    "results_first_posted": "2022-01-04",
    "last_update_posted": "2022-01-04",
    "enrollment": null,
    "sponsor": "Ascendis Pharma Endocrinology Division A/S",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ASND",
    "nct_id": "NCT05246033",
    "title": "A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Multiple Subcutaneous Doses of TransCon CNP Administered Once Weekly in Children With Achondroplasia",
    "status": "UNKNOWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Achondroplasia"
    ],
    "interventions": [
      "TransCon CNP",
      "Placebo for TransCon CNP"
    ],
    "primary_completion_date": "2023-03-15",
    "completion_date": "2024-03",
    "results_first_posted": null,
    "last_update_posted": "2023-11-02",
    "enrollment": null,
    "sponsor": "Ascendis Pharma A/S",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ASND",
    "nct_id": "NCT03803163",
    "title": "A Safety, Tolerability and Pharmacokinetics Study of TransCon Treprostinil in Healthy Adult Male Volunteers",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "TransCon Treprostinil"
    ],
    "primary_completion_date": "2015-06",
    "completion_date": "2015-06",
    "results_first_posted": null,
    "last_update_posted": "2019-01-14",
    "enrollment": null,
    "sponsor": "Ascendis Pharma A/S",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ASND",
    "nct_id": "NCT04615273",
    "title": "A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Growth Hormone Deficiency",
      "Endocrine System Diseases",
      "Hormone Deficiency"
    ],
    "interventions": [
      "Lonapegsomatropin",
      "Placebo",
      "Somatropin"
    ],
    "primary_completion_date": "2023-11-02",
    "completion_date": "2023-12-01",
    "results_first_posted": "2025-01-15",
    "last_update_posted": "2025-01-15",
    "enrollment": null,
    "sponsor": "Ascendis Pharma Endocrinology Division A/S",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ASND",
    "nct_id": "NCT07221851",
    "title": "Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Turner Syndrome",
      "Short Stature Homeobox Gene Mutation",
      "Idiopathic Short Stature",
      "Small for Gestational Age at Delivery"
    ],
    "interventions": [
      "Lonapegsomatropin [SKYTROFA\u00ae]",
      "Somatropin Pen Injector"
    ],
    "primary_completion_date": "2028-02",
    "completion_date": "2029-03",
    "results_first_posted": null,
    "last_update_posted": "2026-01-07",
    "enrollment": null,
    "sponsor": "Ascendis Pharma A/S",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ASND",
    "nct_id": "NCT05654701",
    "title": "Expanded Access Program of Palopegteriparatide in Patients With Hypoparathyroidism",
    "status": "APPROVED_FOR_MARKETING",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Hypoparathyroidism"
    ],
    "interventions": [
      "Palopegteriparatide (TransCon PTH)"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2025-06-27",
    "enrollment": null,
    "sponsor": "Ascendis Pharma Bone Diseases A/S",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ASND",
    "nct_id": "NCT05171855",
    "title": "A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Adult Growth Hormone Deficiency",
      "Endocrine System Diseases",
      "Hormone Deficiency"
    ],
    "interventions": [
      "Lonapegsomatropin"
    ],
    "primary_completion_date": "2024-12-23",
    "completion_date": "2024-12-23",
    "results_first_posted": "2026-01-09",
    "last_update_posted": "2026-01-09",
    "enrollment": null,
    "sponsor": "Ascendis Pharma Endocrinology Division A/S",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ASND",
    "nct_id": "NCT07345494",
    "title": "A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH\u00ae (Palopegteriparatide) During Pregnancy and Breastfeeding",
    "status": "NOT_YET_RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Hypoparathyroidism"
    ],
    "interventions": [
      "Palopegteriparatide"
    ],
    "primary_completion_date": "2036-01",
    "completion_date": "2036-01",
    "results_first_posted": null,
    "last_update_posted": "2026-01-15",
    "enrollment": null,
    "sponsor": "Ascendis Pharma A/S",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ASND",
    "nct_id": "NCT01947907",
    "title": "Safety, PK/PD (Pharmacokinetics/Pharmacodynamics) and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Growth Hormone Deficiency (GHD)"
    ],
    "interventions": [
      "ACP-001",
      "Human Growth Hormone"
    ],
    "primary_completion_date": "2015-07",
    "completion_date": "2015-09",
    "results_first_posted": "2017-01-19",
    "last_update_posted": "2017-01-19",
    "enrollment": null,
    "sponsor": "Ascendis Pharma A/S",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ASND",
    "nct_id": "NCT05929807",
    "title": "A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Achondroplasia"
    ],
    "interventions": [
      "TransCon CNP"
    ],
    "primary_completion_date": "2039-01",
    "completion_date": "2039-03",
    "results_first_posted": null,
    "last_update_posted": "2025-10-27",
    "enrollment": null,
    "sponsor": "Ascendis Pharma Growth Disorders A/S",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AVBP",
    "nct_id": "NCT05364073",
    "title": "Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-Small Cell Lung Cancer (NSCLC)",
      "Metastatic Non-Small Cell Lung Cancer",
      "Advanced Non-Small Cell Lung Cancer",
      "HER2 Exon 20 Mutations",
      "EGFR Exon 20 Mutations",
      "EGFR Uncommon Mutations, Including G719X and S768I"
    ],
    "interventions": [
      "Furmonertinib",
      "Furmonertinib",
      "Furmonertinib",
      "Furmonertinib",
      "Furmonertinib"
    ],
    "primary_completion_date": "2025-06-03",
    "completion_date": "2025-12",
    "results_first_posted": null,
    "last_update_posted": "2025-08-21",
    "enrollment": null,
    "sponsor": "ArriVent BioPharma, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AVBP",
    "nct_id": "NCT05607550",
    "title": "Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Non-Small Cell Lung Cancer",
      "Advanced Non-Small Cell Lung Cancer",
      "EGFR Exon 20 Mutations"
    ],
    "interventions": [
      "furmonertinib 240 mg oral, daily",
      "furmonertinib 160 mg oral, daily",
      "platinum-based chemotherapy"
    ],
    "primary_completion_date": "2025-08-15",
    "completion_date": "2028-02-15",
    "results_first_posted": null,
    "last_update_posted": "2025-06-22",
    "enrollment": null,
    "sponsor": "ArriVent BioPharma, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AVBP",
    "nct_id": "NCT07185997",
    "title": "Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-Small-Cell Lung Cancer",
      "Metastatic Non-Small-Cell Lung Cancer",
      "Advanced Non-Small-Cell Lung Cancer",
      "EGFR P-Loop and Alpha C-Helix Compressing",
      "EGFR PACC",
      "EGFR Uncommon Mutations"
    ],
    "interventions": [
      "Firmonertinib",
      "EGFR-TKI inhibitor based on investigator's choice"
    ],
    "primary_completion_date": "2029-02",
    "completion_date": "2030-12",
    "results_first_posted": null,
    "last_update_posted": "2025-11-19",
    "enrollment": null,
    "sponsor": "ArriVent BioPharma, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AVBP",
    "nct_id": "NCT07066657",
    "title": "A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Locally Advanced or Metastatic Solid Tumors",
      "Colorectal Cancer",
      "Gastric Cancer",
      "Pancreatic Cancer"
    ],
    "interventions": [
      "MRG007"
    ],
    "primary_completion_date": "2029-05",
    "completion_date": "2030-12",
    "results_first_posted": null,
    "last_update_posted": "2025-12-11",
    "enrollment": null,
    "sponsor": "Lepu Biopharma Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AZN",
    "nct_id": "NCT01838499",
    "title": "Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hidradenitis Suppurativa"
    ],
    "interventions": [
      "MEDI8968",
      "Saline"
    ],
    "primary_completion_date": "2014-10",
    "completion_date": "2014-10",
    "results_first_posted": "2016-09-01",
    "last_update_posted": "2016-09-01",
    "enrollment": null,
    "sponsor": "AstraZeneca",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AZN",
    "nct_id": "NCT06465810",
    "title": "Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Transthyretin Amyloidosis",
      "ATTR-CM",
      "ATTRv-PN",
      "ATTR",
      "ATTR-Mixed",
      "hATTR"
    ],
    "interventions": [
      "Treatment of transthyretin (ATTR) amyloidosis in observational study setting"
    ],
    "primary_completion_date": "2031-12-29",
    "completion_date": "2031-12-29",
    "results_first_posted": null,
    "last_update_posted": "2026-01-22",
    "enrollment": null,
    "sponsor": "AstraZeneca",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AZN",
    "nct_id": "NCT07205666",
    "title": "The Eplontersen Pregnancy and Lactation Outcomes Study",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Transthyretin Amyloidosis"
    ],
    "interventions": [],
    "primary_completion_date": "2035-12-30",
    "completion_date": "2035-12-30",
    "results_first_posted": null,
    "last_update_posted": "2026-01-16",
    "enrollment": null,
    "sponsor": "AstraZeneca",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AZN",
    "nct_id": "NCT06252753",
    "title": "Observational Study Protocol: LIVER-R",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Hepatobiliary Cancers"
    ],
    "interventions": [
      "Durvalumab-based combination therapies in observational study setting",
      "Durvalumab-based combination therapies in observational study setting"
    ],
    "primary_completion_date": "2030-12-30",
    "completion_date": "2030-12-30",
    "results_first_posted": null,
    "last_update_posted": "2025-12-26",
    "enrollment": null,
    "sponsor": "AstraZeneca",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "AZN",
    "nct_id": "NCT00528372",
    "title": "A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 2 Diabetes"
    ],
    "interventions": [
      "Dapagliflozin",
      "Dapagliflozin placebo",
      "Metformin"
    ],
    "primary_completion_date": "2009-02",
    "completion_date": "2010-07",
    "results_first_posted": "2014-05-14",
    "last_update_posted": "2015-10-20",
    "enrollment": null,
    "sponsor": "AstraZeneca",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BBIO",
    "nct_id": "NCT05375084",
    "title": "SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non Small Cell Lung Cancer",
      "Solid Tumor"
    ],
    "interventions": [
      "BBP-398 with nivolumab"
    ],
    "primary_completion_date": "2024-04-12",
    "completion_date": "2024-07-15",
    "results_first_posted": null,
    "last_update_posted": "2024-12-12",
    "enrollment": null,
    "sponsor": "Navire Pharma Inc., a BridgeBio company",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BBIO",
    "nct_id": "NCT04528836",
    "title": "First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Tumor, Solid"
    ],
    "interventions": [
      "BBP-398 (Formerly known as IACS-15509)"
    ],
    "primary_completion_date": "2024-03-22",
    "completion_date": "2024-07-30",
    "results_first_posted": null,
    "last_update_posted": "2024-12-12",
    "enrollment": null,
    "sponsor": "Navire Pharma Inc., a BridgeBio company",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BBIO",
    "nct_id": "NCT05480865",
    "title": "SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor, Adult",
      "Metastatic Solid Tumor",
      "Metastatic NSCLC",
      "Non Small Cell Lung Cancer"
    ],
    "interventions": [
      "BBP-398",
      "sotorasib"
    ],
    "primary_completion_date": "2024-08-22",
    "completion_date": "2024-08-22",
    "results_first_posted": null,
    "last_update_posted": "2024-12-12",
    "enrollment": null,
    "sponsor": "Navire Pharma Inc., a BridgeBio company",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BCAX",
    "nct_id": "NCT04429542",
    "title": "Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Head and Neck Squamous Cell Carcinoma",
      "Squamous Cell Carcinoma of Anal Canal",
      "Colorectal Cancer",
      "Squamous Cell Carcinoma of the Lung",
      "EGFR Amplification",
      "Epithelial Ovarian Cancer",
      "Pancreas Cancer",
      "Cutaneous Squamous Cell Carcinoma",
      "Head and Neck Neoplasms",
      "Carcinoma, Squamous Cell",
      "Squamous Cell Carcinoma of Head and Neck"
    ],
    "interventions": [
      "BCA101",
      "Pembrolizumab"
    ],
    "primary_completion_date": "2026-12-31",
    "completion_date": "2027-06-01",
    "results_first_posted": null,
    "last_update_posted": "2025-08-15",
    "enrollment": null,
    "sponsor": "Bicara Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BCAX",
    "nct_id": "NCT06788990",
    "title": "FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Head and Neck Squamous Cell Carcinoma",
      "Recurrent Head and Neck Squamous Cell Carcinoma"
    ],
    "interventions": [
      "Ficerafusp alfa",
      "Pembrolizumab (KEYTRUDA\u00ae)",
      "Placebo"
    ],
    "primary_completion_date": "2028-04",
    "completion_date": "2029-07",
    "results_first_posted": null,
    "last_update_posted": "2026-01-22",
    "enrollment": null,
    "sponsor": "Bicara Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BIOA",
    "nct_id": "NCT04705597",
    "title": "Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Covid19"
    ],
    "interventions": [
      "BGE-175",
      "Placebo"
    ],
    "primary_completion_date": "2022-04-20",
    "completion_date": "2022-05-19",
    "results_first_posted": "2023-07-03",
    "last_update_posted": "2023-07-03",
    "enrollment": null,
    "sponsor": "BioAge Labs, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BIOA",
    "nct_id": "NCT06141889",
    "title": "Pharmacokinetics Study of Azelaprag (BGE-105) in Older Adult Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteer Study"
    ],
    "interventions": [
      "Azelaprag"
    ],
    "primary_completion_date": "2024-01-26",
    "completion_date": "2024-02-02",
    "results_first_posted": null,
    "last_update_posted": "2024-02-23",
    "enrollment": null,
    "sponsor": "BioAge Labs, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BIOA",
    "nct_id": "NCT06515418",
    "title": "Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Obesity"
    ],
    "interventions": [
      "Oral Azelaprag (BGE-105)",
      "Oral Placebo for Azelaprag (BGE-105)",
      "Tirzepatide",
      "Tirzepatide Placebo"
    ],
    "primary_completion_date": "2025-02-06",
    "completion_date": "2025-02-12",
    "results_first_posted": null,
    "last_update_posted": "2025-03-13",
    "enrollment": null,
    "sponsor": "BioAge Labs, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BIOA",
    "nct_id": "NCT05152641",
    "title": "Study to Evaluate Efficacy and Safety of BGE-117 in Moderately to Severely Anemic Older Individuals After Major Hip Surgery",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Posthemorrhagic Anemia"
    ],
    "interventions": [
      "BGE-117, 4mg",
      "Ferrous Sulfate",
      "Matching Placebo",
      "BGE-117, 12mg"
    ],
    "primary_completion_date": "2023-04",
    "completion_date": "2024-07",
    "results_first_posted": null,
    "last_update_posted": "2022-05-05",
    "enrollment": null,
    "sponsor": "BioAge Labs, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BIOA",
    "nct_id": "NCT04815603",
    "title": "Study to Evaluate Efficacy and Safety of BGE-117 in the Treatment of Anemia of Aging",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Anemia"
    ],
    "interventions": [
      "BGE-117",
      "Placebo"
    ],
    "primary_completion_date": "2022-04",
    "completion_date": "2022-04",
    "results_first_posted": null,
    "last_update_posted": "2022-05-05",
    "enrollment": null,
    "sponsor": "BioAge Labs, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BMRN",
    "nct_id": "NCT00048711",
    "title": "Open-Label Study of Efficacy and Safety of Recombinant Human N-acetylgalactosamine 4-sulfatase in Patients With MPS VI",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Mucopolysaccharidosis VI"
    ],
    "interventions": [
      "N-acetylgalactosamine 4-sulfatase"
    ],
    "primary_completion_date": null,
    "completion_date": "2006-06",
    "results_first_posted": null,
    "last_update_posted": "2009-08-25",
    "enrollment": null,
    "sponsor": "BioMarin Pharmaceutical",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BMRN",
    "nct_id": "NCT02576795",
    "title": "Gene Therapy Study in Severe Haemophilia A Patients (270-201)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Severe Haemophilia A"
    ],
    "interventions": [
      "valoctocogene roxaparvovec"
    ],
    "primary_completion_date": "2024-02-14",
    "completion_date": "2024-02-14",
    "results_first_posted": "2025-04-10",
    "last_update_posted": "2025-04-10",
    "enrollment": null,
    "sponsor": "BioMarin Pharmaceutical",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BMRN",
    "nct_id": "NCT01819727",
    "title": "An Open-Label Phase 3 Study of BMN 165 for Adults With PKU Not Previously Treated w/ BMN 165",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Phenylketonuria"
    ],
    "interventions": [
      "BMN 165"
    ],
    "primary_completion_date": "2015-11-25",
    "completion_date": "2015-11-25",
    "results_first_posted": "2018-09-10",
    "last_update_posted": "2019-02-26",
    "enrollment": null,
    "sponsor": "BioMarin Pharmaceutical",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BMRN",
    "nct_id": "NCT01858103",
    "title": "BMN 110 US Expanded Access Program",
    "status": "APPROVED_FOR_MARKETING",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Mucopolysaccharidosis IVA",
      "Morquio A Syndrome",
      "MPS IVA"
    ],
    "interventions": [
      "BMN 110"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2014-04-02",
    "enrollment": null,
    "sponsor": "BioMarin Pharmaceutical",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BMRN",
    "nct_id": "NCT02365376",
    "title": "Collection and Storage of Human Biospecimens for Research Into Rare Diseases and Medical Conditions",
    "status": "UNKNOWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Rare Genetic Disorders"
    ],
    "interventions": [],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2015-02-18",
    "enrollment": null,
    "sponsor": "BioMarin Pharmaceutical",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BMRN",
    "nct_id": "NCT02963350",
    "title": "A Multicenter, Multi-national Open-label Program to Provide BMN 190 to Patients Diagnosed With CLN2 Disease",
    "status": "APPROVED_FOR_MARKETING",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "CLN2 Disease"
    ],
    "interventions": [
      "BMN190, recombinant human tripeptidyl peptidase-1 (rhTPP1)"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2017-07-24",
    "enrollment": null,
    "sponsor": "BioMarin Pharmaceutical",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BMRN",
    "nct_id": "NCT01016392",
    "title": "Observational Study on the Long Term Safety of Kuvan\u00ae Treatment in Patients With Hyperphenylalaninemia (HPA) Due to Phenylketonuria (PKU) or BH4 Deficiency",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Hyperphenylalaninemia (HPA) Due to Phenylketonuria (PKU) or Tetrahydrobiopterin (BH4) Deficiency"
    ],
    "interventions": [],
    "primary_completion_date": "2021-05-31",
    "completion_date": "2021-05-31",
    "results_first_posted": null,
    "last_update_posted": "2022-04-15",
    "enrollment": null,
    "sponsor": "BioMarin Pharmaceutical",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BMRN",
    "nct_id": "NCT02191917",
    "title": "A Study of Respiratory Muscle Strength in Patients With Late-onset Pompe Disease (LOPD)",
    "status": "TERMINATED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Late-onset Pompe Disease"
    ],
    "interventions": [
      "Respiratory muscle strength measurements by different techniques."
    ],
    "primary_completion_date": "2016-06-22",
    "completion_date": "2016-06-22",
    "results_first_posted": "2023-01-09",
    "last_update_posted": "2023-01-09",
    "enrollment": null,
    "sponsor": "BioMarin Pharmaceutical",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BMRN",
    "nct_id": "NCT05579548",
    "title": "A Global, Multicenter Study to Assess Maternal, Fetal and Infant Outcomes of Exposure to Palynziq\u00ae (Pegvaliase) During Pregnancy and Breastfeeding",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Phenylketonuria, Maternal"
    ],
    "interventions": [
      "Pegvaliase"
    ],
    "primary_completion_date": "2032-10-04",
    "completion_date": "2032-10-04",
    "results_first_posted": null,
    "last_update_posted": "2025-11-28",
    "enrollment": null,
    "sponsor": "BioMarin Pharmaceutical",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BMRN",
    "nct_id": "NCT01977820",
    "title": "Sapropterin on Cognitive Abilities in Young Adults With Phenylketonuria",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Phenylketonuria"
    ],
    "interventions": [
      "Sapropterin",
      "Placebo"
    ],
    "primary_completion_date": "2014-11",
    "completion_date": "2014-11",
    "results_first_posted": "2016-02-12",
    "last_update_posted": "2018-02-22",
    "enrollment": null,
    "sponsor": "BioMarin Pharmaceutical",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BMRN",
    "nct_id": "NCT03424018",
    "title": "An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Achondroplasia"
    ],
    "interventions": [
      "BMN 111"
    ],
    "primary_completion_date": "2031-06",
    "completion_date": "2031-06",
    "results_first_posted": null,
    "last_update_posted": "2025-01-09",
    "enrollment": null,
    "sponsor": "BioMarin Pharmaceutical",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BMRN",
    "nct_id": "NCT00104247",
    "title": "Study to Evaluate the Safety and Efficacy of Phenoptin\u2122 in Subjects With Phenylketonuria Who Have Elevated Phenylalanine Levels",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Phenylketonurias"
    ],
    "interventions": [
      "sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin"
    ],
    "primary_completion_date": null,
    "completion_date": "2006-02",
    "results_first_posted": "2009-04-16",
    "last_update_posted": "2014-07-23",
    "enrollment": null,
    "sponsor": "BioMarin Pharmaceutical",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BMRN",
    "nct_id": "NCT01957059",
    "title": "A Phase I/II Study of BMN053 in Subjects With Duchenne Muscular Dystrophy (DMD)",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy"
    ],
    "interventions": [
      "Regimen Selection Phase Group 2",
      "Regimen Selection Phase Group 3",
      "Treatment Phase Group 4",
      "Regimen Selection Phase Group 1 (COMPLETED)",
      "Dosing Extension"
    ],
    "primary_completion_date": "2016-08-03",
    "completion_date": "2016-08-03",
    "results_first_posted": null,
    "last_update_posted": "2017-12-08",
    "enrollment": null,
    "sponsor": "BioMarin Pharmaceutical",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BMRN",
    "nct_id": "NCT04452513",
    "title": "A Prospective Clinical Study of Phenylketonuria (PKU)",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Phenylketonurias"
    ],
    "interventions": [],
    "primary_completion_date": "2022-06-02",
    "completion_date": "2022-06-02",
    "results_first_posted": null,
    "last_update_posted": "2023-03-14",
    "enrollment": null,
    "sponsor": "BioMarin Pharmaceutical",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BMRN",
    "nct_id": "NCT03197766",
    "title": "A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Achondroplasia"
    ],
    "interventions": [
      "BMN 111",
      "Placebo"
    ],
    "primary_completion_date": "2019-10-30",
    "completion_date": "2019-10-30",
    "results_first_posted": "2022-03-02",
    "last_update_posted": "2022-03-02",
    "enrollment": null,
    "sponsor": "BioMarin Pharmaceutical",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BMRN",
    "nct_id": "NCT02724228",
    "title": "A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Achondroplasia"
    ],
    "interventions": [
      "BMN 111"
    ],
    "primary_completion_date": "2027-12",
    "completion_date": "2028-02",
    "results_first_posted": null,
    "last_update_posted": "2025-01-09",
    "enrollment": null,
    "sponsor": "BioMarin Pharmaceutical",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BMRN",
    "nct_id": "NCT01230801",
    "title": "Safety/Tolerability/Pharmacokinetic (PK)/Pharmacodynamics (PD) Study of BMN701 in Patients With Late-Onset Pompe Disease",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pompe Disease"
    ],
    "interventions": [
      "BMN 701"
    ],
    "primary_completion_date": "2013-03-06",
    "completion_date": "2013-03-06",
    "results_first_posted": "2018-06-11",
    "last_update_posted": "2018-06-11",
    "enrollment": null,
    "sponsor": "BioMarin Pharmaceutical",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BMRN",
    "nct_id": "NCT04480567",
    "title": "AAV Gene Therapy Study for Subjects with PKU",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Phenylketonuria (PKU)"
    ],
    "interventions": [
      "BMN 307"
    ],
    "primary_completion_date": "2027-12",
    "completion_date": "2027-12",
    "results_first_posted": null,
    "last_update_posted": "2024-12-12",
    "enrollment": null,
    "sponsor": "BioMarin Pharmaceutical",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BMRN",
    "nct_id": "NCT00225615",
    "title": "A Phase 3, Multicenter, Open-Label Extension Study of Phenoptin in Subjects With PKU Who Have Elevated Phenylalanine Levels",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Phenylketonurias"
    ],
    "interventions": [
      "sapropterin dihydrochloride"
    ],
    "primary_completion_date": null,
    "completion_date": "2006-06",
    "results_first_posted": null,
    "last_update_posted": "2009-08-20",
    "enrollment": null,
    "sponsor": "BioMarin Pharmaceutical",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BMRN",
    "nct_id": "NCT06780332",
    "title": "Rapid Drug Desensitization Study in Adults Experiencing Hypersensitivity Reactions to Palynziq",
    "status": "RECRUITING",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Phenylketonuria",
      "PKU"
    ],
    "interventions": [
      "RDD to Palynziq"
    ],
    "primary_completion_date": "2025-11",
    "completion_date": "2025-11",
    "results_first_posted": null,
    "last_update_posted": "2025-01-23",
    "enrollment": null,
    "sponsor": "BioMarin Pharmaceutical",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BMRN",
    "nct_id": "NCT03864029",
    "title": "Retrospective Observational Safety Effectiveness With Kuvan in hpA",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Tetrahydrobiopterin Deficiency"
    ],
    "interventions": [
      "KUVAN"
    ],
    "primary_completion_date": "2018-03-09",
    "completion_date": "2018-07-25",
    "results_first_posted": null,
    "last_update_posted": "2019-03-07",
    "enrollment": null,
    "sponsor": "BioMarin Pharmaceutical",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BMRN",
    "nct_id": "NCT01889862",
    "title": "Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Phenylketonuria (PKU)"
    ],
    "interventions": [
      "BMN165 20mg/day",
      "BMN165 40mg/day",
      "Placebo"
    ],
    "primary_completion_date": "2016-01-13",
    "completion_date": "2019-02-05",
    "results_first_posted": "2019-07-12",
    "last_update_posted": "2021-05-21",
    "enrollment": null,
    "sponsor": "BioMarin Pharmaceutical",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BMRN",
    "nct_id": "NCT01965912",
    "title": "Kuvan\u00ae's Effect on the Cognition of Children With Phenylketonuria",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Phenylketonuria"
    ],
    "interventions": [
      "Kuvan\u00ae"
    ],
    "primary_completion_date": "2023-01-04",
    "completion_date": "2023-01-04",
    "results_first_posted": null,
    "last_update_posted": "2023-04-24",
    "enrollment": null,
    "sponsor": "BioMarin Pharmaceutical",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BMRN",
    "nct_id": "NCT06382155",
    "title": "A Phase 2 Study of Vosoritide in Children with Idiopathic Short Stature",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Idiopathic Short Stature"
    ],
    "interventions": [
      "Vosoritide Injection",
      "Human Growth Hormone",
      "Placebo"
    ],
    "primary_completion_date": "2026-06",
    "completion_date": "2036-12",
    "results_first_posted": null,
    "last_update_posted": "2025-01-20",
    "enrollment": null,
    "sponsor": "BioMarin Pharmaceutical",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BMRN",
    "nct_id": "NCT01212744",
    "title": "Safety, Tolerability, and Efficacy Study of rAvPAL-PEG Administered Daily in Subjects With Phenylketonuria (PKU)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Phenylketonuria"
    ],
    "interventions": [
      "rAvPAL-PEG"
    ],
    "primary_completion_date": "2015-04",
    "completion_date": "2015-04",
    "results_first_posted": "2019-02-26",
    "last_update_posted": "2019-02-26",
    "enrollment": null,
    "sponsor": "BioMarin Pharmaceutical",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BMRN",
    "nct_id": "NCT03392974",
    "title": "Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kg",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hemophilia A"
    ],
    "interventions": [
      "Valoctocogene Roxaparvovec"
    ],
    "primary_completion_date": "2019-05-22",
    "completion_date": "2023-06-05",
    "results_first_posted": "2021-10-08",
    "last_update_posted": "2023-10-03",
    "enrollment": null,
    "sponsor": "BioMarin Pharmaceutical",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BMRN",
    "nct_id": "NCT01697319",
    "title": "Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Mucopolysaccharidosis IVA",
      "Morquio A Syndrome",
      "MPS IVA"
    ],
    "interventions": [
      "BMN 110"
    ],
    "primary_completion_date": "2014-10",
    "completion_date": "2014-10",
    "results_first_posted": "2016-01-12",
    "last_update_posted": "2016-01-12",
    "enrollment": null,
    "sponsor": "BioMarin Pharmaceutical",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BMRN",
    "nct_id": "NCT05580692",
    "title": "A Prospective Study Evaluating Seroprevalence and Seroconversion of Antibodies Against Adeno-associated Virus (AAV)",
    "status": "TERMINATED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hemophilia A"
    ],
    "interventions": [
      "Biospecimen Collection"
    ],
    "primary_completion_date": "2024-07-31",
    "completion_date": "2024-07-31",
    "results_first_posted": null,
    "last_update_posted": "2024-08-19",
    "enrollment": null,
    "sponsor": "BioMarin Pharmaceutical",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BMRN",
    "nct_id": "NCT06280209",
    "title": "A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular Dystrophy",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy"
    ],
    "interventions": [
      "BMN 351"
    ],
    "primary_completion_date": "2026-09-30",
    "completion_date": "2026-09-30",
    "results_first_posted": null,
    "last_update_posted": "2025-06-19",
    "enrollment": null,
    "sponsor": "BioMarin Pharmaceutical",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "BMRN",
    "nct_id": "NCT01376908",
    "title": "Kuvan\u00ae in Phenylketonuria Patients Less Than 4 Years Old",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Phenylketonuria"
    ],
    "interventions": [
      "Kuvan\u00ae",
      "Phenylalanine (Phe)-restricted diet"
    ],
    "primary_completion_date": "2014-07",
    "completion_date": "2017-02-17",
    "results_first_posted": "2016-05-12",
    "last_update_posted": "2017-09-15",
    "enrollment": null,
    "sponsor": "BioMarin Pharmaceutical",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CADL",
    "nct_id": "NCT04495153",
    "title": "CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non Small Cell Lung Cancer"
    ],
    "interventions": [
      "Aglatimagene besadenovec"
    ],
    "primary_completion_date": "2024-12-31",
    "completion_date": "2026-12",
    "results_first_posted": null,
    "last_update_posted": "2025-08-22",
    "enrollment": null,
    "sponsor": "Candel Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CADL",
    "nct_id": "NCT02446093",
    "title": "Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Borderline Resectable Pancreatic Adenocarcinoma"
    ],
    "interventions": [
      "Aglatimagene besadenovec",
      "Chemoradiation",
      "Stereotactic body radiation therapy",
      "Surgery"
    ],
    "primary_completion_date": "2025-12",
    "completion_date": "2026-07",
    "results_first_posted": null,
    "last_update_posted": "2024-01-08",
    "enrollment": null,
    "sponsor": "Candel Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CADL",
    "nct_id": "NCT00638612",
    "title": "AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pancreatic Adenocarcinoma",
      "Pancreatic Cancer"
    ],
    "interventions": [
      "AdV-tk",
      "Valacyclovir"
    ],
    "primary_completion_date": "2013-05",
    "completion_date": "2015-06",
    "results_first_posted": null,
    "last_update_posted": "2023-08-25",
    "enrollment": null,
    "sponsor": "Candel Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CADL",
    "nct_id": "NCT03131037",
    "title": "Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lung Cancer"
    ],
    "interventions": [
      "CAN-2409 + valacyclovir"
    ],
    "primary_completion_date": "2021-12-01",
    "completion_date": "2023-09-20",
    "results_first_posted": null,
    "last_update_posted": "2025-07-11",
    "enrollment": null,
    "sponsor": "Candel Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CADL",
    "nct_id": "NCT01436968",
    "title": "Phase 3 Study of ProstAtak\u00ae Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Prostate Cancer"
    ],
    "interventions": [
      "Aglatimagene besadenovec + valacyclovir",
      "Placebo + valacyclovir"
    ],
    "primary_completion_date": "2024-08",
    "completion_date": "2030-12",
    "results_first_posted": null,
    "last_update_posted": "2025-07-30",
    "enrollment": null,
    "sponsor": "Candel Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CADL",
    "nct_id": "NCT01997190",
    "title": "Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Malignant Pleural Effusion",
      "Lung Cancer",
      "Mesothelioma",
      "Breast Cancer",
      "Ovarian Cancer"
    ],
    "interventions": [
      "AdV-tk + valacyclovir"
    ],
    "primary_completion_date": "2015-12",
    "completion_date": "2018-02",
    "results_first_posted": null,
    "last_update_posted": "2023-08-25",
    "enrollment": null,
    "sponsor": "Candel Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CADL",
    "nct_id": "NCT00751270",
    "title": "Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Malignant Glioma",
      "Glioblastoma Multiforme",
      "Anaplastic Astrocytoma"
    ],
    "interventions": [
      "AdV-tk",
      "Valacyclovir"
    ],
    "primary_completion_date": "2010-01",
    "completion_date": "2011-01",
    "results_first_posted": null,
    "last_update_posted": "2023-08-25",
    "enrollment": null,
    "sponsor": "Candel Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CADL",
    "nct_id": "NCT00634231",
    "title": "A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Malignant Glioma",
      "Recurrent Ependymoma"
    ],
    "interventions": [
      "AdV-tk",
      "valacyclovir",
      "Radiation"
    ],
    "primary_completion_date": "2015-12",
    "completion_date": "2021-06",
    "results_first_posted": null,
    "last_update_posted": "2023-08-25",
    "enrollment": null,
    "sponsor": "Candel Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CADL",
    "nct_id": "NCT07332000",
    "title": "A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Prostate Cancer Patients Treated by Radiotherapy"
    ],
    "interventions": [
      "aglatimagene besadenovec + valacyclovir"
    ],
    "primary_completion_date": "2026-06",
    "completion_date": "2026-06",
    "results_first_posted": null,
    "last_update_posted": "2026-01-12",
    "enrollment": null,
    "sponsor": "Candel Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CADL",
    "nct_id": "NCT00589875",
    "title": "Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Malignant Glioma",
      "Glioblastoma Multiforme",
      "Anaplastic Astrocytoma",
      "High Grade Glioma"
    ],
    "interventions": [
      "CAN-2409",
      "Valacyclovir",
      "Temozolomide",
      "Radiation therapy"
    ],
    "primary_completion_date": "2015-12",
    "completion_date": "2016-08",
    "results_first_posted": "2024-04-03",
    "last_update_posted": "2024-04-03",
    "enrollment": null,
    "sponsor": "Candel Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CADL",
    "nct_id": "NCT02768363",
    "title": "Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Prostate Cancer"
    ],
    "interventions": [
      "aglatimagene besadenovec",
      "placebo",
      "valacyclovir"
    ],
    "primary_completion_date": "2024-11",
    "completion_date": "2026-12",
    "results_first_posted": null,
    "last_update_posted": "2025-07-30",
    "enrollment": null,
    "sponsor": "Candel Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CADL",
    "nct_id": "NCT03576612",
    "title": "GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Glioma, Malignant"
    ],
    "interventions": [
      "AdV-tk",
      "Valacyclovir",
      "Radiation",
      "Temozolomide",
      "Nivolumab",
      "Laboratory Biomarker Analysis"
    ],
    "primary_completion_date": "2023-06-30",
    "completion_date": "2023-06-30",
    "results_first_posted": null,
    "last_update_posted": "2025-02-14",
    "enrollment": null,
    "sponsor": "Candel Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CCCC",
    "nct_id": "NCT07015983",
    "title": "A Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lupus Erythematosus, Systemic",
      "Lupus Nephritis"
    ],
    "interventions": [
      "CC-97540",
      "Fludarabine",
      "Cyclophosphamide"
    ],
    "primary_completion_date": "2028-05-17",
    "completion_date": "2032-06-15",
    "results_first_posted": null,
    "last_update_posted": "2026-01-20",
    "enrollment": null,
    "sponsor": "Juno Therapeutics, Inc., a Bristol-Myers Squibb Company",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CCCC",
    "nct_id": "NCT05668585",
    "title": "A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumors",
      "Melanoma",
      "NSCLC",
      "CRC",
      "ATC"
    ],
    "interventions": [
      "CFT1946",
      "Trametinib",
      "Cetuximab"
    ],
    "primary_completion_date": "2025-11-05",
    "completion_date": "2025-11-05",
    "results_first_posted": null,
    "last_update_posted": "2025-11-21",
    "enrollment": null,
    "sponsor": "C4 Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CCCC",
    "nct_id": "NCT04190628",
    "title": "Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumor",
      "BRAF V600 Mutation"
    ],
    "interventions": [
      "ABM-1310",
      "Cobimetinib"
    ],
    "primary_completion_date": "2024-04-05",
    "completion_date": "2024-04-05",
    "results_first_posted": null,
    "last_update_posted": "2024-05-21",
    "enrollment": null,
    "sponsor": "ABM Therapeutics Corporation",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CGON",
    "nct_id": "NCT01438112",
    "title": "Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Transitional Cell Carcinoma",
      "Bladder Cancer",
      "Carcinoma in Situ",
      "Carcinoma in Situ Concurrent With Papillary Tumors"
    ],
    "interventions": [
      "CG0070 Adenovirus Vector",
      "Control Arm: Quadruple Choice"
    ],
    "primary_completion_date": "2016-06",
    "completion_date": "2016-06",
    "results_first_posted": null,
    "last_update_posted": "2021-04-14",
    "enrollment": null,
    "sponsor": "CG Oncology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CGON",
    "nct_id": "NCT05249101",
    "title": "A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Pancreatic Adenocarcinoma"
    ],
    "interventions": [
      "Ivaltinostat",
      "Capecitabine"
    ],
    "primary_completion_date": "2026-06",
    "completion_date": "2026-07",
    "results_first_posted": null,
    "last_update_posted": "2025-12-19",
    "enrollment": null,
    "sponsor": "CG Pharmaceuticals, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CGON",
    "nct_id": "NCT06443944",
    "title": "An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG",
    "status": "AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Non-Muscle Invasive Bladder Cancer",
      "Urothelial Carcinoma",
      "Urologic Cancer",
      "Bladder Cancer"
    ],
    "interventions": [
      "Cretostimogene Grenadenorepvec",
      "n-dodecyl-B-D-maltoside"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2025-12-16",
    "enrollment": null,
    "sponsor": "CG Oncology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CGON",
    "nct_id": "NCT06567743",
    "title": "Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "High-Risk Non-Muscle-Invasive Bladder Cancer"
    ],
    "interventions": [
      "Cretostimogene Grenadenorepvec"
    ],
    "primary_completion_date": "2027-03-31",
    "completion_date": "2027-12-30",
    "results_first_posted": null,
    "last_update_posted": "2025-10-08",
    "enrollment": null,
    "sponsor": "CG Oncology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CGON",
    "nct_id": "NCT02365818",
    "title": "Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bladder Cancer"
    ],
    "interventions": [
      "CG0070"
    ],
    "primary_completion_date": "2018-08",
    "completion_date": "2019-02",
    "results_first_posted": null,
    "last_update_posted": "2021-04-14",
    "enrollment": null,
    "sponsor": "CG Oncology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CHRS",
    "nct_id": "NCT05359861",
    "title": "Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatocellular Carcinoma"
    ],
    "interventions": [
      "SRF388",
      "Atezolizumab",
      "Bevacizumab",
      "Placebo"
    ],
    "primary_completion_date": "2025-06-30",
    "completion_date": "2025-07-08",
    "results_first_posted": null,
    "last_update_posted": "2025-11-10",
    "enrollment": null,
    "sponsor": "Coherus Oncology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CHRS",
    "nct_id": "NCT05635643",
    "title": "Study of CHS-114 in Participants With Advanced Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumor",
      "Head and Neck Squamous Cell Carcinoma"
    ],
    "interventions": [
      "CHS-114",
      "toripalimab"
    ],
    "primary_completion_date": "2026-02",
    "completion_date": "2026-02",
    "results_first_posted": null,
    "last_update_posted": "2025-08-01",
    "enrollment": null,
    "sponsor": "Coherus Oncology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CHRS",
    "nct_id": "NCT05177770",
    "title": "Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Castration-resistant Prostate Cancer",
      "Prostate Cancer"
    ],
    "interventions": [
      "SRF617",
      "etrumadenant",
      "zimberelimab"
    ],
    "primary_completion_date": "2023-04-05",
    "completion_date": "2023-04-05",
    "results_first_posted": "2024-05-17",
    "last_update_posted": "2025-05-08",
    "enrollment": null,
    "sponsor": "Coherus Oncology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CHRS",
    "nct_id": "NCT06679985",
    "title": "A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatocellular Carcinoma"
    ],
    "interventions": [
      "Casdozokitug",
      "Toripalimab",
      "Bevacizumab"
    ],
    "primary_completion_date": "2027-09",
    "completion_date": "2027-09",
    "results_first_posted": null,
    "last_update_posted": "2026-01-07",
    "enrollment": null,
    "sponsor": "Coherus Oncology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CHRS",
    "nct_id": "NCT04374877",
    "title": "Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumor",
      "Clear Cell Renal Cell Carcinoma",
      "Hepatocellular Carcinoma",
      "Non-small Cell Lung Cancer"
    ],
    "interventions": [
      "CHS-388",
      "Pembrolizumab",
      "Toripalimab"
    ],
    "primary_completion_date": "2025-05-28",
    "completion_date": "2025-06-05",
    "results_first_posted": null,
    "last_update_posted": "2025-11-10",
    "enrollment": null,
    "sponsor": "Coherus Oncology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CHRS",
    "nct_id": "NCT02115750",
    "title": "Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rheumatoid Arthritis"
    ],
    "interventions": [
      "Etanercept",
      "CHS-0214"
    ],
    "primary_completion_date": "2015-10",
    "completion_date": "2016-05",
    "results_first_posted": "2019-06-26",
    "last_update_posted": "2019-06-26",
    "enrollment": null,
    "sponsor": "Coherus Oncology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CHRS",
    "nct_id": "NCT04336098",
    "title": "Study of SRF617 in Patients With Advanced Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumor"
    ],
    "interventions": [
      "SRF617",
      "Gemcitabine",
      "Albumin-Bound Paclitaxel",
      "Pembrolizumab"
    ],
    "primary_completion_date": "2023-08-25",
    "completion_date": "2023-08-25",
    "results_first_posted": null,
    "last_update_posted": "2024-06-04",
    "enrollment": null,
    "sponsor": "Coherus Oncology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CHRS",
    "nct_id": "NCT05757492",
    "title": "Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumor",
      "Non-Small Cell Lung Cancer",
      "Hepatocellular Carcinoma"
    ],
    "interventions": [
      "CHS-006 (anti-TIGIT)",
      "toripalimab (anti-PD-1)"
    ],
    "primary_completion_date": "2024-07-31",
    "completion_date": "2024-07-31",
    "results_first_posted": null,
    "last_update_posted": "2025-05-01",
    "enrollment": null,
    "sponsor": "Coherus Oncology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CHRS",
    "nct_id": "NCT02489227",
    "title": "Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Plaque Psoriasis"
    ],
    "interventions": [
      "CHS-1420",
      "Adalimumab"
    ],
    "primary_completion_date": "2016-05-06",
    "completion_date": "2017-03",
    "results_first_posted": "2019-10-18",
    "last_update_posted": "2020-04-08",
    "enrollment": null,
    "sponsor": "Coherus Oncology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CHRS",
    "nct_id": "NCT02486939",
    "title": "A Long Term Safety Extension Study (CHS-0214-05)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rheumatoid Arthritis",
      "Plaque Psoriasis"
    ],
    "interventions": [
      "CHS-0214"
    ],
    "primary_completion_date": "2017-09",
    "completion_date": "2017-10",
    "results_first_posted": "2018-12-27",
    "last_update_posted": "2018-12-27",
    "enrollment": null,
    "sponsor": "Coherus Oncology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CHRS",
    "nct_id": "NCT02650973",
    "title": "Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 With Neulasta",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "CHS-1701",
      "Pegfilgrastim"
    ],
    "primary_completion_date": "2016-06",
    "completion_date": "2016-06",
    "results_first_posted": null,
    "last_update_posted": "2016-08-01",
    "enrollment": null,
    "sponsor": "Coherus Oncology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CHRS",
    "nct_id": "NCT02134210",
    "title": "Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Plaque Psoriasis"
    ],
    "interventions": [
      "Etanercept",
      "CHS-0214"
    ],
    "primary_completion_date": "2015-07-27",
    "completion_date": "2016-05-12",
    "results_first_posted": "2019-05-13",
    "last_update_posted": "2019-06-28",
    "enrollment": null,
    "sponsor": "Coherus Oncology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CHRS",
    "nct_id": "NCT06657144",
    "title": "A Study of CHS-114 in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Solid Tumor",
      "Advanced Solid Tumor"
    ],
    "interventions": [
      "CHS-114",
      "Toripalimab",
      "5 Fluorouracil",
      "Cisplatin"
    ],
    "primary_completion_date": "2027-05",
    "completion_date": "2027-05",
    "results_first_posted": null,
    "last_update_posted": "2026-01-13",
    "enrollment": null,
    "sponsor": "Coherus Oncology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CHRS",
    "nct_id": "NCT02418104",
    "title": "Assessing the Immunogenicity of 2 Subcutaneous Doses of CHS-1701 (Coherus Pegfilgrastim) With 2 Subcutaneous Doses Neulasta\u00ae",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Immunity, Humoral"
    ],
    "interventions": [
      "CHS-1701",
      "Pegfilgrastim (Neulasta)"
    ],
    "primary_completion_date": "2015-12",
    "completion_date": "2015-12",
    "results_first_posted": null,
    "last_update_posted": "2016-01-07",
    "enrollment": null,
    "sponsor": "Coherus Oncology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CHRS",
    "nct_id": "NCT02385851",
    "title": "Comparison of the Pharmacokinetic and Pharmacodynamic Biosimilarity of CHS-1701 (Coherus Pegfilgrastim) With Neulasta\u00ae (Pegfilgrastim)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bioequivalence"
    ],
    "interventions": [
      "CHS-1701",
      "Pegfilgrastim"
    ],
    "primary_completion_date": "2015-07",
    "completion_date": "2015-07",
    "results_first_posted": null,
    "last_update_posted": "2015-08-13",
    "enrollment": null,
    "sponsor": "Coherus Oncology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CHRS",
    "nct_id": "NCT06457503",
    "title": "A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer",
    "status": "RECRUITING",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Nasopharyngeal Cancer Recurrent"
    ],
    "interventions": [
      "Toripalimab",
      "Cisplatin",
      "Gemcitabine",
      "Carboplatin"
    ],
    "primary_completion_date": "2027-12",
    "completion_date": "2027-12",
    "results_first_posted": null,
    "last_update_posted": "2025-10-21",
    "enrollment": null,
    "sponsor": "Coherus Oncology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CHRS",
    "nct_id": "NCT06389526",
    "title": "A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced or Metastatic Solid Tumors"
    ],
    "interventions": [
      "CHS-1000",
      "Toripalimab"
    ],
    "primary_completion_date": "2028-05-30",
    "completion_date": "2028-05-30",
    "results_first_posted": null,
    "last_update_posted": "2024-09-19",
    "enrollment": null,
    "sponsor": "Coherus Oncology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CHRS",
    "nct_id": "NCT04662892",
    "title": "An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca",
    "status": "UNKNOWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Febrile Neutropenia",
      "Non-myeloid Malignancy"
    ],
    "interventions": [
      "Pegfilgrastim-Cbqv"
    ],
    "primary_completion_date": "2022-11-01",
    "completion_date": "2022-12-15",
    "results_first_posted": null,
    "last_update_posted": "2020-12-23",
    "enrollment": null,
    "sponsor": "Coherus Oncology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CMPS",
    "nct_id": "NCT03428958",
    "title": "A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Colorectal Cancer",
      "Colorectal Neoplasms",
      "Colorectal Carcinoma",
      "Colorectal Tumors",
      "Neoplasms, Colorectal"
    ],
    "interventions": [
      "NUC-3373 + leucovorin",
      "NUC-3373",
      "NUFOX",
      "NUFOX + VEGF pathway inhibitor",
      "NUFOX + EGFR inhibitor",
      "NUFIRI",
      "NUFIRI + VEGF pathway inhibitor",
      "NUFIRI + EGFR inhibitor",
      "NUC-3373 + bevacizumab"
    ],
    "primary_completion_date": "2024-03-19",
    "completion_date": "2024-03-21",
    "results_first_posted": "2025-04-23",
    "last_update_posted": "2025-04-23",
    "enrollment": null,
    "sponsor": "NuCana plc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "COGT",
    "nct_id": "NCT02776813",
    "title": "Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lymphoma"
    ],
    "interventions": [
      "ACTR087",
      "rituximab"
    ],
    "primary_completion_date": "2020-02-12",
    "completion_date": "2020-02-12",
    "results_first_posted": null,
    "last_update_posted": "2020-03-31",
    "enrollment": null,
    "sponsor": "Cogent Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "COGT",
    "nct_id": "NCT04996875",
    "title": "(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Systemic Mastocytosis (AdvSM)",
      "SM With an Associated Hematologic Neoplasm (SM-AHN)",
      "Mast Cell Leukemia (MCL)",
      "Aggressive Systemic Mastocytosis (ASM)"
    ],
    "interventions": [
      "bezuclastinib"
    ],
    "primary_completion_date": "2025-09",
    "completion_date": "2026-07",
    "results_first_posted": null,
    "last_update_posted": "2025-05-30",
    "enrollment": null,
    "sponsor": "Cogent Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "COGT",
    "nct_id": "NCT06915766",
    "title": "Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis",
    "status": "AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Systemic Mastocytoses, Indolent",
      "Systemic Mastocytoses, Aggressive"
    ],
    "interventions": [
      "Bezuclastinib"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2025-11-05",
    "enrollment": null,
    "sponsor": "Cogent Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "COGT",
    "nct_id": "NCT03189836",
    "title": "Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lymphoma"
    ],
    "interventions": [
      "ACTR707",
      "rituximab"
    ],
    "primary_completion_date": "2020-09-21",
    "completion_date": "2020-09-21",
    "results_first_posted": null,
    "last_update_posted": "2021-10-11",
    "enrollment": null,
    "sponsor": "Cogent Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "COGT",
    "nct_id": "NCT03266692",
    "title": "Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple Myeloma",
      "Multiple Myeloma in Relapse",
      "Refractory Multiple Myeloma"
    ],
    "interventions": [
      "ACTR087",
      "SEA-BCMA"
    ],
    "primary_completion_date": "2019-10-01",
    "completion_date": "2019-10-01",
    "results_first_posted": null,
    "last_update_posted": "2020-03-30",
    "enrollment": null,
    "sponsor": "Cogent Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "COGT",
    "nct_id": "NCT05208047",
    "title": "(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Gastrointestinal Stromal Tumors",
      "Metastatic Cancer"
    ],
    "interventions": [
      "CGT9486 plus sunitinib",
      "CGT9486",
      "Sunitinib",
      "Sunitinib",
      "Midazolam",
      "CGT9486 plus sunitinib"
    ],
    "primary_completion_date": "2025-09-30",
    "completion_date": "2026-09",
    "results_first_posted": null,
    "last_update_posted": "2025-11-25",
    "enrollment": null,
    "sponsor": "Cogent Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "COGT",
    "nct_id": "NCT06777316",
    "title": "A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Intrahepatic Cholangiocarcinoma (Icc)",
      "Cholangiocarcinoma",
      "Other Solid Tumors, Adult",
      "FGFR2 Gene Fusion/Rearrangement",
      "FGFR2 Gene Amplification",
      "FGFR2 Gene Short Variants",
      "FGFR3 Gene Fusion/Rearrangement",
      "FGFR3 Gene Amplification",
      "FGFR3 Gene Short Variants",
      "FGFR2 Genetic Alterations",
      "FGFR3 Genetic Alterations",
      "Advanced Solid Tumors"
    ],
    "interventions": [
      "CGT4859"
    ],
    "primary_completion_date": "2027-03",
    "completion_date": "2027-06",
    "results_first_posted": null,
    "last_update_posted": "2025-07-30",
    "enrollment": null,
    "sponsor": "Cogent Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "COGT",
    "nct_id": "NCT06948955",
    "title": "Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors",
    "status": "AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors"
    ],
    "interventions": [
      "Bezuclastinib",
      "Sunitinib"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2025-12-08",
    "enrollment": null,
    "sponsor": "Cogent Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "COGT",
    "nct_id": "NCT02401815",
    "title": "CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Gastrointestinal Stromal Tumors"
    ],
    "interventions": [
      "CGT9486",
      "Pexidartinib",
      "Sunitinib"
    ],
    "primary_completion_date": "2020-05-11",
    "completion_date": "2020-05-11",
    "results_first_posted": "2025-02-14",
    "last_update_posted": "2025-02-14",
    "enrollment": null,
    "sponsor": "Cogent Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "COGT",
    "nct_id": "NCT03680560",
    "title": "Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor",
      "HER-2 Protein Overexpression"
    ],
    "interventions": [
      "ACTR T Cell Product",
      "Trastuzumab"
    ],
    "primary_completion_date": "2020-03-12",
    "completion_date": "2020-03-12",
    "results_first_posted": null,
    "last_update_posted": "2020-03-31",
    "enrollment": null,
    "sponsor": "Cogent Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "COGT",
    "nct_id": "NCT07361562",
    "title": "A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumor, Adult",
      "ERBB2 Altered Breast Cancer",
      "ERBB2 Gene Amplification",
      "HER2 Overexpression",
      "Non-Small Cell Lung Cancer",
      "HER2"
    ],
    "interventions": [
      "CGT4255"
    ],
    "primary_completion_date": "2028-05",
    "completion_date": "2028-11",
    "results_first_posted": null,
    "last_update_posted": "2026-01-23",
    "enrollment": null,
    "sponsor": "Cogent Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "COGT",
    "nct_id": "NCT02840110",
    "title": "Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product",
    "status": "TERMINATED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "B Cell Lymphomas",
      "Multiple Myeloma",
      "Solid Tumor",
      "HER-2 Protein Overexpression"
    ],
    "interventions": [
      "ACTR T Cell Product"
    ],
    "primary_completion_date": "2020-10-23",
    "completion_date": "2021-02-23",
    "results_first_posted": null,
    "last_update_posted": "2021-10-11",
    "enrollment": null,
    "sponsor": "Cogent Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "COGT",
    "nct_id": "NCT05186753",
    "title": "(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "SSM",
      "Mastocytosis, Indolent",
      "Mastocytosis, Systemic",
      "Mastocytosis",
      "ISM",
      "BMM",
      "Smoldering Systemic Mastocytosis",
      "Bone Marrow Mastocytosis"
    ],
    "interventions": [
      "Bezuclastinib Tablets (Formulation A)",
      "Bezuclastinib Tablets (Formulation B)",
      "Placebo Tablets"
    ],
    "primary_completion_date": "2025-05-22",
    "completion_date": "2030-04",
    "results_first_posted": null,
    "last_update_posted": "2025-10-29",
    "enrollment": null,
    "sponsor": "Cogent Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "COLL",
    "nct_id": "NCT03454841",
    "title": "Daily Variability of Platelet Aggregation in Patients With Myocardial Infarction Treated With Prasugrel and Ticagrelor",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Acute Myocardial Infarction"
    ],
    "interventions": [
      "Prasugrel",
      "Ticagrelor"
    ],
    "primary_completion_date": "2019-02-28",
    "completion_date": "2019-02-28",
    "results_first_posted": null,
    "last_update_posted": "2020-02-26",
    "enrollment": null,
    "sponsor": "Collegium Medicum w Bydgoszczy",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "COLL",
    "nct_id": "NCT02772640",
    "title": "Effectiveness of Treatment of Hypercholesterolemia With Rosuvastatin and Ezetimibe",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypercholesterolemia"
    ],
    "interventions": [
      "Rosuvastatin and Ezetimibe morning or evening administration"
    ],
    "primary_completion_date": "2019-01",
    "completion_date": "2020-05",
    "results_first_posted": null,
    "last_update_posted": "2021-02-02",
    "enrollment": null,
    "sponsor": "Collegium Medicum w Bydgoszczy",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "COLL",
    "nct_id": "NCT02612116",
    "title": "Comparison of Administration Strategies of Ticagrelor in Patients With Unstable Angina Pectoris, a Pharmacokinetic / Pharmacodynamic Study",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Unstable Angina Pectoris"
    ],
    "interventions": [
      "Pulverized ticagrelor sublingually",
      "Pulverized ticagrelor orally",
      "Integral ticagrelor"
    ],
    "primary_completion_date": "2016-08",
    "completion_date": "2016-09",
    "results_first_posted": null,
    "last_update_posted": "2016-10-19",
    "enrollment": null,
    "sponsor": "Collegium Medicum w Bydgoszczy",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "COLL",
    "nct_id": "NCT07203846",
    "title": "Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "ACS - Acute Coronary Syndrome",
      "Ticagrelor",
      "Microbiota",
      "Platelet Aggregation",
      "Myocardial Infarction (MI)",
      "Blood Platelets",
      "Drug Effects",
      "Platelet Aggregation Inhibitors",
      "Drug Resistance",
      "Platelet Function Tests",
      "Dysbiosis",
      "Anti-Bacterial Agents",
      "Rifaximin"
    ],
    "interventions": [
      "Rifaximin"
    ],
    "primary_completion_date": "2026-12-31",
    "completion_date": "2027-06-30",
    "results_first_posted": null,
    "last_update_posted": "2025-10-02",
    "enrollment": null,
    "sponsor": "Collegium Medicum w Bydgoszczy",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "COLL",
    "nct_id": "NCT04476173",
    "title": "ANalgesic Efficacy and Safety of MOrphiNe Versus Methoxyflurane in Patients With Acute Myocardial Infarction",
    "status": "UNKNOWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "ST Elevation Myocardial Infarction",
      "Non ST Segment Elevation Acute Coronary Syndrome"
    ],
    "interventions": [
      "Methoxyflurane - Penthrox",
      "Morphine"
    ],
    "primary_completion_date": "2024-06-30",
    "completion_date": "2024-12-30",
    "results_first_posted": null,
    "last_update_posted": "2023-09-11",
    "enrollment": null,
    "sponsor": "Collegium Medicum w Bydgoszczy",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "COLL",
    "nct_id": "NCT04941105",
    "title": "Impact of PCSK9 Inhibition on Clinical Outcome in Patients During the Inflammatory Stage of the COVID-19",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Sars-CoV-2 Infection"
    ],
    "interventions": [
      "Evolocumab",
      "Saline solution"
    ],
    "primary_completion_date": "2022-05-17",
    "completion_date": "2022-05-17",
    "results_first_posted": null,
    "last_update_posted": "2023-04-21",
    "enrollment": null,
    "sponsor": "Collegium Medicum w Bydgoszczy",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "COLL",
    "nct_id": "NCT01685684",
    "title": "Oxycodone DETERx\u2122 Versus Placebo in Chronic Low Back Pain (CLBP)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Low Back Pain"
    ],
    "interventions": [
      "Oxycodone DETERx",
      "Placebo"
    ],
    "primary_completion_date": "2014-06",
    "completion_date": "2014-07",
    "results_first_posted": "2017-02-23",
    "last_update_posted": "2020-10-19",
    "enrollment": null,
    "sponsor": "Collegium Pharmaceutical, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "COLL",
    "nct_id": "NCT03764722",
    "title": "Effectiveness of a Repetitive Use of 24-hour Levosimendan Infusions in Patients With Severe Systolic Heart Failure in Order to Prevent Rehospitalizations",
    "status": "UNKNOWN",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Systolic Heart Failure"
    ],
    "interventions": [
      "Levosimendan"
    ],
    "primary_completion_date": "2021-12-31",
    "completion_date": "2021-12-31",
    "results_first_posted": null,
    "last_update_posted": "2018-12-05",
    "enrollment": null,
    "sponsor": "Collegium Medicum w Bydgoszczy",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRMD",
    "nct_id": "NCT01391520",
    "title": "Efficacy and Safety of Deferiprone in Patients With Chronic Kidney Disease Undergoing a Cardiac Catheterization and Receiving Contrast Agent",
    "status": "WITHDRAWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Kidney Injury"
    ],
    "interventions": [
      "deferiprone",
      "Placebo"
    ],
    "primary_completion_date": "2013-03",
    "completion_date": "2013-06",
    "results_first_posted": null,
    "last_update_posted": "2020-08-24",
    "enrollment": null,
    "sponsor": "CorMedix",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRMD",
    "nct_id": "NCT06707480",
    "title": "Expanded Access Program for Patients At Risk for Catheter-related Infections Who Are Not Eligible for DefenCath\u00ae Clinical Trials",
    "status": "AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Catheter-related Bloodstream Infection"
    ],
    "interventions": [
      "Taurolidine and Heparin"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2024-11-27",
    "enrollment": null,
    "sponsor": "CorMedix",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRMD",
    "nct_id": "NCT01146925",
    "title": "Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Contrast-Induced Acute Kidney Injury"
    ],
    "interventions": [
      "CRMD-001-Deferiprone",
      "Placebo"
    ],
    "primary_completion_date": "2011-06",
    "completion_date": "2011-06",
    "results_first_posted": null,
    "last_update_posted": "2011-06-27",
    "enrollment": null,
    "sponsor": "CorMedix",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRMD",
    "nct_id": "NCT02651428",
    "title": "Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Kidney Failure, Chronic",
      "Catheter-Related Infections"
    ],
    "interventions": [
      "Neutrolin",
      "Heparin"
    ],
    "primary_completion_date": "2018-10",
    "completion_date": "2018-10",
    "results_first_posted": "2021-08-31",
    "last_update_posted": "2025-02-25",
    "enrollment": null,
    "sponsor": "CorMedix",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRMD",
    "nct_id": "NCT06822426",
    "title": "Comparing The Safety And Efficacy Of DEFENCATH\u00ae In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Central Line Associated Blood Stream Infections (CLABSI)"
    ],
    "interventions": [
      "(taurolidine and heparin) catheter lock solution",
      "Heparin"
    ],
    "primary_completion_date": "2027-01",
    "completion_date": "2027-01",
    "results_first_posted": null,
    "last_update_posted": "2025-12-24",
    "enrollment": null,
    "sponsor": "CorMedix",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRMD",
    "nct_id": "NCT06714864",
    "title": "Open-Label Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to < 18 Years of Age",
    "status": "RECRUITING",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Catheter-Related Infections"
    ],
    "interventions": [
      "(taurolidine and heparin) catheter lock solution",
      "Standard of Care"
    ],
    "primary_completion_date": "2026-01",
    "completion_date": "2026-03",
    "results_first_posted": null,
    "last_update_posted": "2025-11-04",
    "enrollment": null,
    "sponsor": "CorMedix",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRVS",
    "nct_id": "NCT04280328",
    "title": "Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple Myeloma"
    ],
    "interventions": [
      "Ciforadenant",
      "daratumumab"
    ],
    "primary_completion_date": "2021-09-21",
    "completion_date": "2022-03-01",
    "results_first_posted": null,
    "last_update_posted": "2022-03-11",
    "enrollment": null,
    "sponsor": "Corvus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRVS",
    "nct_id": "NCT03237988",
    "title": "Study to Evaluate the Pharmacokinetics of a New Tablet Formulation of CPI-444 in Fed and Fasted Healthy Male and Female Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Subjects"
    ],
    "interventions": [
      "CPI-444 Capsules",
      "CPI-444 Tablets"
    ],
    "primary_completion_date": "2017-09-20",
    "completion_date": "2017-10-04",
    "results_first_posted": null,
    "last_update_posted": "2018-01-26",
    "enrollment": null,
    "sponsor": "Corvus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRVS",
    "nct_id": "NCT04464395",
    "title": "Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID-19"
    ],
    "interventions": [
      "CPI-006",
      "Standard of Care"
    ],
    "primary_completion_date": "2021-03-01",
    "completion_date": "2021-07-09",
    "results_first_posted": null,
    "last_update_posted": "2021-07-21",
    "enrollment": null,
    "sponsor": "Corvus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRVS",
    "nct_id": "NCT06345404",
    "title": "Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atopic Dermatitis"
    ],
    "interventions": [
      "Soquelitinib",
      "Placebo"
    ],
    "primary_completion_date": "2025-10",
    "completion_date": "2025-11",
    "results_first_posted": null,
    "last_update_posted": "2025-07-22",
    "enrollment": null,
    "sponsor": "Corvus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRVS",
    "nct_id": "NCT03454451",
    "title": "CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-Small Cell Lung Cancer",
      "Renal Cell Cancer",
      "Colorectal Cancer",
      "Triple Negative Breast Cancer",
      "Cervical Cancer",
      "Ovarian Cancer",
      "Pancreatic Cancer",
      "Endometrial Cancer",
      "Sarcoma",
      "Squamous Cell Carcinoma of the Head and Neck",
      "Bladder Cancer",
      "Metastatic Castration Resistant Prostate Cancer",
      "Non-hodgkin Lymphoma"
    ],
    "interventions": [
      "CPI-006",
      "CPI-006 + ciforadenant",
      "CPI-006 + pembrolizumab",
      "CPI-006",
      "CPI-006 + ciforadenant",
      "CPI-006 + pembrolizumab"
    ],
    "primary_completion_date": "2022-12-28",
    "completion_date": "2023-02-19",
    "results_first_posted": null,
    "last_update_posted": "2023-12-21",
    "enrollment": null,
    "sponsor": "Corvus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRVS",
    "nct_id": "NCT02655822",
    "title": "Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Renal Cell Cancer",
      "Metastatic Castration Resistant Prostate Cancer"
    ],
    "interventions": [
      "Ciforadenant",
      "Ciforadenant",
      "Ciforadenant",
      "Ciforadenant + atezolizumab",
      "Ciforadenant"
    ],
    "primary_completion_date": "2021-06",
    "completion_date": "2021-07",
    "results_first_posted": null,
    "last_update_posted": "2021-08-30",
    "enrollment": null,
    "sponsor": "Corvus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRVS",
    "nct_id": "NCT04734873",
    "title": "CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Covid-19"
    ],
    "interventions": [
      "CPI-006 2 mg/kg + SOC",
      "CPI-006 1 mg/kg + SOC",
      "Placebo + SOC"
    ],
    "primary_completion_date": "2021-08-18",
    "completion_date": "2021-08-18",
    "results_first_posted": "2022-08-23",
    "last_update_posted": "2022-09-21",
    "enrollment": null,
    "sponsor": "Corvus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRVS",
    "nct_id": "NCT06561048",
    "title": "Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Peripheral T-Cell Lymphoma, Not Otherwise Specified",
      "Angioimmunoblastic T-cell Lymphoma",
      "Follicular T-Cell Lymphoma",
      "Nodal Peripheral T-Cell Lymphoma With TFH Phenotype",
      "Systemic Anaplastic Large Cell Lymphoma",
      "Lymphoma, T-Cell, Peripheral",
      "Lymphoma, T-Cell"
    ],
    "interventions": [
      "Soquelitinib",
      "Belinostat",
      "Pralatrexate"
    ],
    "primary_completion_date": "2026-11",
    "completion_date": "2028-07",
    "results_first_posted": null,
    "last_update_posted": "2025-04-17",
    "enrollment": null,
    "sponsor": "Corvus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CRVS",
    "nct_id": "NCT03952078",
    "title": "A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "T-cell Lymphoma"
    ],
    "interventions": [
      "CPI-818"
    ],
    "primary_completion_date": "2026-04-30",
    "completion_date": "2026-04-30",
    "results_first_posted": null,
    "last_update_posted": "2025-04-16",
    "enrollment": null,
    "sponsor": "Corvus Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CSTL",
    "nct_id": "NCT02120781",
    "title": "Controlled Study to Evaluate the Safety and Efficacy of Azficel-T for Vocal Fold Scarring and Age-Related Dysphonia",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dysphonia Resulting From Vocal Fold Scarring",
      "Age-related Dysphonia"
    ],
    "interventions": [
      "Azficel-T (autologous fibroblasts)",
      "Placebo"
    ],
    "primary_completion_date": "2016-04",
    "completion_date": "2016-12-21",
    "results_first_posted": "2021-06-03",
    "last_update_posted": "2021-06-03",
    "enrollment": null,
    "sponsor": "Castle Creek Biosciences, LLC.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CSTL",
    "nct_id": "NCT00654654",
    "title": "Safety and Efficacy Study of Isolagen TherapyTM in Treatment of Facial Wrinkles and Creases",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Facial Wrinkles and Creases"
    ],
    "interventions": [
      "Autologous Human Fibroblasts (azficel-T)"
    ],
    "primary_completion_date": "2008-06",
    "completion_date": "2008-06",
    "results_first_posted": "2012-03-13",
    "last_update_posted": "2012-03-13",
    "enrollment": null,
    "sponsor": "Castle Creek Biosciences, LLC.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CSTL",
    "nct_id": "NCT06892639",
    "title": "Evaluation of D-Fi for the Treatment of Wounds Due to DEB",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dystrophic Epidermolysis Bullosa"
    ],
    "interventions": [
      "D-Fi"
    ],
    "primary_completion_date": "2027-09",
    "completion_date": "2042-02",
    "results_first_posted": null,
    "last_update_posted": "2025-07-28",
    "enrollment": null,
    "sponsor": "Castle Creek Biosciences, LLC.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CSTL",
    "nct_id": "NCT02376920",
    "title": "5 Year Registry Study to Track Clinical Application of DecisionDx-UM Assay Results and Associated Patient Outcomes",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Uveal Melanoma"
    ],
    "interventions": [],
    "primary_completion_date": "2022-04",
    "completion_date": "2022-04",
    "results_first_posted": null,
    "last_update_posted": "2022-05-16",
    "enrollment": null,
    "sponsor": "Castle Biosciences Incorporated",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CSTL",
    "nct_id": "NCT00655356",
    "title": "Safety and Efficacy Study of Isolagen Therapy in the Treatment of Nasolabial Fold Wrinkles",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bilateral Nasolabial Fold Wrinkles"
    ],
    "interventions": [
      "Autologous Human Fibroblasts (azficel-T)",
      "Placebo"
    ],
    "primary_completion_date": "2008-07",
    "completion_date": "2009-05",
    "results_first_posted": "2012-03-13",
    "last_update_posted": "2012-03-13",
    "enrollment": null,
    "sponsor": "Castle Creek Biosciences, LLC.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CSTL",
    "nct_id": "NCT04213261",
    "title": "A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Recessive Dystrophic Epidermolysis Bullosa"
    ],
    "interventions": [
      "FCX-007 (dabocemagene autoficel; see below for FCX-007 description)"
    ],
    "primary_completion_date": "2023-01-17",
    "completion_date": "2037-07",
    "results_first_posted": "2024-04-01",
    "last_update_posted": "2024-04-01",
    "enrollment": null,
    "sponsor": "Castle Creek Biosciences, LLC.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CSTL",
    "nct_id": "NCT00649428",
    "title": "Safety and Efficacy Study of Isolagen TherapyTM in the Treatment of Nasolabial Fold Wrinkles",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bilateral Nasolabial Fold Wrinkles"
    ],
    "interventions": [
      "Autologous Human Fibroblast (azficel-T)",
      "Placebo"
    ],
    "primary_completion_date": "2008-07",
    "completion_date": "2009-05",
    "results_first_posted": "2012-03-13",
    "last_update_posted": "2012-03-13",
    "enrollment": null,
    "sponsor": "Castle Creek Biosciences, LLC.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CSTL",
    "nct_id": "NCT00642642",
    "title": "Safety and Efficacy Study of Autologous Fibroblasts in the Treatment of Severe Facial Acne Scarring",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acne Scarring of the Face"
    ],
    "interventions": [
      "Autologous Human Fibroblasts (azficel-T)",
      "Placebo"
    ],
    "primary_completion_date": "2009-03",
    "completion_date": "2009-03",
    "results_first_posted": "2013-08-21",
    "last_update_posted": "2013-08-21",
    "enrollment": null,
    "sponsor": "Castle Creek Biosciences, LLC.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CSTL",
    "nct_id": "NCT02407561",
    "title": "Prospective Validation Study for the Proprietary Rectal and Anal Cancer Protein Expression Assays",
    "status": "TERMINATED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Rectal Adenocarcinoma",
      "Anal Adenocarcinoma",
      "Anal Squamous Cell Carcinoma"
    ],
    "interventions": [],
    "primary_completion_date": "2016-07",
    "completion_date": "2016-07",
    "results_first_posted": null,
    "last_update_posted": "2018-01-25",
    "enrollment": null,
    "sponsor": "Castle Biosciences Incorporated",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CSTL",
    "nct_id": "NCT03740724",
    "title": "A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Morphea",
      "Scleroderma, Localized",
      "Scleroderma"
    ],
    "interventions": [
      "FCX-013",
      "veledimex"
    ],
    "primary_completion_date": "2020-09-23",
    "completion_date": "2022-04-21",
    "results_first_posted": "2022-06-24",
    "last_update_posted": "2024-01-23",
    "enrollment": null,
    "sponsor": "Castle Creek Biosciences, LLC.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CSTL",
    "nct_id": "NCT01858753",
    "title": "Pilot Study of Azficel-T for the Treatment of Restrictive Burn Scars",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Restrictive Burn Scars"
    ],
    "interventions": [
      "Autologous fibroblasts",
      "placebo sterile saline"
    ],
    "primary_completion_date": "2016-05",
    "completion_date": "2016-07",
    "results_first_posted": "2021-07-19",
    "last_update_posted": "2021-10-13",
    "enrollment": null,
    "sponsor": "Castle Creek Biosciences, LLC.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CSTL",
    "nct_id": "NCT02810951",
    "title": "A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Epidermolysis Bullosa Dystrophica, Recessive"
    ],
    "interventions": [
      "FCX-007"
    ],
    "primary_completion_date": "2020-09-29",
    "completion_date": "2022-04-18",
    "results_first_posted": "2021-09-16",
    "last_update_posted": "2023-02-08",
    "enrollment": null,
    "sponsor": "Castle Creek Biosciences, LLC.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CSTL",
    "nct_id": "NCT00620737",
    "title": "Pilot Safety and Efficacy Study of Isolagen Therapy in Treatment of Restrictive Burn Scars",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Restrictive Burn Scars of Joint Area"
    ],
    "interventions": [
      "Autologous Human Fibroblasts (Isolagen TherapyTM)",
      "Placebo"
    ],
    "primary_completion_date": "2008-12",
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2012-02-10",
    "enrollment": null,
    "sponsor": "Castle Creek Biosciences, LLC.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CSTL",
    "nct_id": "NCT00655889",
    "title": "Safety and Efficacy Study of Isolagen TherapyTM in Treatment of Interdental Papillary Insufficiency",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Interdental Papillary Insufficiency"
    ],
    "interventions": [
      "Autologous Human Fibroblasts (azficel-T)"
    ],
    "primary_completion_date": "2008-04",
    "completion_date": "2008-07",
    "results_first_posted": "2013-08-15",
    "last_update_posted": "2021-03-23",
    "enrollment": null,
    "sponsor": "Castle Creek Biosciences, LLC.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CSTL",
    "nct_id": "NCT02355587",
    "title": "Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Patient Outcomes",
    "status": "TERMINATED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Cutaneous Melanoma"
    ],
    "interventions": [],
    "primary_completion_date": "2021-07",
    "completion_date": "2021-07-31",
    "results_first_posted": null,
    "last_update_posted": "2021-10-08",
    "enrollment": null,
    "sponsor": "Castle Biosciences Incorporated",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CSTL",
    "nct_id": "NCT02355574",
    "title": "5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results",
    "status": "TERMINATED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Cutaneous Melanoma"
    ],
    "interventions": [],
    "primary_completion_date": "2021-02",
    "completion_date": "2021-07",
    "results_first_posted": null,
    "last_update_posted": "2021-10-08",
    "enrollment": null,
    "sponsor": "Castle Biosciences Incorporated",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CTNM",
    "nct_id": "NCT07284459",
    "title": "Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Idiopathic Pulmonary Fibrosis"
    ],
    "interventions": [
      "PIPE-791 Dose A",
      "PIPE-791 Dose B",
      "Placebo"
    ],
    "primary_completion_date": "2028-05",
    "completion_date": "2028-06",
    "results_first_posted": null,
    "last_update_posted": "2025-12-23",
    "enrollment": null,
    "sponsor": "Contineum Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CTNM",
    "nct_id": "NCT04462198",
    "title": "Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing Loss",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Sensorineural Hearing Loss"
    ],
    "interventions": [
      "PIPE-505",
      "Placebo"
    ],
    "primary_completion_date": "2021-06-17",
    "completion_date": "2021-06-17",
    "results_first_posted": "2025-03-04",
    "last_update_posted": "2025-04-01",
    "enrollment": null,
    "sponsor": "Contineum Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CTNM",
    "nct_id": "NCT06683612",
    "title": "PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Idiopathic Pulmonary Fibrosis (IPF)",
      "Idiopathic Pulmonary Fibrosis",
      "Multiple Sclerosis",
      "Multiple Sclerosis, MS",
      "Multiple Sclerosis, Primary Progressive",
      "Multiple Sclerosis, Progressive",
      "Multiple Sclerosis, Secondary Progressive",
      "Healthy",
      "Healthy Volunteers"
    ],
    "interventions": [
      "PIPE-791"
    ],
    "primary_completion_date": "2025-06-04",
    "completion_date": "2025-06-12",
    "results_first_posted": null,
    "last_update_posted": "2025-08-06",
    "enrollment": null,
    "sponsor": "Contineum Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CTNM",
    "nct_id": "NCT06083753",
    "title": "Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsing Remitting Multiple Sclerosis"
    ],
    "interventions": [
      "PIPE-307 Dose A",
      "PIPE-307 Dose B",
      "Placebo"
    ],
    "primary_completion_date": "2025-07-14",
    "completion_date": "2025-08-04",
    "results_first_posted": null,
    "last_update_posted": "2025-10-23",
    "enrollment": null,
    "sponsor": "Contineum Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CTNM",
    "nct_id": "NCT04725175",
    "title": "Phase I Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of of PIPE-307 and Food Effect in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple Sclerosis"
    ],
    "interventions": [
      "PIPE-307",
      "Placebo oral tablet"
    ],
    "primary_completion_date": "2021-09-01",
    "completion_date": "2021-09-01",
    "results_first_posted": null,
    "last_update_posted": "2021-11-03",
    "enrollment": null,
    "sponsor": "Contineum Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CTNM",
    "nct_id": "NCT06810245",
    "title": "Study of PIPE-791 for Subjects With Chronic Osteoarthritis Pain or Chronic Low Back Pain",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Osteoarthritis Pain",
      "Chronic Low Back Pain"
    ],
    "interventions": [
      "PIPE-791",
      "Placebo"
    ],
    "primary_completion_date": "2025-12-15",
    "completion_date": "2026-02-15",
    "results_first_posted": null,
    "last_update_posted": "2025-11-05",
    "enrollment": null,
    "sponsor": "Contineum Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CTNM",
    "nct_id": "NCT04941781",
    "title": "PET Study to Determine the Relationship Between Plasma Concentrations and Muscarinic Type 1 Receptor (M1AChR) Occupancy of PIPE-307 in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple Sclerosis"
    ],
    "interventions": [
      "PIPE-307"
    ],
    "primary_completion_date": "2021-11-10",
    "completion_date": "2021-11-10",
    "results_first_posted": null,
    "last_update_posted": "2022-10-05",
    "enrollment": null,
    "sponsor": "Contineum Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "CTNM",
    "nct_id": "NCT05983939",
    "title": "Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of PIPE-791 and Food Effect in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple Sclerosis"
    ],
    "interventions": [
      "PIPE-791",
      "Placebo"
    ],
    "primary_completion_date": "2024-02-01",
    "completion_date": "2024-02-01",
    "results_first_posted": null,
    "last_update_posted": "2024-02-14",
    "enrollment": null,
    "sponsor": "Contineum Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "DSGN",
    "nct_id": "NCT01631903",
    "title": "Extension of Study ZPV-200",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Uterine Fibroids"
    ],
    "interventions": [
      "telepristone acetate 12 mg",
      "telepristone acetate 3 mg",
      "telepristone acetate 6 mg",
      "telepristone acetate 12 mg",
      "telepristone acetate 24 mg"
    ],
    "primary_completion_date": "2014-04",
    "completion_date": "2014-04",
    "results_first_posted": null,
    "last_update_posted": "2014-04-16",
    "enrollment": null,
    "sponsor": "Repros Therapeutics Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ENTA",
    "nct_id": "NCT04927793",
    "title": "Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Respiratory Syncytial Virus (RSV)"
    ],
    "interventions": [
      "EDP-938"
    ],
    "primary_completion_date": "2021-07-04",
    "completion_date": "2021-07-04",
    "results_first_posted": null,
    "last_update_posted": "2022-03-23",
    "enrollment": null,
    "sponsor": "Enanta Pharmaceuticals, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ENTA",
    "nct_id": "NCT04633187",
    "title": "Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory Tract",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Respiratory Syncytial Virus Infections"
    ],
    "interventions": [
      "EDP-938",
      "Placebo"
    ],
    "primary_completion_date": "2023-05-31",
    "completion_date": "2023-05-31",
    "results_first_posted": "2024-08-22",
    "last_update_posted": "2024-08-22",
    "enrollment": null,
    "sponsor": "Enanta Pharmaceuticals, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ENTA",
    "nct_id": "NCT02652377",
    "title": "EDP-494-001: A Study of EDP-494 in Healthy Subjects and Hepatitis C Patients",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatitis C"
    ],
    "interventions": [
      "EDP-494",
      "Placebo"
    ],
    "primary_completion_date": "2016-12-27",
    "completion_date": "2016-12-27",
    "results_first_posted": null,
    "last_update_posted": "2017-01-23",
    "enrollment": null,
    "sponsor": "Enanta Pharmaceuticals, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ENTA",
    "nct_id": "NCT02918929",
    "title": "A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Presumptive NAFLD"
    ],
    "interventions": [
      "EDP 305",
      "Placebo"
    ],
    "primary_completion_date": "2017-06",
    "completion_date": "2017-06",
    "results_first_posted": null,
    "last_update_posted": "2017-08-21",
    "enrollment": null,
    "sponsor": "Enanta Pharmaceuticals, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ENTA",
    "nct_id": "NCT03783897",
    "title": "A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "NASH - Nonalcoholic Steatohepatitis"
    ],
    "interventions": [
      "EDP-305",
      "Oral Contraceptive"
    ],
    "primary_completion_date": "2019-06-04",
    "completion_date": "2019-06-18",
    "results_first_posted": null,
    "last_update_posted": "2019-07-24",
    "enrollment": null,
    "sponsor": "Enanta Pharmaceuticals, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ENTA",
    "nct_id": "NCT00989872",
    "title": "Safety and Pharmacokinetics of Ascending Single Oral Doses of EDP-322 in Nonfasting and Fasting Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Skin and Soft Tissue Infections",
      "Methicillin-resistant Staphylococcus Aureus"
    ],
    "interventions": [
      "EDP-322"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2009-10-06",
    "enrollment": null,
    "sponsor": "Enanta Pharmaceuticals, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ENTA",
    "nct_id": "NCT05568706",
    "title": "A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "RSV Infection"
    ],
    "interventions": [
      "EDP-938",
      "Placebo"
    ],
    "primary_completion_date": "2025-06-23",
    "completion_date": "2025-06-23",
    "results_first_posted": null,
    "last_update_posted": "2025-07-01",
    "enrollment": null,
    "sponsor": "Enanta Pharmaceuticals, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ENTA",
    "nct_id": "NCT05594602",
    "title": "Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects.",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID-19"
    ],
    "interventions": [
      "EDP-235",
      "EDP-235",
      "EDP-235",
      "Itraconazole",
      "Carbamazepine",
      "Quinidine"
    ],
    "primary_completion_date": "2022-12-14",
    "completion_date": "2022-12-30",
    "results_first_posted": null,
    "last_update_posted": "2023-04-27",
    "enrollment": null,
    "sponsor": "Enanta Pharmaceuticals, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ENTA",
    "nct_id": "NCT03394924",
    "title": "A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Primary Biliary Cholangitis"
    ],
    "interventions": [
      "EDP-305 1 mg",
      "EDP-305 2.5 mg",
      "Placebo"
    ],
    "primary_completion_date": "2019-12-19",
    "completion_date": "2020-01-16",
    "results_first_posted": "2021-05-18",
    "last_update_posted": "2021-05-18",
    "enrollment": null,
    "sponsor": "Enanta Pharmaceuticals, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ENTA",
    "nct_id": "NCT02173574",
    "title": "Two-way Interaction Between Alisporivir and EDP239",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatitis C Virus"
    ],
    "interventions": [
      "DEB025",
      "EDP239"
    ],
    "primary_completion_date": "2014-11",
    "completion_date": "2014-11",
    "results_first_posted": null,
    "last_update_posted": "2015-01-09",
    "enrollment": null,
    "sponsor": "Enanta Pharmaceuticals, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ENTA",
    "nct_id": "NCT01999725",
    "title": "Evaluation of the Safety and Pharmacokinetics of a Single Oral Dose of EDP-788",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Safety in Normal Volunteers"
    ],
    "interventions": [
      "EDP-788",
      "Placebo"
    ],
    "primary_completion_date": "2014-09",
    "completion_date": "2014-09",
    "results_first_posted": null,
    "last_update_posted": "2015-01-09",
    "enrollment": null,
    "sponsor": "Enanta Pharmaceuticals, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ENTA",
    "nct_id": "NCT05594615",
    "title": "Drug-Drug Interaction Study Between EDP-235, Midazolam, Caffeine and Rosuvastatin in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID-19"
    ],
    "interventions": [
      "EDP-235",
      "Midazolam",
      "Rosuvastatin",
      "Caffeine"
    ],
    "primary_completion_date": "2022-11-04",
    "completion_date": "2022-11-18",
    "results_first_posted": null,
    "last_update_posted": "2023-04-27",
    "enrollment": null,
    "sponsor": "Enanta Pharmaceuticals, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ENTA",
    "nct_id": "NCT05616728",
    "title": "A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID-19"
    ],
    "interventions": [
      "EDP-235",
      "Placebo"
    ],
    "primary_completion_date": "2023-02-08",
    "completion_date": "2023-06-29",
    "results_first_posted": "2024-08-19",
    "last_update_posted": "2024-08-19",
    "enrollment": null,
    "sponsor": "Enanta Pharmaceuticals, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ENTA",
    "nct_id": "NCT04559126",
    "title": "A Study of EDP-297 in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "NASH - Nonalcoholic Steatohepatitis With Liver Fibrosis"
    ],
    "interventions": [
      "EDP-297",
      "Placebo"
    ],
    "primary_completion_date": "2021-06-21",
    "completion_date": "2021-06-21",
    "results_first_posted": null,
    "last_update_posted": "2021-10-29",
    "enrollment": null,
    "sponsor": "Enanta Pharmaceuticals, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ENTA",
    "nct_id": "NCT06917508",
    "title": "A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "RSV Infection",
      "Drug Drug Interaction"
    ],
    "interventions": [
      "EDP-323",
      "Midazolam",
      "Caffeine",
      "Rosuvastatin"
    ],
    "primary_completion_date": "2025-06-06",
    "completion_date": "2025-06-13",
    "results_first_posted": null,
    "last_update_posted": "2025-07-01",
    "enrollment": null,
    "sponsor": "Enanta Pharmaceuticals, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ENTA",
    "nct_id": "NCT04196101",
    "title": "A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Respiratory Syncytial Virus"
    ],
    "interventions": [
      "EDP-938",
      "Placebo"
    ],
    "primary_completion_date": "2022-01-04",
    "completion_date": "2022-01-04",
    "results_first_posted": "2023-10-30",
    "last_update_posted": "2023-10-30",
    "enrollment": null,
    "sponsor": "Enanta Pharmaceuticals, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ENTA",
    "nct_id": "NCT03748628",
    "title": "Absorption, Metabolism and Excretion (AME) Study of [14C]EDP-305 in Healthy Male Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "NASH - Nonalcoholic Steatohepatitis"
    ],
    "interventions": [
      "EDP-305"
    ],
    "primary_completion_date": "2018-10-13",
    "completion_date": "2018-10-13",
    "results_first_posted": null,
    "last_update_posted": "2018-11-21",
    "enrollment": null,
    "sponsor": "Enanta Pharmaceuticals, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ENTA",
    "nct_id": "NCT04783753",
    "title": "Drug-Drug Interaction Study Between EDP-514, Itraconazole, Carbamazepine, and Quinidine in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatitis B"
    ],
    "interventions": [
      "EDP-514",
      "EDP-514",
      "EDP-514",
      "Itraconazole",
      "Carbamazepin",
      "Quinidine"
    ],
    "primary_completion_date": "2021-06-28",
    "completion_date": "2021-07-09",
    "results_first_posted": null,
    "last_update_posted": "2021-08-16",
    "enrollment": null,
    "sponsor": "Enanta Pharmaceuticals, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ENTA",
    "nct_id": "NCT04816721",
    "title": "A Study to Evaluate EDP 938 Regimens in Children With RSV",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Respiratory Syncytial Virus (RSV)"
    ],
    "interventions": [
      "EDP-938",
      "Placebo"
    ],
    "primary_completion_date": "2024-08-19",
    "completion_date": "2024-08-19",
    "results_first_posted": "2025-07-08",
    "last_update_posted": "2025-07-28",
    "enrollment": null,
    "sponsor": "Enanta Pharmaceuticals, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ENTA",
    "nct_id": "NCT03384823",
    "title": "A Study of EDP-938 in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "RSV Infection"
    ],
    "interventions": [
      "EDP-938",
      "Placebo"
    ],
    "primary_completion_date": "2018-07-03",
    "completion_date": "2018-07-03",
    "results_first_posted": null,
    "last_update_posted": "2018-10-10",
    "enrollment": null,
    "sponsor": "Enanta Pharmaceuticals, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ENTA",
    "nct_id": "NCT04378010",
    "title": "A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-Alcoholic Steatohepatitis"
    ],
    "interventions": [
      "EDP-305 1.5 mg",
      "EDP-305 2 mg",
      "Placebo"
    ],
    "primary_completion_date": "2021-10-04",
    "completion_date": "2021-11-30",
    "results_first_posted": "2023-05-19",
    "last_update_posted": "2023-05-19",
    "enrollment": null,
    "sponsor": "Enanta Pharmaceuticals, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ENTA",
    "nct_id": "NCT00270517",
    "title": "Comparative Study of EDP-420 Versus Another Antibiotic in the Treatment of Community Acquired Pneumonia",
    "status": "UNKNOWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Community Acquired Pneumonia"
    ],
    "interventions": [
      "EDP-420 / Duration of Treatment - 3 days",
      "Telithromycin / Duration of Treatment - 7 days"
    ],
    "primary_completion_date": null,
    "completion_date": "2007-07",
    "results_first_posted": null,
    "last_update_posted": "2006-09-19",
    "enrollment": null,
    "sponsor": "Enanta Pharmaceuticals, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ENTA",
    "nct_id": "NCT00990145",
    "title": "Multiple Ascending-Dose Study of EDP 322 in Healthy Adult Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "MRSA, SSTI"
    ],
    "interventions": [
      "EDP-322"
    ],
    "primary_completion_date": "2009-03",
    "completion_date": "2009-09",
    "results_first_posted": null,
    "last_update_posted": "2009-10-08",
    "enrollment": null,
    "sponsor": "Enanta Pharmaceuticals, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ENTA",
    "nct_id": "NCT03691623",
    "title": "A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "RSV Infection"
    ],
    "interventions": [
      "EDP-938 Dose 1",
      "EDP-938 Dose 2",
      "Placebo",
      "EDP-938 Dose 3",
      "EDP-938 Dose 4",
      "Placebo"
    ],
    "primary_completion_date": "2019-09-30",
    "completion_date": "2019-10-18",
    "results_first_posted": "2022-05-03",
    "last_update_posted": "2022-05-03",
    "enrollment": null,
    "sponsor": "Enanta Pharmaceuticals, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ENTA",
    "nct_id": "NCT04470388",
    "title": "A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic HBV Infection"
    ],
    "interventions": [
      "EDP-514",
      "Placebo"
    ],
    "primary_completion_date": "2021-08-30",
    "completion_date": "2021-08-30",
    "results_first_posted": null,
    "last_update_posted": "2022-01-11",
    "enrollment": null,
    "sponsor": "Enanta Pharmaceuticals, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ENTA",
    "nct_id": "NCT02255968",
    "title": "Evaluation of the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of EDP-788",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "EDP-788",
      "Placebo"
    ],
    "primary_completion_date": "2014-10",
    "completion_date": "2014-10",
    "results_first_posted": null,
    "last_update_posted": "2015-05-12",
    "enrollment": null,
    "sponsor": "Enanta Pharmaceuticals, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ENTA",
    "nct_id": "NCT03610945",
    "title": "Drug-drug Interaction Study Between EDP-305, Fluconazole and Quinidine in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "NASH - Nonalcoholic Steatohepatitis"
    ],
    "interventions": [
      "Fluconazole",
      "Quinidine",
      "EDP-305",
      "EDP-305"
    ],
    "primary_completion_date": "2018-08-15",
    "completion_date": "2018-08-21",
    "results_first_posted": null,
    "last_update_posted": "2018-12-05",
    "enrollment": null,
    "sponsor": "Enanta Pharmaceuticals, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ENTA",
    "nct_id": "NCT03207425",
    "title": "A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "NASH"
    ],
    "interventions": [
      "EDP 305"
    ],
    "primary_completion_date": "2017-09-16",
    "completion_date": "2017-09-19",
    "results_first_posted": null,
    "last_update_posted": "2017-11-06",
    "enrollment": null,
    "sponsor": "Enanta Pharmaceuticals, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ENTA",
    "nct_id": "NCT03755778",
    "title": "Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "RSV Infection"
    ],
    "interventions": [
      "EDP-938",
      "EDP-938",
      "EDP-938",
      "Itraconazole",
      "Rifampin",
      "Quinidine"
    ],
    "primary_completion_date": "2019-01-21",
    "completion_date": "2019-01-27",
    "results_first_posted": null,
    "last_update_posted": "2019-06-14",
    "enrollment": null,
    "sponsor": "Enanta Pharmaceuticals, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ENTA",
    "nct_id": "NCT05587478",
    "title": "A Study of EDP-323 in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "RSV Infection"
    ],
    "interventions": [
      "EDP-323",
      "Placebo"
    ],
    "primary_completion_date": "2023-03-29",
    "completion_date": "2023-03-29",
    "results_first_posted": null,
    "last_update_posted": "2023-09-01",
    "enrollment": null,
    "sponsor": "Enanta Pharmaceuticals, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ENTA",
    "nct_id": "NCT04971512",
    "title": "A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION.",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Hepatitis B Virus Infection"
    ],
    "interventions": [
      "EDP-721",
      "Placebo (Part 1)",
      "EDP-721 (Part 2)",
      "Placebo (Part 2)",
      "EDP-514",
      "Placebo (Part 2)"
    ],
    "primary_completion_date": "2021-12-20",
    "completion_date": "2021-12-20",
    "results_first_posted": null,
    "last_update_posted": "2022-02-14",
    "enrollment": null,
    "sponsor": "Enanta Pharmaceuticals, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ENTA",
    "nct_id": "NCT04008004",
    "title": "A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic HBV Infection"
    ],
    "interventions": [
      "EDP-514",
      "Placebo"
    ],
    "primary_completion_date": "2021-07-14",
    "completion_date": "2021-07-14",
    "results_first_posted": null,
    "last_update_posted": "2022-01-11",
    "enrollment": null,
    "sponsor": "Enanta Pharmaceuticals, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ENTA",
    "nct_id": "NCT03750383",
    "title": "Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "RSV Infection"
    ],
    "interventions": [
      "EDP-938",
      "EDP-938",
      "Cyclosporine",
      "Prednisone"
    ],
    "primary_completion_date": "2018-11-17",
    "completion_date": "2018-12-13",
    "results_first_posted": null,
    "last_update_posted": "2019-02-12",
    "enrollment": null,
    "sponsor": "Enanta Pharmaceuticals, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ENTA",
    "nct_id": "NCT03187496",
    "title": "Drug-drug Interaction Study Between EDP-305, Midazolam, Caffeine and Rosuvastatin in Healthy Volunteers.",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "NASH"
    ],
    "interventions": [
      "Midazolam",
      "Caffeine",
      "Rosuvastatin",
      "EDP-305"
    ],
    "primary_completion_date": "2017-06-01",
    "completion_date": "2017-06-14",
    "results_first_posted": null,
    "last_update_posted": "2017-08-21",
    "enrollment": null,
    "sponsor": "Enanta Pharmaceuticals, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ENTA",
    "nct_id": "NCT06847464",
    "title": "A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "RSV Infection",
      "Drug Drug Interaction (DDI)"
    ],
    "interventions": [
      "EDP-323",
      "Itraconazole",
      "EDP-323",
      "carbamazepine",
      "EDP-323",
      "Quinidine",
      "EDP-323",
      "fluconazole"
    ],
    "primary_completion_date": "2025-05-24",
    "completion_date": "2025-06-01",
    "results_first_posted": null,
    "last_update_posted": "2025-07-01",
    "enrollment": null,
    "sponsor": "Enanta Pharmaceuticals, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ENTA",
    "nct_id": "NCT06601192",
    "title": "A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "RSV Infection",
      "QTc Interval"
    ],
    "interventions": [
      "zelicapavir (therapeutic dose)",
      "zelicapavir (supratherapeutic dose)",
      "Placebo",
      "moxifloxacin"
    ],
    "primary_completion_date": "2025-02-02",
    "completion_date": "2025-02-25",
    "results_first_posted": null,
    "last_update_posted": "2025-07-28",
    "enrollment": null,
    "sponsor": "Enanta Pharmaceuticals, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ENTA",
    "nct_id": "NCT01856426",
    "title": "Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatitis C"
    ],
    "interventions": [
      "EDP239",
      "Placebo"
    ],
    "primary_completion_date": "2014-11",
    "completion_date": "2015-10",
    "results_first_posted": null,
    "last_update_posted": "2016-01-29",
    "enrollment": null,
    "sponsor": "Enanta Pharmaceuticals, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ENTA",
    "nct_id": "NCT04498741",
    "title": "Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "RSV Infection"
    ],
    "interventions": [
      "EDP-938",
      "EDP-938",
      "EDP-938",
      "Tacrolimus",
      "Dabigatran",
      "Rosuvastatin",
      "EDP-938",
      "Midazolam"
    ],
    "primary_completion_date": "2021-05-27",
    "completion_date": "2021-06-01",
    "results_first_posted": null,
    "last_update_posted": "2021-10-13",
    "enrollment": null,
    "sponsor": "Enanta Pharmaceuticals, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ENTA",
    "nct_id": "NCT05246878",
    "title": "A Study of EDP-235 in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "SARS CoV 2 Infection"
    ],
    "interventions": [
      "EDP-235",
      "Placebo"
    ],
    "primary_completion_date": "2022-07-20",
    "completion_date": "2022-07-20",
    "results_first_posted": null,
    "last_update_posted": "2022-08-19",
    "enrollment": null,
    "sponsor": "Enanta Pharmaceuticals, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ENTA",
    "nct_id": "NCT03213145",
    "title": "Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "NASH - Nonalcoholic Steatohepatitis"
    ],
    "interventions": [
      "intraconazole",
      "Rifampin",
      "EDP 305"
    ],
    "primary_completion_date": "2017-08-10",
    "completion_date": "2017-09-07",
    "results_first_posted": null,
    "last_update_posted": "2017-11-06",
    "enrollment": null,
    "sponsor": "Enanta Pharmaceuticals, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ENTA",
    "nct_id": "NCT04871724",
    "title": "Drug-Drug Interaction Study Between Fluconazole and EDP-938 in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "RSV Infection"
    ],
    "interventions": [
      "EDP-938",
      "Fluconazole"
    ],
    "primary_completion_date": "2021-03-30",
    "completion_date": "2021-04-16",
    "results_first_posted": null,
    "last_update_posted": "2021-05-04",
    "enrollment": null,
    "sponsor": "Enanta Pharmaceuticals, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ENTA",
    "nct_id": "NCT06170242",
    "title": "A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "RSV Infection"
    ],
    "interventions": [
      "EDP-323 Dose Regimen 1",
      "EDP-323 Dose Regimen 2",
      "Placebo"
    ],
    "primary_completion_date": "2024-06-17",
    "completion_date": "2024-07-12",
    "results_first_posted": "2025-10-07",
    "last_update_posted": "2025-10-07",
    "enrollment": null,
    "sponsor": "Enanta Pharmaceuticals, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ENTA",
    "nct_id": "NCT03421431",
    "title": "A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-Alcoholic Steatohepatitis"
    ],
    "interventions": [
      "EDP-305 Dose 1",
      "EDP-305 Dose 2",
      "Placebo"
    ],
    "primary_completion_date": "2019-06-14",
    "completion_date": "2019-07-10",
    "results_first_posted": "2021-09-16",
    "last_update_posted": "2021-09-16",
    "enrollment": null,
    "sponsor": "Enanta Pharmaceuticals, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "EOLS",
    "nct_id": "NCT02334436",
    "title": "A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Glabellar Frown Lines"
    ],
    "interventions": [
      "Botulinum toxin, Type A",
      "0.9% sterile, unpreserved saline"
    ],
    "primary_completion_date": "2015-09",
    "completion_date": "2015-12",
    "results_first_posted": "2019-02-27",
    "last_update_posted": "2019-03-27",
    "enrollment": null,
    "sponsor": "Evolus, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "EOLS",
    "nct_id": "NCT02428608",
    "title": "Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Glabellar Frown Lines"
    ],
    "interventions": [
      "DWP-450 (Botulinum purified neurotoxin, Type A)"
    ],
    "primary_completion_date": "2016-10",
    "completion_date": "2016-11",
    "results_first_posted": "2019-02-05",
    "last_update_posted": "2019-04-24",
    "enrollment": null,
    "sponsor": "Evolus, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "EOLS",
    "nct_id": "NCT05481931",
    "title": "Non Interventional Safety Study of NUCEIVA for the Treatment of Moderate-to-Severe Glabellar Lines",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Glabellar Frown Lines"
    ],
    "interventions": [
      "prabotulinumtoxinA"
    ],
    "primary_completion_date": "2026-01",
    "completion_date": "2026-01",
    "results_first_posted": null,
    "last_update_posted": "2025-08-05",
    "enrollment": null,
    "sponsor": "Evolus, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "EOLS",
    "nct_id": "NCT02334423",
    "title": "A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Glabellar Frown Lines"
    ],
    "interventions": [
      "Botulinum toxin, Type A",
      "0.9% sterile, unpreserved saline"
    ],
    "primary_completion_date": "2015-12",
    "completion_date": "2015-12",
    "results_first_posted": "2019-02-26",
    "last_update_posted": "2019-03-27",
    "enrollment": null,
    "sponsor": "Evolus, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "EOLS",
    "nct_id": "NCT05320393",
    "title": "Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Glabellar Frown Lines"
    ],
    "interventions": [
      "PrabotulinumtoxinA-Xvfs",
      "OnabotulinumtoxinA",
      "PrabotulinumtoxinA-Xvfs"
    ],
    "primary_completion_date": "2023-05-22",
    "completion_date": "2023-05-22",
    "results_first_posted": "2024-09-04",
    "last_update_posted": "2024-09-04",
    "enrollment": null,
    "sponsor": "Evolus, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "EOLS",
    "nct_id": "NCT02184988",
    "title": "Safety Study of DWP-450 (Botulinum Purified Neurotoxin, Type A) Injection to Treat Glabellar Lines",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Glabellar Frown Lines"
    ],
    "interventions": [
      "Botulinum purified neurotoxin, Type A"
    ],
    "primary_completion_date": "2015-12",
    "completion_date": "2015-12",
    "results_first_posted": "2019-02-05",
    "last_update_posted": "2019-04-24",
    "enrollment": null,
    "sponsor": "Evolus, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ESPR",
    "nct_id": "NCT01105598",
    "title": "A Multiple Ascending Dose Study of ETC-1002 in Subjects With Mild Dyslipidemia",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Mild Dyslipidemia"
    ],
    "interventions": [
      "ETC-1002 or placebo",
      "ETC-1002 or placebo",
      "ETC-1002 or placebo"
    ],
    "primary_completion_date": "2010-10-02",
    "completion_date": "2010-10-02",
    "results_first_posted": null,
    "last_update_posted": "2019-03-28",
    "enrollment": null,
    "sponsor": "Esperion Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ESPR",
    "nct_id": "NCT03337308",
    "title": "A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hyperlipidemias"
    ],
    "interventions": [
      "Bempedoic Acid + Ezetimibe Fixed-Dose Combination",
      "Bempedoic Acid",
      "Ezetimibe",
      "Placebos"
    ],
    "primary_completion_date": "2018-06-18",
    "completion_date": "2018-07-18",
    "results_first_posted": "2020-04-08",
    "last_update_posted": "2020-04-08",
    "enrollment": null,
    "sponsor": "Esperion Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ESPR",
    "nct_id": "NCT05694260",
    "title": "A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypercholesterolemia"
    ],
    "interventions": [
      "Bempedoic acid"
    ],
    "primary_completion_date": "2025-06-04",
    "completion_date": "2025-06-04",
    "results_first_posted": null,
    "last_update_posted": "2025-08-08",
    "enrollment": null,
    "sponsor": "Esperion Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ESPR",
    "nct_id": "NCT03051100",
    "title": "Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypercholesterolemia"
    ],
    "interventions": [
      "Bempedoic acid 180mg",
      "Ezetimibe 10mg",
      "Atorvastatin 20mg",
      "Placebo"
    ],
    "primary_completion_date": "2017-06-01",
    "completion_date": "2017-07-05",
    "results_first_posted": "2020-04-03",
    "last_update_posted": "2020-04-03",
    "enrollment": null,
    "sponsor": "Esperion Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ESPR",
    "nct_id": "NCT02993406",
    "title": "Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cardiovascular Diseases",
      "Statin Adverse Reaction"
    ],
    "interventions": [
      "Bempedoic acid 180 mg tablet",
      "Matching placebo tablet"
    ],
    "primary_completion_date": "2022-11-07",
    "completion_date": "2022-11-07",
    "results_first_posted": "2024-01-03",
    "last_update_posted": "2024-01-03",
    "enrollment": null,
    "sponsor": "Esperion Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ESPR",
    "nct_id": "NCT03001076",
    "title": "Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypercholesterolemia",
      "Atherosclerosis",
      "Statin Adverse Reaction"
    ],
    "interventions": [
      "Bempedoic acid",
      "Ezetimibe",
      "Placebo"
    ],
    "primary_completion_date": "2018-01-11",
    "completion_date": "2018-02-12",
    "results_first_posted": "2020-04-03",
    "last_update_posted": "2020-05-11",
    "enrollment": null,
    "sponsor": "Esperion Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ESPR",
    "nct_id": "NCT01941836",
    "title": "Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypercholesterolemia"
    ],
    "interventions": [
      "ETC-1002",
      "Ezetimibe"
    ],
    "primary_completion_date": "2014-10",
    "completion_date": "2014-11",
    "results_first_posted": null,
    "last_update_posted": "2019-03-29",
    "enrollment": null,
    "sponsor": "Esperion Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ESPR",
    "nct_id": "NCT02044627",
    "title": "Single Radiolabeled Dose Study to Investigate the Absorption, Metabolism and Excretion of [14C]-ETC-1002",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hyperlipidemia"
    ],
    "interventions": [
      "[14C-ETC-1002]"
    ],
    "primary_completion_date": "2014-01",
    "completion_date": "2014-01",
    "results_first_posted": null,
    "last_update_posted": "2019-02-15",
    "enrollment": null,
    "sponsor": "Esperion Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ESPR",
    "nct_id": "NCT02666664",
    "title": "Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypercholesterolemia",
      "Atherosclerotic Cardiovascular Diseases"
    ],
    "interventions": [
      "ETC-1002",
      "Placebo"
    ],
    "primary_completion_date": "2018-02-21",
    "completion_date": "2018-03-28",
    "results_first_posted": "2020-04-20",
    "last_update_posted": "2020-05-11",
    "enrollment": null,
    "sponsor": "Esperion Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ESPR",
    "nct_id": "NCT01607294",
    "title": "A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hyperlipidemia",
      "Type 2 Diabetes"
    ],
    "interventions": [
      "ETC-1002",
      "Placebo"
    ],
    "primary_completion_date": "2012-10",
    "completion_date": "2012-10",
    "results_first_posted": null,
    "last_update_posted": "2019-03-29",
    "enrollment": null,
    "sponsor": "Esperion Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ESPR",
    "nct_id": "NCT01751984",
    "title": "A Study of the Efficacy and Safety of ETC-1002 in Participants With Statin Intolerance",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypercholesterolemia"
    ],
    "interventions": [
      "ETC-1002",
      "Placebo"
    ],
    "primary_completion_date": "2013-05-01",
    "completion_date": "2013-05-01",
    "results_first_posted": "2022-04-04",
    "last_update_posted": "2022-04-04",
    "enrollment": null,
    "sponsor": "Esperion Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ESPR",
    "nct_id": "NCT06021951",
    "title": "Milk-Only Lactation Study to Evaluate the Concentration of Bempedoic Acid and Bempedoic Acid/Ezetimibe Fixed Combination Drug Product (FCDP) in the Breast Milk of Healthy Lactating Women",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Lactating Women"
    ],
    "interventions": [
      "Bempedoic Acid 180 MG Oral Tablet",
      "Bempedoic Acid/Ezetimibe 180 MG-10 MG Oral Tablet"
    ],
    "primary_completion_date": "2024-02-21",
    "completion_date": "2024-03-22",
    "results_first_posted": "2025-04-11",
    "last_update_posted": "2025-04-11",
    "enrollment": null,
    "sponsor": "Esperion Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ESPR",
    "nct_id": "NCT03067441",
    "title": "Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypercholesterolemia",
      "Atherosclerotic Cardiovascular Disease"
    ],
    "interventions": [
      "bempedoic acid"
    ],
    "primary_completion_date": "2019-11-05",
    "completion_date": "2019-11-05",
    "results_first_posted": "2020-12-22",
    "last_update_posted": "2021-03-01",
    "enrollment": null,
    "sponsor": "Esperion Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ESPR",
    "nct_id": "NCT02178098",
    "title": "Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypercholesterolemia",
      "Hypertension"
    ],
    "interventions": [
      "ETC-1002",
      "Placebo"
    ],
    "primary_completion_date": "2015-05-22",
    "completion_date": "2015-05-22",
    "results_first_posted": "2023-04-04",
    "last_update_posted": "2023-04-04",
    "enrollment": null,
    "sponsor": "Esperion Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ESPR",
    "nct_id": "NCT03193047",
    "title": "Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypercholesterolemia"
    ],
    "interventions": [
      "bempedoic acid 180mg",
      "placebo",
      "evolocumab"
    ],
    "primary_completion_date": "2018-01-29",
    "completion_date": "2018-02-19",
    "results_first_posted": "2020-04-03",
    "last_update_posted": "2020-04-03",
    "enrollment": null,
    "sponsor": "Esperion Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ESPR",
    "nct_id": "NCT02991118",
    "title": "Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypercholesterolemia",
      "Atherosclerotic Cardiovascular Disease"
    ],
    "interventions": [
      "bempedoic acid",
      "placebo"
    ],
    "primary_completion_date": "2018-08-22",
    "completion_date": "2018-08-22",
    "results_first_posted": "2020-04-27",
    "last_update_posted": "2020-04-27",
    "enrollment": null,
    "sponsor": "Esperion Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ESPR",
    "nct_id": "NCT01485146",
    "title": "A Multiple Ascending Dose Study of ETC-1002 in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Safety Evaluation of Escalating Doses"
    ],
    "interventions": [
      "ETC-1002"
    ],
    "primary_completion_date": "2012-01-25",
    "completion_date": "2012-01-25",
    "results_first_posted": null,
    "last_update_posted": "2019-03-28",
    "enrollment": null,
    "sponsor": "Esperion Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ESPR",
    "nct_id": "NCT01779453",
    "title": "A Study of the Safety, Pharmacokinetic Drug Interaction and Efficacy of ETC-1002 and Atorvastatin in Subjects With Hypercholesterolemia",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypercholesterolemia"
    ],
    "interventions": [
      "ETC-1002",
      "Placebo",
      "Atorvastatin"
    ],
    "primary_completion_date": "2013-08",
    "completion_date": "2013-08",
    "results_first_posted": null,
    "last_update_posted": "2019-03-29",
    "enrollment": null,
    "sponsor": "Esperion Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ESPR",
    "nct_id": "NCT02988115",
    "title": "Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypercholesterolemia",
      "Atherosclerotic Cardiovascular Disease",
      "Statin Adverse Reaction"
    ],
    "interventions": [
      "bempedoic acid",
      "placebo"
    ],
    "primary_completion_date": "2018-03-16",
    "completion_date": "2018-03-16",
    "results_first_posted": "2020-04-03",
    "last_update_posted": "2020-04-03",
    "enrollment": null,
    "sponsor": "Esperion Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ESPR",
    "nct_id": "NCT01262638",
    "title": "A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dyslipidemia"
    ],
    "interventions": [
      "ETC-1002",
      "Placebo"
    ],
    "primary_completion_date": "2011-08-23",
    "completion_date": "2011-08-23",
    "results_first_posted": "2021-03-16",
    "last_update_posted": "2021-03-17",
    "enrollment": null,
    "sponsor": "Esperion Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ESPR",
    "nct_id": "NCT05103254",
    "title": "Bempedoic Acid Pregnancy Surveillance Program",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Pregnancy",
      "Hyperlipidemias"
    ],
    "interventions": [
      "Bempedoic Acid",
      "Bempedoic Acid / Ezetimibe"
    ],
    "primary_completion_date": "2032-05",
    "completion_date": "2032-05",
    "results_first_posted": null,
    "last_update_posted": "2024-05-17",
    "enrollment": null,
    "sponsor": "Esperion Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ESPR",
    "nct_id": "NCT02072161",
    "title": "Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypercholesterolemia"
    ],
    "interventions": [
      "ETC-1002",
      "Placebo",
      "Statin Therapy"
    ],
    "primary_completion_date": "2015-01",
    "completion_date": "2015-01",
    "results_first_posted": null,
    "last_update_posted": "2019-03-29",
    "enrollment": null,
    "sponsor": "Esperion Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ESPR",
    "nct_id": "NCT03531905",
    "title": "Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes",
      "Diabetes Mellitus, Type 2",
      "Cholesterolemia"
    ],
    "interventions": [
      "Bempedoic acid + Ezetimibe FDC Oral Tablet",
      "Ezetimibe 10 mg Oral Tablet",
      "Placebo Oral Tablet",
      "Placebo oral capsule"
    ],
    "primary_completion_date": "2019-06-18",
    "completion_date": "2019-06-18",
    "results_first_posted": "2020-04-09",
    "last_update_posted": "2020-04-09",
    "enrollment": null,
    "sponsor": "Esperion Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ESPR",
    "nct_id": "NCT02659397",
    "title": "A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hyperlipidemia"
    ],
    "interventions": [
      "ETC-1002",
      "Atorvastatin",
      "Placebo"
    ],
    "primary_completion_date": "2016-07",
    "completion_date": "2016-07",
    "results_first_posted": null,
    "last_update_posted": "2019-03-29",
    "enrollment": null,
    "sponsor": "Esperion Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "EYPT",
    "nct_id": "NCT06683742",
    "title": "A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Wet Age Related Macular Degeneration",
      "wAMD"
    ],
    "interventions": [
      "EYP-1901",
      "Aflibercept (2.0 mg)"
    ],
    "primary_completion_date": "2026-10",
    "completion_date": "2027-10",
    "results_first_posted": null,
    "last_update_posted": "2026-01-07",
    "enrollment": null,
    "sponsor": "EyePoint Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "EYPT",
    "nct_id": "NCT05383209",
    "title": "Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Nonproliferative Diabetic Retinopathy"
    ],
    "interventions": [
      "EYP-1901",
      "Sham IVT"
    ],
    "primary_completion_date": "2024-02-12",
    "completion_date": "2024-05-06",
    "results_first_posted": "2025-07-28",
    "last_update_posted": "2025-08-15",
    "enrollment": null,
    "sponsor": "EyePoint Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "EYPT",
    "nct_id": "NCT05191706",
    "title": "Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract",
    "status": "RECRUITING",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cataract"
    ],
    "interventions": [
      "Dexamethasone",
      "Prednisolone Acetate Ophthalmic"
    ],
    "primary_completion_date": "2026-01",
    "completion_date": "2026-02",
    "results_first_posted": null,
    "last_update_posted": "2025-04-03",
    "enrollment": null,
    "sponsor": "EyePoint Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "EYPT",
    "nct_id": "NCT05550350",
    "title": "A Study to Evaluate the Efficacy and Safety of DEXYCU\u00ae for the Treatment of Ocular Pain Associated With Cataract Surgery",
    "status": "WITHDRAWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cataract"
    ],
    "interventions": [
      "Dexycu",
      "Placebo/Vehicle"
    ],
    "primary_completion_date": "2023-09",
    "completion_date": "2023-09",
    "results_first_posted": null,
    "last_update_posted": "2025-08-11",
    "enrollment": null,
    "sponsor": "EyePoint Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "EYPT",
    "nct_id": "NCT02748512",
    "title": "Utilization and Safety of the Mk II Inserter and the Safety of the FAI Insert in Non-Infectious Uveitis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-Infectious Uveitis"
    ],
    "interventions": [
      "FAI Insert administered using the Mk II inserter",
      "FAI Insert administered using the Mk I inserter"
    ],
    "primary_completion_date": "2017-08-17",
    "completion_date": "2017-08-17",
    "results_first_posted": "2020-05-01",
    "last_update_posted": "2020-05-01",
    "enrollment": null,
    "sponsor": "EyePoint Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "EYPT",
    "nct_id": "NCT05070728",
    "title": "Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal (FAI) Insert",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Uveitis",
      "Uveitis, Posterior",
      "Uveitis, Intermediate"
    ],
    "interventions": [
      "Sham Injector",
      "FAI Insert"
    ],
    "primary_completion_date": "2023-04-12",
    "completion_date": "2023-04-12",
    "results_first_posted": "2024-12-19",
    "last_update_posted": "2024-12-19",
    "enrollment": null,
    "sponsor": "EyePoint Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "EYPT",
    "nct_id": "NCT04511650",
    "title": "Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID-19",
      "Acute Respiratory Distress Syndrome (ARDS)"
    ],
    "interventions": [
      "Razuprotafib Subcutaneous Solution",
      "Placebo Subcutaneous Solution"
    ],
    "primary_completion_date": "2021-02-26",
    "completion_date": "2021-02-26",
    "results_first_posted": "2023-06-08",
    "last_update_posted": "2023-06-08",
    "enrollment": null,
    "sponsor": "EyePoint Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "EYPT",
    "nct_id": "NCT05381948",
    "title": "Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Wet Age-related Macular Degeneration"
    ],
    "interventions": [
      "EYP-1901",
      "Aflibercept 2mg/0.05mL Inj,Oph"
    ],
    "primary_completion_date": "2023-11-29",
    "completion_date": "2024-04-24",
    "results_first_posted": "2025-10-02",
    "last_update_posted": "2025-10-15",
    "enrollment": null,
    "sponsor": "EyePoint Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "EYPT",
    "nct_id": "NCT05550363",
    "title": "A Study to Evaluate the Efficacy and Safety of DEXYCU\u00ae for the Treatment of Ocular Pain Associated With Cataract Surgery (2)",
    "status": "WITHDRAWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cataract"
    ],
    "interventions": [
      "Dexycu",
      "Placebo/Vehicle"
    ],
    "primary_completion_date": "2023-09",
    "completion_date": "2023-09",
    "results_first_posted": null,
    "last_update_posted": "2024-04-03",
    "enrollment": null,
    "sponsor": "EyePoint Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "EYPT",
    "nct_id": "NCT03197870",
    "title": "The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Nonproliferative Diabetic Retinopathy"
    ],
    "interventions": [
      "AKB-9778",
      "Placebo"
    ],
    "primary_completion_date": "2019-01-09",
    "completion_date": "2019-02-09",
    "results_first_posted": "2023-06-27",
    "last_update_posted": "2023-06-27",
    "enrollment": null,
    "sponsor": "EyePoint Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "EYPT",
    "nct_id": "NCT04405245",
    "title": "Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ocular Hypertension",
      "Primary Open Angle Glaucoma"
    ],
    "interventions": [
      "Latanoprost ophthalmic solution",
      "AKB-9778 4%",
      "Placebo"
    ],
    "primary_completion_date": "2020-11-05",
    "completion_date": "2020-11-05",
    "results_first_posted": "2023-05-25",
    "last_update_posted": "2023-05-25",
    "enrollment": null,
    "sponsor": "EyePoint Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "EYPT",
    "nct_id": "NCT02746991",
    "title": "Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior Uveitis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Posterior Uveitis",
      "Intermediate Uveitis",
      "Panuveitis"
    ],
    "interventions": [
      "Sham Injection",
      "FAI Insert"
    ],
    "primary_completion_date": "2019-10-04",
    "completion_date": "2019-10-04",
    "results_first_posted": "2020-07-07",
    "last_update_posted": "2020-07-21",
    "enrollment": null,
    "sponsor": "EyePoint Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "EYPT",
    "nct_id": "NCT06099184",
    "title": "Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetic Macular Edema"
    ],
    "interventions": [
      "EYP-1901",
      "Aflibercept 2Mg/0.05Ml Inj,Oph"
    ],
    "primary_completion_date": "2024-10-24",
    "completion_date": "2024-10-24",
    "results_first_posted": null,
    "last_update_posted": "2025-03-04",
    "enrollment": null,
    "sponsor": "EyePoint Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "EYPT",
    "nct_id": "NCT04290676",
    "title": "DEXYCU (Dexamethasone Intraocular Suspension) 9% Retrospective Study 001",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Cataract"
    ],
    "interventions": [
      "DEXYCU (dexamethasone intraocular suspension) 9%."
    ],
    "primary_completion_date": "2020-05-01",
    "completion_date": "2020-05-01",
    "results_first_posted": "2021-05-26",
    "last_update_posted": "2021-05-26",
    "enrollment": null,
    "sponsor": "EyePoint Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "EYPT",
    "nct_id": "NCT06668064",
    "title": "A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Wet Age Related Macular Degeneration",
      "wAMD"
    ],
    "interventions": [
      "EYP-1901",
      "Aflibercept (2.0 mg)"
    ],
    "primary_completion_date": "2026-08",
    "completion_date": "2027-08",
    "results_first_posted": null,
    "last_update_posted": "2026-01-07",
    "enrollment": null,
    "sponsor": "EyePoint Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "EYPT",
    "nct_id": "NCT01694186",
    "title": "Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-Infectious Uveitis"
    ],
    "interventions": [
      "FAI insert",
      "Sham injection"
    ],
    "primary_completion_date": "2018-03-26",
    "completion_date": "2018-03-26",
    "results_first_posted": "2020-03-23",
    "last_update_posted": "2021-04-02",
    "enrollment": null,
    "sponsor": "EyePoint Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "EYPT",
    "nct_id": "NCT04747197",
    "title": "First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Wet Age-related Macular Degeneration"
    ],
    "interventions": [
      "EYP-1901"
    ],
    "primary_completion_date": "2022-05-11",
    "completion_date": "2022-05-11",
    "results_first_posted": null,
    "last_update_posted": "2023-07-19",
    "enrollment": null,
    "sponsor": "EyePoint Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GHRS",
    "nct_id": "NCT05757869",
    "title": "A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atrial Fibrillation"
    ],
    "interventions": [
      "Milvexian",
      "Apixaban",
      "Placebo",
      "Apixaban Placebo"
    ],
    "primary_completion_date": "2026-10-31",
    "completion_date": "2026-10-31",
    "results_first_posted": null,
    "last_update_posted": "2026-01-16",
    "enrollment": null,
    "sponsor": "Janssen Research & Development, LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GMAB",
    "nct_id": "NCT04424641",
    "title": "A Study on the Safety of GEN1044 (DuoBody\u00ae-CD3x5T4) in Patients With Malignant Solid Tumors",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Locally Advanced or Metastatic Solid Tumor(s)",
      "Prostate Cancer",
      "Esophageal Cancer",
      "Triple Negative Breast Cancer (TNBC)",
      "Squamous Cell Carcinoma of Head and Neck (SCCHN)",
      "Non-small Cell Lung Cancer (NSCLC)",
      "Bladder Cancer",
      "Uterine Cancer"
    ],
    "interventions": [
      "GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4."
    ],
    "primary_completion_date": "2021-10-29",
    "completion_date": "2021-10-29",
    "results_first_posted": "2023-02-01",
    "last_update_posted": "2023-07-25",
    "enrollment": null,
    "sponsor": "Genmab",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GMAB",
    "nct_id": "NCT05451810",
    "title": "A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diffuse Large B-Cell Lymphoma",
      "Classic Follicular Lymphoma"
    ],
    "interventions": [
      "Epcoritamab"
    ],
    "primary_completion_date": "2027-03",
    "completion_date": "2027-03",
    "results_first_posted": null,
    "last_update_posted": "2025-01-24",
    "enrollment": null,
    "sponsor": "Genmab",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GMAB",
    "nct_id": "NCT07225270",
    "title": "Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ovarian Cancer",
      "Platinum-sensitive Ovarian Cancer",
      "PSOC"
    ],
    "interventions": [
      "Rina-S",
      "Bevacizumab"
    ],
    "primary_completion_date": "2028-10",
    "completion_date": "2030-04",
    "results_first_posted": null,
    "last_update_posted": "2026-01-07",
    "enrollment": null,
    "sponsor": "Genmab",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GMAB",
    "nct_id": "NCT04623541",
    "title": "Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsed/Refractory Chronic Lymphocytic Leukemia",
      "Small Lymphocytic Lymphoma",
      "Richter's Syndrome",
      "Treatment-na\u00efve High Risk Chronic Lymphocytic Leukemia"
    ],
    "interventions": [
      "Epcoritamab",
      "Epcoritamab",
      "rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone",
      "Venetoclax",
      "Epcoritamab",
      "Lenalidomide",
      "Epcoritamab",
      "Pirtobrutinib",
      "Epcoritamab"
    ],
    "primary_completion_date": "2028-02",
    "completion_date": "2028-04",
    "results_first_posted": null,
    "last_update_posted": "2026-01-07",
    "enrollment": null,
    "sponsor": "Genmab",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GMAB",
    "nct_id": "NCT03576131",
    "title": "GEN1029 (HexaBody\u00ae-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Colorectal Cancer",
      "Non-small Cell Lung Cancer",
      "Triple Negative Breast Cancer",
      "Renal Cell Carcinoma",
      "Gastric Cancer",
      "Pancreatic Cancer",
      "Urothelial Cancer"
    ],
    "interventions": [
      "GEN1029 (HexaBody\u00ae-DR5/DR5)"
    ],
    "primary_completion_date": "2021-10-12",
    "completion_date": "2021-10-12",
    "results_first_posted": "2022-12-12",
    "last_update_posted": "2023-08-01",
    "enrollment": null,
    "sponsor": "Genmab",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GMAB",
    "nct_id": "NCT06508658",
    "title": "A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diffuse Large B-Cell Lymphoma"
    ],
    "interventions": [
      "Epcoritamab",
      "Rituximab",
      "Lenalidomide",
      "Oxaliplatin",
      "Gemcitabine"
    ],
    "primary_completion_date": "2028-01",
    "completion_date": "2028-01",
    "results_first_posted": null,
    "last_update_posted": "2026-01-07",
    "enrollment": null,
    "sponsor": "Genmab",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GMAB",
    "nct_id": "NCT05586321",
    "title": "Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor, Adult"
    ],
    "interventions": [
      "GEN1056"
    ],
    "primary_completion_date": "2025-10-23",
    "completion_date": "2025-10-23",
    "results_first_posted": null,
    "last_update_posted": "2025-11-24",
    "enrollment": null,
    "sponsor": "Genmab",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GMAB",
    "nct_id": "NCT00542308",
    "title": "Zalutumumab in Non-curable Patients With SCCHN",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Head and Neck Cancer",
      "Squamous Cell Cancer"
    ],
    "interventions": [
      "Zalutumumab"
    ],
    "primary_completion_date": "2011-08",
    "completion_date": "2011-08",
    "results_first_posted": "2014-08-27",
    "last_update_posted": "2023-08-03",
    "enrollment": null,
    "sponsor": "Genmab",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GMAB",
    "nct_id": "NCT06984328",
    "title": "Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cutaneous Melanoma",
      "Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID)",
      "Metastatic Cutaneous Melanoma (Stage IV)"
    ],
    "interventions": [
      "Acasunlimab",
      "Pembrolizumab"
    ],
    "primary_completion_date": "2027-07-15",
    "completion_date": "2029-07-15",
    "results_first_posted": null,
    "last_update_posted": "2026-01-12",
    "enrollment": null,
    "sponsor": "Genmab",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GMAB",
    "nct_id": "NCT06619236",
    "title": "Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Platinum-resistant Ovarian Cancer"
    ],
    "interventions": [
      "Rina-S",
      "Paclitaxel",
      "Topotecan",
      "Pegylated liposomal doxorubicin (PLD)",
      "Gemcitabine"
    ],
    "primary_completion_date": "2027-02",
    "completion_date": "2028-05-23",
    "results_first_posted": null,
    "last_update_posted": "2026-01-06",
    "enrollment": null,
    "sponsor": "Genmab",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GMAB",
    "nct_id": "NCT07288177",
    "title": "Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-small Cell Lung Cancer (NSCLC)"
    ],
    "interventions": [
      "Rina-S"
    ],
    "primary_completion_date": "2027-11-22",
    "completion_date": "2028-11-22",
    "results_first_posted": null,
    "last_update_posted": "2026-01-23",
    "enrollment": null,
    "sponsor": "Genmab",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GMAB",
    "nct_id": "NCT03625037",
    "title": "First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "DLBCL",
      "High-grade B-cell Lymphoma (HGBCL)",
      "Primary Mediastinal Large B-cell Lymphoma (PMBCL)",
      "FL",
      "MCL",
      "Small Lymphocytic Lymphoma (SLL)",
      "Marginal Zone Lymphoma (MZL)",
      "Indolent B-cell Non-Hodgkin Lymphoma (iNHL)",
      "Aggressive B-cell Non-Hodgkin Lymphoma (aNHL)"
    ],
    "interventions": [
      "Epcoritamab"
    ],
    "primary_completion_date": "2029-01",
    "completion_date": "2029-01",
    "results_first_posted": null,
    "last_update_posted": "2026-01-07",
    "enrollment": null,
    "sponsor": "Genmab",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GMAB",
    "nct_id": "NCT06057038",
    "title": "A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Malignant Solid Tumor"
    ],
    "interventions": [
      "GEN1042",
      "Pembrolizumab",
      "Cisplatin",
      "Carboplatin",
      "5-Fluorouracil"
    ],
    "primary_completion_date": "2026-11-28",
    "completion_date": "2026-11-28",
    "results_first_posted": null,
    "last_update_posted": "2026-01-06",
    "enrollment": null,
    "sponsor": "Genmab",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GMAB",
    "nct_id": "NCT04663347",
    "title": "Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diffuse Large B-Cell Lymphoma",
      "Follicular Lymphoma"
    ],
    "interventions": [
      "rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone",
      "rituximab and lenalidomide",
      "rituximab and bendamustine",
      "rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin",
      "gemcitabine and oxaliplatin",
      "Epcoritamab",
      "rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone",
      "Lenalidomide",
      "rituximab, ifosfamide, carboplatin, and etoposide phosphate",
      "Epcoritamab",
      "Epcoritamab",
      "Epcoritamab",
      "Epcoritamab",
      "Epcoritamab",
      "Epcoritamab",
      "Epcoritamab",
      "Rituximab and Lenalidomide",
      "Epcoritamab"
    ],
    "primary_completion_date": "2027-09-30",
    "completion_date": "2027-09-30",
    "results_first_posted": null,
    "last_update_posted": "2026-01-09",
    "enrollment": null,
    "sponsor": "Genmab",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GMAB",
    "nct_id": "NCT07166094",
    "title": "Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Endometrial Cancer",
      "Recurrent or Progressive Endometrial Cancer"
    ],
    "interventions": [
      "Rina-S",
      "IC"
    ],
    "primary_completion_date": "2028-11",
    "completion_date": "2029-02",
    "results_first_posted": null,
    "last_update_posted": "2026-01-06",
    "enrollment": null,
    "sponsor": "Genmab",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GMAB",
    "nct_id": "NCT05579366",
    "title": "Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "High Grade Epithelial Ovarian Cancer",
      "High Grade Serous Ovarian Cancer",
      "Primary Peritoneal Carcinoma",
      "Fallopian Tube Cancer",
      "Endometrial Cancer",
      "Non-small Cell Lung Cancer",
      "Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC)",
      "Mesothelioma",
      "Breast Adenocarcinoma",
      "Triple Negative Breast Cancer",
      "Hormone Receptor-positive/Her2 Negative Breast Cancer",
      "Platinum-resistant Ovarian Cancer (PROC)",
      "Platinum Sensitive Ovarian Cancer (PSOC)",
      "Primary Refractory Ovarian Cancer",
      "Uterine Cancer"
    ],
    "interventions": [
      "Rina-S",
      "Carboplatin",
      "Bevacizumab",
      "Pembrolizumab"
    ],
    "primary_completion_date": "2027-07",
    "completion_date": "2027-10",
    "results_first_posted": null,
    "last_update_posted": "2026-01-07",
    "enrollment": null,
    "sponsor": "Genmab",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GRAL",
    "nct_id": "NCT05205967",
    "title": "REFLECTION: A Clinical Practice Learning Program for Galleri\u00ae",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Early Detection of Cancer",
      "Cancer"
    ],
    "interventions": [
      "MCED",
      "SOC"
    ],
    "primary_completion_date": "2025-09-30",
    "completion_date": "2026-10-30",
    "results_first_posted": null,
    "last_update_posted": "2025-11-26",
    "enrollment": null,
    "sponsor": "GRAIL, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GRAL",
    "nct_id": "NCT02889978",
    "title": "The Circulating Cell-free Genome Atlas Study",
    "status": "UNKNOWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Neoplasms",
      "Cancer"
    ],
    "interventions": [],
    "primary_completion_date": "2024-03",
    "completion_date": "2024-03",
    "results_first_posted": null,
    "last_update_posted": "2023-09-13",
    "enrollment": null,
    "sponsor": "GRAIL, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GRAL",
    "nct_id": "NCT05673018",
    "title": "Galleri\u00ae in the Medicare Population.",
    "status": "RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cancer"
    ],
    "interventions": [
      "Multi-Cancer Early Detection Test (Galleri\u00ae)"
    ],
    "primary_completion_date": "2030-09",
    "completion_date": "2030-09",
    "results_first_posted": null,
    "last_update_posted": "2025-12-01",
    "enrollment": null,
    "sponsor": "GRAIL, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GRAL",
    "nct_id": "NCT03085888",
    "title": "The STRIVE Study: Development of a Blood Test for Early Detection of Multiple Cancer Types",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Neoplasms",
      "Cancer"
    ],
    "interventions": [],
    "primary_completion_date": "2022-06-30",
    "completion_date": "2024-04-01",
    "results_first_posted": null,
    "last_update_posted": "2024-09-20",
    "enrollment": null,
    "sponsor": "GRAIL, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GRAL",
    "nct_id": "NCT04241796",
    "title": "Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test Into Clinical Practice",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cancer"
    ],
    "interventions": [
      "Multi-Cancer Early Detection Test"
    ],
    "primary_completion_date": "2021-12-01",
    "completion_date": "2022-01-05",
    "results_first_posted": null,
    "last_update_posted": "2022-10-25",
    "enrollment": null,
    "sponsor": "GRAIL, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GRAL",
    "nct_id": "NCT05611632",
    "title": "Does Screening With the Galleri Test in the NHS Reduce the Likelihood of a Late-stage Cancer Diagnosis in an Asymptomatic Population? A Randomised Clinical Trial",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cancer"
    ],
    "interventions": [
      "Multi-cancer early detection test (Galleri test)"
    ],
    "primary_completion_date": "2026-06",
    "completion_date": "2030-07",
    "results_first_posted": null,
    "last_update_posted": "2025-02-14",
    "enrollment": null,
    "sponsor": "GRAIL, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GRAL",
    "nct_id": "NCT06603259",
    "title": "The Galleri\u00ae Community Research Program",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Data Collection"
    ],
    "interventions": [],
    "primary_completion_date": "2025-12",
    "completion_date": "2025-12",
    "results_first_posted": null,
    "last_update_posted": "2024-09-19",
    "enrollment": null,
    "sponsor": "GRAIL, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GRFS",
    "nct_id": "NCT00323856",
    "title": "Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Severe Hemophilia A"
    ],
    "interventions": [
      "Alphanate SD/HT"
    ],
    "primary_completion_date": "2018-12-11",
    "completion_date": "2018-12-14",
    "results_first_posted": "2022-06-09",
    "last_update_posted": "2025-01-16",
    "enrollment": null,
    "sponsor": "Grifols Biologicals, LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "GRFS",
    "nct_id": "NCT01983241",
    "title": "Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pulmonary Emphysema in Alpha-1 PI Deficiency"
    ],
    "interventions": [
      "Alpha-1 MP",
      "0.9% Sodium Chloride for Injection, USP"
    ],
    "primary_completion_date": "2026-08",
    "completion_date": "2027-01",
    "results_first_posted": null,
    "last_update_posted": "2025-01-15",
    "enrollment": null,
    "sponsor": "Grifols Therapeutics LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "HRTX",
    "nct_id": "NCT03705065",
    "title": "Bupivacaine HCl PK and Safety in Augmentation Mammoplasty",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Analgesia"
    ],
    "interventions": [
      "Bupivacaine HCl"
    ],
    "primary_completion_date": "2018-10-08",
    "completion_date": "2018-11-05",
    "results_first_posted": null,
    "last_update_posted": "2018-12-07",
    "enrollment": null,
    "sponsor": "Heron Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "HRTX",
    "nct_id": "NCT04470622",
    "title": "Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID-19"
    ],
    "interventions": [
      "Aprepitant injectable emulsion",
      "Saline Placebo"
    ],
    "primary_completion_date": "2021-04-09",
    "completion_date": "2021-06-03",
    "results_first_posted": "2022-08-30",
    "last_update_posted": "2022-08-30",
    "enrollment": null,
    "sponsor": "Heron Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "HRTX",
    "nct_id": "NCT02106494",
    "title": "A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chemotherapy-induced Nausea and Vomiting"
    ],
    "interventions": [
      "APF530",
      "Ondansetron",
      "Ondansetron placebo",
      "APF530 placebo",
      "Fosaprepitant",
      "Dexamethasone"
    ],
    "primary_completion_date": "2015-05",
    "completion_date": "2015-05",
    "results_first_posted": "2016-12-28",
    "last_update_posted": "2016-12-28",
    "enrollment": null,
    "sponsor": "Heron Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "HRTX",
    "nct_id": "NCT06109428",
    "title": "A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Analgesia"
    ],
    "interventions": [
      "HTX-011",
      "Bupivacaine Hydrochloride",
      "Ibuprofen",
      "Acetaminophen",
      "Luer lock applicator"
    ],
    "primary_completion_date": "2022-03-29",
    "completion_date": "2022-04-07",
    "results_first_posted": null,
    "last_update_posted": "2023-10-31",
    "enrollment": null,
    "sponsor": "Heron Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "HRTX",
    "nct_id": "NCT03974932",
    "title": "Total Knee Arthroplasty (TKA) Study of HTX-011 in an Multimodal Analgesic Regimen (MMA) Regimen",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Analgesia"
    ],
    "interventions": [
      "HTX-011",
      "Ibuprofen",
      "Acetaminophen",
      "Celecoxib",
      "+/- Bupivacaine HCl",
      "Luer Lock Applicator",
      "HTX-011"
    ],
    "primary_completion_date": "2020-12-07",
    "completion_date": "2021-01-07",
    "results_first_posted": "2023-08-31",
    "last_update_posted": "2023-08-31",
    "enrollment": null,
    "sponsor": "Heron Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "HRTX",
    "nct_id": "NCT03922048",
    "title": "Pediatric Postoperative Analgesia Herniorrhaphy Study",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Analgesia"
    ],
    "interventions": [
      "HTX-011",
      "Bupivacaine HCl",
      "HTX-011",
      "HTX-011",
      "HTX-011",
      "Luer Lock Applicator"
    ],
    "primary_completion_date": "2025-11",
    "completion_date": "2025-12",
    "results_first_posted": null,
    "last_update_posted": "2023-06-05",
    "enrollment": null,
    "sponsor": "Heron Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "HRTX",
    "nct_id": "NCT03011333",
    "title": "Phase 2B Upper Extremity Nerve Block Study",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Postoperative Pain"
    ],
    "interventions": [
      "HTX-011",
      "Bupivacaine HCl without epinephrine",
      "Saline Placebo"
    ],
    "primary_completion_date": "2018-02-01",
    "completion_date": "2018-03-19",
    "results_first_posted": "2021-10-29",
    "last_update_posted": "2025-03-07",
    "enrollment": null,
    "sponsor": "Heron Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "HRTX",
    "nct_id": "NCT04911062",
    "title": "HTX-011 in Spinal Surgery",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Post-Operative Pain",
      "Lumbar Laminectomy"
    ],
    "interventions": [
      "Bupivacaine HCI without epinephrine",
      "HTX-011",
      "Luer Lock Applicator"
    ],
    "primary_completion_date": "2022-07-29",
    "completion_date": "2022-08-26",
    "results_first_posted": null,
    "last_update_posted": "2023-06-12",
    "enrollment": null,
    "sponsor": "Heron Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "HRTX",
    "nct_id": "NCT00343460",
    "title": "APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Nausea and Vomiting",
      "Unspecified Adult Solid Tumor, Protocol Specific"
    ],
    "interventions": [
      "APF530",
      "dexamethasone",
      "Palonosetron Hydrochloride",
      "placebo"
    ],
    "primary_completion_date": "2008-09",
    "completion_date": "2009-02",
    "results_first_posted": "2016-12-28",
    "last_update_posted": "2017-02-23",
    "enrollment": null,
    "sponsor": "Heron Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "HRTX",
    "nct_id": "NCT06668987",
    "title": "A Study of the Boron Neutron Capture Therapy (BNCT) Using B10 L-BPA in Recurrent Meningioma",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Meningioma",
      "Boron Neutron Capture Therapy"
    ],
    "interventions": [
      "B10 L-BPA Injection"
    ],
    "primary_completion_date": "2026-06",
    "completion_date": "2026-12",
    "results_first_posted": null,
    "last_update_posted": "2025-06-12",
    "enrollment": null,
    "sponsor": "Heron Neutron Medical Corp.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "HRTX",
    "nct_id": "NCT02471898",
    "title": "A Phase 2, Two-Part Evaluation of the Efficacy and Safety of Locally Administered HTX-011 for Postoperative Analgesia Following Bunionectomy",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Analgesia"
    ],
    "interventions": [
      "HTX-011",
      "Placebo"
    ],
    "primary_completion_date": "2015-09",
    "completion_date": "2015-09",
    "results_first_posted": null,
    "last_update_posted": "2017-02-14",
    "enrollment": null,
    "sponsor": "Heron Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "HRTX",
    "nct_id": "NCT02689258",
    "title": "Evaluation of the Efficacy and Safety of HTX-011 for Postoperative Analgesia Following Abdominoplasty Surgery",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Postoperative Pain"
    ],
    "interventions": [
      "HTX-011B",
      "Placebo",
      "HTX-011A",
      "HTX-002",
      "Bupivicaine HCl"
    ],
    "primary_completion_date": "2017-03",
    "completion_date": "2017-04",
    "results_first_posted": "2023-10-04",
    "last_update_posted": "2023-10-04",
    "enrollment": null,
    "sponsor": "Heron Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "HRTX",
    "nct_id": "NCT03718039",
    "title": "Phase 2 Bunionectomy HTX-011 Administration Study",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Postoperative Pain"
    ],
    "interventions": [
      "HTX-011",
      "Luer Lock applicator",
      "Vial access device",
      "aprepitant"
    ],
    "primary_completion_date": "2019-01-31",
    "completion_date": "2019-03-11",
    "results_first_posted": "2023-06-26",
    "last_update_posted": "2023-06-26",
    "enrollment": null,
    "sponsor": "Heron Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "HRTX",
    "nct_id": "NCT04398329",
    "title": "Dose-Escalation Study of HTX-034 Following Bunionectomy",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bunions"
    ],
    "interventions": [
      "HTX-034",
      "HTX-034",
      "Luer lock applicator",
      "Bupivacaine HCl"
    ],
    "primary_completion_date": "2021-07-01",
    "completion_date": "2021-08-03",
    "results_first_posted": null,
    "last_update_posted": "2022-02-15",
    "enrollment": null,
    "sponsor": "Heron Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "HRTX",
    "nct_id": "NCT05434663",
    "title": "Safety Study of Repeat Doses of SUSTOL in Adults",
    "status": "UNKNOWN",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chemotherapy-Induced Nausea and Vomiting (CINV)"
    ],
    "interventions": [
      "SUSTOL"
    ],
    "primary_completion_date": "2025-10",
    "completion_date": "2025-10",
    "results_first_posted": null,
    "last_update_posted": "2023-07-28",
    "enrollment": null,
    "sponsor": "Heron Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "HRTX",
    "nct_id": "NCT04047537",
    "title": "Placebo-Controlled Clinical Nutrition Study of the Metabolic Effects of Food Product WBF-0011 in Type 2 Diabetes",
    "status": "TERMINATED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 2 Diabetes Mellitus"
    ],
    "interventions": [
      "Medical Food Formulation 1",
      "Medical Food Formulation 2",
      "Placebo"
    ],
    "primary_completion_date": "2020-04-15",
    "completion_date": "2020-05-30",
    "results_first_posted": null,
    "last_update_posted": "2022-05-06",
    "enrollment": null,
    "sponsor": "Pendulum Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "HRTX",
    "nct_id": "NCT03015532",
    "title": "Total Knee Arthroplasty Infiltration Study for Postoperative Analgesia",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Postoperative Pain"
    ],
    "interventions": [
      "HTX-011",
      "Saline Placebo",
      "Bupivicaine HCl",
      "Ropivacaine"
    ],
    "primary_completion_date": "2018-04-20",
    "completion_date": "2018-05-16",
    "results_first_posted": "2021-10-27",
    "last_update_posted": "2025-03-07",
    "enrollment": null,
    "sponsor": "Heron Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "HRTX",
    "nct_id": "NCT03237481",
    "title": "Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Postoperative Pain"
    ],
    "interventions": [
      "HTX-011",
      "Bupivacaine HCl",
      "Saline placebo",
      "Luer-lock applicator",
      "Vial access device"
    ],
    "primary_completion_date": "2017-12-22",
    "completion_date": "2018-01-16",
    "results_first_posted": "2021-10-27",
    "last_update_posted": "2025-03-07",
    "enrollment": null,
    "sponsor": "Heron Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "HRTX",
    "nct_id": "NCT03295721",
    "title": "Bunionectomy Study for Postoperative Analgesia (EPOCH 1)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Postoperative Pain"
    ],
    "interventions": [
      "HTX-011",
      "Saline Placebo",
      "Bupivacaine HCl",
      "Luer-lock applicator",
      "Vial access device"
    ],
    "primary_completion_date": "2018-01-08",
    "completion_date": "2018-03-13",
    "results_first_posted": "2021-10-27",
    "last_update_posted": "2025-03-07",
    "enrollment": null,
    "sponsor": "Heron Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "HRTX",
    "nct_id": "NCT04102267",
    "title": "Extended Delivery of Bupivacaine Study in Herniorrhaphy",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Analgesia"
    ],
    "interventions": [
      "Bupivacaine liposome injectable suspension",
      "Bupivacaine HCl without epinephrine via continuous infusion"
    ],
    "primary_completion_date": "2018-09-03",
    "completion_date": "2018-10-26",
    "results_first_posted": null,
    "last_update_posted": "2019-09-26",
    "enrollment": null,
    "sponsor": "Heron Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "HRTX",
    "nct_id": "NCT02504580",
    "title": "A Pilot Study to Investigate the Safety, Efficacy, Pharmacokinetics and Bioavailability of HTX-011, HTX-002, or HTX-009 Administered Via Injection and/or Topical Application Following Unilateral Open Inguinal Herniorrhaphy",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Postoperative Pain"
    ],
    "interventions": [
      "HTX-011",
      "Placebo",
      "HTX-002",
      "Bupivacaine HCI (Marcaine)",
      "HTX-011A",
      "HTX-011B",
      "HTX-009"
    ],
    "primary_completion_date": "2017-03",
    "completion_date": "2017-04",
    "results_first_posted": "2023-10-04",
    "last_update_posted": "2023-10-04",
    "enrollment": null,
    "sponsor": "Heron Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "HRTX",
    "nct_id": "NCT03695367",
    "title": "Phase 2 Herniorrhaphy Study for Opioid Elimination",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Postoperative Pain"
    ],
    "interventions": [
      "HTX-011",
      "Luer lock applicator",
      "Vial access device",
      "Ibuprofen",
      "Acetaminophen",
      "Ketorolac"
    ],
    "primary_completion_date": "2018-11-20",
    "completion_date": "2018-12-15",
    "results_first_posted": "2021-07-02",
    "last_update_posted": "2021-10-25",
    "enrollment": null,
    "sponsor": "Heron Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "HRTX",
    "nct_id": "NCT05109312",
    "title": "A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE. Master Protocol HTX-011-401.",
    "status": "UNKNOWN",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Analgesia"
    ],
    "interventions": [
      "Bupivacaine Hydrochloride",
      "Bupivacaine Hydrochloride",
      "HTX-011",
      "Luer lock applicator",
      "Ibuprofen",
      "Acetaminophen"
    ],
    "primary_completion_date": "2024-06",
    "completion_date": "2024-06",
    "results_first_posted": null,
    "last_update_posted": "2023-10-26",
    "enrollment": null,
    "sponsor": "Heron Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "IMMP",
    "nct_id": "NCT06726265",
    "title": "Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)"
    ],
    "interventions": [
      "eftilagimod alfa",
      "carboplatin plus paclitaxel",
      "cisplatin or carboplatin + pemetrexed",
      "pembrolizumab (KEYTRUDA\u00ae)",
      "Placebo"
    ],
    "primary_completion_date": "2027-06",
    "completion_date": "2029-09",
    "results_first_posted": null,
    "last_update_posted": "2026-01-27",
    "enrollment": null,
    "sponsor": "Immutep S.A.S.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "IMMP",
    "nct_id": "NCT05747794",
    "title": "Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination with Paclitaxel Chemotherapy",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Carcinoma"
    ],
    "interventions": [
      "eftilagimod alpha",
      "Paclitaxel",
      "placebo"
    ],
    "primary_completion_date": "2026-10-31",
    "completion_date": "2027-07-31",
    "results_first_posted": null,
    "last_update_posted": "2024-12-17",
    "enrollment": null,
    "sponsor": "Immutep S.A.S.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "IMVT",
    "nct_id": "NCT06980805",
    "title": "A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Subacute Cutaneous Lupus Erythematosus",
      "Chronic Cutaneous Lupus Erythematosus"
    ],
    "interventions": [
      "IMVT-1402",
      "Placebo"
    ],
    "primary_completion_date": "2027-04",
    "completion_date": "2027-04",
    "results_first_posted": null,
    "last_update_posted": "2025-12-26",
    "enrollment": null,
    "sponsor": "Immunovant Sciences GmbH",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "IMVT",
    "nct_id": "NCT07286006",
    "title": "A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Graves' Disease"
    ],
    "interventions": [
      "IMVT-1402"
    ],
    "primary_completion_date": "2030-03",
    "completion_date": "2030-03",
    "results_first_posted": null,
    "last_update_posted": "2025-12-16",
    "enrollment": null,
    "sponsor": "Immunovant Sciences GmbH",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "IMVT",
    "nct_id": "NCT03938545",
    "title": "ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Graves' Ophthalmopathy (GO)"
    ],
    "interventions": [
      "RVT-1401 (Administered via subcutaneous injection)",
      "Placebo (Administered via subcutaneous injection)"
    ],
    "primary_completion_date": "2021-02-02",
    "completion_date": "2021-04-15",
    "results_first_posted": "2022-09-22",
    "last_update_posted": "2022-09-22",
    "enrollment": null,
    "sponsor": "Immunovant Sciences GmbH",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "IMVT",
    "nct_id": "NCT05403541",
    "title": "Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Generalized Myasthenia Gravis"
    ],
    "interventions": [
      "Batoclimab 680 mg SC weekly",
      "Batoclimab 340 mg SC weekly",
      "Matching Placebo SC",
      "Batoclimab 340 mg SC bi-weekly"
    ],
    "primary_completion_date": "2025-03",
    "completion_date": "2025-04",
    "results_first_posted": null,
    "last_update_posted": "2024-08-07",
    "enrollment": null,
    "sponsor": "Immunovant Sciences GmbH",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "IMVT",
    "nct_id": "NCT07039916",
    "title": "Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Generalized Myasthenia Gravis"
    ],
    "interventions": [
      "IMVT-1402",
      "IMVT-1402",
      "Placebo",
      "IMVT-1402"
    ],
    "primary_completion_date": "2027-12",
    "completion_date": "2028-12",
    "results_first_posted": null,
    "last_update_posted": "2025-12-26",
    "enrollment": null,
    "sponsor": "Immunovant Sciences GmbH",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "IMVT",
    "nct_id": "NCT05907668",
    "title": "A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Graves Disease"
    ],
    "interventions": [
      "IMVT-1401 (batoclimab)"
    ],
    "primary_completion_date": "2025-07",
    "completion_date": "2025-07",
    "results_first_posted": null,
    "last_update_posted": "2025-05-15",
    "enrollment": null,
    "sponsor": "Immunovant Sciences GmbH",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "IMVT",
    "nct_id": "NCT05517447",
    "title": "Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Thyroid Eye Disease"
    ],
    "interventions": [
      "Observational cohort study",
      "Batoclimab"
    ],
    "primary_completion_date": "2026-08",
    "completion_date": "2026-08",
    "results_first_posted": null,
    "last_update_posted": "2025-10-20",
    "enrollment": null,
    "sponsor": "Immunovant Sciences GmbH",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "IMVT",
    "nct_id": "NCT04253236",
    "title": "To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA).",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Warm Autoimmune Hemolytic Anemia"
    ],
    "interventions": [
      "RVT-1401 680 mg/weekly",
      "RVT-1401 340 mg/weekly"
    ],
    "primary_completion_date": "2021-04-01",
    "completion_date": "2021-04-01",
    "results_first_posted": "2022-07-28",
    "last_update_posted": "2022-07-28",
    "enrollment": null,
    "sponsor": "Immunovant Sciences GmbH",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "IMVT",
    "nct_id": "NCT05581199",
    "title": "To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Inflammatory Demyelinating Polyneuropathy"
    ],
    "interventions": [
      "Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly",
      "Batoclimab 340 mg SC weekly",
      "Placebo"
    ],
    "primary_completion_date": "2026-01",
    "completion_date": "2027-01",
    "results_first_posted": null,
    "last_update_posted": "2024-11-25",
    "enrollment": null,
    "sponsor": "Immunovant Sciences GmbH",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "IMVT",
    "nct_id": "NCT07188844",
    "title": "An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Inflammatory Demyelinating Polyneuropathy"
    ],
    "interventions": [
      "Batoclimab"
    ],
    "primary_completion_date": "2028-11",
    "completion_date": "2028-11",
    "results_first_posted": null,
    "last_update_posted": "2025-12-26",
    "enrollment": null,
    "sponsor": "Immunovant Sciences GmbH",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "IMVT",
    "nct_id": "NCT07018323",
    "title": "A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Graves' Disease"
    ],
    "interventions": [
      "IMVT-1402",
      "IMVT-1402",
      "Placebo"
    ],
    "primary_completion_date": "2027-05",
    "completion_date": "2027-05",
    "results_first_posted": null,
    "last_update_posted": "2026-01-26",
    "enrollment": null,
    "sponsor": "Immunovant Sciences GmbH",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "IMVT",
    "nct_id": "NCT03922321",
    "title": "Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Graves' Ophthalmopathy"
    ],
    "interventions": [
      "RVT-1401"
    ],
    "primary_completion_date": "2020-02-29",
    "completion_date": "2020-05-21",
    "results_first_posted": "2022-01-24",
    "last_update_posted": "2022-01-24",
    "enrollment": null,
    "sponsor": "Immunovant Sciences GmbH",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "IMVT",
    "nct_id": "NCT05524571",
    "title": "Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Thyroid Eye Disease"
    ],
    "interventions": [
      "Batoclimab",
      "Placebo"
    ],
    "primary_completion_date": "2026-03",
    "completion_date": "2026-03",
    "results_first_posted": null,
    "last_update_posted": "2025-12-26",
    "enrollment": null,
    "sponsor": "Immunovant Sciences GmbH",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "IMVT",
    "nct_id": "NCT07032662",
    "title": "IMVT-1402 in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Inflammatory Demyelinating Polyneuropathy"
    ],
    "interventions": [
      "IMVT-1402",
      "Placebo"
    ],
    "primary_completion_date": "2028-08",
    "completion_date": "2030-05",
    "results_first_posted": null,
    "last_update_posted": "2026-01-20",
    "enrollment": null,
    "sponsor": "Immunovant Sciences GmbH",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "IMVT",
    "nct_id": "NCT05517421",
    "title": "Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Thyroid Eye Disease"
    ],
    "interventions": [
      "Batoclimab",
      "Placebo"
    ],
    "primary_completion_date": "2025-11-02",
    "completion_date": "2025-11-18",
    "results_first_posted": null,
    "last_update_posted": "2025-12-03",
    "enrollment": null,
    "sponsor": "Immunovant Sciences GmbH",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "IMVT",
    "nct_id": "NCT06727604",
    "title": "A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Graves' Disease"
    ],
    "interventions": [
      "IMVT-1402",
      "IMVT-1402",
      "Placebo"
    ],
    "primary_completion_date": "2028-06",
    "completion_date": "2028-06",
    "results_first_posted": null,
    "last_update_posted": "2026-01-20",
    "enrollment": null,
    "sponsor": "Immunovant Sciences GmbH",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "IMVT",
    "nct_id": "NCT06754462",
    "title": "A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rheumatoid Arthritis"
    ],
    "interventions": [
      "IMVT-1402",
      "Placebo"
    ],
    "primary_completion_date": "2027-09",
    "completion_date": "2027-09",
    "results_first_posted": null,
    "last_update_posted": "2025-12-12",
    "enrollment": null,
    "sponsor": "Immunovant Sciences GmbH",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "IMVT",
    "nct_id": "NCT03863080",
    "title": "A Study of RVT-1401 in Myasthenia Gravis (MG) Patients",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Myasthenia Gravis"
    ],
    "interventions": [
      "RVT-1401",
      "Placebo"
    ],
    "primary_completion_date": "2020-10-07",
    "completion_date": "2020-12-21",
    "results_first_posted": "2023-12-20",
    "last_update_posted": "2023-12-20",
    "enrollment": null,
    "sponsor": "Immunovant Sciences GmbH",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "IMVT",
    "nct_id": "NCT06979531",
    "title": "Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Primary Sj\u00f6gren's Syndrome"
    ],
    "interventions": [
      "IMVT-1402",
      "Placebo"
    ],
    "primary_completion_date": "2028-07",
    "completion_date": "2028-07",
    "results_first_posted": null,
    "last_update_posted": "2026-01-20",
    "enrollment": null,
    "sponsor": "Immunovant Sciences GmbH",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "INVA",
    "nct_id": "NCT06746883",
    "title": "A Study to Assess the Safety and Risk of Hypersensitivity Reactions of Sulbactam-durlobactam in Adults With Acinetobacter Baumannii-calcoaceticus (ABC) Complex Infection",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)"
    ],
    "interventions": [
      "Non-interventional"
    ],
    "primary_completion_date": "2029-01-31",
    "completion_date": "2029-01-31",
    "results_first_posted": null,
    "last_update_posted": "2025-11-19",
    "enrollment": null,
    "sponsor": "Innoviva Specialty Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "INVA",
    "nct_id": "NCT06801223",
    "title": "A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)"
    ],
    "interventions": [
      "Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours)",
      "Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours)",
      "Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 8 hours)",
      "Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 12 hours)"
    ],
    "primary_completion_date": "2028-05-05",
    "completion_date": "2028-05-20",
    "results_first_posted": null,
    "last_update_posted": "2026-01-12",
    "enrollment": null,
    "sponsor": "Innoviva Specialty Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "IVVD",
    "nct_id": "NCT05791318",
    "title": "A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of the Monoclonal Antibody VYD222 in Healthy Adult Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID-19"
    ],
    "interventions": [
      "VYD222",
      "Placebo"
    ],
    "primary_completion_date": "2024-05-08",
    "completion_date": "2024-05-08",
    "results_first_posted": null,
    "last_update_posted": "2024-05-31",
    "enrollment": null,
    "sponsor": "Invivyd, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "IVVD",
    "nct_id": "NCT04859517",
    "title": "Evaluation of ADG20 for the Prevention of COVID-19",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID-19"
    ],
    "interventions": [
      "ADG20",
      "Placebo"
    ],
    "primary_completion_date": "2022-11-04",
    "completion_date": "2022-11-04",
    "results_first_posted": "2024-08-20",
    "last_update_posted": "2024-08-20",
    "enrollment": null,
    "sponsor": "Invivyd, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "IVVD",
    "nct_id": "NCT07298434",
    "title": "Study of VYD2311 for the Prevention of COVID-19",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID-19"
    ],
    "interventions": [
      "VYD2311-SD",
      "VYD2311-MD",
      "Placebo"
    ],
    "primary_completion_date": "2026-03",
    "completion_date": "2026-06",
    "results_first_posted": null,
    "last_update_posted": "2026-01-26",
    "enrollment": null,
    "sponsor": "Invivyd, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "IVVD",
    "nct_id": "NCT04805671",
    "title": "Evaluation of ADG20 for the Treatment of Mild or Moderate COVID-19",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID-19"
    ],
    "interventions": [
      "ADG20",
      "Normal saline"
    ],
    "primary_completion_date": "2022-02-10",
    "completion_date": "2022-11-03",
    "results_first_posted": "2024-02-06",
    "last_update_posted": "2024-02-06",
    "enrollment": null,
    "sponsor": "Invivyd, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "IVVD",
    "nct_id": "NCT06004128",
    "title": "Provide Pre-approval Single-patient Expanded Access (Compassionate Use) of VYD222 for Patients With Symptomatic COVID-19 Refractory to Other Treatments",
    "status": "NO_LONGER_AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "COVID-19"
    ],
    "interventions": [
      "VYD222"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2024-06-03",
    "enrollment": null,
    "sponsor": "Invivyd, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "IVVD",
    "nct_id": "NCT06039449",
    "title": "A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID-19",
      "SARS-CoV-2"
    ],
    "interventions": [
      "VYD222 (pemivibart)",
      "Normal saline"
    ],
    "primary_completion_date": "2024-11-19",
    "completion_date": "2024-11-19",
    "results_first_posted": null,
    "last_update_posted": "2024-12-09",
    "enrollment": null,
    "sponsor": "Invivyd, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "IVVD",
    "nct_id": "NCT06523153",
    "title": "A Study of the Investigational Monoclonal Antibody, VYD2311, in Healthy Participants",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID-19"
    ],
    "interventions": [
      "VYD2311",
      "Placebo"
    ],
    "primary_completion_date": "2025-05",
    "completion_date": "2025-05",
    "results_first_posted": null,
    "last_update_posted": "2024-11-19",
    "enrollment": null,
    "sponsor": "Invivyd, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KALV",
    "nct_id": "NCT03466099",
    "title": "Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetic Macular Edema"
    ],
    "interventions": [
      "KVD001 Injection",
      "Sham Procedure"
    ],
    "primary_completion_date": "2019-10-10",
    "completion_date": "2019-10-10",
    "results_first_posted": "2020-12-08",
    "last_update_posted": "2021-01-28",
    "enrollment": null,
    "sponsor": "KalVista Pharmaceuticals, Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KALV",
    "nct_id": "NCT02193113",
    "title": "A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetic Macular Edema"
    ],
    "interventions": [
      "KVD001 Injection"
    ],
    "primary_completion_date": "2015-06-04",
    "completion_date": "2015-06-04",
    "results_first_posted": null,
    "last_update_posted": "2017-03-03",
    "enrollment": null,
    "sponsor": "KalVista Pharmaceuticals, Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KALV",
    "nct_id": "NCT05118958",
    "title": "Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hereditary Angioedema"
    ],
    "interventions": [
      "KVD824 Prototype 1 modified-release tablet",
      "KVD824 Prototype 2 modified-release tablet",
      "KVD824 Immediate-Release Capsule",
      "Placebo to KVD824 Prototype 1",
      "KVD824 Prototype 3 modified-release tablet"
    ],
    "primary_completion_date": "2020-12-01",
    "completion_date": "2020-12-01",
    "results_first_posted": null,
    "last_update_posted": "2021-11-12",
    "enrollment": null,
    "sponsor": "KalVista Pharmaceuticals, Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KALV",
    "nct_id": "NCT06467084",
    "title": "Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hereditary Angioedema"
    ],
    "interventions": [
      "KVD900 150 mg",
      "KVD900 300 mg",
      "KVD900 600 mg"
    ],
    "primary_completion_date": "2026-01-15",
    "completion_date": "2026-01-15",
    "results_first_posted": null,
    "last_update_posted": "2026-01-23",
    "enrollment": null,
    "sponsor": "KalVista Pharmaceuticals, Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KALV",
    "nct_id": "NCT05178355",
    "title": "A Single and Multiple Doses Safety, Tolerability, Pharmacokinetics and Food Effect Study of KVD824 in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hereditary Angioedema"
    ],
    "interventions": [
      "KVD824",
      "Placebo to KVD824"
    ],
    "primary_completion_date": "2019-06-21",
    "completion_date": "2019-06-21",
    "results_first_posted": null,
    "last_update_posted": "2022-02-17",
    "enrollment": null,
    "sponsor": "KalVista Pharmaceuticals, Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KALV",
    "nct_id": "NCT06628713",
    "title": "Treatment of Angioedema Attacks in Adolescent and Adult Patients 12 Years and Older With HAE Type I or II With Sebetralstat",
    "status": "APPROVED_FOR_MARKETING",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Hereditary Angioedema"
    ],
    "interventions": [
      "Sebetralstat"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2025-08-06",
    "enrollment": null,
    "sponsor": "KalVista Pharmaceuticals, Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KALV",
    "nct_id": "NCT05055258",
    "title": "A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Angioedema, Hereditary, Types I and II"
    ],
    "interventions": [
      "KVD824",
      "Placebo to KVD824"
    ],
    "primary_completion_date": "2022-10-27",
    "completion_date": "2022-10-27",
    "results_first_posted": null,
    "last_update_posted": "2023-10-10",
    "enrollment": null,
    "sponsor": "KalVista Pharmaceuticals, Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KALV",
    "nct_id": "NCT07216378",
    "title": "Treatment of Angioedema Attacks in Pediatric (Ages 2-11) Post-Trial and Naive Patients With HAE With Sebetralstat",
    "status": "AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Hereditary Angioedema"
    ],
    "interventions": [
      "Sebetralstat"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2025-11-12",
    "enrollment": null,
    "sponsor": "KalVista Pharmaceuticals, Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KALV",
    "nct_id": "NCT04208412",
    "title": "A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hereditary Angioedema"
    ],
    "interventions": [
      "KVD900",
      "Placebo"
    ],
    "primary_completion_date": "2020-12-08",
    "completion_date": "2020-12-08",
    "results_first_posted": "2023-02-08",
    "last_update_posted": "2025-05-02",
    "enrollment": null,
    "sponsor": "KalVista Pharmaceuticals, Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KALV",
    "nct_id": "NCT05511922",
    "title": "PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hereditary Angioedema"
    ],
    "interventions": [
      "KVD900 600 mg",
      "Drug: KVD900 300 mg"
    ],
    "primary_completion_date": "2026-06-30",
    "completion_date": "2026-06-30",
    "results_first_posted": null,
    "last_update_posted": "2025-07-18",
    "enrollment": null,
    "sponsor": "KalVista Pharmaceuticals, Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KALV",
    "nct_id": "NCT05259917",
    "title": "A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hereditary Angioedema"
    ],
    "interventions": [
      "Placebo",
      "KVD900 600 mg",
      "KVD900 300 mg"
    ],
    "primary_completion_date": "2023-12-31",
    "completion_date": "2023-12-31",
    "results_first_posted": "2024-07-19",
    "last_update_posted": "2025-05-02",
    "enrollment": null,
    "sponsor": "KalVista Pharmaceuticals, Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KALV",
    "nct_id": "NCT07009262",
    "title": "A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Hereditary Angioedema"
    ],
    "interventions": [
      "Inapplicable"
    ],
    "primary_completion_date": "2025-11-25",
    "completion_date": "2025-11-25",
    "results_first_posted": null,
    "last_update_posted": "2026-01-13",
    "enrollment": null,
    "sponsor": "KalVista Pharmaceuticals, Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KALV",
    "nct_id": "NCT04349800",
    "title": "A Single Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of KVD900 (Sebetralstat) in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hereditary Angioedema"
    ],
    "interventions": [
      "KVD900",
      "Placebo to KVD900"
    ],
    "primary_completion_date": "2018-09-10",
    "completion_date": "2018-09-10",
    "results_first_posted": null,
    "last_update_posted": "2025-04-29",
    "enrollment": null,
    "sponsor": "KalVista Pharmaceuticals, Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KALV",
    "nct_id": "NCT05505916",
    "title": "An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hereditary Angioedema"
    ],
    "interventions": [
      "KVD900 600 mg",
      "KVD900 300 mg"
    ],
    "primary_completion_date": "2026-06-30",
    "completion_date": "2026-06-30",
    "results_first_posted": null,
    "last_update_posted": "2024-12-27",
    "enrollment": null,
    "sponsor": "KalVista Pharmaceuticals, Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KMDA",
    "nct_id": "NCT02614872",
    "title": "Study to Evaluate the Safety and Efficacy of Intravenous Glassia\u00ae Treatment in Lung Transplantation",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Transplantation, Lung Rejection"
    ],
    "interventions": [
      "GLASSIA\u00ae and Institution standard of care (SOC)"
    ],
    "primary_completion_date": "2019-04-11",
    "completion_date": "2019-05-07",
    "results_first_posted": null,
    "last_update_posted": "2021-09-01",
    "enrollment": null,
    "sponsor": "Kamada, Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KMDA",
    "nct_id": "NCT04550325",
    "title": "Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Covid19",
      "Pneumonia, Viral"
    ],
    "interventions": [
      "Kamada Anti-SARS-CoV-2"
    ],
    "primary_completion_date": "2020-11-26",
    "completion_date": "2020-11-26",
    "results_first_posted": null,
    "last_update_posted": "2021-01-05",
    "enrollment": null,
    "sponsor": "Kamada, Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KMDA",
    "nct_id": "NCT00460096",
    "title": "Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alpha 1-Antitrypsin Deficiency"
    ],
    "interventions": [
      "Kamada-API"
    ],
    "primary_completion_date": null,
    "completion_date": "2007-09",
    "results_first_posted": null,
    "last_update_posted": "2007-10-17",
    "enrollment": null,
    "sponsor": "Kamada, Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KMDA",
    "nct_id": "NCT02005848",
    "title": "Phase II Study to Evaluate the Efficacy and Safety of Glassia\u00ae in Type-1 Diabetes",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "New Onset Type-1 Diabetes"
    ],
    "interventions": [
      "Alpha-1 Antitrypsin",
      "Placebo"
    ],
    "primary_completion_date": "2017-02",
    "completion_date": "2017-02",
    "results_first_posted": null,
    "last_update_posted": "2018-10-11",
    "enrollment": null,
    "sponsor": "Kamada, Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KMDA",
    "nct_id": "NCT02001688",
    "title": "Phase II, Safety and Efficacy Study of Kamada-alpha-1-antitrypsin (AAT) for Inhalation\"",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alpha-1 Antitrypsin Deficiency"
    ],
    "interventions": [
      "Kamada-AAT for Inhalation, 80mg",
      "Placebo",
      "Kamada-AAT for Inhalation, 160mg"
    ],
    "primary_completion_date": "2016-02",
    "completion_date": "2016-05",
    "results_first_posted": "2020-01-18",
    "last_update_posted": "2020-01-18",
    "enrollment": null,
    "sponsor": "Kamada, Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KMDA",
    "nct_id": "NCT02912845",
    "title": "Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rabies"
    ],
    "interventions": [
      "KamRAB - HRIG"
    ],
    "primary_completion_date": "2019-11-13",
    "completion_date": "2019-11-13",
    "results_first_posted": null,
    "last_update_posted": "2021-09-05",
    "enrollment": null,
    "sponsor": "Kamada, Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KMDA",
    "nct_id": "NCT02040090",
    "title": "Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rabies"
    ],
    "interventions": [
      "Active rabies vaccine (US-FDA approved)"
    ],
    "primary_completion_date": "2014-08",
    "completion_date": "2014-08",
    "results_first_posted": "2021-09-29",
    "last_update_posted": "2021-09-29",
    "enrollment": null,
    "sponsor": "Kamada, Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KMDA",
    "nct_id": "NCT00499837",
    "title": "Phase II Study of the Safety and Efficacy of Inhaled Alpha-1 Antitrypsin (AAT ) in Cystic Fibrosis Patients",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cystic Fibrosis"
    ],
    "interventions": [
      "Aerosolized, human, plasma-derived Alpha-1 Antitrypsin"
    ],
    "primary_completion_date": "2008-07",
    "completion_date": "2008-07",
    "results_first_posted": null,
    "last_update_posted": "2016-06-09",
    "enrollment": null,
    "sponsor": "Kamada, Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KMDA",
    "nct_id": "NCT01217671",
    "title": "International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Emphysema"
    ],
    "interventions": [
      "Kamada AAT for inhalation",
      "Placebo"
    ],
    "primary_completion_date": "2014-11",
    "completion_date": "2015-06",
    "results_first_posted": null,
    "last_update_posted": "2019-11-29",
    "enrollment": null,
    "sponsor": "Kamada, Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KMDA",
    "nct_id": "NCT01304537",
    "title": "Study of the Safety and Efficacy of Intravenous Alpha-1 Antitrypsin in Type 1 Diabetes Mellitus",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 1 Diabetes Mellitus"
    ],
    "interventions": [
      "Alpha-1 Antitrypsin 40mg (AAT, Glassia\u00ae)",
      "Alpha-1 Antitrypsin 60mg (AAT, Glassia\u00ae)",
      "Alpha-1 Antitrypsin 80mg (AAT, Glassia\u00ae)"
    ],
    "primary_completion_date": "2012-11",
    "completion_date": "2012-11",
    "results_first_posted": null,
    "last_update_posted": "2016-06-09",
    "enrollment": null,
    "sponsor": "Kamada, Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KMDA",
    "nct_id": "NCT04204252",
    "title": "Phase III, Efficacy and Safety of \"Kamada-AAT for Inhalation\"",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alpha 1-Antitrypsin Deficiency"
    ],
    "interventions": [
      "Alpha 1-Antitrypsin",
      "Placebo"
    ],
    "primary_completion_date": "2028-12",
    "completion_date": "2031-06",
    "results_first_posted": null,
    "last_update_posted": "2025-09-04",
    "enrollment": null,
    "sponsor": "Kamada, Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KOD",
    "nct_id": "NCT06990399",
    "title": "A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Macular Edema Secondary to Inflammation"
    ],
    "interventions": [
      "KSI-101",
      "Sham Comparator"
    ],
    "primary_completion_date": "2026-02",
    "completion_date": "2027-07",
    "results_first_posted": null,
    "last_update_posted": "2025-09-10",
    "enrollment": null,
    "sponsor": "Kodiak Sciences Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KOD",
    "nct_id": "NCT04592419",
    "title": "A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Macular Edema",
      "Retinal Vein Occlusion"
    ],
    "interventions": [
      "KSI-301",
      "Aflibercept",
      "Sham Procedure"
    ],
    "primary_completion_date": "2022-06-10",
    "completion_date": "2023-01-19",
    "results_first_posted": "2024-06-06",
    "last_update_posted": "2024-06-26",
    "enrollment": null,
    "sponsor": "Kodiak Sciences Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KOD",
    "nct_id": "NCT06556368",
    "title": "A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Wet Age-related Macular Degeneration"
    ],
    "interventions": [
      "Tarcocimab tedromer",
      "Tabirafusp tedromer",
      "Aflibercept"
    ],
    "primary_completion_date": "2026-08",
    "completion_date": "2027-08",
    "results_first_posted": null,
    "last_update_posted": "2025-10-27",
    "enrollment": null,
    "sponsor": "Kodiak Sciences Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KOD",
    "nct_id": "NCT06270836",
    "title": "A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetic Retinopathy"
    ],
    "interventions": [
      "Tarcocimab",
      "Sham injection"
    ],
    "primary_completion_date": "2026-01-31",
    "completion_date": "2026-01-31",
    "results_first_posted": null,
    "last_update_posted": "2025-03-30",
    "enrollment": null,
    "sponsor": "Kodiak Sciences Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KOD",
    "nct_id": "NCT05066230",
    "title": "A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-proliferative Diabetic Retinopathy"
    ],
    "interventions": [
      "KSI-301",
      "Sham injection"
    ],
    "primary_completion_date": "2023-08-03",
    "completion_date": "2023-08-31",
    "results_first_posted": "2024-09-05",
    "last_update_posted": "2024-09-05",
    "enrollment": null,
    "sponsor": "Kodiak Sciences Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KOD",
    "nct_id": "NCT03790852",
    "title": "Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Wet Age-related Macular Degeneration",
      "Retinal Vein Occlusion",
      "Diabetic Macular Edema"
    ],
    "interventions": [
      "KSI-301"
    ],
    "primary_completion_date": "2021-06-02",
    "completion_date": "2022-06-09",
    "results_first_posted": null,
    "last_update_posted": "2024-03-20",
    "enrollment": null,
    "sponsor": "Kodiak Sciences Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KOD",
    "nct_id": "NCT06996080",
    "title": "A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Macular Edema Secondary to Inflammation"
    ],
    "interventions": [
      "KSI-101",
      "Sham Comparator"
    ],
    "primary_completion_date": "2026-12",
    "completion_date": "2027-07",
    "results_first_posted": null,
    "last_update_posted": "2025-09-12",
    "enrollment": null,
    "sponsor": "Kodiak Sciences Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KOD",
    "nct_id": "NCT04964089",
    "title": "A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Wet Age-related Macular Degeneration"
    ],
    "interventions": [
      "KSI-301",
      "Aflibercept",
      "Sham Procedure"
    ],
    "primary_completion_date": "2023-03-28",
    "completion_date": "2023-04-06",
    "results_first_posted": "2024-05-02",
    "last_update_posted": "2024-07-03",
    "enrollment": null,
    "sponsor": "Kodiak Sciences Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KOD",
    "nct_id": "NCT04611152",
    "title": "A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetic Macular Edema"
    ],
    "interventions": [
      "KSI-301",
      "Aflibercept",
      "Sham Procedure"
    ],
    "primary_completion_date": "2023-05-11",
    "completion_date": "2023-08-31",
    "results_first_posted": "2024-08-22",
    "last_update_posted": "2024-08-22",
    "enrollment": null,
    "sponsor": "Kodiak Sciences Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KOD",
    "nct_id": "NCT04603937",
    "title": "A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetic Macular Edema"
    ],
    "interventions": [
      "KSI-301",
      "Aflibercept",
      "Sham Procedure"
    ],
    "primary_completion_date": "2023-04-27",
    "completion_date": "2023-08-31",
    "results_first_posted": "2024-08-22",
    "last_update_posted": "2024-08-22",
    "enrollment": null,
    "sponsor": "Kodiak Sciences Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KOD",
    "nct_id": "NCT04049266",
    "title": "A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Wet Macular Degeneration"
    ],
    "interventions": [
      "KSI-301",
      "Aflibercept",
      "Sham Procedure"
    ],
    "primary_completion_date": "2021-11-17",
    "completion_date": "2022-04-26",
    "results_first_posted": "2024-07-18",
    "last_update_posted": "2024-07-18",
    "enrollment": null,
    "sponsor": "Kodiak Sciences Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KROS",
    "nct_id": "NCT05927012",
    "title": "A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia).",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Iron Deficiency Anemia"
    ],
    "interventions": [
      "KER-047"
    ],
    "primary_completion_date": "2025-08-29",
    "completion_date": "2026-01-04",
    "results_first_posted": null,
    "last_update_posted": "2023-11-24",
    "enrollment": null,
    "sponsor": "Keros Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KROS",
    "nct_id": "NCT05975905",
    "title": "A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study).",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pulmonary Arterial Hypertension"
    ],
    "interventions": [
      "Dose A KER-012",
      "Dose B KER-012",
      "Dose C KER-012",
      "Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks"
    ],
    "primary_completion_date": "2025-03-05",
    "completion_date": "2025-03-11",
    "results_first_posted": null,
    "last_update_posted": "2025-09-30",
    "enrollment": null,
    "sponsor": "Keros Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KYTX",
    "nct_id": "NCT06193889",
    "title": "KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Myasthenia Gravis",
      "Generalized Myasthenia Gravis"
    ],
    "interventions": [
      "Standard of Care Treatment",
      "Standard lymphodepletion regimen",
      "KYV-101"
    ],
    "primary_completion_date": "2027-09",
    "completion_date": "2028-09",
    "results_first_posted": null,
    "last_update_posted": "2025-11-20",
    "enrollment": null,
    "sponsor": "Kyverna Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KYTX",
    "nct_id": "NCT05938725",
    "title": "KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lupus Nephritis",
      "Lupus Nephritis - World Health Organization (WHO) Class III",
      "Lupus Nephritis - WHO Class IV"
    ],
    "interventions": [
      "KYV-101 anti-CD19 CAR-T cell therapy",
      "Standard lymphodepletion regimen"
    ],
    "primary_completion_date": "2026-08",
    "completion_date": "2027-08",
    "results_first_posted": null,
    "last_update_posted": "2025-10-29",
    "enrollment": null,
    "sponsor": "Kyverna Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KYTX",
    "nct_id": "NCT06384976",
    "title": "KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple Sclerosis, Primary Progressive",
      "Multiple Sclerosis, Secondary Progressive",
      "Multiple Sclerosis",
      "MS"
    ],
    "interventions": [
      "KYV-101",
      "Standard lymphodepletion regimen",
      "Anti-CD20 mAB"
    ],
    "primary_completion_date": "2027-04",
    "completion_date": "2029-01",
    "results_first_posted": null,
    "last_update_posted": "2025-01-13",
    "enrollment": null,
    "sponsor": "Kyverna Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KYTX",
    "nct_id": "NCT06400303",
    "title": "KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Systemic Sclerosis",
      "Systemic Sclerosis - Diffuse Cutaneous",
      "Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria"
    ],
    "interventions": [
      "KYV-101",
      "Standard lymphodepletion regimen"
    ],
    "primary_completion_date": "2026-03",
    "completion_date": "2027-03",
    "results_first_posted": null,
    "last_update_posted": "2025-10-08",
    "enrollment": null,
    "sponsor": "Kyverna Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KYTX",
    "nct_id": "NCT06342960",
    "title": "KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lupus Nephritis",
      "Lupus Nephritis - WHO Class III",
      "Lupus Nephritis - WHO Class IV"
    ],
    "interventions": [
      "KYV-101 anti-CD19 CAR-T cell therapy",
      "Standard lymphodepletion regimen"
    ],
    "primary_completion_date": "2028-10",
    "completion_date": "2029-01",
    "results_first_posted": null,
    "last_update_posted": "2025-10-29",
    "enrollment": null,
    "sponsor": "Kyverna Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "KYTX",
    "nct_id": "NCT06588491",
    "title": "KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person Syndrome",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Stiff-Person Syndrome",
      "SPS"
    ],
    "interventions": [
      "Standard lymphodepletion regimen"
    ],
    "primary_completion_date": "2026-04",
    "completion_date": "2026-12",
    "results_first_posted": null,
    "last_update_posted": "2025-12-22",
    "enrollment": null,
    "sponsor": "Kyverna Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LRMR",
    "nct_id": "NCT04255680",
    "title": "A Study to Assess Variation in Potential Biomarkers in Friedreich Ataxia",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Friedreich Ataxia"
    ],
    "interventions": [
      "Buccal Swabs and Blood Draws"
    ],
    "primary_completion_date": "2020-06-30",
    "completion_date": "2020-06-30",
    "results_first_posted": null,
    "last_update_posted": "2020-08-18",
    "enrollment": null,
    "sponsor": "Larimar Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LRMR",
    "nct_id": "NCT04519567",
    "title": "Multiple Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Friedreich Ataxia"
    ],
    "interventions": [
      "CTI-1601",
      "Placebo"
    ],
    "primary_completion_date": "2021-03-16",
    "completion_date": "2021-03-16",
    "results_first_posted": null,
    "last_update_posted": "2021-06-30",
    "enrollment": null,
    "sponsor": "Larimar Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LRMR",
    "nct_id": "NCT06447025",
    "title": "An Open Label Extension Study of CTI-1601 in Subjects With Friedreich's Ataxia",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Friedreich Ataxia"
    ],
    "interventions": [
      "CTI-1601"
    ],
    "primary_completion_date": "2027-01",
    "completion_date": "2027-01",
    "results_first_posted": null,
    "last_update_posted": "2024-06-06",
    "enrollment": null,
    "sponsor": "Larimar Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LRMR",
    "nct_id": "NCT05579691",
    "title": "A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Friedreich Ataxia"
    ],
    "interventions": [
      "CTI-1601",
      "Placebo"
    ],
    "primary_completion_date": "2023-12-04",
    "completion_date": "2023-12-04",
    "results_first_posted": null,
    "last_update_posted": "2024-11-29",
    "enrollment": null,
    "sponsor": "Larimar Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LRMR",
    "nct_id": "NCT04176991",
    "title": "Single Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Friedreich Ataxia"
    ],
    "interventions": [
      "CTI-1601",
      "Placebo"
    ],
    "primary_completion_date": "2020-10-31",
    "completion_date": "2020-10-31",
    "results_first_posted": null,
    "last_update_posted": "2020-11-12",
    "enrollment": null,
    "sponsor": "Larimar Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LRMR",
    "nct_id": "NCT05028764",
    "title": "Determine Range of Tissue Frataxin Concentrations and Other Potential Biomarkers",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Friedreich Ataxia",
      "Healthy Volunteers"
    ],
    "interventions": [
      "Buccal Swabs, Blood Draws and Skin Punch Biopsy"
    ],
    "primary_completion_date": "2022-02-04",
    "completion_date": "2022-02-04",
    "results_first_posted": null,
    "last_update_posted": "2022-02-24",
    "enrollment": null,
    "sponsor": "Larimar Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LRMR",
    "nct_id": "NCT06681766",
    "title": "A Study to Assess Nomlabofusp in Adolescents and Children with Friedreich's Ataxia",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Friedreich Ataxia"
    ],
    "interventions": [
      "Nomlabofusp",
      "Placebo"
    ],
    "primary_completion_date": "2025-08",
    "completion_date": "2025-08",
    "results_first_posted": null,
    "last_update_posted": "2025-02-21",
    "enrollment": null,
    "sponsor": "Larimar Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LXEO",
    "nct_id": "NCT03634007",
    "title": "Gene Therapy for APOE4 Homozygote of Alzheimer's Disease",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alzheimer Disease",
      "Early Onset Alzheimer Disease"
    ],
    "interventions": [
      "LX1001"
    ],
    "primary_completion_date": "2024-11-07",
    "completion_date": "2024-11-07",
    "results_first_posted": null,
    "last_update_posted": "2025-10-20",
    "enrollment": null,
    "sponsor": "Lexeo Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LXEO",
    "nct_id": "NCT06109181",
    "title": "Gene Therapy for ACM Due to a PKP2 Pathogenic Variant",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Arrhythmogenic Cardiomyopathy",
      "PKP2-ACM",
      "PKP2-ARVC"
    ],
    "interventions": [
      "LX2020"
    ],
    "primary_completion_date": "2026-12",
    "completion_date": "2027-03",
    "results_first_posted": null,
    "last_update_posted": "2025-11-12",
    "enrollment": null,
    "sponsor": "Lexeo Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LXEO",
    "nct_id": "NCT06976606",
    "title": "A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Arrhythmogenic Cardiomyopathy",
      "PKP2-ACM",
      "PKP2-ARVC"
    ],
    "interventions": [],
    "primary_completion_date": "2027-07",
    "completion_date": "2027-09",
    "results_first_posted": null,
    "last_update_posted": "2025-05-16",
    "enrollment": null,
    "sponsor": "Lexeo Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LXEO",
    "nct_id": "NCT07050160",
    "title": "Long-term Follow-up Study of Gene Therapy for Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 Pathogenic Variant",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Arrhythmogenic Cardiomyopathy",
      "PKP2-ACM",
      "PKP2-ARVC"
    ],
    "interventions": [],
    "primary_completion_date": "2030-08",
    "completion_date": "2030-08",
    "results_first_posted": null,
    "last_update_posted": "2025-11-12",
    "enrollment": null,
    "sponsor": "Lexeo Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LXEO",
    "nct_id": "NCT05400330",
    "title": "Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alzheimer Disease"
    ],
    "interventions": [
      "LX1001"
    ],
    "primary_completion_date": "2028-11",
    "completion_date": "2028-11",
    "results_first_posted": null,
    "last_update_posted": "2025-07-01",
    "enrollment": null,
    "sponsor": "Lexeo Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LXEO",
    "nct_id": "NCT05445323",
    "title": "Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Friedreich Ataxia",
      "Cardiomyopathy, Secondary"
    ],
    "interventions": [
      "Low dose LX2006",
      "Mid Dose LX2006",
      "High Dose LX2006"
    ],
    "primary_completion_date": "2029-09",
    "completion_date": "2029-09",
    "results_first_posted": null,
    "last_update_posted": "2025-12-23",
    "enrollment": null,
    "sponsor": "Lexeo Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LXEO",
    "nct_id": "NCT06865482",
    "title": "Clinical Course Of Disease In Participants With FA-CM",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Friedreich Ataxia",
      "Cardiomyopathy"
    ],
    "interventions": [],
    "primary_completion_date": "2027-09",
    "completion_date": "2027-09",
    "results_first_posted": null,
    "last_update_posted": "2026-01-09",
    "enrollment": null,
    "sponsor": "Lexeo Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LYEL",
    "nct_id": "NCT05891197",
    "title": "A Biomarker Screening Protocol for Participants With Solid Tumors",
    "status": "TERMINATED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Triple Negative Breast Cancer",
      "Non-small Cell Lung Cancer",
      "Non Small Cell Lung Cancer",
      "Non Small Cell Lung Cancer Metastatic",
      "Non-Small Cell Carcinoma of Lung, TNM Stage 4",
      "Advanced Breast Cancer",
      "Advanced Lung Carcinoma",
      "NSCLC",
      "NSCLC, Recurrent",
      "NSCLC Stage IV",
      "Relapsed Cancer",
      "Relapse/Recurrence",
      "Recurrent Breast Cancer",
      "Recurrent NSCLC",
      "Platinum-resistant Ovarian Cancer",
      "Ovarian Cancer",
      "Primary Peritoneal Carcinoma",
      "Fallopian Tube Cancer",
      "Endometrial Cancer",
      "Endometrioid Tumor",
      "High Grade Serous Carcinoma",
      "Ovarian Epithelial Cancer"
    ],
    "interventions": [],
    "primary_completion_date": "2025-02-05",
    "completion_date": "2025-02-05",
    "results_first_posted": null,
    "last_update_posted": "2025-07-01",
    "enrollment": null,
    "sponsor": "Lyell Immunopharma, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LYEL",
    "nct_id": "NCT07188558",
    "title": "A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Large B-cell Lymphoma",
      "Lymphoma, B-Cell",
      "Relapsed Non-Hodgkin Lymphoma",
      "Refractory Non-Hodgkin Lymphoma",
      "Non-Hodgkin Lymphoma",
      "Non-Hodgkin Lymphoma Refractory/ Relapsed",
      "Diffuse Large B Cell Lymphoma (DLBCL)",
      "Diffuse Large B Cell Lymphoma Refractory",
      "Diffuse Large B Cell Lymphoma Relapsed"
    ],
    "interventions": [
      "rondecabtagene autoleucel",
      "axicabtagene ciloleucel",
      "lisocabtagene maraleucel"
    ],
    "primary_completion_date": "2029-12",
    "completion_date": "2032-01",
    "results_first_posted": null,
    "last_update_posted": "2026-01-21",
    "enrollment": null,
    "sponsor": "Lyell Immunopharma, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LYEL",
    "nct_id": "NCT05826535",
    "title": "Study of LYL314 in Aggressive Large B-Cell Lymphoma",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsed Non-Hodgkin Lymphoma",
      "Refractory Non-Hodgkin Lymphoma",
      "Non-Hodgkin Lymphoma",
      "Large B-cell Lymphoma"
    ],
    "interventions": [
      "LYL314",
      "Fludarabine",
      "Cyclophosphamide"
    ],
    "primary_completion_date": "2028-12-31",
    "completion_date": "2031-06-30",
    "results_first_posted": null,
    "last_update_posted": "2026-01-13",
    "enrollment": null,
    "sponsor": "Lyell Immunopharma, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LYEL",
    "nct_id": "NCT05573035",
    "title": "A Study to Investigate LYL845 in Adults With Solid Tumors",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Melanoma",
      "Non-small Cell Lung Cancer",
      "Colorectal Cancer"
    ],
    "interventions": [
      "LYL845"
    ],
    "primary_completion_date": "2025-01-09",
    "completion_date": "2025-01-09",
    "results_first_posted": null,
    "last_update_posted": "2025-07-01",
    "enrollment": null,
    "sponsor": "Lyell Immunopharma, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LYEL",
    "nct_id": "NCT05274451",
    "title": "A Study to Investigate LYL797 in Adults With Solid Tumors",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Triple Negative Breast Cancer",
      "TNBC - Triple-Negative Breast Cancer",
      "Non-small Cell Lung Cancer",
      "Non Small Cell Lung Cancer",
      "Non Small Cell Lung Cancer Metastatic",
      "Non-Small Cell Carcinoma of Lung, TNM Stage 4",
      "Advanced Breast Cancer",
      "Advanced Lung Carcinoma",
      "NSCLC",
      "NSCLC, Recurrent",
      "NSCLC Stage IV",
      "Relapsed Cancer",
      "Relapse/Recurrence",
      "Recurrent Breast Cancer",
      "Recurrent NSCLC",
      "Platinum-resistant Ovarian Cancer",
      "Ovarian Cancer",
      "Primary Peritoneal Carcinoma",
      "Fallopian Tube Cancer",
      "Endometrial Cancer",
      "Endometrioid Tumor",
      "High Grade Serous Carcinoma",
      "Ovarian Epithelial Cancer"
    ],
    "interventions": [
      "LYL797"
    ],
    "primary_completion_date": "2024-11-27",
    "completion_date": "2024-11-27",
    "results_first_posted": null,
    "last_update_posted": "2025-07-01",
    "enrollment": null,
    "sponsor": "Lyell Immunopharma, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "LYEL",
    "nct_id": "NCT06153095",
    "title": "A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)",
    "status": "WITHDRAWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Systemic Lupus Erythematosus",
      "Lupus Nephritis"
    ],
    "interventions": [
      "IMPT-514",
      "IMPT-514",
      "IMPT-514"
    ],
    "primary_completion_date": "2025-01-09",
    "completion_date": "2025-01-09",
    "results_first_posted": null,
    "last_update_posted": "2025-02-10",
    "enrollment": null,
    "sponsor": "Lyell Immunopharma, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MCRB",
    "nct_id": "NCT03759041",
    "title": "A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ulcerative Colitis"
    ],
    "interventions": [
      "Vancomycin Pre-Treatment",
      "Placebo for Vancomycin Pre-Treatment",
      "SER-287",
      "Placebo for SER-287"
    ],
    "primary_completion_date": "2021-05-28",
    "completion_date": "2021-10-13",
    "results_first_posted": "2022-06-21",
    "last_update_posted": "2022-08-12",
    "enrollment": null,
    "sponsor": "Seres Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MCRB",
    "nct_id": "NCT02437487",
    "title": "SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Clostridium Difficile"
    ],
    "interventions": [
      "SER-109",
      "Placebo"
    ],
    "primary_completion_date": "2016-07",
    "completion_date": "2016-10",
    "results_first_posted": "2018-07-26",
    "last_update_posted": "2018-07-26",
    "enrollment": null,
    "sponsor": "Seres Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MCRB",
    "nct_id": "NCT03183128",
    "title": "ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Clostridium Difficile Infection"
    ],
    "interventions": [
      "SER-109",
      "Placebo"
    ],
    "primary_completion_date": "2020-07-03",
    "completion_date": "2020-09-29",
    "results_first_posted": "2023-04-27",
    "last_update_posted": "2023-04-27",
    "enrollment": null,
    "sponsor": "Seres Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MCRB",
    "nct_id": "NCT04995653",
    "title": "A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Allogeneic Hematopoietic Stem Cell Transplantation"
    ],
    "interventions": [
      "Vancomycin Pre-Treatment",
      "Vancomycin Placebo",
      "SER-155",
      "SER-155 Placebo"
    ],
    "primary_completion_date": "2024-07-23",
    "completion_date": "2024-07-23",
    "results_first_posted": null,
    "last_update_posted": "2024-10-01",
    "enrollment": null,
    "sponsor": "Seres Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MCRB",
    "nct_id": "NCT02618187",
    "title": "A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ulcerative Colitis"
    ],
    "interventions": [
      "SER-287",
      "Placebo",
      "Placebo Pre-Treat",
      "Vancomycin Pre-Treat"
    ],
    "primary_completion_date": "2017-12-06",
    "completion_date": "2018-01-26",
    "results_first_posted": "2019-06-20",
    "last_update_posted": "2019-06-20",
    "enrollment": null,
    "sponsor": "Seres Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MCRB",
    "nct_id": "NCT02830542",
    "title": "SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Clostridium Difficile Infection"
    ],
    "interventions": [
      "SER-262",
      "Placebo"
    ],
    "primary_completion_date": "2018-05",
    "completion_date": "2018-08",
    "results_first_posted": null,
    "last_update_posted": "2023-02-06",
    "enrollment": null,
    "sponsor": "Seres Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MIRM",
    "nct_id": "NCT01438411",
    "title": "Open Label, Continuation Study of Cholic Acid in Subjects With Inborn Errors of Bile Acid Synthesis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bile Acid Synthesis Defect"
    ],
    "interventions": [
      "Cholic Acid"
    ],
    "primary_completion_date": "2016-07",
    "completion_date": "2016-07",
    "results_first_posted": "2020-08-21",
    "last_update_posted": "2023-10-03",
    "enrollment": null,
    "sponsor": "Mirum Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MIRM",
    "nct_id": "NCT06193928",
    "title": "Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Alagille Syndrome",
      "Progressive Familial Intrahepatic Cholestasis"
    ],
    "interventions": [
      "Livmarli",
      "Livmarli"
    ],
    "primary_completion_date": "2028-09-20",
    "completion_date": "2030-09-20",
    "results_first_posted": null,
    "last_update_posted": "2025-05-25",
    "enrollment": null,
    "sponsor": "Mirum Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MIRM",
    "nct_id": "NCT02047318",
    "title": "An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alagille Syndrome"
    ],
    "interventions": [
      "LUM001 (Maralixibat)"
    ],
    "primary_completion_date": "2020-06-17",
    "completion_date": "2020-06-17",
    "results_first_posted": "2021-11-19",
    "last_update_posted": "2021-11-19",
    "enrollment": null,
    "sponsor": "Mirum Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MIRM",
    "nct_id": "NCT02061540",
    "title": "Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Primary Sclerosing Cholangitis (PSC)"
    ],
    "interventions": [
      "LUM001"
    ],
    "primary_completion_date": "2016-02",
    "completion_date": "2016-02",
    "results_first_posted": "2017-04-12",
    "last_update_posted": "2019-03-29",
    "enrollment": null,
    "sponsor": "Mirum Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MIRM",
    "nct_id": "NCT02571192",
    "title": "A Study to Investigate How the Study Drug SHP626 is Eliminated From the Body After One Dose",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-Alcoholic Steatohepatitis"
    ],
    "interventions": [
      "SHP626",
      "5.95 \u03bcCi RAD"
    ],
    "primary_completion_date": "2015-10-01",
    "completion_date": "2015-10-01",
    "results_first_posted": null,
    "last_update_posted": "2019-05-01",
    "enrollment": null,
    "sponsor": "Mirum Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MIRM",
    "nct_id": "NCT04729751",
    "title": "A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Progressive Familial Intrahepatic Cholestasis",
      "Alagille Syndrome",
      "Cholestatic Liver Disease"
    ],
    "interventions": [
      "Maralixibat"
    ],
    "primary_completion_date": "2024-12-17",
    "completion_date": "2024-12-17",
    "results_first_posted": null,
    "last_update_posted": "2025-02-06",
    "enrollment": null,
    "sponsor": "Mirum Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MIRM",
    "nct_id": "NCT03353454",
    "title": "A Placebo-controlled Study of Maralixibat (SHP625) in Pediatric Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC)",
    "status": "WITHDRAWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Progressive Familial Intrahepatic Cholestasis (PFIC)"
    ],
    "interventions": [
      "Maralixibat",
      "Placebo"
    ],
    "primary_completion_date": "2020-06-15",
    "completion_date": "2020-06-15",
    "results_first_posted": null,
    "last_update_posted": "2019-03-18",
    "enrollment": null,
    "sponsor": "Mirum Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MIRM",
    "nct_id": "NCT04168385",
    "title": "MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cholestatic Liver Disease"
    ],
    "interventions": [
      "Maralixibat"
    ],
    "primary_completion_date": "2024-09-04",
    "completion_date": "2024-09-04",
    "results_first_posted": "2025-12-08",
    "last_update_posted": "2025-12-08",
    "enrollment": null,
    "sponsor": "Mirum Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MIRM",
    "nct_id": "NCT04663308",
    "title": "A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Primary Sclerosing Cholangitis"
    ],
    "interventions": [
      "Volixibat",
      "Placebo"
    ],
    "primary_completion_date": "2026-06",
    "completion_date": "2027-04",
    "results_first_posted": null,
    "last_update_posted": "2026-01-15",
    "enrollment": null,
    "sponsor": "Mirum Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MIRM",
    "nct_id": "NCT05050136",
    "title": "A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Primary Biliary Cholangitis",
      "PBC"
    ],
    "interventions": [
      "Volixibat",
      "Placebo"
    ],
    "primary_completion_date": "2027-04",
    "completion_date": "2027-07",
    "results_first_posted": null,
    "last_update_posted": "2026-01-20",
    "enrollment": null,
    "sponsor": "Mirum Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MIRM",
    "nct_id": "NCT02475317",
    "title": "Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid Excretion",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "Placebo",
      "Maralixibat",
      "Volixibat"
    ],
    "primary_completion_date": "2015-12-01",
    "completion_date": "2015-12-01",
    "results_first_posted": null,
    "last_update_posted": "2019-04-04",
    "enrollment": null,
    "sponsor": "Mirum Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MIRM",
    "nct_id": "NCT01903460",
    "title": "Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alagille Syndrome"
    ],
    "interventions": [
      "LUM001",
      "Placebo"
    ],
    "primary_completion_date": "2015-02",
    "completion_date": "2015-03",
    "results_first_posted": "2015-12-07",
    "last_update_posted": "2019-03-28",
    "enrollment": null,
    "sponsor": "Mirum Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MIRM",
    "nct_id": "NCT02131623",
    "title": "Validation of the Itch Reported Outcome (ItchRO) Diaries in Pediatric Cholestatic Liver Disease",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Alagille Syndrome",
      "Progressive Familial Intrahepatic Cholestasis"
    ],
    "interventions": [],
    "primary_completion_date": "2015-03",
    "completion_date": "2015-03",
    "results_first_posted": null,
    "last_update_posted": "2019-03-18",
    "enrollment": null,
    "sponsor": "Mirum Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MIRM",
    "nct_id": "NCT02287779",
    "title": "Safety and Tolerability Study of SHP626 in Overweight and Obese Adults",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-Alcoholic Steatohepatitis"
    ],
    "interventions": [
      "SHP626",
      "Placebo"
    ],
    "primary_completion_date": "2015-06-19",
    "completion_date": "2015-06-19",
    "results_first_posted": "2016-12-07",
    "last_update_posted": "2019-03-26",
    "enrollment": null,
    "sponsor": "Mirum Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MIRM",
    "nct_id": "NCT03115086",
    "title": "The REPLACE Registry for Cholbam\u00ae (Cholic Acid)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Bile Acid Synthesis Disorders"
    ],
    "interventions": [
      "Cholbam"
    ],
    "primary_completion_date": "2038-07",
    "completion_date": "2039-07",
    "results_first_posted": null,
    "last_update_posted": "2023-10-02",
    "enrollment": null,
    "sponsor": "Mirum Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MIRM",
    "nct_id": "NCT04718961",
    "title": "A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA)",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Intrahepatic Cholestasis of Pregnancy"
    ],
    "interventions": [
      "Volixibat",
      "Placebo"
    ],
    "primary_completion_date": "2022-12-07",
    "completion_date": "2022-12-07",
    "results_first_posted": "2024-08-06",
    "last_update_posted": "2024-08-06",
    "enrollment": null,
    "sponsor": "Mirum Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MIRM",
    "nct_id": "NCT01115582",
    "title": "Efficacy of To Be Marketed (TBM) Cholic Acid Capsules Used to Treat Children With Inborn Errors of Bile Acid Synthesis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Inborn Errors of Bile Acid Synthesis"
    ],
    "interventions": [
      "Cholic acid"
    ],
    "primary_completion_date": "2010-08",
    "completion_date": "2010-08",
    "results_first_posted": "2016-12-09",
    "last_update_posted": "2023-10-03",
    "enrollment": null,
    "sponsor": "Mirum Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MIRM",
    "nct_id": "NCT04270682",
    "title": "Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "CTX"
    ],
    "interventions": [
      "Blinded CDCA 250 mg TID",
      "Placebo",
      "Open-Label CDCA 250 mg TID",
      "Rescue Medication CDCA 250 mg TID",
      "CDCA Weight-Based Dose TID"
    ],
    "primary_completion_date": "2023-07-13",
    "completion_date": "2023-10-04",
    "results_first_posted": "2024-10-28",
    "last_update_posted": "2024-10-28",
    "enrollment": null,
    "sponsor": "Mirum Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MIRM",
    "nct_id": "NCT04524390",
    "title": "Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Biliary Atresia"
    ],
    "interventions": [
      "Maralixibat",
      "Placebo"
    ],
    "primary_completion_date": "2023-11-07",
    "completion_date": "2024-02-07",
    "results_first_posted": "2025-02-17",
    "last_update_posted": "2025-03-19",
    "enrollment": null,
    "sponsor": "Mirum Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MIRM",
    "nct_id": "NCT02160782",
    "title": "Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alagille Syndrome"
    ],
    "interventions": [
      "LUM001 (Maralixibat)",
      "Placebo"
    ],
    "primary_completion_date": "2020-05-28",
    "completion_date": "2020-05-28",
    "results_first_posted": "2021-07-14",
    "last_update_posted": "2021-07-14",
    "enrollment": null,
    "sponsor": "Mirum Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MIRM",
    "nct_id": "NCT00007020",
    "title": "Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Infantile Refsum's Disease",
      "Zellweger Syndrome",
      "Adrenoleukodystrophy",
      "Peroxisomal Disorders",
      "Cholestasis"
    ],
    "interventions": [
      "Cholic Acids"
    ],
    "primary_completion_date": "2009-12",
    "completion_date": "2009-12",
    "results_first_posted": "2020-07-15",
    "last_update_posted": "2023-10-03",
    "enrollment": null,
    "sponsor": "Mirum Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MIRM",
    "nct_id": "NCT01904058",
    "title": "Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "PBC",
      "Primary Biliary Cirrhosis"
    ],
    "interventions": [
      "LUM001",
      "Placebo",
      "Ursodeoxycholic Acid"
    ],
    "primary_completion_date": "2015-04",
    "completion_date": "2015-04",
    "results_first_posted": "2016-07-06",
    "last_update_posted": "2019-03-27",
    "enrollment": null,
    "sponsor": "Mirum Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MIRM",
    "nct_id": "NCT06553768",
    "title": "Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)"
    ],
    "interventions": [
      "Maralixibat",
      "Placebo"
    ],
    "primary_completion_date": "2026-10",
    "completion_date": "2027-02",
    "results_first_posted": null,
    "last_update_posted": "2025-12-11",
    "enrollment": null,
    "sponsor": "Mirum Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MIRM",
    "nct_id": "NCT07290257",
    "title": "Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli\u00ae in Patients With Alagille Syndrome in the European Union (LEAP-EU)",
    "status": "RECRUITING",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alagille Syndrome"
    ],
    "interventions": [
      "Livmarli Oral Product"
    ],
    "primary_completion_date": "2030-09-22",
    "completion_date": "2030-12-22",
    "results_first_posted": null,
    "last_update_posted": "2025-12-18",
    "enrollment": null,
    "sponsor": "Mirum Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MIRM",
    "nct_id": "NCT02117713",
    "title": "An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alagille Syndrome"
    ],
    "interventions": [
      "LUM001 (Maralixibat)"
    ],
    "primary_completion_date": "2020-06-01",
    "completion_date": "2020-06-01",
    "results_first_posted": "2021-06-22",
    "last_update_posted": "2021-07-01",
    "enrollment": null,
    "sponsor": "Mirum Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MIRM",
    "nct_id": "NCT02321306",
    "title": "An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Primary Biliary Cirrhosis"
    ],
    "interventions": [
      "LUM001"
    ],
    "primary_completion_date": "2017-12",
    "completion_date": "2018-03",
    "results_first_posted": null,
    "last_update_posted": "2019-03-19",
    "enrollment": null,
    "sponsor": "Mirum Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MIRM",
    "nct_id": "NCT04530994",
    "title": "A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome (ALGS)",
    "status": "APPROVED_FOR_MARKETING",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Alagille Syndrome"
    ],
    "interventions": [
      "maralixibat"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2021-10-20",
    "enrollment": null,
    "sponsor": "Mirum Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MIRM",
    "nct_id": "NCT02787304",
    "title": "Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-Alcoholic Steatohepatitis"
    ],
    "interventions": [
      "SHP626",
      "Placebo"
    ],
    "primary_completion_date": "2018-07-27",
    "completion_date": "2018-07-27",
    "results_first_posted": "2019-11-25",
    "last_update_posted": "2019-11-25",
    "enrollment": null,
    "sponsor": "Mirum Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MIRM",
    "nct_id": "NCT07209462",
    "title": "Study of MRM-3379 in Male Participants With Fragile X Syndrome",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fragile X Syndrome"
    ],
    "interventions": [
      "Low dose of MRM-3379",
      "Middle Dose of MRM-3379",
      "High dose of MRM-3379",
      "Placebo",
      "Low dose of MRM-3379 Open-Label"
    ],
    "primary_completion_date": "2027-10",
    "completion_date": "2027-10",
    "results_first_posted": null,
    "last_update_posted": "2026-01-26",
    "enrollment": null,
    "sponsor": "Mirum Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MIRM",
    "nct_id": "NCT02057718",
    "title": "Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Progressive Familial Intrahepatic Cholestasis (PFIC)"
    ],
    "interventions": [
      "LUM001 (Maralixibat)"
    ],
    "primary_completion_date": "2020-05-08",
    "completion_date": "2020-05-08",
    "results_first_posted": "2021-07-12",
    "last_update_posted": "2023-10-23",
    "enrollment": null,
    "sponsor": "Mirum Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MIRM",
    "nct_id": "NCT03905330",
    "title": "A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Progressive Familial Intrahepatic Cholestasis (PFIC)"
    ],
    "interventions": [
      "Maralixibat",
      "Placebo"
    ],
    "primary_completion_date": "2022-09-01",
    "completion_date": "2022-09-01",
    "results_first_posted": "2023-12-11",
    "last_update_posted": "2023-12-11",
    "enrollment": null,
    "sponsor": "Mirum Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MIRM",
    "nct_id": "NCT04185363",
    "title": "An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Progressive Familial Intrahepatic Cholestasis (PFIC)"
    ],
    "interventions": [
      "Maralixibat"
    ],
    "primary_completion_date": "2025-04-23",
    "completion_date": "2025-04-23",
    "results_first_posted": null,
    "last_update_posted": "2025-06-29",
    "enrollment": null,
    "sponsor": "Mirum Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MIRM",
    "nct_id": "NCT02057692",
    "title": "Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Alagille Syndrome"
    ],
    "interventions": [
      "LUM001",
      "Placebo"
    ],
    "primary_completion_date": "2016-11-16",
    "completion_date": "2016-11-16",
    "results_first_posted": "2018-01-23",
    "last_update_posted": "2019-03-26",
    "enrollment": null,
    "sponsor": "Mirum Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MLYS",
    "nct_id": "NCT05001945",
    "title": "Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypertension, Renal"
    ],
    "interventions": [
      "MLS-101 (Part I)",
      "Placebo (Part I)",
      "Placebo (Part II)",
      "MLS-101 (Part II)"
    ],
    "primary_completion_date": "2022-09-07",
    "completion_date": "2022-10-07",
    "results_first_posted": "2024-01-05",
    "last_update_posted": "2024-01-05",
    "enrollment": null,
    "sponsor": "Mineralys Therapeutics Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MLYS",
    "nct_id": "NCT06785454",
    "title": "A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Obstructive Sleep Apnea",
      "Hypertension"
    ],
    "interventions": [
      "Lorundrostat",
      "Placebo"
    ],
    "primary_completion_date": "2025-12-17",
    "completion_date": "2025-12-29",
    "results_first_posted": null,
    "last_update_posted": "2026-01-13",
    "enrollment": null,
    "sponsor": "Mineralys Therapeutics Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MLYS",
    "nct_id": "NCT06150924",
    "title": "Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Kidney Disease"
    ],
    "interventions": [
      "Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD",
      "Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD"
    ],
    "primary_completion_date": "2025-02-27",
    "completion_date": "2025-04-23",
    "results_first_posted": null,
    "last_update_posted": "2025-07-08",
    "enrollment": null,
    "sponsor": "Mineralys Therapeutics Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MLYS",
    "nct_id": "NCT05968430",
    "title": "Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypertension"
    ],
    "interventions": [
      "lorundrostat",
      "Placebo"
    ],
    "primary_completion_date": "2025-12",
    "completion_date": "2026-12",
    "results_first_posted": null,
    "last_update_posted": "2025-06-15",
    "enrollment": null,
    "sponsor": "Mineralys Therapeutics Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MLYS",
    "nct_id": "NCT06153693",
    "title": "Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypertension"
    ],
    "interventions": [
      "Placebo",
      "lorundrostat Dose 1",
      "lorundrostat Dose 2"
    ],
    "primary_completion_date": "2024-12-10",
    "completion_date": "2025-01-24",
    "results_first_posted": null,
    "last_update_posted": "2025-12-11",
    "enrollment": null,
    "sponsor": "Mineralys Therapeutics Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "MLYS",
    "nct_id": "NCT05769608",
    "title": "A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypertension"
    ],
    "interventions": [
      "Placebo",
      "lorundrostat Dose 1",
      "lorundrostat Dose 2"
    ],
    "primary_completion_date": "2025-01-15",
    "completion_date": "2025-01-15",
    "results_first_posted": null,
    "last_update_posted": "2026-01-20",
    "enrollment": null,
    "sponsor": "Mineralys Therapeutics Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NUVB",
    "nct_id": "NCT05303519",
    "title": "SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Glioma",
      "Astrocytoma, Grade IV",
      "IDH1-mutant Glioma",
      "Astrocytoma, IDH-Mutant, Grade 3",
      "Astrocytoma, IDH-Mutant, Grade 4",
      "Astrocytoma, IDH-Mutant, Grade 2",
      "Oligodendroglioma",
      "Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted"
    ],
    "interventions": [
      "safusidenib",
      "Placebo"
    ],
    "primary_completion_date": "2028-12-01",
    "completion_date": "2030-12-01",
    "results_first_posted": null,
    "last_update_posted": "2026-01-27",
    "enrollment": null,
    "sponsor": "Nuvation Bio Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NUVB",
    "nct_id": "NCT07154706",
    "title": "Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-small Cell Lung Cancer (NSCLC)"
    ],
    "interventions": [
      "Taletrectinib",
      "Placebo"
    ],
    "primary_completion_date": "2030-08-30",
    "completion_date": "2033-08-30",
    "results_first_posted": null,
    "last_update_posted": "2025-12-09",
    "enrollment": null,
    "sponsor": "Nuvation Bio Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NUVB",
    "nct_id": "NCT04541225",
    "title": "Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Glioma",
      "Glioma, Malignant",
      "Glioma, Mixed",
      "Glial Cell Tumors",
      "Breast Cancer",
      "Breast Carcinoma",
      "Cancer of Breast",
      "Cancer of the Breast",
      "Breast Tumor",
      "Malignant Tumor of Breast",
      "Advanced Breast Cancer",
      "Advanced Breast Carcinoma",
      "Metastatic Breast Cancer",
      "Metastatic Breast Carcinoma",
      "Prostate Cancer",
      "Prostatic Cancer",
      "Cancer of Prostate",
      "Cancer of the Prostate",
      "Prostate Neoplasm",
      "Castrate Resistant Prostate Cancer",
      "Castration-resistant Prostate Cancer",
      "Castration Resistant Prostatic Neoplasms",
      "Glioblastoma",
      "Recurrent Glioblastoma"
    ],
    "interventions": [
      "NUV-422"
    ],
    "primary_completion_date": "2022-08-31",
    "completion_date": "2022-08-31",
    "results_first_posted": null,
    "last_update_posted": "2023-07-14",
    "enrollment": null,
    "sponsor": "Nuvation Bio Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NUVB",
    "nct_id": "NCT04617054",
    "title": "Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor"
    ],
    "interventions": [
      "AB-106"
    ],
    "primary_completion_date": "2024-12-06",
    "completion_date": "2024-12-06",
    "results_first_posted": null,
    "last_update_posted": "2026-01-21",
    "enrollment": null,
    "sponsor": "Nuvation Bio Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NUVB",
    "nct_id": "NCT06841874",
    "title": "Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC",
    "status": "NO_LONGER_AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Lung Neoplasms",
      "Respiratory Tract Neoplasms",
      "Thoracic Neoplasms",
      "Neoplasms by Site",
      "Neoplasms",
      "Lung Diseases",
      "Respiratory Tract Diseases",
      "Carcinoma",
      "Bronchogenic Carcinoma",
      "Non Small Cell Carcinoma of the Lung",
      "ROS1-positive Non-Small Cell Lung Cancer (NSCLC)"
    ],
    "interventions": [
      "Taletrectinib"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2025-12-24",
    "enrollment": null,
    "sponsor": "Nuvation Bio Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NUVB",
    "nct_id": "NCT05191017",
    "title": "Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC",
    "status": "WITHDRAWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Prostate Cancer",
      "Prostatic Cancer",
      "Cancer of Prostate",
      "Cancer of the Prostate",
      "Prostate Neoplasm",
      "Castrate Resistant Prostate Cancer",
      "Castration Resistant Prostatic Cancer",
      "Castration Resistant Prostatic Neoplasms"
    ],
    "interventions": [
      "NUV-422",
      "Enzalutamide"
    ],
    "primary_completion_date": "2025-01",
    "completion_date": "2026-07",
    "results_first_posted": null,
    "last_update_posted": "2022-08-05",
    "enrollment": null,
    "sponsor": "Nuvation Bio Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NUVB",
    "nct_id": "NCT05191004",
    "title": "Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC",
    "status": "WITHDRAWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Breast Cancer",
      "Metastatic Breast Cancer",
      "Breast Cancer",
      "Breast Carcinoma",
      "Cancer of the Breast",
      "Cancer of Breast",
      "Malignant Tumor of Breast",
      "Breast Tumor"
    ],
    "interventions": [
      "NUV-422",
      "Fulvestrant"
    ],
    "primary_completion_date": "2025-06",
    "completion_date": "2026-09",
    "results_first_posted": null,
    "last_update_posted": "2023-07-11",
    "enrollment": null,
    "sponsor": "Nuvation Bio Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NUVB",
    "nct_id": "NCT05609929",
    "title": "Study the Effect of Omeprazole on AB-106 Pharmacokinetics",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pharmacokinetic Study"
    ],
    "interventions": [
      "Multiple administration of omeprazole Single administration of AB-106"
    ],
    "primary_completion_date": "2023-01-20",
    "completion_date": "2023-01-20",
    "results_first_posted": null,
    "last_update_posted": "2024-11-21",
    "enrollment": null,
    "sponsor": "Nuvation Bio Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NUVB",
    "nct_id": "NCT06334432",
    "title": "Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumor",
      "HER2-negative Breast Cancer",
      "Metastatic Castration-resistant Prostate Cancer (mCRPC)",
      "Pancreatic Cancer",
      "Platinum-resistant Ovarian Cancer (PROC)"
    ],
    "interventions": [
      "NUV-1511"
    ],
    "primary_completion_date": "2027-03",
    "completion_date": "2027-10",
    "results_first_posted": null,
    "last_update_posted": "2026-01-14",
    "enrollment": null,
    "sponsor": "Nuvation Bio Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NUVB",
    "nct_id": "NCT05252390",
    "title": "NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumor",
      "Ovarian Cancer",
      "Ovary Cancer",
      "Cancer of Ovary",
      "Cancer of the Ovary",
      "Ovary Neoplasm",
      "Pancreatic Cancer",
      "Pancreas Cancer",
      "Cancer of Pancreas",
      "Cancer of the Pancreas",
      "Pancreas Neoplasm",
      "Prostate Cancer",
      "Prostatic Cancer",
      "Cancer of Prostate",
      "Cancer of the Prostate",
      "Prostate Neoplasm",
      "Castrate Resistant Prostate Cancer",
      "Castration Resistant Prostatic Cancer",
      "Castration Resistant Prostatic Neoplasms",
      "Triple-negative Breast Cancer",
      "Triple Negative Breast Cancer",
      "Triple Negative Breast Neoplasms",
      "Breast Cancer",
      "Breast Carcinoma",
      "Cancer of Breast",
      "Cancer of the Breast",
      "Breast Tumor"
    ],
    "interventions": [
      "NUV-868",
      "Olaparib",
      "Enzalutamide"
    ],
    "primary_completion_date": "2024-07-15",
    "completion_date": "2024-07-15",
    "results_first_posted": null,
    "last_update_posted": "2025-11-06",
    "enrollment": null,
    "sponsor": "Nuvation Bio Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NUVB",
    "nct_id": "NCT06564324",
    "title": "A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non Small Cell Lung Cancer"
    ],
    "interventions": [
      "Taletrectinib",
      "Crizotinib"
    ],
    "primary_completion_date": "2029-01",
    "completion_date": "2030-09",
    "results_first_posted": null,
    "last_update_posted": "2025-11-21",
    "enrollment": null,
    "sponsor": "Nuvation Bio Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NUVB",
    "nct_id": "NCT02279433",
    "title": "A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumors"
    ],
    "interventions": [
      "DS6051b"
    ],
    "primary_completion_date": "2019-03",
    "completion_date": "2019-03",
    "results_first_posted": null,
    "last_update_posted": "2025-06-24",
    "enrollment": null,
    "sponsor": "Nuvation Bio Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NUVB",
    "nct_id": "NCT05357820",
    "title": "A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 PK",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor"
    ],
    "interventions": [
      "AB-106, Itraconazole",
      "AB-106, Rifampicin"
    ],
    "primary_completion_date": "2021-12-03",
    "completion_date": "2021-12-03",
    "results_first_posted": null,
    "last_update_posted": "2024-11-21",
    "enrollment": null,
    "sponsor": "Nuvation Bio Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NUVB",
    "nct_id": "NCT04919811",
    "title": "Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non Small Cell Lung Cancer"
    ],
    "interventions": [
      "Taletrectinib"
    ],
    "primary_completion_date": "2025-06-11",
    "completion_date": "2027-12",
    "results_first_posted": null,
    "last_update_posted": "2026-01-07",
    "enrollment": null,
    "sponsor": "Nuvation Bio Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NUVB",
    "nct_id": "NCT05357911",
    "title": "A Study on the Effect of AB-106 on the Pharmacokinetics of Digoxin",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor"
    ],
    "interventions": [
      "AB-106, digoxin"
    ],
    "primary_completion_date": "2021-08-20",
    "completion_date": "2021-12-03",
    "results_first_posted": null,
    "last_update_posted": "2024-11-21",
    "enrollment": null,
    "sponsor": "Nuvation Bio Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NVAX",
    "nct_id": "NCT01290419",
    "title": "Safety Study of Respiratory Syncytial Virus (RSV)-Fusion (F) Protein Particle Vaccine",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Respiratory Syncytial Virus Infections"
    ],
    "interventions": [
      "RSV-F Particle Vaccine",
      "RSV-F Particle Vaccine",
      "RSV-F Particle Vaccine",
      "RSV-F Particle Vaccine",
      "Placebo",
      "RSV-F Particle Vaccine",
      "RSV-F Particle Vaccine"
    ],
    "primary_completion_date": "2011-12",
    "completion_date": "2011-12",
    "results_first_posted": null,
    "last_update_posted": "2012-03-08",
    "enrollment": null,
    "sponsor": "Novavax",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NVAX",
    "nct_id": "NCT05112848",
    "title": "A Study to Evaluate Safety and Immunogenicity of a COVID-19 Vaccine in People Living With HIV at Risk for SARS-CoV-2 (COVID-19)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "SARS-CoV-2 Infection"
    ],
    "interventions": [
      "NVX-CoV2373"
    ],
    "primary_completion_date": "2022-05-23",
    "completion_date": "2022-11-30",
    "results_first_posted": null,
    "last_update_posted": "2023-03-16",
    "enrollment": null,
    "sponsor": "Novavax",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NVAX",
    "nct_id": "NCT02296463",
    "title": "A Phase I Randomized, Observer-Blinded, Dose-Ranging Study in Healthy Subjects 24 to <72 Months of Age",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Respiratory Synctial Virus"
    ],
    "interventions": [
      "RSV F Vaccine with adjuvant (0.5mL injection)",
      "RSV F Vaccine (0.5mL injection)",
      "Hepatitis A Vaccine (0.5mL injection)",
      "Placebo (0.5mL injection)"
    ],
    "primary_completion_date": "2015-09",
    "completion_date": "2016-04",
    "results_first_posted": null,
    "last_update_posted": "2016-04-28",
    "enrollment": null,
    "sponsor": "Novavax",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NVAX",
    "nct_id": "NCT05372588",
    "title": "Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID-19",
      "SARS CoV 2 Infection"
    ],
    "interventions": [
      "NVX-CoV2515",
      "NVX-Cov2373",
      "NVX-CoV2373 + NVX-CoV2515",
      "NVX-CoV2540",
      "NVX-CoV2373 + NVX-CoV2540"
    ],
    "primary_completion_date": "2022-07-17",
    "completion_date": "2024-04-07",
    "results_first_posted": null,
    "last_update_posted": "2024-04-23",
    "enrollment": null,
    "sponsor": "Novavax",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NVAX",
    "nct_id": "NCT01960686",
    "title": "RSV F Dose-Ranging Study in Women",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Respiratory Syncytial Virus Infections"
    ],
    "interventions": [
      "Low dose RSV F Antigen",
      "High dose RSV F Antigen",
      "Dose 1 of Aluminum Adjuvant",
      "Dose 2 of Aluminum Adjuvant",
      "Dose 3 of Aluminum Adjuvant",
      "Dose 4 of Aluminum Adjuvant",
      "Placebo"
    ],
    "primary_completion_date": "2014-04",
    "completion_date": "2014-04",
    "results_first_posted": null,
    "last_update_posted": "2016-05-26",
    "enrollment": null,
    "sponsor": "Novavax",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NVAX",
    "nct_id": "NCT02247726",
    "title": "RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Respiratory Syncytial Virus Infections"
    ],
    "interventions": [
      "Saline Placebo (0.5mL injection)",
      "RSV F vaccine (0.5mL injection)"
    ],
    "primary_completion_date": "2016-07",
    "completion_date": "2016-07",
    "results_first_posted": null,
    "last_update_posted": "2022-05-27",
    "enrollment": null,
    "sponsor": "Novavax",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NVAX",
    "nct_id": "NCT02078674",
    "title": "A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1\u2122 Adjuvant",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Influenza (Pandemic)"
    ],
    "interventions": [
      "Monovalent Avian Influenza VLP (H7N9)",
      "Matrix-M1\u2122 adjuvant",
      "Placebo"
    ],
    "primary_completion_date": "2015-07",
    "completion_date": "2015-07",
    "results_first_posted": null,
    "last_update_posted": "2016-09-23",
    "enrollment": null,
    "sponsor": "Novavax",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NVAX",
    "nct_id": "NCT07079670",
    "title": "Safety and Immunogenicity of NVX-CoV2705",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID-19",
      "SARS-CoV-2 Infection"
    ],
    "interventions": [
      "NVX-CoV2705"
    ],
    "primary_completion_date": "2026-04-16",
    "completion_date": "2026-06-16",
    "results_first_posted": null,
    "last_update_posted": "2025-07-23",
    "enrollment": null,
    "sponsor": "Novavax",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NVAX",
    "nct_id": "NCT04583995",
    "title": "A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "SARS-CoV-2 Infection",
      "COVID-19"
    ],
    "interventions": [
      "SARS-CoV-2 rS/Matrix M1-Adjuvant",
      "Placebo",
      "Licensed seasonal influenza vaccine"
    ],
    "primary_completion_date": "2022-03-29",
    "completion_date": "2022-03-29",
    "results_first_posted": null,
    "last_update_posted": "2025-05-08",
    "enrollment": null,
    "sponsor": "Novavax",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NVAX",
    "nct_id": "NCT02608502",
    "title": "A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Respiratory Syncytial Virus (RSV)"
    ],
    "interventions": [
      "RSV-F Vaccine",
      "Phosphate Buffer Placebo"
    ],
    "primary_completion_date": "2016-12",
    "completion_date": "2016-12",
    "results_first_posted": null,
    "last_update_posted": "2022-07-19",
    "enrollment": null,
    "sponsor": "Novavax",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NVAX",
    "nct_id": "NCT06485752",
    "title": "Phase 3 Lot Consistency Study of Trivalent Hemagglutinin Nanoparticle Influenza Vaccine",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID-19"
    ],
    "interventions": [
      "tNIV 1 and Matrix-M Adjuvant"
    ],
    "primary_completion_date": "2025-02-04",
    "completion_date": "2025-02-04",
    "results_first_posted": null,
    "last_update_posted": "2025-03-11",
    "enrollment": null,
    "sponsor": "Novavax",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NVAX",
    "nct_id": "NCT02593071",
    "title": "Safety and Immunogenicity of the RSV-F Vaccine in Older Adults Previously Treated With the Same Vaccine or Placebo in the Prior Year.",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Respiratory Syncytial Virus (RSV)"
    ],
    "interventions": [
      "RSV-F Vaccine",
      "Phosphate Buffer Placebo"
    ],
    "primary_completion_date": "2016-11",
    "completion_date": "2016-11",
    "results_first_posted": null,
    "last_update_posted": "2022-05-27",
    "enrollment": null,
    "sponsor": "Novavax",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NVAX",
    "nct_id": "NCT05029856",
    "title": "Evaluation of the Safety and Immunogenicity of SII Vaccine Constructs Based on the SARS-CoV-2 (COVID-19) Variant in Adults",
    "status": "WITHDRAWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Covid19"
    ],
    "interventions": [
      "SII B.1.351",
      "SII B.1.351",
      "SII Bivalent",
      "SII Bivalent",
      "SII B.1.617.2"
    ],
    "primary_completion_date": "2022-08",
    "completion_date": "2022-08",
    "results_first_posted": null,
    "last_update_posted": "2022-05-31",
    "enrollment": null,
    "sponsor": "Novavax",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NVAX",
    "nct_id": "NCT06409663",
    "title": "A Strain Change Study for SARS-CoV-2 rS Vaccines",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Severe Acute Respiratory Syndrome Coronavirus 2 Infection"
    ],
    "interventions": [
      "NVX-CoV2705 Vaccine"
    ],
    "primary_completion_date": "2024-10-15",
    "completion_date": "2025-04-17",
    "results_first_posted": null,
    "last_update_posted": "2025-07-18",
    "enrollment": null,
    "sponsor": "Novavax",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NVAX",
    "nct_id": "NCT01897701",
    "title": "A(H7N9) VLP Antigen Dose Ranging Study With Adjuvant 1",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Avian Influenza"
    ],
    "interventions": [
      "Monovalent Avian Influenza VLP (H7N9)",
      "Adjuvant 1",
      "Placebo"
    ],
    "primary_completion_date": "2014-08",
    "completion_date": "2014-08",
    "results_first_posted": null,
    "last_update_posted": "2014-10-13",
    "enrollment": null,
    "sponsor": "Novavax",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NVAX",
    "nct_id": "NCT01561768",
    "title": "A Study to Evaluate the Immune Response and Safety of a Seasonal Virus-Like Particle Influenza Vaccine in Healthy Young Adults",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Influenza"
    ],
    "interventions": [
      "Novavax Quadrivalent vaccine",
      "Novavax Quadrivalent vaccine",
      "Novavax Quadrivalent vaccine",
      "Novavax Trivalent vaccine",
      "cTIV"
    ],
    "primary_completion_date": "2013-01",
    "completion_date": "2013-01",
    "results_first_posted": null,
    "last_update_posted": "2013-07-18",
    "enrollment": null,
    "sponsor": "Novavax",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NVAX",
    "nct_id": "NCT04120194",
    "title": "Phase 3 Pivotal Trial of NanoFlu\u2122 in Older Adults",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Influenza, Human"
    ],
    "interventions": [
      "NanoFlu",
      "Fluzone Quadrivalent"
    ],
    "primary_completion_date": "2020-10-29",
    "completion_date": "2020-12-13",
    "results_first_posted": "2023-05-06",
    "last_update_posted": "2023-05-06",
    "enrollment": null,
    "sponsor": "Novavax",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NVAX",
    "nct_id": "NCT04533399",
    "title": "A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "SARS-CoV-2 Infection",
      "COVID-19"
    ],
    "interventions": [
      "SARS-CoV-2 rS/Matrix-M1 Adjuvant",
      "Placebo"
    ],
    "primary_completion_date": "2021-12-07",
    "completion_date": "2022-01-19",
    "results_first_posted": null,
    "last_update_posted": "2022-02-17",
    "enrollment": null,
    "sponsor": "Novavax",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NVAX",
    "nct_id": "NCT01014806",
    "title": "Evaluate the Safety and Immunogenicity of a Seasonal Influenza Virus-Like Particle (VLP) Vaccine in Older Adults",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Influenza"
    ],
    "interventions": [
      "Influenza VLP Vaccine",
      "TIV"
    ],
    "primary_completion_date": "2010-05",
    "completion_date": "2010-05",
    "results_first_posted": null,
    "last_update_posted": "2013-07-18",
    "enrollment": null,
    "sponsor": "Novavax",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NVAX",
    "nct_id": "NCT02307851",
    "title": "Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Influenza"
    ],
    "interventions": [
      "Quadrivalent VLP Vaccine",
      "Comparator TIV"
    ],
    "primary_completion_date": "2015-06",
    "completion_date": "2015-06",
    "results_first_posted": null,
    "last_update_posted": "2016-09-23",
    "enrollment": null,
    "sponsor": "Novavax",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NVAX",
    "nct_id": "NCT01072799",
    "title": "Safety and Immunogenicity of an A (H1N1) 2009 Influenza Virus-like Particle (VLP) Vaccine",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Seasonal Influenza"
    ],
    "interventions": [
      "Placebo",
      "A/H1N1 2009 Influenza VLP Vaccine"
    ],
    "primary_completion_date": "2012-03",
    "completion_date": "2012-03",
    "results_first_posted": null,
    "last_update_posted": "2012-04-25",
    "enrollment": null,
    "sponsor": "Novavax",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NVAX",
    "nct_id": "NCT02370589",
    "title": "Study to Evaluate the Immunogenicity and Safety of an Ebola Virus (EBOV) Glycoprotein (GP) Vaccine in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ebola"
    ],
    "interventions": [
      "Base Dose EBOV GP Vaccine",
      "2x Base Dose EBOV GP Vaccine",
      "4x Base Dose EBOV GP Vaccine",
      "8x Base Dose EBOV GP Vaccine",
      "Placebo",
      "Matrix-M Adjuvant"
    ],
    "primary_completion_date": "2016-04",
    "completion_date": "2016-04",
    "results_first_posted": null,
    "last_update_posted": "2021-11-24",
    "enrollment": null,
    "sponsor": "Novavax",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NVAX",
    "nct_id": "NCT06482359",
    "title": "Lot Consistency Study of COVID-19 and Influenza Combination Vaccine",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID-19",
      "Influenza"
    ],
    "interventions": [
      "coformulated CIC Vaccine",
      "Fluzone HD trivalent"
    ],
    "primary_completion_date": "2025-11-16",
    "completion_date": "2026-05-17",
    "results_first_posted": null,
    "last_update_posted": "2025-03-11",
    "enrollment": null,
    "sponsor": "Novavax",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NVAX",
    "nct_id": "NCT00519389",
    "title": "Safety, Reactogenicity and Immunogenicity of an H5N1 VLP",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pandemic Influenza"
    ],
    "interventions": [
      "H5N1 VLP Vaccine",
      "Placebo"
    ],
    "primary_completion_date": "2008-11",
    "completion_date": "2008-11",
    "results_first_posted": null,
    "last_update_posted": "2013-06-21",
    "enrollment": null,
    "sponsor": "Novavax",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NVAX",
    "nct_id": "NCT04611802",
    "title": "A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults \u2265 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "SARS-CoV Infection",
      "Covid19"
    ],
    "interventions": [
      "SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)",
      "Placebo (Initial Vaccination Period)",
      "SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period)",
      "Placebo (Crossover Vaccination period)",
      "SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)",
      "SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination)"
    ],
    "primary_completion_date": "2023-04-10",
    "completion_date": "2023-12-15",
    "results_first_posted": null,
    "last_update_posted": "2023-12-21",
    "enrollment": null,
    "sponsor": "Novavax",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NVAX",
    "nct_id": "NCT05875701",
    "title": "Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID-19"
    ],
    "interventions": [
      "NVX-CoV2373",
      "SARS-CoV-2 rS antigen/Matrix-M Adjuvant"
    ],
    "primary_completion_date": "2023-11-11",
    "completion_date": "2023-11-11",
    "results_first_posted": "2025-06-26",
    "last_update_posted": "2025-06-26",
    "enrollment": null,
    "sponsor": "Novavax",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NVAX",
    "nct_id": "NCT04368988",
    "title": "Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID-19"
    ],
    "interventions": [
      "SARS-CoV-2 rS - Phase 1",
      "SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1",
      "Normal saline solution (NSS), Placebo - Phase 1",
      "Normal saline solution (NSS), Placebo - Phase 2",
      "SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1",
      "Normal saline solution (NSS), Placebo, Day 21 - Phase 1",
      "SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2"
    ],
    "primary_completion_date": "2022-06-01",
    "completion_date": "2022-06-01",
    "results_first_posted": null,
    "last_update_posted": "2023-04-10",
    "enrollment": null,
    "sponsor": "Novavax",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NVAX",
    "nct_id": "NCT07086222",
    "title": "Efficacy and Safety of NVX-CoV2705",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID-19",
      "Sars-CoV-2 Infection"
    ],
    "interventions": [
      "NVX-CoV2705",
      "Placebo"
    ],
    "primary_completion_date": "2026-01-09",
    "completion_date": "2026-07-09",
    "results_first_posted": null,
    "last_update_posted": "2025-08-03",
    "enrollment": null,
    "sponsor": "Novavax",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NVAX",
    "nct_id": "NCT04961541",
    "title": "Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "SARS-CoV Infection",
      "Covid19"
    ],
    "interventions": [
      "ICC Vaccine",
      "qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant",
      "SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with Matrix-M1 Adjuvant"
    ],
    "primary_completion_date": "2021-12-22",
    "completion_date": "2022-04-22",
    "results_first_posted": "2025-04-10",
    "last_update_posted": "2025-04-10",
    "enrollment": null,
    "sponsor": "Novavax",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NVAX",
    "nct_id": "NCT03293498",
    "title": "Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Influenza"
    ],
    "interventions": [
      "NanoFlu",
      "Fluzone HD - Day 0",
      "Fluzone HD - Day 21",
      "Saline - Day 21"
    ],
    "primary_completion_date": "2018-03-14",
    "completion_date": "2018-10-29",
    "results_first_posted": "2022-12-21",
    "last_update_posted": "2022-12-21",
    "enrollment": null,
    "sponsor": "Novavax",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NVAX",
    "nct_id": "NCT06633835",
    "title": "Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID-19",
      "Vaccine-Preventable Diseases",
      "SARS CoV 2 Infection"
    ],
    "interventions": [
      "protein subunit: Novavax COVID-19 vaccine",
      "Pfizer mRNA COVID-19 vaccine"
    ],
    "primary_completion_date": "2025-06-30",
    "completion_date": "2025-08-31",
    "results_first_posted": null,
    "last_update_posted": "2025-03-10",
    "enrollment": null,
    "sponsor": "Novavax",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NVAX",
    "nct_id": "NCT03026348",
    "title": "Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1\u2122 Adjuvants In Clinically-Stable Older Adults",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Respiratory Syncytial Viruses"
    ],
    "interventions": [
      "RSV F Vaccine with Aluminum Phosphate Adjuvant",
      "RSV F Vaccine",
      "Matrix-M1 Adjuvant",
      "Phosphate Buffer"
    ],
    "primary_completion_date": "2017-04",
    "completion_date": "2018-05-18",
    "results_first_posted": null,
    "last_update_posted": "2021-12-06",
    "enrollment": null,
    "sponsor": "Novavax",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NVAX",
    "nct_id": "NCT05519839",
    "title": "A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID-19",
      "Influenza"
    ],
    "interventions": [
      "qNIV Vaccine with Matrix-M Adjuvant",
      "Influenza Vaccine",
      "CIC Vaccine with Matrix-M Adjuvant",
      "Placebo Comparator",
      "SARS-CoV-2 rS Vaccine with Matrix-M Adjuvant"
    ],
    "primary_completion_date": "2023-07-25",
    "completion_date": "2023-12-24",
    "results_first_posted": null,
    "last_update_posted": "2024-07-16",
    "enrollment": null,
    "sponsor": "Novavax",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NVAX",
    "nct_id": "NCT05463068",
    "title": "Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID-19",
      "SARS-CoV-2 Infection"
    ],
    "interventions": [
      "NVX-Cov2373"
    ],
    "primary_completion_date": "2022-08-17",
    "completion_date": "2022-09-01",
    "results_first_posted": null,
    "last_update_posted": "2023-07-20",
    "enrollment": null,
    "sponsor": "Novavax",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NVAX",
    "nct_id": "NCT05975060",
    "title": "A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID-19"
    ],
    "interventions": [
      "XBB.1.5 Vaccine (Booster)",
      "XBB.1.5 Vaccine (single dose)"
    ],
    "primary_completion_date": "2023-11-15",
    "completion_date": "2024-05-20",
    "results_first_posted": null,
    "last_update_posted": "2024-05-30",
    "enrollment": null,
    "sponsor": "Novavax",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NVAX",
    "nct_id": "NCT03658629",
    "title": "Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Influenza, Human"
    ],
    "interventions": [
      "NanoFlu (Quad-NIV)",
      "Matrix-M Adjuvant",
      "Placebo",
      "Fluzone HD",
      "Flublok Quadrivalent",
      "Influenza Vaccine"
    ],
    "primary_completion_date": "2019-04-26",
    "completion_date": "2019-04-26",
    "results_first_posted": "2022-11-04",
    "last_update_posted": "2022-11-04",
    "enrollment": null,
    "sponsor": "Novavax",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NVAX",
    "nct_id": "NCT05973006",
    "title": "Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID-19"
    ],
    "interventions": [
      "NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine",
      "Prototype/XBB.1.5 Bivalent Vaccine (5 \u00b5g)"
    ],
    "primary_completion_date": "2024-04-01",
    "completion_date": "2024-09-30",
    "results_first_posted": "2025-07-15",
    "last_update_posted": "2025-07-15",
    "enrollment": null,
    "sponsor": "Novavax",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "NVAX",
    "nct_id": "NCT01596725",
    "title": "A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 2",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Influenza (Pandemic)"
    ],
    "interventions": [
      "Monovalent Avian Influenza VLP (H5N1)",
      "Monovalent Avian Influenza VLP (H5N1)",
      "Monovalent Avian Influenza VLP (H5N1); Adjuvant",
      "Monovalent Avian Influenza VLP (H5N1); Adjuvant",
      "Monovalent Avian Influenza VLP (H5N1); Adjuvant",
      "Saline Placebo"
    ],
    "primary_completion_date": "2012-08",
    "completion_date": "2013-08",
    "results_first_posted": null,
    "last_update_posted": "2014-02-06",
    "enrollment": null,
    "sponsor": "Novavax",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OCUL",
    "nct_id": "NCT04050865",
    "title": "A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Allergic Conjunctivitis"
    ],
    "interventions": [
      "Dexamethasone, 0.4mg",
      "Placebo plug with no drug"
    ],
    "primary_completion_date": "2020-02-28",
    "completion_date": "2020-02-28",
    "results_first_posted": "2021-10-07",
    "last_update_posted": "2021-10-07",
    "enrollment": null,
    "sponsor": "Ocular Therapeutix, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OCUL",
    "nct_id": "NCT05695417",
    "title": "Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy",
    "status": "UNKNOWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-proliferative Diabetic Retinopathy"
    ],
    "interventions": [
      "OTX-TKI",
      "Sham"
    ],
    "primary_completion_date": "2024-01",
    "completion_date": "2024-12",
    "results_first_posted": null,
    "last_update_posted": "2023-12-08",
    "enrollment": null,
    "sponsor": "Ocular Therapeutix, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OCUL",
    "nct_id": "NCT06223958",
    "title": "Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Neovascular Age-Related Macular Degeneration"
    ],
    "interventions": [
      "OTX-TKI (axitinib implant)",
      "Aflibercept"
    ],
    "primary_completion_date": "2026-04-29",
    "completion_date": "2027-09-27",
    "results_first_posted": null,
    "last_update_posted": "2025-04-18",
    "enrollment": null,
    "sponsor": "Ocular Therapeutix, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OCUL",
    "nct_id": "NCT01845038",
    "title": "Multi-Arm Feasibility Study Evaluating OTX-TP Compared to Timolol in Treatment of Subjects With Open Angle Glaucoma",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Glaucoma"
    ],
    "interventions": [
      "OTX-TPa ~4\u00b5g/day over 2 mos. with natural tears drops",
      "OTX-TPb ~3\u00b5g/day over 3 months with natural tears drops",
      "Timolol Maleate (0.5%) dosed twice daily with punctum plug without drug"
    ],
    "primary_completion_date": "2014-03",
    "completion_date": "2014-05",
    "results_first_posted": null,
    "last_update_posted": "2016-12-12",
    "enrollment": null,
    "sponsor": "Ocular Therapeutix, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OCUL",
    "nct_id": "NCT04362670",
    "title": "Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI in Subjects With Dry Eye Disease.",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dry Eye Disease"
    ],
    "interventions": [
      "OTX-CSI",
      "Placebo Vehicle"
    ],
    "primary_completion_date": "2021-08-11",
    "completion_date": "2021-08-11",
    "results_first_posted": "2023-11-14",
    "last_update_posted": "2023-11-14",
    "enrollment": null,
    "sponsor": "Ocular Therapeutix, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OCUL",
    "nct_id": "NCT02988882",
    "title": "OTX-15-002: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Allergic Conjunctivitis"
    ],
    "interventions": [
      "Dexamethasone",
      "Placebo Vehicle"
    ],
    "primary_completion_date": "2016-04-27",
    "completion_date": "2016-04-27",
    "results_first_posted": "2018-04-30",
    "last_update_posted": "2020-10-12",
    "enrollment": null,
    "sponsor": "Ocular Therapeutix, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OCUL",
    "nct_id": "NCT04989699",
    "title": "Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Neovascular Age-Related Macular Degeneration"
    ],
    "interventions": [
      "OTX-TKI/Sham",
      "Aflibercept/Sham"
    ],
    "primary_completion_date": "2023-02-06",
    "completion_date": "2023-12-18",
    "results_first_posted": null,
    "last_update_posted": "2024-01-26",
    "enrollment": null,
    "sponsor": "Ocular Therapeutix, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OCUL",
    "nct_id": "NCT02310815",
    "title": "ReSure Sealant Post Approval Study",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Adverse Events"
    ],
    "interventions": [
      "ReSure Sealant"
    ],
    "primary_completion_date": "2016-02",
    "completion_date": "2016-04",
    "results_first_posted": null,
    "last_update_posted": "2016-12-05",
    "enrollment": null,
    "sponsor": "Ocular Therapeutix, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OCUL",
    "nct_id": "NCT02914509",
    "title": "Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Open Angle Glaucoma",
      "Ocular Hypertension"
    ],
    "interventions": [
      "Travoprost",
      "Placebo Vehicle"
    ],
    "primary_completion_date": "2019-03-30",
    "completion_date": "2019-03-30",
    "results_first_posted": "2021-10-11",
    "last_update_posted": "2021-10-11",
    "enrollment": null,
    "sponsor": "Ocular Therapeutix, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OCUL",
    "nct_id": "NCT01800175",
    "title": "Non-Significant Risk Feasibility Study to Assess Retention and Replacement of the OTX Punctum Plug",
    "status": "UNKNOWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Subjects"
    ],
    "interventions": [
      "Punctum Plug"
    ],
    "primary_completion_date": "2016-12",
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2016-02-11",
    "enrollment": null,
    "sponsor": "Ocular Therapeutix, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OCUL",
    "nct_id": "NCT01498224",
    "title": "ReSure Sealant Pivotal Study",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cataract Surgery Incision Leak"
    ],
    "interventions": [
      "ReSure Sealant",
      "Sutures"
    ],
    "primary_completion_date": "2012-11",
    "completion_date": "2012-11",
    "results_first_posted": null,
    "last_update_posted": "2016-12-12",
    "enrollment": null,
    "sponsor": "Ocular Therapeutix, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OCUL",
    "nct_id": "NCT05335122",
    "title": "A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Open Angle Glaucoma",
      "Ocular Hypertension"
    ],
    "interventions": [
      "OTX-TIC low dose Travoprost Intracameral Implant",
      "OTX-TIC high dose Travoprost Intracameral Implant",
      "Durysta, Bimatoprost Intracameral Implant 10 \u00b5g"
    ],
    "primary_completion_date": "2024-01-24",
    "completion_date": "2025-01-24",
    "results_first_posted": null,
    "last_update_posted": "2025-03-21",
    "enrollment": null,
    "sponsor": "Ocular Therapeutix, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OCUL",
    "nct_id": "NCT02445326",
    "title": "OTX-14-007: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Allergic Conjunctivitis"
    ],
    "interventions": [
      "Dexamethasone",
      "Placebo Vehicle"
    ],
    "primary_completion_date": "2015-08",
    "completion_date": "2015-09",
    "results_first_posted": "2018-03-29",
    "last_update_posted": "2018-03-29",
    "enrollment": null,
    "sponsor": "Ocular Therapeutix, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OCUL",
    "nct_id": "NCT02034019",
    "title": "Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Post Ocular Surgical Inflammation and Pain"
    ],
    "interventions": [
      "Dexamethasone",
      "Punctum Plug"
    ],
    "primary_completion_date": "2014-12",
    "completion_date": "2015-02",
    "results_first_posted": "2020-01-31",
    "last_update_posted": "2020-01-31",
    "enrollment": null,
    "sponsor": "Ocular Therapeutix, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OCUL",
    "nct_id": "NCT02309736",
    "title": "OTX-14-002: Device Exposure Registry",
    "status": "WITHDRAWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Endophthalmitis"
    ],
    "interventions": [
      "ReSure Sealant"
    ],
    "primary_completion_date": "2020-04",
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2020-02-05",
    "enrollment": null,
    "sponsor": "Ocular Therapeutix, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OCUL",
    "nct_id": "NCT05307081",
    "title": "An Observational, Qualitative Study Assessing Eye Drop Administration",
    "status": "UNKNOWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Ocular Injury"
    ],
    "interventions": [
      "Artificial Tears"
    ],
    "primary_completion_date": "2023-07",
    "completion_date": "2023-12",
    "results_first_posted": null,
    "last_update_posted": "2022-09-16",
    "enrollment": null,
    "sponsor": "Ocular Therapeutix, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OCUL",
    "nct_id": "NCT05814757",
    "title": "OTX-DED for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dry Eye Syndromes",
      "Eye Diseases"
    ],
    "interventions": [
      "OTX-DED",
      "Controlled Insertion",
      "Collagen Punctal Plug"
    ],
    "primary_completion_date": "2024-05-22",
    "completion_date": "2024-05-22",
    "results_first_posted": null,
    "last_update_posted": "2024-07-10",
    "enrollment": null,
    "sponsor": "Ocular Therapeutix, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OCUL",
    "nct_id": "NCT04945824",
    "title": "A Human Factors Study to Evaluate a Novel Intracanalicular Insertion Device in Healthy Subjects",
    "status": "TERMINATED",
    "phase": "EARLY_PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "Dexamethasone Ophthalmic",
      "Dilator"
    ],
    "primary_completion_date": "2022-11-01",
    "completion_date": "2022-11-01",
    "results_first_posted": null,
    "last_update_posted": "2023-02-06",
    "enrollment": null,
    "sponsor": "Ocular Therapeutix, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OCUL",
    "nct_id": "NCT04360174",
    "title": "CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypertension",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ocular Hypertension",
      "Open Angle Glaucoma"
    ],
    "interventions": [
      "OTX-TIC"
    ],
    "primary_completion_date": "2021-05-24",
    "completion_date": "2021-05-24",
    "results_first_posted": "2024-10-01",
    "last_update_posted": "2024-10-01",
    "enrollment": null,
    "sponsor": "Ocular Therapeutix, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OCUL",
    "nct_id": "NCT02736175",
    "title": "OTX-15:003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Post-Surgical Ocular Pain",
      "Post-Surgical Ocular Inflammation"
    ],
    "interventions": [
      "Dexamethasone",
      "Placebo Vehicle"
    ],
    "primary_completion_date": "2016-05",
    "completion_date": "2016-07",
    "results_first_posted": "2017-10-11",
    "last_update_posted": "2017-11-13",
    "enrollment": null,
    "sponsor": "Ocular Therapeutix, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OCUL",
    "nct_id": "NCT00774228",
    "title": "I-ZIP Ocular Bandage Pivotal Study",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cataract"
    ],
    "interventions": [
      "I-ZIP Ocular Bandage",
      "Oasis 24 Hour Soft Shield Collagen Corneal Shield"
    ],
    "primary_completion_date": "2009-07",
    "completion_date": "2009-08",
    "results_first_posted": null,
    "last_update_posted": "2021-09-29",
    "enrollment": null,
    "sponsor": "Ocular Therapeutix, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OCUL",
    "nct_id": "NCT03630315",
    "title": "CLN-0046: Treatment of AMD Subjects With OTX-TKI",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Neovascular Age-related Macular Degeneration"
    ],
    "interventions": [
      "OTX-TKI",
      "OTX-TKI",
      "OTX-TKI",
      "OTX-TKI",
      "Anti-VEGF",
      "OTX-TKI",
      "Anti-VEGF"
    ],
    "primary_completion_date": "2024-01-10",
    "completion_date": "2024-01-10",
    "results_first_posted": null,
    "last_update_posted": "2024-07-10",
    "enrollment": null,
    "sponsor": "Ocular Therapeutix, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OCUL",
    "nct_id": "NCT07235085",
    "title": "A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-Proliferative Diabetic Retinopathy"
    ],
    "interventions": [
      "Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24",
      "Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24",
      "Sham/mock procedure of intravitreal injection followed by a second sham/mock procedure at Week 24"
    ],
    "primary_completion_date": "2027-03",
    "completion_date": "2027-03",
    "results_first_posted": null,
    "last_update_posted": "2025-11-19",
    "enrollment": null,
    "sponsor": "Ocular Therapeutix, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OCUL",
    "nct_id": "NCT02089113",
    "title": "OTX-14-003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Post-Surgical Ocular Pain",
      "Post-Surgical Ocular Inflammation"
    ],
    "interventions": [
      "Dexamethasone",
      "Placebo Vehicle"
    ],
    "primary_completion_date": "2015-01",
    "completion_date": "2015-03",
    "results_first_posted": "2016-03-30",
    "last_update_posted": "2019-09-26",
    "enrollment": null,
    "sponsor": "Ocular Therapeutix, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OCUL",
    "nct_id": "NCT02062905",
    "title": "OTX-14-001: A Phase 2 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Allergic Conjunctivitis"
    ],
    "interventions": [
      "Dexamethasone",
      "Placebo Vehicle"
    ],
    "primary_completion_date": "2014-08",
    "completion_date": "2014-11",
    "results_first_posted": "2016-05-09",
    "last_update_posted": "2019-09-11",
    "enrollment": null,
    "sponsor": "Ocular Therapeutix, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OCUL",
    "nct_id": "NCT02468700",
    "title": "OTX-14-006: A Phase 2 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Dry Eye",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dry Eye"
    ],
    "interventions": [
      "Dexamethasone",
      "Placebo Vehicle"
    ],
    "primary_completion_date": "2015-08",
    "completion_date": "2015-11",
    "results_first_posted": "2018-03-29",
    "last_update_posted": "2018-03-29",
    "enrollment": null,
    "sponsor": "Ocular Therapeutix, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OCUL",
    "nct_id": "NCT02312544",
    "title": "Phase 2b Study Evaluating Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Glaucoma",
      "Ocular Hypertension"
    ],
    "interventions": [
      "OTX-TP",
      "Timolol"
    ],
    "primary_completion_date": "2015-09",
    "completion_date": "2015-12",
    "results_first_posted": null,
    "last_update_posted": "2016-12-14",
    "enrollment": null,
    "sponsor": "Ocular Therapeutix, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OCUL",
    "nct_id": "NCT01666210",
    "title": "Phase II Study Evaluating Safety/Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ocular Inflammation and Pain"
    ],
    "interventions": [
      "OTX-DP (Dexamethasone punctum plug)",
      "Placebo Vehicle Punctum Plug"
    ],
    "primary_completion_date": "2013-08",
    "completion_date": "2013-08",
    "results_first_posted": "2017-04-27",
    "last_update_posted": "2021-10-19",
    "enrollment": null,
    "sponsor": "Ocular Therapeutix, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OCUL",
    "nct_id": "NCT06495918",
    "title": "Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Neovascular Age-related Macular Degeneration"
    ],
    "interventions": [
      "OTX-TKI",
      "Aflibercept",
      "Aflibercept"
    ],
    "primary_completion_date": "2027-01-08",
    "completion_date": "2027-01-08",
    "results_first_posted": null,
    "last_update_posted": "2025-06-17",
    "enrollment": null,
    "sponsor": "Ocular Therapeutix, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OLMA",
    "nct_id": "NCT07085767",
    "title": "Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Cancer",
      "Locally Advanced Breast Cancer",
      "Metastatic Breast Cancer",
      "ER Positive Breast Cancer",
      "HER2 Negative Breast Carcinoma"
    ],
    "interventions": [
      "Palazestrant",
      "Letrozole-matching placebo",
      "Ribociclib",
      "Letrozole",
      "Palazestrant matching-placebo"
    ],
    "primary_completion_date": "2028-12",
    "completion_date": "2032-01",
    "results_first_posted": null,
    "last_update_posted": "2026-01-07",
    "enrollment": null,
    "sponsor": "Olema Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OLMA",
    "nct_id": "NCT06784193",
    "title": "Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)",
      "Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)",
      "Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)",
      "Metastatic Breast Cancer",
      "Fulvestrant",
      "Palazestrant"
    ],
    "interventions": [
      "OP-3136",
      "Fulvestrant",
      "Palazestrant"
    ],
    "primary_completion_date": "2027-05-30",
    "completion_date": "2027-08-30",
    "results_first_posted": null,
    "last_update_posted": "2025-10-10",
    "enrollment": null,
    "sponsor": "Olema Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OLMA",
    "nct_id": "NCT04505826",
    "title": "A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hormone Receptor Positive Breast Carcinoma",
      "HER2-negative Breast Cancer"
    ],
    "interventions": [
      "OP-1250"
    ],
    "primary_completion_date": "2024-07-30",
    "completion_date": "2024-07-30",
    "results_first_posted": null,
    "last_update_posted": "2025-08-24",
    "enrollment": null,
    "sponsor": "Olema Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OLMA",
    "nct_id": "NCT05508906",
    "title": "Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Breast Cancer",
      "ER-positive Breast Cancer",
      "HER2-negative Breast Cancer",
      "Breast Cancer",
      "Locally Advanced Breast Cancer"
    ],
    "interventions": [
      "Palazestrant",
      "Ribociclib",
      "Alpelisib",
      "Everolimus",
      "Atirmociclib"
    ],
    "primary_completion_date": "2027-12-31",
    "completion_date": "2028-01-31",
    "results_first_posted": null,
    "last_update_posted": "2025-10-22",
    "enrollment": null,
    "sponsor": "Olema Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OLMA",
    "nct_id": "NCT06016738",
    "title": "OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Cancer",
      "Advanced Breast Cancer",
      "Metastatic Breast Cancer",
      "ER Positive Breast Cancer",
      "HER2 Negative Breast Carcinoma"
    ],
    "interventions": [
      "Palazestrant",
      "Fulvestrant",
      "Anastrozole",
      "Letrozole",
      "Exemestane"
    ],
    "primary_completion_date": "2026-06-30",
    "completion_date": "2027-09-30",
    "results_first_posted": null,
    "last_update_posted": "2025-08-29",
    "enrollment": null,
    "sponsor": "Olema Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OLMA",
    "nct_id": "NCT05266105",
    "title": "A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Cancer"
    ],
    "interventions": [
      "Palazestrant",
      "Palbociclib"
    ],
    "primary_completion_date": "2026-03",
    "completion_date": "2026-03",
    "results_first_posted": null,
    "last_update_posted": "2025-11-24",
    "enrollment": null,
    "sponsor": "Olema Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "OPCH",
    "nct_id": "NCT05689892",
    "title": "Shared Decision Making in Paediatric Inflammatory Bowel Disease",
    "status": "UNKNOWN",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Inflammatory Bowel Diseases",
      "Crohn Disease",
      "Ulcerative Colitis",
      "IBD"
    ],
    "interventions": [
      "Decision Coach Sessions"
    ],
    "primary_completion_date": "2025-04",
    "completion_date": "2025-12",
    "results_first_posted": null,
    "last_update_posted": "2023-12-11",
    "enrollment": null,
    "sponsor": "London Health Sciences Centre",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ORKA",
    "nct_id": "NCT06944379",
    "title": "ORKA-002-211 A Phase I Study to Evaluate ORKA-002 in Healthy Volunteers Following A Single Dose",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "ORKA-002",
      "Placebo"
    ],
    "primary_completion_date": "2027-01",
    "completion_date": "2027-01",
    "results_first_posted": null,
    "last_update_posted": "2025-09-26",
    "enrollment": null,
    "sponsor": "Oruka Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ORKA",
    "nct_id": "NCT07090330",
    "title": "ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Plaque Psoriasis"
    ],
    "interventions": [
      "ORKA-001 Induction Dose",
      "Placebo",
      "ORKA-001 Maintenance Dose"
    ],
    "primary_completion_date": "2026-09",
    "completion_date": "2027-05",
    "results_first_posted": null,
    "last_update_posted": "2025-11-03",
    "enrollment": null,
    "sponsor": "Oruka Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ORKA",
    "nct_id": "NCT06698939",
    "title": "ORKA-001 in Healthy Volunteers",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "ORKA-001",
      "Placebo"
    ],
    "primary_completion_date": "2026-06",
    "completion_date": "2026-06",
    "results_first_posted": null,
    "last_update_posted": "2025-05-18",
    "enrollment": null,
    "sponsor": "Oruka Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ORKA",
    "nct_id": "NCT07290569",
    "title": "Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Plaque Psoriasis"
    ],
    "interventions": [
      "ORKA-001",
      "Placebo"
    ],
    "primary_completion_date": "2027-06",
    "completion_date": "2028-12",
    "results_first_posted": null,
    "last_update_posted": "2025-12-18",
    "enrollment": null,
    "sponsor": "Oruka Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PACB",
    "nct_id": "NCT03586427",
    "title": "AGN-241751 in the Treatment of Major Depressive Disorder",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Depressive Disorder, Major"
    ],
    "interventions": [
      "AGN-241751",
      "Placebo"
    ],
    "primary_completion_date": "2019-07-22",
    "completion_date": "2019-08-21",
    "results_first_posted": "2022-08-02",
    "last_update_posted": "2022-08-03",
    "enrollment": null,
    "sponsor": "Syndeio Biosciences, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PACB",
    "nct_id": "NCT05787587",
    "title": "A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced or Metastatic Solid Tumors",
      "Breast Cancer",
      "Ovarian Cancer",
      "Prostate Cancer",
      "Endometrial Cancer",
      "Colorectal Cancer",
      "Head and Neck Cancers",
      "Extensive Stage Small Cell Lung Cancer (ES-SCLC)",
      "NSCLC"
    ],
    "interventions": [
      "IDE-161",
      "Pembrolizumab"
    ],
    "primary_completion_date": "2026-10",
    "completion_date": "2027-05",
    "results_first_posted": null,
    "last_update_posted": "2026-01-23",
    "enrollment": null,
    "sponsor": "IDEAYA Biosciences",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PACB",
    "nct_id": "NCT03576066",
    "title": "A Study Evaluating ABI-H0731 as Adjunctive Therapy in Participants With Chronic Hepatitis B Infection",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Hepatitis B"
    ],
    "interventions": [
      "ABI-H0731",
      "SOC NUC",
      "Placebo Oral Tablet"
    ],
    "primary_completion_date": "2019-07-05",
    "completion_date": "2019-07-05",
    "results_first_posted": "2021-01-28",
    "last_update_posted": "2021-02-17",
    "enrollment": null,
    "sponsor": "Assembly Biosciences",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PACB",
    "nct_id": "NCT05270668",
    "title": "Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diffuse Cutaneous Systemic Sclerosis",
      "Interstitial Lung Disease"
    ],
    "interventions": [
      "Tulisokibart",
      "Companion diagnostic ( CDx)",
      "Placebo"
    ],
    "primary_completion_date": "2026-04-30",
    "completion_date": "2029-07-31",
    "results_first_posted": null,
    "last_update_posted": "2025-10-20",
    "enrollment": null,
    "sponsor": "Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PACB",
    "nct_id": "NCT05987332",
    "title": "IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Uveal Melanoma"
    ],
    "interventions": [
      "IDE196",
      "Crizotinib",
      "Pembrolizumab",
      "Ipilimumab",
      "Nivolumab",
      "Dacarbazine"
    ],
    "primary_completion_date": "2027-01-15",
    "completion_date": "2028-01-15",
    "results_first_posted": null,
    "last_update_posted": "2025-11-10",
    "enrollment": null,
    "sponsor": "IDEAYA Biosciences",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PACB",
    "nct_id": "NCT01281189",
    "title": "Phase 3 Study of Dexpramipexole in ALS",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Amyotrophic Lateral Sclerosis"
    ],
    "interventions": [
      "Dexpramipexole",
      "Placebo"
    ],
    "primary_completion_date": "2012-11",
    "completion_date": "2012-11",
    "results_first_posted": "2021-06-07",
    "last_update_posted": "2021-06-07",
    "enrollment": null,
    "sponsor": "Knopp Biosciences",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PACB",
    "nct_id": "NCT06547489",
    "title": "GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Major Depressive Disorder"
    ],
    "interventions": [
      "Zelquistinel"
    ],
    "primary_completion_date": "2026-08-31",
    "completion_date": "2026-12-31",
    "results_first_posted": null,
    "last_update_posted": "2025-11-25",
    "enrollment": null,
    "sponsor": "Syndeio Biosciences, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PACB",
    "nct_id": "NCT06226805",
    "title": "Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Ischemic Stroke"
    ],
    "interventions": [
      "BB-031",
      "Placebo"
    ],
    "primary_completion_date": "2027-06",
    "completion_date": "2027-09",
    "results_first_posted": null,
    "last_update_posted": "2026-01-27",
    "enrollment": null,
    "sponsor": "Basking Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PACB",
    "nct_id": "NCT03893682",
    "title": "A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Lymphocytic Leukemia",
      "Small Lymphocytic Lymphoma",
      "Non-Hodgkin's Lymphoma"
    ],
    "interventions": [
      "CG-806"
    ],
    "primary_completion_date": "2024-05-17",
    "completion_date": "2024-05-17",
    "results_first_posted": null,
    "last_update_posted": "2025-03-07",
    "enrollment": null,
    "sponsor": "Aptose Biosciences Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PACB",
    "nct_id": "NCT01622088",
    "title": "Phase 3 Extension Study of Dexpramipexole in ALS",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Amyotrophic Lateral Sclerosis"
    ],
    "interventions": [
      "Dexpramipexole"
    ],
    "primary_completion_date": "2013-02",
    "completion_date": "2013-02",
    "results_first_posted": "2022-04-07",
    "last_update_posted": "2022-05-03",
    "enrollment": null,
    "sponsor": "Knopp Biosciences",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PACB",
    "nct_id": "NCT04208958",
    "title": "Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Cancer",
      "Melanoma",
      "Gastric Cancer",
      "Gastroesophageal Junction Adenocarcinoma",
      "Colorectal Cancer"
    ],
    "interventions": [
      "VE800",
      "Nivolumab",
      "Vancomycin Oral Capsule"
    ],
    "primary_completion_date": "2021-08-26",
    "completion_date": "2023-02-23",
    "results_first_posted": "2023-08-29",
    "last_update_posted": "2025-10-27",
    "enrollment": null,
    "sponsor": "Vedanta Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PACB",
    "nct_id": "NCT03577171",
    "title": "A Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Participants With Chronic Hepatitis B Virus Infection (cHBV)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Hepatitis B"
    ],
    "interventions": [
      "ABI-H0731",
      "SOC ETV",
      "Placebo Oral Tablet"
    ],
    "primary_completion_date": "2019-06-21",
    "completion_date": "2019-06-21",
    "results_first_posted": "2021-01-28",
    "last_update_posted": "2021-01-28",
    "enrollment": null,
    "sponsor": "Assembly Biosciences",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PACB",
    "nct_id": "NCT04454567",
    "title": "A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Hepatitis B"
    ],
    "interventions": [
      "ABI-H0731",
      "Placebo",
      "NrtI"
    ],
    "primary_completion_date": "2021-04-08",
    "completion_date": "2021-04-08",
    "results_first_posted": "2022-10-20",
    "last_update_posted": "2022-10-20",
    "enrollment": null,
    "sponsor": "Assembly Biosciences",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PBYI",
    "nct_id": "NCT00915018",
    "title": "Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Cancer"
    ],
    "interventions": [
      "Neratinib",
      "Trastuzumab",
      "Paclitaxel"
    ],
    "primary_completion_date": "2013-08",
    "completion_date": "2018-06-28",
    "results_first_posted": "2017-11-06",
    "last_update_posted": "2018-08-22",
    "enrollment": null,
    "sponsor": "Puma Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PBYI",
    "nct_id": "NCT00864487",
    "title": "Study Evaluating The Potential Effect Of Rifampin On The Pharmacokinetics Of Neratinib",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Subjects"
    ],
    "interventions": [
      "Neratinib"
    ],
    "primary_completion_date": "2009-05",
    "completion_date": "2009-05",
    "results_first_posted": null,
    "last_update_posted": "2012-05-14",
    "enrollment": null,
    "sponsor": "Puma Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PBYI",
    "nct_id": "NCT00300781",
    "title": "Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Neoplasms",
      "Neoplasms"
    ],
    "interventions": [
      "neratinib"
    ],
    "primary_completion_date": "2008-04",
    "completion_date": "2018-01-30",
    "results_first_posted": "2017-09-13",
    "last_update_posted": "2018-08-14",
    "enrollment": null,
    "sponsor": "Puma Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PBYI",
    "nct_id": "NCT01827267",
    "title": "Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HER2-mutant Non-Small Cell Lung Cancer"
    ],
    "interventions": [
      "neratinib",
      "temsirolimus"
    ],
    "primary_completion_date": "2016-09-20",
    "completion_date": "2017-10-06",
    "results_first_posted": "2017-09-11",
    "last_update_posted": "2018-07-03",
    "enrollment": null,
    "sponsor": "Puma Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PBYI",
    "nct_id": "NCT01808573",
    "title": "A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HER2+ Metastatic Breast Cancer (MBC)"
    ],
    "interventions": [
      "neratinib",
      "capecitabine",
      "lapatinib"
    ],
    "primary_completion_date": "2018-09-28",
    "completion_date": "2019-12-09",
    "results_first_posted": "2019-12-11",
    "last_update_posted": "2021-06-11",
    "enrollment": null,
    "sponsor": "Puma Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PBYI",
    "nct_id": "NCT00958724",
    "title": "Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Malignant Solid Tumors"
    ],
    "interventions": [
      "Neratinib",
      "Vinorelbine"
    ],
    "primary_completion_date": "2010-04",
    "completion_date": "2010-04",
    "results_first_posted": "2018-02-26",
    "last_update_posted": "2018-06-28",
    "enrollment": null,
    "sponsor": "Puma Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PBYI",
    "nct_id": "NCT00266877",
    "title": "Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Carcinoma, Non-Small-Cell Lung",
      "Lung Neoplasms"
    ],
    "interventions": [
      "HKI-272"
    ],
    "primary_completion_date": "2009-01",
    "completion_date": "2009-01",
    "results_first_posted": "2018-04-13",
    "last_update_posted": "2018-04-13",
    "enrollment": null,
    "sponsor": "Puma Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PBYI",
    "nct_id": "NCT06369285",
    "title": "A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hormone Receptor Positive HER-2 Negative Breast Cancer",
      "Metastatic Breast Cancer",
      "Recurrent Breast Cancer"
    ],
    "interventions": [
      "Alisertib",
      "Endocrine therapy"
    ],
    "primary_completion_date": "2027-06-30",
    "completion_date": "2028-12-31",
    "results_first_posted": null,
    "last_update_posted": "2025-12-10",
    "enrollment": null,
    "sponsor": "Puma Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PBYI",
    "nct_id": "NCT01142063",
    "title": "A Single Dose Bioequivalence Study Of Neratinib In Healthy Subjects",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "Neratinib",
      "Neratinib",
      "Neratinib",
      "Neratinib"
    ],
    "primary_completion_date": "2010-09",
    "completion_date": "2010-09",
    "results_first_posted": null,
    "last_update_posted": "2012-05-14",
    "enrollment": null,
    "sponsor": "Puma Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PBYI",
    "nct_id": "NCT01111825",
    "title": "Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Cancer"
    ],
    "interventions": [
      "Temsirolimus",
      "Neratinib"
    ],
    "primary_completion_date": "2016-07",
    "completion_date": "2016-07",
    "results_first_posted": "2017-11-07",
    "last_update_posted": "2018-09-26",
    "enrollment": null,
    "sponsor": "Puma Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PBYI",
    "nct_id": "NCT00706030",
    "title": "Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Cancer",
      "Advanced Malignant Solid Tumors"
    ],
    "interventions": [
      "neratinib",
      "vinorelbine"
    ],
    "primary_completion_date": "2009-10",
    "completion_date": "2018-06-07",
    "results_first_posted": "2018-05-08",
    "last_update_posted": "2018-08-09",
    "enrollment": null,
    "sponsor": "Puma Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PBYI",
    "nct_id": "NCT01128842",
    "title": "A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Malignant Solid Tumors"
    ],
    "interventions": [
      "Neratinib",
      "Capecitabine"
    ],
    "primary_completion_date": "2011-03",
    "completion_date": "2011-03",
    "results_first_posted": "2018-12-19",
    "last_update_posted": "2018-12-19",
    "enrollment": null,
    "sponsor": "Puma Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PBYI",
    "nct_id": "NCT01953926",
    "title": "Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations"
    ],
    "interventions": [
      "Neratinib",
      "Fulvestrant",
      "Trastuzumab",
      "Paclitaxel"
    ],
    "primary_completion_date": "2023-01-02",
    "completion_date": "2023-01-02",
    "results_first_posted": "2024-03-12",
    "last_update_posted": "2024-03-12",
    "enrollment": null,
    "sponsor": "Puma Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PBYI",
    "nct_id": "NCT02334501",
    "title": "Open-label PK Study to Evaluate Lansoprazole and Neratinib in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "Lansoprazole",
      "Neratinib"
    ],
    "primary_completion_date": "2014-10",
    "completion_date": "2014-10",
    "results_first_posted": null,
    "last_update_posted": "2016-05-11",
    "enrollment": null,
    "sponsor": "Puma Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PBYI",
    "nct_id": "NCT00777101",
    "title": "Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Breast Cancer",
      "Breast Cancer"
    ],
    "interventions": [
      "Neratinib",
      "Lapatinib",
      "Capecitabine"
    ],
    "primary_completion_date": "2011-03",
    "completion_date": "2018-06-03",
    "results_first_posted": "2017-11-09",
    "last_update_posted": "2018-08-09",
    "enrollment": null,
    "sponsor": "Puma Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PBYI",
    "nct_id": "NCT00768469",
    "title": "Study Evaluating Safety And Tolerability, Solid Tumor",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Malignant Solid Tumors"
    ],
    "interventions": [
      "Neratinib",
      "Paclitaxel"
    ],
    "primary_completion_date": "2011-01",
    "completion_date": "2011-01",
    "results_first_posted": "2018-11-19",
    "last_update_posted": "2018-11-19",
    "enrollment": null,
    "sponsor": "Puma Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PBYI",
    "nct_id": "NCT00397046",
    "title": "A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Tumors"
    ],
    "interventions": [
      "neratinib"
    ],
    "primary_completion_date": "2009-03",
    "completion_date": "2009-03",
    "results_first_posted": "2018-02-19",
    "last_update_posted": "2018-09-14",
    "enrollment": null,
    "sponsor": "Puma Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PBYI",
    "nct_id": "NCT00781430",
    "title": "Study Evaluating The PK And Safety Of Neratinib In Healthy Subjects And Subjects With Chronic Liver Disease",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatic Insufficiency"
    ],
    "interventions": [
      "Neratinib (HKI-272)"
    ],
    "primary_completion_date": "2010-02",
    "completion_date": "2010-02",
    "results_first_posted": null,
    "last_update_posted": "2012-05-14",
    "enrollment": null,
    "sponsor": "Puma Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PBYI",
    "nct_id": "NCT00878709",
    "title": "Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Cancer"
    ],
    "interventions": [
      "neratinib",
      "placebo"
    ],
    "primary_completion_date": "2014-08-21",
    "completion_date": "2019-10-04",
    "results_first_posted": "2017-10-09",
    "last_update_posted": "2021-06-11",
    "enrollment": null,
    "sponsor": "Puma Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PBYI",
    "nct_id": "NCT00932464",
    "title": "Study Evaluating The Effect Of A High-Fat Meal On The Pharmacokinetics Of Neratinib",
    "status": "WITHDRAWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "Neratinib",
      "Neratinib"
    ],
    "primary_completion_date": "2012-08",
    "completion_date": "2012-08",
    "results_first_posted": null,
    "last_update_posted": "2012-05-14",
    "enrollment": null,
    "sponsor": "Puma Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PBYI",
    "nct_id": "NCT00708903",
    "title": "Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Cancer"
    ],
    "interventions": [
      "neratinib",
      "Placebo",
      "Moxifloxacin"
    ],
    "primary_completion_date": "2008-07",
    "completion_date": "2008-07",
    "results_first_posted": null,
    "last_update_posted": "2012-05-14",
    "enrollment": null,
    "sponsor": "Puma Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PBYI",
    "nct_id": "NCT00741260",
    "title": "Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Cancer"
    ],
    "interventions": [
      "Neratinib",
      "Capecitabine"
    ],
    "primary_completion_date": "2010-11",
    "completion_date": "2018-06",
    "results_first_posted": "2017-11-09",
    "last_update_posted": "2018-09-05",
    "enrollment": null,
    "sponsor": "Puma Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PBYI",
    "nct_id": "NCT00398567",
    "title": "A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Breast Cancer"
    ],
    "interventions": [
      "HKI-272",
      "trastuzumab"
    ],
    "primary_completion_date": "2009-07-31",
    "completion_date": "2018-03-02",
    "results_first_posted": "2018-04-13",
    "last_update_posted": "2018-07-24",
    "enrollment": null,
    "sponsor": "Puma Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PBYI",
    "nct_id": "NCT00366600",
    "title": "Study Evaluating HKI-272 Administered to Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "neratinib"
    ],
    "primary_completion_date": "2006-12",
    "completion_date": "2006-12",
    "results_first_posted": null,
    "last_update_posted": "2017-09-11",
    "enrollment": null,
    "sponsor": "Puma Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PBYI",
    "nct_id": "NCT00814060",
    "title": "Study Evaluating TwoTablet Formulations of Neratinib (HKI-272)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Subjects"
    ],
    "interventions": [
      "neratinib"
    ],
    "primary_completion_date": "2009-03",
    "completion_date": "2009-03",
    "results_first_posted": null,
    "last_update_posted": "2012-05-14",
    "enrollment": null,
    "sponsor": "Puma Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PBYI",
    "nct_id": "NCT00146172",
    "title": "Study Evaluating HKI-272 in Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Neoplasms"
    ],
    "interventions": [
      "neratinib"
    ],
    "primary_completion_date": "2007-01",
    "completion_date": "2007-01",
    "results_first_posted": "2018-02-13",
    "last_update_posted": "2018-09-17",
    "enrollment": null,
    "sponsor": "Puma Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PBYI",
    "nct_id": "NCT00498745",
    "title": "Study Comparing 2 New Formulations of HKI-272 in Healthy Adult Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "neratinib"
    ],
    "primary_completion_date": null,
    "completion_date": "2007-09",
    "results_first_posted": null,
    "last_update_posted": "2012-05-14",
    "enrollment": null,
    "sponsor": "Puma Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PBYI",
    "nct_id": "NCT06095505",
    "title": "A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Small Cell Lung Cancer"
    ],
    "interventions": [
      "Alisertib"
    ],
    "primary_completion_date": "2027-04-30",
    "completion_date": "2027-10-31",
    "results_first_posted": null,
    "last_update_posted": "2025-11-12",
    "enrollment": null,
    "sponsor": "Puma Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PBYI",
    "nct_id": "NCT00380328",
    "title": "HKI-272 Ketoconazole Drug Interaction Study",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "neratinib"
    ],
    "primary_completion_date": null,
    "completion_date": "2006-11",
    "results_first_posted": null,
    "last_update_posted": "2012-05-14",
    "enrollment": null,
    "sponsor": "Puma Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PBYI",
    "nct_id": "NCT00445458",
    "title": "A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Breast Cancer",
      "Advanced Malignant Solid Tumors",
      "Breast Neoplasms"
    ],
    "interventions": [
      "HKI-272",
      "Paclitaxel"
    ],
    "primary_completion_date": "2011-05",
    "completion_date": "2018-02-07",
    "results_first_posted": "2018-05-09",
    "last_update_posted": "2018-07-26",
    "enrollment": null,
    "sponsor": "Puma Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PBYI",
    "nct_id": "NCT00838539",
    "title": "Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Neoplasms",
      "Malignant Carcinoma"
    ],
    "interventions": [
      "Neratinib",
      "Temsirolimus"
    ],
    "primary_completion_date": "2011-06",
    "completion_date": "2013-12",
    "results_first_posted": "2018-02-26",
    "last_update_posted": "2018-09-18",
    "enrollment": null,
    "sponsor": "Puma Biotechnology, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PGEN",
    "nct_id": "NCT06538480",
    "title": "Zopa Retreatment and Vector Shedding in Adults With RRP",
    "status": "RECRUITING",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Recurrent Respiratory Papillomatosis",
      "Papillomavirus Infection",
      "Papillomaviridae"
    ],
    "interventions": [
      "Zopapogene imadenovec (Zopa)"
    ],
    "primary_completion_date": "2027-12-02",
    "completion_date": "2028-12-02",
    "results_first_posted": null,
    "last_update_posted": "2025-12-15",
    "enrollment": null,
    "sponsor": "Precigen, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PGEN",
    "nct_id": "NCT03927261",
    "title": "PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Myeloid Leukemia",
      "Myelodysplastic Syndromes"
    ],
    "interventions": [
      "PRGN-3006 T Cells"
    ],
    "primary_completion_date": "2024-08-01",
    "completion_date": "2025-08-01",
    "results_first_posted": null,
    "last_update_posted": "2024-11-08",
    "enrollment": null,
    "sponsor": "Precigen, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PGEN",
    "nct_id": "NCT03907527",
    "title": "Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Platinum-Resistant Fallopian Tube Carcinoma",
      "Platinum-Resistant Ovarian Carcinoma",
      "Platinum-Resistant Primary Peritoneal Carcinoma",
      "Recurrent Fallopian Tube Carcinoma",
      "Recurrent Ovarian Carcinoma",
      "Recurrent Primary Peritoneal Carcinoma",
      "Refractory Fallopian Tube Carcinoma",
      "Refractory Ovarian Carcinoma",
      "Refractory Primary Peritoneal Carcinoma",
      "Stage III Fallopian Tube Cancer AJCC V8",
      "Stage III Ovarian Cancer AJCC V8",
      "Stage III Primary Peritoneal Cancer AJCC V8",
      "Stage IIIA Fallopian Tube Cancer AJCC V8",
      "Stage IIIA Ovarian Cancer AJCC V8",
      "Stage IIIA Primary Peritoneal Cancer AJCC V8",
      "Stage IIIA1 Fallopian Tube Cancer AJCC V8",
      "Stage IIIA1 Ovarian Cancer AJCC V8",
      "Stage IIIA2 Fallopian Tube Cancer AJCC V8",
      "Stage IIIA2 Ovarian Cancer AJCC V8",
      "Stage IIIB Fallopian Tube Cancer AJCC V8",
      "Stage IIIB Ovarian Cancer AJCC V8",
      "Stage IIIB Primary Peritoneal Cancer AJCC V8",
      "Stage IIIC Fallopian Tube Cancer AJCC V8",
      "Stage IIIC Ovarian Cancer AJCC V8",
      "Stage IIIC Primary Peritoneal Cancer AJCC V8",
      "Stage IV Fallopian Tube Cancer AJCC V8",
      "Stage IV Ovarian Cancer AJCC V8",
      "Stage IV Primary Peritoneal Cancer AJCC V8",
      "Stage IVA Fallopian Tube Cancer AJCC V8",
      "Stage IVA Ovarian Cancer AJCC V8",
      "Stage IVA Primary Peritoneal Cancer AJCC V8",
      "Stage IVB Fallopian Tube Cancer AJCC V8",
      "Stage IVB Ovarian Cancer AJCC V8",
      "Stage IVB Primary Peritoneal Cancer AJCC V8"
    ],
    "interventions": [
      "PRGN-3005 UltraCAR-T cells",
      "PRGN-3005 UltraCAR-T cells"
    ],
    "primary_completion_date": "2024-12-15",
    "completion_date": "2028-11-15",
    "results_first_posted": null,
    "last_update_posted": "2024-11-08",
    "enrollment": null,
    "sponsor": "Precigen, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PGEN",
    "nct_id": "NCT04724980",
    "title": "Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Recurrent Respiratory Papillomatosis",
      "Papillomavirus Infections",
      "Papillomaviridae"
    ],
    "interventions": [
      "PRGN-2012 - Phase I; Dose Level 1",
      "PRGN-2012 - Phase I; Dose Level 2",
      "PRGN-2012 - Phase II; Dose Level 2"
    ],
    "primary_completion_date": "2024-06-05",
    "completion_date": "2026-06-05",
    "results_first_posted": null,
    "last_update_posted": "2025-06-11",
    "enrollment": null,
    "sponsor": "Precigen, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PGEN",
    "nct_id": "NCT06157151",
    "title": "PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cervical Cancer",
      "HPV-Related Carcinoma",
      "HPV-Related Malignancy",
      "Recurrent Cervical Carcinoma",
      "Metastatic Cervical Cancer"
    ],
    "interventions": [
      "PRGN-2009 plus Pembrolizumab",
      "Pembrolizumab alone"
    ],
    "primary_completion_date": "2028-01-30",
    "completion_date": "2028-01-30",
    "results_first_posted": null,
    "last_update_posted": "2025-11-14",
    "enrollment": null,
    "sponsor": "Precigen, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PGEN",
    "nct_id": "NCT03751007",
    "title": "A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recent-onset Diagnosed Type 1 Diabetes (T1D)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes type1"
    ],
    "interventions": [
      "AG019 - Low Dose",
      "Teplizumab",
      "Placebo-AG019",
      "Placebo-Teplizumab",
      "AG019 - High Dose",
      "AG019 - High Dose"
    ],
    "primary_completion_date": "2021-10-13",
    "completion_date": "2021-10-13",
    "results_first_posted": "2023-02-01",
    "last_update_posted": "2023-02-01",
    "enrollment": null,
    "sponsor": "Precigen Actobio T1D, LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PRME",
    "nct_id": "NCT02723448",
    "title": "Aclarubicin for the Treatment of Retinal Vasculopathy With Cerebral Leukodystrophy",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Vasculopathy, Retinal, With Cerebral Leukodystrophy",
      "Cerebroretinal Vasculopathy, Hereditary"
    ],
    "interventions": [
      "aclarubicin"
    ],
    "primary_completion_date": "2020-07-23",
    "completion_date": "2020-07-23",
    "results_first_posted": null,
    "last_update_posted": "2020-11-19",
    "enrollment": null,
    "sponsor": "Washington University School of Medicine",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PRME",
    "nct_id": "NCT05098977",
    "title": "The Usefulness of Assessing Heart Rate Variability in Patients With Acute Myocardial Infarction",
    "status": "UNKNOWN",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Myocardial Infarction",
      "Autonomic Dysfunction"
    ],
    "interventions": [
      "Heart rate variability measurement",
      "Percutaneous coronary intervention"
    ],
    "primary_completion_date": "2023-10",
    "completion_date": "2024-10",
    "results_first_posted": null,
    "last_update_posted": "2021-11-05",
    "enrollment": null,
    "sponsor": "Grigore T. Popa University of Medicine and Pharmacy",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "PRME",
    "nct_id": "NCT05969756",
    "title": "Early Treatments for Preventing Occlusal Caries Lesions",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Caries; Initial",
      "Occlusal Caries",
      "Caries,Dental"
    ],
    "interventions": [
      "Fluoride varnish",
      "Conventional etch and rinse sealant",
      "Self-etch sealant"
    ],
    "primary_completion_date": "2024-10-10",
    "completion_date": "2024-10-15",
    "results_first_posted": null,
    "last_update_posted": "2024-09-20",
    "enrollment": null,
    "sponsor": "Hue University of Medicine and Pharmacy",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RAPP",
    "nct_id": "NCT03697252",
    "title": "A Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia"
    ],
    "interventions": [
      "Xanomeline and Trospium Chloride Capsules",
      "Placebo Capsules"
    ],
    "primary_completion_date": "2019-09-04",
    "completion_date": "2019-09-04",
    "results_first_posted": "2020-09-28",
    "last_update_posted": "2020-10-26",
    "enrollment": null,
    "sponsor": "Karuna Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RCUS",
    "nct_id": "NCT06120075",
    "title": "A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Cancer"
    ],
    "interventions": [
      "AB801",
      "Docetaxel"
    ],
    "primary_completion_date": "2026-11",
    "completion_date": "2026-11",
    "results_first_posted": null,
    "last_update_posted": "2026-01-02",
    "enrollment": null,
    "sponsor": "Arcus Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RCUS",
    "nct_id": "NCT04575311",
    "title": "A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "AB680",
      "Placebo"
    ],
    "primary_completion_date": "2021-09-22",
    "completion_date": "2021-09-22",
    "results_first_posted": null,
    "last_update_posted": "2024-05-24",
    "enrollment": null,
    "sponsor": "Arcus Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RCUS",
    "nct_id": "NCT05277012",
    "title": "A Study to Evaluate Pharmacokinetics (PK) of Etrumadenant Tablet and Capsule Formulations in Healthy Adult Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants"
    ],
    "interventions": [
      "Etrumadenant"
    ],
    "primary_completion_date": "2022-03-31",
    "completion_date": "2022-03-31",
    "results_first_posted": null,
    "last_update_posted": "2024-05-24",
    "enrollment": null,
    "sponsor": "Arcus Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RCUS",
    "nct_id": "NCT06919991",
    "title": "Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants"
    ],
    "interventions": [
      "Casdatifan",
      "Itraconazole",
      "Phenytoin"
    ],
    "primary_completion_date": "2025-10-18",
    "completion_date": "2025-10-18",
    "results_first_posted": null,
    "last_update_posted": "2025-11-13",
    "enrollment": null,
    "sponsor": "Arcus Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RCUS",
    "nct_id": "NCT05411146",
    "title": "A Study Investigating the Safety, Absorption, and Elimination of Radioactively Labeled Etrumadenant, a New Compound in the Treatment of Cancer",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants"
    ],
    "interventions": [
      "[14C]-etrumadenant"
    ],
    "primary_completion_date": "2022-07-07",
    "completion_date": "2022-07-07",
    "results_first_posted": null,
    "last_update_posted": "2024-05-24",
    "enrollment": null,
    "sponsor": "Arcus Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RCUS",
    "nct_id": "NCT06004921",
    "title": "A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AB801 in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cancer"
    ],
    "interventions": [
      "AB801",
      "Placebo"
    ],
    "primary_completion_date": "2024-02-23",
    "completion_date": "2024-02-23",
    "results_first_posted": null,
    "last_update_posted": "2024-08-28",
    "enrollment": null,
    "sponsor": "Arcus Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RCUS",
    "nct_id": "NCT04087018",
    "title": "Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumors"
    ],
    "interventions": [
      "zimberelimab"
    ],
    "primary_completion_date": "2024-06-17",
    "completion_date": "2024-06-17",
    "results_first_posted": null,
    "last_update_posted": "2024-09-19",
    "enrollment": null,
    "sponsor": "Arcus Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RCUS",
    "nct_id": "NCT05154136",
    "title": "A Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetic Profile of Etrumadenant in Healthy Adult Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants"
    ],
    "interventions": [
      "Etrumadenant",
      "Itraconazole"
    ],
    "primary_completion_date": "2021-12-10",
    "completion_date": "2021-12-10",
    "results_first_posted": null,
    "last_update_posted": "2024-05-24",
    "enrollment": null,
    "sponsor": "Arcus Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RCUS",
    "nct_id": "NCT07364214",
    "title": "Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24)",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants"
    ],
    "interventions": [
      "Quemliclustat"
    ],
    "primary_completion_date": "2026-03",
    "completion_date": "2026-04",
    "results_first_posted": null,
    "last_update_posted": "2026-01-23",
    "enrollment": null,
    "sponsor": "Arcus Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RCUS",
    "nct_id": "NCT05891171",
    "title": "Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Cancer",
      "Advanced Malignancies",
      "Bladder Cancer",
      "Cervical Cancer",
      "Esophageal Cancer",
      "Gastric Cancer",
      "Gastroesophageal-junction Cancer (GEJ)",
      "Head and Neck Squamous Cell Carcinoma (HNSCC)",
      "Non-Small Cell Lung Cancer (NSCLC)",
      "Ovarian Cancer",
      "Renal Cell Carcinoma (RCC)",
      "Triple Negative Breast Cancer (TNBC)"
    ],
    "interventions": [
      "AB598",
      "Zimberelimab",
      "Fluorouracil",
      "Leucovorin",
      "Oxaliplatin"
    ],
    "primary_completion_date": "2026-03",
    "completion_date": "2026-03",
    "results_first_posted": null,
    "last_update_posted": "2026-01-05",
    "enrollment": null,
    "sponsor": "Arcus Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RCUS",
    "nct_id": "NCT03629756",
    "title": "A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-small Cell Lung Cancer",
      "Squamous Cell Carcinoma of the Head and Neck",
      "Breast Cancer",
      "Colorectal Cancer",
      "Melanoma",
      "Bladder Cancer",
      "Ovarian Cancer",
      "Endometrial Cancer",
      "Merkel Cell Carcinoma",
      "GastroEsophageal Cancer",
      "Renal Cell Carcinoma",
      "Castration-resistant Prostate Cancer"
    ],
    "interventions": [
      "Etrumadenant",
      "Zimberelimab"
    ],
    "primary_completion_date": "2021-08-18",
    "completion_date": "2021-09-03",
    "results_first_posted": null,
    "last_update_posted": "2024-05-24",
    "enrollment": null,
    "sponsor": "Arcus Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RCUS",
    "nct_id": "NCT04262856",
    "title": "Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non Small Cell Lung Cancer",
      "Nonsquamous Non Small Cell Lung Cancer",
      "Squamous Non Small Cell Lung Cancer",
      "Lung Cancer"
    ],
    "interventions": [
      "Domvanalimab",
      "Etrumadenant",
      "Zimberelimab"
    ],
    "primary_completion_date": "2025-06-05",
    "completion_date": "2025-07-09",
    "results_first_posted": null,
    "last_update_posted": "2025-08-26",
    "enrollment": null,
    "sponsor": "Arcus Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RCUS",
    "nct_id": "NCT05117554",
    "title": "Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile With Oral AB521 in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants"
    ],
    "interventions": [
      "casdatifan",
      "Placebo",
      "Midazolam"
    ],
    "primary_completion_date": "2023-02-17",
    "completion_date": "2023-02-17",
    "results_first_posted": null,
    "last_update_posted": "2024-10-17",
    "enrollment": null,
    "sponsor": "Arcus Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RCUS",
    "nct_id": "NCT04736173",
    "title": "Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non Small Cell Lung Cancer",
      "Nonsquamous Non Small Cell Lung Cancer",
      "Squamous Non Small Cell Lung Cancer",
      "Lung Cancer"
    ],
    "interventions": [
      "Domvanalimab",
      "Zimberelimab",
      "Carboplatin",
      "Paclitaxel",
      "Pemetrexed",
      "Pembrolizumab"
    ],
    "primary_completion_date": "2027-05",
    "completion_date": "2027-05",
    "results_first_posted": null,
    "last_update_posted": "2025-12-15",
    "enrollment": null,
    "sponsor": "Arcus Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RCUS",
    "nct_id": "NCT03628677",
    "title": "A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor, Unspecified, Adult"
    ],
    "interventions": [
      "Domvanalimab",
      "Zimberelimab"
    ],
    "primary_completion_date": "2025-01-23",
    "completion_date": "2025-01-23",
    "results_first_posted": null,
    "last_update_posted": "2025-02-04",
    "enrollment": null,
    "sponsor": "Arcus Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RCUS",
    "nct_id": "NCT03720678",
    "title": "A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "GastroEsophageal Cancer",
      "Colorectal Cancer"
    ],
    "interventions": [
      "etrumadenant",
      "mFOLFOX"
    ],
    "primary_completion_date": "2021-01-27",
    "completion_date": "2021-06-25",
    "results_first_posted": null,
    "last_update_posted": "2024-05-24",
    "enrollment": null,
    "sponsor": "Arcus Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RCUS",
    "nct_id": "NCT05329766",
    "title": "A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Gastrointestinal Tract Malignancies"
    ],
    "interventions": [
      "Domvanalimab",
      "Quemliclustat",
      "Zimberelimab",
      "Fluorouracil",
      "Leucovorin",
      "Oxaliplatin"
    ],
    "primary_completion_date": "2027-01",
    "completion_date": "2027-06",
    "results_first_posted": null,
    "last_update_posted": "2025-12-31",
    "enrollment": null,
    "sponsor": "Arcus Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RCUS",
    "nct_id": "NCT03677973",
    "title": "A Study to Investigate the Safety of AB680 in Healthy Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "AB680",
      "Placebo"
    ],
    "primary_completion_date": "2019-08-19",
    "completion_date": "2019-08-19",
    "results_first_posted": null,
    "last_update_posted": "2024-05-24",
    "enrollment": null,
    "sponsor": "Arcus Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RCUS",
    "nct_id": "NCT05999513",
    "title": "A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants"
    ],
    "interventions": [
      "casdatifan"
    ],
    "primary_completion_date": "2023-10-31",
    "completion_date": "2023-10-31",
    "results_first_posted": null,
    "last_update_posted": "2024-10-17",
    "enrollment": null,
    "sponsor": "Arcus Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RCUS",
    "nct_id": "NCT07011719",
    "title": "Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Clear Cell Renal Cell Carcinoma",
      "Advanced Clear Cell Renal Cell Carcinoma"
    ],
    "interventions": [
      "Casdatifan",
      "Cabozantinib",
      "Placebo"
    ],
    "primary_completion_date": "2028-04",
    "completion_date": "2030-12",
    "results_first_posted": null,
    "last_update_posted": "2025-12-23",
    "enrollment": null,
    "sponsor": "Arcus Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RCUS",
    "nct_id": "NCT05536141",
    "title": "A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Clear Cell Renal Cell Carcinoma",
      "Solid Tumors"
    ],
    "interventions": [
      "casdatifan",
      "Cabozantinib",
      "Zimberelimab"
    ],
    "primary_completion_date": "2027-07",
    "completion_date": "2027-07",
    "results_first_posted": null,
    "last_update_posted": "2026-01-02",
    "enrollment": null,
    "sponsor": "Arcus Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RCUS",
    "nct_id": "NCT04381832",
    "title": "Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Prostatic Neoplasms, Castration-Resistant",
      "Androgen-Resistant Prostatic Neoplasms",
      "Castration Resistant Prostatic Neoplasms",
      "Prostatic Cancer, Castration-Resistant"
    ],
    "interventions": [
      "Etrumadenant",
      "Zimberelimab",
      "Quemliclustat",
      "Enzalutamide",
      "Docetaxel",
      "SG"
    ],
    "primary_completion_date": "2024-08-30",
    "completion_date": "2024-08-30",
    "results_first_posted": null,
    "last_update_posted": "2025-07-22",
    "enrollment": null,
    "sponsor": "Arcus Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RCUS",
    "nct_id": "NCT05568095",
    "title": "A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Upper Gastrointestinal Tract Adenocarcinoma"
    ],
    "interventions": [
      "Domvanalimab",
      "Zimberelimab",
      "Capecitabine",
      "Fluorouracil",
      "Leucovorin",
      "Oxaliplatin",
      "Nivolumab"
    ],
    "primary_completion_date": "2026-06",
    "completion_date": "2026-06",
    "results_first_posted": null,
    "last_update_posted": "2025-12-23",
    "enrollment": null,
    "sponsor": "Arcus Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RCUS",
    "nct_id": "NCT04660812",
    "title": "An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Colorectal Cancer"
    ],
    "interventions": [
      "AB680",
      "Etrumadenant",
      "Zimberelimab",
      "Bevacizumab",
      "m-FOLFOX-6 regimen",
      "Regorafenib"
    ],
    "primary_completion_date": "2025-09-05",
    "completion_date": "2025-09-05",
    "results_first_posted": null,
    "last_update_posted": "2025-10-20",
    "enrollment": null,
    "sponsor": "Arcus Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RCUS",
    "nct_id": "NCT03719326",
    "title": "A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "TNBC - Triple-Negative Breast Cancer",
      "Ovarian Cancer"
    ],
    "interventions": [
      "Etrumadenant",
      "IPI-549",
      "Pegylated liposomal doxorubicin (PLD)",
      "nanoparticle albumin-bound paclitaxel (NP)"
    ],
    "primary_completion_date": "2021-07-01",
    "completion_date": "2021-07-02",
    "results_first_posted": null,
    "last_update_posted": "2024-05-24",
    "enrollment": null,
    "sponsor": "Arcus Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RCUS",
    "nct_id": "NCT06680232",
    "title": "Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HEPATITIS B CHRONIC"
    ],
    "interventions": [
      "PBGENE-HBV"
    ],
    "primary_completion_date": "2025-12",
    "completion_date": "2026-12",
    "results_first_posted": null,
    "last_update_posted": "2025-09-26",
    "enrollment": null,
    "sponsor": "Precision BioSciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RCUS",
    "nct_id": "NCT06608927",
    "title": "Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Pancreatic Ductal Adenocarcinoma"
    ],
    "interventions": [
      "Quemliclustat",
      "Placebo",
      "Nab-paclitaxel",
      "Gemcitabine"
    ],
    "primary_completion_date": "2030-11-30",
    "completion_date": "2030-11-30",
    "results_first_posted": null,
    "last_update_posted": "2025-12-23",
    "enrollment": null,
    "sponsor": "Arcus Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RCUS",
    "nct_id": "NCT04772989",
    "title": "A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumor",
      "Non Small Cell Lung Cancer (NSCLC)",
      "Melanoma",
      "Cervical Cancer",
      "Multiple Myeloma",
      "Lymphoma, Non-Hodgkin",
      "Diffuse Large B Cell Lymphoma (DLBCL)",
      "Gastric Cancer",
      "Gastroesophageal Junction Adenocarcinoma",
      "Esophageal Cancer"
    ],
    "interventions": [
      "AB308",
      "Zimberelimab"
    ],
    "primary_completion_date": "2025-08-25",
    "completion_date": "2025-08-25",
    "results_first_posted": null,
    "last_update_posted": "2025-08-28",
    "enrollment": null,
    "sponsor": "Arcus Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RCUS",
    "nct_id": "NCT03846310",
    "title": "A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non Small Cell Lung Cancer Metastatic",
      "Non Small Cell Lung Cancer",
      "Nonsquamous Nonsmall Cell Neoplasm of Lung",
      "Sensitizing EGFR Gene Mutation"
    ],
    "interventions": [
      "Etrumadenant",
      "Zimberelimab",
      "Carboplatin",
      "Pemetrexed",
      "Pembrolizumab"
    ],
    "primary_completion_date": "2024-11-18",
    "completion_date": "2024-11-18",
    "results_first_posted": null,
    "last_update_posted": "2024-12-09",
    "enrollment": null,
    "sponsor": "Arcus Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RCUS",
    "nct_id": "NCT04104672",
    "title": "A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Pancreatic Cancer"
    ],
    "interventions": [
      "AB680",
      "Zimberelimab",
      "Nab-paclitaxel",
      "Gemcitabine"
    ],
    "primary_completion_date": "2027-05",
    "completion_date": "2027-05",
    "results_first_posted": null,
    "last_update_posted": "2026-01-05",
    "enrollment": null,
    "sponsor": "Arcus Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ROIV",
    "nct_id": "NCT04351243",
    "title": "A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "COVID-19"
    ],
    "interventions": [
      "Gimsilumab",
      "Placebo"
    ],
    "primary_completion_date": "2020-12-01",
    "completion_date": "2021-04-01",
    "results_first_posted": "2021-12-10",
    "last_update_posted": "2021-12-14",
    "enrollment": null,
    "sponsor": "Kinevant Sciences GmbH",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RYTM",
    "nct_id": "NCT00623441",
    "title": "E-Five Registry: A World-Wide Registry With The Endeavor Zotarolimus Eluting Coronary Stent",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Coronary Artery Disease"
    ],
    "interventions": [
      "Endeavor Zotarolimus Eluting Coronary Stent"
    ],
    "primary_completion_date": "2007-11",
    "completion_date": "2009-02",
    "results_first_posted": "2011-12-16",
    "last_update_posted": "2015-11-23",
    "enrollment": null,
    "sponsor": "Medtronic Cardiac Rhythm and Heart Failure",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RYTM",
    "nct_id": "NCT00839566",
    "title": "PAF-HEFT (Permanent Atrial Fibrillation in Heart Failure Trial)",
    "status": "TERMINATED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atrial Fibrillation",
      "Heart Failure"
    ],
    "interventions": [
      "Ablation",
      "Rate Control"
    ],
    "primary_completion_date": "2012-03",
    "completion_date": "2012-07",
    "results_first_posted": null,
    "last_update_posted": "2025-07-03",
    "enrollment": null,
    "sponsor": "Medtronic Cardiac Rhythm and Heart Failure",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RYTM",
    "nct_id": "NCT01357642",
    "title": "Epinephrine Inhalation Aerosol USP: For Evaluation Of Efficacy And Safety In Asthma Patients",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Asthma"
    ],
    "interventions": [
      "Epinephrine inhalation aerosol",
      "Placebo",
      "epinephrine inhalation aerosol"
    ],
    "primary_completion_date": "2011-11",
    "completion_date": "2011-12",
    "results_first_posted": null,
    "last_update_posted": "2016-03-11",
    "enrollment": null,
    "sponsor": "Amphastar Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RYTM",
    "nct_id": "NCT05774756",
    "title": "A Trial of Setmelanotide in Acquired Hypothalamic Obesity",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypothalamic Obesity"
    ],
    "interventions": [
      "Setmelanotide",
      "Placebo"
    ],
    "primary_completion_date": "2025-03-18",
    "completion_date": "2027-04-16",
    "results_first_posted": null,
    "last_update_posted": "2025-07-02",
    "enrollment": null,
    "sponsor": "Rhythm Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "RYTM",
    "nct_id": "NCT05093634",
    "title": "EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Obesity",
      "Genetic Obesity"
    ],
    "interventions": [
      "Setmelanotide",
      "Placebo"
    ],
    "primary_completion_date": "2025-12",
    "completion_date": "2025-12",
    "results_first_posted": null,
    "last_update_posted": "2025-10-15",
    "enrollment": null,
    "sponsor": "Rhythm Pharmaceuticals, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SGMT",
    "nct_id": "NCT07216313",
    "title": "A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "Denifanstat",
      "Resmetirom"
    ],
    "primary_completion_date": "2025-10-20",
    "completion_date": "2025-10-20",
    "results_first_posted": null,
    "last_update_posted": "2026-01-23",
    "enrollment": null,
    "sponsor": "Sagimet Biosciences Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SGMT",
    "nct_id": "NCT03938246",
    "title": "Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)"
    ],
    "interventions": [
      "TVB-2640 25 mg (US)",
      "TVB-2640 50 mg (US)",
      "Placebo (US)",
      "TVB-2640 50 mg (China)",
      "Placebo (China)",
      "TVB-2640 75 mg (US)"
    ],
    "primary_completion_date": "2021-10-02",
    "completion_date": "2021-10-02",
    "results_first_posted": "2024-12-19",
    "last_update_posted": "2024-12-19",
    "enrollment": null,
    "sponsor": "Sagimet Biosciences Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SGMT",
    "nct_id": "NCT05835180",
    "title": "A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-alcoholic Steatohepatitis",
      "Hepatic Impairment",
      "Cirrhosis"
    ],
    "interventions": [
      "TVB-2640 - 50 mg"
    ],
    "primary_completion_date": "2023-12-18",
    "completion_date": "2023-12-18",
    "results_first_posted": null,
    "last_update_posted": "2023-12-26",
    "enrollment": null,
    "sponsor": "Sagimet Biosciences Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SGMT",
    "nct_id": "NCT06692283",
    "title": "A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH",
    "status": "WITHDRAWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "MASLD",
      "MASH",
      "NASH",
      "Metabolic Dysfunction-Associated Steatotic Liver Disease",
      "Metabolic Dysfunction-Associated Steatohepatitis",
      "Nonalcoholic Steatohepatitis",
      "Nonalcoholic Fatty Liver"
    ],
    "interventions": [
      "denifanstat",
      "Placebo"
    ],
    "primary_completion_date": "2026-06",
    "completion_date": "2027-06",
    "results_first_posted": null,
    "last_update_posted": "2025-05-15",
    "enrollment": null,
    "sponsor": "Sagimet Biosciences Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SGMT",
    "nct_id": "NCT06989840",
    "title": "Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acne"
    ],
    "interventions": [
      "TVB-3567",
      "Placebo"
    ],
    "primary_completion_date": "2025-12-01",
    "completion_date": "2026-01-01",
    "results_first_posted": null,
    "last_update_posted": "2025-05-25",
    "enrollment": null,
    "sponsor": "Sagimet Biosciences Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SGMT",
    "nct_id": "NCT04906421",
    "title": "Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease"
    ],
    "interventions": [
      "TVB-2640",
      "Placebo"
    ],
    "primary_completion_date": "2023-10-02",
    "completion_date": "2023-10-02",
    "results_first_posted": "2025-05-09",
    "last_update_posted": "2025-05-09",
    "enrollment": null,
    "sponsor": "Sagimet Biosciences Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SGMT",
    "nct_id": "NCT05657834",
    "title": "Open-label Study of the Absorption, Metabolism, and Excretion of [14C]TVB-2640 Following a Single Oral Dose in Healthy Male Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "[14C]-TVB-2640"
    ],
    "primary_completion_date": "2022-12-21",
    "completion_date": "2022-12-21",
    "results_first_posted": null,
    "last_update_posted": "2022-12-28",
    "enrollment": null,
    "sponsor": "Sagimet Biosciences Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SGMT",
    "nct_id": "NCT02223247",
    "title": "A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Malignant Tumor"
    ],
    "interventions": [
      "TVB-2640"
    ],
    "primary_completion_date": "2017-06",
    "completion_date": "2017-06",
    "results_first_posted": null,
    "last_update_posted": "2017-08-14",
    "enrollment": null,
    "sponsor": "Sagimet Biosciences Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SGMT",
    "nct_id": "NCT06594523",
    "title": "A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis",
    "status": "WITHDRAWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "MASH",
      "NASH",
      "Metabolic Dysfunction-associated Steatohepatitis",
      "Noncirrhotic Metabolic Dysfunction-associated Steatohepatitis",
      "Nonalcoholic Steatohepatitis",
      "Nonalcoholic Fatty Liver"
    ],
    "interventions": [
      "Denifanstat",
      "Placebo"
    ],
    "primary_completion_date": "2030-12",
    "completion_date": "2030-12",
    "results_first_posted": null,
    "last_update_posted": "2025-05-15",
    "enrollment": null,
    "sponsor": "Sagimet Biosciences Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SLDB",
    "nct_id": "NCT06120075",
    "title": "A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Cancer"
    ],
    "interventions": [
      "AB801",
      "Docetaxel"
    ],
    "primary_completion_date": "2026-11",
    "completion_date": "2026-11",
    "results_first_posted": null,
    "last_update_posted": "2026-01-02",
    "enrollment": null,
    "sponsor": "Arcus Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SLDB",
    "nct_id": "NCT04891718",
    "title": "CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia",
    "status": "WITHDRAWN",
    "phase": "EARLY_PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumour"
    ],
    "interventions": [
      "MVC-101",
      "Nivolumab",
      "MVC-101 + Nivolumab"
    ],
    "primary_completion_date": "2022-06-05",
    "completion_date": "2022-06-05",
    "results_first_posted": null,
    "last_update_posted": "2022-07-08",
    "enrollment": null,
    "sponsor": "Presage Biosciences",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SLDB",
    "nct_id": "NCT06614140",
    "title": "Personalized Neoantigen Cancer Vaccine for Patients with Solid Tumors",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cancer",
      "Solid Tumor, Adult"
    ],
    "interventions": [
      "Personalized Neoantigen Peptide Vaccine with Poly-ICLC and Checkpoint Inhibitors"
    ],
    "primary_completion_date": "2025-08-15",
    "completion_date": "2025-08-15",
    "results_first_posted": null,
    "last_update_posted": "2024-09-26",
    "enrollment": null,
    "sponsor": "Seqker Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SLDB",
    "nct_id": "NCT07002203",
    "title": "Personalized Neoantigen Peptide Vaccines for Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumors",
      "Advanced Cancer",
      "Recurrent Cancer",
      "Neoantigen-Specific Immunotherapy",
      "Personalized Cancer Vaccine"
    ],
    "interventions": [
      "Personalized Neoantigen Peptide Vaccine"
    ],
    "primary_completion_date": "2027-08",
    "completion_date": "2027-08",
    "results_first_posted": null,
    "last_update_posted": "2025-12-01",
    "enrollment": null,
    "sponsor": "Seqker Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SLDB",
    "nct_id": "NCT02440685",
    "title": "A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lymphoma, Large B-Cell, Diffuse",
      "Lymphoma, Mantle-Cell",
      "Lymphoma, Follicular",
      "Cancer",
      "Neoplasm",
      "Tumor",
      "Lymphoma, Malignant",
      "Lymphoma, B-cell",
      "Lymphoma, Non-Hodgkin",
      "B-Cell Chronic Lymphocytic Leukemia",
      "B-Cell Leukemia, Chronic",
      "B-Lymphocytic Leukemia, Chronic",
      "Chronic Lymphocytic Leukemia",
      "Leukemia, Lymphocytic, Chronic",
      "Leukemia, Lymphocytic, Chronic, B Cell",
      "Myelofibrosis",
      "Chronic Idiopathic Myelofibrosis",
      "Idiopathic Myelofibrosis",
      "Lymphoma, T Cell, Peripheral",
      "Peripheral T-Cell Lymphoma",
      "T-Cell Lymphoma, Peripheral"
    ],
    "interventions": [
      "ASN002 Dose Escalation",
      "ASN002 RD"
    ],
    "primary_completion_date": "2018-06",
    "completion_date": "2018-07",
    "results_first_posted": "2023-06-07",
    "last_update_posted": "2023-06-07",
    "enrollment": null,
    "sponsor": "Asana BioSciences",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SLDB",
    "nct_id": "NCT06499350",
    "title": "A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Malignant Solid Tumors"
    ],
    "interventions": [
      "FC084CSA+Tislelizumab combination (dose escalation)",
      "RP2D of FC084CSA+Tislelizumab combination (dose expansion)"
    ],
    "primary_completion_date": "2026-02-01",
    "completion_date": "2026-09-01",
    "results_first_posted": null,
    "last_update_posted": "2025-08-07",
    "enrollment": null,
    "sponsor": "FindCure Biosciences (ZhongShan) Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SLDB",
    "nct_id": "NCT05470933",
    "title": "A Study Explore WJ01075 Tablets in Patients With Advanced Solid Tumors",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumors"
    ],
    "interventions": [
      "WJ01075"
    ],
    "primary_completion_date": "2023-04-18",
    "completion_date": "2023-04-18",
    "results_first_posted": null,
    "last_update_posted": "2023-09-01",
    "enrollment": null,
    "sponsor": "Suzhou Junjing BioSciences Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SLDB",
    "nct_id": "NCT01495663",
    "title": "Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cancer"
    ],
    "interventions": [
      "I-131-CLR1404"
    ],
    "primary_completion_date": "2013-11",
    "completion_date": "2014-01",
    "results_first_posted": null,
    "last_update_posted": "2015-02-26",
    "enrollment": null,
    "sponsor": "Cellectar Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SLDB",
    "nct_id": "NCT06720987",
    "title": "A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "KRAS G12C Mutation",
      "KRAS G12S Mutation",
      "Solid Tumor Malignancies",
      "CRC (Colorectal Cancer)"
    ],
    "interventions": [
      "KQB365",
      "Cetuximab"
    ],
    "primary_completion_date": "2029-06-30",
    "completion_date": "2030-06-30",
    "results_first_posted": null,
    "last_update_posted": "2025-07-11",
    "enrollment": null,
    "sponsor": "Kumquat Biosciences Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SLDB",
    "nct_id": "NCT07321106",
    "title": "A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Colorectal Cancer",
      "Colorectal Cancer (CRC)",
      "Colorectal (Colon or Rectal) Cancer",
      "CRC",
      "Metastatic Colon Cancer",
      "Colon Cancer",
      "Advanced Colorectal Cancer"
    ],
    "interventions": [
      "CBI-1214"
    ],
    "primary_completion_date": "2029-04",
    "completion_date": "2029-10",
    "results_first_posted": null,
    "last_update_posted": "2026-01-06",
    "enrollment": null,
    "sponsor": "Cartography Biosciences",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SLDB",
    "nct_id": "NCT05787587",
    "title": "A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced or Metastatic Solid Tumors",
      "Breast Cancer",
      "Ovarian Cancer",
      "Prostate Cancer",
      "Endometrial Cancer",
      "Colorectal Cancer",
      "Head and Neck Cancers",
      "Extensive Stage Small Cell Lung Cancer (ES-SCLC)",
      "NSCLC"
    ],
    "interventions": [
      "IDE-161",
      "Pembrolizumab"
    ],
    "primary_completion_date": "2026-10",
    "completion_date": "2027-05",
    "results_first_posted": null,
    "last_update_posted": "2026-01-23",
    "enrollment": null,
    "sponsor": "IDEAYA Biosciences",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SLDB",
    "nct_id": "NCT05544552",
    "title": "Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Locally Advanced Urothelial Carcinoma",
      "Metastatic Urothelial Carcinoma",
      "Solid Tumor",
      "Urothelial Carcinoma",
      "Solid Tumor, Adult",
      "Bladder Cancer",
      "Non-muscle-invasive Bladder Cancer",
      "FGFR3 Gene Mutation",
      "FGFR3 Gene Alteration",
      "Advanced Solid Tumor",
      "Advanced Urothelial Carcinoma",
      "Urinary Tract Cancer",
      "Urinary Tract Tumor",
      "Urinary Tract Carcinoma"
    ],
    "interventions": [
      "TYRA-300"
    ],
    "primary_completion_date": "2026-11",
    "completion_date": "2027-06",
    "results_first_posted": null,
    "last_update_posted": "2026-01-12",
    "enrollment": null,
    "sponsor": "Tyra Biosciences, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SLDB",
    "nct_id": "NCT06452160",
    "title": "A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Mesothelioma",
      "Epithelioid Hemangioendothelioma(EHE)",
      "Solid Tumor"
    ],
    "interventions": [
      "BGC515"
    ],
    "primary_completion_date": "2027-06",
    "completion_date": "2027-12",
    "results_first_posted": null,
    "last_update_posted": "2024-08-09",
    "enrollment": null,
    "sponsor": "BridGene Biosciences Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SLDB",
    "nct_id": "NCT05462236",
    "title": "MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Colorectal Cancer"
    ],
    "interventions": [
      "Tinodasertib",
      "Pembrolizumab",
      "Irinotecan"
    ],
    "primary_completion_date": "2024-09-30",
    "completion_date": "2026-10-15",
    "results_first_posted": null,
    "last_update_posted": "2024-07-09",
    "enrollment": null,
    "sponsor": "AUM Biosciences Pte Ltd",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SLDB",
    "nct_id": "NCT04592484",
    "title": "A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumor"
    ],
    "interventions": [
      "CDK-002"
    ],
    "primary_completion_date": "2022-08-03",
    "completion_date": "2022-12-23",
    "results_first_posted": null,
    "last_update_posted": "2023-02-08",
    "enrollment": null,
    "sponsor": "Codiak BioSciences",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SLDB",
    "nct_id": "NCT03241173",
    "title": "A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Malignancies"
    ],
    "interventions": [
      "INCAGN01949",
      "Nivolumab",
      "Ipilimumab"
    ],
    "primary_completion_date": "2019-09-17",
    "completion_date": "2019-09-17",
    "results_first_posted": "2022-09-27",
    "last_update_posted": "2022-09-27",
    "enrollment": null,
    "sponsor": "Incyte Biosciences International S\u00e0rl",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SLDB",
    "nct_id": "NCT06792435",
    "title": "XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pancreatic Adenocarcinoma Metastatic",
      "Lung Cancer (NSCLC)",
      "Ovarian Cancer",
      "Colorectal Cancer Metastatic",
      "Biliary Tract Cancer",
      "Gastric Carcinoma",
      "Gastroesophageal Junction Adenocarcinoma"
    ],
    "interventions": [
      "XNW27011",
      "XNW27011"
    ],
    "primary_completion_date": "2025-06-30",
    "completion_date": "2025-12-31",
    "results_first_posted": null,
    "last_update_posted": "2025-02-07",
    "enrollment": null,
    "sponsor": "Evopoint Biosciences Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SLDB",
    "nct_id": "NCT06902350",
    "title": "Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Neoplasms",
      "Glioblastoma, Adult",
      "Small Cell Lung Carcinoma (SCLC)"
    ],
    "interventions": [
      "CS231295"
    ],
    "primary_completion_date": "2029-04",
    "completion_date": "2029-04",
    "results_first_posted": null,
    "last_update_posted": "2025-05-25",
    "enrollment": null,
    "sponsor": "Chipscreen Biosciences, Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SLDB",
    "nct_id": "NCT02128282",
    "title": "Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cholangiocarcinoma"
    ],
    "interventions": [
      "CX-4945",
      "Cisplatin",
      "Gemcitabine"
    ],
    "primary_completion_date": "2020-11-06",
    "completion_date": "2021-08-05",
    "results_first_posted": null,
    "last_update_posted": "2021-10-22",
    "enrollment": null,
    "sponsor": "Senhwa Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SLDB",
    "nct_id": "NCT05704985",
    "title": "Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cancer",
      "Solid Tumor",
      "Colorectal Cancer",
      "Pancreas Cancer",
      "Non Small Cell Lung Cancer",
      "Head and Neck Cancer",
      "Gynecologic Cancer",
      "Skin Cancer",
      "Kidney Cancer"
    ],
    "interventions": [
      "DK210 (EGFR)",
      "Radiation therapy",
      "Immune checkpoint blockers",
      "Chemotherapy"
    ],
    "primary_completion_date": "2025-07",
    "completion_date": "2025-10",
    "results_first_posted": null,
    "last_update_posted": "2025-05-29",
    "enrollment": null,
    "sponsor": "DEKA Biosciences",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SLDB",
    "nct_id": "NCT04890613",
    "title": "Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumor"
    ],
    "interventions": [
      "CX-5461"
    ],
    "primary_completion_date": "2025-12",
    "completion_date": "2026-12",
    "results_first_posted": null,
    "last_update_posted": "2025-08-13",
    "enrollment": null,
    "sponsor": "Senhwa Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SLDB",
    "nct_id": "NCT05326035",
    "title": "A Study of WJ05129 in Advanced Malignant Solid Tumors",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Locally Advanced or Metastatic Malignant Solid Tumors"
    ],
    "interventions": [
      "WJ05129",
      "Paclitaxel injection"
    ],
    "primary_completion_date": "2023-12-26",
    "completion_date": "2023-12-26",
    "results_first_posted": null,
    "last_update_posted": "2025-10-02",
    "enrollment": null,
    "sponsor": "Suzhou Junjing BioSciences Co., Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SLDB",
    "nct_id": "NCT02049957",
    "title": "Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Cancer"
    ],
    "interventions": [
      "Sapanisertib",
      "Fulvestrant",
      "Exemestane"
    ],
    "primary_completion_date": "2018-06-29",
    "completion_date": "2018-06-29",
    "results_first_posted": "2020-01-27",
    "last_update_posted": "2023-02-08",
    "enrollment": null,
    "sponsor": "Calithera Biosciences, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SLDB",
    "nct_id": "NCT05181865",
    "title": "Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors",
    "status": "WITHDRAWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pancreas Cancer",
      "Gastric Cancer",
      "Solid Tumor"
    ],
    "interventions": [
      "1 mg/kg IV FL-301",
      "3 mg/kg IV FL-301",
      "10 mg/kg IV FL-301",
      "20 mg/kg IV FL-301",
      "30 mg/kg IV FL-301",
      "RP2D, IV FL-301",
      "RP2D, IV FL-301",
      "RP2D, IV FL-301"
    ],
    "primary_completion_date": "2022-01-18",
    "completion_date": "2022-01-18",
    "results_first_posted": null,
    "last_update_posted": "2022-02-07",
    "enrollment": null,
    "sponsor": "Flame Biosciences",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SLDB",
    "nct_id": "NCT05068427",
    "title": "Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non Small Cell Lung Cancer"
    ],
    "interventions": [
      "Chidamide",
      "Envafolimab"
    ],
    "primary_completion_date": "2023-02-23",
    "completion_date": "2024-05-16",
    "results_first_posted": null,
    "last_update_posted": "2024-08-07",
    "enrollment": null,
    "sponsor": "Chipscreen Biosciences, Ltd.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SLDB",
    "nct_id": "NCT00369252",
    "title": "Phase I Study of Nimotuzumab in Solid Tumours",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced and/or Metastatic Solid Tumours"
    ],
    "interventions": [
      "Nimotuzumab (TheraCIM h-R3)"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2007-02-28",
    "enrollment": null,
    "sponsor": "YM BioSciences",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SLDB",
    "nct_id": "NCT04265534",
    "title": "KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-Small Cell Lung Cancer",
      "Non-squamous Non-small-cell Lung Cancer",
      "Non-Squamous Non-Small Cell Neoplasm of Lung",
      "KEAP1 Gene Mutation",
      "NRF2 Gene Mutation",
      "NFE2L2 Gene Mutation"
    ],
    "interventions": [
      "Telaglenastat",
      "Carboplatin Chemotherapy",
      "Pemetrexed Chemotherapy",
      "Pembrolizumab Immunotherapy",
      "Placebo",
      "Folic acid 400 -1000 \u03bcg",
      "Vitamin B12 1000 \u03bcg",
      "Dexamethasone 4 mg"
    ],
    "primary_completion_date": "2021-11-05",
    "completion_date": "2022-02-09",
    "results_first_posted": null,
    "last_update_posted": "2022-09-21",
    "enrollment": null,
    "sponsor": "Calithera Biosciences, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SLDB",
    "nct_id": "NCT06723964",
    "title": "A Study of AP505 Injection in Patients With Advanced Malignant Solid Tumors",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumors"
    ],
    "interventions": [
      "AP505"
    ],
    "primary_completion_date": "2024-10-31",
    "completion_date": "2025-11-30",
    "results_first_posted": null,
    "last_update_posted": "2024-12-09",
    "enrollment": null,
    "sponsor": "AP Biosciences Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SLDB",
    "nct_id": "NCT04674748",
    "title": "To Assess the Safety, Tolerability and Pharmacokinetics of INCB086550",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumors"
    ],
    "interventions": [
      "INCB086550"
    ],
    "primary_completion_date": "2022-05-13",
    "completion_date": "2022-05-13",
    "results_first_posted": null,
    "last_update_posted": "2025-09-24",
    "enrollment": null,
    "sponsor": "Incyte Biosciences Japan GK",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SLDB",
    "nct_id": "NCT03163667",
    "title": "CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Clear Cell Renal Cell Carcinoma"
    ],
    "interventions": [
      "Placebo",
      "CB-839",
      "everolimus"
    ],
    "primary_completion_date": "2019-04-26",
    "completion_date": "2020-06-01",
    "results_first_posted": "2022-09-15",
    "last_update_posted": "2022-09-15",
    "enrollment": null,
    "sponsor": "Calithera Biosciences, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SLDB",
    "nct_id": "NCT02756364",
    "title": "Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Neoplasms"
    ],
    "interventions": [
      "Fulvestrant",
      "Sapanisertib"
    ],
    "primary_completion_date": "2019-11-25",
    "completion_date": "2019-11-25",
    "results_first_posted": "2020-12-19",
    "last_update_posted": "2023-02-08",
    "enrollment": null,
    "sponsor": "Calithera Biosciences, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SLDB",
    "nct_id": "NCT03910530",
    "title": "A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumors",
      "Metastatic Solid Tumors"
    ],
    "interventions": [
      "Retifanlimab",
      "INCB001158",
      "Retifanlimab + INCB001158"
    ],
    "primary_completion_date": "2021-12-14",
    "completion_date": "2021-12-14",
    "results_first_posted": null,
    "last_update_posted": "2022-02-25",
    "enrollment": null,
    "sponsor": "Incyte Biosciences Japan GK",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SLDB",
    "nct_id": "NCT06915753",
    "title": "Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Metastatic Hepatocellular Carcinoma",
      "Solid Tumors",
      "Solid Tumor, Adult",
      "FGFR Gene Amplification",
      "FGFR Gene Alterations",
      "FGFR3 Gene Alteration",
      "FGFR3 Gene Mutation",
      "Advanced Solid Tumors",
      "FGFR4 Gene Mutation",
      "FGFR4 Gene Fusions",
      "FGF19 Gene Amplification",
      "FGF19 Gene Overexpression",
      "FGFR3 Gene Fusions",
      "Locally Advanced Unresectable Hepatocellular Carcinoma"
    ],
    "interventions": [
      "TYRA-430"
    ],
    "primary_completion_date": "2028-01",
    "completion_date": "2028-09",
    "results_first_posted": null,
    "last_update_posted": "2025-11-20",
    "enrollment": null,
    "sponsor": "Tyra Biosciences, Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SLDB",
    "nct_id": "NCT03126110",
    "title": "Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Malignancies",
      "Metastatic Cancer"
    ],
    "interventions": [
      "INCAGN01876",
      "Nivolumab",
      "Ipilimumab"
    ],
    "primary_completion_date": "2021-11-09",
    "completion_date": "2021-11-09",
    "results_first_posted": "2022-12-28",
    "last_update_posted": "2025-08-14",
    "enrollment": null,
    "sponsor": "Incyte Biosciences International S\u00e0rl",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SLDB",
    "nct_id": "NCT05947474",
    "title": "ORB-011 In Patients With Advanced Solid Tumors",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Cancer"
    ],
    "interventions": [
      "ORB-011"
    ],
    "primary_completion_date": "2025-12",
    "completion_date": "2025-12",
    "results_first_posted": null,
    "last_update_posted": "2025-08-24",
    "enrollment": null,
    "sponsor": "Orionis Biosciences Inc",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SLDB",
    "nct_id": "NCT02243917",
    "title": "A Phase 1 Study Evaluating CB-5083 in Subjects With Advanced Solid Tumors",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumors"
    ],
    "interventions": [
      "CB-5083"
    ],
    "primary_completion_date": "2017-08-25",
    "completion_date": "2017-08-25",
    "results_first_posted": null,
    "last_update_posted": "2018-02-27",
    "enrollment": null,
    "sponsor": "Cleave Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SLDB",
    "nct_id": "NCT04855435",
    "title": "Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumor"
    ],
    "interventions": [
      "MBS8(1V270)"
    ],
    "primary_completion_date": "2025-12",
    "completion_date": "2026-06",
    "results_first_posted": null,
    "last_update_posted": "2025-05-13",
    "enrollment": null,
    "sponsor": "MonTa Biosciences ApS",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SLDB",
    "nct_id": "NCT04087018",
    "title": "Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumors"
    ],
    "interventions": [
      "zimberelimab"
    ],
    "primary_completion_date": "2024-06-17",
    "completion_date": "2024-06-17",
    "results_first_posted": null,
    "last_update_posted": "2024-09-19",
    "enrollment": null,
    "sponsor": "Arcus Biosciences, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SMMT",
    "nct_id": "NCT03043651",
    "title": "Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEF",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pulmonary Hypertension Associated With HFpEF"
    ],
    "interventions": [
      "Oral treprostinil"
    ],
    "primary_completion_date": "2020-03-02",
    "completion_date": "2020-03-02",
    "results_first_posted": "2020-10-22",
    "last_update_posted": "2020-10-22",
    "enrollment": null,
    "sponsor": "United Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SMMT",
    "nct_id": "NCT02784002",
    "title": "A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Clostridium Difficile Infection"
    ],
    "interventions": [
      "Ridinilazole",
      "Fidaxomicin"
    ],
    "primary_completion_date": "2016-08",
    "completion_date": "2016-08",
    "results_first_posted": null,
    "last_update_posted": "2017-10-12",
    "enrollment": null,
    "sponsor": "Summit Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SMMT",
    "nct_id": "NCT06741228",
    "title": "A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Generalized Anxiety Disorder"
    ],
    "interventions": [
      "Placebo",
      "MM120 (LSD D-Tartrate)"
    ],
    "primary_completion_date": "2026-05",
    "completion_date": "2026-11",
    "results_first_posted": null,
    "last_update_posted": "2026-01-27",
    "enrollment": null,
    "sponsor": "Definium Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SMMT",
    "nct_id": "NCT00653432",
    "title": "Safety and Effectiveness of Monovisc\u00ae Injection for Osteoarthritis of the Knee",
    "status": "COMPLETED",
    "phase": "NA",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Osteoarthritis"
    ],
    "interventions": [
      "Monovisc\u00ae",
      "Saline"
    ],
    "primary_completion_date": "2009-12",
    "completion_date": "2010-02",
    "results_first_posted": "2020-09-01",
    "last_update_posted": "2023-07-11",
    "enrollment": null,
    "sponsor": "Anika Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNDX",
    "nct_id": "NCT05406817",
    "title": "Study of Radiolabeled Revumenib in Adults With Acute Leukemia",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Leukemia"
    ],
    "interventions": [
      "Revumenib"
    ],
    "primary_completion_date": "2024-11-18",
    "completion_date": "2024-11-18",
    "results_first_posted": null,
    "last_update_posted": "2025-01-10",
    "enrollment": null,
    "sponsor": "Syndax Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNDX",
    "nct_id": "NCT02708680",
    "title": "Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Cancer"
    ],
    "interventions": [
      "Entinostat",
      "Atezolizumab",
      "Placebo"
    ],
    "primary_completion_date": "2021-03-31",
    "completion_date": "2021-03-31",
    "results_first_posted": "2023-09-14",
    "last_update_posted": "2024-12-04",
    "enrollment": null,
    "sponsor": "Syndax Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNDX",
    "nct_id": "NCT02915523",
    "title": "Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Epithelial Ovarian Cancer",
      "Peritoneal Cancer",
      "Fallopian Tube Cancer"
    ],
    "interventions": [
      "entinostat",
      "avelumab",
      "Placebo"
    ],
    "primary_completion_date": "2019-02-21",
    "completion_date": "2021-04-21",
    "results_first_posted": "2024-01-10",
    "last_update_posted": "2024-01-10",
    "enrollment": null,
    "sponsor": "Syndax Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNDX",
    "nct_id": "NCT05731947",
    "title": "Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Colorectal Cancer",
      "Solid Tumors"
    ],
    "interventions": [
      "Revumenib",
      "Chemotherapy"
    ],
    "primary_completion_date": "2025-12",
    "completion_date": "2027-08",
    "results_first_posted": null,
    "last_update_posted": "2025-05-13",
    "enrollment": null,
    "sponsor": "Syndax Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNDX",
    "nct_id": "NCT03192111",
    "title": "A Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired Renal Function",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Renal Impairment",
      "Healthy Volunteer"
    ],
    "interventions": [
      "Entinostat"
    ],
    "primary_completion_date": "2017-11-23",
    "completion_date": "2017-11-23",
    "results_first_posted": null,
    "last_update_posted": "2018-04-13",
    "enrollment": null,
    "sponsor": "Syndax Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNDX",
    "nct_id": "NCT03187015",
    "title": "A Study to Examine the Effects of Entinostat on Midazolam in Healthy Adult Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Drug Interaction",
      "Healthy Volunteer"
    ],
    "interventions": [
      "Entinostat",
      "Midazolam"
    ],
    "primary_completion_date": "2017-06-04",
    "completion_date": "2017-08-22",
    "results_first_posted": null,
    "last_update_posted": "2018-08-16",
    "enrollment": null,
    "sponsor": "Syndax Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNDX",
    "nct_id": "NCT02909452",
    "title": "Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Neoplasms",
      "Neoplasms, Glandular and Epithelial",
      "Neoplasms by Histologic Type",
      "Bronchial Neoplasms",
      "Lung Neoplasms",
      "Respiratory Tract Neoplasms",
      "Thoracic Neoplasms",
      "Digestive System Neoplasms",
      "Endocrine Gland Neoplasms",
      "Carcinoma, Non-Small-Cell Lung",
      "Lung Diseases",
      "Breast Diseases",
      "Renal Neoplasm",
      "Solid Tumors"
    ],
    "interventions": [
      "Entinostat",
      "Pembrolizumab"
    ],
    "primary_completion_date": "2019-07-17",
    "completion_date": "2021-02-09",
    "results_first_posted": null,
    "last_update_posted": "2022-01-25",
    "enrollment": null,
    "sponsor": "Syndax Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNDX",
    "nct_id": "NCT00828854",
    "title": "Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "ER+ Breast Cancer"
    ],
    "interventions": [
      "Entinostat",
      "Aromatase Inhibitor (AI) Therapy"
    ],
    "primary_completion_date": "2009-11-24",
    "completion_date": "2009-11-24",
    "results_first_posted": "2022-06-30",
    "last_update_posted": "2022-06-30",
    "enrollment": null,
    "sponsor": "Syndax Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNDX",
    "nct_id": "NCT06226571",
    "title": "A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Myeloid Leukemias"
    ],
    "interventions": [
      "SNDX-5613",
      "Chemotherapy Regimen",
      "HiDAC"
    ],
    "primary_completion_date": "2027-02",
    "completion_date": "2027-02",
    "results_first_posted": null,
    "last_update_posted": "2025-12-02",
    "enrollment": null,
    "sponsor": "Syndax Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNDX",
    "nct_id": "NCT05918913",
    "title": "Expanded Access Program for Revumenib",
    "status": "NO_LONGER_AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Relapsed/Refractory Acute Leukemia"
    ],
    "interventions": [
      "Revumenib"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2025-09-05",
    "enrollment": null,
    "sponsor": "Syndax Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNDX",
    "nct_id": "NCT00866333",
    "title": "A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hodgkin's Lymphoma"
    ],
    "interventions": [
      "Entinostat"
    ],
    "primary_completion_date": "2013-02-08",
    "completion_date": "2013-02-08",
    "results_first_posted": "2019-10-22",
    "last_update_posted": "2019-10-22",
    "enrollment": null,
    "sponsor": "Syndax Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNDX",
    "nct_id": "NCT02820961",
    "title": "Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Cancer",
      "Estrogen Receptor Positive Breast Cancer"
    ],
    "interventions": [
      "entinostat",
      "exemestane"
    ],
    "primary_completion_date": "2018-09-10",
    "completion_date": "2021-07-12",
    "results_first_posted": null,
    "last_update_posted": "2021-12-15",
    "enrollment": null,
    "sponsor": "Syndax Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNDX",
    "nct_id": "NCT05326516",
    "title": "A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsed/Refractory Leukemias",
      "Acute Lymphoblastic Leukemia",
      "Acute Lymphocytic Leukemia",
      "Mixed Phenotype Acute Leukemia",
      "Acute Myeloid Leukemia",
      "Acute Undifferentiated Leukemia"
    ],
    "interventions": [
      "Revumenib",
      "Chemotherapy Regimen 1",
      "Chemotherapy Regimen 2"
    ],
    "primary_completion_date": "2024-07-29",
    "completion_date": "2024-07-29",
    "results_first_posted": null,
    "last_update_posted": "2024-08-13",
    "enrollment": null,
    "sponsor": "Syndax Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNDX",
    "nct_id": "NCT00602030",
    "title": "Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-Small-Cell Lung Carcinoma",
      "Carcinoma, Non-Small Cell Lung"
    ],
    "interventions": [
      "Entinostat",
      "Placebo",
      "Erlotinib"
    ],
    "primary_completion_date": "2010-02-04",
    "completion_date": "2012-02-01",
    "results_first_posted": "2022-06-28",
    "last_update_posted": "2022-08-22",
    "enrollment": null,
    "sponsor": "Syndax Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNDX",
    "nct_id": "NCT02437136",
    "title": "Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-Small Cell Lung Cancer",
      "Melanoma",
      "Mismatch Repair-Proficient Colorectal Cancer"
    ],
    "interventions": [
      "entinostat",
      "pembrolizumab"
    ],
    "primary_completion_date": "2022-09-29",
    "completion_date": "2022-09-29",
    "results_first_posted": "2025-03-20",
    "last_update_posted": "2025-03-20",
    "enrollment": null,
    "sponsor": "Syndax Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNDX",
    "nct_id": "NCT01594398",
    "title": "Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lung Cancer",
      "Non Small Cell Lung Cancer (NSCLC)",
      "Breast Cancer",
      "Estrogen Receptor Breast Cancer"
    ],
    "interventions": [
      "entinostat",
      "entinostat",
      "Erlotinib",
      "Erlotinib",
      "Exemestane",
      "Exemestane"
    ],
    "primary_completion_date": "2014-04",
    "completion_date": "2014-05",
    "results_first_posted": null,
    "last_update_posted": "2021-11-19",
    "enrollment": null,
    "sponsor": "Syndax Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNDX",
    "nct_id": "NCT04415073",
    "title": "A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Coronavirus",
      "COVID",
      "ARDS",
      "Cytokine Storm",
      "Cytokine Release Syndrome"
    ],
    "interventions": [
      "SNDX-6352",
      "Placebo"
    ],
    "primary_completion_date": "2020-07-13",
    "completion_date": "2020-07-13",
    "results_first_posted": "2022-07-22",
    "last_update_posted": "2022-07-22",
    "enrollment": null,
    "sponsor": "Syndax Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNDX",
    "nct_id": "NCT03238027",
    "title": "A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Solid Tumor",
      "Metastatic Tumor",
      "Locally Advanced Malignant Neoplasm",
      "Unresectable Malignant Neoplasm"
    ],
    "interventions": [
      "Axatilimab",
      "Durvalumab"
    ],
    "primary_completion_date": "2020-11-20",
    "completion_date": "2020-11-20",
    "results_first_posted": null,
    "last_update_posted": "2024-05-17",
    "enrollment": null,
    "sponsor": "Syndax Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNDX",
    "nct_id": "NCT03604692",
    "title": "A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Graft-versus-host-disease"
    ],
    "interventions": [
      "axatilimab"
    ],
    "primary_completion_date": "2022-08-12",
    "completion_date": "2024-10-18",
    "results_first_posted": "2024-11-27",
    "last_update_posted": "2025-09-15",
    "enrollment": null,
    "sponsor": "Syndax Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNDX",
    "nct_id": "NCT02922946",
    "title": "Study to Determine the Effect of the Timing of a Meal on the Pharmacokinetics of Entinostat",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Volunteers",
      "Healthy Volunteers",
      "Human Volunteers",
      "Normal Volunteers"
    ],
    "interventions": [
      "Entinostat"
    ],
    "primary_completion_date": "2017-05-20",
    "completion_date": "2017-06-26",
    "results_first_posted": null,
    "last_update_posted": "2018-08-16",
    "enrollment": null,
    "sponsor": "Syndax Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNDX",
    "nct_id": "NCT00750698",
    "title": "A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non Small Cell Lung Cancer"
    ],
    "interventions": [
      "Entinostat",
      "Erlotinib"
    ],
    "primary_completion_date": "2010-05",
    "completion_date": "2010-06",
    "results_first_posted": "2023-07-06",
    "last_update_posted": "2023-07-06",
    "enrollment": null,
    "sponsor": "Syndax Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNDX",
    "nct_id": "NCT04710576",
    "title": "A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Graft-versus-host-disease"
    ],
    "interventions": [
      "Axatilimab"
    ],
    "primary_completion_date": "2023-04-07",
    "completion_date": "2027-12",
    "results_first_posted": "2024-10-10",
    "last_update_posted": "2025-09-03",
    "enrollment": null,
    "sponsor": "Syndax Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNDX",
    "nct_id": "NCT00754312",
    "title": "A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Cancer"
    ],
    "interventions": [
      "SNDX-275"
    ],
    "primary_completion_date": "2009-02-28",
    "completion_date": "2009-02-28",
    "results_first_posted": null,
    "last_update_posted": "2022-06-06",
    "enrollment": null,
    "sponsor": "Syndax Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNDX",
    "nct_id": "NCT04065399",
    "title": "A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Myeloid Leukemia",
      "Acute Lymphoblastic Leukemia",
      "Mixed Lineage Acute Leukemia",
      "Mixed Phenotype Acute Leukemia",
      "Acute Leukemia of Ambiguous Lineage"
    ],
    "interventions": [
      "revumenib",
      "cobicistat"
    ],
    "primary_completion_date": "2027-12-15",
    "completion_date": "2027-12-15",
    "results_first_posted": null,
    "last_update_posted": "2025-11-10",
    "enrollment": null,
    "sponsor": "Syndax Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNDX",
    "nct_id": "NCT00676663",
    "title": "Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Cancer",
      "Estrogen Receptor-Positive Breast Cancer",
      "Breast Cancer, Estrogen Receptor-Positive",
      "ER+ Breast Cancer"
    ],
    "interventions": [
      "entinostat",
      "exemestane",
      "Placebo"
    ],
    "primary_completion_date": "2011-01-29",
    "completion_date": "2012-11-26",
    "results_first_posted": "2019-10-24",
    "last_update_posted": "2022-05-11",
    "enrollment": null,
    "sponsor": "Syndax Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNDX",
    "nct_id": "NCT02922933",
    "title": "A Study to Examine the Effect of Omeprazole, Famotidine, and an Acidic Beverage on the Pharmacokinetics of Entinostat in Healthy Adult Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Volunteers",
      "Healthy Volunteers",
      "Human Volunteers",
      "Normal Volunteers"
    ],
    "interventions": [
      "entinostat",
      "Omeprazole",
      "Famotidine"
    ],
    "primary_completion_date": "2017-04-19",
    "completion_date": "2017-05-08",
    "results_first_posted": null,
    "last_update_posted": "2018-08-16",
    "enrollment": null,
    "sponsor": "Syndax Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNDX",
    "nct_id": "NCT02897778",
    "title": "Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Neoplasms",
      "Neoplasms, Glandular and Epithelial",
      "Neoplasms by Histologic Type",
      "Bronchial Neoplasms",
      "Lung Neoplasms",
      "Respiratory Tract Neoplasms",
      "Thoracic Neoplasms",
      "Digestive System Neoplasms",
      "Endocrine Gland Neoplasms",
      "Carcinoma, Non-Small-Cell Lung",
      "Lung Diseases",
      "Breast Neoplasms",
      "Breast Diseases",
      "Renal Neoplasm",
      "Solid Tumors"
    ],
    "interventions": [
      "Entinostat",
      "Placebo"
    ],
    "primary_completion_date": "2017-03-13",
    "completion_date": "2017-03-13",
    "results_first_posted": null,
    "last_update_posted": "2022-04-28",
    "enrollment": null,
    "sponsor": "Syndax Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNDX",
    "nct_id": "NCT02115594",
    "title": "Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer",
    "status": "WITHDRAWN",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Breast Cancer"
    ],
    "interventions": [
      "Fulvestrant",
      "Entinostat",
      "Placebo"
    ],
    "primary_completion_date": "2015-12",
    "completion_date": "2016-06",
    "results_first_posted": null,
    "last_update_posted": "2014-10-08",
    "enrollment": null,
    "sponsor": "Syndax Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNDX",
    "nct_id": "NCT06132256",
    "title": "MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Idiopathic Pulmonary Fibrosis"
    ],
    "interventions": [
      "Axatilimab",
      "Placebo"
    ],
    "primary_completion_date": "2026-09",
    "completion_date": "2026-11",
    "results_first_posted": null,
    "last_update_posted": "2025-12-22",
    "enrollment": null,
    "sponsor": "Syndax Pharmaceuticals",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNY",
    "nct_id": "NCT00280605",
    "title": "ALF-ONE : ALFuzosin ONcE Daily",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Prostatic Hyperplasia"
    ],
    "interventions": [
      "Alfuzosin"
    ],
    "primary_completion_date": "2006-02",
    "completion_date": "2006-02",
    "results_first_posted": null,
    "last_update_posted": "2010-08-31",
    "enrollment": null,
    "sponsor": "Sanofi",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNY",
    "nct_id": "NCT01839175",
    "title": "Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Neisseria Meningitidis",
      "Bacterial Infections",
      "Virus Diseases"
    ],
    "interventions": [
      "Hexavalent vaccine",
      "NeisVac-C",
      "Prevenar 13",
      "RotaTeq",
      "Nimenrix",
      "M-M-RVAXPRO"
    ],
    "primary_completion_date": "2014-07",
    "completion_date": "2015-02",
    "results_first_posted": null,
    "last_update_posted": "2017-09-11",
    "enrollment": null,
    "sponsor": "Sanofi Pasteur, a Sanofi Company",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNY",
    "nct_id": "NCT00477373",
    "title": "Gulf Evaluation of VAlproate (Depakine Chrono) in maNia Study",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bipolar Disorder"
    ],
    "interventions": [
      "depakine chrono"
    ],
    "primary_completion_date": "2007-12",
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2008-12-19",
    "enrollment": null,
    "sponsor": "Sanofi",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNY",
    "nct_id": "NCT04269551",
    "title": "A Safety and Tolerability Study of BIVV020 in Adults With Cold Agglutinin Disease",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Autoimmune Haemolytic Anaemia"
    ],
    "interventions": [
      "BIVV020"
    ],
    "primary_completion_date": "2022-01-06",
    "completion_date": "2022-01-06",
    "results_first_posted": null,
    "last_update_posted": "2025-09-22",
    "enrollment": null,
    "sponsor": "Bioverativ, a Sanofi company",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNY",
    "nct_id": "NCT01233895",
    "title": "Study of AVE1642 Anti-IGF1R Monoclonal Antibody in Patients With Advanced Multiple Myeloma",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple Myeloma"
    ],
    "interventions": [
      "AVE1642",
      "Velcade"
    ],
    "primary_completion_date": "2008-09",
    "completion_date": "2008-09",
    "results_first_posted": null,
    "last_update_posted": "2010-11-03",
    "enrollment": null,
    "sponsor": "Sanofi",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNY",
    "nct_id": "NCT06968975",
    "title": "Real-world Study of Treatment Outcomes in Chronic Inflammatory Demyelinating Polyneuropathy/Polyradiculoneuropathy (CIDP)",
    "status": "RECRUITING",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Polyneuropathy, Inflammatory Demyelinating, Chronic"
    ],
    "interventions": [],
    "primary_completion_date": "2027-05-17",
    "completion_date": "2027-05-17",
    "results_first_posted": null,
    "last_update_posted": "2025-06-29",
    "enrollment": null,
    "sponsor": "Sanofi",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNY",
    "nct_id": "NCT00174681",
    "title": "Tulip Study: Testing the Usefulness of Lantus When Initiated Prematurely In Patients With Type 2 Diabetes",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes Mellitus, Type 2"
    ],
    "interventions": [
      "Insulin Glargine"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2011-01-11",
    "enrollment": null,
    "sponsor": "Sanofi",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNY",
    "nct_id": "NCT00611507",
    "title": "A Phase II Study of Oxaliplatin in Association With 5FU and Folinic Acid in the Treatment of Subjects With Non-Surgical or Advanced Metastatic Gastric Cancer",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Stomach Neoplasms"
    ],
    "interventions": [
      "Oxaliplatin, 5-Fluorouracil"
    ],
    "primary_completion_date": null,
    "completion_date": "2004-04",
    "results_first_posted": null,
    "last_update_posted": "2008-03-25",
    "enrollment": null,
    "sponsor": "Sanofi",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNY",
    "nct_id": "NCT00701831",
    "title": "Assessment of Insulin Glargine in Type 2 Patients for Good Glycemic Control",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes Mellitus, Type 2"
    ],
    "interventions": [
      "Insulin glargine"
    ],
    "primary_completion_date": "2010-10",
    "completion_date": "2010-10",
    "results_first_posted": null,
    "last_update_posted": "2010-11-04",
    "enrollment": null,
    "sponsor": "Sanofi",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNY",
    "nct_id": "NCT00811395",
    "title": "Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple Sclerosis"
    ],
    "interventions": [
      "Teriflunomide",
      "Placebo (for teriflunomide)",
      "Interferon-\u03b2 [IFN-\u03b2]",
      "Glatiramer Acetate [GA]"
    ],
    "primary_completion_date": "2010-04",
    "completion_date": "2010-04",
    "results_first_posted": "2012-12-31",
    "last_update_posted": "2012-12-31",
    "enrollment": null,
    "sponsor": "Sanofi",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNY",
    "nct_id": "NCT00331981",
    "title": "Amisulpride in Schizophrenic Patients",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia"
    ],
    "interventions": [
      "Amisulpride"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2008-04-10",
    "enrollment": null,
    "sponsor": "Sanofi",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNY",
    "nct_id": "NCT05692154",
    "title": "A Placebo-controlled Study of 2-day Pre-treatment With Fexofenadine in Seasonal Allergic Rhinitis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Seasonal Allergic Rhinitis"
    ],
    "interventions": [
      "Fexofenadine",
      "Placebo"
    ],
    "primary_completion_date": "2023-03-14",
    "completion_date": "2023-03-14",
    "results_first_posted": "2024-05-16",
    "last_update_posted": "2025-09-09",
    "enrollment": null,
    "sponsor": "Opella Healthcare Group SAS, a Sanofi Company",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNY",
    "nct_id": "NCT01753453",
    "title": "An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem Cells",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple Myeloma"
    ],
    "interventions": [
      "Plerixafor",
      "Granulocyte-colony stimulating factor (G-CSF)"
    ],
    "primary_completion_date": "2016-09",
    "completion_date": "2016-09",
    "results_first_posted": null,
    "last_update_posted": "2021-02-23",
    "enrollment": null,
    "sponsor": "Sanofi",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNY",
    "nct_id": "NCT01475539",
    "title": "Sequential Inactivated Poliomyelitis Vaccine Followed by Oral Poliomyelitis Vaccine Versus Oral Poliomyelitis Vaccine",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Polio",
      "Poliomyelitis"
    ],
    "interventions": [
      "Injectable inactivated types 1, 2 and 3 poliovirus + Live oral Polio",
      "Injectable inactivated types 1, 2 and 3 poliovirus + Live oral Polio",
      "Live oral poliovirus type 1, 2 and 3"
    ],
    "primary_completion_date": "2013-05",
    "completion_date": "2013-11",
    "results_first_posted": null,
    "last_update_posted": "2015-01-12",
    "enrollment": null,
    "sponsor": "Sanofi Pasteur, a Sanofi Company",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNY",
    "nct_id": "NCT00078455",
    "title": "Study of ILX651 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non-Small-Cell Lung Carcinoma"
    ],
    "interventions": [
      "ILX651"
    ],
    "primary_completion_date": null,
    "completion_date": "2005-08",
    "results_first_posted": null,
    "last_update_posted": "2015-03-05",
    "enrollment": null,
    "sponsor": "Genzyme, a Sanofi Company",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNY",
    "nct_id": "NCT00622115",
    "title": "Etude (Study) Phase I Enox - UnFractionated Heparin (UFH)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Thrombosis"
    ],
    "interventions": [
      "Enoxaparin"
    ],
    "primary_completion_date": "2007-11",
    "completion_date": "2007-11",
    "results_first_posted": null,
    "last_update_posted": "2011-03-15",
    "enrollment": null,
    "sponsor": "Sanofi",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNY",
    "nct_id": "NCT00259376",
    "title": "American-Australian-African Trial With Dronedarone in Patients With Atrial Fibrillation or Atrial Flutter for the Maintenance of Sinus Rhythm",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Atrial Fibrillation",
      "Atrial Flutter"
    ],
    "interventions": [
      "Dronedarone (SR33589)",
      "placebo"
    ],
    "primary_completion_date": "2003-09",
    "completion_date": "2003-09",
    "results_first_posted": null,
    "last_update_posted": "2010-02-15",
    "enrollment": null,
    "sponsor": "Sanofi",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNY",
    "nct_id": "NCT05086315",
    "title": "First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Lymphocytic Leukaemia",
      "Acute Myeloid Leukaemia Refractory",
      "Myelodysplastic Syndromes",
      "Blastic Plasmacytoid Dendritic Cell Neoplasia"
    ],
    "interventions": [
      "SAR443579"
    ],
    "primary_completion_date": "2025-06-13",
    "completion_date": "2025-06-13",
    "results_first_posted": null,
    "last_update_posted": "2025-12-15",
    "enrollment": null,
    "sponsor": "Sanofi",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNY",
    "nct_id": "NCT02749890",
    "title": "Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 2 Diabetes Mellitus"
    ],
    "interventions": [
      "Insulin glargine/Lixisenatide (HOE901/AVE0010)",
      "Lixisenatide (AVE0010)",
      "Oral anti-diabetic drugs"
    ],
    "primary_completion_date": "2018-05",
    "completion_date": "2018-05",
    "results_first_posted": null,
    "last_update_posted": "2020-06-16",
    "enrollment": null,
    "sponsor": "Sanofi",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNY",
    "nct_id": "NCT00855855",
    "title": "Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Haemophilus Infections",
      "Diphtheria",
      "Tetanus",
      "Polio",
      "Pertussis"
    ],
    "interventions": [
      "DTaP-IPV/Hib"
    ],
    "primary_completion_date": "2014-12",
    "completion_date": "2014-12",
    "results_first_posted": null,
    "last_update_posted": "2022-04-25",
    "enrollment": null,
    "sponsor": "Sanofi Pasteur, a Sanofi Company",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNY",
    "nct_id": "NCT04210349",
    "title": "Study of Shenzhen Quadrivalent Inactivated Influenza Vaccine Versus the Shenzhen Trivalent Inactivated Influenza Vaccine in Chinese Subjects From 6 Months of Age",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Influenza"
    ],
    "interventions": [
      "Quadrivalent Influenza Vaccine",
      "Trivalent Influenza Vaccine 1 SP Shz TIV1",
      "Trivalent Influenza Vaccine 2 SP Shz TIV2"
    ],
    "primary_completion_date": "2020-12-01",
    "completion_date": "2020-12-01",
    "results_first_posted": null,
    "last_update_posted": "2025-09-16",
    "enrollment": null,
    "sponsor": "Sanofi Pasteur, a Sanofi Company",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNY",
    "nct_id": "NCT06224348",
    "title": "A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dermatitis Atopic"
    ],
    "interventions": [
      "Amlitelimab",
      "Placebo",
      "Topical corticosteroids",
      "Topical calcineurin inhibitors"
    ],
    "primary_completion_date": "2025-08-21",
    "completion_date": "2025-11-01",
    "results_first_posted": null,
    "last_update_posted": "2025-12-02",
    "enrollment": null,
    "sponsor": "Sanofi",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNY",
    "nct_id": "NCT00263029",
    "title": "Preoperative Radiotherapy/ Oxaliplatin/ Capecitabine Treatment For Unresectable Locally-advanced Rectal Cancer",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rectal Neoplasms"
    ],
    "interventions": [
      "Oxaliplatin",
      "Capecitabine",
      "Radiotherapy"
    ],
    "primary_completion_date": "2007-03",
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2009-09-18",
    "enrollment": null,
    "sponsor": "Sanofi",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNY",
    "nct_id": "NCT06141473",
    "title": "Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple Sclerosis"
    ],
    "interventions": [
      "Frexalimab",
      "Teriflunomide",
      "Placebo infusion",
      "Placebo tablet",
      "MRI contrast-enhancing agents",
      "Cholestyramine",
      "Activated charcoal"
    ],
    "primary_completion_date": "2027-05-06",
    "completion_date": "2027-05-06",
    "results_first_posted": null,
    "last_update_posted": "2026-01-27",
    "enrollment": null,
    "sponsor": "Sanofi",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNY",
    "nct_id": "NCT03275454",
    "title": "A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple- Dose BIVV009 in Participants With Chronic Immune Thrombocytopenia (ITP)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Purpura, Thrombocytopenic, Idiopathic"
    ],
    "interventions": [
      "BIVV009 6.5 grams",
      "BIVV009 7.5 grams"
    ],
    "primary_completion_date": "2021-02-16",
    "completion_date": "2021-02-16",
    "results_first_posted": null,
    "last_update_posted": "2023-05-18",
    "enrollment": null,
    "sponsor": "Bioverativ, a Sanofi company",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNY",
    "nct_id": "NCT00941369",
    "title": "Health Assessment, Patient Treatment Satisfaction and Quality-of-Life in Insulin-Naive Type 2 Diabetes Patients",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetes Mellitus, Type 2"
    ],
    "interventions": [
      "Insulin Glargine (HOE901)/NPH Insulin"
    ],
    "primary_completion_date": "2012-10",
    "completion_date": "2012-10",
    "results_first_posted": null,
    "last_update_posted": "2012-11-22",
    "enrollment": null,
    "sponsor": "Sanofi",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNY",
    "nct_id": "NCT00206661",
    "title": "Safety and Efficacy Study in the Treatment of Pediatric Crohn's Disease",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Crohn Disease"
    ],
    "interventions": [
      "Sargramostim (Leukine)",
      "Sargramostim (Leukine)"
    ],
    "primary_completion_date": "2006-12",
    "completion_date": "2006-12",
    "results_first_posted": null,
    "last_update_posted": "2013-12-04",
    "enrollment": null,
    "sponsor": "Genzyme, a Sanofi Company",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNY",
    "nct_id": "NCT00260351",
    "title": "Immunogenicity and Safety of Verorab\u2122 in Indian Population",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rabies"
    ],
    "interventions": [
      "Purified Verocell Rabies Vaccine",
      "Purified Verocell Rabies Vaccine",
      "Purified Verocell Rabies Vaccine"
    ],
    "primary_completion_date": "2008-08",
    "completion_date": "2008-10",
    "results_first_posted": null,
    "last_update_posted": "2014-01-14",
    "enrollment": null,
    "sponsor": "Sanofi Pasteur, a Sanofi Company",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNY",
    "nct_id": "NCT01954394",
    "title": "Open Label Study of Long Term Safety Evaluation of Alirocumab",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypercholesterolemia"
    ],
    "interventions": [
      "Alirocumab",
      "Lipid-Modifying Therapy (LMT)"
    ],
    "primary_completion_date": "2017-06-30",
    "completion_date": "2017-06-30",
    "results_first_posted": "2018-07-24",
    "last_update_posted": "2018-07-24",
    "enrollment": null,
    "sponsor": "Sanofi",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNY",
    "nct_id": "NCT00373529",
    "title": "A Study of Clofarabine for Older Patients With Newly Diagnosed Acute Myelogenous Leukemia (AML) (CLASSIC II)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Acute Myelogenous Leukemia",
      "Acute Myeloid Leukemia"
    ],
    "interventions": [
      "clofarabine"
    ],
    "primary_completion_date": "2008-05",
    "completion_date": "2010-05",
    "results_first_posted": "2011-03-24",
    "last_update_posted": "2014-04-14",
    "enrollment": null,
    "sponsor": "Genzyme, a Sanofi Company",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNY",
    "nct_id": "NCT00930553",
    "title": "An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple Sclerosis, Relapsing-Remitting"
    ],
    "interventions": [
      "alemtuzumab"
    ],
    "primary_completion_date": "2016-02",
    "completion_date": "2016-02",
    "results_first_posted": "2017-05-15",
    "last_update_posted": "2017-05-15",
    "enrollment": null,
    "sponsor": "Genzyme, a Sanofi Company",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNY",
    "nct_id": "NCT00418886",
    "title": "Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Non Small Cell Lung Cancer",
      "Lung Cancer"
    ],
    "interventions": [
      "Vandetanib",
      "Pemetrexed"
    ],
    "primary_completion_date": "2008-09",
    "completion_date": "2023-02-14",
    "results_first_posted": "2012-03-26",
    "last_update_posted": "2024-12-31",
    "enrollment": null,
    "sponsor": "Genzyme, a Sanofi Company",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SNY",
    "nct_id": "NCT02973321",
    "title": "A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Type 2 Diabetes Mellitus"
    ],
    "interventions": [
      "SAR425899",
      "Placebo",
      "Liraglutide",
      "Metformin"
    ],
    "primary_completion_date": "2017-12-27",
    "completion_date": "2017-12-27",
    "results_first_posted": "2021-02-09",
    "last_update_posted": "2022-03-24",
    "enrollment": null,
    "sponsor": "Sanofi",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SRPT",
    "nct_id": "NCT04004065",
    "title": "Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Expansion (Part B) in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy"
    ],
    "interventions": [
      "Vesleteplirsen"
    ],
    "primary_completion_date": "2023-10-30",
    "completion_date": "2025-02-07",
    "results_first_posted": null,
    "last_update_posted": "2025-03-10",
    "enrollment": null,
    "sponsor": "Sarepta Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SRPT",
    "nct_id": "NCT02500381",
    "title": "Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy"
    ],
    "interventions": [
      "SRP-4045",
      "SRP-4053",
      "Placebo"
    ],
    "primary_completion_date": "2024-11-12",
    "completion_date": "2025-10-16",
    "results_first_posted": null,
    "last_update_posted": "2025-11-18",
    "enrollment": null,
    "sponsor": "Sarepta Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SRPT",
    "nct_id": "NCT03985878",
    "title": "A Study to Evaluate Safety, Tolerability, and Efficacy of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) Who Have Completed Study 4658-102 (NCT03218995)",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy"
    ],
    "interventions": [
      "Eteplirsen"
    ],
    "primary_completion_date": "2022-08-31",
    "completion_date": "2022-08-31",
    "results_first_posted": "2023-08-18",
    "last_update_posted": "2023-08-18",
    "enrollment": null,
    "sponsor": "Sarepta Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SRPT",
    "nct_id": "NCT04626674",
    "title": "A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Muscular Dystrophy, Duchenne"
    ],
    "interventions": [
      "delandistrogene moxeparvovec"
    ],
    "primary_completion_date": "2027-12-31",
    "completion_date": "2028-02-29",
    "results_first_posted": null,
    "last_update_posted": "2025-12-29",
    "enrollment": null,
    "sponsor": "Sarepta Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SRPT",
    "nct_id": "NCT06246513",
    "title": "A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Limb-girdle Muscular Dystrophy"
    ],
    "interventions": [
      "SRP-9003",
      "Glucocorticoid"
    ],
    "primary_completion_date": "2025-03-04",
    "completion_date": "2029-11-30",
    "results_first_posted": null,
    "last_update_posted": "2025-07-10",
    "enrollment": null,
    "sponsor": "Sarepta Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SRPT",
    "nct_id": "NCT00229749",
    "title": "Study of AVI-4065 in Healthy Volunteers and Chronic Active HCV Patients",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatitis C"
    ],
    "interventions": [
      "AVI-4065 Injection"
    ],
    "primary_completion_date": "2006-10",
    "completion_date": "2007-01",
    "results_first_posted": null,
    "last_update_posted": "2008-04-10",
    "enrollment": null,
    "sponsor": "Sarepta Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SRPT",
    "nct_id": "NCT03769116",
    "title": "A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy (DMD)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Muscular Dystrophy, Duchenne"
    ],
    "interventions": [
      "delandistrogene moxeparvovec",
      "placebo"
    ],
    "primary_completion_date": "2020-12-08",
    "completion_date": "2023-08-16",
    "results_first_posted": "2023-09-15",
    "last_update_posted": "2024-11-14",
    "enrollment": null,
    "sponsor": "Sarepta Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SRPT",
    "nct_id": "NCT00387283",
    "title": "Pharmacokinetic Study in Cerebral Spinal Fluid After a Single Dose of AVI-4020",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "West Nile Virus"
    ],
    "interventions": [
      "AVI-4020 Injection"
    ],
    "primary_completion_date": "2006-12",
    "completion_date": "2009-06",
    "results_first_posted": null,
    "last_update_posted": "2009-07-08",
    "enrollment": null,
    "sponsor": "Sarepta Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SRPT",
    "nct_id": "NCT05967351",
    "title": "A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy"
    ],
    "interventions": [
      "delandistrogene moxeparvovec"
    ],
    "primary_completion_date": "2030-11-30",
    "completion_date": "2030-11-30",
    "results_first_posted": null,
    "last_update_posted": "2025-01-17",
    "enrollment": null,
    "sponsor": "Sarepta Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SRPT",
    "nct_id": "NCT00244647",
    "title": "A Phase 1b Study Evaluating RESTEN-MP in Subjects With Focal de Novo Stenosis",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Coronary Artery Disease",
      "Coronary Stent Restenosis"
    ],
    "interventions": [
      "RESTEN-MP"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2008-04-10",
    "enrollment": null,
    "sponsor": "Sarepta Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SRPT",
    "nct_id": "NCT05906251",
    "title": "A Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of SRP-6004 in Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2B/R2 (LGMD2B/R2, Dysferlin [DYSF] Related)",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Limb Girdle Muscular Dystrophy"
    ],
    "interventions": [
      "SRP-6004"
    ],
    "primary_completion_date": "2025-06-13",
    "completion_date": "2025-06-13",
    "results_first_posted": null,
    "last_update_posted": "2025-09-04",
    "enrollment": null,
    "sponsor": "Sarepta Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SRPT",
    "nct_id": "NCT06270719",
    "title": "An Observational Study Comparing Delandistrogene Moxeparvovec With Standard of Care in Participants With Duchenne Muscular Dystrophy",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy"
    ],
    "interventions": [
      "Delandistrogene Moxeparvovec",
      "Standard of Care"
    ],
    "primary_completion_date": "2029-12-31",
    "completion_date": "2038-12-31",
    "results_first_posted": null,
    "last_update_posted": "2025-12-02",
    "enrollment": null,
    "sponsor": "Sarepta Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SRPT",
    "nct_id": "NCT06747273",
    "title": "Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9004 Administered by Systemic Infusion in Limb Girdle Muscular Dystrophy Type 2D/R3 Participants in the United States",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Limb Girdle Muscular Dystrophy",
      "Limb Girdle Muscular Dystrophy Type 2D/R3"
    ],
    "interventions": [
      "SRP-9004"
    ],
    "primary_completion_date": "2025-06-18",
    "completion_date": "2025-06-18",
    "results_first_posted": null,
    "last_update_posted": "2025-09-04",
    "enrollment": null,
    "sponsor": "Sarepta Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SRPT",
    "nct_id": "NCT01566877",
    "title": "A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7288 in Healthy Adult Volunteers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Marburg Hemorrhagic Fever"
    ],
    "interventions": [
      "AVI-7288",
      "Placebo"
    ],
    "primary_completion_date": "2014-01",
    "completion_date": "2014-01",
    "results_first_posted": null,
    "last_update_posted": "2014-05-07",
    "enrollment": null,
    "sponsor": "Sarepta Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SRPT",
    "nct_id": "NCT00844597",
    "title": "Dose-Ranging Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy (DMD) Patients",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy"
    ],
    "interventions": [
      "AVI-4658 for Injection"
    ],
    "primary_completion_date": "2010-06",
    "completion_date": "2010-12",
    "results_first_posted": "2015-10-06",
    "last_update_posted": "2015-10-06",
    "enrollment": null,
    "sponsor": "Sarepta Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SRPT",
    "nct_id": "NCT03675126",
    "title": "An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051 (Vesleteplirsen)",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Muscular Dystrophy, Duchenne"
    ],
    "interventions": [
      "SRP-5051"
    ],
    "primary_completion_date": "2021-08-25",
    "completion_date": "2021-08-25",
    "results_first_posted": "2024-09-19",
    "last_update_posted": "2024-09-19",
    "enrollment": null,
    "sponsor": "Sarepta Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SRPT",
    "nct_id": "NCT03652259",
    "title": "Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-Girdle Muscular Dystrophy, Type 2E (LGMD2E) (Beta-Sarcoglycan Deficiency)",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Limb-Girdle Muscular Dystrophy, Type 2E"
    ],
    "interventions": [
      "SRP-9003"
    ],
    "primary_completion_date": "2025-01-14",
    "completion_date": "2025-01-14",
    "results_first_posted": null,
    "last_update_posted": "2026-01-20",
    "enrollment": null,
    "sponsor": "Sarepta Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SRPT",
    "nct_id": "NCT06597656",
    "title": "A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma Exchange (Plasmapheresis) in Participants With Duchenne Muscular Dystrophy (DMD) and Pre-existing Antibodies to AAVrh74",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy"
    ],
    "interventions": [
      "delandistrogene moxeparvovec",
      "Plasmapheresis"
    ],
    "primary_completion_date": "2025-08-05",
    "completion_date": "2025-08-05",
    "results_first_posted": null,
    "last_update_posted": "2025-09-04",
    "enrollment": null,
    "sponsor": "Sarepta Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SRPT",
    "nct_id": "NCT03532542",
    "title": "An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy"
    ],
    "interventions": [
      "Casimersen",
      "Golodirsen"
    ],
    "primary_completion_date": "2023-07-26",
    "completion_date": "2023-07-26",
    "results_first_posted": "2024-09-19",
    "last_update_posted": "2024-09-19",
    "enrollment": null,
    "sponsor": "Sarepta Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SRPT",
    "nct_id": "NCT03375255",
    "title": "A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 (Vesleteplirsen) in Patients With Duchenne Muscular Dystrophy (DMD)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Muscular Dystrophy, Duchenne"
    ],
    "interventions": [
      "SRP-5051"
    ],
    "primary_completion_date": "2019-08-19",
    "completion_date": "2019-08-19",
    "results_first_posted": null,
    "last_update_posted": "2022-07-06",
    "enrollment": null,
    "sponsor": "Sarepta Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SRPT",
    "nct_id": "NCT00381433",
    "title": "Pharmacokinetic Study of a Single Dose of AVI-4065 in Cerebral Spinal Fluid",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Encephalitis"
    ],
    "interventions": [
      "AVI-4065 Injection"
    ],
    "primary_completion_date": "2006-10",
    "completion_date": "2009-06",
    "results_first_posted": null,
    "last_update_posted": "2009-07-08",
    "enrollment": null,
    "sponsor": "Sarepta Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SRPT",
    "nct_id": "NCT06241950",
    "title": "A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74)",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy"
    ],
    "interventions": [
      "delandistrogene moxeparvovec",
      "imlifidase"
    ],
    "primary_completion_date": "2025-10-10",
    "completion_date": "2025-10-10",
    "results_first_posted": null,
    "last_update_posted": "2025-11-20",
    "enrollment": null,
    "sponsor": "Sarepta Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SRPT",
    "nct_id": "NCT02710500",
    "title": "rAAVrh74.MHCK7.DYSF.DV for Treatment of Dysferlinopathies",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dysferlinopathy"
    ],
    "interventions": [
      "rAAVrh74.MHCK7.DYSF.DV"
    ],
    "primary_completion_date": "2019-07",
    "completion_date": "2019-07",
    "results_first_posted": null,
    "last_update_posted": "2021-05-13",
    "enrollment": null,
    "sponsor": "Sarepta Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SRPT",
    "nct_id": "NCT02420379",
    "title": "Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy (DMD)"
    ],
    "interventions": [
      "eteplirsen"
    ],
    "primary_completion_date": "2018-12-17",
    "completion_date": "2018-12-17",
    "results_first_posted": "2020-07-22",
    "last_update_posted": "2021-01-25",
    "enrollment": null,
    "sponsor": "Sarepta Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SRPT",
    "nct_id": "NCT03218995",
    "title": "Study of Eteplirsen in Young Participants With Duchenne Muscular Dystrophy (DMD) Amenable to Exon 51 Skipping",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy"
    ],
    "interventions": [
      "Eteplirsen"
    ],
    "primary_completion_date": "2021-03-10",
    "completion_date": "2021-03-10",
    "results_first_posted": "2021-12-09",
    "last_update_posted": "2021-12-09",
    "enrollment": null,
    "sponsor": "Sarepta Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SRPT",
    "nct_id": "NCT01375985",
    "title": "Safety Study of Single Administration Intravenous Treatment for Influenza",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Influenza"
    ],
    "interventions": [
      "AVI-7100",
      "Placebo"
    ],
    "primary_completion_date": "2011-08",
    "completion_date": "2011-11",
    "results_first_posted": null,
    "last_update_posted": "2013-06-11",
    "enrollment": null,
    "sponsor": "Sarepta Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SRPT",
    "nct_id": "NCT06952686",
    "title": "A Study of SRP-9005 in Limb Girdle Muscular Dystrophy Type 2C/R5 Pediatric and Adult Participants",
    "status": "WITHDRAWN",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Muscular Dystrophies, Limb-Girdle"
    ],
    "interventions": [
      "SRP-9005",
      "Corticosteroid"
    ],
    "primary_completion_date": "2030-11-30",
    "completion_date": "2032-03-30",
    "results_first_posted": null,
    "last_update_posted": "2025-08-06",
    "enrollment": null,
    "sponsor": "Sarepta Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SRPT",
    "nct_id": "NCT02255552",
    "title": "Study of Eteplirsen in DMD Patients",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy (DMD)"
    ],
    "interventions": [
      "eteplirsen"
    ],
    "primary_completion_date": "2019-06-14",
    "completion_date": "2019-06-14",
    "results_first_posted": "2020-07-01",
    "last_update_posted": "2021-01-25",
    "enrollment": null,
    "sponsor": "Sarepta Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SRPT",
    "nct_id": "NCT02310906",
    "title": "Phase I/II Study of SRP-4053 in DMD Patients",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy"
    ],
    "interventions": [
      "Placebo",
      "SRP-4053"
    ],
    "primary_completion_date": "2019-03-25",
    "completion_date": "2019-03-25",
    "results_first_posted": "2020-10-19",
    "last_update_posted": "2020-10-19",
    "enrollment": null,
    "sponsor": "Sarepta Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SRPT",
    "nct_id": "NCT02286947",
    "title": "Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Muscular Dystrophy, Duchenne"
    ],
    "interventions": [
      "Eteplirsen"
    ],
    "primary_completion_date": "2017-04-21",
    "completion_date": "2018-03-23",
    "results_first_posted": "2019-02-20",
    "last_update_posted": "2020-03-30",
    "enrollment": null,
    "sponsor": "Sarepta Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SRPT",
    "nct_id": "NCT01540409",
    "title": "Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy (DMD)"
    ],
    "interventions": [
      "AVI-4658 (Eteplirsen)"
    ],
    "primary_completion_date": "2016-04-15",
    "completion_date": "2017-08-16",
    "results_first_posted": "2019-07-10",
    "last_update_posted": "2020-03-30",
    "enrollment": null,
    "sponsor": "Sarepta Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SRPT",
    "nct_id": "NCT05881408",
    "title": "A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy"
    ],
    "interventions": [
      "delandistrogene moxeparvovec",
      "placebo"
    ],
    "primary_completion_date": "2027-05-31",
    "completion_date": "2028-06-30",
    "results_first_posted": null,
    "last_update_posted": "2025-06-22",
    "enrollment": null,
    "sponsor": "Sarepta Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SRPT",
    "nct_id": "NCT05876780",
    "title": "A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [\u03b2-SG] Deficiency)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Limb Girdle Muscular Dystrophy"
    ],
    "interventions": [
      "SRP-9003"
    ],
    "primary_completion_date": "2028-08-28",
    "completion_date": "2028-08-28",
    "results_first_posted": null,
    "last_update_posted": "2024-12-24",
    "enrollment": null,
    "sponsor": "Sarepta Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SRPT",
    "nct_id": "NCT05096221",
    "title": "A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy"
    ],
    "interventions": [
      "delandistrogene moxeparvovec",
      "placebo"
    ],
    "primary_completion_date": "2023-10-04",
    "completion_date": "2024-10-25",
    "results_first_posted": "2024-12-10",
    "last_update_posted": "2025-07-08",
    "enrollment": null,
    "sponsor": "Sarepta Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SRPT",
    "nct_id": "NCT03375164",
    "title": "A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy"
    ],
    "interventions": [
      "delandistrogene moxeparvovec"
    ],
    "primary_completion_date": "2023-04-25",
    "completion_date": "2023-04-25",
    "results_first_posted": "2024-05-23",
    "last_update_posted": "2024-11-14",
    "enrollment": null,
    "sponsor": "Sarepta Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SRPT",
    "nct_id": "NCT06606340",
    "title": "A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice",
    "status": "ENROLLING_BY_INVITATION",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy"
    ],
    "interventions": [
      "Eteplirsen",
      "Golodirsen",
      "Casimersen"
    ],
    "primary_completion_date": "2033-12-31",
    "completion_date": "2033-12-31",
    "results_first_posted": null,
    "last_update_posted": "2025-09-10",
    "enrollment": null,
    "sponsor": "Sarepta Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SRPT",
    "nct_id": "NCT00451256",
    "title": "Safety and Efficacy Study of AVI-5126 When Used on Vein Grafts Before Use in Heart by-Pass Graft Surgery (CABG)",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cardiovascular Disease",
      "Coronary Artery Bypass"
    ],
    "interventions": [
      "AVI-5126"
    ],
    "primary_completion_date": "2007-11",
    "completion_date": "2009-03",
    "results_first_posted": null,
    "last_update_posted": "2009-07-08",
    "enrollment": null,
    "sponsor": "Sarepta Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SRPT",
    "nct_id": "NCT01593072",
    "title": "A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers",
    "status": "WITHDRAWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ebola Hemorrhagic Fever"
    ],
    "interventions": [
      "AVI-7537",
      "Normal Saline Solution (NSS)"
    ],
    "primary_completion_date": "2013-01",
    "completion_date": "2013-01",
    "results_first_posted": null,
    "last_update_posted": "2013-01-24",
    "enrollment": null,
    "sponsor": "Sarepta Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SRPT",
    "nct_id": "NCT00343148",
    "title": "Pharmacokinetic Study of a Single Dose of AVI-4126 (RESTEN-NG\u00ae) in Cerebral Spinal Fluid",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Neoplasms"
    ],
    "interventions": [
      "AVI-4126 Injection (RESTEN-NG\u00ae)"
    ],
    "primary_completion_date": "2006-06",
    "completion_date": "2009-06",
    "results_first_posted": null,
    "last_update_posted": "2009-07-08",
    "enrollment": null,
    "sponsor": "Sarepta Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SRPT",
    "nct_id": "NCT01396239",
    "title": "Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy"
    ],
    "interventions": [
      "AVI-4658 (Eteplirsen)",
      "Placebo"
    ],
    "primary_completion_date": "2012-02",
    "completion_date": "2012-06",
    "results_first_posted": "2015-11-09",
    "last_update_posted": "2020-03-30",
    "enrollment": null,
    "sponsor": "Sarepta Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SRPT",
    "nct_id": "NCT02530905",
    "title": "Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy"
    ],
    "interventions": [
      "SRP-4045",
      "Placebo"
    ],
    "primary_completion_date": "2018-10-03",
    "completion_date": "2018-10-03",
    "results_first_posted": "2021-05-17",
    "last_update_posted": "2021-05-17",
    "enrollment": null,
    "sponsor": "Sarepta Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SRPT",
    "nct_id": "NCT01353027",
    "title": "Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ebola Hemorrhagic Fever"
    ],
    "interventions": [
      "Placebo",
      "AVI-6002"
    ],
    "primary_completion_date": "2011-11",
    "completion_date": "2011-11",
    "results_first_posted": null,
    "last_update_posted": "2012-03-28",
    "enrollment": null,
    "sponsor": "Sarepta Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SRPT",
    "nct_id": "NCT00248066",
    "title": "Safety and Efficacy of RESTEN-MP When Used in Conjunction With a Bare Metal Stent in Coronary Arteries",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Coronary Artery Disease",
      "Coronary Restenosis"
    ],
    "interventions": [
      "RESTEN-MP"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2007-02-08",
    "enrollment": null,
    "sponsor": "Sarepta Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SVRA",
    "nct_id": "NCT01537666",
    "title": "Inhaled Vancomycin Tolerability, Safety and Pharmacokinetics",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy",
      "Cystic Fibrosis"
    ],
    "interventions": [
      "AeroVanc",
      "IV vancomycin hydrochloride"
    ],
    "primary_completion_date": "2012-03",
    "completion_date": "2012-03",
    "results_first_posted": "2014-03-04",
    "last_update_posted": "2014-03-31",
    "enrollment": null,
    "sponsor": "Savara Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SVRA",
    "nct_id": "NCT06546098",
    "title": "Molgramostim Nebulizer Solution Expanded Access Program Protocol",
    "status": "AVAILABLE",
    "phase": "N/A",
    "study_type": "EXPANDED_ACCESS",
    "conditions": [
      "Autoimmune Pulmonary Alveolar Proteinosis"
    ],
    "interventions": [
      "Molgramostim nebulizer solution"
    ],
    "primary_completion_date": null,
    "completion_date": null,
    "results_first_posted": null,
    "last_update_posted": "2026-01-07",
    "enrollment": null,
    "sponsor": "Savara Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SVRA",
    "nct_id": "NCT03482752",
    "title": "Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Autoimmune Pulmonary Alveolar Proteinosis"
    ],
    "interventions": [
      "Molgramostim"
    ],
    "primary_completion_date": "2021-01-14",
    "completion_date": "2021-01-14",
    "results_first_posted": "2024-07-03",
    "last_update_posted": "2024-07-03",
    "enrollment": null,
    "sponsor": "Savara Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SVRA",
    "nct_id": "NCT02468908",
    "title": "Inhaled Molgramostim (rhGM-CSF) in Healthy Adult Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pulmonary Alveolar Proteinosis",
      "Bronchiectasis",
      "Cystic Fibrosis",
      "Acute Respiratory Distress Syndrome"
    ],
    "interventions": [
      "Molgramostim",
      "Placebo"
    ],
    "primary_completion_date": "2015-10",
    "completion_date": "2015-10",
    "results_first_posted": null,
    "last_update_posted": "2017-02-23",
    "enrollment": null,
    "sponsor": "Savara Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SVRA",
    "nct_id": "NCT03597347",
    "title": "Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial Infection",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Mycobacterium Infections, Nontuberculous",
      "Cystic Fibrosis (CF)"
    ],
    "interventions": [
      "Molgramostim nebulizer solution",
      "PARI eFlow nebulizer system"
    ],
    "primary_completion_date": "2020-10-02",
    "completion_date": "2020-10-02",
    "results_first_posted": "2021-10-11",
    "last_update_posted": "2023-01-10",
    "enrollment": null,
    "sponsor": "Savara Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SVRA",
    "nct_id": "NCT03181932",
    "title": "AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "MRSA",
      "Cystic Fibrosis"
    ],
    "interventions": [
      "Vancomycin inhalation powder",
      "Placebo inhalation powder",
      "Vancomycin inhalation powder"
    ],
    "primary_completion_date": "2020-07-28",
    "completion_date": "2021-01-15",
    "results_first_posted": "2021-11-05",
    "last_update_posted": "2022-12-16",
    "enrollment": null,
    "sponsor": "Savara Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SVRA",
    "nct_id": "NCT04544293",
    "title": "Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Autoimmune Pulmonary Alveolar Proteinosis"
    ],
    "interventions": [
      "Molgramostim",
      "Placebo",
      "Molgramostim Open-label"
    ],
    "primary_completion_date": "2023-11-30",
    "completion_date": "2027-05-30",
    "results_first_posted": "2025-08-07",
    "last_update_posted": "2025-08-07",
    "enrollment": null,
    "sponsor": "Savara Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SVRA",
    "nct_id": "NCT01746095",
    "title": "Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Cystic Fibrosis"
    ],
    "interventions": [
      "Vancomycin hydrochloride inhalation powder",
      "Placebo inhalation powder"
    ],
    "primary_completion_date": "2014-11",
    "completion_date": "2014-11",
    "results_first_posted": "2020-01-13",
    "last_update_posted": "2020-01-13",
    "enrollment": null,
    "sponsor": "Savara Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SVRA",
    "nct_id": "NCT03421743",
    "title": "Pilot Trial of Inhaled Molgramostim in Non-tuberculous Mycobacterial (NTM) Infection",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Mycobacterium Infections, Nontuberculous"
    ],
    "interventions": [
      "Inhaled molgramostim",
      "Antimycobacterial regimen"
    ],
    "primary_completion_date": "2019-10-15",
    "completion_date": "2020-01-13",
    "results_first_posted": "2024-07-03",
    "last_update_posted": "2024-07-03",
    "enrollment": null,
    "sponsor": "Savara Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SVRA",
    "nct_id": "NCT02702180",
    "title": "Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Autoimmune Pulmonary Alveolar Proteinosis"
    ],
    "interventions": [
      "Molgramostim",
      "Placebo",
      "PARI eFlow nebulizer system"
    ],
    "primary_completion_date": "2019-04-19",
    "completion_date": "2019-09-27",
    "results_first_posted": "2022-04-15",
    "last_update_posted": "2023-04-12",
    "enrollment": null,
    "sponsor": "Savara Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SVRA",
    "nct_id": "NCT06431776",
    "title": "Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Autoimmune Pulmonary Alveolar Proteinosis"
    ],
    "interventions": [
      "Molgramostim"
    ],
    "primary_completion_date": "2027-01",
    "completion_date": "2027-08",
    "results_first_posted": null,
    "last_update_posted": "2024-05-29",
    "enrollment": null,
    "sponsor": "Savara Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SYRE",
    "nct_id": "NCT06672718",
    "title": "A Study of SPY002-091 in Healthy Volunteers",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "SPY002-091",
      "Placebo"
    ],
    "primary_completion_date": "2026-02-18",
    "completion_date": "2026-06-22",
    "results_first_posted": null,
    "last_update_posted": "2025-08-17",
    "enrollment": null,
    "sponsor": "Spyre Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SYRE",
    "nct_id": "NCT07148414",
    "title": "A Study of SPY072 in Rheumatic Disease",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Rheumatoid Arthritis",
      "Psoriatic Arthritis",
      "Axial Spondyloarthritis",
      "Rheumatic Diseases",
      "Rheumatic Joint Disease",
      "PsA (Psoriatic Arthritis)",
      "AxSpA",
      "Rheumatologic Disease"
    ],
    "interventions": [
      "SPY002-072",
      "Placebo"
    ],
    "primary_completion_date": "2026-10-31",
    "completion_date": "2028-03-31",
    "results_first_posted": null,
    "last_update_posted": "2026-01-07",
    "enrollment": null,
    "sponsor": "Spyre Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SYRE",
    "nct_id": "NCT06873724",
    "title": "SPY003-207 in Healthy Volunteers",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "SPY003-207",
      "Placebo"
    ],
    "primary_completion_date": "2026-12",
    "completion_date": "2026-12",
    "results_first_posted": null,
    "last_update_posted": "2025-06-04",
    "enrollment": null,
    "sponsor": "Spyre Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SYRE",
    "nct_id": "NCT07012395",
    "title": "A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Ulcerative Colitis",
      "Inflammatory Bowel Diseases",
      "Colitis",
      "Colitis, Ulcerative"
    ],
    "interventions": [
      "SPY001",
      "SPY002",
      "SPY003",
      "Placebo"
    ],
    "primary_completion_date": "2026-06",
    "completion_date": "2028-03",
    "results_first_posted": null,
    "last_update_posted": "2026-01-21",
    "enrollment": null,
    "sponsor": "Spyre Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SYRE",
    "nct_id": "NCT06448247",
    "title": "A Study of SPY001-001 in Healthy Volunteers",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "SPY001-001",
      "Placebo"
    ],
    "primary_completion_date": "2026-05-05",
    "completion_date": "2026-05-05",
    "results_first_posted": null,
    "last_update_posted": "2025-02-26",
    "enrollment": null,
    "sponsor": "Spyre Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "SYRE",
    "nct_id": "NCT06622070",
    "title": "A Study of SPY002-072 in Healthy Volunteers",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "SPY002-072",
      "Placebo"
    ],
    "primary_completion_date": "2026-04-03",
    "completion_date": "2026-08-08",
    "results_first_posted": null,
    "last_update_posted": "2024-11-27",
    "enrollment": null,
    "sponsor": "Spyre Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TECX",
    "nct_id": "NCT06616974",
    "title": "A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pulmonary Hypertension",
      "Heart Failure With Preserved Ejection Fraction"
    ],
    "interventions": [
      "TX000045- Dose A",
      "TX000045- Dose B",
      "Placebo"
    ],
    "primary_completion_date": "2026-10-09",
    "completion_date": "2026-11-20",
    "results_first_posted": null,
    "last_update_posted": "2025-12-04",
    "enrollment": null,
    "sponsor": "Tectonic Therapeutic",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TRDA",
    "nct_id": "NCT04245917",
    "title": "Natural History Study of MNGIE",
    "status": "SUSPENDED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Mitochondrial Neurogastrointestinal Encephalomyopathy"
    ],
    "interventions": [
      "Non-interventional"
    ],
    "primary_completion_date": "2025-02",
    "completion_date": "2026-02",
    "results_first_posted": null,
    "last_update_posted": "2021-07-22",
    "enrollment": null,
    "sponsor": "Entrada Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TRDA",
    "nct_id": "NCT07037862",
    "title": "A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy (DMD)"
    ],
    "interventions": [
      "ENTR-601-44",
      "ENTR-601-44 - matching placebo"
    ],
    "primary_completion_date": "2029-03-28",
    "completion_date": "2029-03-28",
    "results_first_posted": null,
    "last_update_posted": "2025-12-15",
    "enrollment": null,
    "sponsor": "Entrada Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TRDA",
    "nct_id": "NCT07038824",
    "title": "A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Duchenne Muscular Dystrophy (DMD)"
    ],
    "interventions": [
      "ENTR-601-45",
      "ENTR-601-45 - matching placebo"
    ],
    "primary_completion_date": "2029-03-01",
    "completion_date": "2029-03-01",
    "results_first_posted": null,
    "last_update_posted": "2025-12-15",
    "enrollment": null,
    "sponsor": "Entrada Therapeutics, Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TRVI",
    "nct_id": "NCT05962151",
    "title": "Refractory Chronic Cough Improvement Via NAL ER (RIVER)",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Refractory Chronic Cough"
    ],
    "interventions": [
      "NAL ER",
      "Placebo"
    ],
    "primary_completion_date": "2025-01-06",
    "completion_date": "2025-01-06",
    "results_first_posted": null,
    "last_update_posted": "2025-03-14",
    "enrollment": null,
    "sponsor": "Trevi Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TRVI",
    "nct_id": "NCT02143648",
    "title": "Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Uremic Pruritus",
      "Pruritus"
    ],
    "interventions": [
      "nalbuphine HCl ER tablets 60 mg BID",
      "nalbuphine HCl ER tablets 120mg BID",
      "Placebo tablets BID"
    ],
    "primary_completion_date": "2015-07",
    "completion_date": "2015-07",
    "results_first_posted": "2020-09-07",
    "last_update_posted": "2025-05-21",
    "enrollment": null,
    "sponsor": "Trevi Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TRVI",
    "nct_id": "NCT04030026",
    "title": "A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Idiopathic Pulmonary Fibrosis"
    ],
    "interventions": [
      "NAL ER",
      "Placebo"
    ],
    "primary_completion_date": "2022-05-27",
    "completion_date": "2022-05-27",
    "results_first_posted": "2025-05-29",
    "last_update_posted": "2025-05-29",
    "enrollment": null,
    "sponsor": "Trevi Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TRVI",
    "nct_id": "NCT07036029",
    "title": "NAL ER IPF Respiratory Function and Safety Study",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Idiopathic Pulmonary Fibrosis"
    ],
    "interventions": [
      "NAL ER",
      "Placebo"
    ],
    "primary_completion_date": "2026-02",
    "completion_date": "2026-02",
    "results_first_posted": null,
    "last_update_posted": "2026-01-21",
    "enrollment": null,
    "sponsor": "Trevi Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TRVI",
    "nct_id": "NCT02174419",
    "title": "Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Prurigo Nodularis",
      "Nodularis Prurigo",
      "Prurigo",
      "Pruritus"
    ],
    "interventions": [
      "nalbuphine HCl ER tablets 90 mg BID",
      "nalbuphine HCl ER tablets 180 mg BID",
      "Placebo tablets BID"
    ],
    "primary_completion_date": "2016-08",
    "completion_date": "2016-08",
    "results_first_posted": "2020-08-21",
    "last_update_posted": "2025-05-21",
    "enrollment": null,
    "sponsor": "Trevi Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TRVI",
    "nct_id": "NCT02373215",
    "title": "Phase 1 Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Uremic Pruritus"
    ],
    "interventions": [
      "Nalbuphine HCL ER"
    ],
    "primary_completion_date": "2013-11",
    "completion_date": "2013-11",
    "results_first_posted": null,
    "last_update_posted": "2025-05-22",
    "enrollment": null,
    "sponsor": "Trevi Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TRVI",
    "nct_id": "NCT05964335",
    "title": "Cough Reduction in IPF With Nalbuphine ER",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Idiopathic Pulmonary Fibrosis"
    ],
    "interventions": [
      "NAL ER",
      "Placebo",
      "NAL ER",
      "NAL ER"
    ],
    "primary_completion_date": "2025-04-24",
    "completion_date": "2025-04-24",
    "results_first_posted": null,
    "last_update_posted": "2025-06-27",
    "enrollment": null,
    "sponsor": "Trevi Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TRVI",
    "nct_id": "NCT03497975",
    "title": "PRISM Study-Pruritus Relief Through Itch Scratch Modulation",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Prurigo Nodularis"
    ],
    "interventions": [
      "Nalbuphine ER Tablets",
      "Placebo Tablets"
    ],
    "primary_completion_date": "2022-05-10",
    "completion_date": "2023-02-24",
    "results_first_posted": "2025-06-24",
    "last_update_posted": "2025-06-24",
    "enrollment": null,
    "sponsor": "Trevi Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TRVI",
    "nct_id": "NCT02143973",
    "title": "Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Uremic Pruritus",
      "Pruritus"
    ],
    "interventions": [
      "nalbuphine HCl ER"
    ],
    "primary_completion_date": "2016-01",
    "completion_date": "2016-01",
    "results_first_posted": "2020-09-07",
    "last_update_posted": "2025-05-21",
    "enrollment": null,
    "sponsor": "Trevi Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TRVI",
    "nct_id": "NCT04018664",
    "title": "Oral Abuse Potential Study of Nalbuphine",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Nalbuphine",
      "Opioid Abuse"
    ],
    "interventions": [
      "Nalbuphine HCl solution",
      "Placebo solution"
    ],
    "primary_completion_date": "2018-12-03",
    "completion_date": "2020-06-02",
    "results_first_posted": "2020-08-31",
    "last_update_posted": "2025-05-21",
    "enrollment": null,
    "sponsor": "Trevi Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TRVI",
    "nct_id": "NCT02174432",
    "title": "Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Prurigo Nodularis",
      "Nodularis Prurigo",
      "Prurigo"
    ],
    "interventions": [
      "nalbuphine HCl ER"
    ],
    "primary_completion_date": "2017-09-03",
    "completion_date": "2017-09-03",
    "results_first_posted": "2020-10-23",
    "last_update_posted": "2025-05-21",
    "enrollment": null,
    "sponsor": "Trevi Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TRVI",
    "nct_id": "NCT04020016",
    "title": "Nalbuphine ER Effects of Liver Disease on Pharmacokinetics and Itch",
    "status": "UNKNOWN",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Nalbuphine",
      "Hepatic Impairment"
    ],
    "interventions": [
      "Nalbuphine ER",
      "Nalbuphine ER -"
    ],
    "primary_completion_date": "2020-11",
    "completion_date": "2020-12",
    "results_first_posted": null,
    "last_update_posted": "2020-10-06",
    "enrollment": null,
    "sponsor": "Trevi Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "TRVI",
    "nct_id": "NCT07015398",
    "title": "A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Participants"
    ],
    "interventions": [
      "NAL ER",
      "Pirfenidone",
      "Nintedanib"
    ],
    "primary_completion_date": "2025-09-12",
    "completion_date": "2025-09-26",
    "results_first_posted": null,
    "last_update_posted": "2025-10-10",
    "enrollment": null,
    "sponsor": "Trevi Therapeutics",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT00147654",
    "title": "Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Urinary Incontinence"
    ],
    "interventions": [
      "Tolterodine ER 4 mg QD",
      "Tamsulosin 0.4 mg QD"
    ],
    "primary_completion_date": null,
    "completion_date": "2006-05",
    "results_first_posted": null,
    "last_update_posted": "2021-01-27",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT01330472",
    "title": "An Bioequivalence Study Of Xanax Extended Release Tablets From Two Different Manufacturing Sites",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Subjects"
    ],
    "interventions": [
      "Xanax XR tablets 3 mg (sourced from Caugus)",
      "Xanax XR tablets 3 mg (sourced from Barceloneta)"
    ],
    "primary_completion_date": "2011-06",
    "completion_date": "2011-06",
    "results_first_posted": null,
    "last_update_posted": "2021-01-28",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT00603473",
    "title": "A Phase III Open-Label Study Of Gabapentin As Adjunctive Therapy In Japanese Pediatric Patients With Partial Seizures",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Epilepsies, Partial"
    ],
    "interventions": [
      "gabapentin"
    ],
    "primary_completion_date": "2009-12",
    "completion_date": "2009-12",
    "results_first_posted": "2011-02-21",
    "last_update_posted": "2021-02-03",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT05319756",
    "title": "Study Evaluating the Abuse Potential of NEURONTIN\u00ae in Healthy Non-drug Dependent, Recreational Opioid Users",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Abuse Potential"
    ],
    "interventions": [
      "gabapentin 600 mg",
      "gabapentin 1200 mg",
      "gabapentin 600 mg and oxycodone HCl 20 mg",
      "gabapentin 1200 mg and oxycodone HCl 20 mg",
      "oxycodone HCl 20 mg",
      "placebo"
    ],
    "primary_completion_date": "2021-12-31",
    "completion_date": "2021-12-31",
    "results_first_posted": "2023-08-14",
    "last_update_posted": "2023-08-14",
    "enrollment": null,
    "sponsor": "Viatris Specialty LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT04255277",
    "title": "To Study the Effect of Cenerimod on the Electrical Activity of the Heart, in Men and Women. To Study the Effect of Cenerimod on the Use of Oral Contraceptives in Women. To Study the Effect That Charcoal Has on the Elimination of Cenerimod From the Body, in Women and Men.",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Subjects"
    ],
    "interventions": [
      "Combined oral contraceptives (COC)",
      "Moxifloxacin 400mg",
      "Cenerimod 0.5 mg",
      "Cenerimod 4 mg",
      "Charcoal, activated",
      "Matching Placebo"
    ],
    "primary_completion_date": "2021-09-14",
    "completion_date": "2021-10-18",
    "results_first_posted": null,
    "last_update_posted": "2025-09-22",
    "enrollment": null,
    "sponsor": "Viatris Innovation GmbH",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT00424372",
    "title": "A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin For Postherpetic Neuralgia",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Neuralgia, Postherpetic"
    ],
    "interventions": [
      "pregabalin"
    ],
    "primary_completion_date": "2008-08-19",
    "completion_date": "2008-08-19",
    "results_first_posted": "2009-09-28",
    "last_update_posted": "2021-08-27",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT02060487",
    "title": "Effects of Oral Sildenafil on Mortality in Adults With PAH",
    "status": "TERMINATED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pulmonary Arterial Hypertension"
    ],
    "interventions": [
      "sildenafil citrate",
      "sildenafil citrate",
      "sildenafil citrate"
    ],
    "primary_completion_date": "2021-02-26",
    "completion_date": "2021-02-26",
    "results_first_posted": "2022-05-10",
    "last_update_posted": "2022-05-13",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT00645268",
    "title": "A Multicenter, Double-blind Study to Evaluate the Effect of Pretreatment With a Daily Dose of Sildenafil on the As-Needed Efficacy of Viagra in Men With Erectile Dysfunction and Type 2 Diabetes",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Erectile Dysfunction",
      "Diabetes Mellitus, Type 2"
    ],
    "interventions": [
      "sildenafil",
      "placebo",
      "sildenafil"
    ],
    "primary_completion_date": null,
    "completion_date": "2004-01",
    "results_first_posted": null,
    "last_update_posted": "2021-02-01",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT01727791",
    "title": "A Study Of Pregabalin (Lyrica) Drug Levels In Urine, Plasma And Breast Milk Of Healthy Lactating Women",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Lactating Women"
    ],
    "interventions": [
      "pregabalin (Lyrica)"
    ],
    "primary_completion_date": "2013-08",
    "completion_date": "2013-08",
    "results_first_posted": "2016-05-18",
    "last_update_posted": "2021-01-28",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT00141310",
    "title": "Sildenafil Citrate for the Treatment of Established Pre-Eclampsia",
    "status": "TERMINATED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pre-eclampsia"
    ],
    "interventions": [
      "Sildenafil citrate"
    ],
    "primary_completion_date": null,
    "completion_date": "2006-04",
    "results_first_posted": null,
    "last_update_posted": "2021-02-01",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT00635531",
    "title": "A Study to Evaluate the Use of Extended Release Alprazolam in the Treatment of Adolescents With Panic Disorder",
    "status": "TERMINATED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Panic Disorder"
    ],
    "interventions": [
      "placebo",
      "alprazolam XR"
    ],
    "primary_completion_date": null,
    "completion_date": "2004-09",
    "results_first_posted": null,
    "last_update_posted": "2021-01-28",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT00143130",
    "title": "Pregabalin In Partial Seizures Extension Study",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Seizures"
    ],
    "interventions": [
      "Pregabalin"
    ],
    "primary_completion_date": null,
    "completion_date": "2007-09",
    "results_first_posted": null,
    "last_update_posted": "2021-01-28",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT00830167",
    "title": "Randomized, Double-Blind, Placebo-Controlled Study Of Pregabalin In Patients With Fibromyalgia",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Fibromyalgia"
    ],
    "interventions": [
      "Placebo",
      "Pregabalin"
    ],
    "primary_completion_date": "2011-05",
    "completion_date": "2011-05",
    "results_first_posted": "2012-06-01",
    "last_update_posted": "2021-01-25",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT00141219",
    "title": "Pregabalin Peripheral Neuropathic Pain Study",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetic Neuropathies",
      "Neuralgia"
    ],
    "interventions": [
      "pregabalin",
      "Placebo"
    ],
    "primary_completion_date": "2007-12",
    "completion_date": "2007-12",
    "results_first_posted": "2009-03-13",
    "last_update_posted": "2021-02-09",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT05648500",
    "title": "A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Lupus Erythematosus, Systemic"
    ],
    "interventions": [
      "Cenerimod",
      "Placebo"
    ],
    "primary_completion_date": "2026-10-31",
    "completion_date": "2027-05-01",
    "results_first_posted": null,
    "last_update_posted": "2026-01-14",
    "enrollment": null,
    "sponsor": "Viatris Innovation GmbH",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT01838044",
    "title": "Efficacy and Safety Study of Celecoxib and Pregabalin Compared With Celecoxib Monotherapy, in Patients With Chronic Low Back Pain Having a Neuropathic Component",
    "status": "TERMINATED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chronic Low Back Pain With a Neuropathic Component"
    ],
    "interventions": [
      "pregabalin and celecoxib",
      "Placebo and celecoxib"
    ],
    "primary_completion_date": "2015-05",
    "completion_date": "2015-06",
    "results_first_posted": "2016-09-01",
    "last_update_posted": "2021-01-28",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT01455428",
    "title": "Pregabalin for Treatment of Patients With Postherpetic Neuralgia (PHN)",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Postherpetic Neuralgia ( PHN )"
    ],
    "interventions": [
      "Lyrica (pregabalin)",
      "Placebo"
    ],
    "primary_completion_date": "2014-01",
    "completion_date": "2014-01",
    "results_first_posted": "2015-05-22",
    "last_update_posted": "2021-01-28",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT00994461",
    "title": "Study Of Celecoxib In Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "Celecoxib",
      "Loxoprofen",
      "Placebo"
    ],
    "primary_completion_date": "2010-04",
    "completion_date": "2010-04",
    "results_first_posted": "2011-05-17",
    "last_update_posted": "2021-02-02",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT01202422",
    "title": "An Investigation Of The Absorption And Pharmacokinetics Of Multiple Doses Of Two Controlled Release Pregabalin Tablets As Compared To Multiple Doses Of The Immediate Release Pregabalin Capsule",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy"
    ],
    "interventions": [
      "Pregabalin controlled release, 165 mg",
      "Pregabalin controlled release, 330 mg",
      "Pregabalin immediate release, 150 mg"
    ],
    "primary_completion_date": "2010-11",
    "completion_date": "2010-11",
    "results_first_posted": null,
    "last_update_posted": "2021-01-22",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT01078285",
    "title": "Effectiveness Of A Program That Includes Counseling And Patient Support On Adherence To Treatment With Lipitor",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Medication Non-Adherence"
    ],
    "interventions": [
      "No Patient Counseling",
      "Adherence Counseling"
    ],
    "primary_completion_date": "2011-11",
    "completion_date": "2011-11",
    "results_first_posted": null,
    "last_update_posted": "2021-02-18",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT00634985",
    "title": "Safety and Efficacy of Eletriptan for the Treatment of Migraine in Subjects Unsuccessfully Treated With Nonsteroidal Anti-inflammatory Drugs",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Migraine"
    ],
    "interventions": [
      "eletriptan"
    ],
    "primary_completion_date": null,
    "completion_date": "2003-12",
    "results_first_posted": null,
    "last_update_posted": "2021-01-27",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT00380874",
    "title": "Prevention And Treatment Of Chemotherapy-Induced Peripheral Neuropathy In Subjects With Advanced Colorectal Cancer",
    "status": "TERMINATED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Chemotherapy-Induced Peripheral Neuropathy"
    ],
    "interventions": [
      "Pregabalin",
      "Placebo"
    ],
    "primary_completion_date": "2008-03",
    "completion_date": "2008-03",
    "results_first_posted": "2009-04-17",
    "last_update_posted": "2021-02-11",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT00415623",
    "title": "A Comparative Study Between Amlodipine 10mg And 5mg With Hypertension For Whom 5mg Is Insufficient",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypertension"
    ],
    "interventions": [
      "Amlodipine",
      "Amlodipine"
    ],
    "primary_completion_date": "2007-10",
    "completion_date": "2007-10",
    "results_first_posted": "2008-12-09",
    "last_update_posted": "2021-02-11",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT02868359",
    "title": "PROs in Chronic Cervical Pain Patients With Accompanying Upper Limb Radiating Pain Treated With Pregabalin",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Cervical Pain",
      "Neuropathic Pain",
      "Radiating Pain"
    ],
    "interventions": [
      "No Intervention"
    ],
    "primary_completion_date": "2017-10-24",
    "completion_date": "2017-10-24",
    "results_first_posted": null,
    "last_update_posted": "2021-01-20",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT03768726",
    "title": "Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bipolar Disorder"
    ],
    "interventions": [
      "Ziprasidone",
      "Placebo"
    ],
    "primary_completion_date": "2020-07-31",
    "completion_date": "2020-07-31",
    "results_first_posted": "2021-04-27",
    "last_update_posted": "2021-06-16",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT01747915",
    "title": "A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures.",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Generalized Tonic Clonic Seizures"
    ],
    "interventions": [
      "Pregabalin Dose Level 1",
      "Pregabalin Dose Level 2",
      "Placebo"
    ],
    "primary_completion_date": "2019-02-20",
    "completion_date": "2019-02-20",
    "results_first_posted": "2019-08-28",
    "last_update_posted": "2021-01-20",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT00137397",
    "title": "A Study to Measure the Effect of Tolterodine Extended Release on the Thickness of the Bladder Wall in Patients With Overactive Bladder",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Urinary Incontinence"
    ],
    "interventions": [
      "Tolterodine ER",
      "Placebo"
    ],
    "primary_completion_date": null,
    "completion_date": "2006-08",
    "results_first_posted": null,
    "last_update_posted": "2021-01-27",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT01062113",
    "title": "Study To Evaluate Efficacy And Safety Of An Additional Dose Of Celecoxib (YM177) In Patients With Post-Tooth Extraction Pain",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pain"
    ],
    "interventions": [
      "Celecoxib",
      "Celecoxib",
      "Placebo"
    ],
    "primary_completion_date": "2010-08",
    "completion_date": "2010-08",
    "results_first_posted": "2012-11-19",
    "last_update_posted": "2021-02-02",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT04406896",
    "title": "The Effect of Reduced Liver Function on Selatogrel Pharmacokinetics",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Subjects",
      "Hepatic Impairment"
    ],
    "interventions": [
      "Selatogrel"
    ],
    "primary_completion_date": "2020-10-23",
    "completion_date": "2020-10-23",
    "results_first_posted": null,
    "last_update_posted": "2025-07-04",
    "enrollment": null,
    "sponsor": "Viatris Innovation GmbH",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT00232180",
    "title": "A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Heart Failure"
    ],
    "interventions": [
      "Eplerenone"
    ],
    "primary_completion_date": "2010-05",
    "completion_date": "2012-01",
    "results_first_posted": "2011-06-27",
    "last_update_posted": "2020-12-22",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT05004311",
    "title": "The Effect of Severe Kidney Impairment on Cenerimod Pharmacokinetics",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy",
      "Renal Impairment"
    ],
    "interventions": [
      "Cenerimod"
    ],
    "primary_completion_date": "2023-07-27",
    "completion_date": "2023-08-10",
    "results_first_posted": null,
    "last_update_posted": "2025-09-22",
    "enrollment": null,
    "sponsor": "Viatris Innovation GmbH",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT00381095",
    "title": "A Study To Evaluate Pregabalin In The Treatment Of Moderate To Severe Chronic Bone Pain Related To Metastatic Cancer",
    "status": "TERMINATED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bone Neoplasms",
      "Pain, Intractable",
      "Cancer"
    ],
    "interventions": [
      "Pregabalin",
      "Placebo"
    ],
    "primary_completion_date": "2010-10",
    "completion_date": "2010-10",
    "results_first_posted": "2011-09-27",
    "last_update_posted": "2021-01-20",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT01379144",
    "title": "A Study Comparing The Efficacy, Safety And Tolerability Of Latanoprost 75, 100 And 125 ug/ml To Xalatan In The Treatment Of Primary Open-Angle Glaucoma And Ocular Hypertension",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Primary Open Angle Glaucoma",
      "Ocular Hypertension"
    ],
    "interventions": [
      "latanoprost 75 ug",
      "latanoprost 100 ug",
      "latanoprost 125 ug",
      "latanoprost 50 ug"
    ],
    "primary_completion_date": "2003-03",
    "completion_date": "2003-04",
    "results_first_posted": null,
    "last_update_posted": "2021-02-02",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT00584519",
    "title": "Control of Metabolic and Cardiovascular Risk in Patients With Schizophrenia and Overweight",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Schizophrenia"
    ],
    "interventions": [
      "non-interventional"
    ],
    "primary_completion_date": "2009-06",
    "completion_date": "2009-06",
    "results_first_posted": null,
    "last_update_posted": "2021-02-21",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT01270828",
    "title": "Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Post Herpetic Neuralgia"
    ],
    "interventions": [
      "Pregabalin",
      "placebo"
    ],
    "primary_completion_date": "2014-09",
    "completion_date": "2014-11",
    "results_first_posted": "2016-01-13",
    "last_update_posted": "2021-01-28",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT00620867",
    "title": "Efficacy and Safety of Celecoxib Versus Ibuprofen in the Treatment of Osteoarthritis of the Knee (United States)",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Osteoarthritis, Knee"
    ],
    "interventions": [
      "Ibuprofen",
      "celecoxib",
      "placebo"
    ],
    "primary_completion_date": "2003-03",
    "completion_date": "2003-03",
    "results_first_posted": null,
    "last_update_posted": "2021-02-21",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT00163163",
    "title": "Carotid Atorvastatin Study in Hyperlipidemic Post-Menopausal Women",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hypercholesterolaemia"
    ],
    "interventions": [
      "Echographic measurements",
      "Blood samples"
    ],
    "primary_completion_date": null,
    "completion_date": "2006-07",
    "results_first_posted": null,
    "last_update_posted": "2021-02-18",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT00645515",
    "title": "A Study Comparing the Safety and Efficacy of Ziprasidone and Risperidone for the Treatment of Chronic Schizophrenia",
    "status": "TERMINATED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Schizophrenia"
    ],
    "interventions": [
      "Ziprasidone",
      "Risperidone"
    ],
    "primary_completion_date": null,
    "completion_date": "2003-12",
    "results_first_posted": null,
    "last_update_posted": "2021-02-21",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT00245609",
    "title": "Trial of Pregabalin, Alprazolam, and Placebo in Subjects With Anxiety Prior to Dental Procedure",
    "status": "COMPLETED",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Dental Anxiety"
    ],
    "interventions": [
      "Pregabalin",
      "Alprazolam",
      "Placebo"
    ],
    "primary_completion_date": null,
    "completion_date": "2006-10",
    "results_first_posted": null,
    "last_update_posted": "2021-01-22",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT00795938",
    "title": "Study to Compare the Blood Levels of Sildenafil Following Administration of an Experimental Tablet vs. the Conventional Oral Tablet in Healthy Subjects.",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Erectile Dysfunction"
    ],
    "interventions": [
      "Sildenafil",
      "Sildenafil",
      "Sildenafil"
    ],
    "primary_completion_date": "2008-11",
    "completion_date": "2008-11",
    "results_first_posted": null,
    "last_update_posted": "2021-02-01",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT00644748",
    "title": "A Study on the Efficacy and Safety of Gabapentin in the Treatment of Patients With Painful Diabetic Neuropathy",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Diabetic Neuropathies"
    ],
    "interventions": [
      "gabapentin"
    ],
    "primary_completion_date": null,
    "completion_date": "2004-08",
    "results_first_posted": null,
    "last_update_posted": "2021-02-02",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT00159809",
    "title": "Efficacy Study Measuring The Impact Of Treatment With Viagra On The Depressive Symptoms Of Men With Erectile Dysfunction",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Impotence",
      "Depression"
    ],
    "interventions": [
      "Viagra (Sildenafil citrate)"
    ],
    "primary_completion_date": null,
    "completion_date": "2004-08",
    "results_first_posted": null,
    "last_update_posted": "2021-02-01",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT01773993",
    "title": "Special Investigation of Pregabalin for Fibromyalgia (Regulatory Post Marketing Commitment Plan)",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Pain Associated With Fibromyalgia"
    ],
    "interventions": [
      "Pregabalin"
    ],
    "primary_completion_date": "2017-07",
    "completion_date": "2017-07",
    "results_first_posted": "2019-05-03",
    "last_update_posted": "2023-10-10",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT00640809",
    "title": "Comparison of Small Bowel Lesions Associated With Celecoxib Versus Ibuprofen Plus Omeprazole",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Bowel Diseases, Inflammatory"
    ],
    "interventions": [
      "Celecoxib",
      "Placebo",
      "Ibuprofen plus Omeprazole"
    ],
    "primary_completion_date": null,
    "completion_date": "2004-04",
    "results_first_posted": null,
    "last_update_posted": "2021-02-02",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT00866463",
    "title": "A Study to Compare the Blood Levels of Sildenafil Following Administration of an Experimental Tablet vs. the Conventional Oral Tablet in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Erectile Dysfunction"
    ],
    "interventions": [
      "Sildenafil",
      "Sildenafil",
      "Sildenafil"
    ],
    "primary_completion_date": "2008-10",
    "completion_date": "2008-10",
    "results_first_posted": null,
    "last_update_posted": "2021-02-01",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT01720524",
    "title": "A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn",
    "status": "COMPLETED",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Pulmonary Hypertension, Familial Persistent, of the Newborn"
    ],
    "interventions": [
      "placebo",
      "iv sildenafil"
    ],
    "primary_completion_date": "2018-10-17",
    "completion_date": "2020-09-28",
    "results_first_posted": "2020-03-25",
    "last_update_posted": "2021-08-16",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT00346216",
    "title": "Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Arthritis, Rheumatoid"
    ],
    "interventions": [
      "celecoxib",
      "Ibuprofen",
      "Naproxen"
    ],
    "primary_completion_date": "2016-04-12",
    "completion_date": "2016-04-12",
    "results_first_posted": "2017-05-01",
    "last_update_posted": "2021-03-03",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT00633438",
    "title": "Effect of Celecoxib Versus Placebo Before and After Knee Surgery on Overall Use of Analgesics After Surgery",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Arthroscopy"
    ],
    "interventions": [
      "Placebo",
      "Celecoxib"
    ],
    "primary_completion_date": null,
    "completion_date": "2004-06",
    "results_first_posted": null,
    "last_update_posted": "2021-02-21",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT01243138",
    "title": "Africa and Middle East Cardiovascular Epidemiological Study",
    "status": "COMPLETED",
    "phase": "N/A",
    "study_type": "OBSERVATIONAL",
    "conditions": [
      "Obesity",
      "Smoking",
      "Dyslipidemia",
      "Diabetes Mellitus",
      "Hypertension"
    ],
    "interventions": [],
    "primary_completion_date": "2012-04",
    "completion_date": "2012-04",
    "results_first_posted": null,
    "last_update_posted": "2021-02-18",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "VTRS",
    "nct_id": "NCT00139776",
    "title": "Study Of \"Continuous Use\" Of Celecoxib Vs. \"Usual or Intermittent Use\"",
    "status": "COMPLETED",
    "phase": "PHASE4",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Osteoarthritis, Knee",
      "Osteoarthritis, Hip"
    ],
    "interventions": [
      "Celecoxib",
      "Celecoxib"
    ],
    "primary_completion_date": "2008-02",
    "completion_date": "2008-02",
    "results_first_posted": "2009-05-19",
    "last_update_posted": "2021-03-29",
    "enrollment": null,
    "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ZBIO",
    "nct_id": "NCT06559163",
    "title": "A Study of Obexelimab in Patients With Systemic Lupus Erythematosus",
    "status": "RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Systemic Lupus Erythematosus"
    ],
    "interventions": [
      "Obexelimab",
      "Placebo"
    ],
    "primary_completion_date": "2026-06",
    "completion_date": "2026-09",
    "results_first_posted": null,
    "last_update_posted": "2025-07-30",
    "enrollment": null,
    "sponsor": "Zenas BioPharma (USA), LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ZBIO",
    "nct_id": "NCT05542303",
    "title": "A Safety, Tolerability and Pharmacokinetics Study of ZB001 in Healthy Subjects",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "ZB001 for injection",
      "ZB001 for injection",
      "ZB001 for injection"
    ],
    "primary_completion_date": "2023-04-04",
    "completion_date": "2023-04-04",
    "results_first_posted": null,
    "last_update_posted": "2025-04-06",
    "enrollment": null,
    "sponsor": "Zenas BioPharma (USA), LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ZBIO",
    "nct_id": "NCT05776121",
    "title": "Study of ZB001 in Chinese Patients With Thyroid Eye Disease",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Thyroid Eye Disease"
    ],
    "interventions": [
      "ZB001 for injection",
      "ZB001 for injection"
    ],
    "primary_completion_date": "2024-04-17",
    "completion_date": "2024-04-17",
    "results_first_posted": null,
    "last_update_posted": "2025-04-11",
    "enrollment": null,
    "sponsor": "Zenas BioPharma (USA), LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ZBIO",
    "nct_id": "NCT05662241",
    "title": "A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "IgG4 Related Disease"
    ],
    "interventions": [
      "Obexelimab",
      "Placebo"
    ],
    "primary_completion_date": "2025-11-15",
    "completion_date": "2029-02-15",
    "results_first_posted": null,
    "last_update_posted": "2025-10-27",
    "enrollment": null,
    "sponsor": "Zenas BioPharma (USA), LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ZBIO",
    "nct_id": "NCT05794516",
    "title": "A Safety and Pharmacokinetics Study of ZB004 in Healthy Participants",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "interventions": [
      "ZB004",
      "Placebo"
    ],
    "primary_completion_date": "2024-03-21",
    "completion_date": "2024-03-21",
    "results_first_posted": null,
    "last_update_posted": "2025-04-13",
    "enrollment": null,
    "sponsor": "Zenas BioPharma (USA), LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ZBIO",
    "nct_id": "NCT07299019",
    "title": "A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis",
    "status": "NOT_YET_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Secondary Progressive Multiple Sclerosis"
    ],
    "interventions": [
      "Orelabrutinib",
      "Placebo"
    ],
    "primary_completion_date": "2030-06",
    "completion_date": "2030-07",
    "results_first_posted": null,
    "last_update_posted": "2026-01-12",
    "enrollment": null,
    "sponsor": "Zenas BioPharma (USA), LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ZBIO",
    "nct_id": "NCT06564311",
    "title": "A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE2",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Relapsing Multiple Sclerosis"
    ],
    "interventions": [
      "Obexelimab",
      "Placebo"
    ],
    "primary_completion_date": "2025-08-28",
    "completion_date": "2026-02",
    "results_first_posted": null,
    "last_update_posted": "2025-11-17",
    "enrollment": null,
    "sponsor": "Zenas BioPharma (USA), LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ZBIO",
    "nct_id": "NCT05638854",
    "title": "A Study to Evaluate Safety and Pharmacokinetics of ZB002 in Healthy Participants and Participants With Rheumatoid Arthritis",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers",
      "Rheumatoid Arthritis"
    ],
    "interventions": [
      "ZB002",
      "Placebo",
      "ZB002",
      "Placebo"
    ],
    "primary_completion_date": "2025-07",
    "completion_date": "2025-07",
    "results_first_posted": null,
    "last_update_posted": "2025-04-08",
    "enrollment": null,
    "sponsor": "Zenas BioPharma (USA), LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ZBIO",
    "nct_id": "NCT07067463",
    "title": "A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis",
    "status": "RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Multiple Sclerosis (MS) Primary Progressive"
    ],
    "interventions": [
      "Orelabrutinib",
      "Placebo"
    ],
    "primary_completion_date": "2030-06",
    "completion_date": "2030-07",
    "results_first_posted": null,
    "last_update_posted": "2025-12-04",
    "enrollment": null,
    "sponsor": "Zenas BioPharma (USA), LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ZBIO",
    "nct_id": "NCT05786573",
    "title": "A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)",
    "status": "ACTIVE_NOT_RECRUITING",
    "phase": "PHASE3",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Warm Autoimmune Hemolytic Anemia"
    ],
    "interventions": [
      "Obexelimab",
      "Obexelimab",
      "Placebo"
    ],
    "primary_completion_date": "2026-06-30",
    "completion_date": "2026-08-31",
    "results_first_posted": null,
    "last_update_posted": "2025-06-25",
    "enrollment": null,
    "sponsor": "Zenas BioPharma (USA), LLC",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ZYME",
    "nct_id": "NCT03821233",
    "title": "A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers",
    "status": "COMPLETED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "HER2-expressing Cancers"
    ],
    "interventions": [
      "ZW49"
    ],
    "primary_completion_date": "2024-09-27",
    "completion_date": "2024-10-08",
    "results_first_posted": null,
    "last_update_posted": "2025-01-29",
    "enrollment": null,
    "sponsor": "Zymeworks BC Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ZYME",
    "nct_id": "NCT06555744",
    "title": "A Study of ZW191 in Participants With Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Advanced Solid Tumors"
    ],
    "interventions": [
      "ZW191"
    ],
    "primary_completion_date": "2026-12",
    "completion_date": "2027-01",
    "results_first_posted": null,
    "last_update_posted": "2025-07-22",
    "enrollment": null,
    "sponsor": "Zymeworks BC Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ZYME",
    "nct_id": "NCT06523803",
    "title": "A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers",
    "status": "TERMINATED",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Mesothelin-expressing Advanced Cancers"
    ],
    "interventions": [
      "ZW171"
    ],
    "primary_completion_date": "2025-09-30",
    "completion_date": "2025-10-01",
    "results_first_posted": null,
    "last_update_posted": "2025-10-21",
    "enrollment": null,
    "sponsor": "Zymeworks BC Inc.",
    "collected_at": "2026-01-27"
  },
  {
    "ticker": "ZYME",
    "nct_id": "NCT07164313",
    "title": "A Study of ZW251 in Participants With Advanced Solid Tumors",
    "status": "RECRUITING",
    "phase": "PHASE1",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Hepatocellular Carcinoma"
    ],
    "interventions": [
      "ZW251"
    ],
    "primary_completion_date": "2027-09",
    "completion_date": "2028-05",
    "results_first_posted": null,
    "last_update_posted": "2025-11-12",
    "enrollment": null,
    "sponsor": "Zymeworks BC Inc.",
    "collected_at": "2026-01-27"
  }
]